PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sheehan, WJ; Rangsithienchai, PA; Wood, RA; Rivard, D; Chinratanapisit, S; Perzanowski, MS; Chew, GL; Seltzer, JM; Matsui, EC; Phipatanakul, W				Sheehan, William J.; Rangsithienchai, Pitud A.; Wood, Robert A.; Rivard, Don; Chinratanapisit, Sasawan; Perzanowski, Matthew S.; Chew, Ginger L.; Seltzer, James M.; Matsui, Elizabeth C.; Phipatanakul, Wanda			Pest and allergen exposure and abatement in inner-city asthma: A Work Group Report of the American Academy of Allergy, Asthma & Immunology Indoor Allergy/Air Pollution Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergies; environmental allergens; indoor allergens; pest; rodents; inner city; abatement; mouse; cockroach	URBAN ELEMENTARY-SCHOOLS; NORTHEASTERN UNITED-STATES; SKIN-TEST SENSITIVITY; MIDDLE-CLASS CHILDREN; MOUSE ALLERGEN; COCKROACH ALLERGEN; ENVIRONMENTAL INTERVENTION; LOW-INCOME; AGRICULTURAL HEALTH; CHILDHOOD ASTHMA	Our work group report details the importance of pest allergen exposure in inner-city asthma. We will focus specifically on mouse and cockroach exposure. We will discuss how exposure to these pests is common in the inner city and what conditions exist in urban areas that might lead to increased exposure. We will discuss how exposure is associated with allergen sensitization and asthma morbidity. Finally, we will discuss different methods of intervention and the effectiveness of these tactics. (J Allergy Clin Irnmunol 2010;125:575-81.)	[Sheehan, William J.; Rangsithienchai, Pitud A.; Chinratanapisit, Sasawan; Phipatanakul, Wanda] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Sheehan, William J.; Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA; [Rangsithienchai, Pitud A.] Northwestern Univ, Dept Med, Mcgaw Med Ctr, Evanston Program, Evanston, IL USA; [Wood, Robert A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Rivard, Don] Rivards Resources IPM, Waltham, MA USA; [Chinratanapisit, Sasawan] Bhumibol Adulyadej Hosp, Dept Pediat, Bangkok, Thailand; [Perzanowski, Matthew S.; Chew, Ginger L.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Perzanowski, Matthew S.; Chew, Ginger L.] Columbia Ctr Childrens Environm Hlth, New York, NY USA; [Seltzer, James M.] Worcester Med Ctr, Fallon Clin, Worcester, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Northwestern University; Johns Hopkins University; Columbia University	Phipatanakul, W (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	wanda.phipatanakul@childrens.harvard.edu		Matsui, Elizabeth/0000-0001-8134-5593	Phadia; AstraZeneca; ACAAI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073964, T32AI007512] Funding Source: NIH RePORTER	Phadia(Phadia); AstraZeneca(AstraZeneca); ACAAI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: R. Wood receives research support front the NIH and is on the Advisory Board for FAAN. M. Perzanowski receives honorarium for speaking from Indoor Biotechnologies and received travel support from Phadia. J. M. Seltzer has provided legal consultation services/expert witness testimony in cases related to personal injury related to environmental exposures, including allergens. E. Matsui receives research support from the NIH. W. Phipatanakul receives research support from the NIH, AstraZeneca, and the ACAAI. The rest of the authors declare that they have no conflict of interest.	Abramson SL, 2006, J SCHOOL HEALTH, V76, P246, DOI 10.1111/j.1746-1561.2006.00105.x; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34, DOI 10.1016/S1081-1206(10)63611-3; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Berg J, 2008, J URBAN HEALTH, V85, P52, DOI 10.1007/s11524-007-9232-0; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Bradman A, 2005, ENVIRON HEALTH PERSP, V113, P1795, DOI 10.1289/ehp.7588; Chaudhuri Nita, 2004, Reviews on Environmental Health, V19, P197; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 2006, ANN ALLERG ASTHMA IM, V97, P502, DOI 10.1016/S1081-1206(10)60942-8; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Eggleston PA, 2001, ANN ALLERG ASTHMA IM, V87, P44, DOI 10.1016/S1081-1206(10)62340-X; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hoppin JA, 2009, EUR RESPIR J, V34, P1296, DOI 10.1183/09031936.00005509; Hoppin JA, 2008, AM J RESP CRIT CARE, V177, P11, DOI 10.1164/rccm.200706-821OC; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Katial RK, 2003, IMMUNOL ALLERGY CLIN, V23, P483, DOI 10.1016/S0889-8561(03)00002-X; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Krop EJM, 2007, INT ARCH ALLERGY IMM, V144, P296, DOI 10.1159/000106318; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lilly CM, 2005, J ALLERGY CLIN IMMUN, V115, pS526, DOI 10.1016/j.jaci.2005.01.028; Malone AM, 2008, J ASTHMA, V45, P313, DOI 10.1080/02770900801911202; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Matsui EC, 2007, J ALLERGY CLIN IMMUN, V119, P910, DOI 10.1016/j.jaci.2006.12.663; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; McConnell R, 2003, ANN ALLERG ASTHMA IM, V91, P546, DOI 10.1016/S1081-1206(10)61532-3; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Peiris-John RJ, 2005, RESP MED, V99, P1319, DOI 10.1016/j.rmed.2005.02.001; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Perry TT, 2008, ANN ALLERG ASTHMA IM, V100, P358, DOI 10.1016/S1081-1206(10)60599-6; Peters JL, 2007, J URBAN HEALTH, V84, P185, DOI 10.1007/s11524-006-9146-2; Phipatanakul W, 2008, ALLERGY, V63, P1512, DOI 10.1111/j.1398-9995.2008.01679.x; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593, DOI 10.1016/S1081-1206(10)61139-8; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Phipatanakul W, 2004, ANN ALLERG ASTHMA IM, V92, P420, DOI 10.1016/S1081-1206(10)61777-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Phipatanakul W, 2007, J ALLERGY CLIN IMMUN, V120, P954, DOI 10.1016/j.jaci.2007.05.010; Phipatanakul W, 2006, PEDIATR ANN, V35, P646; Platts-Mills T, 2007, AM FAM PHYSICIAN, V76, P675; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Rabito FA, 2007, J URBAN HEALTH, V84, P782, DOI 10.1007/s11524-007-9216-0; Ramachandran G, 2005, J OCCUP ENVIRON HYG, V2, P553, DOI 10.1080/15459620500324453; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Salo PW, 2009, ENVIRON HEALTH PERSP, V117, P387, DOI 10.1289/ehp.11847; Sarinho E, 2004, BRAZ J MED BIOL RES, V37, P503, DOI 10.1590/S0100-879X2004000400007; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sever ML, 2007, J ALLERGY CLIN IMMUN, V120, P849, DOI 10.1016/j.jaci.2007.07.003; Sharma HP, 2008, J ALLERGY CLIN IMMUN, V121, P933, DOI 10.1016/j.jaci.2008.01.023; Sharma HP, 2007, PEDIATR CLIN N AM, V54, P103, DOI 10.1016/j.pcl.2006.11.007; Sheehan WJ, 2009, ANN ALLERG ASTHMA IM, V102, P125, DOI 10.1016/S1081-1206(10)60242-6; Silva JM, 2005, PEDIAT ALLERG IMM-UK, V16, P393, DOI 10.1111/j.1399-3038.2005.00308.x; Simons E, 2007, J URBAN HEALTH, V84, P577, DOI 10.1007/s11524-007-9205-3; Slager RE, 2009, OCCUP ENVIRON MED, V66, P718, DOI 10.1136/oem.2008.041798; Teach SJ, 2006, PEDIATRICS, V117, pS152, DOI 10.1542/peds.2005-2000M; Turyk M, 2006, J ASTHMA, V43, P453, DOI 10.1080/02770900600758333; Wang CL, 2008, J COMMUN HEALTH, V33, P31, DOI 10.1007/s10900-007-9064-6; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904	75	74	77	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					575	581		10.1016/j.jaci.2010.01.023	http://dx.doi.org/10.1016/j.jaci.2010.01.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226293	Green Accepted			2022-12-18	WOS:000275883200011
J	Bacharier, LB; Guilbert, TW; Zeiger, RS; Strunk, RC; Morgan, WJ; Lemanske, RF; Moss, M; Szefler, SJ; Krawiec, M; Boehmer, S; Mauger, D; Taussig, LM; Martinez, FD				Bacharier, Leonard B.; Guilbert, Theresa W.; Zeiger, Robert S.; Strunk, Robert C.; Morgan, Wayne J.; Lemanske, Robert F.; Moss, Mark; Szefler, Stanley J.; Krawiec, Marzena; Boehmer, Susan; Mauger, David; Taussig, Lynn M.; Martinez, Fernando D.		Natl Heart Lung & Blood Inst; Childhood Asthma Res Educ Network	Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; inhaled corticosteroids; response	CHILDHOOD ASTHMA	Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 mu g twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects. (J Allergy Clin Immunol 2009;123:1077-82.)	[Bacharier, Leonard B.] Washington Univ, Dept Pediat, St Louis Childrens Hosp, St Louis, MO 63017 USA; [Bacharier, Leonard B.; Strunk, Robert C.] Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63017 USA; [Guilbert, Theresa W.; Lemanske, Robert F.; Moss, Mark] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Morgan, Wayne J.; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA; [Szefler, Stanley J.; Krawiec, Marzena; Taussig, Lynn M.] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; [Boehmer, Susan; Mauger, David] Penn State Univ, Dept Publ Hlth Sci, University Pk, PA 16802 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego; University of Arizona; National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bacharier, LB (corresponding author), Washington Univ, Dept Pediat, St Louis Childrens Hosp, St Louis, MO 63017 USA.	bacharier_L@kids.wustl.edu		Zeiger, Robert/0000-0001-5788-5063; Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health; AstraZeneca; GlaxoSmithKline; Genentech; Merck; Sanofi-aventis; TEVA Pharmaceuticals; National Institutes of Health/University of Wisconsin; National Institutes of Health/National Heart, Lung, and Blood Institute Childhood Asthma Management Program; National Institutes of Health/National Heart, Lung, and Blood Institute Asthma Clinical Research Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium; Ross Pharmaceuticals; American Lung Association; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064305, U10HL064313, U10HL064307, U10HL064295, U10HL064287, U10HL064288] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Merck(Merck & Company); Sanofi-aventis(Sanofi-Aventis); TEVA Pharmaceuticals(Teva Pharmaceutical Industries); National Institutes of Health/University of Wisconsin(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Heart, Lung, and Blood Institute Childhood Asthma Management Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Heart, Lung, and Blood Institute Asthma Clinical Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Ross Pharmaceuticals; American Lung Association; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Disclosure of potential conflict of interest: L. B. Bacharier has received honoraria from AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Aerocrine and has served on the advisory board for Schering-Plough. T. W. Guilbert has received honoraria from GlaxoSmithKline, AstraZeneca, PeerPoint Medical Education Institute, Merck, and Antidote; has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, and the National Institutes of Health; and is a member of the American Lung Association, the American Thoracic Society, and the American Academy of Pediatrics. R. S. Zeiger has served as a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from AstraZeneca, GlaxoSmithKline, Genentech, Merck, the National Heart, Lung, and Blood Institute, Sanofi-aventis, and TEVA Pharmaceuticals. W. J. Morgan has served as a consultant for the Cystic Fibrosis Foundation and Genentech and has received research support front the National Institutes of Health/University of Wisconsin. R. F. Lemanske, Jr, has received honoraria as a speaker for Merck, has served as a consultant for GlaxoSmithKline, and has received research support from the National Heart, Lung, and Blood Institute. M. Moss served as the president of the Wisconsin Allergy Society from 2005 to 2007. S. J. Szefler has served as a consultant for AstraZeneca, GlaxoSmithKline, Aventis, Genentech, Merck and bus received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute Childhood Asthma Management Program, the National Heart, Lung, and Blood Institute Childhood Asthma Research and Education, the National Institutes of Health/National Heart, Lung, and Blood Institute Asthma Clinical Research Network, the National Institutes of Health/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium, and Ross Pharmaceuticals. M. Krawiec has served on the speakers' bureau for Merck and GlaxoSmithKline and as it consultant for Novartis, has received research support front the American Lung Association, and has served as an expert witness for Parexel. F. D. Martinez has served oil the advisory board for Merck, has received lecture fees from Merck and Pfizer, and has served as a consultant for GlaxoSmithKline and MedImmune. The rest of the authors have declared that they have no conflict of interest.	Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; Miller PE, 2007, VET OPHTHALMOL, V10, P1, DOI 10.1111/j.1463-5224.2007.00587.x; Natl. Asthma Educ. Prev. Prog, 2007, 3 US DEP HHS NAT AST; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Szefler S, 2000, NEW ENGL J MED, V343, P1054	11	74	78	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1077	1082		10.1016/j.jaci.2008.12.1120	http://dx.doi.org/10.1016/j.jaci.2008.12.1120			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19230959	Green Accepted			2022-12-18	WOS:000266309400015
J	Murata, J; Abe, R; Shimizu, H				Murata, Junko; Abe, Riichiro; Shimizu, Hiroshi			Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Soluble Fas ligand; Stevens-Johnson syndrome; toxic epidermal necrolysis	VERSUS-HOST-DISEASE; ERYTHEMA MULTIFORME; RHEUMATIC-DISEASES; SERUM; ASSOCIATION; EXPRESSION; HEPATITIS; CD95	Background: It is difficult to distinguish the early phase of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) from other ordinary types of drug-induced skin reactions (ODSRs). Levels of several serum soluble factors, including soluble Fas ligand (sFasL), have been reported to be increased in patients with SJS/TEN; however, the marker to predict the onset of SJS/TEN before the development of skin detachment or mucosal lesions has not been identified. Objective: We sought to determine whether sFasL might be a useful marker in the early stages of SJS/TEN. Methods: Sera of 19 patients with SJS and 16 patients with TEN at I or multiple time points were obtained from Japanese multiple hospitals. The disease onset (day 1) was defined when erosion/ulceration of the mucocutaneous or ocular lesion first developed. For the investigation of soluble factors, including sFasL, TNF-alpha, IFN-gamma, IL-6, and sCD40 ligand, we used ELISAs and Cytometric Bead Arrays. Results: Before disease onset (day -4 to approximately -2), 7 samples were available, and we detected the highest concentrations of sFasL in 5 (71.4%) of 7 patients. Increased sFasL levels decreased rapidly within 5 days of disease onset. In all 32 patients with ODSRs and 33 healthy control subjects, no increase of sFasL levels was detected. Other soluble factor concentrations did not show significant difference with those seen in patients with SJS/TEN before disease onset and ODSRs. Conclusion: The sFasL levels of sera in patients with SJS/TEN are significantly increased before development of skin detachment, mucosal lesions, or both. (J Allergy Clin Immunol 2008;122:992-1000.)	[Shimizu, Hiroshi] Hokkaido Univ, Dept Dermatol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Shimizu, H (corresponding author), Hokkaido Univ, Dept Dermatol, Grad Sch Med, Kita Ku, N 15 W 7, Sapporo, Hokkaido 0608638, Japan.	shimizu@med.hokudai.ac.jp	Abe, Riichiro/A-5450-2012; Shimizu, Hiroshi/A-5193-2012; Kim, Seongman/N-6910-2014					Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; ALJANADI M, 1993, J CLIN IMMUNOL, V13, P58, DOI 10.1007/BF00920636; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Becker DS, 1998, LANCET, V351, P1417, DOI 10.1016/S0140-6736(97)11369-1; Caproni M, 2006, BRIT J DERMATOL, V154, P1006, DOI 10.1111/j.1365-2133.2006.07211.x; Chen DY, 2007, ARTHRIT RHEUM-ARTHR, V57, P1530, DOI 10.1002/art.23088; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Dainichi T, 2007, DERMATOLOGY, V215, P86, DOI 10.1159/000102045; Das H, 1999, BRIT J HAEMATOL, V104, P795, DOI 10.1046/j.1365-2141.1999.01246.x; Hein OV, 2005, CRIT CARE, V9, pR323, DOI 10.1186/cc3532; Lee JY, 2004, J VIRAL HEPATITIS, V11, P130, DOI 10.1046/j.1365-2893.2003.00486.x; Luther J, 2007, AM J CLIN DERMATOL, V8, P221, DOI 10.2165/00128071-200708040-00004; Mizutani Y, 2001, CANCER, V92, P287, DOI 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4; Nozawa K, 1997, ARTHRITIS RHEUM, V40, P1126, DOI 10.1002/art.1780400617; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Rzany B, 1996, J CLIN EPIDEMIOL, V49, P769, DOI 10.1016/0895-4356(96)00035-2; SEKIYAMA KD, 1994, CLIN EXP IMMUNOL, V98, P71; Stur K, 2007, J INVEST DERMATOL, V127, P802, DOI 10.1038/sj.jid.5700648; Takada S, 2000, AM J HEMATOL, V64, P133, DOI 10.1002/(SICI)1096-8652(200006)64:2<133::AID-AJH12>3.3.CO;2-Q; Tomokuni A, 1999, CLIN EXP IMMUNOL, V118, P441; Ueta M, 2007, AM J OPHTHALMOL, V143, P367, DOI 10.1016/j.ajo.2006.09.029; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wolkenstein P, 1998, LANCET, V352, P1586, DOI 10.1016/S0140-6736(98)02197-7; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017	24	74	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					992	1000		10.1016/j.jaci.2008.06.013	http://dx.doi.org/10.1016/j.jaci.2008.06.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18692887				2022-12-18	WOS:000260940100020
J	Mrabet-Dahbi, S; Dalpke, AH; Niebuhr, M; Frey, M; Draing, C; Brand, S; Heeg, K; Werfel, T; Renz, H				Mrabet-Dahbi, Salima; Dalpke, Alexander H.; Niebuhr, Margarete; Frey, Markus; Draing, Christian; Brand, Stephanie; Heeg, Klaus; Werfel, Thomas; Renz, Harald			The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; innate immunity; Toll-like receptor; skin; inflammation; cytokines	STAPHYLOCOCCAL-ENTEROTOXIN-B; LIPOTEICHOIC ACID; T-CELLS; INTERFERON-GAMMA; SKIN; POLYMORPHISM; AUREUS; KERATINOCYTES; ECZEMA; TLR2	Background: Impaired host defense mechanisms may crucially modulate the pathogenesis of atopic dermatitis (AD). More than 10% of patients with AD are heterozygous for the Toll-like receptor 2 (TLR-2) R753Q single nucleotide polymorphism (SNP) and exhibit severe eczema. Objective: To elucidate the functional effect of the TLR-2 mutation and its putative relevance for AD. Methods: Using the human embryonic kidney 293 transfection system, we characterized the properties of the TLR-2 R753Q SNP. Moreover, TLR-2 expression, IL-8 production, and cytokine secretion were analyzed in monocytes and CD4(+) T cells of patients with AD with and without the mutant TLR-2 gene. Results: Human embryonic kidney 293 transfectants mimicking this heterozygous mutation produced less IL-8 when stimulated with lipoteichoic acid (LTA), heat-inactivated Staphylococcus aureus or triacylated lipopeptides requiring the TILR-2/1 heterodimer. Suppressed production of IL-8 was confirmed in monocytes from patients with mutant AD after stimulation with peptidoglycan. Cell surface TLR-2 expression was severely impaired in CD3/CD28 activated CD4+ T cells of patients with AD bearing the mutant receptor, which could be restored on LTA stimulation. In contrast, LTA decreased TLR-2 expression among nonatopic individuals and patients with AD with the TLR-2 wild-type gene. T cells from patients with AD exhibited markedly suppressed IL-2 production after macrophage-activating lipopeptide-2 activation. However, no difference was found between mutant and wild-type patients with AD for IL-5, TNF-alpha, IFN-gamma, and IL-2 production. Conclusion: Collectively, the outcome of innate and adaptive immune responses in AD is modulated by the TLR-2 R753Q SNP.	[Mrabet-Dahbi, Salima; Renz, Harald] Univ Marburg, Cent Lab, Dept Clin Chem & Mol Diagnost, D-35033 Marburg, Germany; [Dalpke, Alexander H.; Frey, Markus; Heeg, Klaus] Univ Heidelberg, Dept Med Microbiol & Hyg, Heidelberg, Germany; [Draing, Christian] Hannover Med Sch, Dept Dermatol & Allergol, D-3000 Hannover, Germany; [Niebuhr, Margarete; Werfel, Thomas] Univ Konstanz, Dept Biol, Constance, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg; Hannover Medical School; University of Konstanz	Renz, H (corresponding author), Univ Marburg, Cent Lab, Dept Clin Chem & Mol Diagnost, Baldinger St, D-35033 Marburg, Germany.	renzh@med.uni-inarburg.de	Werfel, Thomas/B-6921-2012					Abeck D, 1998, BRIT J DERMATOL, V139, P13; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Breuer K, 2005, CLIN EXP ALLERGY, V35, P1088, DOI 10.1111/j.1365-2222.2005.02295.x; BruchGerharz D, 1996, J EXP MED, V184, P2007, DOI 10.1084/jem.184.5.2007; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hadley JS, 2005, INFECT IMMUN, V73, P7613, DOI 10.1128/IAI.73.11.7613-7619.2005; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Saloga J, 1996, J INVEST DERMATOL, V106, P982, DOI 10.1111/1523-1747.ep12338479; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; Schroder NWJ, 2005, J IMMUNOL, V175, P2534, DOI 10.4049/jimmunol.175.4.2534; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; von Aulock S, 2004, INFECT IMMUN, V72, P1828, DOI 10.1128/IAI.72.3.1828-1831.2004; Wesch D, 2006, J IMMUNOL, V176, P1348, DOI 10.4049/jimmunol.176.3.1348; WILLIAMS REA, 1990, BRIT J DERMATOL, V123, P493; Zhang QW, 2005, J CLIN INVEST, V115, P2855, DOI 10.1172/JCI25429	33	74	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1013	1019		10.1016/j.jaci.2007.11.029	http://dx.doi.org/10.1016/j.jaci.2007.11.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234309				2022-12-18	WOS:000254884000030
J	Simons, FER				Simons, F. Estelle R.			Anaphylaxis in infants: Can recognition and management be improved?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						anaphylaxis; systemic allergic reaction; infant; atopic; urticariti food allergy tryptase; epinephrine; H-1-antihistamines	ALLERGIC REACTIONS; FOOD ALLERGY; CHILDREN; EPINEPHRINE; MILK		Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Natl Training Program Allergy & Asthma, Canadian Inst Hlth Res,Dept Immunol, Winnipeg, MB, Canada	University of Manitoba; Institute for Work & Health; University of Manitoba	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Bansal PJ, 2005, ANN ALLERG ASTHMA IM, V94, P55, DOI 10.1016/S1081-1206(10)61286-0; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Buckley MG, 2001, CLIN EXP ALLERGY, V31, P1696, DOI 10.1046/j.1365-2222.2001.01213.x; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Hogan MB, 1998, ANN ALLERG ASTHMA IM, V81, P140, DOI 10.1016/S1081-1206(10)62800-1; Kimata H, 2004, CLIN EXP ALLERGY, V34, P1910, DOI 10.1111/j.1365-2222.2004.02128.x; Levin ME, 2005, PEDIATRICS, V116, P1223, DOI 10.1542/peds.2005-0020; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Pessler F, 2004, PEDIATR ALLERGY IMMU, V15, P183, DOI 10.1046/j.1399-3038.2003.00087.x; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Roberts JR, 2006, J ALLERGY CLIN IMMUN, V117, pS42, DOI 10.1016/j.jaci.2005.12.173; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; SHEIKH A, 2007, COCHRANE DB SYST REV, V1; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; SIMONS FER, 2004, INT J WORLD ALLERG S, V1, P242; Starke PR, 2005, NEW ENGL J MED, V352, P2653, DOI 10.1056/NEJM200506233522522; Young M.C., 2003, PEDIAT ALLERGY PRINC, P643	21	74	78	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					537	540		10.1016/j.jaci.2007.06.025	http://dx.doi.org/10.1016/j.jaci.2007.06.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17765754				2022-12-18	WOS:000249505400009
J	Baptist, AP; Warrier, I; Arora, R; Ager, J; Massanari, RM				Baptist, Alan P.; Warrier, Indulekha; Arora, Rachna; Ager, Joel; Massanari, R. Michael			Hospitalized patients with asthma who leave against medical advice: Characteristics, reasons, and outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; against medical advice; relapse; recurrence; patient readmission; patient discharge; socioeconomic status; insurance; health	LENGTH-OF-STAY; READMISSION; DISCHARGES; ADMISSION; IMPACT; RISK	Background: A discharge against medical advice (AMA) after an asthma hospitalization is a frustrating problem for health care providers, yet little is known about this occurrence. Objective: To determine the baseline characteristics, reasons for leaving, and clinical outcomes of patients with asthma who leave AMA. Methods: A retrospective study from 1999 to 2004 of all asthma discharges from 3 large hospitals in Detroit compared those who left AMA with those who left with medical approval. Results: There were 180 patients who left AMA and 3457 patients who had a standard discharge. Patients with asthma who left AMA were more likely to be younger, male, have Medicaid or lack insurance, require intensive care unit admission, and have a lower socioeconomic status than patients with asthma discharged with approval (P <.05 for all comparisons). There was no difference in race, day of the week admitted, or month admitted. Among records that documented a reason for leaving AMA, the most common was dissatisfaction with care, although a variety of motives were found. Finally, patients who left AMA were more likely to have an asthma relapse within 30 days. This included both emergency department revisits (21.7% vs 5.4%; P <.001) and readmission to the hospital (8.5% vs 3.2%; P <.001). Conclusion: Patients with asthma who leave AMA have demographic and hospital admission characteristics that differ from those who leave with approval. The reasons why patients with asthma leave AMA are varied. Within 30 days, patients with asthma who leave AMA have much higher readmission and emergency department return rates. Clinical implications: Patients with asthma who leave AMA are at increased risk of relapse.	Wayne State Univ, Sch Med, Allergy Immunol Sect, Dept Internal Med, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Div Allergy & Immunol, Dept Pediat, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Healthcare Effectiveness Res, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Baptist, AP (corresponding author), Wayne State Univ, Sch Med, Allergy Immunol Sect, Dept Internal Med, 4201 St Antoine,UHC Suite 5C, Detroit, MI 48201 USA.	abaptist@med.wayne.edu						Anis AH, 2002, CAN MED ASSOC J, V167, P633; Armenian SH, 1999, DRUG ALCOHOL DEPEN, V56, P1, DOI 10.1016/S0376-8716(99)00027-7; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Brook M, 2006, PSYCHIAT SERV, V57, P1192, DOI 10.1176/appi.ps.57.8.1192; Burt C W, 1996, Adv Data, P1; Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016, DOI 10.1164/ajrccm.157.4.9704036; Chan ACH, 2004, JAIDS-J ACQ IMM DEF, V35, P56, DOI 10.1097/00126334-200401010-00008; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; Green P, 2004, AM J DRUG ALCOHOL AB, V30, P489, DOI 10.1081/ADA-120037390; HARRISON ML, 1995, CAN MED ASSOC J, V153, P745; Hwang SW, 2003, CAN MED ASSOC J, V168, P417; Khan SR, 2003, RESPIROLOGY, V8, P77; Lin HC, 2005, J ASTHMA, V42, P537, DOI 10.1080/02770900500214783; LONG JP, 1982, J FAM PRACTICE, V15, P551; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; OCHITILL HN, 1985, J CHRON DIS, V38, P79, DOI 10.1016/0021-9681(85)90010-4; Okoromah C N, 2004, Niger Postgrad Med J, V11, P21; Saitz R, 1999, AM J MED, V107, P507, DOI 10.1016/S0002-9343(99)00262-4; Saitz R, 2000, J GEN INTERN MED, V15, P103, DOI 10.1046/j.1525-1497.2000.12068.x; SCHLAUCH RW, 1979, NEW ENGL J MED, V300, P22, DOI 10.1056/NEJM197901043000106; Srivastava R, 2003, PEDIATRICS, V112, P278, DOI 10.1542/peds.112.2.278; Strinko J M, 2000, J Emerg Nurs, V26, P223, DOI 10.1016/S0099-1767(00)90094-1; TARGUM SD, 1982, AM J PSYCHIAT, V139, P657; Thomas AJ, 2006, AM J EPIDEMIOL, V164, P586, DOI 10.1093/aje/kwj234; To T, 1996, PEDIATRICS, V98, P191; U.S. Census Bureau, 2000, AM FACT FIND; Weber EJ, 2002, AM J MED, V113, P371, DOI 10.1016/S0002-9343(02)01242-1; Weingart SN, 1998, J GEN INTERN MED, V13, P568, DOI 10.1046/j.1525-1497.1998.00169.x; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033	30	74	75	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					924	929		10.1016/j.jaci.2006.11.695	http://dx.doi.org/10.1016/j.jaci.2006.11.695			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17239431				2022-12-18	WOS:000245729500022
J	Untersmayr, E; Vestergaard, H; Malling, HJ; Jensen, LB; Platzer, MH; Boltz-Nitulescu, G; Scheiner, O; Skov, PS; Jensen-Jarolim, E; Poulsen, LK				Untersmayr, Eva; Vestergaard, Helle; Malling, Hans-Jorgen; Jensen, Louise Bjerremann; Platzer, Michael H.; Boltz-Nitulescu, George; Scheiner, Otto; Skov, Per Stahl; Jensen-Jarolim, Erika; Poulsen, Lars K.			Incomplete digestion of codfish represents a risk factor for anaphylaxis in patients with allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; gastric digestion; anaphylaxis; skill tests; double-blind placebo-controlled food challenge; threshold levels; codfish; protein absorption	FOOD ALLERGY; DOUBLE-BLIND; PEANUT ALLERGY; ABSORPTION; PROTEINS; ALLERGENICITY; POPULATION; QUANTITIES; ACTIVATION; CHALLENGE	Background: Fish represents one of the most important allergenic foods causing severe allergic reactions. Nevertheless, it has been shown that gastric digestion significantly reduces its allergenic capacity. Objective: In this study, we assessed the absorption kinetics of fish proteins and investigated the clinical reactivity of patients with fish allergy to codfish digested at physiological or elevated gastric pH. Methods: Healthy individuals were openly challenged with codfish and blood samples were evaluated by histamine release for absorbed fish allergens. Patients with allergy were recruited on the basis of previously diagnosed codfish allergy. Fish extracts were digested with gastric enzymes at pH 2.0 and 3.0 and used for histamine release, skin prick tests, and titrated double-blind placebo-controlled food challenges. Results: Ingestion experiments in subjects without allergy revealed absorption of biologically active fish allergens only 10 minutes after ingestion with maximal serum levels after I to 2 hours. Incubation of fish proteins with digestive enzymes at pH 2.0 resulted in a fragmentation of the proteins leading to a reduced biological activity evidenced by a significantly smaller wheal reaction and reduced histamine release. Fish digested at pH 3.0 revealed comparable reactivity patterns as undigested extracts. Moreover, these test materials triggered reactions at 10-fold to 30-fold lower cumulated challenge doses in patients with allergy. Conclusion: Our data indicate the paramount importance of gastric digestion for fish allergens because the quantitatively significant absorption and elicitation of symptoms seemed to take place in the intestine. Clinical implications: Hindered digestion puts patients with fish allergy at risk to develop severe allergic reactions at minute amounts of allergens.	Natl Univ Hosp, Lab Med Allergol, Allergy Clin, DK-2100 Copenhagen O, Denmark; Med Univ Vienna, Ctr Physiol & Pathophysiol, Vienna, Austria; Reference Lab, Copenhagen, Denmark	Medical University of Vienna	Poulsen, LK (corresponding author), Natl Univ Hosp, Lab Med Allergol, Allergy Clin, FIN 7551,Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	lkpallgy@inet.uni2.dk	Poulsen, Lars K/J-3065-2019; Untersmayr, Eva/GRY-4470-2022; Jensen-Jarolim, Erika/C-5120-2018	Poulsen, Lars K/0000-0002-1730-847X; Jensen-Jarolim, Erika/0000-0003-4019-5765; Untersmayr, Eva/0000-0002-1963-499X	Austrian Science Fund FWF [H 220, F 1808] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Brunner M, 1928, ARCH INTERN MED, V42, P172, DOI 10.1001/archinte.1928.00130200024002; Carreno I, 2005, FOOD DRUG LAW J, V60, P375; CARSON RP, 1969, AM HEART J, V77, P579, DOI 10.1016/0002-8703(69)90541-9; Dirks CG, 2005, J ALLERGY CLIN IMMUN, V115, P1321, DOI 10.1016/j.jaci.2005.03.027; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hansen TK, 2004, FOOD CHEM TOXICOL, V42, P2037, DOI 10.1016/j.fct.2004.08.008; HANSEN TK, 1992, ALLERGY, V47, P610, DOI 10.1111/j.1398-9995.1992.tb02383.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Hourihane JOB, 2001, ALLERGY, V56, P86, DOI 10.1034/j.1398-9995.2001.00926.x; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kimura T, 2002, BIOL PHARM BULL, V25, P149, DOI 10.1248/bpb.25.149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laoprasert N, 1998, J FOOD PROTECT, V61, P1522, DOI 10.4315/0362-028X-61.11.1522; Malling HJ., 2003, ALLERGY, V48, P55; Marchal R, 2002, J AGR FOOD CHEM, V50, P177, DOI 10.1021/jf0105539; Mari A, 2005, CURR OPIN ALLERGY CL, V5, P267, DOI 10.1097/01.all.0000168793.27948.b0; Mills ENC, 2004, ALLERGY, V59, P1262, DOI 10.1111/j.1398-9995.2004.00720.x; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Moneret-Vautrin DA, 2004, CURR OPIN ALLERGY CL, V4, P215, DOI 10.1097/01.all.0000129454.42340.23; *OP SCI PAN DIET P, 2004, EFSA J, V184, P1; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; Richter C, 1998, BIOCHEM J, V335, P481, DOI 10.1042/bj3350481; Rolland JM, 2006, NUTRITION, V22, P882, DOI 10.1016/j.nut.2006.06.002; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Scholl L, 2005, AM J CLIN NUTR, V81, P154; SKOV PS, 1985, ALLERGY, V40, P213; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2005, J ALLERGY CLIN IMMUN, V115, P377, DOI 10.1016/j.jaci.2004.10.029; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Walzer M, 1927, J IMMUNOL, V14, P143; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wuthrich B, 2001, ALLERGY, V56, P102, DOI 10.1034/j.1398-9995.2001.00930.x	41	74	74	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					711	717		10.1016/j.jaci.2006.10.039	http://dx.doi.org/10.1016/j.jaci.2006.10.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17215033	Bronze, Green Accepted			2022-12-18	WOS:000244925000026
J	Gelfand, EW; Dakhanna, A				Gelfand, EW; Dakhanna, A			CD8(+) T lymphocytes and leukotriene B-4: Novel interactions in the persistence and progression of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD8; T cells; leukotriene B-4; IL-13; asthma	LUNG-FUNCTION DECLINE; AIRWAY HYPERRESPONSIVENESS; TH2 CELLS; EFFECTOR; INFLAMMATION; INTERLEUKIN-5; REQUIREMENT; DEPLETION; IL-4; 5-LIPOXYGENASE	The contribution of CD8(+) T cells to the development of airway hyperresponsiveness and airway inflammation has received increased attention recently. CD8(+) T cells, which are capable of secreting T(H)2 cytokines, including IL-4, IL-5, and IL-13, have been described in asthmatic subjects and in animals sensitized and challenged with allergen. A subset of these IL-13-producing CD8(+) T cells, effector memory CD8(+) T cells in the mouse, express a high-affinity receptor for leukotriene B-4 (BLT1), and expression of this receptor is essential for their accumulation in the lung and development of airway hyperresponsiveness and airway inflammation. A similar subset of CD8(+)/BLT1(+)/IL-13(+) T cells has also been identified in the bronchoalveolar lavage fluid of asthmatic subjects, suggesting a pathogenic role for this unique subset of CD8(+) T cells in asthma.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [P01 HL036577-21A15977, HL-36577, P01 HL036577, HL-61005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Cibella F, 2002, CHEST, V122, P1944, DOI 10.1378/chest.122.6.1944; Coyle AJ, 1996, ANN NY ACAD SCI, V796, P97, DOI 10.1111/j.1749-6632.1996.tb32571.x; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GELFAND EW, 2006, IN PRESS J ALLERGY C; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Huang TJ, 1999, IMMUNOLOGY, V96, P416; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; JOETHAM A, 2003, AM J RESP CRIT CARE, V167, pA943; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; OLIVENSTEIN R, 1993, J CLIN INVEST, V92, P1477, DOI 10.1172/JCI116725; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; Peters-Golden M, 2003, PROSTAG LEUKOTR ESS, V69, P99, DOI 10.1016/S0952-3278(03)00070-X; Prescott SL, 1998, J IMMUNOL, V160, P4730; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; Suzuki M, 1999, J IMMUNOL, V163, P5574; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; TAUBE C, 2006, IN PRESS J IMMUNOL; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Wenzel SE, 1997, PHARMACOTHERAPY, V17, pS3; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	45	74	83	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					577	582		10.1016/j.jaci.2005.12.1340	http://dx.doi.org/10.1016/j.jaci.2005.12.1340			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522456				2022-12-18	WOS:000236263100012
J	Soundararajan, S; Kikuchi, Y; Joseph, K; Kaplan, AP				Soundararajan, S; Kikuchi, Y; Joseph, K; Kaplan, AP			Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; autoimmune; IgG subclasses; basophils; anti-IgE receptor	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; HISTAMINE-RELEASE; ANTI-IGE; SEROLOGICAL MEDIATOR; ALPHA AUTOANTIBODIES; BASOPHILS; IDENTIFICATION; BINDING; SERA	Background: Chronic urticaria is caused by a complement fixing, IgG antibody directed to the a-subunit of the IgE receptor, which is present in 35% to 45% of patients. This autoimmune subgroup can be identified by an autologous skin test or histamine release from human basophils or cutaneous mast cells. However, binding assays do not correlate with these functional assays. We considered the possibility that pathogenic antibody may be present within particular IgG subclasses, which might facilitate development of a binding method that can reliably screen patients. Objective: To determine the subclass distribution of IgG antireceptor antibodies on the basis of histamine release, and to assess the possibility that a subclass specific ELISA binding method could be used to screen patients.. Methods: We isolated patient IgG by protein G affinity chromatography and then isolated patient IgG subclasses 1, 2, 3, and 4 by a combination of antibody affinity chromatography and protein A affinity chromatography. The ability of each subclass to activate basophils was assayed by histamine release. Results: Patient IgG subclasses IgG(1), IgG(3), and to a lesser degree IgG(4) have antibody capable of activating basophils to release histamine, whereas IgG(2) is inactive. Immunoblot or RAST assay that is subclass-specific does not correlate with histamine release as a result of nonfunctional but binding antibody within IgG subclasses 1, 3, or 4, and complement activation by IgG(1) and IgG(3). Conclusion: Purification of IgG subclasses from patients with chronic urticaria demonstrates functional antibody in IgG, and IgG(3) and occasionally TgG(4). Nonfunctional antibody within IgG(2) plus nonfunctional antibody mixed with functional antibody within IgG(1), IgG(3), and IgG(4) and effects of complement are responsible for a lack of correlation of histamine release with binding assays even if subclass-specific.	Med Univ S Carolina, Dept Med, Div Pulm Crit Care Allergy & Clin Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Inst Inflammat Res, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Crit Care Allergy & Clin Immunol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.	kaplana@musc.edu						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 2003, ALLERGY, V58, P802, DOI 10.1034/j.1398-9995.2003.00195.x; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1988, BRIT J DERMATOL, V119, P179, DOI 10.1111/j.1365-2133.1988.tb03199.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 2001, FASEB J, V15, P2268, DOI 10.1096/fj.00-0890hyp; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; KIKUCHI Y, 2003, ALLERGYI CLIN IMM S1, P225; Pachlopnik JM, 2004, J AUTOIMMUN, V22, P43, DOI 10.1016/j.jaut.2003.09.007; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Soundararajan S., 2004, Journal of Allergy and Clinical Immunology, V113, pS85, DOI 10.1016/j.jaci.2003.12.287; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	21	74	78	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					815	821		10.1016/j.jaci.2004.12.1120	http://dx.doi.org/10.1016/j.jaci.2004.12.1120			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806004				2022-12-18	WOS:000228373400023
J	Covar, RA; Spahn, JD; Martin, RJ; Silkoff, PE; Sundstrom, DA; Murphy, J; Szefler, SJ				Covar, RA; Spahn, JD; Martin, RJ; Silkoff, PE; Sundstrom, DA; Murphy, J; Szefler, SJ			Safety and application of induced sputum analysis in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; asthma; eosinophils; exhaled nitric oxide; induced sputum; inflammatory markers; pulmonary function	EXHALED NITRIC-OXIDE; AIRWAY INFLAMMATION; CHILDREN; EOSINOPHILS; BIOPSY	Background: The value of sputum induction in pediatric asthma lies in its potential to directly and noninvasively assess airway inflammation in children, because bronchoscopy and biopsy carry some risk. The Childhood Asthma Management Program (CAMP) study was designed to evaluate the long-term effects of budesonide and nedocromil compared with placebo in children with mild to moderate asthma across 8 centers. Objective: At the Denver CAMP site, we sought to evaluate the safety of sputum induction, to determine differences in airway inflammation between treatment groups by using induced sputum analysis, and to examine correlations between other biomarkers and sputum eosinophils. Methods: Sputum induction was performed, and exhaled nitric oxide, circulating eosinophil counts, and serum eosinophil cationic protein were obtained at treatment discontinuation and after washout. Spirometry and a methacholine challenge were also performed according to the CAMP protocol. Results: Ninety of 117 children provided an adequate sputum sample for analysis. In 9 subjects (3 nedocromil and 6 placebo), sputum induction resulted in bronchospasm. These subjects had greater disease severity, as measured by a lower median prebronchodilator FEV1 percentage predicted (85.0% vs 96.0%; P = .024) and FEV1/FVC ratio (70.0% vs 79.0%; P = .0008); greater bronchodilator reversibility (16.5% vs 6.8%; P = .004); higher serum IgE (1390.0 vs 495.0 ng/mL; P = .017) and circulating eosinophil count (757.0 vs 282.0/mm(3); P = .04); greater use of prednisone (1.9 vs 0.9 courses per 100 person-years; P = .05); and greater supplemental inhaled steroid doses (85.3 vs 0 mg; P = .016). At treatment discontinuation, budesonide-treated patients had a lower median (1st, 3rd quartile) sputum percentage eosinophil (SPEos) (0.2% [0%, 1.2%] vs 0.8% [0.2%, 4.6%]; P = .03) compared with those treated with placebo; no significant difference was noted between nedocromil- and placebo-treated patients. Higher SPEos at the time of treatment discontinuation was associated with asthma worsening that required rescue prednisone (n = 23) during the washout period compared with patients who remained stable (3.6% [0.4%, 6.4%] vs 0.6% [0.2%, 3.2%] SPEos; P = .023). Finally, greater SPEos was associated with atopy, higher bronchodilator reversibility, lower FEV1/FVC ratio, higher exhaled nitric oxide levels, circulating eosinophils, sputum and serum eosinophil cationic protein, more prednisone courses during the treatment period, and greater asthma severity. Conclusions: Sputum induction is a relatively noninvasive and safe procedure that can provide information on eosinophilic inflammation and treatment response and is also associated with several measures of asthma control. However, this procedure still remains a research tool in asthma because of its requirements for technical expertise.	Natl Jewish Med & Res Ctr, Ira J Jacqueline Neimark Lab Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Allergy Clin Immunol, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Pulm Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health	Covar, RA (corresponding author), Natl Jewish Med & Res Ctr, Ira J Jacqueline Neimark Lab Clin Pharmacol, 1400 Jackson St, Denver, CO 80206 USA.	covarr@njc.org	silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199	NCRR NIH HHS [5 MO 1RR00051] Funding Source: Medline; NHLBI NIH HHS [N01 HR 16048] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Bush A, 2000, AM J RESP CRIT CARE, V162, pS18, DOI 10.1164/ajrccm.162.supplement_1.maic-5; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Midulla F, 2003, EUR RESPIR J, V22, P698, DOI 10.1183/09031936.02.00113202; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Szefler S, 2000, NEW ENGL J MED, V343, P1054; WONG HF, 1997, AM J RESP CRIT CARE, V52, P372	16	74	79	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					575	582		10.1016/j.jaci.2004.06.036	http://dx.doi.org/10.1016/j.jaci.2004.06.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356559	Bronze			2022-12-18	WOS:000223799600016
J	Hong, JH; Lee, SI; Kim, KE; Yong, TS; Seo, JT; Sohn, MH; Shin, DM				Hong, JH; Lee, SI; Kim, KE; Yong, TS; Seo, JT; Sohn, MH; Shin, DM			German cockroach extract activates protease-activated receptor 2 in human airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						German cockroach; Ca2+ signaling; protease-activated receptor; allergen; human airway epithelial cell	IGE ANTIBODY-RESPONSES; BLATTELLA-GERMANICA; MOLECULAR-CLONING; MITE ALLERGENS; CALCIUM; ASTHMA; EXPRESSION; EXPOSURE; SIGNAL	Background: The German cockroach has been reported to act as an allergen that might be associated with a protease reaction in asthma. However, the molecular identities of the antigens in German cockroach extract (GCE) with protease activity and the protease-activated receptors (PARs) that are activated by GCE in human airway epithelial cells have not been characterized. Objective: We investigated the direct effect of GCE on Ca2+ signaling in human airway epithelial cells and the type of PARs activated by GCE. Methods: The Ca2+-sensitive dye Fura2 was used to determine intracellular Ca2+ concentration ([Ca2+](i)) by means of spectrofluorometry. Results: GCE induced a baseline type of [Ca2+](i), oscillations in a dose-dependent manner. The oscillations persisted for long periods of time in the absence of Ca2+ entry across the plasma membrane, suggesting that the observed [Ca2+](i) increases were due to Ca2+ release from intracellular stores. Accordingly, after depleting endoplasmic reticulum Ca2+ with thapsigargin, an endoplasmic reticulum Ca2+ ATPase inhibitor, the GCE-mediated [Ca2+](i) signals were abolished. Whereas desensitization of PAR-1, PAR-3, and PAR-4 had no effect on GCE-mediated Ca2+ mobilization, no GCE-mediated [Ca2+](i) increase was observed after desensitization of PAR-2. Conclusions: These results indicate that GCE has a direct effect on human airway epithelial cells, in particular generating [Ca2+](i) oscillations through Ca2+ release from thapsigargin-sensitive Ca2+ stores through activation of PAR-2.	Yonsei Univ, Coll Dent, Dept Oral Biol, Oral Sci Res Ctr,Brain Korea 21 Project Med Sci, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea; Yonsei Univ, Coll Med, Inst Allergy, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Parasitol, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Shin, DM (corresponding author), Yonsei Univ, Coll Dent, Dept Oral Biol, Oral Sci Res Ctr,Brain Korea 21 Project Med Sci, 134 Sinchon Dong, Seoul, South Korea.			Yong, Tai-Soon/0000-0002-3445-0769; Sohn, Myung Hyun/0000-0002-2478-487X; Shin, Dong Min/0000-0001-6042-0435				Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, INT ARCH ALLERGY IMM, V107, P295, DOI 10.1159/000237006; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bhat RK, 2003, CLIN EXP ALLERGY, V33, P35, DOI 10.1046/j.1365-2222.2002.01481.x; Dewitt Sharon, 2003, Methods Mol Biol, V225, P47; JOHNSON GA, 1970, J PHARMACOL EXP THER, V171, P80; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; Misra UK, 2002, CELL SIGNAL, V14, P327, DOI 10.1016/S0898-6568(01)00268-6; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	21	74	75	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					315	319		10.1016/j.jaci.2003.11.026	http://dx.doi.org/10.1016/j.jaci.2003.11.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767448				2022-12-18	WOS:000188885700021
J	Bager, P; Melbye, M; Rostgaard, K; Benn, CS; Westergaard, T				Bager, P; Melbye, M; Rostgaard, K; Benn, CS; Westergaard, T			Mode of delivery and risk of allergic rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergic rhinitis; asthma; cesarean section; risk factors; epidemiology; complications; obstetrics	CESAREAN-SECTION; RESPIRATORY-DISTRESS; MICROFLORA; INFANTS; BIRTH; COMPLICATIONS; PREGNANCIES; FLORA	Background: It has been hypothesized that cesarean section might increase the risk of developing allergic disease by depriving the fetus and newborn of exposure to maternal microflora. Furthermore, it has been suggested that complicated modes of delivery might be associated with an increased risk of asthma. Objective: The purpose of this investigation was to study whether cesarean section and other complicated modes of delivery are associated with an increased risk of allergic rhinitis or asthma. Methods: Information on self-reported allergic rhinitis, asthma ever, current asthma, and occupation was obtained from 9722 singleton women born in Denmark during the period 1973-1977 who participated in a national cohort study during the period 1997-2001. For these women, information was available on mode of delivery (spontaneous delivery, cesarean section, vacuum extraction, or other complicated mode of delivery, such as rotation/traction or use of forceps), gestational age, birth weight, and length at birth from the Danish Medical Birth Register. Information on parity and maternal age was obtained from the Danish Civil Registration System. Results: The odds ratios (ORs) of allergic rhinitis were 1.16 (95% Cl, 0.90-1.49) for cesarean section and 1.06 (95% Cl, 0.85-1.32) for other complicated modes of delivery in comparison with spontaneous delivery. The corresponding ORs of asthma ever were 1.33 (95% Cl, 1.02-1.74) and 1.18 (95% CI, 0.94-1.49) for cesarean section and other complicated modes of delivery, respectively, and the ORs of current asthma were 1.22 (95% Cl, 0.87-1.73) and 1.26 (95% Cl, 0.94-1.68), respectively, in comparison with spontaneous delivery. Conclusions: Our findings do not support the hypothesis that cesarean section or other complicated modes of delivery are associated with the development of allergic rhinitis. However, there might be a positive association with development of asthma-in particular, for cesarean section-that was not explained by gestational age, birth weight, ponderal index, smallness for gestational age, parity, maternal age, or occupation.	Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Statens Serum Inst, DK-2300 Copenhagen S, Denmark	Aarhus University; Statens Serum Institut	Westergaard, T (corresponding author), Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Statens Serum Inst, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.		Bager, Peter/R-3310-2019	Bager, Peter/0000-0002-3577-8459; melbye, mads/0000-0001-8264-6785; Rostgaard, Klaus/0000-0001-6220-9414				Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x; BENNET R, 1987, INFECTION, V15, P332, DOI 10.1007/BF01647733; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; FAXELIUS G, 1983, ARCH DIS CHILD, V58, P262, DOI 10.1136/adc.58.4.262; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Gronlund MM, 2000, ARCH DIS CHILD-FETAL, V83, pF186, DOI 10.1136/fn.83.3.F186; Jessen P, 1982, Ugeskr Laeger, V144, P417; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Levine EM, 2001, OBSTET GYNECOL, V97, P439, DOI 10.1016/S0029-7844(00)01150-9; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; Madar J, 1999, ACTA PAEDIATR, V88, P1244, DOI 10.1080/080352599750030365; Martinez FD, 2001, J ALLERGY CLIN IMMUN, V107, pS449, DOI 10.1067/mai.2001.114993; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; Montgomery SM, 2000, ALLERGY, V55, P916, DOI 10.1034/j.1398-9995.2000.00480.x; MURPHY BEP, 1983, ENDOCR REV, V4, P150; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; NIELSEN TF, 1984, ACTA OBSTET GYN SCAN, V63, P109, DOI 10.3109/00016348409154644; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; *SAS I INC, 1996, SAS STAT CHANG ENH T; Schaubel D, 1996, J ASTHMA, V33, P255, DOI 10.3109/02770909609055366; SPERLING LS, 1994, ACTA OBSTET GYN SCAN, V73, P129, DOI 10.3109/00016349409013415; Stephenson P A, 1993, Paediatr Perinat Epidemiol, V7, P45, DOI 10.1111/j.1365-3016.1993.tb00600.x; van den Berg A, 2001, EUR J OBSTET GYN R B, V98, P9, DOI 10.1016/S0301-2115(01)00292-5; Wang L, 1999, J PERINAT MED, V27, P195; Westergaard T, 1997, BMJ-BRIT MED J, V314, P775, DOI 10.1136/bmj.314.7083.775; WHITE E, 1985, AM J EPIDEMIOL, V121, P651, DOI 10.1093/aje/121.5.651; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814	32	74	75	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					51	56		10.1067/mai.2003.34	http://dx.doi.org/10.1067/mai.2003.34			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532096				2022-12-18	WOS:000180465500008
J	Strunk, RC; Sternberg, AL; Bacharier, LB; Szefler, SJ				Strunk, RC; Sternberg, AL; Bacharier, LB; Szefler, SJ		Childhood Asthma Management Progra	Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nocturnal; asthma; Childhood Asthma Management Program; patient characteristics; peak flow rates		Background: Nocturnal symptoms of asthma are a cause of significant morbidity and are included as a central feature in the categorization of asthma severity. Objectives: Data from the Childhood Asthma Management Program were used to estimate the prevalence of nocturnal awakenings; in 1041 children with mild-to-moderate asthma and to investigate the relationships between awakenings and peak flows, severity of asthma, and allergen sensitivity and exposure. Methods: Daily diary care data were recorded during a 28-day interval in the Childhood Asthma Management Program screening process. The data on morning and evening peak ones, overall symptom codes, albuterol use for symptoms, and nocturnal awakenings for asthma symptoms were analyzed and compared with measures of personal characteristics, pulmonary function, and environmental characteristies of the patients. Results: Three hundred fifty-one (33.7%) children experienced 1 or more night awakenings caused by asthma during the 28-day screening period while not taking any maintenance medications. Greater risk of night awakening was associated with more severe asthma (greater responsiveness to bronchodilator, airway reactivity to methacholine, peak flow variability, and use of albuterol for symptoms, all P<.0001) and atopy (increased IgE and allergy skin test reactivity, both P=.0002). Those with a positive skin test response to dog and a high level of dog allergen in the home had a greater risk of night awakening caused by asthma (P=.01), as did those with a positive skin test response to cat and a high level of cat allergen in the home (P=.04). Mean daily symptom code and use of albuterol for asthma symptoms increased in the 3 days immediately before a single awakening compared with in the 4 to 6 days before the awakening (P=.02 and P=.01, respectively); however, both morning and evening peak flows as a percentage of personal best were similar in both intervals. Mean daily symptom code and daily use of albuterol were greater in the 3 days after an awakening than in the 3 days before (P<.0001 and P=.0002, respectively). Mean evening peak flow percentage of personal best the day after an episode of awakening was lower when a second consecutive awakening occurred than when there was only a single awakening (P=.01). Conclusions: Nocturnal awakening occurred in one third of the children with mild-to-mode rate asthma during a month of relative stability and appears to be an indicator of asthma that is becoming increasingly severe.	Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat,Div Allergy & Pulm Med, St Louis, MO USA; Johns Hopkins Univ, Ctr Clin Trials, Baltimore, MD USA; Natl Jewish Med & Res Ctr, Denver, CO USA	St. Louis Children's Hospital; Washington University (WUSTL); Johns Hopkins University; National Jewish Health	Strunk, RC (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, 660 S Euclid Ave,WUSM Box 8208, St Louis, MO 63110 USA.			Bereket Yucel, Selda/0000-0003-0066-7182; Nimmagadda, Sai/0000-0003-0653-1323; Fisher, Edwin/0000-0003-0234-7465; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063				Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Childhood Asthma Management Program Res Grp, 1999, J ASTHMA, V36, P217; CHIPPS BE, 1980, PEDIATRICS, V65, P1157; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; Diggle P., 2002, ANAL LONGITUDINAL DA; *EXP PAN REP 2, 1997, NIH PUBL NAT HEART L; Fix A, 1997, J ASTHMA, V34, P329, DOI 10.3109/02770909709067223; MARTIN R, 1990, IMMUNOL ALLERGY PRAC, V12, P165; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MARTIN RJ, 1993, NOCTURNAL ASTHMA MEC, P71; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Szefler SJ, 1998, ANN ALLERG ASTHMA IM, V81, P571; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	16	74	74	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					395	403		10.1067/mai.2002.127433	http://dx.doi.org/10.1067/mai.2002.127433			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209085				2022-12-18	WOS:000177936900008
J	Braccioni, F; Dorman, SC; O'Byrne, PM; Inman, MD; Denburg, JA; Parameswaran, K; Baatjes, AJ; Foley, R; Gauvreau, GM				Braccioni, F; Dorman, SC; O'Byrne, PM; Inman, MD; Denburg, JA; Parameswaran, K; Baatjes, AJ; Foley, R; Gauvreau, GM			The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil progenitors; peripheral blood; bone marrow; cysteinyl leukotrienes; montelukast; atopy	COLONY-STIMULATING FACTOR; ARACHIDONIC-ACID; HL-60 CELLS; ALLERGEN CHALLENGE; HUMAN MYELOPOIESIS; ASTHMATIC SUBJECTS; MONONUCLEAR-CELLS; LIPID MEDIATORS; STROMAL CELLS; LAVAGE FLUID	Background: The accumulation of eosinophils into the peripheral blood and airways of asthmatic subjects is, in part, dependent on cysteinyl leukotrienes (cysLTs). However, the effect of cysLTs on peripheral blood and bone marrow eosinophil progenitor cells in allergic subjects is not known. Objective: The purpose of this study was to evaluate the effects of leukotriene (LT) D-4 and LTE4 and the cysLT(1) receptor antagonist montelukast on peripheral blood and bone marrow cosinophil-basophil progenitor growth and development in atopic subjects. Methods: Semisolid methylcellulose cultures for peripheral blood and bone marrow eosinophil-basophil colonies were counted after incubation with or without addition of LTD4, LTE4, and montelukast in the presence of suboptimal concentrations of GM-CSF, IL-3, and IL-5. Results: Peripheral blood eosinophil-basophil colony-forming unit cultures grown in the presence of GM-CSF and bone marrow eosinophil-basophil colony-forming units grown in the presence of IL-5 were significantly increased by the addition of LTD4 (0.1 mumol/L). This increase was suppressed by montelukast (1 mumol/L). Conclusion: This study has demonstrated that the cysLT LTD4 can stimulate proliferation of eosinophil hematopoietic progenitor cells in the presence of eosinophilopoietic cytokines. The suppressive effect by montelukast demonstrates that this is a cysLT(1) receptor-mediated effect.	St Josephs Healthcare, Firestone Inst Resp Hlth, Asthma Res Grp, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; McMaster University	O'Byrne, PM (corresponding author), St Josephs Hosp, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			O'Byrne, Paul/0000-0003-0979-281X				Anderson KM, 1995, LEUKEMIA RES, V19, P789, DOI 10.1016/0145-2126(95)00043-7; Baswick EN, 2000, AM J RESP CRIT CARE, V161, pA832; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Cheng HY, 1996, PHARM RES-DORDR, V13, P445, DOI 10.1023/A:1016056912698; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; DENBURG JA, 1985, BLOOD, V66, P312; Denizot Y, 1999, MEDIAT INFLAMM, V8, P31, DOI 10.1080/09629359990694; Denizot Y, 1998, CYTOKINE, V10, P781, DOI 10.1006/cyto.1998.0360; Denizot Y, 1999, CYTOKINE, V11, P606, DOI 10.1006/cyto.1998.0467; Desplat V, 1999, MEDIAT INFLAMM, V8, P115, DOI 10.1080/09629359990612; Desplat V, 2000, BLOOD CELL MOL DIS, V26, P427, DOI 10.1006/bcmd.2000.0321; ESTROV Z, 1988, BRIT J HAEMATOL, V69, P321, DOI 10.1111/j.1365-2141.1988.tb02369.x; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Gauvreau GM, 1998, AM J RESP CELL MOL, V19, P55, DOI 10.1165/ajrcmb.19.1.2871; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gauvreau GM, 2000, AM J RESP CRIT CARE, V162, P2139, DOI 10.1164/ajrccm.162.6.2001120; GEORGITIS JW, 1995, INT ARCH ALLERGY IMM, V106, P416, DOI 10.1159/000236875; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Kay AB, 1999, J ALLERGY CLIN IMMUN, V103, pS203; KHAN MA, 1993, LEUKEMIA RES, V17, P759, DOI 10.1016/0145-2126(93)90109-X; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Laitinen LA, 1999, AM J RESP CRIT CARE, V159, pA642; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LINDGREN JA, 1993, J LIPID MEDIATOR, V6, P313; Lynch KR, 1999, NATURE, V399, P789; MALSTROM K, 1999, ANN INTERN MED, V130, P487; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; Miller AM, 1997, J CELL PHYSIOL, V170, P309, DOI 10.1002/(SICI)1097-4652(199703)170:3<309::AID-JCP12>3.3.CO;2-Y; MILLER AM, 1986, EXP HEMATOL, V14, P760; Miyata Y, 2001, BIOCHEM BIOPH RES CO, V283, P655, DOI 10.1006/bbrc.2001.4840; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; PASQUALE D, 1993, EXP HEMATOL, V21, P1361; Patry C, 1996, PROSTAG LEUKOTR ESS, V54, P361, DOI 10.1016/S0952-3278(96)90050-2; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SCOGGAN KA, 1995, BLOOD, V86, P3507, DOI 10.1182/blood.V86.9.3507.bloodjournal8693507; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; STENKE L, 1993, BLOOD, V81, P352; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125	45	74	82	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					96	101		10.1067/mai.2002.125000	http://dx.doi.org/10.1067/mai.2002.125000			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110827	Bronze			2022-12-18	WOS:000176870300019
J	Devouassoux, G; Saxon, A; Metcalfe, DD; Prussin, C; Colomb, MG; Brambilla, C; Diaz-Sanchez, D				Devouassoux, G; Saxon, A; Metcalfe, DD; Prussin, C; Colomb, MG; Brambilla, C; Diaz-Sanchez, D			Chemical constituents of diesel exhaust particles induce IL-4 production and histamine release by human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; IL-4; histamine; diesel exhaust particles; allergy; pollution	BRONCHIAL EPITHELIAL-CELLS; NF-KAPPA-B; IN-VIVO; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; CYTOKINE EXPRESSION; NASAL CHALLENGE; EXPOSURE; IGE; ACTIVATION	Background: An epidemiologic relationship between airway allergic diseases and exposure to atmospheric pollutants has been demonstrated and suggested to be one factor in the increasing prevalence of asthma. Diesel exhaust particles (DEPs) have been shown to participate in the development of allergic airway inflammation, in which the targets include macrophages, B and T cells, epithelial cells, and mast cells. In addition to the adjuvant effect of DEPs on total and allergen-specific IgE production, DEPs also act to induce chemokines and cytokines and may play a key role in primary sensitization. Objective: DEPs have been shown to increase local IL-4-containing Kit(+) cells soon after in vivo nasal challenge. The aim of this study was to examine the effects of DEPs on human basophils, a key source of IL-4. Methods: Peripheral blood leukocytes from allergic and control subjects were cultured in the presence of organic extracts of DEP (DEPex) with or without allergen. The cultures were analyzed for IL-4-containing cells by using multiparameter flow cytometry, IL-4 secretion with ELISA, and histamine release. Results: Basophils, when exposed in vitro to DEPex, expressed IL-4 and released histamine significantly (P < .01) more than with antigen activation. DEPex did not synergize with allergen in cytokine production and histamine release. DEPex-induced basophil IL-4 expression peaked at 2 hours and persisted through 20 hours, in contrast to allergen-induced IL-4, which was transient. The effect of DEPex on basophil cytokine expression and histamine release was dose dependent and occurred with cells from both allergic and nonallergic subjects. DEPex induced IL-4 expression and histamine release in highly enriched basophil populations, suggesting it acts directly on basophils. Other peripheral blood leukocytes, including T cells, did not contribute to this cytokine expression. Preincubation with N-acetylcysteine completely abrogated DEPex-driven basophil IL-4 expression. Conclusions: Basophils are a direct target for DEPex, inducing IL-4 expression and histamine release in an IgE-allergen independent fashion. N-acetyleysteine inhibition of DEPex-driven IL-4 expression provides evidence that generation of reactive oxygen species is required for the effects observed. The capability of DEPex to activate basophils in both allergic and nonallergic subjects suggests a potential role of this pollutant in the increasing prevalence of allergic diseases.	CHU Grenoble, Hop A Michallon, Dept Immunol, F-38043 Grenoble 09, France; INSERM, EMI 9924, Grenoble, France; Dept Resp Med, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med, Div Clin Immunol, Los Angeles, CA 90024 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Grenoble 1, Inst A Bonniot, Grenoble, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Devouassoux, G (corresponding author), CHU Grenoble, Hop A Michallon, DMAS, Dept Resp Med, BP 217, F-38043 Grenoble 09, France.			Prussin, Calman/0000-0002-3917-3326	NIAID NIH HHS [AI-50495] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000607, Z01AI000709, P01AI050495] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe S, 2000, AM J RESP CELL MOL, V22, P296, DOI 10.1165/ajrcmb.22.3.3711; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304; BICE DE, 1985, FUND APPL TOXICOL, V5, P1075, DOI 10.1016/0272-0590(85)90143-5; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280, DOI 10.1164/ajrccm.161.1.9904110; Hiura TS, 1999, J IMMUNOL, V163, P5582; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352, DOI 10.1164/ajrccm.162.2.9809035; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138, DOI 10.1164/ajrccm.157.4.9708066; MURUNAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Prell RA, 1997, J IMMUNOL, V158, P2695; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550, DOI 10.1164/ajrccm.161.2.9905052; Suzuki Takahito, 1993, Japanese Journal of Allergology, V42, P963; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Takizawa H, 1999, J IMMUNOL, V162, P4705; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628	36	74	78	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					847	853		10.1067/mai.2002.122843	http://dx.doi.org/10.1067/mai.2002.122843			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994710	Bronze			2022-12-18	WOS:000175687800016
J	Michel, O; Dentener, M; Corazza, F; Buurman, W; Rylander, R				Michel, O; Dentener, M; Corazza, F; Buurman, W; Rylander, R			Healthy subjects express differences in clinical responses to inhaled lipopolysaccharide that are related with inflammation and with atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; fever; airway responsiveness; inflammation; atopy	PERMEABILITY-INCREASING PROTEIN; ENDOTOXIN EXPOSURE; BINDING PROTEIN; INDUCED SPUTUM; BRONCHIAL RESPONSIVENESS; DENDRITIC CELLS; SOLUBLE CD14; DUST; POLYMORPHISM; DETERMINANT	Background: Endotoxin and its purified derivative LPS are important contaminants of both domestic and occupational environments that have been related to airway diseases. A body of data suggests that there is considerable interindividual variability in LPS sensitivity. Objective: The aim of the study was to relate the individual clinical responses to inhaled LPS with the inflammatory process and the atopic status. Methods: Fifteen healthy subjects were challenged each week by inhalation,vith saline solution or LPS (0.5, 5, or 50 mug). The systemic response was defined by the increase in body temperature, blood neutrophilia, acute-phase proteins (C-reactive protein and LPS-binding protein [LBP]), and E-selectin. The LPS-induced airway response was defined as the increase in airway responsiveness and related to the cell count and concentration of TNF-alpha, myeloperoxidase, and eosinophil cationic protein in induced sputum. The atopic status was defined as an increase in IgE or a positive skin prick test result. Results: Subjects (n = 7) with a significant increase in body temperature had a larger increase in the systemic inflammatory response (blood neutrophilia; P < .01) and in blood concentrations of C-reactive protein (P < .02) and LBP (P < .01). Subjects with a significant increase in airway responsiveness (n = 8) had an increase in the sputum concentration of eosinophil cationic protein (P < .01), The amplitude of the systemic response (increase in body temperature [P < .001], blood neutrophilia [P < .02], and rise in LBP [P < .05] and decrease in FEV, [P < .01]) were inversely associated with the atopic status, suggesting a link between atopy and LPS responsiveness. Conclusions: The clinical response to LPS occurs systemically or locally and is associated with inflammation. The atopic status was inversely related to the systemic inflammation.	Hop Univ St Pierre, Clin Allergol, B-1000 Brussels, Belgium; Hop Univ St Pierre, Clin Resp Dis, B-1000 Brussels, Belgium; Free Univ Brussels, CHU Brugmann, Clin Haematol, Brussels, Belgium; Maastricht Univ, Dept Pulmonol, Maastricht, Netherlands; Maastricht Univ, Dept Surg, Maastricht, Netherlands; Univ Gothenburg, Dept Environm Med, Gothenburg, Sweden	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Maastricht University; Maastricht University; University of Gothenburg	Michel, O (corresponding author), Free Univ Brussels, CHU St Pierre, Clin Allergol & Resp Dis, Rue Haute 290, B-1000 Brussels, Belgium.		Corazza, Francis V/O-1262-2013; Michel, Prof. Dr. Olaf/B-3673-2012; michel, olivier/G-5016-2010	Corazza, Francis V/0000-0001-9487-2712; Michel, Prof. Dr. Olaf/0000-0003-4289-5693; michel, olivier/0000-0002-1528-1277				Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bloemen PGM, 1997, CLIN EXP ALLERGY, V27, P128; BOUMA MG, 1997, IMMUNOCHEMISTRY, V2, P181; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; DENTENER MA, 1995, J INFECT DIS, V171, P739, DOI 10.1093/infdis/171.3.739; DENTENER MA, 1993, J IMMUNOL, V151, P4258; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365, DOI 10.1164/ajrccm.149.2.8306031; FROON AHM, 1995, J INFECT DIS, V171, P1250, DOI 10.1093/infdis/171.5.1250; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Henderson B, 1998, BACTERIA-CYTOKINE INTERACTIONS IN HEALTH AND DISEASE, P1; Heuertz RM, 1996, J IMMUNOL, V156, P3412; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; JABARA HH, 1994, J IMMUNOL, V153, P972; Jones HA, 1997, EUR RESPIR J, V10, P795; Khair OA, 1996, EUR RESPIR J, V9, P1913, DOI 10.1183/09031936.96.09091913; LEEUWENBERG JFM, 1994, J IMMUNOL, V152, P4036; LEEUWENBERG JFM, 1994, J IMMUNOL, V152, P5070; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Lefort J, 1998, J IMMUNOL, V161, P474; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; NAKANO M, 1992, BACTERIAL ENDOTOXIC, V1, P311; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAMADORI G, 1990, PATHOBIOLOGY, V58, P89, DOI 10.1159/000163569; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Rylander R., 1997, INT J OCCUP ENV HEAL, V3, pS1, DOI 10.1179/oeh.1997.3.1.1.; Sudo N, 1997, J IMMUNOL, V159, P1739; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; Thorn J, 1998, THORAX, V53, P1047, DOI 10.1136/thx.53.12.1047; VANDERZWAN JC, 1982, CLIN ALLERGY, V12, P547; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15, DOI 10.1164/ajrccm.157.1.9703087; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONESSEN S, 1990, J TOXICOL-CLIN TOXIC, V28, P389, DOI 10.3109/15563659009038584; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; Woolcock AJ, 2000, AM J RESP CRIT CARE, V161, pS215, DOI 10.1164/ajrccm.161.supplement_2.a1q4-14	48	74	75	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					797	804		10.1067/mai.2001.114249	http://dx.doi.org/10.1067/mai.2001.114249			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344345				2022-12-18	WOS:000168812300006
J	Xu, B; Pekkanen, J; Hartikainen, AL; Jarvelin, MR				Xu, B; Pekkanen, J; Hartikainen, AL; Jarvelin, MR			Caesarean section and risk of asthma and allergy in adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy caesarean section; birth cohort; Finland		This study evaluated the relationship of caesarean section to the risk of asthma in adulthood, The data were based on a prospective birth cohort born in northern Finland in 1966, In 1997, when the members of the cohort were 31 years old, information on current doctor-diagnosed asthma and other allergic disorders was obtained from 1953 subjects by a selfadministered questionnaire and skin prick test. Caesarean section had a strong effect on current doctor-diagnosed asthma in adulthood with an adjusted odds ratio (OR) of 3.23 (95% CI 1.53, 6.80), However, no substantial effects were observed for atopy, hay fever, and atopic eczema.	Univ Oulu, Dept Publ Hlth & Gen Practice, Oulu, Finland; Univ Oulu, Univ Hosp, Dept Obstet & Gynaecol, Oulu, Finland; Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; Imperial College London	Xu, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England.			Jarvelin, Marjo-Riitta/0000-0002-2149-0630				Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; HARTIKAINEN AL, 1973, ACTA U OUL D, V4, P5; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814; Xu BZ, 2000, THORAX, V55, P691, DOI 10.1136/thorax.55.8.691	5	74	76	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					732	733						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295666				2022-12-18	WOS:000168190100029
J	Nakao, F; Ihara, K; Kusuhara, K; Sasaki, Y; Kinukawa, N; Takabayashi, A; Nishima, S; Hara, T				Nakao, F; Ihara, K; Kusuhara, K; Sasaki, Y; Kinukawa, N; Takabayashi, A; Nishima, S; Hara, T			Association of IFN-gamma and IFN regulatory factor 1 polymorphisms with childhood atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-gamma; IFN regulatory factor 1; IFN-gamma receptor; atopic asthma; polymorphism	HUMAN INTERFERON-GAMMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; SERUM IGE LEVELS; FACTOR-I; GENE; PROMOTER; CHILDREN; RECEPTOR; INHIBITION; ACTIVATION	Background: IFN-gamma and related molecules play important roles in the differentiation and function of T(H)2 cells. Objective: We sought to determine whether IFNG and related genes contribute to any susceptibility to atopic asthma, a representative T(H)2-dominant disorder. Methods: We investigated the association of IFNG (CA repeat polymorphism within the first intron), IRF1 (GT repeat polymorphism within the intron 7), IFNGR1 (Val 14 Met), and IFNGR2 (Gln 64 Arg) gene polymorphisms with atopic asthma in the Japanese child population. Results: A significant association (P = .0018) was observed between IFNG gene polymorphism and atopic asthma. The tendency was more prominent in patients with age of onset of 3 years or younger (P = .0004) or patients with a family history of allergic diseases (P = .0038). Furthermore, there was a significant association between IRF1 gene whole-allele distribution and atopic asthma (P = .014). The tendency was more prominent in patients with onset at 3 years of age or less (P = .0058). On the other hand, IFNGR1 and IFNGR2 gene polymorphisms showed no association with atopic asthma. Conclusion: These results suggested that among IFNG and related genes, IFNG and IRF1 genes confer genetic susceptibility to atopic asthma in Japanese children.	Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med Informat, Fukuoka 8128582, Japan; Natl Minami Fukuoka Chest Hosp, Div Pediat, Fukuoka, Japan	Kyushu University; Kyushu University	Nakao, F (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.			Ihara, Kenji/0000-0002-8831-1991				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Awad M, 1999, HUM IMMUNOL, V60, P343, DOI 10.1016/S0198-8859(98)00133-5; AWATA T, 1994, DIABETOLOGIA, V37, P1159, DOI 10.1007/BF00418381; Bream JH, 2000, IMMUNOGENETICS, V51, P50, DOI 10.1007/s002510050008; COFFMAN RL, 1986, J IMMUNOL, V136, P949; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; DEL PG, 1988, J IMMUNOL, V140, P4193; Gao PS, 1999, BIOCHEM BIOPH RES CO, V263, P425, DOI 10.1006/bbrc.1999.1368; Goenka S, 1999, J IMMUNOL, V163, P4663; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hayden C, 1997, CLIN EXP ALLERGY, V27, P1412, DOI 10.1111/j.1365-2222.1997.tb02985.x; IIKURA Y, 1992, ANN ALLERGY, V68, P233; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; Johannesen J, 1997, EUR J IMMUNOGENET, V24, P377, DOI 10.1046/j.1365-2370.1997.d01-113.x; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; LECONIAT M, 1989, HUM GENET, V84, P92, DOI 10.1007/BF00210682; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nakashima H, 1999, FEBS LETT, V453, P187, DOI 10.1016/S0014-5793(99)00701-2; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Siegmund T, 1998, THYROID, V8, P1013, DOI 10.1089/thy.1998.8.1013; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; Takabayashi A, 2000, EXP CLIN IMMUNOGENET, V17, P63, DOI 10.1159/000019125; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tanaka Y, 1999, IMMUNOGENETICS, V49, P266, DOI 10.1007/s002510050492; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; Young HA, 1996, J INTERF CYTOK RES, V16, P563, DOI 10.1089/jir.1996.16.563; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	38	74	82	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					499	504		10.1067/mai.2001.113051	http://dx.doi.org/10.1067/mai.2001.113051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240951	Bronze			2022-12-18	WOS:000167793300012
J	Forrest, S; Dunn, K; Elliott, K; Fitzpatrick, E; Fullerton, J; McCarthy, M; Brown, J; Hill, D; Williamson, R				Forrest, S; Dunn, K; Elliott, K; Fitzpatrick, E; Fullerton, J; McCarthy, M; Brown, J; Hill, D; Williamson, R			Identifying genes predisposing to atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; candidate loci; mapping; 5q31; interleukin cluster; D5S404; atopy; linkage analysis; atopy; association studies	LINKAGE ANALYSIS; RECEPTOR GENE; DERMATITIS; ASSOCIATION; 11Q13; CHROMOSOME-11Q; FAMILIES; SUBUNIT; ASTHMA; DNA	Background: Genetic and environmental factors are known to play a role in the development of atopic diseases such as asthma, eczema, and rhinitis, However, the atopy gene (or genes) has yet to be defined. Studies of familial asthma have identified several regions that may contain genes predisposing to atopy but the data for candidate regions do not show agreement, which may be due to heterogeneity, ascertainment bias, or stochastic factors. Factors such as an early age of onset, a positive family history, and a clearly defined phenotype favor a genetic origin and improve the chance of identifying genes that predispose to atopy. Objective: We sought to define genes that predispose to the development of atopic eczema. Methods: We have studied nuclear families with multiple cases of early-onset atopic eczema for involvement of the candidate regions on chromosomes 5q31 (IL gene cluster), 11q13 (high-affinity FC epsilon receptor), 14q11.2 (mast cell chymase), and 16p12 (IL-4 receptor alpha-chain, IL4RA gene). Results: Using a recessive model, we find a maximum parametric log of the odds of linkage score of 2.25 and nonparametric score of 2.54 (P = .006) for a region on chromosome 5q31, which we postulate contains a gene predisposing to atopic eczema, but lack of support for linkage to 11q13. Transmission disequilibrium tests do not support an association with candidate polymorphisms in the mast cell chymase and IL4RA genes. Conclusion: We have identified a clinically homogeneous cohort of patients with atopic eczema to identify genetic factors predisposing to the development of atopy. We postulate that there are certain loci that predispose to atopy in general and other loci that determine which of the atopic phenotypes is expressed.	Murdoch Inst Res Birth Defects, Parkville, Vic, Australia; St Marys Hosp, Imperial Coll Sch Med, Div Med, London, England; Royal Childrens Hosp, Allergy Ctr, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Imperial College London; Royal Children's Hospital Melbourne	Forrest, S (corresponding author), Royal Childrens Hosp, Murdoch Inst, Flemington Rd, Parkville, Vic 3052, Australia.		Fullerton, Janice/F-8485-2013; McCarthy, Mark/M-3763-2015	Fullerton, Janice/0000-0003-4014-4490; McCarthy, Mark/0000-0002-4393-0510				COLEMAN R, 1993, LANCET, V341, P1121, DOI 10.1016/0140-6736(93)93130-S; COOKSON WOCM, 1992, LANCET, V340, P1110; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Folster-Holst R, 1998, HUM GENET, V102, P236, DOI 10.1007/s004390050685; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kruse S, 1999, IMMUNOLOGY, V96, P365; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; LENCH N, 1988, LANCET, V1, P1356; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; Mao XQ, 1996, LANCET, V348, P581, DOI 10.1016/S0140-6736(95)10244-2; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McGinnis RE, 1998, ANN HUM GENET, V62, P159, DOI 10.1046/j.1469-1809.1998.6220159.x; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Roitt I., 1998, IMMUNOLOGY; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; WATSON M, 1995, ANN HUM GENET, V59, P403, DOI 10.1111/j.1469-1809.1995.tb00759.x	31	74	77	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1066	1070		10.1016/S0091-6749(99)70090-4	http://dx.doi.org/10.1016/S0091-6749(99)70090-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550754				2022-12-18	WOS:000083778400032
J	Karamloo, F; Schmitz, N; Scheurer, S; Foetisch, K; Hoffmann, A; Haustein, D; Vieths, S				Karamloo, F; Schmitz, N; Scheurer, S; Foetisch, K; Hoffmann, A; Haustein, D; Vieths, S			Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergens; Bet v 5; complementary DNA; isoflavone reductase; cross-reaction	PISUM-SATIVUM L; ESCHERICHIA-COLI; IGE-BINDING; DISEASE RESISTANCE; HISTAMINE ANALYSIS; CROSS-REACTIVITY; APPLE ALLERGEN; PLANT FOODS; EXPRESSION; PROFILIN	Background: Birch pollen is a major cause of pollinosis and is responsible for cross-reactive oral allergies to fruits, nuts, and vegetables. The major allergen, Bet v 1, has been extensively characterized, and 3 minor allergens, Bet v 2, Bet v 3, and Bet v 4, have been cloned and sequenced. Recently, another birch pollen protein with an apparent mass of 35 kd was described as a new IgE-binding protein in birch pollen with cross-reacting homologues in plant foods. Objective: The aim of this study was to determine the primary structure of the 35-kd birch pollen allergen and to investigate its immunologic properties. Methods: On the basis of a known complementary DNA fragment, a PCR strategy was applied to obtain the full-length nucleotide sequence of the coding region. The protein was expressed as His-Tag fusion protein in Escherichia coli and purified by Ni-chelate affinity chromatography, Nonfusion protein was obtained by cyanogen bromide treatment of the fusion protein. IgE-binding characteristics and potential allergenicity were investigated by immunoblot, immunoblot inhibition analysis, rat basophil leukemia-cell mediator release assay, and basophil histamine release and compared with those of natural (n) Bet v 5, recombinant (r)Bet v 1, and rBet v 2. Results: Recombinant Bet v 5 has a mass of 33 kd, an isoelectric point of 9.0, and sequence identity of 60% to 80% to isoflavone reductase homologue proteins from various plants. On immunoblots the recombinant Bet v 5 bound IgE from 9 (32%) of 28 sera from patients allergic to birch pollen with a CAP class of at least 3; Bet v 1 was detected by 89% of these patients. IgE immunoblot and inhibition experiments showed that nBet v 5 and rBet v 5 shared identical epitopes. A rabbit antiserum raised against pea isoflavone reductase and patients' IgE reacted with Bet v 5 and proteins of similar size in several vegetable foods, including exotic fruits. A similar reaction pattern was obtained with 2 Bet v 5-specific mAbs. Furthermore, Bet v 5 triggered a dose-dependent mediator release from rat basophil leukemia 2H3 cells passively sensitized with murine anti-birch pollen IgE and from basophils of a Bet v 5-reactive subject with birch pollen allergy. In contrast, no mediator release could be induced from basophils of a subject who was monosensitized to Bet v 1. Conclusions: This 33-kd protein, designated as Bet v 5, is a new minor allergen in birch pollen and may be responsible for pollen-related oral allergy to specific foods in a minority of patients with birch pollen allergy Amino acid sequence comparison and immunoreactivity to anti-isoflavone reductase serum indicate that Bet v 5 is related to isoflavone reductase, a protein family that is involved in plant defense reactions.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany	Paul Ehrlich Institute	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.		Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boehm M, 1997, BIOL CHEM, V378, P687, DOI 10.1515/bchm.1997.378.7.687; Breitenbach M, 1996, ADV EXP MED BIOL, V409, P117; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CABELLERO T, 1998, INVEST ALLERGOL CLIN, V8, P6; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; Faber C, 1996, J BIOL CHEM, V271, P19243, DOI 10.1074/jbc.271.32.19243; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; HOFFMANN A, 1997, J ALLERGY CLIN IMMUN, V99, P1; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1993, INT ARCH ALLERGY IMM, V102, P249, DOI 10.1159/000236533; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; Spangfort MD, 1997, INT ARCH ALLERGY IMM, V113, P243, DOI 10.1159/000237559; Spangfort MD, 1996, ADV EXP MED BIOL, V409, P251; SUN YJ, 1991, ARCH BIOCHEM BIOPHYS, V284, P167, DOI 10.1016/0003-9861(91)90279-R; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S, 1998, SCAND J IMMUNOL, V47, P263; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; VIETHS S, 1997, HDB PLANT FUNGAL TOX, P157; Weiss C, 1996, INT ARCH ALLERGY IMM, V110, P282, DOI 10.1159/000237300; Wellhausen A, 1996, Z ERNAHRUNGSWISS, V35, P348, DOI 10.1007/BF01610553; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	41	74	78	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					991	999		10.1016/S0091-6749(99)70080-1	http://dx.doi.org/10.1016/S0091-6749(99)70080-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550744				2022-12-18	WOS:000083778400022
J	Hirschwehr, R; Heppner, C; Spitzauer, S; Sperr, WR; Valent, P; Berger, U; Horak, F; Jager, S; Kraft, D; Valenta, R				Hirschwehr, R; Heppner, C; Spitzauer, S; Sperr, WR; Valent, P; Berger, U; Horak, F; Jager, S; Kraft, D; Valenta, R			Identification of common allergenic structures in mugwort and ragweed pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						weed allergy; mugwort (Artemisia vulgaris); ragweed (Ambrosia elatior); IgE cross-reactivity; profilin; histamine release; nasal provocation	CROSS-REACTIVE ALLERGEN; ARTEMISIA-VULGARIS L; PLANT-DERIVED FOOD; AMB-A-II; MAJOR ALLERGEN; GLYCOPROTEIN ALLERGEN; HISTAMINE-RELEASE; ESCHERICHIA-COLI; RECOMBINANT AMB; PROFILIN	Background: Despite the rare occurrence of ragweed in Middle Europe, a surprisingly high number of patients allergic to mugwort, a frequently encountered weed, display IgE reactivity against ragweed pollen allergens. Objective: The aim of this study was to investigate whether the high prevalence of IgE reactivity against ragweed in patients allergic to mugwort is caused by the presence of common allergenic determinants. We also sought to characterize any cross-reactive allergens. Methods: Common allergenic structures in mugwort and ragweed pollen were characterized by qualitative IgE immunoblot inhibition experiments performed with natural allergen extracts and recombinant allergens. The degree of cross-reactivity was estimated by quantitative CAP-FEIA competitions. The clinical significance of cross-reactive IgE antibodies was studied with histamine release experiments and nasal provocation tests. Results: Mugwort and ragweed RAST values were significantly correlated in a population of 82 Austrian patients allergic to mugwort. IgE antibodies cross-reacted with allergens of comparable molecular weight that were present in both extracts: By using recombinant birch profilin and specific antisera for IgE inhibition experiments, profilin was identified as one of the cross-reactive components in mugwort and ragweed pollen. Preincubation of sera from patients allergic to mugwort with mugwort extract inhibited IgE binding to ragweed pollen extract greater than 80%. Mugwort and ragweed pollen extract induced comparable histamine release and reduction of nasal air how in a patient with IgE reactivity against the major mugwort allergen Art v 1. Conclusion: In addition to profilin, mugwort and ragweed pollen contain a number of cross-reactive allergens, among them the major mugwort allergen Art v 1. Cross-reactive IgE antibodies can lead to clinically significant allergic reactions.	Univ Vienna, AKH, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, AKH, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Otorhinolaryngol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; University of Vienna	Valenta, R (corresponding author), Univ Vienna, AKH, Inst Gen & Expt Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Sperr, Mast/V-4767-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019	Sperr, Mast/0000-0002-7778-5219; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Sperr, Wolfgang/0000-0003-3288-8027				ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; BOND JF, 1991, J IMMUNOL, V146, P3380; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Charpin J., 1974, ATLAS EUROPEAN ALLER; DECHAMP C, 1995, ALLERG IMMUNOL PARIS, V320, P323; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ENDRE L, 1996, INT REV ALLERGOL CLI, V2, P74; FISCHER S, 1996, J ALLERGY CLIN IMMUN, V233, P484; FRENZ DA, 1995, ANN ALLERG ASTHMA IM, V75, P417; GHOSH B, 1991, GENE, V101, P231, DOI 10.1016/0378-1119(91)90416-9; GHOSH B, 1993, J IMMUNOL, V150, P5391; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296, DOI 10.1159/000235512; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HENRYSSON S, 1957, ELEMENTARSTATISTIK; HORAK F, 1993, ALLERGY, V48, P226, DOI 10.1111/j.1398-9995.1993.tb00720.x; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1980, ALLERGY, V35, P187, DOI 10.1111/j.1398-9995.1980.tb01738.x; KLAPPER DG, 1980, BIOCHEMISTRY-US, V19, P5729, DOI 10.1021/bi00566a010; KUO MC, 1993, MOL IMMUNOL, V30, P1077, DOI 10.1016/0161-5890(93)90154-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; Mezei Gyorgyi, 1995, Orvosi Hetilap, V136, P1721; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; NILSEN BM, 1990, MOL IMMUNOL, V27, P1047, DOI 10.1016/0161-5890(90)90128-M; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treudler R, 1995, ALLERGO J, V5, P267; TURCICH MP, 1993, PLANT MOL BIOL, V23, P1061, DOI 10.1007/BF00021820; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; ZHU XJ, 1995, J IMMUNOL, V155, P5064	53	74	78	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				196	206		10.1016/S0091-6749(98)70384-7	http://dx.doi.org/10.1016/S0091-6749(98)70384-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500752	Bronze			2022-12-18	WOS:000072244800008
J	vanHalteren, AGS; vanderCammen, MJF; Biewenga, J; Savelkoul, HFJ; Kraal, G				vanHalteren, AGS; vanderCammen, MJF; Biewenga, J; Savelkoul, HFJ; Kraal, G			IgE and mast cell responses on intestinal allergen exposure: A murine model to study the onset of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; histamine; food allergy	STIMULATORY FACTOR-I; MONOCLONAL-ANTIBODIES; B-CELLS; MICE; INTERLEUKIN-4; EXPRESSION; SECONDARY; BASOPHILS; BINDING; VIVO	Objective: Allergic reactions to food are characterized by enhanced allergen-specific IgE serum levels and the activation of intestinal mast cells. Here we describe a murine model for the onset of food allergy and the role of cytokines in the regulation of food-induced IgE responses. Methods: Mice were primed systemically with low doses of alum-precipitated ovalbumin. Subsequent intragastric challenge led to enhanced sensitization. Results: Compared with baseline ovalbumin-specific IgE levels before challenge (0.23 +/- 0.06 optical density [OD] units), ovalbumin-challenged mice showed significantly elevated IgE levels (0.86 +/- 0.23 OD units) after intragastric challenge, which were not observed in control animals (0.29 +/- 0.06 OD units). IgE levels mirrored intestinal mast cell activation measured by decreased histamine levels in duodenal specimens, in ovalbumin-challenged mice (92.6 +/- 7.9 ng/0.1 gm tissue weight) but not in saline-challenged mice (135.4 +/- 18.3 ng/0.1 gm tissue weight), compared with baseline levels (141.1 +/- 4.1 ng/0.1 gm tissue weight). Changes in IgE and histamine levels after intragastric challenge could be blocked by treating the animals with neutralizing antibodies against IL-4 or IL-10. Although it is generally accepted that ingestion of food allergens leads to a state of immunologic unresponsiveness (i.e., oral tolerance), it is shown here that low-dose systemic priming followed by intragastric challenge leads to sensitization instead of unresponsiveness. Conclusions: Our murine model shows an important correlation between T-H2 cytokines, IgE production, and histamine release. Hence, this in vivo model provides a useful tool with which the complex mechanism underlying sensitization to food allergens can be studied.	ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	vanHalteren, AGS (corresponding author), VRIJE UNIV AMSTERDAM,DEPT CELL BIOL & IMMUNOL,AMSTERDAM,NETHERLANDS.		Savelkoul, Huub FJ/F-6026-2012					Aabin B, 1996, INT ARCH ALLERGY IMM, V109, P50, DOI 10.1159/000237231; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547, DOI 10.1159/000237098; CROWE SE, 1992, GASTROENTEROLOGY, V103, P1075, DOI 10.1016/0016-5085(92)90047-3; DURANDY A, 1995, J IMMUNOL, V154, P1560; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PERDUE MH, 1984, GASTROENTEROLOGY, V86, P391; PERDUE MH, 1984, AM J PHYSIOL, V247, P632; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; SAVELKOUL HFJ, 1994, J IMMUNOL METHODS, V172, P33, DOI 10.1016/0022-1759(94)90376-X; SEGURS N, 1994, J ALELRGY CLIN IMMUN, V94, P757; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VANOMMEN R, 1994, SCAND J IMMUNOL, V40, P491; VANSPREEUWEL JP, 1984, J CLIN PATHOL, V37, P601, DOI 10.1136/jcp.37.6.601; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220	24	74	75	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				94	99						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003216	Bronze			2022-12-18	WOS:A1997WD06100013
J	delPozo, MD; Moneo, I; deCorres, LF; Audicana, MT; Munoz, D; Fernandez, E; Navarro, JA; Garcia, M				delPozo, MD; Moneo, I; deCorres, LF; Audicana, MT; Munoz, D; Fernandez, E; Navarro, JA; Garcia, M			Laboratory determinations in Anisakis simplex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						parasite; Anisakis simplex; anaphylaxis; fish; allergy; IgE; IgG; immunoblotting	GASTRIC ANISAKIASIS; ANTIGENS	Background: Anaphylactic reactions caused by the fish nematode, Anisakis simpl Objective: This study was undertaken to confirm, by histamine release tests, that A. simplex is able to trigger IgE-mediated reactions and to describe the serologic profiles in this sensitization. Methods: Twelve patients who had anaphylactic symptoms after ingestion of cooked fish and positive prick test results and determinations of IgE to A. simplex were studied by indirect IgG ELISA and IgG and IgE immunoblotting. Sera from subjects parasitized with other nematodes, patients with fish allergy, and healthy donors were induced as controls. A histamine release test was performed in a representative case. Results: IgE immunoblotting was a specific test to detect A. simplex allergy. IgE-reacting bands were found in serum samples from 11 of our patients. Specific IgG antibodies were found by ELISA and immunoblotting, but this response was less specific. Histamine release was positive with A. simplex extract and negative with fish. Conclusion: A specific and intense immune response to an A. simplex extract was found in our patients. A. simplex is able to elicit anaphylactic reactions, and A. simplex allergy should be suspected in patients with allergic symptoms after ingestion of fish. A positive prick test response to A. simplex and negative response to fish is good indication for a diagnosis of A. simplex allergy.	HOSP SANTIAGO APOSTOL, SERV ALERGOL, E-01004 VITORIA, SPAIN; HOSP CARLOS 3, CTR NACL INVEST CIENT, SERV IMMUNOL, MADRID, SPAIN	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Hospital Carlos III			Fernandez, Eduardo/S-8206-2016	Fernandez, Eduardo/0000-0002-7052-6011				AKAO N, 1990, J HELMINTHOL, V64, P310, DOI 10.1017/S0022149X00012359; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; Deardorff T L, 1991, Hawaii Med J, V50, P9; DESOWITZ RS, 1985, T ROY SOC TROP MED H, V79, P256, DOI 10.1016/0035-9203(85)90351-7; IGLESIAS R, 1993, PARASITE IMMUNOL, V15, P243, DOI 10.1111/j.1365-3024.1993.tb00607.x; IKEDA K, 1989, GASTROINTEST ENDOSC, V35, P304, DOI 10.1016/S0016-5107(89)72797-8; KAGEI N, 1992, INT J PARASITOL, V22, P251, DOI 10.1016/0020-7519(92)90111-W; Kasuya S, 1992, Arerugi, V41, P106; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KASUYA S, 1989, ACI NEWS, V1, P13; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; KIM H, 1991, NEUROPSYCHOLOGIA, V29, P93, DOI 10.1016/0028-3932(91)90095-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDOVIST A, 1992, SEAF SPEC IGE AT DER; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO T, 1992, RADIOLOGY, V183, P97, DOI 10.1148/radiology.183.1.1549697; MONEO I, 1995, OCCUP MED-OXFORD, V45, P151, DOI 10.1093/occmed/45.3.151; Moneo I., 1993, Inmunologia, V12, P54; PETIT C, 1989, METHOD ENZYMOL, V178, P144; PETITHORY JC, 1991, B ACAD NAT MED PARIS, V175, P273; PETITHORY JC, 1986, MED MALADIES INFECT, V16, P157, DOI 10.1016/S0399-077X(86)80219-0; PETITHORY JC, 1988, LETT INFECTIOLOGUE, V2, P96	22	74	78	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					977	984		10.1016/S0091-6749(96)80073-X	http://dx.doi.org/10.1016/S0091-6749(96)80073-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655894				2022-12-18	WOS:A1996UG08600013
J	BAUR, X				BAUR, X			HYPERSENSITIVITY PNEUMONITIS (EXTRINSIC ALLERGIC ALVEOLITIS) INDUCED BY ISOCYANATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ISOCYANATES; EXTRINSIC ALLERGIC ALVEOLITIS; HYPERSENSITIVITY PNEUMONITIS; IGG ANTIBODIES; RESTRICTIVE VENTILATION PATTERN; CHEST X-RAY FILM; BRONCHOALVEOLAR LAVAGE FLUID	TRIMELLITIC-ANHYDRIDE; DIPHENYLMETHANE DIISOCYANATE; WORKERS; EXPOSURE; ANTIBODIES; INHALATION; DISEASE; MDI	Background: Chemical-induced hypersensitivity pneumonitis has been so far rarely described. The purpose of this study was to find out whether hypersensitivity pneumonitis is a common disorder in isocyanate workers. Methods: Company physicians' case histories of 1780 isocyanate workers were evaluated. In 16 subjects suspected of having isocyanate-induced hypersensitivity pneumonitis, chest x-ray films were made; levels of IgE and IgG antibodies to isocyanate-human serum albumin were estimated; conjugates and isocyanate challenge tests, bronchoalveolar lavage fluid analyses, and/or lung histologic investigations were performed. Results: Each of the 14 study patients who had hypersensitivity pneumonitis had work-related dyspnea and fever occurring several hours after the start of work with isocyanates. Typical clinical findings were the reduction of lung diffusing capacity (n = 10), reticular or nodular lung patterns in the x-ray film (n = 9), and serum Ige antibodies specific to isocyanate-human serum albumin conjugates (n = 10). Restrictive ventilation patterns in the inhalation challenge tests (n = 5), lymphocytic and/or neutrophilic alveolitis seen in bronchoalveolar lavage fluid analyses (n = 7), and lymphohistiocytic patterns mostly associated with mild fibrosis in lung histology (n = 5) confirmed the diagnosis. Conclusions: Occupational exposure to isocyanate vapors and aerosols induces typical hypersensitivity pneumonitis in at least 1% of the isocyanate workers with symptoms. Diphenylmethane diisocyanate was found to be the main cause of this disorder.			BAUR, X (corresponding author), RUHR UNIV, OCCUPAT MED RES INST, BUERKLE COMP PL 1, D-44789 BOCHUM, GERMANY.							BASCOM R, 1985, AM REV RESPIR DIS, V131, P463; BAUR X, 1984, J OCCUP ENVIRON MED, V26, P285; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; BIAGINI RE, 1988, J ALLERGY CLIN IMMUN, V82, P25; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; COTES JE, 1993, EUR RESPIR J, V6, P41, DOI 10.1183/09041950.041s1693; CZUPPON AB, 1994, ALLERGY, V49, P337, DOI 10.1111/j.1398-9995.1994.tb02278.x; DEWAIR MA, 1982, J CLIN CHEM CLIN BIO, V20, P337; FINK JN, 1978, AM REV RESPIR DIS, V118, P955; GERHARDSSON L, 1992, J OCCUP ENVIRON MED, V34, P989; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54, DOI 10.1164/ajrccm/148.1.54; HENDRICK DJ, 1980, THORAX, V35, P415, DOI 10.1136/thx.35.6.415; KLECH H, 1989, EUR RESPIR J, V2, P561; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; QUNAJER PH, 1993, EUR RESPIR J, V16, P5; SELDEN AI, 1989, SCAND J WORK ENV HEA, V15, P234, DOI 10.5271/sjweh.1857; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; WALKER CL, 1989, J OCCUP ENVIRON MED, V31, P315; WASS U, 1990, SCAND J WORK ENV HEA, V16, P208, DOI 10.5271/sjweh.1802; YOSHIZAWA Y, 1989, ANN INTERN MED, V110, P31, DOI 10.7326/0003-4819-110-1-31; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; ZEISS CR, 1987, J ALLERGY CLIN IMMUN, V79, P59, DOI 10.1016/S0091-6749(87)80017-9	24	74	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1004	1010		10.1016/S0091-6749(95)70101-X	http://dx.doi.org/10.1016/S0091-6749(95)70101-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751497				2022-12-18	WOS:A1995QY91700012
J	CAROLAN, EJ; CASALE, TB				CAROLAN, EJ; CASALE, TB			EFFECTS OF NEUROPEPTIDES ON NEUTROPHIL MIGRATION THROUGH NONCELLULAR AND ENDOTHELIAL BARRIERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEUTROPHILS; CHEMOTAXIS; NEUROPEPTIDES; NEUROGENIC INFLAMMATION	SUBSTANCE-P; POLYMORPHONUCLEAR LEUKOCYTES; NEUROGENIC INFLAMMATION; RESPIRATORY-TRACT; NEUROKININ-A; RAT TRACHEA; SOMATOSTATIN; CELLS; TACHYKININS; MONONUCLEAR	Background: Neuropeptides and neutrophils are postulated to be important immune effector molecules and cells, respectively, in a variety of lung inflammatory conditions. Methods: We examined the effects of three lung neuropeptides, substance P vasoactive intestinal peptide (VIP), and somatostatin and two relatively protease-resistant peptides, helodermin and sandostatin, on human neutrophil migration across 3 mum pore filters and human endothelial monolayers cultured on these filters. Results: At concentrations of 1 to 10 mumol/L, substance P induced significant neutrophil migration that was dose-responsive and equivalent through endothelium and filters. Neither VIP, helodermin, somatostatin, nor sandostatin induced significant neutrophil migration through either barrier at doses of 10(-14) to 10(-5) mol/L. Because VIP and somatostatin have been reported to inhibit some inflammatory cell functions, we also examined their effects on chemoattractant-induced neutrophil migration. Pretreatment of neutrophils and/or endothelium with VIP or somatostatin at either 10(-5) or 10(-10) mol/L did not significantly inhibit formyl-methionyl-leucyl-phenylalanine-, leukotriene B4-, or platelet activating factor-induced neutrophil migration through naked filters or endothelium. Thus only substance P had significant effects on neutrophil chemotaxis. Conclusions: Substance P, but not VIP or somatostatin, may be important in directly influencing neutrophil migration across endothelium towards lung inflammatory sites. However, all three neuropeptides might still modulate neutrophil functions and lung inflammatory responses through effects on other lung cells.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES05605-02] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BIENENSTOCK J, 1990, MOL ASPECTS IMMUNE R, P55; BONDESSON L, 1991, ACTA PHYSIOL SCAND, V141, P477, DOI 10.1111/j.1748-1716.1991.tb09108.x; CAROLAN EJ, 1990, J IMMUNOL, V145, P2561; CASALE TB, 1991, J ALLERGY CLIN IMMUN, V88, P1, DOI 10.1016/0091-6749(91)90292-V; CASALE TB, 1990, CELL PHYSL, V258, pC639; DENBURG JA, 1991, INT ARCH ALLER A IMM, V94, P127, DOI 10.1159/000235343; FERRANTE A, 1978, J IMMUNOL METHODS, V24, P389, DOI 10.1016/0022-1759(78)90143-6; FOREMAN J, 1983, AGENTS ACTIONS, V13, P105, DOI 10.1007/BF01967311; GALLIN JI, 1973, J IMMUNOL, V110, P233; HACHISU M, 1991, J PHARMACOBIO-DYNAM, V14, P126, DOI 10.1248/bpb1978.14.126; KATZ MD, 1989, CLIN PHARMACY, V8, P255; KIMBALL ES, 1988, J IMMUNOL, V141, P3564; KRCO CJ, 1986, IMMUNOL INVEST, V15, P103, DOI 10.3109/08820138609094136; LEMBECK F, 1982, EUR J PHARMACOL, V85, P171, DOI 10.1016/0014-2999(82)90462-9; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; MANTYH PW, 1989, PEPTIDES, V10, P627, DOI 10.1016/0196-9781(89)90154-X; MARASCO WA, 1981, BIOCHEM BIOPH RES CO, V99, P1065, DOI 10.1016/0006-291X(81)90727-0; MARTLING CR, 1987, LIFE SCI, V40, P1633, DOI 10.1016/0024-3205(87)90130-5; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MCDONALD DM, 1988, J NEUROCYTOL, V17, P583, DOI 10.1007/BF01260988; MUSCETTOLA M, 1990, IMMUNOBIOLOGY, V180, P419, DOI 10.1016/S0171-2985(11)80303-7; PAYAN DG, 1987, AM REV RESPIR DIS, V136, pS39, DOI 10.1164/ajrccm/136.6_Pt_2.S39; PAYAN DG, 1984, CELL IMMUNOL, V84, P433, DOI 10.1016/0008-8749(84)90117-5; PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P530; RABIER M, 1991, J LIPID MEDIATOR, V4, P265; ROCHARVEILLER M, 1986, PHARMACOLOGY, V33, P266, DOI 10.1159/000138225; SAID SI, 1990, LIFE SCI, V47, P21; SCHREIBER J, 1988, BIOMED BIOCHIM ACTA, V47, P445; UMENO E, 1990, J APPL PHYSIOL, V69, P2131, DOI 10.1152/jappl.1990.69.6.2131; WEIDERMANN CJ, 1989, ARCH PHARM, V340, P183; WOZNIAK A, 1989, IMMUNOLOGY, V68, P359	34	74	75	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					589	598		10.1016/0091-6749(93)90083-R	http://dx.doi.org/10.1016/0091-6749(93)90083-R			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	7691915				2022-12-18	WOS:A1993MC59000011
J	SCHOU, C; HANSEN, GN; LINTNER, T; LOWENSTEIN, H				SCHOU, C; HANSEN, GN; LINTNER, T; LOWENSTEIN, H			ASSAY FOR THE MAJOR DOG ALLERGEN, CAN F I - INVESTIGATION OF HOUSE DUST SAMPLES AND COMMERCIAL DOG EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENVIRONMENTAL ALLERGEN; AEROALLERGEN; DOG HAIR AND DANDER; ELISA; RABBIT ANTIBODY	MITE; ANTIBODIES; EXPOSURE	Monospecific rabbit antibodies were used to develop a sensitive two-site enzyme immunoassay to measure a major dog hair and dander allergen, Can f I. This Can f I assay demonstrated no reaction with 17 heterologous allergen sources, including dog albumin, cat, guinea pig, and horse. Analysis of serial dilutions of purified Can f I and the international standard for dog was parallel. The assay was considered specific for Can f I with a lower limit of detection at 0.03-mu-g/ml. Total imprecision was from 2% to 6%. Commercial dog extracts for specific immunotherapy contained from 0.7 to 290-mu-g of Can f I per milliliter. The assay was used to measure Can f I in 136 house dust samples collected from 103 homes across the United States. Concentration of the dog allergen was expressed as micrograms of Can f I per gram of dust. Prevalence of Can f I in the dust samples ranged from < 0.3 to 10,000-mu-g/gm. Serial dilutions of samples containing Can F I were paralle to the standard. The median Can f I value for homes with a dog in residence was 120-mu-g/gm, and for homes with no dog, 3-mu-g/gm. With few exceptions, homes with no dog in residence had < 10-mu-g/gm. This Can f I assay will provide useful information for assessing commercial extracts as well as monitoring dog-allergen exposure and allergen-control methods.	VESPA LABS,SPRING MILLS,PA		SCHOU, C (corresponding author), ALK RES,BOGE ALLE 10-12,DK-2970 HORSHOLM,DENMARK.							BLANDS J, 1977, ACTA ALLERGOL, V32, P142; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; KROUWER JS, 1984, CLIN CHEM, V30, P290; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1987, J ALLERGY CLIN IMMUN, V80, P541, DOI 10.1016/0091-6749(87)90005-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V87, P828, DOI 10.1016/0091-6749(91)90129-C; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265	16	74	74	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					847	853		10.1016/0091-6749(91)90240-O	http://dx.doi.org/10.1016/0091-6749(91)90240-O			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744355				2022-12-18	WOS:A1991GW26200004
J	MIADONNA, A; TEDESCHI, A; BRASCA, C; FOLCO, G; SALA, A; MURPHY, RC				MIADONNA, A; TEDESCHI, A; BRASCA, C; FOLCO, G; SALA, A; MURPHY, RC			MEDIATOR RELEASE AFTER ENDOBRONCHIAL ANTIGEN CHALLENGE IN PATIENTS WITH RESPIRATORY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MILAN,DEPT MED INFECT DIS & IMMUNOPATHOL,I-20122 MILAN,ITALY; UNIV MILAN,DEPT RESP MED,I-20122 MILAN,ITALY; UNIV MILAN,INST PHARMACOL SCI,I-20122 MILAN,ITALY; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	University of Milan; University of Milan; University of Milan; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Sala, Angelo/H-5478-2019	Sala, Angelo/0000-0001-9290-0257				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ARNOUX B, 1987, B EUR PHYSIOPATH RES, V23, P119; CAPRON M, 1981, J IMMUNOL, V126, P2087; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAVIDSON AB, 1987, AM REV RESPIR DIS, V315, P333; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FERREIRA SH, 1976, EUR J PHARMACOL, V39, P379, DOI 10.1016/0014-2999(76)90147-3; FREELAND HS, 1988, AM REV RESPIR DIS, V138, P389, DOI 10.1164/ajrccm/138.2.389; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HAYES EC, 1983, J IMMUNOL, V131, P429; KELLY CA, 1987, THORAX, V42, P624, DOI 10.1136/thx.42.8.624; LAGUNOFF D, 1983, EXP LUNG RES, V4, P121, DOI 10.3109/01902148309055009; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LAM S, 1985, CHEST, P86; LEVINE L, 1981, P NATL ACAD SCI-BIOL, V78, P7692, DOI 10.1073/pnas.78.12.7692; MACDERMOT J, 1984, PROSTAGLANDINS, V27, P163, DOI 10.1016/0090-6980(84)90071-6; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MELEWICZ FM, 1982, CLIN EXP IMMUNOL, V49, P364; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MIADONNA A, 1989, AM REV RESPIR DIS, V140, P142, DOI 10.1164/ajrccm/140.1.142; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; REES PJ, 1985, THORAX, V40, P603, DOI 10.1136/thx.40.8.603; SAUTEBIN L, 1984, PROSTAGLANDINS, V27, P361, DOI 10.1016/0090-6980(84)90192-8; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TONNEL AB, 1983, LANCET, V1, P1406; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880	37	74	75	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					906	913		10.1016/0091-6749(90)90076-G	http://dx.doi.org/10.1016/0091-6749(90)90076-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	1692050				2022-12-18	WOS:A1990DD95900014
J	WACHS, M; PROUD, D; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; NORMAN, PS; NACLERIO, RM				WACHS, M; PROUD, D; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; NORMAN, PS; NACLERIO, RM			OBSERVATIONS ON THE PATHOGENESIS OF NASAL PRIMING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 20136, AI 07290] Funding Source: Medline; NINDS NIH HHS [NS 22488] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022488] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLANSMITH MR, 1984, J ALLERGY CLIN IMMUN, V73, P49, DOI 10.1016/0091-6749(84)90483-4; ATKINS PC, 1984, IMMUNOL ALLERGY PRAC, V6, P15; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BLYTHE S, 1986, AM REV RESPIR DIS, V134, P1246; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; CAPRON M, 1981, J IMMUNOL, V126, P2087; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DELEHUNT JC, 1984, AM REV RESPIR DIS, V130, P748; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; HASTIE R, 1979, LAB INVEST, V40, P554; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; KONNO A, 1983, EUR J RESPIR DIS, V64, P155; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; LARSEN GL, 1985, J ALLERGY CLIN IMMUN, V76, P665, DOI 10.1016/0091-6749(85)90668-2; MARSH DG, 1975, ANTIGENS, V3, P271; MITCHELL EB, 1982, LANCET, V1, P127; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1985, IMMUNOBIOLOGY AUTOIM, P267; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PELIKAN Z, 1984, ANN ALLERGY, V52, P111; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4	39	74	77	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				492	501		10.1016/0091-6749(89)90362-X	http://dx.doi.org/10.1016/0091-6749(89)90362-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2477429				2022-12-18	WOS:A1989AW76000010
J	RHOADES, RB; STAFFORD, CT; JAMES, FK				RHOADES, RB; STAFFORD, CT; JAMES, FK			SURVEY OF FATAL ANAPHYLACTIC REACTIONS TO IMPORTED FIRE ANT STINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL GEORGIA,DEPT MED,ALLERGY IMMUNOL SECT,AUGUSTA,GA 30912; MED COLL GEORGIA,DEPT PEDIAT,AUGUSTA,GA 30912	University System of Georgia; Augusta University; University System of Georgia; Augusta University								ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; Bloom F L, 1984, J Fla Med Assoc, V71, P87; BOWEN R, 1951, South Med J, V44, P836, DOI 10.1097/00007611-195109000-00014; CLEMMER DI, 1975, SOUTHERN MED J, V68, P1133, DOI 10.1097/00007611-197509000-00017; HENSEL AE, 1983, ANN ALLERGY, V50, P359; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; PARRISH HM, 1963, AM J MED SCI, V245, P129; Rhoades R.B., 1977, MED ASPECTS IMPORTED; RHOADES RB, 1988, J ALLERGY CLIN IMMUN, V81, P202, DOI 10.1016/0091-6749(88)90373-9; Stablein J.J., 1985, IMMUNOL ALLERGY PRAC, V7, P279; Yeager W, 1978, J Med Assoc Ga, V67, P101	11	74	78	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					159	162		10.1016/0091-6749(89)90319-9	http://dx.doi.org/10.1016/0091-6749(89)90319-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2760357				2022-12-18	WOS:A1989AL83600004
J	KALINER, M				KALINER, M			ASTHMA AND MAST-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KALINER, M (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892, USA.							FRIEDMAN MM, 1987, AM REV RESPIR DIS, V135, P157; FRIEDMAN MM, IN PRESS J ALLERGY C; KALINER M, 1987, JAMA-J AM MED ASSOC, V258, P2851, DOI 10.1001/jama.258.20.2851; KALINER MA, 1987, CHEST S, V91, P171; KEAHEY TM, 1987, J ALLERGY CLIN IMMUN, V80, P831, DOI 10.1016/S0091-6749(87)80273-7; KOWALSKI ML, 1988, J IMMUNOL, V140, P3905; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LUNDBLAD L, 1985, EUR J PHARMACOL, V113, P461, DOI 10.1016/0014-2999(85)90098-6; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PERSSON CGA, 1986, LANCET, V2, P1126; SERTL K, 1988, AM REV RESPIR DIS, V138, P151, DOI 10.1164/ajrccm/138.1.151; SHELHAMER JH, 1987, AIRWAYS NEURAL CONTR, P575	12	74	75	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				510	520		10.1016/0091-6749(89)90031-6	http://dx.doi.org/10.1016/0091-6749(89)90031-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645347	Bronze			2022-12-18	WOS:A1989T449100002
J	SULLIVAN, TJ; ONG, RC; GILLIAM, LK				SULLIVAN, TJ; ONG, RC; GILLIAM, LK			STUDIES OF THE MULTIPLE-DRUG ALLERGY SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	74	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					270	270						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900414
J	NIELSEN, J; WELINDER, H; SCHUTZ, A; SKERFVING, S				NIELSEN, J; WELINDER, H; SCHUTZ, A; SKERFVING, S			SPECIFIC SERUM ANTIBODIES AGAINST PHTHALIC-ANHYDRIDE IN OCCUPATIONALLY EXPOSED SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NIELSEN, J (corresponding author), UNIV LUND HOSP,DEPT OCCUPAT MED,S-22185 LUND,SWEDEN.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; AHLBERG RW, 1984, RESPIRATORY ALLERGY, P123; BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P714, DOI 10.1016/0091-6749(83)90635-8; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHESTER EH, 1977, CLIN ALLERGY, V7, P15, DOI 10.1111/j.1365-2222.1977.tb01419.x; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; GWYNN CM, 1982, LANCET, V1, P254; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; NORDMAN H, 1987, 22ND INT C OCC HLTH; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PERELMUTTER L, 1984, ANN ALLERGY, V52, P64; POPLER A, 1980, PRAKOV LEK, V32, P216; ROSE GA, 1968, WHO MONOGRAPH SERIES, P160; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; STANWORTH DR, 1983, CLIN REV ALLERG, V1, P183; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WERNFORS M, 1986, INT ARCH ALLER A IMM, V79, P77, DOI 10.1159/000233946; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1965, LANCET, V1, P777; 1984, ARBETARSKYDDSSTYRELS, P20	23	74	75	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					126	133		10.1016/0091-6749(88)90062-0	http://dx.doi.org/10.1016/0091-6749(88)90062-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392364				2022-12-18	WOS:A1988P400400021
J	ZEASKE, R; BRUNS, WT; FINK, JN; GREENBERGER, PA; COLBY, H; LIOTTA, JL; ROBERTS, M				ZEASKE, R; BRUNS, WT; FINK, JN; GREENBERGER, PA; COLBY, H; LIOTTA, JL; ROBERTS, M			IMMUNE-RESPONSES TO ASPERGILLUS IN CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226; CHILDRENS HOSP WISCONSIN,CTR CYSTIC FIBROSIS,MILWAUKEE,WI; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Medical College of Wisconsin; Children's Hospital of Wisconsin; Cystic Fibrosis Foundation; Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; AUERBACH HS, 1985, LANCET, V2, P686; BARBERO GJ, 1982, J PEDIATR-US, V100, P914, DOI 10.1016/S0022-3476(82)80511-8; DAVIS JB, 1976, CLIN ALLERGY, V6, P329, DOI 10.1111/j.1365-2222.1976.tb01913.x; FERGELSON J, 1983, 12TH P ANN M EUR WOR; GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; KURUP VP, 1978, AM J CLIN PATHOL, V69, P414; KURUP VP, 1978, MICROBIOS, V19, P191; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LEVINSON H, 1983, CYSTIC FIBROSIS; MEARNS M, 1967, LANCET, V1, P538; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; NELSON PA, 1979, CLIN DIAGNOSIS MANAG, P858; RACHELEFSKY GS, 1974, AM J DIS CHILD, V128, P355, DOI 10.1001/archpedi.1974.02110280085010; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; SCHWARTZ RH, 1981, J ALLERGY CLIN IMMUN, V68, P290, DOI 10.1016/0091-6749(81)90154-8; VANSELOW NA, 1960, MANUAL CLIN ALLERGY, P55; WARNER JO, 1976, ARCH DIS CHILD, V51, P507, DOI 10.1136/adc.51.7.507; WARREN C P W, 1975, Clinical Allergy, V5, P1, DOI 10.1111/j.1365-2222.1975.tb01831.x; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0	23	74	78	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					73	77		10.1016/0091-6749(88)90054-1	http://dx.doi.org/10.1016/0091-6749(88)90054-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392373				2022-12-18	WOS:A1988P400400013
J	DAUL, CB; MORGAN, JE; HUGHES, J; LEHRER, SB				DAUL, CB; MORGAN, JE; HUGHES, J; LEHRER, SB			PROVOCATION-CHALLENGE STUDIES IN SHRIMP-SENSITIVE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL & ALLERGY SECT,NEW ORLEANS,LA 70118; TULANE UNIV,MED CTR,DEPT PEDIAT,CLIN IMMUNOL & ALLERGY SECT,NEW ORLEANS,LA 70118	Tulane University; Tulane University	DAUL, CB (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,ALLERGY SECT,1514 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.				NIAID NIH HHS [AI-19266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; AMLOT PL, 1985, INT ARCH ALLER A IMM, V77, P171, DOI 10.1159/000233776; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CASTRO A, 1977, RES COMMUN CHEM PATH, V16, P199; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1978, ALLERGY PRINCIPLES P, V2, P1159; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; REIMANN HJ, 1985, CLIN ALLERGY, V15, P195, DOI 10.1111/j.1365-2222.1985.tb02273.x; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; Siegal S., 1956, NONPARAMETRIC STAT B, DOI [10.1037/13191-000, DOI 10.1037/13191-000]; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	26	74	75	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1180	1186		10.1016/0091-6749(88)90888-3	http://dx.doi.org/10.1016/0091-6749(88)90888-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379230	Bronze			2022-12-18	WOS:A1988P002300018
J	LICHTENSTEIN, LM				LICHTENSTEIN, LM			HISTAMINE-RELEASING FACTORS AND IGE HETEROGENEITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LICHTENSTEIN, LM (corresponding author), JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,SCH MED,DEPT MED, DIV CLIN IMMUNOL, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA.				NIAID NIH HHS [AI 08270, AI 07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; FISHER RH, 1987, J ALLERGY CLIN IMMUN, V79, P196; HAAKFRENDSCHO M, 1986, J ALLERGY CLIN IMMUN, V77, P230; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LIU MC, 1986, J IMMUNOL, V136, P2588; MACDONALD SM, 1988, J ALLERGY CLIN IMMUN, V81, P301, DOI 10.1016/0091-6749(88)90767-1; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1987, J ALLERGY CLIN IMMUN, V79, P248; MACDONALD SM, 1987, CLIN RES, V35, pA641; MACDONALD SM, IN PRESS FED P; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MASSEY WA, IN PRESS FED P; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OKUDA M, 1978, ARCH OHREN NASEN KEH, V221, P215, DOI 10.1007/BF01886298; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; THUESON DO, 1979, J IMMUNOL, V123, P626; TUNG R, 1982, J IMMUNOL, V128, P2067; WARNER JA, 1986, J IMMUNOL, V136, P2583; WEISS M, 1988, J ALLERGY CLIN IMMUN, V81, P224, DOI 10.1016/0091-6749(88)90459-9	28	74	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				814	820		10.1016/0091-6749(88)90936-0	http://dx.doi.org/10.1016/0091-6749(88)90936-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2453542				2022-12-18	WOS:A1988N703600008
J	BOUSQUET, J; FONTEZ, A; AZNAR, R; ROBINETLEVY, M; MICHEL, FB				BOUSQUET, J; FONTEZ, A; AZNAR, R; ROBINETLEVY, M; MICHEL, FB			COMBINATION OF PASSIVE AND ACTIVE IMMUNIZATION IN HONEYBEE VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR REG TRANSFUS SANGUINE HERAULT,MONTPELLIER,FRANCE		BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					BARANDUN S, 1962, VOX SANG, V7, P157, DOI 10.1111/j.1423-0410.1962.tb03240.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P332, DOI 10.1016/0091-6749(84)90405-6; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1985, ALLERGY TODAY, V3, P10; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; KISTLER P, 1962, VOX SANG, V7, P414, DOI 10.1111/j.1423-0410.1962.tb03274.x; KOBLET H, 1967, VOX SANG, V13, P93; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; MORELL A, 1980, VOX SANG, V38, P272, DOI 10.1111/j.1423-0410.1980.tb02367.x; MUELLER HL, 1959, NEW ENGL J MED, V261, P374, DOI 10.1056/NEJM195908202610803; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1985, J ALLERGY CLIN IMMUN, V75, P208, DOI 10.1016/0091-6749(85)90548-2; REISMAN RE, 1983, ALLERGY PRINCIPLES P, P1361; ROMER J, 1982, VOX SANG, V42, P62; THOMPSON RA, 1981, IMMUNOHEMOTHERAPY GU, P431; URBANEK R, 1983, CLIN ALLERGY, V13, P229, DOI 10.1111/j.1365-2222.1983.tb02592.x; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P179; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5; ZELEZNICK LD, 1977, J ALLERGY CLIN IMMUN, V59, P2, DOI 10.1016/0091-6749(77)90169-5; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	24	74	77	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					947	954		10.1016/0091-6749(87)90245-4	http://dx.doi.org/10.1016/0091-6749(87)90245-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584749				2022-12-18	WOS:A1987H904400017
J	ARLIAN, LG; GEIS, DP; VYSZENSKIMOHER, DL; BERNSTEIN, IL; GALLAGHER, JS				ARLIAN, LG; GEIS, DP; VYSZENSKIMOHER, DL; BERNSTEIN, IL; GALLAGHER, JS			CROSS ANTIGENIC AND ALLERGENIC PROPERTIES OF THE HOUSE DUST MITE DERMATOPHAGOIDES-FARINAE AND THE STORAGE MITE TYROPHAGUS-PUTRESCENTIAE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT PHYSIOL,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DAYTON,OH 45435; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267	Wright State University Dayton; Wright State University Dayton; University of Cincinnati	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT BIOL SCI,DAYTON,OH 45435, USA.				PHS HHS [R01 A1 13702] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MC, 1981, J IMMUNOL, V127, P972; ARLIAN LG, 1979, J MED ENTOMOL, V16, P128, DOI 10.1093/jmedent/16.2.128; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; AXELSEN NH, 1973, SCAND J IMMUNOL, V2, P101, DOI 10.1111/j.1365-3083.1973.tb03787.x; AXELSEN NH, 1973, SCAND J IMMUNOL, V2, P91, DOI 10.1111/j.1365-3083.1973.tb03785.x; AXELSEN NH, 1973, SCAND J IMMUNOL, V2, P71, DOI 10.1111/j.1365-3083.1973.tb03782.x; BRADY J, 1970, J APPL ECOL, V7, P331, DOI 10.2307/2401384; CUNNINGTON AM, 1967, ACTA ALLERGOL, V22, P415; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; CUTHBERT OD, 1980, CLIN ALLERGY, V10, P601, DOI 10.1111/j.1365-2222.1980.tb02142.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; GREEN WF, 1978, CLIN ALLERGY, V8, P135, DOI 10.1111/j.1365-2222.1978.tb00458.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HUGHES AM, 1976, MIN AGR FISH FOOD TE, V9; INGRAM CG, 1979, LANCET, V2, P1330; JEFFREY IG, 1976, J STORED PROD RES, V12, P149, DOI 10.1016/0022-474X(76)90003-5; KRANTZ G. W., 1961, ANN ENT SOC AMER, V54, P169, DOI 10.1093/aesa/54.2.169; Krantz GW, 1978, MANUAL ACAROLOGY, V2nd; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; MUMCUOGLU Y, 1977, ACTA ALLERGOL, V32, P333; SINHA R. N., 1964, PROC ENTOMOL SOC MANITOBA, V20, P19; SINHA RN, 1968, ANN ENTOMOL SOC AM, V61, P938, DOI 10.1093/aesa/61.4.938; SINHA RN, 1963, ADV ACAROLOGY, V1, P480; SOLOMON ME, 1961, MITES HOUSES SHOPS O; Spieksma F. Th. M., 1967, Acarologia, V9, P226; SPIEKSMA FT, 1969, ACTA ALLERGOL, V24, P124, DOI 10.1111/j.1398-9995.1969.tb03762.x; TERHO EO, 1982, ALLERGY, V37, P15, DOI 10.1111/j.1398-9995.1982.tb04112.x; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WARREN P, 1974, J ALLERGY CLIN IMMUN, V33, P139; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WILLIAMS NORMAN, 1964, J OCCUP MED, V6, P319, DOI 10.1097/00043764-196408000-00001; WOODCOCK AA, 1980, CLIN ALLERGY, V10, P609, DOI 10.1111/j.1365-2222.1980.tb02143.x; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	35	74	74	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					172	179		10.1016/0091-6749(84)90282-3	http://dx.doi.org/10.1016/0091-6749(84)90282-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747138				2022-12-18	WOS:A1984TE22600010
J	BUSSE, WW; KOPP, DE; MIDDLETON, E				BUSSE, WW; KOPP, DE; MIDDLETON, E			FLAVONOID MODULATION OF HUMAN NEUTROPHIL FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14260; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260	University of Wisconsin System; University of Wisconsin Madison; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI 15685, AI 10404, AI 00343] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; ALLEN RC, 1974, BIOCHEM BIOPH RES CO, V60, P909, DOI 10.1016/0006-291X(74)90401-X; BABIOR BM, 1976, J CLIN INVEST, V58, P989, DOI 10.1172/JCI108553; BABIOR GL, 1981, J CLIN INVEST, V67, P1724, DOI 10.1172/JCI110210; BAUMANN J, 1980, PROSTAGLANDINS, V20, P627, DOI 10.1016/0090-6980(80)90103-3; BENNETT JP, 1981, ARZNEIMITTEL-FORSCH, V31-1, P433; BERTON G, 1980, BIOCHIM BIOPHYS ACTA, V595, P47, DOI 10.1016/0005-2736(80)90246-1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUSSE WW, 1981, AM REV RESPIR DIS, V123, P654; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; DECHATELET LR, 1982, J IMMUNOL, V129, P1589; DECHATELET LR, 1978, J RETICULOENDOTH SOC, V24, P73; FANTONE JC, 1982, AM J PATHOL, V107, P397; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; FEWTRELL CMS, 1977, BIOCHIM BIOPHYS ACTA, V469, P52, DOI 10.1016/0005-2736(77)90325-X; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gabors M, 1972, ANTIINFLAMMATORY ACT; GOMPERTS BD, 1983, BIOCHEM J, V210, P737, DOI 10.1042/bj2100737; HOPE WC, 1983, BIOCHEM PHARMACOL, V32, P367, DOI 10.1016/0006-2952(83)90569-5; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LEE TP, 1982, LIFE SCI, V31, P2765, DOI 10.1016/0024-3205(82)90723-8; MCPHAIL LC, 1976, J CLIN INVEST, V58, P774, DOI 10.1172/JCI108528; MIDDLETON E, 1982, BIOCHEM PHARMACOL, V31, P1449, DOI 10.1016/0006-2952(82)90044-2; MIDDLETON E, 1981, J IMMUNOL, V127, P546; MIDDLETON E, BIOCH PHARM; NAKAMURA M, 1981, BIOCHEM BIOPH RES CO, V98, P743, DOI 10.1016/0006-291X(81)91175-X; PATRIARCA P, 1971, ARCH BIOCHEM BIOPHYS, V145, P255, DOI 10.1016/0003-9861(71)90034-8; PRENDERGAST E, 1981, J CLIN MICROBIOL, V13, P390, DOI 10.1128/JCM.13.2.390-392.1981; Schneider C, 1979, Adv Exp Med Biol, V121, P371; SHOWELL HJ, 1981, J RETICULOENDOTH SOC, V30, P167; SMOLEN JE, 1980, J CLIN INVEST, V65, P1077, DOI 10.1172/JCI109760; STANKOVA L, 1976, J LAB CLIN MED, V88, P640; TABUER AI, 1983, FED P, V42, P2063; VOLPI M, 1980, BIOCHEM BIOPH RES CO, V92, P1231, DOI 10.1016/0006-291X(80)90418-0; WEENING RS, 1975, J LAB CLIN MED, V85, P245; WEISS SJ, 1982, LAB INVEST, V47, P5; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	39	74	79	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					801	809		10.1016/0091-6749(84)90450-0	http://dx.doi.org/10.1016/0091-6749(84)90450-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6327791				2022-12-18	WOS:A1984SV82900006
J	HOLFORDSTREVENS, V; WARREN, P; WONG, C; MANFREDA, J				HOLFORDSTREVENS, V; WARREN, P; WONG, C; MANFREDA, J			SERUM TOTAL IMMUNOGLOBULIN-E LEVELS IN CANADIAN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT IMMUNOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT SOCIAL & PREVENT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT COMP,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba								BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BURR ML, 1975, THORAX, V30, P663, DOI 10.1136/thx.30.6.663; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; EISENHART C, 1947, TECHNIQUES STATISTIC; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRATER WC, 1983, ANN ALLERGY, V50, P317; HAAHTELA T, 1982, ALLERGY, V37, P597, DOI 10.1111/j.1398-9995.1982.tb02346.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSO.SG, 1967, LANCET, V2, P951; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; JOHANSSON SGO, 1982, ANN ALLERGY, V48, P325; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; KOJIMA S, 1972, AM J TROP MED HYG, V21, P913, DOI 10.4269/ajtmh.1972.21.913; MERRETT TG, 1980, CLIN ALLERGY, V10, P433, DOI 10.1111/j.1365-2222.1980.tb02126.x; NYE L, 1975, CLIN ALLERGY, V3, P13; PAUWELS R, 1978, ALLERGY, V33, P254, DOI 10.1111/j.1398-9995.1978.tb01545.x; PEPYS J, 1975, CLIN ASPECTS IMMUNOL; SEARS MR, 1980, CLIN ALLERGY, V10, P423, DOI 10.1111/j.1365-2222.1980.tb02125.x; WALTON CHA, 1945, CAN MED ASSOC J, V53, P529; Walton CHA, 1940, CAN MED ASSOC J, V42, P430; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; 1981, CLIN EXP IMMUNOL, V46, P662	33	74	75	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					516	522		10.1016/0091-6749(84)90363-4	http://dx.doi.org/10.1016/0091-6749(84)90363-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6707394				2022-12-18	WOS:A1984SM08900014
J	MULLER, UR; HORAT, W; WUTHRICH, B; CONROY, M; REISMAN, RE				MULLER, UR; HORAT, W; WUTHRICH, B; CONROY, M; REISMAN, RE			ANAPHYLAXIS AFTER HYMENOPTERA STINGS IN 3 PATIENTS WITH URTICARIA PIGMENTOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SPITA SCHWYZ,DIV MED,ZURICH,SWITZERLAND; INSELSPITAL,INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; UNIV SPITAL ZURICH,DEPT DERMATOL,DIV ALLERGY,ZURICH,SWITZERLAND	University of Bern; University Hospital of Bern; Buffalo General Medical Center; University of Zurich; University Zurich Hospital	MULLER, UR (corresponding author), ZIEGLERSPITAL,DIV MED,CH-3001 BERN,SWITZERLAND.							BERRENS L, 1979, BRIT J DERMATOL, V101, P230; BERTHER T, 1980, SCHWEIZ MED WSCHR, V110, P758; DECAROLI C, 1972, J ALLERGY CLIN IMMUN, V70, P219; GOLDEN BK, 1982, J ALLERGY CLIN IMMUN, V69, P124; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HEINER DC, 1979, ADV ALLERGOLOGY APPL, P312; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1976, CLIN ALLERGY, V6, P203; MULLER U, 1977, CLIN ALLERGY, V7, P147, DOI 10.1111/j.1365-2222.1977.tb01435.x; MULLER U, 1982, INT ARCH ALLER A IMM, V68, P312; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; REISMAN RE, 1978, ALLERGY PRINCIPLES P, P1100; RUSSELL FE, 1975, JAMA-J AM MED ASSOC, V233, P341, DOI 10.1001/jama.233.4.341; SELCOW JE, 1980, J ALLERGY CLIN IMMUN, V65, P400, DOI 10.1016/0091-6749(80)90220-1; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SUTTER MC, 1967, ARCH DERMATOL, V86, P217; WUTHRICH B, 1981, SCHWEIZ MED WSCHR, V111, P1756	21	74	74	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					685	689		10.1016/0091-6749(83)90630-9	http://dx.doi.org/10.1016/0091-6749(83)90630-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6196389				2022-12-18	WOS:A1983RW04800009
J	BERNSTEIN, DI; PATTERSON, R; ZEISS, CR				BERNSTEIN, DI; PATTERSON, R; ZEISS, CR			CLINICAL AND IMMUNOLOGICAL EVALUATION OF TRIMELLITIC ANHYDRIDE EXPOSED AND PHTHALIC-ANHYDRIDE EXPOSED WORKERS USING A QUESTIONNAIRE WITH COMPARATIVE-ANALYSIS OF ENZYME-LINKED IMMUNOSORBENT AND RADIOIMMUNOASSAY STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University					NHLBI NIH HHS [HL 15389] Funding Source: Medline; PHS HHS [U.S.P.H.S. 11403] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD D, 1979, LANCET, V2, P326; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; SCHLUETER DP, 1978, J OCCUP ENVIRON MED, V20, P183, DOI 10.1097/00043764-197803000-00006; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	12	74	74	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					311	318		10.1016/S0091-6749(82)80009-2	http://dx.doi.org/10.1016/S0091-6749(82)80009-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7061772				2022-12-18	WOS:A1982NF69700009
J	BARNES, PJ; WILSON, NM; VICKERS, H				BARNES, PJ; WILSON, NM; VICKERS, H			PRAZOSIN, AN ALPHA1-ADRENOCEPTOR ANTAGONIST, PARTIALLY INHIBITS EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HAMMERSMITH HOSP, DEPT PAEDIAT, LONDON W12 0HS, ENGLAND	Imperial College London	BARNES, PJ (corresponding author), HAMMERSMITH HOSP, DEPT MED, LONDON W12 0HS, ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANTHRACITE RF, 1971, PSYCHOSOM MED, V33, P481, DOI 10.1097/00006842-197111000-00001; BARNES P, 1979, LIFE SCI, V25, P1207, DOI 10.1016/0024-3205(79)90462-4; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; BARNES PJ, 1981, THORAX, V36, P378, DOI 10.1136/thx.36.5.378; BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; BARNES PJ, 1980, CLIN SCI, V58, P457, DOI 10.1042/cs0580457; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BIANCO S, 1974, BMJ-BRIT MED J, V4, P18, DOI 10.1136/bmj.4.5935.18; BIANCO S, 1972, British Journal of Diseases of the Chest, V66, P27, DOI 10.1016/S0007-0971(72)80004-4; BIEL M, 1978, RESPIRATION, V35, P78; CAMBRIDGE D, 1977, MED J AUSTRALIA, V2, P2, DOI 10.5694/j.1326-5377.1977.tb107750.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; DAVIES SE, 1968, BRIT MED J, V3, P953; GADDIE J, 1972, British Journal of Diseases of the Chest, V66, P141, DOI 10.1016/S0007-0971(72)80036-6; GRAHAM RM, 1979, NEW ENGL J MED, V300, P232, DOI 10.1056/NEJM197902013000505; GRIFFIN JP, 1972, LANCET, V1, P1288; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; IVERSEN LL, 1969, BRIT J PHARMACOL, V37, P627, DOI 10.1111/j.1476-5381.1969.tb08501.x; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KNEUSSL MP, 1978, J APPL PHYSIOL, V45, P307, DOI 10.1152/jappl.1978.45.2.307; LANGER SZ, 1974, BIOCHEM PHARMACOL, V23, P1793, DOI 10.1016/0006-2952(74)90187-7; MATHE AA, 1971, J PHARM PHARMACOL, V23, P905, DOI 10.1111/j.2042-7158.1971.tb09891.x; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; Nickerson M, 1975, PHARMACOL BASIS, P533; NOUSIAINEN OT, 1977, PHARMACOLOGY, V15, P469; PATEL KR, 1975, LANCET, V1, P348; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PATEL KR, 1974, CLIN ALLERGY, V4, P311, DOI 10.1111/j.1365-2222.1975.tb01868.x; PATEL KR, 1973, CLIN ALLERGY, V3, P439, DOI 10.1111/j.1365-2222.1973.tb01351.x; PRIME FJ, 1972, B PHYSIO-PATHOL RESP, V8, P99; SIMONSSON BG, 1972, SCAND J RESPIR DIS, V53, P227; SNASHALL PD, 1978, CLIN SCI, V54, P238; Szentivanyi A, 1979, Triangle, V18, P109; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TAYLOR SH, 1965, CLIN SCI, V28, P265; WOOD AJ, 1976, BRIT J CLIN PHARMACO, V3, P199, DOI 10.1111/j.1365-2125.1976.tb00592.x	39	74	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					411	415		10.1016/0091-6749(81)90193-7	http://dx.doi.org/10.1016/0091-6749(81)90193-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	6118384				2022-12-18	WOS:A1981MU79000001
J	BLOCH, KJ; WALKER, WA				BLOCH, KJ; WALKER, WA			EFFECT OF LOCALLY INDUCED INTESTINAL ANAPHYLAXIS ON THE UPTAKE OF A BYSTANDER ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MED SERV, ALLERGY UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, PEDIAT GASTROINTESTINAL & NUTR UNIT, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	BLOCH, KJ (corresponding author), MASSACHUSETTS GEN HOSP, MED SERV, CLIN IMMUNOL UNIT, BOSTON, MA 02114 USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM021505] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-23099, AM-16269, AM-21505] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZIN H, 1976, IMMUNOLOGY, V30, P679; BERNSTEIN ID, 1968, INT ARCH ALLER A IMM, V33, P521, DOI 10.1159/000230068; BLOCH KJ, 1979, GASTROENTEROLOGY, V77, P1039; BUCKLEY RH, 1969, NEW ENGL J MED, V281, P465, DOI 10.1056/NEJM196908282810903; BYARS NE, 1976, CLIN EXP IMMUNOL, V24, P352; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; FALCHUK KR, 1976, GASTROENTEROLOGY, V70, P5; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; JARRETT EEE, 1976, IMMUNOLOGY, V30, P671; KUNKEL HG, 1959, ELECTROPHORESIS, P225; MURRAY M, 1971, IMMUNOLOGY, V21, P17; PIERCE NF, 1975, J EXP MED, V142, P1550, DOI 10.1084/jem.142.6.1550; ROTHBERG RM, 1967, J IMMUNOL, V98, P386; TAYLOR KB, 1964, GASTROENTEROLOGY, V46, P99; THOMAS HC, 1974, IMMUNOLOGY, V27, P631; TOMASI TB, 1980, TRANSPLANTATION, V29, P353, DOI 10.1097/00007890-198005000-00001; URQUHART GM, 1965, EXP PARASITOL, V17, P210, DOI 10.1016/0014-4894(65)90023-8; Walzer Matthew, 1942, JOUR ALLERGY, V13, P554, DOI 10.1016/S0021-8707(42)90068-6; WILLIAMS CA, 1967, METHODS IMMUNOLOGY I, V1, P201	20	74	75	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					312	316		10.1016/0091-6749(81)90027-0	http://dx.doi.org/10.1016/0091-6749(81)90027-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204787				2022-12-18	WOS:A1981LL69700010
J	HEIMER, D; SHIM, C; WILLIAMS, MH				HEIMER, D; SHIM, C; WILLIAMS, MH			THE EFFECT OF SEQUENTIAL INHALATIONS OF METAPROTERENOL AEROSOL IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRONX MUNICIPAL HOSP CTR,ALBERT EINSTEIN COLL MED,BRONX,NY 10461; BRONX MUNICIPAL HOSP CTR,DEPT MED,CHEST SERV,BRONX,NY 10461; BRONX MUNICIPAL HOSP CTR,DIV PULM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine								DULFANO MJ, 1977, ANN ALLERGY, V39, P266; EMIRGIL C, 1977, ANN ALLERGY, V39, P415; LARSSON S, 1977, Scandinavian Journal of Respiratory Diseases Supplementum, V101, P79; PENNOCK BE, 1977, CHEST, V72, P731, DOI 10.1378/chest.72.6.731; POPA VT, 1976, CHEST, V70, P205, DOI 10.1378/chest.70.2.205; RILEY DJ, 1979, CHEST, V76, P501, DOI 10.1378/chest.76.5.501; RUFFIN RE, 1978, THORAX, V33, P689, DOI 10.1136/thx.33.6.689; SACKNER MA, 1978, CHEST, V73, P802, DOI 10.1378/chest.73.6.802; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WILDBOLZ U, 1978, LUNG, V154, P273; WILLIAMS MH, 1975, AM REV RESPIR DIS, V111, P321; WILLIAMS MH, 1976, ASTHMA DISCUSSIONS P, P46	12	74	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					75	77		10.1016/0091-6749(80)90141-4	http://dx.doi.org/10.1016/0091-6749(80)90141-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	7381125				2022-12-18	WOS:A1980JZ54100011
J	WILSON, MR; GAUMER, HR; SALVAGGIO, JE				WILSON, MR; GAUMER, HR; SALVAGGIO, JE			ACTIVATION OF ALTERNATIVE COMPLEMENT PATHWAY AND GENERATION OF CHEMOTACTIC FACTORS BY ASBESTOS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, MED CTR, DEPT MED, CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA	Tulane University								ALLISON AC, 1971, INHALED PARTICLES 3, V1, P437; ARROYAVE CM, 1976, J IMMUNOL, V116, P821; BOGOVSKI JG, 1973, IARC8 SCIENT PUBL, P1; GOTZE O, 1972, NEW ENGL J MED, V286, P180, DOI 10.1056/NEJM197201272860403; HOLT PF, 1964, J PATHOL BACTERIOL, V87, P15, DOI 10.1002/path.1700870103; KANG K, TO BE PUBLISHED; LEW FT, 1975, J IMMUNOL, V115, P884; LIGHT WG, 1977, NATURE, V265, P537, DOI 10.1038/265537a0; MACNAB G, 1967, NATURE, V214, P522, DOI 10.1038/214522a0; MAY JE, 1973, NEW ENGL J MED, V289, P706, DOI 10.1056/NEJM197310042891401; MORGAN A, 1974, ENVIRON RES, V7, P330, DOI 10.1016/0013-9351(74)90034-6; NELSON RD, 1975, J IMMUNOL, V115, P1650; PARKES W R, 1973, British Journal of Diseases of the Chest, V67, P261; PILLEMER L, 1955, SCIENCE, V122, P545, DOI 10.1126/science.122.3169.545; ROBERTSON J, 1976, J IMMUNOL, V117, P900; TIMBRELL V, 1972, POWDER TECHNOL, V5, P279, DOI 10.1016/0032-5910(72)80032-9; TIMBRELL V, 1969, PNEUMOCONIOSIS, P28	17	74	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					218	222		10.1016/0091-6749(77)90133-6	http://dx.doi.org/10.1016/0091-6749(77)90133-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	DX458	198450				2022-12-18	WOS:A1977DX45800003
J	MARX, JJ; FLAHERTY, DK				MARX, JJ; FLAHERTY, DK			ACTIVATION OF COMPLEMENT SEQUENCE BY EXTRACTS OF BACTERIA AND FUNGI ASSOCIATED WITH HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARSHFIELD MED FDN INC,IMMUNOL LABS,MARSHFIELD,WI 54449; UNIV WISCONSIN,ALLERGY LABS,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison								BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P347, DOI 10.1159/000230850; CAMPBELL D, 1964, METHODS IMMUNOLOGY; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; FLAHERTY DK, 1974, J ALLERGY CLIN IMMUN, V53, P329, DOI 10.1016/0091-6749(74)90116-X; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; GOTZE O, 1971, J EXP MED, V134, pS90; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; OSLER AG, 1973, PROG ALLERGY, V17, P51, DOI 10.1159/000313290; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; POSKITT TR, 1973, J EXP MED, V138, P715, DOI 10.1084/jem.138.3.715; SCHULTZ DR, 1971, COMPLEMENT SYSTEM MO; VERROUST PJ, 1974, KIDNEY INT, V6, P157, DOI 10.1038/ki.1974.94; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8	14	74	74	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					328	334		10.1016/0091-6749(76)90089-0	http://dx.doi.org/10.1016/0091-6749(76)90089-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	1262608	Bronze			2022-12-18	WOS:A1976BM68900006
J	Lyons, JJ; Chovanec, J; O'Connell, MP; Liu, YH; Selb, J; Zanotti, R; Bai, Y; Kim, J; Le, QT; DiMaggio, T; Schwartz, LB; Komarow, HD; Rijavec, M; Carter, MC; Milner, JD; Bonadonna, P; Metcalfe, DD; Korosec, P				Lyons, Jonathan J.; Chovanec, Jack; O'Connell, Michael P.; Liu, Yihui; Selb, Julij; Zanotti, Roberta; Bai, Yun; Kim, Jiwon; Le, Quang T.; DiMaggio, Tom; Schwartz, Lawrence B.; Komarow, Hirsh D.; Rijavec, Matija; Carter, Melody C.; Milner, Joshua D.; Bonadonna, Patrizia; Metcalfe, Dean D.; Korosec, Peter			Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; venom; hypersensitivity; idiopathic anaphylaxis; mast cell activation; hereditary alpha-tryptasemia		Background: An elevated basal serum tryptase level is associated with severe systemic anaphylaxis, most notably caused by Hymenoptera envenomation. Although clonal mast cell disease is the culprit in some individuals, it does not fully explain this clinical association. Objective: Our aim was to determine the prevalence and associated impact of tryptase genotypes on anaphylaxis in humans. Methods: Cohorts with systemic mastocytosis (SM) and venom as well as idiopathic anaphylaxis from referral centers in Italy, Slovenia, and the United States, underwent tryptase genotyping by droplet digital PCR. Associated anaphylaxis severity (Mueller scale) was subsequently examined. Healthy volunteers and controls with nonatopic disease were recruited and tryptase was genotyped by droplet digital PCR and in silico analysis of genome sequence, respectively. The effects of pooled and recombinant human tryptases, protease activated receptor 2 agonist and antagonist peptides, and a tryptase-neutralizing mAb on human umbilical vein endothelial cell permeability were assayed using a Transwell system. Results: Hereditary alpha-tryptasemia (H alpha T)-a genetic trait caused by increased alpha-tryptase-encoding Tryptase-alpha/beta 1 (TPSAB1) copy number resulting in elevated BST level-was common in healthy individuals (5.6% [n = 7 of 125]) and controls with nonatopic disease (5.3% [n = 21 of 398]). H alpha T-was associated with grade IV venom anaphylaxis (relative risk 5 2.0; P<.05) and more prevalent in both idiopathic anaphylaxis (n = 8 of 47; [17%; P = .006]) and SM (n = 10 of 82 [12.2%; P = .03]) relative to the controls. Among patients with SM, concomitant HaT was associated with increased risk for systemic anaphylaxis (relative risk = 9.5; P = .007). In vitro, protease-activated receptor-2-dependent vascular permeability was induced by pooled mature tryptases but not alpha- or beta-tryptase homotetramers. Conclusions: Risk for severe anaphylaxis in humans is associated with inherited differences in alpha-tryptase-encoding copies at TPSAB1.	[Lyons, Jonathan J.; Chovanec, Jack; O'Connell, Michael P.; Liu, Yihui; Bai, Yun; Kim, Jiwon; DiMaggio, Tom; Komarow, Hirsh D.; Carter, Melody C.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Selb, Julij; Rijavec, Matija; Korosec, Peter] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Zanotti, Roberta] Dept Med, Sect Hematol, Verona, Italy; [Le, Quang T.; Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA; [Milner, Joshua D.] Columbia Univ, Div Allergy Immunol & Rheumatol, New York, NY USA; [Bonadonna, Patrizia] Verona Univ Hosp, Allergy Unit, Verona, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Commonwealth University; Columbia University; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Lyons, JJ (corresponding author), NIH, 9000 Rockville Pike,Bldg 29B,Room 5NN18, Bethesda, MD 20892 USA.	jonathan.lyons@nih.gov		Selb, Julij/0000-0001-9499-6504	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Aberer E, 2015, AUSTRALAS J DERMATOL, V56, P7, DOI 10.1111/ajd.12146; Aniceto V, 2019, INT ARCH ALLERGY IMM, V179, P201, DOI 10.1159/000497235; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Cohen SS, 2014, BRIT J HAEMATOL, V166, P521, DOI 10.1111/bjh.12916; Fellinger C, 2014, ALLERGOL IMMUNOPATH, V42, P544, DOI 10.1016/j.aller.2014.05.002; Greiner G, 2018, CLIN CHEM, V64, P547, DOI 10.1373/clinchem.2017.277897; Gulen T, 2014, CLIN EXP ALLERGY, V44, P121, DOI 10.1111/cea.12225; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Hox V, 2016, J ALLERGY CLIN IMMUN, V138, P187, DOI 10.1016/j.jaci.2015.11.024; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Jara-Acevedo M, 2015, MODERN PATHOL, V28, P1138, DOI 10.1038/modpathol.2015.72; Kristensen T, 2014, AM J HEMATOL, V89, P493, DOI 10.1002/ajh.23672; Kucharewicz I, 2007, J INVEST ALLERG CLIN, V17, P65; Lyons JJ, 2018, IMMUNOL ALLERGY CLIN, V38, P483, DOI 10.1016/j.iac.2018.04.003; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Maun HR, 2019, CELL, V179, P417, DOI 10.1016/j.cell.2019.09.009; Mueller H L, 1966, J Asthma Res, V3, P331; Le QT, 2019, J EXP MED, V216, P2348, DOI 10.1084/jem.20190701; Rathore APS, 2019, J CLIN INVEST, V129, P4180, DOI 10.1172/JCI128426; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sabato V, 2018, J CLIN IMMUNOL, V38, P457, DOI 10.1007/s10875-018-0506-y; Sahiner UM, 2014, ALLERGY, V69, P265, DOI 10.1111/all.12317; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893	32	73	73	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					622	632		10.1016/j.jaci.2020.06.035	http://dx.doi.org/10.1016/j.jaci.2020.06.035		FEB 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32717252	Bronze			2022-12-18	WOS:000616665800024
J	Hellings, PW; Steelant, B				Hellings, Peter W.; Steelant, Brecht			Epithelial barriers in allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelial cell; tight junction; airway inflammation; epigenetics	CLARA CELL PROTEIN; AIRWAY EPITHELIUM; BASAL-CELLS; CHRONIC RHINOSINUSITIS; HISTONE DEACETYLASES; JUNCTION FORMATION; PROGENITOR CELLS; TIGHT JUNCTIONS; INNATE IMMUNITY; STEM-CELLS	The respiratory epithelium provides a physical, functional, and immunologic barrier to protect the host from the potential harming effects of inhaled environmental particles and to guarantee maintenance of a healthy state of the host. When compromised, activation of immune/inflammatory responses against exogenous allergens, microbial substances, and pollutants might occur, rendering individuals prone to develop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma. The airway epithelium in asthma and upper airway diseases is dysfunctional due to disturbed tight junction formation. By putting the epithelial barrier to the forefront of the pathophysiology of airway inflammation, different approaches to diagnose and target epithelial barrier defects are currently being developed. Using single-cell transcriptomics, novel epithelial cell types are being unraveled that might play a role in chronicity of respiratory diseases. We here review and discuss the current understandings of epithelial barrier defects in type 2 driven chronic inflammation of the upper and lower airways, the estimated contribution of these novel identified epithelial cells to disease, and the current clinical challenges in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma.	[Hellings, Peter W.] Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Herestr 49, B-3000 Leuven, Belgium; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Hellings, Peter W.; Steelant, Brecht] Katholieke Univ Leuven, Allergy & Clin Immunol Res Unit, Dept Microbiol Immunol & Transplantat, Leuven, Belgium; [Hellings, Peter W.] Univ Hosp Ghent, Dept Otorhinolaryngol, Lab Upper Airway Res, Ghent, Belgium; [Steelant, Brecht] Univ Crete, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Iraklion, Crete, Greece	KU Leuven; University Hospital Leuven; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; Ghent University; Ghent University Hospital; University of Crete	Hellings, PW (corresponding author), Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Herestr 49, B-3000 Leuven, Belgium.	Peter.hellings@kuleuven.be			Belgian Federal Government [IUAP P7/30]; Agentschap voor Innovatie doorWetenschap en Technologie (IWT) [130260]; research council of the KU Leuven [GOA 14/011]	Belgian Federal Government; Agentschap voor Innovatie doorWetenschap en Technologie (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); research council of the KU Leuven(KU Leuven)	The author's laboratory (P.W.H.) is supported by grants from the Belgian Federal Government (grant no. IUAP P7/30), Agentschap voor Innovatie doorWetenschap en Technologie (IWT) (TBM project no. 130260), and the research council of the KU Leuven (grant no. GOA 14/011). B.S. is a postdoctoral fellow of the Fund for Scientific Research Flanders (FWO).	Aggarwal S, 2011, BIOCHEM J, V433, P51, DOI 10.1042/BJ20100249; Amatngalim GD, 2015, J IMMUNOL, V194, P3340, DOI 10.4049/jimmunol.1402169; Barnes PJ, 2005, EUR RESPIR J, V25, P1084, DOI 10.1183/09031936.05.00139104; Basnet S, 2019, AM J RESP CELL MOL, V61, P450, DOI 10.1165/rcmb.2018-0220OC; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Blomberg A, 2003, EUR RESPIR J, V22, P883, DOI 10.1183/09031936.03.00048203; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonser LR, 2017, J CLIN MED, V6; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Broeckaert F, 2000, ANN NY ACAD SCI, V923, P68; BUCKLE FG, 1975, J ALLERGY CLIN IMMUN, V55, P213, DOI 10.1016/0091-6749(75)90139-6; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Carey RM, 2019, NUTRIENTS, V11; Ceteci F, 2012, NEOPLASIA, V14, P1164, DOI 10.1593/neo.121088; Cokugras H, 2001, THORAX, V56, P25, DOI 10.1136/thorax.56.1.25; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Crystal Ronald G, 2008, Proc Am Thorac Soc, V5, P772, DOI 10.1513/pats.200805-041HR; Cutz E, 2013, SEMIN CELL DEV BIOL, V24, P40, DOI 10.1016/j.semcdb.2012.09.003; Davies Donna E, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS244, DOI 10.1513/AnnalsATS.201407-304AW; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Callejas FD, 2015, LARYNGOSCOPE, V125, pE158, DOI 10.1002/lary.25147; DelDonno M, 1997, CHEST, V111, P1255, DOI 10.1378/chest.111.5.1255; EVANS MJ, 1989, AM J RESP CELL MOL, V1, P463, DOI 10.1165/ajrcmb/1.6.463; Everman JL, 2019, J ALLERGY CLIN IMMUN, V144, P962, DOI 10.1016/j.jaci.2019.01.052; Fasano A, 2000, LANCET, V355, P1518, DOI 10.1016/S0140-6736(00)02169-3; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Fokkens WJ, 2020, RHINOLOGY, V58, P1, DOI 10.4193/Rhin20.401; Forno E, 2019, LANCET RESP MED, V7, P336, DOI 10.1016/S2213-2600(18)30466-1; Fuchs FS, 2013, EUR RESPIR J, V41, P1401, DOI 10.1183/09031936.00062512; Fukuda K, 2019, CANCER RES, V79, P1658, DOI 10.1158/0008-5472.CAN-18-2052; Garg A, 2019, CURR TOP DEV BIOL, V132, P67, DOI 10.1016/bs.ctdb.2018.12.002; Georas S, 2019, J ASTHMA, V56, P1257, DOI 10.1080/02770903.2018.1536145; Georas SN, 2019, J ALLERGY CLIN IMMUN, V144, P1172, DOI 10.1016/j.jaci.2019.09.007; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gerbe F, 2016, MUCOSAL IMMUNOL, V9, P1353, DOI 10.1038/mi.2016.68; Gohy S, 2020, CLIN EXP ALLERGY, V50, P135, DOI 10.1111/cea.13539; Gon Y, 2018, ALLERGOL INT, V67, P12, DOI 10.1016/j.alit.2017.08.011; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Gu XL, 2014, AM J RESP CELL MOL, V50, P637, DOI 10.1165/rcmb.2013-0199OC; Guseh JS, 2009, DEVELOPMENT, V136, P1751, DOI 10.1242/dev.029249; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Heijink IH, 2014, AM J RESP CRIT CARE, V189, P1439, DOI 10.1164/rccm.201311-1982LE; Hellings PW, 2017, ALLERGY, V72, P1297, DOI 10.1111/all.13162; Hellings PW, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0186-3; Hens G, 2007, J ALLERGY CLIN IMMUN, V120, P472, DOI 10.1016/j.jaci.2007.03.047; HIJIYA K, 1978, J ELECTRON MICROSC, V27, P223; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; ILOWITE JS, 1989, AM REV RESPIR DIS, V139, P1139, DOI 10.1164/ajrccm/139.5.1139; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Kim SHJ, 2010, J R SOC INTERFACE, V7, P1157, DOI 10.1098/rsif.2010.0041; Kiyokawa H, 2020, DEV GROWTH DIFFER, V62, P67, DOI 10.1111/dgd.12628; Wolterink RGJK, 2018, IMMUNITY, V49, P9, DOI 10.1016/j.immuni.2018.06.010; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kohanski MA, 2018, J ALLERGY CLIN IMMUN, V142, P460, DOI 10.1016/j.jaci.2018.03.019; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Kozu Y, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0078-z; Krohn IK, 2018, ALLERGY, V73, P1084, DOI 10.1111/all.13349; Krohn IK, 2020, ALLERGY, V75, P1155, DOI 10.1111/all.14132; Kropski JA, 2009, CHEST, V135, P1440, DOI 10.1378/chest.08-2465; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Laucho-Contreras ME, 2015, EUR RESPIR J, V45, P1544, DOI 10.1183/09031936.00134214; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Lehmann AD, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-26; LEMARCHAND P, 1992, AM REV RESPIR DIS, V145, P147, DOI 10.1164/ajrccm/145.1.147; Linnoila RI, 2006, LAB INVEST, V86, P425, DOI 10.1038/labinvest.3700412; London NR, 2016, LARYNSCOPE INVESTIG, V1, P49, DOI 10.1002/lio2.21; Loxham M, 2017, J ALLERGY CLIN IMMUN, V139, P1736, DOI 10.1016/j.jaci.2017.04.005; Lutter R, 2019, J ALLERGY CLIN IMMUN, V144, P926, DOI 10.1016/j.jaci.2019.07.021; Martens K, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0225-8; Martinez-Anton A, 2006, CURR ALLERGY ASTHM R, V6, P189, DOI 10.1007/s11882-006-0034-3; Montoro DT, 2018, NATURE, V560, P319, DOI 10.1038/s41586-018-0393-7; Morimoto M, 2012, DEVELOPMENT, V139, P4365, DOI 10.1242/dev.083840; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Patel NN, 2019, INT FORUM ALLERGY RH, V9, P730, DOI 10.1002/alr.22334; Patel NN, 2018, J PATHOG, V2018, DOI 10.1155/2018/9541987; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Perez CA, 2003, CELL CALCIUM, V33, P541, DOI 10.1016/S0143-4160(03)00059-9; Petecchia L, 2009, CHEST, V135, P1502, DOI 10.1378/chest.08-1780; Petrek M, 2002, BIOMARKERS, V7, P58, DOI 10.1080/13547500110086892; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Ridley C, 2018, BIOCHEM SOC T, V46, P1099, DOI 10.1042/BST20170402; Rittirsch D, 2013, AM J PHYSIOL-LUNG C, V304, pL863, DOI 10.1152/ajplung.00196.2012; Rock JR, 2011, CELL STEM CELL, V8, P639, DOI 10.1016/j.stem.2011.04.003; Rock JR, 2010, DIS MODEL MECH, V3, P545, DOI 10.1242/dmm.006031; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Ruan YC, 2014, J CELL SCI, V127, P4396, DOI 10.1242/jcs.148098; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Seumois G, 2019, J ALLERGY CLIN IMMUN, V144, P1150, DOI 10.1016/j.jaci.2019.09.014; Shah VS, 2016, SCIENCE, V351, P503, DOI 10.1126/science.aad5589; Shahana S, 2005, RESP MED, V99, P429, DOI 10.1016/j.rmed.2004.08.013; Shang Y, 2013, AM J RESP CELL MOL, V49, P279, DOI 10.1165/rcmb.2012-0403OC; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2020, CURR OPIN PULM MED, V26, P20, DOI 10.1097/MCP.0000000000000638; Steelant B, 2019, J ALLERGY CLIN IMMUN, V144, P1242, DOI 10.1016/j.jaci.2019.04.027; Steelant B, 2018, J ALLERGY CLIN IMMUN, V141, P951, DOI 10.1016/j.jaci.2017.08.039; Steelant B, 2016, RHINOLOGY, V54, P195, DOI 10.4193/Rhino15.376; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stefanowicz D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044213; Sturgeon C, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1251384; Sui P, 2018, SCIENCE, V360; TAYLOR SM, 1983, J APPL PHYSIOL, V55, P614, DOI 10.1152/jappl.1983.55.2.614; Tellez GF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163967; Teoh KT, 2010, MOL BIOL CELL, V21, P3838, DOI 10.1091/mbc.E10-04-0338; Thiberville L, 2007, AM J RESP CRIT CARE, V175, P22, DOI 10.1164/rccm.200605-684OC; Thomas B, 2010, J ALLERGY CLIN IMMUN, V126, P722, DOI 10.1016/j.jaci.2010.05.046; Tripathi A, 2009, P NATL ACAD SCI USA, V106, P16799, DOI 10.1073/pnas.0906773106; Van Gerven L, 2018, ALLERGY, V73, P1784, DOI 10.1111/all.13453; Van Gerven L, 2018, ALLERGY, V73, P248, DOI 10.1111/all.13245; Van Lommel A, 2001, Paediatr Respir Rev, V2, P171, DOI 10.1053/prrv.2000.0126; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Whitsett JA, 2018, ANN AM THORAC SOC, V15, pS143, DOI 10.1513/AnnalsATS.201802-128AW; Worgall TS, 2017, CURR OPIN CLIN NUTR, V20, P99, DOI 10.1097/MCO.0000000000000349; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yang RX, 2019, INT J MOL MED, V44, P535, DOI 10.3892/ijmm.2019.4233; Yu F, 2017, MOL MED REP, V15, P2969, DOI 10.3892/mmr.2017.6413; Yu XM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04619; Zhu LX, 2019, AM J RESP CELL MOL, V60, P695, DOI 10.1165/rcmb.2018-0199OC	127	73	75	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1499	1509		10.1016/j.jaci.2020.04.010	http://dx.doi.org/10.1016/j.jaci.2020.04.010			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32507228	Bronze, Green Published			2022-12-18	WOS:000539157800002
J	Konvinse, KC; Trubiano, JA; Pavlos, R; James, I; Shaffer, CM; Bejan, CA; Schutte, RJ; Ostrov, DA; Pilkinton, MA; Rosenbach, M; Zwerner, JP; Williams, KB; Bourke, J; Martinez, P; Rwandamuriye, F; Chopra, A; Watson, M; Redwood, AJ; White, KD; Mallal, SA; Phillips, EJ				Konvinse, Katherine C.; Trubiano, Jason A.; Pavlos, Rebecca; James, Ian; Shaffer, Christian M.; Bejan, Cosmin A.; Schutte, Ryan J.; Ostrov, David A.; Pilkinton, Mark A.; Rosenbach, Misha; Zwerner, Jeffrey P.; Williams, Kristina B.; Bourke, Jack; Martinez, Patricia; Rwandamuriye, Francois; Chopra, Abha; Watson, Mark; Redwood, Alec J.; White, Katie D.; Mallal, Simon A.; Phillips, Elizabeth J.			HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vancomycin; drug reaction with eosinophilia and systemic symptoms; human leukocyte antigen; antibiotic allergy; delayed hypersensitivity; T-cell hypersensitivity	HYPERSENSITIVITY; HLA; HLA-B-ASTERISK-5701	Background: Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant morbidity and mortality and commonly occurs in the setting of combination antibiotic therapy, affecting future treatment choices. Variations in HLA class I in particular have been associated with serious T cell-mediated adverse drug reactions, which has led to preventive screening strategies for some drugs. Objective: We sought to determine whether variation in the HLA region is associated with vancomycin-induced DRESS. Methods: Probable vancomycin-induced DRESS cases were matched 1:2 with tolerant control subjects based on sex, race, and age by using BioVU, Vanderbilt's deidentified electronic health record database. Associations between DRESS and carriage of HLA class I and II alleles were assessed by means of conditional logistic regression. An extended sample set from BioVU was used to conduct a time-to-event analysis of those exposed to vancomycin with and without the identified HLA risk allele. Results: Twenty-three subjects met the inclusion criteria for vancomycin-associated DRESS. Nineteen (82.6%) of 23 cases carried HLA-A*32:01 compared with 0 (0%) of 46 of the matched vancomycin-tolerant control subjects (P = 1 x 10(-8)) and 6.3% of the BioVU population (n = 54,249, P = 2 x 10(-16)). Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks. Conclusions: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry. HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.	[Konvinse, Katherine C.; Mallal, Simon A.; Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Shaffer, Christian M.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN USA; [Bejan, Cosmin A.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA; [Pilkinton, Mark A.; Williams, Kristina B.; White, Katie D.; Mallal, Simon A.; Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA; [Zwerner, Jeffrey P.] Vanderbilt Univ, Med Ctr, Dept Dermatol, Nashville, TN USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Trubiano, Jason A.] Austin Hlth, Dept Infect Dis, Heidelberg, Vic, Australia; [Trubiano, Jason A.] Peter MacCallum Canc Ctr, Dept Infect Dis, Natl Ctr Infect Canc, Parkville, Vic, Australia; [Trubiano, Jason A.] Univ Melbourne, Dept Med, Parkville, Vic, Australia; [Pavlos, Rebecca] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia; [James, Ian; Rwandamuriye, Francois; Chopra, Abha; Watson, Mark; Redwood, Alec J.; Mallal, Simon A.; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia; [Schutte, Ryan J.; Ostrov, David A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Rosenbach, Misha] Hosp Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; [Bourke, Jack; Martinez, Patricia] Fiona Stanley Hosp, Dept Clin Immunol, Murdoch, WA, Australia; [Martinez, Patricia] Royal Perth Hosp, Dept Clin Immunol, Perth, WA, Australia; [Martinez, Patricia] Univ Western Australia, Fac Med Dent & Hlth Sci, Sch Med, Div Pathol & Lab Med, Crawley, Vic, Australia	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Peter Maccallum Cancer Center; University of Melbourne; Telethon Kids Institute; University of Western Australia; Murdoch University; State University System of Florida; University of Florida; University of Pennsylvania; Pennsylvania Medicine; Royal Perth Hospital; University of Western Australia; University of Western Australia	Phillips, EJ (corresponding author), 1161 21st Ave S,A2200 MCN, Nashville, TN 37232 USA.	elizabeth.j.phillips@vumc.org	Redwood, Alec/A-6138-2008; Mallal, Simon Alexander/HDM-9561-2022; Pavlos, Rebecca/AAY-9072-2020; Redwood, Alec/Z-3387-2019	Redwood, Alec/0000-0001-8601-8292; Mallal, Simon Alexander/0000-0002-7036-1309; Pavlos, Rebecca/0000-0002-8884-9855; Redwood, Alec/0000-0001-8601-8292; Konvinse, Katherine/0000-0003-2451-9256; Trubiano, Jason/0000-0002-5111-6367; Rwandamuriye, Francois Xavier/0000-0002-3456-3931; Chopra, Abha/0000-0001-5008-9080	National Institutes of Health [F30 AI131780, P50 GM115305, T32 GM7347, P30 AI110527, R34 AI136815, R21 AI139021, T32 AI007474, K12 HL143956, R01 AI134648]; National Centre for Infections in Cancer; Austin Medical Research Foundation; National Health andMedical ResearchCouncil of Australia; National Institutes of Health (NIH) [S10RR025141]; CTSA grants [UL1TR002243, UL1TR000445, UL1RR024975]; National Cancer Center/NIH Cancer Center Support Grant [5P30 CA68485-19];  [U01HG004798];  [R01NS032830];  [RC2GM092618];  [P50GM115305];  [U01HG006378];  [U19HL065962];  [R01HD074711]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD074711] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002243, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL143956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI110527, T32AI007474, R21AI139021, R01AI134648, R34AI136815, F30AI131780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305, T32GM007347] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Centre for Infections in Cancer; Austin Medical Research Foundation; National Health andMedical ResearchCouncil of Australia; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA grants; National Cancer Center/NIH Cancer Center Support Grant; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (F30 AI131780, P50 GM115305, T32 GM7347, P30 AI110527, R34 AI136815, R21 AI139021, T32 AI007474, K12 HL143956, and R01 AI134648), the National Centre for Infections in Cancer, the Austin Medical Research Foundation, and the National Health andMedical ResearchCouncil of Australia. Someof the data set(s) used for the analyses described were obtained fromVanderbilt University Medical Center's Synthetic Derivative and BioVU, which are supported by numerous sources: institutional funding, private agencies, and federal grants. These include the National Institutes of Health (NIH)-funded Shared Instrumentation grant S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, and R01HD074711 and additional funding sources listed at https://victr.vanderbilt.edu/pub/biovu/.We additionally acknowledge the Vanderbilt Translational Pathology Shared Resource supported by National Cancer Center/NIH Cancer Center Support Grant 5P30 CA68485-19.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aota N, 2009, AUTOIMMUN REV, V8, P488, DOI 10.1016/j.autrev.2009.02.029; BADEN LA, 1988, ARCH DERMATOL, V124, P1186, DOI 10.1001/archderm.124.8.1186; Blumenthal KG, 2019, LANCET, V393, P183, DOI 10.1016/S0140-6736(18)32218-9; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Ghislain Pierre-Dominique, 2002, Dermatol Online J, V8, P5; Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166; Gragert L, 2013, HUM IMMUNOL, V74, P1313, DOI 10.1016/j.humimm.2013.06.025; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Kardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501; Karnes JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172444; Keane NM, 2014, AIDS, V28, P1891, DOI 10.1097/QAD.0000000000000345; Keane NM, 2012, IMMUNOL CELL BIOL, V90, P224, DOI 10.1038/icb.2011.34; Lin YF, 2014, CLIN INFECT DIS, V58, P1377, DOI 10.1093/cid/ciu126; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; Minhas JS, 2016, ANN ALLERG ASTHMA IM, V116, P544, DOI 10.1016/j.anai.2016.03.030; Morito H, 2014, CLIN EXP DERMATOL, V39, P284, DOI 10.1111/ced.12246; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Pavlos R, 2012, PHARMACOGENOMICS, V13, P1285, DOI [10.2217/PGS.12.108, 10.2217/pgs.12.108]; Rapin N, 2008, IMMUNOGENETICS, V60, P759, DOI 10.1007/s00251-008-0330-2; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Trubiano JA, 2018, J ALLER CL IMM-PRACT, V6, P1287, DOI 10.1016/j.jaip.2017.09.004	29	73	75	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					183	192		10.1016/j.jaci.2019.01.045	http://dx.doi.org/10.1016/j.jaci.2019.01.045			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30776417	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000473432800021
J	Davidson, WF; Leung, DYM; Beck, LA; Berin, CM; Boguniewicz, M; Busse, WW; Chatila, TA; Geha, RS; Gern, JE; Guttman-Yassky, E; Irvine, AD; Kim, BS; Kong, HH; Lack, G; Nadeau, KC; Schwaninger, J; Simpson, A; Simpson, EL; Spergel, JM; Togias, A; Wahn, U; Wood, RA; Woodfolk, JA; Ziegler, SF; Plaut, M				Davidson, Wendy F.; Leung, Donald Y. M.; Beck, Lisa A.; Berin, Cecilia M.; Boguniewicz, Mark; Busse, William W.; Chatila, Talal A.; Geha, Raif S.; Gern, James E.; Guttman-Yassky, Emma; Irvine, Alan D.; Kim, Brian S.; Kong, Heidi H.; Lack, Gideon; Nadeau, Kari C.; Schwaninger, Julie; Simpson, Angela; Simpson, Eric L.; Spergel, Jonathan M.; Togias, Alkis; Wahn, Ulrich; Wood, Robert A.; Woodfolk, Judith A.; Ziegler, Steven F.; Plaut, Marshall			Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions''	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic march; atopic dermatitis; food allergy; asthma; skin barrier; skin microbiome; biomarkers; interventions	THYMIC STROMAL LYMPHOPOIETIN; TRANSEPIDERMAL WATER-LOSS; SKIN BARRIER DYSFUNCTION; FOOD ALLERGY; STAPHYLOCOCCUS-AUREUS; T-CELLS; CYTOKINE MODULATION; IMMUNE DEVELOPMENT; RECURRENT WHEEZE; PREDICTIVE-VALUE	Atopic dermatitis (AD) affects up to 20% of children worldwide and is an increasing public health problem, particularly in developed countries. Although AD in infants and young children can resolve, there is a well-recognized increased risk of sequential progression from AD to other atopic diseases, including food allergy (FA), allergic rhinitis, allergic asthma, and allergic rhinoconjunctivitis, a process referred to as the atopic march. The mechanisms underlying the development of AD and subsequent progression to other atopic comorbidities, particularly FA, are incompletely understood and the subject of intense investigation. Other major research objectives are the development of effective strategies to prevent AD and FA, as well as therapeutic interventions to inhibit the atopic march. In 2017, the Division of Allergy, Immunology, and Transplantation of the National Institute of Allergy and Infectious Diseases sponsored a workshop to discuss current understanding and important advances in these research areas and to identify gaps in knowledge and future research directions. International and national experts in the field were joined by representatives from several National Institutes of Health institutes. Summaries of workshop presentations, key conclusions, and recommendations are presented herein.	[Davidson, Wendy F.; Schwaninger, Julie; Togias, Alkis; Plaut, Marshall] NIAID, NIH, Rockville, MD USA; [Leung, Donald Y. M.; Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA; [Leung, Donald Y. M.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Aurora, CO USA; [Beck, Lisa A.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA; [Berin, Cecilia M.] Icahn Sch Med Mt Sinai, Dept Pediat, Mindich Child Hlth & Dev Inst, Inst Immunol, New York, NY 10029 USA; [Boguniewicz, Mark] Univ Colorado, Sch Med, Aurora, CO USA; [Busse, William W.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Chatila, Talal A.] Harvard Med Sch, Div Immunol, Dept Pediat, Boston Childrens Hosp, Boston, MA 02115 USA; [Geha, Raif S.] Harvard Med Sch, Div Immunol, Childrens Hosp, Boston, MA 02115 USA; [Geha, Raif S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA; [Irvine, Alan D.] Our Ladys Childrens Hosp, Paediat Dermatol, Crumlin, Ireland; [Irvine, Alan D.] Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Dublin, Ireland; [Kim, Brian S.] Washington Univ, Sch Med, Ctr Study Itch, Div Dermatol,Dept Med, St Louis, MO 63130 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63130 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA; [Kong, Heidi H.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Kings Coll London,Dept Women & Childrens Hlth, Peter Gorer Dept Immunobiol,Fac Life Sci & Med, Sch Life Course Sci,Paediat Allergy, London, England; [Nadeau, Kari C.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Nadeau, Kari C.] Stanford Univ, Dept Med, Dept Pediat, Stanford, CA 94305 USA; [Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Infect Immun & Resp Med, Sch Biol Sci, Manchester, Lancs, England; [Simpson, Eric L.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Spergel, Jonathan M.] Childrens Hosp Philadelphia, Dept Pediat, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Spergel, Jonathan M.] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Woodfolk, Judith A.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; [Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA USA; [Kong, Heidi H.] NIAMSD, Dermatol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Rochester; Icahn School of Medicine at Mount Sinai; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; National Children's Research Centre (NCRC); National Children's Research Centre (NCRC); Trinity College Dublin; Trinity College Dublin; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Stanford University; Stanford University; University of Manchester; Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johns Hopkins University; University of Virginia; Benaroya Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.	LeungD@njhealth.org	Irvine, Alan D/A-3982-2008; Kim, Brian/GZK-6649-2022; Kong, Heidi H/L-4856-2018	Irvine, Alan D/0000-0002-9048-2044; Kim, Brian/0000-0002-8100-7161; Kong, Heidi H/0000-0003-4424-064X; berin, cecilia/0000-0002-9051-9249; Lack, Gideon/0000-0001-7350-4021; Simpson, Angela/0000-0003-2733-6666	NATIONAL CANCER INSTITUTE [ZIABC010938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI126915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577, R01AR070116] Funding Source: NIH RePORTER; MRC [G0601361, MR/K002449/1] Funding Source: UKRI; Medical Research Council [MR/K002449/1, G0601361] Funding Source: Medline; NIAID NIH HHS [R01 AI126915] Funding Source: Medline; NIAMS NIH HHS [K08 AR065577, U34 AR065739, R01 AR070116] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alduraywish SA, 2017, PEDIAT ALLERG IMM-UK, V28, P30, DOI 10.1111/pai.12651; Bacharier LB, 2019, AM J RESP CRIT CARE, V199, P71, DOI 10.1164/rccm.201801-0190OC; Barnetson RS, 1993, ALLERGY; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Belgrave DCM, 2015, CURR DERMATOL REP, V4, P221, DOI 10.1007/s13671-015-0121-6; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Berdyshev E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98006; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin LH, 2012, J ALLERGY CLIN IMMUN, V130, P683, DOI 10.1016/j.jaci.2012.06.019; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Brandner JM, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974451; Brough HA, 2018, CLIN EXP ALLERGY, V48, P586, DOI 10.1111/cea.13111; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brunner PM, 2017, ALLERGY, V72, P2017, DOI 10.1111/all.13223; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Busse WW, 2018, ANN ALLERG ASTHMA IM, V120, P116, DOI 10.1016/j.anai.2017.10.029; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; du Toit G, 2018, J ALLERGY CLIN IMMUN, V141, P1343, DOI 10.1016/j.jaci.2017.09.034; Dyjack N, 2018, J ALLERGY CLIN IMMUN, V141, P1298, DOI 10.1016/j.jaci.2017.10.046; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Fleury OM, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00994-16; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gern JE, 2017, J ALLERGY CLIN IMMUN, V140, P836, DOI 10.1016/j.jaci.2016.10.052; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gough H, 2015, PEDIAT ALLERG IMM-UK, V26, P431, DOI 10.1111/pai.12410; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Han HW, 2017, IMMUNOL REV, V278, P116, DOI 10.1111/imr.12546; Han HW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01863-5; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Hata TR, 2010, BRIT J DERMATOL, V163, P659, DOI 10.1111/j.1365-2133.2010.09892.x; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Hill DA, 2018, ANN ALLERG ASTHMA IM, V120, P131, DOI 10.1016/j.anai.2017.10.037; Hill DA, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0673-z; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim J, 2016, J ALLERGY CLIN IMMUN, V137, P1282, DOI 10.1016/j.jaci.2015.12.1306; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Larson RP, 2013, J IMMUNOL, V190, P4474, DOI 10.4049/jimmunol.1201677; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lowe AJ, 2018, BRIT J DERMATOL, V178, pE19, DOI 10.1111/bjd.15747; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Malmberg LP, 2010, CLIN EXP ALLERGY, V40, P1491, DOI 10.1111/j.1365-2222.2010.03567.x; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; Matricardi PM, 2010, EUR RESPIR J, V35, P701, DOI 10.1183/09031936.00163709; McAleer MA, 2018, BR J DERMATOL; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Muehling LM, 2018, J INFECT DIS, V217, P381, DOI 10.1093/infdis/jix514; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Ong PY, 2016, CLIN REV ALLERG IMMU, V51, P329, DOI 10.1007/s12016-016-8548-5; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Oyoshi MK, 2016, J ALLERGY CLIN IMMUN, V138, P283, DOI 10.1016/j.jaci.2015.12.1304; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Pyun BY, 2015, ALLERGY ASTHMA IMMUN, V7, P101, DOI 10.4168/aair.2015.7.2.101; Rachid R, 2016, CURR OPIN PEDIATR, V28, P748, DOI 10.1097/MOP.0000000000000427; Reynolds LA, 2017, NAT REV IMMUNOL, V17, P518, DOI 10.1038/nri.2017.39; Riethmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P1573, DOI 10.1016/j.jaci.2015.04.042; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Romeo MJ, 2014, J ALLERGY CLIN IMMUN, V133, P952, DOI 10.1016/j.jaci.2013.08.006; Ruzicka T, 2017, NEW ENGL J MED, V376, P2093, DOI 10.1056/NEJMc1704013; */* S   5, 2010, J ALLERGY CLIN IMM S, V126, pS, DOI DOI 10.1016/J.JACI.2010.10.007; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Schneider L, 2016, PEDIATR DERMATOL, V33, P388, DOI 10.1111/pde.12867; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Singh AM, 2010, J ALLERGY CLIN IMMUN, V125, P491, DOI 10.1016/j.jaci.2009.11.026; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tauber M, 2016, J ALLERGY CLIN IMMUN, V137, P1272, DOI 10.1016/j.jaci.2015.07.052; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Totte JEE, 2016, BRIT J DERMATOL, V175, P687, DOI 10.1111/bjd.14566; Tran MM, 2018, J ALLERGY CLIN IMMUN, V141, P601, DOI 10.1016/j.jaci.2017.08.024; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Vermeulen EM, 2018, J ALLER CL IMM-PRACT, V6, P1336, DOI 10.1016/j.jaip.2017.10.019; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wahn U, 2000, ALLERGY, V55, P591, DOI 10.1034/j.1398-9995.2000.00111.x; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wang YH, 2016, F1000RES, V5, pF1000, DOI 10.12688/f1000research.9497.1; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Wisniewski JA, 2013, CLIN EXP ALLERGY, V43, P1160, DOI 10.1111/cea.12169; Wisniewski JA, 2018, J ALLERGY CLIN IMMUN, V141, P2048, DOI 10.1016/j.jaci.2017.08.020; Wood RA, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Wood RA, 2011, J ALLERGY CLIN IMMUN, V127, P913, DOI 10.1016/j.jaci.2010.12.1122; Yoshida K, 2014, J ALLERGY CLIN IMMUN, V134, P856, DOI 10.1016/j.jaci.2014.08.001	143	73	83	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					894	913		10.1016/j.jaci.2019.01.003	http://dx.doi.org/10.1016/j.jaci.2019.01.003			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30639346	Green Accepted, Bronze			2022-12-18	WOS:000460272900007
J	Park, CO; Fu, XJ; Jiang, XD; Pan, YD; Teague, JE; Collins, N; Tian, T; O'Malley, JT; Emerson, RO; Kim, JH; Jung, Y; Watanabe, R; Fuhlbrigge, RC; Carbone, FR; Gebhardt, T; Clark, RA; Lin, CP; Kupper, TS				Park, Chang Ook; Fu, Xiujun; Jiang, Xiaodong; Pan, Youdong; Teague, Jessica E.; Collins, Nicholas; Tian, Tian; O'Malley, John T.; Emerson, Ryan O.; Kim, Ji Hye; Jung, Yookyung; Watanabe, Rei; Fuhlbrigge, Robert C.; Carbone, Francis R.; Gebhardt, Thomas; Clark, Rachael A.; Lin, Charles P.; Kupper, Thomas S.			Staged development of long-lived T-cell receptor alpha beta T(H)17 resident memory T-cell population to Candida albicans after skin infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Resident memory T cells; T-RM; Candida albicans; IL-17; T(H)17; CD4(+) T-RM	NONLYMPHOID TISSUE; MEDIATED-IMMUNITY; DISTINCT; HUMANS; MICE; RETENTION	Background: Candida albicans is a dimorphic fungus to which human subjects are exposed early in life, and by adulthood, it is part of the mycobiome of skin and other tissues. Neonatal skin lacks resident memory T (T-RM) cells, but in adults the C albicans skin test is a surrogate for immunocompetence. Young adult mice raised under specific pathogen-free conditions are naive to C albicans and have been shown recently to have an immune system resembling that of neonatal human subjects. Objective: We studied the evolution of the adaptive cutaneous immune response to Candida species. Methods: We examined both human skin T cells and the de novo and memory immune responses in a mouse model of C albicans skin infection. Results: In mice the initial IL-17-producing cells after C albicans infection were dermal gamma delta T cells, but by day 7, alpha beta TH17 effector T cells were predominant. By day 30, the majority of C albicans-reactive IL-17-producing T cells were CD4 T-RM cells. Intravital microscopy showed that CD4 effector T cells were recruited to the site of primary infection and were highly motile 10 days after infection. Between 30 and 90 days after infection, these CD4 T cells became increasingly sessile, acquired expression of CD69 and CD103, and localized to the papillary dermis. These established T-RM cells produced IL-17 on challenge, whereas motile migratory memory T cells did not. T-RM cells rapidly clear an infectious challenge with C albicans more effectively than recirculating T cells, although both populations participate. We found that in normal human skin IL-17-producing CD4(+) T-RM cells that responded to C albicans in an MHC class II-restricted fashion could be identified readily. Conclusions: These studies demonstrate that C albicans infection of skin preferentially generates CD4(+) IL-17-producing T-RM cells, which mediate durable protective immunity.	[Park, Chang Ook; Jiang, Xiaodong; Pan, Youdong; Teague, Jessica E.; Tian, Tian; O'Malley, John T.; Watanabe, Rei; Fuhlbrigge, Robert C.; Clark, Rachael A.; Kupper, Thomas S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, 77 Ave Louis Pasteur, Boston, MA 02115 USA; [Fu, Xiujun; Jung, Yookyung; Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA USA; [Fu, Xiujun; Jung, Yookyung; Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA; [Collins, Nicholas; Carbone, Francis R.; Gebhardt, Thomas] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic, Australia; [Emerson, Ryan O.] Adapt Biotechnol, Seattle, WA USA; [Park, Chang Ook; Kim, Ji Hye] Yonsei Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Park, Chang Ook; Kim, Ji Hye] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Seoul, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Melbourne; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kupper, TS (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tkupper@bwh.harvard.edu	Kupper, Thomas/O-4962-2019; Carbone, Francis/ABF-2141-2020; Watanabe, Rei/CAH-9893-2022	Kim, Ji Hye/0000-0003-2734-1174; Gebhardt, Thomas/0000-0002-3768-9468; Park, Chang Ook/0000-0003-3856-1201; Jung, Yookyung/0000-0003-2790-6016	National Institutes of Health [R01AI041707, R01AI127654, R01AR065807, TR01AI097128, R01AR063962]; Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI14C1324, HI14C1799]; NATIONAL CANCER INSTITUTE [R01CA203721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI127654, R01AI097128, R01AI041707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065807, P30AR069625, R01AR063962] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health grants R01AI041707, R01AI127654, and R01AR065807 (to T.S.K.), TR01AI097128 (to T.S.K. and R.A.C.), and R01AR063962 (to R.A.C.). C.O.P. was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C1324, HI14C1799).	Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Bromley SK, 2013, J IMMUNOL, V190, P970, DOI 10.4049/jimmunol.1202805; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Clark RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010641; Collins N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11514; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Glennie ND, 2015, J EXP MED, V212, P1405, DOI 10.1084/jem.20142101; Gray EE, 2011, J IMMUNOL, V186, P6091, DOI 10.4049/jimmunol.1100427; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; Iijima N, 2014, SCIENCE, V346, P93, DOI 10.1126/science.1257530; Jiang XD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169397; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Kashem SW, 2016, TRENDS IMMUNOL, V37, P440, DOI 10.1016/j.it.2016.04.007; Kashem SW, 2015, IMMUNITY, V42, P356, DOI 10.1016/j.immuni.2015.01.008; Kim P, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2839043; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Lagunes L, 2016, EUR J CLIN MICROBIOL, V35, P1221, DOI 10.1007/s10096-016-2658-0; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Liu LZ, 2010, NAT MED, V16, P224, DOI 10.1038/nm.2078; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Mackay LK, 2015, J IMMUNOL, V194, P2059, DOI 10.4049/jimmunol.1402256; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; MOESGAARD F, 1987, ALLERGY, V42, P591, DOI 10.1111/j.1398-9995.1987.tb00389.x; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Park CO, 2015, NAT MED, V21, P688, DOI 10.1038/nm.3883; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Reese TA, 2016, CELL HOST MICROBE, V19, P713, DOI 10.1016/j.chom.2016.04.003; Schlapbach C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007828; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Skon CN, 2013, NAT IMMUNOL, V14, P1285, DOI 10.1038/ni.2745; Soltesz B, 2015, INT REV IMMUNOL, V34, P348, DOI 10.3109/08830185.2015.1049345; Sumaria N, 2011, J EXP MED, V208, P505, DOI 10.1084/jem.20101824; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Thome JJC, 2015, TRENDS IMMUNOL, V36, P428, DOI 10.1016/j.it.2015.05.003; Tomura M, 2008, P NATL ACAD SCI USA, V105, P10871, DOI 10.1073/pnas.0802278105; Tomura M, 2010, J CLIN INVEST, V120, P883, DOI 10.1172/JCI40926; Wang XW, 2016, INFECT DIS CLIN N AM, V30, P85, DOI 10.1016/j.idc.2015.10.010; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Zaid A, 2014, P NATL ACAD SCI USA, V111, P5307, DOI 10.1073/pnas.1322292111	41	73	76	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					647	662		10.1016/j.jaci.2017.09.042	http://dx.doi.org/10.1016/j.jaci.2017.09.042			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29128674	Bronze, Green Accepted			2022-12-18	WOS:000440664400030
J	Baurecht, H; Ruhlemann, MC; Rodriguez, E; Thielking, F; Harder, I; Erkens, AS; Stolzl, D; Ellinghaus, E; Hotze, M; Lieb, W; Wang, S; Heinsen-Groth, FA; Franke, A; Weidinger, S				Baurecht, Hansjorg; Ruhlemann, Malte C.; Rodriguez, Elke; Thielking, Frederieke; Harder, Inken; Erkens, Anna-Sophie; Stolzl, Dora; Ellinghaus, Eva; Hotze, Melanie; Lieb, Wolfgang; Wang, Sheng; Heinsen-Groth, Femke-Anouska; Franke, Andre; Weidinger, Stephan			Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; lipidome; microbiome	GENOME-WIDE ASSOCIATION; ATOPIC-DERMATITIS; STAPHYLOCOCCUS-AUREUS; BACTERIAL; GUIDELINES; DIVERSITY; SEQUENCES; STRATEGY; DATABASE; PROFILE	Background: Genomic approaches have revealed characteristic site specificities of skin bacterial community structures. In addition, in children with atopic dermatitis (AD), characteristic shifts were described at creases and, in particular, during flares, which have been postulated to mirror disturbed skin barrier function, cutaneous inflammation, or both. Objective: We sought to comprehensively analyze microbial configurations in patients with AD across body sites and to explore the effect of distinct abnormalities of epidermal barrier function. Methods: The skin microbiome was determined by using bacterial 16S rRNA sequencing at 4 nonlesional body sites, as well as acute and chronic lesions of 10 patients with AD and 10 healthy control subjects matched for age, sex, and filaggrin (FLG) mutation status. Nonlesional sampling sites were characterized for skin physiology parameters, including chromatography-based lipid profiling. Results: Epidermal lipid composition, in particular levels of long-chain unsaturated free fatty acids, strongly correlated with bacterial composition, in particular Propionibacteria and Corynebacteria abundance. AD displayed a distinct community structure, with increased abundance and altered composition of staphylococcal species across body sites, the strongest loss of diversity and increase in Staphylococcus aureus seen on chronic lesions, and a progressive shift from nonlesional skin to acute and chronic lesions. FLG-deficient skin showed a distinct microbiome composition resembling in part the AD-related pattern. Conclusion: Epidermal barrier integrity and function affect the skin microbiome composition. AD shows an altered microbial configuration across diverse body sites, which is most pronounced at sites of predilection and AD. Eczematous affection appears to be a more important determinant than body site.	[Baurecht, Hansjorg; Rodriguez, Elke; Thielking, Frederieke; Harder, Inken; Erkens, Anna-Sophie; Stolzl, Dora; Hotze, Melanie; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Campus Kiel,Rosalind Franklin Str 7, D-24105 Kiel, Germany; [Ruhlemann, Malte C.; Ellinghaus, Eva; Heinsen-Groth, Femke-Anouska; Franke, Andre] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Lieb, Wolfgang] Christian Albrechts Univ Kiel, Inst Epidemiol, Kiel, Germany; [Lieb, Wolfgang] Christian Albrechts Univ Kiel, Biobank PopGen, Kiel, Germany; [Wang, Sheng] Hangzhou Dianzi Univ, Coll Life Informat Sci & Instrument Engn, Hangzhou, Zhejiang, Peoples R China	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; University of Kiel; University of Kiel; Hangzhou Dianzi University	Weidinger, S (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Campus Kiel,Rosalind Franklin Str 7, D-24105 Kiel, Germany.	sweidinger@dermatology.uni-kiel.de	Franke, Andre/B-2151-2010; Rodríguez, Elke/C-4259-2013; Wang, Sheng/AAA-3958-2021; Rühlemann, Malte Christoph/AAA-6528-2019; Lieb, Wolfgang/AAC-7650-2022; Ellinghaus, Eva/E-6490-2012	Franke, Andre/0000-0003-1530-5811; Rodríguez, Elke/0000-0003-3692-3950; Wang, Sheng/0000-0003-4041-3216; Rühlemann, Malte Christoph/0000-0002-0685-0052; Ellinghaus, Eva/0000-0003-2914-3382	DFG Clusters of Excellence "Inflammation at Interfaces'' [EXC306, EXC306/2]; German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (sysINFLAME) [01ZX1306A]	DFG Clusters of Excellence "Inflammation at Interfaces''; German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (sysINFLAME)(Federal Ministry of Education & Research (BMBF))	The project received infrastructure support through the DFG Clusters of Excellence "Inflammation at Interfaces'' (grants EXC306 and EXC306/2) and was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (sysINFLAME, grant 01ZX1306A).	Aagaard K, 2013, FASEB J, V27, P1012, DOI 10.1096/fj.12-220806; Angelova-Fischer I, 2012, BRIT J DERMATOL, V167, P787, DOI 10.1111/j.1365-2133.2012.11049.x; Belkaid Y, 2016, NAT REV IMMUNOL, V16, P353, DOI 10.1038/nri.2016.48; Bernard K, 2012, J CLIN MICROBIOL, V50, P3152, DOI 10.1128/JCM.00796-12; Bloch KC, 1997, MEDICINE, V76, P30, DOI 10.1097/00005792-199701000-00003; Bomar L, 2016, MBIO, V7, DOI 10.1128/mBio.01725-15; Bouslimani A, 2015, P NATL ACAD SCI USA, V112, pE2120, DOI 10.1073/pnas.1424409112; BURBIDGE JB, 1988, J AM STAT ASSOC, V83, P123, DOI 10.2307/2288929; Chuong CM, 2006, EXP DERMATOL, V15, P547; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; du Plessis J, 2013, SKIN RES TECHNOL, V19, P265, DOI 10.1111/srt.12037; Dunn P.K., 1996, J COMPUT GRAPH STAT, V5, P236; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Eichenfield LF, 2004, ALLERGY, V59, P86, DOI 10.1111/j.1398-9995.2004.00569.x; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Gao Z, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002719; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Harder J, 2010, J INVEST DERMATOL, V130, P1355, DOI 10.1038/jid.2009.432; Hirasawa Y, 2010, J INVEST DERMATOL, V130, P614, DOI 10.1038/jid.2009.257; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kottner J, 2013, ARCH DERMATOL RES, V305, P315, DOI 10.1007/s00403-012-1313-6; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Mukherjee S, 2016, SCI REP-UK, V6, DOI 10.1038/srep36062; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nothlings U, 2012, BUNDESGESUNDHEITSBLA, V55, P831, DOI 10.1007/s00103-012-1487-2; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; R Development Core Team, 2021, LANG ENV STAT COMP; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Schreml S, 2012, DERMATOLOGY, V224, P66, DOI 10.1159/000337029; Smeekens SP, 2014, J INNATE IMMUN, V6, P253, DOI 10.1159/000351912; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; van Smeden J, 2016, CURR PROBL DERMATOL, V49, P8, DOI 10.1159/000441540; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Wang J, 2016, NAT GENET, V48, P1396, DOI 10.1038/ng.3695; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; WILLIAMS REA, 1990, BRIT J DERMATOL, V123, P493; Witten D., 2013, PMA PENALIZED MULTIV; Witten DM, 2009, BIOSTATISTICS, V10, P515, DOI 10.1093/biostatistics/kxp008; Yamada T, 2006, COMPUT STAT DATA AN, V50, P2111, DOI 10.1016/j.csda.2005.03.006; Yoon SH, 2017, INT J SYST EVOL MICR, V67, P1613, DOI 10.1099/ijsem.0.001755; Zeeuwen PLJM, 2017, J ALLERGY CLIN IMMUN, V139, P1368, DOI 10.1016/j.jaci.2016.09.017; Zeeuwen PLJM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r101; Zeileis A, 2004, J STAT SOFTW, V11, DOI [10.18637/jss.v011.i10, DOI 10.18637/JSS.V011.I10]; ZEILEIS A., 2006, J STAT SOFTW, V16, P1, DOI DOI 10.18637/JSS.V016.I09; Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08	56	73	79	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1668	+		10.1016/j.jaci.2018.01.019	http://dx.doi.org/10.1016/j.jaci.2018.01.019			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29421277				2022-12-18	WOS:000432148200014
J	Teufelberger, AR; Nordengrun, M; Braun, H; Maes, T; De Grove, K; Holtappels, G; O'Brien, C; Provoost, S; Hammad, H; Goncalves, A; Beyaert, R; Declercq, W; Vandenabeele, P; Krysko, DV; Broker, BM; Bachert, C; Krysko, O				Teufelberger, Andrea R.; Nordengruen, Maria; Braun, Harald; Maes, Tania; De Grove, Katrien; Holtappels, Gabriele; O'Brien, Clara; Provoost, Sharen; Hammad, Hamida; Goncalves, Amanda; Beyaert, Rudi; Declercq, Wim; Vandenabeele, Peter; Krysko, Dmitri V.; Broeker, Barbara M.; Bachert, Claus; Krysko, Olga			The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; Staphylococcus aureus; sensitization; serine protease	HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; ALLERGIC LUNG INFLAMMATION; INNATE LYMPHOID-CELLS; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; DENDRITIC CELLS; ENTEROTOXIN-B; IN-VITRO; ASTHMA	Background: Chronic airway inflammatory diseases, such as chronic rhinosinusitis with nasal polyps and asthma, show increased nasal Staphylococcus aureus colonization. Staphylococcus aureus-derived serine protease-like protein (Spl) D and other closely related proteases secreted by S aureus have recently been identified as inducers of allergic asthma in human subjects and mice, but their mechanism of action is largely unknown. Objective: We investigated the role of recombinant SplD in driving T-H(2)-biased responses and IgE formation in a murine model of allergic asthma. Methods: Allergic asthma was induced in C57BL/6 J wild-type mice, Toll-like receptor (TLR) 4 knockout (Tlr4(-/-)) mice, and recombination-activating gene (Rag2) knockout (Rag2(-/-)) mice by means of repeated intratracheal applications of SplD. Inflammatory parameters in the airways were assessed by means of flow cytometry, ELISA, Luminex, and immunohistochemistry. Serum SplD-specific IgE levels were analyzed by using ELISA. Results: We observed that repeated intratracheal exposure to SplD led to IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell hyperplasia in the airways. Blocking IL-33 activity with a soluble ST2 receptor significantly decreased the numbers of eosinophils, IL-13(+) type 2 innate lymphoid cells and IL-13(+) CD4(+) T cells and IL-5 and IL-13 production by lymph node cells but had no effect on IgE production. SplD-induced airway inflammation and IgE production were largely dependent on the presence of the functional adaptive immune system and independent of TLR4 signaling. Conclusion: The S aureus-derived protein SplD is a potent allergen of S aureus and induces a T-H(2)-biased inflammatory response in the airways in an IL-33-dependent but TRL4-independent manner. The soluble ST2 receptor could be an efficient strategy to interfere with SplD-induced T-H(2) inflammation but does not prevent the allergic sensitization.	[Teufelberger, Andrea R.; Holtappels, Gabriele; O'Brien, Clara; Bachert, Claus; Krysko, Olga] Univ Ghent, Upper Airways Res Lab, Dept Otorhinolaryngol, Ghent, Belgium; [Teufelberger, Andrea R.; Braun, Harald; Hammad, Hamida; Goncalves, Amanda; Beyaert, Rudi; Declercq, Wim; Vandenabeele, Peter] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [Maes, Tania; De Grove, Katrien; Provoost, Sharen] Univ Ghent, Lab Translat Res Obstruct Pulm Dis, Ghent, Belgium; [Krysko, Dmitri V.] Univ Ghent, Dept Basic Med Sci, Ghent, Belgium; [Teufelberger, Andrea R.; Declercq, Wim; Vandenabeele, Peter] VIB Ctr Inflammat Res, Mol Signalling & Cell Death Unit, Ghent, Belgium; [Braun, Harald; Beyaert, Rudi] VIB Ctr Inflammat Res, Mol Signal Transduct Inflammat Unit, Ghent, Belgium; [Hammad, Hamida] VIB Ctr Inflammat Res, Immunoregulat & Mucosal Immunol, Ghent, Belgium; [Goncalves, Amanda] VIB Ctr Inflammat Res, VIB Bio Imaging Core Ghent, Ghent, Belgium; [Hammad, Hamida] Univ Med Greifswald, Dept Immunol, Greifswald, Germany	Ghent University; Ghent University; Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Greifswald Medical School	Krysko, O (corresponding author), Univ Ghent, Upper Airways Res Lab, Dept Otorhinolaryngol, UZ Gent, De Pintelaan 185,MRB2, B-9000 Ghent, Belgium.	olga.krysko@ugent.be	Bröker, Barbara M/O-4850-2015; Bachert, Claus/J-8825-2012; Krysko, Dmitri V./AAE-9368-2019; Krysko, Olga/C-2481-2009; Maes, Tania/M-8675-2016; Vandenabeele, Peter/AAD-5793-2022; Hammad, Hamida/J-9391-2015; Vandenabeele, Peter/C-8597-2009	Bröker, Barbara M/0000-0002-5020-8542; Krysko, Dmitri V./0000-0002-9692-2047; Krysko, Olga/0000-0001-5019-0752; Maes, Tania/0000-0002-3037-6928; Vandenabeele, Peter/0000-0002-6669-8822; Hammad, Hamida/0000-0003-3762-8603; Nordengrun, Maria/0000-0002-5749-8861; Goncalves, Amanda Maffioletti Mac Cord/0000-0003-2748-3033; Braun, Harald/0000-0002-3491-9504; Teufelberger, Andrea/0000-0002-1142-949X	interuniversity attraction poles [P7/30, BOF 14-GOA-019]; German Research Council [DFG: GRK 1870, TRR34, GRK 1870]; FWO-Vlaanderen; IOF UGent Advanced project grant (Ghent University); Fund for Scientific Research Flanders (FWO-Vlaanderen); Exzellenzforderprogramm Mecklenburg-Vorpommern, Germany (Card-ii-Omics);  [IAP 7/32];  [FWO G.0875.11];  [FWO G.0973.11];  [FWO G.0A45.12N];  [FWO G.0787.13N];  [FWO G.0E04.16N];  [FWO G.0C31.14N];  [BOF09/01M00709];  [BOF16/MET_V/007]	interuniversity attraction poles(Belgian Federal Science Policy Office); German Research Council(German Research Foundation (DFG)); FWO-Vlaanderen(FWO); IOF UGent Advanced project grant (Ghent University); Fund for Scientific Research Flanders (FWO-Vlaanderen)(FWO); Exzellenzforderprogramm Mecklenburg-Vorpommern, Germany (Card-ii-Omics); ; ; ; ; ; ; ; ; 	Supported by interuniversity attraction poles P7/30, BOF 14-GOA-019 and by the German Research Council (DFG: GRK 1870, TRR34). A.R.T. is a doctoral fellow paid by FWO-Vlaanderen. R.B. and H.B. are supported by an IOF UGent Advanced project grant (Ghent University) and the Fund for Scientific Research Flanders (FWO-Vlaanderen). S.P. is a postdoctoral researcher paid by FWO-Vlaanderen. M.N. is a doctoral fellow supported by the German Research Council (GRK 1870) and the Exzellenzforderprogramm Mecklenburg-Vorpommern, Germany (Card-ii-Omics). P.V.'s research group is supported by IAP 7/32, FWO G.0875.11, FWO G.0973.11, FWO G.0A45.12N, FWO G.0787.13N, FWO G.0E04.16N, FWO G.0C31.14N, BOF09/01M00709, and BOF16/MET_V/007.	Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Broker BM, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010031; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Cho SH, 2001, J INVEST DERMATOL, V116, P658, DOI 10.1046/j.0022-202x.2001.01331.x; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; de Boer JD, 2014, INNATE IMMUN-LONDON, V20, P618, DOI 10.1177/1753425913503387; Ebeling C, 2007, J IMMUNOL, V179, P2910, DOI 10.4049/jimmunol.179.5.2910; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hartl D, 2007, NAT MED, V13, P1423, DOI 10.1038/nm1690; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Jacquet Alain, 2013, ISRN Allergy, V2013, P735031, DOI 10.1155/2013/735031; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Krysko O, 2013, ALLERGY, V68, P446, DOI 10.1111/all.12102; Kusch H, 2014, INT J MED MICROBIOL, V304, P133, DOI 10.1016/j.ijmm.2013.11.005; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Li CW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003918; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; Lopez ML, 2014, CELL IMMUNOL, V288, P47, DOI 10.1016/j.cellimm.2014.02.004; Maes T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-7; Matsui K, 2012, J INVEST ALLERG CLIN, V22, P80; Matsuwaki Y, 2009, J IMMUNOL, V183, P6708, DOI 10.4049/jimmunol.0901220; Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Oboki K, 2011, ALLERGY ASTHMA IMMUN, V3, P81, DOI 10.4168/aair.2011.3.2.81; Provoost S, 2016, J ALLERGY CLIN IMMUN, V139; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Reed SB, 2001, INFECT IMMUN, V69, P1521, DOI 10.1128/IAI.69.3.1521-1527.2001; Reginald K, 2011, CLIN EXP ALLERGY, V41, P357, DOI 10.1111/j.1365-2222.2010.03655.x; Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1; Sachse F, 2010, ALLERGY, V65, P1430, DOI 10.1111/j.1398-9995.2010.02381.x; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stentzel S, 2017, J ALLERGY CLIN IMMUN, V139, P492, DOI 10.1016/j.jaci.2016.03.045; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Thammavongsa V, 2015, NAT REV MICROBIOL, V13, P529, DOI 10.1038/nrmicro3521; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; van Helden MJ, 2013, CURR OPIN IMMUNOL, V25, P745, DOI 10.1016/j.coi.2013.10.002; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Zdzalik M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076812; Zdzalik M, 2012, FEMS IMMUNOL MED MIC, V66, P220, DOI 10.1111/j.1574-695X.2012.01005.x; Zoltowska AM, 2016, CLIN EXP ALLERGY, V46, P479, DOI 10.1111/cea.12683	63	73	75	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					549	559		10.1016/j.jaci.2017.05.004	http://dx.doi.org/10.1016/j.jaci.2017.05.004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28532656	Bronze			2022-12-18	WOS:000424410800012
J	Burks, AW; Sampson, HA; Plaut, M; Lack, G; Akdis, CA				Burks, A. Wesley; Sampson, Hugh A.; Plaut, Marshall; Lack, Gideon; Akdis, Cezmi A.			Treatment for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; food immunotherapy; oral immuno-therapy; sublingual immunotherapy; epicutaneous immunotherapy	PEANUT ORAL IMMUNOTHERAPY; COWS MILK ALLERGY; TERM-FOLLOW-UP; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; EPICUTANEOUS IMMUNOTHERAPY; SUSTAINED UNRESPONSIVENESS; ADVERSE EVENTS; EGG ALLERGY; CHILDREN	The prevalence of IgE-mediated food allergy is an increasing public health concern effecting millions of persons worldwide. The current standard of treatment is strict avoidance of the offending food or foods, and to date, there are no regulatory approved treatments for food allergy. A significant amount of research has been directed at various forms of food immunotherapy, including oral, sublingual, and epicutaneous delivery routes. Although oral immunotherapy has shown the greatest promise for efficacy in terms of the amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile compared with sublingual immunotherapy and epicutaneous immunotherapy, which offers the least protection but has the best safety and tolerability profile. Studies have been conducted with adding adjuvants and anti-IgE to enhance either the efficacy or safety of food immunotherapy. Multiple concepts of food immunotherapy beyond these first-generation treatments are in either animal or early phase 1 studies.	[Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, Kravis Childrens Hosp, Elliot & Roslyn Jaffe Food Allergy Inst,Div Aller, New York, NY 10029 USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lack, Gideon] Kings Coll London, Dept Paediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland	University of North Carolina; University of North Carolina Chapel Hill; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Swiss Institute of Allergy & Asthma Research; University of Zurich	Burks, AW (corresponding author), Univ N Carolina, Dept Pediat, 4032 Bondurant Hall,Campus Box 7200, Chapel Hill, NC 27599 USA.	wesley.burks@unc.edu	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Lack, Gideon/0000-0001-7350-4021	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI15416, UM1AI109565] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Ang WXG, 2016, J CLIN INVEST, V126, P4103, DOI 10.1172/JCI87492; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Berin MC, 2016, IMMUNOL ALLERGY CLIN, V36, P87, DOI 10.1016/j.iac.2015.08.002; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caminiti L, 2015, J ALLER CL IMM-PRACT, V3, P532, DOI 10.1016/j.jaip.2015.01.017; Chad L, 2013, ALLERGY, V68, P1605, DOI 10.1111/all.12262; Dawicki W, 2017, J ALLERGY CLIN IMMUN, V139, P1608, DOI 10.1016/j.jaci.2016.07.042; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Dhami S, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0113-z; Dunn Galvin A, 2017, ALLERGY; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DMWR, 2012, J ALLERGY CLIN IMMUN, V129, pAB248; Fuentes-Aparicio V, 2014, PEDIAT ALLERG IMM-UK, V25, P103, DOI 10.1111/pai.12137; Gernez Y, 2017, J ALLER CL IMM-PRACT, V5, P250, DOI 10.1016/j.jaip.2016.12.004; Gonzalez-Cervera J, 2017, ANN ALLERG ASTHMA IM, V118, P582, DOI 10.1016/j.anai.2017.02.006; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Kulis M, 2011, IMMUNOL RES, V49, P216, DOI 10.1007/s12026-010-8183-9; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nurmatov U, 2014, BRIT J NUTR, V111, P12, DOI 10.1017/S0007114513002353; Pajno GB, 2010, ANN ALLERG ASTHMA IM, V105, P376, DOI 10.1016/j.anai.2010.03.015; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Ramesh M, 2016, J ALLERGY CLIN IMMUN, V137, P1764, DOI 10.1016/j.jaci.2015.12.1327; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Shaker MS, 2017, J ALLER CL IMM-PRACT, V5, P1707, DOI 10.1016/j.jaip.2017.04.016; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Stallings VA, 2016, FINDING PATH SAFETY, P576; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Vazquez-Ortiz M, 2013, CLIN EXP ALLERGY, V43, P92, DOI 10.1111/cea.12012; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Virkud YV, 2017, J ALLERGY CLIN IMMUN, V139, P882, DOI 10.1016/j.jaci.2016.07.030; Wang J, 2015, J ALLERGY CLIN IMMUN, V136, P962, DOI 10.1016/j.jaci.2015.04.029; Wasserman RL, 2014, J ALLER CL IMM-PRACT, V2, P91, DOI 10.1016/j.jaip.2013.10.001; Wood RA, 2013, ALLERGY, V68, P803, DOI 10.1111/all.12158; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010	70	73	76	3	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					1	9		10.1016/j.jaci.2017.11.004	http://dx.doi.org/10.1016/j.jaci.2017.11.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	29307409	Bronze			2022-12-18	WOS:000419312200001
J	Sun, QZ; Liu, L; Wang, H; Mandal, J; Khan, P; Hostettler, KE; Stolz, D; Tamm, M; Molino, A; Lardinois, D; Lu, SM; Roth, M				Sun, Qingzhu; Liu, Li; Wang, Hui; Mandal, Jyotshna; Khan, Petra; Hostettler, Katrin E.; Stolz, Daiana; Tamm, Michael; Molino, Antonio; Lardinois, Didier; Lu, Shemin; Roth, Michael			Constitutive high expression of protein arginine methyltransferase 1 in asthmatic airway smooth muscle cells is caused by reduced microRNA-19a expression and leads to enhanced remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway wall remodeling; primary airway smooth muscle cell; protein arginine methyltransferase 1; miR-19a; extracellular signal-regulated kinase; STAT1	INDUCED PULMONARY INFLAMMATION; GROWTH FACTOR-BB; STIMULATED PROLIFERATION; CYCLE REGULATION; LUNG; DISEASE; BRONCHOCONSTRICTION; BETA(2)-AGONISTS; FIBROBLASTS; MIGRATION	Background: In asthma remodeling airway smooth muscle cells (ASMCs) contribute to airway wall thickness through increased proliferation, migration, and extracellular matrix deposition. Previously, we described that protein arginine methyltransferase 1 (PRMT1) participates in airway remodeling in pulmonary inflammation in E3 rats. Objective: We sought to define the asthma-specific regulatory mechanism of PRMT1 in human ASMCs. Methods: ASMCs from healthy subjects and asthmatic patients were activated with platelet-derived growth factor (PDGF)-BB. PRMT1 was localized by means of immunohistochemistry in human lung tissue sections and by means of immunofluorescence in isolated ASMCs. PRMT1 activity was suppressed by the pan-PRMT inhibitor AMI-1, signal transducer and activator of transcription 1 (STAT1) was suppressed by small interfering RNA, and extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK) was suppressed by PD98059. MicroRNAs (miRs) were assessed by using real-time quantitative PCR and regulated by miR mimics or inhibitors. Results: PRMT1 expression was significantly increased in lung tissue sections and in isolated ASMCs of patients with severe asthma. PDGF-BB significantly increased PRMT1 expression through ERK1/2 MAPK and STAT1 signaling in control ASMCs, whereas in ASMCs from asthmatic patients, these proteins were constitutively expressed. ASMCs from asthmatic patients had reduced miR-19a expression, causing upregulation of ERK1/2 MAPK, STAT1, and PRMT1. Inhibition of PRMT1 abrogated collagen type I and fibronectin deposition, cell proliferation, and migration of ASMCs from asthmatic patients. Conclusions: PRMT1 is a central regulator of tissue remodeling in ASMCs from asthmatic patients through the pathway: PDGF-BB-miR-19a-ERK1/2 MAPK and STAT1. Low miR-19a expression in ASMCs from asthmatic patients is the key event that results in constitutive increased PRMT1 expression and remodeling. Therefore PRMT1 is an attractive target to limit airway wall remodeling in asthmatic patients.	[Sun, Qingzhu; Liu, Li; Lu, Shemin] Xi An Jiao Tong Univ, Hlth Sci Ctr, Minist Educ, Dept Biochem & Mol Biol,Key Lab Environm & Genes, Xian, Shaanxi, Peoples R China; [Sun, Qingzhu; Mandal, Jyotshna; Khan, Petra; Hostettler, Katrin E.; Stolz, Daiana; Tamm, Michael; Roth, Michael] Univ Basel, Pneumol & Pulm Cell Res, Basel, Switzerland; [Wang, Hui] Univ Basel, Stem Cells & Hematopoiesis, Dept Biomed, Basel, Switzerland; [Wang, Hui] Univ Hosp Basel, Basel, Switzerland; [Molino, Antonio] Univ Naples Federico II, Dept Resp Dis, Naples, Italy; [Lardinois, Didier] Univ Hosp Basel, Dept Thorac Surg, Basel, Switzerland	Xi'an Jiaotong University; University of Basel; University of Basel; University of Basel; University of Naples Federico II; University of Basel	Roth, M (corresponding author), Univ Basel, Pulm Cell Res & Pneumol, CH-4031 Basel, Switzerland.; Roth, M (corresponding author), Univ Hosp, Dept Biomed, CH-4031 Basel, Switzerland.	Michael.roth@usb.ch	Roth, Michael/H-8657-2019; Lu, Shemin/AAI-6479-2021; molino, antonio/N-8133-2016; Lu, Shemin/M-3350-2018	Roth, Michael/0000-0002-8139-2821; Lu, Shemin/0000-0002-5535-8320; molino, antonio/0000-0001-6966-9640; Lu, Shemin/0000-0001-8250-850X; Hostettler, Katrin/0000-0001-8118-7441; Stolz, Daiana/0000-0003-0099-882X	National Natural Science Foundation of China [31601033]; Swiss Government Excellence Scholarship [2014.0405]; Swiss National Foundation [310030_130740]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Swiss Government Excellence Scholarship; Swiss National Foundation(Swiss National Science Foundation (SNSF))	Supported by the National Natural Science Foundation of China (no. 31601033), a Swiss Government Excellence Scholarship (#2014.0405), and a Swiss National Foundation grant (#310030_130740).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; [Anonymous], 2015, ANN AM THORAC SOC; [Anonymous], 2016, CELL SIGNAL; Berair R, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-145; Bourke JE, 2011, EUR RESPIR J, V37, P173, DOI 10.1183/09031936.00008109; Burgess JK, 2008, J CELL PHYSIOL, V216, P673, DOI 10.1002/jcp.21450; Chakir J, 2015, ANN AM THORAC SOC; Deshpande DA, 2015, DRUG DEVELOP RES, V76, P286, DOI 10.1002/ddr.21267; Dolhnikoff M, 2009, J ALLERGY CLIN IMMUN, V123, P1090, DOI 10.1016/j.jaci.2009.02.032; Escobar J, 2012, FREE RADICAL BIO MED, V52, P819, DOI 10.1016/j.freeradbiomed.2011.11.009; Fang YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066915; Gosens R, 2015, CHEST, V147, P798, DOI 10.1378/chest.14-1142; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Harb H, 2015, J ALLERGY CLIN IMMUN, V135, P15, DOI 10.1016/j.jaci.2014.11.009; Hirota JA, 2011, AM J RESP CELL MOL, V45, P566, DOI 10.1165/rcmb.2010-0277OC; Hosoki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126035; Ingram JL, 2006, CURR MOL MED, V6, P409, DOI 10.2174/156652406777435426; Ito I, 2009, CLIN EXP ALLERGY, V39, P1370, DOI 10.1111/j.1365-2222.2009.03293.x; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Jones RL, 2014, AM J RESP CELL MOL, V50, P246, DOI 10.1165/rcmb.2013-0029OC; Joshi Sachindra R, 2012, Mol Cell Pharmacol, V4, P1; Karakiulakis G, 2007, J BIOL CHEM, V282, P908, DOI 10.1074/jbc.M602178200; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Krymskaya VP, 2004, FASEB J, V18, P428, DOI 10.1096/fj.04-2869fje; Laliena A, 2012, J PINEAL RES, V53, P270, DOI 10.1111/j.1600-079X.2012.00995.x; Lambers C, 2014, BIOCHEM PHARMACOL, V91, P400, DOI 10.1016/j.bcp.2014.07.026; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Li PC, 2015, MAR DRUGS, V13, P3046, DOI 10.3390/md13053046; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Martinez-Nunez RT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111659; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Nicholson TB, 2009, PHARMACOL RES, V60, P466, DOI 10.1016/j.phrs.2009.07.006; Page K, 2000, FRONT BIOSCI-LANDMRK, V5, pD258, DOI 10.2741/Page; Pintus G, 2003, CARDIOVASC RES, V59, P934, DOI 10.1016/S0008-6363(03)00526-1; Simeone-Penney MC, 2008, AM J PHYSIOL-LUNG C, V294, pL698, DOI 10.1152/ajplung.00529.2007; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; Simpson LJ, 2014, NAT IMMUNOL, V15, P1162, DOI 10.1038/ni.3026; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Sun QZ, 2015, J IMMUNOL, V195, P298, DOI 10.4049/jimmunol.1402465; Sun QZ, 2012, J IMMUNOL, V188, P3506, DOI 10.4049/jimmunol.1102635; Togo S, 2008, AM J RESP CRIT CARE, V178, P248, DOI 10.1164/rccm.200706-929OC; Westergren-Thorsson G, 2010, CLIN RESPIR J, V4, P1, DOI 10.1111/j.1752-699X.2010.00190.x; Yu ZL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/679109; Zhou P, 2016, INT J ONCOL, V48, P1737, DOI 10.3892/ijo.2016.3392	45	73	77	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					510	+		10.1016/j.jaci.2016.11.013	http://dx.doi.org/10.1016/j.jaci.2016.11.013			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28081849	Bronze			2022-12-18	WOS:000406855500023
J	Seppo, AE; Autran, CA; Bode, L; Jarvinen, KM				Seppo, Antti E.; Autran, Chloe A.; Bode, Lars; Jaervinen, Kirsi M.			Human milk oligosaccharides and development of cow's milk allergy in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MICROBIOTA		[Seppo, Antti E.; Jaervinen, Kirsi M.] Univ Rochester, Sch Med & Dent, Div Allergy & Immunol, Rochester, NY 14642 USA; [Seppo, Antti E.; Jaervinen, Kirsi M.] Univ Rochester, Sch Med & Dent, Ctr Food Allergy, Dept Pediat, Rochester, NY 14642 USA; [Seppo, Antti E.; Jaervinen, Kirsi M.] Golisano Childrens Hosp, Rochester, NY 14642 USA; [Autran, Chloe A.; Bode, Lars] Univ Calif San Diego, La Jolla, CA 92093 USA	University of Rochester; University of Rochester; University of Rochester; University of California System; University of California San Diego	Seppo, AE (corresponding author), Univ Rochester, Sch Med & Dent, Div Allergy & Immunol, Rochester, NY 14642 USA.; Seppo, AE (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Food Allergy, Dept Pediat, Rochester, NY 14642 USA.; Seppo, AE (corresponding author), Golisano Childrens Hosp, Rochester, NY 14642 USA.	antti_seppo@URMC.Rochester.edu			National Institute of Allergy and Infectious Diseases [K08 AI091655]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI122126, K08AI091655] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The project described was supported by the National Institute of Allergy and Infectious Diseases (grant no. K08 AI091655 to K.M.J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.	Arvinen KMJ, 2015, J ALLERGY CLIN IMMUN, V135, P1390, DOI 10.1016/j.jaci.2014.10.051; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Bode L, 2012, AM J CLIN NUTR, V96, P831, DOI 10.3945/ajcn.112.039503; Lewis ZT, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0071-z; Naarding MA, 2005, J CLIN INVEST, V115, P3256, DOI 10.1172/JCI25105; Sprenger N, 2016, EUR J NUTR, V24; Thurl S, 2010, BRIT J NUTR, V104, P1261, DOI 10.1017/S0007114510002072; Yu ZT, 2013, GLYCOBIOLOGY, V23, P169, DOI 10.1093/glycob/cws138	8	73	79	14	56	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					708	+		10.1016/j.jaci.2016.08.031	http://dx.doi.org/10.1016/j.jaci.2016.08.031			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27702672	Green Accepted			2022-12-18	WOS:000397002400044
J	Bateman, ED; Buhl, R; O'Byrne, PM; Humbert, M; Reddel, HK; Sears, MR; Jenkins, C; Harrison, TW; Quirce, S; Peterson, S; Eriksson, G				Bateman, Eric D.; Buhl, Roland; O'Byrne, Paul M.; Humbert, Marc; Reddel, Helen K.; Sears, Malcolm R.; Jenkins, Christine; Harrison, Tim W.; Quirce, Santiago; Peterson, Stefan; Eriksson, Goeran			Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; budesonide/formoterol maintenance and reliever therapy; exacerbations; Global Initiative for Asthma; predictors; risk score	QUALITY-OF-LIFE; PSYCHOMETRIC TOOLS; RELIEVER THERAPY; DOUBLE-BLIND; MAINTENANCE; COMBINATION; OBESITY; BUDESONIDE/FORMOTEROL; ASSOCIATION; PREDICTORS	Background: Identifying patients at risk of future severe asthma exacerbations, those whose asthma might be less treatment responsive, or both might guide treatment selection. Objective: We sought to investigate predictors for failure to achieve Global Initiative for Asthma (GINA)-defined good current asthma control and severe exacerbations on treatment and to develop a simple risk score for exacerbations (RSE) for clinical use. Methods: A large data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting beta(2)-agonist therapy was analyzed. Baseline patient characteristics were investigated to determine dominant predictors for uncontrolled asthma at 3 months and for severe asthma exacerbations within 12 months of commencing treatment. The RSE, right censored at 6 months to include all 3 studies, was based on the dominant predictors for exacerbations in two thirds of the data set and validated in one third. Results: Patients (n = 7446) whose symptoms were not controlled on GINA treatment steps 3 and 4 and with 1 or more exacerbations (as judged by a clinician based on patient records, history, or both) in the previous year were included. On multivariate analysis, GINA step, reliever use, postbronchodilator FEV1, and 5-item Asthma Control Questionnaire score were dominant (all P < .001) predictors for both the risk of uncontrolled asthma and severe exacerbations. Additional dominant predictors for uncontrolled asthma were smoking status and asthma symptom scores and an additional predictor for severe exacerbation was body mass index. An exponential increase in risk was observed with increments in RSE based on 5 selected predictors for exacerbations. Conclusion: Risk of uncontrolled asthma at 3 months and a severe exacerbation within 12 months can be estimated from simple clinical assessments. Prospective validation of these predictive factors and the RSE is required. Use of these models might guide the management of asthmatic patients.	[Bateman, Eric D.] Univ Cape Town, Dept Med, Div Pulmonol, ZA-7700 Cape Town, South Africa; [Buhl, Roland] Mainz Univ Hosp, Dept Pulm, Mainz, Germany; [O'Byrne, Paul M.; Sears, Malcolm R.] McMaster Univ, Fac Hlth Sci, Michael G DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada; [Humbert, Marc] Univ Paris 11, Serv Pneumol & Reanimat Resp, Hop Antoine Beclere, AP HP, Clamart, France; [Reddel, Helen K.] Univ Sydney, Woolcock Inst Med Res, Clin Management Grp, Sydney, NSW 2006, Australia; [Jenkins, Christine] George Inst Global Hlth, Resp Grp, Sydney, NSW, Australia; [Harrison, Tim W.] Univ Nottingham, Resp Res Unit, Nottingham NG7 2RD, England; [Quirce, Santiago] Hosp La Paz Inst Hlth Res IdiPAZ, Dept Allergy, Madrid, Spain; [Peterson, Stefan] StatMind AB, Lund, Sweden; [Eriksson, Goeran] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden	University of Cape Town; University Hospital Mainz; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Sydney; Woolcock Institute of Medical Research; George Institute for Global Health; University of Sydney; University of Nottingham; Lund University; Skane University Hospital	Bateman, ED (corresponding author), Univ Cape Town, Dept Med, Div Pulmonol, George St, ZA-7700 Cape Town, South Africa.	Eric.Bateman@uct.ac.za	Humbert, Marc/ABD-5112-2021; s, q/AAD-7171-2020; Humbert, Marc/AAC-8459-2019; Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Humbert, Marc/0000-0003-0703-2892; Reddel, Helen/0000-0002-6695-6350; O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca; ALK-Abello; Boehringer Ingelheim; Chiesi; GlaxoSmithKline; Novartis; Pfizer; Takeda; Actelion; Aeras; Almirall; Forest; Hoffman La Roche; Merck; TEVA; AstraZeneca AB, Molndal, Sweden	AstraZeneca(AstraZeneca); ALK-Abello; Boehringer Ingelheim(Boehringer Ingelheim); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Pfizer(Pfizer); Takeda(Takeda Pharmaceutical Company Ltd); Actelion; Aeras; Almirall(Almirall); Forest; Hoffman La Roche; Merck(Merck & Company); TEVA(Teva Pharmaceutical Industries); AstraZeneca AB, Molndal, Sweden(AstraZeneca)	The analysis was sponsored by AstraZeneca. E.D.B. has served as a consultant to ALK-Abello, Almirall, Cephalon, Hoffman La Roche, ICON, and MS Consulting Group; been involved with advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, Elevation Pharma, Forest, GlaxoSmithKline, Merck, Napp, Novartis, and Nycomed; and received lecture fees from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, and Takeda; his institution has received remuneration for participation in clinical trials sponsored by Actelion, Aeras, Almirall, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Hoffman La Roche, Merck, Novartis, Takeda, and TEVA. S.P. and G.E. were employees of AstraZeneca at the time this analysis was conducted. The analysis was funded by AstraZeneca AB, Molndal, Sweden.	Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Blakey JD, 2013, PRIM CARE RESP J, V22, P344, DOI 10.4104/pcrj.2013.00063; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Eid NS, 2004, CLIN PEDIATR, V43, P793, DOI 10.1177/000992280404300903; Farah CS, 2011, CHEST, V140, P659, DOI 10.1378/chest.11-0027; Forno E, 2010, CHEST, V138, P1156, DOI 10.1378/chest.09-2426; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenberg S, 2012, J ALLERGY CLIN IMMUN, V130, P1071, DOI 10.1016/j.jaci.2012.07.057; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Harrell F. E., 2001, REGRESSION MODELING; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; O'Byrne PM, 2012, CLIN EXP ALLERGY, V42, P706, DOI 10.1111/j.1365-2222.2012.03965.x; O'Byrne PM, 2010, EUR RESPIR J, V36, P269, DOI 10.1183/09031936.00124009; Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084; Pakhale S, 2010, CHEST, V137, P1316, DOI 10.1378/chest.09-2491; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pedersen SE, 2007, J ALLERGY CLIN IMMUN, V120, P1036, DOI 10.1016/j.jaci.2007.07.016; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Schatz M, 2008, AM J MANAG CARE, V14, P206; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schatz M, 2012, CHEST, V141, P66, DOI 10.1378/chest.11-0574; Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x; Tierney WM, 2004, J GEN INTERN MED, V19, P237, DOI 10.1111/j.1525-1497.2004.30311.x; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794	40	73	74	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1457	U102		10.1016/j.jaci.2014.08.015	http://dx.doi.org/10.1016/j.jaci.2014.08.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25258144	Green Submitted			2022-12-18	WOS:000355933400007
J	Bousquet, J; Gern, JE; Martinez, FD; Anto, JM; Johnson, CC; Holt, PG; Lemanske, RF; Le Souef, PN; Tepper, RS; von Mutius, ERM; Arshad, SH; Bacharier, LB; Becker, A; Belanger, K; Bergstrom, A; Bernstein, DI; Cabana, MD; Carroll, KN; Castro, M; Cooper, PJ; Gillman, MW; Gold, DR; Henderson, J; Heinrich, J; Hong, SJ; Jackson, DJ; Keil, T; Kozyrskyj, AL; Carlsen, KCL; Miller, RL; Momas, I; Morgan, WJ; Noel, P; Ownby, DR; Pinart, M; Ryan, PH; Schwaninger, JM; Sears, MR; Simpson, A; Smit, HA; Stern, DA; Subbarao, P; Valenta, R; Wang, XB; Weiss, ST; Wood, R; Wright, AL; Wright, RJ; Togias, A; Gergen, PJ				Bousquet, Jean; Gern, James E.; Martinez, Fernando D.; Anto, Josep M.; Johnson, Christine C.; Holt, Patrick G.; Lemanske, Robert F., Jr.; Le Souef, Peter N.; Tepper, Robert S.; von Mutius, Erika R. M.; Arshad, S. Hasan; Bacharier, Leonard B.; Becker, Allan; Belanger, Kathleen; Bergstrom, Anna; Bernstein, David I.; Cabana, Michael D.; Carroll, Kecia N.; Castro, Mario; Cooper, Philip J.; Gillman, Matthew W.; Gold, Diane R.; Henderson, John; Heinrich, Joachim; Hong, Soo-Jong; Jackson, Daniel J.; Keil, Thomas; Kozyrskyj, Anita L.; Carlsen, Karin C. Lodrup; Miller, Rachel L.; Momas, Isabelle; Morgan, Wayne J.; Noel, Patricia; Ownby, Dennis R.; Pinart, Mariona; Ryan, Patrick H.; Schwaninger, Julie M.; Sears, Malcolm R.; Simpson, Angela; Smit, Henriette A.; Stern, Debra A.; Subbarao, Padmaja; Valenta, Rudolf; Wang, Xiaobin; Weiss, Scott T.; Wood, Robert; Wright, Anne L.; Wright, Rosalind J.; Togias, Alkis; Gergen, Peter J.			Birth cohorts in asthma and allergic diseases: Report of a NIAID/NHLBI/MeDALL joint workshop	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; birth cohorts; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Allergy and Infectious Disease (NIAID); Mechanisms of the Development of Allergy (MeDALL)	EXHALED NITRIC-OXIDE; WHEEZING RHINOVIRUS ILLNESSES; 1ST 6 YEARS; LUNG-FUNCTION; EARLY-LIFE; AIRWAY RESPONSIVENESS; CHILDHOOD ASTHMA; YOUNG-CHILDREN; BRONCHODILATOR RESPONSIVENESS; PRESCHOOL-CHILDREN	Population-based birth cohorts on asthma and allergies increasingly provide new insights into the development and natural history of the diseases. More than 130 birth cohorts focusing on asthma and allergy have been initiated in the last 30 years. A National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Mechanisms of the Development of Allergy (MeDALL; Framework Programme 7 of the European Commission) joint workshop was held in Bethesda, Maryland, on September 11-12, 2012, with 3 objectives: (1) documenting the knowledge that asthma/allergy birth cohorts have provided, (2) identifying the knowledge gaps and inconsistencies, and (3) developing strategies for moving forward, including potential new study designs and the harmonization of existing asthma birth cohort data. The meeting was organized around the presentations of 5 distinct workgroups: (1) clinical phenotypes, (2) risk factors, (3) immune development of asthma and allergy, (4) pulmonary development, and (5) harmonization of existing birth cohorts. This article presents the workgroup reports and provides Web links (AsthmaBirthCohorts.niaid.nih.gov or www.medall-fp7.eu), where the reader will find tables describing the characteristics of the birth cohorts included in this report, the type of data collected at differing ages, and a selected bibliography provided by the participating birth cohorts.	[Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] INSERM, U1018, Villejuif, France; [Gern, James E.; Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Martinez, Fernando D.; Stern, Debra A.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Anto, Josep M.; Pinart, Mariona] CREAL, Barcelona, Spain; [Anto, Josep M.; Pinart, Mariona] IMIM Hosp del Mar Res Inst, Barcelona, Spain; [Anto, Josep M.; Pinart, Mariona] CIBERESP, Barcelona, Spain; [Anto, Josep M.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Johnson, Christine C.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Brisbane, Qld, Australia; [Holt, Patrick G.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Le Souef, Peter N.] Univ Western Australia, Princess Margaret Hosp Children, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Tepper, Robert S.] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA; [von Mutius, Erika R. M.] Univ Munich, Dr von Hauner Childrens Hosp, D-81377 Munich, Germany; [Arshad, S. Hasan] Univ Southampton, Fac Med, Isle Of Wight, England; [Arshad, S. Hasan] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Bacharier, Leonard B.] Washington Univ, St Louis, MO 63130 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO USA; [Becker, Allan] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Belanger, Kathleen] Yale Univ, Sch Publ Hlth, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA; [Bergstrom, Anna] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Bernstein, David I.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45221 USA; [Cabana, Michael D.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Cabana, Michael D.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Carroll, Kecia N.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO 63130 USA; [Cooper, Philip J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Cooper, Philip J.] Pontificia Univ Catolica Ecuador, Escuela Biol, Quito, Ecuador; [Gillman, Matthew W.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Gold, Diane R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA; [Gold, Diane R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Henderson, John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Heinrich, Joachim] German Ctr Environm Hlth, Helmholtz Zentrum, Inst Epidemiol 1, Munich, Germany; [Hong, Soo-Jong] Univ Ulsan, Coll Med, Asan Med Ctr,Dept Pediat, Res Ctr Standardizat Allerg Dis,Childhood Asthma, Seoul, South Korea; [Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Kozyrskyj, Anita L.] Univ Alberta, Dept Pediat, Fac Med & Dent, Edmonton, AB, Canada; [Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Oslo, Norway; [Carlsen, Karin C. Lodrup] Univ Oslo, N-0316 Oslo, Norway; [Miller, Rachel L.] Columbia Univ, Dept Med, Div Pulm Allergy & Critcare Med, New York, NY USA; [Momas, Isabelle] Paris Descartes Univ, Dept Publ Hlth & Biostat, Paris, France; [Momas, Isabelle] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Miller, Rachel L.] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA; [Noel, Patricia] NHLBI, Div Lung Dis, NIH, Bethesda, MD 20892 USA; [Ownby, Dennis R.] Georgia Regents Univ, Augusta, GA USA; [Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Schwaninger, Julie M.; Togias, Alkis; Gergen, Peter J.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Sears, Malcolm R.] McMaster Univ, AstraZeneca Chair Resp Epidemiol, Dept Med, Hamilton, ON L8S 4L8, Canada; [Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Resp & Allergy, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England; [Simpson, Angela] Univ Hosp South Manchester, Manchester, Lancs, England; [Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Subbarao, Padmaja] Univ Toronto, Dept Pediat, Toronto, ON M5S 1A1, Canada; [Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Wang, Xiaobin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Weiss, Scott T.] Harvard Univ, Sch Med, Dept Med, Channing Div Network Med, Boston, MA USA; [Wood, Robert] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Wright, Anne L.] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA; [Wright, Anne L.] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA; [Wright, Rosalind J.] Icahn Sch Med, Dept Pediat, Mt Sinai, NY USA; [Wright, Rosalind J.] Icahn Sch Med, Mindich Child Hlth & Dev Inst, Mt Sinai, NY USA	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Henry Ford Health System; Henry Ford Hospital; Telethon Kids Institute; University of Western Australia; University of Queensland; University of Western Australia; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; University of Munich; University of Southampton; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of Manitoba; Yale University; Karolinska Institutet; University System of Ohio; University of Cincinnati; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University; Washington University (WUSTL); Liverpool School of Tropical Medicine; University of Liverpool; Pontificia Universidad Catolica del Ecuador; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Bristol; Helmholtz Association; University of Ulsan; Asan Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Alberta; University of Oslo; University of Oslo; Columbia University; UDICE-French Research Universities; Universite Paris Cite; University of Arizona; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Georgia; Augusta University; Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McMaster University; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Utrecht University; Utrecht University Medical Center; University of Toronto; Medical University of Vienna; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Harvard Medical School; Johns Hopkins University; University of Arizona; University of Arizona; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bousquet, J (corresponding author), Ctr Hosp Montpellier, F-34295 Montpellier 05, France.	jean.bousquet@inserm.fr	Pinart Gilberga, Mariona/GLS-8842-2022; Ryan, Patrick/HDO-1133-2022; Ryan, Patrick H/L-7062-2015; Bousquet, Jean/O-4221-2019; Le Souef, Peter N/H-5256-2014; Anto, J M/H-2676-2014; Holt, Patrick G/H-1548-2011; Hong, Soo-Jong/AAR-1788-2020; Pinart, Mariona/L-1931-2015; Heinrich, Joachim/N-1720-2013	Pinart Gilberga, Mariona/0000-0002-8223-1325; Anto, J M/0000-0002-4736-8529; Holt, Patrick G/0000-0003-1193-0935; Hong, Soo-Jong/0000-0003-1409-2113; Pinart, Mariona/0000-0002-8223-1325; Heinrich, Joachim/0000-0002-9620-1629; momas, isabelle/0000-0003-4344-3787; Subbarao, Padmaja/0000-0003-0394-1933; Simpson, Angela/0000-0003-2733-6666; Cooper, Philip/0000-0002-6770-6871; Valenta, Rudolf/0000-0001-5944-3365; Le Souef, Peter/0000-0003-0930-1654; Bacharier, Leonard/0000-0003-0432-2704; von Mutius, Erika/0000-0002-8893-4515	MeDALL (Mechanisms of the Development of Allergy, EU) [261357]; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases; Division of Lung Diseases, National Heart, Lung, and Blood Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079, KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI089473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009600, R01ES013163] Funding Source: NIH RePORTER; Medical Research Council [G0400473, G0601361, G0900453] Funding Source: researchfish; MRC [G0601361, G0900453, G0400473] Funding Source: UKRI	MeDALL (Mechanisms of the Development of Allergy, EU); Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Lung Diseases, National Heart, Lung, and Blood Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by MeDALL (Mechanisms of the Development of Allergy, EU FP7 Grant agreement no. 261357). The workshop was supported in part by funds from the Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, and the Division of Lung Diseases, National Heart, Lung, and Blood Institute.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Alamo L, 2012, PEDIATR RADIOL, V42, P273, DOI 10.1007/s00247-011-2303-0; Altes TA, 2006, J MAGN RESON IMAGING, V24, P1277, DOI 10.1002/jmri.20723; Amin R, 2010, THORAX, V65, P379, DOI 10.1136/thx.2009.125831; Anto JM, 2012, J ALLERGY CLIN IMMUN, V129, P943, DOI 10.1016/j.jaci.2012.01.047; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bertelsen RJ, 2010, PEDIAT ALLERG IMM-UK, V21, P612, DOI 10.1111/j.1399-3038.2010.01066.x; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Bousquet J, 2011, GENOME MED, V3, DOI 10.1186/gm259; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774, DOI 10.1183/09031936.97.10081774; Carlsen KCL, 2004, PEDIAT ALLERG IMM-UK, V15, P323, DOI 10.1111/j.1399-3038.2004.00147.x; Carlsten C, 2011, PEDIATR PULM, V46, P175, DOI 10.1002/ppul.21347; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2011, J ALLERGY CLIN IMMUN, V127, P1082, DOI 10.1016/j.jaci.2011.01.024; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; Debley J, 2012, PEDIATR PULM, V47, P421, DOI 10.1002/ppul.21567; Dobrin R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r55; Eller E, 2008, ALLERGY, V63, P1491, DOI 10.1111/j.1398-9995.2008.01790.x; Feher A, 1996, J APPL PHYSIOL, V80, P2019, DOI 10.1152/jappl.1996.80.6.2019; Flexeder C, 2012, ALLERGY, V67, P257, DOI 10.1111/j.1398-9995.2011.02748.x; Gabriele C, 2012, EUR RESPIR J, V39, P567, DOI 10.1183/09031936.00151010; Gangell CL, 2010, PEDIATR PULM, V45, P419, DOI 10.1002/ppul.21192; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Goldstein AB, 2001, AM J RESP CRIT CARE, V164, P447, DOI 10.1164/ajrccm.164.3.2005080; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hohmann C, 2014, INT ARCH ALLERGY IMM; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Hong XM, 2010, J ALLERGY CLIN IMMUN, V126, P1059, DOI 10.1016/j.jaci.2010.08.029; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; Keil T, 2006, ALLERGY, V61, P1104, DOI 10.1111/j.1398-9995.2006.01167.x; Keil T, 2006, ALLERGY, V61, P221, DOI 10.1111/j.1398-9995.2006.00989.x; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; Latzin P, 2006, AM J RESP CRIT CARE, V174, P1292, DOI 10.1164/rccm.200606-782OC; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lell MM, 2011, INVEST RADIOL, V46, P116, DOI 10.1097/RLI.0b013e3181f33b1d; Li Y, 2011, IMMUNOBIOLOGY, V216, P947, DOI 10.1016/j.imbio.2011.01.003; Long FR, 1999, RADIOLOGY, V212, P588, DOI 10.1148/radiology.212.2.r99au06588; Lum S, 2007, THORAX, V62, P341, DOI 10.1136/thx.2006.068262; Lupinek C, 2013, METHODS; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez T, 2003, J APPL PHYSIOL, V94, P2384, DOI 10.1152/japplphysiol.00758.2002; Neuman A, 2012, AM J RESP CRIT CARE, V186, P1037, DOI 10.1164/rccm.201203-0501OC; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI 10.1097/EDE.0b013e31816a1ce3; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Ranciere F, 2013, ALLERGY, V68, P1158, DOI 10.1111/all.12208; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P397, DOI 10.1016/j.jaci.2011.04.044; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Sarria EE, 2012, EUR RESPIR J, V39, P992, DOI 10.1183/09031936.00064811; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Smith AK, 2013, NEW ENGL J MED, V368, P2448, DOI 10.1056/NEJMp1303295; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220, DOI 10.1152/jappl.1982.53.5.1220; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Tischer CG, 2011, ALLERGY, V66, P1570, DOI 10.1111/j.1398-9995.2011.02712.x; TURNER DJ, 1995, AM J RESP CRIT CARE, V151, P1441, DOI 10.1164/ajrccm.151.5.7735598; Turner SW, 2009, AM J RESP CRIT CARE, V179, P98, DOI 10.1164/rccm.200805-804OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Vrijheid M, 2012, ENVIRON HEALTH PERSP, V120, P29, DOI 10.1289/ehp.1103823; Wheelock CE, 2013, EUR RESPIR J, V42, P802, DOI 10.1183/09031936.00078812	94	73	72	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1535	1546		10.1016/j.jaci.2014.01.018	http://dx.doi.org/10.1016/j.jaci.2014.01.018			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24636091	Green Accepted, Green Submitted			2022-12-18	WOS:000336672500004
J	Yu, S; Kim, HY; Chang, YJ; DeKruyff, RH; Umetsu, DT				Yu, Sanhong; Kim, Hye Young; Chang, Ya-Jen; DeKruyff, Rosemarie H.; Umetsu, Dale T.			Innate lymphoid cells and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperreactivity; innate lymphoid cells; natural killer T cells; allergy; asthma; influenza	KILLER T-CELLS; AIRWAY HYPERREACTIVITY; INTESTINAL INFLAMMATION; ALLERGIC INFLAMMATION; TYPE-2 IMMUNITY; LUNG; POPULATION; CYTOKINE; PROMOTES; ALPHA	Asthma is a complex and heterogeneous disease with several phenotypes, including an allergic asthma phenotype characterized by T(H)2 cytokine production and associated with allergen sensitization and adaptive immunity. Asthma also includes nonallergic asthma phenotypes, such as asthma associated with exposure to air pollution, infection, or obesity, that require innate rather than adaptive immunity. These innate pathways that lead to asthma involve macrophages, neutrophils, natural killer T cells, and innate lymphoid cells, newly described cell types that produce a variety of cytokines, including IL-5 and IL-13. We review the recent data regarding innate lymphoid cells and their role in asthma.	[Yu, Sanhong; DeKruyff, Rosemarie H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Kim, Hye Young] Seoul Natl Univ, Coll Med, Dept Med Sci, Seoul, South Korea; [Chang, Ya-Jen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Umetsu, Dale T.] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Seoul National University (SNU); Academia Sinica - Taiwan; Roche Holding; Genentech	Umetsu, DT (corresponding author), Genentech Inc, One DNA Way, San Francisco, CA 94080 USA.	umetsud@gene.com	Chang, Ya-Jen/O-1584-2018; Kim, Hye Young/AAF-7609-2020	Chang, Ya-Jen/0000-0003-1377-6142; Kim, Hye Young/0000-0001-5978-512X				Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Albacker LA, 2013, NAT MED, V19, P1297, DOI 10.1038/nm.3321; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bernink J, 2013, IMMUNOL REV, V252, P133, DOI 10.1111/imr.12034; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Guo XH, 2014, IMMUNITY, V40, P25, DOI 10.1016/j.immuni.2013.10.021; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; Kamekura R, 2012, CLIN EXP ALLERGY, V42, P218, DOI 10.1111/j.1365-2222.2011.03867.x; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kruglov AA, 2013, SCIENCE, V342, P1243, DOI 10.1126/science.1243364; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Kwon BI, 2013, AM J RESP CRIT CARE, V188, P577, DOI 10.1164/rccm.201302-0295OC; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI 10.1038/mi.2009.96; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007; Possot C, 2011, NAT IMMUNOL, V12, P949, DOI 10.1038/ni.2105; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sanos SL, 2011, IMMUNOLOGY, V132, P453, DOI 10.1111/j.1365-2567.2011.03410.x; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Serafini N, 2014, J EXP MED, V211, P199, DOI 10.1084/jem.20131038; Sonnenberg GF, 2012, SCIENCE, V336, P1321, DOI 10.1126/science.1222551; Sonnenberg GF, 2011, IMMUNITY, V34, P122, DOI 10.1016/j.immuni.2010.12.009; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Zhou L, 2012, IMMUNITY, V37, P589, DOI 10.1016/j.immuni.2012.10.002	77	73	75	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					943	950		10.1016/j.jaci.2014.02.015	http://dx.doi.org/10.1016/j.jaci.2014.02.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24679467				2022-12-18	WOS:000333531700001
J	Bertelsen, RJ; Brantsaeter, AL; Magnus, MC; Haugen, M; Myhre, R; Jacobsson, B; Longnecker, MP; Meltzer, HM; London, SJ				Bertelsen, Randi J.; Brantsaeter, Anne Lise; Magnus, Maria C.; Haugen, Margaretha; Myhre, Ronny; Jacobsson, Bo; Longnecker, Matthew P.; Meltzer, Helle M.; London, Stephanie J.			Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; eczema; microbiome; Norwegian Mother and Child Cohort Study; probiotics; rhinoconjunctivitis	NORWEGIAN MOTHER; GUT MICROBIOTA; DOUBLE-BLIND; LACTOBACILLUS-RHAMNOSUS; EPIDEMIOLOGIC RESEARCH; INTESTINAL MICROFLORA; WOMEN; FOOD; SUPPLEMENTATION; COHORT	Background: Whether probiotics, which can influence the microbiome, prevent infant eczema or allergic disease remains an open question. Most studies have focused on high-risk infants. Objectives: We sought to assess whether consumption of probiotic milk products protects against atopic eczema, rhinoconjunctivitis, and asthma in early childhood in a large population-based pregnancy cohort (the Norwegian Mother and Child Cohort study). Methods: We examined associations between consumption of probiotic milk products in pregnancy and infancy with questionnaire-reported atopic eczema, rhinoconjunctivitis, and asthma in 40,614 children. Relative risks (RRs) were calculated by using general linear models adjusted for potential confounders. Results: Consumption of probiotic milk in pregnancy was associated with a slightly reduced relative risk (RR) of atopic eczema at 6 months (adjusted RR, 0.94; 95% CI, 0.89-0.99) and of rhinoconjunctivitis between 18 and 36 months (adjusted RR, 0.87; 95% CI, 0.78-0.98) compared with no consumption during pregnancy. Maternal history of allergic disease did not notably influence the associations. When both the mother (during pregnancy) and infant (after 6 months of age) had consumed probiotic milk, the adjusted RR of rhinoconjunctivitis was 0.80 (95% CI, 0.68-0.93) relative to no consumption by either. Probiotic milk consumption was not associated with asthma at 36 months. Conclusions: In this population-based cohort consumption of probiotic milk products was related to a reduced incidence of atopic eczema and rhinoconjunctivitis, but no association was seen for incidence of asthma by 36 months of age.	[Bertelsen, Randi J.] Norwegian Inst Publ Hlth, Dept Food Water & Cosmet, N-0403 Oslo, Norway; [Brantsaeter, Anne Lise; Haugen, Margaretha; Meltzer, Helle M.] Norwegian Inst Publ Hlth, Dept Exposure & Risk Assessment, N-0403 Oslo, Norway; [Magnus, Maria C.] Norwegian Inst Publ Hlth, Dept Chron Dis, N-0403 Oslo, Norway; [Myhre, Ronny; Jacobsson, Bo] Norwegian Inst Publ Hlth, Dept Genes & Environm, N-0403 Oslo, Norway; [Bertelsen, Randi J.; Magnus, Maria C.; Longnecker, Matthew P.; London, Stephanie J.] NIEHS, Epidemiol Branch, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; [Jacobsson, Bo] Sahlgrens Acad, Dept Obstet & Gynecol, Gothenburg, Sweden	Norwegian Institute of Public Health (NIPH); Norwegian Institute of Public Health (NIPH); Norwegian Institute of Public Health (NIPH); Norwegian Institute of Public Health (NIPH); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Gothenburg	Bertelsen, RJ (corresponding author), Norwegian Inst Publ Hlth, Dept Food Water & Cosmet, Div Environm Med, POB 4404, N-0403 Oslo, Norway.	randi.jacobsen.bertelsen@fhi.no	Jacobsson, Bo/O-8007-2014; Bertelsen, Randi J/N-6917-2017; London, Stephanie/C-3734-2019; Brantsaeter, Anne Lise/H-7014-2016; Haugen, Margaretha/H-7007-2016	Jacobsson, Bo/0000-0001-5079-2374; Bertelsen, Randi J/0000-0001-5319-525X; London, Stephanie/0000-0003-4911-5290; Brantsaeter, Anne Lise/0000-0001-6315-7134; Longnecker, Matthew/0000-0001-6073-5322; Haugen, Margaretha/0000-0001-5924-5000; Meltzer, Helle Margrete/0000-0002-3591-7017	Norwegian Ministry of Health; Norwegian Ministry of Education and Research; National Institute of Environmental Health Sciences [N01 ES 75558]; Division of Intramural Research [ZIA ES049019]; National Institute of Neurological Disorders and Stroke [1 UO1 NS 047537-01]; Norwegian Research Council/FUGE [151918/S10]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044008, ZIAES049019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS047537] Funding Source: NIH RePORTER	Norwegian Ministry of Health; Norwegian Ministry of Education and Research; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Norwegian Research Council/FUGE(Research Council of Norway); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health, the Norwegian Ministry of Education and Research, the National Institute of Environmental Health Sciences (contract N01 ES 75558) and the Division of Intramural Research (contract ZIA ES049019), the National Institute of Neurological Disorders and Stroke (grant 1 UO1 NS 047537-01), and the Norwegian Research Council/FUGE (grant 151918/S10).	Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Brantsaeter AL, 2008, MATERN CHILD NUTR, V4, P28, DOI 10.1111/j.1740-8709.2007.00103.x; Brantsaeter AL, 2011, AM J EPIDEMIOL, V174, P807, DOI 10.1093/aje/kwr168; Brantsaeter AL, 2009, J NUTR, V139, P1162, DOI 10.3945/jn.109.104968; Donnet-Hughes A, 2010, P NUTR SOC, V69, P407, DOI 10.1017/S0029665110001898; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Dreyer NA, 2010, HEALTH AFFAIR, V29, P1818, DOI 10.1377/hlthaff.2010.0666; FAO/WHO, 2002, REP JOINT FAO WHO EX; Fernandez L, 2013, PHARMACOL RES, V69, P1, DOI 10.1016/j.phrs.2012.09.001; Fiocchi A, 2012, WORLD ALLERGY ORGAN, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0; Foolad N, 2012, ARCH DERMATOL; Furu K, 2011, J CLIN EPIDEMIOL, V64, P878, DOI 10.1016/j.jclinepi.2010.10.014; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Gueimonde M, 2006, J PEDIATR GASTR NUTR, V42, P166, DOI 10.1097/01.mpg.0000189346.25172.fd; Gueimonde M, 2006, J PEDIATR GASTR NUTR, V42, P604, DOI 10.1097/01.mpg.0000221897.45910.d3; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P255, DOI 10.1111/j.1399-3038.2011.01239.x; Isolauri E, 2008, CURR PHARM DESIGN, V14, P1368, DOI 10.2174/138161208784480207; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kuitunen M, 2012, INT ARCH ALLERGY IMM, V159, P162, DOI 10.1159/000336157; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170; Meltzer HM, 2008, MATERN CHILD NUTR, V4, P14, DOI 10.1111/j.1740-8709.2007.00104.x; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005090.pub2; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Perez PF, 2007, PEDIATRICS, V119, pE724, DOI 10.1542/peds.2006-1649; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Rautava S, 2005, J ALLERGY CLIN IMMUN, V116, P31, DOI 10.1016/j.jaci.2005.02.010; Rautava S, 2012, J ALLERGY CLIN IMMUN, V130, P1355, DOI 10.1016/j.jaci.2012.09.003; Rautava S, 2012, NEONATOLOGY, V102, P178, DOI 10.1159/000339182; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rose MA, 2011, CLIN EXP ALLERGY, V41, P1819, DOI 10.1111/j.1365-2222.2011.03876.x; Sanders ME, 2011, ANN NY ACAD SCI, V1219, pE1, DOI 10.1111/j.1749-6632.2010.05956.x; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Slashinski MJ, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-28; Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417; Tang MLK, 2010, CURR OPIN PEDIATR, V22, P626, DOI 10.1097/MOP.0b013e32833d9728; Torjusen H, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-612; Vandenbroucke JP, 2008, PLOS MED, V5, P339, DOI 10.1371/journal.pmed.0050067; Vitali B, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-236; West CE, 2012, CLIN EXP ALLERGY, V42, P540, DOI 10.1111/j.1365-2222.2011.03941.x; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x	47	73	79	0	58	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					165	+		10.1016/j.jaci.2013.07.032	http://dx.doi.org/10.1016/j.jaci.2013.07.032			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24034345	Green Accepted			2022-12-18	WOS:000329105700023
J	Kerzerho, J; Maazi, H; Speak, AO; Szely, N; Lombardi, V; Khoo, B; Geryak, S; Lam, J; Soroosh, P; Van Snick, J; Akbari, O				Kerzerho, Jerome; Maazi, Hadi; Speak, Anneliese O.; Szely, Natacha; Lombardi, Vincent; Khoo, Bryant; Geryak, Stacey; Lam, Jonathan; Soroosh, Pejman; Van Snick, Jacques; Akbari, Omid			Programmed cell death ligand 2 regulates T(H)9 differentiation and induction of chronic airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic airway hyperreactivity; Aspergillus fumigatus; T(H)9; costimulation; programmed cell death ligand 2; TGF-beta	ENHANCING ACTIVITY MEA; TGF-BETA; T-CELLS; ASPERGILLUS-FUMIGATUS; INCREASED EXPRESSION; RECEPTOR EXPRESSION; ASTHMATIC RESPONSE; IL-9 PRODUCTION; CUTTING EDGE; INTERLEUKIN-9	Background: Asthma is defined as a chronic inflammatory disease of the airways; however, the underlying physiologic and immunologic processes are not fully understood. Objective: The aim of this study was to determine whether T(H)9 cells develop in vivo in a model of chronic airway hyperreactivity (AHR) and what factors control this development. Method: We have developed a novel chronic allergen exposure model using the clinically relevant antigen Aspergillus fumigatus to determine the time kinetics of T(H)9 development in vivo. Results: T(H)9 cells were detectable in the lungs after chronic allergen exposure. The number of T(H)9 cells directly correlated with the severity of AHR, and anti-IL-9 treatment decreased airway inflammation. Moreover, we have identified programmed cell death ligand (PD-L) 2 as a negative regulator of T(H)9 cell differentiation. Lack of PD-L2 was associated with significantly increased TGF-beta and IL-1 alpha levels in the lungs, enhanced pulmonary T(H)9 differentiation, and higher morbidity in the sensitized mice. Conclusion: Our findings suggest that PD-L2 plays a pivotal role in the regulation of T(H)9 cell development in chronic AHR, providing novel strategies for modulating adaptive immunity during chronic allergic responses. (J Allergy Clin Immunol 2013; 131:1048-57.)	[Kerzerho, Jerome; Maazi, Hadi; Speak, Anneliese O.; Szely, Natacha; Lombardi, Vincent; Khoo, Bryant; Geryak, Stacey; Lam, Jonathan; Akbari, Omid] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Soroosh, Pejman] Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA USA; [Van Snick, Jacques] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium	University of Southern California; Johnson & Johnson; Johnson & Johnson USA; Ludwig Institute for Cancer Research	Akbari, O (corresponding author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	Soroosh, Pejman/AAD-8386-2021	Maazi, Hadi/0000-0002-8979-3769; Speak, Anneliese/0000-0003-4890-4685	National Institutes of Health Public Health Service Grant [R01 AI066020]; American Lung Association Fellowship; Fonds National de la Recherche Scientifique Medicale de Belgique; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066020] Funding Source: NIH RePORTER	National Institutes of Health Public Health Service Grant; American Lung Association Fellowship; Fonds National de la Recherche Scientifique Medicale de Belgique(Fonds de la Recherche Scientifique - FNRS); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health Public Health Service Grant R01 AI066020 (to O.A.), the American Lung Association Fellowship (to V. L.), and the Fonds National de la Recherche Scientifique Medicale de Belgique (to J.V.S.).; Disclosure of potential conflict of interest: H. Maazi, B. Khoo, S. Geryak, J. Lam, and O. Akbari have received grants from the National Institutes of Health. J. Van Snick has received grants from Fonds National de la Recherche Scientifique Medicale de Belgique. The rest of the authors declare that they have no relevant conflicts of interest.	Akbari O, 2010, MUCOSAL IMMUNOL, V3, P81, DOI 10.1038/mi.2009.112; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Bhathena PR, 2000, LUNG, V178, P149, DOI 10.1007/s004080000018; Burton OT, 2010, J IMMUNOL, V185, P2754, DOI 10.4049/jimmunol.1001365; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Deppong C, 2006, J IMMUNOL, V176, P3909, DOI 10.4049/jimmunol.176.7.3909; Doherty TA, 2011, NAT MED, V17, P596, DOI 10.1038/nm.2356; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Elyaman W, 2009, P NATL ACAD SCI USA, V106, P12885, DOI 10.1073/pnas.0812530106; Erpenbeck VJ, 2003, CHEST, V123, p370S; Fairs A, 2010, AM J RESP CRIT CARE, V182, P1362, DOI 10.1164/rccm.201001-0087OC; Gandhi R, 2007, J IMMUNOL, V178, P4017, DOI 10.4049/jimmunol.178.7.4017; GESSNER A, 1993, IMMUNOBIOLOGY, V189, P419, DOI 10.1016/S0171-2985(11)80414-6; Goswami R, 2012, J IMMUNOL, V188, P968, DOI 10.4049/jimmunol.1102840; Gounni AS, 2000, BLOOD, V96, P2163; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; Huber S, 2010, BLOOD, V116, P3311, DOI 10.1182/blood-2010-02-271981; HULTNER L, 1990, EXP HEMATOL, V18, P873; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Jones CP, 2012, J ALLERGY CLIN IMMUN, V129, P1000, DOI 10.1016/j.jaci.2011.12.965; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kimura A, 2007, P NATL ACAD SCI USA, V104, P12099, DOI 10.1073/pnas.0705268104; Lesterhuis WJ, 2011, MOL IMMUNOL, V49, P1, DOI 10.1016/j.molimm.2011.09.014; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Lombardi V, 2012, MUCOSAL IMMUNOL, V5, P432, DOI 10.1038/mi.2012.20; Lombardi V, 2010, INT ARCH ALLERGY IMM, V151, P179, DOI 10.1159/000242355; Lombardi V, 2010, J IMMUNOL, V184, P2107, DOI 10.4049/jimmunol.0901208; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Matsumoto K, 2004, J IMMUNOL, V172, P2530, DOI 10.4049/jimmunol.172.4.2530; Messal N, 2011, MOL IMMUNOL, V48, P2214, DOI 10.1016/j.molimm.2011.06.436; Mizutani N, 2012, J IMMUNOL, V188, P5694, DOI 10.4049/jimmunol.1103176; Nowak EC, 2009, J EXP MED, V206, P1653, DOI 10.1084/jem.20090246; Ochi H, 2006, NAT MED, V12, P627, DOI 10.1038/nm1408; Oflazoglu E, 2004, EUR J IMMUNOL, V34, P3326, DOI 10.1002/eji.200425197; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038; Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360; Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025; Reader JR, 2003, AM J RESP CELL MOL, V28, P664, DOI 10.1165/rcmb.2002-0207OC; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Richard M, 2000, P NATL ACAD SCI USA, V97, P767, DOI 10.1073/pnas.97.2.767; SCHMITT E, 1994, J IMMUNOL, V153, P3989; SCHMITT E, 1991, J IMMUNOL, V147, P3848; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Singh AK, 2011, ALLERGY, V66, P155, DOI 10.1111/j.1398-9995.2010.02458.x; Singhera GK, 2008, EXP LUNG RES, V34, P579, DOI 10.1080/01902140802369372; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Tan CY, 2010, J IMMUNOL, V185, P6795, DOI 10.4049/jimmunol.1001676; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 2007, INT IMMUNOL, V19, P1, DOI 10.1093/intimm/dxl117; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Uyttenhove C, 2010, EUR J IMMUNOL, V40, P2230, DOI 10.1002/eji.200940281; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Vermeer PD, 2003, AM J RESP CELL MOL, V28, P286, DOI 10.1165/rcmb.4887; Wilhelm C, 2012, NAT IMMUNOL, V13, P637, DOI 10.1038/ni.2303; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wong MT, 2010, IMMUNOL CELL BIOL, V88, P624, DOI 10.1038/icb.2010.53	66	73	79	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1048	+		10.1016/j.jaci.2012.09.027	http://dx.doi.org/10.1016/j.jaci.2012.09.027			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23174661	Green Accepted, Bronze			2022-12-18	WOS:000317187200012
J	Meltzer, EO; Schatz, M; Nathan, R; Garris, C; Stanford, RH; Kosinski, M				Meltzer, Eli O.; Schatz, Michael; Nathan, Robert; Garris, Cindy; Stanford, Richard H.; Kosinski, Mark			Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; nonallergic rhinitis; rhinitis control; patient-reported outcome; Rhinitis Control Assessment Test	QUALITY-OF-LIFE; ASTHMA CONTROL TEST; VALIDATION; INSTRUMENT; BURDEN	Background: The Rhinitis Control Assessment Test (RCAT) is a brief, patient-completed tool to evaluate rhinitis symptom control. Objective: We sought to test the reliability, validity, and responsiveness of RCAT and to estimate a cut-point score and minimal important difference (MID). Methods: A total of 402 patients 12 years of age and older with allergic or nonallergic rhinitis were enrolled in a noninterventional study. Patients completed the RCAT (6 items; score range, 6-30) and had Total Nasal Symptom Scores (TNSSs) measured at baseline and 2 weeks later. Physicians completed a global assessment of rhinitis symptom control (Physician's Global Assessment) and disease severity. Internal consistency, test-retest reliability, convergent validity, known-groups validity, and responsiveness were evaluated. The MID was determined by using distribution-and anchor-based methods. Content validity of the RCAT was assessed in individual interviews with a separate group of 58 adult patients. Results: Internal consistency and test-retest reliability of RCAT scores were 0.77 and 0.78, respectively. Convergent validity correlation between RCAT and TNSS scores was 0.57, and that between RCAT and Physician's Global Assessment scores was 0.34. Mean RCAT scores differed significantly (P<.001) across patient groups, differing in TNSS (F = 72.7), Physician's Global Assessment score (F = 28.6), and disease severity (F = 34.1) in the hypothesized direction. Results suggested a cut-point score of 21 or less can be used to identify patients who are experiencing rhinitis symptom control problems. The preliminary estimate of the MID was 3 points. Patients found RCAT items comprehensive, easy to understand, and relevant. Conclusion: The RCAT demonstrated adequate reliability, validity, and responsiveness and was deemed acceptable and appropriate by patients. This tool can facilitate the detection of rhinitis symptom control problems, and its brevity supports its usefulness in clinical care. (J Allergy Clin Immunol 2013;131:379-86.)	[Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Schatz, Michael] Kaiser Permanente, San Diego, CA USA; [Nathan, Robert] Asthma & Allergy Associates, Colorado Springs, CO USA; [Garris, Cindy; Stanford, Richard H.] GlaxoSmithKline R&D, Res Triangle Pk, NC USA; [Kosinski, Mark] Qual Metr, Providence, RI USA	Kaiser Permanente; GlaxoSmithKline	Stanford, RH (corresponding author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	Richard.h.stanford@gsk.com		Garris, Cindy/0000-0002-2685-1204	GlaxoSmithKline; Alcon; Apotex; AstraZeneca; Boehringer Ingelheim; MedImmune; Novartis; Proctor Gamble; Sepracor; Schering-Plough; Sunovion; Teva; Aerocrine; Merck; Genentech; ISTA; CSL Behring; Shionogi	GlaxoSmithKline(GlaxoSmithKline); Alcon(Novartis); Apotex; AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); MedImmune(AstraZenecaMedimmune); Novartis(Novartis); Proctor Gamble(Procter & Gamble); Sepracor; Schering-Plough(Merck & CompanySchering Plough Corporation); Sunovion; Teva(Teva Pharmaceutical Industries); Aerocrine; Merck(Merck & Company); Genentech(Roche HoldingGenentech); ISTA; CSL Behring; Shionogi	E. O. Meltzer has been supported by one or more grants from GlaxoSmithKline; has consultancy arrangements with Alcon, Alexza, AstraZeneca, Bausch + Lomb, Boehringer Ingelheim, Dey, ISTA, Johnson & Johnson, Kalypsys, Meda, Merck, ONO Pharma, OptiNose, Proctor & Gamble, Rigel, Sanofi-Aventis, Sepracor, Sunovion, and Teva; is employed by the Allergy and Asthma Medical Group and Research Center; has received one or more grants from or has one or more grants pending with Alcon, Apotex, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MedImmune, Novartis, Proctor & Gamble, Sepracor, Schering-Plough, Sunovion, and Teva; and has received one or more payments for lecturing from or is on the speakers' bureau for Alcon, Dey, ISTA, Merck, Sepracor, Sunovion, and Teva. M. Schatz has been supported by one or more grants from GlaxoSmithKline; has consultancy arrangements with Amgen, GlaxoSmithKline, Merck, and Boston Scientific; and has received one or more grants from or has one or more grants pending with Aerocrine, Merck, Genentech, and GlaxoSmithKline. R. Nathan has received one or more consulting fees or honoraria from GlaxoSmithKline, ISTA, Merck, CSL Behring, Teva, and Shionogi. C. Garris and R. Stanford are employed by and own stock/stock options in GlaxoSmithKline. M. Kosinski declares that he has no relevant conflicts of interest.	Cohen J., 1988, STAT POWER ANAL BEHA; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kerlinger FN, 1973, FDN BEHAV RES, V2nd; Kosinski M, 2009, CURR MED RES OPIN, V25, P717, DOI 10.1185/03007990802711602 ; Meltzer EO, 2009, ALLERGY ASTHMA PROC, V30, P244, DOI 10.2500/aap.2009.30.3230; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nathan RA, 2010, PATIENT, V3, P91, DOI 10.2165/11318410-000000000-00000; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Nunnally J., 1994, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2008, ANN ALLERG ASTHMA IM, V101, P240, DOI 10.1016/S1081-1206(10)60488-7; Schatz M, 2010, ANN ALLERG ASTHMA IM, V104, P118, DOI 10.1016/j.anai.2009.11.063; U. S. Deparatment of Health and Human Services, NIH PUBL, V15-3859; US Department of Health and Human Services, 2008, FDA GUID IND PAT REP; Wyrwich KW, 2002, QUAL LIFE RES, V11, P1, DOI 10.1023/A:1014485627744; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2	21	73	76	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					379	386		10.1016/j.jaci.2012.10.022	http://dx.doi.org/10.1016/j.jaci.2012.10.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23219170				2022-12-18	WOS:000314661500015
J	Chaudhuri, R; McSharry, C; Brady, J; Donnelly, I; Grierson, C; McGuinness, S; Jolly, L; Weir, CJ; Messow, CM; Spears, M; Miele, G; Nocka, K; Crowther, D; Thompson, J; Brannigan, M; Lafferty, J; Sproule, M; MacNee, W; Connell, M; Murchison, JT; Shepherd, MC; Feuerstein, G; Miller, DK; Thomson, NC				Chaudhuri, Rekha; McSharry, Charles; Brady, Jeffrey; Donnelly, Iona; Grierson, Christal; McGuinness, Stephen; Jolly, Lisa; Weir, Christopher J.; Messow, C. Martina; Spears, Mark; Miele, Gino; Nocka, Karl; Crowther, Dan; Thompson, Joyce; Brannigan, Maureen; Lafferty, Jane; Sproule, Michael; MacNee, William; Connell, Martin; Murchison, John T.; Shepherd, Malcolm C.; Feuerstein, Giora; Miller, Douglas K.; Thomson, Neil C.			Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Matrix metalloproteinase 12; tissue inhibitor of metalloproteinases 1 and 2; MMP12 expression; emphysema; chronic obstructive pulmonary disease; asthma; smoker	INVESTIGATE AIRWAY INFLAMMATION; MACROPHAGE ELASTASE; CIGARETTE-SMOKING; SMOOTH-MUSCLE; MMP-12; EMPHYSEMA; SMOKERS; INCREASE; MARKERS; CELLS	Background: Matrix metalloproteinase (MMP)-12 has been implicated in the pathogenesis of both chronic obstructive pulmonary disease (COPD) and asthma. The influence of disease severity on sputum MMP-12 concentrations and activity is not known. Objectives: We sought to examine the relationship between disease severity assessed by means of lung function and computed tomography (CT) and induced sputum MMP-12 concentrations and activity in patients with asthma and COPD. Methods: In 208 subjects (109 asthmatic patients, smokers and never smokers, mild, moderate, and severe; 53 patients with COPD, smokers and exsmokers, mild, moderate, and severe; and 46 healthy control subjects, smokers and never smokers), we measured induced sputum MMP-12 concentrations (ELISA) and enzyme activity (fluorescence resonance energy transfer), sputum cell MMP12 mRNA expression (quantitative PCR [qPCR]), diffusing capacity for carbon monoxide (DLCO), and CT assessment of emphysema (percentage of low-attenuation areas at less 2950 Hounsfield units). Results: Sputum MMP-12 concentrations are greater in patients with COPD and smokers with asthma than in healthy nonsmokers (P = .003 and P = .035, respectively) but similar to those seen in healthy smokers. In patients with COPD, disease severity, when measured by means of CT-assessed emphysema, but not by means of spirometry or DLCO values, is directly associated with sputum MMP-12 concentrations and activity. In the asthma groups there is no significant association between disease severity and sputum MMP-12 concentrations or activity. Conclusions: Sputum MMP-12 concentrations and activity in patients with COPD are directly associated with the extent of emphysema measured by means of CT. This finding supports a role for MMP-12 in the pathogenesis of COPD and might suggest that blocking MMP-12 activity in patients with COPD could prevent the further development of emphysema. (J Allergy Clin Immunol 2012; 129: 655-63.)	[Messow, C. Martina] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 OYN, Lanark, Scotland; [Brady, Jeffrey; Grierson, Christal; McGuinness, Stephen; Miele, Gino; Nocka, Karl; Crowther, Dan; Feuerstein, Giora; Miller, Douglas K.] Pfizer Res, Translat Med Res Collaborat, Dundee, Scotland; [Brady, Jeffrey; Grierson, Christal; McGuinness, Stephen; Miele, Gino; Nocka, Karl; Crowther, Dan; Feuerstein, Giora; Miller, Douglas K.] Pfizer Res, Translat Med Res Collaborat, Cambridge, MA USA; [Brady, Jeffrey; Grierson, Christal; McGuinness, Stephen; Miele, Gino; Nocka, Karl; Crowther, Dan; Feuerstein, Giora; Miller, Douglas K.] Pfizer Res, Translat Med Res Collaborat, Collegeville, PA USA; [Weir, Christopher J.] Univ Edinburgh, MRC Hub Trials Methodol Res, Edinburgh EH8 9YL, Midlothian, Scotland; [Sproule, Michael] Gartnavel Royal Hosp, Dept Radiol, Glasgow G12 OYN, Lanark, Scotland; [MacNee, William; Connell, Martin; Murchison, John T.] Univ Edinburgh, Ctr Inflammat Res Med Phys & Clin Radiol, Edinburgh EH8 9YL, Midlothian, Scotland	University of Glasgow; Pfizer; University of Dundee; Pfizer; Pfizer; University of Edinburgh; Gartnavel Royal Hospital; University of Edinburgh	Thomson, NC (corresponding author), Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 OYN, Lanark, Scotland.	neil.thomson@glasgow.ac.uk		Messow, Claudia-Martina/0000-0003-0082-9946; McSharry, Charles/0000-0003-4758-9038; Weir, Christopher/0000-0002-6494-4903; Spears, Mark/0000-0003-4381-5819; MacNee, William/0000-0002-3692-1448; Thomson, Neil/0000-0003-1632-6630	Translational Medicine Research Collaboration [INF-GU-090]; NHS Health Boards (Greater Glasgow & Clyde, Lothian, Grampian, and Tayside); Scottish Enterprise; Pfizer; NHS Research Scotland (NRS) through Scottish Primary Care Research Network; MRC [G0901697, G0800803] Funding Source: UKRI; Medical Research Council [G0800803, G0901697] Funding Source: researchfish	Translational Medicine Research Collaboration; NHS Health Boards (Greater Glasgow & Clyde, Lothian, Grampian, and Tayside); Scottish Enterprise; Pfizer(Pfizer); NHS Research Scotland (NRS) through Scottish Primary Care Research Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by an award (INF-GU-090) from the Translational Medicine Research Collaboration, a consortium made up of the Universities of Glasgow, Edinburgh, Aberdeen, and Dundee and the 4 associated NHS Health Boards (Greater Glasgow & Clyde, Lothian, Grampian, and Tayside), Scottish Enterprise, and Pfizer (formerly Wyeth) and supported financially by NHS Research Scotland (NRS) through the Scottish Primary Care Research Network.; K. Nocka is employed by Pfizer. D. Crowther is a previous employee of Pfizer and is a visiting Fellow at the Cranfield University and an honorary lecturer at the University of Dundee. W. MacNee has received research support from Pfizer. D. K. Miller is a Pfizer/Wyeth employee. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; [Anonymous], 2010, R LANG ENV STAT COMP; [Anonymous], GLOBAL STRATEGY DIAG; [Anonymous], R LANGUAGE ENV STAT; Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807; Aviles B, 2006, ARCH BRONCONEUMOL, V42, P235, DOI 10.1157/13088028; Barnes Peter J, 2008, Proc Am Thorac Soc, V5, P857, DOI 10.1513/pats.200807-069TH; Boschetto P, 2006, THORAX, V61, P1037, DOI 10.1136/thx.2006.058321; Chaudhuri R, 2008, ALLERGY, V63, P132, DOI 10.1111/j.1398-9995.2007.01538.x; Chiba Y, 2007, BIOL PHARM BULL, V30, P318, DOI 10.1248/bpb.30.318; Churg A, 2007, AM J RESP CELL MOL, V37, P144, DOI 10.1165/rcmb.2006-0345OC; Cobos-Correa A, 2009, NAT CHEM BIOL, V5, P628, DOI 10.1038/nchembio.196; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Coxson HO, 2009, AM J RESP CRIT CARE, V180, P588, DOI 10.1164/rccm.200901-0159PP; Demedts IK, 2006, THORAX, V61, P196, DOI 10.1136/thx.2005.042432; Demedts IK, 2005, CURR OPIN PHARMACOL, V5, P257, DOI 10.1016/j.coph.2004.12.005; Elias Jack A, 2006, Proc Am Thorac Soc, V3, P494, DOI 10.1513/pats.200603-068MS; Elkington Paul T., 2009, V531, P253, DOI 10.1007/978-1-59745-396-7_16; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Elkington PTG, 2005, CLIN EXP IMMUNOL, V142, P12, DOI [10.1111/j.1365-2249.2005.02840.x, 10.1111/j.1365-2249.2005.02840.X]; Global Initiative for Asthma (GINA) NHLaBI National Institutes of Health, GINA REP GLOB STRAT; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Ilumets Helen, 2007, Int J Chron Obstruct Pulmon Dis, V2, P369; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LaPan P, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-40; Lavigne MC, 2004, BIOCHEM BIOPH RES CO, V324, P534, DOI 10.1016/j.bbrc.2004.09.080; Mair G, 2009, EUR RESPIR J, V33, P536, DOI 10.1183/09031936.00111808; Matsuoka S, 2010, RADIOGRAPHICS, V30, P55, DOI 10.1148/rg.301095110; Molet S, 2005, INFLAMM RES, V54, P31, DOI 10.1007/s00011-004-1319-4; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Spears M, 2010, EXPERT REV CLIN IMMU, V6, P257, DOI 10.1586/ECI.09.85; Taddese S, 2008, MATRIX BIOL, V27, P420, DOI 10.1016/j.matbio.2008.02.001; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Van Lint P, 2007, J LEUKOCYTE BIOL, V82, P1375, DOI 10.1189/jlb.0607338; Warner RL, 2004, AM J PATHOL, V165, P1921, DOI 10.1016/S0002-9440(10)63244-0; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Xie SP, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-148	41	73	74	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					655	U106		10.1016/j.jaci.2011.12.996	http://dx.doi.org/10.1016/j.jaci.2011.12.996			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22305682				2022-12-18	WOS:000301189300008
J	Pescovitz, MD; Torgerson, TR; Ochs, HD; Ocheltree, E; Mcgee, P; Krause-Steinrauf, H; Lachin, JM; Canniff, J; Greenbaum, C; Herold, KC; Skyler, JS; Weinberg, A				Pescovitz, Mark D.; Torgerson, Troy R.; Ochs, Hans D.; Ocheltree, Elizabeth; McGee, Paula; Krause-Steinrauf, Heidi; Lachin, John M.; Canniff, Jennifer; Greenbaum, Carla; Herold, Kevan C.; Skyler, Jay S.; Weinberg, Adriana		Type 1 Diabet TrialNet Study Grp	Effect of rituximab on human in vivo antibody immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B lymphocytes; human; diabetes; antibodies; immunization; CD20	ANTI-CD20 MONOCLONAL-ANTIBODY; BETA-CELL FUNCTION; SEROLOGICAL MEMORY; HUMORAL IMMUNITY; CLINICAL-TRIAL; LYMPHOMA; THERAPY; TRANSPLANTATION; IDEC-C2B8; DEPLETION	Background: B-lymphocyte depletion with rituximab has been shown to benefit patients with various autoimmune diseases. We have previously demonstrated that this benefit is also apparent in patients with newly diagnosed type 1 diabetes. Objectives: The effect of rituximab on in vivo antibody responses, particularly during the period of B-lymphocyte depletion, is incompletely determined. This study was designed to assess this knowledge void. Methods: In patients with recent-onset type 1 diabetes treated with rituximab (n = 46) or placebo (n = 29), antibody responses to neoantigen phiX174 during B-lymphocyte depletion and with hepatitis A (as a second neoantigen) and tetanus/diphtheria (as recall antigens) after B-lymphocyte recovery were studied. Anti-tetanus, diphtheria, mumps, measles, and rubella titers were measured before and after treatment by means of ELISA. Antibody titers and percentage IgM versus percentage IgG to phiX174 were measured by means of phage neutralization. B-lymphocyte subsets were determined by means of flow cytometry. Results: No change occurred in preexisting antibody titers. Tetanus/diphtheria and hepatitis A immunization responses were protective in the rituximab-treated subjects, although significantly blunted compared with those seen in the controls subjects, when immunized at the time of B-lymphocyte recovery. Anti-phiX174 responses were severely reduced during the period of B-lymphocyte depletion, but with B-lymphocyte recovery, anti-phiX174 responses were within the normal range. Conclusions: During the time of B-lymphocyte depletion, rituximab recipients had a decreased antibody response to neoantigens and significantly lower titers after recall immunization with diphtheria and tetanus toxoid. With recovery, immune responses return toward normal. Immunization during the time of B-lymphocyte depletion, although ineffective, does not preclude a subsequent response to the antigen. (J Allergy Clin Immunol 2011;128:1295-302.)	[Skyler, Jay S.] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA; [Pescovitz, Mark D.] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA; [Pescovitz, Mark D.] Indiana Univ, Dept Microbiol & Immunol, Indianapolis, IN 46204 USA; [Torgerson, Troy R.; Ochs, Hans D.; Ocheltree, Elizabeth] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Torgerson, Troy R.; Ochs, Hans D.; Ocheltree, Elizabeth] Seattle Childrens Res Inst, Seattle, WA USA; [McGee, Paula; Krause-Steinrauf, Heidi; Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA; [Canniff, Jennifer] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Weinberg, Adriana] Univ Colorado Denver, Dept Med, Aurora, CO USA; [Weinberg, Adriana] Univ Colorado Denver, Dept Pathol, Aurora, CO USA; [Greenbaum, Carla] Benaroya Res Inst, Seattle, WA USA; [Herold, Kevan C.] Yale Univ, Dept Immunobiol, New Haven, CT USA; [Herold, Kevan C.] Yale Univ, Dept Internal Med, New Haven, CT USA	University of Miami; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle; Seattle Children's Hospital; George Washington University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Benaroya Research Institute; Yale University; Yale University	Skyler, JS (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, 1450 NW 10th Ave,Suite 3054, Miami, FL 33136 USA.	jskyler@miami.edu	Toledo, Frederico/G-9071-2013; Skyler, Jay S/F-4211-2016	Toledo, Frederico/0000-0002-6570-9948; Skyler, Jay/0000-0003-1136-8110; Lachin, John/0000-0001-9838-2841	National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; Juvenile Diabetes Research Foundation International; American Diabetes Association; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Bayhill Therapeutics; Halozyme Inc; Osiris Therapeutics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK061041, U01DK061034] Funding Source: NIH RePORTER	National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); American Diabetes Association(American Diabetes Association); National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Bayhill Therapeutics; Halozyme Inc; Osiris Therapeutics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group. TrialNet is a clinical trials network funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Center for Research Resources; the Juvenile Diabetes Research Foundation International; and the American Diabetes Association.; T. R. Torgerson has consultant arrangements with Baxter Biosciences. J. M. Lachin has consultant arrangements with Genentech, Bayhill Therapeutics, GlaxoSmithKline, and TolerRx. C. Greenbaum receives research support from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, the Juvenile Diabetes Research Foundation International, and the National Institutes of Health/National Institute of Allergy and Infectious Diseases. J. S. Skyler is on the Board of Directors for Amylin Pharmaceuticals and DexCom Inc, has consultant arrangements with Sanofi-Aventis and BD Technologies, and has received research support from Bayhill Therapeutics, Halozyme Inc, and Osiris Therapeutics. The rest of the authors have declared that they have no conflict of interest.	Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Bearden CM, 2005, AM J TRANSPLANT, V5, P50, DOI 10.1111/j.1600-6143.2003.00646.x; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P3612, DOI 10.1002/art.22211; Coiffier B, 1998, BLOOD, V92, P1927; Di Genova G, 2006, BLOOD, V107, P2806, DOI 10.1182/blood-2005-08-3255; DiLillo DJ, 2008, J IMMUNOL, V180, P361, DOI 10.4049/jimmunol.180.1.361; Eibl N, 2002, CLIN IMMUNOL, V103, P249, DOI 10.1006/clim.2002.5220; FASS L, 1973, TRANSPLANTATION, V16, P630, DOI 10.1097/00007890-197312000-00015; Fogelman I, 2000, J INFECT DIS, V182, P435, DOI 10.1086/315739; FUDENBERG H, 1971, PEDIATRICS, V47, P927; Gong Q, 2005, J IMMUNOL, V174, P817, DOI 10.4049/jimmunol.174.2.817; Gonzalez-Stawinski GV, 2001, CLIN IMMUNOL, V98, P175, DOI 10.1006/clim.2000.4980; Greenbaum CJ, 2008, DIABETES CARE, V31, P1966, DOI 10.2337/dc07-2451; Horwitz SM, 2004, BLOOD, V103, P777, DOI 10.1182/blood-2003-04-1257; MALONEY DG, 1994, BLOOD, V84, P2457; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; OCHS HD, 1992, BLOOD, V80, P1163; OCHS HD, 1988, J CLIN IMMUNOL, V8, P57, DOI 10.1007/BF00915157; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OCHS HD, 1980, BLOOD, V55, P243; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Rao A, 2008, PEDIATR BLOOD CANCER, V50, P822, DOI 10.1002/pbc.21264; Rubinstein A, 2000, AIDS, V14, pF55, DOI 10.1097/00002030-200003100-00004; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Sidner Richard A, 2004, Hum Antibodies, V13, P55; Tobinai K, 1998, ANN ONCOL, V9, P527, DOI 10.1023/A:1008265313133; van der Kolk LE, 2002, BLOOD, V100, P2257, DOI 10.1182/blood.V100.6.2257.h81802002257_2257_2259; Vieira CA, 2004, TRANSPLANTATION, V77, P542, DOI 10.1097/01.TP.0000112934.12622.2B; Wedgwood R J, 1975, Birth Defects Orig Artic Ser, V11, P331; WIEDERMANN G, 1990, VACCINE, V8, P581, DOI 10.1016/0264-410X(90)90013-C; WITHERSPOON RP, 1982, TRANSPLANTATION, V33, P143, DOI 10.1097/00007890-198202000-00008	35	73	76	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1295	U655		10.1016/j.jaci.2011.08.008	http://dx.doi.org/10.1016/j.jaci.2011.08.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21908031	Green Accepted			2022-12-18	WOS:000298342700020
J	Rezaee, F; Meednu, N; Emo, JA; Saatian, B; Chapman, TJ; Naydenov, NG; De Benedetto, A; Beck, LA; Ivanov, AI; Georas, SN				Rezaee, Fariba; Meednu, Nida; Emo, Jason A.; Saatian, Bahman; Chapman, Timothy J.; Naydenov, Nayden G.; De Benedetto, Anna; Beck, Lisa A.; Ivanov, Andrei I.; Georas, Steve N.			Polyinosinic:polycytidylic acid induces protein kinase D-dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; polyI:C; Toll-like receptor 3; epithelial permeability; protein kinase C; tight junctions; adherens junctions	E-CADHERIN; MYOSIN-II; SELECTIVE-INHIBITION; STRUCTURAL BASIS; TIGHT JUNCTIONS; C-ALPHA; ACTIVATION; EXPRESSION; SECRETION; APOPTOSIS	Background: Disruption of the epithelial barrier might be a risk factor for allergen sensitization and asthma. Viral respiratory tract infections are strongly associated with asthma exacerbation, but the effects of respiratory viruses on airway epithelial barrier function are not well understood. Many viruses generate double-stranded RNA, which can lead to airway inflammation and initiate an antiviral immune response. Objectives: We investigated the effects of the synthetic double-stranded RNA polyinosinic:polycytidylic acid (polyI:C) on the structure and function of the airway epithelial barrier in vitro. Methods: 16HBE14o- human bronchial epithelial cells and primary airway epithelial cells at an air-liquid interface were grown to confluence on Transwell inserts and exposed to polyI:C. We studied epithelial barrier function by measuring transepithelial electrical resistance and paracellular flux of fluorescent markers and structure of epithelial apical junctions by means of immunofluorescence microscopy. Results: PolyI:C induced a profound decrease in transepithelial electrical resistance and increase in paracellular permeability. Immunofluorescence microscopy revealed markedly reduced junctional localization of zonula occludens-1, occludin, E-cadherin, beta-catenin, and disorganization of junction-associated actin filaments. PolyI:C induced protein kinase D (PKD) phosphorylation, and a PKD antagonist attenuated polyI:C-induced disassembly of apical junctions and barrier dysfunction. Conclusions: PolyI:C has a powerful and previously unsuspected disruptive effect on the airway epithelial barrier. PolyI:C-dependent barrier disruption is mediated by disassembly of epithelial apical junctions, which is dependent on PKD signaling. These findings suggest a new mechanism potentially underlying the associations between viral respiratory tract infections, airway inflammation, and allergen sensitization. (J Allergy Clin Immunol 2011;128:1216-24.)	[Meednu, Nida; Emo, Jason A.; Saatian, Bahman; Chapman, Timothy J.; Georas, Steve N.] Univ Rochester, Med Ctr, Div Pulm & Crit Care Med, Dept Med, Rochester, NY 14610 USA; [Rezaee, Fariba] Univ Rochester, Med Ctr, Div Pediat Pulm, Dept Pediat, Rochester, NY 14610 USA; [Naydenov, Nayden G.; Ivanov, Andrei I.] Univ Rochester, Med Ctr, Dept Med, Div Gastroenterol & Hepatol, Rochester, NY 14610 USA; [De Benedetto, Anna; Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14610 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Georas, SN (corresponding author), Univ Rochester, Med Ctr, Div Pulm & Crit Care Med, Dept Med, 601 Elmwood Ave, Rochester, NY 14610 USA.	steve_georas@urmc.rochester.edu	Rezaee, Fariba/AAI-1437-2021; Ivanov, Andrei/V-1672-2019; Иванов, Александр/R-4514-2019	Rezaee, Fariba/0000-0002-7625-3341; Иванов, Александр/0000-0003-3475-2182; Meednu, Nida/0000-0002-2868-3339; Chapman, Timothy/0000-0002-2337-2136	National Institutes of Health (NIH) [R01 HL071933, P30 ES 01247, R01 DK083968, DK084953, T32 HD057821, T32 HL066988]; National Eczema Association; University of Rochester Department of Pediatrics; Centocor; Regeneron; Genentech; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068373, T32HD057821] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL066988, R01HL071933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083968, R01DK084953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Eczema Association; University of Rochester Department of Pediatrics; Centocor; Regeneron(Regeneron); Genentech(Roche HoldingGenentech); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health (NIH) grant R01 HL071933 (to S.N.G.), Pilot Project Funding supported by NIH grant P30 ES 01247 (to S.N.G.), NIH grants R01 DK083968 and DK084953 (to A.I.I.), NIH grant T32 HD057821 (to F.R.), NIH grant T32 HL066988 (to T.J.C.), the National Eczema Association (to A.D.), and a Bradford Fellowship from the University of Rochester Department of Pediatrics (to F.R.).; L. A. Beck receives research support from Centocor, Regeneron, and Genentech. S. N. Georas receives research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908; Anderson JM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002584; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; Comstock AT, 2011, J VIROL, V85, P6795, DOI 10.1128/JVI.02074-10; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Fischer S, 2007, BLOOD, V110, P2457, DOI 10.1182/blood-2006-08-040691; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Goto Y, 2000, AM J RESP CELL MOL, V23, P712, DOI 10.1165/ajrcmb.23.6.4031; Hagele H, 2009, NEPHROL DIAL TRANSPL, V24, P3312, DOI 10.1093/ndt/gfp339; Heijink IH, 2007, J IMMUNOL, V178, P7678, DOI 10.4049/jimmunol.178.12.7678; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Ivanov AI, 2008, FRONT BIOSCI-LANDMRK, V13, P6662, DOI 10.2741/3180; Ivanov AI, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-36; Johnson J, 2007, J BIOL CHEM, V282, P15022, DOI 10.1074/jbc.M700421200; Kim YI, 2010, J IMMUNOL, V184, P3145, DOI 10.4049/jimmunol.0903718; LAKE FR, 1994, AM J PHYSIOL, V266, pC134, DOI 10.1152/ajpcell.1994.266.1.C134; Langlet C, 2010, EUR J IMMUNOL, V40, P505, DOI 10.1002/eji.200939391; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Masuyama K, 2003, J ALLERGY CLIN IMMUN, V112, P208, DOI 10.1067/mai.2003.1526; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Michallet MC, 2008, IMMUNITY, V28, P651, DOI 10.1016/j.immuni.2008.03.013; Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; O'Hara JR, 2008, FRONT BIOSCI-LANDMRK, V13, P7008, DOI 10.2741/3206; Ohkuni T, 2011, TOXICOL APPL PHARM, V250, P29, DOI 10.1016/j.taap.2010.09.023; Paone A, 2008, CARCINOGENESIS, V29, P1334, DOI 10.1093/carcin/bgn149; Ren M, 2009, IMMUNITY, V30, P521, DOI 10.1016/j.immuni.2009.03.007; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P1, DOI 10.1111/j.1749-6632.2009.04925.x; Scott KGE, 2002, GASTROENTEROLOGY, V123, P1179, DOI 10.1053/gast.2002.36002; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649, DOI 10.1152/ajpcell.2001.281.2.C649; Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Theriot JA, 2000, TRAFFIC, V1, P19, DOI 10.1034/j.1600-0854.2000.010104.x; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Itallie CM, 2009, MOL BIOL CELL, V20, P3930, DOI 10.1091/mbc.E09-04-0320; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zeng WW, 2010, CELL, V141, P315, DOI 10.1016/j.cell.2010.03.029	63	73	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1216	U546		10.1016/j.jaci.2011.08.035	http://dx.doi.org/10.1016/j.jaci.2011.08.035			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21996340	Green Accepted, Bronze			2022-12-18	WOS:000298342700009
J	Slattery, MJ; Essex, MJ; Paletz, EM; Vanness, ER; Infante, M; Rogers, GM; Gern, JE				Slattery, Marcia J.; Essex, Marilyn J.; Paletz, Elliott M.; Vanness, Erin R.; Infante, Mauricio; Rogers, Gregory M.; Gern, James E.			Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISORDERS		[Slattery, Marcia J.; Essex, Marilyn J.; Paletz, Elliott M.; Rogers, Gregory M.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Vanness, Erin R.] Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI USA; [Slattery, Marcia J.; Gern, James E.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Gern, James E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Infante, Mauricio] Mayo Clin Hlth Syst, Rochester, MN USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Slattery, MJ (corresponding author), Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.	mslattery@wisc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH066073] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bender BG, 2008, J AM ACAD DERMATOL, V58, P415, DOI 10.1016/j.jaad.2007.10.010; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lewis-Jones S, 2006, INT J CLIN PRACT, V60, P984, DOI 10.1111/j.1742-1241.2006.01047.x; Linnet J, 1999, BRIT J DERMATOL, V140, P268; Stortelder Frans, 2010, J Am Acad Psychoanal Dyn Psychiatry, V38, P503, DOI 10.1521/jaap.2010.38.3.503; Timbremont B, 2004, J CLIN CHILD ADOLESC, V33, P149, DOI 10.1207/S15374424JCCP3301_14; van Gastel W, 2008, DEPRESS ANXIETY, V25, P1046, DOI 10.1002/da.20452; Wittkowski A, 2004, J PSYCHOSOM RES, V57, P195, DOI 10.1016/S0022-3999(03)00572-5	9	73	77	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					668	671		10.1016/j.jaci.2011.05.003	http://dx.doi.org/10.1016/j.jaci.2011.05.003			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS		Green Accepted			2022-12-18	WOS:000294283400030
J	Arkestal, K; Sibanda, E; Thors, C; Troye-Blomberg, M; Mduluza, T; Valenta, R; Gronlund, H; van Hage, M				Arkestal, Kurt; Sibanda, Elopy; Thors, Cecilia; Troye-Blomberg, Marita; Mduluza, Takafira; Valenta, Rudolf; Gronlund, Hans; van Hage, Marianne			Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-alpha 1,3-galactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Galactose-alpha 1,3-galactose; cat IgA; Fel d 5; cat dander extract; cat allergy; parasitic infection	FEL D 1; INDUCED ANAPHYLAXIS; CAT; CHILDREN; ASTHMA; ATOPY; REACTIVITY; INFUSION; ASCARIS; FEL-D-1	Background: The carbohydrate epitope galactose-alpha 1,3galactose (a-Gal) is abundantly expressed on nonprimate mammalian proteins. We have recently shown that alpha-Gal is responsible for the IgE binding to cat IgA, a newly identified cat allergen (Fel d 5). Objective: We sought to investigate the diagnostic relevance of IgE antibodies to Fel d 5 and a-Gal among parasite-infected patients from central Africa without cat allergy compared with patients with cat allergy from the same region. Methods: Sera from 47 parasite-infected patients and 31 patients with cat allergy were analyzed for total IgE and IgE antibodies against cat dander extract (CDE) by using the ImmunoCAP system. Inhibition assay was performed with a-Gal on solid phase-bound CDE. The presence of IgE specific for the major cat allergen Fel d 1, Fel d 5, and alpha-Gal was analyzed by means of ELISA. Results: Among the 47 parasite-infected patients, 85% had IgE antibodies against alpha-Gal (OD; median, 0.175; range, 0.1021.466) and 66% against Fel d 5 (OD; median, 0.13; range, 0.1031.285). Twenty-four of the parasite-infected patients were sensitized to CDE, and 21 of them had IgE antibodies to Fel d 5 and a-Gal. There was no correlation between IgE levels to CDE and rFel d 1 among the parasite-infected patients but a strong correlation between CDE and Fel d 5 and alpha-Gal (P <. 001). Among the group with cat allergy, only 5 patients had IgE to alpha-Gal, and nearly 75% (n 5 23) had IgE to rFel d 1 (median, 7.07 kU(A)/L; range, 0.51-148.5 kUA/ L). In contrast, among the patients with cat allergy, there was a correlation between IgE levels to CDE and rFel d 1 (P <.05) but no correlation between CDE and Fel d 5 and alpha-Gal. Conclusion: IgE to alpha-Gal causes impaired allergy diagnostics in parasite-infected patients. Screening for IgE to rFel d 1 and other allergens without carbohydrates might identify patients with true cat sensitization/ allergy in parasite-infested areas. (J Allergy Clin Immunol 2011;127:1024-8.)	[Arkestal, Kurt; Gronlund, Hans; van Hage, Marianne] Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; [Arkestal, Kurt; Gronlund, Hans; van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [Sibanda, Elopy] Univ Zimbabwe, Sch Med, Harare, Zimbabwe; [Thors, Cecilia] Karolinska Inst, Swedish Inst Infect Dis Control, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden; [Troye-Blomberg, Marita] Stockholm Univ, Wenner Gren Inst, Dept Immunol, S-10691 Stockholm, Sweden; [Mduluza, Takafira] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe; [Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol, Vienna, Austria; [Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol, Div Immunopathol, Vienna, Austria; [Gronlund, Hans; van Hage, Marianne] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Karolinska Institutet; University of Zimbabwe; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Stockholm University; University of Zimbabwe; Medical University of Vienna; Medical University of Vienna; Karolinska Institutet	van Hage, M (corresponding author), Karolinska Univ Hosp Solna, Dept Med, Clin Immunol & Allergy Unit, L2 04, SE-17176 Stockholm, Sweden.	marianne.van.hage@ki.se	Troye-Blomberg, Marita/B-9210-2016; van Hage, Marianne/A-9678-2017	Troye-Blomberg, Marita/0000-0002-2804-0325; van Hage, Marianne/0000-0003-3091-1596; Gronlund, Hans/0000-0003-4882-7624; Valenta, Rudolf/0000-0001-5944-3365	Swedish Research Council; Swedish Asthma and Allergy Association's Research Foundation; Swedish Heart-Lung Foundation; Hesselman Foundation; King Gustaf V 80th Birthday Foundation; Konsul Th C Bergh Foundation; Stockholm County Council; Centre for Allergy Research at the Karolinska Institute; Bernard Osher Initiative for Research on Severe Asthma; Karolinska Institutet; Austrian Science Fund; Christian Doppler Research Association; IWF (Austrian Science Fund); Christian Doppler Research Association, Biomay	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Asthma and Allergy Association's Research Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Hesselman Foundation; King Gustaf V 80th Birthday Foundation; Konsul Th C Bergh Foundation; Stockholm County Council(Stockholm County Council); Centre for Allergy Research at the Karolinska Institute(Karolinska Institutet); Bernard Osher Initiative for Research on Severe Asthma; Karolinska Institutet(Karolinska Institutet); Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; IWF (Austrian Science Fund)(Austrian Science Fund (FWF)); Christian Doppler Research Association, Biomay	Supported by the Swedish Research Council, the Swedish Asthma and Allergy Association's Research Foundation, the Swedish Heart-Lung Foundation, the Hesselman Foundation, the King Gustaf V 80th Birthday Foundation, the Konsul Th C Bergh Foundation, the Stockholm County Council, the Centre for Allergy Research at the Karolinska Institute, the Bernard Osher Initiative for Research on Severe Asthma, the Karolinska Institutet, the Austrian Science Fund, and the Christian Doppler Research Association.; Disclosure of potential conflict of interest: R. Valenta has received research support from IWF (Austrian Science Fund), the Christian Doppler Research Association, Biomay, and Phadia and has consulted for Biomay and Phadia. M. van Hage has received research support from the Swedish Research Council, the Stockholm County Council, and the Swedish Asthma and Allergy Association's Research Foundation. The rest of the authors have declared that they have no conflict of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Adedoyin J, 2006, J IMMUNOL METHODS, V310, P117, DOI 10.1016/j.jim.2006.01.001; Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P399, DOI 10.1097/01.all.0000182536.55650.d0; Calvert J, 2010, J ALLERGY CLIN IMMUN, V125, P100, DOI 10.1016/j.jaci.2009.09.010; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2010, CURR ALLERGY ASTHM R, V10, P29, DOI 10.1007/s11882-009-0079-1; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; Gronlund H, 2008, CLIN EXP ALLERGY, V38, P1275, DOI 10.1111/j.1365-2222.2008.03003.x; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Gronlund H, 2010, INT ARCH ALLERGY IMM, V151, P265, DOI 10.1159/000250435; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Hokke CH, 2007, EXP PARASITOL, V117, P275, DOI 10.1016/j.exppara.2007.06.003; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Obeng BB, 2008, CURR OPIN ALLERGY CL, V8, P391, DOI 10.1097/ACI.0b013e32830ebb70; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Saarne T, 2010, PEDIAT ALLERG IMM-UK, V21, P277, DOI 10.1111/j.1399-3038.2009.00894.x; Simon PM, 1998, TRANSPLANTATION, V65, P346, DOI 10.1097/00007890-199802150-00009; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; Westritschnig K, 2003, CLIN EXP ALLERGY, V33, P22, DOI 10.1046/j.1365-2222.2003.01540.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	32	73	73	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1024	1028		10.1016/j.jaci.2011.01.033	http://dx.doi.org/10.1016/j.jaci.2011.01.033			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21376382				2022-12-18	WOS:000289055800025
J	Miller, EK; Williams, JV; Gebretsadik, T; Carroll, KN; Dupont, WD; Mohamed, YA; Morin, LL; Heil, L; Minton, PA; Woodward, K; Liu, ZW; Hartert, TV				Miller, E. Kathryn; Williams, John V.; Gebretsadik, Tebeb; Carroll, Kecia N.; Dupont, William D.; Mohamed, Yassir A.; Morin, Laura-Lee; Heil, Luke; Minton, Patricia A.; Woodward, Kimberly; Liu, Zhouwen; Hartert, Tina V.			Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; HRVC; infants; atopy; asthma; bronchiolitis; maternal	HUMAN METAPNEUMOVIRUS INFECTION; POLYMERASE-CHAIN-REACTION; TRANSCRIPTION-PCR ASSAY; HOSPITALIZED CHILDREN; SYNCYTIAL VIRUS; ASTHMA EXACERBATIONS; YOUNG-CHILDREN; HONG-KONG; BRONCHIOLITIS; LIFE	Background: Risk factors for severe human rhinovirus (HRV)associated infant illness are unknown. Objectives: We sought to examine the role of HRV infection in infant respiratory tract illness and assess viral and host risk factors for HRV-associated disease severity. Methods: We used a prospective cohort of term, previously healthy infants enrolled during an inpatient or outpatient visit for acute upper or lower respiratory tract illness during the fall-spring months of 2004-2008. Illness severity was determined by using an ordinal bronchiolitis severity score, with higher scores indicating more severe disease. HRV was identified by means of real-time RT-PCR. The VP4/VP2 region from HRV-positive specimens was sequenced to determine species. Results: Of 630 infants with bronchiolitis or upper respiratory tract illnesses (URIs), 162 (26%) had HRV infection; HRV infection was associated with 18% of cases of bronchiolitis and 47% of cases of URI. Among infants with HRV infection, 104 (64%) had HRV infection alone. Host factors associated with more severe HRV-associated illness included a maternal and family history of atopy (median score of 3.5 [interquartile range [IQR], 1.0-7.8] vs 2.0 [IQR, 1.0-5.2] and 3.5 [IQR, 1.0-7.5] vs 2.0 [IQR, 0-4.0]). In adjusted analyses maternal history of atopy conferred an increase in the risk for more severe HRVassociated bronchiolitis (odds ratio, 2.39; 95% CI, 1.14-4.99; P = .02). In a similar model maternal asthma was also associated with greater HRV-associated bronchiolitis severity (odds ratio, 2.49, 95% CI, 1.10-5.67; P = .03). Among patients with HRV infection, 35% had HRVA, 6% had HRVB, and 30% had HRVC. Conclusion: HRV infection was a frequent cause of bronchiolitis and URIs among previously healthy term infants requiring hospitalization or unscheduled outpatient visits. Substantial viral genetic diversity was seen among the patients with HRV infection, and predominant groups varied by season and year. Host factors, including maternal atopy, were associated with more severe infant HRV-associated illness. (J Allergy Clin Immunol 2011;127:883-91.)	[Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Miller, E. Kathryn; Williams, John V.; Carroll, Kecia N.; Mohamed, Yassir A.; Morin, Laura-Lee; Heil, Luke] Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; [Williams, John V.] Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37232 USA; [Gebretsadik, Tebeb; Dupont, William D.; Liu, Zhouwen] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu	Dupont, William D./I-4430-2012; Williams, John/ABE-3227-2020	Williams, John/0000-0001-8377-5175	Thrasher New Investigator Award; Thrasher Research Fund Clinical Research Grant; NIH [K24 AI 077930, UL1 RR024975, K01 AI070808, U01 HL 072471, R01 AI 05884, R01 HS018454, R01 HS019669, K12 ES 015855]; National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); MedImmune;  [KL2 RR24977-03]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS019669, R01HS018454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024978, UL1RR024975, KL2RR024977] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070808, K24AI077930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K12ES015855] Funding Source: NIH RePORTER	Thrasher New Investigator Award; Thrasher Research Fund Clinical Research Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); ; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by KL2 RR24977-03 (to E. K. M.), a Thrasher New Investigator Award (to E. K. M.), a Thrasher Research Fund Clinical Research Grant (to T. V. H.), an NIH mid-career investigator award K24 AI 077930 (to T. V. H.), UL1 RR024975 (Vanderbilt CTSA), and an NIH K01 AI070808 mentored clinical science award (to K.N.C.). T. V. H. is also supported by NIH grants U01 HL 072471, R01 AI 05884, R01 HS018454, R01 HS019669, and NIH K12 ES 015855.; Disclosure of potential conflict of interest: E. K. Miller has received research support from Thrasher and VCTRS K12 and is a member of the American Academy of Allergy, Asthma & Immunology's EORD Committee. J. V. Williams has served as a consultant for MedImmune and Novartis and serves on the scientific advisory board for Quidel. K. N. Carroll has received research support from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH). W. D. Dupont has received research support from the NIH. T. V. Hartert is on the Scientific Advisory Committee, is a speaker for Merck, and has received research support from MedImmune and the NIH. The rest of the authors have declared that they have no conflict of interest.	Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689; Arden KE, 2010, REV MED VIROL, V20, P156, DOI 10.1002/rmv.644; Briese T, 2008, EMERG INFECT DIS, V14, P944, DOI 10.3201/eid1406.080271; Calvo C, 2010, ACTA PAEDIATR, V99, P883, DOI 10.1111/j.1651-2227.2010.01714.x; Calvo C, 2010, PEDIATR INFECT DIS J, V29, P717, DOI 10.1097/INF.0b013e3181d7a708; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Cheuk DKL, 2007, PEDIATR INFECT DIS J, V26, P995, DOI 10.1097/INF.0b013e3181586b63; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003; Ferreira A, 2002, RESPIRATION, V69, P136, DOI 10.1159/000056316; Gern JE, 2002, AM J MED, V112, p19S; Goebel J, 2000, CLIN PEDIATR, V39, P213, DOI 10.1177/000992280003900404; Han TH, 2009, ARCH VIROL, V154, P987, DOI 10.1007/s00705-009-0383-z; Hartert TV, 2010, RESPIROLOGY, V15, P691, DOI 10.1111/j.1440-1843.2010.01743.x; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, pS46, DOI 10.1164/ajrccm/152.4_Pt_2.S46; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Khuri-Bulos N, 2010, SCAND J INFECT DIS, V42, P368, DOI 10.3109/00365540903496544; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Linsuwanon P, 2009, J INFECTION, V59, P115, DOI 10.1016/j.jinf.2009.05.009; Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Mackay IM, 2008, EMERG INFECT DIS, V14, P1823, DOI 10.3201/eid1411.080725; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; McErlean P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001847; Midulla F, 2010, ARCH DIS CHILD, V95, P35, DOI 10.1136/adc.2008.153361; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Miron Dan, 2010, Pediatr Infect Dis J, V29, pe7, DOI 10.1097/INF.0b013e3181c2a212; Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002; Piotrowska Z, 2009, PEDIATR INFECT DIS J, V28, P25, DOI 10.1097/INF.0b013e3181861da0; Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312; Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3; Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; TAL A, 1983, PEDIATRICS, V71, P13; Talbot HK, 2010, INFECT CONT HOSP EP, V31, P683, DOI 10.1086/653202; Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27; Talbot HKB, 2009, J MED VIROL, V81, P853, DOI 10.1002/jmv.21443; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tan BH, 2009, EMERG INFECT DIS, V15, P1318, DOI 10.3201/eid1508.090321; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274; Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392; Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001	63	73	74	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					883	891		10.1016/j.jaci.2010.11.041	http://dx.doi.org/10.1016/j.jaci.2010.11.041			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21269669	Green Published, Green Accepted, Bronze			2022-12-18	WOS:000289055800008
J	Haberg, SE; London, SJ; Nafstad, P; Nilsen, RM; Ueland, PM; Vollset, SE; Nystad, W				Haberg, Siri E.; London, Stephanie J.; Nafstad, Per; Nilsen, Roy M.; Ueland, Per Magne; Vollset, Stein Emil; Nystad, Wenche			Maternal folate levels in pregnancy and asthma in children at age 3 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NEURAL-TUBE DEFECTS; FOLIC-ACID; SUPPLEMENTATION; PREVENTION; VITAMIN; COHORT		[Haberg, Siri E.; Nafstad, Per; Nystad, Wenche] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [London, Stephanie J.] NIEHS, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [London, Stephanie J.] NIEHS, Lab Resp Biol, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Nafstad, Per] Univ Oslo, Dept Gen Practice & Community Med, Fac Med, N-0316 Oslo, Norway; [Nilsen, Roy M.] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; [Ueland, Per Magne] Haukeland Hosp, Lab Clin Biochem, N-5021 Bergen, Norway; [Ueland, Per Magne] Univ Bergen, Pharmacol Sect, Inst Med, N-5020 Bergen, Norway; [Vollset, Stein Emil] Norwegian Inst Publ Hlth, Bergen, Norway	Norwegian Institute of Public Health (NIPH); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Oslo; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Norwegian Institute of Public Health (NIPH)	Haberg, SE (corresponding author), Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway.	siri.haberg@fhi.no	London, Stephanie/C-3734-2019; Ueland, Per M/C-7340-2013	London, Stephanie/0000-0003-4911-5290; Nilsen, Roy Miodini/0000-0002-6340-4593; Ueland, Per Magne/0000-0002-1903-0571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049019, ZIAES049019, N01ES085433, Z01ES044008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS047537] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES044008, Z01 ES049019-12, Z01 ES049019] Funding Source: Medline; NIEHS NIH HHS [N01ES85433, N01-ES-85433] Funding Source: Medline; NINDS NIH HHS [1 U01 NS047537-01, U01 NS047537] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; FURU K, 2010, J CLIN EPID IN PRESS; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; 1991, LANCET, V338, P131	8	73	76	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					262	264		10.1016/j.jaci.2010.10.004	http://dx.doi.org/10.1016/j.jaci.2010.10.004			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094522	Green Accepted, Bronze			2022-12-18	WOS:000285917300037
J	Liu, AH; Zeiger, RS; Sorkness, CA; Ostrom, NK; Chipps, BE; Rosa, K; Watson, ME; Kaplan, MS; Meurer, JR; Mahr, TA; Blaiss, MS; Piault-Louis, E; McDonald, J				Liu, Andrew H.; Zeiger, Robert S.; Sorkness, Christine A.; Ostrom, Nancy K.; Chipps, Bradley E.; Rosa, Kathleen; Watson, Maria E.; Kaplan, Michael S.; Meurer, John R.; Mahr, Todd A.; Blaiss, Michael S.; Piault-Louis, Elisabeth; McDonald, Jeffrey			The Childhood Asthma Control Test*: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pediatric; control; symptom assessment; questionnaire; disease management		Background: The Childhood Asthma Control Test (C-ACT) has demonstrated validity in classifying children aged 4 to 11 years as having either "well-controlled'' or "not well-controlled'' asthma. However, new asthma management guidelines distinguish 3 levels of asthma control. Objective: We sought to determine a second cut point on the C-ACT to identify children with "very poorly controlled'' asthma. Methods: Binomial logistic regression was performed on data from 671 children. The specialist's rating of control was the criterion measure. Specialists' severity ratings, specialists' assessment of therapy, and FEV1 percent predicted were used to assess the clinical validity of the cut point. Results: A cut point of 12 was selected because it correctly classified the highest percentage of participants (66.3%) as having "very poorly controlled'' (vs "not well controlled'') asthma and demonstrated high specificity (89.8%) and moderate positive predictive value (69.1%). Children scoring 12 or less versus 13 to 19 had lower mean FEV1 percent predicted (79.8% vs 92.6%, P = .0002) and were more frequently stepped up in therapy (72.9% vs 53.6%, P = .0131) and rated as having severe asthma (13.6% vs 4.5%, P = .0005). One month later, significant differences in C-ACT scores and lung function between these 2 groups persisted. The mean C-ACT score of participants classified as "very poorly controlled'' was significantly lower than that of participants classified as "not well-controlled'' (17.2 vs 20.3, respectively; P = .0001). Conclusion: A second cut point of 12 or less on the C-ACT identifies children with the lowest level of control, who are at risk for poorer outcomes, and is conceptually consistent with the classification of "very poorly controlled'' asthma adopted by asthma management guidelines. (J Allergy Clin Immunol 2010;126:267-73.)	[Liu, Andrew H.] Natl Jewish Hlth, Denver, CO 80206 USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Denver, CO USA; [Zeiger, Robert S.] Kaiser Permanente So Calif Reg, Pasadena, CA USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Ostrom, Nancy K.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Rosa, Kathleen; Piault-Louis, Elisabeth; McDonald, Jeffrey] Mapi Values USA LLC, Boston, MA USA; [Watson, Maria E.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Kaplan, Michael S.] Kaiser, LAMC, Los Angeles, CA USA; [Meurer, John R.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Mahr, Todd A.] Gundersen Lutheran Med Ctr, La Crosse, WI USA; [Blaiss, Michael S.] Univ Tennessee Hlth Sci Ctr, Memphis, TN USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kaiser Permanente; University of Wisconsin System; University of Wisconsin Madison; GlaxoSmithKline; Medical College of Wisconsin; Gundersen Lutheran Medical Center; University of Tennessee System; University of Tennessee Health Science Center	Liu, AH (corresponding author), Natl Jewish Hlth, 1400 Jackson St,K1023, Denver, CO 80206 USA.	LiuA@NJHealth.org		Meurer, John/0000-0001-7139-1289; Zeiger, Robert/0000-0001-5788-5063	GlaxoSmithKline; Novartis; Aerocrine; Genentech; Merck; AstraZeneca; TEVA Pharmaceuticals; Schering-Plough; Sandoz; UCB; Alcon; Alexza; Amgen; Antigen Lans; Apotex; Astellas; Boehringer Ingelheim; Capnia; Critical Therapeutics; MAP; MEDA; Teva; Aventis; Sepracor; Centers for Disease Control and Prevention; US Department of Housing and Urban Development; National Institutes of Health; Medical College of Wisconsin Asthma Coalition	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Aerocrine; Genentech(Roche HoldingGenentech); Merck(Merck & Company); AstraZeneca(AstraZeneca); TEVA Pharmaceuticals(Teva Pharmaceutical Industries); Schering-Plough(Merck & CompanySchering Plough Corporation); Sandoz(Novartis); UCB(UCB Pharma SA); Alcon(Novartis); Alexza; Amgen(Amgen); Antigen Lans; Apotex; Astellas(Astellas Pharmaceuticals); Boehringer Ingelheim(Boehringer Ingelheim); Capnia; Critical Therapeutics; MAP; MEDA; Teva(Teva Pharmaceutical Industries); Aventis(Sanofi-Aventis); Sepracor; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Department of Housing and Urban Development; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical College of Wisconsin Asthma Coalition	GlaxoSmithKline provided research funding.; A. H. Liu has served on the speakers' bureau for Merck, Aerocrine, and Phadia; has served on the speakers' bureau and advisory board for GlaxoSmithKline and AstraZeneca; and has received a research grant from Novartis. R. S. Zeiger is a consultant for AstraZeneca, Aerocrine, Genentech, Merck, Schering-Plough, and MedImmune; has received research support from Aerocrine, Genentech, Merck, and GlaxoSmithKline; and has received research support from and supplied drugs to the CARE Network Clinical Trial from Merck, AstraZeneca, TEVA Pharmaceuticals, and GlaxoSmithKline. C. A. Sorkness is on the advisory board for GlaxoSmithKline, Schering-Plough, and AstraZeneca and has received research support from Schering-Plough and Sandoz. N. K. Ostrom is a consultant and speaker for AstraZeneca, TEVA, GlaxoSmithKline, MAP, MEDA, Merck, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough, and UCB; and has received research support from UCB, Alcon, Alexza, Amgen, Antigen Lans, Apotex, Astellas, AstraZeneca, Boehringer Ingelheim, Capnia, Critical Therapeutics, GlaxoSmithKline, MAP, MEDA, Merck, Novartis, Schering-Plough, and Teva. B. E. Chipps is on the speakers' bureau and is an advisor for Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering-Plough, Sepracor, and Merck; is on the speakers' bureau for Boehringer Ingelheim and Pfizer; and has received research support from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Schering-Plough, Sepracor, and Merck. M. S. Kaplan is on the advisory board for Dey Pharmaceuticals and has received research support from Genentech and Aerocrine. J. R. Meurer has received research support from the Centers for Disease Control and Prevention, the US Department of Housing and Urban Development, the National Institutes of Health, and the Medical College of Wisconsin Asthma Coalition; is the Coalition Director of the Fight Asthma Milwaukee Allies; and is an executive committee member of the Wisconsin Asthma Coalition. T. A. Mahr is on the speakers' bureau for GlaxoSmithKline, Alcon, AstraZeneca, Genentech, Merck, Novartis, Sanofi-Aventis, and UCB; has received research support from GlaxoSmithKline, AstraZeneca, Novartis, and Alcon; is on various committees for the American College of Allergy, Asthma & Immunology and NAP; is on the board for the Wisconsin Asthma Coalition; and is on the Leadership Board for the American Lung Association Wisconsin. M. S. Blaiss is a speaker for AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, Akon, Teva, UCB, Novartis, and Genentech; has served as an expert witness regarding patent drug cases; and is the Secretary Treasurer for RAD. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 2007, EXP PAN REP 3 GUID D; *GLOB IN ASTHMA, 2009, GLOB STRAT ASTHM MAN; Guilbert T, 2008, J ALLERGY CLIN IMMUN, V121, pS148, DOI 10.1016/j.jaci.2007.12.1126; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schmier JK, 2007, ANN ALLERG ASTHMA IM, V98, P245, DOI 10.1016/S1081-1206(10)60713-2; SORKNESS CA, 2007, AM THOR SOC INT C MA	7	73	76	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					267	U15		10.1016/j.jaci.2010.05.031	http://dx.doi.org/10.1016/j.jaci.2010.05.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624640				2022-12-18	WOS:000281203800011
J	Simons, FER; Edwards, ES; Read, EJ; Clark, S; Liebelt, EL				Simons, F. Estelle R.; Edwards, Eric S.; Read, Edward J., Jr.; Clark, Sunday; Liebelt, Erica L.			Voluntarily reported unintentional injections from epinephrine auto-injectors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epinephrine auto-injector; adrenaline auto-injector; anaphylaxis; acute allergic reaction; unintentional injection; needle stick injury; sharps injury	ANAPHYLAXIS; EPIDEMIOLOGY; ALLERGY; HOSPITALIZATIONS; ADRENALINE; COMMUNITY; EPIPEN; TRENDS	Background: Epinephrine auto-injectors provide life-saving prehospital treatment for individuals experiencing anaphylaxis in community settings. Objective: To determine the number, demographics, and associated circumstances and outcomes of unintentional injections from epinephrine auto-injectors. Methods: We searched the databases of the American Association of Poison Control Centers and the Food and Drug Administration's Safety Information and Adverse Event. Report System for these incidents as reported by members of the public and by health care professionals. Results: From 1994 to 2007, a total of 15,190 unintentional injections from epinephrine auto-injectors were reported to US Poison Control Centers, 60% of them from 2003 to 2007. Those unintentionally injected had a median age of 14 years (interquartile range, 8-35), 55% were female, and 85% were injected in a home or other residence. Management was documented in only 4101 cases (27%), of whom 53% were observed without intervention, 29% were treated, 13% were neither held for observation nor treated, and 4% refused treatment. In contrast, from 1969 to 2007, only 105 unintentional injections from epinephrine auto-injectors were reported to MedWatch. Forty percent of these occurred during attempts to treat allergic reactions. Injuries resulting in permanent sequelae were rarely reported to either US Poison Control Centers or to MedWatch. Conclusion: The number of reported unintentional injections front epinephrine auto-injectors increased annually from 1994 to 2007. To prevent these unintentional injections, improved epinephrine auto-injector design is needed, along with increased vigilance in training the trainers and in training and coaching the users, as well as efforts to increase public awareness of the role of epinephrine auto-injectors in the first-aid treatment of anaphylaxis in the community. (J Allergy Clin Immunol 2010;125:419-23.)	[Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; [Edwards, Eric S.] Virginia Commonwealth Univ, Dept Pharm, Richmond, VA USA; [Read, Edward J., Jr.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA; [Read, Edward J., Jr.] McGuire VA Med Ctr, Dept Emergency Med, Richmond, VA USA; [Clark, Sunday] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA; [Liebelt, Erica L.] Univ Alabama Birmingham, Sch Med, Dept Pediat & Emergency Med, Med Toxicol Serv, Birmingham, AL USA	University of Manitoba; Virginia Commonwealth University; Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Simons, FER (corresponding author), Room FE125,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca	Clark, Sunday/AAA-5458-2021		Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Disclosure of potential conflict of interest: F E. R. Simons has received research support from the Canadian Institutes of Health Research and serves on advisory boards for Dey, Intelliject, ALK-Abello, Lincoln Medical, and Sciele. E. S. Edwards owns stock in Intelliject. E. J. Read. Jr, is an investor and a scientific advisor for Intelliject. S. Clark has received consulting fees front Dey and Partners Healthcare/Massachusetts General Hospital. E. L. Liebelt is an examination test question writer for the American Board of pediatrics; has served as an expert witness on the topics, of salicylate poisoning. phenytoin toxicity. and opiate toxicity: and is President of the American College of Medical Toxicology.	Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Fitzcharles-Bowe Colleen, 2007, Hand (N Y), V2, P5, DOI 10.1007/s11552-006-9012-4; Gosbee John W, 2004, Jt Comm J Qual Saf, V30, P696; Gosbee Laura Lin, 2004, Jt Comm J Qual Saf, V30, P220; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; KAYE R, GUIDANCE IND FDA PRE; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Libelt EL, 2008, CLIN TOXICOL, V46, P389; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; MAGUIRE WM, 1990, AM J EMERG MED, V8, P46, DOI 10.1016/0735-6757(90)90295-B; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Mehr S, 2007, PEDIAT ALLERG IMM-UK, V18, P448, DOI 10.1111/j.1399-3038.2007.00529.x; MUCK A, 2007, ACAD EMERG MED, V14, pS196; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P282, DOI 10.1016/S1081-1206(10)60332-8; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; *US FDA, CTR DRUG EV RES ADV	28	73	73	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					419	423		10.1016/j.jaci.2009.10.056	http://dx.doi.org/10.1016/j.jaci.2009.10.056			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159254				2022-12-18	WOS:000274764000021
J	Honda, T; Matsuoka, T; Ueta, M; Kabashima, K; Miyachi, Y; Narumiya, S				Honda, Tetsuya; Matsuoka, Toshiyuki; Ueta, Mayumi; Kabashima, Kenji; Miyachi, Yoshiki; Narumiya, Shuh			Prostaglandin E-2-EP3 signaling suppresses skin inflammation in murine contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin E-2; EP3 receptor; contact hypersensitivity	RECEPTOR SUBTYPE EP3; ARACHIDONIC-ACID; T-CELLS; PSORIASIS; DERMATITIS; KERATINOCYTES; MOUSE; MICE; INDOMETHACIN; RECRUITMENT	Background: Prostaglandin (PG) E-2 exerts a variety of actions through 4 G protein-coupled receptors designated as EP1, EP2, EP3, and EP4. We have reported that PGE(2) acts on EP3 in airway epithelial cells and exerts anti-inflammatory actions in ovalbumin-induced murine allergic asthma. Although EP3 is also expressed in skin and PGE(2) is produced abundantly during skin allergic inflammation, the role of PGE(2)-EP3 signaling in skin allergic inflammation remains unknown. Objective: We sought to investigate whether PGE(2)-EP3 signaling exerts anti-inflammatory actions in skin allergic inflammation. Methods: We used a murine contact hypersensitivity (CHS) model and examined the role of EP3 by using an EP3-selective agonist, ONO-AE-248 (AE248), and EP3-deficient mice. The inflammation was evaluated by the thickness and histology of the hapten-challenged ear. Inflammation-associated changes in gene expression and effects of AE248 were examined by means of microarray analysis of the skin. Localization of EP3 was examined by staining for beta-galactosidase knocked in at the EP3 locus in EP3-deficient mice. EP3 action was also examined in cultured keratinocytes. Results: Administration of AE248 during the elicitation phase significantly suppressed CHS compared with that seen in vehicle-treated mice. Microarray analysis revealed that administration of AE248 inhibited the gene expression of neutrophil-recruiting chemokines, including CXCL1, at the elicitation site. X-gal staining in EP3-deficient mice revealed EP3 expression in keratinocytes, which was further confirmed by anti-EP3 antibody in wild-type mice. In cultured keratinocytes AE248 suppressed CXCL1 production induced by TNF-alpha. Conclusion: PGE(2)-EP3, signaling inhibits keratinocytes activation and exerts anti-inflammatory actions in murine CHS. (J Allergy Clin Immunol 2009;124:809-18.)	[Honda, Tetsuya; Matsuoka, Toshiyuki; Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; [Honda, Tetsuya; Kabashima, Kenji; Miyachi, Yoshiki] Kyoto Univ, Fac Med, Dept Dermatol, Kyoto 6068501, Japan; [Ueta, Mayumi] Kyoto Prefectural Univ, Dept Ophthalmol, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto Prefectural University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554	Japanese Ministry of Education, Culture, Sports, Science, and Technology; National Institute of Biomedical Innovation of Japan; Takeda Scientific Foundation; ONO Research Foundation; Fujiwara Memorial Foundation; Japan Society for the Promotion of Science	Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation of Japan(National Institute of Biomedical Innovation); Takeda Scientific Foundation(Takeda Science Foundation (TSF)); ONO Research Foundation; Fujiwara Memorial Foundation; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Supported in part by grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science. and Technology: the National Institute of Biomedical Innovation of Japan; the Takeda Scientific Foundation; the ONO Research Foundation and the Fujiwara Memorial Foundation; and Japan Society for the Promotion of Science.	AHLUWALIA A, 1994, J PHARMACOL EXP THER, V268, P1526; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Dilulio NA, 1999, EUR J IMMUNOL, V29, P3485, DOI 10.1002/(SICI)1521-4141(199911)29:11<3485::AID-IMMU3485>3.0.CO;2-B; Eberhard J, 2000, ANAL BIOCHEM, V280, P258, DOI 10.1006/abio.2000.4540; Engeman T, 2004, J LEUKOCYTE BIOL, V76, P941, DOI 10.1189/jlb.0304193; Goulet JL, 2004, J IMMUNOL, V173, P1321, DOI 10.4049/jimmunol.173.2.1321; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; HEBBORN P, 1988, ARCH DERMATOL, V124, P387, DOI 10.1001/archderm.124.3.387; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kanda N, 2004, J ALLERGY CLIN IMMUN, V114, P1403, DOI 10.1016/j.jaci.2004.08.041; Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265; Konger RL, 2005, EXP DERMATOL, V14, P914, DOI 10.1111/j.1600-0625.2005.00381.x; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Latta M, 2007, IMMUNOLOGY, V121, P555, DOI 10.1111/j.1365-2567.2007.02603.x; LAZAROVA AZ, 1989, CLIN EXP DERMATOL, V14, P260, DOI 10.1111/j.1365-2230.1989.tb00949.x; Matsuoka T, 2007, THESCIENTIFICWORLDJO, V7, P1329, DOI 10.1100/tsw.2007.182; Mitsui G, 2003, IMMUNOL LETT, V86, P191, DOI 10.1016/S0165-2478(03)00017-8; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nguyen MT, 2002, J IMMUNOL, V169, P4586, DOI 10.4049/jimmunol.169.8.4586; POWLES AV, 1987, BRIT J DERMATOL, V117, P799, DOI 10.1111/j.1365-2133.1987.tb07364.x; RUZICKA T, 1982, INT ARCH ALLER A IMM, V69, P347, DOI 10.1159/000233198; RUZICKA T, 1987, J INVEST DERMATOL, V88, P120, DOI 10.1111/1523-1747.ep12525265; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Scortegagna M, 2008, BLOOD, V111, P3343, DOI 10.1182/blood-2007-10-115758; Takeshita K, 2004, INT IMMUNOL, V16, P947, DOI 10.1093/intimm/dxh096; Tober KL, 2007, J INVEST DERMATOL, V127, P214, DOI 10.1038/sj.jid.5700502; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P466, DOI 10.1016/j.jaci.2008.09.044; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963	34	73	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					809	818		10.1016/j.jaci.2009.04.029	http://dx.doi.org/10.1016/j.jaci.2009.04.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19541354				2022-12-18	WOS:000270802800028
J	Grunebaum, E; Bates, A; Roifman, CM				Grunebaum, Eyal; Bates, Andrea; Roifman, Chaim M.			Omenn syndrome is associated with mutations in DNA ligase IV	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERE COMBINED IMMUNODEFICIENCY; DEFICIENCY; PATIENT		[Grunebaum, Eyal] Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grunebaum, E (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Gennery AR, 2006, BRIT MED BULL, V77-78, P71, DOI 10.1093/bmb/ldl006; Gruhn B, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-5; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Toita N, 2007, AM J MED GENET A, V143A, P742, DOI 10.1002/ajmg.a.31644; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	9	73	76	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1219	1220		10.1016/j.jaci.2008.08.031	http://dx.doi.org/10.1016/j.jaci.2008.08.031			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18845326	Bronze			2022-12-18	WOS:000261711800023
J	Sleiman, PMA; Annaiah, K; Imielinski, M; Bradfield, JP; Kim, CE; Frackelton, EC; Glessner, JT; Eckert, AW; Otieno, FG; Santa, E; Thomas, K; Smith, RM; Glaberson, W; Garris, M; Gunnlaugsson, S; Chiavacci, RM; Allen, J; Spergel, J; Grundmeier, R; Grunstein, MM; Magnusson, M; Bisgaard, H; Grant, SFA; Hakonarson, H				Sleiman, Patrick M. A.; Annaiah, Kiran; Imielinski, Marcin; Bradfield, Jonathan P.; Kim, Cecilia E.; Frackelton, Edward C.; Glessner, Joseph T.; Eckert, Andrew W.; Otieno, F. George; Santa, Erin; Thomas, Kelly; Smith, Ryan M.; Glaberson, Wendy; Garris, Maria; Gunnlaugsson, Sigfus; Chiavacci, Rosetta M.; Allen, Julian; Spergel, Jonathan; Grundmeier, Robert; Grunstein, Michael M.; Magnusson, Mark; Bisgaard, Hans; Grant, Struan F. A.; Hakonarson, Hakon			ORMDL3 variants associated with asthma susceptibility in North Americans of European ancestry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPRESSION; GENE		[Sleiman, Patrick M. A.; Annaiah, Kiran; Imielinski, Marcin; Bradfield, Jonathan P.; Kim, Cecilia E.; Frackelton, Edward C.; Glessner, Joseph T.; Eckert, Andrew W.; Otieno, F. George; Santa, Erin; Thomas, Kelly; Smith, Ryan M.; Glaberson, Wendy; Garris, Maria; Gunnlaugsson, Sigfus; Chiavacci, Rosetta M.; Grant, Struan F. A.; Hakonarson, Hakon] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Ctr Appl Genom,Div Human Genet, Philadelphia, PA 19104 USA; [Allen, Julian; Grunstein, Michael M.; Hakonarson, Hakon] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Pulm Med, Philadelphia, PA 19104 USA; [Spergel, Jonathan] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Grundmeier, Robert] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Bioinformat, Philadelphia, PA 19104 USA; [Magnusson, Mark; Grant, Struan F. A.; Hakonarson, Hakon] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Bisgaard, Hans] Univ Copenhagen, Dept Hlth Sci, Copenhagen, Denmark	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Copenhagen	Sleiman, PMA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Ctr Appl Genom,Div Human Genet, Philadelphia, PA 19104 USA.	hakonarson@chop.edu	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Spergel, Jonathan/0000-0002-4658-5353; Glessner, Joseph/0000-0001-5131-2811				CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; Falush D, 2003, GENETICS, V164, P1567; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Hakonarson H, 2007, NATURE, V448, P591, DOI 10.1038/nature06010; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; NEWMANTAYLOR A, 1995, LANCET, V345, P296, DOI 10.1016/S0140-6736(95)90280-5; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015	9	73	80	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1225	1227		10.1016/j.jaci.2008.06.041	http://dx.doi.org/10.1016/j.jaci.2008.06.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18760456				2022-12-18	WOS:000261711800026
J	Muller, UR; Jutel, M; Reimers, A; Zumkehr, J; Huber, C; Kriegel, C; Steiner, U; Haeberli, G; Akdis, M; Helbling, A; Schnyder, B; Blaser, K; Akdis, C				Mueller, Ulrich R.; Jutel, Marek; Reimers, Andrea; Zumkehr, Judith; Huber, Clarissa; Kriegel, Carola; Steiner, Urs; Haeberli, Gabrielle; Akdis, Muebeccel; Helbling, Arthur; Schnyder, Benno; Blaser, Kurt; Akdis, Cezmi			Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Venom immunotherapy; antihistamine preventive medication; T cells; cytokines; histamine receptors	ALLERGEN-SPECIFIC IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; T-CELL; ULTRARUSH-IMMUNOTHERAPY; DOUBLE-BLIND; HISTAMINE; EFFICACY; PRETREATMENT; INTERLEUKIN-10; PREMEDICATION	Background: H1 antihistamines increase safety during allergen-specific immunotherapy and might influence the outcome because of immunoregulatory effects. Objective: We sought to analyze the influence of 5 mg of levocetirizine (LC) on the safety, efficacy, and immunologic effects of ultrarush honeybee venom immunotherapy (BVIT). Method: In a double-blind, placebo-controlled study 54 patients with honeybee venom allergy received LC or placebo from 2 days before BVIT to day 21. Side effects during dose increase and systemic allergic reactions (SARs) to a sting challenge after 120 days were analyzed. Allergen-specific immune response was investigated in skin, serum, and allergen-stimulated T-cell cultures. Results: Side effects were significantly more frequent in patients receiving placebo. Four patients receiving placebo dropped out because of side effects. SARs to the sting challenge occurred in 8 patients (6 in the LC group and 2 in the placebo group). Seven SARs were only cutaneous, and I in the placebo group was also respiratory. Difference of SARs caused by the sting challenge was insignificant. Specific IgG levels increased significantly in both groups. Major allergen phospholipase A(2)-stimulated T cells from both groups showed a slightly decreased proliferation. The decrease in IFN-gamma and IL-13 levels with placebo was not prominent with LC, whereas IL-10 levels showed a significant increase in the LC group only. Decreased histamine receptor (HR)1/HR2 ratio in allergen-specific T cells on day 21 in the placebo group was prevented by LC. Conclusions: LC reduces side effects during dose increase without influencing the efficacy of BVIT. LC modulates the natural course of allergen-specific immune response and affects the expression of HRs and cytokine production by allergen-specific T cells. (J Allergy Clin Immunol 2008;122:1001-7.)	[Mueller, Ulrich R.] Spital Ziegler, Dept Med, Med Klin, Bern, Switzerland; [Jutel, Marek; Zumkehr, Judith; Akdis, Muebeccel; Blaser, Kurt; Akdis, Cezmi] Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; [Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Schnyder, Benno] Univ Bern, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland	Swiss Institute of Allergy & Asthma Research; Wroclaw Medical University; University of Bern	Muller, UR (corresponding author), Spital Ziegler, Dept Med, Med Klin, Morillonstr 75-91, Bern, Switzerland.	ulrich.mueller@spitalnetzbern.ch	Akdis, Cezmi/AAV-4844-2020; Beldar, Sagar V/C-8542-2011	Akdis, Cezmi/0000-0001-8020-019X; 	Swiss National Science Foundation [32.118226, 32-112306]; Global Allergy and Asthma European Network [GA2LEN]; UCB Pharma AG	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; UCB Pharma AG(UCB Pharma SA)	Supported by Swiss National Science Foundation grant nos. 32.118226 and 32-112306, the Global Allergy and Asthma European Network (GA2LEN), and UCB Pharma AG.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Day JH, 2004, INT J CLIN PRACT, V58, P109, DOI 10.1111/j.1368-5031.2004.0117.x; Deruaz U, 2004, J ALLERGY CLIN IMMUN, V113, P669, DOI 10.1016/j.jaci.2004.01.773; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770a; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; JARISCH R, 1988, BUNDESAMT SERA IMPFS, P163; Johansen P, 2008, CLIN EXP ALLERGY, V38, P512, DOI 10.1111/j.1365-2222.2007.02904.x; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; JUTEL M, 1997, ALLERGY S37, V52, P88; Karppinen A, 2002, ALLERGY, V57, P534, DOI 10.1034/j.1398-9995.2002.13201.x; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller UR., 1990, INSECT STING ALLERGY; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Skrbic D, 1996, ALLERGOLOGIE, V19, P123; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x	33	73	75	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1001	1007		10.1016/j.jaci.2008.08.007	http://dx.doi.org/10.1016/j.jaci.2008.08.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18845330				2022-12-18	WOS:000260940100021
J	Lowe, AJ; Carlin, JB; Bennett, CM; Hosking, CS; Abramson, MJ; Hill, DJ; Dharmage, SC				Lowe, Adrian J.; Carlin, John B.; Bennett, Catherine M.; Hosking, Clifford S.; Abramson, Michael J.; Hill, David J.; Dharmage, Shyamali C.			Do boys do the atopic march while girls dawdle?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic march; allergy prevention; eczema; asthma	YOUNG-CHILDREN; ASTHMA; DERMATITIS; RISK; SENSITIZATION; ALLERGY; ECZEMA; ONSET; LIFE; HYPERRESPONSIVENESS	Background: The atopic march hypothesis suggests that infants with eczema are at increased risk of asthma. Others argue that eczema is not a risk factor for asthma unless there is also sensitization or early wheezing. Objective: To examine the role of infantile eczema as a predictor of risk of childhood asthma, while allowing for the effects of early wheeze, sensitization, and sex, both as independent effects and possible effect modifiers. Methods: A total of 620 infants with a family history of allergic disease was recruited. Eczema and wheeze was prospectively documented to 2 years of age. Sensitization was determined by skin prick tests at 6, 12, and 24 months to 6 common food and inhalant allergens. Interviews were conducted at 6 and 7 years to ascertain current asthma. Results: Sufficiently complete data were available for 403 children. Eczema within the first 2 years of life was clearly associated with an increased risk of childhood asthma in boys (adjusted odds ratio, 2.45; 95% CI, 1.31-4.46) but not in girls (odds ratio, 0.88; 95% CI, 0.43-1.77; P for interaction =.031) even with adjustment for the effects of early allergic sensitization and wheeze. If these relationships are causal, an intervention to prevent eczema in boys might reduce the incidence of childhood asthma by as much as 28%. Conclusion: Eczema in the first 2 years of life is associated with an increased risk of childhood asthma in boys, but. there is no evidence of this in girls.	[Lowe, Adrian J.; Carlin, John B.; Bennett, Catherine M.; Dharmage, Shyamali C.] Univ Melbourne, Fac Med Dent & Hlth Sci,Sch Populat Hlth, Dept Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3053, Australia; [Hosking, Clifford S.] John Hunter Childrens Hosp, Dept Pediat, Newcastle, NSW, Australia; [Abramson, Michael J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Hill, David J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	University of Melbourne; Monash University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Lowe, AJ (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci,Sch Populat Hlth, Dept Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Level 2,723 Swanton St, Melbourne, Vic 3053, Australia.	lowe.adrian@gmail.com	Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Abramson, Michael/AAQ-2671-2020	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Abramson, Michael/0000-0002-9954-0538; Bennett, Catherine/0000-0001-9581-1612; Lowe, Adrian/0000-0002-4691-8162				AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; *AUSTR CTR ASTHM M, 2007, ASTHM AUSTR FIND 200; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Carlin JB, 1999, STAT MED, V18, P2655, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2655::AID-SIM202>3.0.CO;2-#; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Devenny A, 2004, BMJ-BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Green RH, 2007, CURR OPIN ALLERGY CL, V7, P43, DOI 10.1097/ACI.0b013e3280118a32; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P229, DOI 10.1111/j.1651-2227.1994.tb13057.x; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Man MM, 1996, J INVEST DERMATOL, V106, P1096; Mao-Qiang Man, 1995, Archives of Dermatology, V131, P809, DOI 10.1001/archderm.131.7.809; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mohrenschlager M, 2006, BRIT J DERMATOL, V154, P505, DOI 10.1111/j.1365-2133.2005.07042.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pucci N, 2005, ALLERGY, V60, P113, DOI 10.1111/j.1398-9995.2004.00622.x; Robertson CF, 2004, MED J AUSTRALIA, V180, P273, DOI 10.5694/j.1326-5377.2004.tb05924.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043	36	73	76	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1190	1195		10.1016/j.jaci.2008.01.034	http://dx.doi.org/10.1016/j.jaci.2008.01.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18313134	Bronze			2022-12-18	WOS:000255961700018
J	Chipps, BE; Szefler, SJ; Simons, ER; Haselkorn, T; Mink, DR; Deniz, Y; Lee, JH				Chipps, Bradley E.; Szefler, Stanley J.; Simons, Estelle R.; Haselkorn, Tmirah; Mink, David R.; Deniz, Yamo; Lee, June H.		TENOR Study Grp	Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; health care use; long-term controllers; lung function; observational; pediatric	3RD NATIONAL-HEALTH; LONG-TERM TREATMENT; BODY-MASS INDEX; CHILDHOOD ASTHMA; NUTRITION EXAMINATION; PULMONARY-FUNCTION; LUNG-FUNCTION; YOUNG-ADULTS; LARGE COHORT; SERUM IGE	Background: Young patients with severe or difficult-to-treat asthma are an understudied population. Objective: To assess age-associated and gender-associated differences in children and adolescents in the observational study, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens. Methods: Cross-sectional baseline data for patients greater than or equal to 6 years and less than or equal to 17 years (n = 1261) were stratified by age group (6-8, 9-11, 12-14, and 15-17 years). The x(2) test for categorical variables and analysis of variance for continuous variables were used to identify differences among age groups, stratified by gender. Results: Most patients had moderate (55%) or severe (41%) asthma by physician assessment. Of those using greater than or equal to 3 long-term controllers (62%), 53% of children (6-11 years) and 44% of adolescents (12-17 years) reported an oral corticosteroid burst and 25% and 19%, respectively, had an emergency department visit in the previous 3 months; 10% and 15%, respectively, reported past intubation. In females, weight for age ranged between the 67th and 70th percentiles; height for age was between the 42nd and 54th percentiles (P < .01 among age groups). Lung function was lower in adolescents than children: prebronchodilator percent predicted forced expiratory volume in 1 second (FEV1)/forced vital capacity was 0.92 (6-8 years) and 0.83 (15-17 years), P less than .05, in males; and 0.94 (6-8 years) and 0.87 (15-17 years), P less than .05, in females. Conclusions: Children and adolescents demonstrated high rates of health care use and loss of lung function, despite using multiple long-term controllers. Clinical implications: Asthma treatments that prevent loss of lung function and reduce health care resource use are needed in young patients with severe or difficult-to-treat asthma.	Capital Allergy & Resp Dis Ctr, Sacramento, CA 95819 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; Genentech Inc, San Francisco, CA 94080 USA; Ovat Res Grp, San Francisco, CA USA	National Jewish Health; University of Manitoba; Roche Holding; Genentech	Chipps, BE (corresponding author), Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA.	BChipps@capitalallergy.com						Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P512, DOI 10.1016/j.jaci.2005.12.1353; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Cabana MD, 2001, ARCH PEDIAT ADOL MED, V155, P1057, DOI 10.1001/archpedi.155.9.1057; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Debley JS, 2004, PEDIATR PULM, V38, P443, DOI 10.1002/ppul.20108; DEY AN, 2005, VITAL HLTH STAT, V10, P1; DOCKERY DW, 1983, AM REV RESPIR DIS, V128, P405, DOI 10.1164/arrd.1983.128.3.405; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Finkelstein JA, 2000, PEDIATRICS, V106, P886; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Limb SL, 2005, J ALLERGY CLIN IMMUN, V116, P1213, DOI 10.1016/j.jaci.2005.09.024; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Romieu I, 2004, PEDIATR PULM, V38, P31, DOI 10.1002/ppul.20042; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316	39	73	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1156	1163		10.1016/j.jaci.2006.12.668	http://dx.doi.org/10.1016/j.jaci.2006.12.668			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17397912	Bronze			2022-12-18	WOS:000246427200016
J	Taylor, DR				Taylor, DR			Nitric oxide as a clinical guide for asthma management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exhaled nitric oxide; FENO; pulmonary; function	SPUTUM; INFLAMMATION; CHILDREN; ADULTS	Asthma is a pathologically heterogeneous disease, and the phenotype is characterized by different types of airway inflammation. Exhaled nitric oxide (FENO) measurements are a surrogate marker specific for eosinophilic airway inflammation. The latter is usually associated with steroid responsiveness, and hence, FENO may be used to guide steroid requirements in certain clinical situations. High FENO levels may be used to predict likely benefits with inhaled corticosteroid (ICS) therapy. Both high and low FENO levels are prognostically significant when withdrawal of ICS treatment is being considered. Studies have shown that, just as for induced sputum, repeated FENO measurements improve the cost-effectiveness of ICS therapy when used to guide dose requirements. In practice, FENO measurements are useful in the management of severe or difficult asthma. High and low FENO levels in symptomatic patients provide the clinician with information that enables active eosinophilic airway inflammation to be included or excluded. Either outcome is helpful in decision making. FENO measurements complement the use of other tests in asthma, but more work is required to determine reference values and cut-points for appropriate interpretation.	Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand	University of Otago	Taylor, DR (corresponding author), Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand.	robin.taylor@stonebow.otago.ac.nz						American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; *NIH, 2002, PUBL NIH; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Powell H, 2003, MED J AUSTRALIA, V178, P223, DOI 10.5694/j.1326-5377.2003.tb05167.x; Smith AD, 2005, CURR OPIN ALLERGY CL, V5, P49, DOI 10.1097/00130832-200502000-00010; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	18	73	78	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					259	262		10.1016/j.jaci.2005.11.010	http://dx.doi.org/10.1016/j.jaci.2005.11.010			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461124				2022-12-18	WOS:000235687300004
J	von Hertzen, L; Makela, MJ; Petays, T; Jousilahti, P; Kosunen, TU; Laatikainen, T; Vartiainen, E; Haahtela, T				von Hertzen, L; Makela, MJ; Petays, T; Jousilahti, P; Kosunen, TU; Laatikainen, T; Vartiainen, E; Haahtela, T			Growing disparities in atopy between the Finns and the Russians: A comparison of 2 generations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; atopy; Finland; Russia	KILLED MYCOBACTERIUM-VACCAE; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; HAY-FEVER; PREVALENCE; SENSITIZATION; CHILDREN; EXPOSURE; INCREASE; LIFE	Background and objective: Western lifestyle has consistently been associated with the current asthma and atopy epidemics. We examined the occurrence and risk factors of atopy among schoolchildren and their mothers in 2 geographically adjacent areas with fundamental differences in living conditions and lifestyles. Methods: A population-based study of 2 generations was carried out in eastern Finland and in western Russia. Randomly selected schoolchildren aged 7 to 16 years (367 in Finland and 446 in Russia) and their mothers (365 and 437, respectively) were enrolled. Data were obtained by using a modified International Study of Asthma and Allergies in Childhood questionnaire and by performing skin prick tests against 14 common airborne and food allergens. Results: In children a 4-fold higher risk for atopy (>= 1 positive prick test result) was found in Finland compared with Russia. Sensitization rates in Finland were generally higher among children compared with those of their mothers, whereas in Russia the opposite trends emerged. Parental farming in early life (< 1 year) in Finland (odds ratio [OR], 0.53; 95% CI, 0.28-0.99) and in Russia (OR, 0.47; 95% CI, 0.22-1.03) and currently in Finland (OR, 0.45; 95% CI, 0.22-0.91) conferred protection against atopy. Having pets, dogs in Finland (OR, 0.57; 95% CI, 0.35-0.95) and cats in Russia (OR, 0.43; 95% Cl, 0.24-0.80), in early life was also inversely associated with atopy. Conclusion: Atopy was several-fold more common in Finland compared with in Russia, and disparities in sensitization rates between the countries have further increased during these generations. The similarity of explanatory variables of atopy in both countries suggests that determinants of atopy are shared, at least in similar geoclimatic conditions.	Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	von Hertzen, L (corresponding author), Univ Helsinki, Cent Hosp, POB 160, FIN-00290 Helsinki, Finland.	leena.vonhertzen@kolumbus.fi	Laatikainen, Tiina/ABD-6622-2021	Laatikainen, Tiina/0000-0002-6614-4782				Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659; ALANEN A, 2004, FINN REV E EUR STUDI, P42; Alanen A., 2000, TEARING CURTAIN OPEN, P55; Andreev EM, 2003, INT J EPIDEMIOL, V32, P437, DOI 10.1093/ije/dyg085; Annus T, 2001, CLIN EXP ALLERGY, V31, P1846, DOI 10.1046/j.1365-2222.2001.01238.x; [Anonymous], 1989, ALLERGY S10, V10, P1; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; Johnson CC, 2002, CURR OPIN ALLERGY CL, V2, P133, DOI 10.1097/00130832-200204000-00009; Kabesch M, 2004, J LEUKOCYTE BIOL, V75, P383, DOI 10.1189/jlb.1003468; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Plavinski SL, 2003, BRIT MED J, V326, P1240, DOI 10.1136/bmj.326.7401.1240; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; von Hertzen L, 2005, ALLERGY, V60, P283, DOI 10.1111/j.1398-9995.2005.00769.x; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492	35	73	74	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					151	157		10.1016/j.jaci.2005.07.028	http://dx.doi.org/10.1016/j.jaci.2005.07.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387599				2022-12-18	WOS:000235687100024
J	Southam, DS; Widmer, N; Ellis, R; Hirota, JA; Inman, MD; Sehmi, R				Southam, DS; Widmer, N; Ellis, R; Hirota, JA; Inman, MD; Sehmi, R			Increased eosinophil-lineage committed progenitors in the lung of allergen-challenged mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophils progenitors; CD34(+); IL-5; eotaxin; lungs; bone marrow; in situ; hematopoiesis	BONE-MARROW; CD34(+) CELLS; ASTHMATIC SUBJECTS; PERIPHERAL-BLOOD; IL-5 RECEPTOR; DIFFERENTIATION; MOBILIZATION; COMMITMENT; EXPRESSION; MUCOSA	Background: There is increasing evidence that hemopoietic progenitor cells may traffic from bone marrow to sites of allergen exposure in asthma and undergo in situ differentiation, contributing to ongoing airway inflammation. However, the isolation and detailed phenotyping of true CD34(+) progenitors from lung tissue during an allergen-induced airway eosinophilia has not been performed. Objective: We attempted to isolate and investigate the in vivo kinetics of hemopoietic progenitor cells and production of eosinophilopoietic mediators in the lung. Methods: In a mouse model of allergic airway inflammation, cells were extracted from lung tissue by enzymatic digestion. Total (CD34(+)45(+)) and eosinophil lineage committed (CD34(+)45(+)IL-5Ralpha(+)) progenitors were enumerated by flow cytometry. Outcome measurements were made 2, 6, 12, 24, 48, and 72 hours and 7 and 14 days after allergen challenge. Results: Compared with saline control, CD34+45+ progenitors were elevated between 6 and 48 hours (P <.05), attenuated by 72 hours and subsequently increased by 14 days (P >.05). CD34+45+IL-5Ra+ progenitors were transiently elevated at 6 hours (P >.05) before a return to preallergen levels by 12 hours and a subsequent increase at 14 days (P <.05). Bronchoalveolar lavage eosinophils were increased at 2 hours, peaking at 72 hours (P <.00625) and declining by 14 days. Both IL-5 and eotaxin levels were increased by 2 hours, peaking at 12 hours (P >.05) and 24 hours (P <.05), respectively. Conclusion: We propose that the increase in CD34(+)45(+)IL-5Ralpha(+) cells and the eosinophilopoietic mediators IL-5 and eotaxin in the lung after allergen exposure may promote in situ differentiation of eosinophils that contribute to ongoing allergic airway inflammation.	McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada	McMaster University	Sehmi, R (corresponding author), St Josephs Hosp, Luke 314,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	sehmir@mcmaster.ca						Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; Inman MD, 1999, AM J RESP CELL MOL, V21, P473, DOI 10.1165/ajrcmb.21.4.3622; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Lamkhioued B, 2003, J IMMUNOL, V170, P537, DOI 10.4049/jimmunol.170.1.537; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9, DOI 10.1165/ajrcmb.20.1.3449; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R., 2003, Current Drug Targets - Inflammation and Allergy, V2, P271, DOI 10.2174/1568010033484007; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Sergejeva S, 2004, BLOOD, V103, P1270, DOI 10.1182/blood-2003-05-1618; Shalit M, 1996, J ALLERGY CLIN IMMUN, V98, P344, DOI 10.1016/S0091-6749(96)70159-8; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; SUTHERS RA, 1992, 14 INT C AC, V1, P1	17	73	83	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					95	102		10.1016/j.jaci.2004.09.022	http://dx.doi.org/10.1016/j.jaci.2004.09.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637553				2022-12-18	WOS:000226267000013
J	Al-Mousawi, MSH; Lovel, H; Behbehani, N; Arifhodzic, N; Woodcock, A; Custovic, A				Al-Mousawi, MSH; Lovel, H; Behbehani, N; Arifhodzic, N; Woodcock, A; Custovic, A			Asthma and sensitization in a community with low indoor allergen levels and low pet-keeping frequency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sensitization; domestic pets; allergen exposure	SKIN-TEST REACTIVITY; CHILDHOOD ASTHMA; RISK-FACTORS; ENVIRONMENTAL EXPOSURE; COCKROACH ALLERGENS; BRONCHIAL-ASTHMA; ADULT ASTHMA; DOG ALLERGEN; SERUM IGE; CAT	Background: Little is known about causes of asthma and sensitization in desert countries. Objective: To investigate risk factors associated with asthma and sensitization in Kuwait. Methods: One hundred sixty children (9-16 years) with physician-diagnosed asthma were recruited and matched (age, sex) with 303 healthy controls. Risk factors were assessed by questionnaires, determination of sensitization status (skin tests and IgE), and home allergen exposure (mite, cat, dog, cockroach; ELISA). Results: Home allergen levels and frequency of pet ownership were very low (cat, 4.1%; dog, 1.5%). The risk of cat sensitization increased significantly among cat owners (odds ratio [OR], 3.53; 95% CI, 1.33-9.41; P =.01), and in children with reported contact with cats during the first year of life (OR, 2.60; 95 % CI, 1.17-5.80; P = .019). In the multivariate analysis, maternal atopy (OR, 1.77; 95% CI, 1.13-2.75; P =.01) and cat ownership (OR, 3.32; 95 % CI, 1.19-9.25; P = .02) remained significant associates of cat sensitization. Current dog ownership significantly increased the risk of sensitization to dog (OR, 6.05; 95 % CI, 1.33-27.54; P = .02). In the multivariate analysis, dog ownership remained the only significant associate of dog sensitization (OR, 6.02; 95 % CI, 1.30-27.96; P =.02). Sensitization to Alternaria was the strongest independent associate of the asthma group. Family history of asthma, history of whooping cough, current cat ownership, and breast-feeding <2 months were other significant and independent risk factors for asthma. Conclusions: Pet ownership markedly increased the risk of sensitization to pets. Despite low allergen exposure, the pattern of childhood asthma in Kuwait follows that described in Western communities (strong association with sensitization).	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Univ Manchester, WHO, Collaborating Ctr Primary Care, Manchester, Lancs, England; Al Rashid Allergy Ctr, Kuwait, Kuwait; Kuwait Univ, Fac Med, Kuwait, Kuwait	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; World Health Organization; Kuwait University	Custovic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.	a.custovic@man.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; al Mousawi M, 2001, ALLERGY, V56, P1237, DOI 10.1034/j.1398-9995.2001.00389.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behbehani NA, 2000, ANN ALLERG ASTHMA IM, V85, P58, DOI 10.1016/S1081-1206(10)62435-0; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DAVIS GS, 1978, AM REV RESPIR DIS, V118, P7; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; ELLULMICALLEF R, 1984, CLIN ALLERGY, V14, P509, DOI 10.1111/j.1365-2222.1984.tb02237.x; Ezeamuzie CI, 2000, ALLERGY, V55, P157, DOI 10.1034/j.1398-9995.2000.00375.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hijazi Z, 2002, J ASTHMA, V39, P603, DOI 10.1081/JAS-120014924; Khadadah M, 2000, J ASTHMA, V37, P481, DOI 10.3109/02770900009055474; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; SORENSEN H, 1985, ANN ALLERGY, V54, P530; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; STRANNEGARD IL, 1990, ALLERGY, V45, P327, DOI 10.1111/j.1398-9995.1990.tb00507.x; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1991, PEDIAT ALLERGY IMMUN, V1, P76; WILKINSON WM, 1964, J TROP MED HYG, V67, P16; Woodcock A, 2001, J ALLERGY CLIN IMMUN, V108, P463, DOI 10.1067/mai.2001.116859	39	73	74	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1389	1394		10.1016/j.jaci.2004.09.005	http://dx.doi.org/10.1016/j.jaci.2004.09.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577842				2022-12-18	WOS:000225577400021
J	Hung, CH; Chen, LC; Zhang, ZJ; Chowdhury, B; Lee, WL; Plunkett, B; Chen, CH; Myers, AC; Huang, SK				Hung, CH; Chen, LC; Zhang, ZJ; Chowdhury, B; Lee, WL; Plunkett, B; Chen, CH; Myers, AC; Huang, SK			Regulation of T(H)2 responses by the pulmonary Clara cell secretory 10-kd protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2; cytokine; Clara cell; CC10; asthma	CUTTING EDGE; UTEROGLOBIN; INHIBITION; GATA-3; RESPONSIVENESS; INFLAMMATION; DEFICIENT; STABILITY; SERUM	Background: Pulmonary Clara cell secretory 10-kd protein (CC10) is a steroid-inducible and potentially anti-inflammatory cytokine, but its direct involvement in the regulation of T-cell responses remains unknown. Objective: The role of CC10 in the regulation of T(H)2 cytokine expression was investigated. Methods: The levels of cytokine and GATA-3 expression were determined by ELISA and RT-PCR, respectively. Bronchoalveolar lavage fluid cell counts were also determined by using a standard protocol. CC10 expression in vivo was determined by immunocytochemistry and Western blotting. Results: In vitro, a significant, dose-dependent suppressive effect of CC10 was found on T(H)2 cytokine expression, but not IFN-gamma, in splenocytes of antigen-sensitized mice. A similar suppressive effect was also noted in polarized CD4(+) T(H)2 cells, but not in naive CD4(+) T cells. In contrast, CC10 was able to induce IFN-gamma expression in naive CD4(+) T cells, but not in polarized T(H)1 cells. Furthermore, the suppression of T(H)2 cytokine expression was concomitant with reduction of a critical transcription factor, GATA-3. Of significance was the finding that although no significant change was found in the decay kinetics of T(H)2 cytokine transcripts, a significant decrease in mRNA stability of GATA-3 was seen in CC10-treated cells. In vivo, reconstitution of the CC10 gene in CC10-deficient mice resulted in significantly lower levels of T(H)2 cytokines, concomitant with a decrease in GATA-3 expression, after challenge with Ag compared with those seen in mock-transduced mice, which are associated with reduced levels of pulmonary eosinophilia. Conclusion: These results demonstrate, that CC10 plays a direct role in the regulation of T-cell-mediated inflammatory responses.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Tri Serv Gen Hosp, Dept Pediat, Taipei, Taiwan; Natl Def Med Ctr, Taipei, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan; NICHHD, NIH, Bethesda, MD 20892 USA; Taipei Med Univ, Taipei, Taiwan	Johns Hopkins University; Johns Hopkins Medicine; Tri-Service General Hospital; National Defense Medical Center; Chang Gung Memorial Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Taipei Medical University	Huang, SK (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	skhuang@jhmi.edu	Hung, Chih-Hsing/C-7296-2009; Huang, Shau-Ku/F-5509-2010		PHS HHS [R01-40274] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Choi M, 2000, ANN NY ACAD SCI, V923, P303; DIERYNCK I, 1995, AM J RESP CELL MOL, V12, P205, DOI 10.1165/ajrcmb.12.2.7865218; Harrod KS, 1998, AM J PHYSIOL-LUNG C, V275, pL924, DOI 10.1152/ajplung.1998.275.5.L924; Hayashida S, 2000, AM J PHYSIOL-LUNG C, V279, pL452, DOI 10.1152/ajplung.2000.279.3.L452; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147, DOI 10.1165/ajrcmb.17.2.2676; Kim S, 2002, AM J PHYSIOL-LUNG C, V283, pL67, DOI 10.1152/ajplung.00404.2001; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124, DOI 10.1164/ajrccm.161.1.9904073; Li XM, 1998, J IMMUNOL, V160, P1378; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; *NAT I HLTH, 1995, PUBL NAT I HLTH; NOAH SB, 2000, J IMMUNOL, V169, P3700; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P930, DOI 10.1164/ajrccm.160.3.9803113; Shijubo N, 1998, LUNG, V176, P257, DOI 10.1007/PL00007608; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; Smits HH, 2001, EUR J IMMUNOL, V31, P1055, DOI 10.1002/1521-4141(200104)31:4<1055::AID-IMMU1055>3.0.CO;2-7; Wang SZ, 2001, AM J PHYSIOL-LUNG C, V281, pL1303, DOI 10.1152/ajplung.2001.281.5.L1303; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhang ZJ, 1999, P NATL ACAD SCI USA, V96, P3963, DOI 10.1073/pnas.96.7.3963; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	32	73	79	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					664	670		10.1016/j.jaci.2004.05.042	http://dx.doi.org/10.1016/j.jaci.2004.05.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356574				2022-12-18	WOS:000223799600030
J	Portnoy, JM; Barnes, CS; Kennedy, K				Portnoy, JM; Barnes, CS; Kennedy, K			Current reviews of allergy and clinical immunology - Sampling for indoor fungi	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						fungi; mold; Stachybotrys species; environmental sampling; surface sampling; air sampling; ergosterol; glucan; mycotoxin; microbially generated volatile organic compounds	VOLATILE ORGANIC-COMPOUNDS; STACHYBOTRYS-CHARTARUM; AIRBORNE FUNGI; COCKROACH ALLERGEN; HOUSE-DUST; MOLD; HOME; SYMPTOMS; EXPOSURE; ENVIRONMENTS	Background: A great deal of concern has arisen recently regarding the potential adverse effects of indoor fungi. Our understanding of this complex problem has been hampered by a lack of standardized protocols for performing an indoor assessment for fungi. Without such standards, it is difficult to compare results from one study with those from another or to measure the effect of indoor fungal contamination on a building and its occupants. Methods: We reviewed the medical literature and here describe a hypothesis-driven approach to planning, sampling, and interpreting the results of indoor assessments for fungi. Results: Fungi cause 3 primary adverse effects: (1) they can damage a building, (2) they can render a building unpleasant to live in by looking and smelling bad, and (3) they might cause adverse health effects in sensitive individuals. Sampling methods used to test hypotheses include air sampling for spores, measurement of allergens in house dust, and determination of microbially generated volatile organic compounds, ergosterols, glucans, and mycotoxins, as well as environmental conditions that lead to fungal contamination. Conclusions: Standardized approaches for performing and reporting assessments of indoor fungi are essential if our understanding of this complex field is to improve.	Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA	Children's Mercy Hospital	Portnoy, JM (corresponding author), Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA.							*AM SOC HEAT REFR, 1989, 621989 AM SOC HEAT R; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P707, DOI 10.1016/S0091-6749(99)70349-0; ARLIAN LG, 1976, J ASTHMA RES, V13, P165, DOI 10.3109/02770907609104172; Bardana EJ, 2003, ANN ALLERG ASTHMA IM, V91, P212, DOI 10.1016/S1081-1206(10)62181-3; Bardana EJ, 2003, IMMUNOL ALLERGY CLIN, V23, P291, DOI 10.1016/S0889-8561(02)00081-4; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P517, DOI 10.1016/S1081-1206(10)62899-2; BARNES C, 2003, IN PRESS ANN ALLERGY; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Burge HA, 1995, BIOAEROSOLS; Cage BR, 1996, ANN ALLERG ASTHMA IM, V77, P401, DOI 10.1016/S1081-1206(10)63339-X; Chapman JA, 2003, ANN ALLERG ASTHMA IM, V91, P222, DOI 10.1016/S1081-1206(10)63522-3; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Chew GL, 2003, ALLERGY, V58, P13, DOI 10.1034/j.1398-9995.2003.00013.x; *COMM HLTH EFF IND, 1993, IND ALL ASS CONTR AD, P185; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579, DOI 10.1136/oem.55.9.579; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Croft WA, 2002, J ENVIRON BIOL, V23, P301; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; Dharmage S, 2002, CLIN EXP ALLERGY, V32, P714, DOI 10.1046/j.1365-2222.2002.01371.x; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Elke K, 1999, J ENVIRON MONITOR, V1, P445, DOI 10.1039/a903034d; Fischer G, 1999, CHEMOSPHERE, V39, P795, DOI 10.1016/S0045-6535(99)00015-6; Fischer G, 2003, ARCH MICROBIOL, V179, P75, DOI 10.1007/s00203-002-0495-2; Fisher F.W., 1998, FUNDAMENTALS DIAGNOS; Flappan SM, 1999, ENVIRON HEALTH PERSP, V107, P927, DOI 10.2307/3454483; FORGACS JOSEPH, 1958, TRANS NEW YORK ACAD SCI, V20, P787; HARRACH B, 1983, APPL ENVIRON MICROB, V45, P1419, DOI 10.1128/AEM.45.5.1419-1422.1983; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; HORNER W, 2003, ASSESSMENT INDOOR EN; Jarvis BB, 2003, PHYTOCHEMISTRY, V64, P53, DOI 10.1016/S0031-9422(03)00275-9; Jarvis Bruce B., 1995, Natural Toxins, V3, P10, DOI 10.1002/nt.2620030104; Johanning E, 1999, BIOAEROSOLS FUNGI MY; Lagana A, 2003, RAPID COMMUN MASS SP, V17, P1037, DOI 10.1002/rcm.1019; LopezDiaz TM, 1997, INT J FOOD MICROBIOL, V35, P129, DOI 10.1016/S0168-1605(96)01211-1; MACHER J, 1999, BIOAEROSOL ASSESSMEN; Matheson MC, 2003, CLIN EXP ALLERGY, V33, P1281, DOI 10.1046/j.1365-2222.2003.01747.x; MAY JC, 2001, HOUSE KILLING ME; Miller JD, 2003, MED MYCOL, V41, P271, DOI 10.1080/1369378031000137350; Muilenberg ML, 2003, IMMUNOL ALLERGY CLIN, V23, P337, DOI 10.1016/S0889-8561(03)00030-4; *NAT HLTH MUS, 2003, SPONT GEN; PORTNOY, 2001, AEROBIOLOGIA, V17, P43; Rampitsch C, 2003, J AGR FOOD CHEM, V51, P5882, DOI 10.1021/jf030173i; Riegel C, 1992, FUNDAMENTALS ATMOSPH; Rogers CA, 2003, IMMUNOL ALLERGY CLIN, V23, P501, DOI 10.1016/S0889-8561(03)00061-4; Rosenbloom Mark, 2002, Am J Ther, V9, P5, DOI 10.1097/00045391-200201000-00003; RUIZHERRERA J, 1991, ANTON LEEUW INT J G, V60, P73, DOI 10.1007/BF00572695; Rylander R, 1998, MEDIAT INFLAMM, V7, P105, DOI 10.1080/09629359891252; Rylander R, 2000, TOXICOLOGY, V152, P47, DOI 10.1016/S0300-483X(00)00291-2; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SCHNURER J, 1993, APPL ENVIRON MICROB, V59, P552; Sebastian A, 2003, APPL ENVIRON MICROB, V69, P3103, DOI 10.1128/AEM.69.6.3103-3109.2003; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; SIMMONS E, 1994, ANCESTORS ALLERGY; Sudakin DL, 1998, AM J IND MED, V34, P183, DOI 10.1002/(SICI)1097-0274(199808)34:2&lt;183::AID-AJIM12&gt;3.0.CO;2-R; United States Institute of Medicine Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; *US ENV PROT AG OF, 2001, EPA PUBL; *US EPA OFF AIR RA, 2003, EPA PUBL; Voorhorst R., 1964, Allergie Asthma, V10, P329; WILKIE K, 1999, BIOAEROSOLS ASSESSME	62	73	76	5	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					189	198		10.1016/j.jaci.2003.11.021	http://dx.doi.org/10.1016/j.jaci.2003.11.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767427	Bronze			2022-12-18	WOS:000188885700001
J	Vlieg-Boerstra, BJ; Bijleveld, CMA; van der Heide, S; Beusekamp, BJ; Wolt-Plompen, SAA; Kukler, J; Brinkman, J; Duiverman, EJ; Dubois, AEJ				Vlieg-Boerstra, BJ; Bijleveld, CMA; van der Heide, S; Beusekamp, BJ; Wolt-Plompen, SAA; Kukler, J; Brinkman, J; Duiverman, EJ; Dubois, AEJ			Development and validation of challenge materials for double-blind, placebo-controlled food challenges in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; challenge materials; recipes; double-blind; placebo-controlled food challenge; sensory testing; triangle test; paired comparison test	COWS MILK ALLERGY; ATOPIC-DERMATITIS; PRACTICAL ASPECTS; ADVERSE-REACTIONS; ELIMINATION DIET; PEANUT ALLERGY; SKIN PRICK; INFANTS; DIAGNOSIS; EGG	Background: The use of double-blind, placebo-controlled food challenges (DBPCFCs) is considered the gold standard for the diagnosis of food allergy. Despite this, materials and methods used in DBPCFCs have not been standardized. Objective: The purpose of this study was to develop and validate recipes for use in DBPCFCs in children by using allergenic foods, preferably in their usual edible form. Methods: Recipes containing milk, soy, cooked egg, raw whole egg, peanut, hazelnut, and wheat were developed. For each food, placebo and active test food recipes were developed that met the requirements of acceptable taste, allowance of a challenge dose high enough to elicit reactions in an acceptable volume, optimal matrix ingredients, and good matching of sensory properties of placebo and active test food recipes. Validation was conducted on the basis of sensory tests for difference by using the triangle test and the paired comparison test. Recipes were first tested by volunteers from the hospital staff and subsequently by a professional panel of food tasters in a food laboratory designed for sensory testing. Recipes were considered to be validated if no statistically significant differences were found. Results: Twenty-seven recipes were developed and found to be valid by the volunteer panel. Of these 27 recipes, 17 could be validated by the professional panel. Conclusion: Sensory testing with appropriate statistical analysis allows for objective validation of challenge materials. We recommend the use of professional tasters in the setting of a food laboratory for best results.	Univ Groningen Hosp, Dept Allergy, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Beatrix Childrens Hosp, NL-9700 RB Groningen, Netherlands; Univ Groningen Hosp, Dept Dietet, NL-9700 RB Groningen, Netherlands; Univ Prof Educ, Food Lab, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Vlieg-Boerstra, BJ (corresponding author), Univ Groningen Hosp, Dept Allergy, POb 30-001, NL-9700 RB Groningen, Netherlands.		Vlieg-Boerstra, Berber/O-1922-2019	Vlieg-Boerstra, Berber/0000-0001-7962-5406				ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; Baehler P, 1996, CLIN EXP ALLERGY, V26, P254, DOI [10.1046/j.1365-2222.1996.d01-310.x, 10.1111/j.1365-2222.1996.tb00089.x]; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1111/j.1398-9995.2001.00922.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Bock SA, 2000, J PEDIATR GASTR NUTR, V30, pS20, DOI 10.1097/00005176-200001001-00004; BRUYNZEELKOOMEN C, 1995, ALLERGY, V50, P623; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; Caffarelli C, 2001, LANCET, V358, P1871, DOI 10.1016/S0140-6736(01)06897-0; CAFFARELLI C, 1995, J ALLERGY CLIN IMMUN, V95, P1215, DOI 10.1016/S0091-6749(95)70078-1; CARTER C, 1995, DOUBLE BLIND FOOD CH, V3, P95; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Grimshaw K. E. C., 2003, Journal of Allergy and Clinical Immunology, V111, pS311, DOI 10.1016/S0091-6749(03)81127-2; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; HILL DJ, 1995, J ALLERGY CLIN IMMUN, V96, P386, DOI 10.1016/S0091-6749(95)70058-7; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; HUIJBERS GB, 1994, J AM DIET ASSOC, V94, P645, DOI 10.1016/0002-8223(94)90163-5; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Lawless H. T., 1998, SENSORY EVALUATION F; Meilgaard M., 2015, SENSORY EVALUATION T, V5, DOI DOI 10.1201/9781439832271; Muraro MA, 2001, PEDIAT ALLERG IMM-UK, V12, P31, DOI 10.1034/j.1399-3038.2001.121407.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; NORGAARD A, 1992, ALLERGY, V47, P503, DOI 10.1111/j.1398-9995.1992.tb00673.x; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; PASTORELLO EA, 1991, ALLERGY PROC, V12, P319, DOI 10.2500/108854191778879089; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Schade R P, 2002, Ned Tijdschr Geneeskd, V146, P1739; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x	37	73	77	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					341	346		10.1016/j.jaci.2003.10.039	http://dx.doi.org/10.1016/j.jaci.2003.10.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767452				2022-12-18	WOS:000188885700025
J	Gauvreau, GM; Becker, AB; Boulet, LP; Chakir, J; Fick, RB; Greene, WL; Killian, KJ; O'Byrne, PM; Reid, JK; Cockcroft, DW				Gauvreau, GM; Becker, AB; Boulet, LP; Chakir, J; Fick, RB; Greene, WL; Killian, KJ; O'Byrne, PM; Reid, JK; Cockcroft, DW			The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sputum eosinophils; allergen inhalation challenge; anti-CD11a antibody; LFA-1	FUNCTION-ASSOCIATED ANTIGEN-1; HUMANIZED MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; BLOOD EOSINOPHILS; INHALED ALBUTEROL; INCREASED NUMBERS; LFA-1 CD11A/CD18; INDUCED SPUTUM; MAST-CELLS; HYPERRESPONSIVENESS	Background: Efalizumab is a humanized IgG(1) mAb against the lymphocyte function antigen-1 (LFA-1) alpha chain, CD11a. Blocking of LFA-1/intercellular adhesion molecule interactions could inhibit asthmatic inflammation by blocking adhesion and activation of LFA-1-positive leukocytes. Objective: A randomized, double-blinded, placebo-controlled, parallel group, multicenter study investigated the effects of efalizumab on allergen-induced airway responsiveness and airway inflammation. Methods: Thirty-five nonsmoking subjects with mild allergic asthma were randomized to receive efalizumab (n = 24) or placebo (n = 11) in 8 weekly subcutaneous doses (0.7 mg/kg conditioning dose followed by 7 weekly doses of 2.0 mg/kg). Allergen challenges were performed at screening and after 4 and 8 weeks of treatment. Samples of sputum (n = 18 subjects) and blood (n = 35 subjects) were collected the day before challenges, and sputum was collected again at 7 and 24 hours after each challenge. Nonparametric tests were used to compare allergen-induced differences between efalizumab and placebo groups. Results: Subjects receiving efalizumab developed headache (48%) and flu syndrome (28%) compared to subjects receiving placebo (0%). After 8 weeks of efalizumab, the maximum late percent fall in FEV1 (late asthmatic response) was inhibited by 50%, but neither the late response nor the late area under the curve was statistically different than placebo (P = .098 and .062, respectively). Efalizumab had no effect on the maximum early percent fall in FEV1 (early asthmatic response) or early area under the curve compared to placebo (P > .59). Efalizumab significantly reduced the postallergen increase in sputum EG2-positive cells and metachromatic cells (P < .05). No other comparisons were statistically different. Conclusions: Blocking of LFA-1/intercellular adhesion module interactions by efalizumab inhibits the development of allergen-induced cellular inflammatory responses measured in induced sputum and might attenuate the late asthmatic response. Larger studies are needed to confirm this.	McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Laval, Laval Hosp, Inst Cardiol & Pneumol, Quebec City, PQ G1K 7P4, Canada; Univ Saskatchewan, Div Resp Med, Saskatoon, SK S7N 0W0, Canada; Genentech Inc, Saskatoon, SK S7N 0W0, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Laval University; University of Saskatchewan; Roche Holding; Genentech	Gauvreau, GM (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Rm 3U25,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			O'Byrne, Paul/0000-0003-0979-281X				AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; ALDRICH MC, 2001, AM J RESP CRIT CARE, V163, pA594; Bauer RJ, 1999, J PHARMACOKINET BIOP, V27, P397, DOI 10.1023/A:1020917122093; Bowles MJ, 2000, TRANSPL IMMUNOL, V8, P75, DOI 10.1016/S0966-3274(00)00007-1; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Cochran WG., 1989, AMES IOWA STATE U PR, V8; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282, DOI 10.1164/ajrccm/144.6.1282; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Dente FL, 1999, THORAX, V54, P622, DOI 10.1136/thx.54.7.622; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Faveeuw C, 2000, INT IMMUNOL, V12, P241, DOI 10.1093/intimm/12.3.241; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Gronke L, 2002, CLIN EXP ALLERGY, V32, P57, DOI 10.1046/j.0022-0477.2001.01297.x; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; ISSEKUTZ AC, 1992, IMMUNOLOGY, V76, P655; ISSEKUTZ TB, 1993, AM J PATHOL, V143, P1286; Klemm A, 2000, CLIN EXP IMMUNOL, V121, P375, DOI 10.1046/j.1365-2249.2000.01265.x; Koarai A, 2003, AM J RESP CRIT CARE, V167, P758, DOI 10.1164/rccm.200206-619OC; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Krueger J, 2000, J INVEST DERMATOL, V115, P333, DOI 10.1046/j.1523-1747.2000.00abs-8.x; LABERGE S, 1995, AM J RESP CRIT CARE, V151, P822; Lantero S, 2002, ALLERGY, V57, P1036, DOI 10.1034/j.1398-9995.2002.23826.x; Lantero S, 1998, EUR RESPIR J, V12, P1094, DOI 10.1183/09031936.98.12051094; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leonardi C, 2001, J ALLERGY CLIN IMMUN, V107, pS309; Louis R, 2002, ALLERGY, V57, P907, DOI 10.1034/j.1398-9995.2002.23608.x; Murphy A, 2000, EUR J IMMUNOL, V30, P3006, DOI 10.1002/1521-4141(200010)30:10<3006::AID-IMMU3006>3.0.CO;2-4; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Obase Y, 2001, ANN ALLERG ASTHMA IM, V86, P304, DOI 10.1016/S1081-1206(10)63303-0; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PALS ST, 1988, J IMMUNOL, V140, P1851; Pesce G, 2001, INT ARCH ALLERGY IMM, V125, P160, DOI 10.1159/000053810; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Poston RS, 2000, TRANSPLANTATION, V69, P2005, DOI 10.1097/00007890-200005270-00006; RABB HA, 1994, AM J RESP CRIT CARE, V149, P1186, DOI 10.1164/ajrccm.149.5.8173758; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; Whitcup SM, 1999, CLIN IMMUNOL, V93, P107, DOI 10.1006/clim.1999.4775; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123	45	73	79	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					331	338		10.1067/mai.2003.1689	http://dx.doi.org/10.1067/mai.2003.1689			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897739				2022-12-18	WOS:000184650600017
J	Sastre, J; Fernandez-Nieto, M; Rico, P; Martin, S; Barber, D; Cuesta, J; Heras, MD; Quirce, S				Sastre, J; Fernandez-Nieto, M; Rico, P; Martin, S; Barber, D; Cuesta, J; Heras, MD; Quirce, S			Specific immunotherapy with a standardized latex extract in allergic workers: A double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; urticaria; rhinoconjunctivitis; asthma; specific immunotherapy	RISK-FACTORS; PREVALENCE	Background: Preventive measures have been proposed to reduce the risk of sensitization to natural rubber latex (NRL), but this is not always feasible. Objective: The aim of this study was to determine the efficacy and safety of specific immunotherapy with a standardized latex extract in sensitized workers. Methods: Twenty-four patients allergic to NRL with contact urticaria (n = 8) and rhinitis or asthma (n = 16) were included (16 in the active group and 8 in the placebo group). Treatment started in a cluster immunotherapy protocol, with injections every week for 3 months and then every other week for another 3 months. Results: Patients in the active group had significantly lower values than patients in the placebo group in skin terms of reactivity to NRL (P < .01), rubbing test results (P = .047), and latex glove use test results (P = .046) after 6 months of treatment. There were no significant differences between the active and placebo groups in symptom scores, use of medication, self-assessment, or methacholine test results either before or after treatment. Differences in nasal and bronchial symptoms during specific inhalation challenges (P = not significant and P = .05, respectively) were observed in favor of the active group. In the. active group 32 systemic reactions were observed (8% of doses), mostly during the build-up period, being more frequent in patients with respiratory symptoms (P = .004). All reactions responded promptly to treatment. Conclusion: Clinical efficacy was shown mainly on cutaneous symptoms, although an improvement in rhinitis and asthma symptoms was also observed during specific inhalation challenges. Latex-specific immunotherapy might be a useful approach for the treatment of latex allergy in sensitized workers.	Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; ALK ABELLO SA, Madrid, Spain	ALK-Abello AS	Sastre, J (corresponding author), Fdn Jimenez Diaz, Serv Alergia, Av Reyes Catolicos 2, E-28040 Madrid, Spain.		rico, pilar/AAG-6038-2020; Barber, Domingo/Y-9516-2019; s, q/AAD-7171-2020	rico, pilar/0000-0002-2269-2568; Barber, Domingo/0000-0002-5488-5700; 				CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; COCKROFT DW, 1977, CLIN ALLERGY, V39, P37; Gudex C, 1996, QUAL LIFE RES, V5, P521, DOI 10.1007/BF00439226; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; Kelly KJ, 1990, MMWR-MORBID MORTAL W, V40, P437; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; MALLING HJ, 1993, ALLERGY, V48, P9; Martin S, 1997, ALLERGY, V52, P97, DOI 10.1111/j.1398-9995.1997.tb02552.x; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; PIPKORN U, 1988, ALLERGY, V43, P81, DOI 10.1111/j.1398-9995.1988.tb00398.x; Quirce S, 2000, CLIN EXP ALLERGY, V30, P839; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; Sutherland MF, 2002, CLIN EXP ALLERGY, V32, P667; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VENN RD, 1987, NEW DRUG APPROVAL PR, P211; Wikborg T, 1996, J ALLERGY CLIN IMMUN, V97, P983	20	73	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					985	994		10.1067/mai.2003.1390	http://dx.doi.org/10.1067/mai.2003.1390			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743562				2022-12-18	WOS:000182904500012
J	Rodriguez-Perez, R; Crespo, JE; Rodriguez, J; Salcedo, G				Rodriguez-Perez, R; Crespo, JE; Rodriguez, J; Salcedo, G			Profilin is a relevant melon allergen susceptible to pepsin digestion in patients with oral allergy syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						melon allergens; profilin; oral allergy syndrome; digestibility	ASPARAGINE-LINKED GLYCANS; LIPID-TRANSFER PROTEIN; CROSS-REACTIVITY; POLLEN; BIRCH; FOODS; APPLE; BET-V-2; FAMILY; GLYCOPROTEINS	Background: Melon allergy has been documented by means of double-blind, placebo-controlled food challenges. The most common clinical feature associated with melon allergy is oral allergy syndrome (OAS). However, no relevant allergens of melon have been identified to date. Objective: We sought to identify melon allergens and analyze their digestibility in human saliva and simulated gastric fluid (SGF) to provide a rationale for the OAS. Methods: Melon, zucchini, cucumber, and watermelon allergens were identified by means of IgE immunoblotting of sera from 21 patients with OAS after melon ingestion confirmed by means of double-blind, placebo-controlled food challenge. Further characterization was performed with rabbit antisera against sunflower pollen profilin and anticomplex glycans. Lability of allergens was assayed by incubation of melon extract in human saliva and SGE Results: Several IgE-binding components between 15 and 60 kd and a main reactive band of 13 kd were detected in melon extract with the pooled sera from patients with melon allergy. As in melon, 13-kd components of zucchini, cucumber, and watermelon extracts were strongly recognized by the IgE antibodies of the patients with melon allergy and were identified as profilins. Putative cross-reacting carbohydrate determinants were also detected. Sera from 71% of patients recognized the melon profilin, and therefore profilin is considered a major allergen. Melon allergens were unaffected by crude human saliva. In contrast, most melon proteins, predominantly the 13-kd component (profilin), were quickly digested in the SGF. Conclusion: In patients with OAS, a 13-kd protein identified as a profilin is a major melon allergen highly susceptible to pepsin digestion.	ETS Ingn Agronomos, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; Univ Madrid, Hosp 12 Octubre, Serv Alergia, Madrid 3, Spain	Hospital Universitario 12 de Octubre	Salcedo, G (corresponding author), ETS Ingn Agronomos, Dept Biotecnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.		Perez, Rosa Rodriguez/F-2634-2013	Perez, Rosa Rodriguez/0000-0003-0771-7103				ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cuesta-Herranz J, 2000, CLIN EXP ALLERGY, V30, P1411, DOI 10.1046/j.1365-2222.2000.00868.x; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; KREMSER M, 1983, Z HAUTKRANKHEITEN, V58, P543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; ORTIZ JCG, 1995, ALLERGY, V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Reindl J, 2000, J ALLERGY CLIN IMMUN, V106, P379, DOI 10.1067/mai.2000.107602; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; Rossi RE, 1996, ALLERGY, V51, P940; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171	26	73	75	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					634	639		10.1067/mai.2003.74	http://dx.doi.org/10.1067/mai.2003.74			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642849	Bronze			2022-12-18	WOS:000181639500030
J	Custovic, A; Simpson, BM; Simpson, A; Hallam, CL; Marolia, H; Walsh, D; Campbell, J; Woodcock, A				Custovic, A; Simpson, BM; Simpson, A; Hallam, CL; Marolia, H; Walsh, D; Campbell, J; Woodcock, A		Natl Asthma Campaign Manchester	Current mite, cat, and dog allergen exposure, pet ownership, and sensitization to inhalant allergens in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; asthma; cat; dog; dust mite; allergens; exposure	INNER-CITY CHILDREN; HOUSE-DUST MITE; RISK-FACTORS; COCKROACH EXPOSURE; MANCHESTER ASTHMA; CHILDHOOD ASTHMA; MOUSE ALLERGEN; EARLY-LIFE; PREVALENCE; HOMES	Background: Simultaneous exposure to more than one allergen might modify the effect of individual allergens. Objective: The purpose of this study was to investigate the effect of current exposures to mite, cat, and dog allergen and pet ownership on sensitization in adults. Methods: Questionnaires, skin tests, and home visits (Der p 1, Fel d 1, and Can f 1, ELISA; mattresses, living room floors) were performed in 2502 adults. Allergen exposure was treated as a continuous variable and divided into quartiles. To investigate the interaction between allergens, quartiles for 3 allergens were added, creating arbitrary combined exposure categories. Results: In the univariate analysis, mite sensitization was associated with Der p 1 in mattresses (odds ratio [OR], 1.10; 95% CI, 1.01 to 1.19; P = .03) and with Can f 1 in living room floors (OR, 1.08; 95% CI, 1.00 to 1.17; P =.05). In a multivariate regression analysis, Der p 1 in mattresses remained an independent associate of mite sensitization (OR, 1.12; 95% CI, 1.02 to 1.23; P = .03) and pollen sensitization (OR, 1.23; 95% Cl, 1.11 to 1.36; P = .0001). The proportion of subjects sensitized to mite increased significantly with the increasing combined exposure categories (P < .0001). The highest prevalence of sensitization to cat and dog was in the medium combined exposure categories. Cat ownership was associated with a reduced prevalence of sensitization to cats (P = .002) and a reduced prevalence of sensitization to dog (P = .003) but had no effect on sensitization to mite and pollen. Conclusions: Sensitization to dust mites increased with the increasing combined exposure. Cat ownership was associated with a lower prevalence of sensitization to cat and dog but not to mite and grass pollen.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Custovic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666				Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2002, CLIN EXP ALLERGY, V32, P335, DOI 10.1046/j.1365-2222.2002.01352.x; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Robinson C, 2001, CLIN EXP ALLERGY, V31, P186, DOI 10.1046/j.1365-2222.2001.01025.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Schulz O, 1999, CLIN EXP ALLERGY, V29, P439, DOI 10.1046/j.1365-2222.1999.00464.x; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844	27	73	75	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					402	407		10.1067/mai.2003.55	http://dx.doi.org/10.1067/mai.2003.55			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589363	Bronze			2022-12-18	WOS:000180942700027
J	Jirapongsananuruk, O; Malech, HL; Kuhns, DB; Niemela, JE; Brown, MR; Anderson-Cohen, M; Fleisher, TA				Jirapongsananuruk, O; Malech, HL; Kuhns, DB; Niemela, JE; Brown, MR; Anderson-Cohen, M; Fleisher, TA			Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic granulomatous disease; CGD; CYBB; diydrorhodamine assay; DHR; gp91(phox); immune deficiency; mutation analysis; phagocyte defect	RESPIRATORY BURST; MUTATIONS	Background: Chronic granulomatous disease (CGD) is a phagocyte disorder caused by mutations in nicotinamide dinucleotide phosphate (NADPH) oxidase subunits. The dihydrorhodamine 123 (DHR) assay is an effective test for CGD that for most patients also might help to differentiate between the 2 most common forms, X-linked (X) gp91(phox) defect CGD and autosomal recessive (AR) p47(phox) defect CGD. However, some male patients with X-CGD have DHR patterns that overlap the AR-CGD pattern. Objective: The purpose of this investigation was to develop a diagnostic paradigm to delineate male patients with X-CGD expressing a DHR pattern suggestive of p47(phox) deficiency. Methods: The DHR assay measured change in fluorescence of DHR-loaded granulocytes after phorbol myristate acetate (PMA) stimulation. Western blot analysis measured the presence of NADPH oxidase subunits gp91(phox), p47(phox), p67(phox), and p22(phox). CYBB exonic sequencing was performed on PCR-amplified genomic DNA through use of intronic flanking primers. Ferricytochrome-c assay evaluated specific superoxide production by PMA-stimulated granulocytes. Results: Although 83% of patients with X-CGD have virtually no neutrophil DHR activity, we found that 17% of patients, proven to have X-CGD by other criteria, have modest DHR activity that is most consistent with p47(phox) deficiency. We describe a diagnostic paradigm to deal with such patients, and we present 2 cases, along with results of additional studies, including carrier evaluation, protein assessment, and mutation analysis, that are useful in establishing the genotype under these circumstances. DHR assays from the 2 patients described showed a fluorescence shift most characteristic of p47(phox)-AR-CGD; however, each of the patients' mothers showed mosaicism with a bimodal DHR pattern. Patient 1 had some gp91(phox) protein with a Y41D mutation and modest superoxide activity. Patient 2 had a normal level of gp91(phox) protein with a C537R mutation without detectable superoxide activity, as determined by ferricytochrome-c assay, despite the modest DHR activity. Conclusions: Evaluation of male patients with CGD with modest DHR activity should initially include evaluation of potential female carriers for mosaicism with the use of the DHR assay. In circumstances in which this is uninformative, patients should be referred to centers capable of additional testing, including Western blot analysis and CYBB mutation analysis, to clarify the disease genotype.	NIH, Warren G Magnuson Clin Ctr, Dept Lab Med, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; NCI, SAIC Frederick, Clin Serv Program, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Fleisher, TA (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Lab Med, Bldg 10,Room 2C-306,10 Ctr Dr,MSC 1508, Bethesda, MD 20892 USA.			Niemela, Julie/0000-0003-4197-3792; Jirapongsananuruk, Orathai/0000-0002-1603-1106; Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000645, ZIAAI000645] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL010304, ZIACL010304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER		Crockard AD, 1997, INT ARCH ALLERGY IMM, V114, P144, DOI 10.1159/000237660; Heyworth PG, 2001, BLOOD CELL MOL DIS, V27, P16, DOI 10.1006/bcmd.2000.0347; Jirapongsananuruk O, 2002, CLIN IMMUNOL, V104, P73, DOI 10.1006/clim.2002.5230; LEVY R, 1990, J IMMUNOL, V145, P2595; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; ROESLER J, 1991, EUR J PEDIATR, V150, P161, DOI 10.1007/BF01963557; Roesler J, 1999, EXP HEMATOL, V27, P505, DOI 10.1016/S0301-472X(98)00024-1; Roos D, 1996, IMMUNOL TODAY, V17, P517; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Vowells SJ, 1996, J PEDIATR-US, V128, P104, DOI 10.1016/S0022-3476(96)70437-7; Vowells SJ, 1996, LANCET, V347, P1048, DOI 10.1016/S0140-6736(96)90189-0; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	13	73	83	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					374	379		10.1067/mai.2003.58	http://dx.doi.org/10.1067/mai.2003.58			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589359				2022-12-18	WOS:000180942700023
J	Tarlo, SM; Easty, A; Eubanks, K; Parsons, CR; Min, F; Juvet, S; Liss, GM				Tarlo, SM; Easty, A; Eubanks, K; Parsons, CR; Min, F; Juvet, S; Liss, GM			Outcomes of a natural rubber latex control program in an Ontario teaching hospital	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 04-06, 2000	SAN DIEGO, CA	Amer Acad Allergy Asthma & Immunol		latex allergy; natural rubber latex allergy; occupational asthma; medical surveillance	ALLERGY; GLOVES; ASTHMA	Background: Allergy to natural rubber latex (NRL) has been frequently reported in health care workers. However, there is little published evidence of the outcome of hospital intervention programs to reduce exposure and detect cases of sensitization early. Objective: This study assesses the effects of intervention to reduce NRL allergy in an Ontario teaching hospital with approximately 8000 employees. Methods: A retrospective review assessed annual numbers of employees visiting the occupational health clinic, allergy clinic, or both for manifestations of NRL allergy compared with the timing of introduction of intervention strategies, such as worker education, voluntary medical surveillance, and hospital conversion to low-protein, powder-free NRL gloves. Results: The number of workers identified with NRL allergy rose annually, from 1 in 1988 to 6 in 1993. When worker education and voluntary medical surveillance were introduced in 1994, a further 25 workers were identified. Nonsterile gloves were changed to low-protein, powder-free NRL gloves in 1995: Diagnoses fell to 8 workers that year, and 2 of the 3 nurses who had been off work because of asthma-anaphylaxis were able to return to work with personal avoidance of NRL products. With a change to lower protein, powder-free NRL sterile gloves in 1997, allergy diagnoses fell to 3, and only I new case was identified subsequently up to May 1999. No increased glove costs were incurred as a result of consolidated glove purchases. Conclusions: This program to reduce NRL allergy in employees was effectively achieved without additional glove costs while reducing expenses from time off work and workers' compensation claims.	Univ Toronto, Univ Hlth Network, Toronto, ON, Canada; Univ Toronto, Dept Med & Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Tarlo, SM (corresponding author), Toronto Western Hosp, EC4-009,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Tarlo, Susan/0000-0002-4746-5310; Juvet, Stephen/0000-0002-7243-556X				Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Hermesch C B, 1999, J Dent Educ, V63, P814; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; Jackson EM, 2000, J EMERG MED, V18, P241, DOI 10.1016/S0736-4679(99)00202-4; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; LISS G, 2000, AM J RESP CRIT CARE, V161, pA731; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; *NIOSH, 1997, PUB DEP HLTH HUM SER, P1; Phillips VL, 1999, AM J PUBLIC HEALTH, V89, P1024, DOI 10.2105/AJPH.89.7.1024; SAARY J, 2001, AM J RESP CRIT CARE, V163, pA809; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Turjanmaa K, 2000, J ALLERGY CLIN IMMUN, V105, pS373, DOI 10.1016/S0091-6749(00)91520-3; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1999, ASTHMA WORKPLACE, P425; YASSIN MS, 1994, ANN ALLERGY, V72, P245	20	73	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					628	633		10.1067/mai.2001.118792	http://dx.doi.org/10.1067/mai.2001.118792			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	485NK	11590392				2022-12-18	WOS:000171760300025
J	Paltiel, AD; Fuhlbrigge, AL; Kitch, BT; Liljas, B; Weiss, ST; Neumann, PJ; Kuntz, KM				Paltiel, AD; Fuhlbrigge, AL; Kitch, BT; Liljas, B; Weiss, ST; Neumann, PJ; Kuntz, KM			Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled corticosteroids; cost-effectiveness analysis; decision analysis; Markov models	FLUTICASONE PROPIONATE POWDER; METERED-DOSE INHALER; BECLOMETHASONE DIPROPIONATE; NEDOCROMIL SODIUM; RISK; SALMETEROL; CHILDREN; THERAPY; THEOPHYLLINE; EFFICACY	Background: Inhaled corticosteroids remain underused among United States-based clinicians in treating mild-to-moderate adult asthma. Objective: The purpose of this investigation was to estimate the clinical impact, health-related quality of life, cost, and cost-effectiveness of inhaled corticosteroid therapy in a population of patients aged 18 years and over with FEV1 = 60% to 100% of predicted normal. Methods: We performed a cost-effectiveness analysis of quick relievers (eg, short-acting beta -agonists) on an as-needed basis plus inhaled corticosteroid therapy versus quick relievers alone. A mathematical simulation model was developed to forecast symptoms, acute exacerbations, quality-adjusted life-years (QALYs), health care costs, and cost-effectiveness, measured in both dollars per QALY gained and dollars per symptom-free day gained. All evaluation outcomes were discounted at an annual rate of 3% and measured over a 10-year planning horizon. Data on the natural history of disease, drug efficacy, patient preferences, and economic costs were obtained from a variety of observational cohorts, randomized trials, and patient surveys. Results: Over a 10-year period, use of inhaled corticosteroids increases total health costs from roughly $5,200 to $8,400 and improves QALYs from 6.8 to 7.0, implying an incremental cost of $13,500 per QALY gained. Costs per symptom-free day gained are $7.50. Both per-person acute exacerbations and hospitalizations are reduced by 33%. The cost-effectiveness findings are sensitive to the assumed efficacy and side-effects of inhaled corticosteroid therapy. Conclusions: Inhaled corticosteroids appear to deliver good comparative value in adults with mild-to-moderate asthma. Although more research is needed to understand their impact on preferences regarding side effects and compliance, these findings might be useful for priority-setting in limited resource situations.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; AstraZeneca, Lund, Sweden; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; AstraZeneca; Harvard University; Harvard T.H. Chan School of Public Health	Paltiel, AD (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.			Paltiel, A. David/0000-0002-4861-3290	NHLBI NIH HHS [1-K08 HL03919-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; Bennett KJ, 1996, QUALITY LIFE PHARMAC; *BRIT THOR SOC, 1993, THORAX, V48, pS1; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; Chapman RH, 2000, MED DECIS MAKING, V20, P451, DOI 10.1177/0272989X0002000409; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; Coventry J A, 1996, J Ambul Care Manage, V19, P9; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Fahy JV, 1998, EUR RESPIR J, V11, P1240, DOI 10.1183/09031936.98.11061240; Finkelstein JA, 2000, ARCH PEDIAT ADOL MED, V154, P563, DOI 10.1001/archpedi.154.6.563; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112, DOI 10.1016/S1081-1206(10)63496-5; *GLAX, 1998, ASTHM AM EX SUMM; Gold MR, 1996, COST EFFECTIVENESS H; Kemp J, 1999, ANN ALLERG ASTHMA IM, V82, P463, DOI 10.1016/S1081-1206(10)62722-6; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; Kitch B, 1999, AM J RESP CRIT CARE, V159, pA135; KITCH B, 1999, ASTHMAS IMPACT SOC; Krahn MD, 1997, MED DECIS MAKING, V17, P142, DOI 10.1177/0272989X9701700204; LEWIS CE, 1984, PEDIATRICS, V74, P478; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P1062, DOI 10.1016/S0091-6749(99)70180-6; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; McFadden ER, 1999, J ALLERGY CLIN IMMUN, V104, P46, DOI 10.1016/S0091-6749(99)70112-0; *MED EC, 1998, DRUG TOP RED BOOK; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P2, DOI 10.1016/S0091-6749(06)80005-9; *NAT ASTHM CAMP, 1998, ASTHM MAN HDB 1998; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NAT ASTHM ED PREV, 1995, NIH PUBL; Nathan RA, 1999, ANN ALLERG ASTHMA IM, V82, P521, DOI 10.1016/S1081-1206(10)63159-6; National Heart Lung and Blood Institute, 2000, MORB MORT 2000 CHART; Neumann PJ, 1999, NEUROLOGY, V52, P1138, DOI 10.1212/WNL.52.6.1138; Neumann PJ, 2000, MED DECIS MAKING, V20, P413, DOI 10.1177/0272989X0002000405; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; O'Byrne PM, 1998, J ALLERGY CLIN IMMUN, V102, P879, DOI 10.1016/S0091-6749(98)70322-7; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Osterman K, 1997, EUR RESPIR J, V10, P2210, DOI 10.1183/09031936.97.10102210; PASHOS CL, 1998, ISPOR LEXICON; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Peden DB, 1998, J ALLERGY CLIN IMMUN, V102, P32, DOI 10.1016/S0091-6749(98)70052-1; Reed CE, 1998, J ALLERGY CLIN IMMUN, V101, P14, DOI 10.1016/S0091-6749(98)70187-3; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; ROSS RN, 1988, CLIN THER, V10, P188; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; Segal R, 1995, Pharm Pract Manag Q, V15, P72; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Slack R, 1997, QUAL HEALTH CARE, V6, P194, DOI 10.1136/qshc.6.4.194; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; Thomas P, 1996, CLIN THER, V18, P939, DOI 10.1016/S0149-2918(96)80050-6; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Toogood J H, 1998, Can Respir J, V5 Suppl A, p50A; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; U.S. Bureau of the Census, 1997, STAT ABSTR US 1997; US Bureau of the Census, 1998, STAT ABSTR US 1998; Wakefield M, 1997, CHEST, V112, P1527, DOI 10.1378/chest.112.6.1527; Wakefield M, 1997, AUST NZ J MED, V27, P277, DOI 10.1111/j.1445-5994.1997.tb01979.x; WEEKS JC, 1991, NEW ENGL J MED, V325, P81, DOI 10.1056/NEJM199107113250202; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1990, J GEN INTERN MED, V5, P277, DOI 10.1007/BF02600391; Weiss K. B, 2000, ASTHMAS IMPACT SOC S; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207	78	73	73	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					39	46		10.1067/mai.2001.116289	http://dx.doi.org/10.1067/mai.2001.116289			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447380				2022-12-18	WOS:000170171200005
J	Jacoby, DB; Costello, RM; Fryer, AD				Jacoby, DB; Costello, RM; Fryer, AD			Eosinophil recruitment to the airway nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						muscarinic receptors; asthma; parasympathetic nerves; hyperresponsiveness; bronchoconstriction	M2 MUSCARINIC RECEPTORS; MAJOR BASIC-PROTEIN; CHALLENGED GUINEA-PIGS; PULMONARY PARASYMPATHETIC NERVES; ALLERGEN-INDUCED ASTHMA; INDUCED BRONCHOCONSTRICTION; INHIBITORY RECEPTORS; IPRATROPIUM BROMIDE; VIRAL-INFECTIONS; INHALED HEPARIN	Increased vagal reflexes contribute to bronchoconstriction in asthma, Antigen challenge of sensitized animals induces vagal hyperresponsiveness. This review will discuss the evidence that eosinophils increase release of acetylcholine from the parasympathetic nerves. After antigen challenge, eosinophils are actively recruited to the airway nerves, possibly through expression of chemotactic substances and adhesion molecules by the nerves. Tachykinins acting on neurokinin 1 receptors activate the eosinophils. Activated eosinophils release eosinophil major basic protein (MBP), which is an endogenous antagonist for Mt muscarinic receptors. The M-2 muscarinic receptors on the parasympathetic nerves in the lungs normally inhibit release of acetylcholine. When Mt receptors are blocked by MBP, acetylcholine release is increased, resulting in hyperresponsiveness. Neutralization of MBP with polyanionic substances restores Mt receptor function and eliminates hyperresponsiveness. Antibodies to MBP prevent Mt receptor dysfunction and hyperresponsiveness, as do antibodies to the adhesion molecule very late antigen 4, which prevent eosinophil migration. A low dose of dexamethasone, which does not affect total eosinophil influx into the lungs and airways, prevents eosinophils from clustering around the nerves and prevents antigen-induced Mt dysfunction and hyperresponsiveness. Furthermore, animal studies show that viral infections, which are important precipitants of asthma attacks, and exposure to air pollutants such as ozone can also activate airway eosinophils, leading to a chain of events similar to that seen after antigen challenge. Finally, a similar clustering of eosinophils around airway nerves, as well as release of MBP onto the nerves, is seen in fatal asthma, suggesting that similar mechanisms may be involved in human airway hyperresponsiveness.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Baltimore, MD USA; Natl Univ Ireland Univ Coll Dublin, Beaumont Hosp, RCSI, Dept Med, Dublin, Ireland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Royal College of Surgeons - Ireland; University College Dublin; Johns Hopkins University	Fryer, AD (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.		Fryer, Allison/F-2420-2014	Fryer, Allison/0000-0003-1712-9831; Jacoby, David/0000-0003-2195-9512				AAS P, 1990, BRIT J PHARMACOL, V101, P73, DOI 10.1111/j.1476-5381.1990.tb12091.x; Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; AYALA LE, 1989, CHEST, V96, P1285, DOI 10.1378/chest.96.6.1285; Belmonte KE, 1998, J APPL PHYSIOL, V85, P1708, DOI 10.1152/jappl.1998.85.5.1708; BERTRAND C, 1993, AM J PHYSIOL, V265, pL507, DOI 10.1152/ajplung.1993.265.5.L507; BLABER LC, 1985, BRIT J PHARMACOL, V86, P723, DOI 10.1111/j.1476-5381.1985.tb08951.x; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; COCKCROFT DW, 1978, CLIN ALLERGY, V8, P361, DOI 10.1111/j.1365-2222.1978.tb00471.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P505; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; Costello RW, 1998, BRIT J PHARMACOL, V124, P267, DOI 10.1038/sj.bjp.0701822; Costello RW, 1997, ASTHMA, P965; CRIMI N, 1992, EUR RESPIR J, V5, P560; DESCHRYVERKECSKEMETI K, 1989, ARCH PATHOL LAB MED, V113, P394; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790, DOI 10.1164/ajrccm.153.6.8665036; EISER NM, 1982, B EUR PHYSIOPATH RES, V18, P449; ELBON CL, 1995, AM J RESP CELL MOL, V12, P320, DOI 10.1165/ajrcmb.12.3.7873198; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P523; EVANS C, 2000, AM J RESP CRIT CARE, V161, pA843; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; EVANS CM, 1998, AM J RESP CRIT CARE, V157, pA599; EVNAS CM, 2000, AM J PHYSIOL-LUNG C, V279, pL477; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; Fryer A, 1997, J PHARMACOL EXP THER, V282, P208; FRYER A, 2000, EUR RESP J S31, V16, pS372; FRYER AD, 1992, J CLIN INVEST, V90, P2292, DOI 10.1172/JCI116116; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973, DOI 10.1111/j.1476-5381.1984.tb16539.x; FRYER AD, 1991, BRIT J PHARMACOL, V102, P267, DOI 10.1111/j.1476-5381.1991.tb12164.x; Fryer AD, 1997, J CLIN INVEST, V99, P2036, DOI 10.1172/JCI119372; FRYER AD, 1987, EUR J PHARMACOL, V139, P187, DOI 10.1016/0014-2999(87)90251-2; GAYRARD P, 1975, POSTGRAD MED J, V51, pS102; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; GUNDEL RH, 1991, J CLIN INVEST, V132, P599; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V54, P134, DOI 10.1152/jappl.1983.54.1.134; HU JR, 1992, MOL PHARMACOL, V42, P311; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; ITO Y, 1988, BRIT J PHARMACOL, V93, P636, DOI 10.1111/j.1476-5381.1988.tb10321.x; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JACOBY DB, 1995, AM J RESP CRIT CARE, V151, pA821; Johansson O, 2000, ARCH DERMATOL RES, V292, P371, DOI 10.1007/s004030000142; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KILLINGSWORTH CR, 1992, BRIT J PHARMACOL, V105, P263, DOI 10.1111/j.1476-5381.1992.tb14244.x; KRESTEN W, 1974, RESPIRATION, V31, P412; KROEGEL C, 1990, J IMMUNOL, V145, P2581; Lowichik A, 1997, PEDIATR PATHOL LAB M, V17, P885, DOI 10.1080/107710497174336; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; Milici AJ, 1998, LAB INVEST, V78, P1239; MINETTE PA, 1988, J APPL PHYSIOL, V64, P2532, DOI 10.1152/jappl.1988.64.6.2532; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OKAYAMA M, 1994, AM J RESP CRIT CARE, V149, P76, DOI 10.1164/ajrccm.149.1.8111602; OREHEK J, 1975, B PHYSIO-PATHOL RESP, V11, P193; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; SAWATZKY D, 2000, AM J RESP CRIT CARE, V161, pA541; Schiller I. W., 1947, ANN ALLERGY, V5, P564; SCHULTHEIS AH, 1994, J APPL PHYSIOL, V76, P1088, DOI 10.1152/jappl.1994.76.3.1088; SCHULTZEWERNINGHAUS G, 1981, RESPIRATION, V41, P239, DOI 10.1159/000194388; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SHEPPARD D, 1983, J APPL PHYSIOL, V54, P130, DOI 10.1152/jappl.1983.54.1.130; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; STEAD R H, 1992, Regional Immunology, V4, P91; YOST B, 2000, AM J RESP CRIT CARE, V161, pA842; Yost BL, 1999, J APPL PHYSIOL, V87, P1272, DOI 10.1152/jappl.1999.87.4.1272; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	71	73	82	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					211	218		10.1067/mai.2001.112940	http://dx.doi.org/10.1067/mai.2001.112940			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174183				2022-12-18	WOS:000167071400002
J	Gern, JE; Busse, WW				Gern, JE; Busse, WW			The role of viral infections in the natural history of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; virus; respiratory syncytial virus; rhinovirus	RESPIRATORY SYNCYTIAL VIRUS; EXPERIMENTAL RHINOVIRUS INFECTION; INDUCED AIRWAY HYPERRESPONSIVENESS; INFLUENZA-A VIRUS; EOSINOPHIL CATIONIC PROTEIN; IN-SITU HYBRIDIZATION; CELLS CLEAR VIRUS; T-CELLS; NASAL SECRETIONS; ALLERGIC SUBJECTS	Viral infections have been related to the inception of recurrent wheezing illnesses and asthma in infants and are probably the most frequent cause of exacerbations of established disease in older children and adults, The well-recognized clinical effects of viral infections are mainly caused by virus-induced immune responses. Clinical studies of natural and experimentally induced viral infections have led to the identification of mechanisms of inflammation that could be involved in producing airway obstruction and lower airway symptoms. In addition, host factors that are associated with more vigorous viral replication or severe clinical illness are beginning to be identified. Advances in molecular virology and our understanding of immune responses to viral infections may lead to the development of new strategies for the prevention and treatment of virus-induced respiratory disorders.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin Hosp, H4-438, Madison, WI 53792 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040685, U19AI034891, U01AI034891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40685, AI34891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; ALWAN WH, 1992, CLIN EXP IMMUNOL, V88, P527; ALWAN WH, 1993, J IMMUNOL, V150, P5211; ARRUDA E, 1995, J INFECT DIS, V171, P1329, DOI 10.1093/infdis/171.5.1329; ARRUDA E, 1991, J MED VIROL, V54, P634; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Avila PC, 1999, J ALLERGY CLIN IMMUN, V103, pS117; Ball TM, 2000, AM J RESP CRIT CARE, V161, pA704; BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207, DOI 10.1165/ajrcmb.10.2.8110476; Bardin PG, 1996, EUR RESPIR J, V9, P2250, DOI 10.1183/09031936.96.09112250; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; BUSSE WW, 1991, AM J RESP CELL MOL, V4, P347, DOI 10.1165/ajrcmb/4.4.347; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DUFF AL, 1993, PEDIATRICS, V92, P535; EGGLESTON PA, 1984, ACTA OTO-LARYNGOL, P25; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; Exelbert RL, 2000, J ALLERGY CLIN IMMUN, V105, pS198, DOI 10.1016/S0091-6749(00)91024-8; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; FOLKERTS G, 1995, AM J RESP CRIT CARE, V151, P1666; FOLKERTS G, 1992, J ALLERGY CLIN IMMUN, V90, P364, DOI 10.1016/S0091-6749(05)80016-8; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; FRYER AD, 2000, ALLERGY CLIN IMMUNOL, V12, P63; GAMA RE, 1989, J MED VIROL, V28, P73, DOI 10.1002/jmv.1890280204; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; Gentile DA, 1999, J ALLERGY CLIN IMMUN, V103, P1045, DOI 10.1016/S0091-6749(99)70177-6; GERN JE, 1995, AM J RESP CRIT CARE, V152, pS40, DOI 10.1164/ajrccm/152.4_Pt_2.S40; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1996, J IMMUNOL, V157, P1605; Gern JE, 1997, J INFECT DIS, V175, P1108, DOI 10.1086/516449; Gern JE, 1996, J IMMUNOL, V156, P621; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Handzel ZT, 1998, J IMMUNOL, V160, P1279; HAYDEN FG, 1986, NEW ENGL J MED, V314, P71, DOI 10.1056/NEJM198601093140202; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HEYMANN PW, 1995, INT ARCH ALLERGY IMM, V107, P380, DOI 10.1159/000237043; HIGGINS PG, 1990, ANTIVIR RES, V14, P339, DOI 10.1016/0166-3542(90)90052-9; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; Jackson M, 1996, J MED VIROL, V49, P161, DOI 10.1002/(SICI)1096-9071(199607)49:3<161::AID-JMV2>3.0.CO;2-2; Jamaluddin M, 1998, J VIROL, V72, P4849, DOI 10.1128/JVI.72.6.4849-4857.1998; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; JOHNSTON SL, 1996, AM J RESP CRIT CARE, V153, pA503; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; Las Heras J, 1983, Pediatr Pathol, V1, P319; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEVANDOWSKI RA, 1988, J MED VIROL, V25, P423, DOI 10.1002/jmv.1890250406; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Patick AK, 1999, ANTIMICROB AGENTS CH, V43, P2444, DOI 10.1128/AAC.43.10.2444; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Rager KJ, 1998, J VIROL, V72, P1171, DOI 10.1128/JVI.72.2.1171-1176.1998; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reijonen TM, 1997, PEDIATR PULM, V24, P35, DOI 10.1002/(SICI)1099-0496(199707)24:1<35::AID-PPUL6>3.3.CO;2-K; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; RIMMELZWAAN GF, 1995, VACCINE, V13, P703; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sareneva T, 1998, J IMMUNOL, V160, P6032; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; SCHUSTER A, 1995, EUR RESPIR J, V8, P10, DOI 10.1183/09031936.95.08010010; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; Stockl J, 1999, J CLIN INVEST, V104, P957, DOI 10.1172/JCI7255; Storch GA, 1998, PEDIATRICS, V102, P648, DOI 10.1542/peds.102.3.648; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Suzuki S, 1998, J ALLERGY CLIN IMMUN, V102, P732, DOI 10.1016/S0091-6749(98)70012-0; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Teran LM, 1999, J INFECT DIS, V179, P677, DOI 10.1086/314618; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WELLIVER RC, 1995, LANCET, V346, P789, DOI 10.1016/S0140-6736(95)91615-6; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101; WINTHER B, 1984, ACTA OTO-LARYNGOL, P19; Yamaya M, 1999, AM J PHYSIOL-LUNG C, V277, pL362, DOI 10.1152/ajplung.1999.277.2.L362; Yoon HJ, 1999, J IMMUNOL, V162, P7461; Yuta A, 1998, AM J PHYSIOL-LUNG C, V274, pL1017, DOI 10.1152/ajplung.1998.274.6.L1017; ZHANG L, 1994, CLIN EXP ALLERGY, V24, P899, DOI 10.1111/j.1365-2222.1994.tb02720.x; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	122	73	76	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					201	212		10.1067/mai.2000.108604	http://dx.doi.org/10.1067/mai.2000.108604			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932062	Bronze			2022-12-18	WOS:000088708100001
J	Langeveld-Wildschut, EG; Bruijnzeel, PLB; Mudde, GC; Versluis, C; Van Leperen-Van Dijk, AG; Bihari, IC; Knol, EF; Thepen, T; Bruijnzeel-Koomen, CAFM; van Reijsen, FC				Langeveld-Wildschut, EG; Bruijnzeel, PLB; Mudde, GC; Versluis, C; Van Leperen-Van Dijk, AG; Bihari, IC; Knol, EF; Thepen, T; Bruijnzeel-Koomen, CAFM; van Reijsen, FC			Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic eczema; atopy patch test; IgE; Fc epsilon RI; T cells; allergen	EPIDERMAL LANGERHANS CELLS; FC-EPSILON-RI; HOUSE-DUST MITE; DERMATITIS PATIENTS; T-CELLS; IGE; INFLAMMATION; AEROALLERGEN; INHALATION; EXPRESSION	Background: Epicutaneous application of aeroallergens induces a positive atopy patch test (APT) response in about 50% of patients with atopic eczema (AE) and sensitization for these allergens. Objective: To elucidate the mechanisms determining the outcome of the APT, the following questions were addressed. Are there differences in clinical features between patients with AE who have positive versus negative APT responses? Is a macroscopically negative APT response also histologically negative, and if so, are there differences in clinically noninvolved skin between the two groups regarding (1) the sensitivity toward an irritant, (2) the composition of cellular infiltrate, (3) the presence of aeroallergen-specific T cells, and ( 1) the number of IgE(+) cells? Methods: Punch biopsy specimens from both house dust mite patch tested and the clinically noninvolved skin of patients with AE who have positive APT responses (n = 10) and negative APT responses (n = 10) and those from the normal skin of atopic individuals without AE (n = 10) and nonatopic volunteers (n = 10) were analyzed by using immunohistochemistry? with mAbs against eosinophil cationic protein, IgE, the high-affinity. receptor for IgE, and CD3 and CD25 mAbs. Furthermore. T-cell lines n ere propagated from noninvolved skin of all patient and control groups. The T-cell lines were tested for house dust mite specificity. Results: Negative APT sites were immunohistochemically similar to clinically noninvolved AE skin. There were no significant differences between patients with AE who had positive and negative APT results regarding either clinical features, the composition of cellular infiltrate, or the presence of allergen-specific T cells in clinically noninvolved skin. However, differences were observed regarding the presence of IgE on epidermal CD1a(+) cells. Conclusion: Our results indicate that a positive APT reaction requires the presence of epidermal IgE(+) CD1a(+) cells in clinically noninvolved skin, but that also other, as yet unknown, discriminatory factors ore involved.	Univ Med Ctr Utrecht, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Prins Maurits Lab, Toegepast Nat Wetenschappelijk Onderzoek, Dept Pharmacol, Rijswijk, Netherlands; Parke Davis & Co, Inst Rech Jouveinal, Dept Allergy & Inflammat, Fresnes, France	Utrecht University; Utrecht University Medical Center; Pfizer	Bruijnzeel-Koomen, CAFM (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, Huispostnr G 02124,POB 85500, NL-3508 GA Utrecht, Netherlands.			Knol, Edward/0000-0001-7368-9820				BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bohle B, 1998, J IMMUNOL, V160, P2022; Brinkman L, 1997, CLIN EXP ALLERGY, V27, P1043, DOI 10.1111/j.1365-2222.1997.tb01256.x; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; BRUIJNZEEL-KOOMEN C A F M, 1989, Allergie et Immunologie (Paris), V21, P219; BRUIJNZEELKOOM CAF, 1988, CLIN EXP IMMUNOL, V74, P137; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; BRUYNZEELKOOMEN CAFM, 1988, BRIT J DERMATOL, V118, P229, DOI 10.1111/j.1365-2133.1988.tb01779.x; Buckley C, 1996, CLIN EXP ALLERGY, V26, P1057, DOI 10.1111/j.1365-2222.1996.tb00644.x; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; Deleuran M, 1998, ACTA DERM-VENEREOL, V78, P241, DOI 10.1080/000155598441783; deVries IJM, 1997, J ALLERGY CLIN IMMUN, V100, P694, DOI 10.1016/S0091-6749(97)70175-1; GRABBE J, 1993, BRIT J DERMATOL, V129, P120, DOI 10.1111/j.1365-2133.1993.tb03512.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; MACKIE RM, 1979, CLIN EXP DERMATOL, V4, P187, DOI 10.1111/j.1365-2230.1979.tb01616.x; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; REISCHL IG, 1996, CLIN EXP ALLERGY, V28, P1043; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Tabata N, 1998, ACTA DERM-VENEREOL, V78, P244; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Tovey ER, 1995, J ALLERGY CLIN IMMUN, V96, P999, DOI 10.1016/S0091-6749(95)70239-3; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; UEHARA M, 1984, ARCH DERMATOL, V120, P1186, DOI 10.1001/archderm.120.9.1186; VADER PCV, 1991, ACTA DERM-VENEREOL, V71, P301; VANREIJSEN FC, 1994, CLIN EXP IMMUNOL, V98, P151; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VIRTANEN T, 1995, J ALLERGY CLIN IMMUN, V96, P411, DOI 10.1016/S0091-6749(95)70061-7; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wistokat-Wulfing A, 1999, CLIN EXP ALLERGY, V29, P513	36	73	77	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1008	1016		10.1067/mai.2000.106544	http://dx.doi.org/10.1067/mai.2000.106544			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808184				2022-12-18	WOS:000087185000022
J	Bommel, H; Li-Weber, M; Serfling, E; Duschl, A				Bommel, H; Li-Weber, M; Serfling, E; Duschl, A			The environmental pollutant pyrene induces the production of IL-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pyrene; IL-4; allergy; polyaromatic hydrocarbons; environmental pollution; diesel exhaust particles	DIESEL EXHAUST PARTICLES; IGE ANTIBODY-PRODUCTION; CYTOKINE PRODUCTION; ADJUVANT ACTIVITY; MICE; INTERLEUKIN-4; CHALLENGE; ALLERGEN; HYDROCARBONS; INFLAMMATION	Background: Epidemiologic studies and experiments with mouse models suggest that polyaromatic hydrocarbons contained in, among others, diesel exhaust particles can promote the development of allergy. Objective: Because IL-4 organizes allergic responses in vivo, we have investigated whether pyrene, a major compound of diesel exhaust particles, can affect the production of IL-4. Methods: IL-4 production by primary human T cells was assessed by ELISA and messenger RNA transcription was detected by Northern blotting. Activation of the IL-4 promoter was tested in reporter gene assays with transiently transfected cell lines. Results: Pyrene induced transcription of IL-4 messenger RNA and expression of IL-4 protein in primary human T cells. Pyrene, but not related polyaromatic hydrocarbons, enhanced basal transcription of the human and mouse IL-4 promoter. Conclusion: Our results suggest that pyrene may promote allergic diseases by inducing the production of IL-4.	Bioctr, D-97074 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Wurzburg, Germany; German Canc Res Ctr, Tumor Immunol Program, D-6900 Heidelberg, Germany	University of Wurzburg; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Duschl, A (corresponding author), Bioctr, Hubland, D-97074 Wurzburg, Germany.		Serfling, Edgar/X-7212-2019; Duschl, Albert/E-5872-2011; V, RAMACHANDRA T/AAC-2335-2019; V, Ramachandra T/Q-5982-2016	Duschl, Albert/0000-0002-7034-9860; V, RAMACHANDRA T/0000-0001-5528-1565; V, Ramachandra T/0000-0001-5528-1565				Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Ezernieks J, 1996, EUR J BIOCHEM, V240, P667, DOI 10.1111/j.1432-1033.1996.0667h.x; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507, DOI 10.1165/ajrcmb.19.3.3143; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; HAYGLASS KT, 1995, IMMUNOL TODAY, V16, P505, DOI 10.1016/0167-5699(95)80040-9; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; Marone G, 1998, IMMUNOL TODAY, V19, P5, DOI 10.1016/S0167-5699(97)01187-0; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Suzuki T, 1996, J CLIN LAB IMMUNOL, V48, P187; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1, DOI 10.1159/000234990; TAKAFUJI S, 1997, ALLERGIC MECH IMMUNO, P99; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 1999, J IMMUNOL, V162, P4705; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063	26	73	75	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					796	802		10.1067/mai.2000.105124	http://dx.doi.org/10.1067/mai.2000.105124			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756232	Bronze			2022-12-18	WOS:000086604100020
J	Helm, RM; Cockrell, G; Connaughton, C; West, CM; Herman, E; Sampson, HA; Bannon, GA; Burks, AW				Helm, RM; Cockrell, G; Connaughton, C; West, CM; Herman, E; Sampson, HA; Bannon, GA; Burks, AW			Mutational analysis of the IgE-binding epitopes of P34/Gly m Bd 30K	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						soybean allergen; P34/Gly m Bd 30K; B-cell epitopes	SOYBEAN-SENSITIVE PATIENTS; ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; THIOL PROTEASES; SOY ALLERGY; PROTEIN; CHILDREN; IDENTIFICATION; SERA; ALLERGENICITY	Background: Peanuts and soybeans are 2 foods that have been shown to be responsible for many atopic disorders. Because of their nutritional benefit, soybean proteins are now being used increasingly in a number of food products. Previous studies have documented multiple allergens in soybean extracts, including glycinin, beta-conglycinin, and the P34/Gly m Bd 30K protein. Objective: Our overall goal was to identify soybean-specific allergens to begin to understand molecular and immunochemical characteristics of legume proteins. The specific aim of the current investigation was to identify the essential amino acid residues necessary for IgE binding in the 5 distinct immunodominant epitopes of P34/Gly m Ed 30K, Methods: Serum IgE from 6 clinically sensitive soybean-allergic individuals was used to identify P34/Gly m Ed 30K in the native and single amino acid substituted peptides with use of the SPOTS peptide synthesis technique to determine critical amino acids required for IgE binding. Results: The intensity of IgE binding and epitope recognition by serum IgE from the individuals varied substantially. With use of serum from 6 clinically soybean-sensitive individuals, 2 of the 5 immunodominant epitopes could be mutagenized to non-IgE binding peptides, Conclusions: Single-site amino acid substitution of the 5 immunodominant epitopes of Gly m Ed 30K with alanine revealed that IgE binding could be reduced or eliminated in epitopes 6 and 16 in the serum obtained from 6 soybean-sensitive patients.	Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Dept Pediat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72202 USA; Agr Res Serv, Climate Stress Lab, USDA, Beltsville, MD USA; Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; United States Department of Agriculture (USDA); Icahn School of Medicine at Mount Sinai	Helm, RM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Dept Pediat, 1120 Marshall St, Little Rock, AR 72202 USA.			Herman, Eliot/0000-0001-9398-0316	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Awazuhara H, 1997, CLIN EXP ALLERGY, V27, P325, DOI 10.1046/j.1365-2222.1997.1240800.x; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; Bruno G, 1997, PEDIAT ALLERG IMM-UK, V8, P190, DOI 10.1111/j.1399-3038.1997.tb00159.x; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; Cantani A, 1997, PEDIAT ALLERG IMM-UK, V8, P59, DOI 10.1111/j.1399-3038.1997.tb00146.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Ji C, 1998, P NATL ACAD SCI USA, V95, P3306, DOI 10.1073/pnas.95.6.3306; KALINSKI A, 1992, J BIOL CHEM, V267, P12068; KALINSKI A, 1990, J BIOL CHEM, V265, P13843; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; OGAWA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1030, DOI 10.1271/bbb.57.1030; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Samoto M, 1996, BIOSCI BIOTECH BIOCH, V60, P1911, DOI 10.1271/bbb.60.1911; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; SAMPSON HA, 1993, ALLERGY PRINCIPLES P, P1661; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vidal C, 1997, ANN ALLERG ASTHMA IM, V79, P350, DOI 10.1016/S1081-1206(10)63027-X	25	73	88	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				378	384		10.1016/S0091-6749(00)90091-5	http://dx.doi.org/10.1016/S0091-6749(00)90091-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669862				2022-12-18	WOS:000085402200026
J	von Hertzen, L; Klaukka, T; Mattila, H; Haahtela, T				von Hertzen, L; Klaukka, T; Mattila, H; Haahtela, T			Mycobacterium tuberculosis infection and the subsequent development of asthma and allergic conditions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; infection; Mycobacterium tuberculosis	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA; BCG VACCINATION; ATOPIC DISEASES; RESPONSES; INTERLEUKIN-12; ASSOCIATION; PREVALENCE; CHILDHOOD; QUESTIONS	Background: Epidemiologic studies have suggested that certain viral infections, as well as exposure to Mycobacterium tuberculosis in early Life, could, at least to some extent, prevent the subsequent development of atopic disease. Objective: We investigated whether M tuberculosis infection in childhood or adolescence has any effect on the development of asthma and allergic conditions in later Life. Methods: The study subjects (n = 1162) were individuals notified to the National Tuberculosis Registry between January I, 1966, and December 31, 1969, who were 20 years of age or younger and had verified or justifiably probable new active tuberculosis of respiratory or other organs. The control subjects were age-matched, sex-matched, and geographically matched control pairs from the Population Registry of the Social Insurance Institution in Finland, The subjects were followed for 28 to 32 years. The prevalence of persistent asthma and allergic conditions among men and women at the end of 1997 were calculated on the basis of the Drug Reimbursement Registry of the Social Insurance Institution in the whole study population and in the subgroup of subjects aged 16 years or younger at the time of M tuberculosis infection. Results: In women a significantly lower prevalence of persistent asthma was found among those aged 16 years or younger at the time of M tuberculosis infection than among the control subjects (3.7% vs 8.3%, respectively; P = .035), The women with a history of tuberculosis also showed a significantly lower prevalence of allergic conditions than the control subjects (8.3% vs 14.0%, respectively; P = .003) when the whole study population of women was considered. In men, however, the only significant difference between the cases and control subjects was found for persistent asthma, with the cases showing a significantly higher prevalence than the control subjects (4.4% and 1,8%, respectively; P = .008). Conclusion: M tuberculosis infection in childhood significantly reduced the occurrence of subsequent asthma in women. Moreover, this infection was also found to reduce the occurrence of allergic conditions in later hfe in women. By contrast, no suppressive effect of M tuberculosis infection in childhood or adolescence on the later development of asthma or allergic conditions could be observed in men. The differences in the natural history of atopic disease between the sexes and the occurrence of tuberculosis mostly in later childhood and adolescence may largely explain our findings.	Finnish Lung Hlth Assoc, Helsinki, Finland; Social Insurance Inst, Helsinki, Finland; Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Dept Allergol, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	von Hertzen, L (corresponding author), Finnish Lung Hlth Assoc, Sibeliuksenkatu 11A 1, Helsinki, Finland.							Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Andersen P, 1997, SCAND J IMMUNOL, V45, P115, DOI 10.1046/j.1365-3083.1997.d01-380.x; BARNES PF, 1989, J IMMUNOL, V142, P1114; BARNES PF, 1993, INFECT IMMUN, V61, P3482, DOI 10.1128/IAI.61.8.3482-3489.1993; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HARO S, 1988, TUBERCULOSIS RESP DI, V18; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; KALYONCU AF, 1992, ALLERGY, V47, P277, DOI 10.1111/j.1398-9995.1992.tb02053.x; Kapsenberg ML, 1998, CURR OPIN IMMUNOL, V10, P607, DOI 10.1016/S0952-7915(98)80077-0; Lee SM, 1996, BLOOD, V88, P945; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nowak D, 1998, CLIN EXP ALLERGY, V28, P1043; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; Serafini U, 1997, ALLERGY, V52, P955, DOI 10.1111/j.1398-9995.1997.tb01257.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Wang CC, 1998, IMMUNOLOGY, V93, P307; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	27	73	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1211	1214		10.1016/S0091-6749(99)70015-1	http://dx.doi.org/10.1016/S0091-6749(99)70015-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589003				2022-12-18	WOS:000084289200015
J	Barata, LT; Ying, S; Meng, Q; Barkans, J; Rajakulasingam, K; Durham, SR; Kay, AB				Barata, LT; Ying, S; Meng, Q; Barkans, J; Rajakulasingam, K; Durham, SR; Kay, AB			IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin; allergic inflammation; interleukin; mRNA; protein	MESSENGER-RNA EXPRESSION; COLONY-STIMULATING FACTOR; BLOOD EOSINOPHILS; INDUCED RHINITIS; DE-GRANULATION; NASAL-MUCOSA; INTERLEUKIN-5; RELEASE; SKIN; CYTOKINES	It has previously been shown that cells mRNA(+) for T-H2-type cytokines (IL-4 and IL-5) infiltrate the site of allergen-induced cutaneous late-phase reactions (LPR) in atopic subjects. In this study we have used the same experimental model to identify the cell source of both IL-4 and IL-5 mRNA and protein product. Allergen-induced LPRs were provoked in the skin of atopic individuals and the sites microscopically examined at 6, 24, and 48 hours. Using single in situ hybridization and immunohistochemistry, we first showed that the numbers of IL-4 and IL-5 mRNA and protein product positive cells peaked at 24 hours. This coincided with the magnitude of the LPR. By double in situ hybridization/immunohistochemistry, we then established (in 24-hour biopsy specimens) that the percentage of CD3(+) T lymphocytes, EG2(+) eosinophils, and tryptase-positive mast cells that were either IL-4 or IL-5 mRNA(+) was 19%, 24%, and 5% and 19%, 20%, and 5%, respectively. Conversely, the percentage of EG2(+) and tryptase-positive cells that were IL-4 or IL-5 protein product positive were 62% and 53% and 72% and 29%, respectively. IL-4 and IL-5 protein did not colocalize to CD3(+) cells. CD68(+) macrophages were negative in both in situ hybridization and immunohistochemistry. With eosinophils we obtained direct evidence of time-dependent stimulus-induced IL-4 and IL-5 mRNA transcription by semiquantitative reverse transcription-polymerase chain reaction of cells incubated with either IgG- or sIgA-coated particles in vitro. Taken together, these experiments suggest that eosinophils, mast cells, and T cells all contribute in variable degrees to the expression of IL-4 and IL-5 in human cutaneous LPR. The failure to colocalize IL-4/IL-5 protein (as opposed to mRNA) to CD3(+) cells is attributed to the inability of T lymphocytes to store and concentrate sufficient intracellular amounts of these cytokines to produce positive immunostaining.	Natl Heart & Lung Inst, Imperial Coll, Sch Med, London SW3 6LY, England	Imperial College London	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dovehouse St,Royal Brompton Campus, London SW3 6LY, England.			Taborda Barata, Luis/0000-0001-6649-8890	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Barata LT, 1997, EUR J IMMUNOL, V27, P1236, DOI 10.1002/eji.1830270527; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRAIG SS, 1989, LAB INVEST, V60, P147; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; IRANI AMA, 1987, J IMMUNOL, V138, P4381; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KITA H, 1992, J IMMUNOL, V149, P629; MOQBEL R, 1995, J IMMUNOL, V155, P4939; NONAKA M, 1995, J IMMUNOL, V155, P3234; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TILL S, 1995, EUR J IMMUNOL, V25, P2727, DOI 10.1002/eji.1830251002; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Ying S, 1996, EUR J IMMUNOL, V26, P70, DOI 10.1002/eji.1830260111; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Ying S, 1997, J IMMUNOL, V158, P3539	33	73	79	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				222	230		10.1016/S0091-6749(98)70387-2	http://dx.doi.org/10.1016/S0091-6749(98)70387-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500756	Bronze			2022-12-18	WOS:000072244800012
J	Chen, ZP; Cremer, R; Posch, A; RaulfHeimsoth, M; Rihs, HP; Baur, X				Chen, ZP; Cremer, R; Posch, A; RaulfHeimsoth, M; Rihs, HP; Baur, X			On the allergenicity of Hev b 1 among health care workers and patients with spina bifida allergic to natural rubber latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; Hev b 1; IgE; spina bifida; rubber elongation factor	ELONGATION-FACTOR; BRASILIENSIS; PROTEINS; IGE; HYPERSENSITIVITY; IDENTIFICATION; HEV-B-1; PREVALENCE; ANTIBODIES; CHILDREN	Background: Recent studies have caused much controversy about the prevalence of IgE antibodies to Hev b 1 among health care workers (HCWs) and patients with spina bifida (SB) who are allergic to latex. This investigation was carried out to verify the results reported. Method: Serum samples from 140 patients with SB as well as from 105 HCWs allergic to latex were tested by enzyme allergosorbest test (EAST) and EAST-inhibition assay to evaluate the rate and degree of sensitization to highly purified Hev b 1. Results: Eighty-one percent of patients with SB who were allergic to latex had IgE antibodies against Hev b 1. The prevalence of anti-Hev b 1 antibodies among HCWs allergic to latex was 52.3%. In 15 of 33 serum samples from patients with SB that were randomly tested, the IgE binding to commercial latex allergens could be completely inhibited by Hev b 1; in only six cases was the maximum inhibition of IgE binding to latex by Hev b 1 less than 50%. Testing two monoclonal anti-Hev b 1 antibodies with extracts of five brands of latex gloves revealed a predominant presence of Hev b 1 protein as a monomer or its aggregates. Molecular analysis of human leukocyte antigen-D region genes DRB and DQB1 suggested no statistically significant correlation between the human leukocyte antigen alleles tested and IgE responsiveness to Hev b 1. Conclusions: Our results indicate that Hev b 1 not only makes significant contributions to the IgE binding to latex, but it is also the unique sensitizer in about 45% of patients with SB who are allergic to latex.	CHILDRENS HOSP,COLOGNE,GERMANY		Chen, ZP (corresponding author), RUHR UNIV BOCHUM,RES INST OCCUPAT MED BGFA,DEPT ALLERGOL,BUERKLE CAMP PL 1,D-44789 BOCHUM,GERMANY.							AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; Chen Z, 1996, J ALLERGY CLIN IMMUN, V97, P982; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LU LJ, 1995, J IMMUNOL, V155, P2721; MARSH DG, 1990, GENETIC ENV FACTORS, P97; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; Muguerza J, 1996, CLIN EXP ALLERGY, V26, P1177, DOI 10.1046/j.1365-2222.1996.d01-269.x; Porri F, 1997, ANESTHESIOLOGY, V86, P599, DOI 10.1097/00000542-199703000-00011; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; RaulfHeimsoth M, 1996, J ALLERGY CLIN IMMUN, V98, P640, DOI 10.1016/S0091-6749(96)70098-2; Rihs HP, 1997, TISSUE ANTIGENS, V49, P92, DOI 10.1111/j.1399-0039.1997.tb02719.x; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; TODT JC, 1994, J ALLERGY CLIN IMMUN, V93, P283; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	25	73	74	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					684	693		10.1016/S0091-6749(97)70174-X	http://dx.doi.org/10.1016/S0091-6749(97)70174-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389300				2022-12-18	WOS:A1997YG20200017
J	Bernstein, JM; Gorfien, J; Noble, B; Yankaskas Jr				Bernstein, JM; Gorfien, J; Noble, B; Yankaskas, JR			Nasal polyposis: Immunohistochemistry and bioelectrical findings (a hypothesis for the development of nasal polyps)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; inferior turbinate; immunoglobulin; sodium channel; chloride channel; macrophage; plasma cells; colony-stimulating factors; glucocorticoids; secretory component	EPITHELIAL-CELLS; CYSTIC-FIBROSIS; ION-TRANSPORT; SINUS SURGERY; MAST-CELLS; ASTHMA; EOSINOPHILS; HISTAMINE; RHINITIS; MUCOSA	Nasal polyps and turbinates were obtained from individuals undergoing surgery for symptomatic nasal obstruction caused by nonatopic rhinosinusitis or allergic rhinosinusitis. One part of the tissue from each patient was fixed in neutral buffered formalin and prepared for study by histochemical and immunohistochemical methods. Monoclonal antibodies were used to identify macrophages, lymphocytes, and plasma cells. In most cases (12 of 16, 75%) the remainder of the polyp and turbinate samples was treated with protease to achieve disaggregation of the epithelial cells. Those cells were cultured on permeable collagen matrix supports. Transepithelial potential difference and resistance were measured daily. At the time of maximal transepithelial potential difference, the epithelial cells were mounted in modified Ussing chambers and exposed to a sodium-positive channel blocker (amiloride hydrochloride) and to selected chloride-negative channel agonists (isoproterenol bitartrate and adenosine triphosphate). Middle turbinates and polyps were found to have more macrophages, lymphocytes, plasma cells, HLA-DR-positive cells, and eosinophils than the inferior turbinates. Epithelial cells obtained from polyps exhibited higher transepithelial potential differences and equivalent short-circuit currents than turbinate cell cultures. The responses to amiloride, isoproterenol, and adenosine triphosphate were also greater for polyp than for turbinate cultures. A theory for the pathogenesis of nasal polyps is proposed. Local release of inflammatory mediators could cause sodium absorption and chloride permeability to be higher in polyps than in turbinate epithelia. Increased sodium absorption is consistent with the hypothesis that epithelial fluid absorption contributes to the development of nasal polyps and is a result of the increased recruitment of inflammatory cells, which are present in nasal polyps.	SUNY BUFFALO, DEPT OTOLARYNGOL, BUFFALO, NY USA; SUNY BUFFALO, DEPT PEDIAT, BUFFALO, NY USA; SUNY BUFFALO, DEPT COMMUN SCI & DISORDERS, BUFFALO, NY USA; SUNY COLL BUFFALO, CHILDRENS HOSP BUFFALO, DIV INFECT DIS, BUFFALO, NY 14222 USA; SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY USA; UNIV N CAROLINA, DEPT MED, DIV PULM DIS, CHAPEL HILL, NC USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; Buffalo State College; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of North Carolina; University of North Carolina Chapel Hill								ALBAZZAZ F, 1981, AM J PHYSIOL, V240, P101; BERNSTEIN JM, 1994, ARCH OTOLARYNGOL, V120, P993; BERNSTEIN JM, 1990, AM J RHINOL, V4, P45; BJERKE K, 1990, SCAND J IMMUNOL, V32, P61, DOI 10.1111/j.1365-3083.1990.tb02894.x; Brandtzaeg P., IMMUNOLOGY EAR, V1987, P63; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CAUNA N, 1972, ANN OTO RHINOL LARYN, V81, P41, DOI 10.1177/000348947208100105; COOKSON WOCM, 1989, LANCET, V1, P1292; DENBURG JA, 1991, INT ARCH ALLER A IMM, V94, P127, DOI 10.1159/000235343; Denburg JA, 1990, AM J RHINOL, V4, P29; DRAKELEE A, 1992, J LARYNGOL OTOL, V106, P1084, DOI 10.1017/S0022215100121826; DUFFY JP, 1993, J HISTOTECHNOL, V16, P143, DOI 10.1179/his.1993.16.2.143; ENGLISH GM, 1986, LARYNGOSCOPE, V96, P374; GAULDIE J, 1992, AM REV RESPIR DIS, V145, P14; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; HOLOPAINEN E, 1979, ACTA OTO-LARYNGOL, V87, P330, DOI 10.3109/00016487909126428; Jordana M, 1989, Agents Actions Suppl, V28, P85; LEIKAUF GD, 1985, AM J PHYSIOL, V248, P48; MARIN MG, 1977, J APPL PHYSIOL, V42, P735, DOI 10.1152/jappl.1977.42.5.735; MOLONEY JR, 1980, CLIN OTOLARYNGOL, V5, P183, DOI 10.1111/j.1365-2273.1980.tb01645.x; OGAWA H, 1986, ACTA OTO-LARYNGOL, P18; OHNISHI M, 1989, J ALLERGY CLIN IMMUN, V83, P1091, DOI 10.1016/0091-6749(89)90451-X; OHTOSHI T, 1991, INT ARCH ALLER A IMM, V95, P376, DOI 10.1159/000235476; RUHNO J, 1990, ALLERGY, V45, P370, DOI 10.1111/j.1398-9995.1990.tb00513.x; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; SMALL P, 1981, ANN ALLERGY, V46, P317; STOOP AE, 1992, EUR ARCH OTO-RHINO-L, V249, P313, DOI 10.1007/BF00179379; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; TACHA DE, 1994, J HISTOTECHNOL, V17, P365, DOI 10.1179/his.1994.17.4.365; TOS M, 1977, J LARYNGOL OTOL, V91, P827, DOI 10.1017/S0022215100084449; WILLUMSEN JN, 1989, AM J PHYSIOL, V256, P1033; WONG D, 1992, AM J RHINOL, V6, P195, DOI 10.2500/105065892781976637; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	34	73	85	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					165	175		10.1016/S0091-6749(97)70091-5	http://dx.doi.org/10.1016/S0091-6749(97)70091-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042040				2022-12-18	WOS:A1997WH83100003
J	Adachi, T; Motojima, S; Hirata, A; Fukuda, T; Kihara, N; Kosaku, A; Ohtake, H; Makino, S				Adachi, T; Motojima, S; Hirata, A; Fukuda, T; Kihara, N; Kosaku, A; Ohtake, H; Makino, S			Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; bronchial asthma; eosinophil; glucocorticoid; guinea pig; interleukin-5; macrolide; theophylline	BRONCHIAL EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; INVITRO SURVIVAL; IN-VITRO; T-CELLS; ASTHMA; INTERLEUKIN-5; ERYTHROMYCIN; EXPRESSION; INHIBIT	Background: Glucocorticoids have long been used as the most potent drugs in the treatment of bronchial asthma. Data reported recently have led to the proposal that theophylline and macrolides have antiinflammatory effects. Objective: We examined the abilities of theophylline, glucocorticoids, and macrolides to counteract the prolongation of eosinophil survival caused by IL-5. Methods: purified guinea pig eosinophils were cultured in the presence or absence of human IL-5 and with or without the aforementioned drugs at various concentrations. The percentage of cells alive after 3 days in culture was determined. Results: Aminophylline (AM), methylpredrisolone (MP), erythromycin (EM), and clarithromycin (CAM) suppressed the IL-5 induced prolongation of eosinophil survival in a dose-dependent manner: The effects of these drugs on eosinophil survival were significantly greater at low concentrations of IL-5 than at high concentrations of IL-5. When eosinophils were cultured in the presence of IL-5 (I ng/ml) with physiologic concentrations of MP (10(-6) mol/L), AM (10(-4) mol/L), and either EM or CAM (both 10 mu g/ml) the effect of IL-5 was almost completely abolished and the morphologic changes in eosinophils observed by electron microscopy were consistent with apoptosis. DNA extracted from eosinophils cultured with IL-5 and each of the drugs was definitely fragmented. Conclusions: One mechanism of the effectiveness of these drugs is induction of eosinophil apoptosis. Some combination of these drugs may be useful in the treatment of bronchial asthma.	DOKKYO UNIV, SCH MED, DEPT MED & CLIN IMMUNOL, MIBU, TOCHIGI 32102, JAPAN; DOKKYO UNIV, SCH MED, CLIN SCI LAB, MIBU, TOCHIGI, JAPAN; DOKKYO UNIV, SCH MED, DEPT PHYSIOL, MIBU, TOCHIGI, JAPAN; KIHARA HOSP, DEPT RESP MED, TOKYO, JAPAN	Dokkyo Medical University; Dokkyo Medical University; Dokkyo Medical University								ADACHI T, 1995, AM J RESP CRIT CARE, V151, P618; Adachi Tetsuya, 1995, Dokkyo Journal of Medical Sciences, V22, P171; BERETA M, 1994, EXP CELL RES, V212, P230, DOI 10.1006/excr.1994.1139; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ENDRES S, 1991, IMMUNOLOGY, V72, P56; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HALLSWORTH MP, 1992, IMMUNOLOGY, V75, P382; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HIRATA A, 1994, J ALLERGY CLIN IMMUN, V93, P245; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KADOTA J, 1993, AM REV RESPIR DIS, V147, P153, DOI 10.1164/ajrccm/147.1.153; KEICHO N, 1993, J ANTIBIOT, V46, P1406, DOI 10.7164/antibiotics.46.1406; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KITA H, 1991, J IMMUNOL, V146, P2712; KONNO S, 1993, LIFE SCI, V52, pPL25, DOI 10.1016/0024-3205(93)90154-U; LAGENTE V, 1994, EUR J PHARMACOL, V255, P253, DOI 10.1016/0014-2999(94)90107-4; LAMAS AM, 1991, J IMMUNOL, V147, P254; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MARY D, 1987, J IMMUNOL, V139, P1179; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MIYATAKE H, 1991, CHEST, V99, P670, DOI 10.1378/chest.99.3.670; OHTA K, 1994, J ALLERGY CLIN IMMUN, V93, P200; OISHI K, 1994, INFECT IMMUN, V62, P4145, DOI 10.1128/IAI.62.10.4145-4152.1994; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; TAKIZAWA H, 1995, BIOCHEM BIOPH RES CO, V210, P781, DOI 10.1006/bbrc.1995.1727; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; WALLEN N, 1991, J IMMUNOL, V147, P3490; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	42	73	78	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S207	S215		10.1016/S0091-6749(96)70068-4	http://dx.doi.org/10.1016/S0091-6749(96)70068-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977529	Bronze			2022-12-18	WOS:A1996WC44700006
J	Konig, P; Shaffer, J				Konig, P; Shaffer, J			The effect of drug therapy on long-term outcome of childhood asthma: A possible preview of the international guidelines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; antiinflammatory; cromolyn sodium; corticosteroids; beta-agonists; pm bronchodilators; clinical outcomes; retrospective study	NATURAL-HISTORY; FOLLOW-UP; CHILDREN; GROWTH; STATEMENT	Background: International guidelines classify childhood asthma as mild, moderate, and severe and recommend treatment with ''as needed'' bronchodilators, cromolyn sodium, and inhaled corticosteroids, respectively. Recently, some investigators proposed inhaled corticosteroids as first-line therapy to avoid possible irreversible airway obstruction. This article describes a retrospective study assessing the effect of the guidelines' approach on the long-term outcome of childhood asthma and the possible effect of delaying initiation of administration of corticosteroids. Methods: A retrospective review was performed on the charts of 175 children, and an end-of-study questionnaire plus results of spirometry completed the data. The mean age at start of study was 6.5 years, and the children were followed up for 2.2 to 16.8 years (mean, 8.4 years). Treatments included bronchodilators as needed only (patients with mild asthma), cromolyn sodium (patients with model-ate asthma) and inhaled corticosteroids (patients with severe asthma). Results: Frequency of symptoms, unscheduled doctors' visits, emergency department visits, hospitalizations, and missed school days decreased for the whole group. Statistically significant between-treatment differences favored both antiinflammatory therapies over as-needed bronchodilator treatment (cromolyn sodium: symptoms, p < 0.05; hospitalizations, p < 0.05; corticosteroids: emergency department visits, p < 0.05; hospitalizations, p < 0.05). Mean spirometry results improved, and the postbronchodilator values approached normal by study end. Assessed by treatment, spirometry decreased with bronchodilators but improved in patients treated with cromolyn sodium or inhaled corticosteroids. Delay in starting administration of cromolyn sodium had an unfavorable effect on clinical outcomes (p < 0.01) and spirometry (p < 0.05); delay in starting administration of corticosteroids did not. Conclusions: Treatment with antiinflammatory drugs (cromolyn sodium or inhaled corticosteroids), but not as-needed bronchodilators alone, improves the long-term prognosis of asthma. It is possible that starting administration of nonsteroid antiinflammatory agents earlier than the present recommendations could further improve clinical outcomes, but prospective studies are needed.	UNIV MISSOURI, HLTH SCI CTR, DEPT RESP THERAPY, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Konig, P (corresponding author), UNIV MISSOURI, HLTH SCI CTR, DIV PULM & ALLERGY, DEPT CHILD HLTH, COLUMBIA, MO 65212 USA.		König, Peter/ABB-2380-2020	König, Peter/0000-0003-3654-5267				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BROWN HM, 1973, BRIT MED J, V3, P161, DOI 10.1136/bmj.3.5872.161; CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DICKMAN ML, 1971, AM REV RESPIR DIS, V104, P680; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213, DOI 10.1001/archpedi.1968.02100010215010; KAPLAN BA, 1992, J ASTHMA, V29, P39, DOI 10.3109/02770909209110639; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KOKKONEN J, 1993, EUR RESPIR J, V6, P657; KONIG P, 1981, AM J DIS CHILD, V135, P1053; KONIG P, 1973, CLIN ALLERGY, V3, P395, DOI 10.1111/j.1365-2222.1973.tb01347.x; KONIG P, 1983, CURRENT THERAPY, P580; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; *NAT HEART LUNG BL, 1992, NIH PUBL; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; Polgar G, 1971, PULMONARY FUNCTION T; ROORDA RJ, 1993, AM REV RESPIR DIS, V148, P1490, DOI 10.1164/ajrccm/148.6_Pt_1.1490; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308, DOI 10.1152/jappl.1969.26.3.308	32	73	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1103	1111		10.1016/S0091-6749(96)80198-9	http://dx.doi.org/10.1016/S0091-6749(96)80198-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977512				2022-12-18	WOS:A1996WB37800016
J	Siler, DJ; Cornish, K; Hamilton, RG				Siler, DJ; Cornish, K; Hamilton, RG			Absence of cross-reactivity of IgE antibodies from subjects allergic to Hevea brasiliensis latex with a new source of natural rubber latex from guayule (Parthenium argentatum)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; cross-reactivity; human IgE; mouse IgG; guayule latex	PLANT SOURCES; SPINA-BIFIDA; PROTEINS; ANAPHYLAXIS; SENSITIVITY; ANTIGENS	Background: Natural rubber latex sensitization is caused by proteins from the latex of Hevea brasiliensis, the Brazilian rubber tree. Alternative non-cross-reactive latex rubber sources are needed for the manufacture of nonallergenic medical devices (e.g., catheters) that require elasticity, which is not currently provided by synthetic materials. Methods: We have studied the ability of IgE antibodies from subjects allergic to Hevea latex and IgG antibodies from hyperimmunized mice to detect proteins derived from guayule (Parthenium argentatum), an alternative rubber source, using a direct binding and competitive inhibition RAST and Western blot analysis. Results: IgE antibodies from 62 subjects allergic to Hevea latex (46 adults and 16 children with spina bifida) and om serum pools of adults allergic to Hevea latex (n = 183), pediatric patients (n = 101), and patients with spina bifida (n = 53), as well as IgG antibodies from hyperimmunized mice, were unable to detect any proteins in guayule by RAST or Western blot analysis. No competitive inhibition of IgE anti-Hevea binding to Hevea solid phase was detected by the preincubation of sera from subjects allergic to Hevea latex with soluble guayule latex before RAST analysis. Conclusions: These results demonstrate that proteins in guayule latex are not cross-reactive with Hevea latex allergens. Devices that require the elasticity provided by rubber may be manufactured with guayule latex as an alternative rubber source for patients with Hevea latex allergy.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	Johns Hopkins University	Siler, DJ (corresponding author), ARS,USDA,WESTERN REG RES CTR,800 BUCHANAN ST,ALBANY,CA 94710, USA.		Cornish, Katrina/A-9773-2013	Cornish, Katrina/0000-0002-3327-2454	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031867] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-31867] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; BER DJ, 1993, J ALLERGY CLIN IMMUN, V91, P271; Butler J.E., 1991, IMMUNOCHEMISTRY SOLI; CAREY AB, 1995, ANN ALLERG ASTHMA IM, V74, P317; CORNISH K, 1990, PHYTOCHEMISTRY, V29, P3909; CORNISH K, 1993, Patent No. 145456; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; Hamilton R. G., 1996, Journal of Allergy and Clinical Immunology, V97, P429, DOI 10.1016/S0091-6749(96)81204-8; HAMILTON RG, 1995, J LAB CLIN MED, V123, P156; HAMILTON RG, IN PRESS J ALLERGY C; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; HAMMOND BC, 1965, USDA TECHNICAL B, V1327; JONES EP, 1948, IND ENG CHEM, V40, P864, DOI 10.1021/ie50461a019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU LJ, 1995, ALLERGY, V50, P545, DOI 10.1111/j.1398-9995.1995.tb01197.x; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; SCHRANK PJ, 1993, J ALLERGY CLIN IMMUN, V91, P385; Siler D. J., 1994, Industrial Crops and Products, V2, P307, DOI 10.1016/0926-6690(94)90122-8; SILER DJ, 1995, ANAL BIOCHEM, V229, P278, DOI 10.1006/abio.1995.1413; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SRIRAMARAO P, 1993, INT ARCH ALLERGY IMM, V100, P79, DOI 10.1159/000236391; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; West JE, 1991, GUAYULE NATURAL RUBB, P17; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	29	73	75	2	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				895	902		10.1016/S0091-6749(96)80005-4	http://dx.doi.org/10.1016/S0091-6749(96)80005-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939152				2022-12-18	WOS:A1996VU76400005
J	Benard, A; Desreumeaux, P; Huglo, D; Hoorelbeke, A; Tonnel, AB; Wallaert, B				Benard, A; Desreumeaux, P; Huglo, D; Hoorelbeke, A; Tonnel, AB; Wallaert, B			Increased intestinal permeability in bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intestinal permeability; asthma; CrEDTA	INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; ATOPIC ECZEMA; CELIAC-DISEASE; CR-51 EDTA; PULMONARY; ABSORPTION	T lymphocytes are a major component of bronchial inflammatory processes in asthma. Because lymphocytes have the ability to migrate from one mucosal site to another, we initiated this prospective study to demonstrate mucosal abnormalities of the digestive barrier in asthma. To establish this we studied intestinal permeability in a group of 37 patients with asthma (21 allergic and 16 nonallergic) by measuring chromium 51-labeled ethylenediaminetetraacetatic acid (CrEDTA) urinary recovery. The results were compared with those obtained in a group of 13 nonasthmatic patients with chronic obstructive pulmonary disease and 26 healthy control subjects. Urinary recovery of CrEDTA was significantly higher in patients with asthma (2.5% +/- 1.95%) than in patients with chronic obstructive pulmonary disease (1.16% +/- 0.48%) and healthy control subjects (1.36% +/- 0.14%). There was no significant difference in intestinal permeability between patients with allergic asthma (2.94% +/- 2.4%) and those with nonallergic asthma (1.92% +/- 0.9%). Intestinal permeability was not correlated with the severity of asthma as measured by FEV(1). Similarly, intestinal permeability did not significantly vary according to Aas score or steroid treatment. Serum IgE values and eosinophil blood count were not correlated with intestinal permeability. Intestinal permeability was evaluated sequentially in seven patients with asthma (4 allergic and 3 nonallergic) with a mean interval of 7.6 months (range, 2 to 13 months) and did not significantly change. Our results support the hypothesis that a general defect of the whole mucosal system is present as a cause or a consequence of bronchial asthma.	HOP CALMETTE, SERV PNEUMOL & IMMUNOALLERGOL, F-59037 LILLE, FRANCE; INST PASTEUR, UNITE INSERM U416, F-59019 LILLE, FRANCE; HOP C HURIEZ, GASTROENTEROL SERV, LILLE, FRANCE; HOP C HURIEZ, NUCL MED SERV, LILLE, FRANCE	Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille								ADENIS A, 1992, GUT, V33, P678, DOI 10.1136/gut.33.5.678; ATHERTON DJ, 1984, BRIT J DERMATOL, V111, P34, DOI 10.1111/j.1365-2133.1984.tb05258.x; BJARNASON I, 1983, LANCET, V1, P323; BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318; BONNIERE P, 1986, GUT, V27, P919, DOI 10.1136/gut.27.8.919; CAFFARELLI C, 1993, CLIN EXP ALLERGY, V23, P28, DOI 10.1111/j.1365-2222.1993.tb02480.x; Cohen MB, 1930, J IMMUNOL, V18, P419; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; HERESBACH D, 1994, GASTROEN CLIN BIOL, V18, P638; HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003-4819-105-6-883; JACKSON PG, 1981, LANCET, V1, P1285; JENKINS RT, 1987, AM J GASTROENTEROL, V82, P1159; KNUTSON TW, 1993, J ALLERGY CLIN IMMUN, V91, P553, DOI 10.1016/0091-6749(93)90261-D; KONTOUKARAKITSOS K, 1975, J ALLERGY CLIN IMMUN, V55, P241, DOI 10.1016/0091-6749(75)90143-8; LESKOWITZ S, 1972, Clinical Allergy, V2, P237, DOI 10.1111/j.1365-2222.1972.tb01288.x; LIFSCHITZ CH, 1990, J PEDIATR GASTR NUTR, V10, P283, DOI 10.1097/00005176-199004000-00002; MARIN ML, 1983, AM J GASTROENTEROL, V78, P537; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; Mestecky J, 1978, Adv Exp Med Biol, V107, P185; PIRONI L, 1990, DIGEST DIS SCI, V35, P582, DOI 10.1007/BF01540405; RESNICK RH, 1990, DIGEST DIS SCI, V35, P205, DOI 10.1007/BF01536764; ROBERTSON DAF, 1989, DIGESTION, V42, P98, DOI 10.1159/000199832; RUDZIK R, 1975, J IMMUNOL, V114, P1599; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; UKABAM SO, 1984, BRIT J DERMATOL, V110, P649, DOI 10.1111/j.1365-2133.1984.tb04699.x; WALLAERT B, 1994, AM J RESP CRIT CARE, V150, P802, DOI 10.1164/ajrccm.150.3.8087355; WALLAERT B, 1985, CHEST, V87, P363, DOI 10.1378/chest.87.3.363; WALLAERT B, 1992, AM REV RESPIR DIS, V145, P1440, DOI 10.1164/ajrccm/145.6.1440; WALLAERT B, 1995, AM J CRIT CARE RESPI, V151, pA776; Walzer M, 1927, J IMMUNOL, V14, P143; WARD M, 1977, LANCET, V2, P903; 1985, LANCET, V2, P256	33	73	76	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1173	1178		10.1016/S0091-6749(96)70181-1	http://dx.doi.org/10.1016/S0091-6749(96)70181-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648009				2022-12-18	WOS:A1996VD60700001
J	MARKS, GB; TOVEY, ER; TOELLE, BG; WACHINGER, S; PEAT, JK; WOOLCOCK, AJ				MARKS, GB; TOVEY, ER; TOELLE, BG; WACHINGER, S; PEAT, JK; WOOLCOCK, AJ			MITE ALLERGEN (DER-P-1) CONCENTRATION IN HOUSES AND ITS RELATION TO THE PRESENCE AND SEVERITY OF ASTHMA IN A POPULATION OF SYDNEY SCHOOLCHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ALLERGENS; HOUSE DUST MITE; RISK	DUST MITES; AUSTRALIAN SCHOOLCHILDREN; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; SEASONAL-VARIATION; EXPOSURE; CHILDREN; DERMATOPHAGOIDES; PREVALENCE; ANTIGEN	House dust mite (HDM) allergen exposure and its relation to HDM allergy and asthma was assessed BE a case-control study conducted over three seasons in 74 Sydney schoolchildren, 33 of whom were allergic to HDM and 12 of whom had current asthma. In each season, histamine inhalation tests and skin prick tests were performed, symptom questionnaires were administered, and dust samples were collected. The mean concentrations of HDM allergen (in micrograms of Der p I PEI. gram of fine dust) were: bed, 38.9 (95% confidence interval [CI] 31.8 to 47.5); bedroom floor; 22.4 (95% CI, 18.3 to 27.5); nod lounge room floor; 13.7 (95% CI, 10.7 to 17.6). The mean of the highest allergen concentration in each house was 51.0 (95% CI, 43.2 to 60.1). All brit two subjects had at least one site in all seasons within HDM allergen concentration greater than 10 mu g/gm, the proposed threshold for asthma symptoms. Subjects with allergy to HDM, symptoms of asthma, or airway hyperresponsiveness did not have higher HDM allergen concentrations in their houses. In this study we were unable to test hypotheses concerning proposed thresholds for risk of sensitization and for risk of asthma symptoms because virtually all subjects were exposed to HDM allergen levels above the proposed thresholds.			MARKS, GB (corresponding author), UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA.		Marks, Guy B./F-5058-2013; Tovey, Euan R/G-8604-2017; Toelle, Brett G/B-1531-2008	Marks, Guy B./0000-0002-8976-8053; Tovey, Euan R/0000-0002-1802-7266; Toelle, Brett G/0000-0002-7375-0019				ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; FRIEDMAN M, 1975, LANCET, V1, P310; GREEN WF, 1986, AUST NZ J MED, V16, P639, DOI 10.1111/j.1445-5994.1986.tb00002.x; GREEN WF, 1983, MED J AUSTRALIA, V2, P259, DOI 10.5694/j.1326-5377.1983.tb122450.x; HADDI E, 1989, AM REV RESPIR DIS, V137, pA390; HART BJ, 1990, CLIN EXP ALLERGY, V20, P203, DOI 10.1111/j.1365-2222.1990.tb02669.x; HENDERSON AJW, 1990, ALLERGY, V45, P445, DOI 10.1111/j.1398-9995.1990.tb01095.x; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; HUSS K, 1990, Journal of Allergy and Clinical Immunology, V85, P186; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MELIA RJW, 1979, INT J EPIDEMIOL, V8, P333, DOI 10.1093/ije/8.4.333; MILLER JD, 1989, J ALLERGY CLIN IMMUN, V83, P262; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NASBITZ C, 1990, J ALLERGY CLIN IMM S, V85, P183; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338, DOI 10.1164/ajrccm/144.2.338; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPIEKSMA FTM, 1976, ALLERGOL IMMUNOPATH, V4, P419; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; TOVEY ER, 1975, MED J AUSTRALIA, V2, P770, DOI 10.5694/j.1326-5377.1975.tb106278.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1988, METEROLOGICAL SUMMAR	42	73	76	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					441	448		10.1016/S0091-6749(95)70285-7	http://dx.doi.org/10.1016/S0091-6749(95)70285-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560653				2022-12-18	WOS:A1995TA09500002
J	TAITEL, MS; KOTSES, H; BERNSTEIN, IL; BERNSTEIN, DI; CREER, TL				TAITEL, MS; KOTSES, H; BERNSTEIN, IL; BERNSTEIN, DI; CREER, TL			A SELF-MANAGEMENT PROGRAM FOR ADULT ASTHMA .2. COST-BENEFIT-ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADULT ASTHMA; COST-BENEFIT ANALYSIS; COST-EFFECTIVENESS; DIRECT COSTS; INDIRECT COSTS; SELF-MANAGEMENT	HEALTH-EDUCATION	Background: We performed a cost-benefit analysis of a previously described self-management program for adult asthma. Methods: Direct and indirect cost data from 37 subjects Mho participated in the selfmanagement program were analyzed. In particular, costs incurred by the subjects 1 year before participation were compared with costs incurred 1 year after participation. Results: The cost-benefit analysis indicated that tire program was beneficial, reducing the cost of asthma to each patient by $475.29. The benefit came primarily from reductions in hospital admissions (reduced fron $18,488 to $1538) and income lost as a result of asthma (reduced from $11,593 to $4589). The asthma self-management program cost $208.33 per patient. Comparison of the program cost with the program benefit produced a 1:2.28 cost-benefit ratio, demonstrating that the program more than paid for itself. Conclusion: A self-managenment program for adult asthma effectively reduced the cost associated with asthma. The findings are especially salient because the subjects' asthma was generally tinder good medical control when they participated in the program. The savings were therefore nor the result of improved medical treatment; medical treatment was a controlled parameter, nor a variable, in the self-management study. The self-management program for adult asthma was cost-beneficial.	OHIO UNIV,DEPT PSYCHOL,ATHENS,OH 45701; CTR ALLERGY & ASTHMA,CINCINNATI,OH	Ohio University			Taitel, Michael/AAR-5837-2021	Taitel, Michael/0000-0002-3582-4451	NHLBI NIH HHS [HL 32538] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032538] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; DETER HC, 1986, J PSYCHOSOM RES, V30, P173, DOI 10.1016/0022-3999(86)90047-4; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; MARION RJ, 1985, ANN ALLERGY, V54, P31; Warner KE, 1982, COST BENEFIT COST EF; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; WINDSOR RA, 1990, AM J PUBLIC HEALTH, V80, P1519, DOI 10.2105/AJPH.80.12.1519; 1989, DATA FACT SHEET ASTH; 1990, WORLD CURRENCY MONIT	11	73	75	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					672	676		10.1016/S0091-6749(95)70171-0	http://dx.doi.org/10.1016/S0091-6749(95)70171-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	QM017	7897149				2022-12-18	WOS:A1995QM01700006
J	KEITH, PK; CONWAY, M; EVANS, S; WONG, DA; JORDANA, G; PENGELLY, D; DOLOVICH, J				KEITH, PK; CONWAY, M; EVANS, S; WONG, DA; JORDANA, G; PENGELLY, D; DOLOVICH, J			NASAL POLYPS - EFFECTS OF SEASONAL ALLERGEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NASAL POLYPS; RAGWEED; EOSINOPHIL; EOSINOPHIL CATIONIC PROTEIN; ALBUMIN	EOSINOPHIL CATIONIC PROTEIN; MAST-CELLS; LYMPHOCYTES; SECRETIONS; HISTAMINE; RHINITIS; MUCOSA	Nasal polyps are characterized by chronic eosinophilic inflammation and often coexist with rhinitis and asthma. Many patients with polyps have no detectable allergy, and it is considered that allergy, at least in many cases, is not relevant to polyp pathogenesis. To explore the association of nasal polyps with allergy, 16 patients with polyps and ragweed allergy (PRW+) and 16 patients with polyps who were not allergic to ragweed (PRW-) were compared with patients without polyps, 16 who were allergic to ragweed (NPRW+) and 16 who were not allergic to ragweed (NPRW-), before and during the ragweed season. The level of ragweed allergy was comparable in the PRW+ and NPRW+ populations as determined by ragweed skin test wheal diameter, ragweed IgE RAST percent binding, and total serum IgE. Symptom scores before the ragweed season recorded on visual analog scales for the symptoms of blockage, sneezing, decreased smell, itch, postnasal drip, and runny nose were high in patients in the PRW+ and PRW- groups and did not change during ragweed season. Mean symptom scores were low in the NPRW+ group before ragweed season and increased during the season to levels similar to those of patients in the PRW+ and PRW- groups. Preseason nasal lavage albumin concentration was higher in subjects with polyps than those without polyps (58.5, 98) versus (13.6, 15 mug/ml) (p = 0.02) and did not change significantly in any group with seasonal exposure. Data are presented as mean, 1 SD; comparisons are made with unpaired t tests. The preseason percent eosinophils in the nasal irrigation fluid was higher in the subjects with polyps than in subjects without polyps (18, 25) versus (0.9, 2%), (p = 0.0002) and changed little for patients in the PRW+ group during ragweed season. In the NPRW+ group the percent eosinophils increased greatly from low preseason counts, (comparison made with paired t test) (2.2%) to 28, 33% (p = 0.02), the latter comparable to those of subjects with polyps. The nasal lavage eosinophil cationic protein concentration out of season was higher in subjects with polyps than in those without polyps (9.7, 10) versus (1.4, 1.0) (p = 0. 0001) and did not change in subjects with polyps during seasonal exposure. Nasal resistance was measured by head-out body plethysmography. It was slightly higher in subjects with polyps than in those without polyps out of season. In conclusion, highly ragweed-allergic patients with polyps had symptoms and elevated markers of nasal mucosal inflammation (percent eosinophils and eosinophil cationic protein and albumin concentrations) out of season, and these did not increase in relation to natural seasonal allergen exposure. Ragweed allergic subjects with no polyps had large seasonal increases in symptoms and nasal irrigation fluid percent eosinophils. We conclude that ongoing conditions, perhaps nasal airway mucosal inflammation, in nasal polyposis may lead to a loss of susceptibility to potential additional effects of inhaled allergen.	MCMASTER UNIV,DEPT MED,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT PAEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT ENGN,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University			Wong, Dennis A/AAH-2958-2020					AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; CAPLIN I., 1971, ANN ALLERGY, V29, P63; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DOLOVICH J, 1990, RHINITIS ASTHMA SIMI, P233; Drake-Lee AS, 1989, RHINITIS MECH MANAGE, P141; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FINOTTO S, IN PRESS CLIN EXP IM; KANAI M, IN PRESS AM J RESPIR; KEITH PK, 1992, ANN ALLERGY, V68, P90; KERN RA, 1933, J ALLERGY, V4, P485; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NIINIMAA V, 1979, J APPL PHYSIOL, V47, P1336, DOI 10.1152/jappl.1979.47.6.1336; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; POWELL KR, 1977, J INFECT DIS, V136, P109, DOI 10.1093/infdis/136.1.109; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RUHNO J, 1990, ALLERGY, V45, P370, DOI 10.1111/j.1398-9995.1990.tb00513.x; SETTIPANE G, 1977, J ALLERGY CLIN IMMUN, V58, P17; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; SMALL P, 1985, ANN ALLERGY, V55, P736; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x; WONG D, 1992, J RHINOL, V6, P195	27	73	74	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					567	574		10.1016/S0091-6749(94)70068-0	http://dx.doi.org/10.1016/S0091-6749(94)70068-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151059	Bronze			2022-12-18	WOS:A1994ND14000003
J	KAMADA, AK; HILL, MR; IKLE, DN; BRENNER, AM; SZEFLER, SJ				KAMADA, AK; HILL, MR; IKLE, DN; BRENNER, AM; SZEFLER, SJ			EFFICACY AND SAFETY OF LOW-DOSE TROLEANDOMYCIN THERAPY IN CHILDREN WITH SEVERE, STEROID-REQUIRING ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALTERNATIVE THERAPY; ASTHMA; GLUCOCORTICOIDS; METHYLPREDNISOLONE; PREDNISONE; PREDNISOLONE; STEROID-SPARING; TROLEANDOMYCIN	DEPENDENT ASTHMA; METHYLPREDNISOLONE ELIMINATION; TAO	Background: Troleandomycin (TAO), a macrolide antibiotic, was studied as an alternative treatment in 18 children with severe, steroid-requiring asthma. Methods: In this investigation three treatment arms were used in randomized, double-blind, parallel fashion: combination TAO and methylprednisolone (MPn), combination TAO and prednisone, and MPn alone. Results: All groups tolerated a considerable reduction in glucocorticoid dose over the 12 weeks of the study: 80% +/- 6% for TAO-MPn, 55% +/- 8% for TAO-prednisone, and 44% +/- 14% for MPn alone. These reductions are all statistically significant (p < 0.05) within groups, and the differences between groups were statistically significant between the TAO-MPn and MPn alone groups. The concentration of methacholine required to induce a 20% decrease in forced expiratory volume in 1 second and pulmonary function were not significantly improved in any treatment group. Safety parameters including blood chemistry and hematology, adrenal function assessment, bone densitometry, and muscle strength testing, were not altered significantly. Two patients who received TAO had elevated liver enzyme levels; one required discontinuation of TAO and one experienced spontaneous resolution without intervention. Lack of statistically significant changes in the efficacy parameters were likely a result of small sample size and effects of the glucocorticoid dose taper. Conclusions: TAO is safe and may be a reasonable treatment alternative in a limited trial for patients who are unable to tolerate tapering of their glucocorticoid dosage. Therapy should be guided by the goal of treatment, that is, glucocorticoid dose reduction or improvement of pulmonary function with appropriate monitoring of pulmonary function and adverse effects.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST K-926,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV CLIN PHARMACOL,NEIMARK LAB CLIN PHARMACOL PEDIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV ALLERGY & IMMUNOL,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV BIOSTAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DIV CLIN PEDIAT,DENVER,CO 80206	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health			Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246	FDA HHS [FD-R 000278] Funding Source: Medline	FDA HHS		ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; BALL BD, 1990, ANN ALLERGY, V65, P37; EITCHES RW, 1985, AM J DIS CHILD, V139, P264, DOI 10.1001/archpedi.1985.02140050058022; FOX JL, 1961, PENN MED J, V64, P634; GREOS L S, 1990, Journal of Allergy and Clinical Immunology, V85, P195; GREOS LS, 1991, AM REV RESPIR DIS, V144, P586, DOI 10.1164/ajrccm/144.3_Pt_1.586; GREOS LS, 1990, AM REV RESPIR DIS, V141, P933; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KAMADA AK, 1992, PHARMACOTHERAPY, V12, P98; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; ROSENBERG SM, 1991, CHEST, V100, P849, DOI 10.1378/chest.100.3.849; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; SZEFLER SJ, 1982, J ALLERGY CLIN IMMUN, V69, P455, DOI 10.1016/0091-6749(82)90121-X; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V87, P867; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2; 1987, AM REV RESPIR DIS, V136, P225	23	73	74	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					873	882		10.1016/0091-6749(93)90345-G	http://dx.doi.org/10.1016/0091-6749(93)90345-G			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473676				2022-12-18	WOS:A1993KY25100008
J	DEROM, EY; PAUWELS, RA; VANDERSTRAETEN, MEF				DEROM, EY; PAUWELS, RA; VANDERSTRAETEN, MEF			THE EFFECT OF INHALED SALMETEROL ON METHACHOLINE RESPONSIVENESS IN SUBJECTS WITH ASTHMA UP TO 12 HOURS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SALMETEROL; BRONCHODILATION; SYMPATHOMIMETICS; AEROSOL; SALBUTAMOL; ASTHMA; METHACHOLINE CHALLENGE; PROTECTIVE EFFECT	BRONCHIAL RESPONSIVENESS; HISTAMINE; AGONIST; SALBUTAMOL	The duration of the protective effect of 50 and 100-mu-g of inhaled salmeterol against methacholine-induced bronchoconstriction was compared with that of 200-mu-g of inhaled salbutamol in 12 patients with asthma with a baseline FEV1 of at least 70% and a provocative concentration of inhaled methacholine causing a 20% fall in FEV1 (PC20) greater-than-or-equal-to 8 mg/ml. The study was placebo controlled, double blind, randomized, and crossover. The bronchodilating effect was no longer significant 4 hours after inhalation of salbutamol, whereas the effect was still present 12 hours after administration of 50 and 100-mu-g of salmeterol. All active treatments caused PC20 to increase at 1 hour (p < 0.05). PC20 (milligrams per milliliter) thus reached 3.7 +/- 0.8 after placebo, 13.8 +/- 3.0 after 50-mu-g of salmeterol, 23.2 +/- 4.7 after 100-mu-g of salmeterol, and 13.9 +/- 3.4 after 200-mu-g of salbutamol. The protective effect of 200-mu-g of salbutamol was no longer significant at 4 hours, whereas both doses of salmeterol protected against methacholine challenge up to 12 hours after inhalation (p < 0.01). An increased incidence of tremor (2/12) and palpitations (2/12) was recorded after inhalation of 100-mu-g of salmeterol. We conclude that inhalation of 50 or 100-mu-g of salmeterol causes a long-lasting bronchodilatation and protects against methacholine-induced bronchoconstriction for at least 12 hours.			DEROM, EY (corresponding author), STATE UNIV GHENT HOSP,DEPT RESP DIS,DE PINTELAAN 185,B-9000 GHENT,BELGIUM.							AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; AHRENS RC, 1987, CHEST, V92, pS15; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BECKER AB, 1989, J ALLERGY CLIN IMMUN, V84, P891, DOI 10.1016/0091-6749(89)90385-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; OBRYNE PM, 1982, AM REV RESPIR DIS, V125, P281; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; TWENTYMAN OP, 1990, AM REV RESPIR DIS, V336, P1338; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674	17	73	73	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					811	815		10.1016/0091-6749(92)90435-5	http://dx.doi.org/10.1016/0091-6749(92)90435-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1560164				2022-12-18	WOS:A1992HN86000005
J	LOSADA, E; HINOJOSA, M; QUIRCE, S; SANCHEZCANO, M; MONEO, I				LOSADA, E; HINOJOSA, M; QUIRCE, S; SANCHEZCANO, M; MONEO, I			OCCUPATIONAL ASTHMA CAUSED BY ALPHA-AMYLASE INHALATION - CLINICAL AND IMMUNOLOGICAL FINDINGS AND BRONCHIAL RESPONSE PATTERNS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALPHA-AMYLASE; ASPERGILLUS-ORYZAE; ENZYMES; BRONCHIAL PROVOCATION TEST; OCCUPATIONAL ASTHMA	REVERSE ENZYME-IMMUNOASSAY; RAST	Inhalation of dust from different enzymes can be the cause of occupational asthma in exposed workers. Alpha-Amylase, derived from Aspergillus oryzae, is one of these enzymes, although there are few studies in the medical literature that refer to its allergologic properties and to clinical studies in sensitized patients. The results obtained in a study performed in 83 pharmaceutical-industry workers exposed to powdered alpha-amylase are described in this article. The existence of sensitization to this enzyme was demonstrated in 26 of the workers by positive skin tests. Specific IgE values were significantly higher in workers with positive skin tests than in workers with negative skin tests (p < 0.001). The bronchial provocation test with alpha-amylase was positive in six of the 14 patients challenged, and only immediate bronchial responses were observed; the same type of response was obtained by nasal provocation. One of the workers had a positive response to oral provocation with this enzyme, presenting abdominal, skin, and respiratory symptoms a few minutes after ingestion. Consequently, we consider that the bronchial asthma presented by the workers was due to an immediate-type, IgE-dependent, immunologic mechanism.	HOSP RAMON & CAJAL,DEPT IMMUNOL,MADRID,SPAIN	Hospital Universitario Ramon y Cajal	LOSADA, E (corresponding author), HOSP RAMON & CAJAL,SERV ALERGIA,DEPT ALLERGY,CTRA COLMENAR KM 9-1,E-28034 MADRID,SPAIN.		s, q/AAD-7171-2020					BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BAUR X, 1986, LANCET, V1, P43; BIRNBAUM J, 1988, REV MAL RESPIR, V5, P519; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; DOMINGUEZ J, 1984, ALLERGY, V39, P529, DOI 10.1111/j.1398-9995.1984.tb00874.x; FLINDT MLH, 1979, LANCET, P1407; GALLEGUILLOS F, 1978, CLIN ALLERGY, V8, P21, DOI 10.1111/j.1365-2222.1978.tb00443.x; GOMEZ MLD, 1986, B EUR PHYSIOPATHO S8, V22, P117; HARTMANN AL, 1983, SCHWEIZ MED WSCHR, V113, P265; HINOJOSA M, 1984, J ALLERGY CLIN IMMUN, V77, P782; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; LOSADA E, 1985, P EUROPEAN ACADEMY A, P159; LOSADA E, 1986, REV ESP ALERGOL IMMU, V1, P29; MONEO I, 1983, INT ARCH ALLER A IMM, V71, P285, DOI 10.1159/000233406; PAWELS R, 1978, LANCET, V1, P1669; PEPYS J, 1969, LANCET, V1, P1181; WIESSMANN KJ, 1985, EUR J RESPIR DIS, V66, P13; ZWEIMAN B, 1966, J ALLERGY, V39, P11	19	73	74	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				118	125		10.1016/S0091-6749(05)80048-X	http://dx.doi.org/10.1016/S0091-6749(05)80048-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730831				2022-12-18	WOS:A1992GZ90800014
J	BASCOM, R; PIPKORN, U; PROUD, D; DUNNETTE, S; GLEICH, GJ; LICHTENSTEIN, LM; NACLERIO, RM				BASCOM, R; PIPKORN, U; PROUD, D; DUNNETTE, S; GLEICH, GJ; LICHTENSTEIN, LM; NACLERIO, RM			MAJOR BASIC-PROTEIN AND EOSINOPHIL-DERIVED NEUROTOXIN CONCENTRATIONS IN NASAL-LAVAGE FLUID AFTER ANTIGEN CHALLENGE - EFFECT OF SYSTEMIC CORTICOSTEROIDS AND RELATIONSHIP TO EOSINOPHIL INFLUX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED,DEPT MED,DIV CLIN IMMUNOL, PROFESSIONAL OFF BLDG,SUITE 402, BALTIMORE, MD 21239 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA; MAYO CLIN & MAYO FDN, SCH MED, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, SCH MED, DEPT MED, ROCHESTER, MN 55905 USA	Johns Hopkins University; Johns Hopkins University; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004866, R01AI008270, R37AI004866, R37AI008270, P50AI020136] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20136, AI 04866, AI 08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BORGEAT P, 1984, J ALLERGY CLIN IMMUN, V74, P310, DOI 10.1016/0091-6749(84)90122-2; CAPRON A, 1983, 12TH P C EUR AC ALL, P17; CAPRON M, 1981, J IMMUNOL, V126, P1764; CAPRON M, 1984, J IMMUNOL, V132, P462; CAPRON M, 1981, J IMMUNOL, V126, P2087; CAPRON M, 1985, INT ARCH ALLER A IMM, V77, P246, DOI 10.1159/000233801; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GLEICH GJ, 1987, J ALLERGY CLIN IMMUN, V80, P412, DOI 10.1016/0091-6749(87)90063-7; HOGG JC, 1984, CURRENT CLIN PRACTIC, V25, P3; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KAY AB, 1984, IMMUNOLOGY LUNG UPPE, P139; LEE TC, 1984, J BIOL CHEM, V259, P5526; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MATTSON DE, 1981, STATISTICS, P349; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OWEN WF, 1987, J IMMUNOL, V138, P532; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1983, J ALLERGY CLIN IMMUN, V72, P657, DOI 10.1016/0091-6749(83)90625-5; PELIKAN Z, 1986, ANN ALLERGY, V56, P414; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	48	73	78	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					338	346		10.1016/0091-6749(89)90418-1	http://dx.doi.org/10.1016/0091-6749(89)90418-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778240				2022-12-18	WOS:A1989AR19900011
J	KING, TP; JOSLYN, A; KOCHOUMIAN, L				KING, TP; JOSLYN, A; KOCHOUMIAN, L			ANTIGENIC CROSS-REACTIVITY OF VENOM PROTEINS FROM HORNETS, WASPS, AND YELLOW JACKETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KING, TP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI 17021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKRE RD, 1980, AGR HDB USDA, V552; COOPER HM, 1984, MOL IMMUNOL, V21, P479, DOI 10.1016/0161-5890(84)90063-4; GADDE J, 1984, Journal of Allergy and Clinical Immunology, V73, P159; GIALLONGO A, 1982, J IMMUNOL METHODS, V52, P379, DOI 10.1016/0022-1759(82)90009-6; GOLDEN DBK, 1981, 37TH P ANN M AM AC A, P57; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1982, ANN ALLERGY, V48, P82; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; Meyer K., 1971, ENZYMES, V5, P307; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISSIG JL, 1955, J BIOL CHEM, V217, P959; TUNG AS, 1976, J IMMUNOL, V116, P676; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0	23	73	74	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					621	628		10.1016/0091-6749(85)90040-5	http://dx.doi.org/10.1016/0091-6749(85)90040-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989148	Bronze			2022-12-18	WOS:A1985AHV0700014
J	DAJANI, BM; SLIMAN, NA; SHUBAIR, KS; HAMZEH, YS				DAJANI, BM; SLIMAN, NA; SHUBAIR, KS; HAMZEH, YS			BRONCHOSPASM CAUSED BY INTRAVENOUS HYDROCORTISONE SODIUM SUCCINATE (SOLU-CORTEF) IN ASPIRIN-SENSITIVE ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JORDAN UNIV HOSP, DEPT INTERNAL MED, AMMAN, JORDAN	University of Jordan								COMAISH S, 1969, BRIT J DERMATOL, V81, P919, DOI 10.1111/j.1365-2133.1969.tb15974.x; HAYHURST M, 1978, S AFR MED J, V53, P259; KING RA, 1960, LANCET, V2, P1093; KOUNIS NG, 1976, ANN ALLERGY, V36, P203; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; OGARRA JA, 1962, BMJ-BRIT MED J, P615, DOI 10.1136/bmj.1.5278.615; PARTRIDGE MR, 1978, BRIT MED J, V1, P1521, DOI 10.1136/bmj.1.6126.1521; Sunaga Y, 1978, Nihon Kyobu Shikkan Gakkai Zasshi, V16, P793	8	73	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					201	204		10.1016/0091-6749(81)90184-6	http://dx.doi.org/10.1016/0091-6749(81)90184-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7264102	Bronze			2022-12-18	WOS:A1981MG54400006
J	HARVEY, RP; WEGS, J; SCHOCKET, AL				HARVEY, RP; WEGS, J; SCHOCKET, AL			A CONTROLLED TRIAL OF THERAPY IN CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV CLIN IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIAID NIH HHS [AI 12028, AI 07166] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COHEN SH, 1980, J ALLERGY CLIN IMMUN, V65, P189; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; KENNES B, 1977, CLIN ALLERGY, V7, P35, DOI 10.1111/j.1365-2222.1977.tb01422.x; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; WARIN RP, 1974, URTICARIA, P33	8	73	73	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					262	266		10.1016/0091-6749(81)90149-4	http://dx.doi.org/10.1016/0091-6749(81)90149-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6116728	Bronze			2022-12-18	WOS:A1981ML52500003
J	MARSH, DG; NORMAN, PS; ROEBBER, M; LICHTENSTEIN, LM				MARSH, DG; NORMAN, PS; ROEBBER, M; LICHTENSTEIN, LM			STUDIES ON ALLERGOIDS FROM NATURALLY-OCCURRING ALLERGENS .3. PREPARATION OF RAGWEED POLLEN ALLERGOIDS BY ALDEHYDE MODIFICATION IN 2 STEPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOWARD HUGHES MED INST,BALTIMORE,MD	Howard Hughes Medical Institute	MARSH, DG (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI 08270, AI 09565, AI 10304] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; CHASE MW, 1967, PREPARATION IMMUNOGE, P197; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P197, DOI 10.1016/0091-6749(72)90083-8; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; LOWENSTEIN H, 1981, J IMMUNOL, V126, P2501; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DT, UNPUBLISHED; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MORAN DM, 1976, INT ARCH ALLER A IMM, V50, P693, DOI 10.1159/000231548; MORAN DM, 1977, INT ARCH ALLER A IMM, V54, P315, DOI 10.1159/000231843; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PLATTSMILLS TAE, 1980, J ALLERGY CLIN IMMUN, V65, P406; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577	27	73	75	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					449	459		10.1016/0091-6749(81)90199-8	http://dx.doi.org/10.1016/0091-6749(81)90199-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	6171586				2022-12-18	WOS:A1981MU79000008
J	MCINTOSH, K				MCINTOSH, K			BRONCHIOLITIS AND ASTHMA - POSSIBLE COMMON PATHOGENETIC PATHWAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO, MED CTR, DEPT PEDIAT, DENVER, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHERNE W, 1970, J CLIN PATHOL, V23, P7, DOI 10.1136/jcp.23.1.7; BEEM M, 1967, J IMMUNOL, V98, P1115; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; CONNOLLY JH, 1969, ACTA PAEDIATR SCAND, V58, P116, DOI 10.1111/j.1651-2227.1969.tb04693.x; DABBOUS IA, 1966, PEDIATRICS, V37, P477; DISNEY M E, 1971, Clinical Allergy, V1, P399, DOI 10.1111/j.1365-2222.1971.tb00791.x; FOUCARD T, 1971, ACTA PAEDIATR SCAND, V60, P621, DOI 10.1111/j.1651-2227.1971.tb07001.x; FREEMAN GL, 1962, AM J DIS CHILD, V104, P330, DOI 10.1001/archpedi.1962.02080030332002; FREEMAN GL, 1966, CLIN PEDIATR, V5, P586, DOI 10.1177/000992286600501004; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; GARDNER PS, 1970, BMJ-BRIT MED J, V1, P327, DOI 10.1136/bmj.1.5692.327; HAMPTON SF, 1963, J ALLERGY, V34, P63, DOI 10.1016/0021-8707(63)90086-8; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; HOORN B, 1965, BRIT J EXP PATHOL, V46, P109; HORN MEC, 1973, CHEST              S, V63, P44; HUHTI E, 1974, ANN ALLERGY, V33, P145; JACOBS JW, 1971, LANCET, V1, P871; Kapakian AZ., 1968, PERSPECT VIROL, V6, P125; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; KNIGHT V, 1973, VIRAL MYCOPLASMAL IN; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCINTOSH K, 1974, PEDIATR RES, V8, P689, DOI 10.1203/00006450-197407000-00001; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; NELIGAN GA, 1970, BMJ-BRIT MED J, V3, P146, DOI 10.1136/bmj.3.5715.146; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; PHELAN PD, 1969, PEDIATRICS, V44, P493; POLMAR SH, 1972, PEDIATRICS, V50, P279; REED SE, 1972, INFECT IMMUN, V6, P68, DOI 10.1128/IAI.6.1.68-76.1972; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SCOTT R, 1974, J HYG-CAMBRIDGE, V72, P111, DOI 10.1017/S0022172400023275; SNYDER RD, 1970, ANN ALLERGY, V28, P307; STAANA P, 1970, P SOC EXP BIOL MED, V134, P499; TYRRELL DAJ, 1965, BRIT J EXP PATHOL, V46, P514	36	73	73	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					595	604		10.1016/0091-6749(76)90011-7	http://dx.doi.org/10.1016/0091-6749(76)90011-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	180072	Bronze, Green Published			2022-12-18	WOS:A1976BV05400011
J	Lee, MJ; Kang, MJ; Lee, SY; Lee, E; Kim, K; Won, S; Suh, DI; Kim, KW; Sheen, YH; Ahn, K; Kim, BS; Hong, SJ				Lee, Min-Jung; Kang, Mi-Jin; Lee, So-Yeon; Lee, Eun; Kim, Kangjin; Won, Sungho; Suh, Dong In; Kim, Kyung Won; Sheen, Youn Ho; Ahn, Kangmo; Kim, Bong-Soo; Hong, Soo-Jong			Perturbations of gut microbiome genes in infants with atopic dermatitis according to feeding type	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; infant; gut; microbiome; immune	EARLY-LIFE; INTESTINAL MICROBIOTA; METABOLISM; AGE; INFLAMMATION; CHILDHOOD; RECEPTORS; DIVERSITY; COMMUNITY; BACTERIA	Background: Perturbations of the infant gut microbiota can shape development of the immune system and link to the risk of allergic diseases. Objective: We sought to understand the role of the gutmicrobiome in patients with atopic dermatitis (AD). The metagenome of the infant gut microbiome was analyzed according to feeding types. Methods: Composition of the gut microbiota was analyzed in fecal samples from 129 infants (6 months old) by using pyrosequencing, including 66 healthy infants and 63 infants with AD. The functional profile of the gut microbiome was analyzed by means of whole-metagenome sequencing (20 control subjects and 20 patients with AD). In addition, the total number of bacteria in the feces was determined by using real-time PCR. Results: The gut microbiome of 6-month-old infants was different based on feeding types, and 2 microbiota groups (Bifidobacterium species-dominated and Escherichia/Veillonella species-dominated groups) were found in breast-fed and mixed-fed infants. Bacterial cell amounts in the feces were lower in infants with AD than in control infants. Although no specific taxa directly correlated with AD in 16S rRNA gene results, whole-metagenome analysis revealed differences in functional genes related to immune development. The reduction in genes for oxidative phosphorylation, phosphatidylinositol 3-kinase-Akt signaling, estrogen signaling, nucleotide-binding domain-like receptor signaling, and antigen processing and presentation induced by reduced colonization of mucin-degrading bacteria (Akkermansia muciniphila, Ruminococcus gnavus, and Lachnospiraceae bacterium 2_1_58FAA) was significantly associated with stunted immune development in the AD group compared with the control group (P < .05). Conclusions: Alterations in the gut microbiome can be associated with AD because of different bacterial genes that can modulate host immune cell function.	[Lee, Min-Jung; Kim, Bong-Soo] Hallym Univ, Dept Life Sci, Multidisciplinary Genome Inst, Chunchon 24252, Gangwon Do, South Korea; [Kang, Mi-Jin] Hallym Univ, Environm Hlth Ctr, Childhood Asthma Atopy Ctr, Asan Inst Life Sci, Chunchon, South Korea; [Lee, So-Yeon; Hong, Soo-Jong] Univ Ulsan, Coll Med, Childhood Asthma Atopy Ctr, Environm Hlth Ctr,Dept Pediat, Seoul, South Korea; [Lee, Eun] Chonnam Natl Univ Hosp, Dept Pediat, Gwangju, South Korea; [Kim, Kangjin; Won, Sungho] Seoul Natl Univ, Dept Publ Hlth Sci, Seoul, South Korea; [Won, Sungho] Seoul Natl Univ, Inst Hlth & Environm, Seoul, South Korea; [Suh, Dong In] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Kim, Kyung Won] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Sheen, Youn Ho] CHA Univ, Coll Med, Dept Pediat, CHA Gangnam Med Ctr, Seoul, South Korea; [Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Dept Pediat, Environm Hlth Ctr Atop Dis,Samsung Med Ctr, Seoul, South Korea	Hallym University; Hallym University; University of Ulsan; Chonnam National University; Chonnam National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University Health System; Pochon Cha University; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, BS (corresponding author), Hallym Univ, Dept Life Sci, Multidisciplinary Genome Inst, Chunchon 24252, Gangwon Do, South Korea.; Hong, SJ (corresponding author), Univ Ulsan, Coll Med, Childhood Asthma Atopy Ctr, Dept Pediat,Environm Hlth Ctr,Asan Med Ctr, Seoul 05505, South Korea.	bkim79@hallym.ac.kr; sjhong@amc.seoul.kr	Ahn, Kangmo/F-4609-2014; Hong, Soo-Jong/AAR-1788-2020	Hong, Soo-Jong/0000-0003-1409-2113; Kim, Kyung Won/0000-0003-4529-6135; Kim, Kangjin/0000-0002-3966-3309; Suh, Dong In/0000-0002-7817-8728	National Research Foundation of Korea (NRF) - Ministry of Science, Communications Technology (ICT), and Future Planning [NRF-2014R1A2A1A10050687]	National Research Foundation of Korea (NRF) - Ministry of Science, Communications Technology (ICT), and Future Planning	Supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, Communications Technology (ICT), and Future Planning (NRF-2014R1A2A1A10050687).	Abella V, 2017, NAT REV RHEUMATOL, V13, P100, DOI 10.1038/nrrheum.2016.209; Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Ali MS, 2015, J CLIN EPIDEMIOL, V68, P122, DOI 10.1016/j.jclinepi.2014.08.011; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; [Anonymous], 2013, DIVERSITY-BASEL, DOI DOI 10.3390/d5030627; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Candela M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-95; Chen CC, 2016, PEDIAT ALLERG IMM-UK, V27, P254, DOI 10.1111/pai.12522; Chiu T, 2005, AM J PHYSIOL-GASTR L, V288, pG182, DOI 10.1152/ajpgi.00200.2004; Derrien M, 2004, INT J SYST EVOL MICR, V54, P1469, DOI 10.1099/ijs.0.02873-0; Dominguez-Bello MG, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad2741; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Goodman WA, 2014, MUCOSAL IMMUNOL, V7, P1255, DOI 10.1038/mi.2014.15; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Jeon YS, 2013, CURR MICROBIOL, V67, P557, DOI 10.1007/s00284-013-0401-y; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Koren O, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002863; Koropatkin NM, 2012, NAT REV MICROBIOL, V10, P323, DOI 10.1038/nrmicro2746; Lee E, 2016, ANN ALLERG ASTHMA IM, V117, P91, DOI 10.1016/j.anai.2016.04.019; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009-0026; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Mueller NT, 2015, TRENDS MOL MED, V21, P109, DOI 10.1016/j.molmed.2014.12.002; Nylund L, 2015, ALLERGY, V70, P241, DOI 10.1111/all.12549; Parlato M, 2014, INT J MOL SCI, V15, P9594, DOI 10.3390/ijms15069594; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281; Ridlon JM, 2014, CURR OPIN GASTROEN, V30, P332, DOI 10.1097/MOG.0000000000000057; Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139; Song H, 2016, J ALLERGY CLIN IMMUN, V137, P852, DOI 10.1016/j.jaci.2015.08.021; Storro O, 2011, CLIN EXP ALLERGY, V41, P1545, DOI 10.1111/j.1365-2222.2011.03817.x; Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142; Tourneur E, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/270301; Nguyen TL, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0338-0; Waligora-Dupriet AJ, 2011, ANAEROBE, V17, P91, DOI 10.1016/j.anaerobe.2011.04.003; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; West CE, 2015, CLIN EXP ALLERGY, V45, P1419, DOI 10.1111/cea.12566; Wopereis H, 2014, PEDIAT ALLERG IMM-UK, V25, P428, DOI 10.1111/pai.12232; Yang HJ, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-109; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zheng HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166026	46	72	75	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1310	1319		10.1016/j.jaci.2017.11.045	http://dx.doi.org/10.1016/j.jaci.2017.11.045			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29339259	Bronze			2022-12-18	WOS:000429197800017
J	Sanjuan, MA; Sagar, D; Kolbeck, R				Sanjuan, Miguel A.; Sagar, Divya; Kolbeck, Roland			Role of IgE in autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; autoimmunity; interferon; plasmacytoid dendritic cells; basophil; systemic lupus erythematosus; bullous pemphigoid; chronic spontaneous urticaria; atopic dermatitis	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLASMACYTOID DENDRITIC CELLS; TOTAL SERUM IGE; IMMUNOGLOBULIN-E; ATOPIC-DERMATITIS; INTERFERON-ALPHA; CHRONIC URTICARIA; I INTERFERONS; AUTOANTIBODIES; ANTIBODIES	There is accumulating evidence to suggest that IgE plays a significant role in autoimmunity. The presence of circulating self-reactive IgE in patients with autoimmune disorders has been long known but, at the same time, largely understudied. However, studies have shown that the increased IgE concentration is not associated with higher prevalence for atopy and allergy in patients with autoimmune diseases, such as systemic lupus erythematosus. IgE-mediated mechanisms are conventionally known to facilitate degranulation of mast cells and basophils and promote T(H)2 immunity, mechanisms that are not only central to mounting an appropriate defense against parasitic worms, noxious substances, toxins, venoms, and environmental irritants but that also trigger exuberant allergic reactions in patients with allergies. More recently, IgE autoantibodies have been recognized to participate in the self-inflicted damaging immune responses that characterize autoimmunity. Such autoimmune responses include direct damage on tissue-containing autoantigens, activation and migration of basophils to lymph nodes, and, as observed most recently, induction of type 1 interferon responses from plasmacytoid dendritic cells. The importance of IgE as a central pathogenic mechanism in autoimmunity has now been clinically validated by the approval of omalizumab, an anti-IgE mAb, for patients with chronic spontaneous urticaria and for the clinical benefit of patients with bullous pemphigoid. In this review we summarize recent reports describing the prevalence of self-reactive IgE and discuss novel findings that incriminate IgE as central in the pathogenesis of inflammatory autoimmune disorders.	[Sanjuan, Miguel A.; Sagar, Divya; Kolbeck, Roland] MedImmune, Res, Resp Inflammat & Autoimmun Dept, Gaithersburg, MD USA	AstraZeneca; Medimmune	Sanjuan, MA (corresponding author), One MedImmune Way, Gaithersburg, MD 20878 USA.	sanjuanm@medimmune.com	Sanjuán, Miguel AF/B-7709-2011	Sanjuán, Miguel AF/0000-0003-3515-0837				Aichberger KJ, 2005, J IMMUNOL, V175, P1286, DOI 10.4049/jimmunol.175.2.1286; Aldebert D, 1996, BLOOD, V87, P2354, DOI 10.1182/blood.V87.6.2354.bloodjournal8762354; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Atta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293; Atta AM, 2004, BRAZ J MED BIOL RES, V37, P1497, DOI 10.1590/S0100-879X2004001000008; Aydogan K, 2006, CLIN EXP DERMATOL, V31, P424, DOI 10.1111/j.1365-2230.2005.02039.x; BAIRD B, 1989, INT ARCH ALLER A IMM, V88, P23, DOI 10.1159/000234742; BARONE C, 1981, ARTHRITIS RHEUM, V24, P1441, DOI 10.1002/art.1780241120; Bave U, 2003, J IMMUNOL, V171, P3296, DOI 10.4049/jimmunol.171.6.3296; CAMUSSI G, 1982, INT ARCH ALLER A IMM, V69, P358, DOI 10.1159/000233200; Cao XT, 2016, NAT REV IMMUNOL, V16, P35, DOI 10.1038/nri.2015.8; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027; Cipriani F, 2014, J DERMATOL, V41, P569, DOI 10.1111/1346-8138.12464; Concha LB, 2004, ALLERGY ASTHMA PROC, V25, P293; Confino-Cohen R, 2012, J ALLERGY CLIN IMMUN, V129, P1307, DOI 10.1016/j.jaci.2012.01.043; Crow MK, 2010, RHEUM DIS CLIN N AM, V36, P173, DOI 10.1016/j.rdc.2009.12.008; Dema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066; Dema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424; Dimson OG, 2003, J INVEST DERMATOL, V120, P784, DOI 10.1046/j.1523-1747.2003.12146.x; Dopp R, 2000, J AM ACAD DERMATOL, V42, P577, DOI 10.1016/S0190-9622(00)90168-3; DVORAK AM, 1982, J INVEST DERMATOL, V78, P91, DOI 10.1111/1523-1747.ep12505711; ELKAYAM O, 1995, ALLERGY, V50, P94; Fairley JA, 2007, J INVEST DERMATOL, V127, P2605, DOI 10.1038/sj.jid.5700958; Fairley JA, 2009, J ALLERGY CLIN IMMUN, V123, P704, DOI 10.1016/j.jaci.2008.11.035; Ferrer M, 2010, CLIN EXP ALLERGY, V40, P1760, DOI 10.1111/j.1365-2222.2010.03582.x; Furie R, 2015, ARTHRITIS RHEUMATOL, V67; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Gokturk B, 2014, SCAND J IMMUNOL, V80, P354, DOI 10.1111/sji.12200; Gomez MR, 2010, J IMMUNOL, V185, P7180, DOI 10.4049/jimmunol.1002319; Guo J, 1997, CLIN IMMUNOL IMMUNOP, V82, P157, DOI 10.1006/clin.1996.4297; Hatada Y, 2013, INT ARCH ALLERGY IMM, V161, P154, DOI 10.1159/000350388; Henault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hradetzky S, 2015, ALLERGO J, V24, P32, DOI 10.1007/s15007-015-0737-7; Hradetzky S, 2014, J INVEST DERMATOL, V134, P1570, DOI 10.1038/jid.2014.25; Huber JP, 2014, J IMMUNOL, V192, P5687, DOI 10.4049/jimmunol.1301908; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Iwata Y, 2008, ARCH DERMATOL, V144, P41, DOI 10.1001/archdermatol.2007.9; JONES DH, 1985, J IMMUNOL, V135, P3348; KAUFMAN LD, 1989, ANN RHEUM DIS, V48, P201, DOI 10.1136/ard.48.3.201; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Khamashta M, 2016, ANN RHEUM DIS; Kinaciyan T, 2002, J ALLERGY CLIN IMMUN, V109, P717, DOI 10.1067/mai.2002.123303; Kolkhir P, 2016, CLIN EXP ALLERGY, V46, P275, DOI 10.1111/cea.12673; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; LAURENT J, 1986, AM J NEPHROL, V6, P413, DOI 10.1159/000167202; Liphaus BL, 2012, CLINICS, V67, P1275, DOI 10.6061/clinics/2012(11)09; Ludwig RJ, 2013, TRENDS MOL MED, V19, P501, DOI 10.1016/j.molmed.2013.06.003; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Messingham KAN, 2014, IMMUNOL RES, V59, P273, DOI 10.1007/s12026-014-8547-7; Messingham KAN, 2012, HYBRIDOMA, V31, P111, DOI 10.1089/hyb.2011.0102; Messingham KAN, 2009, J IMMUNOL METHODS, V346, P18, DOI 10.1016/j.jim.2009.04.013; Mikol DD, 2006, J NEUROIMMUNOL, V180, P40, DOI 10.1016/j.jneuroim.2006.06.030; Morton S, 1998, ANN RHEUM DIS, V57, P660, DOI 10.1136/ard.57.11.660; Mouchess ML, 2011, IMMUNITY, V35, P721, DOI 10.1016/j.immuni.2011.10.009; Muino JC, 1999, J CLIN IMMUNOL, V19, P215, DOI 10.1023/A:1020516029883; Muro Y, 2001, J DERMATOL SCI, V25, P171, DOI 10.1016/S0923-1811(01)00084-6; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; O'Donnell BF, 1999, BRIT J DERMATOL, V140, P853, DOI 10.1046/j.1365-2133.1999.02815.x; Ochs RL, 2000, J ALLERGY CLIN IMMUN, V105, P1211, DOI 10.1067/mai.2000.107039; OKAMURA M, 1993, ANN RHEUM DIS, V52, P14, DOI 10.1136/ard.52.1.14; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Parks CG, 2010, LUPUS, V19, P1614, DOI 10.1177/0961203310379870; Pellegrino MG, 2002, AIDS RES HUM RETROV, V18, P363, DOI 10.1089/088922202753519142; PERMIN H, 1978, ACTA PATH MICRO IM C, V86, P245; PROVOST TT, 1974, CLIN EXP IMMUNOL, V18, P193; REBHUN J, 1983, ANN ALLERGY, V50, P34; Reich K, 2016, J ALLERGY CLIN IMMUN; Rhyner C, 2011, ALLERGY, V66, P1127, DOI 10.1111/j.1398-9995.2011.02581.x; Ronnblom L, 2008, LUPUS, V17, P394, DOI 10.1177/0961203308090020; Rowland SL, 2014, J EXP MED, V211, P1977, DOI 10.1084/jem.20132620; RUSSI JC, 1993, J CLIN MICROBIOL, V31, P819, DOI 10.1128/JCM.31.4.819-823.1993; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Sato A, 1999, J CLIN ENDOCR METAB, V84, P3602, DOI 10.1210/jc.84.10.3602; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Sekigawa I, 2008, RHEUMATOL INT, V28, P623, DOI 10.1007/s00296-007-0494-3; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Seshan SV, 2009, ARCH PATHOL LAB MED, V133, P233, DOI 10.1043/1543-2165-133.2.233; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Smith-Norowitz TA, 2011, INT J MED SCI, V8, P239, DOI 10.7150/ijms.8.239; Stitt JM, 2013, CURR ALLERGY ASTHM R, V13, P555, DOI 10.1007/s11882-013-0366-8; SWIETER M, 1989, IMMUNOLOGY, V66, P606; Tang TS, 2012, J ALLERGY CLIN IMMUN, V129, P1209, DOI 10.1016/j.jaci.2012.02.002; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; TUMA SN, 1981, AM J NEPHROL, V1, P31, DOI 10.1159/000166485; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; WINTROUB BU, 1978, NEW ENGL J MED, V298, P417, DOI 10.1056/NEJM197802232980803; Wozniacka A, 2003, MEDIAT INFLAMM, V12, P95, DOI 10.1080/0962935031000097709; Yu KK, 2014, J AM ACAD DERMATOL, V71, P468, DOI 10.1016/j.jaad.2014.04.053; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015; Zhao ZT, 2016, J ALLERGY CLIN IMMUN; Zhu HL, 2015, GENOM PROTEOM BIOINF, V13, P210, DOI 10.1016/j.gpb.2015.09.001; Zuberbier T, 2014, ALLERGY, V69, pE1, DOI 10.1111/all.12370	103	72	76	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1651	1661		10.1016/j.jaci.2016.04.007	http://dx.doi.org/10.1016/j.jaci.2016.04.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27264000	Bronze			2022-12-18	WOS:000377527200003
J	Yang, Q; Ge, MQ; Kokalari, B; Redai, IG; Wang, XX; Kemeny, DM; Bhandoola, A; Haczku, A				Yang, Qi; Ge, Moyar Q.; Kokalari, Blerina; Redai, Imre G.; Wang, Xinxin; Kemeny, David M.; Bhandoola, Avinash; Haczku, Angela			Group 2 innate lymphoid cells mediate ozone-induced airway inflammation and hyperresponsiveness in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ozone; group 2 innate lymphoid cells; airway hyperresponsiveness	PUBLIC-HEALTH BENEFITS; NATURAL HELPER-CELLS; TYPE-2 IMMUNITY; ADAPTIVE IMMUNITY; POLLUTION CONTROL; ASTHMA; HYPERREACTIVITY; LUNG; EOSINOPHILS; EXPRESSION	Background: Asthmatic patients are highly susceptible to air pollution and in particular to the effects of ozone (O-3) inhalation, but the underlying mechanisms remain unclear. Objective: Using mouse models of O-3-induced airway inflammation and airway hyperresponsiveness (AHR), we sought to investigate the role of the recently discovered group 2 innate lymphoid cells (ILC2s). Methods: C57BL/6 and BALB/c mice were exposed to Aspergillus fumigatus, O-3, or both (3 ppm for 2 hours). ILC2s were isolated by means of fluorescence-activated cell sorting and studied for Il5 and Il13 mRNA expression. ILC2s were depleted with anti-Thy1.2 mAb and replaced by means of intratracheal transfer of ex vivo expanded Thy1.1 ILC2s. Cytokine levels (ELISA and quantitative PCR), inflammatory cell profile, and AHR (flexiVent) were assessed in the mice. Results: In addition to neutrophil influx, O-3 inhalation elicited the appearance of eosinophils and IL-5 in the airways of BALB/c but not C57BL/6 mice. Although O-3-induced expression of IL-33, a known activator of ILC2s, in the lung was similar between these strains, isolated pulmonary ILC2s from O-3-exposed BALB/c mice had significantly greater Il5 and Il13 mRNA expression than C57BL/6 mice. This suggested that an altered ILC2 function in BALB/c mice might mediate the increased O-3 responsiveness. Indeed, anti-Thy1.2 treatment abolished but ILC2s added back dramatically enhanced O-3-induced AHR. Conclusions: O-3-induced activation of pulmonary ILC2s was necessary and sufficient to mediate asthma-like changes in BALB/c mice. This previously unrecognized role of ILC2s might help explain the heightened susceptibility of human asthmatic airways to O-3 exposure.	[Yang, Qi; Wang, Xinxin; Bhandoola, Avinash] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Yang, Qi; Bhandoola, Avinash] NCI, T Cell Biol & Dev Sect, Lab Genome Integr, NIH, Bethesda, MD 20892 USA; [Ge, Moyar Q.; Kokalari, Blerina; Redai, Imre G.; Haczku, Angela] Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; [Ge, Moyar Q.; Haczku, Angela] Univ Calif Davis, Translat Lung Biol Ctr, Pulm Crit Care & Sleep Med, One Shields Ave, Davis, CA 95616 USA; [Ge, Moyar Q.; Kemeny, David M.] Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; University of California System; University of California Davis; National University of Singapore	Haczku, A (corresponding author), Univ Calif Davis, Translat Lung Biol Ctr, Pulm Crit Care & Sleep Med, One Shields Ave, Davis, CA 95616 USA.; Bhandoola, A (corresponding author), NCI, T Cell Biol & Dev Sect, Lab Genome Integr, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.	avinash.bhandoola@nih.gov; haczku@ucdavis.edu	HACZKU, ANGELA/A-8486-2013; Ge, Qing/N-5855-2016; Wang, Xin/GYU-1129-2022; Wang, Xin/AAN-8435-2021	HACZKU, ANGELA/0000-0002-1301-4941; Wang, Xin/0000-0002-4457-7376; Ge, Qing/0000-0002-5407-342X	 [R01AI072197];  [RC1ES018505];  [P30ES013508];  [R21 AI059621];  [AI098428]; NATIONAL CANCER INSTITUTE [ZIABC011633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI098428, R01AI059621, R56AI059621, R01AI072197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [RC1ES018505, P30ES013508] Funding Source: NIH RePORTER	; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grant R01AI072197 (to A.H.), RC1ES018505 (to A.H.), P30ES013508 (to A.H.), R21 AI059621 (to A.B. and A.H.), and AI098428 (to A.B.).	Atochina EN, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-15; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bosson J, 2003, CLIN EXP ALLERGY, V33, P777, DOI 10.1046/j.1365-2222.2003.01662.x; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Frischer T, 2001, CLIN EXP ALLERGY, V31, P1213, DOI 10.1046/j.1365-2222.2001.01155.x; Gao YD, 2010, PULM PHARMACOL THER, V23, P182, DOI 10.1016/j.pupt.2009.12.005; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; HATCH GE, 1994, AM J RESP CRIT CARE, V150, P676, DOI 10.1164/ajrccm.150.3.8087337; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Ishii Y, 1998, AM J PHYSIOL-LUNG C, V274, pL171, DOI 10.1152/ajplung.1998.274.1.L171; Jain D, 2008, IMMUNOBIOLOGY, V213, P499, DOI 10.1016/j.imbio.2007.12.002; Johnston RA, 2007, AM J RESP CELL MOL, V37, P477, DOI 10.1165/rcmb.2006-0315OC; Kierstein S, 2008, ALLERGY, V63, P438, DOI 10.1111/j.1398-9995.2007.01587.x; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim KH, 2013, ENVIRON INT, V59, P41, DOI 10.1016/j.envint.2013.05.007; KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379; Ledford DK, 2012, J ALLERGY CLIN IMMUN, V130, P24, DOI 10.1016/j.jaci.2012.02.055; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Li JH, 2012, J ALLERGY CLIN IMMUN, V130, P22, DOI 10.1016/j.jaci.2012.02.047; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1093, DOI 10.1002/eji.201242549; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; Slade R, 1997, AM J PHYSIOL-LUNG C, V272, pL73, DOI 10.1152/ajplung.1997.272.1.L73; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yang Q, 2011, J IMMUNOL, V187, P5505, DOI 10.4049/jimmunol.1102039; ZHANG LY, 1995, EXP LUNG RES, V21, P503, DOI 10.3109/01902149509031755; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	35	72	74	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					571	578		10.1016/j.jaci.2015.06.037	http://dx.doi.org/10.1016/j.jaci.2015.06.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26282284	Green Accepted, Bronze			2022-12-18	WOS:000369235500027
J	Czarnowicki, T; Gonzalez, J; Bonifacio, KM; Shemer, A; Peng, XY; Kunjravia, N; Malajian, D; Fuentes-Duculan, J; Esaki, H; Noda, S; Estrada, Y; Xu, H; Zheng, XZ; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; Gonzalez, Juana; Bonifacio, Kathleen M.; Shemer, Avner; Peng Xiangyu; Kunjravia, Norma; Malajian, Dana; Fuentes-Duculan, Judilyn; Esaki, Hitokazu; Noda, Shinji; Estrada, Yeriel; Xu, Hui; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma			Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; B cells	CD4(+) T-CELLS; PHENOTYPIC ANALYSIS; CYTOKINE PRODUCTION; INFLAMMATORY CELLS; MEMORY; EXPRESSION; IGE; BLOOD; SKIN; ANTIGEN	Background: Atopic dermatitis (AD) and psoriasis pathogeneses involve skin barrier impairment and immune dysregulation; however, the contribution of B-cell imbalances to these diseases has not yet been determined. Objective: We sought to quantify B-cell populations and antibody-secreting cells in the blood of patients with AD, patients with psoriasis, and control subjects. Methods: We studied 34 adults with moderate-to-severe AD (mean SCORAD score, 65), 24 patients with psoriasis (mean Psoriasis Area and Severity Index score, 16), and 27 healthy subjects using an 11-color flow cytometric antibody panel. IgD/CD27 and CD24/CD38 core gating systems were used to determine frequencies of plasmablasts and naive, memory, transitional, and activated B cells. Results: We measured increased CD19(+)CD20(+) B-cell counts in the skin and blood of patients with AD (P < .01). Significantly higher frequencies of chronically activated CD27(+) memory and nonswitched memory B cells were observed in patients with AD (P < .05), with lower values of double-negative populations (4% for patients with AD vs 7% for patients with psoriasis [P = .001] and 6% for control subjects [P = .02]). CD23 expression was highest in patients with AD and correlated with IgE levels (P < .01) and disease severity (r = 0.6, P = .0002). Plasmablast frequencies and IgE expression were highest in all memory subsets of patients with AD (P < .01). Finally, CD19(+)CD24(++)CD38(++) transitional and CD19(+)CD24(-)CD38(-) new memory B-cell counts were higher in patients with AD versus those in patients with psoriasis (2.8% vs 1.4% [P = .001] and 9.2% vs 5.7% [P = .02], respectively). Conclusions: AD is accompanied by systemic expansion of transitional and chronically activated CD27(+) memory, plasmablast, and IgE-expressing memory subsets. These data create a critical basis for the future understanding of this debilitating skin disease.	[Czarnowicki, Tali; Bonifacio, Kathleen M.; Kunjravia, Norma; Malajian, Dana; Fuentes-Duculan, Judilyn; Esaki, Hitokazu; Noda, Shinji; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10065 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, New York, NY 10065 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel; [Peng Xiangyu; Esaki, Hitokazu; Estrada, Yeriel; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Malajian, Dana] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Columbia University	Czarnowicki, T (corresponding author), Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10065 USA.	tczarnowic01@rockefeller.edu		Esaki, Hitokazu/0000-0002-3716-520X	Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1TR0000]; American Dermatological Association Medical Student Fellowship; National Center for Research Resources (NCRR), a component of the NIH [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Dermatological Association Medical Student Fellowship; National Center for Research Resources (NCRR), a component of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	T.C. was cosponsored by the Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust. J.G. was supported in part by grant no. UL1TR0000 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. D.M. received funding from the American Dermatological Association Medical Student Fellowship. J.G.K. was supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the NIH, and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award.	Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Akdis CA, 2003, CLIN EXP ALLERGY, V33, P1618, DOI 10.1111/j.1365-2222.2003.01803.x; Avery DT, 2005, J IMMUNOL, V174, P4034, DOI 10.4049/jimmunol.174.7.4034; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bouaziz JD, 2007, P NATL ACAD SCI USA, V104, P20878, DOI 10.1073/pnas.0709205105; Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; Brisslert M, 2006, IMMUNOLOGY, V117, P548, DOI 10.1111/j.1365-2567.2006.02331.x; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Buffa S, 2013, AGE, V35, P2009, DOI 10.1007/s11357-012-9488-5; BUJANOWSKIWEBER J, 1989, IMMUNOLOGY, V66, P505; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; Cosmi L, 2014, CYTOM PART A, V85A, P36, DOI 10.1002/cyto.a.22348; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELESPESSE G, 1989, J IMMUNOL, V142, P134; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Dondi A, 2013, ALLERGY, V68, P259, DOI 10.1111/all.12070; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Ferenczi K, 2000, J AUTOIMMUN, V14, P63, DOI 10.1006/jaut.1999.0343; Flores-Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407; Flynn S, 1998, J EXP MED, V188, P297, DOI 10.1084/jem.188.2.297; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; Hasannejad H, 2007, J ALLERGY CLIN IMMUN, V120, P69, DOI 10.1016/j.jaci.2007.04.010; Hata TR, 2008, SEMIN CUTAN MED SURG, V27, P144, DOI 10.1016/j.sder.2008.04.002; Jacobi AM, 2003, ARTHRITIS RHEUM, V48, P1332, DOI 10.1002/art.10949; Jimenez-Boj E, 2012, ANN RHEUM DIS, V71, P1868, DOI 10.1136/annrheumdis-2012-201897; Jirapongsananuruk O, 1998, J IMMUNOL, V160, P4622; Kaminski Denise A, 2012, Methods Mol Biol, V900, P109, DOI 10.1007/978-1-60761-720-4_6; Kaminski DA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00302; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Koarada S, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/198206; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Lemoine S, 2011, J AUTOIMMUN, V36, P228, DOI 10.1016/j.jaut.2011.01.005; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Lugovic L, 2001, INT J DERMATOL, V40, P489, DOI 10.1046/j.1365-4362.2001.01203.x; Macallan DC, 2005, BLOOD, V105, P3633, DOI 10.1182/blood-2004-09-3740; Macaulay AE, 1997, J IMMUNOL, V158, P4171; MAURER D, 1992, J IMMUNOL, V148, P3700; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; NAKAMURA K, 1991, BRIT J DERMATOL, V125, P543, DOI 10.1111/j.1365-2133.1991.tb14791.x; OKINO F, 1987, Acta Paediatrica Japonica, V29, P195; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Panzer R, 2014, EXP DERMATOL, V23, P364, DOI 10.1111/exd.12383; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; PENE J, 1989, INT ARCH ALLER A IMM, V90, P32, DOI 10.1159/000235073; Pistoia V, 1997, IMMUNOL TODAY, V18, P343, DOI 10.1016/S0167-5699(97)01080-3; Reddy M, 2004, J IMMUNOL METHODS, V293, P127, DOI 10.1016/j.jim.2004.07.006; Sanz I, 2008, SEMIN IMMUNOL, V20, P67, DOI 10.1016/j.smim.2007.12.006; SARFATI M, 1988, J IMMUNOL, V141, P2195; Sato A, 2006, P NATL ACAD SCI USA, V103, P17343, DOI 10.1073/pnas.0605102103; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Shi YH, 2003, CLIN IMMUNOL, V108, P128, DOI 10.1016/S1521-6616(03)00092-5; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Soler DC, 2013, CLIN IMMUNOL, V149, P111, DOI 10.1016/j.clim.2013.06.007; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; Tangye SG, 2007, J IMMUNOL, V179, P13, DOI 10.4049/jimmunol.179.1.13; Taskapan MO, 2000, ANN ALLERG ASTHMA IM, V84, P3, DOI 10.1016/S1081-1206(10)62731-7; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; Wei CW, 2011, CYTOM PART A, V79A, P894, DOI 10.1002/cyto.a.21112; Weller S, 2008, J EXP MED, V205, P1331, DOI 10.1084/jem.20071555; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Yanaba K, 2013, AM J PATHOL, V182, P2214, DOI 10.1016/j.ajpath.2013.02.042	86	72	75	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					118	+		10.1016/j.jaci.2015.08.027	http://dx.doi.org/10.1016/j.jaci.2015.08.027			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26441226				2022-12-18	WOS:000367724300002
J	Datema, MR; Zuidmeer-Jongejan, L; Asero, R; Barreales, L; Belohlavkova, S; de Blay, F; Bures, P; Clausen, M; Dubakiene, R; Gislason, D; Jedrzejczak-Czechowicz, M; Kowalski, ML; Knulst, AC; Kralimarkova, T; Le, TM; Lovegrove, A; Marsh, J; Papadopoulos, NG; Popov, T; del Prado, N; Purohit, A; Reese, G; Reig, I; Seneviratne, SL; Sinaniotis, A; Versteeg, SA; Vieths, S; Zwinderman, AH; Mills, C; Lidholm, J; Hoffmann-Sommergruber, K; Fernandez-Rivas, M; Ballmer-Weber, B; van Ree, R				Datema, Mareen R.; Zuidmeer-Jongejan, Laurian; Asero, Riccardo; Barreales, Laura; Belohlavkova, Simona; de Blay, Frederic; Bures, Peter; Clausen, Michael; Dubakiene, Ruta; Gislason, David; Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L.; Knulst, Andre C.; Kralimarkova, Tanya; Le, Thuy-My; Lovegrove, Alison; Marsh, Justin; Papadopoulos, Nikolaos G.; Popov, Todor; del Prado, Nayade; Purohit, Ashok; Reese, Gerald; Reig, Isabel; Seneviratne, Suranjith L.; Sinaniotis, Athanasios; Versteeg, Serge A.; Vieths, Stefan; Zwinderman, Aeilko H.; Mills, Clare; Lidholm, Jonas; Hoffmann-Sommergruber, Karin; Fernandez-Rivas, Montserrat; Ballmer-Weber, Barbara; van Ree, Ronald			Hazelnut allergy across Europe dissected molecularly: A EuroPrevall outpatient clinic survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EuroPrevall; hazelnut allergy; component-resolved diagnosis; outpatient clinic	LIPID-TRANSFER PROTEIN; POSITIVE DOUBLE-BLIND; CROSS-REACTIVITY; IGE-BINDING; CORYLUS-AVELLANA; MAJOR ALLERGENS; PEANUT OLEOSIN; FOOD ALLERGY; IDENTIFICATION; SENSITIZATION	Background: Hazelnut allergy is birch pollen-driven in Northern/Western Europe and lipid transfer protein-driven in Spain and Italy. Little is known about other regions and other allergens. Objective: Establishing a molecular map of hazelnut allergy across Europe. Methods: In 12 European cities, subjects reporting reactions to hazelnut (n = 731) were evaluated and sensitization to 24 foods, 12 respiratory allergen sources, and latex was tested by using skin prick test and ImmunoCAP. A subset (124 of 731) underwent a double-blind placebo-controlled food challenge to hazelnut. Sera of 423 of 731 subjects were analyzed for IgE against 7 hazelnut allergens and cross-reactive carbohydrate determinants by ImmunoCAP. Results: Hazelnut allergy was confirmed in 70% of those undergoing double-blind placebo-controlled food challenges. Birch pollen-driven hazelnut sensitization (Cor a 1) dominated in most cities, except in Reykjavik, Sofia, Athens, and Madrid, where reporting of hazelnut allergy was less frequent anyhow. In Athens, IgE against Cor a 8 dominated and strongly correlated with IgE against walnut, peach, and apple and against Chenopodium, plane tree, and mugwort pollen. Sensitization to seed storage proteins was observed in less than 10%, mainly in children, and correlated with IgE to nuts, seeds, and legumes. IgE to Cor a 12, observed in all cities (10% to 25%), correlated with IgE to nuts, seeds, and pollen. Conclusions: In adulthood, the importance of hazelnut sensitization to storage proteins, oleosin (Cor a 12), and Cor a 8 is diluted by the increased role of birch pollen cross-reactivity with Cor a 1. Cor a 8 sensitization in the Mediterranean is probably driven by diet in combination with pollen exposure. Hazelnut oleosin sensitization is prevalent across Europe; however, the clinical relevance remains to be established.	[Datema, Mareen R.; Zuidmeer-Jongejan, Laurian; Versteeg, Serge A.; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [Asero, Riccardo] Clin San Carlo, Ambulatorio Allergol, Paderno Dugnano, Italy; [Barreales, Laura; del Prado, Nayade] IdISSC, Hosp Clin San Carlos, Dept Prevent Med, Clin Epidemiol Unit, Madrid, Spain; [Belohlavkova, Simona] Fac Hosp Bulovka, Dept Pediat, Prague, Czech Republic; [de Blay, Frederic; Purohit, Ashok] Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France; [Bures, Peter; Ballmer-Weber, Barbara] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Clausen, Michael; Gislason, David] Univ Iceland, Fac Med, Landspitali Univ Hosp, Reykjavik, Iceland; [Dubakiene, Ruta] Vilnius State Univ, Fac Med, Vilnius, Lithuania; [Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L.] Med Univ Lodz, Fac Med, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Knulst, Andre C.; Le, Thuy-My] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Kralimarkova, Tanya] Med Univ Sofia, Clin Allergy & Asthma, Sofia, Bulgaria; [Lovegrove, Alison] Rothamsted Res, Dept Plant Biol & Crop Sci, Harpenden, Herts, England; [Marsh, Justin; Mills, Clare] Univ Manchester, Manchester Inst Biotechnol, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England; [Papadopoulos, Nikolaos G.; Sinaniotis, Athanasios] Univ Athens, Pediat Clin 2, Dept Allergy, GR-10679 Athens, Greece; [Papadopoulos, Nikolaos G.] Univ Manchester, Inst Human Dev, Ctr Paediat & Child Hlth, Manchester M13 9PL, Lancs, England; [Popov, Todor; Reese, Gerald; Vieths, Stefan] Fed Inst Vaccines & Biomed, Paul Ehrlich Inst, Div Allergol, Langen, Germany; [Reig, Isabel; Fernandez-Rivas, Montserrat] IdISSC, Hosp Clin San Carlos, Dept Allergy, Madrid, Spain; [Seneviratne, Suranjith L.] St Marys Hosp, Dept Clin Immunol, London, England; [Seneviratne, Suranjith L.] Imperial Coll London, London, England; [Zwinderman, Aeilko H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands; [Lidholm, Jonas] Phadia AB, Uppsala, Sweden; [Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Hospital Clinico San Carlos; Bulovka University Hospital; CHU Strasbourg; University of Zurich; University Zurich Hospital; Landspitali National University Hospital; University of Iceland; Vilnius University; Medical University Lodz; Utrecht University; Utrecht University Medical Center; Medical University Sofia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; University of Manchester; National & Kapodistrian University of Athens; University of Manchester; Paul Ehrlich Institute; Hospital Clinico San Carlos; Imperial College London; Imperial College London; University of Amsterdam; Academic Medical Center Amsterdam; Thermo Fisher Scientific; Phadia; Medical University of Vienna; University of Amsterdam; Academic Medical Center Amsterdam	van Ree, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	r.vanree@amc.uva.nl	Popov, Todor/Q-9928-2016; N.G., Papadopoulos/L-8670-2013; Papadopoulos, Nikolaos/ABE-1774-2021	Popov, Todor/0000-0001-5052-5866; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; Datema, Mareen/0000-0003-2646-9467; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Knulst, Andre/0000-0002-1056-3179; Jedrzejczak-Czechowicz, Monika/0000-0003-2292-2770; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Lidholm, Jonas/0000-0002-7779-3411; Asero, Riccardo/0000-0002-8277-1700	European Union through EuroPrevall [FP6-FOOD-CT-2005-514000]; EU [312147]; Biotechnology and Biological Sciences Research Council [BBS/E/F/00041800] Funding Source: researchfish	European Union through EuroPrevall; EU(European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was funded by the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000). M.R.D., C.M., R.v.R., M.F.-R., and S.V. also received support from the EU 7th framework programme under grant agreement no. 312147.	Akkerdaas JH, 2006, MOL NUTR FOOD RES, V50, P18, DOI 10.1002/mnfr.200500147; Asero R, 2013, EUR ANN ALLERGY CLIN, V45, P160; Asero R, 2013, J INVEST ALLERG CLIN, V23, P37; Asero R, 2003, J ALLERGY CLIN IMMUN, V112, P427, DOI 10.1067/mai.2003.1611; Ballmer-Weber BK, 2012, ALLERGY, V67, P758, DOI 10.1111/j.1398-9995.2012.02827.x; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Burney PGJ, 2014, ALLERGY, V69, P365, DOI 10.1111/all.12341; De Knop KJ, 2011, PEDIAT ALLERG IMM-UK, V22, pe139, DOI 10.1111/j.1399-3038.2011.01112.x; Fernandez-Rivas M, 2015, ALLERGY, V70, P576, DOI 10.1111/all.12585; Figueroa J, 2005, ALLERGY, V60, P48, DOI 10.1111/j.1398-9995.2005.00644.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Gao ZS, 2013, J ALLERGY CLIN IMMUN, V131, P224, DOI 10.1016/j.jaci.2012.07.015; Garino C, 2010, MOL NUTR FOOD RES, V54, P1257, DOI 10.1002/mnfr.200900456; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; Hartz C, 2010, INT ARCH ALLERGY IMM, V153, P335, DOI 10.1159/000316344; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kim HU, 2002, J BIOL CHEM, V277, P22677, DOI 10.1074/jbc.M109298200; Kobayashi S, 2012, BIOSCI BIOTECH BIOCH, V76, P1182, DOI 10.1271/bbb.120063; Kummeling I, 2009, ALLERGY, V64, P1493, DOI 10.1111/j.1398-9995.2009.02046.x; Lauer I, 2004, BIOCHEM J, V383, P327, DOI 10.1042/BJ20041062; Lauer I, 2007, CLIN EXP ALLERGY, V37, P261, DOI 10.1111/j.1365-2222.2007.02653.x; Lauer I, 2008, MOL NUTR FOOD RES, V52, pS262, DOI 10.1002/mnfr.200700426; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Lopez-Torrejon G, 2005, CLIN EXP ALLERGY, V35, P1065, DOI 10.1111/j.1365-2222.2005.02303.x; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Mills ENC, 2007, ALLERGY, V62, P717, DOI 10.1111/j.1398-9995.2007.01425.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pedrosa M, 2012, PEDIAT ALLERG IMM-UK, V23, P654, DOI 10.1111/j.1399-3038.2012.01337.x; Pons L, 2002, ALLERGY, V57, P88, DOI 10.1034/j.1398-9995.57.s72.16.x; Rigby NM, 2008, MOL NUTR FOOD RES, V52, pS251, DOI 10.1002/mnfr.200800083; Rodriguez-Perez R, 2003, ALLERGY, V58, P635, DOI 10.1034/j.1398-9995.2003.00198.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Santos A, 2011, INT ARCH ALLERGY IMM, V155, P191, DOI 10.1159/000321178; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Smith M, 2014, ALLERGY, V69, P913, DOI 10.1111/all.12419; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401; Zuidmeer-Jongejan L, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-4	41	72	73	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					382	391		10.1016/j.jaci.2014.12.1949	http://dx.doi.org/10.1016/j.jaci.2014.12.1949			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25772593	Green Submitted			2022-12-18	WOS:000359004900020
J	Smith, SS; Evans, CT; Tan, BK; Chandra, RK; Smith, SB; Kern, RC				Smith, Stephanie Shintani; Evans, Charlesnika T.; Tan, Bruce K.; Chandra, Rakesh K.; Smith, Sean B.; Kern, Robert C.			National burden of antibiotic use for adult rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLINICAL-PRACTICE GUIDELINE; UNITED-STATES		[Smith, Stephanie Shintani; Tan, Bruce K.; Chandra, Rakesh K.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA; [Smith, Stephanie Shintani; Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA; [Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Dept Vet Affairs, Hines, IL USA; [Smith, Sean B.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University; Feinberg School of Medicine	Smith, SS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA.	s-shintani@northwestern.edu	Smith, Sean/GYJ-6782-2022	Chandra, Rakesh/0000-0002-3612-0026	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000078] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL076139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER; AHRQ HHS [T32 HS000078, T-32 HS 000078] Funding Source: Medline; NHLBI NIH HHS [T32 HL076139] Funding Source: Medline; NIAID NIH HHS [U19 AI106683] Funding Source: Medline; NIDCD NIH HHS [K23 DC012067] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chow AW, 2012, CLIN INFECT DIS, V54, pE72, DOI [10.1093/cid/cis370, 10.1093/cid/cir1043]; Ferguson BJ, 2012, CLIN INFECT DIS, V54, P62, DOI 10.1093/cid/cir747; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI [10.4193/Rhino12.000, 10.4193/Rhino50E2]; Lee LN, 2011, LARYNGOSCOPE, V121, P1092, DOI 10.1002/lary.21550; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; National Center for Health Statistics, 2006, NAMCS MICR FIL DOC H; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Smith SS, 2013, OTOLARYNG HEAD NECK, V148, P852, DOI 10.1177/0194599813479768; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045	12	72	72	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1230	1232		10.1016/j.jaci.2013.07.009	http://dx.doi.org/10.1016/j.jaci.2013.07.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23987794	Bronze, Green Accepted			2022-12-18	WOS:000326235600031
J	Hsu, J; Avila, PC; Kern, RC; Hayes, MG; Schleimer, RP; Pinto, JM				Hsu, Joy; Avila, Pedro C.; Kern, Robert C.; Hayes, M. Geoffrey; Schleimer, Robert P.; Pinto, Jayant M.			Genetics of chronic rhinosinusitis: State of the field and directions forward	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetics; genome; variation; chronic rhinosinusitis; nasal polyposis; single nucleotide polymorphism; polymorphism; candidate gene; linkage; genome wide association study; susceptibility; sinusitis	TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELL EXPRESSION; ALLERGIC FUNGAL SINUSITIS; NASAL POLYPS PATHOGENESIS; GENOME-WIDE ASSOCIATION; FACTOR-ALPHA PROMOTER; CYSTIC-FIBROSIS; INCREASED PREVALENCE; MICROARRAY ANALYSIS; SUSCEPTIBILITY GENES	The cause of chronic rhinosinusitis (CRS) remains unclear. Study of the genetic susceptibility to CRS might be a valuable strategy to understand the pathogenesis of this burdensome disorder. The purpose of this review is to critically evaluate the current literature regarding the genetics of CRS in a comprehensive fashion. The most promising findings from candidate gene studies include the cystic fibrosis transmembrane conductance regulator gene (CFTR), as well as genes involved in antigen presentation, innate and adaptive immune responses, tissue remodeling, and arachidonic acid metabolism. We also review the few hypothesis-independent genetic studies of CRS (ie, linkage analysis and pooling-based genome-wide association studies). Interpretation of the current literature is limited by challenges with study design, sparse replication, few functional correlates of associated polymorphisms, and inadequate examination of linkage disequilibrium or expression quantitative trait loci for reported associations. Given the relationship of CRS to other airway disorders with well-characterized genetic components (eg, asthma), study of the genetics of CRS deserves increased attention and investment, including the organization of large, detailed, and collaborative studies to advance knowledge of the mechanisms that underlie this disorder. (J Allergy Clin Immunol 2013; 131: 977-93.)	[Hsu, Joy; Avila, Pedro C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA; [Hayes, M. Geoffrey] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; [Hayes, M. Geoffrey] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA; [Hayes, M. Geoffrey] Northwestern Univ, Dept Anthropol, Chicago, IL 60611 USA; [Pinto, Jayant M.] Univ Chicago, Pritzker Sch Med, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; University of Chicago	Pinto, JM (corresponding author), Univ Chicago Med & Biol Sci, Dept Surg, Sect Otolaryngol Head & Neck Surg, 5841 South Maryland Ave,Rm E-103,MC 1035, Chicago, IL 60637 USA.	jpinto@surgery.bsd.uchicago.edu		Hayes, M Geoffrey/0000-0002-4617-3981	National Institute on Aging [K23 AG036762, T35 AG029795]; Institute for Translational Medicine at the University of Chicago [KL2RR025000, UL1RR024999]; Allergy, Asthma and Immunology Education and Research Trust (ARTrust); McHugh Otolaryngology Research Fund; Ernest S. Bazley Trust; National Institute of Allergy and Infectious Diseases [AI082984]; National Heart, Lung, and Blood Institute [R37 HL068546, R01 HL078860]; Northwestern University; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999, KL2RR025000] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI082984, P01AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG036762, T35AG029795] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Institute for Translational Medicine at the University of Chicago; Allergy, Asthma and Immunology Education and Research Trust (ARTrust); McHugh Otolaryngology Research Fund; Ernest S. Bazley Trust; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Northwestern University; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	J.M.P. was supported by K23 AG036762 and T35 AG029795 from the National Institute on Aging; the Institute for Translational Medicine (KL2RR025000, UL1RR024999) at the University of Chicago; the Allergy, Asthma and Immunology Education and Research Trust (ARTrust), and the McHugh Otolaryngology Research Fund. J.H. was supported by the Ernest S. Bazley Trust and the Allergy, Asthma and Immunology Education and Research Trust (ARTrust). P. C. A. was supported by AI082984 from the National Institute of Allergy and Infectious Diseases and the Ernest S. Bazley Trust. R. P. S. was supported by R37 HL068546 and R01 HL078860 from the National Heart, Lung, and Blood Institute, and the Ernest S. Bazley Trust. M. G. H. received institutional support from Northwestern University.	Al-Shemari H, 2008, BMC MED GENET, V9, P1, DOI 10.1186/1471-2350-9-21; Allen RD, 1999, MOL IMMUNOL, V36, P1017, DOI 10.1016/S0161-5890(99)00127-3; Alper Ozgul M, 2004, Hum Mutat, V24, P353, DOI 10.1002/humu.9281; Arbag H, 2006, RHINOLOGY, V44, P14; Armengot M, 1997, INT J PEDIATR OTORHI, V40, P27, DOI 10.1016/S0165-5876(97)01490-0; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V118, P70, DOI 10.1016/j.jaci.2006.03.036; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V126, P1139, DOI 10.1016/j.jaci.2010.10.032; Basu K, 2009, J ALLERGY CLIN IMMUN, V124, P1188, DOI 10.1016/j.jaci.2009.07.043; Batikhan H, 2010, EUR ARCH OTO-RHINO-L, V267, P903, DOI 10.1007/s00405-009-1167-5; Beghe B, 2010, ALLERGY, V65, P474, DOI 10.1111/j.1398-9995.2009.02167.x; Bernstein JM, 2009, LARYNGOSCOPE, V119, P1258, DOI 10.1002/lary.20239; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Bosse Y, 2009, HUM GENET, V125, P305, DOI 10.1007/s00439-009-0626-9; Braunstahl GJ, 2005, J ALLERGY CLIN IMMUN, V115, P142, DOI 10.1016/j.jaci.2004.10.041; Bucholtz GA, 1999, AM J RHINOL, V13, P221, DOI 10.2500/105065899781389795; BuSaba NY, 2008, LARYNGOSCOPE, V118, P310, DOI 10.1097/MLG.0b013e31815744b6; Bussu F, 2007, AM J RHINOL, V21, P378, DOI 10.2500/ajr.2007.21.3015; Buysschaert ID, 2010, ALLERGY, V65, P616, DOI 10.1111/j.1398-9995.2009.02227.x; Castano R, 2010, OTOLARYNGOL HEAD NEC, V142, pe1; Castano R, 2010, OTOLARYNG HEAD NECK, V142, P665, DOI 10.1016/j.otohns.2010.01.004; Castano R, 2009, AMJ RHINOL ALLERGY, V23, P377, DOI 10.2500/ajra.2009.23.3303; Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980; Chen Nijun, 2011, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V25, P197; Cheng YK, 2006, ARCH OTOLARYNGOL, V132, P285, DOI 10.1001/archotol.132.3.285; Cho DY, 2011, INT FORUM ALLERGY RH, V1, P123, DOI 10.1002/alr.20028; Cho JS, 2012, CLIN EXP ALLERGY, V42, P872, DOI 10.1111/j.1365-2222.2011.03931.x; Cho JH, 2011, NEW ENGL J MED, V365, P1612, DOI 10.1056/NEJMra1100030; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Ciminelli BM, 2011, ANN HUM BIOL, V38, P203, DOI 10.3109/03014460.2010.507554; Cohen NA, 2006, OTOLARYNG HEAD NECK, V134, P601, DOI 10.1016/j.otohns.2005.11.042; Cormier C, 2009, J OTOLARYNGOL-HEAD N, V38, P133, DOI 10.2310/7070.2008.OA0220; Davila I, 2009, J INVEST ALLERG CLIN, V19, P25; de Alarcon A, 2006, AM J RHINOL, V20, P545, DOI 10.2500/ajr.2006.20.2934; Delagranda A, 2008, RHINOLOGY, V46, P125; DeMarcantonio MA, 2011, OTOLARYNG CLIN N AM, V44, P685, DOI 10.1016/j.otc.2011.03.005; DRAKELEE A, 1992, J LARYNGOL OTOL, V106, P1084, DOI 10.1017/S0022215100121826; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Ekinci S, 2011, OTOLARYNG HEAD NECK, V145, P1036, DOI 10.1177/0194599811417359; Endam LM, 2010, ARCH OTOLARYNGOL, V136, P187, DOI 10.1001/archoto.2009.219; Endam LM, 2009, OTOLARYNG HEAD NECK, V140, P741, DOI 10.1016/j.otohns.2008.12.058; Erbek SS, 2007, ARCH OTOLARYNGOL, V133, P705, DOI 10.1001/archotol.133.7.705; Erbek SS, 2009, AM J RHINOL ALLERGY, V23, P568, DOI 10.2500/ajra.2009.23.3371; Fajardo-Dolci G, 2006, OTOLARYNG HEAD NECK, V135, P243, DOI 10.1016/j.otohns.2006.03.034; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fruth K, 2011, RHINOLOGY, V49, P180, DOI 10.4193/Rhino10.064; Ghosh AK, 2012, J CELL PHYSIOL, V227, P493, DOI 10.1002/jcp.22783; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Gosepath J, 2005, AM J RHINOL, V19, P111, DOI 10.1177/194589240501900201; Greisner WA, 1996, ALLERGY ASTHMA PROC, V17, P283, DOI 10.2500/108854196778662192; Gruneberg H, 1934, J GENET, V29, P367, DOI 10.1007/BF02982233; Harrison P, 2008, RHEUMATOLOGY, V47, P1768, DOI 10.1093/rheumatology/ken374; Hsu J, 2011, AM J RHINOL ALLERGY, V25, P285, DOI 10.2500/ajra.2011.25.3680; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Irving RM, 1997, CLIN OTOLARYNGOL, V22, P519, DOI 10.1046/j.1365-2273.1997.00058.x; Jacob A, 2001, ARCH OTOLARYNGOL, V127, P657, DOI 10.1001/archotol.127.6.657; JACOBS RL, 1983, ANN ALLERGY, V51, P500; Johnson CH, 2012, J CELL PHYSIOL, V227, P2975, DOI 10.1002/jcp.24002; Karjalainen J, 2003, ALLERGY, V58, P393, DOI 10.1034/j.1398-9995.2003.00118.x; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V110, P429, DOI 10.1067/mai.2002.126784; Keles B, 2008, OTOLARYNG HEAD NECK, V139, P580, DOI 10.1016/j.otohns.2008.07.002; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kilty SJ, 2010, AM J RHINOL ALLERGY, V24, pE4, DOI 10.2500/ajra.2010.24.3429; Kim DW, 2011, AM J RHINOL ALLERGY, V25, pE255, DOI 10.2500/ajra.2011.25.3727; Kim JH, 2012, AM J RHINOL ALLERGY, V26, P12, DOI 10.2500/ajra.2012.26.3692; Kim SH, 2007, RESP MED, V101, P490, DOI 10.1016/j.rmed.2006.07.002; Kohyama K, 2011, INT ARCH ALLERGY IMM, V156, P405, DOI 10.1159/000324463; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; Ku CS, 2011, J MED GENET, V48, P721, DOI 10.1136/jmedgenet-2011-100242; Kuchynkova Z, 1995, Cas Lek Cesk, V134, P212; Lane AP, 2006, AM J RHINOL, V20, P138, DOI 10.1177/194589240602000203; Laroche M, 1997, CLIN RHEUMATOL, V16, P207, DOI 10.1007/BF02247852; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Lee SH, 2012, AM J RESP CELL MOL, V46, P842, DOI 10.1165/rcmb.2011-0369OC; Li CW, 2011, J ALLERGY CLIN IMMUN, V127, P765, DOI 10.1016/j.jaci.2010.12.011; Li J, 2003, AM J PHYSIOL-LUNG C, V284, pL307, DOI 10.1152/ajplung.00086.2002; Li XY, 2010, J ALLERGY CLIN IMMUN, V125, P1061, DOI 10.1016/j.jaci.2010.02.023; Lindsay R, 2006, OTOLARYNG HEAD NECK, V134, P724, DOI 10.1016/j.otohns.2005.11.048; LOCKEY RF, 1973, ANN INTERN MED, V78, P57, DOI 10.7326/0003-4819-78-1-57; Luxenberger W, 2000, EUR ARCH OTO-RHINO-L, V257, P137, DOI 10.1007/s004050050210; Martin JA, 2011, NAT REV GENET, V12, P671, DOI 10.1038/nrg3068; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Meltzer EO, 2011, MAYO CLIN PROC, V86, P427, DOI 10.4065/mcp.2010.0392; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Meth MJ, 2009, J ALLERGY CLIN IMMUN, V123, pS159, DOI 10.1016/j.jaci.2008.12.598; Molnar-Gabor E, 2000, LARYNGOSCOPE, V110, P422, DOI 10.1097/00005537-200003000-00017; MOLONEY JR, 1980, CLIN OTOLARYNGOL, V5, P183, DOI 10.1111/j.1365-2273.1980.tb01645.x; Moskwa P, 2007, AM J RESP CRIT CARE, V175, P174, DOI 10.1164/rccm.200607-1029OC; Nakamura O, 1974, OTORHINOLARYNGOLO S1, P25; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ojogun N, 2009, J INFECT DIS, V200, P1685, DOI 10.1086/646616; Orlandi RR, 2007, OTOLARYNG HEAD NECK, V136, P707, DOI 10.1016/j.otohns.2006.11.033; Ozcan C, 2010, EUR ARCH OTO-RHINO-L, V267, P227, DOI 10.1007/s00405-009-1066-9; Palikhe NS, 2010, ALLERGY ASTHMA IMMUN, V2, P134, DOI 10.4168/aair.2010.2.2.134; Park CS, 2011, OTOLARYNG HEAD NECK, V144, P96, DOI 10.1177/0194599810390881; Park SK, 2006, OTOLARYNG HEAD NECK, V135, P928, DOI 10.1016/j.otohns.2006.07.009; Pasaje CFA, 2012, LUNG, V190, P199, DOI 10.1007/s00408-011-9354-8; Pasaje CFA, 2011, J ASTHMA, V48, P539, DOI 10.3109/02770903.2011.589557; Pasaje CFA, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-2; Pascual M, 2008, J INVEST ALLERG CLIN, V18, P241; Payne SC, 2008, AM J RHINOL, V22, P568, DOI 10.2500/ajr.2008.22.3233; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Pescador DB, 2012, J INVEST ALLERG CLIN, V22, P331; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Pinto JM, 2008, LARYNGOSCOPE, V118, P2067, DOI 10.1097/MLG.0b013e3181805147; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Platt M, 2009, CURR OPIN ALLERGY CL, V9, P23, DOI 10.1097/ACI.0b013e32831d8170; Qidwai T, 2011, SCAND J IMMUNOL, V74, P522, DOI 10.1111/j.1365-3083.2011.02602.x; Qu Shen-hong, 2007, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V42, P608; Raman V, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e13; Ramanathan M, 2007, AM J RHINOL, V21, P110, DOI 10.2500/ajr.2007.21.2997; Ramirez-Anguiano J, 2006, OTOLARYNG HEAD NECK, V135, P90, DOI 10.1016/j.otohns.2006.01.009; RAMSEY B, 1992, J ALLERGY CLIN IMMUN, V90, P547, DOI 10.1016/0091-6749(92)90183-3; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Rohlfs EM, 2011, CLIN CHEM, V57, P841, DOI 10.1373/clinchem.2010.159285; Sachse F, 2010, AM J RHINOL ALLERGY, V24, pE10, DOI 10.2500/ajra.2010.24.3416; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Schubert MS, 2004, J ALLERGY CLIN IMMUN, V114, P1376, DOI 10.1016/j.jaci.2004.08.029; Seiberling KA, 2012, INT FORUM ALLERGY RH, V2, P80, DOI 10.1002/alr.20090; Sejima T, 2011, AM J RHINOL ALLERGY, V25, P1, DOI 10.2500/ajra.2011.25.3537; Sekigawa T, 2009, CLIN EXP ALLERGY, V39, P972, DOI 10.1111/j.1365-2222.2009.03229.x; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; Shuto T, 2006, FASEB J, V20, P782, DOI 10.1096/fj.05-4934fje; Sitarek P, 2012, DNA CELL BIOL, V31, P1258, DOI 10.1089/dna.2011.1453; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Sugarman EA, 2004, GENET MED, V6, P392, DOI 10.1097/01.GIM.0000139503.22088.66; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takeuchi K, 1999, LARYNGOSCOPE, V109, P275, DOI 10.1097/00005537-199902000-00018; Takeuchi K, 2000, LARYNGOSCOPE, V110, P1711, DOI 10.1097/00005537-200010000-00027; Tewfik MA, 2009, ALLERGY, V64, P746, DOI 10.1111/j.1398-9995.2008.01889.x; Tewfik MA, 2007, OTOLARYNGOL HEAD NEC, V137, P1; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Tournas A, 2010, J OTOLARYNGOL-HEAD N, V39, P188, DOI 10.2310/7070.2009.090080; Turvey SE, 2010, J ALLERGY CLIN IMMUN, V125, pS24, DOI 10.1016/j.jaci.2009.07.016; Upton DC, 2011, ANN OTO RHINOL LARYN, V120, P780, DOI 10.1177/000348941112001203; Van Bruaene N, 2012, CLIN EXP ALLERGY, V42, P883, DOI 10.1111/j.1365-2222.2011.03898.x; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; VARON R, 1995, HUM MOL GENET, V4, P1463, DOI 10.1093/hmg/4.8.1463; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Wang LF, 2008, ARCH OTOLARYNGOL, V134, P852, DOI 10.1001/archotol.134.8.852; Wang LF, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-85; Wang XJ, 2000, JAMA-J AM MED ASSOC, V284, P1814, DOI 10.1001/jama.284.14.1814; Wang XJ, 2005, ARCH OTOLARYNGOL, V131, P237, DOI 10.1001/archotol.131.3.237; Ward BW, 2010, VITAL HLTH STAT, V10, P1; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Watson Michael S, 2004, Genet Med, V6, P387, DOI 10.1097/01.GIM.0000139506.11694.7C; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Yamamoto M, 2012, CLIN EXP ALLERGY, V42, P760, DOI 10.1111/j.1365-2222.2011.03860.x; Yazdani N, 2012, J INVEST ALLERG CLIN, V22, P406; Yea SS, 2006, AM J RHINOL, V20, P550, DOI 10.2500/ajr.2006.20.2936; Zander KA, 2009, AM J RHINOL ALLERGY, V23, P268, DOI 10.2500/ajra.2009.23.3314; Zhai LJ, 2007, ANN OTO RHINOL LARYN, V116, P66, DOI 10.1177/000348940711600111; Zhang F, 2008, AM J RHINOL, V22, P376, DOI 10.2500/ajr.2008.22.3188; Zhang M, 2012, LIN CHUNG ER BI YAN, V26, P204; Zhang Mei-li, 2012, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V47, P212; Zhang Meili, 2012, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V26, P197, DOI 10.13201/j.issn.1001-1781.2012.05.006; Zhang Y, 2011, J ALLERGY CLIN IMMUN, V127, pAB121, DOI 10.1016/j.jaci.2010.12.483; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039247; Zhang Y, 2011, AM J RHINOL ALLERGY, V25, pE49, DOI 10.2500/ajra.2011.25.3588; Zielinska-Blizniewska H, 2012, MOL BIOL REP, V39, P5449, DOI 10.1007/s11033-011-1345-6	170	72	76	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					977	+		10.1016/j.jaci.2013.01.028	http://dx.doi.org/10.1016/j.jaci.2013.01.028			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23540616	Green Accepted, Bronze			2022-12-18	WOS:000317187200004
J	Burns, SO; Zenner, HL; Plagnol, V; Curtis, J; Mok, K; Eisenhut, M; Kumararatne, D; Doffinger, R; Thrasher, AJ; Nejentsev, S				Burns, Siobhan O.; Zenner, Helen L.; Plagnol, Vincent; Curtis, James; Mok, Kin; Eisenhut, Michael; Kumararatne, Dinakantha; Doffinger, Rainer; Thrasher, Adrian J.; Nejentsev, Sergey			LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Burns, Siobhan O.; Thrasher, Adrian J.] UCL, Inst Child Hlth, Wolfson Ctr Gene Therapy Childhood Dis, Mol Immunol Unit, London, England; [Burns, Siobhan O.; Thrasher, Adrian J.] Great Ormond St Hosp Children Natl Hlth Serv NHS, London, England; [Zenner, Helen L.; Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; [Plagnol, Vincent] UCL, UCL Genet Inst, London, England; [Mok, Kin] UCL, UCL Inst Neurol, London, England; [Eisenhut, Michael] Luton & Dunstable Hosp NHS Fdn Trust, Dept Paediat, Luton, Beds, England; [Kumararatne, Dinakantha; Doffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Cambridge; University of London; University College London; University of London; University College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Burns, SO (corresponding author), UCL, Inst Child Hlth, Wolfson Ctr Gene Therapy Childhood Dis, Mol Immunol Unit, London, England.	a.thrasher@ucl.ac.uk; sn262@medschl.cam.ac.uk	Mok, Kin/U-6893-2019; Mok, Kin Ying/F-5860-2012	Mok, Kin/0000-0003-3145-880X; Mok, Kin Ying/0000-0003-3145-880X; Thrasher, Adrian/0000-0002-6097-6115; Plagnol, Vincent/0000-0002-5597-9215; Burns, Siobhan/0000-0002-3356-9506	National Institute for Health Research [NF-SI-0611-10001] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1259, V1223] Funding Source: researchfish; Medical Research Council [G1001158] Funding Source: Medline; Wellcome Trust [095198, 095198/Z/10/Z, 090233/Z/09/Z, 090233] Funding Source: Medline; MRC [G1001158] Funding Source: UKRI	National Institute for Health Research(National Institute for Health Research (NIHR)); Great Ormond Street Hospital Childrens Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Cooper N, 2009, BRIT J HAEMATOL, V146, P120, DOI 10.1111/j.1365-2141.2009.07715.x; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586	4	72	78	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1428	1432		10.1016/j.jaci.2012.07.035	http://dx.doi.org/10.1016/j.jaci.2012.07.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22981790	Bronze, Green Accepted			2022-12-18	WOS:000311641100031
J	Herr, M; Just, J; Nikasinovic, L; Foucault, C; Le Marec, AM; Giordanella, JP; Momas, I				Herr, Marie; Just, Jocelyne; Nikasinovic, Lydia; Foucault, Christophe; Le Marec, Anne-Marie; Giordanella, Jean-Pierre; Momas, Isabelle			Risk factors and characteristics of respiratory and allergic phenotypes in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; phenotype; infancy; severity; wheeze; risk factors; cluster analysis	WHEEZING PHENOTYPES; PRESCHOOL-CHILDREN; BLOOD EOSINOPHILIA; IMMUNOGLOBULIN-E; CLUSTER-ANALYSIS; ATOPIC DISEASE; BIRTH COHORT; 1ST YEAR; ASTHMA; INFANTS	Background: Unsupervised approaches can be used to analyze complex respiratory and allergic disorders. Objective: We investigated the respiratory and allergic phenotypes of children followed in the Pollution and Asthma Risk: An Infant Study (PARIS) birth cohort. Methods: Information on respiratory and allergic disorders, medical visits, and medications was collected during medical examinations of children at 18 months of age; biomarker data were also collected (total and allergen-specific IgE levels and eosinophilia). Phenotypes were determined by using latent class analysis. Associated risk factors were determined based on answers to questionnaires about environmental exposures. Results: Apart from a reference group, which had a low prevalence of respiratory symptoms or allergies (n = 1271 [69.4%]), 3 phenotypes were identified. On the basis of clinical signs of severity and use of health care resources, we identified a mild phenotype (n = 306 [16.7%]) characterized by occasional mild wheeze and 2 severe phenotypes separated by atopic status. The atopic severe phenotype (n = 59 [3.2%]) included 49 (83%) children with wheezing and was characterized by a high prevalence of atopy (61% with allergenic sensitization) and atopic dermatitis (78%). In contrast, atopy was rare among children with the nonatopic severe phenotype (n = 195 [11%]); this group included 88% of the children with recurrent wheezing. Risk factors for respiratory disease included parental history of asthma, male sex, siblings, day care attendance, exposure to tobacco smoke or molds, indoor renovations, and being overweight, although these factors did not have similar affects on risk for all phenotypes. Conclusion: Atopy should be taken into account when assessing the risk of severe exacerbations (that require hospital-based care) in wheezing infants; precautions should be taken against respiratory irritants and molds and to prevent children from becoming overweight. (J Allergy Clin Immunol 2012;130:389-96.)	[Momas, Isabelle] Univ Paris 05, Lab Sante Publ & Environm, EA 4064, Fac Sci Pharmaceut & Biol, F-75006 Paris, France; [Foucault, Christophe; Giordanella, Jean-Pierre] CPAM Paris, Ctr Examens Sante Enfant Amelot, Paris, France; [Le Marec, Anne-Marie; Momas, Isabelle] Enfance & Sante Mairie Paris, Cellule Cohorte Direct Act Sociale, Paris, France	UDICE-French Research Universities; Universite Paris Cite	Momas, I (corresponding author), Univ Paris 05, Lab Sante Publ & Environm, EA 4064, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	isabelle.momas@parisdescartes.fr		Herr, Marie/0000-0002-1836-705X; momas, isabelle/0000-0003-4344-3787	Social, Childhood, and Health Direction of the Paris Council, Paris Descartes University; French national health insurance system	Social, Childhood, and Health Direction of the Paris Council, Paris Descartes University; French national health insurance system	Supported by the Social, Childhood, and Health Direction of the Paris Council, Paris Descartes University, and the French national health insurance system.	[Anonymous], GLOB STRAT DIAGN MAN; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; BEZDEK JC, 1984, COMPUT GEOSCI, V10, P191, DOI 10.1016/0098-3004(84)90020-7; BORRES MP, 1995, J ALLERGY CLIN IMMUN, V95, P694, DOI 10.1016/S0091-6749(95)70174-5; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Clarisse B, 2007, EUR J EPIDEMIOL, V22, P203, DOI 10.1007/s10654-007-9109-2; Clarisse B, 2003, ENVIRON RES, V92, P245, DOI 10.1016/S0013-9351(03)00039-2; Dassonville C, 2008, INDOOR AIR, V18, P480, DOI 10.1111/j.1600-0668.2008.00549.x; Dassonville C, 2009, INDOOR AIR, V19, P314, DOI 10.1111/j.1600-0668.2009.00594.x; Dassonville C, 2008, ENVIRON RES, V108, P80, DOI 10.1016/j.envres.2008.04.006; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Gern JE, 2000, J ALLERGY CLIN IMMUN, V105, pS497, DOI 10.1016/S0091-6749(00)90050-2; Hagenaars J., 2002, APPL LATENT CLASS AN, DOI DOI 10.1017/CBO9780511499531; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Halkidi M, 2001, J INTELL INF SYST, V17, P107, DOI 10.1023/A:1012801612483; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Herr M, 2012, CLIN EXP ALLERGY, V42, P275, DOI 10.1111/j.1365-2222.2011.03933.x; Herr M, 2011, ALLERGY, V66, P214, DOI 10.1111/j.1398-9995.2010.02467.x; Just J, 2008, CLIN EXP ALLERGY, V38, P767, DOI 10.1111/j.1365-2222.2008.02966.x; KAJOSAARI M, 1981, ALLERGY, V36, P329, DOI 10.1111/j.1398-9995.1981.tb01584.x; Kusel MMH, 2008, CLIN EXP ALLERGY, V38, P1921, DOI 10.1111/j.1365-2222.2008.03138.x; Lannero E, 2002, PEDIAT ALLERG IMM-UK, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; LeRoux B., 2010, MULTIPLE CORRES ANAL, V163; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Perkin MR, 2006, PEDIAT ALLERG IMM-UK, V17, P118, DOI 10.1111/j.1399-3038.2005.00364.x; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; Soderstrom L, 2011, ALLERGY, V66, P1058, DOI 10.1111/j.1398-9995.2011.02578.x; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Visser CAN, 2010, PEDIATR PULM, V45, P149, DOI 10.1002/ppul.21161; Wijga A, 2011, J ALLERGY CLIN IMMUN, V127, P275, DOI 10.1016/j.jaci.2010.09.022	49	72	74	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					389	+		10.1016/j.jaci.2012.05.054	http://dx.doi.org/10.1016/j.jaci.2012.05.054			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846748	Bronze			2022-12-18	WOS:000307002200018
J	Just, J; Gouvis-Echraghi, R; Couderc, R; Guillemot-Lambert, N; Saint-Pierre, P				Just, Jocelyne; Gouvis-Echraghi, Rahele; Couderc, Remy; Guillemot-Lambert, Nathalie; Saint-Pierre, Philippe			Novel severe wheezy young children phenotypes: Boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Risk factors; allergy; ICS; preschool children	FOOD ALLERGY; BIRTH COHORT; 1ST YEAR; ASTHMA; CHILDHOOD; LIFE; SENSITIZATION; RHINITIS; INFANCY; GENDER	Background: Recurrent wheezing during infancy is a heterogeneous disorder that has been associated with early-onset asthma. Objective: To identify phenotypes of severe recurrent wheezing and therapeutic approaches. Methods: We performed cluster analysis with 20 variables of 551 children with active asthma, younger than 36 months old, and enrolled in the Trousseau Asthma Program. Results: We identified 3 independent clusters of children with wheezing. Cluster 1, mild episodic viral wheeze (n = 327), consisted of children with wheezing related only to colds (71%), mild disease (76%), and mainly normal chest x-ray results. Cluster 2, nonatopic uncontrolled wheeze (n = 157), was characterized by moderate to severe disease (91%), uncontrolled wheezing despite high doses of inhaled corticosteroids (55%), parents with asthma, and increased levels of ferritine. Cluster 3, atopic multiple-trigger wheeze (n = 67), included more children with multiple-trigger wheeze (68%) than did clusters 1 or 2; eczema (75%); a positive result from the Phadiatop Infant test (90%); increased levels of IgE, IgA, and IgG; and abnormal results from chest x-rays. In separate analysis, 1 parameter for boys (increased total level of IgE) and 2 parameters for girls (wheezing severity and increased total level of IgE) properly classified 90% of boys and 83% of girls in the appropriate cluster. Significant associations were found between overcrowding, molds and cockroaches at home, and atopic multiple-trigger wheeze and between day-care attendance and nonatopic uncontrolled wheeze in other parts. Conclusion: We identified different phenotypes of recurrent wheezing in young children by using cluster analysis with usual variables. These phenotypes require confirmation in longer, follow-up studies. (J Allergy Clin Immunol 2012;130:103-10.)	[Just, Jocelyne; Gouvis-Echraghi, Rahele; Guillemot-Lambert, Nathalie] Univ Paris 06, Grp Hosp Trousseau La Roche Guyon, Ctr Asthme & Allergies, F-75012 Paris, France; [Couderc, Remy] Univ Paris 06, Grp Hosp Trousseau La Roche Guyon, Serv Biochim & Biol Mol, F-75012 Paris, France; [Saint-Pierre, Philippe] UPMC, Lab Stat Theor & Appl, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Just, J (corresponding author), Univ Paris 06, Grp Hosp Trousseau La Roche Guyon, Ctr Asthme & Allergies, 26 Ave Docteur Arnold Netter, F-75012 Paris, France.	jocelyne.just@trs.aphp.fr						ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 2017, CLASSIFICATION REGRE; Cho SH, 2006, ANN ALLERG ASTHMA IM, V97, P539, DOI 10.1016/S1081-1206(10)60947-7; Clarisse B, 2009, PEDIAT ALLERG IMM-UK, V20, P126, DOI 10.1111/j.1399-3038.2008.00743.x; Dahlberg PE, 2009, CLIN EXP ALLERGY, V39, P1324, DOI 10.1111/j.1365-2222.2009.03322.x; de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; Federico MJ, 2003, PEDIATR CLIN N AM, V50, P655, DOI 10.1016/S0031-3955(03)00045-2; Global Strategy for Asthma Management and Prevention, 2005, GLOB STRAT ASTHM MAN; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; HAS, 2009, ASTHM ENF MOINS 36 M; Herr M, 2011, ALLERGY, V66, P214, DOI 10.1111/j.1398-9995.2010.02467.x; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Just J, 2008, CLIN EXP ALLERGY, V38, P767, DOI 10.1111/j.1365-2222.2008.02966.x; Just J, 2012, EUR RESP J; Kaufman L., 1990, FINDING GROUPS DATA; Keil T, 2006, ALLERGY, V61, P221, DOI 10.1111/j.1398-9995.2006.00989.x; Kurukulaaratchy RJ, 2011, CLIN EXP ALLERGY, V41, P851, DOI 10.1111/j.1365-2222.2011.03765.x; Kuyucu S, 2004, PEDIAT ALLERG IMM-UK, V15, P62, DOI 10.1046/j.0905-6157.2003.00115.x; Lowe AJ, 2008, J ALLERGY CLIN IMMUN, V121, P1190, DOI 10.1016/j.jaci.2008.01.034; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mudarri D, 2007, INDOOR AIR, V17, P226, DOI 10.1111/j.1600-0668.2007.00474.x; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Rackemann F M, 1941, Trans Am Clin Climatol Assoc, V57, P60; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rona RJ, 2000, THORAX, V55, P239, DOI 10.1136/thorax.55.3.239; Rosenbaum PF, 2010, J EXPO SCI ENV EPID, V20, P503, DOI 10.1038/jes.2009.27; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4; Taylor DR, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-82; Vogel NM, 2008, J ASTHMA, V45, P862, DOI 10.1080/02770900802444195; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	42	72	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					103	+		10.1016/j.jaci.2012.02.041	http://dx.doi.org/10.1016/j.jaci.2012.02.041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22502798				2022-12-18	WOS:000306644800014
J	Lin, J; Bruni, FM; Fu, ZY; Maloney, J; Bardina, L; Boner, AL; Gimenez, G; Sampson, HA				Lin, Jing; Bruni, Francesca M.; Fu, Zhiyan; Maloney, Jennifer; Bardina, Ludmilla; Boner, Attilio L.; Gimenez, Gustavo; Sampson, Hugh A.			A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epitope mapping; peptide microarray; peanut allergy; bioinformatics; machine learning; allergy diagnosis; epitope biomarker	MACHINE-LEARNING-METHODS; IGE-BINDING EPITOPES; FOOD CHALLENGES; DOUBLE-BLIND; MUTATIONAL ANALYSIS; ARA H1; CHILDREN; MILK; IDENTIFICATION; IMMUNOTHERAPY	Background: Peanut allergy is relatively common, typically permanent, and often severe. Double-blind, placebo-controlled food challenge is considered the gold standard for the diagnosis of food allergy-related disorders. However, the complexity and potential of double-blind, placebo-controlled food challenge to cause life-threatening allergic reactions affects its clinical application. A laboratory test that could accurately diagnose symptomatic peanut allergy would greatly facilitate clinical practice. Objective: We sought to develop an allergy diagnostic method that could correctly predict symptomatic peanut allergy by using peptide microarray immunoassays and bioinformatic methods. Methods: Microarray immunoassays were performed by using the sera from 62 patients (31 with symptomatic peanut allergy and 31 who had outgrown their peanut allergy or were sensitized but were clinically tolerant to peanut). Specific IgE and IgG(4) binding to 419 overlapping peptides (15 mers, 3 offset) covering the amino acid sequences of Ara h 1, Ara h 2, and Ara h 3 were measured by using a peptide microarray immunoassay. Bioinformatic methods were applied for data analysis. Results: Individuals with peanut allergy showed significantly greater IgE binding and broader epitope diversity than did peanut-tolerant individuals. No significant difference in IgG4 binding was found between groups. By using machine learning methods, 4 peptide biomarkers were identified and prediction models that can predict the outcome of double-blind, placebo-controlled food challenges with high accuracy were developed by using a combination of the biomarkers. Conclusions: In this study, we developed a novel diagnostic approach that can predict peanut allergy with high accuracy by combining the results of a peptide microarray immunoassay and bioinformatic methods. Further studies are needed to validate the efficacy of this assay in clinical practice. (J Allergy Clin Immunol 2012;129:1321-8.)	[Lin, Jing; Fu, Zhiyan; Maloney, Jennifer; Bardina, Ludmilla; Gimenez, Gustavo; Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY 10029 USA; [Bruni, Francesca M.; Boner, Attilio L.] Univ Verona, Dept Pediat, I-37100 Verona, Italy	Icahn School of Medicine at Mount Sinai; University of Verona	Lin, J (corresponding author), Mt Sinai Sch Med, Box 1198, New York, NY 10029 USA.	jing.s.lin@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI44236, AI066738]; National Center for Research Resources [RR026134]; Food Allergy Initiative (FAI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Food Allergy Initiative (FAI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H.A.S. was funded in part by grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (grant nos. AI44236 and AI066738) and the National Center for Research Resources (grant no. RR026134).; Disclosure of potential conflict of interest: H. A. Sampson is a consultant for Allertein Therapeutics, LLC; is on the advisory board for ImmusanT and Novartis; has received research support from the Food Allergy Initiative (FAI) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases; is a consultant and scientific advisor for the FAI; is a medical advisor for the Food Allergy and Anaphylaxis Network; is a scientific advisor for the University of Nebraska FARRP; and is 45% owner of Herbal Springs, LLC. The rest of the authors declare that they have no relevant conflicts of interest.	Abeel T, 2009, BIOINFORMATICS, V25, pI313, DOI 10.1093/bioinformatics/btp191; Arima S, 2012, BIOSTATISTICS, V13, P101, DOI 10.1093/biostatistics/kxr022; Ayuso R, 2010, J ALLERGY CLIN IMMUN, V125, P1286, DOI 10.1016/j.jaci.2010.03.010; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Ferrer-Costa C, 2004, PROTEINS, V57, P811, DOI 10.1002/prot.20252; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Florkowski Christopher M, 2008, Clin Biochem Rev, V29 Suppl 1, pS83; Griner P F, 1981, Ann Intern Med, V94, P557; Hourihane JO, 1997, J ROY SOC MED, V90, P40, DOI 10.1177/0141076897090030S07; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Ji HK, 2005, BIOINFORMATICS, V21, P3629, DOI 10.1093/bioinformatics/bti593; Johnson K, 2011, J ALLERGY CLIN IMMUN, V127, pAB71, DOI 10.1016/j.jaci.2010.12.294; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Krishnan VG, 2003, BIOINFORMATICS, V19, P2199, DOI 10.1093/bioinformatics/btg297; Lin J, 2009, CURR OPIN ALLERGY CL, V9, P357, DOI 10.1097/ACI.0b013e32832d05ba; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Pirooznia M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S1-S13; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; van Wijk F, 2004, CLIN EXP ALLERGY, V34, P1422, DOI 10.1111/j.1365-2222.2004.02062.x; Vickery BP, 2010, J ALLERGY CLIN IMMUN, V125, pAB20, DOI 10.1016/j.jaci.2009.12.111; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Wohrl S, 2006, ALLERGY, V61, P633, DOI 10.1111/j.1398-9995.2006.01078.x	47	72	73	0	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1321	U202		10.1016/j.jaci.2012.02.012	http://dx.doi.org/10.1016/j.jaci.2012.02.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22444503	Green Accepted			2022-12-18	WOS:000303418000022
J	Kulis, M; Saba, K; Kim, EH; Bird, JA; Kamilaris, N; Vickery, BP; Staats, H; Burks, AW				Kulis, Michael; Saba, Katie; Kim, Edwin H.; Bird, J. Andrew; Kamilaris, Nikolas; Vickery, Brian P.; Staats, Herman; Burks, A. Wesley			Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN-A		[Kulis, Michael; Saba, Katie; Kim, Edwin H.; Bird, J. Andrew; Kamilaris, Nikolas; Vickery, Brian P.; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Staats, Herman] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Kulis, M (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA.	wesley.burks@duke.edu		Staats, Herman/0000-0003-1039-1087; Bird, John/0000-0003-3772-6078; Vickery, Brian/0000-0002-7243-5543	National Center for Complementary & Integrative Health [R01AT004435] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT004435-04, R01 AT004435] Funding Source: Medline	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1293, DOI 10.1046/j.1365-2222.2002.01470.x; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Luthviksson BR, 2005, CLIN EXP ALLERGY, V35, P64, DOI 10.1111/j.1365-2222.2005.02141.x; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x	9	72	72	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1159	1162		10.1016/j.jaci.2011.11.045	http://dx.doi.org/10.1016/j.jaci.2011.11.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22236732	Green Accepted			2022-12-18	WOS:000302144600039
J	De Benedetto, A; Slifka, MK; Rafaels, NM; Kuo, IH; Georas, SN; Boguniewicz, M; Hata, T; Schneider, LC; Hanifin, JM; Gallo, RL; Johnson, DC; Barnes, KC; Leung, DYM; Beck, LA				De Benedetto, Anna; Slifka, Mark K.; Rafaels, Nicholas M.; Kuo, I-Hsin; Georas, Steve N.; Boguniewicz, Mark; Hata, Tissa; Schneider, Lynda C.; Hanifin, Jon M.; Gallo, Richard L.; Johnson, David C.; Barnes, Kathleen C.; Leung, Donald Y. M.; Beck, Lisa A.			Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SINGLE-NUCLEOTIDE POLYMORPHISMS; EXPRESSION; FILAGGRIN; JUNCTIONS; SELECTION; BARRIER; ENTRY		[De Benedetto, Anna; Kuo, I-Hsin; Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14627 USA; [Georas, Steve N.] Univ Rochester, Div Pulm & Crit Care Med, Med Ctr, Rochester, NY 14627 USA; [Slifka, Mark K.; Johnson, David C.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Beaverton, OR USA; [Rafaels, Nicholas M.; Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Boguniewicz, Mark; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hata, Tissa; Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA; [Schneider, Lynda C.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA	University of Rochester; University of Rochester; Oregon Health & Science University; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins Medicine; National Jewish Health; University of California System; University of California San Diego; Harvard University; Boston Children's Hospital	De Benedetto, A (corresponding author), Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14627 USA.	Lisa_Beck@URMC.Rochester.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NCRR NIH HHS [P51 RR000163, K01 RR000163] Funding Source: Medline; NIAID NIH HHS [HHSN266200400029C, N01 AI040029, HHSN272201000020C, N01 AI40033, HHSN272201000017C, HHSN272201000020I, N01AI40033] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000163, P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Eichenfield LF, 2004, ALLERGY, V59, P86, DOI 10.1111/j.1398-9995.2004.00569.x; Fan JB, 2006, METHOD ENZYMOL, V410, P57, DOI 10.1016/S0076-6879(06)10003-8; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gonzalez-Mariscal L, 2009, FRONT BIOSCI-LANDMRK, V14, P731, DOI 10.2741/3276; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Howie BN, 2006, HUM GENET, V120, P58, DOI 10.1007/s00439-006-0182-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Schelhaas M, 2003, J GEN VIROL, V84, P2473, DOI 10.1099/vir.0.19226-0; Shimazaki J, 2009, INVEST OPHTH VIS SCI, V50, P5672, DOI 10.1167/iovs.09-3820; Yoshida Y, 2009, INVEST OPHTH VIS SCI, V50, P2103, DOI 10.1167/iovs.08-3046	20	72	75	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					242	U407		10.1016/j.jaci.2011.02.014	http://dx.doi.org/10.1016/j.jaci.2011.02.014			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21489616	Green Accepted			2022-12-18	WOS:000292245600043
J	Niespodziana, K; Focke-Tejkl, M; Linhart, B; Civaj, V; Blatt, K; Valent, P; van Hage, M; Gronlund, H; Valenta, R				Niespodziana, Katarzyna; Focke-Tejkl, Margarete; Linhart, Birgit; Civaj, Vera; Blatt, Katharina; Valent, Peter; van Hage, Marianne; Gronlund, Hans; Valenta, Rudolf			A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recombinant allergen; cat allergy; Fel d 1; peptide; hypoallergenic vaccine; immunotherapy	ALLERGEN-SPECIFIC IMMUNOTHERAPY; LATE ASTHMATIC REACTIONS; BIRCH POLLEN ALLERGEN; T-CELL PEPTIDES; IMMUNOGLOBULIN-E; CLINICAL-EFFICACY; CONTROLLED TRIAL; MAJOR ALLERGEN; DOMESTIC CAT; FEL-D-1	Background: Allergen-specific immunotherapy is clinically effective for the treatment of cat allergy but shows a high rate of side effects. Objective: We sought to engineer recombinant fusion proteins for cat immunotherapy that allow reducing both IgE-mediated and T cell-mediated side effects. Methods: Fusion proteins consisting of the hepatitis B virus-derived PreS domain and 2 nonallergenic Fel d 1-derived peptides were expressed in Escherichia coli and purified. IgE reactivity and allergenic activity of Fel d 1 and the fusion proteins were compared by using IgE-binding assays and basophil activation tests in patients with cat allergy. Mice and rabbits were immunized subcutaneously with Fel d 1 and the fusion proteins to investigate the allergenicity of the vaccines and the development of Fel d 1-specific IgG antibodies. Results: The recombinant fusion proteins showed no relevant IgE reactivity and exhibited more than 1000-fold reduced allergenic activity in basophil activation tests. On immunization of mice and rabbits, the fusion proteins induced Fel d 1-specific IgG antibodies that inhibited the binding of allergic patients' IgE to the allergen without allergic sensitization to Fel d 1. Conclusion: The described recombinant fusion proteins exhibit strongly reduced IgE-mediated allergenic activity, contain less than 40% of the Fel d 1 sequence, and thus lack many of the specific T-cell epitopes. Therefore they should represent safe vaccines for the treatment of cat allergy. (J Allergy Clin Immunol 2011;127:1562-70.)	[Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Allergy Res,Div Immunopatho, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, A-1090 Vienna, Austria; [van Hage, Marianne; Gronlund, Hans] Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne; Gronlund, Hans] Univ Hosp, Stockholm, Sweden	Medical University of Vienna; Medical University of Vienna; Karolinska Institutet	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Allergy Res,Div Immunopatho, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Test, PV/U-9451-2019; van Hage, Marianne/A-9678-2017; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016	van Hage, Marianne/0000-0003-3091-1596; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Gronlund, Hans/0000-0003-4882-7624; Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund (FWF) [DK-W1212-B13, L214-B13, F1815, 1820]; Biomay, Vienna, Austria; Christian Doppler Research Association, Austria; Swedish Research Council; Swedish Asthma and Allergy Association's Research Foundation; Biomay; Phadia	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Biomay, Vienna, Austria; Christian Doppler Research Association, Austria; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Asthma and Allergy Association's Research Foundation; Biomay; Phadia(Phadia)	Supported by grants DK-W1212-B13, L214-B13, F1815, and 1820 of the Austrian Science Fund (FWF); by research grants from Biomay, Vienna, Austria, and the Christian Doppler Research Association, Austria; and by the Swedish Research Council and Swedish Asthma and Allergy Association's Research Foundation.; M. van Hage has received research support from the Swedish Research Council and the Swedish Asthma and Allergy Association's Research Foundation. R. Valenta has received research support from Biomay, Phadia, and the Austrian Science Fund (FWF) and has consulted for Biomay and Phadia. The rest of the authors have declared that they have no conflict of interest.	Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Campana R, 2010, J ALLERGY CLIN IMMUN, V126, P1024, DOI 10.1016/j.jaci.2010.05.023; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Gronlund H, 2008, CLIN EXP ALLERGY, V38, P1275, DOI 10.1111/j.1365-2222.2008.03003.x; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Gronlund H, 2010, INT ARCH ALLERGY IMM, V151, P265, DOI 10.1159/000250435; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2007, J IMMUNOL, V178, P3924, DOI 10.4049/jimmunol.178.6.3924; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; MILICH DR, 1988, IMMUNOL TODAY, V9, P380, DOI 10.1016/0167-5699(88)91239-X; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Neurath A R, 1988, Adv Virus Res, V34, P65, DOI 10.1016/S0065-3527(08)60516-3; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1974, J IMMUNOL, V113, P1668; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Saarne T, 2005, CLIN EXP ALLERGY, V35, P657, DOI 10.1111/j.1365-2222.2005.02234.x; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Schumann A, 2007, J VIRAL HEPATITIS, V14, P592, DOI 10.1111/j.1365-2893.2007.00848.x; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; SISKIND GW, 1966, J EXP MED, V123, P673, DOI 10.1084/jem.123.4.673; Sylvan SPE, 2009, VACCINE, V28, P446, DOI 10.1016/j.vaccine.2009.10.023; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	46	72	76	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1562	U375		10.1016/j.jaci.2011.02.004	http://dx.doi.org/10.1016/j.jaci.2011.02.004			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21411130	Green Accepted			2022-12-18	WOS:000291048500038
J	Marwick, JA; Caramori, G; Casolari, P; Mazzoni, F; Kirkham, PA; Adcock, IM; Chung, KF; Papi, A				Marwick, John A.; Caramori, Gaetano; Casolari, Paolo; Mazzoni, Federico; Kirkham, Paul A.; Adcock, Ian M.; Chung, Kian Fan; Papi, Alberto			A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phosphoinositol 3-kinase; oxidative stress; Akt; macrophage; glucocorticoid insensitivity; chronic obstructive disease	HISTONE DEACETYLASE ACTIVITY; CLASS-IA PI3K; OXIDATIVE STRESS; AIRWAY INFLAMMATION; LIPID-PEROXIDATION; ASTHMA; INHIBITION; RESISTANCE; ACTIVATION; PI3K-DELTA	Background: Glucocorticoid function is markedly impaired in the lungs of patients with chronic obstructive pulmonary disease (COPD). This reduction in glucocorticoid sensitivity might`be due to an oxidant-mediated increase in phosphoinositol 3 kinase (PI3K) delta signaling. Objective: We sought to determine the role of PI3K delta in the reduced glucocorticoid responsiveness in patients with COPD. Methods: Peripheral lung tissue was obtained from 24 patients with COPD, 20 age-matched smokers with normal lung function, and 13 nonsmokers. Peripheral blood monocytes were isolated from 9 patients with COPD and 7 age-matched smokers with normal lung function and from healthy volunteers. Results: The expressions of PI3K delta and Akt phosphorylation were increased in macrophages from patients with COPD compared with those from control groups of age-matched smokers and nonsmokers. In vitro oxidative stress induced phosphorylation of Akt in monocytes and macrophages, which was abolished by means of selective inhibition of PI3K delta but not PI3K gamma. Dexamethasone was less effective at repressing LPS-induced GM-CSF and CXC motif chemokine 8 release in blood monocytes from patients with COPD compared with age-matched smokers. This reduced sensitivity was reversed by inhibition of PI3K delta but not PI3K gamma. Conclusion: PI3K delta expression and signaling is increased in the lungs of patients with COPD. Selective inhibition of PI3K delta might restore glucocorticoid function in patients with COPD and might therefore present a potential therapeutic target. (J Allergy Clin Immunol 2010;125:1146-53.)	[Marwick, John A.] Univ Edinburgh, Sch Med, MRC Ctr Inflammat Res, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland; [Marwick, John A.; Kirkham, Paul A.; Papi, Alberto] Univ Ferrara, Ctr Ric Asma & BPCO, I-44100 Ferrara, Italy; [Marwick, John A.; Caramori, Gaetano; Casolari, Paolo; Mazzoni, Federico; Adcock, Ian M.; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Sect Airways Dis, Natl Heart & Lung Inst, London SW7 2AZ, England	University of Edinburgh; University of Ferrara; Imperial College London	Marwick, JA (corresponding author), Univ Edinburgh, Sch Med, MRC Ctr Inflammat Res, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	john.marwick@ed.ac.uk	Adcock, Ian/L-3217-2019; Chung, Kian Fan/I-8456-2019; Papi, alberto/AAC-1888-2019; Chung, Kian Fan/B-1872-2012; Caramori, Gaetano/AAS-8611-2020	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Caramori, Gaetano/0000-0002-9807-327X; PAPI, ALBERTO/0000-0002-6924-4500; Adcock, Ian/0000-0003-2101-8843	European Respiratory Society [87]; Medical Research Council (UK) [0700900]; Wellcome Trust UK; MRC; Royal Society; GlaxoSmithKline; Chiesi Farmaceutici; AstraZeneca; Boehringer Ingelheim; MRC [G0700900] Funding Source: UKRI; Medical Research Council [G0700900, G0801056B] Funding Source: researchfish	European Respiratory Society; Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust UK(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Royal Society(Royal Society of London); GlaxoSmithKline(GlaxoSmithKline); Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Disclosure of potential conflict of interest: J. A. Marwick receives research support from the European Respiratory Society (Fellowship number 87) and the Medical Research Council (UK) (MRC grant support number 0700900). I. M. Adcock receives research support from the Wellcome Trust, the MRC, and the Royal Society, and has received travel grants from Boehringer Ingelheim. K. F. Chung serves on advisory boards for Merck. Boehringer Ingelheim, and Gilead and receives research support from the Medical Research Council, the Wellcome Trust UK, and GlaxoSmithKline. A. Papi receives research support from Chiesi Farmaceutici, AstraZeneca, and Boehringer Ingelheim. The rest of the authors have declared that they have no conflict of interest.	Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Beesley AH, 2009, BRIT J CANCER, V100, P1926, DOI 10.1038/sj.bjc.6605072; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Ciencewicki J, 2008, J ALLERGY CLIN IMMUN, V122, P456, DOI 10.1016/j.jaci.2008.08.004; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2001, FASEB J, V15, pA473; ITO K, 2008, J ALLERGY CLIN IMMUN, V31, P1334; Kok K, 2009, TRENDS BIOCHEM SCI, V34, P115, DOI 10.1016/j.tibs.2009.01.003; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Marwick JA, 2007, EXPERT OPIN THER TAR, V11, P745, DOI 10.1517/14728222.11.6.745; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Marwick JA, 2008, BIOCHEM BIOPH RES CO, V377, P797, DOI 10.1016/j.bbrc.2008.10.065; Molnarfi N, 2008, MOL IMMUNOL, V45, P3419, DOI 10.1016/j.molimm.2008.04.001; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369, DOI 10.1164/ajrccm.162.2.9909025; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Ricciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034; Santus P, 2005, AM J RESP CRIT CARE, V171, P838, DOI 10.1164/rccm.200404-558OC; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Varani K, 2006, AM J RESP CRIT CARE, V173, P398, DOI 10.1164/rccm.200506-869OC	36	72	76	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1146	1153		10.1016/j.jaci.2010.02.003	http://dx.doi.org/10.1016/j.jaci.2010.02.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20381852	Green Submitted			2022-12-18	WOS:000277686700026
J	Luger, EO; Fokuhl, V; Wegmann, M; Abram, M; Tillack, K; Achatz, G; Manz, RA; Worm, M; Radbruch, A; Renz, H				Luger, Elke O.; Fokuhl, Verena; Wegmann, Michael; Abram, Melanie; Tillack, Kati; Achatz, Gernot; Manz, Rudolf A.; Worm, Margitta; Radbruch, Andreas; Renz, Harald			Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasma cells; allergy; inflammation; memory; lung; mucosa	EPSILON-HEAVY-CHAIN; MEMORY B-CELLS; DENDRITIC CELLS; IMMUNOSUPPRESSIVE TREATMENT; RHEUMATOID-ARTHRITIS; ANTIBODY-RESPONSES; GENE TRANSCRIPTS; SECRETING CELLS; GERMINAL CENTER; IGE ANTIBODY	Background: Allergen-specific IgE antibodies are responsible for the pathogenesis of type I hypersensitivity. In patients with allergy, IgE titers can persist in the apparent absence of allergen for years. Seasonal allergen exposure triggers clinical symptoms and enhances allergen-specific IgE. Whether allergen-specific plasma cells originating from seasonal allergen exposures can survive and become long-lived is so far unclear. Objective: We analyzed the localization and lifetimes of allergen-specific IgE-secreting, IgA-secreting, and IgG(1)-secreting plasma cells after allergen inhalation in an ovalbumin-induced murine model of allergic asthma. Methods: Ovalbumin-specific IgG(1)-secreting, IgA-secreting, and IgE-secreting cells in lungs, spleen, and bone marrow were isolated and tested for antibody secretion by the ELISpot technique. Longevity of ovalbumin-specific plasma cells was determined by cyclophosphamide treatment, which depletes proliferating plasmablasts but leaves plasma cells untouched. Ovalbumin aerosol-induced infiltrates in lungs were localized by confocal microscopy. Results: Long-lived ovalbumin-specific plasma cells were generated by systemic sensitization and survived in bone marrow and spleen, maintaining systemic ovalbumin-specific titers of IgG, IgA, and IgE. On inhalation of ovalbumin-containing aerosol, sensitized mice developed airway inflammation and more ovalbumin-specific IgG(1)-secreting, IgA-secreting, and IgE-secreting cells in the lungs and in secondary lymphoid organs. These plasma cells joined the pool of ovalbumin-specific plasma cells in the bone marrow and became long-lived-that is, they are resistant to cyclophosphamide. Termination of ovalbumin inhalation depleted ovalbumin-specific plasma cells from the lungs, but they persisted in spleen and bone marrow. Conclusion: Our results show that inhalation of aerosolized allergen generates long-lived, allergen-specific IgG(1)-secreting, IgA-secreting, and IgE-secreting plasma cells that survive cytostatic treatment. (J Allergy Clin Immunol 2009;124:819-26.)	[Luger, Elke O.; Fokuhl, Verena; Tillack, Kati; Manz, Rudolf A.; Radbruch, Andreas] DRFZ, D-10117 Berlin, Germany; [Luger, Elke O.; Worm, Margitta] Charite, Allergy Ctr Charite, Berlin, Germany; [Wegmann, Michael; Abram, Melanie; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany; [Achatz, Gernot] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria	Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg; Salzburg University	Luger, EO (corresponding author), DRFZ, Charitepl 1, D-10117 Berlin, Germany.	luger@drfz.de	Manz, Rudolf A/C-8340-2011; Achatz, Gernot/E-5073-2011	Wegmann, Michael/0000-0002-1658-1554; Radbruch, Andreas/0000-0001-5753-0000; Worm, Margitta/0000-0002-3449-1245	Charite; DRFZ; DFG	Charite; DRFZ; DFG(German Research Foundation (DFG))	E.O.L. was supported by the Charite and the DRFZ. V.F. M.A., A.R., and H.R. were supported by the DFG.	Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Brunette MG, 1996, PEDIATR NEPHROL, V10, P67, DOI 10.1007/BF00863450; Camacho SA, 1998, IMMUNOL TODAY, V19, P511, DOI 10.1016/S0167-5699(98)01327-9; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Cyster JG, 2003, IMMUNOL REV, V194, P48, DOI 10.1034/j.1600-065X.2003.00041.x; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Ehl S, 1997, J EXP MED, V185, P1241, DOI 10.1084/jem.185.7.1241; HABA S, 1994, J IMMUNOL, V152, P51; Hallstrand TS, 2004, BLOOD, V104, P3086, DOI 10.1182/blood-2004-05-1775; HOLT PG, 1984, CELL IMMUNOL, V89, P281, DOI 10.1016/0008-8749(84)90330-7; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Manz RA, 1998, INT IMMUNOL, V10, P1703, DOI 10.1093/intimm/10.11.1703; Manz RA, 2002, EUR J IMMUNOL, V32, P923, DOI 10.1002/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1; MILLER JJ, 1964, J IMMUNOL, V92, P673; Moser K, 2006, CURR OPIN IMMUNOL, V18, P265, DOI 10.1016/j.coi.2006.03.004; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Ochsenbein AF, 2000, P NATL ACAD SCI USA, V97, P13263, DOI 10.1073/pnas.230417497; Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; WYCZOLKOWSKA J, 1983, INT ARCH ALLER A IMM, V72, P16, DOI 10.1159/000234834; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	37	72	75	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					819	826		10.1016/j.jaci.2009.06.047	http://dx.doi.org/10.1016/j.jaci.2009.06.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815119	Bronze			2022-12-18	WOS:000270802800029
J	Sykes, A; Johnston, SL				Sykes, Annemarie; Johnston, Sebastian L.			Etiology of asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exacerbations; virus; bacteria; allergen	CHLAMYDIA-PNEUMONIAE; EPITHELIAL-CELLS; INFECTION; RHINOVIRUS; EXPOSURE; RISK; FREQUENCY; SEVERITY	Asthma exacerbations are common, and the major morbidity, mortality, and health care costs associated with asthma are related to exacerbations. The majority are related to viral infection, and although progress has been made in identifying the mechanisms of virus-induced asthma exacerbations, there is still much to be learned. Allergen exposure causes some exacerbations and can participate in virus-induced exacerbations, as can other environmental exposures. A role for atypical bacterial infection in exacerbations is also increasingly recognized. Exacerbations are characterized by airway inflammation, which can differ in type depending on whether it is primarily infective or allergic in origin. An increased understanding of the inflammatory pathways might lead to identification of targets for the development of novel prevention or treatment strategies.	[Sykes, Annemarie] Univ London Imperial Coll Sci Technol & Med, MRC, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London W2 1PG, England	Imperial College London; Imperial College London; University of London; King's College London	Sykes, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Natl Heart & Lung Inst, Dept Resp Med, Norfolk Pl, London W2 1PG, England.	Annemarie.sykes@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Biscione GL, 2004, EUR RESPIR J, V24, P745, DOI 10.1183/09031936.04.00049004; Blasi F, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-83; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Jahn HU, 2000, J INFECT DIS, V182, P1678, DOI 10.1086/317608; Johnston SL, 2006, J ALLERGY CLIN IMMUN, V117, P1233, DOI 10.1016/j.jaci.2006.03.035; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KaukorantaTolvanen SSE, 1996, MICROB PATHOGENESIS, V21, P215, DOI 10.1006/mpat.1996.0056; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MESSAGE SD, 2008, P NATL ACAD IN PRESS; Mills GD, 2000, INT J EPIDEMIOL, V29, P280, DOI 10.1093/ije/29.2.280; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; Redecke V, 1998, AM J RESP CELL MOL, V19, P721, DOI 10.1165/ajrcmb.19.5.3072; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046	31	72	76	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					685	688		10.1016/j.jaci.2008.08.017	http://dx.doi.org/10.1016/j.jaci.2008.08.017			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014758				2022-12-18	WOS:000259989000007
J	Smith, CW				Smith, C. Wayne			Adhesion molecules and receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						integrins; selectins; immunoglobulin superfamily; leukocytes; adhesion; shear stress; intercellular adhesion molecule; junctional adhesion molecule	INTEGRIN REGULATION; STRUCTURAL BASIS; CATCH BONDS; LEUKOCYTE; DEFICIENCY; TRAFFICKING; ALPHA	Adhesion molecules are necessary for leukocyte trafficking and differentiation. They serve to initiate cell-cell interactions under conditions of shear, and they sustain the cell-cell and cell-matrix interactions needed for cellular locomotion. They also can serve directly as signaling molecules activating pathways critical to cell functions, and they can act as accessory molecules maintaining cellular contacts necessary for signaling through other receptors. Given their critical role in the emigration of leukocytes into sites of inflammation, genetic mutations that thwart adhesion molecule expression or function can produce profound disruptions in host defense. Adhesion molecules might serve as therapeutic targets for inflammatory diseases.	Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine	Smith, CW (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, 1100 Bates,Rm 6014, Houston, TX 77030 USA.	cwsmith@bcm.tmc.edu						Alon R, 2007, IMMUNITY, V26, P17, DOI 10.1016/j.immuni.2007.01.002; Dunehoo AL, 2006, J PHARM SCI-US, V95, P1856, DOI 10.1002/jps.20676; Etzioni A, 2004, CURR OPIN ALLERGY CL, V4, P485, DOI 10.1097/00130832-200412000-00003; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Hellbusch CC, 2007, J BIOL CHEM, V282, P10762, DOI 10.1074/jbc.M700314200; Helmus Y, 2006, BLOOD, V107, P3959, DOI 10.1182/blood-2005-08-3334; Hordijk PL, 2006, FEBS J, V273, P4408, DOI 10.1111/j.1742-4658.2006.05440.x; Huang MT, 2006, BLOOD, V107, P4721, DOI 10.1182/blood-2005-11-4683; Huang MT, 2005, BLOOD, V106, P1636, DOI 10.1182/blood-2004-12-4716; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Joshi A, 2006, J CLIN PHARMACOL, V46, P10, DOI 10.1177/0091270005283282; Kaneider NC, 2006, FEBS J, V273, P4416, DOI 10.1111/j.1742-4658.2006.05441.x; Kapiotis S, 2006, ARTERIOSCL THROM VAS, V26, P2541, DOI 10.1161/01.ATV.0000245795.08139.70; Kinashi T, 2007, ADV IMMUNOL, V93, P185, DOI 10.1016/S0065-2776(06)93005-3; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Lee G, 2006, BLOOD, V108, P2064, DOI 10.1182/blood-2006-03-006759; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Malech HL, 2007, CURR OPIN HEMATOL, V14, P29, DOI 10.1097/00062752-200701000-00007; Mandell KJ, 2005, ADV DRUG DELIVER REV, V57, P857, DOI 10.1016/j.addr.2005.01.005; Movahedi M, 2007, J CLIN IMMUNOL, V27, P302, DOI 10.1007/s10875-006-9069-4; Nyman-Huttunen H, 2006, J CELL SCI, V119, P3057, DOI 10.1242/jcs.03045; Petri B, 2006, FEBS J, V273, P4399, DOI 10.1111/j.1742-4658.2006.05439.x; Pitchford SC, 2005, BLOOD, V105, P2074, DOI 10.1182/blood-2004-06-2282; Sperandio M, 2006, FEBS J, V273, P4377, DOI 10.1111/j.1742-4658.2006.05437.x; STAUNTON DE, 2007, ADV IMMUNOL, V91, P111; Thomas W, 2006, J CELL BIOL, V174, P911, DOI 10.1083/jcb.200609029; Wang YM, 2005, CIRCULATION, V112, P2993, DOI 10.1161/CIRCULATIONAHA.105.571315; Witkowska AM, 2004, EUR CYTOKINE NETW, V15, P91; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7; Zarbock A, 2007, BLOOD REV, V21, P99, DOI 10.1016/j.blre.2006.06.001; Zhu C, 2005, BIORHEOLOGY, V42, P443; Zollner TM, 2007, EXP DERMATOL, V16, P1, DOI 10.1111/j.1600-0625.2006.00503.x	32	72	85	4	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S375	S379		10.1016/j.jaci.2007.07.030	http://dx.doi.org/10.1016/j.jaci.2007.07.030			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241685				2022-12-18	WOS:000253426600004
J	Sands, MF; Blume, JW; Schwartz, SA				Sands, Mark F.; Blume, Jessica W.; Schwartz, Stanley A.			Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTI-IGE; ASTHMA; EOSINOPHIL		Univ Buffalo State Univ New York, Div Rheumatol Allergy & Immunol, Buffalo, NY USA; VA Western New York Hlth Syst, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sands, MF (corresponding author), Univ Buffalo State Univ New York, Div Rheumatol Allergy & Immunol, Buffalo, NY USA.	mfsands@buffalo.edu	Schwartz, Stanley A./AAP-8852-2021	Schwartz, Stanley A./0000-0002-8664-1380				Avila PC, 2007, ANNU REV MED, V58, P185, DOI 10.1146/annurev.med.58.061705.145252; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Frigas E, 2006, IMMUNOL ALLERGY CLIN, V26, P739, DOI 10.1016/j.iac.2006.09.004; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Noga O, 2006, J ALLERGY CLIN IMMUN, V117, P1493, DOI 10.1016/j.jaci.2006.02.028; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184	9	72	72	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					979	981		10.1016/j.jaci.2007.07.041	http://dx.doi.org/10.1016/j.jaci.2007.07.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931567				2022-12-18	WOS:000250157700046
J	Hasannejad, H; Takahashi, R; Kimishima, M; Hayakawa, K; Shiohara, T				Hasannejad, Habib; Takahashi, Ryo; Kimishima, Momoko; Hayakawa, Kazuhito; Shiohara, Tetsuo			Selective impairment of Toll-like receptor 2-mediated proinflammatory cytokine production by monocytes from patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						proinflammatory monocytes; Fc epsilon RI; Toll-like receptor 2; atopic dermatitis	PERIPHERAL-BLOOD; DENDRITIC CELLS; RECOGNITION; TLR2; IGE; ACTIVATION; EXPRESSION; APOPTOSIS; CHILDREN; SUBSETS	Background: The skin of patients with atopic dermatitis (AD) exhibits a striking susceptibility to infection with gram-positive bacteria and herpes simplex virus (HSV), which are known to stimulate Toll-like receptor (TLR) 2. Objective: We investigated whether TLR2-mediated proinflammatory cytokine production by monocytes is selectively impaired in patients with AD and, if so, whether high Fc epsilon.RI levels on the monocytes could be related to the impairment. Methods: The 2 subpopulations of monocytes, CD14(dim) proinflammatory and CD14(bright) classical monocytes, from patients with AD and healthy control subjects were stimulated to produce IL-1 beta and TNF-a with phorbol 12-myristate 13-acetate/ionomycin, LPS (TLR4 ligand), or Pam3Cys (TLR2 ligand) for 4 hours, and simultaneous flow cytometric assessment of surface phenotype and intracellular cytokine synthesis was performed. Surface expression of TLR2, TLR4, and Fc epsilon RI on the monocyte subpopulations was also assessed by means of How cytometry. Results: TLR2-mediated IL-1 beta and TNF-a production by either the CD14(dim), or CD14(bright) monocytes was found to be selectively impaired in patients with AD. The most remarkable reduction in TLR2-mediated proinflammatory cytokine production was observed in CD14(dim) monocytes expressing high Fc epsilon RI levels from patients with AD. This reduction was restored by means of downregulation of their Fc epsilon RI expression after preculture in the absence of IgE. Conclusion: Monocytes, particularly the proinflammatory monocytes, from patients with AD are functionally defective in their capacity to produce proinflammatory cytokines on TLR2 stimuli in part because of the high levels of their Fc epsilon RI expression. Clinical implications: This selective impairment of monocytes would explain why patients with AD are specifically susceptible to cutaneous staphylococcal and streptococcal and HSV infections.	Kyorin Univ, Sch Med, Div Flow Cytometry, Mitaka, Tokyo 1818611, Japan; Kyorin Univ, Sch Med, Dept Dermatol, Mitaka, Tokyo 1818611, Japan	Kyorin University; Kyorin University	Takahashi, R (corresponding author), Kyorin Univ, Sch Med, Div Flow Cytometry, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	ryo@kyorin-u.ac.jp						Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Ancuta P, 2000, EUR J IMMUNOL, V30, P1872, DOI 10.1002/1521-4141(200007)30:7<1872::AID-IMMU1872>3.0.CO;2-2; Beeren IMJ, 2005, J ALLERGY CLIN IMMUN, V116, P228, DOI 10.1016/j.jaci.2005.02.039; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; BORISH L, 1991, J IMMUNOL, V146, P63; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; FINGERLE G, 1993, BLOOD, V82, P3170; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goodyear HM, 1996, BRIT J DERMATOL, V134, P85, DOI 10.1046/j.1365-2133.1996.d01-731.x; GROSSET P, 2001, J ALLERGY CLIN INVES, V107, P114; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Horelt A, 2002, EUR J IMMUNOL, V32, P1319, DOI 10.1002/1521-4141(200205)32:5<1319::AID-IMMU1319>3.0.CO;2-2; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kang SSW, 2006, J AM ACAD DERMATOL, V54, P951, DOI 10.1016/j.jaad.2005.05.004; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Katsuta M, 2006, J IMMUNOL, V176, P7736, DOI 10.4049/jimmunol.176.12.7736; Kondo N, 2004, CLIN EXP ALLERGY, V34, P363, DOI 10.1111/j.1365-2222.2004.01901.x; Kurt-Jones EA, 2004, P NATL ACAD SCI USA, V101, P1315, DOI 10.1073/pnas.0308057100; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Matsui E, 2000, CLIN EXP ALLERGY, V30, P1250, DOI 10.1046/j.1365-2222.2000.00931.x; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Qiao HH, 2006, BLOOD, V107, P610, DOI 10.1182/blood-2005-06-2271; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Sato A, 2006, P NATL ACAD SCI USA, V103, P17343, DOI 10.1073/pnas.0605102103; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Xia HZ, 1997, J IMMUNOL, V159, P2911	34	72	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					69	75		10.1016/j.jaci.2007.04.010	http://dx.doi.org/10.1016/j.jaci.2007.04.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17531301				2022-12-18	WOS:000248066400010
J	Gibson, PG; Powell, H; Ducharme, FM				Gibson, Peter G.; Powell, Heather; Ducharme, Francine M.			Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; long-acting beta-agonist; inhaled corticosteroid; systematic review	PERSISTENT ASTHMA; BUDESONIDE; SALMETEROL; FORMOTEROL; INFLAMMATION; EFFICACY; SAFETY	Background: Combination therapy with long-acting beta-agonists (LABAs)/inhaled corticosteroids (ICSs) has become established as effective maintenance treatment for asthma. Objective: To compare and contrast the efficacy and safety of LABAs/ICSs against different maintenance ICS strategies in adults with asthma. Methods: Cochrane systematic reviews of randomized controlled trials (to April 2004) were identified that compared the addition of LABA to ICS against 3 inhaled corticosteroid strategies: (1) a similar dose (n = 4312 subjects), (2) a higher dose (n = 4951), and (3) a similar dose in steroid-naive subjects (n = 968). The outcomes evaluated were asthma exacerbations, asthma control, and adverse effects. Pediatric studies were excluded. Results: The addition of LABA to ICSs significantly reduced the risk of exacerbations compared with a similar ICS dose, number needed to treat = 18. The effects of LABA/ICSs on exacerbations compared with the other maintenance inhaled corticosteroid strategies were not statistically significant. LABA added to inhaled corticosteroids led to significant improvements in asthma control compared with all 3 maintenance ICS strategies. There was an increased risk of tremor with LABA/ICSs that reached significance for initial therapy, number needed to harm = 21, and compared with higher ICS doses, number needed to harm = 74. Conclusion: Maintenance asthma therapy with LABA/ICSs has differential effects on asthma control and asthma exacerbations. Clinical implications: The greatest benefit and least harm of LABAs comes when they are added to a similar ICS dose in adults with symptomatic asthma.	Univ Newcastle, John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton, NSW, Australia; Univ Newcastle, Sch Med & Populat Hlth, Callaghan, NSW, Australia; McGill Univ, Ctr Hlth, Dept Pediat, Montreal Childrens Hosp, Montreal, PQ H3A 2T5, Canada; Cooperat Res Ctr Asthma, Camperdown, NSW, Australia	Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; University of Newcastle; McGill University	Gibson, PG (corresponding author), John Hunter Hosp, HMRI, Hunter Reg Mail Ctr, Level 3,Locked Bag 1, New Lambton, NSW 2310, Australia.	Peter.Gibson@hnehealth.nsw.gov.au	Ducharme, Francine/N-8332-2013; gibson, peter/G-6194-2014	Ducharme, Francine/0000-0001-5096-0614; gibson, peter/0000-0001-5865-489X				Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2001, CURR OPIN ALLERGY CL, V1, P211; *BRIT THOR SOC, 2003, THORAX S1, V58, pI1; *CAN ASTHM CONS GU, 2005, CMAJ S, V173, pS1; *COCHR COLL, MET AN CONT DAT; *COOP RES CTR ASS, 2005, EC IMP COOP RES CTR; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GREENSTONE IR, 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jenkins C, 2006, RESPIROLOGY, V11, P276, DOI 10.1111/j.1440-1843.2006.00856.x; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Koopmans JG, 2006, THORAX, V61, P306, DOI 10.1136/thx.2005.051292; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; MURRAY JJ, 2004, ANN ALLERG ASTHMA IM, V94, P410; *NAT ASTHM COUNC, 2002, ASTHM MAN HBD 2002; *NAT I HLTH, 2002, PUBL NAT I HLTH; Nathan RA, 2006, CLIN THER, V28, P73, DOI 10.1016/j.clinthera.2006.01.008; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; New Zealand Guidelines Group, 2002, BEST PRACT EV BAS GU; Ni Chroinin M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005535; NICHROININ M, 2005, COCHRANE LIB, V2; Overbeck SE, 2005, CHEST, V128, P1121, DOI 10.1378/chest.128.3.1121; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Powell H, 2003, MED J AUSTRALIA, V178, P223, DOI 10.5694/j.1326-5377.2003.tb05167.x; Strand AM, 2004, RESP MED, V98, P1008, DOI 10.1016/j.rmed.2004.03.004	28	72	74	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					344	350		10.1016/j.jaci.2006.10.043	http://dx.doi.org/10.1016/j.jaci.2006.10.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291852	Bronze			2022-12-18	WOS:000244327900011
J	Andrews, AL; Nasir, T; Bucchieri, F; Holloway, JW; Holgate, ST; Davies, DE				Andrews, Allison-Lynn; Nasir, Tosia; Bucchieri, Fabio; Holloway, John W.; Holgate, Stephen T.; Davies, Donna E.			IL-13 receptor alpha 2: A regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; cytokine receptors; signal transduction	BRONCHIAL EPITHELIAL-CELLS; INTERLEUKIN-13 RECEPTOR; B-CELLS; GENE-EXPRESSION; ALLERGIC-ASTHMA; ALPHA-2 CHAIN; IN-VITRO; IL-13R-ALPHA-2; CLONING; IDENTIFICATION	Background: IL-13 and IL-4 share many functional properties as a result of their use of a common receptor complex comprising IL-13 receptor alpha 1 (IL-13R alpha 1) and IL-4 receptor a (IL,4R alpha). The nonsignaling receptor IL-13 receptor alpha 2 (IL-13R alpha 2) binds IL-13 with high affinity and specificity and is believed to be a decoy receptor for IL-13. Objective: We sought to examine the inhibitory effects of soluble and membrane-bound IL-13R alpha 2 on IL-13- and IL-4-mediated effects. Methods: Primary human fibroblasts were grown from endobronchial biopsy specimens obtained from volunteers. Upregulation of IL-13R alpha 2 mRNA was measured by means of RT-PCR, and the level of surface expression was measured by means of FACS. Results: We found that a recombinant soluble form of IL-13R alpha 2 blocked the effects of IL-13, but not IL-4, in fibroblasts in vitro. However, we found that the transmembrane form of IL-13Ra2 could attenuate both IL-13 and IL-4 responses, even though the response to TNF-alpha was unaffected. Furthermore, we found that IL-13R alpha 2 became associated with IL-4R alpha in the presence of IL-4. Addition of a blocking antibody to the extracellular domain of IL-13Ra2 restored responses of both IL-13 and IL-4. Conclusion: The ability of IL-13R alpha 2 to regulate IL-4 was previously unrecognized in primary airway cells. These data reveal a novel role for IL-13Roe2 as a negative regulator of both IL-13 and IL-4 signaling in human bronchial fibroblasts. Clinical implications: It appears that IL-13R alpha 2 might be a powerful suppressor of T(H)2-mediated responses and thus represents a potential therapeutic target for the treatment of asthma.	Southampton Gen Hosp, Brooke Labs MP888, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO9 5NH, Hants, England; Univ Palermo, Human Anat Sect, Dept Expt Med, I-90133 Palermo, Italy	University of Southampton; University of Southampton; University of Palermo	Davies, DE (corresponding author), Southampton Gen Hosp, Brooke Labs MP888, Div Infect Inflammat & Repair, Level F S Block, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012; Bucchieri, Fabio/F-8877-2012; Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; BUCCHIERI, Fabio/0000-0002-0209-8668; Davies, Donna/0000-0002-5117-2991	MRC [G19/34] Funding Source: UKRI; Medical Research Council [G0800766, G19/34] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andrews AL, 2002, J BIOL CHEM, V277, P46073, DOI 10.1074/jbc.M209560200; Canfield S, 2005, J IMMUNOL, V174, P2494, DOI 10.4049/jimmunol.174.5.2494; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Jakubzick C, 2004, J CLIN PATHOL, V57, P477, DOI 10.1136/jcp.2003.012799; Joshi BH, 2003, CROAT MED J, V44, P455; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Lordan JL, 2002, J IMMUNOL, V169, P407, DOI 10.4049/jimmunol.169.1.407; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Mintz A, 2002, NEOPLASIA, V4, P388, DOI 10.1038/sj.neo.7900234; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rahaman SO, 2002, CANCER RES, V62, P1103; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yasunaga S, 2003, CYTOKINE, V24, P293, DOI 10.1016/j.cyto.2003.08.006; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zheng T, 2003, J ALLERGY CLIN IMMUN, V111, P720, DOI 10.1067/mai.2003.1383; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	40	72	81	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					858	865		10.1016/j.jaci.2006.06.041	http://dx.doi.org/10.1016/j.jaci.2006.06.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030238	Bronze			2022-12-18	WOS:000241434200012
J	Boguniewicz, M; Schmid-Grendelmeier, P; Leung, DYM				Boguniewicz, Mark; Schmid-Grendelmeier, Peter; Leung, Donald Y. M.			Atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						atopic dermatitis; Staphylococcus aurcus; herpes simplex virus; Malassezia species; topical calcineurin inhibitors; epidermal barrier; specific immunotherapy; omalizumab	TACROLIMUS		Natl Jewish Med & Res Ctr, Div Pediat AllergyImmunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80202 USA; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Zurich; University Zurich Hospital	Boguniewicz, M (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat AllergyImmunol, 1400 Jackson St,Room J310, Denver, CO 80206 USA.	boguniewiczm@njc.org						Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Boguniewicz Mark, 2003, Journal of Allergy and Clinical Immunology, V112, pS140, DOI 10.1016/j.jaci.2003.09.031; De Knott HMR, 2006, CONTACT DERMATITIS, V54, P92, DOI 10.1111/j.0105-1873.2006.00774.x; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Hauk PJ, 2001, J ALLERGY CLIN IMMUN, V107, P391, DOI 10.1067/mai.2001.112848; Kyllonen H, 2004, BRIT J DERMATOL, V150, P1174, DOI 10.1111/j.1365-2133.2004.06017.x; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; Paul C, 2006, PEDIATRICS, V117, pE118, DOI 10.1542/peds.2005-1188; Reitamo S, 2001, J ALLERGY CLIN IMMUN, V107, P445, DOI 10.1067/mai.2001.113521; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, P1419, DOI 10.1016/j.jaci.2006.01.051; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x	16	72	78	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					40	43		10.1016/j.jaci.2006.04.044	http://dx.doi.org/10.1016/j.jaci.2006.04.044			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815136				2022-12-18	WOS:000239184800004
J	Russano, AM; Agea, E; Corazzi, L; Postle, AD; De Libero, G; Porcelli, S; de Benedictis, FM; Spinozzi, F				Russano, Anna M.; Agea, Elisabetta; Corazzi, Lanfranco; Postle, Antyony D.; De Libero, Gennaro; Porcelli, Steven; de Benedictis, Fernando M.; Spinozzi, Fabrizio			Recognition of pollen-derived phosphatidylethanolamine by human CD1d-restricted gamma delta T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cypress pollen; olive pollen; phospholpids; phosphatidyl-ethanolamine; rhinitis; nasal mucosa; gamma delta T lymphocytes; T-cell clones; CD1-restriction; cytokines; IL-4; skin prick tests; spicific IgE	ANTIGEN RECOGNITION; LYMPHOCYTES BEARING; CYTOKINE ANALYSIS; PROTECTIVE ROLE; NKT CELLS; RECEPTOR; TUBERCULOSIS; ACTIVATION; V-ALPHA-14; EXPANSION	Background: Evidences from mice and human beings indicate that gamma delta T cells could be relevant in recognition of stress-induced self and/or yet unidentified inhaled foreign antigens. Their specificity differs from classic MHC-restricted alpha beta T cells and involves the immunoglobulin-like structure of they gamma delta T-cell receptor with the recognition of small organic molecules, alkylamines, and self lipid compounds presented by CD1(+) dendritic cells. Objective: Because CD1 receptors are mainly devoted to lipid antigen presentation, we sought to determine whether exogenous pollen membrane lipids may act as allergens for CD1-restricted gamma delta T cells. Methods: Peripheral blood and nasal mucosa-associated gamma delta T cells were cloned from normal controls and cypress-sensitive subjects and tested for their antigen specificity and CD1-restriction with phospholipids extracted from tree pollen grains, as well with other natural or synthetic compounds. Phospholipid reactivity of cloned gamma delta T cells was measured by mean of proliferative response and cytokine release as well as by testing their helper activity on IgE production in vitro and in vivo. Results: Cloned gamma delta T lymphocytes from subjects with allergy, but not normal controls, were found to recognize pollen-derived phosphatidyl-ethanolamine (PE) in a CD1d-restricted fashion. Only 16:0/18:2 and 18:2/18:2 PE were stimulatory, whereas no response was recorded for disaturated PE, phosphatidylcholine, neutral lipids, or protein extract. Proliferating clones secreted both T(H)1-type and T(H)2-type cytokines and drove IgE production in vitro and in vivo. Conclusion: CD1d-restricted gamma delta T cells specific for phospholipids can represent a key mucosal regulatory subset for the control of early host reactivity against tree pollens. Clinical implications: By knowing how lipid allergen constituents interact with mucosal immune system, we can expand our possibilities in diagnostic and therapeutic interventions.	Univ Perugia, Dept Clin & Hlth Med, I-06122 Perugia, Italy; Univ Perugia, Dept Internal Med, Biochem Sect, I-06122 Perugia, Italy; Univ Southampton, Sch Med, Infect Inflammat & Repair Div, Southampton SO9 5NH, Hants, England; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Albert Einstein Coll Med, Bronx, NY 10467 USA; Salesi Chilrens Hosp, Dept Paediat, Div Paediat Med, Ancona, Italy	University of Perugia; University of Perugia; University of Southampton; University of Basel; Yeshiva University; Albert Einstein College of Medicine	Spinozzi, F (corresponding author), Univ Perugia, Dept Clin & Hlth Med, I-06122 Perugia, Italy.	spinozzi@unipg.it	; De Libero, Gennaro/P-2694-2017	CORAZZI, Lanfranco/0000-0001-5184-6610; Postle, Anthony/0000-0001-7361-0756; De Libero, Gennaro/0000-0003-0853-7868	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048933, R01AI045889] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48933, R01 AI45889] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; BAEZA I, 1994, J MOL EVOL, V39, P560, DOI 10.1007/BF00160401; BALBI B, 1993, AM REV RESPIR DIS, V148, P1685, DOI 10.1164/ajrccm/148.6_Pt_1.1685; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Battistini L, 1997, J IMMUNOL, V159, P3723; Bedinger Patricia A., 1994, Trends in Cell Biology, V4, P132, DOI 10.1016/0962-8924(94)90068-X; Benlagha K, 2000, SEMIN IMMUNOL, V12, P537, DOI 10.1006/smim.2000.0276; BERTOTTO A, 1993, EUR J IMMUNOL, V23, P1177, DOI 10.1002/eji.1830230531; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797; De Libero G, 2000, SPRINGER SEMIN IMMUN, V22, P219, DOI 10.1007/s002810000043; De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631; Ferrick DA, 2000, SPRINGER SEMIN IMMUN, V22, P283, DOI 10.1007/s002810000047; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garcia VE, 1997, J IMMUNOL, V159, P1328; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; Jackman RM, 1998, IMMUNITY, V8, P341, DOI 10.1016/S1074-7613(00)80539-7; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kabelitz D, 2000, INT ARCH ALLERGY IMM, V122, P1, DOI 10.1159/000024353; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LADEL CH, 1995, EUR J IMMUNOL, V25, P2877, DOI 10.1002/eji.1830251025; Li HM, 1998, NATURE, V391, P502, DOI 10.1038/35172; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Pawankar RU, 1996, AM J RESP CRIT CARE, V153, P1655, DOI 10.1164/ajrccm.153.5.8630617; Rauch J, 2003, J BIOL CHEM, V278, P47508, DOI 10.1074/jbc.M308089200; SCALISE F, 1992, IMMUNOLOGY, V76, P668; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCIAMMAS R, 1994, J IMMUNOL, V152, P5392; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TSUJI M, 1994, P NATL ACAD SCI USA, V91, P345, DOI 10.1073/pnas.91.1.345; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	41	72	74	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1178	1184		10.1016/j.jaci.2006.01.001	http://dx.doi.org/10.1016/j.jaci.2006.01.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675349	Bronze			2022-12-18	WOS:000237436300033
J	Valerio, CR; Murray, P; Arlian, LG; Slater, JE				Valerio, CR; Murray, P; Arlian, LG; Slater, JE			Bacterial 16S ribosomal DNA in house dust mite cultures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen extracts; house dust mites; endotoxin; lipopolysaccharide; bacteria; allergen immunotherapy	BARTONELLA-QUINTANA; LIPOPOLYSACCHARIDE; AMPLIFICATION; HENSELAE; DISEASE; PCR	Background: Allergen extracts prepared from Dermatophagoides farinae contain significantly more endotoxin than Dermatophagoides pteronyssinus extracts, and extracts from both mite extracts contain more endotoxin than pollen extracts. Attempts to culture bacteria from mite cultures have failed to establish the sources of the endotoxin. Objective: To determine the bacterial sources of endotoxin in mite extracts. Methods: Live mites of both species were obtained from 2 sources, DNA was extracted from the mites, and DNA encoding bacterial 16S ribosomal RNA was amplified by using specific primers. The amount of bacterial DNA in each mite DNA sample was determined by quantitative PCR using an internal standard, and sequence homologies were determined from amplifications performed by using a high-fidelity DNA polymerase. Results: DNA from D farinae appeared to contain between 11-fold and 24-fold more 16S ribosomal gene copies than the genomic DNA from D pteronyssinus (P <= .003). Sequence analysis indicated the dominant presence of at least 3 phylogenetic clusters of Bartonella species (henselae, quintana, vinsonii, and grahamii), as well as uncharacterized alpha-proteobacteria, from both D farinae and D pteronyssinus. In a few clones, sequences from Escherichia coli, Pseudomonas species, and Acinetobacter species were also identified. Conclusion: House dust mite DNA contains evidence of Bartonella and other Gram-negative species. These Gram-negative species are likely to be the sources of the endotoxin found in mite allergenic extracts.	Ctr Biol Evaluat & Res, US FDA, Rockville, MD 20852 USA; Natl Inst Hlth, Bethesda, MD USA; Wright State Univ, Dayton, OH 45435 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; University System of Ohio; Wright State University Dayton	Slater, JE (corresponding author), Ctr Biol Evaluat & Res, US FDA, HFM 422,1401 Rockville Pike, Rockville, MD 20852 USA.	slaterj@cber.fda.gov						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bown KJ, 2004, EMERG INFECT DIS, V10, P684, DOI 10.3201/eid1004.030455; Brown T.A., 2002, GENOMES, V2nd edition; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Halos L, 2004, APPL ENVIRON MICROB, V70, P6302, DOI 10.1128/AEM.70.10.6302-6305.2004; Jeyaprakash A, 2003, J INVERTEBR PATHOL, V84, P96, DOI 10.1016/j.jip.2003.08.007; Matera G, 2003, INT IMMUNOPHARMACOL, V3, P853, DOI 10.1016/S1567-5769(03)00059-6; MILLER MA, 1990, CLIN APPL LIMULUS AM, P1; REGNERY R, 1995, EMERG INFECT DIS, V1, P16; Rolain JM, 2003, EMERG INFECT DIS, V9, P338, DOI 10.3201/eid0903.020278; Schabereiter-Gurtner C, 2003, J MICROBIOL METH, V52, P251, DOI 10.1016/S0167-7012(02)00186-0; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; SMITH TF, 1986, ANN ALLERGY, V57, P410; Tompkins LS, 1997, NEW ENGL J MED, V337, P1916, DOI 10.1056/NEJM199712253372610; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; [US Department of Health and Human Services Public Health Service Food and Drug Administration], 1987, GUID VAL LIM AM LYS; Valerio C., 2004, Journal of Allergy and Clinical Immunology, V113, pS136, DOI 10.1016/j.jaci.2003.12.489; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; WELCH DF, 2003, MANUAL CLIN MICROBIO, P824; Wheeler AW, 2004, EXPERT OPIN BIOL TH, V4, P1473, DOI 10.1517/14712598.4.9.1473; WOLFF SM, 1973, J INFECT DIS, V128, pS259, DOI 10.1093/infdis/128.Supplement_1.S259; Zahringer U, 2004, J BIOL CHEM, V279, P21046, DOI 10.1074/jbc.M313370200	23	72	75	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1296	1300		10.1016/j.jaci.2005.09.046	http://dx.doi.org/10.1016/j.jaci.2005.09.046			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337462				2022-12-18	WOS:000235687000021
J	Johnson, VJ; Yucesoy, B; Luster, MI				Johnson, VJ; Yucesoy, B; Luster, MI			Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toluene diisocyanate; occupational asthnia; IL-1; IL-1 receptor type I; IL-1 beta; IL-1 alpha; TDI	DEPENDENT ANTIBODY-PRODUCTION; EOSINOPHILIC INFLAMMATION; OCCUPATIONAL ASTHMA; ADHESION MOLECULES; T-CELLS; MICE; SENSITIZATION; INHIBITION; INDUCTION; MIGRATION	Background: IL-1 is a pleotropic cytokine that has been shown to play a prominent role in asthma induced by large molecular-weight proteins. Increased IL-1 inummostaining in the submucosa of patients with toluene diisocyanate (TDI)-induced asthma has also been observed, suggesting that this cytokine might also be important in asthma associated with low-molecular-weight chemicals. Objective: We sought to determine the role of IL-1 signaling in airway reactivity and inflammation by using a marine model of TDI-induced asthma. Methods: C57BL/6 mice were exposed to TDI by means of vapor inhalation (20 ppb; 4 hours per day, 5 days per week, for 6 weeks) and then challenged 2 weeks later by inhalation with 20 ppb TDI vapor for 1 hour. Results: Sensitized-challenged mice showed increased airway hyperresponsiveness (AHR), increased levels of TDI-specific IgG(1) antibodies, airway epithelial thickening, inflammation consisting of infiltrating lymphocytes and eosinophils, and increased mRNA expression of IL-4, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in the lung. Prevention of IL-1 signaling through deletion of the IL-1 receptor type I or administration of neutralizing antibodies to both IL-1P and IL-1 alpha abrogated the development of TDI-induced asthma. A partial reduction in AHR and TDI-specific IgG(1) levels was observed in mice administered anti-IL-1p, whereas anti-IL-1 alpha had no effect on either parameter. Antibodies to IL-1 beta or IL-1 alpha alone blocked airway inflammation and the expression of IL-4 and adhesion molecules in the lung. Conclusions: These results suggest that IL-1 signaling is critical for AHR and airway inflammation, with wIL-1 beta and IL-1 alpha having unique and overlapping roles in TDI-induced occupational asthma.	NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Johnson, VJ (corresponding author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,Mail Stop 3014, Morgantown, WV 26505 USA.	vjohnson3@cdc.gov	Yucesoy, Berran/B-4497-2009; Johnson, Victor/A-7910-2009	Johnson, Victor J./0000-0002-3471-6483	NIEHS NIH HHS [Y1-ES0001-06] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Broide DH, 2000, BLOOD, V95, P263; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; EBISAWA M, 1992, J IMMUNOL, V149, P4021; FUHLBRIGGE RC, 1988, J IMMUNOL, V141, P2643; Gautrin D, 2003, EUR RESPIR J, V22, P551, DOI 10.1183/09031936.03.00047803; Glaccum MB, 1997, J IMMUNOL, V159, P3364; Hellings PW, 2002, EUR J IMMUNOL, V32, P585, DOI 10.1002/1521-4141(200202)32:2<585::AID-IMMU585>3.0.CO;2-U; Helmby H, 2004, EUR J IMMUNOL, V34, P3674, DOI 10.1002/eji.200425452; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; HOGAN MB, 1995, J ALLERGY CLIN IMMUN, V95, P913, DOI 10.1016/S0091-6749(95)70137-0; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Johnson VJ, 2004, CURR OPIN ALLERGY CL, V4, P105, DOI 10.1097/01.all.0000123966.96233.ce; Kline JN, 1998, J IMMUNOL, V160, P2555; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Macedo-Soares MF, 2004, J ALLERGY CLIN IMMUN, V114, P97, DOI 10.1016/j.jaci.2004.03.033; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; Matheson JM, 2005, TOXICOL SCI, V84, P99, DOI 10.1093/toxsci/kfi051; Matheson JM, 2005, TOXICOL SCI, V84, P88, DOI 10.1093/toxsci/kfi050; Matheson JM, 2002, AM J RESP CELL MOL, V27, P396, DOI 10.1165/rcmb.4614; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nakae S, 2001, J IMMUNOL, V167, P90, DOI 10.4049/jimmunol.167.1.90; Nakae S, 2001, IMMUNOLOGY, V104, P402, DOI 10.1046/j.1365-2567.2001.01337.x; Ott MG, 2003, CRIT REV TOXICOL, V33, P1, DOI 10.1080/713611031; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Steel R.G.D., 1980, PRINCIPLES STAT; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; Whelan R, 2004, EUR RESPIR J, V24, P559, DOI 10.1183/09031936.04.00133803; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	31	72	81	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					851	858		10.1016/j.jaci.2005.07.008	http://dx.doi.org/10.1016/j.jaci.2005.07.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210060				2022-12-18	WOS:000235686600020
J	Kato, T; Takai, T; Mitsuishi, K; Okumura, K; Ogawa, H				Kato, T; Takai, T; Mitsuishi, K; Okumura, K; Ogawa, H			Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1: Biochemical skin barrier against mite cysteine proteases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite; Der p 1; Der f 1; cysteme protease; skin-derived protease inhibitor; cystatin A; keratinocyte; IL-8; atopic dermatitis	HOUSE-DUST MITE; ATOPIC-DERMATITIS; PROTEINASE-INHIBITOR; EPITHELIAL-CELLS; ALLERGEN DER-P-1; DER-F-1; RELEASE; INFLAMMATION; EXPRESSION; CLEAVAGE	Background: Der p 1 and Der f 1 are the most immunodominant allergens produced by house dust mites and are suspected to be involved in the pathogenesis of allergy through their cysteine protease activity. However, stimulation of keratinocytes by these protease allergens and protective systems in the skin against them have not been well investigated. Objective: We purified and identified the dominant skin-derived inhibitor against the proteolytic activities of these allergens and analyzed its effect on keratinocyte activation. Methods: Recombinant allergens were used for the experiments. We analyzed whether human sweat inhibits the enzymatic activities of Der p 1 and Der f 1 and used sweat as the skin-derived material to isolate the inhibitor. The inhibitor was purified by means of column chromatography and subsequently identified by means of protein sequencing and immunoblotting. Keratinocytes were stimulated with the allergens in the absence or presence of the inhibitor, and the concentration of secreted IL-8 was measured. Results: Sweat inhibited the proteolytic activities of Der p 1 and Der f 1. The sweat inhibitor was identified as cystatin A. The stimulation of normal human keratinocytes and the human keratinocyte cell line HaCaT with these protease allergens upregulated IL-8 secretion, and addition of cystatin A blocked this upregulation. Normal human keratinocytes secreted cystatin A into the medium. Conclusions: The proteolytic activity of Der p 1 and Der f 1 stimulates human keratinocytes in vitro. Cystatin A produced by keratinocytes is the dominant biochemical skin barrier that eliminates the enzymatic activity of these mite cysteine proteases and prevents them from stimulating keratinocytes.	Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Aventis Pharma Ltd, Sanofi Aventis Grp, Tokyo, Japan	Juntendo University; Juntendo University; Juntendo University; Sanofi-Aventis	Takai, T (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-takai@med.juntendo.ac.jp	Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355				Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Comoy EE, 1998, J IMMUNOL, V160, P2456; Friedmann PS, 1999, CLIN EXP ALLERGY, V29, P869, DOI 10.1046/j.1365-2222.1999.00647.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Iwakiri K, 2004, J INVEST DERMATOL, V122, P937, DOI 10.1111/j.0022-202X.2004.22415.x; John RJ, 2000, CLIN EXP ALLERGY, V30, P784, DOI 10.1046/j.1365-2222.2000.00840.x; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; King C, 1998, J IMMUNOL, V161, P3645; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Mascia F, 2002, J ALLERGY CLIN IMMUN, V109, P532, DOI 10.1067/mai.2002.121830; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Ogawa Hideoki, 1993, Journal of Dermatological Science, V5, P197, DOI 10.1016/0923-1811(93)90767-J; Palungwachira P, 2002, J DERMATOL, V29, P573, DOI 10.1111/j.1346-8138.2002.tb00182.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; TAKAI T, IN PRESS INT ARCH AL; TAKEDA A, 1989, J BIOCHEM, V105, P986, DOI 10.1093/oxfordjournals.jbchem.a122792; Takeda A, 2002, J INVEST DERMATOL, V118, P147, DOI 10.1046/j.0022-202x.2001.01610.x; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Yasueda H, 2003, CLIN EXP ALLERGY, V33, P1654, DOI 10.1111/j.1365-2222.2003.01820.x; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x; YOKOZEKI H, 1991, AM J PHYSIOL, V260, pR314, DOI 10.1152/ajpregu.1991.260.2.R314; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	36	72	77	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					169	176		10.1016/j.jaci.2005.03.044	http://dx.doi.org/10.1016/j.jaci.2005.03.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990791				2022-12-18	WOS:000235686300026
J	Linhart, B; Hartl, A; Jahn-Schmid, B; Verdino, P; Keller, W; Krauth, MT; Valent, P; Horak, F; Wiedermann, U; Thalhamer, J; Ebner, C; Kraft, D; Valenta, R				Linhart, B; Hartl, A; Jahn-Schmid, B; Verdino, P; Keller, W; Krauth, MT; Valent, P; Horak, F; Wiedermann, U; Thalhamer, J; Ebner, C; Kraft, D; Valenta, R			A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; recombinant allergens; allergy vaccine	PHL P 2; BET V 1; BIRCH POLLEN; T-CELL; MAJOR ALLERGEN; IGE BINDING; PRATENSE; PROTEIN; IMMUNOTHERAPY; ANTIBODIES	Background: Allergy vaccines based on natural allergen extracts contain greatly varying amounts of individual allergens with different immunogenicity. Objective: To develop a novel type of allergy vaccine for complex allergen sources that combines defined amounts of the major allergens in the form of single hybrid molecules. Methods: A hybrid molecule was engineered by PCR-based mending and expression of the cDNAs coding for the 4 major grass pollen allergens and compared with its single components by circular dichroism analysis, T-cell proliferation, ELISA competition, and histamine release assays. Immune responses to the hybrid molecule were studied in BALB/c mice and rat basophil leukemia assays. Results: The hybrid contained most of the B-cell epitopes of grass pollen and could be used to diagnose allergy in 98% (n = 652) of patients allergic to grass pollen. Immunization of mice and rabbits with the hybrid induced stronger and earlier IgG antibody responses than equimolar mixtures of the components, which can be explained by the induction of stronger T-cell responses by the hybrid versus the individual components. IgG antibodies induced by vaccination with the hybrid blocked immediate allergic reactions, as demonstrated by rat basophil degranulation assays in a murine model of grass pollen allergy. Conclusion: We demonstrate for grass pollen allergy that recombinant hybrid molecules covering the spectrum of the disease-eliciting epitopes of complex allergen sources can be engineered.	Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, A-1090 Vienna, Austria; Karl Franzens Univ Graz, Inst Genet, Graz, Austria; Salzburg Univ, A-5020 Salzburg, Austria; Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; Med Univ Vienna, Dept Otolaryngol, Vienna, Austria	Medical University of Vienna; University of Graz; Salzburg University; Medical University of Vienna; Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	Thalhamer, Josef/E-5787-2011; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Keller, Walter/AAW-1501-2021; Valent, Peter/B-8533-2016	Thalhamer, Josef/0000-0003-2285-6400; Gamperl, Susi/0000-0003-0456-5095; Keller, Walter/0000-0002-2261-958X; Valent, Peter/0000-0003-0456-5095; Wiedermann, Ursula/0000-0002-1302-3223; Hartl, Arnulf/0000-0001-9626-6425; Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365				Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS559, DOI 10.1016/S0091-6749(00)90060-5; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; De Marino S, 1999, STRUCT FOLD DES, V7, P943; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1995, J IMMUNOL, V154, P1932; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Kay A.B., 1997, ALLERGY ALLERGIC DIS; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; WIDE L, 1967, LANCET, V2, P1105; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	40	72	81	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1010	1016		10.1016/j.jaci.2004.12.1142	http://dx.doi.org/10.1016/j.jaci.2004.12.1142			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867859				2022-12-18	WOS:000229055100017
J	Johnson, CC; Ownby, DR; Havstad, SL; Peterson, EL				Johnson, CC; Ownby, DR; Havstad, SL; Peterson, EL			Family history, dust mite exposure in early childhood, and risk for pediatric atopy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; atopy; bronchial hyperreactivity; children; home allergen level; IgE; skin testing	MIDDLE-CLASS CHILDREN; ALLERGEN EXPOSURE; RESPIRATORY SYMPTOMS; CAT ALLERGENS; SERUM IGE; HYPERRESPONSIVENESS; SENSITIZATION; AREA; AIR	Background: Dust mite allergen exposure is considered a major determinant of sensitization to these allergens during childhood and a risk factor for pediatric asthma. Objective: By using a birth cohort in a setting with a substantial burden of dust mite allergen, we evaluated exposure and risk for outcomes related to allergy and asthma. Methods: We collected dust from the bedrooms of 428 children born from 1987 to 1989 and measured Der f 1 and Der p 1 (mug/g dust, combined). Follow-up at 6 to 7 years of age included clinical examination, skin prick testing, specific serum g measurement, and methacholine challenge. Results: No overall association was evident for any outcome except bronchial hyperresponsiveness (adjusted odds ratio [OR], 0.62; 95% CI, 0.38-1.00; P < .050; and OR, 0.53; CI, 0.27-1.04; P < .065 for dust mite allergen levels greater than or equal to2 mug/g and >10 mug/g, respectively). With a parental history of allergy and asthma, there was an association between a positive dust mite skin test (OR, 2.09; CI, 0.93-4.73; P < .076) and dust mite allergen level >10 mug/g. The inverse was true for children without a parental history. Dust mite exposure of >10 mug/g was associated with a decreased risk of current atopic asthma among children with a parental history (OR, 0.39; CI, 0.05-3.13; P < .376), but with increased risk if without a parental history (OR, 1.52; CI, 0.22-10.6; P < .673). Conclusion: Parental history is an important independent variable in the relationship between early dust mite exposure and atopic outcomes. Increased exposure during infancy is associated with a higher risk for sensitization in the presence of a positive parental history, but is protective among children of parents without a history of atopic disease.	Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Wayne State Univ, Nat Inst Environm Hlth Sci, Ctr Mol & Cellular Toxicol Human Applicat, Detroit, MI USA; Med Coll Georgia, Sect Allergy Immunol, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Wayne State University; University System of Georgia; Augusta University	Johnson, CC (corresponding author), Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, 1 Ford Pl,5C, Detroit, MI 48202 USA.	cjohnso1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024156, R01AI050681, R56AI050681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24156, AI 50681] Funding Source: Medline; NIEHS NIH HHS [P03ES06639] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; Cabral ALB, 1999, AM J RESP CRIT CARE, V159, P1819, DOI 10.1164/ajrccm.159.6.9805093; Charpin D, 2001, LANCET, V357, P1043, DOI 10.1016/S0140-6736(05)71616-0; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Grad R, 2000, LANCET, V356, P1369, DOI 10.1016/S0140-6736(00)02834-8; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lau S, 2001, LANCET, V357, P1042, DOI 10.1016/S0140-6736(05)71615-9; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21, DOI 10.1016/S1081-1206(10)63365-0; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Peterson EL, 1999, J ALLERGY CLIN IMMUN, V104, P348, DOI 10.1016/S0091-6749(99)70378-7; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; Wickman M, 2001, LANCET, V357, P1042, DOI 10.1016/S0140-6736(05)71613-5; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3	26	72	78	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					105	110		10.1016/j.jaci.2004.04.007	http://dx.doi.org/10.1016/j.jaci.2004.04.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241351				2022-12-18	WOS:000222534300015
J	Cohn, RD; Arbes, SJ; Yin, M; Jaramillo, R; Zeldin, DC				Cohn, RD; Arbes, SJ; Yin, M; Jaramillo, R; Zeldin, DC			National prevalence and exposure risk for mouse allergen in US households	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergens; mouse allergen; mus m 1	LABORATORY-ANIMAL ALLERGY; RESPONSE RELATIONSHIPS; SENSITIZATION; WORKERS; RATS; CHALLENGE; ENDOTOXIN; CHILDREN; ASTHMA; LEAD	Background: Exposure to mouse allergen is a known cause of asthma in occupational settings and exhibits high prevalence and association with allergic sensitization in inner-city home environments. It has never been characterized on a nationally representative scale. Objective: This study was designed to characterize mouse allergen prevalence in a representative sample of US homes and to assess risk factors for increased concentrations. Methods: Allergen, questionnaire, and observational data were analyzed from the first National Survey of Lead and Allergens in Housing, a cross-sectional survey of 831 US housing units. Allergen levels were characterized and related to demographic factors and household characteristics. Results: Detectable levels of mouse allergen (Mus m 1) exist in 82% of US homes. Kitchen floor concentrations exceed 1.6 mug/ g, a level associated with increased sensitization rates, in 22% of homes. Increased concentrations (>1.6 mug/g) were observed in high-rise apartments and mobile homes, older homes, and low-income homes. Odds of having increased concentrations were increased when rodent (odds ratio [OR], 3.38) or cockroach (OR, 1.81) problems were reported and when floor mopping (OR, 2.17) was performed instead of vacuuming. Conclusions: Household mouse allergen is widespread in many settings at levels that might contribute to asthma morbidity. The likelihood of exposure can be assessed by consideration of demographic and household determinants.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Constella Grp Inc, Durham, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zeldin, DC (corresponding author), NIEHS, NIH, 111 Alexander Dr,Mail Drop D2-02, Res Triangle Pk, NC 27709 USA.		Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041, Z01ES025043, ZIAES025043, ZIAES025041, Z01ES025044] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bryant DH, 1995, MED J AUSTRALIA, V163, P415, DOI 10.5694/j.1326-5377.1995.tb124657.x; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; Gordon S, 1997, OCCUP ENVIRON MED, V54, P135, DOI 10.1136/oem.54.2.135; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Jacobs DE, 2002, ENVIRON HEALTH PERSP, V110, pA599, DOI 10.1289/ehp.021100599; JONES RB, 1995, AM IND HYG ASSOC J, V56, P398, DOI 10.1202/0002-8894(1995)056<0398:TEORHO>2.0.CO;2; Krakowiak A, 1999, EUR RESPIR J, V14, P352, DOI 10.1034/j.1399-3003.1999.14b19.x; Lieutier-Colas F, 2001, CLIN EXP ALLERGY, V31, P1449, DOI 10.1046/j.1365-2222.2001.01180.x; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Phipatanakul Wanda, 2002, Curr Allergy Asthma Rep, V2, P412, DOI 10.1007/s11882-002-0075-1; RENSTROM A, 1995, EUR RESPIR J, V8, P1514; SAKAGUCHI M, 1990, LAB ANIM SCI, V40, P613; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P474, DOI 10.1016/0091-6749(82)90124-5; VENABLES KM, 1988, BRIT J IND MED, V45, P660; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527	24	72	73	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1167	1171		10.1016/j.jaci.2003.12.592	http://dx.doi.org/10.1016/j.jaci.2003.12.592			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208600	Green Submitted			2022-12-18	WOS:000222091000024
J	Lopez-Torrejon, G; Salcedo, G; Martin-Esteban, M; Diaz-Perales, A; Pascual, CY; Sanchez-Monge, R				Lopez-Torrejon, G; Salcedo, G; Martin-Esteban, M; Diaz-Perales, A; Pascual, CY; Sanchez-Monge, R			Len c 1, a major allergen and vicilin from lentil seeds: Protein isolation and cDNA cloning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; lentil; vicilin; major allergen; cDNA; cloning; Ara h 1; vicilin subunits	ASPARAGINE-LINKED GLYCANS; ATOPIC-DERMATITIS; STORAGE PROTEINS; PEANUT ALLERGY; FOOD ALLERGEN; IDENTIFICATION; ANAPHYLAXIS; IGE; CHICKPEA; BINDING	Background: Lentils are among the main plant foods causing allergic reactions in pediatric patients in the Mediterranean area and in many Asian communities. However, very few reports have been devoted to identifying lentil allergens. Seed storage proteins of the vicilin family have been characterized as major allergens in several seed legumes and tree nuts. Objective: We sought to evaluate the role of lentil vicilins as food allergens. Methods: A serum pool and individual sera from 22 patients with lentil allergy were used in different IgE-binding assays. Mature lentil vicilin was isolated by means of cation-exchange chromatography, followed by reverse-phase HPLC, and characterized by means of N-terminal amino acid sequencing, matrix-assisted laser desorption/ionization mass spectrometry (MALDI) analysis, complex asparagine-linked glycan detection, specific IgE immunodetection with individual sera, and ELISA inhibition assays. Complete cDNAs encoding lentil vicilin variants were isolated by means of PCR with primers based on the amino acid sequence of the allergen. Results: A major IgE-binding component of approximately 50 kd was detected in lentil extracts. This component was isolated and characterized, showing a single N-terminal amino acid sequence homologous to those of legume vicilins and a broad peak (maximum at 48,613 d) in MALDI analysis. The purified allergen was recognized by 77% (17/22) of the individual sera from patients with lentil allergy and reached up to 65% inhibition of the IgE binding to the crude lentil extract. The allergen showed 3 isoforms varying in their degree of N-glycosylation. Two cDNA clones encoding different allergen variants were isolated. The amino acid sequences deduced from both clones (415 and 418 residues; 47.4 and 47.8 kd) showed greater than 50% identity with major peanut (Ara h 1) and soybean (conglutinin subunits) allergens belonging to the vicilin family. Furthermore, these sequences included those of the previously characterized lentil allergen Len c 1.02 (108 amino acid residues of the C-terminal domain) and those of a novel lentil IgE-binding protein of 26 kd. Conclusion: The mature 48-kd lentil vicilin, designated Len c 1.01, is a major allergen. Two of its processing fragments, corresponding to subunits of 12 to 16 kd (previously named Len c 1) and 26 kd, are also relevant lentil IgE-binding proteins. The sequence homology of Len c 1.01 to those of major allergens from peanut, soybean, walnut, and cashew can help to investigate potential cross-reactions among these plant foods.	UPM, Unidad Bioquim, Dept Biotecnol, ETS Ingn Agron, Madrid 28040, Spain; Hosp Infantil La Paz, Serv Alergia, La Paz, Bolivia	Universidad Politecnica de Madrid	Sanchez-Monge, R (corresponding author), UPM, Unidad Bioquim, Dept Biotecnol, ETS Ingn Agron, Ciudad Univ, Madrid 28040, Spain.		Díaz-Perales, Araceli/D-8433-2016	Díaz-Perales, Araceli/0000-0002-1093-3627; Lopez-Torrejon, Gema/0000-0003-2588-4378				Astwood JD, 2002, J ALLERGY CLIN IMMUN, V110, P26, DOI 10.1067/mai.2002.125690; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CASEY R, 1999, SEED PROTEINS, P17; CHANG S, 1993, PLANT MOL BIOL REP, V11, P133; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; de Miera LES, 1998, MOL BIOL EVOL, V15, P303, DOI 10.1093/oxfordjournals.molbev.a025927; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; IBANEZ MD, 1999, ALLERGY, V54, P1209; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; MARTIN JA, 1992, ALLERGY, V47, P185, DOI 10.1111/j.1398-9995.1992.tb00962.x; Niphadkar PV, 1997, ALLERGY, V52, P115, DOI 10.1111/j.1398-9995.1997.tb02559.x; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; Pascual CY, 1999, J ALLERGY CLIN IMMUN, V103, P154, DOI 10.1016/S0091-6749(99)70539-7; Patil SP, 2001, ANN ALLERG ASTHMA IM, V87, P140, DOI 10.1016/S1081-1206(10)62209-0; San Ireneo MM, 2000, J INVEST ALLERG CLIN, V10, P187; Sanchez-Monge R, 2000, J ALLERGY CLIN IMMUN, V106, P955, DOI 10.1067/mai.2000.109912; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Taylor SL, 1987, FOOD ALLERGY, P21; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1; Wang F, 2002, J ALLERGY CLIN IMMUN, V110, P160, DOI 10.1067/mai.2002.125208; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61	29	72	78	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1208	1215		10.1016/j.jaci.2003.08.035	http://dx.doi.org/10.1016/j.jaci.2003.08.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657885				2022-12-18	WOS:000187154200028
J	Golden, DBK; Tracy, JM; Freeman, TM; Hoffman, DR				Golden, DBK; Tracy, JM; Freeman, TM; Hoffman, DR		Insect Comm Am Academy Allergy As	Negative venom skin test results in patients with histories of systemic reaction to a sting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin test; insect venoin; insect sting; hymenoptera; anaphylaxis; venom immunotherapy; RAST	RADIOALLERGOSORBENT TEST; ALLERGY; IMMUNOTHERAPY; DIAGNOSIS; BEE; HYPERSENSITIVITY; SENSITIVITY	For more than 20 years venom immunotherapy has been the preferred treatment for Hymenoptera allergy and venom skin testing the preferred diagnostic test. Most allergists consider venom skin tests to be highly accurate and interpret a negative venom skin test result to indicate the absence of insect allergy. Furthermore, current practice guidelines do not adequately address the question of how best to manage the patient with a convincing history of insect allergy but negative skin test results. Recent case reports and published studies have forced us to reexamine this important management issue and to consider what role in vitro venom testing might have in the management of insect allergy. We reviewed the current status of what is known about the management of individuals with a history of insect allergy but negative venom skin test results and suggested modifications of current working guidelines.	Amer Acad Allergy Asthma & Immunol, Insect Allergy Comm, Milwaukee, WI 53202 USA		Golden, DBK (corresponding author), Amer Acad Allergy Asthma & Immunol, Insect Allergy Comm, 611 E Wells St, Milwaukee, WI 53202 USA.							BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; DAY JH, 1986, J ALLERGY CLIN IMMUN, V77, P142; DAY JH, 1994, J ALLERGY CLIN IMMUN, V93, P691, DOI 10.1016/0091-6749(94)90249-6; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P182, DOI 10.1016/S0091-6749(97)70222-7; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.115095; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P193, DOI 10.1016/0091-6749(83)90099-4; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Light WC, 2001, J ALLERGY CLIN IMMUN, V107, P925, DOI 10.1067/mai.2001.114985; MULLER U, 1993, ALLERGY, V48, P37; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SCHWARTZ H J, 1984, Journal of Allergy and Clinical Immunology, V73, P189; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SELCOW JE, 1980, J ALLERGY CLIN IMMUN, V65, P400, DOI 10.1016/0091-6749(80)90220-1; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	30	72	74	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					495	498		10.1067/mai.2003.1606	http://dx.doi.org/10.1067/mai.2003.1606			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679806				2022-12-18	WOS:000185231200006
J	Bernstein, DI; Biagini, RE; Karnani, R; Hamilton, R; Murphy, K; Bernstein, C; Arija, S; Berendts, B; Yeang, HY				Bernstein, DI; Biagini, RE; Karnani, R; Hamilton, R; Murphy, K; Bernstein, C; Arija, S; Berendts, B; Yeang, HY			In vivo sensitization to purified Hevea brasiliensis proteins in health care workers sensitized to natural rubber latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; natural rubber latex; Hev b; Hev b 13; skin prick test; latex allergy; health care workers	SPINA-BIFIDA; ALLERGENS; HEV-B-1; CLONING; IGE	Background: Thirteen proteins of natural rubber latex (Hevea brasiliensis) known to bind human IgE have been isolated and characterized as Hev b allergens. However, the in vivo importance of native Hev b allergens has not been defined in health care workers (HCWs) with natural rubber latex (NRL) allergy Objectives: The principal aim of this study was to identify the major in vivo Hev b allergens in HCWs with NRL allergy confirmed by percutaneous sensitivity to nonammoniated latex (NAL). Methods: Skin prick testing was performed with 7 (native) proteins purified from NAL (Hev b 1, 2, 3, 4, 6.01, 7.01, and a newly described Hev b 13) and recombinant Hev b 5 in 62 HCWs with histories of NRL allergy (group 1) confirmed by percutaneous reactivity to NAL and in 49 atopic HCWs without NRL allergy (group 2). Serial 10-fold concentrations of Hev b proteins (5 x 10(-5) mug/mL to 50 mug/mL) were tested; serum samples of subjects were assayed for serum specific IgE by immunoassays. Results: Hev b 2, Hev b 5, Hev b 6.01, and Hev b 13 produced skin reactions in more than 60% of group I subjects, with Hev b 1, 3, 4, and 7.01 eliciting reactions in less than 50%. Only I of 49 group 2 workers reacted to a single Hev b antigen (Hev b 13). Specificity of 7 Hev b allergens was 100% and 98% for Hev b 13 in identifying workers with confirmed NRL allergy. Specific IgE by AlaSTAT and CAP immunoassays was elevated in 40 of 60 (67%) and 33 of 62 (53%) of NAL-reactive workers and produced false-positive test results in 4 of 49 (8%) and 3 of 48 (6%) group 2 subjects, respectively. Conclusion: Hev b 2,5, and 6.01 are major in vivo allergens and Hev b 13 is a new major in vivo allergen among HCWs with allergy to NRL.	Univ Cincinnati, Coll Med, Cincinnati, OH USA; NIOSH, Div Appl Res & Technol, US Dept HHS, Publ Hlth Serv,Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Berstein Clin Res Ctr, Cincinnati, OH USA; SV Lebedev Synthet Rubber Res Inst, Kuala Lumpur, Malaysia	University System of Ohio; University of Cincinnati; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); United States Public Health Service; Johns Hopkins University	Bernstein, DI (corresponding author), Div Immunol & Allergy, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NIEHS NIH HHS [Y02ES10189] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010189] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; PALACIOS AS, 2001, ALLERGOL IMMUNOPATH, V29, P212; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Rihs HP, 2000, CLIN EXP ALLERGY, V30, P1285; Scheiner O, 1999, INT ARCH ALLERGY IMM, V118, P311, DOI 10.1159/000024113; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Yeang HY, 2000, J INVEST ALLERG CLIN, V10, P215; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342	15	72	76	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					610	616		10.1067/mai.2003.164	http://dx.doi.org/10.1067/mai.2003.164			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642845				2022-12-18	WOS:000181639500026
J	Boguniewicz, M; Sampson, H; Leung, SB; Harbeck, R; Leung, DYM				Boguniewicz, M; Sampson, H; Leung, SB; Harbeck, R; Leung, DYM			Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; EXOTOXINS; IGE		Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy Immunol, New York, NY USA	National Jewish Health; Icahn School of Medicine at Mount Sinai	Boguniewicz, M (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA.							Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; SCHLIEVERT PM, 1988, METHOD ENZYMOL, V165, P3439; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; STALDER JF, 1994, BRIT J DERMATOL, V131, P536; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x	9	72	77	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					651	652						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590398				2022-12-18	WOS:000171760300031
J	Schmid-Ott, G; Jaeger, B; Meyer, S; Stephan, E; Kapp, A; Werfel, T				Schmid-Ott, G; Jaeger, B; Meyer, S; Stephan, E; Kapp, A; Werfel, T			Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; T lymphocytes; IL-4; IL-5; IFN-gamma; cutaneous lymphocyte-associated antigen; stress; experimental study	NATURAL-KILLER-CELLS; T-CELLS; ACTIVATION ANTIGEN; BACTERIAL SUPERANTIGENS; INTERFERON-GAMMA; GENE-EXPRESSION; INTERLEUKIN-12; STIMULATION; PROVOCATION; MODULATION	Background: Mental stress is believed to induce an exacerbation of atopic dermatitis (AD). Until now, however, only few psychoneuroendocrinologic mechanisms underlying the link between psychological stress and exacerbation or maintenance of AD have been described. Objective: Our purpose was to conduct an investigation of immunologic parameters in the form of membrane molecules and cytokines with potential relevance for the cutaneous inflammation in an established psychological laboratory stress model. Methods: Patients with AD (n = 15) and healthy controls (n = 15) were exposed to mental stress, as described in a previous report. In vitro analyses were completed 1 hour before, immediately after, and I hour after mental stress exposure. Lymphocyte subpopulations, the cutaneous lymphocyte-associated antigen (CLA), the membrane molecule CD69(+) (early activation antigen), and intracellular IL-4, IL-5, and IFN-gamma in blood-derived lymphocytes were analyzed by flow cytometry. IL4 in the supernatant of concanavalin-A-stimulated PBMCs was determined by ELISA. Results: An increase in heart rate and blood pressure was demonstrated during psychological stress in patients with AD and healthy volunteers. We found significantly higher stress-induced increase of CLA(+) lymphocytes, T helper cells expressing IL-5, and both CD4(+) and CD8(+) lymphocytes expressing IFN-gamma on mitogenic stimulation in patients with AD mi comparison with healthy controls. In addition, we observed an earlier increase in the secretion of IL-4 in the supernatant of mitogen-stimulated lymphocytes during psychological stress in patients with AD in comparison with healthy volunteers. Conclusion: A higher stress-induced increase of CLA+ cells in the circulation in patients with AD compared to healthy controls might indicate an increased ability of T lymphocytes in AD to migrate to the skin during this psychological condition. In addition, the data of this study suggest a different stress-induced cytokine profile in circulating lymphocytes in patients with AD compared to healthy controls.	Hannover Med Sch, Dept Psychosmat Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Dermatol & Allergol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Schmid-Ott, G (corresponding author), Hannover Med Sch, Dept Psychosmat Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Werfel, Thomas/B-6921-2012	Kapp, Alexander/0000-0002-1748-6276				Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; ARNETZ BB, 1991, ACTA DERM-VENEREOL, P9; BAUME DM, 1990, CELL IMMUNOL, V131, P352, DOI 10.1016/0008-8749(90)90260-X; BISELLI R, 1992, SCAND J IMMUNOL, V35, P439, DOI 10.1111/j.1365-3083.1992.tb02879.x; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59, P419, DOI 10.1097/00006842-199707000-00012; Busse WW, 2000, J ALLERGY CLIN IMMUN, V105, pS593; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; Elsner J, 1999, ALLERGY, V54, P15, DOI 10.1111/all.1999.54.1.15; Esterling BA, 1996, PSYCHOSOM MED, V58, P264, DOI 10.1097/00006842-199605000-00010; Gerritsen W, 1996, PSYCHOSOM MED, V58, P273, DOI 10.1097/00006842-199605000-00011; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; Kodama A, 1999, J ALLERGY CLIN IMMUN, V104, P173, DOI 10.1016/S0091-6749(99)70130-2; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LEHMANN DA, 1988, J EXP MED, V168, P853; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Lina G, 1998, J CLIN MICROBIOL, V36, P1042, DOI 10.1128/JCM.36.4.1042-1045.1998; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Maes M, 1998, CYTOKINE, V10, P313, DOI 10.1006/cyto.1997.0290; Mochizuki M, 1998, J IMMUNOL, V160, P60; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PICKER LJ, 1990, AM J PATHOL, V136, P1053; RABINOWICH H, 1993, J IMMUNOL, V150, P4844; Ringsberg KC, 1999, J ALLERGY CLIN IMMUN, V103, P601, DOI 10.1016/S0091-6749(99)70231-9; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Schmid-Ott G, 1998, PSYCHOTHER PSYCHOSOM, V67, P37, DOI 10.1159/000012257; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Schmid-Ott G, 1999, ACTA DERM-VENEREOL, V79, P443; Song C, 1999, PSYCHIAT RES, V85, P293, DOI 10.1016/S0165-1781(99)00012-8; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Werfel T, 1997, ALLERGY, V52, P465, DOI 10.1111/j.1398-9995.1997.tb01031.x	46	72	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					455	462		10.1067/mai.2001.117800	http://dx.doi.org/10.1067/mai.2001.117800			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544468				2022-12-18	WOS:000171215400020
J	Gibson, PG				Gibson, PG			Monitoring the patient with asthma: An evidence-based approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; monitoring; peak flow; control; symptoms; quality management	PEAK EXPIRATORY FLOW; SELF-MANAGEMENT PLANS; RANDOMIZED CONTROLLED TRIAL; LONG-TERM TREATMENT; GENERAL-PRACTICE; EDUCATION-PROGRAM; HEALTH-CARE; QUALITY IMPROVEMENT; OCCUPATIONAL ASTHMA; CLINICAL GUIDELINES	The monitoring of symptoms, airflow obstruction, and exacerbations is essential to asthma management. Patients who practice self-monitoring in conjunction with use of a written action plan and regular medical review have significantly fewer hospitalizations, emergency department visits, and Lost time from work. Either symptom monitoring or peak expiratory flow monitoring is satisfactory, provided the results are interpreted with reference to the patient's own baseline asthma status. Regular monitoring by physicians also improves health outcomes for patients, provided the physician is systematic and monitors control, medications, and skills at regular intervals. Additional monitoring tools are under evaluation, and these include measures of airway responsiveness, airway inflammation, and Internet-based monitoring systems. Administrators need to monitor the quality and cost of care, as well as compliance with national management guidelines. Assessment of the hospitalization rate and regular audit may achieve these aims in the hospital setting. The best way to assess and monitor asthma in primary care remains an unresolved yet crucial issue because primary care physicians manage the vast burden of illness caused by asthma, Monitoring asthma outcomes is an essential step toward the successful implementation of national guidelines for the management of asthma.	John Hunter Hosp, Dept Resp & Sleep Med, Airway Res Ctr, Newcastle, NSW 2310, Australia	John Hunter Hospital	Gibson, PG (corresponding author), John Hunter Hosp, Dept Resp & Sleep Med, Airway Res Ctr, Newcastle, NSW 2310, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Ayres JG, 1996, EUR RESPIR J, V9, P886, DOI 10.1183/09031936.96.09050886; Berg J, 1997, Clin Nurs Res, V6, P225, DOI 10.1177/105477389700600304; Brand PLP, 1999, THORAX, V54, P103, DOI 10.1136/thx.54.2.103; Brewin A M, 1995, Br J Nurs, V4, P81; Bringelson L S, 1998, J Soc Health Syst, V5, P50; Brommels M, 1997, JOINT COMM J QUAL IM, V23, P23, DOI 10.1016/S1070-3241(16)30291-7; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; ChanYeung M, 1996, AM J RESP CRIT CARE, V154, P889, DOI 10.1164/ajrccm.154.4.8887581; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; COWIE L, 1997, CHEST, V112, P1134; Douma WR, 1998, EUR RESPIR J, V12, P848, DOI 10.1183/09031936.98.12040848; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Finkelstein J, 1998, J AM MED INFORM ASSN, P336; Finkelstein J, 2000, CHEST, V117, P148, DOI 10.1378/chest.117.1.148; Flaherty JH, 1998, J AM GERIATR SOC, V46, P31, DOI 10.1111/j.1532-5415.1998.tb01010.x; Gannon PFG, 1999, EUR RESPIR J, V14, P28, DOI 10.1034/j.1399-3003.1999.14a07.x; GARRETT J, 1994, THORAX, V49, P976, DOI 10.1136/thx.49.10.976; Gibson P G, 1996, J Qual Clin Pract, V16, P87; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Gibson PG, 1999, MED J AUSTRALIA, V171, P67, DOI 10.5694/j.1326-5377.1999.tb123521.x; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; GIBSON PG, 1998, AIRWAYS MODULE COCHR; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Heard AR, 1999, MED J AUSTRALIA, V171, P68, DOI 10.5694/j.1326-5377.1999.tb123522.x; HENRY RL, 1993, J PAEDIATR CHILD H, V29, P32, DOI 10.1111/j.1440-1754.1993.tb00436.x; *HUNT EXP ADV GROU, 1996, REP ASTHM OUTC HUNT; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Knoell DL, 1998, PHARMACOTHERAPY, V18, P1365; Kokubu F, 1999, Arerugi, V48, P700; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Kotses H, 1996, J ASTHMA, V33, P113, DOI 10.3109/02770909609054539; Koyama H, 1998, RESP MED, V92, P505, DOI 10.1016/S0954-6111(98)90299-2; Lahdensuo A, 1996, BRIT MED J, V312, P748; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Loeppke R, 1999, Jt Comm J Qual Improv, V25, P55; Malo JL, 1999, EUR RESPIR J, V13, P477, DOI 10.1183/09031936.99.13347799; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Mulloy E, 1996, IRISH MED J, V89, P226; Neri M, 1996, ALLERGY, V51, P313, DOI 10.1111/j.1398-9995.1996.tb00091.x; *NIH NAT HEART LUN, 1997, NIH PUBL; Paggiaro PL, 1997, EUR RESPIR J, V10, pS39; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Premaratne UN, 1999, BRIT MED J, V318, P1251; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; Richman MJ, 1998, PEDIATR ANN, V27, P563, DOI 10.3928/0090-4481-19980901-08; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; Rothe TB, 1997, EUR RESPIR J, V10, P961; RUBINFELD AR, 1976, LANCET, V1, P882; Schoch OD, 1998, RESPIRATION, V65, P320, DOI 10.1159/000029286; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SLY PD, 1994, BRIT MED J, V308, P572, DOI 10.1136/bmj.308.6928.572; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; TEO S, 1995, J PAEDIATR CHILD H, V31, P130, DOI 10.1111/j.1440-1754.1995.tb00761.x; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540, DOI 10.1164/ajrccm.157.2.9703060; Verschelden P, 1996, EUR RESPIR J, V9, P880, DOI 10.1183/09031936.96.09050880; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; YANK G, 1995, BEHAV SCI, V40, P85, DOI 10.1002/bs.3830400202; YOON R, 1993, THORAX, V48, P1110, DOI 10.1136/thx.48.11.1110; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	72	72	73	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				17	26		10.1067/mai.2000.108307	http://dx.doi.org/10.1067/mai.2000.108307			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887300				2022-12-18	WOS:000088393300002
J	Nelson, HS				Nelson, HS			The importance of allergens in the development of asthma and the persistence of symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			allergic rhinitis; asthma; indoor allergens; pollen	HOUSE-DUST-MITE; VENTILATED HEALTHY HOMES; AIRWAY HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; RELATIVE RISKS; CAT ALLERGEN; EXPOSURE; CHILDREN; REDUCTION; AVOIDANCE	The importance of allergies and allergens in the development and persistence of asthma is suggested by 3 lines of evidence. First, a number of epidemiologic studies demonstrate that sensitization to indoor allergens and the spores of the outdoor seasonal fungus Alternaria is a risk factor for the development of asthma in both children and adults. Sensitivity to pollens, on the other hand, rarely constitutes a risk for asthma but does constitute a risk for seasonal allergic rhinitis, Second, several studies, again in both children and adults, have demonstrated that, in persons sensitive to indoor allergens, the severity of asthma symptoms will vary with the level of exposure. Third, the elimination of exposure to house-dust mites has produced a remarkable reversal of asthma in sensitive children and adults. Not only have symptoms and pulmonary function improved, but there has also been evidence of a reduction in airway inflammation and hyperresponsiveness, Taken together, these studies make a strong argument for the importance of allergy and allergen exposure as aggravating factors in asthma in both children and adults and reinforce the importance of the identification and treatment of these allergen sensitivities.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.							Campbell MJ, 1997, BRIT MED J, V315, P1012, DOI 10.1136/bmj.315.7114.1012; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/ajrccm.157.3.9702070; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HARVING H, 1994, ALLERGY, V49, P713, DOI 10.1111/j.1398-9995.1994.tb02092.x; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Magnan A, 1998, EUR RESPIR J, V12, P1073, DOI 10.1183/09031936.98.12051073; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; OMENAAS E, 1995, AM J RESP CRIT CARE, V152, P1158, DOI 10.1164/ajrccm.152.4.7551364; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PIACENTINI GL, 1993, J ALLERGY CLIN IMMUN, V92, P644, DOI 10.1016/0091-6749(93)90006-2; Piacentini GL, 1996, J ALLERGY CLIN IMMUN, V97, P1079, DOI 10.1016/S0091-6749(96)70261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHIBASAKI M, 1990, ANN ALLERGY, V65, P489; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; TURNER KJ, 1988, CLIN ALLERGY, V18, P331, DOI 10.1111/j.1365-2222.1988.tb02880.x; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; VERVLOET D, 1991, ALLERGY, V46, P544; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; ZOCK JP, 1994, EUR RESPIR J, V7, P1254, DOI 10.1183/09031936.94.07071254	29	72	75	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S628	S632						5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856169				2022-12-18	WOS:000087862200007
J	MacGlashan, D; Lichtenstein, LM; McKenzie-White, J; Chichester, K; Henry, AJ; Sutton, BJ; Gould, HJ				MacGlashan, D; Lichtenstein, LM; McKenzie-White, J; Chichester, K; Henry, AJ; Sutton, BJ; Gould, HJ			Upregulation of Fc epsilon RI on human basophils by IgE antibody is mediated by interaction of IgE with Fc epsilon RI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptors; basophils; IgE antibody	IN-VIVO; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; LYMPHOCYTES-B; ALPHA-SUBUNIT; MAST-CELLS; EXPRESSION; RECEPTOR; CD23; SECRETION	Background: IgE is now known to upregulate the expression of Fc epsilon RI on human basophils, It is not known which receptor on basophils mediates this process of upregulation, Objective: We sought to determine whether galectin-3, Fc epsilon RII (CD23), or Fc epsilon RI were involved in the upregulation of Fc epsilon RI by IgE, Methods: The role of galectin-3 was examined by measuring the influence of alpha-lactose on upregulation, Basophils were examined for expression of Fc epsilon RIT (CD23) by flow cytometry and messenger (m)RNA expression. Functional discrimination between binding to Fc epsilon RII or Fc epsilon RI was examined through the use of mutant IgE-Fc fragments or anti-Fc epsilon RII antibody. Results: Upregulation of Fc epsilon RI on basophils in the presence of IgE was not altered by coincubation with alpha-lactose, eliminating a role for galectin-3. Basophils were not found to express Fc epsilon RII, as determined by flow cytometry with enriched basophil preparations or RT-PCR with highly purified basophil preparations. A mutant of the Fc fragment of IgE (IgE-Fc), which binds to Fc epsilon RI with a greater than 10-fold lower affinity than IgE or wild-type IgE-Fc but exhibits no change in affinity for Fc epsilon RII, allowed us to distinguish between the functions of the two Fc receptors. The mutant (R334S; Henry et al 1997) was required at about 30-fold higher concentration than the wild-type IgE-Fc for the same stimulation of Fc epsilon RI expression on basophils, thus excluding a role for FcRII in the response. In addition, treatment of basophils with anti-Fc epsilon RII antibody (MHM6), which is known to be competitive with IgE, had no effect on the expression of Fc epsilon RI or the ability of IgE to upregulate expression of Fc epsilon RI, Conclusion: Collectively, these data indicate that IgE interacts with Fc epsilon RI to upregulate its expression on human basophils.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Kings Coll London, Randall Inst, London WC2R 2LS, England	Johns Hopkins University; Johns Hopkins Medicine; University of London; King's College London	MacGlashan, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.			Gould, Hannah/0000-0003-0411-688X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042220, R01AI020253] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20253, AI42220] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7118, DOI 10.1073/pnas.86.18.7118; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; CRAIG SS, 1995, ANAT RECORD, V242, P211, DOI 10.1002/ar.1092420210; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; FLORESROMO L, 1990, EUR J IMMUNOL, V20, P2465, DOI 10.1002/eji.1830201116; GOFF LK, 1988, IMMUNOLOGY, V65, P213; GOLDSTEIN B, 1979, J IMMUNOL, V122, P830; GORDON J, 1987, IMMUNOLOGY, V60, P517; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; HSU DK, 1992, J BIOL CHEM, V267, P14167; ISHIZAKA K, 1970, CLIN EXP IMMUNOL, V6, P25; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; LAING JG, 1989, J BIOL CHEM, V264, P1907; Lantz CS, 1997, J IMMUNOL, V158, P2517; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Marolewski AE, 1998, BIOCHEM J, V333, P573, DOI 10.1042/bj3330573; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; PAULEUGENE N, 1992, J IMMUNOL, V149, P3066; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YOUNG RJ, 1995, PROTEIN ENG, V8, P193, DOI 10.1093/protein/8.2.193	29	72	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				492	498		10.1016/S0091-6749(99)70399-4	http://dx.doi.org/10.1016/S0091-6749(99)70399-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452777	Bronze			2022-12-18	WOS:000082364800048
J	KleinJan, A; Dijkstra, MD; Boks, SS; Severijnen, LAWFM; Mulder, PGH; Fokkens, WJ				KleinJan, A; Dijkstra, MD; Boks, SS; Severijnen, LAWFM; Mulder, PGH; Fokkens, WJ			Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen provocation; hayfever; cytokines; eosinophils; nasal mucosa; biopsy; in situ hybridization; mRNA	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; INDUCED RHINITIS; MAST-CELLS; T-CELLS; TISSUE EOSINOPHILIA; BRONCHIAL BIOPSIES; INTERLEUKIN-5 GENE; MOLECULAR-CLONING	Background: Allergic inflammation is regulated by the local production and release of several cytokines. Objectives: This study was designed to assess the changes in mRNA cytokine-positive cells after allergen provocation and to compare these cytokines with tissue eosinophilia as a marker of allergic inflammation. Methods: A grass pollen allergen provocation study was conducted in autumn, out of the hay fever season. Nasal mucosal biopsy specimens were taken before provocation and 1 hour, 24 hours, and 1 week after allergen provocation. Eosinophils and mRNA-positive cells (in situ hybridization for IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IFN-gamma, RANTES, and TNF-alpha) were assessed in the biopsy specimens. Results: After allergen provocation, an increase in cell number was found for eosinophils and cells expressing mRNA for the chemokines IL-8 and RANTES and for the T-H2 cytokines IL-10 and IL-13. Significant correlations were found between eosinophils and RANTES and eosinophils and IFN-gamma in the early phase and between eosinophils and IL-5 and eosinophils and RANTES in the late phase. The increase in eosinophils and IL-10 and IL-13 mRNA-positive cells could still be observed 1 week after allergen provocation. Conclusions: Nasal allergen provocation induced significant tissue eosinophilia and a significant increase in IL-8, IL-13, and RANTES mRNA-positive cells. A significant increase in eosinophils and IL-10 and IL-13 mRNA-positive cells compared with baseline can still be observed 1 week after a single allergen provocation.	Erasmus Univ, Erasmus Med Ctr, Dept Otorhinolaryngol, NL-3015 GD Rotterdam, Netherlands; Erasmus Univ, Erasmus Med Ctr, Dept Biostat, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	KleinJan, A (corresponding author), Erasmus Univ, Erasmus Med Ctr, Dept Otorhinolaryngol, Room Ee1655,Dr Molewaterpl 50, NL-3015 GD Rotterdam, Netherlands.		Fokkens, Wytske WJ/ABF-2185-2020					ALAM R, 1993, J IMMUNOL, V150, P3442; BACHERT C, 1995, EUR ARCH OTO-RHINO-L, V252, pS44, DOI 10.1007/BF02484434; Bachert C, 1998, AM J RHINOL, V12, P3, DOI 10.2500/105065898782103007; BACHERT C, 1995, INT ARCH ALLERGY IMM, V107, P106, DOI 10.1159/000236945; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BLOCH B, 1993, J HISTOCHEM CYTOCHEM, V41, P1751, DOI 10.1177/41.12.8245422; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Busse W, 1995, ASTHMA RHINITIS; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CYBULSKY MI, 1988, LAB INVEST, V58, P365; DOUGLASS JA, 1994, AM J RESP CRIT CARE, V150, P1108, DOI 10.1164/ajrccm.150.4.7921444; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FONG Y, 1990, CLIN IMMUNOL IMMUNOP, V55, P157, DOI 10.1016/0090-1229(90)90094-7; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; Godthelp T, 1996, J ALLERGY CLIN IMMUN, V97, P800, DOI 10.1016/S0091-6749(96)80158-8; Gosset P, 1997, CLIN EXP ALLERGY, V27, P379; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; Jahnsen FL, 1997, AM J PATHOL, V150, P2113; KARLSSON MG, 1994, APMIS, V102, P753, DOI 10.1111/j.1699-0463.1994.tb05230.x; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KLEIN SC, 1995, APMIS, V103, P345, DOI 10.1111/j.1699-0463.1995.tb01118.x; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; MALEFIJT TD, 1991, THESIS U LEIDEN LEID; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Moss RB, 1997, CLIN EXP ALLERGY, V27, P406; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MYGIND N, 1994, EUR RESPIR REV, V4, P247; NOAH TL, 1995, AM J RESP CRIT CARE, V152, P1290, DOI 10.1164/ajrccm.152.4.7551384; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696, DOI 10.1164/ajrccm.155.2.9032215; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78, DOI 10.1016/S0091-6749(97)70198-2; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Saito H, 1997, INT ARCH ALLERGY IMM, V114, P81, DOI 10.1159/000237647; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; TAGA T, 1995, HUMAN CYTOKINES THEI, P142; TANABE T, 1987, J BIOL CHEM, V262, P16580; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TERADA N, 1994, ACTA OTO-LARYNGOL, V114, P203, DOI 10.3109/00016489409126043; VanHoffen E, 1996, AM J PATHOL, V149, P1991; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; Weido AJ, 1996, ANN ALLERG ASTHMA IM, V77, P407, DOI 10.1016/S1081-1206(10)63340-6; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Ying S, 1997, J IMMUNOL, V158, P3539; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	59	72	75	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				441	450		10.1016/S0091-6749(99)70469-0	http://dx.doi.org/10.1016/S0091-6749(99)70469-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069878				2022-12-18	WOS:000079175700013
J	Hizawa, N; Freidhoff, LR; Chiu, YF; Ehrlich, E; Luehr, CA; Anderson, JL; Duffy, DL; Duston, GM; Weber, JL; Huang, SK; Barnes, KC; Marsh, DG; Beaty, TH				Hizawa, N; Freidhoff, LR; Chiu, YF; Ehrlich, E; Luehr, CA; Anderson, JL; Duffy, DL; Duston, GM; Weber, JL; Huang, SK; Barnes, KC; Marsh, DG; Beaty, TH		Collaborative Study Genetics Asthma	Genetic regulation of Dermatophagoides pteronyssinus-specific IgE responsiveness: A genome-wide multipoint linkage analysis in families recruited through 2 asthmatic sibs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE-DUST-MITE; HUMAN IMMUNE-RESPONSE; IMMUNOGLOBULIN-E RESPONSES; SHORT RAGWEED ALLERGEN; DER-P-I; UNDERLYING ASTHMA; BIOZZI MICE; POLLEN; SENSITIVITY; MARKERS	Background: Dermatophagoides pteronyssinus (Der p) is one of the most frequently implicated allergens in atopic diseases. Although HLA could play an important role in the development of the IgE response to the Der p allergens, genetic regulation by non-HLA genes influences certain HLA-associated IgE responses to complex allergens. Objective: To clarify genetic control for the expression of Der p-specific IgE, responsiveness, we conducted a genome-wide search for genes influencing Der p-specific IgE antibody levels by using 45 Caucasian and 53 African American families ascertained as part of the Collaborative Study on tho Genetics of Asthma (CSGA). Methods: Specific IgE antibody levels to the Der p crude allergen and to the purified allergens Der p 1 and Der p 2 were measured. Multipoint, nonparametric linkage analysis of 370 polymorphic markers was performed with the GENE-HUNTER program. Results: The best evidence of genes controlling specific IgE response to Der p was obtained in 2 novel regions: chromosomes 2q21-q23 (P =.0033 for Caucasian subjects) and 8p23-p21 (P =.0011 for African American subjects). Three regions previously proposed as candidate regions for atopy, total IgE, or asthma also showed evidence for linkage to Der p-specific IgE responsiveness: 6p21 (P =.0064) and 13q32-q34 (P = 0.0064) in Caucasian subjects and 5q23-q33 (P = 0.0071) in African American subjects. Conclusions: No single locus generated overwhelming evidence for linkage in terms of established criteria and guidelines for a genome-wide screening, which supports previous assertions of a heterogeneous etiology for Der p-specific IgE responsiveness. Two novel regions, 2q21-q23 and 8p23-p21, that were identified in this study merit additional study.	Johns Hopkins Asthma & Allergy Ctr, Sch Med, Baltimore, MD 21224 USA; Johns Hopkins Sch Hyg, Dept Biostat, Baltimore, MD USA; Beckman Instruments Inc, Chaska, MN USA; Johns Hopkins Sch Hyg, Dept Epidemiol, Baltimore, MD USA; Queensland Inst Med Res, Epidemiol & Populat Hlth Unit, Brisbane, Qld 4006, Australia; Howard Univ, Coll Med, Dept Microbiol, Washington, DC USA; Marshfield Med Res Fdn, Marshfield, WI 54449 USA; NHLBI, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; QIMR Berghofer Medical Research Institute; Howard University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Sch Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Chiu, Yen-Feng/E-3847-2010; Huang, Shau-Ku/F-5509-2010; Duffy, David L/B-7392-2013	Duffy, David L/0000-0001-7227-632X	NHLBI NIH HHS [HL/AI 49612] Funding Source: Medline; NIAID NIH HHS [AI20059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; BLUMENTHAL MN, 1974, SCIENCE, V184, P1301, DOI 10.1126/science.184.4143.1301; BLUMENTHAL MN, 1987, CHEST, V91, pS176, DOI 10.1378/chest.91.6.176S; CARDABA B, 1993, HUM IMMUNOL, V38, P293, DOI 10.1016/0198-8859(93)90557-H; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DUBOVSKY J, 1995, HUM MOL GENET, V4, P449, DOI 10.1093/hmg/4.3.449; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; FORD SA, 1990, CLIN EXP ALLERGY, V20, P27, DOI 10.1111/j.1365-2222.1990.tb02771.x; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; Ismail A, 1997, J ALLERGY CLIN IMMUN, V99, P216, DOI 10.1016/S0091-6749(97)70099-X; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LUEHR C, 1995, 16 EUR C ALL CLIN IM; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; MORTON NE, 1997, GENETICS ALLERGY AST, P111; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; OBRIEN RM, 1994, CLIN EXP ALLERGY, V24, P737, DOI 10.1111/j.1365-2222.1994.tb00984.x; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; Puel A, 1996, P NATL ACAD SCI USA, V93, P14742, DOI 10.1073/pnas.93.25.14742; PUEL A, 1995, J IMMUNOL, V154, P5799; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; THOMPSON SJ, 1988, IMMUNOLOGY, V64, P311; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YOUNG RP, 1992, CLIN EXP ALLERGY, V22, P205, DOI 10.1111/j.1365-2222.1992.tb03074.x; YSSEL H, 1992, J IMMUNOL, V148, P738; ZWOLLO P, 1991, IMMUNOGENETICS, V33, P141	47	72	75	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					436	442		10.1016/S0091-6749(98)70132-0	http://dx.doi.org/10.1016/S0091-6749(98)70132-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768585	hybrid			2022-12-18	WOS:000076212800017
J							AAAI Board Directors	Anaphylaxis in schools and other child-care settings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FOOD		AAAAI, Execut Off, Milwaukee, WI 53202 USA		AAAI Board Directors (corresponding author), AAAAI, Execut Off, 611 E Wells St, Milwaukee, WI 53202 USA.							*ALL SECT CAN PED, 1994, FAT AN REACT FOOD CH, V150, P337; *AM AC ALL IMM BOA, 1994, J ALLERGY CLIN IMMUN, V94, P666; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1992, J ALLERGY CLIN IMMUN, V90, P683, DOI 10.1016/0091-6749(92)90143-P; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; VALENTINE MD, 1979, ANN INTERN MED, V90, P119, DOI 10.7326/0003-4819-90-1-119; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	72	74	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					173	176						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH					2022-12-18	WOS:000075537100004
J	Erjefalt, JS; Andersson, M; Greiff, L; Korsgren, M; Gizycki, M; Jeffery, PK; Persson, GA				Erjefalt, JS; Andersson, M; Greiff, L; Korsgren, M; Gizycki, M; Jeffery, PK; Persson, GA			Cytolysis and piecemeal degranulation as distinct modes of activation of airway mucosal eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; nasal polyps; eosinophils; cytolysis; apoptosis; degranulation; eosinophil peroxidase; electron microscopy	MAJOR BASIC-PROTEIN; CELL-DEATH; ULTRASTRUCTURAL EVIDENCE; BRONCHIAL-ASTHMA; LYMPHOCYTES-T; ATOPIC ASTHMA; IN-VIVO; APOPTOSIS; INFLAMMATION; RESOLUTION	Background: Cytotoxic eosinophil granule proteins are considered important in the pathogenesis of inflammatory airway diseases, including asthma, rhinitis, and polyposis. However, little is known about the mechanisms involved in the deposition of these tissue-damaging granular products in vivo. Objective: We sought to determine the occurrence of degranulating eosinophils, those with morphologic evidence of cytolysis with associated clusters of free eosinophil granules (Cfegs), and to identify the frequency of apoptotic eosinophils in inflamed upper airway tissue. Methods: Eosinophil-rich nasal polyps were processed for transmission electron microscopy and for light microscopic evaluation of whole-mount preparations subjected to deep tissue staining for eosinophil peroxidase. Results: The mean proportion of eosinophil subtypes were intact and resting (6.8%), intact but degranulating (83%), cytolytic or Cfegs (9.9%), and apoptotic (0.0%). All degranulating eosinophils exhibited piecemeal degranulation, The occurrence of Cfegs was confirmed in nonsectioned whole-mount preparations. Depending on the appearance of their core and matrix, the specific granules were divided into four subtypes, and a degranulation index (altered per total granules) was calculated for each eosinophil. Cytolytic eosinophils had a much lower degranulation index than intact eosinophils present in the same tissue (P <.001). Conclusions: These data indicate that eosinophil cytolysis is present in human airway mucosa, that its occurrence is not an artifact of the means of tissue handling, and that cytolysis of eosinophils may occur without prior extensive degranulation, We suggest that eosinophil cytolysis is a major activation mechanism, which occurs along with, but is distinct from, other types of degranulation.	Univ Lund Hosp, Dept Physiol & Neurosci, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Clin Pharmacol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Otolaryngol, S-22185 Lund, Sweden; Astro Draco AB, Preclin Res, Lund, Sweden; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst,Lung Pathol Unit, Asthma & Allergy Res Grp, London, England	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Imperial College London	Erjefalt, JS (corresponding author), Univ Lund Hosp, Dept Physiol & Neurosci, E Blocket, S-22185 Lund, Sweden.			Erjefalt, Jonas/0000-0002-6716-3010				Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477, DOI 10.1164/ajrccm/145.6.1477; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1994, J ALLERGY CLIN IMMUN, V94, P1250, DOI 10.1016/0091-6749(94)90339-5; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; DVORAK AM, 1992, AM J PATHOL, V140, P795; DVORAK AM, 1991, AM J PATHOL, V138, P69; ERJAFALT JS, 1997, CLIN EXP ALLERGY, V27, P1345; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1458, DOI 10.1046/j.1365-2222.1997.1200932.x; Erjefalt JS, 1996, AM J RESP CRIT CARE, V153, P1666, DOI 10.1164/ajrccm.153.5.8630618; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, J IMMUNOL, V135, P1349; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GLEICH GJ, 1987, J ALLERGY CLIN IMMUN, V80, P412, DOI 10.1016/0091-6749(87)90063-7; Greiff L, 1998, ALLERGY, V53, P200, DOI 10.1111/j.1398-9995.1998.tb03871.x; JAHNSEN FL, 1995, J LEUKOCYTE BIOL, V57, P513, DOI 10.1002/jlb.57.3.513; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; MAJNO G, 1995, AM J PATHOL, V146, P3; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MOY JN, 1993, J ALLERGY CLIN IMMUN, V92, P598, DOI 10.1016/0091-6749(93)90084-S; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P117, DOI 10.1016/S0165-6147(97)01042-0; Persson CGA, 1997, THORAX, V52, P569, DOI 10.1136/thx.52.6.569; RACZ P, 1982, TROPENMED PARASITOL, V33, P213; ROCHESTER CL, 1995, CHEST, V107, pS117, DOI 10.1378/chest.107.3_Supplement.117S; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SASAKI Y, 1989, ANN ALLERGY, V63, P306; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Shimizu S, 1996, ONCOGENE, V12, P2045; Simm A, 1997, J CELL SCI, V110, P819; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; TAKASAKA T, 1990, AM J RHINOL, V4, P159; TORPIER G, 1988, CLIN EXP IMMUNOL, V74, P404; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Ueda N, 1997, Adv Ren Replace Ther, V4, P17; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604, DOI 10.1164/ajrccm/146.3.604; WATANABE K, 1977, CLIN ALLERGY, V7, P263, DOI 10.1111/j.1365-2222.1977.tb01451.x; Weiler CR, 1996, J LEUKOCYTE BIOL, V60, P493, DOI 10.1002/jlb.60.4.493; WEILER JM, 1995, IMMUNOLOGY, V84, P213; WELLER PF, 1995, AM J RESP CELL MOL, V13, P610, DOI 10.1165/ajrcmb.13.5.7576698; WELLER PF, 1994, ASTHMA RHINITIS, P255; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; ZABUCCHI G, 1991, J PATHOL, V163, P225, DOI 10.1002/path.1711630307	53	72	73	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					286	294		10.1016/S0091-6749(98)70098-3	http://dx.doi.org/10.1016/S0091-6749(98)70098-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723674				2022-12-18	WOS:000075537100023
J	Pincus, DJ; Humeston, TR; Martin, RJ				Pincus, DJ; Humeston, TR; Martin, RJ			Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled steroids; chronotherapy; dose timing; triamcinolone acetonide	DOSING FREQUENCY; BUDESONIDE	Background: Chronotherapy studies with inhaled corticosteroids have shown optimal therapeutic benefit when steroids are administered four times per day (QID) or once daily at 3 PM. Objective: This study evaluated whether more convenient once-daily dosage times (8 AM and 5:30 PM) produce improvement in asthma equivalent to QID. Methods: Efficacy outcome measures included FEV1, peak expiratory flow rates, bronchial responsiveness, use of beta(2)-agonists, nocturnal awakenings, and responses to a quality of life questionnaire. Systemic effects were blood eosinophil count, cortisol level, 24-hour urinary cortisol, and evaluation for oral candidiasis and dysphonia. Results: Baseline measurements for all three treatment groups were similar. For morning peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.001) and the 5:30 PM group (p = 0.003), but not the 8 AM group (p = 0.75). For evening peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.005) and the 5:30 PM group (p = 0.01), but not for the 8 AM group (p = 0.47). There mere significant improvements in all other outcome variables for each group except PC20. There was a significant improvement in PC20 only in the QID group. The systemic effects of the three regimens were comparable. Conclusion: Dosing of inhaled steroid at 5:30 PM had no increased systemic effects and produced efficacy similar to QID dosing. Dosing at 8 AM did not produce results consistently comparable to QID dosing. Optimal once-daily dosing of inhaled steroid is between 3 PM and 5:30 PM.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Martin, RJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [M01RR00051] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*ACCP ATS JOINT CO, 1975, CHEST, V67, P583; AYD FJ, 1974, JAMA-J AM MED ASSOC, V230, P263, DOI 10.1001/jama.230.2.263; DAHL R, 1982, EUR J RESPIR DIS, V63, P268; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3	7	72	74	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				771	774		10.1016/S0091-6749(97)70272-0	http://dx.doi.org/10.1016/S0091-6749(97)70272-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438485	Bronze			2022-12-18	WOS:000071353600009
J	Virchow, JC; Kroegel, C; Walker, C; Matthys, H				Virchow, JC; Kroegel, C; Walker, C; Matthys, H			Inflammatory determinants of asthma severity: Mediator and cellular changes in bronchoalveolar lavage fluid of patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic asthma; bronchoalveolar lavage; cytokines; intrinsic asthma; T-helper lymphocytes; T-suppressor lymphocytes	ACTIVATED T-CELLS; NONALLERGIC ASTHMA; SYMPTOMATIC ASTHMA; PERIPHERAL-BLOOD; ATOPIC ASTHMA; MAST-CELLS; EOSINOPHILIA; CYTOKINES; ALLERGEN; DISEASE	Cellular and mediator profiles in bronchoalveolar lavage have not been compared systematically between patients with asthma of different severities, mainly because the patients with more severe asthma have an increased need for antiinflammatory medication. Information is limited to comparisons of allergic and intrinsic asthma, which can be distinguished clinically. When patients from these two groups with similar degrees of bronchial hyperresponsiveness were compared, both groups showed increased numbers of activated T-helper lymphocytes; those in the allergic group expressed the IL-2 receptor (C25+) whereas in patients with intrinsic asthma there was also an increased number of T-suppressor cells with the activation markers CD25, class II histocompatibility antigen, and very late activation antigen-1, as well as T-helper cells class II histocompatibility antigen and very late activation antigen-1. This pattern is compatible with a more chronic T-cell activation in patients with intrinsic asthma. In patients with allergic asthma the cytokine pattern is compatible with a pure T-H2 response (elevated IL-4 and IL-5); however intrinsic asthma is characterized by elevated IL-5 and IL-2 but not IL-4. Our own findings show similar concentrations of IL-1, IL-8, and granulocyte-macrophage colony-stimulating factor in bronchoalveolar lavage fluid of patients with allergic and intrinsic asthma, whereas IL-6 and interferon-gamma tended to be higher in patients with intrinsic asthma. There are probably fundamental differences in the pathogenesis of allergic and intrinsic asthma. These findings suggest that asthma does not depend on the presence of IgE or IL-4, although both may contribute to the pathogenesis of atopic asthma. The only common pathway in the different presentations of asthma that has been related to clinical symptoms appears to be IL-5-mediated activation of eosinophils; therapies aimed at this mechanism may be promising.			Virchow, JC (corresponding author), UNIV FREIBURG,MED CLIN,DEPT PNEUMOL,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.							BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; KROEGEL C, 1993, NEW ENGL J MED, V328, P1639; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; *NAT HEART LUNG BL, 1992, EUR RESPIR J, V5, P601; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116, DOI 10.1164/ajrccm/146.1.116; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; VIRCHOW JC, 1994, AM J RESP CRIT CARE, V149, pA954; VIRCHOW JC, 1994, J ALLERGY CLIN IMMUN, V94, P204; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	23	72	73	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S27	S33						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939174				2022-12-18	WOS:A1996VW14000006
J	Goldberg, A; ConfinoCohen, R; Fishman, A; Beyth, Y; Altaras, M				Goldberg, A; ConfinoCohen, R; Fishman, A; Beyth, Y; Altaras, M			A modified, prolonged desensitization protocol in carboplatin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HYPERSENSITIVITY REACTIONS		TEL AVIV UNIV,SACKLER SCH MED,SAPIR MED CTR,GYNECOL ONCOL UNIT,DEPT OBSTET & GYNECOL,RAMAT AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,SAPIR MED CTR,ALLERGY & CLIN IMMUNOL UNIT,DEPT OBSTET & GYNECOL,RAMAT AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine								ACKLAND SP, 1985, CANCER TREAT REP, V69, P562; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; PLANNER RS, 1991, J NATL CANCER I, V83, P1763, DOI 10.1093/jnci/83.23.1763-a; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; TRISSEL LA, 1988, NCI INVESTIGATIONAL; WEIDMANN B, 1994, CANCER, V73, P2218, DOI 10.1002/1097-0142(19940415)73:8<2218::AID-CNCR2820730830>3.0.CO;2-1; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V90, P681, DOI 10.1016/0091-6749(92)90142-O	7	72	73	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					841	843		10.1016/S0091-6749(96)70134-3	http://dx.doi.org/10.1016/S0091-6749(96)70134-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876561				2022-12-18	WOS:A1996VM66500018
J	SUR, S; GLEICH, GJ; SWANSON, MC; BARTEMES, KR; BROIDE, DH				SUR, S; GLEICH, GJ; SWANSON, MC; BARTEMES, KR; BROIDE, DH			EOSINOPHILIC INFLAMMATION IS ASSOCIATED WITH ELEVATION OF INTERLEUKIN-5 IN THE AIRWAYS OF PATIENTS WITH SPONTANEOUS SYMPTOMATIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; EOSINOPHIL; ASTHMA; EOSINOPHIL-DERIVED NEUROTOXIN	COLONY-STIMULATING FACTOR; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES; MESSENGER-RNA; MAST-CELL; TRANSGENIC MICE; EXPRESSION; CHALLENGE; CYTOKINE; IL-5	In vitro and in vivo studies have shown an important role for interleukin-5 (IL-5) in regulating eosinophil proliferation, survival, and effector function. Because eosinophilic inflammation is an important component of symptomatic episodes of asthma, we have investigated whether increased levels of IL-5 protein are present in bronchoalveolar lavage (BAL) fluid of patients with spontaneously symptomatic asthma (FEV(1), 61% predicted; FEF(25%-75%), 30% predicted) compared with patients with asymptomatic asthma (FEV(1), 88% predicted; FEF(25%-75%), 76% predicted). The percent of BAL eosinophils (10.5% vs 0.6%) (p = 0.0001) and eosinophil-derived neurotoxin (386.0 ng/ml vs 6.3 ng/ml) (p = 0.0001) was greater in BAL fluids derived from patients with symptomatic asthma compared with patients with asymptomatic asthma. Levels of IL-5 measured with an immunoradiometric assay were significantly higher in patients with symptomatic asthma (n = 26) compared with those with asymptomatic asthma (n = 18) (274 pg/ml vs < 13 pg/ml) (p = 0.02). The increased IL-5 levels were noted in a subset of patients with symptomatic asthma with BAL absolute eosinophil counts greater than 10(6) (IL-5, 664 pg/ml; n = 10) as opposed to patients with symptomatic asthma with BAL eosinophil counts less than 10(6) (IL-5, < 13 pg/ml; n = 16) (p = 0.005). This study Suggests that IL-5 is not only induced in experimental models of allergen-induced asthma but can also be detected as asthma progresses from the asymptomatic to the clinically symptomatic state in subjects with significant BAL eosinophilia.	UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; E CAROLINA UNIV,SCH MED,DEPT MED & PEDIAT,GREENVILLE,NC; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego; Mayo Clinic; University of North Carolina; East Carolina University; University of California System; University of California San Diego				Broide, David/0000-0001-8405-9090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI015231, R01AI031155] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07047, AI 31155, AI 15231] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BRADDING P, 1993, J IMMUNOL, V151, P3853; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HITOSHI Y, 1991, INT IMMUNOL, V3, P135, DOI 10.1093/intimm/3.2.135; LANG DM, 1991, ANN ALLERGY, V67, P325; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116, DOI 10.1164/ajrccm/146.1.116; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; 1987, AM REV RESPIR DIS, V136, P225	21	72	73	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				661	668		10.1016/S0091-6749(95)70265-2	http://dx.doi.org/10.1016/S0091-6749(95)70265-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499683				2022-12-18	WOS:A1995TG52800012
J	LANGEVELDWILDSCHUT, EG; VANMARION, MW; THEPEN, T; MUDDE, GC; BRUIJNZEEL, PLB; BRUIJNZEELKOOMEN, CAFM				LANGEVELDWILDSCHUT, EG; VANMARION, MW; THEPEN, T; MUDDE, GC; BRUIJNZEEL, PLB; BRUIJNZEELKOOMEN, CAFM			EVALUATION OF VARIABLES INFLUENCING THE OUTCOME OF THE ATOPY PATCH TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPY PATCH TEST; ATOPIC ECZEMA; ATOPIC DERMATITIS; GRASS POLLEN; DERMATOPHAGOIDES PTERONYSSINUS	HOUSE DUST MITE; DERMATITIS; IGE; SKIN; PATIENT; CELLS; ASSAY	Background: The number of positive atopy patch test (APT) results in patients with atopic eczema (AE) varies in different studies, probably because of different test techniques. Variables that may influence the outcome of the APT were evaluated. Methods: APTs were performed in 84 patients with AE, 30 control patients with atopic disease, and 85 healthy volunteers, with house dust mite and grass pollen allergens in concentrations of 100, 1000, 10,000 and 100,000 allergenic units/ml. The influence of 0, 10 or 20 tape strippings was investigated. The tests were performed on the back and/or the antecubital fossa and evaluated after 20 minutes and 24, 48, and 72 hours. In all patients the total and specific serum IgE levels were measured. Results: The maximal number of positive APT results were obtained under the following conditions: an allergen concentration equal to 10,000 allergenic units/ml, 10 tape strippings and readings at 24 and 48 hours. Positive APT results were observed in five of 30 control patients with atopic disease and in none of 85 healthy volunteers. Statistically significantly higher total and allergen-specific serum IgE levels were found in the group of patients with AE with positive APT results. Conclusions: We recommend the previously described conditions to get an optimal method for APT. The correlation between the APT and the total and specific serum IgE suggests an important role for IgE in the reaction mechanism behind the APT.	STATE UNIV UTRECHT HOSP, DEPT DERMATOL, DERMATOALLERGOL UNIT, 3508 GA UTRECHT, NETHERLANDS; SANDOZ FORSCH INST VIENNA, VIENNA, AUSTRIA; TNO, DEPT PHARMACOL, 2280 AA RIJSWIJK, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Novartis; Sandoz; Netherlands Organization Applied Science Research								AUGUST PJ, 1984, BRIT J DERMATOL, V111, P10; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Drebotg S, 1989, ALLERGY S10, V44, P22; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; KORT HSM, 1993, ALLERGY, V48, P468, DOI 10.1111/j.1398-9995.1993.tb00747.x; LANGELAND T, 1989, ACTA DERM-VENEREOL, P105; MITCHELL EB, 1982, LANCET, V1, P127; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; RAJKA G, 1967, ACTA DERM-VENEREOL, V47, P158; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; Steel R.D.G., 1980, PRINCIPLES PROCEDURE, P663; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VADER PCV, 1991, ACTA DERM-VENEREOL, V71, P301; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VIELUF D, 1993, ALLERGO J, V2, P35; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x	24	72	74	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					66	73		10.1016/S0091-6749(95)70034-X	http://dx.doi.org/10.1016/S0091-6749(95)70034-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622765				2022-12-18	WOS:A1995RK38300009
J	BERNSTEIN, JA; STAUDER, T; BERNSTEIN, DI; BERNSTEIN, IL				BERNSTEIN, JA; STAUDER, T; BERNSTEIN, DI; BERNSTEIN, IL			A COMBINED RESPIRATORY AND CUTANEOUS HYPERSENSITIVITY SYNDROME INDUCED BY WORK EXPOSURE TO QUATERNARY AMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						QUATERNARY AMINES; OCCUPATIONAL ASTHMA; BENZALKONIUM CHLORIDE	INHALED PRESERVATIVES; BENZALKONIUM CHLORIDE; ASTHMATIC SUBJECTS	The quaternary amine, benzalkonium chloride, has been associated with cutaneous and mucosal delayed hypersensitivity reactions and with paradoxical bronchoconstriction after use of aerosolized asthma medications. Until now, quatenary amines have not been reported to cause occupational asthma. We describe a case of occupational asthma caused by prolonged exposure to a cleaning solution containing benzalkonium chloride in the workplace. Single-blind, placebo-controlled, open-room challenges were performed to determine the specific agent responsible for the patient's symptoms. Pulmonary function and epicutaneous challenge tests were also performed. The patient had positive responses to challenges with a liquid toilet bowl cleaner containing benzalkonium chloride but was unreactive to other agents tested. Removal from the workplace resulted in complete resolution of symptoms. The exact mechanisms responsible for occupational asthma induced by quaternary amines remain unknown; however, this case emphasizes the importance of recognizing reactive chemicals as possible causes.			BERNSTEIN, JA (corresponding author), UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV IMMUNOL,231 BETHESDA AVE,ML 563,CINCINNATI,OH 45267, USA.							BERNSTEIN IL, 1989, ADVERSE REACTIONS DR, P291; HAGMAR L, 1982, J OCCUP ENVIRON MED, V24, P193, DOI 10.1097/00043764-198203000-00010; Malo Jean-Luc, 1993, P481; SLY RM, 1990, AM REV RESPIR DIS, V142, P1466, DOI 10.1164/ajrccm/142.6_Pt_1.1466a; ZHANG YG, 1990, AM REV RESPIR DIS, V141, P1405, DOI 10.1164/ajrccm/141.6.1405	5	72	73	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					257	259		10.1016/0091-6749(94)90048-5	http://dx.doi.org/10.1016/0091-6749(94)90048-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064078				2022-12-18	WOS:A1994PC92600017
J	TANIGUCHI, Y; TAMURA, G; HONMA, M; AIZAWA, T; MARUYAMA, N; SHIRATO, K; TAKISHIMA, T				TANIGUCHI, Y; TAMURA, G; HONMA, M; AIZAWA, T; MARUYAMA, N; SHIRATO, K; TAKISHIMA, T			THE EFFECT OF AN ORAL LEUKOTRIENE ANTAGONIST, ONO-1078, ON ALLERGEN-INDUCED IMMEDIATE BRONCHOCONSTRICTION IN ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYSTEINYL LEUKOTRIENES; ASTHMA; ANTAGONIST; ONO-1078; ALLERGEN CHALLENGE	ATOPIC SUBJECTS; HUMAN-LUNG; AIRWAY; ANTIGEN; INHALATION; CHALLENGE; HISTAMINE; L-649,923; ASPIRIN; RELEASE	Background: Cysteinyl leukotrienes are potent contractile agonists for airway smooth muscle. To examine the relative role of cysteinyl leukotrienes in immediate airway obstruction in human subjects with asthma after allergen challenge, we investigated the effect of ONO-1078, a potent receptor antagonist of cysteinyl leukotrienes, on the response. Methods: ONO-1078 and an inactive placebo, in 150-mg capsule form, were administered every 12 hours for 1 week, in a double-blind, cross-over fashion. To examine the effect on the early part of the response, total respiratory resistance (Rrs) was continuously evaluated for 10 minutes after the start of a 1-minute exposure to an appropriate concentration of allergen. Rrs and FEV1.0 were estimated every 10 minutes for 60 minutes after the exposure. Results: ONO-1078 significantly reduced percent changes in Rrs and FEV1.0 from 20 to 60 minutes after the exposure, as well as percent maximum changes in these indices, although the treatment did not alter the time from the start of allergen exposure to the beginning of elevation of Rrs, the time from the start to the point at which total respiratory conductance decreased by 35% from its baseline value, or percent changes in Rrs or FEV1.0 10 minutes after the exposure. Conclusions: Therefore, we conclude that cysteinyl leukotrienes primarily mediate a later part of immediate airway obstruction after allergen exposure.	TOHOKU UNIV, SCH MED,DEPT INTERNAL MED 1,1-1 SEIRYO MACHI, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Tohoku University								ADAMS GK, 1979, J IMMUNOL, V122, P555; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; BEL EH, 1990, J ALLERGY CLIN IMMUN, V85, P1067, DOI 10.1016/0091-6749(90)90052-6; BISGAARD H, 1987, CLIN SCI, V72, P585, DOI 10.1042/cs0720585; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; MOIRA CY, 1989, J ALLERGY CLIN IMMUN, V84, P762, DOI 10.1016/0091-6749(89)90306-0; NAKAGAWA T, 1990, ADV PROSTAGLANDIN TH, V21, P465; Obata T, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P229; Obata T, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P540; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E	18	72	72	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					507	512		10.1016/0091-6749(93)90074-P	http://dx.doi.org/10.1016/0091-6749(93)90074-P			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409112				2022-12-18	WOS:A1993MC59000002
J	MALO, JL; LARCHEVEQUE, J; TRUDEAU, C; DAQUINO, C; CARTIER, A				MALO, JL; LARCHEVEQUE, J; TRUDEAU, C; DAQUINO, C; CARTIER, A			SHOULD WE MONITOR PEAK EXPIRATORY FLOW-RATES OR RECORD SYMPTOMS WITH A SIMPLE DIARY IN THE MANAGEMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY OBSTRUCTION; BRONCHIAL DISEASES; LUNG DISEASES; BRONCHI	DOSE-RESPONSE CURVES; BRONCHIAL RESPONSIVENESS; HISTAMINE; REACTIVITY; FREQUENCY; PATTERNS; METER; PLAN	Background: Various means of monitoring asthma severity have been proposed to reduce morbidity and mortality rates. We compared two means of assessing asthma flare-ups: monitoring peak expiratory flow rate (PEFR) and keeping a symptom diary. Methods: This was a crossover randomized study. After a 2-week baseline period during which spirometry and PC20 methacholine were assessed, subjects were asked to record either PEFRs or to keep a symptom diary morning and evening for 6 months; a second baseline assessment separated the two periods. Subjects were asked to contact the study coordinator if the following occurred: (1) in the period of PEFR monitoring, daily fluctuations in PEFR were >20% or the absolute value fell to <80% of baseline or both occurred; (2) in the period of symptom diary monitoring there were nocturnal symptoms or a persistence of morning dyspnea after inhaled bronchodilator or a reduction in the duration of effect of the bronchodilator or it was impossible to go to work or school or all occurred. In that case they were asked to come to the hospital to confirm the flare-up through investigation for significant changes in FEV1 or PC20 or both. Forty subjects completed a 6-month symptom diary or PEFR recording period respectively, and 20 completed both. Results: A total of 31 exacerbations were reported in 28 different subjects; three subjects had two flare-ups. Thirteen of 19 (69%) flare-ups were confirmed during the symptom diary period and 9 of 12 (75%) during PEFR monitoring. Nocturnal awakenings and morning falls in PEFR greater-than-or-equal-to 20% were the most frequent occurrences. Conclusions: We conclude that a simple symptom diary may be as useful as serial PEFR monitoring in documenting asthmatic flare-ups.	HOP SACRE COEUR, DEPT MED, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BEAUPRE A, 1981, THORAX, V36, P731, DOI 10.1136/thx.36.10.731; BERUBE D, 1991, CHEST, V99, P831, DOI 10.1378/chest.99.4.831; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; Guidelines for management of asthma in adults: I-Chronic persistent asthma, 1990, BMJ-BRIT MED J, V301, P651; HARGREAVE FE, 1988, POSTGRAD MED J, V64, P74; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HETZEL MR, 1977, THORAX, V32, P418, DOI 10.1136/thx.32.4.418; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HIGGS CMB, 1986, THORAX, V41, P671, DOI 10.1136/thx.41.9.671; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P834, DOI 10.1016/0091-6749(90)90065-C; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; OREHEK J, 1982, B EUR PHYSIOPATH RES, V18, P601; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; SAETTA M, 1989, EUR RESPIR J, V2, P1008; SILVERMAN BA, 1987, PEDIATR ASTHMA ALLER, V1, P241; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; WOOLCOCK A, 1989, MED J AUSTRALIA, V151, P650, DOI 10.5694/j.1326-5377.1989.tb139640.x; 1991, NIH913042 PUBL	28	72	72	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					702	709		10.1016/0091-6749(93)90189-M	http://dx.doi.org/10.1016/0091-6749(93)90189-M			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454792	Bronze			2022-12-18	WOS:A1993KU20300002
J	KEATING, MU; JONES, RT; WORLEY, NJ; SHIVELY, CA; YUNGINGER, JW				KEATING, MU; JONES, RT; WORLEY, NJ; SHIVELY, CA; YUNGINGER, JW			IMMUNOASSAY OF PEANUT ALLERGENS IN FOOD-PROCESSING MATERIALS AND FINISHED FOODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO CLIN & MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO GRAD SCH MED,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901; HERSHEY FOODS CORP,CTR TECH,HERSHEY,PA	Mayo Clinic; Mayo Clinic; Mayo Clinic; The Hershey Company			Shively, Carol/L-2921-2019					Anderson M.C., 1986, METHODOLOGY RAST INH, P1; ANDERSON MC, 1986, RAST INHIBITION PROC; ATKINS FM, 1988, J ALLERGY CLIN IMMUN, V82, P242, DOI 10.1016/0091-6749(88)91006-8; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; FRIES JH, 1982, ANN ALLERGY, V48, P220; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HEINER DC, 1975, J ALLERGY CLIN IMMUN, V55, P82; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; RICHMAN PG, 1988, J BIOL STAND, V16, P225, DOI 10.1016/0092-1157(88)90010-8; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; TAYLOR S L, 1982, Journal of Allergy and Clinical Immunology, V69, P128; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1983, J FOOD PROTECT, V46, P625, DOI 10.4315/0362-028X-46.7.625; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	19	72	77	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					41	44		10.1016/S0091-6749(05)80121-6	http://dx.doi.org/10.1016/S0091-6749(05)80121-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370388	Bronze			2022-12-18	WOS:A1990DQ68800007
J	JOOS, GF; PAUWELS, RA; VANDERSTRAETEN, ME				JOOS, GF; PAUWELS, RA; VANDERSTRAETEN, ME			THE EFFECT OF NEDOCROMIL SODIUM ON THE BRONCHOCONSTRICTOR EFFECT OF NEUROKININ-A IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											JOOS, GF (corresponding author), STATE UNIV GHENT HOSP,DEPT RESP DIS,DE PINTELAAN 185,B-9000 GHENT,BELGIUM.							ALI H, 1986, INT ARCH ALLER A IMM, V79, P413, DOI 10.1159/000234011; BARNES PJ, 1986, LANCET, V1, P242; BENYON RC, 1987, J IMMUNOL, V138, P861; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRIMI E, 1987, CLIN ALLERGY, V17, P135, DOI 10.1111/j.1365-2222.1987.tb02331.x; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; EADY RP, 1986, EUR J RESPIR DIS, V69, P112; FEWTRELL CMS, 1982, J PHYSIOL-LONDON, V330, P393, DOI 10.1113/jphysiol.1982.sp014347; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FOX JET, 1983, LIFE SCI, V33, P817, DOI 10.1016/0024-3205(83)90619-7; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GRUNSTEIN MM, 1984, J APPL PHYSIOL, V57, P1238, DOI 10.1152/jappl.1984.57.4.1238; JACKSON DM, 1977, BRIT J PHARMACOL, V61, P257, DOI 10.1111/j.1476-5381.1977.tb08413.x; JAEGER MJ, 1964, J APPL PHYSIOL, V19, P813, DOI 10.1152/jappl.1964.19.4.813; JOHNSON AR, 1973, P SOC EXP BIOL MED, V142, P1252; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; JOOS GF, 1988, AM REV RESPIR DIS, V137, P1038, DOI 10.1164/ajrccm/137.5.1038; KARLSSON JA, 1985, TACHYKININ ANTAGONIS, P181; LUNDBERG JM, 1984, CELL TISSUE RES, V235, P251; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P473, DOI 10.1111/j.1748-1716.1982.tb07170.x; LUNDBERG JM, 1984, ACTA PHYSIOL SCAND, V120, P217, DOI 10.1111/j.1748-1716.1984.tb00127.x; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; LUNDBERG JM, 1985, TACHYKININ ANTAGONIS, P159; MARTLING CR, 1987, LIFE SCI, V40, P1633, DOI 10.1016/0024-3205(87)90130-5; PAUWELS R, 1988, AM REV RESPIR DIS, V137, pA212; PIOTROWSKI W, 1985, N-S ARCH PHARMACOL, V331, P364, DOI 10.1007/BF00500821; POLAK JM, 1986, ARCH INT PHARMACOD T, V280, P16; SKOFITSCH G, 1983, N-S ARCH PHARMACOL, V322, P153, DOI 10.1007/BF00512389; TANAKA DT, 1986, J APPL PHYSIOL, V60, P458, DOI 10.1152/jappl.1986.60.2.458; TERENGHI G, 1983, NEUROSCI LETT, V36, P229, DOI 10.1016/0304-3940(83)90005-8; WELLS E, 1986, J IMMUNOL, V137, P3941	32	72	73	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					663	668		10.1016/0091-6749(89)90080-8	http://dx.doi.org/10.1016/0091-6749(89)90080-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2538499				2022-12-18	WOS:A1989T859600014
J	STANKUS, RP; MENON, PK; RANDO, RJ; GLINDMEYER, H; SALVAGGIO, JE; LEHRER, SB				STANKUS, RP; MENON, PK; RANDO, RJ; GLINDMEYER, H; SALVAGGIO, JE; LEHRER, SB			CIGARETTE SMOKE-SENSITIVE ASTHMA - CHALLENGE STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,DELTA REG PRIMATE RES CTR,DEPT MED,PULM DIS SECT,COVINGTON,LA 70433	Tulane University	STANKUS, RP (corresponding author), TULANE UNIV,DELTA REG PRIMATE RES CTR,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,1700 PERDIDO ST,COVINGTON,LA 70433, USA.		Rando, Roy/AAN-6118-2020					CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DAHMS TE, 1981, CHEST, V80, P530, DOI 10.1378/chest.80.5.530; HINDS WC, 1975, NEW ENGL J MED, V292, P844, DOI 10.1056/NEJM197504172921606; LEBOWITZ MD, 1981, AM REV RESPIR DIS, V123, P16; LEHRER SB, 1984, J ALLERGY CLIN IMMUN, V73, P240, DOI 10.1016/S0091-6749(84)80014-7; NORMAN V, 1977, TOBACCO CHEM RES C, V30, P5; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; STERLING TD, 1982, JAPCA J AIR WASTE MA, V32, P250, DOI 10.1080/00022470.1982.10465397; WIEDEMANN HP, 1986, CHEST, V89, P180, DOI 10.1378/chest.89.2.180; ZUSSMAN BM, 1980, ANN ALLERGY, V45, P304; 1980, AM THORAC SOC NEWS, V6, P11; DHHS77157C PUBL	12	72	73	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				331	338		10.1016/0091-6749(88)90003-6	http://dx.doi.org/10.1016/0091-6749(88)90003-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170982				2022-12-18	WOS:A1988Q322900003
J	JUHLIN, L; DEVOS, C; RIHOUX, JP				JUHLIN, L; DEVOS, C; RIHOUX, JP			INHIBITING EFFECT OF CETIRIZINE ON HISTAMINE-INDUCED AND 48/80-INDUCED WHEALS AND FLARES, EXPERIMENTAL DERMOGRAPHISM, AND COLD-INDUCED URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UCB, Braine lAlleud, BELGIUM	UCB Pharma SA	JUHLIN, L (corresponding author), UNIV HOSP UPPSALA, DEPT DERMATOL, S-75185 UPPSALA, SWEDEN.							DEVOS C, 1985, ANN ALLERGY, V55, P392; GIBSON JR, 1984, DERMATOLOGICA, V169, P179, DOI 10.1159/000249599; MARTZ BL, 1982, ARZNEIMITTELFORSCH, V32-2, P1153; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269	7	72	74	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					599	602		10.1016/0091-6749(87)90014-5	http://dx.doi.org/10.1016/0091-6749(87)90014-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	2959719				2022-12-18	WOS:A1987K522400014
J	BRIK, A; TASHKIN, DP; GONG, H; DAUPHINEE, B; LEE, E				BRIK, A; TASHKIN, DP; GONG, H; DAUPHINEE, B; LEE, E			EFFECT OF CETIRIZINE, A NEW HISTAMINE H-1 ANTAGONIST, ON AIRWAY DYNAMICS AND RESPONSIVENESS TO INHALED HISTAMINE IN MILD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BEAUPRE A, 1982, THORAX, V37, P124, DOI 10.1136/thx.37.2.124; BOUHUYS A, 1974, BREATHING, P187; Box G., 1978, STAT EXPERIMENTERS A, P245; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COLEBATCH HJH, 1979, AUST NZ J MED, V9, P477; DEVOS C, 1985, ANN ALLERGY, V55, P392; DOUGLAS WW, 1965, PHARM BASIS THERAPEU, P638; EISER NM, 1978, THORAX, V33, P534; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FISH JE, 1977, J ALLERGY CLIN IMMUN, V60, P41, DOI 10.1016/0091-6749(77)90081-1; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; FISH JE, 1979, J ALLERGY CLIN IMMUN, V64, P592, DOI 10.1016/0091-6749(79)90019-8; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HUME K. M., 1957, THORAX, V12, P276, DOI 10.1136/thx.12.3.276; JENNE JJ, 1983, PROVOCATIVE CHALLENG, V2, P63; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NATHAN RA, 1979, AM REV RESPIR DIS, V120, P1251; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NOGRADY SG, 1978, THORAX, V33, P700, DOI 10.1136/thx.33.6.700; NOGRADY SG, 1978, THORAX, V33, P479, DOI 10.1136/thx.33.4.479; OREHEK J, 1981, AM REV RESPIR DIS, V123, P269; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P691; WOENNE R, 1978, J ALLERGY CLIN IMMUN, V62, P119, DOI 10.1016/0091-6749(78)90089-1; ZAMEL N, 1983, CHEST, V83, P35, DOI 10.1378/chest.83.1.35; 1986, INVESTIGATORS REFERE; 1955, LANCET, V2, P1182	35	72	73	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					51	56		10.1016/S0091-6749(87)80190-2	http://dx.doi.org/10.1016/S0091-6749(87)80190-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	2885355				2022-12-18	WOS:A1987J219400008
J	SALVAGGIO, JE				SALVAGGIO, JE			HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SALVAGGIO, JE (corresponding author), TULANE UNIV,MED CTR,DEPT MED,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							ALLEN EM, 1981, CELL IMMUNOL, V58, P61, DOI 10.1016/0008-8749(81)90149-0; ALLEN EM, 1977, J IMMUNOL, V119, P343; BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; BICE D, 1975, INT ARCH ALLER A IMM, V55, P267; BICE DE, 1976, J ALLERGY CLIN IMMUN, V58, P250, DOI 10.1016/0091-6749(76)90130-5; BOROS DL, 1975, J IMMUNOL, V114, P1437; BOROS DL, 1983, ALLERGY PRINCIPLES P, P103; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; CASHNER FM, 1979, CLIN EXP IMMUNOL, V36, P266; CHENSUE SW, 1979, J IMMUNOL, V123, P1409; CHMELIK F, 1974, J ALLERGY CLIN IMMUN, V54, P180, DOI 10.1016/0091-6749(74)90055-4; COSTABEL U, 1985, AM REV RESPIR DIS, V131, P337; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; EDWARDS J H, 1974, Clinical Allergy, V4, P379, DOI 10.1111/j.1365-2222.1974.tb01399.x; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HARRIS JO, 1976, AM REV RESPIR DIS, V114, P29; KAWAI T, 1984, CHEST, V85, P311, DOI 10.1378/chest.85.3.311; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; KOBAYASHI K, 1985, J IMMUNOL, V134, P358; KOBAYASHI K, 1985, J IMMUNOL, V135, P2996; KOPP WC, 1985, AM REV RESPIR DIS, V132, P1027; KUNKEL SL, 1984, J CLIN INVEST, V74, P514, DOI 10.1172/JCI111449; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MOORE VL, 1979, J RETICULOENDOTHEL S, V25, pA50; MORNEX JF, 1984, J ALLERGY CLIN IMMUN, V74, P719, DOI 10.1016/0091-6749(84)90236-7; PATTERSON R, 1976, AM J MED, V60, P144, DOI 10.1016/0002-9343(76)90543-X; PEPYS J, 1969, MONOGR ALLERGY, V4, P44; PHANUPHAK P, 1975, CHEST, V68, P753, DOI 10.1378/chest.68.6.753; RAMAZZINI B, 1940, MORBIS ARTIFICIUM DI; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; RICHERSON HB, 1981, J ALLERGY CLIN IMMUN, V68, P226, DOI 10.1016/0091-6749(81)90188-3; SALVAGGIO J, 1975, J ALLERGY CLIN IMMUN, V56, P364, DOI 10.1016/0091-6749(75)90130-X; SCHRIER DJ, 1981, NATURE, V289, P405, DOI 10.1038/289405a0; SCHRIER DJ, 1982, J IMMUNOL, V128, P1466; SCHUYLER MR, 1978, ANN INTERN MED, V88, P355, DOI 10.7326/0003-4819-88-3-355; STANKUS RP, 1978, J IMMUNOL, V120, P685; UNGER JD, 1968, RADIOLOGY, V90, P683, DOI 10.1148/90.4.683; WILKIE B, 1973, PATHOL MICROBIOL, V39, P393, DOI 10.1159/000162686; WILSON B, 1984, J ALLERGY CLIN IMMUN, V130, P766; WILSON BD, 1982, J IMMUNOL, V129, P2160	46	72	73	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					558	571		10.1016/S0091-6749(87)80149-5	http://dx.doi.org/10.1016/S0091-6749(87)80149-5			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	2951425	Bronze			2022-12-18	WOS:A1987G972000002
J	LEHRER, SB; LOPEZ, M; BUTCHER, BT; OLSON, J; REED, M; SALVAGGIO, JE				LEHRER, SB; LOPEZ, M; BUTCHER, BT; OLSON, J; REED, M; SALVAGGIO, JE			BASIDIOMYCETE MYCELIA AND SPORE-ALLERGEN EXTRACTS - SKIN-TEST REACTIVITY IN ADULTS WITH SYMPTOMS OF RESPIRATORY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEHRER, SB (corresponding author), TULANE UNIV,MED CTR,SCH MED,IMMUNOL CLIN,NEW ORLEANS,LA 70112, USA.				NIAID NIH HHS [AI-20331] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; GIANNINI EH, 1975, ANN ALLERGY, V35, P372; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; LEHREER S B, 1982, Journal of Allergy and Clinical Immunology, V69, P97; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; LEHRER SB, 1984, MOLD ALLERGY WORKSHO, P81; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOPEZ M, 1975, J ALLERGY CLIN IMMUN, V55, P90; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297; OBRIEN IM, 1978, CLIN ALLERGY, V8, P535, DOI 10.1111/j.1365-2222.1978.tb01507.x; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SANTILLI J, 1985, ANN ALLERGY, V55, P469; SANTILLI J JR, 1982, Journal of Allergy and Clinical Immunology, V69, P98; Weber NS, 1985, FIELD GUIDE SO MUSHR, P280	17	72	74	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				478	485		10.1016/0091-6749(86)90036-9	http://dx.doi.org/10.1016/0091-6749(86)90036-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760405				2022-12-18	WOS:A1986E114800017
J	DRUCE, HM; WRIGHT, RH; KOSSOFF, D; KALINER, MA				DRUCE, HM; WRIGHT, RH; KOSSOFF, D; KALINER, MA			CHOLINERGIC NASAL HYPERREACTIVITY IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								Andersen, 1982, NOSE UPPER AIRWAY PH, P45; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; COLE P, 1983, ANN OTO RHINOL LARYN, V92, P196, DOI 10.1177/000348948309200220; COLE P, 1984, AM REV RESPIR DIS, V129, P351; DIETZLER DN, 1980, GRADWOHLS CLIN LAB M, V1, P210; DRUCE H, 1984, Journal of Allergy and Clinical Immunology, V73, P146; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HASEGAWA M, 1982, ANN OTO RHINOL LARYN, V91, P112, DOI 10.1177/000348948209100125; HASEGAWA M, 1978, Rhinology (Utrecht), V16, P243; JOHANSSON SGO, 1976, INT ARCH ALLER A IMM, V52, P364, DOI 10.1159/000231703; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KING M, 1979, BIORHEOLOGY, V16, P57; KING M, 1979, J APPL PHYSIOL, V47, P26, DOI 10.1152/jappl.1979.47.1.26; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P219, DOI 10.3109/00016487609120888; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OKUDA M, 1983, ANN ALLERGY, V51, P51; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; SHELHAMER J, 1984, EAR NOSE THROAT J, V63, P82; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; STOKSTED P, 1953, Acta Otolaryngol Suppl, V109, P159; WIDDICOMBE JG, 1982, NOSE UPPER AIRWAY PH, P215; WOLFF HG, 1948, T ASSOC AM PHYSICIAN, V61, P313	27	72	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					445	452		10.1016/0091-6749(85)90725-0	http://dx.doi.org/10.1016/0091-6749(85)90725-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031317				2022-12-18	WOS:A1985ARC0900005
J	BUSSE, WW; SOSMAN, JM				BUSSE, WW; SOSMAN, JM			ISOPROTERENOL INHIBITION OF ISOLATED HUMAN NEUTROPHIL FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NIAID NIH HHS [AI 15685, AI 10404, AI 00343] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; ALLEN RC, 1974, BIOCHEM BIOPH RES CO, V60, P909, DOI 10.1016/0006-291X(74)90401-X; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUSSE WW, 1981, AM REV RESPIR DIS, V123, P654; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1976, SCIENCE, V194, P737, DOI 10.1126/science.185696; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; DECHATELET LR, 1978, J RETICULOENDOTH SOC, V24, P73; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; GALANT SP, 1980, J LAB CLIN MED, P9615; HENSON P, 1974, J IMMUNOL, V107, P1535; IGNARRO LJ, 1973, SCIENCE, V180, P1181, DOI 10.1126/science.180.4091.1181; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; JOHNSON KJ, 1981, J CLIN INVEST, V67, P983, DOI 10.1172/JCI110149; MARONE G, 1980, J IMMUNOL, V125, P2277; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; MELMON KL, 1981, AM J MED, V71, P100, DOI 10.1016/0002-9343(81)90264-3; PRENDERGAST E, 1981, J CLIN MICROBIOL, V13, P390, DOI 10.1128/JCM.13.2.390-392.1981; SHEPPARD H, 1973, P235; SMOLEN JE, 1980, J CLIN INVEST, V65, P1077, DOI 10.1172/JCI109760; WEENING RS, 1975, J LAB CLIN MED, V85, P245; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; WEISSMANN G, 1971, J EXP MED, V134, P149; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	29	72	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					404	410		10.1016/0091-6749(84)90416-0	http://dx.doi.org/10.1016/0091-6749(84)90416-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6321582				2022-12-18	WOS:A1984SK15500017
J	SIMON, RA				SIMON, RA			ADVERSE REACTIONS TO DRUG ADDITIVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SIMON, RA (corresponding author), SCRIPPS CLIN & RES FDN,DEPT BASIC & CLIN RES,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCRR NIH HHS [RR0083] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRETE JA, 1969, J AMER MED ASSOC, V207, P356, DOI 10.1001/jama.207.2.356; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CLAYTON DE, 1980, CLIN ALLERGY, V10, P341, DOI 10.1111/j.1365-2222.1980.tb02116.x; DOEGLAS HMG, 1975, BRIT J DERMATOL, V93, P135, DOI 10.1111/j.1365-2133.1975.tb06732.x; Feingold B, 1973, ANN CONVENTION AM ME; Feingold BF., 1975, WHY YOUR CHILD IS HY; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GIBSON A, 1980, CLIN ALLERGY, V10, P699, DOI 10.1111/j.1365-2222.1980.tb02154.x; GOLDFARB G, 1984, Journal of Allergy and Clinical Immunology, V73, P135; Habenicht H, 1983, IMMUNOL ALLERGY PRAC, V5, P243; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; KOEPKE J W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; LAHTI A, 1981, LANCET, V1, P1055; LATRONICA RJ, 1969, ORAL SURG ORAL MED O, V28, P439, DOI 10.1016/0030-4220(69)90240-0; LIPTON MA, 1983, J AM DIET ASSOC, V83, P132; LOCKEY SD, 1971, ANN ALLERGY, V29, P461; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; LUMRY WR, 1982, J ALLERGY CLIN IMMUN, V69, P135; NAGEL JE, 1977, JAMA-J AM MED ASSOC, V237, P1594; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; PRENNER BM, 1976, ANN ALLERGY, V37, P180; ROS AM, 1976, BRIT J DERMATOL, V95, P19, DOI 10.1111/j.1365-2133.1976.tb15532.x; ROSENHALL L, 1982, EUR J RESPIR DIS, V63, P410; RUDZKI E, 1980, DERMATOLOGICA, V161, P57, DOI 10.1159/000250331; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SETTIPANE GA, 1976, J ALLERGY CLIN IMMUN, V57, P541, DOI 10.1016/0091-6749(76)90004-X; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Speer K., 1958, MANAGEMENT CHILDHOOD, P23; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STEVENSON DD, UNPUB INCIDENCE TART; THORMANN J, 1980, ALLERGY, V35, P139, DOI 10.1111/j.1398-9995.1980.tb01728.x; THUNE P, 1975, DERMATOLOGICA, V151, P360, DOI 10.1159/000251361; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0	42	72	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					623	630		10.1016/0091-6749(84)90116-7	http://dx.doi.org/10.1016/0091-6749(84)90116-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491109				2022-12-18	WOS:A1984TQ16300013
J	BARNETT, D; BALDO, BA; HOWDEN, MEH				BARNETT, D; BALDO, BA; HOWDEN, MEH			MULTIPLICITY OF ALLERGENS IN PEANUTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MACQUARIE UNIV,SCH CHEM,N RYDE,NSW 2113,AUSTRALIA; CSIRO,DIV FOOD RES,N RYDE,NSW 2113,AUSTRALIA; CSIRO,WHEAT RES UNIT,N RYDE,NSW 2113,AUSTRALIA	Macquarie University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)								AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BALDO BA, 1980, CONT TOPICS MOL IMMU, V8, P41; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; DAUSSANT J, 1969, PLANT PHYSIOL, V44, P471, DOI 10.1104/pp.44.4.471; FISH WW, 1978, ARCH BIOCHEM BIOPHYS, V190, P693, DOI 10.1016/0003-9861(78)90328-4; Gale A E, 1979, Aust Fam Physician, V8, P49; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; GLEESON PA, 1977, AUST J PLANT PHYSIOL, V4, P25, DOI 10.1071/PP9770025; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HEINER DC, 1975, J ALLERGY CLIN IMMUN, V55, P82; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; JOHNSON P, 1950, BIOCHIM BIOPHYS ACTA, V5, P361, DOI 10.1016/0006-3002(50)90183-1; JOHNSON P, 1965, EUR POLYM J, V1, P63; JOHNSON P, 1953, DISCUSS FARADAY SOC, V13, P98; JONES DB, 1930, J AGR RES, V40, P672; KEMP AS, CLIN ALLERGY; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; Leiner I. E., 1976, J FOOD SCI, V41, P1076; LOTAN R, 1975, J BIOL CHEM, V250, P8518; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; MALLEY A, 1976, CLIN EXP IMMUNOL, V25, P159; MALLEY A, 1975, J ALLERGY CLIN IMMUN, V56, P282, DOI 10.1016/0091-6749(75)90102-5; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; NEUCERE NJ, 1969, J AGR FOOD CHEM, V17, P25, DOI 10.1021/jf60161a007; NEUCERE NJ, 1969, ANAL BIOCHEM, V27, P15, DOI 10.1016/0003-2697(69)90215-2; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; SABBAH A, 1977, OUEST MED, V30, P479; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SPEER F, 1976, AM FAM PHYSICIAN, V13, P106; SPEER F, 1975, ANN ALLERGY, V34, P71; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; TZUR R, 1972, BIOCHIM BIOPHYS ACTA, V280, P290, DOI 10.1016/0005-2760(72)90096-3; WALLENBORG B, 1978, 249 LKB PROD AB APPL; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; YU PH, 1977, THESIS TEXAS A M U	41	72	77	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					61	68		10.1016/0091-6749(83)90053-2	http://dx.doi.org/10.1016/0091-6749(83)90053-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6853931				2022-12-18	WOS:A1983QZ19800008
J	BOUCHER, RC; PARE, PD; GILMORE, NJ; MOROZ, LA; HOGG, JC				BOUCHER, RC; PARE, PD; GILMORE, NJ; MOROZ, LA; HOGG, JC			AIRWAY MUCOSAL PERMEABILITY IN ASCARIS-SUUM SENSITIVE RHESUS-MONKEY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV,DEPT PATHOL,LYMAN DUFF LAB,MONTREAL H3A 2B4,QUEBEC,CANADA; MCGILL UNIV CLIN,ROY VICTORIA HOSP,DIV CLIN IMMUNOL,HARRY WEBSTER THORP LABS,MONTREAL,QUEBEC,CANADA	McGill University; McGill University; Royal Victoria Hospital			Pare, Peter D/C-7425-2011					BOUCHER RC, 1977, AM REV RESPIR DIS, V115; BUCKLE FG, 1975, J ALLERGY CLIN IMMUN, V55, P213, DOI 10.1016/0091-6749(75)90139-6; BUSSE WW, 1974, J ALLERGY CLIN IMMUN, V53, P271, DOI 10.1016/0091-6749(74)90105-5; COHEN MB, 1929, J IMMUNOL, V18, P419; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DUNHILL MS, 1975, NEW DIRECTIONS ASTHM, P213; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FAHEY JL, 1958, J CLIN INVEST, V37, P272, DOI 10.1172/JCI103606; FUHR J, 1955, KLIN WOCHENSCHR, V33, P729, DOI 10.1007/BF01473295; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; HUSSAIN R, 1973, J IMMUNOL, V111, P260; KONTOUKARAKITSOS K, 1975, J ALLERGY CLIN IMMUN, V55, P241, DOI 10.1016/0091-6749(75)90143-8; LESKOWITZ S, 1972, Clinical Allergy, V2, P237, DOI 10.1111/j.1365-2222.1972.tb01288.x; LIN MS, 1971, J NUCL MED, V12, P204; PARE PD, 1976, J APPL PHYSIOL, V41, P668, DOI 10.1152/jappl.1976.41.5.668; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1976, J LAB CLIN MED, V87, P65; PATTERSON R, 1974, ANNU REV MED, V25, P53, DOI 10.1146/annurev.me.25.020174.000413; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; RICHARDSON JB, 1973, J ALLERGY CLIN IMMUN, V52, P172, DOI 10.1016/0091-6749(73)90034-1; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SALVAGGIO JE, 1965, INT ARCH ALLER A IMM, V26, P264, DOI 10.1159/000229578; SCHOENBERGER MZ, 1955, Z NATURFORSCH, V105, P474; SMITH HW, 1951, KIDNEY STRUCTURE FUN, P62; SMITH JM, 1963, AM REV RESPIR DIS, V88, P858; WALZER W, 1942, J ALLERGY, V13, P554	26	72	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					134	140		10.1016/0091-6749(77)90039-2	http://dx.doi.org/10.1016/0091-6749(77)90039-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	406301	Bronze			2022-12-18	WOS:A1977DR44800008
J	VEDANTHAN, PK; MENON, MM; BELL, TD; BERGIN, D				VEDANTHAN, PK; MENON, MM; BELL, TD; BERGIN, D			ASPIRIN AND TARTRAZINE ORAL CHALLENGE - INCIDENCE OF ADVERSE RESPONSE IN CHRONIC CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL ASTHMA CTR,DIV MED,DENVER,CO									BALAAM LN, 1972, FUNDAMENTALS BIOMETR; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; DELANEY JC, 1976, CLIN ALLERGY, V6, P365, DOI 10.1111/j.1365-2222.1976.tb01917.x; FALLIERS CJ, 1973, J ALLERGY CLIN IMMUN, V52, P141, DOI 10.1016/0091-6749(73)90030-4; KOPETZKY MT, 1974, J ALLERGY CLIN IMMUN, V53, P1, DOI 10.1016/0091-6749(74)90093-1; LEIST ER, 1974, NEW ENGL J MED, V291, P710, DOI 10.1056/NEJM197410032911406; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; SELNER JC, 1975, NEW ENGL J MED, V292, P372; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SNYDER RD, 1967, ANN ALLERGY, V25, P377; SPEER F, 1958, MANAGEMENT CHILDHOOD; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; WALTON CHA, 1975, CAN MED ASSOC J, V76, P1016; YUNGINGER JW, 1973, J PEDIATR-US, V82, P218, DOI 10.1016/S0022-3476(73)80157-X	17	72	72	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					8	13		10.1016/0091-6749(77)90077-X	http://dx.doi.org/10.1016/0091-6749(77)90077-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	326850				2022-12-18	WOS:A1977DN22400002
J	YUNGINGER, JW; JONES, RT; GLEICH, GJ				YUNGINGER, JW; JONES, RT; GLEICH, GJ			STUDIES ON ALTERNARIA ALLERGENS .2. MEASUREMENT OF RELATIVE POTENCY OF COMMERCIAL ALTERNARIA EXTRACTS BY DIRECT RAST AND BY RAST INHIBITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT INTERN MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; ARONSSON T, 1974, INT ARCH ALLER A IMM, V47, P224, DOI 10.1159/000231216; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CONOVER WJ, 1961, PRACTICAL NONPARAMET, P390; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, UNPUBLISHED OBSERVAT; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; SIMMONS EG, 1967, MYCOLOGIA, V59, P67, DOI 10.2307/3756943; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3	17	72	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					405	413		10.1016/0091-6749(76)90121-4	http://dx.doi.org/10.1016/0091-6749(76)90121-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	987087				2022-12-18	WOS:A1976CD45400007
J	BRYANT, DH; BURNS, MW; LAZARUS, L				BRYANT, DH; BURNS, MW; LAZARUS, L			IDENTIFICATION OF IGG ANTIBODY AS A CARRIER OF REAGINIC ACTIVITY IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUGUSTIN R, 1967, HDB EXPT IMMUNOLOGY, P1076; BACH MK, 1971, J EXP MED, V133, P772, DOI 10.1084/jem.133.4.772; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; Bennich H, 1971, Adv Immunol, V13, P1; BLOCH KJ, 1967, PROG ALLERGY, V10, P84; BLOCH KJ, 1971, BIOCHEMISTRY ACUTE A, P45; BRODER I, 1971, INFLAMMATION IMMUNIT, P334; BRYANT DH, 1973, BRIT MED J, V4, P589, DOI 10.1136/bmj.4.5892.589; BRYANT DH, 1973, MED J AUSTRALIA, V2, P71, DOI 10.5694/j.1326-5377.1973.tb128653.x; FIREMAN P, 1967, J ALLERGY, V40, P259, DOI 10.1016/0021-8707(67)90073-1; GOODFRIEND L, 1966, INT ARCH ALLER A IMM, V30, P542, DOI 10.1159/000229841; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; Kabat E. A., 1961, EXPERIMENTAL IMMUNOC, P556; MORSE HC, 1969, J IMMUNOL, V102, P327; MUNROFORD R, 1971, ANN ALLERGY, V29, P8; NISONOFF A, 1960, ARCH BIOCHEM BIOPHYS, V89, P230, DOI 10.1016/0003-9861(60)90049-7; ORANGE RP, 1970, J IMMUNOL, V105, P1087; PARISH W E, 1971, Clinical Allergy, V1, P369, DOI 10.1111/j.1365-2222.1971.tb00788.x; PARISH WE, 1970, LANCET, V2, P591; RADERMEC.M, 1969, ACTA ALLERGOL, V24, P1, DOI 10.1111/j.1398-9995.1969.tb03718.x; REID RT, 1970, J IMMUNOL, V104, P935; REID RT, 1966, J EXP MED, V123, P845, DOI 10.1084/jem.123.5.845; REID RT, 1968, J ALLERGY, V41, P326, DOI 10.1016/0021-8707(68)90075-0; SCHWARTZ HA, 1973, J IMMUNOL, V110, P1638; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; TERR AI, 1965, J ALLERGY, V36, P433, DOI 10.1016/0021-8707(65)90137-1; WIDE L, 1967, LANCET, V2, P1105; 1972, BRIT MED J, V4, P383	29	72	72	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	6					417	428		10.1016/0091-6749(75)90060-3	http://dx.doi.org/10.1016/0091-6749(75)90060-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ301	812894				2022-12-18	WOS:A1975AZ30100001
J	LIEBERMAN, P; KUNSKE, R; PATTERSON, R				LIEBERMAN, P; KUNSKE, R; PATTERSON, R			COMPLICATIONS OF LONG-TERM STEROID-THERAPY FOR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ANDERSSON E., 1960, ACTA ALLERGOL, V15, P275; ARNOLDSSON H, 1960, ACTA ALLERG KBH   S7, V15, P303; BALDWIN HS, 1961, J ALLERGY, V32, P109, DOI 10.1016/0021-8707(61)90063-6; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; IRWIN JW, 1958, J ALLERGY, V29, P233, DOI 10.1016/0021-8707(58)90007-8; KEENEY E L, 1964, Ariz Med, V21, P463; LIVINGSTO, 1961, LANCET, V1, P1310; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MCALLEN M, 1970, RESPIRATION, V27, P250, DOI 10.1159/000192753; PEARSON RS, 1961, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5222.315; REES HA, 1962, BRIT MED J, V1, P575; ROSE B, 1959, ANN NY ACAD SCI, V82, P913; SCHWARTZ E, 1960, N Y State J Med, V60, P3973; SERAFINI U., 1960, ACTA ALLERGOL, V15, P263; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; SOMNER AR, 1960, BRIT MED J, V1, P1092, DOI 10.1136/bmj.1.5179.1092; THORN GW, 1966, NEW ENGL J MED, V274, P775, DOI 10.1056/NEJM196604072741406; TUFT L, 1962, AM J MED SCI, V244, P686, DOI 10.1097/00000441-196212000-00003; WALSH SD, 1966, BMJ-BRIT MED J, V2, P796, DOI 10.1136/bmj.2.5517.796; 1964, GLUCOSE TOLERANCE 11; 1967, J ALLERGY, V40, P88	21	72	72	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	6					329	+		10.1016/0091-6749(72)90131-5	http://dx.doi.org/10.1016/0091-6749(72)90131-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6593	5025095	Bronze			2022-12-18	WOS:A1972M659300002
J	PATTERSON, R; BLANKENSHIP, ML; PRUZANSKY, JJ; MELLIES, CJ				PATTERSON, R; BLANKENSHIP, ML; PRUZANSKY, JJ; MELLIES, CJ			VIBRATORY ANGIOEDEMA - HEREDITARY TYPE OF PHYSICAL HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUSTEN KF, 1961, J EXP MED, V113, P521, DOI 10.1084/jem.113.3.521; DEMIS DJ, 1963, ANN INTERN MED, V59, P194, DOI 10.7326/0003-4819-59-2-194; GIGLI I, 1968, J IMMUNOL, V100, P1154; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GOODMAN LS, 1965, PHARMACOLOGICAL B ED, P615; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P251; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; VALENTINE MD, 1971, IMMUNOLOGICAL DISEAS, P906	8	72	72	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					174	+		10.1016/0091-6749(72)90048-6	http://dx.doi.org/10.1016/0091-6749(72)90048-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N4708	5050327				2022-12-18	WOS:A1972N470800006
J	Hauck, F; Voss, R; Urban, C; Seidel, MG				Hauck, Fabian; Voss, Rebecca; Urban, Christian; Seidel, Markus G.			Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; malignancy; tumor predis-position; immune surveillance; pre-existing condition	NIJMEGEN-BREAKAGE SYNDROME; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; B-CELL LYMPHOMA; DIAMOND-BLACKFAN-ANEMIA; NON-HODGKIN-LYMPHOMA; BONE-MARROW FAILURE; AUTOSOMAL-DOMINANT; DYSKERATOSIS-CONGENITA; CLINICAL-FEATURES; NATURAL-HISTORY	Malignancies occur with a higher incidence rate and manifest earlier in life in patients with primary immunodeficiency disorders (PIDs) than in the general population. However, no universal mechanism of malignancy predisposition in patients with PIDs has been determined. Despite strong support for the physiologic role of tumor immunosurveillance and the increasing success of strategies in immunologic tumor therapy, which include checkpoint inhibition, mAbs, and engineered T-cell antigen receptors, the incidence and pattern of malignancies in patients with PIDs do not reflect an increased tumor immune escape per se. In contrast, malignancies appear to be restricted to either (1) tissue types bearing the same molecular defect that underlies the PID, such as syndromes of DNA repair deficiency or immune cell-specific maturation or functional defects that suggest a cell-intrinsic oncogenic basis, or (2) other tissues when they are infected by transforming viruses or chronically inflamed, pointing toward extrinsic causes for transformation that are potentially facilitated by but not predominantly caused by a lack of immunosurveillance. Based on recent studies of pre-existing conditions in patients with malignancies and on malignancies in large PID cohorts, we conclude that a large part of tumor predisposition in patients with PIDs is derived from the same molecular defect as the immunodeficiency itself. The presented concept elucidates diverse pathomechanisms and risks of malignancies in patients with PIDs in light of current tumor immune therapies.	[Hauck, Fabian] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Immunodeficiency Unit, Munich, Germany; [Hauck, Fabian] Ludwig Maximilians Univ Munchen, Immunol Diagnost Lab, Munich, Germany; [Voss, Rebecca; Urban, Christian; Seidel, Markus G.] Med Univ Graz, Res Unit Pediat Hematol & Immunol, Div Pediat Hematol Oncol, Dept Pediat & Adolescent Med, Graz, Austria	University of Munich; University of Munich; Medical University of Graz	Seidel, MG (corresponding author), Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Auenbruggerpl 38, A-8036 Graz, Austria.	markus.seidel@medunigraz.at	Hauck, Fabian/H-5556-2016; Seidel, Markus G/N-9951-2017	Hauck, Fabian/0000-0001-9644-2003; Seidel, Markus G/0000-0003-0981-8661	Wilhelm-Sander Foundation; German Center for Infection Research (DZIF); "Steirische Kinderkrebshilfe'' (Styrian Children's Cancer Aid Fund)	Wilhelm-Sander Foundation; German Center for Infection Research (DZIF); "Steirische Kinderkrebshilfe'' (Styrian Children's Cancer Aid Fund)	F.H. is supported by the Wilhelm-Sander Foundation and the German Center for Infection Research (DZIF). M.G.S. is supported by "Steirische Kinderkrebshilfe'' (Styrian Children's Cancer Aid Fund).	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Abolhassani H, 2017, J EXP MED, V214, P91, DOI 10.1084/jem.20160849; Aghamohammadi A, 2007, PEDIATR HEMAT ONCOL, V24, P337, DOI 10.1080/08880010701369982; Albert MH, 2010, BONE MARROW TRANSPL, V45, P622, DOI 10.1038/bmt.2009.207; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Alkhairy OK, 2015, J ALLERGY CLIN IMMUN, V136, P703, DOI 10.1016/j.jaci.2015.02.022; Attarbaschi A, 2016, HAEMATOLOGICA, V101, P1581, DOI 10.3324/haematol.2016.147116; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Basel-Vanagaite L, 2008, HAEMATOLOGICA, V93, P943, DOI 10.3324/haematol.12317; Beier F, 2012, BLOOD, V120, P2990, DOI 10.1182/blood-2012-03-418038; Bienemann K, 2011, BRIT J HAEMATOL, V155, P468, DOI 10.1111/j.1365-2141.2011.08863.x; Bohgaki T, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001381; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Brauer PM, 2016, BLOOD, V128, P783, DOI 10.1182/blood-2015-10-676304; Garcia-Morato MB, 2017, CLIN IMMUNOL, V179, P77, DOI 10.1016/j.clim.2017.03.004; Burger B, 2014, CURR PROBL DERMATOL, V45, P123, DOI 10.1159/000356068; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; BURNET M, 1957, BRIT MED J, V1, P779, DOI 10.1136/bmj.1.5022.779; Byun M, 2013, J EXP MED, V210, P1743, DOI 10.1084/jem.20130592; Cetica V, 2010, J MED GENET, V47, P595, DOI 10.1136/jmg.2009.075341; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Clementi R, 2004, NEW ENGL J MED, V351, P1419, DOI 10.1056/NEJMoa041432; Cohen JI, 2015, CURR TOP MICROBIOL, V390, P241, DOI 10.1007/978-3-319-22822-8_10; Cohen SB, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-71; Corthay A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00197; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Crequer A, 2012, J CLIN INVEST, V122, P3239, DOI 10.1172/JCI62949; Crow YJ, 2004, NEUROPEDIATRICS, V35, P10, DOI 10.1055/s-2003-43552; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; de Miranda NFCC, 2011, ANN NY ACAD SCI, V1246, P50, DOI 10.1111/j.1749-6632.2011.06322.x; De Vos M, 2004, AM J HUM GENET, V74, P954, DOI 10.1086/420796; Dror Y, 2011, ANN NY ACAD SCI, V1242, P40, DOI 10.1111/j.1749-6632.2011.06349.x; Du HY, 2008, BLOOD, V111, P1128, DOI 10.1182/blood-2007-10-120907; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Durandy A, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3904; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Finck A, 2006, EUR J HUM GENET, V14, P867, DOI 10.1038/sj.ejhg.5201634; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; FRIEDMAN HD, 1994, AM J CLIN PATHOL, V101, P432; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; Ghosh S, 2017, HAEMATOLOGICA, V102, pE69, DOI 10.3324/haematol.2016.155838; Ghosh S, 2014, J CLIN IMMUNOL, V34, P892, DOI 10.1007/s10875-014-0110-8; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Gregorek H, 2010, CLIN IMMUNOL, V135, P440, DOI 10.1016/j.clim.2010.01.008; Hahn CN, 2011, NAT GENET, V43, P1012, DOI 10.1038/ng.913; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hathcock KS, 2015, BLOOD, V126, P2291, DOI 10.1182/blood-2015-06-654749; Hauck F, 2013, CURR OPIN ALLERGY CL, V13, P596, DOI 10.1097/ACI.0000000000000014; Hayakawa S, 2016, J CLIN IMMUNOL, V36, P28, DOI 10.1007/s10875-015-0221-x; HECHT F, 1966, LANCET, V2, P1193; Horne A, 2008, BRIT J HAEMATOL, V143, P75, DOI 10.1111/j.1365-2141.2008.07315.x; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Hughes CR, 2012, J CLIN INVEST, V122, P814, DOI 10.1172/JCI60224; HUIJGENS PC, 1977, SCAND J HAEMATOL, V18, P20; Izawa K, 2017, J EXP MED, V214, P73, DOI 10.1084/jem.20160784; Janda A, 2016, BLOOD, V127, P2193, DOI 10.1182/blood-2015-04-642488; Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208; Janov AJ, 1996, MEDICINE, V75, P77, DOI 10.1097/00005792-199603000-00004; Jiang JQ, 2016, CLIN IMMUNOL, V163, P75, DOI 10.1016/j.clim.2015.12.016; Jonkman-Berk BM, 2015, CLIN IMMUNOL, V156, P154, DOI 10.1016/j.clim.2014.10.003; Kalisperati P, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00020; Kim Kyu Yeun, 2015, Korean J Pediatr, V58, P108, DOI 10.3345/kjp.2015.58.3.108; Koch D, 2009, CLIN EXP DERMATOL, V34, pE818, DOI 10.1111/j.1365-2230.2009.03561.x; Kracker S, 2010, CLIN IMMUNOL, V135, P193, DOI 10.1016/j.clim.2010.01.012; Kruger L, 2007, CARCINOGENESIS, V28, P107, DOI 10.1093/carcin/bgl126; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li FY, 2014, BLOOD, V123, P2148, DOI 10.1182/blood-2013-11-538686; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Lipton JM, 2001, J PEDIAT HEMATOL ONC, V23, P39, DOI 10.1097/00043426-200101000-00009; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lo B, 2016, BLOOD, V128, P1037, DOI 10.1182/blood-2016-04-712612; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Makaryan V, 2015, CURR OPIN HEMATOL, V22, P3, DOI 10.1097/MOH.0000000000000105; Makitie O, 1999, J PEDIATR-US, V134, P315, DOI 10.1016/S0022-3476(99)70456-7; Manns MP, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.6; Martin E, 2014, NATURE, V510, P288, DOI 10.1038/nature13386; Meyer S, 2004, CANCER GENET CYTOGEN, V154, P169, DOI 10.1016/j.cancergencyto.2004.02.022; Mirzaa G., 1993, GENEREVIEWS; Moroy T, 2015, BLOOD, V126, P2561, DOI 10.1182/blood-2015-06-655043; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; Myers KC, 2013, HEMATOL ONCOL CLIN N, V27, P117, DOI 10.1016/j.hoc.2012.10.003; Niemela JE, 2011, BLOOD, V117, P2883, DOI 10.1182/blood-2010-07-295501; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Notarangelo LD, 2006, J ALLERGY CLIN IMMUN, V117, P855, DOI 10.1016/j.jaci.2006.01.043; Notarangelo LD, 2008, CURR OPIN ALLERGY CL, V8, P534, DOI 10.1097/ACI.0b013e328310fe7d; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Ostergaard P, 2011, NAT GENET, V43, P929, DOI 10.1038/ng.923; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; Palovcak A, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-016-0134-2; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Pasquet M, 2013, BLOOD, V121, P822, DOI 10.1182/blood-2012-08-447367; Peron S, 2008, J EXP MED, V205, P2465, DOI 10.1084/jem.20080789; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Polityko A, 2010, MOL CYTOGENET, V3, DOI 10.1186/1755-8166-3-5; Price S, 2014, BLOOD, V123, P1989, DOI 10.1182/blood-2013-10-535393; Ramos JT, 1999, ARCH DIS CHILD, V81, P444, DOI 10.1136/adc.81.5.444; Rensing-Ehl A, 2014, BLOOD, V124, P851, DOI 10.1182/blood-2014-03-564286; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rosa DD, 2008, MED MYCOL, V46, P85, DOI 10.1080/13693780701616023; Salavoura K, 2008, ANTICANCER RES, V28, P1263; Salzer E, 2013, HAEMATOLOGICA, V98, P473, DOI 10.3324/haematol.2012.068791; Sato T, 1999, EUR J PEDIATR, V158, P609, DOI 10.1007/s004310051160; Schmid JP, 2012, J EXP MED, V209, P2323, DOI 10.1084/jem.20121303; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Schober T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14209; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schutte P, 2016, EUR J MED GENET, V59, P143, DOI 10.1016/j.ejmg.2015.12.008; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Seidel MG, 2014, BLOOD, V124, P2337, DOI 10.1182/blood-2014-06-583260; Seidemann K, 1999, MED PEDIATR ONCOL, V33, P536, DOI 10.1002/(SICI)1096-911X(199912)33:6<536::AID-MPO3>3.0.CO;2-Z; Shiota M, 2015, J CLIN IMMUNOL, V35, P454, DOI 10.1007/s10875-015-0163-3; Shouval DS, 2016, J PEDIATR GASTR NUTR, V63, pE15, DOI 10.1097/MPG.0000000000000532; Slack J, 2018, J ALLERGY CLIN IMMUN, V141, P322, DOI 10.1016/j.jaci.2017.02.036; Slatter MA, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001419; Smith OP, 1996, BRIT J HAEMATOL, V94, P279, DOI 10.1046/j.1365-2141.1996.d01-1788.x; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Speckmann C, 2017, J ALLERGY CLIN IMMUN, V139, P1302, DOI 10.1016/j.jaci.2016.07.040; Spergel AR, 2013, PEDIATRICS, V132, pE1440, DOI 10.1542/peds.2012-2748; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Stepensky P, 2011, HAEMATOL-HEMATOL J, V96, P472, DOI 10.3324/haematol.2010.033910; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Suarez F, 2015, J CLIN ONCOL, V33, P202, DOI 10.1200/JCO.2014.56.5101; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; Tate G, 2004, J HUM GENET, V49, P223, DOI 10.1007/s10038-004-0135-6; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Veillette A, 2013, CURR OPIN ALLERGY CL, V13, P614, DOI 10.1097/ACI.0000000000000008; Wada T, 2001, P NATL ACAD SCI USA, V98, P8697, DOI 10.1073/pnas.151260498; Walne AJ, 2008, BLOOD, V112, P3594, DOI 10.1182/blood-2008-05-153445; WATSON AR, 1981, ARCH DIS CHILD, V56, P563, DOI 10.1136/adc.56.7.563; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029; Wlodarski MW, 2016, BLOOD, V127, P1387, DOI 10.1182/blood-2015-09-669937; Wolska-Kusnierz B, 2015, J CLIN IMMUNOL, V35, P538, DOI 10.1007/s10875-015-0186-9; WOODS WG, 1981, J PEDIATR-US, V99, P425, DOI 10.1016/S0022-3476(81)80336-8; Wu N, 2016, CURR OPIN IMMUNOL, V38, P45, DOI 10.1016/j.coi.2015.11.003; Yoshii Y, 2016, J EUR ACAD DERMATOL, V30, P529, DOI 10.1111/jdv.12927; Zimmerman R, 2015, PEDIATR BLOOD CANCER, V62, P2071, DOI 10.1002/pbc.25726	146	71	73	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					59	+		10.1016/j.jaci.2017.06.009	http://dx.doi.org/10.1016/j.jaci.2017.06.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28669558	Bronze			2022-12-18	WOS:000419312200006
J	de la Morena, MT; Leonard, D; Torgerson, TR; Cabral-Marques, O; Slatter, M; Aghamohammadi, A; Chandra, S; Murguia-Favela, L; Bonilla, FA; Kanariou, M; Damrongwatanasuk, R; Kuo, CY; Dvorak, CC; Meyts, I; Chen, K; Kobrynski, L; Kapoor, N; Richter, D; DiGiovanni, D; Dhalla, F; Farmaki, E; Speckmann, C; Espanol, T; Shcherbina, A; Hanson, IC; Litzman, J; Routes, JM; Wong, M; Fuleihan, R; Seneviratne, SL; Small, TN; Janda, A; Bezrodnik, L; Seger, R; Raccio, AG; Edgar, JDM; Chou, J; Abbott, JK; van Montfrans, J; Gonzalez-Granado, LI; Bunin, N; Kutukculer, N; Gray, P; Seminario, G; Pasic, S; Aquino, V; Wysocki, C; Abolhassani, H; Dorsey, M; Cunningham-Rundles, C; Knutsen, AP; Sleasman, J; Carvalho, BTC; Condino-Neto, A; Grunebaum, E; Chapel, H; Ochs, HD; Filipovich, A; Cowan, M; Gennery, A; Cant, A; Notarangelo, LD; Roifman, CM				de la Morena, M. Teresa; Leonard, David; Torgerson, Troy R.; Cabral-Marques, Otavio; Slatter, Mary; Aghamohammadi, Asghar; Chandra, Sharat; Murguia-Favela, Luis; Bonilla, Francisco A.; Kanariou, Maria; Damrongwatanasuk, Rongras; Kuo, Caroline Y.; Dvorak, Christopher C.; Meyts, Isabelle; Chen, Karin; Kobrynski, Lisa; Kapoor, Neena; Richter, Darko; DiGiovanni, Daniela; Dhalla, Fatima; Farmaki, Evangelia; Speckmann, Carsten; Espanol, Teresa; Shcherbina, Anna; Hanson, Imelda Celine; Litzman, Jiri; Routes, John M.; Wong, Melanie; Fuleihan, Ramsay; Seneviratne, Suranjith L.; Small, Trudy N.; Janda, Ales; Bezrodnik, Liliana; Seger, Reinhard; Raccio, Andrea Gomez; Edgar, J. David M.; Chou, Janet; Abbott, Jordan K.; van Montfrans, Joris; Gonzalez-Granado, Luis Ignacio; Bunin, Nancy; Kutukculer, Necil; Gray, Paul; Seminario, Gisela; Pasic, Srdjan; Aquino, Victor; Wysocki, Christian; Abolhassani, Hassan; Dorsey, Morna; Cunningham-Rundles, Charlotte; Knutsen, Alan P.; Sleasman, John; Carvalho, Beatriz Tavares Costa; Condino-Neto, Antonio; Grunebaum, Eyal; Chapel, Helen; Ochs, Hans D.; Filipovich, Alexandra; Cowan, Mort; Gennery, Andrew; Cant, Andrew; Notarangelo, Luigi D.; Roifman, Chaim M.			Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-linked hyper-IgM syndrome; CD40 ligand; hematopoietic cell transplantation; defects in class-switch recombination; long-term outcomes; primary immunodeficiency; Karnofsky/Lansky scores	BONE-MARROW-TRANSPLANTATION; CD40 LIGAND DEFICIENCY; PRIMARY IMMUNODEFICIENCY DISEASES; CHRONIC GRANULOMATOUS-DISEASE; WISKOTT-ALDRICH-SYNDROME; EUROPEAN EXPERIENCE; T-CELLS; DEFECTIVE EXPRESSION; CLINICAL-FEATURES; CHILDREN	Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients. Objectives: We sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT. Methods: Physicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression. Results: Twenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5 +/- 7.2 years (range, 0.1-36.2 years). No difference in overall survival was observed between patients treated with or without HCT (P = .671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P < .001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1 year of transplantation. Conclusion: No difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates.	[de la Morena, M. Teresa; Leonard, David; Aquino, Victor; Wysocki, Christian] Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [de la Morena, M. Teresa; Leonard, David; Ochs, Hans D.] Childrens Hlth, Childrens Med Ctr, Dallas, TX USA; [Torgerson, Troy R.] Univ Washington, Seattle, WA 98195 USA; [Torgerson, Troy R.] Seattle Childrens Res Inst, Seattle, WA USA; [Cabral-Marques, Otavio] Univ Lubeck, Dept Rheumatol, Lubeck, Germany; [Slatter, Mary] Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England; [Aghamohammadi, Asghar] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Tehran, Iran; [Chandra, Sharat] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Murguia-Favela, Luis] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Bonilla, Francisco A.] Boston Childrens Hosp, Boston, MA USA; [Kanariou, Maria] Sophia Childrens Hosp Athens, Athens, AL USA; [Damrongwatanasuk, Rongras] Univ S Florida, All Childrens FL, St Petersburg, FL 33701 USA; [Kuo, Caroline Y.] Univ Calif Los Angeles, David Geffen Sch Med, Geffen SOM, Los Angeles, CA 90095 USA; [Dvorak, Christopher C.] UC San Francisco, San Francisco, CA USA; [Meyts, Isabelle] Univ Hosp Leuven, Leuven, Belgium; [Chen, Karin] Univ Utah, Sch Med, Salt Lake City, UT USA; [Kobrynski, Lisa] Emory Univ, Atlanta, GA 30322 USA; [Kapoor, Neena] Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA; [Richter, Darko] Univ Hosp Ctr, Zagreb, Croatia; [DiGiovanni, Daniela] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina; [Dhalla, Fatima] Univ Oxford, Oxford OX1 2JD, England; [Farmaki, Evangelia] Ippokration Gen Hosp, Thessaloniki, Greece; [Speckmann, Carsten] Ctr Chron Immunodeficiency Univ Med Ctr, Dept Pediat & Adolescent Med, Freiburg, Germany; [Espanol, Teresa] Hosp Valle De Hebron, Barcelona, Spain; [Shcherbina, Anna] Res & Clin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia; [Hanson, Imelda Celine] Baylor Texas Childrens Hosp, Houston, TX USA; [Litzman, Jiri] Masaryk Univ, Dept Clin Immunol & Allergol, St Annes Univ Hosp Brno, Fac Med, Brno, Czech Republic; [Routes, John M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; [Wong, Melanie] Childrens Hosp Westmead, Sydney, NSW, Australia; [Fuleihan, Ramsay] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Seneviratne, Suranjith L.] Royal Free Hosp, London, England; [Small, Trudy N.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Janda, Ales] Univ Hosp Motol, Prague, Czech Republic; [Edgar, J. David M.] Reg Immunol Serv, Belfast, Antrim, North Ireland; [Chou, Janet] Childrens Hosp Boston, Boston, MA USA; [Abbott, Jordan K.] Natl Jewish Hlth, Denver, CO USA; [van Montfrans, Joris] UMC Utrecht, Div Pediat Pediat Immunol & Infectieziekten, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Gonzalez-Granado, Luis Ignacio] Inst Invest Hosp 12 Octubre, Unidad Immunodeficiencias Primarias, Madrid, Spain; [Gonzalez-Granado, Luis Ignacio] Inst Invest Hosp 12 Octubre, Unidad Hemato & Oncol Pediat, Madrid, Spain; [Bunin, Nancy] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Kutukculer, Necil] Ege Univ, Fac Med, Izmir, Turkey; [Gray, Paul] Sydney Childrens Hosp, Randwick, NSW, Australia; [Pasic, Srdjan] Mother & Child Hlth Inst Serbia, Belgrade, Serbia; [Dorsey, Morna] UC San Francisco, San Francisco, CA USA; [Cunningham-Rundles, Charlotte] Mt Sinai Hosp, New York, NY 10029 USA; [Knutsen, Alan P.] St Louis Univ, St Louis, MO 63103 USA; [Sleasman, John] Duke Univ, Durham, NC USA; [Carvalho, Beatriz Tavares Costa] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Immunol & Rheumatol, Sao Paulo, Brazil; [Condino-Neto, Antonio] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508 Sao Paulo, Brazil; [Notarangelo, Luigi D.] NIAID, Lab Host Def, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Lubeck; Newcastle University - UK; Tehran University of Medical Sciences; Cincinnati Children's Hospital Medical Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Boston Children's Hospital; State University System of Florida; University of South Florida; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; KU Leuven; University Hospital Leuven; Utah System of Higher Education; University of Utah; Emory University; Children's Hospital Los Angeles; University of Zagreb; Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires; University of Oxford; Hospital Universitari Vall d'Hebron; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Children's Hospital of Wisconsin; University of Sydney; Ann & Robert H. Lurie Children's Hospital of Chicago; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Memorial Sloan Kettering Cancer Center; Motol University Hospital; Harvard University; Boston Children's Hospital; National Jewish Health; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Ege University; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; Saint Louis University; Duke University; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	de la Morena, MT (corresponding author), Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	maite.delamorena@utsouthwestern.edu	Meyts, Isabelle/Z-3295-2019; Abbott, Jordan K/P-2509-2016; Marques, Otavio Cabral/C-8090-2012; Abolhassani, Hassan/B-3465-2014; Dorsey, Morna/V-7270-2018; Routes, john/AAA-4833-2021; Dvorak, Christopher C/AAX-1630-2020; Farmaki, Evangelia/AAA-6768-2022; Richter, Darko/AAJ-8861-2020; Gonzalez-Granado, Luis Ignacio/B-9257-2009; Carvalho, Beatriz/GXA-0720-2022; Rezaei, Nima/B-4245-2008; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Condino-Neto, Antonio/D-4762-2012	Abbott, Jordan K/0000-0001-6334-5266; Abolhassani, Hassan/0000-0002-4838-0407; Dorsey, Morna/0000-0002-9432-3542; Routes, john/0000-0001-8378-3773; Dvorak, Christopher C/0000-0002-6146-3952; Richter, Darko/0000-0002-6559-9056; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Rezaei, Nima/0000-0002-3836-1827; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Condino-Neto, Antonio/0000-0002-1069-3117; Speckmann, Carsten/0000-0002-6217-1556; Aghamohammadi, Asghar/0000-0002-9454-1603; Edgar, John David Moore/0000-0003-2969-4475; Murguia-Favela, Luis/0000-0001-6893-3366; Dhalla, Fatima/0000-0001-9244-2284; Farmaki, Evangelia/0000-0002-5132-8255; Cabral Marques, Otavio/0000-0002-3183-6236; Gray, Paul/0000-0003-2057-3968; Hanson, Imelda/0000-0001-9457-0757; Litzman, Jiri/0000-0002-1926-5426; Kuo, Caroline/0000-0002-9302-0187	Jeffrey Modell Foundation; National Institutes of Health Office of Rare Diseases, National Center for Advancing Translational Sciences and National, Institute of Allergy and Infectious Disease [U54 AI 082973, R13AI094943]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U24AI086037, U54AI082973, ZIAAI001222, P01AI061093] Funding Source: NIH RePORTER	Jeffrey Modell Foundation; National Institutes of Health Office of Rare Diseases, National Center for Advancing Translational Sciences and National, Institute of Allergy and Infectious Disease; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a grant from Jeffrey Modell Foundation (to M.d.l.M.). The Primary Immune Deficiency Treatment Consortium (PIDTC) is supported by the National Institutes of Health Office of Rare Diseases, National Center for Advancing Translational Sciences and National, Institute of Allergy and Infectious Disease grants U54 AI 082973 and R13AI094943.	Al-Saud B, 2015, PEDIATR TRANSPLANT, V19, P634, DOI 10.1111/petr.12538; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Allewelt H, 2015, PEDIATR BLOOD CANCER, V62, P2216, DOI 10.1002/pbc.25711; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANATVALA N, 1994, ARCH DIS CHILD, V71, P150, DOI 10.1136/adc.71.2.150; Bordigoni P, 1998, BONE MARROW TRANSPL, V22, P1111, DOI 10.1038/sj.bmt.1701497; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; Cabral-Marques O, 2014, J CLIN IMMUNOL, V34, P146, DOI 10.1007/s10875-013-9980-4; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Cole T, 2013, J ALLERGY CLIN IMMUN, V132, P1150, DOI 10.1016/j.jaci.2013.05.031; COOPER MD, 1974, CLIN IMMUNOL IMMUNOP, V2, P416, DOI 10.1016/0090-1229(74)90059-2; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Duplantier JE, 2001, CLIN IMMUNOL, V98, P313, DOI 10.1006/clim.2000.4994; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; Hadzic N, 2000, NEW ENGL J MED, V342, P320, DOI 10.1056/NEJM200002033420504; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hubbard N, 2016, BLOOD, V127, P2513, DOI 10.1182/blood-2015-11-683235; Jacobsohn DA, 2004, PEDIATRICS, V113, P122, DOI 10.1542/peds.113.2.e122; Jain A, 1999, J CLIN INVEST, V103, P1151, DOI 10.1172/JCI5891; Khawaja K, 2001, ARCH DIS CHILD, V84, P508, DOI 10.1136/adc.84.6.508; Kikuta A, 2006, BONE MARROW TRANSPL, V38, P665, DOI 10.1038/sj.bmt.1705511; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Lee WI, 2013, PEDIATR INFECT DIS J, V32, P1010, DOI 10.1097/INF.0b013e3182936280; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Madkaikar M, 2014, BLOOD CELL MOL DIS, V53, P99, DOI 10.1016/j.bcmd.2014.05.008; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MAYER L, 1985, J EXP MED, V161, P134, DOI 10.1084/jem.161.1.134; MENSINK EJBM, 1987, HUM GENET, V76, P96; Miga A., 2000, Immunological Investigations, V29, P111, DOI 10.3109/08820130009062292; Mitsui-Sekinaka K, 2015, J ALLERGY CLIN IMMUN, V136, P1018, DOI 10.1016/j.jaci.2015.02.020; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; NOELLE RJ, 1995, CLIN IMMUNOL IMMUNOP, V76, pS203, DOI 10.1016/S0090-1229(95)90234-1; Notarangelo LD, 2006, J ALLERGY CLIN IMMUN, V117, P855, DOI 10.1016/j.jaci.2006.01.043; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; ROSEN FS, 1961, PEDIATRICS, V28, P182; Sato T, 2007, PEDIATR INT, V49, P795, DOI 10.1111/j.1442-200X.2007.02468.x; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Seyama K, 1998, J INFECT DIS, V178, P318, DOI 10.1086/515633; THOMAS C, 1995, NEW ENGL J MED, V333, P426, DOI 10.1056/NEJM199508173330705; Tomizawa D, 2004, AM J HEMATOL, V76, P33, DOI 10.1002/ajh.20044; Tsuji Y, 2006, BONE MARROW TRANSPL, V37, P469, DOI 10.1038/sj.bmt.1705273; Wang LL, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/683160; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Winkelstein JA, 2006, MEDICINE, V85, P193; Ziegner UHM, 2002, CLIN IMMUNOL, V102, P19, DOI 10.1006/clim.2001.5140	52	71	71	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1282	1292		10.1016/j.jaci.2016.07.039	http://dx.doi.org/10.1016/j.jaci.2016.07.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27697500	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000398771800023
J	Sirvent, S; Soria, I; Cirauqui, C; Cases, B; Manzano, AI; Diez-Rivero, CM; Reche, PA; Lopez-Relano, J; Martinez-Naves, E; Canada, FJ; Jimenez-Barbero, J; Subiza, J; Casanovas, M; Fernandez-Caldas, E; Subiza, JL; Palomares, O				Sirvent, Sofia; Soria, Irene; Cirauqui, Cristina; Cases, Barbara; Manzano, Ana I.; Diez-Rivero, Carmen M.; Reche, Pedro A.; Lopez-Relano, Juan; Martinez-Naves, Eduardo; Javier Canada, F.; Jimenez-Barbero, Jesus; Subiza, Javier; Casanovas, Miguel; Fernandez-Caldas, Enrique; Luis Subiza, Jose; Palomares, Oscar			Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; vaccines; neoglycans; allergoids; mannan; immunomodulation; dendritic cells; regulatory T cells	NECROSIS-FACTOR-ALPHA; INTRALYMPHATIC IMMUNOTHERAPY; IMMUNE REGULATION; TOLERANCE; RECEPTOR; MICROBIOTA; FRAGMENTS; CONSENSUS; RESPONSES; LECTINS	Background: Allergen immunotherapy (AIT) is the only curative treatment for allergy. AIT faces pitfalls related to efficacy, security, duration, and patient compliance. Novel vaccines overcoming such inconveniences are in demand. Objectives: We sought to study the immunologic mechanisms of action for novel vaccines targeting dendritic cells (DCs) generated by coupling glutaraldehyde-polymerized grass pollen allergoids to nonoxidized mannan (PM) compared with glutaraldehyde-polymerized allergoids (P) or native grass pollen extracts (N). Methods: Skin prick tests and basophil activation tests with N, P, or PM were performed in patients with grass pollen allergy. IgE-blocking experiments, flow cytometry, confocal microscopy, cocultures, suppression assays, real-time quantitative PCR, ELISAs, and ELISpot assays were performed to assess allergen capture by human DCs and T-cell responses. BALB/c mice were immunized with PM, N, or P. Antibody levels, cytokine production by splenocytes, and splenic forkhead box P3 (FOXP3)(+) regulatory T (Treg) cells were quantified. Experiments with oxidized PM were also performed. Results: PM displays in vivo hypoallergenicity, induces potent blocking antibodies, and is captured by human DCs much more efficiently than N or P by mechanisms depending on mannose receptor- and dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin-mediated internalization. PM endorses human DCs to generate functional FOXP3(+) Treg cells through programmed death ligand 1. Immunization of mice with PM induces a shift to nonallergic responses and increases the frequency of splenic FOXP3(+) Treg cells. Mild oxidation impairs these effects in human subjects and mice, demonstrating the essential role of preserving the carbohydrate structure of mannan. Conclusions: Allergoids conjugated to nonoxidized mannan represent suitable vaccines for AIT. Our findings might also be of the utmost relevance to development of therapeutic interventions in other immune tolerance-related diseases.	[Sirvent, Sofia; Cirauqui, Cristina; Palomares, Oscar] Univ Complutense Madrid, Dept Biochem & Mol Biol, Sch Chem, Ciudad Univ S-N, E-28040 Madrid, Spain; [Soria, Irene; Cases, Barbara; Casanovas, Miguel; Fernandez-Caldas, Enrique; Luis Subiza, Jose] Inmunotek, Alcala De Henares, Spain; [Soria, Irene; Luis Subiza, Jose] Hosp Clin San Carlos, Dept Immunol, Madrid, Spain; [Manzano, Ana I.; Javier Canada, F.; Jimenez-Barbero, Jesus] Ctr Invest Biol, Madrid, Spain; [Diez-Rivero, Carmen M.; Reche, Pedro A.; Lopez-Relano, Juan; Martinez-Naves, Eduardo; Luis Subiza, Jose] Univ Complutense Madrid, Dept Microbiol Immunol 1, Sch Med, Madrid, Spain; [Jimenez-Barbero, Jesus] Parque Tecnol Bizkaia, CIC bioGUNE, Bilbao, Spain; [Subiza, Javier] Clin Subiza SA, Madrid, Spain; [Fernandez-Caldas, Enrique] Univ S Florida, Coll Med, Tampa, FL USA	Complutense University of Madrid; Hospital Clinico San Carlos; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Complutense University of Madrid; CIC bioGUNE; State University System of Florida; University of South Florida	Palomares, O (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol, Sch Chem, Ciudad Univ S-N, E-28040 Madrid, Spain.	oscar.palomares@quim.ucm.es	Palomares, Oscar/ABG-5229-2020; JIMENEZ-BARBERO, JESUS/D-4431-2014; Cañada, Francisco J./D-5837-2014; MARTINEZ-NAVES, EDUARDO/Y-6177-2019; Reche, Pedro A/B-1881-2013	JIMENEZ-BARBERO, JESUS/0000-0001-5421-8513; Cañada, Francisco J./0000-0003-4462-1469; Reche, Pedro A/0000-0003-3966-5838; MARTINEZ-NAVES, EDUARDO/0000-0001-8136-9042; Palomares, Oscar/0000-0003-4516-0369; Cirauqui, Cristina/0000-0002-4064-6485; Lopez-Relano, Juan/0000-0001-9620-3299	CDTI [IDI-20110410, IDI-20141131]; MINECO; MINECO, Spain [SAF-2014-52706]; European Social Fund; Torres Quevedo [PTQ-12-05787, PTQ-10-04075]	CDTI; MINECO(Spanish Government); MINECO, Spain(Spanish Government); European Social Fund(European Social Fund (ESF)); Torres Quevedo	Supported by grants IDI-20110410 and IDI-20141131 from CDTI and MINECO. The authors' laboratories are supported by grant SAF-2014-52706 (to O.P.) from MINECO, Spain. O.P. is a Ramon y Cajal Scholar funded by MINECO and the European Social Fund. I.S. and B.C. are recipients of Torres Quevedo (grants PTQ-12-05787 and PTQ-10-04075, respectively).	Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Altfeld MA, 2000, J VIROL, V74, P8541, DOI 10.1128/JVI.74.18.8541-8549.2000; APOSTOLOPOULOS V, 1995, P NATL ACAD SCI USA, V92, P10128, DOI 10.1073/pnas.92.22.10128; Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C; Apostolopoulos V, 2013, J DRUG DELIV, V2013, DOI 10.1155/2013/869718; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; de Roock S, 2011, J ALLERGY CLIN IMMUN, V128, P1369, DOI 10.1016/j.jaci.2011.08.006; Durand M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00129; Focke-Tejkl M, 2012, CURR OPIN ALLERGY CL, V12, P555, DOI 10.1097/ACI.0b013e328357ca53; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gadermaier E, 2016, ALLERGY, V71, P36, DOI 10.1111/all.12710; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Geuking MB, 2011, IMMUNITY, V34, P794, DOI 10.1016/j.immuni.2011.03.021; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Heydenreich B, 2012, IMMUNOLOGY, V136, P208, DOI 10.1111/j.1365-2567.2012.03571.x; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Iborra S, 2015, IMMUNOBIOLOGY, V220, P175, DOI 10.1016/j.imbio.2014.09.013; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Johnson MA, 2013, CHEM SOC REV, V42, P4327, DOI 10.1039/c2cs35382b; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kristiansen KA, 2010, CARBOHYD RES, V345, P1264, DOI 10.1016/j.carres.2010.02.011; Lambrecht Bart N, 2009, Handb Exp Pharmacol, P99, DOI 10.1007/978-3-540-71029-5_5; Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007; LLOYD KO, 1970, BIOCHEMISTRY-US, V9, P3446, DOI 10.1021/bi00819a025; Malling H J, 1997, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P157; Manzano AI, 2016, GLYCOCONJUGATE J, V33, P93, DOI 10.1007/s10719-015-9640-4; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Moingeon P, 2012, HUM VACC IMMUNOTHER, V8, P1492, DOI 10.4161/hv.21688; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Patel P, 2014, J ALLERGY CLIN IMMUN, V133; Patel P, 2014, J ALLERGY CLIN IMMUN, V133, P121, DOI 10.1016/j.jaci.2013.05.032; Rabe H, 2014, IMMUNOLOGY, V141, P467, DOI 10.1111/imm.12209; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rael E, 2014, J ALLERGY CLIN IMMUN, V134, P1218, DOI 10.1016/j.jaci.2014.08.046; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Salazar F, 2013, J ALLERGY CLIN IMMUN, V132, P27, DOI 10.1016/j.jaci.2013.02.001; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Sheng KC, 2006, IMMUNOLOGY, V118, P372, DOI 10.1111/j.1365-2567.2006.02384.x; Stern JNH, 2010, P NATL ACAD SCI USA, V107, P17280, DOI 10.1073/pnas.1010263107; Subiza J, 2008, CLIN EXP ALLERGY, V38, P987, DOI 10.1111/j.1365-2222.2008.02995.x; Subiza JL, 2014, International patent, Patent No. [PCT/ES2014/070263-WO/2014/162036, 2014070263]; Tada H, 2002, MICROBIOL IMMUNOL, V46, P503, DOI 10.1111/j.1348-0421.2002.tb02727.x; Tseveleki V, 2015, EXP NEUROL, V267, P254, DOI 10.1016/j.expneurol.2014.10.019; Unger WWJ, 2011, CURR OPIN IMMUNOL, V23, P131, DOI 10.1016/j.coi.2010.11.011; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; van Kooyk Y, 2013, MOL IMMUNOL, V55, P143, DOI 10.1016/j.molimm.2012.10.031; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Weinberger EE, 2013, J CONTROL RELEASE, V165, P101, DOI 10.1016/j.jconrel.2012.11.002; Zaleska A, 2014, ALLERGY, V69, P1162, DOI 10.1111/all.12461; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201	63	71	75	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					558	+		10.1016/j.jaci.2016.02.029	http://dx.doi.org/10.1016/j.jaci.2016.02.029			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27177779	hybrid			2022-12-18	WOS:000380835800028
J	Conti, F; Lugo-Reyes, SO; Galicia, LB; He, JX; Aksu, G; de Oliveira, EB; Deswarte, C; Hubeau, M; Karaca, N; de Suremain, M; Guerin, A; Baba, LA; Prando, C; Guerrero, GG; Emiroglu, M; Oz, FN; Nakashimada, MAY; Serrano, EG; Espinosa, S; Barlan, I; Perez, N; Regairaz, L; Morales, HEG; Bezrodnik, L; Di Giovanni, D; Dbaibo, G; Ailal, F; Galicchio, M; Oleastro, M; Chemli, J; Danielian, S; Perez, L; Ortega, MC; Lavin, SS; Hertecant, J; Anal, O; Kechout, N; Al-Idrissi, E; ElGhazali, G; Bondarenko, A; Chernyshova, L; Ciznar, P; Herbigneaux, RM; Diabate, A; Ndaga, S; Konte, B; Czarna, A; Migaud, M; Pedraza-Sanchez, S; Zaidi, MB; Vogt, G; Blanche, S; Benmustapha, I; Mansouri, D; Abel, L; Boisson-Dupuis, S; Mahlaoui, N; Bousfiha, AA; Picard, C; Barbouche, R; Al-Muhsen, S; Espinosa-Rosales, FJ; Kutukculer, N; Condino-Neto, A; Casanova, JL; Bustamante, J				Conti, Francesca; Oswaldo Lugo-Reyes, Saul; Blancas Galicia, Lizbeth; He, Jianxin; Aksu, Guzide; de Oliveira, Edgar Borges, Jr.; Deswarte, Caroline; Hubeau, Marjorie; Karaca, Neslihan; de Suremain, Maylis; Guerin, Antoine; Baba, Laila Ait; Prando, Carolina; Guerrero, Gloria G.; Emiroglu, Melike; Oz, Fatma Nur; Yamazaki Nakashimada, Marco Antonio; Gonzalez Serrano, Edith; Espinosa, Sara; Barlan, Isil; Perez, Nestor; Regairaz, Lorena; Guidos Morales, Hector Eduardo; Bezrodnik, Liliana; Di Giovanni, Daniela; Dbaibo, Ghassan; Ailal, Fatima; Galicchio, Miguel; Oleastro, Matias; Chemli, Jalel; Danielian, Silvia; Perez, Laura; Claudia Ortega, Maria; Soto Lavin, Susana; Hertecant, Joseph; Anal, Ozden; Kechout, Nadia; Al-Idrissi, Eman; ElGhazali, Gehad; Bondarenko, Anastasia; Chernyshova, Liudmyla; Ciznar, Peter; Herbigneaux, Rose-Marie; Diabate, Aminata; Ndaga, Stephanie; Konte, Barik; Czarna, Ambre; Migaud, Melanie; Pedraza-Sanchez, Sigifredo; Bano Zaidi, Mussaret; Vogt, Guillaume; Blanche, Stephane; Benmustapha, Imen; Mansouri, Davood; Abel, Laurent; Boisson-Dupuis, Stephanie; Mahlaoui, Nizar; Bousfiha, Ahmed Aziz; Picard, Capucine; Barbouche, Ridha; Al-Muhsen, Saleh; Espinosa-Rosales, Francisco J.; Kutukculer, Necil; Condino-Neto, Antonio; Casanova, Jean-Laurent; Bustamante, Jacinta			Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycobacteria; BCG; chronic granulomatous disease; tuberculosis; primary immunodeficiency	CLINICAL-FEATURES; 1ST REPORT; 2 CHILDREN; TUBERCULOSIS; MUTATIONS; INFECTIONS; SUSCEPTIBILITY; VACCINATION; OXIDASE; REGION	Background: Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by inborn errors of the phagocyte nicotinamide adenine dinucleotide phosphate oxidase complex. From the first year of life onward, most affected patients display multiple, severe, and recurrent infections caused by bacteria and fungi. Mycobacterial infections have also been reported in some patients. Objective: Our objective was to assess the effect of mycobacterial disease in patients with CGD. Methods: We analyzed retrospectively the clinical features of mycobacterial disease in 71 patients with CGD. Tuberculosis and BCG disease were diagnosed on the basis of microbiological, pathological, and/or clinical criteria. Results: Thirty-one (44%) patients had tuberculosis, and 53 (75%) presented with adverse effects of BCG vaccination; 13 (18%) had both tuberculosis and BCG infections. None of these patients displayed clinical disease caused by environmental mycobacteria, Mycobacterium leprae, or Mycobacterium ulcerans. Most patients (76%) also had other pyogenic and fungal infections, but 24% presented solely with mycobacterial disease. Most patients presented a single localized episode of mycobacterial disease (37%), but recurrence (18%), disseminated disease (27%), and even death (18%) were also observed. One common feature in these patients was an early age at presentation for BCG disease. Mycobacterial disease was the first clinical manifestation of CGD in 60% of these patients. Conclusion: Mycobacterial disease is relatively common in patients with CGD living in countries in which tuberculosis is endemic, BCG vaccine is mandatory, or both. Adverse reactions to BCG and severe forms of tuberculosis should lead to a suspicion of CGD. BCG vaccine is contraindicated in patients with CGD.	[Conti, Francesca; Oswaldo Lugo-Reyes, Saul; Blancas Galicia, Lizbeth; de Oliveira, Edgar Borges, Jr.; Deswarte, Caroline; Hubeau, Marjorie; de Suremain, Maylis; Guerin, Antoine; Guerrero, Gloria G.; Migaud, Melanie; Abel, Laurent; Boisson-Dupuis, Stephanie; Picard, Capucine; Casanova, Jean-Laurent; Bustamante, Jacinta] Inst Natl Sante & Rech Med, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Conti, Francesca; Oswaldo Lugo-Reyes, Saul; Blancas Galicia, Lizbeth; de Oliveira, Edgar Borges, Jr.; Deswarte, Caroline; Hubeau, Marjorie; de Suremain, Maylis; Guerin, Antoine; Guerrero, Gloria G.; Vogt, Guillaume; Abel, Laurent; Boisson-Dupuis, Stephanie; Mahlaoui, Nizar; Picard, Capucine; Casanova, Jean-Laurent; Bustamante, Jacinta] Paris Descartes Univ, Imagine Inst, Paris, France; [Conti, Francesca] Univ Roma Tor Vergata, Dept Publ Hlth & Cellular Biol, Rome, Italy; [Oswaldo Lugo-Reyes, Saul; Blancas Galicia, Lizbeth] Natl Inst Pediat, Immunodeficiencies Res Unit, Mexico City, DF, Mexico; [He, Jianxin] Beijing Childrens Hosp, Nanlishilu Rd 56, Beijing, Peoples R China; [Aksu, Guzide; Karaca, Neslihan] Ege Univ, Dept Pediat, Fac Med, Izmir, Turkey; [de Oliveira, Edgar Borges, Jr.; Condino-Neto, Antonio] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo, Brazil; [Baba, Laila Ait] King Hassan II Univ, Lab Biol & Hlth UARC34, Metab & Immunol Pathol Res Team, Fac Sci Ben Msik, Casablanca, Morocco; [Prando, Carolina] Pele Pequeno Principe Res Inst, Bioinformat Lab, Curitiba, Parana, Brazil; [Emiroglu, Melike] Necmettin Erbakan Univ, Meram Med Fac, Dept Pediat Infect Dis, Konya, Turkey; [Oz, Fatma Nur] Dr Sami Ulus Matern & Childrens Res & Training Ho, Pediat Infect Dis Dept, Ankara, Turkey; [Yamazaki Nakashimada, Marco Antonio; Gonzalez Serrano, Edith; Espinosa, Sara] Natl Inst Pediat, Dept Immunol, Mexico City, DF, Mexico; [Barlan, Isil] Marmara Univ, Dept Pediat Allergy & Immunol, Istanbul, Turkey; [Perez, Nestor; Regairaz, Lorena] Childrens Hosp Super Sor Maria Ludovica, Immunol Unit, La Plata, Buenos Aires, Argentina; [Guidos Morales, Hector Eduardo] Natl Childrens Hosp Benjamin Bloom, Allergy & Immunol Unit, San Salvador, El Salvador; [Bezrodnik, Liliana; Di Giovanni, Daniela] Childrens Hosp Ricardo Gutierrez, Immunol Unit, Buenos Aires, DF, Argentina; [Dbaibo, Ghassan] Amer Univ Beirut, Med Ctr, Dept Pediat, Beirut, Lebanon; [Ailal, Fatima] King Hassan II Univ, Clin Immunol Unit, Casablanca Childrens Hosp, Ibn Rochd Med Sch, Casablanca, Morocco; [Galicchio, Miguel] Childrens Hosp Victor J Vilela, Rosario, Argentina; [Oleastro, Matias; Danielian, Silvia; Perez, Laura] Juan Pedro Garrahan Natl Hosp Pediat, Dept Immunol, Buenos Aires, DF, Argentina; [Chemli, Jalel] Sahloul Hosp, Dept Pediat, Sousse, Tunisia; [Claudia Ortega, Maria] Childrens Hosp San Jose, Bogota, Colombia; [Claudia Ortega, Maria] Sch Med, Bogota, Colombia; [Soto Lavin, Susana] Concepc Reg Hosp, Concepcion, Chile; [Hertecant, Joseph] Tawam Hosp, Dept Pediat, Abu Dhabi, U Arab Emirates; [Anal, Ozden] Dokuz Eylul Univ, Dept Pediat, Fac Med, Izmir, Turkey; [Kechout, Nadia] Pasteur Inst Algeria, Dept Immunol, Dely Ibrahim, Algeria; [Al-Idrissi, Eman; ElGhazali, Gehad] King Fahad Med City, Dept Pediat, Riyadh, Saudi Arabia; [Bondarenko, Anastasia; Chernyshova, Liudmyla] Dept Pediat Infect Dis & Clin Immunol, Kiev, Ukraine; [Ciznar, Peter] Comenius Univ, Univ Childrens Hosp, Sch Med, Dept Pediat, Bratislava, Slovakia; [Herbigneaux, Rose-Marie] Reunion CHU, Hematol Oncol Unit, St Denis, Reunion, France; [Diabate, Aminata; Ndaga, Stephanie; Konte, Barik; Czarna, Ambre; Picard, Capucine] Necker Hosp Sick Children, AP HP, Ctr Study Primary Immunodeficiencies, Paris, France; [Ndaga, Stephanie; Mahlaoui, Nizar; Casanova, Jean-Laurent] Necker Hosp Sick Children, Pediat Hematol Immunol Unit, Paris, France; [Abel, Laurent; Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent; Bustamante, Jacinta] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Pedraza-Sanchez, Sigifredo] Natl Inst Med Sci & Nutr Salvador Zubiran, Biochem Unit, Tlalpan, Mexico; [Bano Zaidi, Mussaret] Hosp Reg Alta Especialidad Peninsula Yucatan, Microbiol Res Lab, Hosp Gen OHoran, Merida, Venezuela; [Bano Zaidi, Mussaret] Hosp Reg Alta Especialidad Peninsula Yucatan, Infect Dis Res Unit, Merida, Venezuela; [Benmustapha, Imen] Pasteur Inst Tunis, Lab Cytoimmunol, Tunis, Tunisia; [Mansouri, Davood] Shahid Beheshti Univ Med Sci, Div Infect Dis & Clin Immunol, Natl Res Inst TB & Lung Dis, Tehran, Iran; [Mahlaoui, Nizar; Picard, Capucine; Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, French Reference Ctr Primary Immune Deficiencies, Paris, France; [Al-Muhsen, Saleh] King Saud Univ, Dept Pediat, Prince Naif Ctr Immunol Res, Coll Med, Riyadh, Saudi Arabia; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Rome Tor Vergata; Capital Medical University; Ege University; Universidade de Sao Paulo; Hassan II University of Casablanca; Hospital Pequeno Principe; Necmettin Erbakan University; Selcuk University; Dr. Sami Ulus Education & Research Hospital; Marmara University; Hospital de Ninos Doctor Ricardo Gutierrez; American University of Beirut; Hassan II University of Casablanca; Hospital de Pediatria Doctor Juan Garrahan; Universite de Sousse; Hopital Sahloul; Fundacion Universitaria de Ciencias de la Salud (FUCS); Dokuz Eylul University; King Fahad Medical City; Comenius University Bratislava; CHU Reunion; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Shahid Beheshti University Medical Sciences; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; King Saud University; Howard Hughes Medical Institute	Bustamante, J (corresponding author), INSERM U1163, Lab Human Genet Infect Dis, 24 Blvd Montparnasse, Paris, France.	jacinta.bustamante@inserm.fr	Al-muhsen, saleh/E-9315-2014; Ciznar, Peter/AAL-7283-2020; Reyes, Saul O Lugo/AAS-7621-2021; Migaud, Mélanie/H-8044-2017; Bustamante, Jacinta/H-7877-2017; MAHLAOUI, Nizar/AAH-6103-2020; Condino-Neto, Antonio/D-4762-2012; Ciznar, Peter/ABE-4459-2021; Dbaibo, Ghassan S./X-2978-2019; Yamazaki-Nakashimada, Marco Antonio/Y-7129-2019; Conti, Francesca/Q-1845-2019; Prando, Carolina/C-4689-2015; Emiroğlu, Melike/AAH-3566-2019; Karaca, Neslihan/AAW-1924-2020; Guérin, Antoine/AAF-6041-2019; Mahlaoui, Nizar/J-7928-2017; Boisson-Dupuis, Stéphanie/I-2040-2017; Deswarte, Caroline/H-8018-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Bondarenko, Anastasiia/AAL-5037-2020; Reyes, Saul O Lugo/AAP-7951-2021; Abel, Laurent/H-8888-2017; mansouri, davood/G-6471-2017; Casanova, Jean-Laurent/I-3418-2017; Chernyshova, Liudmyla/E-9457-2019	Al-muhsen, saleh/0000-0003-3698-9968; Reyes, Saul O Lugo/0000-0002-3730-4150; Migaud, Mélanie/0000-0003-3062-1214; Bustamante, Jacinta/0000-0002-3439-2482; MAHLAOUI, Nizar/0000-0002-0030-8094; Condino-Neto, Antonio/0000-0002-1069-3117; Ciznar, Peter/0000-0003-0566-1644; Yamazaki-Nakashimada, Marco Antonio/0000-0002-7609-3923; Conti, Francesca/0000-0002-3665-8926; Prando, Carolina/0000-0002-9570-9770; Karaca, Neslihan/0000-0002-2202-7082; Guérin, Antoine/0000-0001-6810-1607; Mahlaoui, Nizar/0000-0002-0030-8094; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Deswarte, Caroline/0000-0002-8775-3368; Bondarenko, Anastasiia/0000-0002-9737-2868; Reyes, Saul O Lugo/0000-0002-3730-4150; Abel, Laurent/0000-0001-7016-6493; mansouri, davood/0000-0002-0564-8282; Casanova, Jean-Laurent/0000-0002-7782-4169; Emiroglu, Melike/0000-0003-1307-0246; PALUMBO, GIUSEPPE/0000-0002-1010-2946; VOGT, Guillaume/0000-0001-8192-1247; Chernyshova, Liudmyla/0000-0002-9980-250X; Pedraza-Sanchez, Sigifredo/0000-0002-7062-6979	Department of Public Health and Cellular Biology, University of Rome Tor Vergata; French National Research Agency (ANR); INSERM; University Paris Descartes; Rockefeller University; St Giles Foundation; French National Research Agency (ANR) under the "Investments for the Future" program [ANR-10-IAHU-01]; French National Research Agency (ANR) under the grant IFNGPHOX [ANR13-ISV3-0001-01]; Fundacao de Amparoa Pesquisa do Estado de So Paulo (FAPESP) [2012/11757-2, 2010/51814-0, 2012/51094-2]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [303809/2010-8]; Consejo Nacional de Ciencia y Tecnologia (CONACYT) [182817]	Department of Public Health and Cellular Biology, University of Rome Tor Vergata; French National Research Agency (ANR)(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Paris Descartes; Rockefeller University; St Giles Foundation; French National Research Agency (ANR) under the "Investments for the Future" program(French National Research Agency (ANR)); French National Research Agency (ANR) under the grant IFNGPHOX(French National Research Agency (ANR)); Fundacao de Amparoa Pesquisa do Estado de So Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	F.C. was supported by the Department of Public Health and Cellular Biology, University of Rome Tor Vergata. A.G. was supported by the French National Research Agency (ANR). The Laboratory of Human Genetics of Infectious Diseases is supported by institutional grants from INSERM, University Paris Descartes, the Rockefeller University, and the St Giles Foundation and grants from the French National Research Agency (ANR) under the "Investments for the Future" program (grant no. ANR-10-IAHU-01) and grant IFNGPHOX (no. ANR13-ISV3-0001-01). E.B.d.O. and A.C.-N. are supported by Fundacao de Amparoa Pesquisa do Estado de So Paulo (FAPESP grants 2012/11757-2, 2010/51814-0, and 2012/51094-2) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ grant 303809/2010-8). S.P.-S. is supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT, grant 182817).	Adams LB, 1997, TUBERCLE LUNG DIS, V78, P237, DOI 10.1016/S0962-8479(97)90004-6; ALLEN DM, 1993, J INFECTION, V26, P83, DOI 10.1016/0163-4453(93)97000-N; Baba LA, 2014, J CLIN IMMUNOL, V34, P452, DOI 10.1007/s10875-014-9997-3; Barese C, 2004, J PEDIAT HEMATOL ONC, V26, P656, DOI 10.1097/01.mph.0000139455.29962.be; Boisson-Dupuis S, 2015, IMMUNOL REV, V264, P103, DOI 10.1111/imr.12272; Boisson-Dupuis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018524; Bustamante J, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.043406; Bustamante J, 2007, J ALLERGY CLIN IMMUN, V120, P32, DOI 10.1016/j.jaci.2007.04.034; Bustamante J, 2011, NAT IMMUNOL, V12, P213, DOI 10.1038/ni.1992; Carnide EG, 2005, PEDIATR ALLERGY IMMU, V16, P5, DOI 10.1111/j.1399-3038.2005.00225.x; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; Conti F, 2015, J ALLERGY CLIN IMMUN, V135, P1393, DOI 10.1016/j.jaci.2014.11.004; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; de Oliveira EB, 2012, SCAND J IMMUNOL, V76, P158, DOI 10.1111/j.1365-3083.2012.02714.x; de Oliveira EB, 2011, SCAND J IMMUNOL, V73, P420, DOI 10.1111/j.1365-3083.2010.02501.x; de Oliveira EB, 2015, PEDIATR BLOOD CANCER, V62, P2101, DOI 10.1002/pbc.25674; Deffert C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004325; Deffert C, 2014, CELL MICROBIOL, V16, P1168, DOI 10.1111/cmi.12322; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; El Kares R, 2006, J HUM GENET, V51, P887, DOI 10.1007/s10038-006-0039-8; Elloumi Houda Zghal, 2007, V412, P505, DOI 10.1007/978-1-59745-467-4_31; Fattahi F, 2011, J CLIN IMMUNOL, V31, P792, DOI 10.1007/s10875-011-9567-x; Feinberg J, 2004, EUR J IMMUNOL, V34, P3276, DOI 10.1002/eji.200425221; Fujita M, 2010, CLIN EXP IMMUNOL, V160, P457, DOI 10.1111/j.1365-2249.2010.04092.x; Gentsch M, 2010, HUM MUTAT, V31, P151, DOI 10.1002/humu.21156; Graham SM, 2012, J INFECT DIS, V205, pS199, DOI 10.1093/infdis/jis008; He Jian-Xin, 2010, Zhongguo Dang Dai Er Ke Za Zhi, V12, P490; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; Jabado N, 1998, CLIN INFECT DIS, V27, P1437, DOI 10.1086/515015; Khotaei G, 2012, BRAZ J INFECT DIS, V16, P491, DOI 10.1016/j.bjid.2012.06.024; Koker MY, 2013, J ALLERGY CLIN IMMUN, V132, P1156, DOI 10.1016/j.jaci.2013.05.039; Lee PPW, 2008, PEDIATR INFECT DIS J, V27, P224, DOI 10.1097/INF.0b013e31815b494c; Lin CJ, 2015, PEDIATR NEONATOL, V56, P346, DOI 10.1016/j.pedneo.2013.04.001; Mansoory D, 2003, CLIN INFECT DIS, V37, pE107, DOI 10.1086/377608; Marciano BE, 2015, CLIN INFECT DIS, V60, P1176, DOI 10.1093/cid/ciu1154; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; Naidoo R, 2011, SAMJ S AFR MED J, V101, P768; Oh HB, 2004, J KOREAN MED SCI, V19, P218, DOI 10.3346/jkms.2004.19.2.218; Ohga S, 1997, J INFECTION, V34, P147, DOI 10.1016/S0163-4453(97)92509-3; Reyes SOL, 2011, J ALLERGY CLIN IMMUN, V127, P543, DOI 10.1016/j.jaci.2010.10.049; Roos D, 2010, BLOOD CELL MOL DIS, V45, P246, DOI 10.1016/j.bcmd.2010.07.012; Roos D, 2010, BLOOD CELL MOL DIS, V44, P291, DOI 10.1016/j.bcmd.2010.01.009; Salvator H, 2015, EUR RESPIR J, V45, P1613, DOI 10.1183/09031936.00118414; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Talbot EA, 1997, CLIN INFECT DIS, V24, P1139, DOI 10.1086/513642; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Weening RS, 2000, CLIN EXP IMMUNOL, V122, P410, DOI 10.1046/j.1365-2249.2000.01405.x; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Yang Chul-Su, 2009, Immune Netw, V9, P46, DOI 10.4110/in.2009.9.2.46; Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012	52	71	77	1	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					241	+		10.1016/j.jaci.2015.11.041	http://dx.doi.org/10.1016/j.jaci.2015.11.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26936803	Bronze			2022-12-18	WOS:000379659100026
J	Bonnelykke, K; Ober, C				Bonnelykke, Klaus; Ober, Carole			Leveraging gene-environment interactions and endotypes for asthma gene discovery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rhinovirus; genome-wide association study; gene-environment interactions; 17q asthma locus; CDHR3	GENOME-WIDE ASSOCIATION; HUMAN RHINOVIRUS C; CHILDHOOD ASTHMA; EARLY-LIFE; RESPIRATORY-INFECTIONS; MISSING HERITABILITY; ENDOTOXIN EXPOSURE; ALLERGIC DISEASE; DNA METHYLATION; 17Q21 VARIANTS	Asthma is a heterogeneous clinical syndrome that includes subtypes of disease with different underlying causes and disease mechanisms. Asthma is caused by a complex interaction between genes and environmental exposures; early-life exposures in particular play an important role. Asthma is also heritable, and a number of susceptibility variants have been discovered in genome-wide association studies, although the known risk alleles explain only a small proportion of the heritability. In this review, we present evidence supporting the hypothesis that focusing on more specific asthma phenotypes, such as childhood asthma with severe exacerbations, and on relevant exposures that are involved in gene-environment interactions (GEIs), such as rhinovirus infections, will improve detection of asthma genes and our understanding of the underlying mechanisms. We will discuss the challenges of considering GEIs and the advantages of studying responses to asthma-associated exposures in clinical birth cohorts, as well as in cell models of GEIs, to dissect the context-specific nature of genotypic risks, to prioritize variants in genome-wide association studies, and to identify pathways involved in pathogenesis in subgroups of patients. We propose that such approaches, in spite of their many challenges, present great opportunities for better understanding of asthma pathogenesis and heterogeneity and, ultimately, for improving prevention and treatment of disease.	[Bonnelykke, Klaus] COPSAC Copenhagen Prospect Studies Asthma Childho, Herlev, Denmark; [Bonnelykke, Klaus] Univ Copenhagen, Gentofte Hosp, Copenhagen, Denmark; [Ober, Carole] Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 425, Chicago, IL 60637 USA	University of Copenhagen; Herlev & Gentofte Hospital; University of Chicago	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 425, Chicago, IL 60637 USA.; Bonnelykke, K (corresponding author), Gentofte Univ Hosp, COPSAC Copenhagen Prospect Studies Asthma Childho, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	kb@copsac.com; c-ober@genetics.uchicago.edu		Ober, Carole/0000-0003-4626-9809; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R163-2013-16235, R16-A1694]; Danish Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]; Danish Council for Independent Research [10-082884, 271-08-0815]; Capital Region Research Foundation;  [R01 HL058197];  [U19 AI095230];  [U01 AI106683];  [P01 HL070831];  [R01 HL129735]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL129735, R01HL122712, RC2HL101651, R01HL085197, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106683, U19AI095230, U19AI106683] Funding Source: NIH RePORTER	Lundbeck Foundation(Lundbeckfonden); Danish Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Capital Region Research Foundation; ; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	C.O. is supported by R01 HL058197, U19 AI095230, U01 AI106683, P01 HL070831, and R01 HL129735. K. B. is supported by The Lundbeck Foundation grant no. R163-2013-16235 & R16-A1694; The Danish Ministry of Health grant no. 903516; Danish Council for Strategic Research grant no. 0603-00280B; The Danish Council for Independent Research grant no. 10-082884 & 271-08-0815; and The Capital Region Research Foundation (no grant no.).	Teh AL, 2014, GENOME RES, V24, P1064, DOI 10.1101/gr.171439.113; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Banovich NE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004663; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bosco A, 2012, J ALLERGY CLIN IMMUN, V129, P88, DOI 10.1016/j.jaci.2011.10.038; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Caliskan M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005111; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Cox DW, 2013, AM J RESP CRIT CARE, V188, P1358, DOI 10.1164/rccm.201303-0498OC; Drake KA, 2014, J ALLERGY CLIN IMMUN, V133, P370, DOI 10.1016/j.jaci.2013.06.043; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Gusev A, 2014, AM J HUM GENET, V95, P535, DOI 10.1016/j.ajhg.2014.10.004; Gutierrez-Arcelus M, 2013, ELIFE, V2, DOI 10.7554/eLife.00523; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Hulpiau P, 2009, INT J BIOCHEM CELL B, V41, P349, DOI 10.1016/j.biocel.2008.09.027; Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578; Hylkema Machteld N, 2009, Proc Am Thorac Soc, V6, P660, DOI 10.1513/pats.200907-065DP; Igartua C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6965; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; Lemire M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7326; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Liu Y, 2014, AM J HUM GENET, V94, P485, DOI 10.1016/j.ajhg.2014.02.011; Loss GJ, 2015, AM J RESP CRIT CARE; Lovinsky-Desir S, 2012, CURR ALLERGY ASTHM R, V12, P211, DOI 10.1007/s11882-012-0257-4; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Musone SL, 2008, NAT GENET, V40, P1062, DOI 10.1038/ng.202; Myers RA, 2014, HUM MOL GENET, V23, P5251, DOI 10.1093/hmg/ddu222; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Ober C., 2016, ATS J IN PRESS; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Pacheco KA, 2012, CURR OPIN ALLERGY CL, V12, P111, DOI 10.1097/ACI.0b013e328351518f; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2010, J ALLERGY CLIN IMMUN, V125, P231, DOI 10.1016/j.jaci.2009.10.011; Pickrell JK, 2014, AM J HUM GENET, V94, P559, DOI 10.1016/j.ajhg.2014.03.004; Polderman TJC, 2015, NAT GENET, V47, P702, DOI 10.1038/ng.3285; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; Scholtens S, 2014, J ALLERGY CLIN IMMUN, V133, P885, DOI 10.1016/j.jaci.2013.08.049; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Shi JX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4365; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2010, EUR RESPIR J, V36, P57, DOI 10.1183/09031936.00154509; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Smith EN, 2008, PLOS BIOL, V6, P810, DOI 10.1371/journal.pbio.0060083; Sykes A, 2008, J ALLERGY CLIN IMMUN, V122, P685, DOI 10.1016/j.jaci.2008.08.017; Thomsen SF, 2011, RESP MED, V105, P1147, DOI 10.1016/j.rmed.2011.03.007; Thomsen SF, 2010, J ALLERGY CLIN IMMUN, V126, P626, DOI 10.1016/j.jaci.2010.06.017; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Torres JM, 2014, AM J HUM GENET, V95, P521, DOI 10.1016/j.ajhg.2014.10.001; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Welter D, 2014, NUCLEIC ACIDS RES, V42; West CE, 2015, J ALLERGY CLIN IMMUN, V135, P3, DOI 10.1016/j.jaci.2014.11.012; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yanai I, 2005, BIOINFORMATICS, V21, P650, DOI 10.1093/bioinformatics/bti042; Yang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080048; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	95	71	72	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					667	679		10.1016/j.jaci.2016.01.006	http://dx.doi.org/10.1016/j.jaci.2016.01.006			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26947980	Bronze, Green Accepted			2022-12-18	WOS:000371897500002
J	Doherty, TA; Baum, R; Newbury, RO; Yang, T; Dohil, R; Aquino, M; Doshi, A; Walford, HH; Kurten, RC; Broide, DH; Aceves, S				Doherty, Taylor A.; Baum, Rachel; Newbury, Robert O.; Yang, Tom; Dohil, Ranjan; Aquino, Melissa; Doshi, Ashmi; Walford, Hannah H.; Kurten, Richard C.; Broide, David H.; Aceves, Seema			Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LYMPHOID-CELLS		[Doherty, Taylor A.; Baum, Rachel; Doshi, Ashmi; Walford, Hannah H.; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Newbury, Robert O.; Yang, Tom; Dohil, Ranjan; Aquino, Melissa; Aceves, Seema] Rady Childrens Hosp, San Diego, CA USA; [Yang, Tom; Aquino, Melissa; Aceves, Seema] Univ Calif San Diego, Ctr Infect Immun & Inflammat, Dept Pediat, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Dept Pediat, Div Gastroenterol & Nutr, La Jolla, CA 92093 USA; [Doshi, Ashmi; Walford, Hannah H.] Radys Childrens Hosp San Diego, Div Rheumatol Allergy & Immunol, San Diego, CA USA; [Kurten, Richard C.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Kurten, Richard C.] Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Doherty, TA (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	tdoherty@ucsd.edu		Baum, Rachel/0000-0002-8227-7462; Broide, David/0000-0001-8405-9090; Doherty, Taylor/0000-0003-3256-0398	NCATS NIH HHS [UL1TR000039] Funding Source: Medline; NIAID NIH HHS [R01 AI114585, K08 AI080938, R01 AI092135, AI 107779, AI 092135, T32 AI 007469, AI 70535, AI 72115] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI107779, T32AI007469, R01AI114585, R01AI092135, R01AI072115, K08AI080938] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceves SS, 2015, IMMUNOL ALLERGY CLIN, V35, P145, DOI 10.1016/j.iac.2014.09.007; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Doherty TA, 2015, J LEUKOCYTE BIOL, V97, P455, DOI 10.1189/jlb.5BT0814-374R; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133	10	71	71	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					792	794		10.1016/j.jaci.2015.05.048	http://dx.doi.org/10.1016/j.jaci.2015.05.048			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26233928	Green Accepted			2022-12-18	WOS:000360913300031
J	Mika, M; Mack, I; Korten, I; Qi, WH; Aebi, S; Frey, U; Latzin, P; Hilty, M				Mika, Moana; Mack, Ines; Korten, Insa; Qi, Weihong; Aebi, Suzanne; Frey, Urs; Latzin, Philipp; Hilty, Markus			Dynamics of the nasal microbiota in infancy: A prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal microbiota; bacterial families; toddlers; cohort study; season; age	STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL MICROBIOTA; MORAXELLA-CATARRHALIS; HEALTHY-CHILDREN; COLONIZATION; IMPACT; AIRWAY; LIFE; EPIDEMIOLOGY; COMMUNITIES	Background: Understanding the composition and dynamics of the upper respiratory tract microbiota in healthy infants is a prerequisite to investigate the role of the microbiota in patients with respiratory diseases. This is especially true in early life, when the immune system is in development. Objective: We sought to describe the dynamics of the upper respiratory tract microbiota in healthy infants within the first year of life. Methods: After exclusion of low-quality samples, microbiota characterization was performed by using 16S rDNA pyrosequencing of 872 nasal swabs collected biweekly from 47 unselected infants. Results: Bacterial density increased and diversity decreased within the first year of life (R-2 = 0.95 and 0.73, respectively). A distinct profile for the first 3 months of life was found with increased relative abundances of Staphlyococcaceae and Corynebacteriaceae (exponential decay: R-2 = 0.94 and 0.96, respectively). In addition, relative bacterial abundance and composition differed significantly from summer to winter months. The individual composition of the microbiota changed with increasing time intervals between samples and was best modeled by an exponential function (R-2 = 0.97). Within-subject dissimilarity in a 2-week time interval was consistently lower than that between subjects, indicating a personalized microbiota. Conclusion: This study reveals age and seasonality as major factors driving the composition of the nasal microbiota within the first year of life. A subject's microbiota is personalized but dynamic throughout the first year. These data are indispensable to interpretation of cross-sectional studies and investigation of the role of the microbiota in both healthy subjects and patients with respiratory diseases. They might also serve as a baseline for future intervention studies.	[Mika, Moana; Aebi, Suzanne; Hilty, Markus] Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland; [Mika, Moana; Korten, Insa] Univ Bern, Grad Sch Cellular & Biomed Sci, CH-3010 Bern, Switzerland; [Mack, Ines; Korten, Insa; Latzin, Philipp] Inselspital Bern, Dept Pediat, Div Resp Med, Bern, Switzerland; [Mack, Ines; Korten, Insa; Latzin, Philipp] Univ Bern, CH-3010 Bern, Switzerland; [Mack, Ines; Frey, Urs; Latzin, Philipp] Univ Childrens Hosp UKBB, Basel, Switzerland; [Qi, Weihong] Univ Zurich, Swiss Fed Inst Technol Zurich, Funct Genom Ctr, CH-8006 Zurich, Switzerland; [Hilty, Markus] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Bern; University Hospital of Bern	Hilty, M (corresponding author), Univ Bern, Inst Infect Dis, Friedbuhlstr 51, CH-3010 Bern, Switzerland.	markus.hilty@ifik.unibe.ch	Korten, Insa/AAA-2967-2022; Hilty, Markus/H-9560-2019; Qi, Weihong/ABC-7380-2021; Latzin, Philipp/F-2206-2017	Hilty, Markus/0000-0002-2418-6474; Frey, Urs/0000-0003-3773-2822; Qi, Weihong/0000-0001-8581-908X; Latzin, Philipp/0000-0002-5239-1571	Swiss National Science Foundation [1209932473B_124654, 324730_144280, CRSII3-141875]; Research fund of the Swiss Lung Association Berne; European Society of Clinical Microbiology and Infectious Diseases (ESCMID); European Society of Clinical Microbiology and Infectious Diseases; Swiss Lung Association; CFCH (Swiss Cystic Fibrosis Society) [WS2077670]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Research fund of the Swiss Lung Association Berne; European Society of Clinical Microbiology and Infectious Diseases (ESCMID); European Society of Clinical Microbiology and Infectious Diseases; Swiss Lung Association; CFCH (Swiss Cystic Fibrosis Society)	which is funded by the Swiss National Science Foundation (grants 1209932473B_124654 and 324730_144280). The research leading to these results is funded by the Research fund of the Swiss Lung Association Berne and by a Research Grant (2013) from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). M. M. is funded by a grant from the Swiss National Science Foundation (Sinergia CRSII3-141875).; U. Frey has received research support form the Swiss National Science Foundation (grants 1209932473B_124654 and 324730_144280) as has M. Hilty (Sinergia CRSII3-141875). M. Hilty's institution has also received funding from the European Society of Clinical Microbiology and Infectious Diseases and the Swiss Lung Association; he has received consultancy fees and compensation for travel and other meeting-related expenses from Pfizer and has received or has grants (WS2077670) pending from Pfizer. P. Latzin has received research support from the CFCH (Swiss Cystic Fibrosis Society). The rest of the authors declare that they have no other relevant conflicts of interest.	Bergstrom A, 2014, APPL ENVIRON MICROB, V80, P2889, DOI 10.1128/AEM.00342-14; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P298, DOI 10.1164/rccm.201401-0073OC; Biesbroek G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032942; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5; Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035; Capone KA, 2011, J INVEST DERMATOL, V131, P2026, DOI 10.1038/jid.2011.168; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwards CA, 2002, BRIT J NUTR, V88, pS11, DOI [10.1079/BJN2002625, 10.1079/BJNBJN2002580]; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Faden H, 1997, J INFECT DIS, V175, P1440, DOI 10.1086/516477; FADEN H, 1994, J INFECT DIS, V169, P1312, DOI 10.1093/infdis/169.6.1312; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Fuchs O, 2012, INT J EPIDEMIOL, V41, P366, DOI 10.1093/ije/dyq239; Garzoni C, 2013, THORAX, V68, P1150, DOI 10.1136/thoraxjnl-2012-202917; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2012, J INFECT DIS, V205, P1048, DOI 10.1093/infdis/jis024; Hugenholtz P, 2010, OPEN J, V1, P1; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Krone CL, 2014, INFECT IMMUN, V82, P1725, DOI 10.1128/IAI.01290-13; Laufer AS, 2011, MBIO, V2, DOI 10.1128/mBio.00245-10; Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183; Meichtry J, 2014, VACCINE, V32, P5185, DOI 10.1016/j.vaccine.2014.07.060; Oksanen J., 2013, VEGAN INTRO ORDINATI; Rapola S, 1997, J CLIN MICROBIOL, V35, P1077, DOI 10.1128/JCM.35.5.1077-1079.1997; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Sakwinska O, 2014, J CLIN MICROBIOL, V52, P1590, DOI 10.1128/JCM.03280-13; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Stern G, 2013, AM J RESP CRIT CARE, V187, P1341, DOI 10.1164/rccm.201211-2008OC; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711; Verhaegh SJC, 2011, MICROBIOL-SGM, V157, P169, DOI 10.1099/mic.0.042929-0; von Linstow ML, 2013, AM J RESP CRIT CARE, V188, P1041, DOI 10.1164/rccm.201302-0395LE; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	39	71	80	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					905	+		10.1016/j.jaci.2014.12.1909	http://dx.doi.org/10.1016/j.jaci.2014.12.1909			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25636948	Green Published, hybrid			2022-12-18	WOS:000352238600011
J	Abolhassani, H; Wang, N; Aghamohammadi, A; Rezaei, N; Lee, YN; Frugoni, F; Notarangelo, LD; Pan-Hammarstrom, Q; Hammarstrom, L				Abolhassani, Hassan; Wang, Ning; Aghamohammadi, Asghar; Rezaei, Nima; Lee, Yu Nee; Frugoni, Francesco; Notarangelo, Luigi D.; Pan-Hammarstrom, Qiang; Hammarstrom, Lennart			A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; granulomatous lesion; recombination activation genes; differential diagnosis; mismanagement	V(D)J RECOMBINATION; OMENN-SYNDROME; GENETIC-HETEROGENEITY; DISEASE; AUTOIMMUNITY; DEFICIENCY; TOLERANCE; DEFECTS; CELLS	Background: Recombination-activating gene 1 (RAG1) deficiency presents with a varied spectrum of combined immunodeficiency, ranging from a T-B-NK+ type of disease to a T+B+NK+ phenotype. Objective: We sought to assess the genetic background of patients with common variable immunodeficiency (CVID). Methods: A patient given a diagnosis of CVID, who was born to a consanguineous family and thus would be expected to show an autosomal recessive inheritance, was subjected to clinical evaluation, immunologic assays, homozygosity gene mapping, exome sequencing, Sanger sequencing, and functional analysis. Results: The 14-year-old patient, who had liver granuloma, extranodal marginal zone B-cell lymphoma, and autoimmune neutropenia, presented with a clinical picture resembling CVID. Genetic analysis of this patient showed a homozygous hypomorphic RAG1 mutation (c.1073 G>A, p.C358Y) with a residual functional capacity of 48% of wild-type protein. Conclusion: Our finding broadens the range of disorders associated with RAG1 mutations and might have important therapeutic implications.	[Abolhassani, Hassan; Wang, Ning; Pan-Hammarstrom, Qiang; Hammarstrom, Lennart] Karolinska Univ Hosp Huddinge, Dept Lab Med, Karolinska Inst, Div Clin Immunol, SE-14186 Stockholm, Sweden; [Abolhassani, Hassan; Aghamohammadi, Asghar; Rezaei, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Pediat Ctr Excellence, Res Ctr Immunodeficiencies, Tehran, Iran; [Lee, Yu Nee; Frugoni, Francesco; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Lee, Yu Nee; Frugoni, Francesco; Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA; [Lee, Yu Nee; Frugoni, Francesco; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA	Karolinska Institutet; Karolinska University Hospital; Tehran University of Medical Sciences; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Hammarstrom, L (corresponding author), Karolinska Univ Hosp, Dept Lab Med, Karolinska Inst, Div Clin Immunol, SE-14186 Stockholm, Sweden.	lennart.hammarstrom@ki.se	Abolhassani, Hassan/B-3465-2014; Rezaei, Nima/B-4245-2008; hammarstrom, qiang pan/ABA-4589-2021; Notarangelo, Luigi D/F-9718-2016; Lee, Yu Nee/T-2360-2017	Abolhassani, Hassan/0000-0002-4838-0407; Rezaei, Nima/0000-0002-3836-1827; Notarangelo, Luigi D/0000-0002-8335-0262; Lee, Yu Nee/0000-0001-8648-5253; Frugoni, Francesco/0000-0002-1769-8121; Aghamohammadi, Asghar/0000-0002-9454-1603; pan-hammarstrom, qiang/0000-0003-1990-8804	Swedish Research Council and the European Research Council; National Institutes of Health [U54AI082973, P01AI076210]; Manton Foundation [1-FY-13-500]; Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, U54AI082973] Funding Source: NIH RePORTER	Swedish Research Council and the European Research Council; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Manton Foundation; Jeffrey Modell Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants from the Swedish Research Council and the European Research Council. This work was also supported by National Institutes of Health grant U54AI082973 and grant P01AI076210, the Manton Foundation (grant 1-FY-13-500), and a grant from the Jeffrey Modell Foundation (to L.D.N.).	Abdel-Naser M B, 2006, J Drugs Dermatol, V5, P370; Abolhassani H, 2012, J INVEST ALLERG CLIN, V22, P133; Aghamohammadi A, 2010, ACTA DERMATOVENER CR, V18, P107; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Ardeniz O, 2009, CLIN IMMUNOL, V133, P198, DOI 10.1016/j.clim.2009.05.001; Asai E, 2011, CLIN IMMUNOL, V138, P172, DOI 10.1016/j.clim.2010.11.005; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Cassani B, 2010, J ALLERGY CLIN IMMUN, V125, P209, DOI 10.1016/j.jaci.2009.10.023; Cossu F, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-76; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Gruber TA, 2009, PEDIATR TRANSPLANT, V13, P244, DOI 10.1111/j.1399-3046.2008.00970.x; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Honig M, 2006, CURR OPIN RHEUMATOL, V18, P383; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; IJspeert H, 2014, J ALLERGY CLIN IMMUN, V133, P1124, DOI 10.1016/j.jaci.2013.11.028; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; Karaca NE, 2009, CLIN EXP MED, V9, P339, DOI 10.1007/s10238-009-0053-1; Kutukculer N, 2012, ITAL J PEDIATR, V38, DOI 10.1186/1824-7288-38-8; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Lamperti C, 2012, MOL GENET METAB, V107, P403, DOI 10.1016/j.ymgme.2012.08.020; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Li RQ, 2009, GENOME RES, V19, P1124, DOI 10.1101/gr.088013.108; Liadaki K, 2013, CURR OPIN IMMUNOL, V25, P629, DOI 10.1016/j.coi.2013.06.003; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Reiff A, 2013, J CLIN IMMUNOL, V33, P1289, DOI 10.1007/s10875-013-9953-7; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schuetz C, 2010, AUTOIMMUN REV, V9, P477, DOI 10.1016/j.autrev.2010.02.005; Sharapova SO, 2013, HUM IMMUNOL, V74, P18, DOI 10.1016/j.humimm.2012.10.010; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; van Der Burg M, 2006, HAEMATOLOGICA, V91, P1705; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Xiao Z, 2009, EUR J HUM GENET, V17, P205, DOI 10.1038/ejhg.2008.150	43	71	71	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1375	1380		10.1016/j.jaci.2014.04.042	http://dx.doi.org/10.1016/j.jaci.2014.04.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	24996264	Green Accepted			2022-12-18	WOS:000346075400020
J	Silverberg, JI; Silverberg, NB				Silverberg, Jonathan I.; Silverberg, Nanette B.			Childhood atopic dermatitis and warts are associated with increased risk of infection: A US population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; asthma; allergic disease-rhinoconjunctivitis; hay fever; food allergies; respiratory allergies; warts; verruca vulgaris; age; race; ethnicity; Hispanic; infections; strep throat; influenza; head cold; pneumonia; sinusitis; ear infection; urinary tract infection	PREVALENCE; ECZEMA; FEATURES; CHILDREN; DISEASE	Background: Previous studies suggested that atopic dermatitis (AD) is associated with aberrant immune responses, which might predispose toward both cutaneous and extracutaneous infections. The goal of this study was to determine whether childhood AD is associated with increased risk of warts, extracutaneous infections, and other atopic diseases and how these disorders cosegregate. Methods: The 2007 National Health Interview Survey from a nationally representative sample of 9417 children age 0 to 17 years was used. Results: Children with AD and other atopic disease had higher odds of warts. In contrast, children with AD with or without other atopic disease had higher odds of extracutaneous infections, including strep throat, other sore throat, head or chest cold, influenza/pneumonia, sinus infections, recurrent ear infections, chickenpox, and urinary tract infections (P<.0001). Children with AD and other atopic disease had a higher number of infections than those with either disorder by itself (P<.0001). Warts were also associated with increased odds of all extracutaneous infections (P<.0001), except recurrent ear infections. Children with warts and AD had a higher number of infections than those with either disorder alone (P<.0001). Finally, children with AD and warts had higher odds of ever receiving a diagnosis of asthma, current asthma, asthma exacerbation in the past year, hay fever, and food allergy. Children with AD with warts had even higher odds of asthma, hay fever, and food allergies than those with AD and no warts. Conclusions: The associations between childhood AD, atopic disease, warts, and extracutaneous infections suggest that barrier disruption, immune disruption, or both contribute to susceptibility to warts and extracutaneous infections in children.	Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY USA	Northwestern University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Silverberg, JI (corresponding author), Dept Dermatol, Suite 1400,680 Lake Shore Dr, Chicago, IL 60611 USA.	JonathanISilverberg@gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805				Alotaibi L, 2006, J CLIN VIROL, V36, P133, DOI 10.1016/j.jcv.2006.02.007; Antonsson A, 2003, J GEN VIROL, V84, P1881, DOI 10.1099/vir.0.18836-0; Antonsson A, 2003, J CLIN MICROBIOL, V41, P2509, DOI 10.1128/JCM.41.6.2509-2514.2003; Block S H, 1972, Med J Aust, V2, P626; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; KEIPERT JA, 1971, MED J AUSTRALIA, V1, P267, DOI 10.5694/j.1326-5377.1971.tb87552.x; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LARSSON PA, 1980, ACTA DERM-VENEREOL, V60, P415; Sano Y, 2013, CLIN EXP IMMUNOL, V171, P330, DOI 10.1111/cei.12021; SCHMITT DA, 1990, J INVEST DERMATOL, V94, pS15, DOI 10.1111/1523-1747.ep12874984; Silverberg JI, 2013, J INVEST DERMATOL; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Silverberg JI, 2013, JAMA PEDIATR, V167, P554, DOI 10.1001/jamapediatrics.2013.1319; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stanley MA, 2009, INDIAN J MED RES, V130, P266; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; WILLIAMS H, 1993, ARCH DERMATOL, V129, P717, DOI 10.1001/archderm.129.6.717; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X	23	71	73	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1041	1047		10.1016/j.jaci.2013.08.012	http://dx.doi.org/10.1016/j.jaci.2013.08.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24094542	Bronze			2022-12-18	WOS:000333531700014
J	Witten, M; Malling, HJ; Blom, L; Poulsen, BC; Poulsen, LK				Witten, Marianne; Malling, Hans-Jorgen; Blom, Lars; Poulsen, Britta C.; Poulsen, Lars K.			Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRIALS		[Witten, Marianne; Malling, Hans-Jorgen; Blom, Lars; Poulsen, Britta C.; Poulsen, Lars K.] Copenhagen Univ Hosp, Allergy Clin, Gentofte, Denmark	University of Copenhagen	Witten, M (corresponding author), Copenhagen Univ Hosp, Allergy Clin, Gentofte, Denmark.	lkpallgy@mail.dk	Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X				Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Godicke V, 2010, ALLERGY, V65, P1499, DOI 10.1111/j.1398-9995.2010.02436.x; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Ivers NM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-120; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x	8	71	74	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1248	1252		10.1016/j.jaci.2013.07.033	http://dx.doi.org/10.1016/j.jaci.2013.07.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24035151				2022-12-18	WOS:000326235600039
J	Reber, LL; Marichal, T; Mukai, K; Kita, Y; Tokuoka, SM; Roers, A; Hartmann, K; Karasuyama, H; Nadeau, KC; Tsai, M; Galli, SJ				Reber, Laurent L.; Marichal, Thomas; Mukai, Kaori; Kita, Yoshihiro; Tokuoka, Suzumi M.; Roers, Axel; Hartmann, Karin; Karasuyama, Hajime; Nadeau, Kari C.; Tsai, Mindy; Galli, Stephen J.			Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; allergy; neutrophils; diphtheria toxin; Kit(W-sh/W-sh); mast cells; anaphylaxis; basophils; carboxypeptidase A3; mast cell protease 5	FC-GAMMA RIII; ALLERGIC INFLAMMATION; FOOD ALLERGY; IN-VIVO; MOUSE; NEUTROPHILS; ANTIBODY; DEGRANULATION; PATHOGENESIS; FATALITIES	Background: Studies with c-kit mutant mast cell (MC)-deficient mice and antibody-mediated depletion of basophils suggest that both MCs and basophils can contribute to peanut-induced anaphylaxis (PIA). However, interpretation of data obtained by using such approaches is complicated because c-kit mutant mice have several phenotypic abnormalities in addition to MC deficiency and because basophil-depleting antibodies can also react with MCs. \ Objective: We analyzed (1) the changes in the features of PIA in mice after the selective and inducible ablation of MCs or basophils and (2) the possible importance of effector cells other than MCs and basophils in the PIA response. Methods: Wild-type and various mutant mice were orally sensitized with peanut extract and cholera toxin weekly for 4 weeks and challenged intraperitoneally with peanut extract 2 weeks later. Results: Peanut-challenged, MC-deficient Kit W-sh/W-sh mice had reduced immediate hypothermia, as well as a late-phase decrease in body temperature that was abrogated by antibody-mediated depletion of neutrophils. Diphtheria toxin-mediated selective depletion of MCs or basophils in Mcpt5-Cre; iDTR and Mcpt8 DTR mice, respectively, and treatment of wild-type mice with the basophil-depleting antibody Ba103 significantly reduced peanut-induced hypothermia. Non-c-kit mutant MC-and basophil-deficient Cpa3-Cre; Mcl-1(fl/fl) mice had reduced but still significant responses to peanut. Conclusion: Inducible and selective ablation of MCs or basophils in non-c-kit mutant mice can significantly reduce PIA, but partial responses to peanut can still be observed in the virtual absence of both cell types. The neutrophilia in Kit(W-sh/W-sh) mice might influence the responses of these mice in this PIA model.	[Reber, Laurent L.; Marichal, Thomas; Mukai, Kaori; Tsai, Mindy; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Nadeau, Kari C.] Stanford Univ, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Kita, Yoshihiro; Tokuoka, Suzumi M.] Univ Tokyo, Fac Med, Dept Lipid, Tokyo 1138654, Japan; [Roers, Axel] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Dresden, Germany; [Hartmann, Karin] Univ Cologne, Dept Dermatol, Cologne, Germany; [Karasuyama, Hajime] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, CREST, Dept Immune Regulat,JST, Tokyo, Japan	Stanford University; Stanford University; Stanford University; University of Tokyo; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Cologne; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lane Bldg L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu	Karasuyama, Hajime/A-7966-2011; Reber, Laurent L/K-4148-2014; Hartmann, Karin/N-4865-2015	Karasuyama, Hajime/0000-0003-0689-0836; Reber, Laurent L/0000-0003-3384-6769; Hartmann, Karin/0000-0002-4595-8226; Tsai, Mindy/0000-0002-8421-4721	French "Fondation pour la Recherche Medicale FRM; Lucile Packard Foundation for Children's Health; Stanford CTSA; National Institutes of Health [UL1 RR025744, AI023990, CA072074, AI070813, AI072074]; Belgium American Educational Foundation; German Research Council (DFG) [CRC/SFB832]; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI070813, R37AI023990] Funding Source: NIH RePORTER	French "Fondation pour la Recherche Medicale FRM(Fondation pour la Recherche Medicale); Lucile Packard Foundation for Children's Health; Stanford CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Belgium American Educational Foundation; German Research Council (DFG)(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	L.L.R. is the recipient of fellowships from the French "Fondation pour la Recherche Medicale FRM'' and the Stanford Pediatric Research Fund of the Lucile Packard Foundation for Children's Health and the Stanford CTSA (National Institutes of Health grant UL1 RR025744). T. M. is supported by a fellowship from the Belgium American Educational Foundation and a Marie Curie International outgoing Fellowship for Career Development: 299954. K. H. acknowledges support from the German Research Council (DFG; CRC/SFB832, project A14). S.J.G. acknowledges support from National Institutes of Health grants AI023990, CA072074, and AI070813.; Disclosure of potential conflict of interest: L. L. Reber, T. Marichal, K. Mukai, M. Tsai, and S. J. Galli have been supported by grants from the National Institutes of Health (AI070813, AI023990, and AI072074). The rest of the authors declare that they have no relevant conflicts of interest.	Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Brown MA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00147; CHERVENI.PA, 1969, J CELL PHYSIOL, V73, P25, DOI 10.1002/jcp.1040730104; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Galli SJ, 2005, J ALLERGY CLIN IMMUN, V115, P571, DOI 10.1016/j.jaci.2004.12.1133; Galli SJ, 2005, WILLIAMS HEMATOLOGY, P879; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gernez Y, 2012, J CLIN IMMUNOL, V32, P565, DOI 10.1007/s10875-012-9651-x; Gernez Y, 2011, INT ARCH ALLERGY IMM, V154, P318, DOI 10.1159/000321824; Gibbs BF, 2005, CLIN EXP MED, V5, P43, DOI 10.1007/s10238-005-0064-5; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kalesnikoff J, 2011, METHODS MOL BIOL, V677, P207, DOI 10.1007/978-1-60761-869-0_15; Karasuyama H, 2009, NAT REV IMMUNOL, V9, P9, DOI 10.1038/nri2458; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; Kojima T, 2007, J IMMUNOL, V179, P7093, DOI 10.4049/jimmunol.179.10.7093; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Marone Gianni, 2002, Trends in Immunology, V23, P425, DOI 10.1016/S1471-4906(02)02274-3; MARTIN TR, 1993, J IMMUNOL, V151, P367; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Min B, 2008, NAT IMMUNOL, V9, P1333, DOI 10.1038/ni.f.217; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sullivan BM, 2009, IMMUNITY, V30, P12, DOI 10.1016/j.immuni.2008.12.006; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; Zhou JS, 2007, J EXP MED, V204, P2797, DOI 10.1084/jem.20071391	59	71	71	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					881	+		10.1016/j.jaci.2013.06.008	http://dx.doi.org/10.1016/j.jaci.2013.06.008			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23915716	Green Accepted			2022-12-18	WOS:000325096500015
J	Steinke, JW; Liu, LX; Huyett, P; Negri, J; Payne, SC; Borish, L				Steinke, John W.; Liu, Lixia; Huyett, Phillip; Negri, Julie; Payne, Spencer C.; Borish, Larry			Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; aspirin-tolerant asthma; chronic sinusitis; cytokines; eosinophils; IFN-gamma; nasal polyps	LEUKOTRIENE-RECEPTOR EXPRESSION; CHRONIC HYPERPLASTIC SINUSITIS; NASAL POLYPOSIS; CHRONIC RHINOSINUSITIS; CYTOKINE EXPRESSION; INTOLERANT ASTHMA; MESSENGER-RNA; C-4 SYNTHASE; IN-VITRO; EOSINOPHIL	Background: Aspirin-exacerbated respiratory disease (AERD) is distinguished from aspirin-tolerant asthma/chronic sinusitis in large part by an exuberant infiltration of eosinophils that are characterized by their overexpression of metabolic pathways that drive the constitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs). Objective: We defined the inflammatory milieu that in part drives CysLT overproduction and, in particular, the role of IFN-gamma in the differentiation of eosinophils. Methods: Quantitative real-time PCR was performed for T(H)1 and T(H)2 signature cytokines on tissue from control subjects, patients with chronic hyperplastic eosinophilic sinusitis, and patients with AERD, and their cellular source was determined. The influence of IFN-gamma on maturation, differentiation, and functionality of eosinophils derived from hematopoietic stem cells was determined. Results: Gene expression analysis revealed that tissue from both aspirin-tolerant subjects and patients with AERD display a TH2 cytokine signature; however, AERD was distinguished from chronic hyperplastic eosinophilic sinusitis by the prominent expression of IFN-gamma. Intracellular and immunohistochemical cytokine staining revealed that the major sources of these cytokines were the eosinophils themselves. IFN-gamma promoted the maturation of eosinophil progenitors, as measured by increased mRNA and surface expression of CCR3 and sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8). Additionally, IFN-gamma increased the expression of genes involved in leukotriene synthesis that led to increased secretion of CysLTs. IFN-gamma-matured eosinophil progenitors were also primed, as demonstrated by their enhanced degranulation. Conclusions: High IFN-gamma levels distinguish AERD from aspirin-tolerant asthma and underlie the robust constitutive and aspirin-induced secretion of CysLTs that characterize this disorder.	[Steinke, John W.; Liu, Lixia; Huyett, Phillip; Negri, Julie; Payne, Spencer C.; Borish, Larry] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22903 USA; [Steinke, John W.; Borish, Larry] Univ Virginia Hlth Syst, Carter Immunol Ctr, Charlottesville, VA USA; [Payne, Spencer C.] Univ Virginia Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia	Steinke, JW (corresponding author), Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22903 USA.	js3ch@virginia.edu		Payne, Spencer/0000-0001-9736-4561	National Institutes of Health [R01-AI47737, P01-AI50989]; UVA Patent Office for LUVA cells; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047737, P01AI050989, R01AI057438] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UVA Patent Office for LUVA cells; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R01-AI47737 and P01-AI50989.; Disclosure of potential conflict of interest: J. W. Steinke has received research support from the National Institutes of Health (NIH), has received payment for lectures from the American Academy of Allergy, Asthma & Immunology (AAAAI)/American College of Allergy, Asthma & Immunology (ACAAI) Certification/Recertification Course, and receives royalties for the LUVA human mast cell line. S. C. Payne has consultant arrangements with Medtronic, Acclarent, Cook Medical, and Stryker and has received payment for lectures from Medtronic and Acclarent. L. Borish has received grants from the NIH and DuPont, has consultant arrangements with Endo, has received payment for lectures from Merck, and receives royalties from the UVA Patent Office for LUVA cells. The rest of the authors declare that they have no relevant conflicts of interest..	Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Akuthota P, 2011, J INNATE IMMUN, V3, P113, DOI 10.1159/000323433; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Bachert C, 1999, ACI INT, V11, P130; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; BOYCE JA, 1995, J EXP MED, V182, P49, DOI 10.1084/jem.182.1.49; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; de Bruin AM, 2010, BLOOD, V116, P2559, DOI 10.1182/blood-2009-12-261339; Denburg JA, 2000, THORAX, V55, pS24, DOI 10.1136/thorax.55.suppl_2.S24; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Fujii M, 2005, CHEST, V128, P3148, DOI 10.1378/chest.128.5.3148; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Ikutani M, 2012, J IMMUNOL, V188, P703, DOI 10.4049/jimmunol.1101270; Kamil A, 1998, OTOLARYNG HEAD NECK, V118, P804, DOI 10.1016/S0194-5998(98)70273-6; Kanda A, 2009, J ALLERGY CLIN IMMUN, V124, P573, DOI 10.1016/j.jaci.2009.04.031; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Milanovic M, 2008, J IMMUNOL, V181, P5045, DOI 10.4049/jimmunol.181.7.5045; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Payne SC, 2011, LARYNGOSCOPE, V121, P2262, DOI 10.1002/lary.21969; Payne SC, 2008, AM J RHINOL, V22, P568, DOI 10.2500/ajr.2008.22.3233; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Riechelmann H, 2005, CLIN EXP ALLERGY, V35, P1186, DOI 10.1111/j.1365-2222.2005.02316.x; Shome GP, 2007, ALLERGY ASTHMA PROC, V28, P706, DOI 10.2500/aap.2007.28.3052; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Szczeklik A, 2000, ACI INT, V12, P171; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x	45	71	77	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					856	+		10.1016/j.jaci.2013.05.008	http://dx.doi.org/10.1016/j.jaci.2013.05.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23806637	Green Accepted			2022-12-18	WOS:000325096500012
J	Hiragun, T; Ishii, K; Hiragun, M; Suzuki, H; Kan, T; Mihara, S; Yanase, Y; Bartels, J; Schroder, JM; Hide, M				Hiragun, Takaaki; Ishii, Kaori; Hiragun, Makiko; Suzuki, Hidenori; Kan, Takanobu; Mihara, Shoji; Yanase, Yuhki; Bartels, Joachim; Schroeder, Jens-M.; Hide, Michihiro			Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sweat; atopic dermatitis; Malassezia globosa; histamine release; IgE	MANGANESE SUPEROXIDE-DISMUTASE; TOPICAL ANTIMYCOTIC TREATMENT; FC-EPSILON-RI; IGE-BINDING; MAST-CELLS; MALASSEZIA-SYMPODIALIS; CHOLINERGIC URTICARIA; SEQUENCE SIMILARITIES; JAPANESE GUIDELINE; HISTAMINE-RELEASE	Background: Sweat is a major aggravating factor of atopic dermatitis (AD) and approximately 80% of patients with AD show type I hypersensitivity against sweat. Objective: To identify and characterize an antigen in sweat that induces histamine release from basophils of patients with AD. Methods: Basophil histamine-releasing activity in sweat was purified by a combination of chromatographies, and proteins were analyzed with mass spectrometry. Recombinant proteins of the sweat antigen were generated, and their biological characteristics were studied by immunoblots, histamine release tests, and neutralization assays. Results: We identified a fungal protein, MGL_1304, derived from Malassezia globosa (M globosa) in the purified sweat antigen. Recombinant MGL_1304 induced histamine release from basophils of most of the patients with AD, in accordance with the semi-purified sweat antigen. Moreover, recombinant MGL_1304 abolished the binding of serum IgE of patients with AD to the semi-purified sweat antigen, or vice versa in immunoblot analysis, and attenuated the sensitization of RBL-48 mast cells expressing human Fc epsilon RI by serum IgE. Studies of truncated mutants of MGL_1304 indicated that IgE of patients with AD recognized the conformational structure of MGL_1304 rather than short peptide sequences. Western blot analysis of the whole lysate, the culture supernatant of M globosa, and the semi-purified sweat antigen showed that MGL_1304 was produced as a minor immunological antigen of M globosa with posttranslational modification, cleaved, and secreted as a 17-kDa major histamine-releasing sweat antigen. Conclusion: MGL_1304 is a major allergen in human sweat and could cause type I allergy in patients with AD.	[Hiragun, Takaaki; Ishii, Kaori; Hiragun, Makiko; Suzuki, Hidenori; Kan, Takanobu; Mihara, Shoji; Yanase, Yuhki; Hide, Michihiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Minami Ku, Hiroshima 7348551, Japan; [Hiragun, Takaaki] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima 7348551, Japan; [Suzuki, Hidenori] Hiroshima Bunkyo Womens Univ, Fac Human Sci, Hiroshima, Japan; [Bartels, Joachim; Schroeder, Jens-M.] Univ Hosp Schleswig Holstein, Clin Res Unit Cutaneous Inflammat, Dept Dermatol, Kiel, Germany	Hiroshima University; Hiroshima University; University of Kiel; Schleswig Holstein University Hospital	Hide, M (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ed1h-w1de-road@hiroshima-u.ac.jp	Yanase, Yuhki/U-6082-2017; Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034; Ishii, Kaori/0000-0001-6254-1580	Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology, Japan; Innovation Plaza Hiroshima of JST (Japan Science and Technology Corporation); Ministry of Education, Science, Sports and Culture; Health and Labour Sciences Research Grant; Shimense Healthcare; Novartis Pharma; Ministry of Education, Science, Sports, and Culture; Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology; GlaxoSmithKline; Japan Boehringer Ingelheim; Tanabe-Mitsubishi E; Shionogi; Sanofi-Aventis; Kyouwahakkou-Kirin; Torii; Maruho; MSD; Tanabe-Mitsubishi; Eisai	Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology, Japan; Innovation Plaza Hiroshima of JST (Japan Science and Technology Corporation)(Japan Science & Technology Agency (JST)); Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Health and Labour Sciences Research Grant(Ministry of Health, Labour and Welfare, Japan); Shimense Healthcare; Novartis Pharma; Ministry of Education, Science, Sports, and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology; GlaxoSmithKline(GlaxoSmithKline); Japan Boehringer Ingelheim; Tanabe-Mitsubishi E; Shionogi; Sanofi-Aventis(Sanofi-Aventis); Kyouwahakkou-Kirin; Torii; Maruho; MSD; Tanabe-Mitsubishi; Eisai(Eisai Co Ltd)	This work was supported in part by Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology, Japan; Innovation Plaza Hiroshima of JST (Japan Science and Technology Corporation); the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Young Scientists (B), and Scientific Research (C); and Health and Labour Sciences Research Grant.; M. Hiragun has received lecture fees from Shimense Healthcare and Novartis Pharma. S. Mihara and T. Hiragun have received research support from the Ministry of Education, Science, Sports, and Culture. M. Hide has received research support from the Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER) from Hiroshima Prefectural Institute of Industrial Science and Technology, Innovation Plaza Hiroshima of JST (Japan Science and Technology Corporation), Health and Labour Sciences Research, GlaxoSmithKline, Japan Boehringer Ingelheim, Tanabe-Mitsubishi E, Shionogi, Sanofi-Aventis, Kyouwahakkou-Kirin, Torii, Maruho, Novartis Pharma, and Shimense Healthcare; has received consultancy fees from GlaxoSmithKline, Sanofi-Aventis, and MSD; has received lecture fees from GlaxoSmithKline, Japan Boehringer Ingelheim, Tanabe-Mitsubishi, Shionogi, Kyouwahakkou-Kirin, Maruho, Eisai, and Torii; and receives royalties from Shionogi. The rest of the authors declare that they have no relevant conflicts of interest.	ADACHI K, 1989, ACTA DERM-VENEREOL, P83; Akaza N, 2012, J DERMATOL, V39, P613, DOI 10.1111/j.1346-8138.2011.01477.x; Andersson A, 2004, EUR J BIOCHEM, V271, P1885, DOI 10.1111/j.1432-1033.2004.04098.x; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; BROBERG A, 1995, ACTA DERM-VENEREOL, V75, P46; Darabi K, 2009, J AM ACAD DERMATOL, V60, P125, DOI 10.1016/j.jaad.2008.07.058; Gaitanis G, 2012, CLIN MICROBIOL REV, V25, P106, DOI 10.1128/CMR.00021-11; GILFILLAN AM, 1992, J IMMUNOL, V149, P2445; Gupta AK, 2004, J AM ACAD DERMATOL, V51, P785, DOI 10.1016/j.jaad.2003.12.034; Hide M, 2002, ACTA DERM-VENEREOL, V82, P335, DOI 10.1080/000155502320624050; Hiragun T, 2006, J IMMUNOL, V177, P2047, DOI 10.4049/jimmunol.177.4.2047; Ishibashi Y, 2009, J DERMATOL SCI, V55, P185, DOI 10.1016/j.jdermsci.2009.05.005; Kameyoshi Yoshikazu, 2008, Arerugi, V57, P130; Katayama Ichiro, 2011, Allergology International, V60, P205, DOI [10.2332/allergolint. 11-RAI-0333, 10.2332/allergolint.11-RAI-0333]; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417; Meyer-Hoffert U, 2010, J BIOL CHEM, V285, P32174, DOI 10.1074/jbc.M109.091850; Mochizuki H, 2009, PEDIATR DERMATOL, V26, P223, DOI 10.1111/j.1525-1470.2009.00887.x; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; Murota H, 2010, EUR J DERMATOL, V20, P410, DOI 10.1684/ejd.2010.0928; Okubo Kimihiro, 2011, Allergology International, V60, P171, DOI [10.2332/allergolint.11-RAI-0334, 10.2332/allergolint. 11-RAI-0334]; Rasool O, 2000, EUR J BIOCHEM, V267, P4355, DOI 10.1046/j.1432-1327.2000.01475.x; Saeki H, 2009, J DERMATOL, V36, P563, DOI 10.1111/j.1346-8138.2009.00706.x; Sarri E, 2003, BIOCHEM J, V369, P319, DOI 10.1042/BJ20021347; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmidt M, 1997, EUR J BIOCHEM, V246, P181, DOI 10.1111/j.1432-1033.1997.00181.x; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Shindo H, 2012, ARCH DERMATOL RES, V304, P647, DOI 10.1007/s00403-012-1236-2; Sugita T, 2005, J CLIN MICROBIOL, V43, P2824, DOI 10.1128/JCM.43.6.2824-2829.2005; Sugita T, 2001, J CLIN MICROBIOL, V39, P3486, DOI [10.1128/JCM.39.10.3486-3490.2001, 10.3314/jjmm.42.217]; Svejgaard EI, 2004, J EUR ACAD DERMATOL, V18, P445, DOI 10.1111/j.1468-3083.2004.00963.x; Takahagi S, 2009, BRIT J DERMATOL, V160, P426, DOI 10.1111/j.1365-2133.2008.08862.x; Tanaka A, 2006, EXP DERMATOL, V15, P283, DOI 10.1111/j.0906-6705.2006.00404.x; Vilhelmsson M, 2008, MOL IMMUNOL, V46, P294, DOI 10.1016/j.molimm.2008.07.036; Wong AWK, 2008, INT J DERMATOL, V47, P187, DOI 10.1111/j.1365-4632.2008.03414.x; Xu J, 2007, P NATL ACAD SCI USA, V104, P18730, DOI 10.1073/pnas.0706756104; Zargari A, 2007, ALLERGY, V62, P695, DOI 10.1111/j.1398-9995.2006.01291.x	37	71	78	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					608	+		10.1016/j.jaci.2013.03.047	http://dx.doi.org/10.1016/j.jaci.2013.03.047			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23726042				2022-12-18	WOS:000323612000012
J	Kano, G; Almanan, M; Bochner, BS; Zimmermann, N				Kano, Gen; Almanan, Maha; Bochner, Bruce S.; Zimmermann, Nives			Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: Role for reactive oxygen species-enhanced MEK/ERK activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; cell death; signaling	MAP KINASE PHOSPHATASES; SIGLEC-F; PROTEIN PHOSPHATASES; MOUSE EOSINOPHILS; MAST-CELLS; APOPTOSIS; NECROSIS; ERK; IDENTIFICATION; INFLAMMATION	Background: Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is expressed on human eosinophils, where its ligation induces cell death. Paradoxically, Siglec-8-mediated cell death is markedly enhanced by the presence of the activation and survival factor IL-5 and becomes independent of caspase activity. Objective: In this report we investigate the mechanism of Siglec8- mediated cell death in activated eosinophils. Methods: Human peripheral blood eosinophils were treated with agonistic anti-Siglec-8 antibody and IL-5, and cell death was determined by using flow cytometry and morphology. Phosphorylation of mitogen-activated protein kinase (MAPK) was determined by using phosphoLuminex, flow cytometry, and Western blotting. Reactive oxygen species (ROS) accumulation was determined by using dihydrorhodamine fluorescence. Results: Costimulation with anti-Siglec-8 and IL-5 significantly increased the rate and proportion of cell death by means of necrosis accompanied by granule release compared with that seen after stimulation with anti-Siglec-8 alone, in which apoptosis predominated. Together with the caspase-independent mode of cell death in costimulated cells, these findings suggest the activation of a specific and distinct biochemical pathway of cell death during anti-Siglec-8/IL-5 costimulation. Phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and MAPK-ERK kinase (MEK) 1 was significantly enhanced and sustained in costimulated cells compared with that seen in cells stimulated with IL-5 alone; anti-Siglec-8 alone did not cause ERK1/2 phosphorylation. MEK1 inhibitors blocked anti-Siglec-8/IL-5-induced cell death. ROS accumulation was induced by Siglec-8 ligation in a MEK-independent manner. In contrast, an ROS inhibitor prevented the anti-Siglec-8/IL-5-induced enhancement of ERK phosphorylation and cell death. Exogenous ROS mimicked stimulation by anti-Siglec-8 and was sufficient to induce enhanced cell death in IL-5-treated cells. Collectively, these data suggest that the enhancement of ERK phosphorylation is downstream of ROS generation. Conclusions: In activated eosinophils ligation of Siglec-8 leads to ROS-dependent enhancement of IL-5-induced ERK phosphorylation, which results in a novel mode of biochemically regulated eosinophil cell death.	[Kano, Gen; Almanan, Maha; Zimmermann, Nives] Cincinnati Childrens Hosp, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Kano, Gen; Almanan, Maha; Zimmermann, Nives] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Dept Med, Baltimore, MD USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Johns Hopkins University	Zimmermann, N (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	nives.zimmermann@cchmc.org			National Institutes of Health; Dana foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI079251, R01AI072265, R56AI072265, R21AI088559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, P30DK090971] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	B. S. Bochner has consultancy arrangements with and owns stock in Allakos, Inc and has one or more patents (planned, pending, or issued) related to Siglec-8 and its ligand with and has received royalties from Johns Hopkins University. N. Zimmermann has been supported by one or more grants from the National Institutes of Health and the Dana foundation and is employed by Cincinnati Children's Hospital. The rest of the authors declare that they have no relevant conflicts of interest.	Adamko DJ, 2004, J IMMUNOL METHODS, V291, P101, DOI 10.1016/j.jim.2004.05.003; Aizawa H, 2003, GENOMICS, V82, P521, DOI 10.1016/S0888-7543(03)00171-X; Andina N, 2009, J ALLERGY CLIN IMMUN, V123, P603, DOI 10.1016/j.jaci.2008.12.004; Armengot M, 2009, AMJ RHINOL ALLERGY, V23, P466, DOI 10.2500/ajra.2009.23.3357; Bochner BS, 2009, CLIN EXP ALLERGY, V39, P317, DOI 10.1111/j.1365-2222.2008.03173.x; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Chow JYS, 2010, CELL MOL IMMUNOL, V7, P26, DOI 10.1038/cmi.2009.106; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Duprez L, 2011, IMMUNITY, V35, P908, DOI 10.1016/j.immuni.2011.09.020; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Garcia NV, 2011, J IMMUNOL, V187, P2268, DOI 10.4049/jimmunol.1101008; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kottyan LC, 2009, BLOOD, V114, P2774, DOI 10.1182/blood-2009-05-220681; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Lundqvist-Gustafsson H, 1999, J LEUKOCYTE BIOL, V65, P196, DOI 10.1002/jlb.65.2.196; Matsunaga Yoshiko, 2005, Journal of Toxicological Sciences, V30, P135, DOI 10.2131/jts.30.135; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; O'Reilly MK, 2009, TRENDS PHARMACOL SCI, V30, P240, DOI 10.1016/j.tips.2009.02.005; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Song DJ, 2009, CLIN IMMUNOL, V131, P157, DOI 10.1016/j.clim.2008.11.009; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; Uller L, 2004, AM J RESP CRIT CARE, V170, P742, DOI 10.1164/rccm.200402-240OC; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; von Gunten S, 2008, ANN NY ACAD SCI, V1143, P61, DOI 10.1196/annals.1443.011; Wen T, 2012, J IMMUNOL, V188, P1075, DOI 10.4049/jimmunol.1102222; Willetts L, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-116; Wright BL, 2011, NEW ENGL J MED, V365, P187, DOI 10.1056/NEJMc1103005; Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zhuang SG, 2008, J PHARMACOL EXP THER, V325, P732, DOI 10.1124/jpet.108.136358; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	56	71	71	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					437	445		10.1016/j.jaci.2013.03.024	http://dx.doi.org/10.1016/j.jaci.2013.03.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23684072	Bronze, Green Accepted			2022-12-18	WOS:000322631700022
J	Pinkerton, M; Chinchilli, V; Banta, E; Craig, T; August, A; Bascom, R; Cantorna, M; Harvill, E; Ishmael, FT				Pinkerton, Mark; Chinchilli, Vernon; Banta, Erin; Craig, Timothy; August, Avery; Bascom, Rebecca; Cantorna, Margherita; Harvill, Eric; Ishmael, Faoud T.			Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Pinkerton, Mark; Banta, Erin; Craig, Timothy; Bascom, Rebecca; Ishmael, Faoud T.] Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Hershey, PA 17033 USA; [Chinchilli, Vernon] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [August, Avery] Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY USA; [Cantorna, Margherita; Harvill, Eric] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Ishmael, Faoud T.] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pinkerton, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Hershey, PA 17033 USA.	fishmael@hmc.psu.edu		Harvill, Eric/0000-0001-8893-2133; Pinkerton, Mark/0000-0003-0978-5468	National Center for Complementary & Integrative Health [R01AT005378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS067563] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT005378] Funding Source: Medline; NIAID NIH HHS [R56 AI065507] Funding Source: Medline; NINDS NIH HHS [R01 NS067563] Funding Source: Medline	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen RF, 2010, CLIN EXP ALLERGY, V40, P1482, DOI 10.1111/j.1365-2222.2010.03592.x; Chiba Y, 2010, J PHARMACOL SCI, V114, P264, DOI 10.1254/jphs.10R10FM; Collison A, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-29; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Popov TA, 2011, ANN ALLERG ASTHMA IM, V106, P451, DOI 10.1016/j.anai.2011.02.016; Tomasiak-Lozowska MM, 2012, INT ARCH ALLERGY IMM, V159, P121, DOI 10.1159/000335674; Zhang J, 2012, BBA-REV CANCER, V1826, P32, DOI 10.1016/j.bbcan.2012.03.001	8	71	72	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					217	219		10.1016/j.jaci.2013.03.006	http://dx.doi.org/10.1016/j.jaci.2013.03.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23628339	Bronze			2022-12-18	WOS:000321052300028
J	Lloyd, CM; Saglani, S				Lloyd, Clare M.; Saglani, Sejal			T cells in asthma: Influences of genetics, environment, and T-cell plasticity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; asthma; plasticity; environment; genetics; epigenetics	EOSINOPHILIC AIRWAY INFLAMMATION; ALLERGIC-ASTHMA; TISSUE INFLAMMATION; IMMUNE-RESPONSES; CLUSTER-ANALYSIS; ATOPIC ASTHMA; TH17 CELLS; TGF-BETA; PHENOTYPES; INTERLEUKIN-17	Asthma is classically considered the archetypal T(H)2 disease, with increased circulating IgE levels and eosinophilic inflammation being caused by increased levels of T(H)2-type cytokines. However, this paradigm has been challenged because of the realization that strategies designed to suppress T(H)2 function are not effective for all patients. The clinical phenotype of asthma is notoriously heterogeneous and is affected by genetic and environmental exposures in addition to interactions between airway structural cells, including epithelial cells, and the immune system, as well as contributions from cells other than T(H)2 cells. A combination of genetic and environmental factors is thought to influence whether inflammation resolves or progresses, and the pulmonary epithelium is increasingly recognized to play a key role in this process. This complex interplay has made it increasingly apparent that immune responses are tailored to the individual patient and determined by the weight of each influence, and thus the label of asthma as a T(H)2 disease is too conservative. Indeed, an important concept that needs to be addressed, both in animal models and clinically, is that of T-cell plasticity and how lymphocytic responses are determined by environmental influences.	[Lloyd, Clare M.; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England	Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk	Saglani, Sejal/AAE-5072-2019	Lloyd, Clare/0000-0001-8977-6726; Saglani, Sejal/0000-0001-5192-6418	Medical Research Council [MR/J010529/1] Funding Source: Medline; Wellcome Trust [087618] Funding Source: Medline; MRC [MR/J010529/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Al-Samri MT, 2010, J ALLERGY CLIN IMMUN, V125, P1161, DOI 10.1016/j.jaci.2010.02.005; Bajoriuniene I, 2012, LUNG, V190, P487, DOI 10.1007/s00408-012-9411-y; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Fleming L, 2012, THORAX, V67, P675, DOI 10.1136/thoraxjnl-2011-201064; Fleming L, 2012, THORAX, V67, P193, DOI 10.1136/thx.2010.156836; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hinks TSC, 2012, THORAX, V67, pA55, DOI 10.1136/thoraxjnl-2012-202678.119; Hirahara K, 2011, IMMUNOLOGY, V134, P235, DOI 10.1111/j.1365-2567.2011.03483.x; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Jones CP, 2012, J ALLERGY CLIN IMMUN, V129, P1000, DOI 10.1016/j.jaci.2011.12.965; Kanno Y, 2012, ANNU REV IMMUNOL, V30, P707, DOI 10.1146/annurev-immunol-020711-075058; Karmaus W, 2013, CURR OPIN ALLERGY CL, V13, P63, DOI 10.1097/ACI.0b013e32835ad0e7; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kim BS, 2010, P NATL ACAD SCI USA, V107, P8742, DOI 10.1073/pnas.0911756107; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Malmhall C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040012; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moriwaki A, 2011, BIOCHEM BIOPH RES CO, V404, P922, DOI 10.1016/j.bbrc.2010.12.082; Murdoch JR, 2010, AM J RESP CRIT CARE, V182, P464, DOI 10.1164/rccm.200911-1775OC; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; Nakayamada S, 2012, CURR OPIN IMMUNOL, V24, P297, DOI 10.1016/j.coi.2012.01.014; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Oliphant CJ, 2011, IMMUNOLOGY, V134, P378, DOI 10.1111/j.1365-2567.2011.03499.x; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Suzukawa M, 2012, J IMMUNOL, V189, P3641, DOI 10.4049/jimmunol.1200461; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018; Thunberg S, 2010, ALLERGY, V65, P311, DOI 10.1111/j.1398-9995.2009.02218.x; Trifari S, 2010, EUR J IMMUNOL, V40, P2369, DOI 10.1002/eji.201040848; Tsicopoulos A, 2004, J ALLERGY CLIN IMMUN, V113, P462, DOI 10.1016/j.jaci.2003.12.009; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wei L, 2010, IMMUNITY, V32, P840, DOI 10.1016/j.immuni.2010.06.003; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707	74	71	74	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1267	1275		10.1016/j.jaci.2013.02.016	http://dx.doi.org/10.1016/j.jaci.2013.02.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23541326				2022-12-18	WOS:000318912200001
J	Schafer, B; Piliponsky, AM; Oka, T; Song, CH; Gerard, NP; Gerard, C; Tsai, M; Kalesnikoff, J; Galli, SJ				Schaefer, Beatrix; Piliponsky, Adrian M.; Oka, Tatsuya; Song, Chang Ho; Gerard, Norma P.; Gerard, Craig; Tsai, Mindy; Kalesnikoff, Janet; Galli, Stephen J.			Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylatoxin; anaphylaxis; C3a; C5a; complement; IgE; inflammation; mast cells	HYPERSENSITIVITY REACTIONS; C3A ANAPHYLATOXIN; IN-VIVO; COMPLEMENT ACTIVATION; HUMAN BASOPHILS; EFFECTOR PHASE; C5A; MOUSE; ASTHMA; HMC-1	Background: Mast cells express receptors for complement anaphylatoxins C3a and C5a (ie, C3a receptor [C3aR] and C5a receptor [C5aR]), and C3a and C5a are generated during various IgE-dependent immediate hypersensitivity reactions in vivo. However, it is not clear to what extent mast cell expression of C3aR or C5aR influences C3a- or C5a-induced cutaneous responses or IgE-dependent mast cell activation and passive cutaneous anaphylaxis (PCA) in vivo. Objective: We sought to assess whether mouse skin mast cell expression of C3aR or C5aR influences (1) the cells' responsiveness to intradermal injections of C3a or C5a or (2) the extent of IgE-dependent mast cell degranulation and PCA in vivo. Methods: We measured the magnitude of cutaneous responses to intradermal injections of C3a or C5a and the extent of IgE-dependent mast cell degranulation and PCA responses in mice containing mast cells that did or did not express C3aR or C5aR. Results: The majority of the skin swelling induced by means of intradermal injection of C3a or C5a required that mast cells at the site expressed C3aR or C5aR, respectively, and the extent of IgE-dependent degranulation of skin mast cells and IgE-dependent PCA was significantly reduced when mast cells lacked either C3aR or C5aR. IgE-dependent PCA responses associated with local increases in C3a levels occurred in antibody-deficient mice but not in mice deficient in Fc epsilon RI gamma. Conclusion: Expression of C3aR and C5aR by skin mast cells contributes importantly to the ability of C3a and C5a to induce skin swelling and can enhance mast cell degranulation and inflammation during IgE-dependent PCA in vivo. (J Allergy Clin Immunol 2013;131:541-8.)	[Schaefer, Beatrix; Piliponsky, Adrian M.; Oka, Tatsuya; Song, Chang Ho; Tsai, Mindy; Kalesnikoff, Janet; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Piliponsky, Adrian M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA; [Song, Chang Ho] Chonbuk Natl Univ, Sch Med, Dept Anat, Jeonju, South Korea; [Gerard, Norma P.; Gerard, Craig] Childrens Hosp Boston, Dept Pulm Med, Boston, MA USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Seattle Children's Hospital; Jeonbuk National University; Harvard University; Boston Children's Hospital; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lane Bldg,L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu		Tsai, Mindy/0000-0002-8421-4721	National Institutes of Health [AI023990, CA072074, AI070813]; Deutsche Forschungsgemeinschaft [Scha1464/1 1]; National Institutes of Health; Stanford University Department of Pathology; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI070813, R01AI023990] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford University Department of Pathology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI023990, CA072074, and AI070813 (to S.J.G.) and a grant of the Deutsche Forschungsgemeinschaft (Scha1464/1 1 to B.S.).; S. J. Galli has received research support from the National Institutes of Health and the Stanford University Department of Pathology. The rest of the authors declare that they have no relevant conflicts of interest.	Ali H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-19; Ali H, 2010, IMMUNOL LETT, V128, P36, DOI 10.1016/j.imlet.2009.10.007; Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6; Andrasfalvy M, 2005, J IMMUNOL, V175, P2801, DOI 10.4049/jimmunol.175.5.2801; Atkinson JP, 2006, J CLIN INVEST, V116, P304, DOI 10.1172/JCI27759; Baelder R, 2005, J IMMUNOL, V174, P783, DOI 10.4049/jimmunol.174.2.783; BALLOW M, 1985, J ALLERGY CLIN IMMUN, V76, P473, DOI 10.1016/0091-6749(85)90729-8; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; Chen NJ, 2007, NATURE, V446, P203, DOI 10.1038/nature05559; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Friedberger E, 1909, Z IMMUN EXP THER 2, P208; FRIEDL HP, 1989, AM J PATHOL, V135, P203; Fukuoka Y, 2008, J IMMUNOL, V180, P6307, DOI 10.4049/jimmunol.180.9.6307; FUREDER W, 1995, J IMMUNOL, V155, P3152; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Genovese A, 2010, CHEM IMMUNOL ALLERGY, V95, P98, DOI 10.1159/000315945; GERVASONI JE, 1986, J IMMUNOL, V136, P285; GREISMAN SE, 1958, J IMMUNOL, V81, P214; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huey R, 1986, Biochem Soc Symp, V51, P69; HUGLI TE, 1981, INT ARCH ALLER A IMM, V66, P113, DOI 10.1159/000232882; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; KAJITA T, 1991, AM J PATHOL, V138, P1359; Kalesnikoff J, 2010, CHEM IMMUNOL ALLERGY, V95, P45, DOI 10.1159/000315937; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kimura T, 1998, CLIN EXP IMMUNOL, V111, P484; KUBOTA Y, 1992, Journal of Dermatology (Tokyo), V19, P19; Legler DF, 1996, EUR J IMMUNOL, V26, P753, DOI 10.1002/eji.1830260405; LEPOW IH, 1970, AM J PATHOL, V61, P13; LIM HW, 1991, J INVEST DERMATOL, V97, P305, DOI 10.1111/1523-1747.ep12480568; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465; MARONE G, 2004, NOVART FDN SYMP, V257, P276; Marone Gianni, 2004, Novartis Found Symp, V257, P133; MOUSLI M, 1994, IMMUNOPHARMACOLOGY, V27, P1, DOI 10.1016/0162-3109(94)90002-7; MOUSLI M, 1992, J IMMUNOL, V148, P2456; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Nigrovic PA, 2010, ARTHRITIS RHEUM-US, V62, P3322, DOI 10.1002/art.27659; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; Nilsson G, 1996, J IMMUNOL, V157, P1693; Oschatz C, 2011, IMMUNITY, V34, P258, DOI 10.1016/j.immuni.2011.02.008; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; REGAL JF, 1993, J PHARMACOL EXP THER, V267, P979; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; Settmacher B, 1999, J IMMUNOL, V162, P7409; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; STIMLERGERARD NP, 1985, SURV SYN PATHOL RES, V4, P423; SWERLICK RA, 1989, J INVEST DERMATOL, V93, P417, DOI 10.1111/1523-1747.ep12280306; TOM BH, 1975, INFECT IMMUN, V11, P1284, DOI 10.1128/IAI.11.6.1284-1290.1975; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; Werfel T, 1996, SCAND J IMMUNOL, V44, P30, DOI 10.1046/j.1365-3083.1996.d01-272.x; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YANCEY KB, 1985, J CLIN INVEST, V75, P486, DOI 10.1172/JCI111724; Zhou JS, 2007, J EXP MED, V204, P2797, DOI 10.1084/jem.20071391; Zwirner J, 1998, SCAND J IMMUNOL, V47, P19	65	71	74	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					541	+		10.1016/j.jaci.2012.05.009	http://dx.doi.org/10.1016/j.jaci.2012.05.009			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22728083	Green Accepted			2022-12-18	WOS:000314661500034
J	Choy, DF; Hsu, DK; Seshasayee, D; Fung, MA; Modrusan, Z; Martin, F; Liu, FT; Arron, JR				Choy, David F.; Hsu, Daniel K.; Seshasayee, Dhaya; Fung, Maxwell A.; Modrusan, Zora; Martin, Flavius; Liu, Fu-Tong; Arron, Joseph R.			Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; T(H)2; T(H)17; gene expression microarray; neutrophil; eosinophil	THYMIC STROMAL LYMPHOPOIETIN; MONOCLONAL-ANTIBODY; EXPRESSION; INSIGHTS; ASTHMA; BLOOD; EOSINOPHILS; MECHANISMS; BIOMARKERS; EOTAXIN-3	Background: Atopic dermatitis (AD) and psoriasis are common inflammatory diseases canonically described as involving distinct T-H polarization and granulocytic infiltration. Acute AD lesions are associated with T(H)2 and eosinophilic inflammation, whereas psoriatic lesions are associated with T(H)1/T(H)17 and neutrophilic inflammation. Despite intensive investigation, these pathways remain incompletely understood in vivo in human subjects. Objective: Using AD and psoriatic lesional skin as exemplar T(H)2 and T(H)1/T(H)17 diseased tissue, we sought to clarify common and unique molecular and pathophysiologic features in inflamed skin with different types of inflammatory polarization. Methods: We conducted gene expression microarray analyses to identify distinct and commonly dysregulated expression in AD (based on Hanifin and Rajka criteria) and psoriatic lesions. We defined gene sets (GSs) as comprising genes encoding cytokines, chemokines, and growth factors that were uniquely or jointly dysregulated in patients with AD and those with psoriasis and calculated aggregate GS expression scores for lesional skin of patients with these dermatoses and healthy control skin. Results: The atopic dermatitis gene set (AD-GS) score correlated with systemic and local measures of allergic inflammation, including serum IgE levels, blood eosinophil counts, and tissue eosinophil counts. Unexpectedly, genes encoding neutrophil chemoattractants among the common GS were highly expressed in AD lesional skin. Hematoxylin and eosin and immunohistochemical analyses showed the numbers of neutrophils in AD lesional skin were comparable with those in psoriatic lesional skin, and both were correlated with the extent of expression of neutrophil chemoattractant genes. Conclusion: These data are evidence that neutrophilic inflammation is a feature of lesional AD pathology comorbid with allergic inflammation. (J Allergy Clin Immunol 2012;130:1335-43.)	[Hsu, Daniel K.; Fung, Maxwell A.; Liu, Fu-Tong] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95816 USA; [Choy, David F.; Arron, Joseph R.] Genentech Inc, Dept Immunol Tissue Growth & Repair Biomarker Dis, San Francisco, CA 94080 USA; [Seshasayee, Dhaya; Martin, Flavius] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; [Modrusan, Zora] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Hsu, Daniel K.; Liu, Fu-Tong] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	University of California System; University of California Davis; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Academia Sinica - Taiwan	Liu, FT (corresponding author), Univ Calif Davis, Sch Med, Dept Dermatol, 3301 C St,Suite 1400, Sacramento, CA 95816 USA.	fliu@ucdavis.edu; arron.joseph@gene.com	Liu, FU-TONG/A-5749-2019; Fung, Maxwell/AEM-2111-2022	Liu, FU-TONG/0000-0002-3354-1001; Arron, Joseph/0000-0001-7677-9979; Fung, Maxwell/0000-0003-1771-8257; Choy, David/0000-0003-1351-6113	National Institutes of Health/National Institute of Allergy and Infectious Diseases [RO1 AI20958]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR056343]; National Institutes of Health (NIH); Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR053116, R01AR056343] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grant RO1 AI20958 and National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01AR056343 (to F.-T.L.).; D. F. Choy is employed by and owns stock/stock options in Genentech. D. K. Hsu has received one or more grants from the National Institutes of Health (NIH) and Genentech. M. A. Fung has received one or more grants from the NIH and Genentech. Z. Modrusan has received one or more grants from the NIH and Genentech. F. Martin is employed by and owns stock/stock options in Genentech and Roche. F.-T. Liu has received one or more grants from the NIH and Genentech. J. R. Arron is employed by Genentech and owns stock/stock options in Roche Holdings. D. Seshasaye declares no relevant conflicts of interest.	Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034; Antoniu SA, 2010, CURR OPIN INVEST DR, V11, P1286; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Baum CL, 2005, DERMATOL SURG, V31, P674; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107; Chien YH, 2007, CLIN REV ALLERG IMMU, V33, P178, DOI 10.1007/s12016-007-0041-8; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Colobran R, 2007, CLIN EXP IMMUNOL, V148, P208, DOI 10.1111/j.1365-2249.2007.03344.x; Commins SP, 2010, J ALLERGY CLIN IMMUN, V125, pS53, DOI 10.1016/j.jaci.2009.07.008; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; Elder JT, 2009, GENES IMMUN, V10, P201, DOI 10.1038/gene.2009.11; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Gillitzer R, 1996, J INVEST DERMATOL, V107, P778, DOI 10.1111/1523-1747.ep12371803; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Kopf M, 2010, NAT REV DRUG DISCOV, V9, P703, DOI 10.1038/nrd2805; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Liu FT, 2011, CLIN REV ALLERG IMMU, V41, P298, DOI 10.1007/s12016-011-8252-4; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Mardia KV, 1979, MULTIVARIATE ANAL; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Nakayama T, 2004, J IMMUNOL, V173, P2078, DOI 10.4049/jimmunol.173.3.2078; NICHOLS BA, 1973, LAB INVEST, V29, P27; Noble WS, 2009, NAT BIOTECHNOL, V27, P1135, DOI 10.1038/nbt1209-1135; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pietrzak AT, 2008, CLIN CHIM ACTA, V394, P7, DOI 10.1016/j.cca.2008.04.005; PULFORD KAF, 1988, J CLIN PATHOL, V41, P853, DOI 10.1136/jcp.41.8.853; ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/jem.167.3.1186; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Saegusa J, 2009, AM J PATHOL, V174, P922, DOI 10.2353/ajpath.2009.080500; Scheerens H, 2011, J ALLERGY CLIN IMMUN, V127, pAB164, DOI 10.1016/j.jaci.2010.12.651; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Seveus L, 1997, HISTOCHEM CELL BIOL, V107, P423, DOI 10.1007/s004180050129; Simpson EL, 2005, J AM ACAD DERMATOL, V53, P115, DOI 10.1016/j.jaad.2005.01.130; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Syed F, 2007, BIOMARKERS, V12, P414, DOI 10.1080/13547500701192652; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803	56	71	74	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1335	+		10.1016/j.jaci.2012.06.044	http://dx.doi.org/10.1016/j.jaci.2012.06.044			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22920495	Green Accepted			2022-12-18	WOS:000311641100014
J	Loss, G; Bitter, S; Wohlgensinger, J; Frei, R; Roduit, C; Genuneit, J; Pekkanen, J; Roponen, M; Hirvonen, MR; Dalphin, JC; Dalphin, ML; Riedler, J; von Mutius, E; Weber, J; Kabesch, M; Michel, S; Braun-Fahrlander, C; Lauener, R				Loss, Georg; Bitter, Sondhja; Wohlgensinger, Johanna; Frei, Remo; Roduit, Caroline; Genuneit, Jon; Pekkanen, Juha; Roponen, Marjut; Hirvonen, Maija-Riitta; Dalphin, Jean-Charles; Dalphin, Marie-Laure; Riedler, Josef; von Mutius, Erika; Weber, Juliane; Kabesch, Michael; Michel, Sven; Braun-Fahrlaender, Charlotte; Lauener, Roger		PASTURE Study Grp	Prenatal and early-life exposures alter expression of innate immunity genes: The PASTURE cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; Toll-like receptors; CD14; prenatal; childhood; farming; farm milk; nutrition	TOLL-LIKE RECEPTOR-2; TIME QUANTITATIVE PCR; FARM MILK CONSUMPTION; CHILDHOOD ASTHMA; ATOPIC SENSITIZATION; ALLERGIC DISEASES; POLYMORPHISM; CHILDREN; PROTECT; HEALTH	Background: There is evidence that gene expression of innate immunity receptors is upregulated by farming-related exposures. Objective: We sought to determine environmental and nutritional exposures associated with the gene expression of innate immunity receptors during pregnancy and the first year of a child's life. Methods: For the Protection Against Allergy: Study in Rural Environments (PASTURE) birth cohort study, 1133 pregnant women were recruited in rural areas of Austria, Finland, France, Germany, and Switzerland. mRNA expression of the Toll-like receptor (TLR) 1 through TLR9 and CD14 was assessed in blood samples at birth (n = 938) and year 1 (n = 752). Environmental exposures, as assessed by using questionnaires and a diary kept during year 1, and polymorphisms in innate receptor genes were related to gene expression of innate immunity receptors by using ANOVA and multivariate regression analysis. Results: Gene expression of innate immunity receptors in cord blood was overall higher in neonates of farmers (P for multifactorial multivariate ANOVA = .041), significantly so for TLR7 (adjusted geometric means ratio [aGMR], 1.15; 95% CI, 1.02-1.30) and TLR8 (aGMR, 1.15; 95% CI, 1.04-1.26). Unboiled farm milk consumption during the first year of life showed the strongest association with mRNA expression at year 1, taking the diversity of other foods introduced during that period into account: TLR4 (aGMR, 1.22; 95% CI, 1.03-1.45), TLR5 (aGMR, 1.19; 95% CI, 1.01-1.41), and TLR6 (aGMR, 1.20; 95% CI, 1.04-1.38). A previously described modification of the association between farm milk consumption and CD14 gene expression by the single nucleotide polymorphism CD14/C-1721T was not found. Conclusion: Farming-related exposures, such as raw farm milk consumption, that were previously reported to decrease the risk for allergic outcomes were associated with a change in gene expression of innate immunity receptors in early life. (J Allergy Clin Immunol 2012; 130:523-30.)	[Loss, Georg; Bitter, Sondhja; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Loss, Georg; Bitter, Sondhja; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Wohlgensinger, Johanna; Frei, Remo; Roduit, Caroline; Lauener, Roger] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Wohlgensinger, Johanna; Frei, Remo; Roduit, Caroline; Lauener, Roger] Univ Zurich, Christine Kuhne Ctr Allergy Res & Educ, CH-8006 Zurich, Switzerland; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Pekkanen, Juha; Roponen, Marjut] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Hirvonen, Maija-Riitta] Univ Eastern Finland, Dept Environm Sci, Inhalat Toxicol Lab, Kuopio, Finland; [Dalphin, Jean-Charles; Dalphin, Marie-Laure] Univ Franche Comte, Dept Resp Dis, Univ Hosp, F-25030 Besancon, France; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Germany; [von Mutius, Erika; Weber, Juliane] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, Munich, Germany; [Kabesch, Michael; Michel, Sven] Hannover Med Sch, Clin Paediat Pneumol & Neonatol, Hannover, Germany; [Lauener, Roger] Hochgebirgsklin Davos, Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University Children's Hospital Zurich; University of Zurich; University of Zurich; Ulm University; Finland National Institute for Health & Welfare; University of Eastern Finland; Universite de Franche-Comte; CHU Besancon; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Hannover Medical School	Loss, G (corresponding author), Swiss Trop & Publ Hlth Inst, Socinstr 57,POB 4002, CH-4002 Basel, Switzerland.	georg.loss@unibas.ch	Kabesch, Michael/AAB-5701-2020; Frei, Remo/AAI-9180-2020; Roduit, Caroline/S-4928-2017; Ege, Markus/C-1962-2012; Kabesch, Michael/GZM-1583-2022; Loss, Georg/AAE-7296-2019; Lauener, Roger P/O-8612-2016; Loss, Georg/F-1557-2013; Roponen, Marjut/C-2086-2017; riedler, josef/AAQ-4666-2020; Genuneit, Jon/I-9323-2012	Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Lauener, Roger P/0000-0002-8412-606X; Roponen, Marjut/0000-0002-4442-9090; Genuneit, Jon/0000-0001-5764-1528; Michel, Sven/0000-0003-3604-3187; von Mutius, Erika/0000-0002-8893-4515; Roduit, Caroline/0000-0002-5988-0570	European Union research [QRLT4-CT 2001-00250, KBBE-2-2-06]; Kuhne Foundation; European Union (EU); Academy of Finland; EVO; Farmers' Social Insurance Institution (Mela); European Union; GlaxoSmithKline; ProtectImmun; Novartis; InfectoPharm; Nestle; European Commission; European Research Council (ERC); Roxall; Sanofi Aventis; Allergo-pharma; AstraZeneca; German Research Foundation (DFG); BMBF; Kuthe Foundation; EU; ERC; DFG; European Research Council; European Commission Framework VII program	European Union research; Kuhne Foundation; European Union (EU)(CGIAREuropean Commission); Academy of Finland(Academy of Finland); EVO; Farmers' Social Insurance Institution (Mela); European Union(European Commission); GlaxoSmithKline(GlaxoSmithKline); ProtectImmun; Novartis(Novartis); InfectoPharm; Nestle(Nestle SA); European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); Roxall; Sanofi Aventis(Sanofi-Aventis); Allergo-pharma; AstraZeneca(AstraZeneca); German Research Foundation (DFG)(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); Kuthe Foundation; EU(European Commission); ERC(European Research Council (ERC)European Commission); DFG(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); European Commission Framework VII program	Supported by European Union research grants PASTURE/EFRAIM (QRLT4-CT 2001-00250, KBBE-2-2-06) and the Kuhne Foundation.; J. Pekkanen has received research support from the European Union (EU) FP 7, the Academy of Finland and EVO funding, and the Farmers' Social Insurance Institution (Mela). M. Roponen has received research support from the European Union (FP7). E. von Mutius has received consulting fees from GlaxoSmithKline, ProtectImmun, and Novartis; has received lecture fees from InfectoPharm and Nestle; has received research support from the European Commission and European Research Council (ERC); and has provided legal consultation/expert witness testimony for the UK Research Excellence Framework. J. Weber has received research support from the European Commission. M. Kabesch has received research support from Roxall, GlaxoSmithKline, Novartis, Sanofi Aventis, Allergo-pharma, AstraZeneca, the German Research Foundation (DFG), BMBF, and the EU. R. Lauener has received research support from the Kuthe Foundation and the EU. M. Ege has received research support from the ERC and the DFG. B. Schaub has received research support from the DFG and the EU. M. Depner has received research support from the European Research Council. G. Doekes has received research support from the European Commission Framework VII program. The rest of the authors declare that they have no relevant conflicts of interest.	Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Arocho A, 2006, DIAGN MOL PATHOL, V15, P56, DOI 10.1097/00019606-200603000-00009; Basagana X, 2002, PEDIAT ALLERG IMM-UK, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; Belderbos ME, 2012, PEDIAT ALLERG IMM-UK, V23, P65, DOI 10.1111/j.1399-3038.2011.01230.x; Belderbos M, 2009, CURR OPIN PEDIATR, V21, P762, DOI 10.1097/MOP.0b013e3283325e3a; Bieli C, 2008, ALLERGY, V63, P1633, DOI 10.1111/j.1398-9995.2008.01744.x; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Conroy ME, 2009, CURR OPIN ALLERGY CL, V9, P197, DOI 10.1097/ACI.0b013e32832b3f1d; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Novak N, 2007, ALLERGY, V62, P766, DOI 10.1111/j.1398-9995.2007.01358.x; Perkin MR, 2007, CLIN EXP ALLERGY, V37, P627, DOI 10.1111/j.1365-2222.2007.02715.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Prescott SL, 2008, PAEDIATR RESPIR REV, V9, P3, DOI 10.1016/j.prrv.2007.11.004; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roduit C, 2012, J ALLERGY CLIN IMMUN; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Tesse R, 2011, ALLERGY, V66, P307, DOI 10.1111/j.1398-9995.2010.02489.x; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	34	71	71	0	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					523	+		10.1016/j.jaci.2012.05.049	http://dx.doi.org/10.1016/j.jaci.2012.05.049			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846753	Bronze			2022-12-18	WOS:000307002200037
J	Lau, S; Gerhold, K; Zimmermann, K; Ockeloen, CW; Rossberg, S; Wagner, P; Sulser, C; Bunikowski, R; Witt, I; Wauer, J; Beschorner, J; Menke, G; Hamelmann, E; Wahn, U				Lau, Susanne; Gerhold, Kerstin; Zimmermann, Kurt; Ockeloen, Charlotte W.; Rossberg, Siri; Wagner, Petra; Sulser, Claudia; Bunikowski, Rita; Witt, Imke; Wauer, Juliane; Beschorner, John; Menke, Georg; Hamelmann, Eckard; Wahn, Ulrich			Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; infancy; bacterial lysate; primary prevention	IMMUNE-RESPONSES; EARLY-LIFE; SENSITIZATION; RECEPTOR; ALLERGY; BIRTH; EXPOSURE; ASTHMA; INFLAMMATION; PREVENTION	Background: Lower prevalence of atopy was found in children with continuous exposure to livestock and thus to microbial compounds. In animal models exposure to endotoxin (LPS) decreases allergic sensitization and airway inflammation. Objective: We sought to evaluate the effect of orally applied bacterial lysate in infancy on the prevalence of atopic dermatitis (AD) after the treatment phase at 7 months of age. Methods: This randomized, placebo-controlled trial included 606 newborns with at least single heredity for atopy. From week 5 until the end of month 7, infants were treated orally with bacterial lysate containing heat-killed gram-negative Escherichia coli Symbio and gram-positive Enterococcus faecalis Symbio or its placebo. Children were followed until 3 years of age. Results: There was no difference in the primary outcome between the active and placebo groups in the total study group. AD prevalence was significantly reduced at the end of the intervention phase (31 weeks of age) in the subgroup of infants with single heredity for atopy (relative risk, 0.52; 95% CI, 0.3-0.9). Ten percent (15/154) of infants in the active group had AD compared with 19% (27/145, P = .030) in the placebo group. This was more pronounced in the group of infants with paternal heredity for atopy (11% vs 32%, P = .004; relative risk, 0.34; 95% CI, 0.2-0.7). Conclusion: Feeding of bacterial lysate might have prevented the development of AD, especially in children with paternal atopy, possibly indicating a preventive property only in subjects with a limited risk for atopy. (J Allergy Clin Immunol 2012;129:1040-7.)	[Lau, Susanne; Gerhold, Kerstin; Ockeloen, Charlotte W.; Rossberg, Siri; Wagner, Petra; Sulser, Claudia; Bunikowski, Rita; Witt, Imke; Wauer, Juliane; Beschorner, John; Wahn, Ulrich] Charite Med Univ Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Gerhold, Kerstin] Charite Med Univ Berlin, Berlin Sch Publ Hlth, Berlin, Germany; [Menke, Georg] PAZ Frankfurt AM, Frankfurt, Germany; [Hamelmann, Eckard] Ruhr Univ Bochum, Univ Childrens Hosp St Josef Bochum, Bochum, Germany; [Ockeloen, Charlotte W.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruhr University Bochum; Radboud University Nijmegen	Lau, S (corresponding author), Charite Campus Virchow, Klin Padiatrie Schwerpunkt Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	susanne.lau@charite.de	Hamelmann, Eckard/AAJ-9124-2021; Ockeloen, Charlotte/P-5732-2015	Ockeloen, Charlotte/0000-0003-0329-1520	SymbioPharm Herborn; German Research Foundation DFG [Ha 2162/4-1]; SymbioPharm, Herborn, Germany	SymbioPharm Herborn; German Research Foundation DFG(German Research Foundation (DFG)); SymbioPharm, Herborn, Germany	Supported by SymbioPharm Herborn from 2002 until 2007. The follow-up phase was supported by a grant from the German Research Foundation DFG (Ha 2162/4-1 to Hamelmann and Gerhold/Lau).; U. Wahn has received research support from SymbioPharm, Herborn, Germany. The rest of the authors declare that they have no relevant conflicts of interest.	Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Ahrens B, 2011, INT ARCH ALLERGY IMM, V156, P196, DOI 10.1159/000322352; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V107, P129; Braun-Fahrlander C, 2011, CLIN EXP ALLERGY, V41, P29, DOI 10.1111/j.1365-2222.2010.03665.x; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P390, DOI 10.1016/j.jaci.2010.10.050; Debarry J, 2010, ALLERGY, V65, P690, DOI 10.1111/j.1398-9995.2009.02253.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; Giwercman C, 2010, J ALLERGY CLIN IMMUN, V125, P866, DOI 10.1016/j.jaci.2010.01.026; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johannsen H, 2009, CLIN EXP ALLERGY, V39, P1801, DOI 10.1111/j.1365-2222.2009.03368.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keil T, 2009, ALLERGY, V64, P445, DOI 10.1111/j.1398-9995.2008.01867.x; Martino DJ, 2012, ALLERGY, V67, P191, DOI 10.1111/j.1398-9995.2011.02737.x; Matricardi PM, 2010, CLIN EXP IMMUNOL, V160, P98, DOI 10.1111/j.1365-2249.2010.04130.x; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Peters M, 2010, J ALLERGY CLIN IMMUN, V126, P648, DOI 10.1016/j.jaci.2010.05.011; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Sordillo JE, 2010, CLIN EXP ALLERGY, V40, P902, DOI 10.1111/j.1365-2222.2010.03509.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	37	71	74	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1040	1047		10.1016/j.jaci.2012.02.005	http://dx.doi.org/10.1016/j.jaci.2012.02.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22464674				2022-12-18	WOS:000302144600020
J	Liang, JR; Jiang, DH; Jung, YS; Xie, T; Ingram, J; Church, T; Degan, S; Leonard, M; Kraft, M; Noble, PW				Liang, Jiurong; Jiang, Dianhua; Jung, Yoosun; Xie, Ting; Ingram, Jennifer; Church, Tony; Degan, Simone; Leonard, Maura; Kraft, Monica; Noble, Paul W.			Role of hyaluronan and hyaluronan-binding proteins in human asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; hyaluronan; cytokines; fibroblasts; macrophages	CHEMOKINE GENE-EXPRESSION; HUMAN LUNG; TGF-BETA; OXIDATIVE FRAGMENTATION; AIRWAY INFLAMMATION; INNATE IMMUNITY; TISSUE-INJURY; FIBROBLASTS; ACTIVATION; REGULATOR	Background: The characteristics of human asthma are chronic inflammation and airway remodeling. Hyaluronan, a major extracellular matrix component, accumulates during inflammatory lung diseases, including asthma. Hyaluronan fragments stimulate macrophages to produce inflammatory cytokines. We hypothesized that hyaluronan and its receptors would play a role in human asthma. Objective: To investigate the role of hyaluronan and hyaluronan-binding proteins in human asthma. Methods: Twenty-one subjects with asthma and 25 healthy control subjects underwent bronchoscopy with endobronchial biopsy and bronchoalveolar lavage. Fibroblasts were cultured, and hyaluronan and hyaluronan synthase expression was determined at baseline and after exposure to several mediators relevant to asthma pathobiology. The expression of hyaluronan-binding proteins CD44, TLR (Toll-like receptor)-2, and TLR4 on bronchoalveolar lavage macrophages was determined by flow cytometry. IL-8 production by macrophages in response to hyaluronan fragment stimulation was compared. Results: Airway fibroblasts from patients with asthma produced significantly increased concentrations of lower-molecular-weight hyaluronan compared with those of normal fibroblasts. Hyaluronan synthase 2 mRNA was markedly increased in asthmatic fibroblasts. Asthmatic macrophages showed a decrease in cell surface CD44 expression and an increase in TLR2 and TLR4 expression. Macrophages from subjects with asthma showed an increase in responsiveness to low-molecular-weight hyaluronan stimulation, as demonstrated by increased IL-8 production. Conclusion: Hyaluronan homeostasis is deranged in asthma, with increased production by fibroblasts and decreased CD44 expression on alveolar macrophages. Upregulation of TLR2 and TLR4 on macrophages with increased sensitivity to hyaluronan fragments suggests a novel proinflammatory mechanism by which persistence of hyaluronan fragments could contribute to chronic inflammation and airway remodeling in asthma. (J Allergy Clin Immunol 2011;128:403-11.)	[Liang, Jiurong; Jiang, Dianhua; Jung, Yoosun; Xie, Ting; Ingram, Jennifer; Church, Tony; Leonard, Maura; Kraft, Monica; Noble, Paul W.] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; [Degan, Simone] Duke Univ, Sch Med, Ctr Mol & Biomol Imaging, Durham, NC 27710 USA; [Xie, Ting] Beijing Univ Chinese Med, Beijing, Peoples R China	Duke University; Duke University; Beijing University of Chinese Medicine	Noble, PW (corresponding author), Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, DUMC Box 103000, Durham, NC 27710 USA.	paul.noble@duke.edu	Xie, Ting/B-8531-2013; Liang, Carol Jiurong/AAI-4963-2021; Xie, Ting/I-9538-2019; Xie, Ting/AAA-6050-2022; Jiang, Dianhua/B-1421-2009	Jiang, Dianhua/0000-0002-4508-3829; Xie, Ting/0000-0002-9958-3888; Liang, Jiurong/0000-0001-5179-5016; Degan, Simone/0000-0001-5417-1196	NIH [AI052201, HL06539, P50-HL084917, HL77291]; NIH-NHLBI; Parker B. Francis Family Foundation; GlaxoSmithKline; Merck; Genentech; Novartis; GE Healthcare; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060539, R01HL077291, P50HL084917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052201] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Parker B. Francis Family Foundation; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Genentech(Roche HoldingGenentech); Novartis(Novartis); GE Healthcare(General ElectricGE Healthcare); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIH grants AI052201, HL06539, P50-HL084917, HL77291 (P.W.N.), and P50-HL084917 (M.K.).; J. Ingram receives research support from the NIH-NHLBI and the Parker B. Francis Family Foundation. M. Kraft receives research support from GlaxoSmithKline, Merck, Genentech, Novartis, and GE Healthcare and is vice president of the American Thoracic Society. P. W. Noble receives research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Amara N, 2010, THORAX, V65, P733, DOI 10.1136/thx.2009.113456; Aytekin M, 2008, AM J PHYSIOL-LUNG C, V295, pL789, DOI 10.1152/ajplung.90306.2008; Beckett PA, 2003, THORAX, V58, P163, DOI 10.1136/thorax.58.2.163; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005; Hocking DC, 2002, CHEST, V122, p275S, DOI 10.1378/chest.122.6_suppl.275S; Horton MR, 1998, J IMMUNOL, V160, P3023; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; Jiang DH, 2011, PHYSIOL REV, V91, P221, DOI 10.1152/physrev.00052.2009; Johnsson H, 1997, UPSALA J MED SCI, V102, P199, DOI 10.3109/03009739709178941; Kennedy CI, 2000, J PEDIATR SURG, V35, P874, DOI 10.1053/jpsu.2000.6869; Klagas I, 2009, EUR RESPIR J, V34, P616, DOI 10.1183/09031936.00070808; Kraft M, 2008, EUR RESPIR J, V31, P43, DOI 10.1183/09031936.00103307; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Li M, 1997, ARCH BIOCHEM BIOPHYS, V341, P245, DOI 10.1006/abbi.1997.9970; Liang JR, 2007, J IMMUNOL, V178, P2469, DOI 10.4049/jimmunol.178.4.2469; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MCNEIL JD, 1985, ANN RHEUM DIS, V44, P780, DOI 10.1136/ard.44.11.780; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nigo YI, 2006, P NATL ACAD SCI USA, V103, P2286, DOI 10.1073/pnas.0510685103; Noble Paul W, 2006, Proc Am Thorac Soc, V3, P401, DOI 10.1513/pats.200604-097AW; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Oguchi T, 2004, CONNECT TISSUE RES, V45, P197, DOI 10.1080/03008200490523031; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Que LG, 2009, AM J RESP CRIT CARE, V180, P226, DOI 10.1164/rccm.200901-0158OC; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Schroder NWJ, 2007, ALLERGY, V62, P579, DOI 10.1111/j.1398-9995.2007.01386.x; SODERBERG M, 1989, INT ARCH ALLER A IMM, V88, P373, DOI 10.1159/000234719; Soltes L, 2005, CHEM BIODIVERS, V2, P1242, DOI 10.1002/cbdv.200590094; Spicer Andrew P, 2004, Birth Defects Res C Embryo Today, V72, P89, DOI 10.1002/bdrc.20006; Stern R, 2006, CHEM REV, V106, P818, DOI 10.1021/cr050247k; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tufvesson E, 2000, J CELL BIOCHEM, V77, P298, DOI 10.1002/(SICI)1097-4644(20000501)77:2<298::AID-JCB12>3.0.CO;2-D; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Westergren-Thorsson G, 2002, INT J BIOCHEM CELL B, V34, P1256, DOI 10.1016/S1357-2725(02)00058-4; WESTERGRENTHORSSON G, 1990, EXP CELL RES, V186, P192, DOI 10.1016/0014-4827(90)90227-2; Wilkinson TS, 2004, AM J RESP CELL MOL, V31, P92, DOI 10.1165/rcmb.2003-0380OC; Yao HW, 2010, P NATL ACAD SCI USA, V107, P15571, DOI 10.1073/pnas.1007625107	56	71	75	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					403	U220		10.1016/j.jaci.2011.04.006	http://dx.doi.org/10.1016/j.jaci.2011.04.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21570715	Green Accepted			2022-12-18	WOS:000293280800023
J	Kotz, D; Simpson, CR; Sheikh, A				Kotz, Daniel; Simpson, Colin R.; Sheikh, Aziz			Incidence, prevalence, and trends of general practitioner-recorded diagnosis of peanut allergy in England, 2001 to 2005	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; incidence; prevalence; time trend; primary care; demographic associations; consultation rate	UNITED-STATES; CHILDREN; EPIDEMIOLOGY; ANAPHYLAXIS; MEDICATION; DISORDERS; AVOIDANCE; MONTREAL; DISEASE; COHORTS	Background: Previous descriptions of the epidemiology of peanut allergy have mainly been derived from small cross-sectional studies. Objective: To interrogate a large national research database to provide estimates for the incidence, prevalence, and trends of general practitioner (GP)-recorded diagnosis of peanut allergy in the English population. Methods: Version 10 of the QRESEARCH database was used with data from 2,958,366 patients who were registered with 422 United Kingdom general practices in the years 2001 to 2005. The primary outcome was a recording of clinician-diagnosed peanut allergy. Results: The age-sex standardized incidence rate of peanut allergy in 2005 was 0.08 per 1000 person-years (95% CI, 0.07-0.08), and the prevalence rate was 0.51 per 1000 patients (95% CI, 0.49-0.54). This translated into an estimated 4000 incident cases (95% CI, 3500-4600) and 25,700 prevalent cases (95% CI, 24,400-27,100) of GP-recorded diagnosis of peanut allergy in England in 2005. During the study period, the incidence rate of peanut allergy remained fairly stable, whereas the prevalence rate doubled. In those under 18 years of age, the crude lifetime prevalence rate was higher in males than females. A significant inverse relationship between prevalence and socioeconomic status was found. Conclusion: These data on GP-recorded diagnosis of peanut allergy from a large general practice database suggest a much lower prevalence in peanut allergy than has hitherto been found. This difference may in part be explained by underrecording of peanut allergy in general practice. Further research is needed to assess the true frequency of peanut allergy in the population and whether there has been a true increase in recent years. (J Allergy Clin Immunol 2011;127:623-30.)	[Kotz, Daniel; Simpson, Colin R.; Sheikh, Aziz] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Kotz, Daniel; Sheikh, Aziz] Maastricht Univ Med Ctr, Dept Gen Practice, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands	University of Edinburgh; Maastricht University; Maastricht University Medical Centre (MUMC)	Sheikh, A (corresponding author), Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Simpson, Colin R/L-7180-2014; Sheikh, Aziz/D-2818-2009; Kotz, Daniel/A-1270-2007; Simpson, Colin/I-3974-2019	Simpson, Colin R/0000-0002-5194-8083; Sheikh, Aziz/0000-0001-7022-3056; Kotz, Daniel/0000-0002-9454-023X; Simpson, Colin/0000-0002-5194-8083	NHS Health and Social Care Information Centre; Dutch Asthma Foundation; Chief Scientist's Office of the Scottish Government; Chief Scientist Office [PDF/08/02] Funding Source: researchfish	NHS Health and Social Care Information Centre; Dutch Asthma Foundation; Chief Scientist's Office of the Scottish Government; Chief Scientist Office	Supported by the NHS Health and Social Care Information Centre. D. K. is supported by a short-term research fellowship from the Dutch Asthma Foundation. C. R. S. is supported by a national postdoctoral fellowship from the Chief Scientist's Office of the Scottish Government.	Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Boulay A, 2008, ALLERGY, V63, P797, DOI 10.1111/j.1398-9995.2008.01776.x; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Ghouri N, 2008, J ROY SOC MED, V101, P466, DOI 10.1258/jrsm.2008.080096; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hippisley-Cox J, 2010, TRENDS CONSULTATION; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Lieberman P, 2008, CURR OPIN ALLERGY CL, V8, P316, DOI 10.1097/ACI.0b013e3283036a69; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; *OFF NAT STAT, CENS 2001; Osman Mustafa, 2007, Prim Care Respir J, V16, P28, DOI 10.3132/pcrj.2007.00006; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Simpson CR, 2007, CLIN EXP ALLERGY, V37, P1586, DOI 10.1111/j.1365-2222.2007.02830.x; Simpson CR, 2010, J ROY SOC MED, V103, P98, DOI 10.1258/jrsm.2009.090348; Simpson CR, 2008, J ROY SOC MED, V101, P558, DOI 10.1258/jrsm.2008.080196; Simpson CR, 2009, J ROY SOC MED, V102, P108, DOI 10.1258/jrsm.2009.080211; Simpson CR, 2010, BR J GEN PRACT, V60, pe277; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Townsend P., 1988, HLTH DEPRIVATION; United States Department of Agriculture, FOR AGR SERV PROD SU; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Victorino CC, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-53	31	71	73	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					623	U133		10.1016/j.jaci.2010.11.021	http://dx.doi.org/10.1016/j.jaci.2010.11.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21236479				2022-12-18	WOS:000288018400010
J	Jarvinen, KM; Amalanayagam, S; Shreffler, WG; Noone, S; Sicherer, SH; Sampson, HA; Nowak-Wegrzyn, A				Jarvinen, Kirsi M.; Amalanayagam, Sujitha; Shreffler, Wayne G.; Noone, Sally; Sicherer, Scott H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna			Epinephrine treatment is infrequent and biphasic reactions are rare in food-induced reactions during oral food challenges in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; autoinjector; self-injectable; epinephrine; children; anaphylaxis; oral food challenge; food-induced anaphylaxis; peanut allergy; tree nut allergy; cow's milk allergy; milk allergy; egg allergy; allergic reaction	ANAPHYLACTIC REACTIONS; DOUBLE-BLIND; ATOPIC-DERMATITIS; ALLERGY; MANAGEMENT; FATALITIES; EPIPEN; PEANUT; EGG	Background: Data about epinephrine use and biphasic reactions in childhood food-induced anaphylaxis during oral food challenges are scarce. Objective: To determine the prevalence and risk factors of reactions requiring epinephrine and the rate of biphasic reactions during oral food challenges (OFCs) in children. Methods: Reaction details of positive OFCs in children between 1999 and 2007 were collected by using a computerized database. Selection of patients for OFCs was generally predicated on <= 50% likelihood of a positive challenge and a low likelihood of a severe reaction on the basis of the clinical history, specific IgE levels, and skin prick tests. Results: A total of 436 of 1273 OFCs resulted in a reaction (34%). Epinephrine was administered in 50 challenges (11% of positive challenges, 3.9% overall) for egg (n = 15, 16% of positive OFCs to egg), milk (n = 14, 12%), peanut (n = 10, 26%), tree nuts (n = 4, 33%), soy (n = 3, 7%), wheat (n = 3, 9%), and fish (n = 1, 9%). Reactions requiring epinephrine occurred in older children (median, 7.9 vs 5.8 years; P < .001) and were more often caused by, peanuts (P = .006) compared with reactions not treated with epinephrine. There was no difference in the sex, prevalence of asthma, history of anaphylaxis, specific IgE level, skin prick tests, or amount of food administered. Two doses of epinephrine were required in 3 of 50 patients (6%) reacting to wheat, cow's milk, and pistachio. There was 1 (2%) biphasic reaction. No reaction resulted in life-threatening respiratory or cardiovascular compromise. Conclusion: Older age and reactions to peanuts were risk factors for anaphylaxis during oral food challenges. Reactions requiring multiple doses of epinephrine and biphasic reactions were infrequent. (J Allergy Clin Immunol 2009;124:1267-72.)	[Jarvinen, Kirsi M.] Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Jarvinen, KM (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	kirsi.jarvinen@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854; Jarvinen, Kirsi/0000-0003-1548-6712	NIH [K 12 HD052890, AI44236, AI066738, M01 RR00071]; NIH NIAID [K23 AI059318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052890] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, K23AI059318] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	K.M.J. is supported in part by the 2007 AAAAI Fellow-in-Training Research Award and NIH K 12 HD052890. S.H.S. and H.A.S. are supported in part by grants from the NIH, AI44236 and AI066738. A.N.-W. is supported in part by grant NIH NIAID K23 AI059318. The funding to the General Clinical Research Center conies partially from NIH M01 RR00071.	Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2007, PEDIATRICS, V119, P638, DOI 10.1542/peds.2006-3689; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; SIMONS FER, 2004, WORLD ALLERGY ORG S, P242; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.iac.2007.03.011; Uguz A, 2005, CLIN EXP ALLERGY, V35, P746, DOI 10.1111/j.1365-2222.2005.02257.x	24	71	71	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1267	1272		10.1016/j.jaci.2009.10.006	http://dx.doi.org/10.1016/j.jaci.2009.10.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004784	Green Accepted			2022-12-18	WOS:000273071500019
J	Yu, JE; Knight, AK; Radigan, L; Marron, TU; Zhang, L; Sanchez-Ramon, S; Cunningham-Rundies, C				Yu, Joyce E.; Knight, Adina K.; Radigan, Lin; Marron, Thomas U.; Zhang, Li; Sanchez-Ramon, Silvia; Cunningham-Rundies, Charlotte			Toll-like receptor 7 and 9 defects in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; Toll-like receptor; memory B cell; plasmacytoid dendritic cell; isotype switch; IFN-alpha	PLASMACYTOID DENDRITIC CELLS; MEMORY B-CELLS; DOUBLE-STRANDED-RNA; KAPPA-B; IN-VITRO; ACTIVATION; TLR9; DIFFERENTIATION; DEFICIENCY; MUTATIONS	Background: Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinemia, reduced numbers of peripheral blood isotype-switched memory B cells, and loss of plasma cells. Objective: Because Toll-like receptor (TLR) activation of B cells can initiate and potentially sustain normal B cell functions, we examined functional outcomes of TLR7 and TLR9 signaling in CVID B cells. Methods: TLR7-mediated, TLR7/8-mediated, and TLR9-mediated cell proliferation, isotype switch, and immunoglobulin production by control and CVID B cells or isolated naive and memory B cell subsets were examined. We quantitated TNF-alpha, IL-6, and IL-12 production in response to TLR1-9 ligands and measured IFN-alpha production by TLR7-stimulated PBMCs and isolated plasmacytoid dendritic cells (pDCs). IFN-beta mRNA expression by TLR3-stimulated fibroblasts wits assessed. Results: Unlike CD27(+) B cells of controls, TLR7-activated, TLR7/8-activated, or TLR9-activated CVID B cells or isolated CD27(+) B cells did not proliferate, upregulate CD27, or shed surface IgD. TLR-stimulated CVID B cells failed to upregulate activation-induced cytosine deaminase mRNA or produce IgG and IgA. TLR7-stimulated PBMCs and pDCs produced little or no IFN-alpha. Reconstituting IFN-alpha in TLR7-stimulated CVID B-cell cultures facilitated proliferation, CD27 upregulation, and isotype switch. These TLR defects are restricted because CVID PBMCs stimulated with TLR ligands produced normal amounts of TNF-alpha, IL-6, and IL-12; TLR3-mediated expression of IFN-beta by CVID fibroblasts was normal. Conclusion: Defective TLR7 and TLR9 signaling in CVID B cells and pDCs, coupled with deficient IFN-alpha, impairs CVID B cell functions and prevents TLR-mediated augmentation of humoral immunity in vivo. (J Allergy Clin Immunol 2009;124:349-56.)	[Cunningham-Rundies, Charlotte] Mt Sinai Sch Med, Inst Immunol, Dept Med, New York, NY 10029 USA; [Yu, Joyce E.; Knight, Adina K.; Cunningham-Rundies, Charlotte] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; [Yu, Joyce E.; Knight, Adina K.; Cunningham-Rundies, Charlotte] Mt Sinai Med Ctr, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Cunningham-Rundies, C (corresponding author), Mt Sinai Sch Med, Inst Immunol, Dept Med, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundies@mssm.edu	Sanchez-Ramon, Silvia/I-8242-2019; Sanchez-Ramon, Silvia/AAZ-7670-2020	Sanchez-Ramon, Silvia/0000-0001-9585-6167; Sanchez-Ramon, Silvia/0000-0001-9585-6167	National Institutes of Health [AI-101093, AI-467320, AI-48693]; National Institute of Allergy and Infectious Diseases [03-22]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R18AI048693, R21AI101093] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health grants AI-101093, AI-467320, and AI-48693 and National Institute of Allergy and Infectious Diseases contract 03-22 (C.C.-R.).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bekeredjian-Ding IB, 2005, J IMMUNOL, V174, P4043, DOI 10.4049/jimmunol.174.7.4043; Bekeredjian-Ding I, 2008, J IMMUNOL, V181, P8267, DOI 10.4049/jimmunol.181.12.8267; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355; Braun D, 2002, INT IMMUNOL, V14, P411, DOI 10.1093/intimm/14.4.411; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Capolunghi F, 2008, J IMMUNOL, V180, P800, DOI 10.4049/jimmunol.180.2.800; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Cognasse F, 2008, IMMUNOLOGY, V125, P430, DOI 10.1111/j.1365-2567.2008.02844.x; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Day N, 2004, J PEDIATR-US, V144, P524, DOI 10.1016/j.jpeds.2003.11.025; Deering RP, 2006, CLIN VACCINE IMMUNOL, V13, P68, DOI 10.1128/CVI.13.1.68-76.2006; Fitzgerald-Bocarsly P, 2008, CYTOKINE GROWTH F R, V19, P3, DOI 10.1016/j.cytogfr.2007.10.006; Gantner F, 2003, EUR J IMMUNOL, V33, P1576, DOI 10.1002/eji.200323444; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Glaum MC, 2009, J ALLERGY CLIN IMMUN, V123, P224, DOI 10.1016/j.jaci.2008.09.018; Goldacker S, 2005, CURR OPIN ALLERGY CL, V5, P504, DOI 10.1097/01.all.0000191888.97397.b3; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hanten JA, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-39; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Hasbold J, 1999, IMMUNOL CELL BIOL, V77, P516, DOI 10.1046/j.1440-1711.1999.00874.x; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Heer AK, 2007, J IMMUNOL, V178, P2182, DOI 10.4049/jimmunol.178.4.2182; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jegerlehner A, 2007, J IMMUNOL, V178, P2415, DOI 10.4049/jimmunol.178.4.2415; Kadowaki N, 2002, HUM IMMUNOL, V63, P1126, DOI 10.1016/S0198-8859(02)00751-6; Ko J, 2005, CLIN IMMUNOL, V116, P37, DOI 10.1016/j.clim.2005.03.019; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Meyer-Bahlburg A, 2007, J EXP MED, V204, P3095, DOI 10.1084/jem.20071250; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Poeck H, 2004, BLOOD, V103, P3058, DOI 10.1182/blood-2003-08-2972; Richard K, 2008, J IMMUNOL, V181, P1746, DOI 10.4049/jimmunol.181.3.1746; Ruprecht CR, 2006, EUR J IMMUNOL, V36, P810, DOI 10.1002/eji.200535744; Salt BH, 2008, J ALLERGY CLIN IMMUN, V121, P976, DOI 10.1016/j.jaci.2007.11.014; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Sanchez-Ramon S, 2008, CLIN IMMUNOL, V128, P314, DOI 10.1016/j.clim.2008.02.013; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Traggiai E, 2003, VACCINE, V21, pS35, DOI 10.1016/S0264-410X(03)00198-1; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	56	71	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					349	356		10.1016/j.jaci.2009.05.019	http://dx.doi.org/10.1016/j.jaci.2009.05.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19592080	Green Accepted			2022-12-18	WOS:000268860400024
J	Larsen, GL; Morgan, W; Heldt, GP; Mauger, DT; Boehmer, SJ; Chinchilli, VM; Lemanske, RF; Martinez, F; Strunk, RC; Szefler, SJ; Zeiger, RS; Taussig, LM; Bacharier, LB; Guilbert, TW; Radford, S; Sorkness, CA				Larsen, Gary L.; Morgan, Wayne; Heldt, Gregory P.; Mauger, David T.; Boehmer, Susan J.; Chinchilli, Vernon M.; Lemanske, Robert F., Jr.; Martinez, Fernando; Strunk, Robert C.; Szefler, Stanley J.; Zeiger, Robert S.; Taussig, Lynn M.; Bacharier, Leonard B.; Guilbert, Theresa W.; Radford, Shelley; Sorkness, Christine A.		Natl Heart Lung & Blood Inst	Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; impulse oscillometry; spirometry; therapy of asthma	OSCILLATION TECHNIQUE; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; YOUNG-CHILDREN; LUNG-FUNCTION; RISK; METHACHOLINE; FLUTICASONE; MONTELUKAST; RESISTANCE	Background: Determination of the benefits and limitations of specific physiologic tests has not been well studied in long-term clinical pediatric trials. Objective: We sought to determine the utility of impulse oscillometry in a long-term comparison of 3 controller regimens in children with persistent asthma. Methods: Children 6 to 14 years of age with mild-to-moderate persistent asthma were characterized with oscillometry and spirometry before entry into a clinical trial and then serially during 48 weeks of therapy with either an inhaled corticosteroid, a combination inhaled corticosteroid with a long-acting beta-agonist, or a leukotriene receptor antagonist. Results: The FEV1/forced vital capacity ratio, as well as the forced expiratory flow from 25% to 75% of forced vital capacity in terms of spirometric parameters and the reactance area (XA) from impulse oscillometry, appeared to complement information provided by FEV1 when comparing the tests and factors that appeared to predict a response to treatment. XA was unique in that it, as distinct from spirometric variables, reflected ongoing improvement during the latter part of the trial. In general, improvements in XA during the latter part of the study occurred independently of indices of atopy and the level of airway responsiveness. Conclusion: Assessment of respiratory mechanics over time with oscillometry might offer additional insights into the response of asthmatic patients to therapy. In particular, the pattern of improvement seen in XA over the course of therapy suggests this test might detect alterations in airway mechanics not reflected by spirometry. The possibility that changes in XA reflect ongoing improvement in small airway function deserves additional study. (J Allergy Clin Immunol 2009;123:861-7.)	[Larsen, Gary L.; Szefler, Stanley J.; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Lemanske, Robert F., Jr.; Guilbert, Theresa W.; Sorkness, Christine A.] Univ Wisconsin, Sch Med, Ctr Clin Sci, Madison, WI USA; [Mauger, David T.; Boehmer, Susan J.; Chinchilli, Vernon M.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Heldt, Gregory P.; Zeiger, Robert S.] Univ Calif San Diego, Med Ctr, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif Reg, Dept Allergy, Pasadena, CA USA; [Morgan, Wayne; Martinez, Fernando; Radford, Shelley] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA	National Jewish Health; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego; Kaiser Permanente; University of Arizona	Larsen, GL (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	larseng@njc.org		Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063; Guilbert, Theresa/0000-0002-6932-712X	National Heart, Lung, and Blood Institute [U1OHL064287, 5U10HL064288, 5U10HL064295, 5U10HL064305, 5U10HL064307]; National Jewish Medical and Research Center [M01 RR00051]; Washington University School of Medicine [M01 RR00036]; University of Wisconsin [MO1 RR03186]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR000051, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064295, U10HL064288, U10HL064305, U10HL064307, U10HL064287] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Jewish Medical and Research Center; Washington University School of Medicine; University of Wisconsin; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants U1OHL064287,5U10HL064288,5U10HL064295, 5U10HL064305, and 5U10HL064307 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at National Jewish Medical and Research Center (M01 RR00051), Washington University School of Medicine (M01 RR00036), and the University of Wisconsin (MO1 RR03186).	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arets HGM, 2001, EUR RESPIR J, V18, P655, DOI 10.1183/09031936.01.00204301; BYE MR, 1992, AM J DIS CHILD, V146, P977, DOI 10.1001/archpedi.1992.02160200099037; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DESAGER KN, 1996, INFANT RESP FUNCTION, P355; Ducharme FM, 1997, CHEST, V111, P1519, DOI 10.1378/chest.111.6.1519; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P433; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P27; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Evans TM, 2005, CHEST, V128, P2412, DOI 10.1378/chest.128.4.2412; Frei J, 2005, CHEST, V128, P1266, DOI 10.1378/chest.128.3.1266; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; Goldman MD, 2001, PULM PHARMACOL THER, V14, P341, DOI 10.1006/pupt.2001.0310; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hellinckx J, 1998, EUR RESPIR J, V12, P438, DOI 10.1183/09031936.98.12020438; Jain N, 2005, PEDIATR PULM, V40, P211, DOI 10.1002/ppul.20215; Klug B, 1996, PEDIATR PULM, V21, P290; Larsen GL, 2005, J ALLERGY CLIN IMMUN, V115, P657, DOI 10.1016/j.jaci.2004.12.1112; LARSEN GL, 2003, PEDIAT ALLERGY PRINC, P357; Marotta A, 2003, J ALLERGY CLIN IMMUN, V112, P317, DOI 10.1067/mai.2003.1627; Mitchell H, 1997, PEDIATR PULM, V24, P237; Omar RZ, 1999, STAT MED, V18, P1587, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1587::AID-SIM141>3.0.CO;2-Z; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Vink GR, 2003, PEDIATR PULM, V35, P214, DOI 10.1002/ppul.10235; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	35	71	79	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					861	867		10.1016/j.jaci.2008.10.036	http://dx.doi.org/10.1016/j.jaci.2008.10.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19070356	Bronze, Green Accepted			2022-12-18	WOS:000265058600012
J	Lahtinen, SJ; Boyle, RJ; Kivivuori, S; Oppedisano, F; Smith, KR; Robins-Browne, R; Salminen, SJ; Tang, MLK				Lahtinen, Sampo J.; Boyle, Robert J.; Kivivuori, Satu; Oppedisano, Frances; Smith, Katherine R.; Robins-Browne, Roy; Salminen, Seppo J.; Tang, Mimi L. K.			Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MICROFLORA		[Lahtinen, Sampo J.; Smith, Katherine R.] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; Univ Turku, Funct Foods Forum, SF-20500 Turku, Finland	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Turku	Lahtinen, SJ (corresponding author), Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia.	mimi.tang@rch.org.au	Tang, Mimi/ABD-8350-2020; Robinsbrowne, Roy/ABF-8434-2020	Tang, Mimi/0000-0002-3839-5293; Robinsbrowne, Roy/0000-0001-9179-7884; Boyle, Robert/0000-0002-4913-7580				Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Gueimonde M, 2006, J PEDIATR GASTR NUTR, V42, P166, DOI 10.1097/01.mpg.0000189346.25172.fd; Gueimonde M, 2004, APPL ENVIRON MICROB, V70, P4165, DOI 10.1128/AEM.70.7.4165-4169.2004; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006475.pub2; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Schultz M, 2004, J PEDIATR GASTR NUTR, V38, P293, DOI 10.1097/00005176-200403000-00012; Stsepetove J, 2007, FEMS IMMUNOL MED MIC, V51, P260, DOI 10.1111/j.1574-695X.2007.00306.x; Suzuki S, 2007, CLIN EXP ALLERGY, V37, P506, DOI 10.1111/j.1365-2222.2007.02676.x	10	71	76	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					499	501		10.1016/j.jaci.2008.11.034	http://dx.doi.org/10.1016/j.jaci.2008.11.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19135234				2022-12-18	WOS:000263495000032
J	Kelly, JT; Busse, WW				Kelly, John T.; Busse, William W.			Host immune responses to rhinovirus: Mechanisms in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; exacerbation; rhinovirus; immune response to virus; pathogenesis	BRONCHIAL EPITHELIAL-CELLS; NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; ANTIGEN-PRESENTING CELLS; PERIPHERAL-BLOOD EOSINOPHILS; RESPIRATORY-TRACT INFECTIONS; VIRUS-INDUCED ASTHMA; COMMON COLD; IN-VIVO; HLA-DR	Viral respiratory infections can have a profound effect on many aspects of asthma including its inception, exacerbations, and, possibly, severity. Of the many viral respiratory infections that influence asthma, the common cold virus, rhinovirus, has emerged as the most frequent illness associated with exacerbations and other aspects of asthma. The mechanisms by which rhinovirus influences asthma are not fully established, but current evidence indicates that the immune response to this virus is critical in this process. Many airway cell types are involved in the immune response to rhinovirus, but most important are respiratory epithelial cells and possibly macrophages. Infection of epithelial cells generates a variety of proinflammatory mediators to attract inflammatory cells to the airway with a subsequent worsening of underlying disease. Furthermore, there is evidence that the epithelial airway antiviral response to rhinovirus may be defective in asthma. Therefore, understanding the immune response to rhinovirus is a key step in defining mechanisms of asthma, exacerbations, and, perhaps most importantly, improved treatment.	[Kelly, John T.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Allergy & Clin Immunol, J5-219 CSC,Box 2454,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL069116, R01 HL069116] Funding Source: Medline; NIAID NIH HHS [T32 AI007635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alper CM, 1996, LARYNGOSCOPE, V106, P1298, DOI 10.1097/00005537-199610000-00025; ANDRIES K, 1990, J VIROL, V64, P1117, DOI 10.1128/JVI.64.3.1117-1123.1990; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; BARDIN PG, 1994, CLIN EXP ALLERGY, V24, P457, DOI 10.1111/j.1365-2222.1994.tb00934.x; Bianco A, 1998, EUR RESPIR J, V12, P619, DOI 10.1183/09031936.98.12030619; Bianco A, 2000, CLIN EXP IMMUNOL, V121, P339, DOI 10.1046/j.1365-2249.2000.01301.x; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; Charles CH, 2003, ANTIMICROB AGENTS CH, V47, P1503, DOI 10.1128/AAC.47.5.1503-1508.2003; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Clejan S, 2005, J CELL MOL MED, V9, P457, DOI 10.1111/j.1582-4934.2005.tb00370.x; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; DUFF AL, 1993, PEDIATRICS, V92, P535; Edwards MR, 2007, J BIOL CHEM, V282, P15366, DOI 10.1074/jbc.M701325200; Edwards MR, 2005, PULM PHARMACOL THER, V18, P337, DOI 10.1016/j.pupt.2004.12.015; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FARR BM, 1984, ANTIMICROB AGENTS CH, V26, P31, DOI 10.1128/AAC.26.1.31; Fendrick A Mark, 2003, Am J Ther, V10, P193, DOI 10.1097/00045391-200305000-00006; Fleischer R, 2003, CLIN INFECT DIS, V37, P1722; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gentile DA, 2003, ANN ALLERG ASTHMA IM, V91, P270, DOI 10.1016/S1081-1206(10)63529-6; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1996, J IMMUNOL, V156, P621; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Greenberg SB, 2003, ARCH INTERN MED, V163, P278, DOI 10.1001/archinte.163.3.278; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; GUIDA L, 1994, BLOOD, V84, P2733; Handzel ZT, 1998, J IMMUNOL, V160, P1279; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HAYDEN FG, 1986, NEW ENGL J MED, V314, P71, DOI 10.1056/NEJM198601093140202; Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003; Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069; HAYDEN FG, 1988, ANTIVIR RES, V9, P233, DOI 10.1016/0166-3542(88)90055-1; HEYMANN PW, 1995, INT ARCH ALLERGY IMM, V107, P380, DOI 10.1159/000237043; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Jame AJ, 2007, CLIN EXP ALLERGY, V37, P880, DOI 10.1111/j.1365-2222.2007.02733.x; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Johnston SL, 1997, J INFECT DIS, V175, P323, DOI 10.1093/infdis/175.2.323; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Laza-Stanca V, 2006, J VIROL, V80, P8248, DOI 10.1128/JVI.00162-06; Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004; Lee KK, 2007, PEDIATR PULM, V42, P290, DOI 10.1002/ppul.20578; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LEVANDOWSKI RA, 1986, J INFECT DIS, V153, P743, DOI 10.1093/infdis/153.4.743; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Maugeri C, 2008, BIOORGAN MED CHEM, V16, P3091, DOI 10.1016/j.bmc.2007.12.030; MAWHORTER SD, 1994, IMMUNOLOGY, V81, P584; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; Message SD, 2001, EUR RESPIR J, V18, P1013, DOI 10.1183/09031936.01.00228701; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oberste MS, 1999, J VIROL, V73, P1941, DOI 10.1128/JVI.73.3.1941-1948.1999; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Pacifico L, 2000, CLIN INFECT DIS, V31, P834, DOI 10.1086/314049; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;100::AID-JMV16&gt;3.0.CO;2-D; Papadopoulos NG, 2001, CLIN EXP ALLERGY, V31, P1060, DOI 10.1046/j.1365-2222.2001.01112.x; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pelaia G, 2003, LIFE SCI, V72, P1549, DOI 10.1016/S0024-3205(02)02446-3; Pelaia G, 2001, BIOCHEM PHARMACOL, V62, P1719, DOI 10.1016/S0006-2952(01)00791-2; Pevear DC, 2005, ANTIMICROB AGENTS CH, V49, P4492, DOI 10.1128/AAC.49.11.4492-4499.2005; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Rabin RL, 1999, J IMMUNOL, V162, P3840; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Rosen J, 2001, FORDHAM LAW REV, V70, P1; Rotbart HA, 2000, ANTIVIR CHEM CHEMOTH, V11, P261, DOI 10.1177/095632020001100402; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; SCHUSTER A, 1995, EUR RESPIR J, V8, P10, DOI 10.1183/09031936.95.08010010; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SKONER DP, 1995, CLIN EXP ALLERGY, V25, P561, DOI 10.1111/j.1365-2222.1995.tb01095.x; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPERBER SJ, 1989, J INFECT DIS, V160, P700, DOI 10.1093/infdis/160.4.700; SPERBER SJ, 1989, J INTERFERON RES, V9, P285, DOI 10.1089/jir.1989.9.285; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Stanley MA, 2002, CLIN EXP DERMATOL, V27, P571, DOI 10.1046/j.1365-2230.2002.01151.x; Stokes JR, 1998, EUR RESPIR J, V11, P324, DOI 10.1183/09031936.98.11020324; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tapparel C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-224; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; van Benten IJ, 2001, ALLERGY, V56, P949, DOI 10.1034/j.1398-9995.2001.00212.x; Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; WELLER PF, 1993, J IMMUNOL, V150, P2554; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Zalman LS, 2000, ANTIMICROB AGENTS CH, V44, P1236, DOI 10.1128/AAC.44.5.1236-1241.2000; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	116	71	73	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					671	682		10.1016/j.jaci.2008.08.013	http://dx.doi.org/10.1016/j.jaci.2008.08.013			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014757	Green Accepted			2022-12-18	WOS:000259989000006
J	Pfefferle, PI; Sel, S; Ege, MJ; Buchele, G; Blumer, N; Krauss-Etschmann, S; Herzum, I; Albers, CE; Lauener, RP; Roponen, M; Hirvonen, MR; Vuitton, DA; Riedler, J; Brunekreef, B; Dalphin, JC; Braun-Fahrlander, C; Pekkanen, J; von Mutius, E; Renz, H				Pfefferle, Petra Ina; Sel, Serdar; Ege, Markus Johannes; Buechele, Gisela; Bluemer, Nicole; Krauss-Etschmann, Susanne; Herzum, Ileana; Albers, Christoph E.; Lauener, Roger P.; Roponen, Marjut; Hirvonen, Maija-Riitta; Vuitton, Dominique A.; Riedler, Josef; Brunekreef, Bert; Dalphin, Jean-Charles; Braun-Fahrlaender, Charlotte; Pekkanen, Juha; von Mutius, Erika; Renz, Harald		PASTURE Study Grp	Cord blood allergen-specific IgE is associated with reduced IFN-gamma production by cord blood cells: The Protection against Allergy-Study in Rural Environments (PASTURE) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prenatal; allergen specific IgE; cord blood; prospective birth cohort study; farming environment	ATOPIC SENSITIZATION; PRENATAL EXPOSURE; PREDICTIVE VALUE; RISK; ASTHMA	Background: It is currently discussed whether allergic sensitization may start in utero under the influence of the maternal immune system and environmental determinants. Objective: To investigate the relationship between allergen-specific cord blood (CB) IgE levels, parental sensitization, CB cytokine production, and environmental influences. Methods: As part of an ongoing multicenter birth cohort study, allergen-specific IgE antibodies against 20 common seasonal, perennial, and food allergens were measured in blood samples from 922 neonates, 922 mothers, and 835 fathers. Supernatants from stimulated CB cells were assessed for the production of IL-5, IFN-gamma, IL-10, and TNF-alpha. Results: Allergen-specific IgE antibodies were detectable in 23.9% of newborns. Contamination with maternal serum was excluded by several means of analyses, including the absence of IgA antibodies. Clear correlation between maternal and fetal IgE was found only for hen's egg, cow's milk, and soybean allergen. Fetal IgE correlated negatively with the level of IFN-gamma production, but not with IL-5 and IL-10. Conclusion: Allergen-specific IgE antibodies most probably of fetal origin are detectable in CB and correlate with a lowered CB IFN-gamma production.	[Ege, Markus Johannes; Krauss-Etschmann, Susanne; von Mutius, Erika] Univ Childrens Hosp, Munich, Germany; [Buechele, Gisela] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Krauss-Etschmann, Susanne] Heimholtz Zentrum Munchen, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; [Lauener, Roger P.] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Roponen, Marjut; Hirvonen, Maija-Riitta; Pekkanen, Juha] Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; [Vuitton, Dominique A.] Univ Franche Comte, Res Unit Hlth & Rural Environm, F-25030 Besancon, France; [Riedler, Josef] Childrens Hosp, Schwarzach, Germany; [Brunekreef, Bert] Univ Med Ctr Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Dalphin, Jean-Charles] Univ Hosp, Dept Resp Dis, Besancon, France; [Braun-Fahrlaender, Charlotte] Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland; [PASTURE Study Grp] Protect Allergy Study Rural Environm Study Grp, Claudia Humer, Austria; [Pfefferle, Petra Ina; Sel, Serdar; Bluemer, Nicole; Herzum, Ileana; Albers, Christoph E.; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Ulm University; University Children's Hospital Zurich; University of Zurich; Finland National Institute for Health & Welfare; Universite de Franche-Comte; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Universite de Franche-Comte; CHU Besancon; University of Basel; University of Eastern Finland; Philipps University Marburg	Renz, H (corresponding author), Univ Giessen Klinikum, Dept Clin Chem & Mol Diagnost, Baldingerstr 1, D-35033 Marburg, Germany.	renzh@md.uni-marburg.de	Ege, Markus/C-1962-2012; riedler, josef/AAQ-4666-2020; Krauss-Etschmann, Susanne/H-5198-2018; Roponen, Marjut/C-2086-2017; Albers, Christoph/B-3529-2013; Lauener, Roger P/O-8612-2016; Albers, Christoph E./Y-9703-2019	Ege, Markus/0000-0001-6643-3923; Krauss-Etschmann, Susanne/0000-0001-5945-5702; Roponen, Marjut/0000-0002-4442-9090; Lauener, Roger P/0000-0002-8412-606X; brunekreef, bert/0000-0001-9908-0060; von Mutius, Erika/0000-0002-8893-4515; Reboux, Gabriel/0000-0002-7923-0858				AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Bertino E, 2006, PEDIATR ALLERGY IMMU, V17, P484, DOI 10.1111/j.1399-3038.2006.00449.x; Blumenthal MN, 2004, HUM GENET, V114, P157, DOI 10.1007/s00439-003-1030-5; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Herzum I, 2005, CLIN CHEM LAB MED, V43, P963, DOI 10.1515/CCLM.2005.165; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Kaplan J, 2005, ANN ALLERG ASTHMA IM, V95, P480, DOI 10.1016/S1081-1206(10)61175-1; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Liu Chieh-An, 2003, Chang Gung Med J, V26, P561; Loibichler C., 2002, Clinical and Experimental Allergy, V32, P1546, DOI 10.1046/j.1365-2222.2002.01479.x; Maurer D, 1996, J IMMUNOL, V157, P607; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Piccinni MP, 2002, AM J REPROD IMMUNOL, V47, P289, DOI 10.1034/j.1600-0897.2002.01104.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; ROSENAU MJ, 1906, HYG LAB B, V29, P73; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sadeghnejad A, 2004, THORAX, V59, P936, DOI 10.1136/thx.2004.024224; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Shah Shilpa, 2006, Indian J Med Sci, V60, P13; Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x; Thornton CA, 2003, CLIN EXP ALLERGY, V33, P306, DOI 10.1046/j.1365-2222.2003.01614.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x	32	71	71	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					711	716		10.1016/j.jaci.2008.06.035	http://dx.doi.org/10.1016/j.jaci.2008.06.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18718651				2022-12-18	WOS:000259989000012
J	Borrelli, B; Riekert, KA; Weinstein, A; Rathier, L				Borrelli, Belinda; Riekert, Kristin A.; Weinstein, Andrew; Rathier, Lucille			Brief motivational interviewing as a clinical strategy to promote asthma medication adherence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						motivational interviewing; adherence; medication adherence; brief interventions; health behavior change; asthma management	RANDOMIZED CONTROLLED-TRIAL; PATIENT-CENTERED COMMUNICATION; GENERAL-PRACTICE; COMPLIANCE THERAPY; INHALED CORTICOSTEROIDS; PEDIATRIC ASTHMA; DIABETES CARE; INTERVENTION; EDUCATION; CHILDREN	Patient-centered approaches are associated with better patient retention and treatment outcomes, without increased time and cost. Motivational interviewing (MI) is a patient-centered counseling approach that can be briefly integrated into patient encounters and is specifically designed to enhance motivation to change among patients not ready to change. Existing asthma management approaches (eg, education and self-management) increase resistance among patients not ready or willing to follow medical recommendations. MI helps patients resolve their ambivalence about behavior change and builds their intrinsic motivation before providing education. Although MI overlaps with patient-centered communication, it additionally includes some concrete motivational strategies that can be briefly and easily implemented in medical settings (eg, setting an agenda, assessing motivation and confidence for change, helping the patient weigh the costs and benefits of change, and providing medical advice and health feedback). Reflective listening is used to help patients clarify their ambivalence and diffuse resistance. MI has been shown to be efficacious across a wide variety of health behavior change areas. This article will describe the method and spirit of MI as applied to asthma management by reviewing the principles of MI, brief MI strategies to motivate medication adherence, the evidence base for NIT, and the costs and benefits of building MI into clinical practice.	Brown Med Sch, Ctr Behav & Prevent Med, Providence, RI 02903 USA; Miriam Hosp, Providence, RI 02906 USA; Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; Thomas Jefferson Univ, Jefferson Med Coll, Div Allergy & Immunol, Philadelphia, PA 19107 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Johns Hopkins University; Johns Hopkins Medicine; Jefferson University	Borrelli, B (corresponding author), Brown Med Sch, Ctr Behav & Prevent Med, Coro W,1 Hoppin St,Suite 500, Providence, RI 02903 USA.	Belinda_Borrelli@Brown.edu		Borrelli, Belinda/0000-0002-0859-796X				Aloia Mark S, 2007, Behav Sleep Med, V5, P89; Amrhein PC, 2003, J CONSULT CLIN PSYCH, V71, P862, DOI 10.1037/0022-006X.71.5.862; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; Bauman LJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e6; Bem D.J., 1972, ADV EXP SOC PSYCHOL, V6, P1, DOI DOI 10.1016/S0065-2601(08)60024-6; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bender BG, 2006, J ALLERGY CLIN IMMUN, V118, P899, DOI 10.1016/j.jaci.2006.07.002; BENER BG, 2007, ANN ALLERG ASTHMA IM, V98, P322; Boardman T, 2006, J SUBST ABUSE TREAT, V31, P329, DOI 10.1016/j.jsat.2006.05.006; Borrelli B, 2005, PREV MED, V41, P815, DOI 10.1016/j.ypmed.2005.08.004; Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852; BORRELLI B, 2007, 63 ANN M AM AC ALL A; Borsari B, 2000, J CONSULT CLIN PSYCH, V68, P728, DOI 10.1037//0022-006X.68.4.728; Boulware LE, 2001, AM J PREV MED, V21, P221, DOI 10.1016/S0749-3797(01)00356-7; Boyle D, 2005, ACAD MED, V80, P29, DOI 10.1097/00001888-200501000-00008; Brehm S.S., 1981, PSYCHOL REACTANCE, DOI DOI 10.1016/B978-0-12-129840-1.50005-3; Brown J.M., 1993, PSYCHOL ADDICT BEHAV, V7, P211, DOI DOI 10.1037/0893-164X.7.4.211; Butler CC, 1999, BRIT J GEN PRACT, V49, P611; Cabana MD, 2006, PEDIATRICS, V117, P2149, DOI 10.1542/peds.2005-1055; Cabana MD, 2005, J ALLERGY CLIN IMMUN, V115, P1225, DOI 10.1016/j.jaci.2005.03.004; Carey MP, 2000, HEALTH PSYCHOL, V19, P3, DOI 10.1037/0278-6133.19.1.3; Chambers CV, 1999, RESP MED, V93, P88, DOI 10.1016/S0954-6111(99)90296-2; Cicutto L, 2005, CHEST, V128, P1928, DOI 10.1378/chest.128.4.1928; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; DiIorio Colleen, 2003, J Assoc Nurses AIDS Care, V14, P52; DiLillo V, 2003, COGN BEHAV PRACT, V10, P120, DOI 10.1016/S1077-7229(03)80020-2; Epstein RM, 2005, ANN FAM MED, V3, P415, DOI 10.1370/afm.348; Flocke SA, 2002, J FAM PRACTICE, V51, P835; Fuertes JN, 2007, PATIENT EDUC COUNS, V66, P29, DOI 10.1016/j.pec.2006.09.013; Golin CE, 2006, JAIDS-J ACQ IMM DEF, V42, P42, DOI 10.1097/01.qai.0000219771.97303.0a; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Heather N, 1996, DRUG ALCOHOL REV, V15, P29, DOI 10.1080/09595239600185641; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hing Esther, 2006, Adv Data, P1; Ho J, 2003, J ALLERGY CLIN IMMUN, V111, P498, DOI 10.1067/mai.2003.160; Hodgins DC, 2004, PSYCHOL ADDICT BEHAV, V18, P293, DOI 10.1037/0893-164X.18.3.293; Irwin RS, 2006, CHEST, V130, p73S, DOI 10.1378/chest.130.1_suppl.73S; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kemp R, 1996, BRIT MED J, V312, P345; Kemp R, 1998, BRIT J PSYCHIAT, V172, P413, DOI 10.1192/bjp.172.5.413; Kern DE, 2005, ACAD MED, V80, P8, DOI 10.1097/00001888-200501000-00006; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; KONING CJM, 1995, J ASTHMA, V32, P355, DOI 10.3109/02770909509082760; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; KULIK JA, 1987, J BEHAV MED, V10, P367, DOI 10.1007/BF00846476; Lee CS, 2007, ADDICT BEHAV, V32, P3136, DOI 10.1016/j.addbeh.2007.07.011; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Magar Y, 2005, PATIENT EDUC COUNS, V58, P41, DOI 10.1016/j.pec.2004.05.016; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; MARLATT GA, 1988, J CONSULT CLIN PSYCH, V56, P715, DOI 10.1037/0022-006X.56.5.715; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283; McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022; MILLER W, 2004, J HLTH PROMOT S, P1; Miller W.R., 2002, MOTIVATIONAL INTERVI, V2nd; MILLER WR, 1993, J CONSULT CLIN PSYCH, V61, P455, DOI 10.1037/0022-006X.61.3.455; MILLER WR, 1983, BEHAV PSYCHOTHER, V11, P147, DOI 10.1017/S0141347300006583; MILLER WR, 1983, BEHAV THER, V14, P441, DOI 10.1016/S0005-7894(83)80107-5; Moyers T.B., 2004, J COGN PSYCHOTHER, V18, P291, DOI [https://doi.org/10.1891/jcop.18.4.291.63999, DOI 10.1891/JCOP.18.4.291.63999]; Moyers TB, 2006, J SUBST ABUSE TREAT, V30, P245, DOI 10.1016/j.jsat.2005.12.003; Moyers TB, 2005, J CONSULT CLIN PSYCH, V73, P590, DOI 10.1037/0022-006X.73.4.590; Moyers TB, 2002, J CLIN PSYCHOL, V58, P185, DOI 10.1002/jclp.1142; *NAT HEART LUNG BL, 1997, NIH PUBL; Ockene IS, 1999, ARCH INTERN MED, V159, P725, DOI 10.1001/archinte.159.7.725; Parsons JT, 2005, AIDS PATIENT CARE ST, V19, P31, DOI 10.1089/apc.2005.19.31; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; Put C, 2003, EUR RESPIR J, V21, P109, DOI 10.1183/09031936.03.00267003; Reid SC, 2005, J STUD ALCOHOL, V66, P833, DOI 10.15288/jsa.2005.66.833; Resnicow K, 2002, HEALTH PSYCHOL, V21, P444, DOI 10.1037//0278-6133.21.5.444; Resnicow K, 2001, AM J PUBLIC HEALTH, V91, P1686, DOI 10.2105/AJPH.91.10.1686; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P177, DOI 10.1023/A:1014900328444; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Rollnick S, 1997, PATIENT EDUC COUNS, V31, P191, DOI 10.1016/S0738-3991(97)01004-5; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; Safran DG, 2001, J FAM PRACTICE, V50, P130; SAUNDERS B, 1995, ADDICTION, V90, P415, DOI 10.1046/j.1360-0443.1995.90341510.x; Schmaling KB, 2001, J CLIN PSYCHOL MED S, V8, P167, DOI 10.1023/A:1011365519345; Sherman J, 2001, PHARMACOTHERAPY, V21, P1464, DOI 10.1592/phco.21.20.1464.34485; Smith JR, 2005, THORAX, V60, P1003, DOI 10.1136/thx.2005.043877; Stewart M, 2000, J FAM PRACTICE, V49, P796; Stott NCH, 1996, PATIENT EDUC COUNS, V29, P67, DOI 10.1016/0738-3991(96)00935-4; Stott NCH, 1995, FAM PRACT, V12, P413, DOI 10.1093/fampra/12.4.413; Treasure JL, 1999, BEHAV RES THER, V37, P405, DOI 10.1016/S0005-7967(98)00149-1; Walders N, 2006, CHEST, V129, P292, DOI 10.1378/chest.129.2.292; Weinstein AG, 2005, ANN ALLERG ASTHMA IM, V94, P251, DOI 10.1016/S1081-1206(10)61304-X; WESTON W, 2003, PATIENT CENTERED CAR; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; WILSON S, 2006, 102 INT C AM THOR SO; WOOLLARD J, 1995, CLIN EXP PHARMACOL P, V22, P466, DOI 10.1111/j.1440-1681.1995.tb02046.x	95	71	73	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1023	1030		10.1016/j.jaci.2007.08.017	http://dx.doi.org/10.1016/j.jaci.2007.08.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	231TZ	17904625				2022-12-18	WOS:000250973400007
J	Earle, CD; King, EM; Tsay, A; Pittman, K; Saric, B; Vailes, L; Godbout, R; Oliver, KG; Chapman, MD				Earle, Christopher D.; King, Eva M.; Tsay, Amy; Pittman, Kimberly; Saric, Branka; Vailes, Lisa; Godbout, Rebecca; Oliver, Kerry G.; Chapman, Martin D.			High-throughput fluorescent multiplex array for indoor allergen exposure assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol		indoor allergen; multiplex array; environment; exposure; asthma; indoor air quality	LINKED-IMMUNOSORBENT-ASSAY; FLOW-CYTOMETRIC ASSAY; NUCLEOTIDE POLYMORPHISM ANALYSIS; MICROSPHERE-BASED IMMUNOASSAY; HUMAN CYTOKINES; SIMULTANEOUS QUANTITATION; FLOWMETRIX(TM) SYSTEM; SINGLE-SAMPLE; F-I; ANTIBODIES	Background: Current enzyme immunoassay methods for detection of common indoor allergens in environmental dust samples are labor-intensive and time consuming. Objective: To develop and validate a fluorescent multiplex array to measure 6 (Der p 1, Der f 1, Der p 2, Der f 2, Fel d 1, and Can f 1) indoor allergen levels simultaneously. Methods: A multiplex array for 6 allergens, using mAbs covalently coupled to fluorescent microspheres, was developed using a single universal standard composed of purified natural allergens. The multiplex array was validated by comparing the measured dust mite, cat, and dog allergen levels in household dust samples to those obtained by standard ELISA methods. Results: Linear regression analysis showed a highly significant quantitative correlation between the multiplex array and ELISA for dust mite, cat, and dog allergens: R-2 values ranging from 0.90 to 0.99 (P < .001). In addition, the sensitivity, limit of detection (< 0.1 ng/mL), reproducibility, intra-assay coefficient of variance (< 5%), and interassay coefficient of variance (< 25%) of the fluorescent multiplex array were shown to be equal to or better than the ELISA method. Conclusion: A multiplex array has been developed to measure simultaneously 6 indoor allergens from a single sample. The array will facilitate epidemiologic studies and indoor air quality assessments and can, in principle, be expanded to include other allergens and biologics. Clinical implications: The multiplex array lends itself to clinical studies, population-based environmental surveys, and allergen avoidance studies comparing allergen exposure in large populations over several time points.	Indoor Biotechnol Inc, Charlottesville, VA 22903 USA; Radix Biosolut Inc, Georgetown, Guyana	INDOOR Biotechnologies	Earle, CD (corresponding author), Indoor Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	cearle@inbio.com		Chapman, Martin/0000-0002-0845-3632	NIEHS NIH HHS [ES 55545, ES 45520] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2005, ENVIRON HEALTH PERSP, V113, P665, DOI 10.1289/ehp.7648; Bellisario R, 2001, EARLY HUM DEV, V64, P21, DOI 10.1016/S0378-3782(01)00167-0; Biagini RE, 2004, CLIN DIAGN LAB IMMUN, V11, P50, DOI 10.1128/CDLI.11.1.50-55.2004; Camilla C, 2001, CLIN DIAGN LAB IMMUN, V8, P776, DOI 10.1128/CDLI.8.4.776-784.2001; Carson RT, 1999, J IMMUNOL METHODS, V227, P41, DOI 10.1016/S0022-1759(99)00069-1; Chen JW, 2000, GENOME RES, V10, P549, DOI 10.1101/gr.10.4.549; Chen R, 1999, CLIN CHEM, V45, P1693; Dasso J, 2002, J IMMUNOL METHODS, V263, P23, DOI 10.1016/S0022-1759(02)00028-5; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Dunbar SA, 2003, J MICROBIOL METH, V53, P245, DOI 10.1016/S0167-7012(03)00028-9; Ferrari E, 2004, J ALLERGY CLIN IMMUN, V114, P341, DOI 10.1016/j.jaci.2004.04.028; Fulton RJ, 1997, CLIN CHEM, V43, P1749; Gordon RF, 1997, CLIN CHEM, V43, P1799; Heinrich J, 2006, J ALLERGY CLIN IMMUN, V118, P674, DOI 10.1016/j.jaci.2006.06.012; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kellar KL, 2001, CYTOMETRY, V45, P27, DOI 10.1002/1097-0320(20010901)45:1<27::AID-CYTO1141>3.0.CO;2-I; Kellar KL, 2003, J IMMUNOL METHODS, V279, P277, DOI 10.1016/S0022-1759(03)00248-5; Lal G, 2004, CLIN DIAGN LAB IMMUN, V11, P272, DOI 10.1128/CDLI.11.2.272-279.2004; Lal G, 2005, J IMMUNOL METHODS, V296, P135, DOI 10.1016/j.jim.2004.11.006; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Moss DM, 2004, J PARASITOL, V90, P397, DOI 10.1645/GE-3267; Oliver KG, 1998, CLIN CHEM, V44, P2057; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; Pickering JW, 2002, AM J CLIN PATHOL, V117, P589; Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V113, P388, DOI 10.1016/j.jaci.2003.12.027; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Ree R, 2004, ALLERGY, V59, P571, DOI 10.1111/j.1398-9995.2004.00499.x; Renstrom A, 1997, J ALLERGY CLIN IMMUN, V100, P649, DOI 10.1016/S0091-6749(97)70169-6; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; Taylor JD, 2001, BIOTECHNIQUES, V30, P661, DOI 10.2144/01303dd04; Tsay A., 2002, Clinical and Experimental Allergy, V32, P1596, DOI 10.1046/j.1365-2222.2002.01533.x; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vailes L. D., 2004, Journal of Allergy and Clinical Immunology, V113, pS137, DOI 10.1016/j.jaci.2003.12.491; Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; Willman JH, 2001, AM J CLIN PATHOL, V115, P764, DOI 10.1309/3F13-739A-NA7F-NV3X; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	41	71	73	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					428	433		10.1016/j.jaci.2006.11.004	http://dx.doi.org/10.1016/j.jaci.2006.11.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	137YB	17196246				2022-12-18	WOS:000244327900022
J	Ying, S; Meng, Q; Corrigan, CJ; Lee, TH				Ying, Sun; Meng, Qiu; Corrigan, Chris J.; Lee, Tak H.			Lack of filaggrin expression in the human bronchial mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; EOSINOPHILS; CHEMOKINES; PROTEIN; SKIN		Kings Coll London, Sch Med, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England; MRC, London, England; Asthma United Kingdom Ctr Allerg Mechanisms Asthm, London, England	University of London; King's College London	Ying, S (corresponding author), Kings Coll London, Sch Med, Dept Asthma Allergy & Resp Sci, London WC2R 2LS, England.	chris.corrigan@kcl.ac.uk		Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 1997, J IMMUNOL, V158, P5050; Ying S, 1999, J IMMUNOL, V163, P3976	8	71	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1386	1388		10.1016/j.jaci.2006.08.030	http://dx.doi.org/10.1016/j.jaci.2006.08.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157670				2022-12-18	WOS:000242880300030
J	Burgess, JK; Oliver, BGG; Poniris, MH; Ge, Q; Boustany, S; Cox, N; Moir, LM; Johnson, PRA; Black, JL				Burgess, Janette K.; Oliver, Brian G. G.; Poniris, Maree H.; Ge, Qi; Boustany, Sarah; Cox, Natalie; Moir, Lyn M.; Johnson, Peter R. A.; Black, Judith L.			A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; beta-agonists; corticosteroids; phosphodiesterase inhibitors; fibronectin; connective tissue growth factor; human airway smooth muscle cells	SMOOTH-MUSCLE-CELLS; TISSUE GROWTH-FACTOR; LONG-ACTING BETA(2)-AGONIST; FACTOR-BETA 1; BASEMENT-MEMBRANE; BRONCHIAL HYPERRESPONSIVENESS; FLUTICASONE PROPIONATE; BRONCHOALVEOLAR LAVAGE; EXTRACELLULAR-MATRIX; ADHESION MOLECULES	Background: Airway smooth muscle (ASM) cells may contribute to airway remodeling through the release of growth factors, cytokines, and extracellular matrix (ECM) proteins. The effect of current asthma therapies on this release is not known. Objective: We examined the effect of corticosteroids, long-acting beta(2)-agonists, and a phosphodiesterase 4 (PDE4) inhibitor on ASM-released connective tissue growth factor (CTGF), collagen 1, fibronectin, versican, and IL-6. Methods: Airway smooth muscle cells from individuals with and without asthma were stimulated with TGF-beta with or without the drugs and CTGF and ECM protein expression measured by real-time PCR, cell surface, or matrix-associated ELISA. IL-6 release was measured by ELISA. Bronchial rings from individuals without asthma were incubated with TGF-beta with or without the drugs. Results: Neither corticosteroids nor long-acting beta(2)-agonists reduced TGF-beta-induced CTGF, collagen 1, or fibronectin in either cell type, whereas corticosteroids alone induced the expression of CTGF, collagen 1, and fibronectin. These drugs did not prevent the accumulation of TGF-beta-induced proteins in bronchial rings, whereas the PDE4 inhibitor roflumilast inhibited TGF-beta-induced CTGF, collagen 1, and fibronectin. Conclusion: In our model, current asthma therapies are not able to inhibit matrix protein deposition from ASM cells. The results of this study suggest that the PDE4 inhibitor roflumilast may have a role in regulating the ECM and therefore aspects of airway remodeling in asthma. Clinical implications: Although current asthma therapies are effective in reducing inflammation and symptoms, reversal or prevention of structural changes contributing to remodeling may require additional therapy, which could include PDE4 inhibitors.	Univ Sydney, Dept Pharmacol, Resp Res Grp, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Sydney, NSW, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Burgess, JK (corresponding author), Univ Sydney, Dept Pharmacol, Resp Res Grp, Bosch Bldg,D05, Sydney, NSW 2006, Australia.	janette@pharmacol.usyd.edu.au	Oliver, Brian/E-7939-2010; Ge, Qi/D-3988-2013; Black, Judith L/C-6559-2008; Burgess, Janette K/A-3597-2010; Moir, Lyn/A-8967-2011; Burgess, Janette/M-7117-2019	Oliver, Brian/0000-0002-7122-9262; Burgess, Janette/0000-0001-9868-9966				Aldridge RE, 2000, AM J RESP CRIT CARE, V161, P1459, DOI 10.1164/ajrccm.161.5.9906052; Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Burgess JK, 2006, AM J PHYSIOL-LUNG C, V290, pL153, DOI 10.1152/ajplung.00287.2005; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Chen G, 2002, RESP PHYSIOL NEUROBI, V132, P341, DOI 10.1016/S1569-9048(02)00111-8; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; Dente FL, 1999, THORAX, V54, P622, DOI 10.1136/thx.54.7.622; DURANDARCZYNSKA W, 1993, HISTOCHEMISTRY, V100, P465, DOI 10.1007/BF00267827; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; GRAHAM MF, 1995, GASTROENTEROLOGY, V109, P1454, DOI 10.1016/0016-5085(95)90630-4; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; Johnson PRA, 2006, AM J RESP CRIT CARE, V173, P32, DOI 10.1164/rccm.200406-703OC; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; JOHNSON PRA, 2005, AM J RESP CRIT CARE, V2, pA250; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; McMillan SJ, 2005, CLIN EXP ALLERGY, V35, P388, DOI 10.1111/j.1365-2222.02193.x; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; POIANI GJ, 1994, AM J RESP CRIT CARE, V149, P994, DOI 10.1164/ajrccm.149.4.8143066; Profita M, 2004, ALLERGY, V59, P927, DOI 10.1111/j.1398-9995.2004.00516.x; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Sanz MJ, 2005, PHARMACOL THERAPEUT, V106, P269, DOI 10.1016/j.pharmthera.2004.12.001; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; Tomic R, 2005, CHEST, V127, P257, DOI 10.1378/chest.127.1.257; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; van Schalkwyk E, 2005, J ALLERGY CLIN IMMUN, V116, P292, DOI 10.1016/j.jaci.2005.04.023; Vanacker NJ, 2002, AM J RESP CRIT CARE, V166, P1128, DOI 10.1164/rccm.200203-191OC; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Ward C, 2004, CLIN EXP ALLERGY, V34, P1905, DOI 10.1111/j.1365-2222.2004.02121.x; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047, DOI 10.1164/ajrccm.164.6.2010045	47	71	73	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					649	657		10.1016/j.jaci.2006.05.019	http://dx.doi.org/10.1016/j.jaci.2006.05.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950284				2022-12-18	WOS:000240649000018
J	Bacsi, A; Dharajiya, N; Choudhury, BK; Sur, S; Boldogh, I				Bacsi, A; Dharajiya, N; Choudhury, BK; Sur, S; Boldogh, I			Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen NAD(P)H oxidase; oxidative stress; epithelium; conjunctivitis	MAST-CELL; HYDROGEN-PEROXIDE; SUPEROXIDE-PRODUCTION; STRAND BREAKS; NADPH OXIDASE; OXYGEN; GENERATION; RELEASE; BURST; EOSINOPHILS	Background: Allergic eye diseases are complex inflammatory conditions of the conjunctiva that are becoming increasingly prevalent and present an increasing economic burden because of direct and indirect health expenditures. Objective: We sought to identify factors that may synergize with antigen-induced allergic inflammation and lead to allergic conjunctivitis. We used a murine model of allergic conjunctivitis to test the effect of oxidative stress generated by pollen oxidases using nicotinamide adenine dinuclecifide (reduced) or nicotinamide adenine dinucleotide phosphate (reduced) (NAD[P]H) as an electron donor present in pollen grains. Methods; Reactive oxygen species (ROS) generation by hydrated Ambrosia artemisiifolia pollen (short ragweed pollen; RWP) grains was determined by using 2'-7'-dihydrodichlorofluorescein diacetate, nitroblue tetrazolium reduction, and Amplex Red assay. The RWP-induced changes in intracellular ROS levels were examined in A549 cells, human primary bronchial epithelial cells, and murine conjunctiva. Results: Ragweed pollen grains contain NAD(P)H oxidase activity, which is diphenyleneiodonium-sensitive and quinacrine-sensitive and sodium azide-resistant. These NAD(P)H oxidases generate a superoxide anion that can be converted to H2O2 by pollen grain-associated superoxide dismutase. These diffusible oxygen radicals from pollen grains increase intracellular ROS levels in cultured epithelial cells and murine conjunctiva. Similar phenomena were observed in sensitized and naive mice, indicating that the RWP-induced oxidative stress in conjunctival epithelium is independent of adaptive immunity. Inactivation of NAD(P)H oxidase activity in RWP decreases the immediate-type hypersensitivity and inflammatory cell infiltration into the conjunctiva. Conclusion: Our data suggest that ROS generated by NAD(P)H oxidases in pollen grains intensify immediate allergic reactions and recruitment of inflammatory cells in murine conjunctiva.	Univ Texas, Dept Microbiol & Immunol, Med Branch, Galveston, TX 77555 USA; Univ Texas, Dept Internal Med, Med Branch, Asthma & Allerg Dis Res Ctr, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Boldogh, I (corresponding author), Univ Texas, Dept Microbiol & Immunol, Med Branch, 3-170 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	sboldogh@utmb.edu		Bacsi, Attila/0000-0002-2311-2975	NATIONAL CANCER INSTITUTE [R01CA084461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885, P01AI046004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA84461, R01 CA084461] Funding Source: Medline; NHLBI NIH HHS [R01 HL071163-02, R01-HL071163, R01 HL071163, R01 HL071163-01A2] Funding Source: Medline; NIAID NIH HHS [P01 AI062885-01, P01 AI062885-02, P01 AI46004, P01 AI062885] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES06676, P30 ES006676-09, P30 ES006676-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAGI M, 1994, BIOL PHARM BULL, V17, P732; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; Bagarozzi DA, 1998, PHYTOCHEMISTRY, V47, P593, DOI 10.1016/S0031-9422(97)00634-1; Boldogh I, 2003, TOXICOLOGY, V193, P137, DOI 10.1016/j.tox.2003.08.013; BOLWELL GP, 1995, FREE RADICAL RES, V23, P517, DOI 10.3109/10715769509065273; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350, DOI 10.1165/ajrcmb.23.3.4076; Dechend R, 2003, CIRCULATION, V107, P1632, DOI 10.1161/01.CIR.0000058200.90059.B1; Doke N, 1996, GENE, V179, P45, DOI 10.1016/S0378-1119(96)00423-4; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Frahry G, 2001, PLANTA, V212, P175, DOI 10.1007/s004250000376; Iijima MK, 2001, TOXICOL LETT, V123, P77, DOI 10.1016/S0378-4274(01)00392-7; Jung M, 2000, FREE RADICAL BIO MED, V28, P1295, DOI 10.1016/S0891-5849(00)00211-2; Kalinowski A, 2002, ELECTROPHORESIS, V23, P138, DOI 10.1002/1522-2683(200201)23:1&lt;138::AID-ELPS138&gt;3.0.CO;2-D; Laberge S, 1999, INT ARCH ALLERGY IMM, V119, P120, DOI 10.1159/000024186; Leonardi A, 1999, ACTA OPHTHALMOL SCAN, V77, P21, DOI 10.1111/j.1600-0420.1999.tb01167.x; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; Matsuda F, 2001, Z NATURFORSCH C, V56, P228; Messner KR, 2002, METHOD ENZYMOL, V349, P354, DOI 10.1016/S0076-6879(02)49351-2; Michalec L, 2002, J IMMUNOL, V168, P846, DOI 10.4049/jimmunol.168.2.846; Murphy TM, 1998, PLANT PHYSIOL, V117, P1301, DOI 10.1104/pp.117.4.1301; OGASAWARA H, 1991, Auris Nasus Larynx, V18, P133; Papadakis AK, 1999, PLANT PHYSIOL, V121, P197, DOI 10.1104/pp.121.1.197; PEDEN DB, 1994, AM J PHYSIOL, V267, pL85, DOI 10.1152/ajplung.1994.267.1.L85; Riediker M, 2001, ANN ALLERG ASTHMA IM, V87, P311, DOI 10.1016/S1081-1206(10)62246-6; Rodriguez AA, 2002, PLANT PHYSIOL, V129, P1627, DOI 10.1104/pp.001222; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725, DOI 10.1164/ajrccm.151.6.7767513; Santos FX, 2000, BURNS, V26, P145, DOI 10.1016/S0305-4179(99)00021-2; Schopfer P, 2001, PLANT PHYSIOL, V125, P1591, DOI 10.1104/pp.125.4.1591; Steiner DRS, 2003, J APPL PHYSIOL, V94, P325, DOI 10.1152/japplphysiol.00637.2002; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Sweetlove LJ, 2002, PLANT J, V32, P891, DOI 10.1046/j.1365-313X.2002.01474.x; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; VanGestelen P, 1997, PLANT PHYSIOL, V115, P543, DOI 10.1104/pp.115.2.543; Watkins MT, 1999, BIOCHEM J, V344, P747, DOI 10.1042/0264-6021:3440747; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Wolfreys K, 1997, EUR J IMMUNOL, V27, P297, DOI 10.1002/eji.1830270143; Yoshimaru T, 2002, CLIN EXP ALLERGY, V32, P612, DOI 10.1046/j.0954-7894.2002.01263.x; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zuo L, 2000, AM J PHYSIOL-CELL PH, V279, pC1058, DOI 10.1152/ajpcell.2000.279.4.C1058	45	71	86	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					836	843		10.1016/j.jaci.2005.06.002	http://dx.doi.org/10.1016/j.jaci.2005.06.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210058	Green Submitted, Green Accepted			2022-12-18	WOS:000235686600018
J	Graves, PE; Siroux, V; Guerra, S; Klimecki, WT; Martinez, FD				Graves, PE; Siroux, V; Guerra, S; Klimecki, WT; Martinez, FD			Association of atopy and eczema with polymorphisms in T-cell immunoglobulin domain and mucin domain - IL-2-inducible T-cell kinase gene cluster (i)n chromosome 5q33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; eczema; TIM; ITK; polymorphisms	ASTHMA-SUSCEPTIBILITY LOCI; GENOME-WIDE SEARCH; FALSE DISCOVERY RATE; HEPATITIS-A; HAPLOTYPE RECONSTRUCTION; POPULATION; ITK; CHILDREN; DISEASE; FAMILY	Background: The T-cell immunoglobulin domain and mucin domain (TIM) gene family and the gene for IL-2-inducible T-cell kinase (ITK), located in chromosome 5q33 and potentially involved in the T-cell proliferation and differentiation, are good candidate genes for allergic diseases. Objective: We assessed the role of polymorphisms in the TIM family genes and ITK in atopy, eczema, and asthma. Methods: Twenty-one polymorphisms in the TIM-ITK gene cluster were genotyped in 564 children enrolled in the Tucson Children's Respiratory Study. Skin prick tests to common allergens were performed at age 6.1 years (n = 508), age 10.8 years (n = 539), and age 16.6 years (n = 424). Asthma and eczema were assessed by questionnaire at these 3 points. Averaged relative risks were estimated. Results: One 15-bp insertion/deletion in exon 4 of TIM1 was significantly related to atopy and eczema (relative risk associated with carrying at least 1 rare allele = 1.24 [1.07-1.45], P = .005; and 1.43 [1.01-2.01], P = .004, respectively). The 3 tested single nucleotide polymorphisms (SNPs) in TIM3 were significantly related to atopy and eczema. One of them, at position +4259 calculated from the translation start site, predicts a putative change in the amino acid sequence of the protein, and was the most strongly related to atopy (relative risk = 1.28 [1.12-1.47]; P = .0003). SNPs in the 5' genomic region in ITK, which show moderate linkage disequilibrium with those in TIM3, had an independent effect on atopy. None of the polymorphisms studied was related to asthma. Conclusion: Our findings support a potential role for SNPs in TIM1, TIM3, and ITK, independent of each other, in allergic diseases.	Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona	Graves, PE (corresponding author), Univ Arizona, Arizona Resp Ctr, 1501 N Campbell Ave,PO 245030, Tucson, AZ 85724 USA.	pgraves@u.arizona.edu	siroux, valerie/N-1865-2013	siroux, valerie/0000-0001-7329-7237	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066447, R01HL056177] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56177, HL-66447] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chae SC, 2003, BIOCHEM BIOPH RES CO, V312, P346, DOI 10.1016/j.bbrc.2003.10.125; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Holberg CJ, 2001, J ALLERGY CLIN IMMUN, V108, P772, DOI 10.1067/mai.2001.119158; Kanner SB, 2003, TRENDS IMMUNOL, V24, P249, DOI 10.1016/S1471-4906(03)00071-1; Khademi M, 2004, J IMMUNOL, V172, P7169, DOI 10.4049/jimmunol.172.11.7169; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Marsh DG, 1997, NAT GENET, V15, P389; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Noguchi E, 2003, GENES IMMUN, V4, P170, DOI 10.1038/sj.gene.6363935; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Redlinger T, 1997, AM J PUBLIC HEALTH, V87, P1715, DOI 10.2105/AJPH.87.10.1715; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Sabatti C, 2003, GENETICS, V164, P829; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schaeffer EM, 2001, NAT IMMUNOL, V2, P1183, DOI 10.1038/ni734; SHAPIRO CN, 1992, VACCINE S1, V10, P59; STEINKE JW, 2003, J ALLERGY CLIN IMMUN, V11, pS495; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Wills-Karp M, 2003, NAT IMMUNOL, V4, P1050, DOI 10.1038/ni1103-1050; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	31	71	88	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					650	656		10.1016/j.jaci.2005.05.004	http://dx.doi.org/10.1016/j.jaci.2005.05.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159638	Bronze			2022-12-18	WOS:000235686500028
J	Sicherer, SH; Simons, FER				Sicherer, SH; Simons, FER			Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; self-injectable epinephrine; adrenaline; allergic reaction; food allergy; insect sting allergy	TREE NUT ALLERGY; UNITED-STATES; FOOD HYPERSENSITIVITY; ATOPIC-DERMATITIS; YOUNG-CHILDREN; PEANUT; EPIDEMIOLOGY; POPULATION; PREVALENCE; CHILDHOOD	Anaphylaxis often occurs in the community in the absence of a health care professional. Prompt administration or self-injectable epinephrine as first-aid treatment in the context of a personalized emergency action plan is the key to survival. There is little argument that physicians should prescribe self-injectable epinephrine for individuals who have already experienced anaphylaxis involving respiratory distress or shock triggered by allergens that might be encountered in the community. A quandary faced by physicians is that additional individuals with identified allergy who have no recognized prior history of anaphylaxis or who have a history of mild symptoms after exposure to a known trigger might also be at risk for subsequent life-threatening anaphylaxis and might also warrant prescription of self-injectable epinephrine. Prescribing for the latter individuals requires considerable clinical judgment and has led to controversy regarding possible overprescription or underprescription of self-injectable epinephrine. A second quandary for physicians occurs with regard to the advice they should give to at-risk individuals about actual use of their self-injectable epinephrine. It is difficult for health care professionals, let alone persons with no health care training, to predict whether anaphylaxis symptoms will occur in an at-risk individual after exposure to a known trigger. Moreover, at the onset of an acute allergic reaction, it is difficult to predict the symptoms that will ultimately develop. We examine these 2 common quandaries and provide examples of clinical scenarios and potential pitfalls in the management of persons identified as being at risk for anaphylaxis in the community. Additional studies of the recognition and treatment of anaphylaxis in the community are needed to develop comprehensive, evidence-based recommendations for its management in this setting.	Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, New York, NY 10029 USA; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada	Icahn School of Medicine at Mount Sinai; University of Manitoba; University of Manitoba	Sicherer, SH (corresponding author), Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			NCRR NIH HHS [RR 00071] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; Barbi E, 2004, ALLERGY, V59, P668, DOI 10.1111/j.1398-9995.2004.00398.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Boros CA, 2000, J PAEDIATR CHILD H, V36, P36, DOI 10.1046/j.1440-1754.2000.00444.x; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Cianferoni A, 2004, ANN ALLERG ASTHMA IM, V92, P464, DOI 10.1016/S1081-1206(10)61784-X; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; Davis CO, 1999, PEDIATR EMERG CARE, V15, P116, DOI 10.1097/00006565-199904000-00011; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Foucard T, 1999, ALLERGY, V54, P261, DOI 10.1034/j.1398-9995.1999.00924.x; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; GRABENSTEIN JD, 1989, ANN ALLERGY, V63, P184; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Hu W, 2004, BMJ-BRIT MED J, V329, P852, DOI 10.1136/bmj.329.7470.852; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; Ma SH, 2003, J ALLERGY CLIN IMMUN, V112, P784, DOI 10.1016/S0091-6749(03)02008-6; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Pastorello EA, 2001, J CHROMATOGR B, V756, P11, DOI 10.1016/S0378-4347(01)00067-6; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; SIMONS FER, 2004, INT J WORKD ALLERG S, P242; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	52	71	71	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					575	583		10.1016/j.jaci.2004.12.1122	http://dx.doi.org/10.1016/j.jaci.2004.12.1122			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753907				2022-12-18	WOS:000227687000022
J	MacGlashan, D; Miura, K				MacGlashan, D; Miura, K			Loss of syk kinase during IgE-mediated stimulation of human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells/basophils; signal transduction; kinases; desensitization; secretion	SIGNAL-TRANSDUCTION PATHWAY; FC-EPSILON-RI; TYROSINE KINASE; C-CBL; MESSENGER-RNA; PROTEIN; PHOSPHORYLATION; DESENSITIZATION; ACTIVATION; RBL-2H3	Background: Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing. Objective: To determine the long-term effects of FcepsilonRI aggregation on expression of syk kinase. Methods: Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation. Results: Stimulation results in a 20% loss of syk in I hour and an 80% loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder. Conclusions: Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Miyagi Childrens Hosp, Div Gen Pediat, Sendai, Miyagi, Japan	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			NIAID NIH HHS [AI20253] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; GILBERT HS, 1975, BLOOD, V46, P279; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Komiya A, 2003, INT ARCH ALLERGY IMM, V130, P40, DOI 10.1159/000068374; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MacGlashan D, 2003, J IMMUNOL, V170, P4914, DOI 10.4049/jimmunol.170.10.4914; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V68, P101, DOI 10.1159/000233076; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miura K, 2001, J IMMUNOL, V167, P7027, DOI 10.4049/jimmunol.167.12.7027; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; PRUZANSKY JJ, 1988, IMMUNOLOGY, V65, P443; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3; Youssef LA, 2002, J ALLERGY CLIN IMMUN, V110, P366, DOI 10.1067/mai.2002.127562; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	28	71	73	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1317	1324		10.1016/j.jaci.2004.08.037	http://dx.doi.org/10.1016/j.jaci.2004.08.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577829	Bronze			2022-12-18	WOS:000225577400010
J	Nguyen, XD; Robinson, DS				Nguyen, XD; Robinson, DS			Fluticasone propionate increases CD4(+)CD25(+) T regulatory cell suppression of allergen-stimulated CD4(+)CD25(-) T cells by an IL-10-dependent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticosteroids; allergy; T lymphocytes; IL-10	CYTOKINE GENE-EXPRESSION; PREDNISOLONE TREATMENT; IN-VITRO; ASTHMA; INTERLEUKIN-10; DISEASE; IL-10; CORTICOSTEROIDS; MODULATION; ACTIVATION	Background: Corticosteroids are the most effective antiinflammatory therapy for allergic diseases, and these drugs inhibit T(H)2 T-cell activation. We previously reported that CD4(+)CD25(+) T cells from atopic donors suppressed allergen-stimulated T cells less than those from nonatopic donors. Objective: We sought to determine the effect of fluticasone propionate (FP) on allergen-stimulated CD4(+)CD25(-) T cells and on the suppressive ability of CD4(+)CD25(+) T cells. Methods: CD4(+)CD25(+) and CD4(+)CD25(-) T cells were separated from peripheral blood of atopic and nonatopic volunteers and cultured alone or mixed in the presence of allergen. Effects of FP were assessed by means of addition to cultures or preincubation with CD4(+)CD25(+) T cells. Results: FP inhibited allergen-stimulated proliferation of CD4(+)CD25(-) T cells in a dose-dependent manner. Preincubation of CD4(+)CD25(+) T cells in FP increased subsequent suppressive activity of these cells in allergen-stimulated cultures with CD4(+)CD25(-) T cells. This effect was seen when cells were obtained from both nonatopic and atopic donors but was less for cells obtained from atopic individuals. Prior exposure of CD4(+)CD25(+) T cells to FP also increased subsequent IL-10 production by these cells when stimulated with allergen, and addition of anti-IL-10 antibody reversed the steroid-induced enhancement of suppression in mixed cultures. Conclusion: Increased suppression by CD4(+)CD25(+) T cells might play a role in anti-inflammatory effects of corticosteroids in asthma and allergic diseases.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci & Allergy & Clin Immunol, Leukocyte Biol Sect,Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London	Robinson, DS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	d.s.robinson@imperial.ac.uk						Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; *BRIT THOR SOC, 2003, THORAX S1, V58, pI1; Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Ellis C, 2003, BRIT J DERMATOL, V148, P3, DOI 10.1046/j.1365-2133.148.s63.1.x; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; MAGGI E, 1991, J IMMUNOL, V146, P1169; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Richards DF, 2000, EUR J IMMUNOL, V30, P2344, DOI 10.1002/1521-4141(2000)30:8<2344::AID-IMMU2344>3.0.CO;2-7; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272	29	71	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					296	301		10.1016/j.jaci.2004.04.048	http://dx.doi.org/10.1016/j.jaci.2004.04.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316506	Bronze			2022-12-18	WOS:000223405600013
J	Roy, SR; Schiltz, AM; Marotta, A; Shen, YQ; Liu, AH				Roy, SR; Schiltz, AM; Marotta, A; Shen, YQ; Liu, AH			Bacterial DNA in house and farm barn dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						farm barn; dust; DNA; bacterial DNA; endotoxin; IL-10; IL-12; hygiene; CpG DNA	TOLL-LIKE RECEPTORS; STIMULATORY CPG MOTIFS; MURINE MODEL; IMMUNOSTIMULATORY DNA; AIRWAY INFLAMMATION; ENDOTOXIN EXPOSURE; INNATE IMMUNITY; HUMAN MONOCYTES; CUTTING EDGE; TNF-ALPHA	Background: Early in life, natural exposure to microbial components (eg, endotoxin) may mitigate allergy and asthma development in childhood. Bacterial DNA is a potent stimulus for the innate immune system; its immune stimulatory potential in dust is unknown. Objectives: We sought to quantify bacterial DNA and endotoxin content in dust from urban homes, rural homes, farm homes, and farm barns and to determine if dust DNA is immune-stimulatory. Methods: Total DNA, bacterial DNA, and endotoxin were measured in 32 dust samples. To measure bacterial DNA content, a quantitative polymerase chain reaction assay specific for bacterial ribosomal DNA was developed. Peripheral blood mononuclear cells from 5 adults were stimulated with endotoxin-free dust DNA with/without lipopolysaccharide (LPS) from selected dust samples. IL-12p40, IL-10, and tumor necrosis factor-a were measured in cell supernatants by enzyme-linked immunosorbent assay. Results: Bacterial DNA in dust correlated with endotoxin (r 0.56, P < .001) and total DNA content (r = 0.51, P = .003). The highest bacterial DNA levels were measured in farm barns (mean, 22.1 mug/g dust; range, 1.3 to 56.2), followed by rural homes (6.3 mug/g; 0.2 to 20), farm homes (2.2 mug/g; 0.1 to 9.1), and urban homes (0.6 mug/g; 0.1 to 1.2). Farm barn DNA significantly potentiated (P less than or equal to .05) LPS-induced IL-10 and IL-12 p40 but not tumor necrosis factor-alpha release (13-fold, 3-fold, and 1.5-fold increases, respectively). DNA from 6 urban homes did not demonstrate this LPS-potentiating effect. Conclusions: Endotoxin is a marker for bacterial DNA, which is also higher in locales of lower asthma and allergy prevalence. DNA from farm barn dust augments the immune modulatory effects of endotoxin and may combine with exposure to other such naturally occurring microbial components to mitigate allergy and asthma development.	Natl Jewish Med & Res Ctr, Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Pediat Allergy & Immunol, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004272] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL 04272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bohle B, 2001, J IMMUNOL, V166, P3743, DOI 10.4049/jimmunol.166.6.3743; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burgmann H, 2001, J MICROBIOL METH, V45, P7, DOI 10.1016/S0167-7012(01)00213-5; Chen Y, 2001, GENE THER, V8, P1024, DOI 10.1038/sj.gt.3301482; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cowdery J, 1996, J IMMUNOL, V156, P4570; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Fry NK, 1997, APPL ENVIRON MICROB, V63, P1498, DOI 10.1128/AEM.63.4.1498-1504.1997; Fujieda S, 2000, AM J RESP CRIT CARE, V162, P232, DOI 10.1164/ajrccm.162.1.9906136; Gao JJ, 1999, J IMMUNOL, V163, P4095; Gao JJ, 2001, J IMMUNOL, V166, P6855, DOI 10.4049/jimmunol.166.11.6855; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; HAN J, 1994, ANTISENSE RES DEV, V4, P53, DOI 10.1089/ard.1994.4.53; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HERGERSBERG M, 1991, EXPERIENTIA, V47, P1171, DOI 10.1007/BF01918381; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Krieg AM, 1998, J IMMUNOL, V161, P2428; LEYS EJ, 1994, J CLIN MICROBIOL, V32, P1288, DOI 10.1128/JCM.32.5.1288-1294.1994; Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lyons SR, 2000, J CLIN MICROBIOL, V38, P2362; Maniatis T., 1989, MOL CLONING LAB MAN; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Parronchi P, 1999, J IMMUNOL, V163, P5946; Pisetsky DS, 2000, CLIN IMMUNOL, V96, P198, DOI 10.1006/clim.2000.4897; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Schwartz DA, 1999, J IMMUNOL, V163, P224; Stach JEM, 2001, FEMS MICROBIOL ECOL, V36, P139, DOI 10.1111/j.1574-6941.2001.tb00834.x; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wakkach A, 2000, EUR CYTOKINE NETW, V11, P153; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x; Yeates C, 1998, Biol Proced Online, V1, P40, DOI 10.1251/bpo6; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391	60	71	76	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					571	578		10.1067/mai.2003.1711	http://dx.doi.org/10.1067/mai.2003.1711			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679817				2022-12-18	WOS:000185231200017
J	Cocco, RR; Jarvinen, KM; Sampson, HA; Beyer, K				Cocco, RR; Jarvinen, KM; Sampson, HA; Beyer, K			Mutational analysis of major, sequential IgE-binding epitopes in alpha(s1)-casein, a major cow's milk allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B-cell epitope; alpha(s1)-casein; children; cow's milk allergy; immunoglobulin E; linear; mutational analysis; SPOTs membrane	1ST 3 YEARS; IDENTIFICATION; PROTEIN; CHILDREN	Background: Allergy to cow's milk is common in early childhood, and no therapy other than avoidance exists. In murine models of peanut allergy, immunotherapy with mutated, engineered, proteins appears promising. Objective: We sought to identify the critical amino acids (AAs) for immunoglobulin E (IgE) binding within the major B-cell epitopes of alpha(S1)-casein, a major cow's milk allergen. This will provide the necessary information to alter the cDNA to encode a protein capable of activating milk-specific T cells, but with reduced IgE-binding capacity. Methods: For mutational analysis of the IgE-binding epitopes, peptides of 10-14 AAs in length were synthesized on a derivatized cellulose membrane with single or multiple AA substitutions. Membranes were immunolabeled with pooled sera from 15 cow's-milk-allergic patients and with 8 individual sera. Results: With the pooled sera, substitution of a single AA led to complete abrogation of IgE binding to 2 of 8 peptides and diminished binding in the remainder. Substitution of multiple AAs led to an abrogation of binding in the remaining peptides. In 4 of the 8 peptides, the critical AA identified with pooled sera did not result in significant reduction of IgE binding with I or more individual patients. For these patients, other critical AAs were identified, indicating a more heterogeneous pattern in IgE recognition. Conclusion: This study indicates that single or multiple AA substitutions within IgE-binding epitopes result in reduced binding of milk-specific IgE antibodies by patients' sera. However. for future immunotherapeutic interventions with mutated peptides, critical AAs should be evaluated with individual patient sera to determine B-cell-epitope heterogeneity.	Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Berlin, Germany; Mt Sinai Sch Med, Jaffe Inst Food Allergy, Berlin, Germany		Beyer, K (corresponding author), Charite CVK, Dept Pediat, Augustenburgerpl 1, D-13353 Berlin, Germany.				NCRR NIH HHS [M01 RR00071] Funding Source: Medline; NIAID NIH HHS [AI 24439, AI 44236] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; BOCK SA, 1987, PEDIATRICS, V79, P683; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; HOST A, 1995, EUR J CLIN NUTR, V49, pS13; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Host A, 1997, J ALLERGY CLIN IMMUN, V99, P1988; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; KOHNO Y, 1994, ANN ALLERGY, V73, P419; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; Lehrer SB, 2002, ANN NY ACAD SCI, V964, P69; Li XM, 2002, CURR OPIN ALLERGY CL, V2, P273, DOI 10.1097/00130832-200206000-00019; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Robotham JM, 2002, J ALLERGY CLIN IMMUN, V109, P143, DOI 10.1067/mai.2002.120558; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; STOGER P, 1993, INT ARCH ALLERGY IMM, V102, P399, DOI 10.1159/000236589; Swaisgood H., 1985, FOOD CHEM, V2, P796; Wal JM, 1998, ALLERGY, V53, P1013, DOI 10.1111/j.1398-9995.1998.tb03811.x	25	71	81	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					433	437		10.1067/mai.2003.1617	http://dx.doi.org/10.1067/mai.2003.1617			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897753				2022-12-18	WOS:000184650600031
J	Ho, J; Bender, BG; Gavin, LA; O'Connor, SL; Wamboldt, MZ; Wamboldt, FS				Ho, J; Bender, BG; Gavin, LA; O'Connor, SL; Wamboldt, MZ; Wamboldt, FS			Relations among asthma knowledge, treatment adherence, and outcome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma knowledge; treatment adherence; asthma outcomes	SELF-MANAGEMENT; PARENTAL KNOWLEDGE; RELIABILITY; MORBIDITY; VALIDITY; CHILDREN	Background: Asthma knowledge is frequently assumed to be a prerequisite for optimal asthma treatment. However, the validity of existing asthma knowledge questionnaires has not been rigorously examined, and no contemporary measure of asthma knowledge has received widespread acceptance. Objective: To construct and examine the psychometric properties of an asthma knowledge instrument, and its association with demographic and psychosocial variables, asthma medication adherence, and treatment outcome. Methods: A 25-item Asthma Knowledge Questionnaire was developed with input from national pediatric asthma experts. Parents of 155 children with asthma completed the Asthma Knowledge Questionnaire as well as demographic, family functioning, and home environment measures. Asthma outcomes and adherence with inhaled medication was measured across 12 months. Results: Despite the many steps taken to develop a strong measure of asthma knowledge, reliability was relatively poor. There was also no association between asthma knowledge and treatment adherence or outcomes. Furthermore, asthma knowledge was not a unidimensional construct and was not a simple function of education. Conclusions: Findings from this study, in combination with previous studies of asthma knowledge questionnaires, suggest that the construction of a simple self-report asthma knowledge instrument for use as a primary outcome measure demonstrating mastery of asthma self-management skills may not be achievable. (J Allergy Clin Immunol 2003;111:498-502.).	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Denver, Denver, CO 80208 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	National Jewish Health; University of Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Wamboldt, FS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,A114, Denver, CO 80206 USA.		Ho, Joyce/F-8664-2019	Ho, Joyce/0000-0003-4191-0054	NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [R01-HL53391] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053391] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen RM, 1998, J ASTHMA, V35, P537, DOI 10.3109/02770909809048956; BERNARDBONNIN AC, 1995, J ALLERGY CLIN IMMUN, V95, P34, DOI 10.1016/S0091-6749(95)70150-8; Bertolotti G, 2001, Monaldi Arch Chest Dis, V56, P11; BROOK U, 1993, J ASTHMA, V30, P45, DOI 10.3109/02770909309066379; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FITZCLARENCE CAB, 1990, J PAEDIATR CHILD H, V26, P200, DOI 10.1111/j.1440-1754.1990.tb02429.x; Hollingshead A., 2011, 4 FACTOR INDEX SOCIA, V8; Kolbe J, 1996, CHEST, V109, P86, DOI 10.1378/chest.109.1.86; Meyer IH, 2001, J ASTHMA, V38, P531, DOI 10.1081/JAS-100107117; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moosa SEI, 1997, S AFR MED J, V87, P42; National Heart Lung Blood Institute, 1997, 2 NAT HEART LUNG BLO; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wade SL, 2000, J DEV BEHAV PEDIATR, V21, P340, DOI 10.1097/00004703-200010000-00004; Wamboldt FS, 2002, J PEDIATR-US, V141, P109, DOI 10.1067/mpd.2002.125490; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008	21	71	74	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					498	502		10.1067/mai.2003.160	http://dx.doi.org/10.1067/mai.2003.160			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642828				2022-12-18	WOS:000181639500009
J	Lee, YC; Lee, HK				Lee, YC; Lee, HK			Vascular endothelial growth factor in patients with acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Chonbuk Natl Univ, Sch Med, Dept Internal Med, Chonju 560180, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Res Inst Clin Med, Chonju 560180, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Dept Immunol, Chonju 560180, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Chonju 560180, Chonbuk, South Korea.							COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P39; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FOSTER WM, 1982, ANN OCCUP HYG, V26, P227, DOI 10.1093/annhyg/26.2.227; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Persson CGA, 1996, AM J RESP CRIT CARE, V153, pS9, DOI 10.1164/ajrccm/153.6_Pt_2.S9	5	71	74	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1106	1106		10.1067/mai.2001.115628	http://dx.doi.org/10.1067/mai.2001.115628			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398093				2022-12-18	WOS:000169454800027
J	Lemiere, C; Chaboillez, S; Malo, JL; Cartier, A				Lemiere, C; Chaboillez, S; Malo, JL; Cartier, A			Changes in sputum cell counts after exposure to occupational agents: What do they mean?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; induced sputum; eosinophils; airway hyperresponsiveness	NONSPECIFIC BRONCHIAL REACTIVITY; RED CEDAR ASTHMA; AIRWAY INFLAMMATION; TOLUENE DIISOCYANATE; EOSINOPHILIC BRONCHITIS; ALLERGIC RHINITIS; HYPERRESPONSIVENESS; MECHANISMS; DIAGNOSIS; RESPONSES	Background: Exposure to occupational agents can induce eosinophilic inflammation in subjects with occupational asthma (OA), It might also induce nonspecific changes in airway inflammation in subjects without OA, Objectives: We sought to investigate the changes in airway inflammation induced by exposure to occupational agents in subjects with and without OA and to determine which changes in sputum eosinophil numbers and bronchial responsiveness to methacholine should be regarded as clinically significant for predicting a 20% fall in FEV1. Methods: We performed specific inhalation challenges (SICs) in 3 groups of subjects: subjects reporting a history consistent with OA with a positive SIC response (n = 17); subjects reporting a history consistent with OA with a negative SIC response (n = 14); and asthmatic subjects without any history of OA (n = 10). Induced sputum and methacholine challenges were performed at the end of the control day and again at the end of the last day of exposure; the last day of exposure was always performed in the laboratory. Results: There was an increase in median sputum eosinophil and neutrophil numbers in subjects with positive SIC responses. Cell counts remained unchanged after exposure in asthmatic subjects without OA, A combination of a greater than 0.26 10(6)/mL increase in sputum eosinophil numbers and a decrease in the concentration of methacholine inducing a 20% fall in FEV1 of at least 1.8-fold compared with baseline values predicted a 20% fall in FEV1 in 96% (95% CI, 70%-99%) of patients. Conclusion: Exposure to occupational agents per se does not induce airway inflammation. Changes in both sputum eosinophil counts and methacholine responsiveness are satisfactory predictors of a significant bronchial responsiveness to occupational agents.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada	Universite de Montreal	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 W Gouin, Montreal, PQ H4J 1C5, Canada.							Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; Chakir J, 1996, LAB INVEST, V75, P735; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; CLOUTIER Y, 1992, CHEST, V102, P402, DOI 10.1378/chest.102.2.402; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; FABBRI L, 1991, EUR RESPIR J, V4, P136; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FABBRI LM, 1999, ASTHMA WORKPLACE, P81; GIBSON PG, 1989, LANCET, V1, P1346; Gutierrez V, 1998, ANN ALLERG ASTHMA IM, V81, P143, DOI 10.1016/S1081-1206(10)62801-3; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; Leigh R, 1999, Can Respir J, V6, P194; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976, DOI 10.1164/ajrccm.162.3.9910031; Lemiere C, 1997, J ALLERGY CLIN IMMUN, V100, P852, DOI 10.1016/S0091-6749(97)70286-0; Lemiere C, 1996, ALLERGY, V51, P262; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P47, DOI 10.1111/j.1365-2222.1997.tb01826.x; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; *NAT ASTHM ED PROG, 1991, NAT ASTHM ED PROGR P, V913; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Park HS, 1998, CLIN EXP ALLERGY, V28, P724, DOI 10.1046/j.1365-2222.1998.00299.x; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; VANDENPLAS O, 1991, AM REV RESPIR DIS, V145, P582; Wong AG, 1996, EUR RESPIR J, V9, P2174, DOI 10.1183/09031936.96.09102174	34	71	73	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1063	1068		10.1067/mai.2001.115486	http://dx.doi.org/10.1067/mai.2001.115486			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398086				2022-12-18	WOS:000169454800020
J	Pecquet, S; Bovetto, L; Maynard, F; Fritsche, R				Pecquet, S; Bovetto, L; Maynard, F; Fritsche, R			Peptides obtained by tryptic hydrolysis of bovine beta-lactoglobulin induce specific oral tolerance in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta-lactoglobulin; cow's milk allergy; IgE; allergenicity; cow's milk protein hydrolyzate; hypoallergenicity; oral tolerance; trypsin; tryptic peptides	WHEY HYDROLYSATE; ATOPIC DISEASE; ALLERGIC DISORDERS; IMMUNE-RESPONSES; PROTEIN ANTIGENS; T-CELL; ALLERGENICITY; PROPHYLAXIS; PREVALENCE; ANTIBODY	Background: Oral tolerance against food proteins has been achieved in different animal models with use of native or moderately hydrolyzed proteins as inducers. However, native proteins remain highly allergenic, although it has been demonstrated that protein hydrolyzates and resulting peptides can lose their allergenicity. Objective: This study was designed to evaluate the ability of beta-lactoglobulin hydrolyzate and peptides to induce oral tolerance to native beta-lactoglobulin and to identify tolerogenic beta-lactoglobulin peptides with low allergenicity. Methods: beta-Lactoglobulin was hydrolyzed by trypsin and fractionated by ion exchange chromatography. Peptide enrichment of fractions was evaluated. Balb/c mice were fed beta-lactoglobulin hydrolyzate or fractions by single gavage at day 1. Five days later animals were challenged intraperitoneally with native beta-lactoglobulin. At day 27 delayed-type hypersensitivity was performed. Twenty-four hours later mice were bled, and intestinal contents and spleens were collected. Oral tolerance was measured by titrating specific IgE in sera and intestinal samples. Specific T-cell responses were analyzed by splenocyte proliferation. Antigenicity of hydrolyzate and fractions was evaluated by specific ELISA inhibition, Results: Mice fed either beta-lactoglobulin hydrolyzate or 2 fractions of the hydrolyzate were tolerized against beta-lactoglobulin. Specific serum and intestinal IgE were suppressed. Delayed-type hypersensitivity and proliferative responses were inhibited. One tolerogenic fraction was found to be 50 times less antigenic than the total beta-lactoglobulin hydrolyzate was. Conclusion: These findings support the strategy of inducing oral tolerance in "at-risk" patients by means of tolerogenic cow's milli, peptides or hydrolyzate.	Nestec Ltd, Nestle Res Ctr, Food Immunol Grp, CH-1000 Lausanne, Switzerland; Nestec Ltd, Nestle Res Ctr, Food Sci Grp, CH-1000 Lausanne, Switzerland	Nestle SA; Nestle SA	Pecquet, S (corresponding author), Nestec Ltd, Nestle Res Ctr, Food Immunol Grp, BP44, CH-1000 Lausanne, Switzerland.							ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; ASSELIN J, 1989, J FOOD SCI, V54, P1037, DOI 10.1111/j.1365-2621.1989.tb07938.x; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; DESETA L, 1994, MED SURG PED, V16, P251; ELSON CO, 1984, J IMMUNOL METHODS, V67, P101, DOI 10.1016/0022-1759(84)90089-9; ELSON CO, 1985, SCAND J GASTROENTERO, V20, P1, DOI 10.3109/00365528509093764; ENOMOTO A, 1993, CLIN IMMUNOL IMMUNOP, V66, P136, DOI 10.1006/clin.1993.1017; Fritsche R, 1997, J ALLERGY CLIN IMMUN, V100, P266, DOI 10.1016/S0091-6749(97)70235-5; HACHIMURA S, 1993, BIOSCI BIOTECH BIOCH, V57, P1674, DOI 10.1271/bbb.57.1674; HACHIMURA S, 1994, INT IMMUNOL, V6, P1791, DOI 10.1093/intimm/6.11.1791; HOYNE GF, 1994, IMMUNOLOGY, V83, P190; HUSBY S, 1994, J IMMUNOL, V152, P4663; KAUFMAN HS, 1972, ARCH DERMATOL, V105, P400, DOI 10.1001/archderm.105.3.400; KURISAKI J, 1982, AGR BIOL CHEM TOKYO, V46, P2069, DOI 10.1080/00021369.1982.10865389; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; Matsui M, 1996, ANN NY ACAD SCI, V778, P398, DOI 10.1111/j.1749-6632.1996.tb21156.x; Maynard F, 1998, INT DAIRY J, V8, P125, DOI 10.1016/S0958-6946(98)00030-2; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; PAHUD JJ, 1985, J PEDIATR GASTR NUTR, V4, P408, DOI 10.1097/00005176-198506000-00015; Pecquet S, 1999, IMMUNOLOGY, V96, P278, DOI 10.1046/j.1365-2567.1999.00678.x; SAMPSON HA, 1990, CURR OPIN IMMUNOL, V2, P542, DOI 10.1016/0952-7915(90)90008-5; SCHMIDT E, 1995, NESTLE NUTR WORKS SE, V34, P231; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TAKAHASHI I, 1995, BIOCHEM BIOPH RES CO, V206, P414, DOI 10.1006/bbrc.1995.1057; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WILLEMS R, 1993, ANN ALLERGY, V71, P147	29	71	76	3	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					514	521		10.1067/mai.2000.103049	http://dx.doi.org/10.1067/mai.2000.103049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719302	Bronze			2022-12-18	WOS:000088946700018
J	Silkoff, PE; Robbins, RA; Gaston, B; Lundberg, JON; Townley, RG				Silkoff, PE; Robbins, RA; Gaston, B; Lundberg, JON; Townley, RG			Endogenous nitric oxide in allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; nasal; asthma; rhinitis	UPPER RESPIRATORY-TRACT; EXHALED AIR; ASTHMATIC-PATIENTS; CYSTIC-FIBROSIS; MILD ASTHMA; IN-VITRO; EPITHELIAL-CELLS; NASAL-MUCOSA; RAT LUNG; SYNTHASE	There has been intense research into the role nitric oxide (NO) plays in physiologic and pathologic mechanisms. The presence of NO in exhaled breath and the high concentrations in nasal airways stimulated many studies examining exhaled and nasal NO as potential markers of airway inflammation, enabling repeated monitoring of airway inflammation not possible with invasive tests (eg, bronchoscopy). In airway inflammation, NO is not merely a marker but may have anti-inflammatory and proinflammatory effects. Nasal NO measurement may be used in the noninvasive diagnosis and monitoring of nasal disease, This review was compiled by speakers who gave presentations on NO at the annual meeting of the American Academy of Allergy, Asthma, and Immunology in 1999 on exhaled and nasal NO, in vitro studies of NO, the chemistry of airway NO formation, and standardized measurement of exhaled mediators.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Arizona, Tucson, AZ USA; Univ Virginia, Charlottesville, VA USA; Karolinska Inst, Stockholm, Sweden; Creighton Univ, Omaha, NE 68178 USA	National Jewish Health; University of Arizona; University of Virginia; Karolinska Institutet; Creighton University	Silkoff, PE (corresponding author), Natl Jewish Med & Res Ctr, Denver, CO 80206 USA.		; silkoff, philip/S-9037-2016	Lundberg, Jon/0000-0002-0174-5210; silkoff, philip/0000-0001-6018-5199				Albert J, 1997, ACTA ANAESTH SCAND, V41, P1104, DOI 10.1111/j.1399-6576.1997.tb04852.x; ALVING K, 1993, EUR RESPIR J, V6, P1368; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; Baraldi E, 1997, AM J RESP CRIT CARE, V155, P1680, DOI 10.1164/ajrccm.155.5.9154876; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284, DOI 10.1164/ajrccm.159.4.9807084; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BELENKY SN, 1993, J LAB CLIN MED, V122, P388; BROWN RH, 1995, AM J RESP CRIT CARE, V151, P1239; Canady RG, 1999, AM J RESP CRIT CARE, V159, P311, DOI 10.1164/ajrccm.159.1.9803034; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810, DOI 10.1164/ajrccm.159.6.9809047; de Gouw HWFM, 1998, AM J RESP CRIT CARE, V158, P315, DOI 10.1164/ajrccm.158.1.9703005; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; DEGROOTE MA, 1996, SCIENCE, V19, P272; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Feder LS, 1997, AM J RESP CELL MOL, V17, P436, DOI 10.1165/ajrcmb.17.4.2845; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GASTON B, 1999, AM J RESP CRIT CARE, V1411, P1317; Gaston B., 1997, LUNG SCI FDN, P239; Gaston B., 1997, NITRIC OXIDE LUNG, P75; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; GREALLY P, 1993, ARCH DIS CHILD, V68, P389, DOI 10.1136/adc.68.3.389; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hunt J, 1999, AM J RESP CRIT CARE, V159, pA860; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones KL, 1998, AM J PHYSIOL-LUNG C, V275, pL1120, DOI 10.1152/ajplung.1998.275.6.L1120; JONES KL, 1999, IN PRESS PEDIAT PULM; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; Kanazawa H, 1999, AM J RESP CRIT CARE, V159, P1272, DOI 10.1164/ajrccm.159.4.9808009; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Lundberg J, 1996, ACTA PHYSIOL SCAND, V157, P1; Lundberg JON, 1996, UROLOGY, V48, P700, DOI 10.1016/S0090-4295(96)00423-2; Lundberg JON, 1997, ACTA PHYSIOL SCAND, V159, P51, DOI 10.1046/j.1365-201X.1997.68339000.x; Lundberg JON, 1995, ACTA PHYSIOL SCAND, V155, P467, DOI 10.1111/j.1748-1716.1995.tb09998.x; Lundberg JON, 1996, EUR RESPIR J, V9, P1344, DOI 10.1183/09031936.96.09071344; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323, DOI 10.1136/adc.75.4.323; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; LUNDBERG JON, 1994, LANCET, V344, P1673, DOI 10.1016/S0140-6736(94)90460-X; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Mian KB, 1995, BRIT J PHARMACOL, V116, P3302, DOI 10.1111/j.1476-5381.1995.tb15139.x; PUYBASSET L, 1994, INTENS CARE MED, V20, P319, DOI 10.1007/BF01720903; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Ramis I, 1996, EUR RESPIR J, V9, P202, DOI 10.1183/09031936.96.09020202; Rinder J, 1996, AM J RHINOL, V10, P399; Robbins RA, 1997, AM J RESP CRIT CARE, V155, P268, DOI 10.1164/ajrccm.155.1.9001323; ROBBINS RA, 1996, IMMUNOPHARMACOLOGY A; ROBBINS RA, 1999, CLIN EXP ALLERGY, V159, pA862; Rolla G, 1997, J RHEUMATOL, V24, P1066; Runer T, 1998, OTOLARYNG HEAD NECK, V119, P278, DOI 10.1016/S0194-5998(98)70063-4; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sato E, 1999, AM J PATHOL, V155, P591, DOI 10.1016/S0002-9440(10)65154-1; Sato M, 1998, CLIN EXP ALLERGY, V28, P597; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Schedin U, 1996, PEDIATR RES, V40, P148, DOI 10.1203/00006450-199607000-00025; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Silkoff PE, 1999, CHEST, V116, P754, DOI 10.1378/chest.116.3.754; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 1999, AM J RHINOL, V13, P169, DOI 10.2500/105065899781389803; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822, DOI 10.1164/ajrccm.157.6.9707159; Silkoff PE, 1998, RESP PHYSIOL, V113, P33, DOI 10.1016/S0034-5687(98)00033-4; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940, DOI 10.1164/ajrccm.159.3.9805044; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; SILKOFF PE, 1999, IN PRESS AM J RESP C; Soderman C, 1997, SCAND J GASTROENTERO, V32, P591, DOI 10.3109/00365529709025105; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TOWNLEY RG, 1995, J ALLERGY CLIN IMMUN, V95, P358; Xue C, 1996, J HISTOCHEM CYTOCHEM, V44, P463, DOI 10.1177/44.5.8627003; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247, DOI 10.1164/ajrccm.154.1.8680689; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	99	71	73	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					438	448		10.1067/mai.2000.104938	http://dx.doi.org/10.1067/mai.2000.104938			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719291				2022-12-18	WOS:000088946700007
J	Leyva, L; Torres, MJ; Posadas, S; Blanca, M; Besso, G; O'Valle, F; del Moral, RG; Santamaria, LF; Juarez, C				Leyva, L; Torres, MJ; Posadas, S; Blanca, M; Besso, G; O'Valle, F; del Moral, RG; Santamaria, LF; Juarez, C			Anticonvulsant-induced toxic epidermal necrolysis: Monitoring the immunologic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toxic epidermal necrolysis; anticonvulsant; severe skin reactions; T lymphocytes; cutaneous lymphocyte-associated antigen; homing; cytokines	LYMPHOCYTE-ASSOCIATED ANTIGEN; STEVENS-JOHNSON SYNDROME; HOMING T-CELLS; LYELL SYNDROME; EXPRESSION; GLUCOCORTICOIDS; CARBAMAZEPINE; KERATINOCYTES; INVOLVEMENT; MACROPHAGES	Background: Toxic epidermal necrolysis Is a severe reaction with skin involvement induced by different drugs and other agents. The mechanisms implicated in the induction of the reaction are poorly understood. Objective: Our purpose was to study the involvement of T lymphocytes and other immunocompetent cells in the peripheral blood, blister fluid, and affected skin of 3 patients who had a severe reaction after receiving anticonvulsant medication. Methods: Quantification of T lymphocytes expressing the skin-homing receptor (cutaneous lymphocyte-associated antigen [CLA]) in peripheral blood, skin, and skin blister fluid and assessment of other adhesion molecules, activation markers, and inflammatory interleukins by flow cytometry, immunohistochemistry, and reverse transcription-PCR. Results: An increase in CD3(+)CLA(+) cells paralleling the severity of the disease was observed in both peripheral blood and skin, tending to normalize as soon as patient's conditions improved. E-selectin was detected in endothelial vessels in parallel with CLA expression on lymphocytes. An overexpression of TNF alpha, IFN-gamma, and IL-2 was also observed in PBMCs. The expression of the different markers changed over the course of the disease. Conclusions: These data show an increase in activated T cells expressing the skin-homing receptor in both tissue and peripheral blood accompanying clinical symptoms, with a recruitment of macrophages and an overexpression of cytokines. All these results suggest an important role for T cells in the production of toxic epidermal necrolysis.	Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain; Carlos Haya Hosp, Dept Internal Med, Malaga, Spain; Carlos Haya Hosp, Intens Care Unit, Malaga, Spain; Almirall Prodesfarma SA, Ctr Invest, Barcelona, Spain; Univ Hosp Granada, Dept Pathol, Granada, Spain	Hospital Carlos Haya; Hospital Carlos Haya; Hospital Carlos Haya; Almirall	Juarez, C (corresponding author), Dept Internal Med, Carlos Haya Hosp Complex,Avda Carlos Haya, Malaga 29010, Spain.		OValle, Francisco/AAA-9151-2019; POSADAS, SINFORIANO J/H-8075-2013; Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017	POSADAS, SINFORIANO J/0000-0003-0014-1957; Torres, María José/0000-0001-5228-471X; Santamaria Babi, Luis F/0000-0002-1674-6654				ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BABI LFS, 1995, J IMMUNOL, V154, P1543; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; COSTAS MA, 1997, MEDICINA, V51, P75; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; GUILLAUME JC, 1987, ARCH DERMATOL, V123, P1166, DOI 10.1001/archderm.123.9.1166; HATFIELD SM, 1991, IMMUNOL INVEST, V20, P55, DOI 10.3109/08820139109054925; Leung DYM, 1997, PEDIATR RES, V42, P559, DOI 10.1203/00006450-199711000-00001; LYELL A, 1979, BRIT J DERMATOL, V100, P69, DOI 10.1111/j.1365-2133.1979.tb03571.x; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; MIYAUCHI H, 1991, ARCH DERMATOL, V127, P851, DOI 10.1001/archderm.127.6.851; PAQUET P, 1994, ARCH DERMATOL, V130, P605, DOI 10.1001/archderm.130.5.605; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; REVUZ J, 1987, ARCH DERMATOL, V123, P1160, DOI 10.1001/archderm.123.9.1160; ROUJEAU JC, 1985, BRIT J DERMATOL, V113, P425, DOI 10.1111/j.1365-2133.1985.tb02356.x; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1990, J AM ACAD DERMATOL, V23, P1039, DOI 10.1016/0190-9622(90)70333-D; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Rzany B, 1996, BRIT J DERMATOL, V135, P6; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; VILLADA G, 1992, ARCH DERMATOL, V128, P50, DOI 10.1001/archderm.128.1.50	31	71	71	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				157	165		10.1016/S0091-6749(00)90191-X	http://dx.doi.org/10.1016/S0091-6749(00)90191-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629466				2022-12-18	WOS:000084992100021
J	Kehrl, HR; Peden, DB; Ball, B; Folinsbee, LJ; Horstman, D				Kehrl, HR; Peden, DB; Ball, B; Folinsbee, LJ; Horstman, D			Increased specific airway reactivity of persons with mild allergic asthma after 7.6 hours of exposure to 0.16 ppm ozone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen; bronchial provocation; ozone	RESPONSES; RESPONSIVENESS; INFLAMMATION; POLLUTION; EXERCISE	Background: Exposure to ozone causes decrements in lung function, increased airway reactivity to nonspecific bronchoconstrictors, and lung inflammation, Epidemiology studies show an association between ambient oxidant levels and increased asthma attacks and hospital admissions. Objective: The purpose of our study was to evaluate the response of persons with mild asthma to inhaled allergen after ozone exposure conditions similar to those observed in urban areas of the United States. Methods: Using a double-blind, counter-balanced design, we exposed 9 (5 women and 4 men) subjects with mild atopic asthma (house dust mite sensitive) to clean air and to 0.16 ppm stone for 7.6 hours; exposures were separated by a minimum of 4 weeks. During exposure, subjects performed tight exercise (ventilation = 24 L/min) for 50 minutes of each hour, and pulmonary function was evaluated before and after exposures The morning after exposure, subjects underwent bronchial challenge with inhaled house dust mite allergen (Dermatophagoides farinae), Using a series of doubling allergen concentrations, subjects inhaled 5 breaths of nebulized allergen (0.06 to 500 AU/mL) at 10-minute interval until a minimum of a 20% decrement in FEV1 was elicited. Results: Compared with the change in FEV1 during air exposure, there was a mean 9.1% +/- 2.5% (SEM) decrement in FEV1 observed because of ozone (P < .01), Seven of the 9 subjects required less allergen after ozone exposure than after dr exposure; there was a 0.58 mean dose shift in the doubling concentration of allergen attributable to the ozone exposure (P = .03), Conclusion: These findings indicate that exposure of subjects With mild atopic asthma to ozone at levels sufficient to cause modest decrements in lung function also increases the reactivity to allergen. To the extent that this effect occurs in response to ambient exposures, ozone may be contributing to the aggravation of asthma.	US EPA, Natl Hlth & Environm Effects Res Lab, Human Studies Div MD58B, Clin Res Branch, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC USA	United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill	Kehrl, HR (corresponding author), US EPA, Natl Hlth & Environm Effects Res Lab, Human Studies Div MD58B, Clin Res Branch, Res Triangle Pk, NC 27711 USA.			Peden, David/0000-0003-4526-4627	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; CHEN LL, 1995, AM J RESP CRIT CARE, V51, pA27; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; CRAIN EF, 1994, PEDIATRICS, V94, P356; CROPP GJA, 1980, AM THOR SOC NEWS, V6, P9; Devlin RB, 1996, TOXICOL APPL PHARM, V138, P176, DOI 10.1006/taap.1996.0111; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FOLINSBEE LJ, 1978, ENV STRESS INDIVIDUA, P111; FRAMPTON MW, 1997, 78 HLTH EFF I RES; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158, DOI 10.1164/ajrccm/142.5.1158; Horstman DH, 1995, TOXICOL IND HEALTH, V11, P369, DOI 10.1177/074823379501100401; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124; KLEEBERGER SR, 1989, J TOXICOL ENV HEALTH, V28, P349, DOI 10.1080/15287398909531354; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; McDonnell WF, 1997, AM J RESP CRIT CARE, V156, P715, DOI 10.1164/ajrccm.156.3.9611044; MICHELSON P, 1995, AM J CRIT CARE MED, V151, pA26; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; PEDEN DB, 1995, AM J PHYSIOL, V268, P902; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; SCHOETTLIN CE, 1961, PUBLIC HEALTH REP, V76, P545, DOI 10.2307/4591201; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; STRONG AA, 1978, 600178064 EPA; *US EPA NAT AIR QU, 1995, EPA454R96005; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687	34	71	72	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1198	1204		10.1016/S0091-6749(99)70013-8	http://dx.doi.org/10.1016/S0091-6749(99)70013-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589001	Bronze			2022-12-18	WOS:000084289200013
J	Szefler, SJ				Szefler, SJ			Pharmacodynamics and pharmacokinetics of budesonide: A new nebulized corticosteroid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		budesonide; budesonide inhalation suspension; asthma; inhaled corticosteroid; pharmacokinetics; pharmacodynamics	SYSTEMIC GLUCOCORTICOID POTENCIES; FATTY-ACID CONJUGATION; INHALED BUDESONIDE; AIRWAY INFLAMMATION; BECLOMETHASONE DIPROPIONATE; BRONCHIAL RESPONSIVENESS; MOLECULAR MECHANISMS; THERAPEUTIC EFFICACY; HISTAMINE-RELEASE; EPITHELIAL-CELLS	Underutilization of anti-inflammatory agents in the treatment of asthma has received widespread attention. Inhaled glucocorticosteroids are important agents for the management of asthma in children and adults. Budesonide has a high ratio of topical anti-inflammatory to systemic activity and is one of the most extensively used inhaled glucocorticoids. Budesonide inhalation suspension is the first formulation designed to deliver budesonide by way of nebulization for infants and children under 8 years of age with persistent asthma, Budesonide decreases airway hyperresponsiveness and reduces the number of inflammatory cells and mediators present in the airways of patients with asthma. Budesonide appears to be retained within cells, allowing for a once-daily treatment regimen in certain patient groups. After inhalation of nebulized budesonide, absorption is rapid. Data suggest that plasma concentrations of budesonide are similar in adults and children after inhalation of the same nominal dose from a nebulizer. In children 3 to 6 years of age, total systemic availability of budesonide after dosing with a jet nebulizer was approximately 6% of the labeled dose. Budesonide is highly protein bound, undergoes extensive first-pass hepatic metabolism, is metabolized by the liver cytochrome P450 system, and is primarily excreted in the urine as metabolites. In children 3 to 6 years of age, the volume of distribution at steady state of budesonide inhalation suspension is approximately 3 L/kg, with a terminal elimination half-life of 2.3 hours; systemic clearance is approximately 30 mL/kg. The pharmacodynamic and pharmacokinetic properties of budesonide inhalation suspension allow for potent local anti-inflammatory activity with limited systemic exposure.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Room J209,1400 Jackson St, Denver, CO 80206 USA.							Agertoft L, 1999, ARCH DIS CHILD, V80, P241, DOI 10.1136/adc.80.3.241; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; Anhoj J., 1998, European Respiratory Journal, V12, p378S; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1997, PULM PHARMACOL THER, V10, P3, DOI 10.1006/pupt.1997.0074; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEL EH, 1989, AM REV RESPIR DIS, V139, P427, DOI 10.1164/ajrccm/139.2.427; BERGSTRAND H, 1986, ALLERGY, V41, P319, DOI 10.1111/j.1398-9995.1986.tb00307.x; BERGSTRAND H, 1984, ALLERGY, V39, P217, DOI 10.1111/j.1398-9995.1984.tb02627.x; BORSON DB, 1991, AM J PHYSIOL, V260, pL83, DOI 10.1152/ajplung.1991.260.2.L83; BRATTSAND R, 1982, J STEROID BIOCHEM, V16, P779, DOI 10.1016/0022-4731(82)90035-8; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BRATTSAND R, 1991, AGENTS ACTIONS, V34, P35, DOI 10.1007/BF01993231; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BURKE C, 1992, EUR RESPIR J, V5, P73; Burke C. M., 1994, European Respiratory Journal, V7, p421S; CARLSEN KCL, 1992, ARCH DIS CHILD, V67, P1077; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DAHLSTROM K, 1995, J AER MED, V8, P47; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; Derendorf H, 1998, J ALLERGY CLIN IMMUN, V101, pS440, DOI 10.1016/S0091-6749(98)70156-3; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; EDSBACKER S, 1987, DRUG METAB DISPOS, V15, P403; EDSBACKER S, 1998, RESP DRUG DELIVERY, V6, P71; EDSBACKER S, 1997, LUNG BIOL HEALTH DIS, V97, P381; EVERARD ML, 1993, THORAX, V48, P1045, DOI 10.1136/thx.48.10.1045; FOUCARD T, 1996, ALLERGY, V51, P365; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; JONSSON G, 1995, DRUG METAB DISPOS, V23, P137; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; LOFDAHL CG, 1984, EUR J RESPIR DIS, V65, P69; MARIANAYAGAM L, 1990, American Review of Respiratory Disease, V141, pA215; *MED EC CO, 1999, PHYS DESK REF, P587; Miller-Larsson A, 1998, DRUG METAB DISPOS, V26, P623; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; O'CONNOR B J, 1991, American Review of Respiratory Disease, V143, pA422; PAGGIARO PL, 1994, AM J RESP CRIT CARE, V149, P1447, DOI 10.1164/ajrccm.149.6.8004297; PEDERSEN O, 1997, ALLERGY S, V52, P1; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; REED CE, 1993, IMMUNOL ALLERGY CLIN, V13, P903; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; RYRFELDT A, 1989, BIOCHEM PHARMACOL, V38, P17, DOI 10.1016/0006-2952(89)90143-3; RYRFELDT A, 1984, CLIN PHARMACOL THER, V35, P525, DOI 10.1038/clpt.1984.71; SCHLEIMER RP, 1998, ALLERGY PRINCIPLES P, P638; Smaldone GC, 1998, J AEROSOL MED, V11, P113, DOI 10.1089/jam.1998.11.113; THALEN A, 1989, ACTA DERM-VENEREOL, V69, P11; Thorsson L., 1998, AM J RESP CRIT CARE, V157, pA404; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; Tunek A, 1997, DRUG METAB DISPOS, V25, P1311; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; Wieslander E, 1998, AM J RESP CELL MOL, V19, P477, DOI 10.1165/ajrcmb.19.3.3195; WURTHWEIN G, 1992, PHARM ZELT WISSENSCH, V137, P161	67	71	77	0	20	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	2				S175	S183		10.1016/S0091-6749(99)70059-X	http://dx.doi.org/10.1016/S0091-6749(99)70059-X			9	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	249RH	10518844				2022-12-18	WOS:000083345700004
J	Grant, EN; Wagner, R; Weiss, KB				Grant, EN; Wagner, R; Weiss, KB			Observations on emerging patterns of asthma in our society	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; epidemiology; mortality; hospitalization; prevalence; geographic variations	UNITED-STATES; CHILDHOOD ASTHMA; CHILDREN; HOSPITALIZATION; PREVALENCE; TRENDS; RATES; HEALTH	Epidemiologic studies of temporal and geographic variation in asthma morbidity have identified asthma as an important public health concern. Knowledge gained from these studies has resulted in intense focus on this condition by agencies such as the National Institutes of Health and the World Health Organization. In this report, studies of recent asthma trends and patterns are explored, These studies show increases in US prevalence through 1994. Data on measures of morbidity show complex longitudinal patterns but are notable for large differences in emergency department services and hospitalizations by age and race. Very recent trends for US asthma mortality suggest widening of an existing racial gap. Limited comparisons are possible between these US trends and international trends but do suggest that US increases in prevalence and mortality rates may reflect world-wide patterns. Also, within the US, it is clear that geographic variation exists in asthma prevalence, morbidity, and mortality rates. Changes in certain environmental risk factors and exposures may contribute to recent trends, but little information is available relating specific risk factors to either longitudinal asthma trends, geographic variability, or high-risk populations.	Rush Med Coll, Ctr Hlth Serv Res, Rush Primary Care Inst,Dept Internal Med, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Immunol Microbiol, Rush Presbyterian St Lukes Med Ctr, Chicago, IL USA; Cook Cty Hosp, Dept Pediat, Chicago, IL 60612 USA	Rush University; John H Stroger Junior Hospital Cook County; Rush University; John H Stroger Junior Hospital Cook County	Weiss, KB (corresponding author), Rush Med Coll, Ctr Hlth Serv Res, Rush Primary Care Inst,Dept Internal Med, Rush Presbyterian St Lukes Med Ctr, 1653 W Congress Pkwy,Kidston Bldg,Room 802, Chicago, IL 60612 USA.							ADAMS PF, 1995, VITAL HLTH STAT, V10, P193; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Christiansen SC, 1996, J ASTHMA, V33, P17, DOI 10.3109/02770909609077759; Collins JG, 1997, VITAL HLTH STAT, V10, P1; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; EVANS R, 1991, CHEST, V1087, pS65; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; *HLTH SERV MENT HE, 1971, VIT HLTH STAT; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SLY RM, 1994, ANN ALLERGY, V73, P439; TARGONSKI PV, 1995, J ASTHMA, V32, P365, DOI 10.3109/02770909509082761; Terr AI, 1996, ANN ALLERG ASTHMA IM, V76, P273, DOI 10.1016/S1081-1206(10)63441-2; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; TUUPONEN T, 1993, EUR J PEDIATR, V152, P1042, DOI 10.1007/BF01957234; *US PUBL HLTH SERV, 1976, VIT HLTH STAT; Varner AE, 1998, ANN ALLERG ASTHMA IM, V81, P347, DOI 10.1016/S1081-1206(10)63127-4; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WILKINS K, 1993, CAN MED ASSOC J, V148, P185; Woolcock A J, 1991, Bull Int Union Tuberc Lung Dis, V66, P85; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	28	71	71	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S1	S9		10.1016/S0091-6749(99)70268-X	http://dx.doi.org/10.1016/S0091-6749(99)70268-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452783				2022-12-18	WOS:000082419400001
J	Neustrom, MR; Friesen, C				Neustrom, MR; Friesen, C			Treatment of eosinophilic gastroenteritis with montelukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Kansas City Allergy & Asthma Associates, Overland Pk, KS 66211 USA; Childrens Mercy Hosp, Dept Gastroenterol, Kansas City, MO 64108 USA	Children's Mercy Hospital	Neustrom, MR (corresponding author), Kansas City Allergy & Asthma Associates, 4500 Coll Blvd,Suite 200, Overland Pk, KS 66211 USA.							Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; KESHAVARZIAN A, 1985, GASTROENTEROLOGY, V88, P1041, DOI 10.1016/S0016-5085(85)80026-3; Kita H, 1998, ALLERGY PRINCIPLES P, P242; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183	4	71	75	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				506	506		10.1016/S0091-6749(99)70404-5	http://dx.doi.org/10.1016/S0091-6749(99)70404-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452782				2022-12-18	WOS:000082364800053
J	Hingorani, M; Calder, V; Jolly, G; Buckley, RJ; Lightman, SL				Hingorani, M; Calder, V; Jolly, G; Buckley, RJ; Lightman, SL			Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; adhesion molecules; cytokines; MHC; immunochemistry	INTERLEUKIN-5 MESSENGER-RNA; MAJOR BASIC-PROTEIN; INTERCELLULAR-ADHESION MOLECULE-1; TRANSFORMING GROWTH FACTOR-BETA-1; PERIPHERAL-BLOOD EOSINOPHILS; COLONY-STIMULATING FACTOR; VERNAL KERATOCONJUNCTIVITIS; ATOPIC KERATOCONJUNCTIVITIS; FACTOR-ALPHA; HLA-DR	Background: The pathophysiology of chronic ocular allergic disease is not well understood, An eosinophil infiltrate is characteristic of such disease and eosinophil activity can be related to disease severity and to keratopathy, the most serious complication. Recently, eosinophils have been shown capable of cytokine production, particularly in allergic disease, although the disease-specific cytokine spectrum of tissue eosinophils is unknown. Objectives: We sought to determine eosinophil numbers (absolute numbers and percentage of total leukocytes), cell surface antigen expression, and cytokine production in conjunctiva in chronic allergic eye disease and their relationship to corneal involvement. Methods: Ultrathin sections of conjunctiva were examined by tissue staining and by 1- and 2-color immunohistochemistry. Results: Eosinophil numbers were greater in giant papillary conjunctivitis (GPC) and vernal keratoconjunctivitis (VKC) and not related to corneal involvement, The eosinophil expression of the cell surface antigens intercellular adhesion molecule-1, CD4, IL-2R, and HLA-DR was greater in atopic keratoconjunctivitis (AKC) and VKC, the disorders with corneal disease, than in GPC, in which the cornea is not involved. For most cytokines, localization to eosinophils was greater for VKC and AKC than for GPC, RANTES, TGF-beta, and TNF-alpha localized to eosinophils in all disorders. Variations in the pattern of eosinophil-cytokine localization were found. In VKC IL-3, IL-5, IL-6, and GM-CSF were prominent; in GPC IL-5 was prominent; and in AKC IL-4, IL-8, and GM-CSF were prominent. Conclusions: Chronic ocular allergic disorders affecting the cornea are distinguished from disorders that do not do so by greater expression of eosinophil surface antigens (which may imply greater cell activation) and differences in cytokine localization to eosinophils, These differences may be secondary to the variations in T-cell subsets or a primary phenomenon, Changes in eosinophil function, rather than cell numbers, may be important in clinical variations, such as keratopathy, and may allow future therapeutic exploitation.	Moorfields Eye Hosp, London EC1V 2PD, England; Inst Ophthalmol, London, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Lightman, SL (corresponding author), Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.		Calder, Virginia/AAG-8278-2020	Calder, Virginia/0000-0003-1422-2926				ABELSON MB, 1993, SURV OPHTHALMOL, V38, P115, DOI 10.1016/0039-6257(93)90036-7; Akova Y A, 1994, Ocul Immunol Inflamm, V2, P125, DOI 10.3109/09273949409057069; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barton BE, 1996, MED RES REV, V16, P87, DOI 10.1002/(SICI)1098-1128(199601)16:1<87::AID-MED3>3.3.CO;2-5; Benezra D., 1994, OCUL IMMUNOL INFLA S, V2, pS17; BONINI S, 1993, ANN ALLERGY, V71, P296; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUCKLEY RJ, 1981, T OPHTHAL SOC UK, V101, P234; BUCKLEY RJ, 1988, CORNEA T WORLD C COR, V3, P435; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CZECH W, 1993, J INVEST DERMATOL, V100, P417, DOI 10.1111/1523-1747.ep12472082; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DESREUMAUX P, 1995, GUT, V37, P132, DOI 10.1136/gut.37.1.132; DEVALIA JL, 1993, RESP MED, V87, P405, DOI 10.1016/0954-6111(93)90064-7; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; EHLERS W H, 1992, CLAO Journal, V18, P117; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; FINOTTO S, 1994, J IMMUNOL, V153, P2278; FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; FOSTER CS, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb04250.x; FRIEDLAENDER MH, 1993, SURV OPHTHALMOL, V38, P105, DOI 10.1016/0039-6257(93)90035-6; FUJISAWA T, 1994, INT ARCH ALLERGY IMM, V104, P41, DOI 10.1159/000236748; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRABNER G, 1985, INVEST OPHTHALMOL  S, V26, P3; HAMID Q, 1992, BLOOD, V80, P1496; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HANSEL TT, 1993, AGENT ACTION SUPPL, V43, P197; HOWARTH PH, 1995, INT ARCH ALLERGY IMM, V107, P390, DOI 10.1159/000237048; JAY JL, 1981, BRIT J OPHTHALMOL, V65, P335, DOI 10.1136/bjo.65.5.335; JONES DT, 1994, INVEST OPHTH VIS SCI, V35, P3493; KADIN M, 1993, AM J PATHOL, V142, P11; KAY AB, 1995, INT ARCH ALLERGY IMM, V107, P208, DOI 10.1159/000236979; KROEGEL C, 1992, RESP MED, V86, P375, DOI 10.1016/S0954-6111(06)80004-1; LAMKHIOUED B, 1995, INT ARCH ALLERGY IMM, V107, P122, DOI 10.1159/000236949; LIM KG, 1995, INT ARCH ALLERGY IMM, V107, P342, DOI 10.1159/000237023; Lindemann A, 1995, Cancer Treat Res, V80, P107; MacLeod J. D. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS235; MACLEOD JDA, 1995, VISION RES, V35, pP134; MAGGI E, 1991, J IMMUNOL, V146, P1169; MELANI C, 1993, BLOOD, V81, P2744; METZ D, 1993, INVEST OPHTH VIS SCI, V34, P857; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; PLUMAS J, 1991, EUR J IMMUNOL, V21, P1265, DOI 10.1002/eji.1830210525; PURI RK, 1995, CANC TREAT RES, V810, P143; SAITO H, 1994, INT ARCH ALLERGY IMM, V104, P39, DOI 10.1159/000236747; Sakamoto S, 1996, INT ARCH ALLERGY IMM, V111, P26, DOI 10.1159/000237410; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SANTOS CI, 1994, AM J OPHTHALMOL, V117, P488, DOI 10.1016/S0002-9394(14)70009-1; SCHREINER J, 1985, KLIN MONATSBL AUGENH, V187, P403, DOI 10.1055/s-2008-1054348; Secchi A, 1995, Ocul Immunol Inflamm, V3, P23, DOI 10.3109/09273949509057807; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; TAN XD, 1993, AM J PATHOL, V142, P1858; TANAKA Y, 1994, J INVEST DERMATOL, V103, P589, DOI 10.1111/1523-1747.ep12396899; TOMASSINI M, 1994, OPHTHALMOLOGY, V101, P1808; TROCME SD, 1993, AM J OPHTHALMOL, V115, P640, DOI 10.1016/S0002-9394(14)71463-1; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57, DOI 10.1016/S0002-9394(14)73261-1; TROCME SD, 1994, INVEST OPHTH VIS SCI, V35, P3051; TUFT SJ, 1991, OPHTHALMOLOGY, V98, P150; VENGE P, 1991, CLIN EXP ALLERGY, V21, P31, DOI 10.1111/j.1365-2222.1991.tb01761.x; WALZ TM, 1994, LEUKEMIA, V8, P612; WARDLAW AJ, 1987, ALLERGY, V42, P321, DOI 10.1111/j.1398-9995.1987.tb02218.x; WELLER PF, 1993, J IMMUNOL, V150, P2554; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; YOUSEFI S, 1995, J IMMUNOL, V154, P5481	73	71	74	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					821	830		10.1016/S0091-6749(98)70023-5	http://dx.doi.org/10.1016/S0091-6749(98)70023-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819300				2022-12-18	WOS:000077033400017
J	Baumgart, KW; Britton, WJ; Kemp, A; French, M; Roberton, D				Baumgart, KW; Britton, WJ; Kemp, A; French, M; Roberton, D			The spectrum of primary immunodeficiency disorders in Australia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary; immunodeficiency; register; Australia; gammaglobulin	ATAXIA-TELANGIECTASIA; GENE; DISEASES; FEATURES; CANCER	Background: Primary immunodeficiency disorders (PIDs) are uncommon conditions that require specialized immunologic services for diagnosis and management. It is difficult to estimate the prevalence of these disorders from routinely collected health statistics. Objective: We attempted to describe the prevalence of PID in Australia and the requirements for specific therapies, such as intravenous immunoglobulin, ascertained from a national register of PID. Methods: A national longitudinal cross-sectional survey of patients with PID under the care of clinical immunologists was established by the Australasian Society of Allergy and Clinical Immunology in 1990. Details of diagnosis and therapy were provided for patients with major PIDs including symptomatic IgA, IgG subclass, and complement deficiencies. Subjects with asymptomatic IgA deficiency were not included. The clinical features of the first 500 cases enrolled in the register were analyzed. Results: The most frequent type of PID was predominant antibody deficiency (71%). Common variable immunodeficiency, usually first seen as an antibody deficiency, was the single mast common disorder with an estimated prevalence of 0.77/100,000 in the general population. Other types of PID were infrequent, and of these, severe combined immunodeficiency accounted for 5.2% of cases. The estimated prevalence of all forms of chronic granulomatous disease was 0.08/ 100,000. The national prevalence of all PID cases ascertained from the register was 2.1/100,000, with variation between the larger states ranging from 1.18 to 4.57/100,000. Half (247) of the patients were receiving intravenous immunoglobulin therapy with a median duration of care of 5 to 9 years for the different antibody deficiencies. There was also variation in the patterns of intravenous immunoglobulin use across the country. No new forms of PID were encountered. Conclusion: This study highlights the requirement for the continuing provision of immunoglobulin as replacement therapy for these patients. In addition, the register documents a cohort of patients with PID whose long-term response to current therapy can be evaluated prospectively.	ROYAL CHILDRENS HOSP,DEPT IMMUNOL,MELBOURNE,VIC,AUSTRALIA; ROYAL PERTH HOSP,DEPT CLIN IMMUNOL,PERTH,WA 6001,AUSTRALIA; UNIV ADELAIDE,CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA 5005,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Perth Hospital; University of Western Australia; University of Adelaide	Baumgart, KW (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT MED,DEPT CLIN IMMUNOL,CAMPERDOWN,NSW 2050,AUSTRALIA.							BAUMGART KW, 1992, AUSTR J HOSP PHARM, V23, P148; CHAPEL HM, 1994, BRIT MED J, V308, P581, DOI 10.1136/bmj.308.6928.581; COOPER MD, 1994, FUNDAMENTAL IMMUNOLO, P1034; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; CUNNINGHAMRUNDLES C, 1994, NEW ENGL J MED, V331, P918, DOI 10.1056/NEJM199410063311405; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DINAUER M, 1992, ANNU REV MED, V3, P117; DWYER JM, 1992, NEW ENGL J MED, V326, P107; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; HAYAKAWA H, 1981, J CLIN IMMUNOL, V1, P31, DOI 10.1007/BF00915474; Hosking C S, 1983, Birth Defects Orig Artic Ser, V19, P223; JEFFERIS R, 1990, CLIN EXP IMMUNOL, V81, P357; KELLER T, 1993, MED J AUSTRALIA, V159, P204, DOI 10.5694/j.1326-5377.1993.tb137790.x; LAMAN JD, 1994, CURR OPIN IMMUNOL, V6, P636, DOI 10.1016/0952-7915(94)90153-8; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; LUZI G, 1989, Immunologia Clinica, V8, P45; MCNULTY A, 1994, BRIT MED J, V308, P825, DOI 10.1136/bmj.308.6932.825; ROSEN FS, 1986, CLIN IMMUNOL IMMUNOP, V40, P166, DOI 10.1016/0090-1229(86)90082-6; Rosen FS, 1993, IMMUNODEFICIENCIES, P141; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; Stiehm ER, 1989, IMMUNOLOGIC DISORDER, P157; SULLIVAN JL, 1992, IMMUNODEF REV, V1, P325; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WALDMANN TA, 1995, IMMUNOLOGIC DIS, P287; WALKER A, 1994, ARCH DIS CHILD, V70, P183, DOI 10.1136/adc.70.3.183; WOODS CG, 1992, Q J MED, V82, P169; 1995, CLIN EXP IMMUNOL  S1, V99, P1	28	71	77	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					415	423		10.1016/S0091-6749(97)70257-4	http://dx.doi.org/10.1016/S0091-6749(97)70257-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314356	Bronze			2022-12-18	WOS:A1997XX47900021
J	Schenk, S; Breiteneder, H; Susani, M; Najafian, N; Laffer, S; Duchene, M; Valenta, R; Fischer, G; Scheiner, O; Kraft, D; Ebner, C				Schenk, S; Breiteneder, H; Susani, M; Najafian, N; Laffer, S; Duchene, M; Valenta, R; Fischer, G; Scheiner, O; Kraft, D; Ebner, C			T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): Evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; recombinant Phl p 1; T-cell clone; T-cell epitope; crossreactivity	HOUSE-DUST MITE; BET-V-I; BIRCH POLLEN; OVERLAPPING PEPTIDES; LYMPHOCYTES-T; CLONES; IMMUNOTHERAPY; PHOSPHOLIPASE-A2; DETERMINANT; SPECIFICITY	Background: The use of peptides representing T-cell epitopes of allergens is a modern concept for improvement of specific immunotherapy. A prerequisite for this approach is the identification of T-cell epitopes of atopic allergens. Methods: T-cell lines and 40 T-cell clones (TCC) specific for Phl p 1, the group I allergen of timothy grass (Phleum pratense), were established from the peripheral blood of nine patients allergic to grass pollen and mapped for epitope specificity by using overlapping dodecapeptides. Phenotype and cytokine production profile of TCC were investigated. Representative TCC were analyzed for HLA-restriction, T-cell receptor V beta gene usage, and crossreactivity with grass pollen extracts from Dactylis glomerata, Poa pratensis, Lolium perenne, Secale cereale, and selected amino acid sequence-derived peptides. Results: Patients displayed IgE binding to all grass species investigated. Forty TCC were established. Fifteen T-cell epitopes could be identified on Phl p 1. Of 40 TCC, 39 displayed the helper cell (Th) phenotype; one clone was CD8(+). Specific stimulation induced a Th2-like type of cytokine production in 20 of 39 TCC. Crossreactivity studies revealed crossreacting and non-crossreacting T-cell epitopes. Conclusion: Phl p 1, a major grass pollen allergen, harbors multiple T-cell epitopes. Species-specific and crossreacting T-cell epitopes exist among group I allergens of grasses. Epitope recognition patterns could not be correlated with particular HLA haplotypes. A restricted T-cell receptor V beta gene usage was not observed.	UNIV VIENNA, INST GEN & EXPTL PATHOL, A-1090 VIENNA, AUSTRIA; AUSTRIAN ACAD SCI, INST MOLEC BIOL, A-5020 SALZBURG, AUSTRIA; GEN HOSP, INST BLOOD GRP SEROL, VIENNA, AUSTRIA	University of Vienna; Austrian Academy of Sciences			Duchêne, Michael/G-6659-2019	Duchêne, Michael/0000-0003-1232-3600; Valenta, Rudolf/0000-0001-5944-3365				BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BUNGY GA, 1994, EUR J IMMUNOL, V24, P2098, DOI 10.1002/eji.1830240925; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DHILLON M, 1992, J ALLERGY CLIN IMMUN, V90, P42, DOI 10.1016/S0091-6749(06)80009-6; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; MAEJI NJ, 1990, J IMMUNOL METHODS, V134, P23; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; PANZARA MA, 1992, BIOTECHNIQUES, V12, P728; PEREZ M, 1990, J BIOL CHEM, V265, P16210; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; WALLNER BP, 1994, ALLERGY, V49, P302, DOI 10.1111/j.1398-9995.1994.tb02272.x; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067; YSSEL H, 1992, J IMMUNOL, V148, P738	39	71	84	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				986	996		10.1016/S0091-6749(95)70237-7	http://dx.doi.org/10.1016/S0091-6749(95)70237-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543758				2022-12-18	WOS:A1995TN12400017
J	OHNISHI, T; SUR, S; COLLINS, DS; FISH, JE; GLEICH, GJ; PETERS, SP				OHNISHI, T; SUR, S; COLLINS, DS; FISH, JE; GLEICH, GJ; PETERS, SP			EOSINOPHIL SURVIVAL ACTIVITY IDENTIFIED AS INTERLEUKIN-5 IS ASSOCIATED WITH EOSINOPHIL RECRUITMENT AND DEGRANULATION AND LUNG INJURY 24 HOURS AFTER SEGMENTAL ANTIGEN LUNG CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; EOSINOPHIL SURVIVAL ACTIVITY; IL-5; IGE-MEDIATED PULMONARY INFLAMMATION; SEGMENTAL ANTIGEN CHALLENGE	COLONY-STIMULATING FACTOR; PATHO-PHYSIOLOGY; 3T3 FIBROBLASTS; LATE-PHASE; ASTHMA; INVITRO; CELLS; IL-5; NEUTROPHILS; VIABILITY	Background: Segmental antigen challenge in allergic volunteer subjects leads to the recruitment of inflammatory cells, including eosinophils, to the lung and to lung injury as shown by albumin influx into the alveolar air space. The goal of this study was to determine whether eosinophil-active cytokines, including IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor, are released into the lung 24 hours after segmental antigen challenge of ragweed allergic subjects with allergic rhinitis and to determine whether the presence of the cytokine or cytokines is correlated with markers of lung inflammation and lung injury. Methods: Volunteers underwent challenge with a wide variety of antigen doses, which resulted in the recruitment of inflammatory cell mixtures both with and without eosinophils. Results: Eosinophil survival activity (ESA), the ability of the cytokine to prolong blood eosinophil survival in culture, was found in 5 of 17 ragweed allergic subjects and only in subjects challenged with relatively high doses of ragweed antigen (0.2 ragweed antigen units/ml or more). No ESA was found in bronchoalveolar lavage (BAL) fluid in any of eight nonragweed allergic subjects. This activity could be almost completely neutralized by preincubating RAL fluid with specific antibody to IL-5, although a small contribution by granulocyte-macrophage colony-stimulating factor may also have been present. ESA correlated with eosinophil recruitment (r = 0.72, p < 0.001) and degranulation in the lung (r = 0.63 to 0.81, p < 0.01, for eosinophil granule constituents in BAL fluid) and lung injury as shown by albumin influx into the alveolar air spaces (r = 0.83, p < 0.001). ESA was unrelated to the presence of other inflammatory cells in the lung. Subjects who had IL-5 in BAL fluid appeared to undergo more severe initial reactions to antigen challenge. Conclusions: We conclude that IL-5 is the most important constituent in ESA in the lung 24 hours after antigen challenge and that it correlates with eosinophil recruitment, degranulation, and lung injury.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM MED & CRIT CARE,804 COLL BLDG,PHILADELPHIA,PA 19107; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905	Jefferson University; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI031155, R01AI015231, R01AI024509] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24509, AI15231, AI31155] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEGLEY CG, 1986, BLOOD, V68, P162; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUJISAWA T, 1990, J IMMUNOL, V144, P642; Glantz SA., 1987, PRIMER BIOSTATISTICS; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LAMAS AM, 1991, J IMMUNOL, V147, P254; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PETERS SP, 1992, AM REV RESPIR DIS, V145, pA639; PULLEN GR, 1981, J IMMUNOL METHODS, V43, P87, DOI 10.1016/0022-1759(81)90039-9; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTMAN B, 1966, P NATL ACAD SCI USA, V55, P134, DOI 10.1073/pnas.55.1.134; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P329; TAKAFUJI S, 1991, J IMMUNOL, V147, P3855; WALLEN N, 1991, J IMMUNOL, V147, P3490; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WLAKER C, 1992, AM J REV RESPIR DIS, V146, P109; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	41	71	71	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					607	615		10.1016/0091-6749(93)90085-T	http://dx.doi.org/10.1016/0091-6749(93)90085-T			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409120				2022-12-18	WOS:A1993MC59000013
J	KOWALSKI, ML; SLIWINSKAKOWALSKA, M; IGARASHI, Y; WHITE, MV; WOJCIECHOWSKA, B; BRAYTON, P; KAULBACH, H; ROZNIECKI, J; KALINER, MA				KOWALSKI, ML; SLIWINSKAKOWALSKA, M; IGARASHI, Y; WHITE, MV; WOJCIECHOWSKA, B; BRAYTON, P; KAULBACH, H; ROZNIECKI, J; KALINER, MA			NASAL SECRETIONS IN RESPONSE TO ACETYLSALICYLIC-ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN SENSITIVITY; RHINITIS; NASAL CHALLENGE; HISTAMINE; PGD2; LTC4; NASAL SECRETIONS	ASPIRIN-SENSITIVE RHINOSINUSITIS; PATHO-PHYSIOLOGY; INDUCED ASTHMA; HISTAMINE-RELEASE; ARACHIDONIC-ACID; INDUCED RHINITIS; LEUKOTRIENES; CHALLENGE; PROTEIN; DESENSITIZATION	Background: Acetylsalicylic acid (ASA) induces rhinorrhea in a subset of patients with asthma or chronic rhinosinusitis or both and nasal polyps. The underlying mechanism of the reaction is obscure. Methods: To assess the nasal response to ASA challenge, four groups of patients were challenged orally with ASA: group A (10 ASA-sensitive patients); group B (nine patients with nasal polyps and histories of tolerance to ASA); group C (nine ASA-tolerant patients with chronic allergic rhinitis); and group D (eight healthy nonatopic subjects). Results: Nasal lavages obtained before and after ASA challenge were assayed for proteins (total protein, lactoferrin, lysozyme, albumin) and inflammatory mediators (histamine, prostaglandin D2, and leukotriene C4). ASA challenges induced severe rhinorrhea and congestion and significant increases in mean concentrations of all measured nasal proteins in group A. Histamine and prostaglandin D2 rose, but not significantly. In the two control groups with chronic rhinitis, ASA induced increases in the concentration of proteins and histamine. Leukotriene C4 concentrations were significantly elevated in nasal lavages after ASA challenge in groups A and C only. In group D no symptoms or changes in nasal proteins were observed after aspirin challenge. Conclusions: These observations suggest that production of lipoxygenase products of arachidonate may induce glandular secretions that may participate in the clinical changes associated with ASA sensitivity.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KOWALSKI, ML (corresponding author), MED ACAD LODZ,FAC MED,DEPT PULM & ALLERGOL,KOPCINSKIEGO 22,PL-90153 LODZ,POLAND.		Sliwinska-Kowalska, Mariola/F-6119-2010	Sliwinska-Kowalska, Mariola/0000-0001-7569-3882				ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; BISGAARD H, 1987, ALLERGIC VASOMOTOR R, P189; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; CHANYEUNG M, 1988, AM J RHINOL, V2, P183; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CONROY MC, 1981, ARCH ALLERGY APPL IM, V66, P152; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAVIES RJ, 1987, ALLERGIC VASOMOTOR R, P179; EGGLESTON PA, 1978, INT ARCH ALLER A IMM, V57, P193, DOI 10.1159/000232103; ENGLISH GM, 1987, ARCH OTOLARYNGOL, V113, P377; ENGLISH GM, 1986, LARYNGOSCOPE, V96, P374; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; GOETZL EJ, 1986, J ALLERGY CLIN IMMUN, V77, P693, DOI 10.1016/0091-6749(86)90412-4; GRZELEWSKARZYMOWSKA I, 1981, ALLERGOL IMMUNOPATH, V9, P533; HOLLINGSWORTH HM, 1984, AM REV RESPIR DIS, V130, P373; HOLOPAINEN E, 1979, ACTA OTO-LARYNGOL, V87, P330, DOI 10.3109/00016487909126428; HOSEMANN W G, 1990, Rhinology (Utrecht), V28, P231; JANOWSKI R, 1989, RHINOLOGY S8, V27, P51; JENNEY EVM, 1990, J ALLERGY CLIN IMMUN, V86, P10; JUNG TTK, 1987, LARYNGOSCOPE, V97, P184; KALINER MA, 1988, AIRWAYS NEURAL CONTR, P575; KONNO A, 1983, EUR J RESPIR DIS, V64, P155; KOWALSKI ML, 1987, ANN ALLERGY, V58, P367; KOWALSKI ML, 1984, ALLERGY, V39, P171, DOI 10.1111/j.1398-9995.1984.tb02621.x; KOWALSKI ML, 1986, EUR J RESPIR DIS, V69, P219; KOWALSKI ML, 1985, THORAX, V40, P598, DOI 10.1136/thx.40.8.598; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MCFADDEN EA, 1990, LARYNGOSCOPE, V100, P1043, DOI 10.1288/00005537-199010000-00003; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OGINO S, 1986, ACTA OTOLARYNGOL S S, V430, P21; OKUDA M, 1977, ORL DIGEST, V3, P22; OKUDA M, 1977, ORL DIGEST, V2, P26; OKUDA Y, 1990, J ALLERGY CLIN IMMUN, V86, P548, DOI 10.1016/S0091-6749(05)80211-8; ORTOLANI C, 1984, CLIN ALLERGY, V14, P443, DOI 10.1111/j.1365-2222.1984.tb02228.x; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RAPHAEL GD, 1985, J ALLERGY CLIN IMMUN, V75, P112, DOI 10.1016/0091-6749(85)90164-2; Samter M, 1968, ANN INTERN MED, V68, P875; SETTIPANE GA, 1986, NEW ENGL REG ALLERGY, V7, P32; SHOW RJ, 1985, ALLERGY, V40, P1; SIMON R, 1983, J ALLERGY CLIN IMMUN, V71, P146, DOI 10.1016/0091-6749(83)90356-1; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SZCZEKLIK A, 1986, DRUGS, V32, P148, DOI 10.2165/00003495-198600324-00011; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1989, AGENTS ACTIONS, V27, P39; SZMIDT M, 1981, AGENTS ACTIONS, V11, P105, DOI 10.1007/BF01991472; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; YAMASHITA T, 1989, RHINOLOGY S8, V27, P15	61	71	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					580	598		10.1016/0091-6749(93)90264-G	http://dx.doi.org/10.1016/0091-6749(93)90264-G			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436774				2022-12-18	WOS:A1993KN54800006
J	HAUGAARD, L; NORREGAARD, OFH; DAHL, R				HAUGAARD, L; NORREGAARD, OFH; DAHL, R			IN-HOSPITAL STING CHALLENGE IN INSECT VENOM ALLERGIC PATIENTS AFTER STOPPING VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NATURAL-HISTORY; HYMENOPTERA; HYPERSENSITIVITY; CHILDREN; BEE; IGE	Immunotherapy (IT) in venom-allergic patients has been demonstrated to provide a highly efficient protection from severe reactions to a re-sting. It is not known whether this protection will persist after IT is stopped in patients with remaining venom sensitivity. In 25 adult patients with a previous severe systemic reaction to a Hymenoptera insect sting, 28 in-hospital sting challenges after stopping IT resulted in no systemic reactions. The mean duration of venom IT was 42.8 months (range, 36 to 83 months), and the mean time interval from the time IT was stopped until sting challenge was, in mean, 25.2 months (range, 12 to 36 months). The mean venom-specific IgE after stopping IT was 2.4 PRU/ml (range, 0 to 16.9 PRU/ml), at the day of sting challenge, 2.7 PRU/ml (range, 0 to 22 PRU/ml), and 2 weeks later, 2.4 PRU/ml (range, 0.02 to 27.8 PRU/ml). These changes in IgE were not significant. Venom-specific IgG concentration when IT was stopped was 64 PU/ml (range, 20 to 144 PU/ml), decreasing significantly to the day of sting challenge to 41.1 PU/ml (range, 13 to 84 PU/ml), and 2 weeks later, a significant increase to a mean of 53.5 PU/ml (range, 12 to 117 PU/ml) was found. Our results suggest that venom IT may be stopped after 3 years, regardless of the level of specific antibodies. To confirm this finding, a larger number of patients should be studied.	UNIV HOSP AARHUS, DEPT ANESTHESIOL, DK-8000 AARHUS, DENMARK	Aarhus University	HAUGAARD, L (corresponding author), UNIV HOSP AARHUS, DEPT RESP DIS, DK-8000 AARHUS, DENMARK.		Dahl, Ronahl/F-8170-2013					BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1987, J ALLERGY CLIN IMMUN, V79, P126; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KOBER A, 1987, ALERGOL IMMUNOL CLIN, V2, P319; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; Mueller H L, 1966, J Asthma Res, V3, P331; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHUBERTH KC, 1987, J ALLERGY CLIN IMMUN, V79, P126; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4	19	71	71	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					699	702		10.1016/0091-6749(91)90391-Z	http://dx.doi.org/10.1016/0091-6749(91)90391-Z			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005322				2022-12-18	WOS:A1991FB80100015
J	FUJIMURA, M; SAKAMOTO, S; SAITO, M; MIYAKE, Y; MATSUDA, T				FUJIMURA, M; SAKAMOTO, S; SAITO, M; MIYAKE, Y; MATSUDA, T			EFFECT OF A THROMBOXANE-A2 RECEPTOR ANTAGONIST (AA-2414) ON BRONCHIAL HYPERRESPONSIVENESS TO METHACHOLINE IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GUINEA-PIGS; RESPONSIVENESS; AIRWAY; BRONCHOCONSTRICTION; RELEASE; A2	Bronchial hyperresponsiveness (BHR) to various stimuli is one of the major clinical features of bronchial asthma. In this study, the effect of a thromboxane A2 (TXA2) receptor antagonist, AA-2414, on BHR to methacholine was evaluated in 15 patients with asthma. The methacholine inhalation test was performed before and after oral administration of AA-2414 for 4 days (20 or 40 mg/day). The provocative concentration of methacholine producing a 20% fall in FEV1 (PC20) was measured as an index of BHR. There was a significant increase in PC20 (p < 0.01) from 0.43 (geometric SEM, 1.42) mg/ml to 0.93 (geometric SEM, 1.43) mg/ml after 40 mg/day of AA-2414, whereas baseline values of FVC and FEV1 were not changed by the treatment. Twenty milligrams per day of AA-2414 did not alter the PC20 value nor the parameter of baseline pulmonary functions. These findings might support our hypothesis that the subthreshold concentration of TXA2 in the bronchial tissues, which has no effect on bronchomotor tone per se, may be involved in BHR in asthma. Further studies with more potent and specific TXA2 receptor antagonists are needed to confirm the conclusion.			FUJIMURA, M (corresponding author), KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 3,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.							AIZAWA H, 1985, J APPL PHYSIOL, V59, P1918, DOI 10.1152/jappl.1985.59.6.1918; ASHIDA Y, 1989, PROSTAGLANDINS, V38, P91, DOI 10.1016/0090-6980(89)90019-1; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; BLACK PN, 1988, BR J CLIN PHARM, V25, P667; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P384; FUJIMURA M, 1989, J ASTHMA, V26, P237, DOI 10.3109/02770908909073255; FUJIMURA M, 1988, PROSTAGLANDINS, V35, P427, DOI 10.1016/0090-6980(88)90133-5; FUJIMURA M, 1990, CHEST, V98, P276, DOI 10.1378/chest.98.2.276; FUJIMURA M, 1990, CHEST, V98, P656, DOI 10.1378/chest.98.3.656; FUJIMURA M, 1986, THORAX, V41, P955, DOI 10.1136/thx.41.12.955; FUJIMURA M, 1984, KOKYU, V3, P1066; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; KATSURA M, 1983, ADV PROSTAG THROMB L, V11, P351; LEFORT J, 1984, BRIT J PHARMACOL, V82, P525; MAKINO S, 1982, JPN J ALLERGOL, V31, P1074; NAITO J, 1983, EUR J PHARMACOL, V91, P41, DOI 10.1016/0014-2999(83)90359-X; SHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; UENO A, 1982, PROSTAGLANDINS, V23, P865, DOI 10.1016/0090-6980(82)90130-7; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; YUKAWA T, 1987, JPN J THORAC DIS, V25, P1309	22	71	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				23	27		10.1016/0091-6749(91)90208-6	http://dx.doi.org/10.1016/0091-6749(91)90208-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1825100	Bronze			2022-12-18	WOS:A1991EX98500003
J	BUSSE, W; RANDLEV, B; SEDGWICK, J				BUSSE, W; RANDLEV, B; SEDGWICK, J			THE EFFECT OF AZELASTINE ON NEUTROPHIL AND EOSINOPHIL GENERATION OF SUPEROXIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BABIOR BM, 1984, BLOOD, V64, P959; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRIGHAM KL, 1986, CHEST, V89, P859, DOI 10.1378/chest.89.6.859; CHAND N, 1986, BRIT J PHARMACOL, V87, P443, DOI 10.1111/j.1476-5381.1986.tb10835.x; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V55, P1232, DOI 10.1152/jappl.1983.55.4.1232; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LARSEN GL, 1985, ANNU REV IMMUNOL, V3, P59; Lemanske R F Jr, 1981, Clin Immunol Rev, V1, P547; LITTLE MM, 1987, J ALLERGY CLIN IMMUN, V79, P204; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; SCHIAUTSTATTER IU, 1984, J CLIN INVEST, V73, P1175; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SLATER TF, 1984, BIOCHEM J, V222, P1; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; TANIGUCHI K, 1984, BIOCHEM PHARMACOL, V33, P3165, DOI 10.1016/0006-2952(84)90072-8; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2	29	71	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				400	405		10.1016/0091-6749(89)90125-5	http://dx.doi.org/10.1016/0091-6749(89)90125-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2563742				2022-12-18	WOS:A1989T448900006
J	THORPE, SC; KEMENY, DM; PANZANI, RC; MCGURL, B; LORD, M				THORPE, SC; KEMENY, DM; PANZANI, RC; MCGURL, B; LORD, M			ALLERGY TO CASTOR BEAN .2. IDENTIFICATION OF THE MAJOR ALLERGENS IN CASTOR BEAN-SEEDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUYS HOSP,UNITED MED & DENT SCH,DEPT MED,ST THOMASS ST,LONDON SE1 9RT,ENGLAND; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Warwick								CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; GIFFORD DJ, 1983, PLANT PHYSIOL, V72, P376, DOI 10.1104/pp.72.2.376; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; PANZANI R, 1957, INT ARCH ALLER A IMM, V11, P224, DOI 10.1159/000228420; Spies JR, 1943, J AM CHEM SOC, V65, P1720, DOI 10.1021/ja01249a020; THORPE SC, 1987, INT ARCH ALLERGY APP, V82, P3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOULE RJ, 1978, PLANT PHYSIOL, V61, P1040, DOI 10.1104/pp.61.6.1040	14	71	71	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					67	72		10.1016/0091-6749(88)90053-X	http://dx.doi.org/10.1016/0091-6749(88)90053-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392372				2022-12-18	WOS:A1988P400400012
J	AMBROSINO, DM; UMETSU, DT; SIBER, GR; HOWIE, G; GOULARTE, TA; MICHAELS, R; MARTIN, P; SCHUR, PH; NOYES, J; SCHIFFMAN, G; GEHA, RS				AMBROSINO, DM; UMETSU, DT; SIBER, GR; HOWIE, G; GOULARTE, TA; MICHAELS, R; MARTIN, P; SCHUR, PH; NOYES, J; SCHIFFMAN, G; GEHA, RS			SELECTIVE DEFECT IN THE ANTIBODY-RESPONSE TO HEMOPHILUS-INFLUENZAE TYPE-B IN CHILDREN WITH RECURRENT INFECTIONS AND NORMAL SERUM IGG SUBCLASS LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DIV ALLERGY & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,BOSTON,MA 02115; SUNY DOWNSTATE MED CTR,DEPT MICROBIOL & IMMUNOL,BROOKLYN,NY 11203; MASSACHUSETTS PUBL HLTH BIOL LABS,JAMAICA PLAIN,MA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Stanford University; Harvard University; Brigham & Women's Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018125, P50AI021163, R01AI020373] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21163, AI18125, AI20373] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROSINO DM, 1985, J INFECT DIS, V151, P1174, DOI 10.1093/infdis/151.6.1174; AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; AMMANN AJ, 1977, NEW ENGL J MED, V297, P897, DOI 10.1056/NEJM197710272971701; BASS JL, 1983, NEW ENGL J MED, V309, P430; BEARD LJ, 1986, PEDIATR RES, V20, P937, DOI 10.1203/00006450-198610000-00006; BJORKANDER J, 1986, J ALLERGY CLIN IMMUN, V77, P124; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; MAKELA PH, 1980, LANCET, V2, P547; MATTER L, 1985, NEW ENGL J MED, V312, P1039, DOI 10.1056/NEJM198504183121607; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; OXELIUS VA, 1979, CLIN EXP IMMUNOL, V36, P112; OXELIUS VA, 1974, CLIN EXP IMMUNOL, V17, P19; OXELIUS VA, 1979, ACTA PAEDIATR SCAND, V68, P23, DOI 10.1111/j.1651-2227.1979.tb04424.x; OXELIUS VA, 1982, NEW ENGL J MED, V306, P515, DOI 10.1056/NEJM198203043060905; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; RIESEN WF, 1976, SCAND J IMMUNOL, V5, P383, DOI 10.1111/j.1365-3083.1976.tb00292.x; SCHIFFMAN G, 1980, J IMMUNOL METHODS, V33, P133, DOI 10.1016/S0022-1759(80)80004-4; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SMITH TF, 1984, J PEDIATR-US, V105, P896, DOI 10.1016/S0022-3476(84)80073-6; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VANDERGOESSEN M, 1976, CLIN EXP IMMUNOL, V25, P1117; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633; YOUNT WJ, 1970, J CLIN INVEST, V49, P1957, DOI 10.1172/JCI106415; ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7	28	71	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1175	1179		10.1016/0091-6749(88)90887-1	http://dx.doi.org/10.1016/0091-6749(88)90887-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3259962				2022-12-18	WOS:A1988P002300017
J	REISMAN, RE; DVORIN, DJ; RANDOLPH, CC; GEORGITIS, JW				REISMAN, RE; DVORIN, DJ; RANDOLPH, CC; GEORGITIS, JW			STINGING INSECT ALLERGY - NATURAL-HISTORY AND MODIFICATION WITH VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,DIV ALLERGY,BUFFALO,NY 14260	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					PHS HHS [5R01-140501] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACHMAYER H, 1972, J INSECT PHYSIOL, V18, P1515, DOI 10.1016/0022-1910(72)90230-2; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; CLAYTON WF, 1983, CLIN ALLERGY, V13, P301, DOI 10.1111/j.1365-2222.1983.tb02604.x; CLAYTON WF, 1983, CLIN ALLERGY, V13, P123, DOI 10.1111/j.1365-2222.1983.tb02579.x; ESKRIDGE EM, 1981, TOXICON, V19, P893, DOI 10.1016/0041-0101(81)90087-8; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; OWEN MD, 1977, J INSECT PHYSIOL, V23, P1031, DOI 10.1016/0022-1910(77)90131-7; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN R E, 1984, Journal of Allergy and Clinical Immunology, V73, P187; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1984, TOXICON, V22, P148, DOI 10.1016/0041-0101(84)90148-X; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V68, P406, DOI 10.1016/0091-6749(81)90140-8; SCHUBERTH K C, 1984, Journal of Allergy and Clinical Immunology, V73, P189; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	22	71	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					731	740		10.1016/0091-6749(85)90103-4	http://dx.doi.org/10.1016/0091-6749(85)90103-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008803				2022-12-18	WOS:A1985ALA8400018
J	BUSSE, WW; SWENSON, CA; BORDEN, EC; TREUHAFT, MW; DICK, EC				BUSSE, WW; SWENSON, CA; BORDEN, EC; TREUHAFT, MW; DICK, EC			EFFECT OF INFLUENZA-A VIRUS ON LEUKOCYTE HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT HUMAN ONCOL, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PREVENT MED, MADISON, WI 53706 USA; MARSHFIELD MED FDN INC, MARSHFIELD, WI 54449 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010404, R01AI015685] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10404, AI15685, AI00343] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; BOURNE HR, 1972, J IMMUNOL, V108, P695; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUSSE WW, 1979, AM REV RESPIR DIS, V119, P561; BUSSE WW, 1980, AM REV RESPIR DIS, V122, P641; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENNIS M, 1980, INT ARCH ALLER A IMM, V62, P467, DOI 10.1159/000232551; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; FOREMAN JC, 1981, ANNU REV PHARMACOL, V21, P63, DOI 10.1146/annurev.pa.21.040181.000431; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; HERNANDEZASENSIO M, 1979, J IMMUNOL, V122, P1601; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HORN MEC, 1973, CHEST              S, V63, P44; IDA S, 1980, CLIN EXP IMMUNOL, V41, P380; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; JOHANSEN T, 1980, EUR J PHARMACOL, V62, P329, DOI 10.1016/0014-2999(80)90100-4; KALINER MA, 1980, J ALLERGY CLIN IMMUN, V66, P1, DOI 10.1016/0091-6749(80)90131-1; KAZIMIERCZAK W, 1978, ACTA PHYSL SCAND, V102, P205; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; LEE TP, 1977, J ALLERGY CLIN IMMUN, V59, P408, DOI 10.1016/0091-6749(77)90002-1; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; NICHOLSON KG, 1976, LANCET, V1, P1309; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808	37	71	71	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					382	388		10.1016/0091-6749(83)90066-0	http://dx.doi.org/10.1016/0091-6749(83)90066-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6187791				2022-12-18	WOS:A1983QL12100005
J	KEMENY, DM; HARRIES, MG; YOULTEN, LJF; MACKENZIEMILLS, M; LESSOF, MH				KEMENY, DM; HARRIES, MG; YOULTEN, LJF; MACKENZIEMILLS, M; LESSOF, MH			ANTIBODIES TO PURIFIED BEE VENOM PROTEINS AND PEPTIDES .1. DEVELOPMENT OF A HIGHLY SPECIFIC RAST FOR BEE VENOM ANTIGENS AND ITS APPLICATION TO BEE STING ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KEMENY, DM (corresponding author), GUYS HOSP,SCH MED,DEPT MED,LONDON SE1 9RT,ENGLAND.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ARBESMAN CE, 1976, CLIN ALLERGY, V6, P587, DOI 10.1111/j.1365-2222.1976.tb01945.x; BENTON A W, 1967, Journal of Apicultural Research, V6, P91; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, INT ARCH ALLER A IMM, V42, P430, DOI 10.1159/000230623; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P118; GLEICH GL, 1977, J ALLERGY CLIN IMMUN, V55, P334; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; KARPAS AB, 1977, J ALLERGY CLIN IMMUN, V60, P155, DOI 10.1016/0091-6749(77)90118-X; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1982, INT ARCH ALLER A IMM, V68, P268, DOI 10.1159/000233110; KEMENY DM, 1981, BIOCHEM INT, V2, P145; KEMENY DM, 1982, J IMMUNOL METHODS, V49, P89, DOI 10.1016/0022-1759(82)90369-6; KEMENY DM, 1981, THESIS LONDON U; KING TP, 1976, ARCH BIOCH BIOPHYS, V177, P661; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Light W. C., 1975, Advances in diagnosis of allergy: RAST (Editor R. Evans, III)., P137; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; MIYACHI S, 1979, INT ARCH ALLER A IMM, V58, P160, DOI 10.1159/000232188; NEUMANN W, 1954, ARCH EXP PATHOL PH, V222, P367; OWEN MD, 1979, TOXICON, V17, P94, DOI 10.1016/0041-0101(79)90260-5; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; SETTIPANE GA, 1980, CLIN ALLERGY, V10, P659, DOI 10.1111/j.1365-2222.1980.tb02149.x; SETTIPANE GA, 1979, CLIN ALLERGY, V7, P102; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHKENDEROV S, 1979, Toxicon, V17, P169; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; WIDE L, 1967, LANCET, V2, P1105; YMAN L, 1975, DEV BIOL STANDARDISA, V29	38	71	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					505	514		10.1016/0091-6749(83)90469-4	http://dx.doi.org/10.1016/0091-6749(83)90469-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6601672				2022-12-18	WOS:A1983QQ74200012
J	MATHEWS, KP				MATHEWS, KP			URTICARIA AND ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MATHEWS, KP (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV ALLERGY,ANN ARBOR,MI 48109, USA.							ALPERT E, 1971, NEW ENGL J MED, V285, P185, DOI 10.1056/NEJM197107222850401; BALLOW M, 1975, LANCET, V2, P248; BECKER LC, 1973, JOHNS HOPKINS MED J, V133, P38; BERNSTEIN JE, 1981, J INVEST DERMATOL, V76, P394, DOI 10.1111/1523-1747.ep12520912; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CHODIRKER WB, 1979, CLIN ALLERGY, V9, P201, DOI 10.1111/j.1365-2222.1979.tb01542.x; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; DAVIS RS, 1981, J ALLERGY CLIN IMMUN, V68, P479, DOI 10.1016/0091-6749(81)90202-5; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; EFTEKHARI N, 1980, BRIT J DERMATOL, V103, P33, DOI 10.1111/j.1365-2133.1980.tb15835.x; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; FISHER AA, 1982, CUTIS, V30, P171; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GRAHAM DT, 1950, JAMA-J AM MED ASSOC, V143, P1396, DOI 10.1001/jama.1950.02910510014003; Grant RT, 1936, CLIN SCI, V2, P253; HARRIS A, 1982, Journal of Allergy and Clinical Immunology, V69, P109; HELLGREN L, 1972, Acta Allergologica, V27, P236, DOI 10.1111/j.1398-9995.1972.tb01420.x; ISAACS NJ, 1971, J ALLERGY CLIN IMMUN, V48, P73, DOI 10.1016/0091-6749(71)90089-3; JACOBSON KW, 1980, JAMA-J AM MED ASSOC, V243, P1644, DOI 10.1001/jama.243.16.1644; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LAURELL AB, 1977, INT ARCH ALLER A IMM, V54, P434, DOI 10.1159/000231859; Lewis T., 1927, BLOOD VESSELS HUMAN; MATHEWS KP, 1980, ANN INTERN MED, V93, P443, DOI 10.7326/0003-4819-93-3-443; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V66, P347, DOI 10.1016/0091-6749(80)90113-X; MATHEWS KP, 1981, NEW ENGL J MED, V305, P1090, DOI 10.1056/NEJM198110293051814; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MILINS JL, 1980, J AM ACAD DERMATOL, V3, P349; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; MONROE EW, 1981, J INVEST DERMATOL, V76, P103, DOI 10.1111/1523-1747.ep12525403; MUCKLE TJ, 1979, BRIT J DERMATOL, V100, P87, DOI 10.1111/j.1365-2133.1979.tb03572.x; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; PASRICHA JS, 1973, BRIT J DERMATOL, V89, P587, DOI 10.1111/j.1365-2133.1973.tb07583.x; PATON WDM, 1957, PHARMACOL REV, V9, P269; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; PRENNER BM, 1976, ANN ALLERGY, V37, P180; RAVITS M, 1982, ARCH DERMATOL, V118, P228, DOI 10.1001/archderm.118.4.228; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; RYAN TJ, 1968, BRIT J DERMATOL, V80, P485, DOI 10.1111/j.1365-2133.1968.tb12334.x; SCHAPIRA M, 1981, BLOOD, V58, pA226; SCHWARTZ HR, 1982, MAYO CLIN PROC, V57, P231; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SHELDON JM, 1954, J ALLERGY, V25, P525, DOI 10.1016/S0021-8707(54)90034-9; SIBBALD RG, 1981, BRIT J DERMATOL, V105, P297, DOI 10.1111/j.1365-2133.1981.tb01289.x; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SOTER NA, 1980, J ALLERGY CLIN IMMUN, V66, P358, DOI 10.1016/0091-6749(80)90114-1; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; SUSSMAN GL, 1982, J ALLERGY CLIN IMMUN, V70, P337, DOI 10.1016/0091-6749(82)90022-7; Swinny B, 1941, SOUTH MED J, V34, P855; WARIN RP, 1974, URTICARIA; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; ZEISS CR, 1980, AM J MED, V68, P867, DOI 10.1016/0002-9343(80)90216-8	62	71	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					1	14		10.1016/0091-6749(83)90042-8	http://dx.doi.org/10.1016/0091-6749(83)90042-8			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6189878				2022-12-18	WOS:A1983QZ19800001
J	ROSENBERG, GL; ROSENTHAL, RR; NORMAN, PS				ROSENBERG, GL; ROSENTHAL, RR; NORMAN, PS			INHALATION CHALLENGE WITH RAGWEED POLLEN IN RAGWEED-SENSITIVE ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; GOOD SAMARITAN HOSP,BALTIMORE,MD 21239	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI004866, R01AI004866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 04866, AI 10304] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS KF, 1964, ACTA ALLERGOL, V19, P11, DOI 10.1111/j.1398-9995.1964.tb03220.x; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FONTANA VJ, 1974, J ALLERGY CLIN IMMUN, V54, P235, DOI 10.1016/0091-6749(74)90066-9; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLAND AW, 1955, INT ARCH ALLER A IMM, V6, P45, DOI 10.1159/000228145; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HAMILTON ELIZABETH D., 1959, ACTA ALLERGOL, V13, P143, DOI 10.1111/j.1398-9995.1959.tb02761.x; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; HOBDAY JD, 1971, J ALLERGY CLIN IMMUN, V48, P254, DOI 10.1016/0091-6749(71)90075-3; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NOVEY HS, 1977, AM REV RESPIR DIS, V116, P789, DOI 10.1164/arrd.1977.116.4.789; ROBINSON W, 1958, LANCET, V2, P821; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	27	71	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					302	310		10.1016/0091-6749(83)90084-2	http://dx.doi.org/10.1016/0091-6749(83)90084-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6826990				2022-12-18	WOS:A1983QH18800006
J	DAHLEM, NW; KINSMAN, RA; HORTON, DJ				DAHLEM, NW; KINSMAN, RA; HORTON, DJ			PANIC-FEAR IN ASTHMA - REQUESTS FOR AS NEEDED MEDICATIONS IN RELATION TO PULMONARY-FUNCTION MEASUREMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT BEHAV SCI,PSYCHOPHYSIOL RES LABS,DENVER,CO 80206; NATL JEWISH HOSP & RES CTR,DEPT MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PSYCHIAT,DENVER,CO 80202; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80202	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BIERMAN CW, 1974, PEDIATRICS, V54, P668; BLOCK J, 1964, PSYCHOSOM MED, V26, P307, DOI 10.1097/00006842-196407000-00003; CHAI H, 1973, AM J DIS CHILD, V125, P757, DOI 10.1001/archpedi.1973.04160050095021; COMROE JH, 1962, LUNG, P325; DIRKS JF, 1977, J ASTHMA RES, V14, P61, DOI 10.3109/02770907709098953; DIRKS JF, 1977, PSYCHOSOM MED, V39, P120, DOI 10.1097/00006842-197703000-00006; DIRKS JF, IN PRESS; KINSMAN RA, 1977, PSYCHOSOM MED, V39, P102, DOI 10.1097/00006842-197703000-00005; KINSMAN RA, 1974, PSYCHOSOM MED, V36, P129, DOI 10.1097/00006842-197403000-00005; KINSMAN RA, 1973, J ALLERGY CLIN IMMUN, V52, P284, DOI 10.1016/0091-6749(73)90047-X; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KNAPP PH, 1976, BRONCHIAL ASTHMA MEC, P1055; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; PURCELL K, 1961, PSYCHOSOM MED, V23, P305, DOI 10.1097/00006842-196107000-00007; READ J, 1968, MED J AUST, V1, P881; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; TOOGOOD JH, 1971, AM REV RESPIR DIS, V104, P323, DOI 10.1164/arrd.1971.104.3.323; WINER BJ, 1962, STATISTICAL PRINCIPL	20	71	72	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					295	300		10.1016/0091-6749(77)90108-7	http://dx.doi.org/10.1016/0091-6749(77)90108-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EA243	915146				2022-12-18	WOS:A1977EA24300004
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN BEE VENOM .3. IDENTIFICATION OF ALLERGEN-B OF BEE VENOM AS AN ACID-PHOSPHATASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT PATHOL,CRISS 2,OMAHA,NE 68178	Creighton University								ALLEN SL, 1963, J HISTOCHEM CYTOCHEM, V11, P706, DOI 10.1177/11.6.706; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2	8	71	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					364	366		10.1016/0091-6749(77)90019-7	http://dx.doi.org/10.1016/0091-6749(77)90019-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	853176				2022-12-18	WOS:A1977DF21500005
J	RICHARDSON, JB; HOGG, JC; BOUCHARD, T; HALL, DL				RICHARDSON, JB; HOGG, JC; BOUCHARD, T; HALL, DL			LOCALIZATION OF ANTIGEN IN EXPERIMENTAL BRONCHOCONSTRICTION IN GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV, DEPT PHARMACOL & THERAPEUTICS, 3655 DRUMMOND ST, MONTREAL 109, QUEBEC, CANADA; MCGILL UNIV, DEPT PATHOL, MONTREAL, QUEBEC, CANADA	McGill University; McGill University								AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; CLEMENTI F, 1970, J HISTOCHEM CYTOCHEM, V18, P887, DOI 10.1177/18.12.887; CURRAN PF, 1962, NATURE, V193, P347, DOI 10.1038/193347a0; FILLENZ M, 1970, HERINGBREUER CENTENA, P101; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; HUGON JS, 1968, J HISTOCHEM CYTOCHEM, V16, P229, DOI 10.1177/16.4.229; HUNG KS, 1972, AM J ANAT, V135, P477, DOI 10.1002/aja.1001350404; KIERNAN JA, 1972, Q J EXP PHYSIOL CMS, V57, P311, DOI 10.1113/expphysiol.1972.sp002164; LEDUC EH, 1968, J EXP MED, V127, P109, DOI 10.1084/jem.127.1.109; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724, DOI 10.1111/j.1476-5381.1970.tb09898.x; Olsson Y., 1968, International Review of Cytology, V24, P27, DOI 10.1016/S0074-7696(08)61396-0; PIPER PJ, 1973, BRIT J PHARMACOL, V47, P291, DOI 10.1111/j.1476-5381.1973.tb08327.x; PIPER PJ, 1969, NATURE, V223, P29, DOI 10.1038/223029a0; SCHNEEBE.EE, 1971, J CELL BIOL, V49, P319, DOI 10.1083/jcb.49.2.319; SZIDON JP, 1972, NEW ENGL J MED, V286, P1200, DOI 10.1056/NEJM197206012862208; WARSHAW AL, 1971, LAB INVEST, V25, P675; WEINSTEIN RS, 1972, NEW ENGL J MED, V286, P521, DOI 10.1056/NEJM197203092861006	19	71	71	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	3					172	181		10.1016/0091-6749(73)90034-1	http://dx.doi.org/10.1016/0091-6749(73)90034-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q7045	4725112				2022-12-18	WOS:A1973Q704500006
J	Dand, N; Duckworth, M; Baudry, D; Russell, A; Curtis, CJ; Lee, SH; Evans, I; Mason, KJ; Alsharqi, A; Becher, G; Burden, AD; Goodwin, RG; McKenna, K; Murphy, R; Perera, GK; Rotarescu, R; Wahie, S; Wright, A; Reynolds, NJ; Warren, RB; Griffiths, CEM; Smith, CH; Simpson, MA; Barker, JN; Benham, M; Hussain, S; Kirby, B; Lawson, L; McElhone, K; Ormerod, A; Owen, C; Barnes, MR; Di Meglio, P; Emsley, R; Evans, A; Payne, K; Stocken, D; Barker, J; Burden, D; Griffiths, C; Mason, K; Reynolds, N; Smith, C; Warren, R				Dand, Nick; Duckworth, Michael; Baudry, David; Russell, Alice; Curtis, Charles J.; Lee, Sang Hyuck; Evans, Ian; Mason, Kayleigh J.; Alsharqi, Ali; Becher, Gabrielle; Burden, A. David; Goodwin, Richard G.; McKenna, Kevin; Murphy, Ruth; Perera, Gayathri K.; Rotarescu, Radu; Wahie, Shyamal; Wright, Andrew; Reynolds, Nick J.; Warren, Richard B.; Griffiths, Christopher E. M.; Smith, Catherine H.; Simpson, Michael A.; Barker, Jonathan N.; Benham, Marilyn; Hussain, Sagair; Kirby, Brian; Lawson, Linda; McElhone, Kathleen; Ormerod, Anthony; Owen, Caroline; Barnes, Michael R.; Di Meglio, Paola; Emsley, Richard; Evans, Andrea; Payne, Katherine; Stocken, Deborah; Barker, Jonathan; Burden, David; Griffiths, Christopher; Mason, Kayleigh; Reynolds, Nick; Smith, Catherine; Warren, Richard		BADBIR Study Grp; BSTOP Study Grp; PSORT Consortium	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; psoriatic arthritis; biologic therapy; genetics; pharmacogenetics; treatment response; HLA; adalimumab; ustekinumab; skin disease	BRITISH ASSOCIATION; SUSCEPTIBILITY LOCI; HLA-C; THERAPY; USTEKINUMAB; COHORT; HLA-CW-ASTERISK-0602; STRATIFICATION; IDENTIFICATION; DESIGN	Background: Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treatment cost-effectiveness. Objective: We sought to test whether HLA-C*06:02, the primary genetic susceptibility allele for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed biologics for psoriasis: adalimumab (anti-TNF-alpha) and ustekinumab (anti-IL-12/23). Methods: This study uses a national psoriasis registry that includes longitudinal treatment and response observations and detailed clinical data. HLA alleles were imputed from genome-wide genotype data for 1326 patients for whom 90% reduction in Psoriasis Area and Severity Index score (PASI90) response status was observed after 3, 6, or 12 months of treatment. We developed regression models of PASI90 response, examining the interaction between HLA-C*06:02 and drug type (adalimumab or ustekinumab) while accounting for potentially confounding clinical variables. Results: HLA-C*06:02-negative patients were significantly more likely to respond to adalimumab than ustekinumab at all time points (most strongly at 6 months: odds ratio [OR], 2.95; P = 5.85 x 10(-7)), and the difference was greater in HLA-C*06:02-negative patients with psoriatic arthritis (OR, 5.98; P = 6.89 x 10(-5)). Biologic-naive patients who were HLA-C* 06:02 positive and psoriatic arthritis negative demonstrated significantly poorer response to adalimumab at 12 months (OR, 0.31; P = 3.42 x 10(-4)). Results from HLA-wide analyses were consistent with HLA-C*06:02 itself being the primary effect allele. We found no evidence for genetic interaction between HLA-C*06:02 and ERAP1. Conclusion: This large observational study suggests that reference to HLA-C* 06: 02 status could offer substantial clinical benefit when selecting treatments for severe psoriasis.	[Dand, Nick; Simpson, Michael A.] Kings Coll London, Sch Basic & Med Biosci, London, England; [Duckworth, Michael; Baudry, David; Russell, Alice; Smith, Catherine H.; Barker, Jonathan N.] Kings Coll London, Fac Life Sci & Med, St Johns Inst Dermatol, London, England; [Curtis, Charles J.; Lee, Sang Hyuck] Kings Coll London, Inst Psychiat Psychol & Neurosci, Social Genet & Dev Psychiat Ctr, London, England; [Curtis, Charles J.; Lee, Sang Hyuck] South London & Maudsley NHS Fdn Trust, NIHR Maudsley Biomed Res Ctr, London, England; [Curtis, Charles J.; Lee, Sang Hyuck] Kings Coll London, London, England; [Evans, Ian; Mason, Kayleigh J.; Warren, Richard B.; Griffiths, Christopher E. M.] Univ Manchester, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Fdn Trust,Dermatol Ctr, Manchester, Lancs, England; [Alsharqi, Ali] Royal Liverpool & Brodgreen Univ Hosp Trusts, Liverpool, Merseyside, England; [Becher, Gabrielle] West Glasgow ACH, Alan Lyell Ctr Dermatol, Glasgow, Lanark, Scotland; [Burden, A. David] Univ Glasgow, Inst Infect Inflammat & Immun, Glasgow, Lanark, Scotland; [Goodwin, Richard G.] Aneurin Bevan Univ Hlth Board, Caerleon, Gwent, Wales; [McKenna, Kevin] Belfast City Hosp, Dept Dermatol, Belfast, Antrim, North Ireland; [Murphy, Ruth] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Murphy, Ruth] Sheffield Childrens NHS Fdn Trust, Sheffield, S Yorkshire, England; [Murphy, Ruth] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Perera, Gayathri K.] Chelsea & Westminster Hosp NHS Fdn Trust, West Middlesex Univ Hosp, London, England; [Rotarescu, Radu] Univ Hosp North Midlands, Stoke On Trent, Staffs, England; [Wahie, Shyamal] Univ Hosp North Durham, Durham, England; [Wright, Andrew] Univ Bradford, Ctr Skin Sci, Bradford, W Yorkshire, England; [Wright, Andrew] Bradford Teaching Hosp NHS Fdn Trust, St Lukes Hosp, Dermatol Dept, Bradford, W Yorkshire, England; [Reynolds, Nick J.] Newcastle Univ, Med Sch, Inst Cellular Med, Dermatol Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Reynolds, Nick J.] Newcastle Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Reynolds, Nick J.] Newcastle Univ, Newcastle MRC EPSRC Mol Pathol Node, Newcastle Upon Tyne, Tyne & Wear, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London; Salford Royal NHS Foundation Trust; University of Manchester; University of Glasgow; Belfast City Hospital; University of Sheffield; Sheffield Children's NHS Foundation Trust; Nottingham University Hospital NHS Trust; Imperial College London; University of Bradford; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; UK Research & Innovation (UKRI); Engineering & Physical Sciences Research Council (EPSRC)	Simpson, MA (corresponding author), Kings Coll London, Guys Hosp, Sch Basic & Med Biosci, 8th Floor Tower Wing, London SE1 9RT, England.; Barker, JN (corresponding author), Kings Coll London, Guys Hosp, St Johns Inst Dermatol, 9th Floor Tower Wing, London SE1 9RT, England.	michael.simpson@kcl.ac.uk; jonathan.barker@kcl.ac.uk	Emsley, Richard/N-1342-2016; Mason, Kayleigh J/AAI-5318-2021; Mason, Kayleigh/ABW-1652-2022; Warren, Richard/G-4929-2015; Simpson, Michael/F-4737-2011; Smith, Catherine/G-5268-2012	Emsley, Richard/0000-0002-1218-675X; Mason, Kayleigh J/0000-0002-5419-0669; Curtis, Charles/0000-0002-2992-1941; Reynolds, Nick/0000-0002-6484-825X; Duckworth, Michael/0000-0003-0295-9621; Lee, Sang hyuck/0000-0002-5610-033X; Warren, Richard/0000-0002-2918-6481; Stocken, Deborah/0000-0001-8031-1738; Baudry, David/0000-0003-0784-1286; Simpson, Michael/0000-0002-8539-8753; Smith, Catherine/0000-0001-9918-1144; Dand, Nick/0000-0002-1805-6278	PSORT - Medical Research Council (MRC) Stratified Medicine award [MR/L011808/1]; Psoriasis Association [RG2/10]; NIHR Biomedical Research Centre at King's College London/Guy's and St Thomas' NHS Foundation Trust; Newcastle NIHR Biomedical Research Centre; NIHR Manchester Biomedical Research Centre; British Association of Dermatologists (BAD); Health Data Research UK - UK Medical Research Council [MR/S003126/1]; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; Newcastle NIHR Medtech; Newcastle NIHR In Vitro Diagnostic Co-operative; Newcastle MRC/EPSRC Molecular Pathology Node; MRC [MR/N005872/1, MR/L011808/1, MR/S003126/1] Funding Source: UKRI	PSORT - Medical Research Council (MRC) Stratified Medicine award; Psoriasis Association; NIHR Biomedical Research Centre at King's College London/Guy's and St Thomas' NHS Foundation Trust; Newcastle NIHR Biomedical Research Centre; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); British Association of Dermatologists (BAD); Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; Newcastle NIHR Medtech; Newcastle NIHR In Vitro Diagnostic Co-operative; Newcastle MRC/EPSRC Molecular Pathology Node(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by PSORT, which is in turn funded by a Medical Research Council (MRC) Stratified Medicine award (MR/L011808/1). The Psoriasis Association (RG2/10), the NIHR Biomedical Research Centre at King's College London/Guy's and St Thomas' NHS Foundation Trust, the Newcastle NIHR Biomedical Research Centre, and the NIHR Manchester Biomedical Research Centre. The British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) is coordinated by the University of Manchester. BADBIR is funded by the British Association of Dermatologists (BAD). The BAD receives income from Janssen Cilag, AbbVie, Novartis, Samsung Bioepis, Eli Lilly, Celgene, Almirall, and Hexal AG for providing pharmacovigilance services. This income finances a separate contract between the BAD and the University of Manchester who coordinate BADBIR. All decisions concerning analysis, interpretation, and publication are made independently of any industrial contribution. N.D. was partly supported by Health Data Research UK (MR/S003126/1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; and Wellcome. N.J.R.'s laboratory is funded in part by the Newcastle NIHR Biomedical Research Centre, the Newcastle NIHR Medtech, and the In Vitro Diagnostic Co-operative and the Newcastle MRC/EPSRC Molecular Pathology Node.	Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Baker KF, 2018, ANN RHEUM DIS, V77, P175, DOI 10.1136/annrheumdis-2017-211555; Baye Tesfaye M, 2011, BMC Proc, V5 Suppl 9, pS8, DOI 10.1186/1753-6561-5-S9-S8; Bowes J, 2017, ANN RHEUM DIS, V76, P1774, DOI 10.1136/annrheumdis-2017-211414; Burden AD, 2012, BRIT J DERMATOL, V166, P545, DOI 10.1111/j.1365-2133.2012.10835.x; Chen L, 2018, BRIT J DERMATOL, V178, P854, DOI 10.1111/bjd.16083; Dand N, 2017, HUM MOL GENET, V26, P4301, DOI 10.1093/hmg/ddx328; Das S, 2015, EUR J HUM GENET, V23, P844, DOI 10.1038/ejhg.2014.172; Davison NJ, 2017, BRIT J DERMATOL, V177, P828, DOI 10.1111/bjd.15551; Demidenko E, 2008, STAT MED, V27, P36, DOI 10.1002/sim.2980; Fan X, 2007, ACTA DERM-VENEREOL, V87, P335, DOI 10.2340/00015555-0253; Feng BJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000606; Fowler JF, 2008, J AM ACAD DERMATOL, V59, P772, DOI 10.1016/j.jaad.2008.06.043; Generali E, 2017, J AUTOIMMUN, V83, P51, DOI 10.1016/j.jaut.2017.04.005; Griffiths CEM, 2015, J INVEST DERMATOL, V135, P2903, DOI 10.1038/jid.2015.286; Gudjonsson JE, 2006, J INVEST DERMATOL, V126, P740, DOI 10.1038/sj.jid.5700118; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; Iskandar IYK, 2017, BRIT J DERMATOL, V176, P1297, DOI 10.1111/bjd.15027; Jia X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057858; Knight J, 2012, HUM MOL GENET, V21, P5185, DOI 10.1093/hmg/dds344; Kromer C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189765; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li K, 2016, J INVEST DERMATOL, V136, P2364, DOI 10.1016/j.jid.2016.06.631; Lumley T., 2004, J STAT SOFTW, V9, P1, DOI [10.18637/jss.v009.i08, DOI 10.18637/JSS.V009.I08]; Mahil SK, 2016, SEMIN IMMUNOPATHOL, V38, P11, DOI 10.1007/s00281-015-0539-8; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Menter A, 2008, J AM ACAD DERMATOL, V58, P106, DOI 10.1016/j.jaad.2007.09.010; Morris JA, 2010, BIOINFORMATICS, V26, P1786, DOI 10.1093/bioinformatics/btq280; National Institute for Health and Care Excellence, 2012, PSOR ASS MAN NICE CL; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; R Core Team, 2017, R LANG ENV STAT COMP; Raposo I, 2017, EUR J DERMATOL, V27, P528, DOI 10.1684/ejd.2017.3071; Smith CH, 2017, BRIT J DERMATOL, V177, P628, DOI 10.1111/bjd.15665; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Talamonti M, 2017, BRIT J DERMATOL, V177, P489, DOI 10.1111/bjd.15387; Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; van Vugt LJ, 2018, BRIT J DERMATOL, V178, P86, DOI 10.1111/bjd.15753; Warren RB, 2015, J INVEST DERMATOL, V135, P2632, DOI 10.1038/jid.2015.208; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; World Health Organization, GLOB REP PSOR; WUEPPER KD, 1990, J INVEST DERMATOL, V95, pS2, DOI 10.1111/1523-1747.ep12505638	44	70	73	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2120	2130		10.1016/j.jaci.2018.11.038	http://dx.doi.org/10.1016/j.jaci.2018.11.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578879	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000470113200017
J	Dorjbal, B; Stinson, JR; Ma, CA; Weinreich, MA; Miraghazadeh, B; Hartberger, JM; Frey-Jakobs, S; Weidinger, S; Moebus, L; Franke, A; Schaffer, AA; Bulashevska, A; Fuchs, S; Ehl, S; Limaye, S; Arkwright, PD; Briggs, TA; Langley, C; Bethune, C; Whyte, AF; Alachkar, H; Nejentsev, S; DiMaggio, T; Nelson, CG; Stone, KD; Nason, M; Brittain, EH; Oler, AJ; Veltri, DP; Leahy, TR; Conlon, N; Poli, MC; Borzutzky, A; Cohen, JI; Davis, J; Lambert, MP; Romberg, N; Sullivan, KE; Paris, K; Freeman, AF; Lucas, L; Chandrakasan, S; Savic, S; Hambleton, S; Patel, SY; Jordan, MB; Theos, A; Lebensburger, J; Atkinson, TP; Torgerson, TR; Chinn, IK; Milner, JD; Grimbacher, B; Cook, MC; Snow, AL				Dorjbal, Batsukh; Stinson, Jeffrey R.; Ma, Chi A.; Weinreich, Michael A.; Miraghazadeh, Bahar; Hartberger, Julia M.; Frey-Jakobs, Stefanie; Weidinger, Stephan; Moebus, Lena; Franke, Andre; Schaffer, Alejandro A.; Bulashevska, Alla; Fuchs, Sebastian; Ehl, Stephan; Limaye, Sandhya; Arkwright, Peter D.; Briggs, Tracy A.; Langley, Claire; Bethune, Claire; Whyte, Andrew F.; Alachkar, Hana; Nejentsev, Sergey; DiMaggio, Thomas; Nelson, Celeste G.; Stone, Kelly D.; Nason, Martha; Brittain, Erica H.; Oler, Andrew J.; Veltri, Daniel P.; Leahy, T. Ronan; Conlon, Niall; Poli, Maria C.; Borzutzky, Arturo; Cohen, Jeffrey I.; Davis, Joie; Lambert, Michele P.; Romberg, Neil; Sullivan, Kathleen E.; Paris, Kenneth; Freeman, Alexandra F.; Lucas, Laura; Chandrakasan, Shanmuganathan; Savic, Sinisa; Hambleton, Sophie; Patel, Smita Y.; Jordan, Michael B.; Theos, Amy; Lebensburger, Jeffrey; Atkinson, T. Prescott; Torgerson, Troy R.; Chinn, Ivan K.; Milner, Joshua D.; Grimbacher, Bodo; Cook, Matthew C.; Snow, Andrew L.			Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CARD11; atopy; atopic dermatitis; dominant negative; primary immunodeficiency; immune dysregulation	NF-KAPPA-B; LINKAGE ANALYSIS; CELL; CARMA1; COMPLEX; SYSTEM; MALT1; EXOME	Background: Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor kappa B, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1. Germline CARD11 mutations cause several distinct primary immune disorders in human subjects, including severe combined immune deficiency (biallelic null mutations), B-cell expansion with nuclear factor kappa B and T-cell anergy (heterozygous, gain-of-function mutations), and severe atopic disease (loss-of-function, heterozygous, dominant interfering mutations), which has focused attention on CARD11 mutations discovered by using whole-exome sequencing. Objectives: We sought to determine the molecular actions of an extended allelic series of CARD11 and to characterize the expanding range of clinical phenotypes associated with heterozygous CARD11 loss-of-function alleles. Methods: Cell transfections and primary T-cell assays were used to evaluate signaling and function of CARD11 variants. Results: Here we report on an expanded cohort of patients harboring novel heterozygous CARD11 mutations that extend beyond atopy to include other immunologic phenotypes not previously associated with CARD11 mutations. In addition to (and sometimes excluding) severe atopy, heterozygous missense and indel mutations in CARD11 presented with immunologic phenotypes similar to those observed in signal transducer and activator of transcription 3 loss of function, dedicator of cytokinesis 8 deficiency, common variable immunodeficiency, neutropenia, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome. Pathogenic variants exhibited dominant negative activity and were largely confined to the CARD or coiled-coil domains of the CARD11 protein. Conclusion: These results illuminate a broader phenotypic spectrum associated with CARD11 mutations in human subjects and underscore the need for functional studies to demonstrate that rare gene variants encountered in expected and unexpected phenotypes must nonetheless be validated for pathogenic activity.	[Dorjbal, Batsukh; Stinson, Jeffrey R.; Snow, Andrew L.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol & Mol Therapeut, 4301 Jones Bridge Rd,C-2013, Bethesda, MD 20814 USA; [Ma, Chi A.; Weinreich, Michael A.; DiMaggio, Thomas; Nelson, Celeste G.; Stone, Kelly D.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Nason, Martha; Brittain, Erica H.] NIAID, Biostat Res Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Oler, Andrew J.; Veltri, Daniel P.] NIAID, Bioinformat & Computat Sci Branch, Off Cyber Infrastruct & Computat Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cohen, Jeffrey I.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; [Davis, Joie; Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Miraghazadeh, Bahar; Cook, Matthew C.] Australian Natl Univ, Canberra Hosp, Dept Immunol, Canberra, ACT, Australia; [Miraghazadeh, Bahar; Cook, Matthew C.] Australian Natl Univ, Ctr Personalised Immunol, John Curtin Sch Med Res, Canberra, ACT, Australia; [Hartberger, Julia M.; Frey-Jakobs, Stefanie; Bulashevska, Alla; Fuchs, Sebastian; Ehl, Stephan; Grimbacher, Bodo] Univ Freiburg, Fac Med, Med Ctr, CCI, Freiburg, Germany; [Weidinger, Stephan; Moebus, Lena] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergol, Campus Kiel, Kiel, Germany; [Franke, Andre] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Schaffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bldg 10, Bethesda, MD 20892 USA; [Limaye, Sandhya] Repatriat & Gen Hosp, Concord, NSW, Australia; [Arkwright, Peter D.; Briggs, Tracy A.; Langley, Claire] Univ Manchester, Paediat Allergy & Immunol & Manchester Ctr Genom, Manchester, Lancs, England; [Bethune, Claire; Whyte, Andrew F.] Plymouth Hosp NHS Trust, Dept Clin Immunol, Plymouth, Devon, England; [Alachkar, Hana] Salford Royal Fdn Trust, Immunol, Manchester, Lancs, England; [Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge, England; [Leahy, T. Ronan] Our Ladys Childrens Hosp, Dept Paediat Immunol, Dublin, Ireland; [Leahy, T. Ronan] Our Ladys Childrens Hosp, ID, Dublin, Ireland; [Conlon, Niall] St James Hosp, Dept Immunol, Dublin, Ireland; [Poli, Maria C.; Chinn, Ivan K.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Poli, Maria C.; Chinn, Ivan K.] Texas Childrens Hosp, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Borzutzky, Arturo] Pontificia Univ Catolica Chile, Sch Med, Dept Pediat, Santiago, Chile; [Lambert, Michele P.; Romberg, Neil; Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Div Immunol & Allergy, Philadelphia, PA 19104 USA; [Lambert, Michele P.; Romberg, Neil; Sullivan, Kathleen E.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Paris, Kenneth] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA; [Paris, Kenneth] Childrens Hosp, New Orleans, LA USA; [Lucas, Laura; Chandrakasan, Shanmuganathan] Emory Univ, Sch Med, Div Bone Marrow Transplant, Childrens Healthcare Atlanta, Atlanta, GA USA; [Savic, Sinisa] St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England; [Hambleton, Sophie] Newcastle Univ, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Patel, Smita Y.] Oxford Univ Hosp NHS Trust, Oxford, England; [Patel, Smita Y.] NIHR Oxford Biomed Res Ctr, Oxford, England; [Jordan, Michael B.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45221 USA; [Theos, Amy] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [Lebensburger, Jeffrey] Univ Alabama Birmingham, Dept Pediat Hematol Oncol, Birmingham, AL USA; [Atkinson, T. Prescott] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Torgerson, Troy R.] Univ Washington, Sch Med, Seattle, WA USA; Seattle Childrens Hosp, Seattle, WA USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Australian National University; Canberra Hospital; Australian National University; John Curtin School of Medical Research; University of Freiburg; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; National Institutes of Health (NIH) - USA; Concord Repatriation General Hospital; University of Manchester; University of Plymouth; Salford Royal NHS Foundation Trust; University of Cambridge; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Baylor College of Medicine; Baylor College of Medicine; Pontificia Universidad Catolica de Chile; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Children's Hospital of New Orleans; Children's Healthcare of Atlanta (CHOA); Emory University; Saint James's University Hospital; Newcastle University - UK; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Snow, AL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol & Mol Therapeut, 4301 Jones Bridge Rd,C-2013, Bethesda, MD 20814 USA.	andrew.snow@usuhs.edu	Franke, Andre/B-2151-2010; Bulashevska, Alla/C-4910-2019; Limaye, Sandhya/CAH-6762-2022; Hartberger, Julia/AAU-1110-2020; Chandrakasan, Shanmuganathan/AAM-3430-2020; Savic, Sinisa/Q-6217-2019; Ehl, Stephan/AAM-6006-2020; Leahy, Ronan/AAL-5008-2021; Cook, matthew/F-4151-2019; Lambert, Michele P./AAB-9225-2021; Poli, Cecilia/AAU-1373-2020; Veltri, Daniel/V-7538-2017	Franke, Andre/0000-0003-1530-5811; Savic, Sinisa/0000-0001-7910-0554; Leahy, Ronan/0000-0001-6419-9328; Cook, matthew/0000-0002-3331-9363; Lambert, Michele P./0000-0003-0439-402X; Poli, Cecilia/0000-0001-6817-0573; Ehl, Stephan/0000-0002-9265-2721; Whyte, Andrew F/0000-0003-3000-3977; Veltri, Daniel/0000-0002-6101-6693; Briggs, Tracy/0000-0001-5208-2691; Patel, Smita/0000-0002-6207-2208; Mobus, Lena/0000-0003-0685-0893; Romberg, Neil/0000-0002-1881-5318; Borzutzky, Arturo/0000-0002-7904-262X; Hambleton, Sophie/0000-0001-7954-3267; Chinn, Ivan/0000-0001-5684-5457	National Institutes of Health [UM1HG006542]; Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine; National Library of Medicine; German BMBF [01E01303, 01ZX1306F]; DZIF [TTU 07.801]; NIAID [R21AI109187]; IMPATH [SFB1160]; National Health and Medical Research Council (Australia) [1113577, 1079648]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI109187, ZIAAI000058, ZIAAI001247, ZIAAI000913, ZIAAI001098] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine; National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); German BMBF(Federal Ministry of Education & Research (BMBF)); DZIF; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); IMPATH; National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the patients and their families for participating in this research. All patients were enrolled in institutional review board-approved protocols and provided informed consent. We also thank C. Olsen, C. Lake, K. Voss, R. Chand, and H. Pritchett for technical assistance and statistical analysis and Z. Li in the USUHS Genomics core for primer synthesis and Sanger sequencing support. We thank Dr Lia Menasce and Dr Patrick Shenjere, Histopathology Department, Christie Hospital, Manchester, United Kingdom, for histopathologic data. We thank Drs James R. Lupski, Richard A. Gibbs, and Zeynep H. Coban Akdemir for providing WES and bioinformatics support in the BaylorHopkins Center for Mendelian Genomics (National Institutes of Health grant UM1HG006542) and T. D. Andrews and M. Field for bioinformatics support at the John Curtin School of Medical Research.; Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine; German BMBF grants 01E01303 and 01ZX1306F; the DZIF (TTU 07.801); NIAID extramural award R21AI109187; the SFB1160 (IMPATH); and National Health and Medical Research Council (Australia) grants 1113577 and 1079648.	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Arjunaraja S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00198; Aronica MA, 1999, J IMMUNOL, V163, P5116; Brohl AS, 2015, J CLIN IMMUNOL, V35, P32, DOI 10.1007/s10875-014-0106-4; Chan WP, 2013, MOL CELL BIOL, V33, P429, DOI 10.1128/MCB.00850-12; Dadi H, 2018, J ALLERGY CLIN IMMUN, V141, P1818, DOI 10.1016/j.jaci.2017.06.047; Feng YQ, 2003, 2003 INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND CYBERNETICS, VOLS 1-5, PROCEEDINGS, P2085, DOI 10.1109/ICMLC.2003.1259848; Fuchs S, 2015, BLOOD, V126, P1658, DOI 10.1182/blood-2015-03-631374; GOWER JC, 1971, BIOMETRICS, V27, P857, DOI 10.2307/2528823; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hamilton KS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005169; Hara H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6555; Jattani RP, 2016, J BIOL CHEM, V291, P8338, DOI 10.1074/jbc.M116.717322; Jattani RP, 2016, J BIOL CHEM, V291, P8324, DOI 10.1074/jbc.M115.683714; Juilland M, 2016, CURR OPIN HEMATOL, V23, P402, DOI 10.1097/MOH.0000000000000257; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kaufman L., 2009, FINDING GROUPS DATA; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Landwehr N, 2005, MACH LEARN, V59, P161, DOI 10.1007/s10994-005-0466-3; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Lyons JJ, 2018, J EXP MED, V215, P1009, DOI 10.1084/jem.20172306; Ma CA, 2017, NAT GENET, V49, P1192, DOI 10.1038/ng.3898; Maechler M., 2012, R PACKAGE VERSION; Meininger I, 2016, BIOL CHEM, V397, P1315, DOI 10.1515/hsz-2016-0216; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Pollizzi KN, 2014, NAT REV IMMUNOL, V14, P435, DOI 10.1038/nri3701; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rueda D, 2007, J IMMUNOL, V178, P4373, DOI 10.4049/jimmunol.178.7.4373; Schubert D, 2018, J ALLERGY CLIN IMMUN, V141, P1427, DOI 10.1016/j.jaci.2017.06.042; Shi JH, 2015, MOL IMMUNOL, V68, P546, DOI 10.1016/j.molimm.2015.07.024; Silberstein M, 2006, AM J HUM GENET, V78, P922, DOI 10.1086/504158; Silberstein M, 2013, BIOINFORMATICS, V29, P197, DOI 10.1093/bioinformatics/bts658; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tanner MJ, 2007, J BIOL CHEM, V282, P17141, DOI 10.1074/jbc.M700169200; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; Witten IH, 2011, MOR KAUF D, P1	41	70	75	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1482	1495		10.1016/j.jaci.2018.08.013	http://dx.doi.org/10.1016/j.jaci.2018.08.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30170123	Green Accepted, Bronze			2022-12-18	WOS:000463348900024
J	Essaidi-Laziosi, M; Brito, F; Benaoudia, S; Royston, L; Cagno, V; Fernandes-Rocha, M; Piuz, I; Zdobnov, E; Huang, S; Constant, S; Boldi, MO; Kaiser, L; Tapparel, C				Essaidi-Laziosi, Manel; Brito, Francisco; Benaoudia, Sacha; Royston, Lena; Cagno, Valeria; Fernandes-Rocha, Melanie; Piuz, Isabelle; Zdobnov, Evgeny; Huang, Song; Constant, Samuel; Boldi, Marc-Olivier; Kaiser, Laurent; Tapparel, Caroline			Propagation of respiratory viruses in human airway epithelia reveals persistent virus-specific signatures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory virus; rhinovirus; cytotoxicity; pathogenesis; cytokines; mucociliary clearance; immune response; persistence	HUMAN RHINOVIRUS C; SYNCYTIAL VIRUS; INFLUENZA-VIRUS; CILIATED CELLS; MUCOCILIARY CLEARANCE; BRONCHIAL EPITHELIUM; INFECTION; REPLICATION; MODELS; EPIDEMIOLOGY	Background: The leading cause of acute illnesses, respiratory viruses, typically cause self-limited diseases, although severe complications can occur in fragile patients. Rhinoviruses (RVs), respiratory enteroviruses (EVs), influenza virus, respiratory syncytial viruses (RSVs), and coronaviruses are highly prevalent respiratory pathogens, but because of the lack of reliable animal models, their differential pathogenesis remains poorly characterized. Objective: We sought to compare infections by respiratory viruses isolated from clinical specimens using reconstituted human airway epithelia. Methods: Tissues were infected with RV-A55, RV-A49, RV-B48, RV-C8, and RV-C15; respiratory EV-D68; influenza virus H3N2; RSV-B; and human coronavirus (HCoV)-OC43. Replication kinetics, cell tropism, effect on tissue integrity, and cytokine secretion were compared. Viral adaptation and tissue response were assessed through RNA sequencing. Results: RVs, RSV-B, and HCoV-OC43 infected ciliated cells and caused no major cell death, whereas H3N2 and EV-D68 induced ciliated cell loss and tissue integrity disruption. H3N2 was also detected in rare goblet and basal cells. All viruses, except RV-B48 and HCoV-OC43, altered cilia beating and mucociliary clearance. H3N2 was the strongest cytokine inducer, and HCoV-OC43 was the weakest. Persistent infection was observed in all cases. RNA sequencing highlighted perturbation of tissue metabolism and induction of a transient but important immune response at 4 days after infection. No majority mutations emerged in the viral population. Conclusion: Our results highlight the differential in vitro pathogenesis of respiratory viruses during the acute infection phase and their ability to persist under immune tolerance. These data help to appreciate the range of disease severity observed in vivo and the occurrence of chronic respiratory tract infections in immunocompromised hosts.	[Essaidi-Laziosi, Manel; Royston, Lena; Cagno, Valeria; Piuz, Isabelle; Tapparel, Caroline] Univ Geneva, Med Sch, Dept Microbiol & Mol Med, 1 Rue Michel Servet, Geneva, Switzerland; [Brito, Francisco; Zdobnov, Evgeny] Univ Geneva, Med Sch, Swiss Inst Bioinformat, Geneva, Switzerland; [Benaoudia, Sacha; Huang, Song; Constant, Samuel] Epithelix Sarl, Geneva, Switzerland; [Fernandes-Rocha, Melanie; Kaiser, Laurent; Tapparel, Caroline] Univ Hosp Geneva, Div Med Specialties, Geneva, Switzerland; [Fernandes-Rocha, Melanie; Kaiser, Laurent; Tapparel, Caroline] Univ Hosp Geneva, Virol Lab, Geneva, Switzerland; [Boldi, Marc-Olivier] Univ Geneva, Res Ctr Stat, Fac GSEM, Geneva, Switzerland	University of Geneva; Swiss Institute of Bioinformatics; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Tapparel, C (corresponding author), Univ Geneva, Med Sch, Dept Microbiol & Mol Med, 1 Rue Michel Servet, Geneva, Switzerland.	caroline.tapparel@unige.ch	Cagno, Valeria/AAE-7612-2020; Zdobnov, Evgeny M/K-1133-2012; Zdobnov, Evgeny/AAB-2745-2022	Zdobnov, Evgeny/0000-0002-5178-1498; Royston, Lena/0000-0003-2367-7682; Brito, Francisco/0000-0003-1404-9799; Tapparel Vu, Caroline/0000-0002-0411-6567; Kaiser, Laurent/0000-0002-0857-2252; Cagno, Valeria/0000-0002-5597-334X	Swiss National Science Foundation [310030_166218]; Marie-Heim Vogtlin Foundation [PMPDP3-158269]; Leenaards Foundation [4390]; Sandoz Foundation [9975]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Marie-Heim Vogtlin Foundation; Leenaards Foundation; Sandoz Foundation	Supported by the Swiss National Science Foundation (grant 310030_166218 to C.T.), the Marie-Heim Vogtlin Foundation (grant PMPDP3-158269 to M.E.-L.), the Leenaards Foundation (grant 4390 to C.T.), and the Sandoz Foundation (grant 9975 to C.T.).	Abdelnabi R, 2017, J VIROL, V91, DOI 10.1128/JVI.00487-17; Ambrosioni J, 2014, CLIN MICROBIOL INFEC, V20, pO578, DOI 10.1111/1469-0691.12525; ARRUDA E, 1995, J INFECT DIS, V171, P1329, DOI 10.1093/infdis/171.5.1329; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bertino JS, 2002, AM J MED, V112, p42S; Bochkov YA, 2016, VIROLOGY, V499, P350, DOI 10.1016/j.virol.2016.09.025; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Borg I, 2003, EUR RESPIR J, V21, P944, DOI 10.1183/09031936.03.00088102; Catley MC, 2006, MOL PHARMACOL, V70, P697, DOI 10.1124/mol.106.023150; DENNY FW, 1995, AM J RESP CRIT CARE, V152, pS4, DOI 10.1164/ajrccm/152.4_Pt_2.S4; Dijkman R, 2013, J VIROL, V87, P6081, DOI 10.1128/JVI.03368-12; Esposito S, 2014, EUR J CLIN MICROBIOL, V33, P41, DOI 10.1007/s10096-013-1926-5; Essaidi-Laziosi M, 2016, J VIROL METHODS, V235, P9, DOI 10.1016/j.jviromet.2016.05.004; Griggs TF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0567-0; Hao WD, 2012, J VIROL, V86, P13524, DOI 10.1128/JVI.02094-12; Heaton NS, 2016, IMMUNITY, V44, P46, DOI 10.1016/j.immuni.2015.12.017; Hendley JO, 1999, ADV VIRUS RES, V54, P453, DOI 10.1016/S0065-3527(08)60375-9; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Iravani J, 1978, Ciba Found Symp, P235; Jakiela B, 2014, AM J RESP CELL MOL, V51, P229, DOI 10.1165/rcmb.2013-0395OC; Kalies KU, 2015, TRAFFIC, V16, P1027, DOI 10.1111/tra.12308; Khan Feras, 2015, Emerg Med Clin North Am, V33, pe19; Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Koszalka P, 2017, INFLUENZA OTHER RESP, V11, P240, DOI 10.1111/irv.12446; L'Huillier AG, 2015, VIRUSES-BASEL, V7, P6412, DOI 10.3390/v7122948; Lembo D, 2016, MOL ASPECTS MED, V49, P23, DOI 10.1016/j.mam.2016.04.003; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lupo J, 2015, J CLIN MICROBIOL, V53, P1775, DOI 10.1128/JCM.03484-14; Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845; Mazur I, 2007, CELL MICROBIOL, V9, P1683, DOI 10.1111/j.1462-5822.2007.00902.x; Mitchell H, 2011, J VIROL, V85, P1125, DOI 10.1128/JVI.01722-10; Nakagome K, 2014, J ALLERGY CLIN IMMUN, V134, P332, DOI 10.1016/j.jaci.2014.01.029; Ngaosuwankul N, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-75; Nguyen C, 2016, J INTENSIVE CARE MED, V31, P427, DOI 10.1177/0885066615585944; Peng Y, 2012, BIOINFORMATICS, V28, P1420, DOI 10.1093/bioinformatics/bts174; Persson BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102368; Pittet LA, 2010, AM J RESP CELL MOL, V42, P450, DOI 10.1165/rcmb.2007-0417OC; REED SE, 1969, BRIT J EXP PATHOL, V50, P378; ROCHE WR, 1993, AM REV RESPIR DIS, V148, pS79, DOI 10.1164/ajrccm/148.6_Pt_2.S79; Smith CM, 2014, EUR RESPIR J, V43, P485, DOI 10.1183/09031936.00205312; Smith DJ, 2008, RESP PHYSIOL NEUROBI, V163, P178, DOI 10.1016/j.resp.2008.03.006; Stokes KL, 2011, J VIROL, V85, P5782, DOI 10.1128/JVI.01693-10; Syedbasha M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00119; Tadokoro T, 2014, P NATL ACAD SCI USA, V111, pE3641, DOI 10.1073/pnas.1409781111; Tapparel C, 2013, VIROLOGY, V446, P1, DOI 10.1016/j.virol.2013.06.031; Tapparel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021163; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; Villenave R, 2013, TRENDS MICROBIOL, V21, P238, DOI 10.1016/j.tim.2013.02.004; Wang GS, 2000, J VIROL, V74, P9234, DOI 10.1128/JVI.74.19.9234-9239.2000; Wei Z, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr599; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; WILSON R, 1987, EUR J RESPIR DIS, V70, P272; WINTHER B, 1994, DAN MED BULL, V41, P193; World Health Organization, GLOB HLTH OBS GHO DA; Wu NH, 2016, SCI REP-UK, V6, DOI 10.1038/srep39668; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002	58	70	72	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2074	2084		10.1016/j.jaci.2017.07.018	http://dx.doi.org/10.1016/j.jaci.2017.07.018			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28797733	Green Published, Bronze			2022-12-18	WOS:000434701600014
J	Kuijpers, TW; Tool, ATJ; van der Bijl, I; de Boer, M; van Houdt, M; de Cuyper, IM; Roos, D; van Alphen, F; van Leeuwen, K; Cambridge, EL; Arends, MJ; Dougan, G; Clare, S; Ramirez-Solis, R; Pals, ST; Adams, DJ; Meijer, AB; van den Berg, TK				Kuijpers, Taco W.; Tool, Anton T. J.; van der Bijl, Ivo; de Boer, Martin; van Houdt, Michel; de Cuyper, Iris M.; Roos, Dirk; van Alphen, Floris; van Leeuwen, Karin; Cambridge, Emma L.; Arends, Mark J.; Dougan, Gordon; Clare, Simon; Ramirez-Solis, Ramiro; Pals, Steven T.; Adams, David J.; Meijer, Alexander B.; van den Berg, Timo K.			Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WASP		[Kuijpers, Taco W.] Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands; [Pals, Steven T.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, Sanquin Res, Amsterdam, Netherlands; [Kuijpers, Taco W.; Tool, Anton T. J.; van der Bijl, Ivo; de Boer, Martin; van Houdt, Michel; de Cuyper, Iris M.; Roos, Dirk; van Leeuwen, Karin; van den Berg, Timo K.] Univ Amsterdam, Dept Blood Cell Res, Sanquin Res, Amsterdam, Netherlands; [van Alphen, Floris; Meijer, Alexander B.] Univ Amsterdam, Dept Plasma Prot, Sanquin Res, Amsterdam, Netherlands; [Cambridge, Emma L.; Dougan, Gordon; Clare, Simon; Ramirez-Solis, Ramiro; Adams, David J.] Wellcome Trust Sanger Inst, Hinxton, Cambs, England; [Arends, Mark J.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Div Pathol,Ctr Comparat Pathol,Edinburgh Canc Res, Edinburgh, Midlothian, Scotland	Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; University of Amsterdam; Wellcome Trust Sanger Institute; University of Edinburgh	Kuijpers, TW (corresponding author), Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands.; Kuijpers, TW (corresponding author), Univ Amsterdam, Dept Blood Cell Res, Sanquin Res, Amsterdam, Netherlands.	t.w.kuijpers@amc.nl	van den Berg, Timo K/AAC-2479-2022	Pals, Steven/0000-0002-1419-0939; Ramirez-Solis, Ramiro/0000-0003-4182-173X; Adams, David/0000-0001-9490-0306	Cancer Research UK [13031] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; De Cuyper IM, 2013, BLOOD, V121, pE70, DOI 10.1182/blood-2012-06-437723; Kent T, 2015, NAT STRUCT MOL BIOL, V22, P230, DOI 10.1038/nsmb.2961; Kuijpers TW, 2009, BLOOD, V113, P4740, DOI 10.1182/blood-2008-10-182154; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Yae K, 2006, MOL CELL BIOL, V26, P6185, DOI 10.1128/MCB.00018-06	10	70	70	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					273	+		10.1016/j.jaci.2016.09.061	http://dx.doi.org/10.1016/j.jaci.2016.09.061			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27965109	Green Accepted, Bronze			2022-12-18	WOS:000404542000030
J	Oyeniran, C; Sturgill, JL; Hait, NC; Huang, WC; Avni, D; Maceyka, M; Newton, J; Allegood, JC; Montpetit, A; Conrad, DH; Milstien, S; Spiegel, S				Oyeniran, Clement; Sturgill, Jamie L.; Hait, Nitai C.; Huang, Wei-Ching; Avni, Dorit; Maceyka, Michael; Newton, Jason; Allegood, Jeremy C.; Montpetit, Alison; Conrad, Daniel H.; Milstien, Sheldon; Spiegel, Sarah			Aberrant ORM (yeast)-like protein isoform 3 (ORMDL3) expression dysregulates ceramide homeostasis in cells and ceramide exacerbates allergic asthma in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; ORMDL3; sphingolipid; ceramide; FTY720; house dust mite	SPHINGOLIPID BIOSYNTHESIS; AIRWAY INFLAMMATION; MULTIPLE-SCLEROSIS; MAMMALIAN-CELLS; SPHINGOSINE-1-PHOSPHATE; FTY720; GENE; LUNG; ACTIVATION; MACROPHAGES	Background: Asthma, a chronic inflammatory condition defined by episodic shortness of breath with expiratory wheezing and cough, is a serious health concern affecting more than 250 million persons. Genome-wide association studies have identified ORM (yeast)-like protein isoform 3 (ORMDL3) as a gene associated with susceptibility to asthma. Although its yeast ortholog is a negative regulator of de novo ceramide biosynthesis, how ORMDL3 contributes to asthma pathogenesis is not known. Objectives: We sought to decipher the molecular mechanism for the pathologic functions of ORMDL3 in asthma and the relationship to its evolutionarily conserved role in regulation of ceramide homeostasis. Methods: We determined the relationship between expression of ORMDL3 and ceramide in epithelial and inflammatory cells and in asthma pathogenesis in mice. Results: Although small increases in ORMDL3 expression decrease ceramide levels, remarkably, higher expression in lung epithelial cells and macrophages in vitro and in vivo increased ceramide production, which promoted chronic inflammation, airway hyperresponsiveness, and mucus production during house dust mite-induced allergic asthma. Moreover, nasal administration of the immunosuppressant drug FTY720/fingolimod reduced ORMDL3 expression and ceramide levels and mitigated airway inflammation and hyperreactivity and mucus hypersecretion in house dust mite-challenged mice. Conclusions: Our findings demonstrate that overexpression of ORMDL3 regulates ceramide homeostasis in cells in a complex manner and suggest that local FTY720 administration might be a useful therapeutic intervention for the control of allergic asthma.	[Oyeniran, Clement; Hait, Nitai C.; Huang, Wei-Ching; Avni, Dorit; Maceyka, Michael; Newton, Jason; Allegood, Jeremy C.; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Oyeniran, Clement; Hait, Nitai C.; Huang, Wei-Ching; Avni, Dorit; Maceyka, Michael; Newton, Jason; Allegood, Jeremy C.; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; [Sturgill, Jamie L.; Conrad, Daniel H.] Virginia Commonwealth Univ, Sch Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA; [Sturgill, Jamie L.; Montpetit, Alison] Virginia Commonwealth Univ, Sch Nursing, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, POB 980614, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Maceyka, Michael/B-9277-2008; Newton, Jason/AAN-8428-2020	Avni, Dorit/0000-0002-0444-881X; Newton, Jason/0000-0003-2952-2008; Sturgill, Jamie/0000-0001-8856-3227	NHLBI NIH HHS [T32 HL094290] Funding Source: Medline; NIAID NIH HHS [U19AI077435, R01 AI050094, R01AI50094, U19 AI077435] Funding Source: Medline; NIGMS NIH HHS [R01 GM043880, R37GM043880] Funding Source: Medline; NINR NIH HHS [R00NR012016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094, U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R00NR012016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Berlivet S, 2012, HUM GENET, V131, P1161, DOI 10.1007/s00439-012-1142-x; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Carreras-Sureda A, 2013, HUM MOL GENET, V22, P519, DOI 10.1093/hmg/dds450; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; De Alba J, 2010, EUR RESPIR J, V35, P1377, DOI 10.1183/09031936.00022908; Epstein S, 2012, J LIPID RES, V53, P412, DOI 10.1194/jlr.M022186; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Gupta SD, 2015, J BIOL CHEM, V290, P90, DOI 10.1074/jbc.M114.588236; Gururaj C, 2013, J BIOL CHEM, V288, P20453, DOI 10.1074/jbc.M113.472860; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Hagen-Euteneuer N, 2012, J BIOL CHEM, V287, P9128, DOI 10.1074/jbc.M111.302380; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Han SM, 2010, P NATL ACAD SCI USA, V107, P5851, DOI 10.1073/pnas.0911617107; Haynes CA, 2011, J LIPID RES, V52, P1583, DOI 10.1194/jlr.D015586; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hsu KJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-4; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jin R, 2012, INT J BIOCHEM CELL B, V44, P1174, DOI 10.1016/j.biocel.2012.04.007; Kamocki K, 2013, AM J RESP CELL MOL, V48, P87, DOI 10.1165/rcmb.2012-0254OC; Karmouty-Quintana H, 2012, AM J PHYSIOL-LUNG C, V302, pL736, DOI 10.1152/ajplung.00050.2011; Kiefer K, 2015, J BIOL CHEM, V290, P2822, DOI 10.1074/jbc.M114.595116; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Liu M, 2012, J CELL SCI, V125, P2428, DOI 10.1242/jcs.100578; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Masini E, 2008, J PHARMACOL EXP THER, V324, P548, DOI 10.1124/jpet.107.131565; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Payne SG, 2007, BLOOD, V109, P1077, DOI 10.1182/blood-2006-03-011437; Petrache Irina, 2013, Handb Exp Pharmacol, P247, DOI 10.1007/978-3-7091-1511-4_12; Petrache I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062968; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Raetz CRH, 2006, J LIPID RES, V47, P1097, DOI 10.1194/jlr.M600027-JLR200; Roelants FM, 2011, P NATL ACAD SCI USA, V108, P19222, DOI 10.1073/pnas.1116948108; Sawicka E, 2003, J IMMUNOL, V171, P6206, DOI 10.4049/jimmunol.171.11.6206; Shimobayashi M, 2013, MOL BIOL CELL, V24, P870, DOI 10.1091/mbc.E12-10-0753; Sims K, 2010, J BIOL CHEM, V285, P38568, DOI 10.1074/jbc.M110.170621; Siow DL, 2012, J BIOL CHEM, V287, P40198, DOI 10.1074/jbc.C112.404012; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Sun YD, 2012, MOL BIOL CELL, V23, P2388, DOI 10.1091/mbc.E12-03-0209; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; van Rossum JA, 2014, MULT SCLER J, V20, P1792, DOI 10.1177/1352458514531844; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005765; Zecca C, 2014, PATIENT PREFER ADHER, V8, DOI 10.2147/PPA.S65708	53	70	75	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1035	+		10.1016/j.jaci.2015.02.031	http://dx.doi.org/10.1016/j.jaci.2015.02.031			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25842287	Bronze, Green Accepted			2022-12-18	WOS:000362976300022
J	Gielen, V; Sykes, A; Zhu, J; Chan, B; Macintyre, J; Regamey, N; Kieninger, E; Gupta, A; Shoemark, A; Bossley, C; Davies, J; Saglani, S; Walker, P; Nicholson, SE; Dalpke, AH; Kon, OM; Bush, A; Johnston, SL; Edwards, MR				Gielen, Vera; Sykes, Annemarie; Zhu, Jie; Chan, Brian; Macintyre, Jonathan; Regamey, Nicolas; Kieninger, Elisabeth; Gupta, Atul; Shoemark, Amelia; Bossley, Cara; Davies, Jane; Saglani, Sejal; Walker, Patrick; Nicholson, Sandra E.; Dalpke, Alexander H.; Kon, Onn-Min; Bush, Andrew; Johnston, Sebastian L.; Edwards, Michael R.			Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; asthma; asthma exacerbation; atopy; interferon; innate immunity; cytokine; T(H)2 inflammation; suppressor of cytokine signaling	IMMUNE-RESPONSES; I INTERFERON; ANTIVIRAL RESPONSES; DOUBLE-BLIND; IFN-ALPHA; CELLS; EXPRESSION; DEFICIENT; RECEPTOR; BETA	Background: Rhinovirus infections are the dominant cause of asthma exacerbations, and deficient virus induction of IFN-alpha/beta/lambda in asthmatic patients is important in asthma exacerbation pathogenesis. Mechanisms causing this interferon deficiency in asthmatic patients are unknown. Objective: We sought to investigate the expression of suppressor of cytokine signaling (SOCS) 1 in tissues from asthmatic patients and its possible role in impaired virus-induced interferon induction in these patients. Methods: We assessed SOCS1 mRNA and protein levels in vitro, bronchial biopsy specimens, and mice. The role of SOCS1 was inferred by proof-of-concept studies using overexpression with reporter genes and SOCS1-deficient mice. A nuclear role of SOCS1 was shown by using bronchial biopsy staining, overexpression of mutant SOCS1 constructs, and confocal microscopy. SOCS1 levels were also correlated with asthma-related clinical outcomes. Results: We report induction of SOCS1 in bronchial epithelial cells (BECs) by asthma exacerbation-related cytokines and by rhinovirus infection in vitro. We found that SOCS1 was increased in vivo in bronchial epithelium and related to asthma severity. SOCS1 expression was also increased in primary BECs from asthmatic patients ex vivo and was related to interferon deficiency and increased viral replication. In primary human epithelium, mouse lung macrophages, and SOCS1-deficient mice, SOCS1 suppressed rhinovirus induction of interferons. Suppression of virus-induced interferon levels was dependent on SOCS1 nuclear translocation but independent of proteasomal degradation of transcription factors. Nuclear SOCS1 levels were also increased in BECs from asthmatic patients. Conclusion: We describe a novel mechanism explaining interferon deficiency in asthmatic patients through a novel nuclear function of SOCS1 and identify SOCS1 as an important therapeutic target for asthma exacerbations.	[Gielen, Vera; Sykes, Annemarie; Zhu, Jie; Chan, Brian; Macintyre, Jonathan; Johnston, Sebastian L.; Edwards, Michael R.] Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Gupta, Atul; Shoemark, Amelia; Bossley, Cara; Davies, Jane; Saglani, Sejal; Bush, Andrew] Natl Heart & Lung Inst, Resp Pediat, London, England; [Gielen, Vera; Sykes, Annemarie; Zhu, Jie; Macintyre, Jonathan; Johnston, Sebastian L.; Edwards, Michael R.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, London, England; [Gielen, Vera; Sykes, Annemarie; Zhu, Jie; Macintyre, Jonathan; Gupta, Atul; Shoemark, Amelia; Bossley, Cara; Davies, Jane; Saglani, Sejal; Bush, Andrew; Johnston, Sebastian L.; Edwards, Michael R.] MRC, London, England; [Gielen, Vera; Sykes, Annemarie; Zhu, Jie; Macintyre, Jonathan; Gupta, Atul; Shoemark, Amelia; Bossley, Cara; Davies, Jane; Saglani, Sejal; Bush, Andrew; Johnston, Sebastian L.; Edwards, Michael R.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Sykes, Annemarie; Macintyre, Jonathan; Kon, Onn-Min; Johnston, Sebastian L.] Imperial Coll Healthcare Natl Hlth Serv Trust, London, England; [Regamey, Nicolas; Kieninger, Elisabeth] Univ Bern, Pediat Med, CH-3012 Bern, Switzerland; [Walker, Patrick; Dalpke, Alexander H.] Heidelberg Univ, Dept Infect Dis Med Microbiol & Hyg, D-69115 Heidelberg, Germany; [Nicholson, Sandra E.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Nicholson, Sandra E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia	Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; Imperial College London; University of Bern; Ruprecht Karls University Heidelberg; Walter & Eliza Hall Institute; University of Melbourne	Edwards, MR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Airway Dis Infect Sect, Natl Heart & Lung Inst, St Marys Campus, London W2 1PG, England.	michael.edwards@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012; Saglani, Sejal/AAE-5072-2019; Shoemark, Amelia/I-4068-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; Shoemark, Amelia/0000-0001-7360-6060; , Sandra/0000-0002-1314-2134; Kon, Onn Min/0000-0003-2647-4688; Davies, Jane/0000-0003-3506-1199; Regamey, Nicolas/0000-0001-6849-6469	National Heart Lung Institute Foundation, Imperial College London; Asthma UK [CH11SJ]; MRC Clinical Research Fellowship; British Lung Foundation [P06/13]; MRC project grant [G0601236]; MRC Centre grant [G1000758]; ERC FP7 Advanced grant [233015]; National Institute of Health Research Biomedical Research Centre funding scheme; National Institute of Health Research BRC Project grant [P26095]; Predicta FP7 Collaborative Project grant [260895]; Wellcome Trust; National Institute of Health Research Respiratory Disease Biomedical Research Unit at Royal Brompton; Imperial College London; German Research Foundation [Da592/4, SFB938]; National Health and Medical Research Council Program [461219, 1016647]; Harefield NHS Foundation Trust;  [RF07_04]; MRC [G0601236, G1100238] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B, G1100238, G0601236] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192] Funding Source: researchfish; Asthma UK [RF07/04, AUK-AC-2012-01, 10/058, MRC-Asthma UK Centre] Funding Source: researchfish	National Heart Lung Institute Foundation, Imperial College London; Asthma UK; MRC Clinical Research Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation; MRC project grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Centre grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ERC FP7 Advanced grant; National Institute of Health Research Biomedical Research Centre funding scheme(National Institute for Health Research (NIHR)); National Institute of Health Research BRC Project grant; Predicta FP7 Collaborative Project grant; Wellcome Trust(Wellcome Trust); National Institute of Health Research Respiratory Disease Biomedical Research Unit at Royal Brompton; Imperial College London(General Electric); German Research Foundation(German Research Foundation (DFG)); National Health and Medical Research Council Program(National Health and Medical Research Council (NHMRC) of Australia); Harefield NHS Foundation Trust; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	V.G. was funded by a studentship from the National Heart Lung Institute Foundation, Imperial College London. M.R.E. was supported by a Fellowship and S.L.J. was supported by a Chair from Asthma UK (RF07_04, CH11SJ respectively). A.S. was funded by a MRC Clinical Research Fellowship. This work was supported in part by grants from the British Lung Foundation (P06/13), MRC project grant G0601236, MRC Centre grant G1000758, ERC FP7 Advanced grant 233015 (to SLJ), the National Institute of Health Research Biomedical Research Centre funding scheme, National Institute of Health Research BRC Project grant P26095, Predicta FP7 Collaborative Project grant 260895, and the Wellcome Trust-sponsored Centre for Respiratory Infection (CRI). A.B. was supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. P.W. was supported by the German Research Foundation grants Da592/4 and SFB938. S.E.N. was supported by National Health and Medical Research Council Program grants 461219 and 1016647.	Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bartlett NW, 2012, EMBO MOL MED, V4, P1244, DOI 10.1002/emmm.201201650; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Edwards S, 2013, J IMMUNOL, V190, P2585, DOI 10.4049/jimmunol.1200780; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Fenner JE, 2006, NAT IMMUNOL, V7, P33, DOI 10.1038/ni1287; Fukuyama S, 2009, AM J RESP CRIT CARE, V179, P992, DOI 10.1164/rccm.200806-992OC; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Heller NM, 2004, AM J RESP CELL MOL, V31, P573, DOI 10.1165/rcmb.2004-0195OC; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Iikura K, 2011, INT ARCH ALLERGY IMM, V155, P27, DOI 10.1159/000327262; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; Knosp CA, 2011, J EXP MED, V208, P1523, DOI 10.1084/jem.20101167; Koelsche C, 2009, MOL IMMUNOL, V46, P2474, DOI 10.1016/j.molimm.2009.05.020; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Lee C, 2009, CLIN EXP ALLERGY, V39, P897, DOI 10.1111/j.1365-2222.2009.03217.x; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Osterlund PI, 2007, J IMMUNOL, V179, P3434, DOI 10.4049/jimmunol.179.6.3434; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Piganis RAR, 2011, J BIOL CHEM, V286, P33811, DOI 10.1074/jbc.M111.270207; Pothlichet J, 2008, J IMMUNOL, V180, P2034, DOI 10.4049/jimmunol.180.4.2034; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Sriram U, 2007, J IMMUNOL, V179, P6446, DOI 10.4049/jimmunol.179.10.6446; Strebovsky J, 2011, FASEB J, V25, P863, DOI 10.1096/fj.10-170597; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Thomas BJ, 2009, AM J RESP CELL MOL, V41, P339, DOI 10.1165/rcmb.2008-0316OC; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Vlotides G, 2004, BIOCHEM BIOPH RES CO, V320, P1007, DOI 10.1016/j.bbrc.2004.06.051; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048	48	70	72	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					177	U327		10.1016/j.jaci.2014.11.039	http://dx.doi.org/10.1016/j.jaci.2014.11.039			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25630941	Green Published, hybrid			2022-12-18	WOS:000357542200020
J	Zanotti, R; Lombardo, C; Passalacqua, G; Caimmi, C; Bonifacio, M; De Matteis, G; Perbellini, O; Rossini, M; Schena, D; Busa, M; Marcotulli, MC; Bilo, MB; Franchini, M; Marchi, G; Simioni, L; Bonadonna, P				Zanotti, Roberta; Lombardo, Carla; Passalacqua, Giovanni; Caimmi, Cristian; Bonifacio, Massimiliano; De Matteis, Giovanna; Perbellini, Omar; Rossini, Maurizio; Schena, Donatella; Busa, Moira; Marcotulli, Maria Cinzia; Bilo, Maria Beatrice; Franchini, Maurizio; Marchi, Giovanni; Simioni, Livio; Bonadonna, Patrizia			Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systemic mastocytosis; anaphylaxis; tryptase; Hymenoptera venom allergy	INDOLENT SYSTEMIC MASTOCYTOSIS; BONE-MARROW; ANAPHYLAXIS; RISK; OSTEOPOROSIS	Background: Systemic mastocytosis is a clonal mast cell (MC) disease that can lead to potentially fatal anaphylactic reactions caused by excessive MC mediator release. The prevalence of mastocytosis in patients with Hymenoptera venom allergy is high, and thus the disease should be suspected in patients with severe reactions caused by Hymenoptera stings and increased serum basal tryptase (SBT) levels. Objective: We sought to evaluate the presence of clonal MC disorders in patients seen at our mastocytosis center with Hymenoptera sting-induced anaphylaxis, documented hypotension, absence of urticaria pigmentosa, and normal SBT levels. Methods: Twenty-two patients with Hymenoptera sting-induced anaphylaxis, without skin lesions, and with tryptase levels of less than 11.4 ng/mL underwent bone marrow evaluation. Bone mineral density was assessed in those patients with ascertained mastocytosis. Results: In 16 of 22 patients, a diagnosis of indolent mastocytosis could be established, and 1 patient had a monoclonal MC activation syndrome. Patients with mastocytosis had higher SBT levels (P = .03) but only rarely had angioedema/urticaria associated with hypotension (P = .004). Conclusions: The absence of urticaria or angioedema in severe reactions to Hymenoptera stings with hypotension might represent the most relevant factor in identifying patients with mastocytosis, regardless of their serum tryptase levels.	[Zanotti, Roberta; Bonifacio, Massimiliano; Perbellini, Omar] Azienda Osped Univ Integrata Verona, Dept Med, Sect Hematol, Verona, Italy; [Zanotti, Roberta; Bonifacio, Massimiliano; Rossini, Maurizio; Schena, Donatella; Bonadonna, Patrizia] Azienda Osped Univ Integrata Verona, Multidisciplinary Mastocytosis Outpatient Clin, Verona, Italy; [Lombardo, Carla; Bonadonna, Patrizia] Azienda Osped Univ Integrata Verona, Allergy Unit, Verona, Italy; [Caimmi, Cristian; Rossini, Maurizio] Azienda Osped Univ Integrata Verona, Dept Med, Rheumatol Sect, Verona, Italy; [De Matteis, Giovanna] Azienda Osped Univ Integrata Verona, Clin Chem & Haematol, Verona, Italy; [Schena, Donatella] Azienda Osped Univ Integrata Verona, Dept Med, Dermatol Sect, Verona, Italy; [Passalacqua, Giovanni] Univ Genoa, IRCCS San Martino IST, Allergy & Resp Dis, I-16126 Genoa, Italy; [Busa, Moira] ULSS 13, Dermatol Unit, Venice, Italy; [Marcotulli, Maria Cinzia] Azienda Osped Desenzano, Pulmonol Unit, Brescia, Italy; [Bilo, Maria Beatrice] Osped Riuniti Ancona, Dept Internal Med, Allergy Unit, Verona, Italy; [Franchini, Maurizio] ULSS 10, Allergy Serv, Venice, Italy; [Marchi, Giovanni] ULSS 21 Legnago, Allergy Serv, Verona, Italy; [Simioni, Livio] ULSS 2 Feltre, Allergy Serv, Dept Med, Belluno, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Genoa; IRCCS AOU San Martino IST; ULSS 3 Serenissima; ULSS 4 Veneto Orientale; ULSS 1 Dolomiti; Ospedale di Feltre	Passalacqua, G (corresponding author), Univ Genoa, Allergy & Resp Dis, Lgo R Benzi 10, I-16133 Genoa, Italy.	passalacqua@unige.it	rossini, maurizio/D-6610-2011; Bonifacio, Massimiliano/AAL-4520-2020	Bonifacio, Massimiliano/0000-0003-0716-1686; PERBELLINI, Omar/0000-0002-8278-8916; Rossini, Maurizio/0000-0001-9692-2293				Alvarez-Twose I, 2013, J ALLERGY CLIN IMMUN, V131, P614, DOI 10.1016/j.jaci.2012.10.052; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bonadonna P, 2009, ALLERGY, V64, P1379, DOI 10.1111/j.1398-9995.2009.02108.x; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Lawley W, 2005, MUTAT RES-FUND MOL M, V572, P1, DOI 10.1016/j.mrfmmm.2004.08.015; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V123, P687, DOI 10.1016/j.jaci.2009.02.003; Perbellini O, 2011, CYTOM PART B-CLIN CY, V80B, P362, DOI 10.1002/cyto.b.20606; Reimers A, 2005, SWISS MED WEEKLY, V135, pS14; Rossini M, 2014, IMMUNOL ALLERGY CLIN, V34, P383, DOI 10.1016/j.iac.2014.01.011; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Sonneck K, 2007, INT ARCH ALLERGY IMM, V142, P158, DOI 10.1159/000096442; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; van Doormaal JJ, 2012, ALLERGY, V67, P683, DOI 10.1111/j.1398-9995.2012.02809.x; Zanotti R, 2011, HAEMATOL-HEMATOL J, V96, P482, DOI 10.3324/haematol.2010.034553	20	70	70	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					135	139		10.1016/j.jaci.2014.11.035	http://dx.doi.org/10.1016/j.jaci.2014.11.035			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25605272	Bronze			2022-12-18	WOS:000357542200015
J	Bochner, BS; Zimmermann, N				Bochner, Bruce S.; Zimmermann, Nives			Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Siglec; selectin; dectin; glycan; glycan-binding proteins; sialic acid; treatment; glycobiology	B-CELL TOLERANCE; INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS; HUMAN-EOSINOPHIL APOPTOSIS; HUMAN MAST-CELLS; ANTIINFLAMMATORY ACTIVITY; INHIBITORY RECEPTOR; IN-VIVO; CD33-RELATED SIGLECS; FUNGAL-INFECTIONS; TARGETED DELIVERY	Virtually all cells and extracellular material are heavily decorated by various glycans, yet our understanding of the structure and function of these moieties lags behind the understanding of nucleic acids, lipids, and proteins. Recent years have seen a tremendous acceleration of knowledge in the field of glycobiology, revealing many intricacies and functional contributions that were previously poorly appreciated or even unrecognized. This review highlights several topics relevant to glycoimmunology in which mammalian and pathogen-derived glycans displayed on glycoproteins and other scaffolds are recognized by specific glycan-binding proteins (GBPs), leading to a variety of proinflammatory and anti-inflammatory cellular responses. The focus for this review is mainly on 2 families of GBPs, sialic acid-binding immunoglobulin-like lectins (siglecs) and selectins, that are involved in multiple steps of the immune response, including distinguishing pathogens from self, cell trafficking to sites of inflammation, fine-tuning of immune responses leading to activation or tolerance, and regulation of cell survival. Importantly for the clinician, accelerated rates of discovery in the field of glycoimmunology are being translated into innovative medical approaches that harness the interaction of glycans and GBPs to the benefit of the host and might soon lead to novel diagnostics and therapeutics.	[Bochner, Bruce S.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Zimmermann, Nives] Univ Cincinnati, Coll Med, Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Zimmermann, Nives] Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45221 USA	Northwestern University; Feinberg School of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bochner, BS (corresponding author), Div Allergy Immunol, 240 E Huron St,Rm M-306, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu			National Institutes of Health (NIH) [R01 AI072265, P01 HL107151, R21 AI103853]; Scientific Advisory Board for Allakos; Allakos [SRA 130701]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, R21AI103853] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scientific Advisory Board for Allakos; Allakos; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	B. S. Bochner has received research support from the National Institutes of Health (NIH; grants R01 AI072265 and P01 HL107151); has received a consulting fee from and is a member of the Scientific Advisory Board for Allakos; has patents through Johns Hopkins University; receives royalties from Johns Hopkins University; and has an equity position in Allakos and Glycomimetics. N. Zimmermann has received research support from the NIH (grant R21 AI103853) and Allakos (grant SRA 130701).	Ali SR, 2014, J EXP MED, V211, P1231, DOI 10.1084/jem.20131853; Angata T, 2013, CELL MOL LIFE SCI, V70, P3199, DOI 10.1007/s00018-013-1311-7; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Bandala-Sanchez E, 2013, NAT IMMUNOL, V14, P741, DOI 10.1038/ni.2610; Bochner BS, 2009, CLIN EXP ALLERGY, V39, P317, DOI 10.1111/j.1365-2222.2008.03173.x; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Bokers S, 2014, J IMMUNOL, V192, P2994, DOI 10.4049/jimmunol.1303367; Carlin AF, 2009, BLOOD, V113, P3333, DOI 10.1182/blood-2008-11-187302; Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513; Chang YC, 2014, GLYCOBIOLOGY, V24, P818, DOI 10.1093/glycob/cwu067; Chen GY, 2014, ELIFE, V3, DOI 10.7554/eLife.04066; Chen GY, 2014, GLYCOBIOLOGY, V24, P800, DOI 10.1093/glycob/cwu068; Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988; Chen WL, 2013, CELL, V152, P467, DOI 10.1016/j.cell.2013.01.011; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Chung S, 2014, J IMMUNOL METHODS, V407, P63, DOI 10.1016/j.jim.2014.03.021; Collin M, 2008, P NATL ACAD SCI USA, V105, P4265, DOI 10.1073/pnas.0711271105; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Crocker PR, 2012, ANN NY ACAD SCI, V1253, P102, DOI 10.1111/j.1749-6632.2011.06449.x; Dalziel M, 2014, SCIENCE, V343, P37, DOI 10.1126/science.1235681; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dotan I, 2006, GASTROENTEROLOGY, V131, P366, DOI 10.1053/j.gastro.2006.04.030; Dotan N, 2006, LUPUS, V15, P442, DOI 10.1191/0961203306lu2331oa; Duong BH, 2010, J EXP MED, V207, P173, DOI 10.1084/jem.20091873; Etzioni A, 2000, IMMUNOL REV, V178, P138, DOI 10.1034/j.1600-065X.2000.17805.x; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Grader-Beck T, 2011, ANN RHEUM DIS, V70, P2218, DOI 10.1136/ard.2011.153130; Guo JP, 2011, AM J RESP CELL MOL, V44, P238, DOI 10.1165/rcmb.2010-0007OC; Hoffmann A, 2007, NAT IMMUNOL, V8, P694, DOI 10.1038/ni1480; Hudak JE, 2014, NAT CHEM BIOL, V10, P69, DOI [10.1038/NCHEMBIO.1388, 10.1038/nchembio.1388]; Hudson SA, 2009, J PHARMACOL EXP THER, V330, P608, DOI 10.1124/jpet.109.152439; Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899; Jellusova J, 2010, J IMMUNOL, V184, P3618, DOI 10.4049/jimmunol.0902711; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024; Kardava L, 2011, J CLIN INVEST, V121, P2614, DOI 10.1172/JCI45685; Kawasaki N, 2014, J IMMUNOL, V193, P1560, DOI 10.4049/jimmunol.1303278; Kawasaki N, 2013, P NATL ACAD SCI USA, V110, P7826, DOI 10.1073/pnas.1219888110; Kimura T, 2013, EXPERT OPIN BIOL TH, V13, P35, DOI 10.1517/14712598.2012.725719; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, P1329, DOI 10.1016/j.jaci.2014.10.027; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, P240, DOI 10.1016/j.jaci.2013.05.018; Kiwamoto T, 2013, CURR OPIN ALLERGY CL, V13, P106, DOI 10.1097/ACI.0b013e32835b594a; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007; Lood C, 2012, ARTHRITIS RHEUM-US, V64, P2698, DOI 10.1002/art.34454; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Macauley MS, 2013, J CLIN INVEST, V123, P3074, DOI 10.1172/JCI69187; Mao H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068143; Masuda K, 2007, MOL IMMUNOL, V44, P3122, DOI 10.1016/j.molimm.2007.02.005; McEver RP, 2010, ANNU REV CELL DEV BI, V26, P363, DOI 10.1146/annurev.cellbio.042308.113238; McMillan SJ, 2014, J BIOL CHEM, V289, P20370, DOI 10.1074/jbc.M114.574624; Mizrahi S, 2014, J ALLERGY CLIN IMMUN, V134, P230, DOI 10.1016/j.jaci.2014.03.031; Muller J, 2014, NAT REV RHEUMATOL, V10, P422, DOI 10.1038/nrrheum.2014.54; Nandakumar KS, 2013, P NATL ACAD SCI USA, V110, P10252, DOI 10.1073/pnas.1301480110; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; Nycholat CM, 2012, J AM CHEM SOC, V134, P15696, DOI 10.1021/ja307501e; O'Reilly MK, 2009, TRENDS PHARMACOL SCI, V30, P240, DOI 10.1016/j.tips.2009.02.005; Oliveira JB, 2010, J ALLERGY CLIN IMMUN, V125, pS297, DOI 10.1016/j.jaci.2009.08.043; Paszek MJ, 2014, NATURE, V511, P319, DOI 10.1038/nature13535; Patnode ML, 2013, J BIOL CHEM, V288, P26533, DOI 10.1074/jbc.M113.485409; Paulson JC, 2012, ANN NY ACAD SCI, V1253, P37, DOI 10.1111/j.1749-6632.2011.06362.x; Pfrengle F, 2013, J IMMUNOL, V191, P1724, DOI 10.4049/jimmunol.1300921; Pillai S, 2012, ANNU REV IMMUNOL, V30, P357, DOI 10.1146/annurev-immunol-020711-075018; Powlesland AS, 2010, METHOD ENZYMOL, V480, P165, DOI 10.1016/S0076-6879(10)80009-6; Prasanphanich NS, 2014, GLYCOBIOLOGY, V24, P619, DOI 10.1093/glycob/cwu027; Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109; Rabinovich GA, 2012, ANN NY ACAD SCI, V1253, P1, DOI 10.1111/j.1749-6632.2012.06492.x; Rashmi R, 2009, PEDIATR RES, V66, P266, DOI 10.1203/PDR.0b013e3181b1bc19; Rempel H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001967; Rillahan CD, 2014, CHEM SCI, V5, P2398, DOI 10.1039/c4sc00451e; Rillahan CD, 2012, ANGEW CHEM INT EDIT, V51, P11014, DOI 10.1002/anie.201205831; Rubinstein E, 2011, J PEDIATR GASTR NUTR, V53, P409, DOI 10.1097/MPG.0b013e3182182ff8; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818; Schnaar RL, 2015, J ALLERGY CLIN IMMUN, V135, P609, DOI 10.1016/j.jaci.2014.10.057; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Song DJ, 2009, CLIN IMMUNOL, V131, P157, DOI 10.1016/j.clim.2008.11.009; Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947; Stowell SR, 2014, NAT CHEM BIOL, V10, P470, DOI [10.1038/NCHEMBIO.1525, 10.1038/nchembio.1525]; Suzukawa M, 2013, J IMMUNOL, V190, P5939, DOI 10.4049/jimmunol.1203455; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; Toubai T, 2014, BLOOD, V123, P3512, DOI 10.1182/blood-2013-12-545335; van de Vijver E, 2012, BLOOD CELL MOL DIS, V48, P53, DOI 10.1016/j.bcmd.2011.10.004; van der Kuyl AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000257; Varchetta S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045821; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Varki A, 2012, ANN NY ACAD SCI, V1253, P16, DOI 10.1111/j.1749-6632.2012.06517.x; Varki A, 2010, P NATL ACAD SCI USA, V107, P8939, DOI 10.1073/pnas.0914634107; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; von Gunten S, 2006, BLOOD, V108, P4255, DOI 10.1182/blood-2006-05-021568; von Gunten S, 2014, NAT REV IMMUNOL, V14, P349, DOI 10.1038/nri3401-c1; von Gunten S, 2009, SHOCK, V32, P386, DOI 10.1097/SHK.0b013e3181a1bc98; von Gunten S, 2009, J ALLERGY CLIN IMMUN, V123, P1268, DOI 10.1016/j.jaci.2009.03.013; von Gunten S, 2008, ANN NY ACAD SCI, V1143, P61, DOI 10.1196/annals.1443.011; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Webster RG, 2014, ANN NY ACAD SCI, V1323, P115, DOI 10.1111/nyas.12462; Wun T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101301; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004; Zarbock A, 2011, BLOOD, V118, P6743, DOI 10.1182/blood-2011-07-343566; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	114	70	70	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					598	608		10.1016/j.jaci.2014.11.031	http://dx.doi.org/10.1016/j.jaci.2014.11.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25592986	Green Accepted			2022-12-18	WOS:000351065000002
J	Hox, V; Desai, A; Bandara, G; Gilfillan, AM; Metcalfe, DD; Olivera, A				Hox, Valerie; Desai, Avanti; Bandara, Geethani; Gilfillan, Alasdair M.; Metcalfe, Dean D.; Olivera, Ana			Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; estrogen; nitric oxide synthase; vascular permeability; mast cells	NO SYNTHASE; IDIOPATHIC ANAPHYLAXIS; CARDIOVASCULAR-SYSTEM; BODY-TEMPERATURE; UP-REGULATION; SEX-HORMONES; RELEASE; SHOCK; SENSITIVITY; ACTIVATION	Background: Clinical observations suggest that anaphylaxis is more common in adult women compared with adult men, although the mechanistic basis for this sex bias is not well understood. Objectives: We sought to document sex-dependent differences in a mouse model of anaphylaxis and explore the role of female sex hormones and the mechanisms responsible. Methods: Passive systemic anaphylaxis was induced in female and male mice by using histamine, as well as IgE or IgG receptor aggregation. Anaphylaxis was assessed by monitoring body temperature, release of mast cell mediators and/or hematocrit, and lung weight as a measure of vascular permeability. A combination of ovariectomy, estrogen receptor antagonism, and estrogen administration techniques were used to establish estrogen involvement. Results: Anaphylactic responses were more pronounced in female than male mice. The enhanced severity of anaphylaxis in female mice was eliminated after pretreatment with an estrogen receptor antagonist or ovariectomy but restored after administration of estradiol in ovariectomized mice, demonstrating that the sex-specific differences are due to the female steroid estradiol. Estrogen did not affect mast cell responsiveness or anaphylaxis onset. Instead, it increased tissue expression of endothelial nitric oxide synthase (eNOS). Blockage of NOS activity with the inhibitor L-NG-nitroarginine methyl ester or genetic eNOS deficiency abolished the sex-related differences. Conclusion: Our study defines a contribution of estrogen through its regulation of eNOS expression and nitric oxide production to vascular hyperpermeability and intensified anaphylactic responses in female mice, providing additional mechanistic insights into risk factors and possible implications for clinical management in the further exploration of human anaphylaxis.	[Hox, Valerie; Desai, Avanti; Bandara, Geethani; Gilfillan, Alasdair M.; Metcalfe, Dean D.; Olivera, Ana] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hox, V (corresponding author), NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, Bldg 10,Rm 11C209,10 Ctr Dr MSC-1881, Bethesda, MD 20892 USA.	valeriehox@gmail.com	Hox, Valérie/AAA-5660-2020; Hox, Valerie/AAS-6504-2020	Hox, Valérie/0000-0003-2390-294X; 	Division of Intramural Research Program within the National Institute of Allergy and Infectious Diseases/National Institutes of Health; Research Foundation Flanders (F.W.O.); F.W.O. as well as a Gustave Boel-Sofina-Belgian American Educational Foundation (B.A.E.F.) fellow; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001206, ZIAAI000249, ZIAAI001091, ZIAAI000965, ZIAAI001092] Funding Source: NIH RePORTER	Division of Intramural Research Program within the National Institute of Allergy and Infectious Diseases/National Institutes of Health; Research Foundation Flanders (F.W.O.)(FWO); F.W.O. as well as a Gustave Boel-Sofina-Belgian American Educational Foundation (B.A.E.F.) fellow; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research Program within the National Institute of Allergy and Infectious Diseases/National Institutes of Health and by Research Foundation Flanders (F.W.O.). V.H. was a research fellow and the recipient of a Travel Grant from F.W.O. as well as a Gustave Boel-Sofina-Belgian American Educational Foundation (B.A.E.F.) fellow.	Bauer CS, 2013, ANN ALLERG ASTHMA IM, V111, P107, DOI 10.1016/j.anai.2013.06.001; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown SGA, 2013, MIDDLETONS ALLERGY P, P1237; Caliman IF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080892; Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; Cotter G, 2003, EUR HEART J, V24, P1287, DOI 10.1016/S0195-668X(03)00193-3; Cui H, 2013, J ALLERGY CLIN IMMUN, V132, P1205, DOI 10.1016/j.jaci.2013.07.026; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Evora PRB, 2007, ANN ALLERG ASTHMA IM, V99, P306, DOI 10.1016/S1081-1206(10)60545-5; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Hayashi T, 2003, SCAND J IMMUNOL, V57, P562, DOI 10.1046/j.1365-3083.2003.01269.x; HAYASHI T, 1995, BIOCHEM BIOPH RES CO, V214, P847, DOI 10.1006/bbrc.1995.2364; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; Jensen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014409; Jonsson F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00016; KHAN DA, 1994, ANN ALLERGY, V73, P370; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; Kuehn HS, 2008, CELL SIGNAL, V20, P625, DOI 10.1016/j.cellsig.2007.11.016; Kumar Arvind, 2005, Clin Dev Immunol, V12, P281, DOI 10.1080/17402520500376277; Kvedariene V, 2006, CLIN EXP ALLERGY, V36, P1072, DOI 10.1111/j.1365-2222.2006.02532.x; Laporte JR, 2003, PHARMACOEPIDEM DR S, V12, P195, DOI 10.1002/pds.822; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Lieberman Phillip, 2014, J Allergy Clin Immunol Pract, V2, P358, DOI 10.1016/j.jaip.2014.03.005; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; Miller VM, 2008, PHARMACOL REV, V60, P210, DOI 10.1124/pr.107.08002; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Reckelhoff JF, 1998, AM J HYPERTENS, V11, P97, DOI 10.1016/S0895-7061(97)00360-9; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; ROSSELLI M, 1994, BIOCHEM BIOPH RES CO, V202, P1543, DOI 10.1006/bbrc.1994.2107; RYAN KJ, 1982, CANCER RES, V42, P3342; SLATER JE, 1987, J ALLERGY CLIN IMMUN, V80, P285, DOI 10.1016/0091-6749(87)90033-9; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Teede HJ, 2007, CLIN EXP PHARMACOL P, V34, P672, DOI 10.1111/j.1440-1681.2007.04658.x; Tkaczyk C, 2002, J IMMUNOL METHODS, V268, P239, DOI 10.1016/S0022-1759(02)00210-7; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Yang SM, 2000, J CARDIOVASC PHARM, V36, P242, DOI 10.1097/00005344-200008000-00015; Yang WW, 2000, NEUROPHARMACOLOGY, V39, P2075, DOI 10.1016/S0028-3908(00)00054-X; Zaitsu M, 2007, MOL IMMUNOL, V44, P1977, DOI 10.1016/j.molimm.2006.09.030	52	70	72	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					729	U232		10.1016/j.jaci.2014.11.003	http://dx.doi.org/10.1016/j.jaci.2014.11.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25553642	Green Accepted, Bronze			2022-12-18	WOS:000351065000020
J	Brough, HA; Cousins, DJ; Munteanu, A; Wong, YF; Sudra, A; Makinson, K; Stephens, AC; Arno, M; Ciortuz, L; Lack, G; Turcanu, V				Brough, Helen A.; Cousins, David J.; Munteanu, Alina; Wong, Yuen Fei; Sudra, Asha; Makinson, Kerry; Stephens, Alick C.; Arno, Matthew; Ciortuz, Liviu; Lack, Gideon; Turcanu, Victor			IL-9 is a key component of memory T-H cell peanut-specific responses from children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; peanut sensitization; gene expression; real-time quantitative PCR; microarray; IL-9; T(H)9; IL-5; IL-13; T(H)2	LYMPHOCYTE-RESPONSES; AIRWAY INFLAMMATION; MAST-CELLS; EXPRESSION; TOLERANCE; RECEPTOR; ANTIGEN; GENE; FOOD; TRANSPLANTATION	Background: Differentiation between patients with peanut allergy (PA) and those with peanut sensitization (PS) who tolerate peanut but have peanut-specific IgE, positive skin prick test responses, or both represents a significant diagnostic difficulty. Previously, gene expression microarrays were successfully used to identify biomarkers and explore immune responses during PA immunotherapy. Objective: We aimed to characterize peanut-specific responses from patients with PA, subjects with PS, and atopic children without peanut allergy (NA children). Methods: A preliminary exploratory microarray investigation of gene expression in peanut-activated memory TH subsets from 3 children with PA and 3 NA children identified potential PA diagnostic biomarkers. Microarray findings were confirmed by using real-time quantitative PCR in 30 subjects (12 children with PA, 12 children with PS, and 6 NA children). Flow cytometry was used to identify the TH subsets involved. Results: Among 12,257 differentially expressed genes, IL9 showed the greatest difference between children with PA and NA children (45.59-fold change, P < .001), followed by IL5 and then IL13. Notably, IL9 allowed the most accurate classification of children with PA and NA children by using a machine-learning approach with recursive feature elimination and the random forest algorithm. Skin- and gut-homing TH cells from donors with PA expressed similar T(H)2- and T(H)9-associated genes. Real-time quantitative PCR confirmed that IL9 was the highest differentially expressed gene between children with PA and NA children (23.3-fold change, P < .01) and children with PS (18.5-fold change, P < .05). Intracellular cytokine staining showed that IL-9 and the T(H)2-specific cytokine IL-5 are produced by distinct T-H populations. Conclusion: In this study IL9 best differentiated between children with PA and children with PS (and atopic NA children). Mutually exclusive production of IL-9 and the T(H)2-specific cytokine IL-5 suggests that the IL-9-producing cells belong to the recently described T(H)9 subset.	[Brough, Helen A.; Cousins, David J.; Sudra, Asha; Makinson, Kerry; Stephens, Alick C.; Lack, Gideon; Turcanu, Victor] Kings Coll London, Div Asthma Allergy & Lung Biol, London, England; [Brough, Helen A.; Cousins, David J.; Sudra, Asha; Makinson, Kerry; Stephens, Alick C.; Lack, Gideon; Turcanu, Victor] Kings Coll London, MRC, London, England; [Brough, Helen A.; Cousins, David J.; Sudra, Asha; Makinson, Kerry; Stephens, Alick C.; Lack, Gideon; Turcanu, Victor] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Brough, Helen A.; Cousins, David J.; Sudra, Asha; Makinson, Kerry; Stephens, Alick C.; Lack, Gideon; Turcanu, Victor] Guys Hosp, London SE1 9RT, England; [Cousins, David J.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Munteanu, Alina; Ciortuz, Liviu] Alexandru Ioan Cuza Univ, Fac Comp Sci, Iasi, Romania; [Wong, Yuen Fei; Arno, Matthew] Kings Coll London, Genom Ctr, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Leicester; Alexandru Ioan Cuza University; University of London; King's College London	Turcanu, V (corresponding author), Guys Hosp, Kings Coll London, Div Asthma Allergy & Lung Biol, 5th Floor Bermondsey Wing, London SE1 9RT, England.	victor.turcanu@kcl.ac.uk	Wong, Yuen Fei/N-2615-2017; Wong, Yuen Fei/AAE-2086-2020	Wong, Yuen Fei/0000-0002-8761-2848; Brough, Helen/0000-0001-7203-0813; Lack, Gideon/0000-0001-7350-4021; Cousins, David/0000-0003-3821-9596	National Peanut Board (Project 27) (USA); Medical Research Council UK, Asthma UK; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; Kings College London; Medical Research Council [G1000758] Funding Source: researchfish; Asthma UK [09/020, MRC-AsthmaUKCentre] Funding Source: researchfish	National Peanut Board (Project 27) (USA); Medical Research Council UK, Asthma UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; Kings College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the National Peanut Board (Project 27) (USA) and by the Medical Research Council UK, Asthma UK, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and Kings College London.	Ahyi ANN, 2009, J IMMUNOL, V183, P1598, DOI 10.4049/jimmunol.0803302; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Alari-Pahissa E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048593; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bosco A, 2006, J IMMUNOL, V176, P4766, DOI 10.4049/jimmunol.176.8.4766; Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Bruhn S, 2012, ALLERGY, V67, P33, DOI 10.1111/j.1398-9995.2011.02707.x; Caserta S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035466; Chan SMH, 2012, ALLERGY, V67, P336, DOI 10.1111/j.1398-9995.2011.02765.x; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Connolly S, 2012, BIOCHEM PHARMACOL, V83, P778, DOI 10.1016/j.bcp.2011.12.021; Cortelazzi C, 2013, ACTA DERM-VENEREOL, V93, P183, DOI 10.2340/00015555-1408; Diaz-Uriarte R, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-3; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Flinterman AE, 2010, CLIN EXP ALLERGY, V40, P590, DOI 10.1111/j.1365-2222.2009.03431.x; Furukawa K, 1999, BBA-GEN SUBJECTS, V1473, P54, DOI 10.1016/S0304-4165(99)00169-5; Gagnon AW, 2002, CELL SIGNAL, V14, P595, DOI 10.1016/S0898-6568(02)00012-8; Gonzalo JA, 2007, J IMMUNOL, V179, P1740, DOI 10.4049/jimmunol.179.3.1740; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; Hourihane JO, 2005, ALLERGY, V60, P536, DOI 10.1111/j.1398-9995.2005.00752.x; Jabeen R, 2012, CURR OPIN IMMUNOL, V24, P303, DOI 10.1016/j.coi.2012.02.001; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 2011, CURR ALLERGY ASTHM R, V11, P139, DOI 10.1007/s11882-011-0178-7; Kantele A, 1999, J IMMUNOL, V162, P5173; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Kung TT, 2001, AM J RESP CELL MOL, V25, P600, DOI 10.1165/ajrcmb.25.5.4533; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Meinl W, 2001, BIOCHEM BIOPH RES CO, V288, P855, DOI 10.1006/bbrc.2001.5829; Mittag D, 2010, J IMMUNOL, V184, P4708, DOI 10.4049/jimmunol.0901036; Nagaishi T, 2006, ANN NY ACAD SCI, V1072, P155, DOI 10.1196/annals.1326.004; Nakajima Y, 2008, CLIN EXP ALLERGY, V38, P1499, DOI 10.1111/j.1365-2222.2008.03030.x; Niedoszytko M, 2010, J ALLERGY CLIN IMMUN, V125, P1092, DOI 10.1016/j.jaci.2010.01.021; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Parmentier CN, 2012, J ALLERGY CLIN IMMUN, V129, P1136, DOI 10.1016/j.jaci.2012.01.057; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Saulnier N, 2012, EUR REV MED PHARMACO, V16, P1197; Schuller A, 2011, TRANSPL P, V43, P4032, DOI 10.1016/j.transproceed.2011.08.088; Schwarz DF, 2010, BIOINFORMATICS, V26, P1752, DOI 10.1093/bioinformatics/btq257; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Stassen M, 2012, ANN NY ACAD SCI, V1247, P56, DOI 10.1111/j.1749-6632.2011.06351.x; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Swat A, 2011, BIOCHEM J, V434, P549, DOI 10.1042/BJ20101410; Turcanu V, 2008, CLIN EXP ALLERGY, V38, P1132, DOI 10.1111/j.1365-2222.2008.03016.x; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Xie JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045377; Xu Xuehua, 2012, Commun Integr Biol, V5, P381, DOI 10.4161/cib.20165; Zhang XG, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-197	55	70	71	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1329	+		10.1016/j.jaci.2014.06.032	http://dx.doi.org/10.1016/j.jaci.2014.06.032			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25112699	Green Submitted			2022-12-18	WOS:000346075400015
J	Miller, RL; Peden, DB				Miller, Rachel L.; Peden, David B.			Environmental effects on immune responses in patients with atopy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; mechanisms; innate immunity; adaptive immunity; epigenetic regulation	POLYCYCLIC AROMATIC-HYDROCARBONS; DIESEL EXHAUST PARTICLES; INDUCED AIRWAY INFLAMMATION; PARENTAL STRESS INCREASES; FINE PARTICULATE MATTER; CHILDHOOD ASTHMA; AMBIENT AIR; ANTIOXIDANT SUPPLEMENTATION; PULMONARY EXPOSURE; OXIDATIVE STRESS	Despite attempts and some successes to improve air quality over the decades, current US national trends suggest that exposure to outdoor and indoor air pollution remains a significant risk factor for both the development of asthma and the triggering of asthma symptoms. Emerging science also suggests that environmental exposures during the prenatal period and early childhood years increase the risk of asthma. Multiple mechanisms mediate this risk because a wide range of deleterious air pollutants contribute to the pathogenesis of asthma across a variety of complex asthma phenotypes. In this review we will consider the role of altered innate and adaptive immune responses, gene-environment interactions, epigenetic regulation, and possibly gene-environment-epigene interactions. Gaining a greater understanding of the mechanisms that underlie the effect of exposure to air pollution on asthma, allergies, and other airway diseases can identify targets for therapy. Such interventions will include pollutant source reduction among those most exposed and most vulnerable and novel pharmaceutical strategies to reduce asthma morbidity.	[Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Rheumatol Allergy & Immunol, New York, NY USA; [Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA; [Peden, David B.] Univ N Carolina, Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Chapel Hill, NC USA; [Peden, David B.] Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA	Columbia University; Columbia University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Miller, RL (corresponding author), Columbia Univ, Med Ctr, PH8E-101B,630 W 168 St, New York, NY 10032 USA.	rlm14@cumc.columbia.edu		Peden, David/0000-0003-4526-4627	National Institutes of Health [2R01ES13163 06A1, RO1 ES020926, R01 ES023349]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013163, R01ES023349, P30ES010126, R01ES020926] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants 2R01ES13163 06A1 (to R. L. M.), RO1 ES020926 (to R. L. M.), and R01 ES023349 (to D. B. P.).	Acciani TH, 2013, CLIN EXP ALLERGY, V43, P1406, DOI 10.1111/cea.12200; Ahmad S, 2006, FREE RADICAL BIO MED, V41, P29, DOI 10.1016/j.freeradbiomed.2006.03.004; Alexis NE, 2008, ENVIRON HEALTH PERSP, V116, P799, DOI 10.1289/ehp.10981; Allan K, 2011, J AM DIET ASSOC, V111, P258, DOI 10.1016/j.jada.2010.10.048; Andersen ZJ, 2012, THORAX, V67, P6, DOI 10.1136/thoraxjnl-2011-200711; Auerbach A, 2012, CURR OPIN ALLERGY CL, V12, P133, DOI 10.1097/ACI.0b013e32835113d6; Bauer RN, 2012, J ALLERGY CLIN IMMUN, V129, P14, DOI 10.1016/j.jaci.2011.11.004; Bentayeb M, 2012, INT J TUBERC LUNG D, V16, P1149, DOI 10.5588/ijtld.11.0666; Bind MA, 2012, EPIDEMIOLOGY, V23, P332, DOI 10.1097/EDE.0b013e31824523f0; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Breton CV, 2011, AM J RESP CRIT CARE, V183, P243, DOI 10.1164/rccm.201006-0849OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Carroll WD, 2005, PEDIAT ALLERG IMM-UK, V16, P32, DOI 10.1111/j.1399-3038.2005.00249.x; Chien JW, 2013, CLIN EXP ALLERGY, V43, P1018, DOI 10.1111/cea.12119; Chu S, 2013, J CHEM, V2013, P1; Curjuric I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040175; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dong GH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022470; Factor P, 2011, AM J RESP CELL MOL, V45, P1045, DOI 10.1165/rcmb.2010-0499OC; Fann N, 2012, RISK ANAL, V32, P81, DOI 10.1111/j.1539-6924.2011.01630.x; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Fu A, 2012, CLIN EXP ALLERGY, V42, P1575, DOI 10.1111/j.1365-2222.2012.04055.x; Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200; Halonen JI, 2009, EPIDEMIOLOGY, V20, P143, DOI 10.1097/EDE.0b013e31818c7237; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Heber D, 2014, FOOD FUNCT, V5, P35, DOI 10.1039/c3fo60277j; Heinrich J, 2007, INT J HYG ENVIR HEAL, V210, P617, DOI 10.1016/j.ijheh.2007.07.012; Hirota JA1, 2014, AM J RESP CELL MOL B; Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033; Hwang BF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052715; Inoue KI, 2007, IMMUNOPHARM IMMUNOT, V29, P403, DOI 10.1080/08923970701675002; Inoue KI, 2006, EXP BIOL MED, V231, P1626; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Johnson PRS, 2005, ENVIRON HEALTH PERSP, V113, P1140, DOI 10.1289/ehp.7822; Jung KH, 2014, ENVIRON RES, V128, P35, DOI 10.1016/j.envres.2013.12.002; Jung KH, 2012, ANN ALLERG ASTHMA IM, V109, P249, DOI 10.1016/j.anai.2012.07.019; Jung KH, 2012, ENVIRON INT, V45, P44, DOI 10.1016/j.envint.2012.03.012; Kerkhof M, 2010, THORAX, V65, P690, DOI 10.1136/thx.2009.119636; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Kopriva F, 2013, BIOMED PAP, V157, P367, DOI 10.5507/bp.2013.025; Kunzli N, 2008, EPIDEMIOLOGY, V19, P179, DOI 10.1097/EDE.0b013e3181633c2f; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Lazaar AL, 2011, BRIT J CLIN PHARMACO, V72, P282, DOI 10.1111/j.1365-2125.2011.03968.x; Lin S, 2013, J EXPO SCI ENV EPID, V23, P73, DOI 10.1038/jes.2012.69; Lin WW, 2011, ENVIRON HEALTH PERSP, V119, P1507, DOI 10.1289/ehp.1103461; Liu Jing, 2013, J Toxicol, V2013, P967029, DOI 10.1155/2013/967029; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Lu KD, 2013, J ALLERGY CLIN IMMUN, V131, P1017, DOI 10.1016/j.jaci.2012.12.1570; Madrigano J, 2011, ENVIRON HEALTH PERSP, V119, P977, DOI 10.1289/ehp.1002773; Milan S.J., 2013, COCHRANE LIB, V23, P10; Miller RL, 2010, PEDIATR ALLERGY IMMU, V21, P260, DOI 10.1111/j.1399-3038.2009.00980.x; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Ovrevik J, 2013, TOXICOL LETT, V219, P125, DOI 10.1016/j.toxlet.2013.02.014; Patel MM, 2011, ENVIRON RES, V111, P1222, DOI 10.1016/j.envres.2011.08.004; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Riedl MA, 2009, CLIN IMMUNOL, V130, P244, DOI 10.1016/j.clim.2008.10.007; Romieu I, 2004, THORAX, V59, P8; Rosa MJ, 2011, RESP MED, V105, P869, DOI 10.1016/j.rmed.2010.11.022; Ross K, 2012, J PEDIATR-US, V161, P781, DOI 10.1016/j.jpeds.2012.06.064; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Sienra-Monge JJ, 2004, CLIN EXP IMMUNOL, V138, P317, DOI 10.1111/j.1365-2249.2004.02606.x; Silverman RA, 2010, J ALLERGY CLIN IMMUN, V125, P367, DOI 10.1016/j.jaci.2009.10.061; Sofer T, 2013, EPIGENOMICS-UK, V5, P147, DOI [10.2217/epi.13.16, 10.2217/EPI.13.16]; Spira-Cohen A, 2011, ENVIRON HEALTH PERSP, V119, P559, DOI 10.1289/ehp.1002653; Su HJ, 2013, ARCH ENVIRON OCCUP H, V68, P80, DOI 10.1080/19338244.2011.646360; Su MW, 2013, ALLERGY, V68, P1614, DOI 10.1111/all.12298; Susiarjo M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003401; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Tang WY, 2012, ENVIRON HEALTH PERSP, V120, P1195, DOI 10.1289/ehp.1103744; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Tong HY, 2012, ENVIRON HEALTH PERSP, V120, P952, DOI 10.1289/ehp.1104472; Vagaggini B, 2001, AM J RESP CRIT CARE, V164, P2172, DOI 10.1164/ajrccm.164.12.2009090; van Voorhis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082545; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Wan JX, 2007, INHAL TOXICOL, V19, P177, DOI 10.1080/08958370701496145; Wang S, 2011, HUM HERED, V71, P196, DOI 10.1159/000328006; Weir CH, 2013, RESP MED, V107, P1763, DOI 10.1016/j.rmed.2013.08.010; Wenten M, 2009, AM J EPIDEMIOL, V170, P1494, DOI 10.1093/aje/kwp310; Winquist A, 2012, ENV HLTH, V11, P1; Wu WD, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-31; Wu WD, 2012, FREE RADICAL BIO MED, V53, P721, DOI 10.1016/j.freeradbiomed.2012.05.037; Wu WD, 2011, FREE RADICAL BIO MED, V51, P522, DOI 10.1016/j.freeradbiomed.2011.05.006; Yamazaki S, 2009, J EPIDEMIOL, V19, P143, DOI 10.2188/jea.JE20081025	95	70	74	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1001	1008		10.1016/j.jaci.2014.07.064	http://dx.doi.org/10.1016/j.jaci.2014.07.064			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25439226	Green Accepted, Green Published			2022-12-18	WOS:000344938900002
J	Casale, TB; Stokes, JR				Casale, Thomas B.; Stokes, Jeffrey R.			Immunotherapy: What lies beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Immunotherapy; allergy; asthma; omalizumab; allergens; recombinant; peptide; epicutaneous; intraepithelial; sublingual immunotherapy	SEASONAL ALLERGIC RHINOCONJUNCTIVITIS; LOCAL NASAL IMMUNOTHERAPY; COWS MILK ALLERGY; SUBLINGUAL IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; GRASS-POLLEN; DOUBLE-BLIND; INTRALYMPHATIC IMMUNOTHERAPY; CLINICAL-EFFICACY; PEANUT ALLERGY	Allergen immunotherapy has been used to treat allergic diseases, such as asthma, allergic rhinitis, and venom allergy, since first described over a century ago. The current standard of care in the United States involves subcutaneous administration of clinically relevant allergens for several months, building up to eventual monthly injections for typically 3 to 5 years. Recent advances have improved the safety and efficacy of immunotherapy. The addition of omalizumab or Toll-like receptor agonists to standard subcutaneous immunotherapy has proved beneficial. Altering the extract itself, either through chemical manipulation producing allergoids or directly producing recombinant proteins or significant peptides, has been evaluated with promising results. The use of different administration techniques, such as sublingual immunotherapy, is common in Europe and is on the immediate horizon in the United States. Other methods of administering allergen immunotherapy have been studied, including epicutaneous, intralymphatic, intranasal, and oral immunotherapy. In this review we focus on new types and routes of immunotherapy, exploring recent human clinical trial data. The promise of better immunotherapies appears closer than ever before, but much work is still needed to develop novel immunotherapies that induce immunologic tolerance and enhanced clinical efficacy and safety over that noted for subcutaneous allergen immunotherapy.	[Casale, Thomas B.] Univ S Florida, Div Allergy Immunol, Tampa, FL 33612 USA; [Stokes, Jeffrey R.] Creighton Univ, Div Allergy Immunol, Omaha, NE 68178 USA	State University System of Florida; University of South Florida; Creighton University	Casale, TB (corresponding author), Univ S Florida, Div Allergy Immunol, 12901 Bruce B Downs Blvd,MDC Bldg,3rd Floor,Rm 3, Tampa, FL 33612 USA.	tbcasale@health.usf.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	Stallergenes; Merck; Cirassia; Cytos; ALK-Abello	Stallergenes; Merck(Merck & Company); Cirassia; Cytos; ALK-Abello	T. B. Casale has received consultancy fees from Stallergenes, Merck, Cirassia, and Cytos; is the American Academy of Allergy, Asthma & Immunology Executive Vice President; has received research support from Merck, Stallergenes, ALK-Abello, Circassia, and Cytos; and has received lecture fees from ALK-Abello. J. R. Stokes declares that he has no relevant conflicts of interest.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Calderon MA, 2011, CLIN EXP ALLERGY, V41, P1263, DOI 10.1111/j.1365-2222.2011.03835.x; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Freeman J, 1911, LANCET, V2, P814; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Hoiby AS, 2010, CLIN EXP ALLERGY, V40, P1062, DOI 10.1111/j.1365-2222.2010.03521.x; Horak F, 2011, EXPERT OPIN INV DRUG, V20, P981, DOI 10.1517/13543784.2011.583237; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Johansen P, 2012, HUM VACC IMMUNOTHER, V8, P1525, DOI 10.4161/hv.21948; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Klimek L, 2011, CLIN EXP ALLERGY, V41, P1305, DOI 10.1111/j.1365-2222.2011.03783.x; Kopp MV, 2009, CLIN EXP ALLERGY, V39, P271, DOI 10.1111/j.1365-2222.2008.03121.x; Kopp MV, 2013, PEDIAT ALLERG IMM-UK, V24, P427, DOI 10.1111/pai.12098; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Marcucci F, 2002, ALLERGY, V57, P23, DOI 10.1034/j.1398-9995.2002.13149.x; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; Meyer W, 2013, ALLERGY, V68, P724, DOI 10.1111/all.12148; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Niederberger V, 2007, J ALLERGY CLIN IMMUN, V119, P1013, DOI 10.1016/j.jaci.2006.12.661; Niespodziana K, 2011, J ALLERGY CLIN IMMUN, V127, P1562, DOI 10.1016/j.jaci.2011.02.004; Garcia AN, 2013, EUR ANN ALLERGY CLIN, V45, P78; Noon L, 1911, LANCET, V1, P1572; Nurmatov U, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009014.pub2; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfaar O, 2011, INT ARCH ALLERGY IMM, V154, P336, DOI 10.1159/000321826; Powell RJ, 2007, ALLERGY, V62, P1335, DOI 10.1111/j.1398-9995.2007.01455.x; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Rajakulasingam K, 2012, EUR ANN ALLERGY CLIN, V44, P128; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Rosewich M, 2013, HUM VACC IMMUNOTHER, V9, P1523, DOI 10.4161/hv.24631; Segal M, 2008, WORLD ALLERGY ORGAN, V1, P174, DOI 10.1097/WOX.0b013e318187a310; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Sheikh A, 2012, PRIM CARE RESP J, V21, P41, DOI 10.4104/pcrj.2011.00071; Tsai JJ, 2009, J ASTHMA, V46, P165, DOI 10.1080/02770900802553110; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Witten M, 2013, J ALLERGY CLIN IMMUN, V132, P1248, DOI 10.1016/j.jaci.2013.07.033; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, p[89, e1]; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; Yeung JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009542.pub2	67	70	73	5	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					612	619		10.1016/j.jaci.2014.01.007	http://dx.doi.org/10.1016/j.jaci.2014.01.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24581428				2022-12-18	WOS:000332397600001
J	Rachid, R; Bonilla, FA				Rachid, Rima; Bonilla, Francisco A.			The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: A comprehensive review of the literature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; anti-IgA antibody; IgA deficiency; immunoglobulin therapy	ANAPHYLACTIC TRANSFUSION REACTIONS; COMMON-VARIABLE-IMMUNODEFICIENCY; DEPLETED INTRAVENOUS IMMUNOGLOBULIN; DEFICIENT PATIENTS; BLOOD-DONORS; SUBSTITUTION THERAPY; PREVENTION; HYPOGAMMAGLOBULINEMIA; IMMUNOASSAY; ASSOCIATION	Anaphylactic reactions to immunoglobulin infusions in immunodeficient patients with undetectable IgA have been attributed in several reports to IgG or IgE anti-IgA antibodies. However, other reports have not supported an association between such antibodies and the development of severe reactions. We have reviewed the articles reporting reactions to immunoglobulin products in IgA-deficient patients, as well as those describing the presence of such antibodies in the absence of reactions to infusions. A variety of factors might influence the association of adverse reactions with anti-IgA antibodies, including the serum concentration and isotype (IgG or IgE) of the anti-IgA antibody, its specificity (class or subclass specific), the method of measurement, and the IgA content of the gamma globulin infusion and its route of administration. The role of anti-IgA antibodies in causing anaphylaxis in IgA-deficient patients receiving gamma globulin therapy is still controversial. Larger (multicenter) studies are needed to further evaluate this association. (J Allergy Clin Immunol 2012; 129: 628-34.)	[Rachid, Rima] Harvard Univ, Div Immunol, Childrens Hosp Boston, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Pediat, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Rachid, R (corresponding author), Harvard Univ, Div Immunol, Childrens Hosp Boston, Sch Med, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.	rima.rachid@childrens.harvard.edu			Talecris	Talecris	F. A. Bonilla has consultant arrangements with CSL Behring, Spring Leaf Pharmaceuticals, and Prescription Solutions; receives research support from Talecris; is an advisor/consultant for the Immune Deficiency Foundation, and is BCI Vice Chair for the American Academy of Allergy, Asthma & Immunology. R. Rachid had declared no conflict of interest.	Ahrens N, 2008, CLIN EXP IMMUNOL, V151, P455, DOI 10.1111/j.1365-2249.2007.03483.x; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BJORKANDER J, 1985, INFECTION, V13, P102, DOI 10.1007/BF01642867; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; Campos RD, 2000, J CLIN IMMUNOL, V20, P77; CASSIDY JT, 1975, J ALLERGY CLIN IMMUN, V55, P35, DOI 10.1016/S0091-6749(75)80006-6; CASSIDY JT, 1969, NEW ENGL J MED, V280, P275; CLARK JA, 1983, AM J CLIN PATHOL, V80, P210, DOI 10.1093/ajcp/80.2.210; CUNNINGHAMRUNDLES C, 1986, CLIN IMMUNOL IMMUNOP, V38, P141, DOI 10.1016/0090-1229(86)90133-9; CUNNINGHAMRUNDLES C, 1993, J CLIN IMMUNOL, V13, P272, DOI 10.1007/BF00919386; Eijkhout HW, 2003, NETH J MED, V61, P213; FERREIRA A, 1988, CLIN IMMUNOL IMMUNOP, V47, P199, DOI 10.1016/0090-1229(88)90072-4; FERREIRA A, 1989, VOX SANG, V56, P218, DOI 10.1111/j.1423-0410.1989.tb02032.x; FRANKEL SJ, 1986, ANN ALLERGY, V56, P436; HAMMARSTROM L, 1983, SCAND J IMMUNOL, V18, P509, DOI 10.1111/j.1365-3083.1983.tb00885.x; HEDDERICH U, 1986, CLIN ALLERGY, V16, P339, DOI 10.1111/j.1365-2222.1986.tb01966.x; HOMBURGER HA, 1981, TRANSFUSION, V21, P38, DOI 10.1046/j.1537-2995.1981.21181127481.x; Horn J, 2007, CLIN IMMUNOL, V122, P156, DOI 10.1016/j.clim.2006.10.002; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KOISTINEN J, 1977, J IMMUNOGENET, V4, P295; KOISTINEN J, 1978, BRIT MED J, V2, P923, DOI 10.1136/bmj.2.6142.923; Limaye S, 2001, INTERN MED J, V31, P256, DOI 10.1046/j.1445-5994.2001.00053.x; NADORP JHS, 1973, EUR J CLIN INVEST, V3, P317, DOI 10.1111/j.1365-2362.1973.tb00357.x; PETTY RE, 1985, NEW ENGL J MED, V313, P1620, DOI 10.1056/NEJM198512263132602; Rachid R, 2011, J ALLERGY CLIN IMMUN, V128, P228, DOI 10.1016/j.jaci.2011.01.061; RIVAT L, 1977, CLIN IMMUNOL IMMUNOP, V7, P340, DOI 10.1016/0090-1229(77)90068-X; ROPARS C, 1974, VOX SANG, V27, P294, DOI 10.1111/j.1423-0410.1974.tb02422.x; Rumilla K M, 2009, Immunohematology, V25, P24; Salama A, 2004, TRANSFUSION, V44, P509, DOI 10.1111/j.1537-2995.2004.03316.x; Salama A, 2001, VOX SANG, V81, P45, DOI 10.1046/j.1423-0410.2001.00047.x; SANDLER SG, 1994, BLOOD, V84, P2031; SELIGMANN M, 1991, CLIN EXP IMMUNOL, V84, P23; Sundin U, 1998, CLIN EXP IMMUNOL, V112, P341; SYRJALA MT, 1991, J IMMUNOL METHODS, V139, P265, DOI 10.1016/0022-1759(91)90197-N; VYAS GN, 1968, LANCET, V2, P312; VYAS GN, 1975, J LAB CLIN MED, V85, P838	38	70	74	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					628	634		10.1016/j.jaci.2011.06.047	http://dx.doi.org/10.1016/j.jaci.2011.06.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	21835445				2022-12-18	WOS:000301189300005
J	Poposki, JA; Uzzaman, A; Nagarkar, DR; Chustz, RT; Peters, AT; Suh, LA; Carter, R; Norton, J; Harris, KE; Grammer, LC; Tan, BK; Chandra, RK; Conley, DB; Kern, RC; Schleimer, RP; Kato, A				Poposki, Julie A.; Uzzaman, Ashraf; Nagarkar, Deepti R.; Chustz, Regina T.; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.; Kato, Atsushi			Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; CCL23; CCR1; eosinophils; aspirin sensitivity	ENDOTHELIAL GROWTH-FACTOR; CELL-ACTIVATING FACTOR; CC-CHEMOKINE; MATRIX METALLOPROTEINASE-2; INFLAMMATORY MEDIATORS; DENDRITIC CELLS; MESSENGER-RNA; TNF FAMILY; RECEPTOR 1; MACROPHAGES	Background: Chronic rhinosinusitis (CRS) is a heterogeneous chronic disease characterized by local inflammation of the sinonasal tissues. The pathogenesis of CRS remains controversial, but it has been associated with the accumulation of various immune and inflammatory cells in sinus tissue. Objectives: The objective of this study was to investigate the expression of the chemokine CCL23, which is known to bind to CCR1 and recruit monocytes, macrophages, and dendritic cells, in patients with CRS. Methods: We collected nasal tissue from patients with CRS and control subjects. We assayed mRNA for CCL23 by using real-time PCR and measured CCL23 protein by means of ELISA, immunohistochemistry, and immunofluorescence. Results: CCL23 mRNA levels were significantly increased in nasal polyps (NPs) from patients with CRS with nasal polyps (CRSwNP; P < .05) compared with inferior turbinate and uncinate tissue from patients with CRS or control subjects. CCL23 protein levels were also increased in NPs, although these levels were not statistically significant. Immunohistochemical analysis revealed CCL23 expression in mucosal epithelial cells and inflammatory cells, but accumulation of CCL23(+) inflammatory cells occurred only in NPs. Immunofluorescence data showed CCL23 colocalization with eosinophil cationic protein-positive eosinophils. The concentration of CCL23 in NPs positively correlated with the concentration of eosinophil cationic protein, suggesting that eosinophils are major CCL23-producing cells in NPs. Finally, we found that CCL23 protein levels were significantly increased in NPs from patients with CRSwNP with aspirin sensitivity. Conclusion: Overproduction of CCL23 in NPs might contribute to the pathogenesis of eosinophilic CRSwNP through the recruitment of CCR1(+) inflammatory cells, including monocytes and macrophages, and the amplification of local inflammation. (J Allergy Clin Immunol 2011; 128: 73-81.)	[Poposki, Julie A.; Uzzaman, Ashraf; Nagarkar, Deepti R.; Chustz, Regina T.; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	a-kato@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Grammer, Leslie/0000-0001-6860-2014; Chandra, Rakesh/0000-0002-3612-0026	National Institutes of Health [R01 HL078860, R01 AI072570, R37 HL068546]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants R01 HL078860, R01 AI072570, and R37 HL068546 and by a grant from the Ernest S. Bazley Trust.	Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; Bhandari A, 2004, ACTA OTO-LARYNGOL, V124, P1165, DOI 10.1080/00016480410017152; Cardell LO, 2006, ACTA OTO-LARYNGOL, V126, P375, DOI 10.1080/00016480500395724; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Christophi GP, 2009, LAB INVEST, V89, P742, DOI 10.1038/labinvest.2009.32; Claeys S, 2005, CLIN EXP ALLERGY, V35, P467, DOI 10.1111/j.1365-2222.2005.02215.x; Claeys S, 2004, ALLERGY, V59, P606, DOI 10.1111/j.1398-9995.2004.00471.x; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Erbek SS, 2010, AM J RHINOL ALLERGY, V24, pE79, DOI 10.2500/ajra.2010.24.3480; Forssmann U, 1997, FEBS LETT, V408, P211, DOI 10.1016/S0014-5793(97)00408-0; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hwang J, 2005, CYTOKINE, V30, P254, DOI 10.1016/j.cyto.2005.01.018; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; Jian W, 2009, AM J OTOLARYNG, V30, P24, DOI 10.1016/j.amjoto.2008.01.003; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Lee HS, 2009, AM J RESP CRIT CARE, V180, P1056, DOI 10.1164/rccm.200905-0740OC; Lee JH, 2006, ARCH OTOLARYNGOL, V132, P537, DOI 10.1001/archotol.132.5.537; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Marcella R, 2003, IMMUNOL LETT, V90, P71, DOI 10.1016/S0165-2478(03)00163-9; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Matsumoto K, 2006, INT ARCH ALLERGY IMM, V140, P42, DOI 10.1159/000092710; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Meyer JE, 2005, AM J RHINOL, V19, P15, DOI 10.1177/194589240501900103; Miao ZH, 2007, J IMMUNOL, V178, P7395, DOI 10.4049/jimmunol.178.11.7395; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Muluk NB, 2007, J OTOLARYNGOL, V36, P357, DOI 10.2310/7070.2007.0056; Nagarkar DR, 2010, J IMMUNOL, V185, P2525, DOI 10.4049/jimmunol.1000286; Nardelli B, 1999, J IMMUNOL, V162, P435; Novak H, 2007, J IMMUNOL, V178, P4335, DOI 10.4049/jimmunol.178.7.4335; Olze H, 2006, RHINOLOGY, V44, P145; Park SK, 2009, LARYNGOSCOPE, V119, P409, DOI 10.1002/lary.20085; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Pawliczak R, 2005, CURR ALLERGY ASTHM R, V5, P463, DOI 10.1007/s11882-005-0027-7; Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Rioja I, 2008, ARTHRITIS RHEUM-US, V58, P2257, DOI 10.1002/art.23667; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Son KN, 2006, BIOCHEM BIOPH RES CO, V340, P498, DOI 10.1016/j.bbrc.2005.12.037; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; Yanaba K, 2011, ARCH DERMATOL RES, V303, P29, DOI 10.1007/s00403-010-1078-8; Yao T, 2009, LARYNGOSCOPE, V119, P1053, DOI 10.1002/lary.20191; Youn BS, 1998, BLOOD, V91, P3118, DOI 10.1182/blood.V91.9.3118.3118_3118_3126; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	70	71	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					73	U123		10.1016/j.jaci.2011.03.017	http://dx.doi.org/10.1016/j.jaci.2011.03.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21497884	Green Accepted, Bronze			2022-12-18	WOS:000292245600009
J	Martin, PE; Matheson, MC; Gurrin, L; Burgess, JA; Osborne, N; Lowe, AJ; Morrison, S; Meszaros, D; Giles, GG; Abramson, MJ; Walters, EH; Allen, KJ; Dharmage, SC				Martin, Pamela E.; Matheson, Melanie C.; Gurrin, Lyle; Burgess, John A.; Osborne, Nicholas; Lowe, Adrian J.; Morrison, Stephen; Meszaros, Desiree; Giles, Graham G.; Abramson, Michael J.; Walters, E. Haydn; Allen, Katrina J.; Dharmage, Shyamali C.			Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: A prospective cohort study over 4 decades	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; asthma; rhinitis; population; childhood; adulthood; epidemiology; atopy; atopic march	ALLERGIC RHINITIS; FOLLOW-UP; AGE 7; DERMATITIS; FILAGGRIN; ONSET; SENSITIZATION; PERSISTENCE; MUTATIONS; REMISSION	Background: The evidence on whether the atopic march observed in childhood (ie, the progression from eczema to allergic rhinitis and asthma) extends to adulthood is sparse, and there is no evidence on whether the progression leads to a specific phenotype of asthma. Objective: We sought to assess whether childhood eczema and rhinitis are risk factors for specific phenotypes of adult asthma. Methods: Participants of the Tasmanian Longitudinal Health Study recruited in 1968 (age range, 6.0-7.0 years) were followed up at age 44 years. The risk of current atopic or nonatopic asthma in middle age characterized by sensitization to aeroallergens given childhood eczema, rhinitis, or both was calculated by using multinomial logistic regression. Results: No association was found between childhood eczema or rhinitis and nonatopic adult asthma. In contrast, childhood eczema and rhinitis in combination predicted both new-onset atopic asthma by middle age (adjusted multinomial odds ratio [aMOR], 6.3; 95% CI, 1.7-23.2) and the persistence of childhood asthma to adult atopic asthma (aMOR, 11.7; 95% CI, 3.6-37.9). Participants with childhood eczema alone were at increased risk of new-onset atopic asthma (aMOR, 4.1; 95% CI, 1.9-8.8), whereas rhinitis alone predicted the persistence of childhood asthma to atopic asthma (aMOR, 2.7; 95% CI, 1.3-5.6). Of all asthma, 29.7% of persistent atopic asthma and 18.1% of new-onset atopic asthma could be attributed to having childhood eczema and rhinitis. Conclusion: Childhood eczema and rhinitis are strongly associated with the incidence and persistence of adult atopic asthma. (J Allergy Clin Immunol 2011;127:1473-9.)	[Martin, Pamela E.; Osborne, Nicholas; Lowe, Adrian J.; Allen, Katrina J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Martin, Pamela E.; Osborne, Nicholas; Dharmage, Shyamali C.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Matheson, Melanie C.; Gurrin, Lyle; Burgess, John A.; Lowe, Adrian J.; Giles, Graham G.; Walters, E. Haydn] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia; [Morrison, Stephen] Univ Queensland, Brisbane, Qld, Australia; [Meszaros, Desiree; Walters, E. Haydn] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia; [Giles, Graham G.; Abramson, Michael J.; Walters, E. Haydn] Monash Univ, Clayton, Vic 3800, Australia	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Queensland; University of Tasmania; Menzies Institute for Medical Research; Cancer Council Victoria; Monash University	Dharmage, SC (corresponding author), Univ Melbourne, Sch Populat Hlth, Ctr MEGA Epidemiol, Level 1,723 Swanston St, Carlton, Vic 3052, Australia.	s.dharmage@unimelb.edu.au	Osborne, Nicholas/D-2086-2011; WALTERS, Eugene/AAL-2264-2021; Burgess, John/H-7555-2019; Allen, Katrina/I-4361-2018; Matheson, Melanie C/O-4721-2015; Morrison, Stephen C/H-7936-2013; Abramson, Michael/AAQ-2671-2020	Osborne, Nicholas/0000-0002-6700-2284; Burgess, John/0000-0001-7532-5027; Allen, Katrina/0000-0002-1921-4493; Matheson, Melanie C/0000-0002-5822-3499; Abramson, Michael/0000-0002-9954-0538; Gurrin, Lyle/0000-0001-7052-1969; Lowe, Adrian/0000-0002-4691-8162; Giles, Graham/0000-0003-4946-9099; Walters, Eugene/0000-0002-0993-4374	Australian National Health & Medical Research Council; Clifford Craig Foundation; Asthma Foundations in Tasmania; Victoria; Queensland; University of Melbourne; National Health & Medical Research Council; Australian Egg Corporation; Reckitts Benckiser; National Health and Research Council; Royal Hobart Hospital Research Foundation	Australian National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Clifford Craig Foundation; Asthma Foundations in Tasmania; Victoria; Queensland; University of Melbourne(University of Melbourne); National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Egg Corporation(Australian Eggs); Reckitts Benckiser; National Health and Research Council; Royal Hobart Hospital Research Foundation	Funding for this project was obtained from the Australian National Health & Medical Research Council, the Clifford Craig Foundation, and Asthma Foundations in Tasmania, Victoria, and Queensland and the University of Melbourne. P.E.M. is an Australian Postgraduate Award scholar, K.J.A. is a Viertel Senior Medical Research Fellow, and L.G., M.C.M., A.J.L., and S.C.D. hold National Health & Medical Research Council Awards.; Disclosure of potential conflict of interest: N. Osborne receives research support from the Australian Egg Corporation. M. J. Abramson was part of the Landmark Symposium for GlaxoSmithKline and receives research support from Reckitts Benckiser. E. H. Walters receives research support from the National Health and Research Council and the Royal Hobart Hospital Research Foundation. The rest of the authors have declared that they have no conflict of interest.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; *AUSTR I HLTH WELF, 2010, ASTHM OLD PEOPL AUST; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bodtger U, 2004, J ALLERGY CLIN IMMUN, V114, P1384, DOI 10.1016/j.jaci.2004.08.039; Burgess JA, 2008, J ALLERGY CLIN IMMUN, V122, P280, DOI 10.1016/j.jaci.2008.05.018; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Burgess JA, 2009, J ASTHMA, V46, P429, DOI 10.1080/02770900902846356; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Kandane-Rathnayake RK, 2009, THORAX, V64, P1025, DOI 10.1136/thx.2009.118430; Ker J, 2009, ANN ALLERG ASTHMA IM, V103, P282, DOI 10.1016/S1081-1206(10)60526-1; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Lowe AJ, 2008, J ALLERGY CLIN IMMUN, V121, P1190, DOI 10.1016/j.jaci.2008.01.034; Mandelin JM, 2010, J DERMATOL TREAT, V21, P167, DOI 10.3109/09546630903493329; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; NELSON HS, 1983, ANN ALLERGY, V51, P411; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stupka E, 2009, AM J MED, V122, P6, DOI 10.1016/j.amjmed.2008.09.022; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wharton C, 2006, AUST NZ J PUBL HEAL, V30, P105, DOI 10.1111/j.1467-842X.2006.tb00100.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104	31	70	72	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1473	U233		10.1016/j.jaci.2011.02.041	http://dx.doi.org/10.1016/j.jaci.2011.02.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21458851				2022-12-18	WOS:000291048500024
J	Clark, S; Espinola, J; Rudders, SA; Banerji, A; Camargo, CA				Clark, Sunday; Espinola, Janice; Rudders, Susan A.; Banerji, Aleena; Camargo, Carlos A., Jr.			Frequency of US emergency department visits for food-related acute allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; MULTICENTER		[Clark, Sunday] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Espinola, Janice; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Banerji, Aleena; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Rudders, Susan A.] Hasbro Childrens Hosp, Ctr Asthma & Allergy, Providence, RI USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Hasbro Children's Hospital	Clark, S (corresponding author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.	sunday.clark@gmail.com	Camargo, Carlos A./C-2145-2008; Clark, Sunday/AAA-5458-2021; Banerji, Aleena/ABG-1245-2021	Camargo, Carlos A./0000-0002-5071-7654; 				Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; NAWAR EW, 2007, ADV DATA, V386, P1; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	9	70	71	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					682	683		10.1016/j.jaci.2010.10.040	http://dx.doi.org/10.1016/j.jaci.2010.10.040			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21167574				2022-12-18	WOS:000288018400021
J	Monti, G; Castagno, E; Liguori, SA; Lupica, MM; Tarasco, V; Viola, S; Tovo, PA				Monti, Giovanna; Castagno, Emanuele; Liguori, Stefania Alfonsina; Lupica, Maria Maddalena; Tarasco, Valentina; Viola, Serena; Tovo, Pier Angelo			Food protein-induced enterocolitis syndrome by cow's milk proteins passed through breast milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MANAGEMENT		[Monti, Giovanna; Castagno, Emanuele; Liguori, Stefania Alfonsina; Lupica, Maria Maddalena; Tarasco, Valentina; Viola, Serena; Tovo, Pier Angelo] Univ Turin, Regina Margherita Childrens Hosp, Dept Pediat, I-10124 Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; University of Turin	Monti, G (corresponding author), Univ Turin, Regina Margherita Childrens Hosp, Dept Pediat, I-10124 Turin, Italy.	giovanna.monti@email.it	Castagno, Emanuele/AAU-2634-2021; monti, giovanna/K-3192-2018; Monti, Giovanna/K-2563-2018	Castagno, Emanuele/0000-0001-7756-5075; monti, giovanna/0000-0001-5094-1077; Monti, Giovanna/0000-0003-3854-7880; Tovo, Pier Angelo/0000-0002-0192-3240				Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P371, DOI 10.1097/ACI.0b013e32832d6315; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025	5	70	82	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					679	680		10.1016/j.jaci.2010.10.017	http://dx.doi.org/10.1016/j.jaci.2010.10.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21146866				2022-12-18	WOS:000288018400019
J	Peters, AS; Kellberger, J; Vogelberg, C; Dressel, H; Windstetter, D; Weinmayr, G; Genuneit, J; Nowak, D; von Mutius, E; Radon, K				Peters, Astrid S.; Kellberger, Jessica; Vogelberg, Christian; Dressel, Holger; Windstetter, Doris; Weinmayr, Gudrun; Genuneit, Jon; Nowak, Dennis; von Mutius, Erika; Radon, Katja			Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: A prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; adolescence; disease prediction; occupational exposure	CHILDHOOD ISAAC; RISK-FACTORS; ENVIRONMENTAL-FACTORS; ASTHMA; PREVALENCE; ECZEMA; ALLERGIES; CHILDREN; SENSITIZATION; LIFE	Background: Although it is known that atopic dermatitis (AD) can develop during adolescence, research on its course and predictors in this age group is thus far limited. Objective: We aimed to describe the course of AD over puberty and prospectively determine risk factors for the incidence, recurrence, and persistence of AD until adolescence in a population-based cohort study. Methods: German participants of the International Study of Asthma and Allergies in Childhood Phase II were followed prospectively. The final dataset comprised 2857 adolescents, of whom 2433 were unaffected by AD at baseline. Bivariate and multivariate prediction models for the incidence, recurrence, and persistence of AD using early-life factors, family history of atopic diseases, and job history as predictors were developed. Results: The incidence of AD between ages 9 to 11 and 16 to 20 years was 1.7%, and recurrence was 2.4%. AD persisted in 47.6% of adolescents with AD symptoms at baseline (n = 424). High socioeconomic status, female sex, asthma symptoms and a positive skin prick test response at baseline, parental history of rhinitis/AD, and having worked in a high-risk job were significant predictors for the course of disease. With all the factors present, the probability of the incidence of AD was 21.4% (95% CI, 1.8% to 80.2%) and increased up to 81.7% (95% CI, 47.0% to 95.8%) for recurrence of AD and 87.6% (95% CI, 63.4% to 96.6%) for persistence of AD among those affected by AD. Early-life exposures did not predict the course of AD over puberty. Conclusion: Genetic factors, early allergen sensitization, and having worked in a high-risk job seem to be more important for disease development in late adolescence than other early-life exposures. (J Allergy Clin Immunol 2010;126:590-5.)	[Peters, Astrid S.; Kellberger, Jessica; Dressel, Holger; Windstetter, Doris; Nowak, Dennis; Radon, Katja] Univ Hosp Munich LMU, Unit Occupat & Environm Epidemiol & Net Teaching, Inst & Outpatient Clin Occupat Social & Environm, D-80336 Munich, Germany; [Vogelberg, Christian] Univ Childrens Hosp, Dresden, Germany; [Weinmayr, Gudrun; Genuneit, Jon] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [von Mutius, Erika] Univ Hosp Munich, Dr Haunersches Kinderspital, Munich, Germany	University of Munich; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; University of Munich	Peters, AS (corresponding author), Univ Hosp Munich LMU, Unit Occupat & Environm Epidemiol & Net Teaching, Inst & Outpatient Clin Occupat Social & Environm, D-80336 Munich, Germany.	sekretariat-radon@med.uni-muenchen.de	Genuneit, Jon/I-9323-2012; Gerlich, Jessica/L-2590-2016	Genuneit, Jon/0000-0001-5764-1528; Gerlich, Jessica/0000-0002-0737-9506; von Mutius, Erika/0000-0002-8893-4515; Dressel, Holger/0000-0002-1268-0416	Federal Office for Occupational Safety and Occupational Medicine; Federal Ministry of Labour and Social Affairs (Germany); GlaxoSmithKline; UCB; Protectimmun; Novartis; Airsonett AB	Federal Office for Occupational Safety and Occupational Medicine; Federal Ministry of Labour and Social Affairs (Germany); GlaxoSmithKline(GlaxoSmithKline); UCB(UCB Pharma SA); Protectimmun; Novartis(Novartis); Airsonett AB	Supported by the Federal Office for Occupational Safety and Occupational Medicine and Federal Ministry of Labour and Social Affairs (Germany).; Disclosure of potential conflict of interest: E. von Mutius is a consultant for GlaxoSmithKline, UCB, Protectimmun, and Novartis and receives research support from Airsonett AB. The rest of the authors have declared that they have no conflict of interest.	Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barberio G, 2008, ALLERGY, V63, P1630, DOI 10.1111/j.1398-9995.2008.01710.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Bernsen RMD, 2006, VACCINE, V24, P2035, DOI 10.1016/j.vaccine.2005.10.056; Buggiani G, 2008, DERMATOL THER, V21, P96, DOI 10.1111/j.1529-8019.2008.00176.x; Burney P, 1998, REV EPIDEMIOL SANTE, V46, P491; Capristo C, 2004, ALLERGY, V59, P53, DOI 10.1111/j.1398-9995.2004.00652.x; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; Galli E, 2007, ALLERGY ASTHMA PROC, V28, P540, DOI 10.2500/aap2007.28.3048; Girolomoni G, 2003, ALLERGY, V58, P420, DOI 10.1034/j.1398-9995.2003.00112.x; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; Harris JM, 2007, BRIT J DERMATOL, V156, P698, DOI 10.1111/j.1365-2133.2006.07710.x; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Horton NJ, 2001, AM STAT, V55, P244, DOI 10.1198/000313001317098266; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; Kimata H, 2004, EUR J CLIN INVEST, V34, P165, DOI 10.1111/j.1365-2362.2004.01297.x; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Leonardi S, 2007, ALLERGY ASTHMA PROC, V28, P410, DOI 10.2500/aap.2007.28.2954; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Oien Torbjorn, 2008, Prim Care Respir J, V17, P164, DOI 10.3132/pcrj.2008.00023; Radon K, 2002, EPIDEMIOLOGY, V13, P748, DOI 10.1097/00001648-200211000-00029; Radon K, 2006, SCAND J WORK ENV HEA, V32, P132, DOI 10.5271/sjweh.988; Roberts H, 2006, AUSTRALAS J DERMATOL, V47, P172, DOI 10.1111/j.1440-0960.2006.00266.x; Sebok B, 2006, J EUR ACAD DERMATOL, V20, P418, DOI 10.1111/j.1468-3083.2006.01490.x; Shamssain M, 2007, PEDIAT ALLERG IMM-UK, V18, P149, DOI 10.1111/j.1399-3038.2006.00498.x; Sublett JL, 2005, CURR ALLERGY ASTHM R, V5, P445, DOI 10.1007/s11882-005-0024-x; Vogelberg C, 2007, EUR RESPIR J, V30, P672, DOI 10.1183/09031936.00152906; von Linstow ML, 2002, CLIN EXP ALLERGY, V32, P520, DOI 10.1046/j.0954-7894.2002.01326.x; Wahn U, 2007, NESTLE NUTR WORKS SE, V59, P1, DOI 10.1159/000098508; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Werner S, 2002, BRIT J DERMATOL, V147, P95, DOI 10.1046/j.1365-2133.2002.04782.x; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; YUAN Y, SAS US GROUP INT P 2, pP267; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	42	70	73	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					590	U315		10.1016/j.jaci.2010.06.020	http://dx.doi.org/10.1016/j.jaci.2010.06.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816192				2022-12-18	WOS:000281512500027
J	Hatano, Y; Man, MQ; Uchida, Y; Crumrine, D; Mauro, TM; Feingold, KR; Elias, PM; Holleran, WM				Hatano, Yutaka; Man, Mao-Qiang; Uchida, Yoshikazu; Crumrine, Debra; Mauro, Theodora M.; Feingold, Kenneth R.; Elias, Peter M.; Holleran, Walter M.			Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; barrier function; liver X receptor; mouse model; peroxisome proliferator-activated receptor alpha, beta/delta, and gamma; T(H)2 cells	EPIDERMAL PERMEABILITY BARRIER; STRATUM-CORNEUM HYDRATION; FATTY-ACID-DEFICIENT; CONTACT-DERMATITIS; KERATINOCYTE DIFFERENTIATION; SPHINGOMYELIN DEACYLASE; PATHOGENIC MECHANISMS; SKIN; INFLAMMATION; HOMEOSTASIS	Background: Atopic dermatitis (AD) is a chronic inflammatory dermatosis now increasingly linked to mutations that alter the structure and function of the stratum corneum. Activators of peroxisome proliferator-activated receptors (PPARs) alpha, beta/delta, and gamma and liver X receptor (LXR) regulate epidermal protein And lipid production, leading to superior barrier function. Additionally, some of these activators exhibit potent antihyperplastic and anti-inflammatory activity in irritant contact dermatitis and acute allergic contact dermatitis murine models. Objective: We evaluated the efficacy of PPAR/LXR activation in a hapten (oxazolone [Ox])-induced AD-like model (Ox-AD) in hairless mice. Methods: Ox-AD was established with 10 Ox challenges (every other day) on the flank. After the establishment of Ox-AD, twice-daily topical application with individual PPAR/LXR activators was then performed for 4 days, with continued Ox challenges every other day. The efficacy of topical PPAR/LXR activators to reduce parameters of Ox-AD was assessed physiologically, morphologically, and immunologically. Results: Certain topical activators of PPAR alpha, PPAR beta/delta, and LXR, but not activators of PPAR gamma, reversed the clinical dermatosis, significantly improved barrier function, and increased stratum corneum hydration in Ox-AD mice. In addition, the same activators, but again not PPAR gamma, largely reversed the immunologic abnormalities in Ox-AD mice, including the increased T(H)2 markers, such as tissue eosinophil/mast cell density, serum thymus and activation-related chemokine levels, the density of chemoattractant receptor-homologous molecule expressed on T(H)2-positive lymphocytes (but not serum IgE levels), and reduced IL-1 alpha and TNF-alpha activation, despite ongoing hapten challenges. Conclusion: These results suggest that topical applications of certain activators/ligands of PPAR alpha, PPAR beta/delta, and LXR could be useful for the treatment of AD in human subjects. (J Allergy Clin Immunol 2010;125:160-9.)	[Hatano, Yutaka; Man, Mao-Qiang; Uchida, Yoshikazu; Crumrine, Debra; Mauro, Theodora M.; Feingold, Kenneth R.; Elias, Peter M.; Holleran, Walter M.] Univ Calif San Francisco, Dermatol Serv, Vet Affairs Med, San Francisco, CA 94143 USA; [Feingold, Kenneth R.] Univ Calif San Francisco, Med Metab Serv, Vet Affairs Med Ctr, San Francisco, CA 94143 USA; [Hatano, Yutaka; Man, Mao-Qiang; Uchida, Yoshikazu; Crumrine, Debra; Mauro, Theodora M.; Feingold, Kenneth R.; Elias, Peter M.; Holleran, Walter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Holleran, Walter M.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Hatano, Yutaka] Oita Univ, Fac Med, Oita 87011, Japan; [Man, Mao-Qiang] Zunyi Med Coll, Zunyi, Guizhou, Peoples R China	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oita University; Zunyi Medical University	Holleran, WM (corresponding author), VA Med Ctr, Dermatol Serv 190, 4150 Clement St, San Francisco, CA 94121 USA.	walt.holleran@ucsf.edu	Man, Mao-Qiang/V-5266-2019	Uchida, Yoshikazu/0000-0002-4980-3416; man, mao-qiang/0000-0002-0957-4903	National Institutes of Health [AR19098, AG028492, AI059311]; Medical Research Service, Department of Veterans Affairs; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028492] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Service, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by National Institutes of Health grants AR19098, AG028492, and AI059311 and the Medical Research Service, Department of Veterans Affairs.	Behshad R, 2008, ARCH DERMATOL, V144, P84, DOI 10.1001/archdermatol.2007.22; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Choi EH, 2005, J INVEST DERMATOL, V125, P288, DOI 10.1111/j.0022-202X.2005.23799.x; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cui CY, 1997, J INVEST DERMATOL, V109, P319; Demerjian M, 2006, EXP DERMATOL, V15, P154, DOI 10.1111/j.1600-0625.2006.00402.x; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Elias PM, 1997, IMMUNOL ALLERGY CLIN, V17, P417, DOI 10.1016/S0889-8561(05)70318-0; Elias PM, 2001, ARCH DERMATOL, V137, P1079; Fartasch M, 1997, MICROSC RES TECHNIQ, V38, P361, DOI 10.1002/(SICI)1097-0029(19970815)38:4<361::AID-JEMT4>3.0.CO;2-M; Fowler AJ, 2003, J INVEST DERMATOL, V120, P246, DOI 10.1046/j.1523-1747.2003.12033.x; Hachem JP, 2006, J INVEST DERMATOL, V126, P2074, DOI 10.1038/sj.jid.5700351; Hachem JP, 2005, J INVEST DERMATOL, V125, P510, DOI 10.1111/j.0022-202X.2005.23838.x; Hachem JR, 2005, J INVEST DERMATOL, V125, P790, DOI 10.1111/j.0022-202X.2005.23836.x; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Hatano Y, 2009, J INVEST DERMATOL, V129, P1824, DOI 10.1038/jid.2008.444; Higuchi K, 2000, BIOCHEM J, V350, P747, DOI 10.1042/0264-6021:3500747; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Komuves LG, 2000, J INVEST DERMATOL, V115, P361, DOI 10.1046/j.1523-1747.2000.00076.x; Kusuda S, 1998, J INVEST DERMATOL, V111, P733, DOI 10.1046/j.1523-1747.1998.00370.x; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; MAN MQ, 1993, J INVEST DERMATOL, V101, P185, DOI 10.1111/1523-1747.ep12363729; Mao-Qiang M, 2004, J INVEST DERMATOL, V123, P305, DOI 10.1111/j.0022-202X.2004.23235.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patel TS, 2007, AM J CLIN DERMATOL, V8, P189, DOI 10.2165/00128071-200708040-00001; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Schmuth M, 2008, J LIPID RES, V49, P499, DOI 10.1194/jlr.R800001-JLR200; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Taieb A, 1999, CONTACT DERMATITIS, V41, P177, DOI 10.1111/j.1600-0536.1999.tb06125.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weischer M, 2007, EXP DERMATOL, V16, P385, DOI 10.1111/j.1600-0625.2007.00555.x; WOOD LC, 1994, J INVEST DERMATOL, V103, P834, DOI 10.1111/1523-1747.ep12413597	41	70	78	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					160	169		10.1016/j.jaci.2009.06.049	http://dx.doi.org/10.1016/j.jaci.2009.06.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19818482	Bronze, Green Accepted			2022-12-18	WOS:000273660500019
J	Philip, G; Hustad, C; Noonan, G; Malice, MP; Ezekowitz, A; Reiss, TF; Knorr, B				Philip, George; Hustad, Carolyn; Noonan, Gertrude; Malice, Marie-Pierre; Ezekowitz, Alan; Reiss, Theodore F.; Knorr, Barbara			Reports of suicidality in clinical trials of montelukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Montelukast; placebo; clinical trial; suicide; suicidality; adverse experiences; asthma; allergic rhinitis	UNITED-STATES; IDEATION; BEHAVIOR; LEUKOTRIENES; SEASONALITY; DEPRESSION; EVENTS; TRENDS; PLANS; MICE	Background: In recent years, a number of drugs and drug classes have come under scrutiny by the US Food and Drug Administration regarding suicidality (including suicidal behavior and ideation). Objective: We sought to perform 2 reviews (requested by the US Food and Drug Administration) of the number of events possibly related to suicidality reported in Merck clinical trials of montelukast. Methods: Method I was a descriptive review of clinical adverse experiences (AEs) from 116 studies (double-blind and open-label, adult and pediatric, and single- and multiple-dose studies) completed as of March 2008. Summaries were constructed from investigator-reported AE terms possibly related to suicidality (completed suicide, suicide attempt, and suicidal ideation) or self-injurious behavior. Method 2 used a retrospective adjudication of investigator-reported AEs and other events listed in the study database described as possibly suicidality-related adverse events (PSRAEs) in a prespecified set of 41 double-blind, placebo-controlled trials completed as of April 2008. Results: No completed suicides were reported in any study. For the descriptive review, 20,131 adults and children received montelukast, 9,287 received placebo, and 8,346 received active control; AEs possibly related to suicidality were rare and were similar between the montelukast and placebo or active-control groups. For the adjudicated review across 22,433 patients, there were 730 adjudicated events. In 9,929 patients taking montelukast, 1 PSRAE was identified (classified as suicidal ideation); none were identified in 7,780 and 4,724 patients taking placebo and active control, respectively. Conclusions: Assessed by using 2 complementary methods, there were no reports of completed suicide, and reports of PSRAEs were rare in patients receiving montelukast and similar to those seen in control subjects. (J Allergy Clin Immunol 2009;124:691-6.)	[Philip, George] Merck & Co Inc, Merck Res Labs, N Wales, PA 19454 USA; [Noonan, Gertrude; Ezekowitz, Alan; Reiss, Theodore F.; Knorr, Barbara] Merck & Co Inc, Rahway, NJ 07065 USA; [Malice, Marie-Pierre] Merck & Co Inc, Brussels, Belgium	Merck & Company; Merck & Company; Merck & Company	Philip, G (corresponding author), Merck & Co Inc, Merck Res Labs, 351 N Sumneytown Pike,UG3D-66, N Wales, PA 19454 USA.	george_philip@merck.com			Merck Co, Inc.	Merck Co, Inc.(Merck & Company)	The studies referenced in this article were sponsored by Merck & Co, Inc.	Bisgaard H, 2009, PEDIATR PULM, V44, P568, DOI 10.1002/ppul.21018; Brent DA, 2009, AM J PSYCHIAT, V166, P418, DOI 10.1176/appi.ajp.2008.08070976; Centers for Disease Control and Prevention, 2005, WEB BAS INJ STAT QUE; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Druss B, 2000, ARCH INTERN MED, V160, P1522, DOI 10.1001/archinte.160.10.1522; Fang SH, 2006, NEUROSCIENCE, V140, P969, DOI 10.1016/j.neuroscience.2006.02.051; Goodwin RD, 2005, AM J PUBLIC HEALTH, V95, P717, DOI 10.2105/AJPH.2003.019109; Goodwin Renee D, 2004, Crisis, V25, P99, DOI 10.1027/0227-5910.25.3.99; Guzman A, 2007, J AFFECT DISORDERS, V101, P269, DOI 10.1016/j.jad.2006.11.026; Holbrook JT, 2008, J ALLERGY CLIN IMMUN, V122, P828, DOI 10.1016/j.jaci.2008.07.012; Jick H, 2009, PHARMACOTHERAPY, V29, P165, DOI 10.1592/phco.29.2.165; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Lubell K. M., 2007, Morbidity and Mortality Weekly Report, V56, P905; Manalai P, 2009, EXPERT OPIN DRUG SAF, V8, P273, DOI 10.1517/14740330902932688; *MERCK CO INC, 2009, SINGULAR MONT SOD PR; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Posner K, 2007, AM J PSYCHIAT, V164, P1035, DOI 10.1176/appi.ajp.164.7.1035; POSTOLACHE K, 2008, CURR TREAT OPTION NE, V10, P363; Postolache TT, 2005, MOL PSYCHIATR, V10, P232, DOI 10.1038/sj.mp.4001620; *US FDA, UPD SAF REV FOLL MAR; *US FDA, SMOK CESS AIDS VAR M; US Food and Drug Administration, UPD INF LEUK INH MON; US Food and Drug Administration Web site, EARL COMM ONG SAF RE; *US FOOD DRUG ADV, ZIM RIM TABL 20 MG; Uz T, 2002, RESTOR NEUROL NEUROS, V20, P15; Uz T, 2008, NEUROSCI LETT, V436, P269, DOI 10.1016/j.neulet.2008.03.041; Uz Tolga, 2008, Open Neuropsychopharmacol J, V1, P1, DOI 10.2174/1876523800801010001; Yip PSF, 2006, J AFFECT DISORDERS, V96, P117, DOI 10.1016/j.jad.2006.05.012; SUICIDAL BEHAV IDEAT	31	70	73	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					691	696		10.1016/j.jaci.2009.08.010	http://dx.doi.org/10.1016/j.jaci.2009.08.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815114	Bronze			2022-12-18	WOS:000270802800010
J	Nieto, A; Mazon, A; Parnies, R; Bruno, L; Navarro, M; Montanes, A				Nieto, Antonio; Mazon, Angel; Parnies, Rafael; Bruno, Laura; Navarro, Mariola; Montanes, Ana			Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; bias; funnel plot; immunotherapy; meta-analysis; rhinoconjunctivitis; sublingual; trim and fill	PUBLICATION BIAS; PEDIATRIC-PATIENTS; CLINICAL-TRIALS; EFFICACY; ASTHMA; RECOMMENDATIONS; ANAPHYLAXIS; STATEMENT; RHINITIS; QUALITY	Background: Five published meta-analyses (MAs) seem to prove the efficacy of sublingual immunotherapy in allergic asthma and rhinoconjunctivitis. Objective: We aimed to assess the consistency, magnitude, and robustness of the results of these MAs. Methods: The data reported in the MAs were checked with the data reported in the original studies. Funnel plots were performed to test for potential publication bias, and the trim-and-fill method was used to assess and correct the estimate of the effects if asymmetry was present. Results: The 5 MAs included 43 studies; 17 were used in more than one MA. There were discrepancies among the MAs in the data reported from the same original studies: the MAs reported different estimates for the same outcome or the same estimates for different outcomes in 16 of those 17 studies. The MAs evaluated 15 main outcomes, 10 of which showed benefits that reached statistical significance. Funnel plots showed asymmetry in 7 outcomes, and correction by using the trim-and-fill method led to a decrease in their effect estimates and even to a loss of statistical significance in 4 of the previously significant outcomes. There was inconsistency among the MAs in the benefits when considering age, disease, allergen, or symptoms and medication use. Conclusion: Because of discrepancies, inconsistencies, and lack of robustness, the MAs on sublingual immunotherapy do not provide enough evidence to support its current routine management in patients with allergic asthma or rhinoconjunctivitis. Sensitivity to potential publication bias should be tested and reported in all MAs. (J Allergy Clin Immunol 2009;124:157-61.)	[Nieto, Antonio; Mazon, Angel; Parnies, Rafael; Bruno, Laura; Navarro, Mariola; Montanes, Ana] Childrens Hosp La Fe, Sect Pediat Allergy, Valencia 46009, Spain		Mazon, A (corresponding author), Childrens Hosp La Fe, Sect Pediat Allergy, Av Campanar 21, Valencia 46009, Spain.	amazon@comv.es	Mazon, Angel/ABG-8016-2020	Mazon, Angel/0000-0001-5639-1037				Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Bardy AH, 1998, BRIT J CLIN PHARMACO, V46, P147, DOI 10.1046/j.1365-2125.1998.00759.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Calamita Z, 2007, ALLERGY, V62, P706, DOI 10.1111/j.1398-9995.2007.01344.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Hopewell S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000011.pub2; Larenas-Linnemann DE, 2007, ALLERGY, V62, P704, DOI 10.1111/j.1398-9995.2007.01335.x; Littner Y, 2005, ARCH PEDIAT ADOL MED, V159, P1036, DOI 10.1001/archpedi.159.11.1036; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Rodriguez F, 2006, INT ARCH ALLERGY IMM, V140, P321, DOI 10.1159/000093710; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]	25	70	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					157	161		10.1016/j.jaci.2009.04.015	http://dx.doi.org/10.1016/j.jaci.2009.04.015			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19500824				2022-12-18	WOS:000267909700020
J	Bisgaard, H; Halkjaer, LB; Hinge, R; Giwercman, C; Palmer, C; Silveira, L; Strand, M				Bisgaard, Hans; Halkjaer, Liselotte B.; Hinge, Rikke; Giwercman, Charlotte; Palmer, Colin; Silveira, Lori; Strand, Matthew			Risk analysis of early childhood eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Length at birth; breast-feeding; dog; eczema; filaggrin; risk factor	ATOPIC-DERMATITIS; ASTHMA; FILAGGRIN; CHILDREN; INFANTS; COHORT; BIRTH; LIFE; PREDISPOSE; HISTORY	Background: The increasing prevalence of eczema suggests the role of environmental factors triggering a genetic predisposition. Objective: To analyze the effect of environmental exposures in early life and genetic predisposition on the development of eczema before age 3 years. Methods: The Copenhagen Study on Asthma in Childhood is a prospective clinical study of a birth cohort of 411 children born of mothers with asthma. Eczema was diagnosed, treated, and monitored at the clinical research unit, and complete follow-up for the first 3 years of life was available for 356 children. Risk assessments included filaggrin loss-of-function mutation; parent's atopic disease; sex; social status; previous deliveries; third trimester complications and exposures; anthropometrics at birth; month of birth; duration solely breast-fed; introduction of egg, cow's milk, and fish; time spent in day care; cat and dog at home; feather pillow; nicotine in infant's hair; and temperature and humidity in bedroom. Results: Eczema developed in 43.5% of the infants. Filaggrin mutation (odds ratio [OR], 3.20; 95% CI, 1.46-7.02; P = .004), mother's eczema (OR, 2.80; 95% CI, 1.70-4.63; P < .0001), and father's allergic rhinitis (OR, 1.91; 95% CI, 1.09-3.33; P = .02) were directly associated with risk of eczema. Risk of eczema was significantly reduced by birth length (OR per cm increase, 0.87; 95% CI, 0.78-0.97; P = .02), increased bedroom temperature (probably inverse causality; OR, 0.80; 95% CI, 0.66-0.97; P = .02), and dog living in the home (OR, 0.44; 95% CI, 0.23-0.87; P = .02). Conclusions: Dog exposure reduced the risk of eczema, whereas short length at birth, filaggrin mutation, and parental atopy increased the risk of eczema by age 3 years. (J Allergy Clin Immunol 2009;123:1355-60.)	[Bisgaard, Hans; Halkjaer, Liselotte B.; Hinge, Rikke; Giwercman, Charlotte] Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr Hlth Sci, Copenhagen Prospect Studies Asthma Chilhood, DK-2800 Lyngby, Denmark; [Palmer, Colin] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee DD1 4HN, Scotland; [Silveira, Lori; Strand, Matthew] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA	University of Copenhagen; University of Dundee; National Jewish Health	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr Hlth Sci, Copenhagen Prospect Studies Asthma Chilhood, Ledreborg Alle 34, DK-2800 Lyngby, Denmark.	bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Palmer, Colin NA/C-7053-2008; Strand, Matt/AAU-3762-2021; Bisgaard, Hans/N-4761-2016	Palmer, Colin NA/0000-0002-6415-6560; Strand, Matt/0000-0002-9083-5989; Bisgaard, Hans/0000-0003-4131-7592	Lundbeck Foundation; Pharmacy Foundation of 1991; Dullish Medical Research Council; Danish Pediatric Asthma Center; Danish Lung Association; Hans Skoubys og hustru Emma Skoubys Fond; Oda Pedersens Legal	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation of 1991; Dullish Medical Research Council; Danish Pediatric Asthma Center; Danish Lung Association; Hans Skoubys og hustru Emma Skoubys Fond; Oda Pedersens Legal	Supported by the Lundbeck Foundation, the Pharmacy Foundation of 1991. the Dullish Medical Research Council, the Danish Pediatric Asthma Center, the Danish Lung Association, the Hans Skoubys og hustru Emma Skoubys Fond, and Oda Pedersens Legal.	Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; BERNAARDS CA, 2003, J DATA SCI, V1, P293; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Langan SM, 2007, ARCH DERMATOL, V143, P1570, DOI 10.1001/archderm.143.12.1570; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; LARSEN FS, 1992, ACTA DERM-VENEREOL, P7; Lerbaek A, 2007, BRIT J DERMATOL, V157, P1199, DOI 10.1111/j.1365-2133.2007.08252.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; RAJKA G, 1986, CLIN REV ALLERG, V4, P3; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Sorensen M, 2007, BIOMARKERS, V12, P38, DOI 10.1080/13547500600943148; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x	29	70	74	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1355	1360		10.1016/j.jaci.2009.03.046	http://dx.doi.org/10.1016/j.jaci.2009.03.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19501236	Bronze			2022-12-18	WOS:000266799100029
J	Burgess, JA; Dharmage, SC; Byrnes, GB; Matheson, MC; Gurrin, LC; Wharton, CL; Johns, DP; Abramson, MJ; Hopper, JL; Waiters, EH				Burgess, John A.; Dharmage, Shyamali C.; Byrnes, Graham B.; Matheson, Melanie C.; Gurrin, Lyle C.; Wharton, Cathryn L.; Johns, David P.; Abramson, Michael J.; Hopper, John L.; Waiters, E. Haydn			Childhood eczema and asthma incidence and persistence: A cohort study from childhood to middle age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood eczema; incident asthma; persisting asthma	RESPIRATORY-SYNCYTIAL-VIRUS; ATOPIC-DERMATITIS; FOLLOW-UP; BRONCHIAL HYPERRESPONSIVENESS; YOUNG-CHILDREN; AIRWAY DISEASE; RISK-FACTORS; ASSOCIATION; ALLERGY; BURDEN	Background: The association between eczema and asthma is well documented, but the temporal sequence of this association has not been closely examined. Objectives: To examine the association between childhood eczema and asthma incidence from preadolescence to middle age, and between childhood eczema and asthma persisting to middle age. A further aim was to examine any effect modification by nonallergic childhood exposures on the association between childhood eczema and both childhood asthma and later life incident asthma. Methods: Data were gathered from the 1968, 1974, and 2004 surveys of the Tasmanian Longitudinal Health Study. Multivariable logistic regression examined the association between childhood eczema and childhood asthma. Cox regression examined the association between childhood eczema and asthma incidence in preadolescence, adolescence, and adult life. Binomial regression examined the association between childhood eczema and childhood asthma persisting to age 44 years. Results: Childhood eczema was significantly associated with childhood asthma and with incident asthma in preadolescence (hazard ratio [HR], 1.70; 95% CI, 1.05-2.75), adolescence (HR, 2.14; 95% CI, 1.33-3.46), and adult life (HR, 1.63; 95% Cl, 1.28-2.09). Although childhood eczema was significantly associated with asthma persisting from childhood to middle age (relative risk, 1.54; 95% CI, 1.17-2.04), this association was no longer evident when adjusted for allergic rhinitis. Conclusion: Childhood eczema increased the likelihood of childhood asthma, of new-onset asthma in later life and of asthma persisting into middle age.	[Burgess, John A.; Dharmage, Shyamali C.; Byrnes, Graham B.; Matheson, Melanie C.; Gurrin, Lyle C.; Wharton, Cathryn L.; Hopper, John L.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia; [Johns, David P.; Waiters, E. Haydn] Univ Tasmania, Resp Res Grp, Menzies Res Inst, Hobart, Tas, Australia; [Abramson, Michael J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	University of Melbourne; University of Tasmania; Menzies Institute for Medical Research; Monash University	Burgess, JA (corresponding author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Level 1,723 Swanston St, Carlton, Vic 3053, Australia.	j.burgess@gprad.unimelb.edu.au	Johns, David P/D-1933-2014; Matheson, Melanie C/O-4721-2015; Burgess, John/H-7555-2019; Abramson, Michael/AAQ-2671-2020	Johns, David P/0000-0002-1575-6850; Matheson, Melanie C/0000-0002-5822-3499; Burgess, John/0000-0001-7532-5027; Abramson, Michael/0000-0002-9954-0538; Walters, Eugene/0000-0002-0993-4374; Byrnes, Graham/0000-0003-3893-7539; Gurrin, Lyle/0000-0001-7052-1969				Businco L, 2001, Pediatr Allergy Immunol, V12 Suppl 14, P5; Asher MI, 2001, NEW ZEAL MED J, V114, P114; Australian Bureau of Statistics, 1997, AUSTR STAND CLASS OC; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Beyer K, 2000, J INVEST DERMATOL, V115, P906, DOI 10.1046/j.1523-1747.2000.00096.x; Broberg A, 2000, ALLERGY, V55, P1025, DOI 10.1034/j.1398-9995.2000.00665.x; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Burgess JA, 2006, J ASTHMA, V43, P727, DOI 10.1080/02770900601028587; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; HANCOX RJ, 2001, POCKET GUIDE LUNG FU, pR16; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hosmer W., 2000, APPL LOGISTIC REGRES, V2nd ed.; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kemp AS, 1999, J PAEDIATR CHILD H, V35, P229, DOI 10.1046/j.1440-1754.1999.00343.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lapidus C S, 2001, Med Health R I, V84, P294; LARSEN FS, 1992, ACTA DERM-VENEREOL, P7; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; Ohshima Y, 2002, ANN ALLERG ASTHMA IM, V89, P265, DOI 10.1016/S1081-1206(10)61953-9; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Silver EJ, 1998, J ASTHMA, V35, P437, DOI 10.3109/02770909809048952; Simpson EL, 2005, J AM ACAD DERMATOL, V53, P115, DOI 10.1016/j.jaad.2005.01.130; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stipic-Markovic Asja, 2003, Acta Med Croatica, V57, P281; Su JC, 1997, ARCH DIS CHILD, V76, P159, DOI 10.1136/adc.76.2.159; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wharton C, 2006, AUST NZ J PUBL HEAL, V30, P105, DOI 10.1111/j.1467-842X.2006.tb00100.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; ZAPLETAL A, 1977, Zeitschrift fuer Erkrankungen der Atmungsorgane, V149, P343	46	70	74	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					280	285		10.1016/j.jaci.2008.05.018	http://dx.doi.org/10.1016/j.jaci.2008.05.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18572229	Green Submitted			2022-12-18	WOS:000258426300010
J	Clark, AT; Ewan, PW				Clark, Andrew T.; Ewan, Pamela W.			Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anaphylaxis; peanut; nut; management; epinephrine	NATURAL-HISTORY; MANAGEMENT; PREVALENCE; PROPOSAL; CONTACT; SCHOOLS	Background: The diagnosis of nut allergy causes anxiety. Few studies exist that estimate risk of reactions and inform management. Objective: To describe frequency and circumstances of reactions after the institution of a management plan. Methods: Prospective study of children with peanut/nut allergy with an allergist's management plan. Severity and circumstances of worst reaction before diagnosis (index) and follow-up reactions were evaluated. Results: A total of 785 children were followed for 3640 patient-years from diagnosis. Index reactions were mild in 66% (516), moderate in 29% (224), and severe in 5% (45). Fourteen;percent (114/785) had follow-up reactions (3% annual incidence rate). Ninety percent had the same/reduced severity grade, and 1 of 785(0.1%) had a severe reaction. Preschool children (n = 263) had a low incidence of reactions, and none were severe. There was a 3-fold reduction in injected epinephrine use from that used in the index reaction, required in 1 severe reaction, never twice; 14% (16/114) required no medication, 78% only oral antihistamines. Forty-eight percent reacted to the index nut type, 19% to a different nut (55% sensitized at diagnosis, 14% not sensitized, 31% not tested). Accidental versus index reactions were 4-fold more likely to be a result of contact exposure rather than ingestion. Contact reactions were always mild. Most (53%) reactions occurred at home, 5% in school, 21 % at other sites (21 % not recorded). The nut was given by a parent/self in 69 (61%) reactions or teacher in 5 (4%). Conclusion: With a comprehensive management plan, accidental reactions were uncommon and usually mild, most requiring little treatment; 99.8%, self-treated appropriately and 100% effectively.	[Clark, Andrew T.; Ewan, Pamela W.] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Cambridge, England		Clark, AT (corresponding author), Univ Cambridge, Dept Med, Addenbrookes Hosp, Box 157, Cambridge CB2 2QQ, England.	atclark@doctors.org.uk						Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Clark AT, 2007, ALLERGY, V62, P913, DOI 10.1111/j.1398-9995.2007.01447.x; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Ferdman RM, 2006, ANN ALLERG ASTHMA IM, V97, P73, DOI 10.1016/S1081-1206(10)61373-7; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kapoor S, 2004, ALLERGY, V59, P185, DOI 10.1046/j.1398-9995.2003.00365.x; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; Wainstein BK, 2007, CLIN EXP ALLERGY, V37, P839, DOI 10.1111/j.1365-2222.2007.02726.x; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	25	70	72	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					286	289		10.1016/j.jaci.2008.05.015	http://dx.doi.org/10.1016/j.jaci.2008.05.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18586319				2022-12-18	WOS:000258426300011
J	Oren, E; Banerji, A; Camargo, CA				Oren, Eyal; Banerji, Aleena; Camargo, Carlos A., Jr.			Vitamin D and atopic disorders in an obese population screened for vitamin D deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							D-RECEPTOR LIGANDS; ASTHMA; CHILDREN		[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Ctr D Receptor Activat Res, Boston, MA 02114 USA; [Oren, Eyal; Banerji, Aleena] Massachusetts Gen Hosp, Div Rheumatol, Boston, MA USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Camargo, CA (corresponding author), Massachusetts Gen Hosp, Ctr D Receptor Activat Res, Boston, MA 02114 USA.	ccamargo@pailners.org	Oren, Eyal/AAD-5561-2019; Camargo, Carlos A./C-2145-2008; Banerji, Aleena/ABG-1245-2021	Camargo, Carlos A./0000-0002-5071-7654; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK040561-12, P30 DK040561] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Byremo G, 2006, ALLERGY, V61, P1403, DOI 10.1111/j.1398-9995.2006.01209.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; SIDBURY R, 2008, IN PRESS BR J DERMAT; Simard B, 2004, OBES SURG, V14, P1381, DOI 10.1381/0960892042584021	10	70	75	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					533	534		10.1016/j.jaci.2007.11.005	http://dx.doi.org/10.1016/j.jaci.2007.11.005			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18177693	Bronze			2022-12-18	WOS:000253337800041
J	Siddiqui, S; Sutcliffe, A; Shikotra, A; Woodman, L; Doe, C; McKenna, S; Wardlaw, A; Bradding, P; Pavord, I; Brightling, C				Siddiqui, Salman; Sutcliffe, Amanda; Shikotra, Aarti; Woodman, Lucy; Doe, Camille; McKenna, Sue; Wardlaw, Andrew; Bradding, Peter; Pavord, Ian; Brightling, Christopher			Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophilic bronchitis; vascular remodeling; airway hyperresponsiveness; VEGF	ENDOTHELIAL GROWTH-FACTOR; AIRWAY SMOOTH-MUSCLE; INDUCED SPUTUM; ALLERGIC-ASTHMA; CHRONIC COUGH; MAST-CELLS; ANGIOGENESIS; EXPRESSION; DENSITY; INFLAMMATION	Rationale: Increased vascularity and expression of vascular endothelial growth factor (VEGF) are recognized features of the asthmatic airway. The association of vascular remodeling with airway hyperresponsiveness (AHR) is unclear. Objective: To assess vascular remodeling and sputum VEGF concentration in subjects with asthma, subjects with nonasthmatic eosinophilic bronchitis (EB), and healthy controls. Methods: In cohort 1, 19 patients with asthma (Global Initiative for Asthma [GINA] 1-2, n = 9; GINA 3-5, n = 10), 10 patients with EB, and 11 healthy matched controls were recruited. Expression of the endothelial marker EN4 was assessed in bronchial biopsy samples. Vessels were counted using the validated mean Chalkley count by a blind observer. For cohort 2, a second independent cohort of 31 patients with asthma (GINA 1-2, n = 11; GINA 3-5, n = 20), 14 patients with EB, and 15 matched controls was recruited. Induced sputum supernatant VEGF was measured by ELISA. Results: The mean chalkley count was significantly greater in GINA 3-5 asthma (5.2 [0.4]) and EB (4.8 [0.31) compared with controls (3.5 [0.5]) and demonstrated a significant inverse correlation with the postbronchodilator FEV1, % predicted in patients with asthma (R 2 = 0.28; P =.02). Sputum VEGF concentration was also increased in GINA 3-5 asthma (2365 [1361-4110] pg/g) and EB (4699 [2818-7834] pg/g) compared with controls (1094 [676-1774] pg/g) and was inversely related to postbronchodilator FEV1 % predicted in asthma (R-2 = 0.2; P =.01). Conclusion: Vascular remodeling is a feature of asthma, and EB and is inversely associated with the postbronchodilator FEV1, in asthma, suggesting that vascular remodeling is associated with airflow obstruction but not AHR. Clinical implications: Vascular remodeling is dissociated from AHR in asthma and associated with airflow limitation.	Univ Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University of Leicester	Brightling, C (corresponding author), Univ Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk		Bradding, Peter/0000-0001-8403-0319; Pavord, Ian/0000-0002-4288-5973; Wardlaw, Andrew/0000-0001-6583-0791; brightling, chris/0000-0002-9345-4903	Asthma UK [05/058] Funding Source: researchfish	Asthma UK		Amin K, 2005, ALLERGY, V60, P1241, DOI 10.1111/j.1398-9995.2005.00823.x; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Begueret H, 2007, THORAX, V62, P8, DOI 10.1136/thx.2006.062141; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Berry MA, 2005, CLIN EXP ALLERGY, V35, P598, DOI 10.1111/j.1365-2222.2005.02222.x; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Brightling CE, 2006, CHEST, V129, p116S, DOI 10.1378/chest.129.1_suppl.116S; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; British Thoracic Society Bronchoscopy Guidelines Committee, 2001, THORAX S1, V56, DOI [10.1136/thorax.56.suppl_1.i1, DOI 10.1136/THX.56.SUPPL1.IL]; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chalkley HW, 1943, J NATL CANCER I, V4, P47; Chen J, 2004, THEOR APPL FRACT MEC, V41, P63, DOI 10.1016/j.tafmec.2003.11.006; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Feltis BN, 2006, AM J RESP CRIT CARE, V173, P1201, DOI 10.1164/rccm.200507-1105OC; Hansen S, 2004, HISTOPATHOLOGY, V44, P428, DOI 10.1111/j.1365-2559.2004.01848.x; Hashimoto M, 2005, CHEST, V127, P965, DOI 10.1378/chest.127.3.965; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; JEFFERY K, 2004, P AM THORAC SOC, V1, P176; Juniper E, 1994, HISTAMINE METHACHOLI; Kanazawa H, 2004, AM J RESP CRIT CARE, V169, P1125, DOI 10.1164/rccm.200401-123OC; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Offersen BV, 2003, EUR J CANCER, V39, P881, DOI 10.1016/S0959-8049(02)00663-9; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Park SW, 2004, CHEST, V125, P1998, DOI 10.1378/chest.125.6.1998; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Siddiqui S, 2006, THORAX, V61, P547; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039; 2006, GLOBAL I ASTHMA GUID; 2000, AM J RESPIR CRIT CAR, V162, P2341	43	70	75	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					813	819		10.1016/j.jaci.2007.05.028	http://dx.doi.org/10.1016/j.jaci.2007.05.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17610943				2022-12-18	WOS:000250157700014
J	Vahlkvist, S; Sinding, M; Skamstrup, K; Bisgaard, H				Vahlkvist, Signe; Sinding, Marianne; Skamstrup, Kirsten; Bisgaard, Hans			Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child; fractional exhaled nitric oxide; home monitoring; handheld; pollen		Background: Fractional exhaled nitric oxide (FENO) is a sensitive marker of eosinophilic airway inflammation in asthma. Available methods have restricted measurements to the clinic, giving only a snapshot of the disease, which by nature is highly variable. Objectives: We sought to investigate the feasibility, repeatability, accuracy, sensitivity, and biologic plausibility of new handheld equipment for FENO measurements. We studied day-to-day home measurements of FENO during the birch pollen season in children with allergy to birch pollen and a history of mild asthma and rhinoconjunctivitis during this season, as well as in nonatopic children. Methods: Eleven children with mild asthma and allergy to birch pollen, performed daily home measurements of FENO for 6 weeks before and during the birch pollen season by using a handheld FENO monitor (NIOX MINO). Additionally, FENO (chemiluminescence equipment [NIOX]) and spirometry were measured at the inclusion and completion visit in the clinic. Peak expiratory flow rate (PEFR) and symptoms were recorded daily. Results: Daily FENO (NIOX MINO) increased significantly (P <.001) with increasing pollen count. FENO (NIOX MINO) and FENO (NIOX) exhibited a correlation coefficient of 0.98, but FENO (NIOX MINO) was significantly higher than FENO (NIOX) (P <.01). PEFR and FEV, remained unchanged, and few symptoms were recorded. Conclusion: Exhaled nitric oxide levels increased significantly during the pollen season, even though the patients reported only few asthmatic symptoms and no change in PEFR or spirometry. Daily measurements of FENO (NIOX MINO) might allow early detection of disease deterioration, and future studies could address such a measure for dynamic treatment strategies. Clinical implications: This simple handheld device expands the potential use of FENO to a wider group of asthma clinics and even home measurements.	Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark	University of Copenhagen	Vahlkvist, S (corresponding author), Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark.		Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016; Vahlkvist, Signe/AAE-5494-2019	Bisgaard, Hans/0000-0003-4131-7592; Vahlkvist, Signe/0000-0002-6981-4657				American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; Bisgaard H, 2005, J ALLERGY CLIN IMMUN, V115, P708, DOI 10.1016/j.jaci.2004.11.018; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Hemmingsson Tryggve, 2004, J Clin Monit Comput, V18, P379, DOI 10.1007/s10877-005-1158-z; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; *NAT I HLTH NAT HE, 2003, 023659 NAT I I HLTH; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165	14	70	72	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1272	1276		10.1016/j.jaci.2006.03.018	http://dx.doi.org/10.1016/j.jaci.2006.03.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750986	Bronze			2022-12-18	WOS:000238332300011
J	Taylor, RC; Richmond, P; Upham, JW				Taylor, Rebecca C.; Richmond, Peter; Upham, John W.			Toll-like receptor 2 ligands inhibit T(H)2 responses to mite allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; toll-like receptors; innate immunity; T(H)2 cytokines	DENDRITIC CELLS; INHALANT ALLERGEN; IMMUNE-RESPONSE; CUTTING EDGE; T-CELLS; CHILDREN; ASTHMA; EXPOSURE; ACTIVATION; CHILDHOOD	Background: There is intense interest in the interaction between microbial compounds and allergy. Although Toll-like receptor (TLR)-2 ligands derived from Gram-positive bacteria alter allergic sensitization in animal models, it is not clear what effect TLR2 ligands have on allergen-specific T-cell memory in human beings. Objective: To determine whether in vitro exposure to TLR2 ligands modifies the immune response to house dust mite allergen (HDM). Methods: Blood mononuclear cells were obtained from individuals both allergic (n = 23) and not allergic (n = 22) to HDM, and stimulated with HDM in the presence or absence of TLR2 ligands. Results: In subjects allergic to HDM, IL-5 and IL-13 responses to HDM were inhibited by heat-killed Staphylococcus aureus, staphylococcal lipoteichoic acid, and the synthetic lipoprotein Pam3CSK4 (P < .005; all stimuli). Although the whole staphylococcal bacteria increased IFN-gamma responses, the purified TLR2 ligands lipoteichoic acid and Pam3CSK4 inhibited HDM-specific IFN-gamma synthesis. In contrast, TLR2 ligands had minimal effects on responses to HDM in subjects without allergy. TLR2 ligands induced upregulation of HLA-DR expression but did not inhibit antigen uptake or processing by antigen-presenting cells. Conclusion: Toll-like receptor 2 ligands inhibit allergen-specific T(H)2 responses in sensitized individuals. This effect appears to be mediated by the actions of TLR2 ligands on antigen-presenting cells, and at least for the purified TLR2 ligands does not involve the induction of a strong T(H)1immune response. Clinical implications: These findings provide an impetus for further preclinical studies examining the potential use of TLR2 ligands in allergic disease.	Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Upham, JW (corresponding author), Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	jolinu@ichr.uwa.edu.au	Upham, John/F-4420-2010; Richmond, Peter C/G-3379-2012	Upham, John/0000-0002-0017-3433; Richmond, Peter C/0000-0001-7562-7228				Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Ausiello CM, 1999, INFECT IMMUN, V67, P4064, DOI 10.1128/IAI.67.8.4064-4071.1999; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Daro E, 2000, J IMMUNOL, V165, P49, DOI 10.4049/jimmunol.165.1.49; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HOEGER PH, 1992, J INFECT DIS, V165, P1064, DOI 10.1093/infdis/165.6.1064; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Sun J, 2005, J IMMUNOL, V174, P742, DOI 10.4049/jimmunol.174.2.742; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078	23	70	74	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1148	1154		10.1016/j.jaci.2006.02.014	http://dx.doi.org/10.1016/j.jaci.2006.02.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675345	Bronze			2022-12-18	WOS:000237436300029
J	Wijga, AH; van Houwelingen, AC; Kerkhof, M; Tabak, C; De Jongste, JC; Gerritsen, J; Boshuizen, H; Brunekreef, B; Smit, HA				Wijga, AH; van Houwelingen, AC; Kerkhof, M; Tabak, C; De Jongste, JC; Gerritsen, J; Boshuizen, H; Brunekreef, B; Smit, HA			Breast milk fatty acids and allergic disease in preschool children: The Prevention and Incidence of Asthma and Mite Allergy birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breast milk; fatty acids; allergic symptoms; children; birth cohort	CHILDHOOD ASTHMA; ATOPIC ECZEMA; MOTHERS; DIET; INFANTS; RISK; PREVALENCE; LIFE	Background: Better understanding of the association between early life lipid intakes and the development of allergic diseases is needed. Objective: We prospectively studied breast milk content of n-6, n-3, and trans fatty acids in relation to allergic symptoms at the ages of 1 and 4 years. Methods: Fatty acid content was determined in breast milk samples of 265 (158 allergic and 107 nonallergic) mothers of children participating in the Prevention and Incidence of Asthma and Mite Allergy study. Outcome variables studied were parental reported eczema at age I year, eczema at age 4 years, asthma at age 4 years, and, in a subgroup of 133 children, sensitization at age 4 years. Results: In children of mothers with allergy, breast milk n-3 long chain polyunsaturated fatty acids and the ratio between n-3 and n-6 long chain polyunsaturated fatty acids were inversely associated with asthma and with persistent symptoms (eczema at age 1 year and eczema at age 4 years and/or asthma at age 4 years), but no associations between breast milk fatty acids and sensitization were observed. In children of mothers with allergy, also trans fatty acids tended to be inversely associated with allergic symptoms. In children of mothers without allergy, no associations between breast milk fatty acids and allergic symptoms were observed, but alpha-linolenic acid (18:3n-3) was positively associated with sensitization. Conclusion: In susceptible infants, the risk to develop allergic symptoms, but not the risk of sensitization, was modified by intake of n-3 long chain polyunsaturated fatty acids through breast milk.	Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; Maastricht Univ, Nutr Toxicol & Environm Res Inst, Maastricht, Netherlands; Univ Groningen, Med Ctr, Dept Epidemiol & Bioinformat, Groningen, Netherlands; Erasmus Med Ctr Sophia, Dept Pediat, Div Resp Med, Rotterdam, Netherlands; Univ Groningen, Beatrix Children Clin, Ctr Med, Groningen, Netherlands; Natl Inst Publ Hlth & Environm, Ctr Informat Technol & Methodol, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Maastricht University; University of Groningen; Erasmus University Rotterdam; Erasmus MC; University of Groningen; Netherlands National Institute for Public Health & the Environment; Utrecht University	Wijga, AH (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, Pigeonhole 101,POB 1, NL-3720 BA Bilthoven, Netherlands.	alet.wijga@rivm.nl	Boshuizen, Hendriek/M-3415-2014; Kerkhof, Marjan/A-8846-2008; Boshuizen, Hendriek C/B-3718-2014	Boshuizen, Hendriek/0000-0002-3916-9095; brunekreef, bert/0000-0001-9908-0060				Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BUSINCO L, 1993, J ALLERGY CLIN IMMUN, V91, P1134, DOI 10.1016/0091-6749(93)90315-7; DESCI T, 1995, ANN NUTR METAB, V39, P36; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Duchen K, 2001, LIPIDS, V36, P1033, DOI 10.1007/s11745-001-0814-5; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; Duchen K, 2000, PEDIAT ALLERG IMM-UK, V11, P29, DOI 10.1034/j.1399-3038.2000.00052.x; FOREMANVANDRONGELEN MMHP, 1995, BRIT J NUTR, V73, P405, DOI 10.1079/BJN19950043; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Kankaanpaa P, 2001, ALLERGY, V56, P633, DOI 10.1034/j.1398-9995.2001.00965.x; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P1235, DOI 10.1016/j.jaci.2005.04.004; Plat J, 2005, CURR OPIN LIPIDOL, V16, P31, DOI 10.1097/00041433-200502000-00007; Prescott SL, 2004, CURR OPIN CLIN NUTR, V7, P123, DOI 10.1097/00075197-200403000-00004; Reichardt P, 2004, ALLERGY, V59, P394, DOI 10.1111/j.1398-9995.2003.00429.x; Stephensen CB, 2004, NUTR REV, V62, P486, DOI [10.1111/j.1753-4887.2004.tb00021.x, 10.1301/nr.2004.000-000]; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Thien F. C. K., 2002, COCHRANE DATABASE SY; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Wijga A, 2003, PEDIAT ALLERG IMM-UK, V14, P156, DOI 10.1034/j.1399-3038.2003.00022.x; Wong KW, 2005, J AM DIET ASSOC, V105, P98, DOI 10.1016/j.jada.2004.10.009; WRIGHT S, 1989, BRIT J NUTR, V62, P693, DOI 10.1079/BJN19890069	25	70	75	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					440	447		10.1016/j.jaci.2005.10.022	http://dx.doi.org/10.1016/j.jaci.2005.10.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461146	Green Submitted			2022-12-18	WOS:000235687300027
J	Puxeddu, I; Bader, R; Piliponsky, AM; Reich, R; Levi-Schaffer, F; Berkman, N				Puxeddu, I; Bader, R; Piliponsky, AM; Reich, R; Levi-Schaffer, F; Berkman, N			The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CC chemokine; eotaxin/CCL11; CCR3; fibroblast; myofibroblast; airway remodeling; asthma; alpha-smooth muscle actin	PULMONARY ALLERGIC RESPONSES; MONOCYTE CHEMOATTRACTANT; EOSINOPHIL CHEMOATTRACTANT; GENE-EXPRESSION; AIRWAY HYPERRESPONSIVENESS; ATOPIC ASTHMA; MESSENGER-RNA; IN-VITRO; PROTEIN; CELLS	Background: Eotaxin/CCL11 plays an important role in asthma. It acts through the chemokine receptor CCR3 expressed on hematopoietic and nonhematopoietic cells in the lung. Objective: To determine whether eotaxin/CCL11 modulates lung and bronchial fibroblast properties and thereby might contribute to airway remodeling. Methods: CCR3 expression was characterized on a lung fibroblast line (MRC-5; flow cytometry, fluorescent microscopy, RT-PCR, and Northern blotting), on primary bronchial fibroblasts (flow cytometry), and on fibroblasts in human lung tissue (confocal laser microscopy). The effects of eotaxin/CCL11 on lung fibroblast migration (Boyden chamber), proliferation (tritiated thymidine incorporation), a-smooth muscle actin expression (ELISA), 3-dimensional collagen gel contraction (floating gel), pro-alpha 1(I) collagen mRNA (Northern blotting), total collagen synthesis (tritiated proline incorporation), matrix metalloproteinase activity (gelatin zymography), and TGF-beta(1) release (ELISA) were evaluated. The contribution of eotaxin/CCL11/CCR3 binding on lung fibroblasts was also investigated by neutralizing experiments. Results: CCR3 is constitutively expressed in cultured lung and primary bronchial fibroblasts and colocalizes with specific surface markers for human fibroblasts in lung tissue. Eotaxin/CCL11 selectively modulates fibroblast activities by increasing their proliferation, matrix metalloproteinase 2 activity, and collagen synthesis but not their differentiation into myofibroblasts, contractility in collagen gel, or TGF-beta(1) release. Eotaxin/CCL11 enhances migration of lung fibroblasts in response to nonspecific chemoattractants, and this effect is completely inhibited by anti-CCR3-neutralizing antibodies. Conclusion: These data demonstrate that eotaxin/CCL11 has a direct and selective profibrogenic effect on lung and bronchial fibroblasts, providing a novel mechanism whereby eotaxin/CCL11 can participate in airway remodeling in asthma.	Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Pulmonol, Hadassah Med Ctr, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, POB 12065, IL-91120 Jerusalem, Israel.	fls@cc.huji.ac.il	Puxeddu, Ilaria/AAB-3263-2019	Levi-Schaffer, Francesca/0000-0003-0620-2810				ALBINI A, 1987, CANCER RES, V47, P3239; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; Atamas SP, 2003, AM J RESP CELL MOL, V29, P743, DOI 10.1165/rcmb.2003-0078OC; Belperio JA, 2004, J IMMUNOL, V173, P4692, DOI 10.4049/jimmunol.173.7.4692; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Blease K, 2000, Respir Res, V1, P54, DOI 10.1186/rr13; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Choi ES, 2004, AM J RESP CRIT CARE, V170, P508, DOI 10.1164/rccm.200401-002OC; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Cui CH, 2002, AM J RESP CELL MOL, V27, P329, DOI 10.1165/rcmb.4762; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GharaeeKermani M, 1996, J BIOL CHEM, V271, P17779, DOI 10.1074/jbc.271.30.17779; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; KAY AB, 2004, TRENDS IMMUNOL, V34, P1276; Keane MP, 2004, AM J RESP CRIT CARE, V170, P475, DOI 10.1164/rccm.2406007; Kodali RB, 2004, ARTERIOSCL THROM VAS, V24, P1211, DOI 10.1161/01.ATV.0000131654.90788.f5; LAMKHIOUED B, 2002, J IMMUNOL, V169, P527; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; *NHI, 1992, EUR RESPIR J, V5, P115; Nomura A, 2002, CLIN EXP ALLERGY, V32, P860, DOI 10.1046/j.1365-2745.2002.01404.x; Petering H, 2001, J INVEST DERMATOL, V116, P549, DOI 10.1046/j.1523-1747.2001.01302.x; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Puxeddu A, 2005, INT J BIOCHEM CELL B, V37, P628, DOI 10.1016/j.biocel.2004.09.001; Puxeddu I, 2004, PEDIATR PULM, V38, P222, DOI 10.1002/ppul.20067; Puxeddu Ilaria, 2004, Paediatr Respir Rev, V5 Suppl A, pS31, DOI 10.1016/S1526-0542(04)90007-3; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rozyk KJ, 1997, IMMUNOL LETT, V58, P47; Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Schuh JM, 2001, FASEB J, V15, P228, DOI 10.1096/fj.01-0528fje; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Yamamoto T, 2000, J IMMUNOL, V164, P6174, DOI 10.4049/jimmunol.164.12.6174; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; ZHANG K, 1994, J IMMUNOL, V153, P4733	46	70	77	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					103	110		10.1016/j.jaci.2005.08.057	http://dx.doi.org/10.1016/j.jaci.2005.08.057			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387592				2022-12-18	WOS:000235687100017
J	Schimek, EM; Zwolfer, B; Briza, P; Jahn-Schmid, B; Vogel, L; Vieths, S; Ebner, C; Bohle, B				Schimek, EM; Zwolfer, B; Briza, P; Jahn-Schmid, B; Vogel, L; Vieths, S; Ebner, C; Bohle, B			Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergy; food allergy; oral allergy syndrome; pathogenesis-related protein family 10; Bet v 1; T cell cross-reactivity	BIRCH POLLEN ALLERGEN; CELERY APIUM-GRAVEOLENS; MAJOR ALLERGEN; MOLECULAR CHARACTERIZATION; ATOPIC-DERMATITIS; PRU AV-1; IGE; BET-V-1; EPITOPE; PEANUT	Background: Food allergy to apples, hazelnuts, and celery is frequent in individuals with birch pollen allergy because IgE antibodies specific for the major birch pollen allergen, Bet v 1, cross-react with structurally related allergens in these foods. In addition, T lymphocytes specific for Bet v 1 also cross-react with these dietary proteins. Objective: We sought to evaluate the effects of simulated gastrointestinal degradation of Bet v 1-related food allergens on their mediator-releasing and T cell-activating capacity. Methods: Recombinant Mal d 1, Cor a 1.04, and Api g 1 were incubated separately with pepsin and trypsin. Binding of IgE was tested in immunoblots. After successive incubation with both enzymes, allergens were tested in mast cell mediator release assays and used to stimulate PBMCs and Bet v 1-specific T-cell lines and clones. Proteolytic fragments of allergens were analyzed and sequenced by means of mass spectrometry. Results: Pepsin completely destroyed IgE binding of all allergens within 1 second, and trypsin completely destroyed IgE binding of all allergens within 15 minutes, except for the major hazelnut allergen, which remained intact for 2 hours of trypsinolysis. Allergens after gastrointestinal digestion did not induce basophil activation but induced proliferation in PBMCs from allergic and nonallergic individuals. Digested Mal d 1 and Cor a 1.04 still activated Bet v 1-specific T cells, whereas digested Api g 1 did not. Different proteolytic fragments of Mal d 1 and Cor a 1.04 matching relevant Bet v 1 T-cell epitopes were found. Conclusion: Gastrointestinal degradation of Bet v 1-related food allergens destroys their histamine-releasing, but not T cell-activating, property. Our data emphasize that birch pollen-related foods are relevant activators of pollen-specific T cells.	Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, A-1090 Vienna, Austria; Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; Paul Ehrlich Inst, D-6070 Langen, Germany; Allergy Clin Reumannpl, Vienna, Austria	Medical University of Vienna; Salzburg University; Paul Ehrlich Institute	Bohle, B (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Briza, Peter/D-7309-2012	Briza, Peter/0000-0002-4941-6782; Bohle, Barbara/0000-0002-5105-7985				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Breuer K, 2004, ALLERGY, V59, P988, DOI 10.1111/j.1398-9995.2004.00493.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Kopper RA, 2004, J ALLERGY CLIN IMMUN, V114, P614, DOI 10.1016/j.jaci.2004.05.012; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Werfel T, 1999, INT ARCH ALLERGY IMM, V118, P230, DOI 10.1159/000024081; Wiche R, 2005, BIOCHEM J, V385, P319, DOI 10.1042/BJ20040842; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	35	70	72	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1327	1333		10.1016/j.jaci.2005.09.007	http://dx.doi.org/10.1016/j.jaci.2005.09.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337467				2022-12-18	WOS:000235687000026
J	Lopez-Granados, E; de Diego, RP; Cerdan, AF; Casariego, GF; Rodriguez, MCG				Lopez-Granados, E; de Diego, RP; Cerdan, AF; Casariego, GF; Rodriguez, MCG			A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-linked agammaglobulinemia; Bruton's tyrosine kinase; molecular diagnosis; missense; genotype-phenotype correlation	BRUTONS-TYROSINE-KINASE; B-CELL DEVELOPMENT; DEFICIENT EXPRESSION; MOLECULAR ANALYSIS; SH2 DOMAIN; BTK; GENE; MUTATIONS; XLA; DIAGNOSIS	Background: X-linked (Bruton's) agammaglobulinemia (XLA) is a rare immunodeficiency caused by a block in B-cell development caused by mutations in the Bruton's tyrosine kinase (BTK) gene. Many aspects of XLA and BTK function remain unresolved; atypical presentations have been reported, and no clear genotype-phenotype correlation has been established. Objectives: We sought to contribute to the understanding of XLA through the phenotypic and biochemical characterization of a large group of Spanish patients with agammaglobulinemia. We also sought to classify the mutations according to their severity to analyze a genotype-phenotype correlation. Methods: Clinical and analytic data were collected from the clinical records. We studied the BTK gene, protein expression, and function, and the findings were correlated with the phenotypic information. Results: Fifty-four patients were given diagnoses of XLA. We identified 38 different mutations in BTK, 26 not described in other patients, and several uncommon clinical phenotypes or analytic characteristics were found. The statistical analysis shows that less severe mutations or minimal detection of protein by means of How cytometry are associated with decreased severity in clinical and analytic data, demonstrating a clear relation between the type of mutation and the disease expressivity. However, some exemptions to this rule were noted. Conclusions: XLA is a variable disease. Globally, a genotypephenotype correlation is observed, but individual discrepancies between the severity of the mutation and the clinical and analytic phenotype suggest that other loci or ambient factors significantly influence the disease presentation and evolution.	Univ Hosp Le Paz, Immunol Unit, Madrid, Spain		Lopez-Granados, E (corresponding author), John Radcliffe Hosp, Dept Clin Immunol, Level 7, Oxford OX3 9DU, England.	eduardo.lopez@clinical-medicine.oxford.ac.uk		Perez de Diego, Rebeca/0000-0001-8426-8765				BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BRUTON OC, 1952, PEDIATRICS, V9, P722; Bykowsky MJ, 1996, AM J HUM GENET, V58, P477; Conley ME, 1999, CLIN IMMUNOL, V93, P189, DOI 10.1006/clim.1999.4798; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; Conley ME, 2002, J PEDIATR-US, V141, P566, DOI 10.1067/mpd.2002.127711; de Diego RP, 2005, J ALLERGY CLIN IMMUN, V115, P205, DOI 10.1016/j.jaci.2004.07.059; Futatani T, 1998, BLOOD, V91, P595; Gaspar HB, 1998, CLIN EXP IMMUNOL, V111, P334; Granados EL, 2002, J CLIN INVEST, V110, P1029, DOI 10.1172/JCI200215658; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; Hansson H, 2001, FEBS LETT, V508, P11, DOI 10.1016/S0014-5793(01)03018-6; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JIN H, 1995, HUM MOL GENET, V4, P693, DOI 10.1093/hmg/4.4.693; KORNFELD SJ, 1994, NEW ENGL J MED, V331, P949; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Mao C, 2001, J BIOL CHEM, V276, P41435, DOI 10.1074/jbc.M104828200; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tzeng SR, 2000, PROTEIN SCI, V9, P2377, DOI 10.1110/ps.9.12.2377; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 2001, ADV GENET, V43, P103, DOI 10.1016/S0065-2660(01)43005-7; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P2403, DOI 10.1093/hmg/4.12.2403; Wang YL, 2000, TRENDS BIOCHEM SCI, V25, P300, DOI 10.1016/S0968-0004(00)01561-9	32	70	76	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					690	697		10.1016/j.jaci.2005.04.043	http://dx.doi.org/10.1016/j.jaci.2005.04.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159644				2022-12-18	WOS:000235686500034
J	Williams, JV; Tollefson, SJ; Heymann, PW; Carper, HT; Patrie, J; Crowe, JE				Williams, JV; Tollefson, SJ; Heymann, PW; Carper, HT; Patrie, J; Crowe, JE			Human metapneumovirus infection in children hospitalized for wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Univ Virginia, Hlth Syst, Dept Pediat, Charlottesville, VA USA; Univ Virginia, Hlth Syst, Dept Hlth Evaluat Sci, Charlottesville, VA USA	Vanderbilt University; Vanderbilt University; University of Virginia; University of Virginia	Williams, JV (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, D-7235 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.		Williams, John/ABE-3227-2020; Crowe, James/B-5549-2009	Williams, John/0000-0001-8377-5175; Crowe, James/0000-0002-0049-1079	NIAID NIH HHS [P01 AI050989, R03 AI054790, R03 AI 54790, 1P01 AI 50989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI054790, P01AI050989] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agresti A, 2001, BIOMETRICS, V57, P963, DOI 10.1111/j.0006-341X.2001.00963.x; Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482; GEM JE, 2004, J ALLERGY CLIN IMMUN, V114, P236; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Maertzdorf J, 2004, J CLIN MICROBIOL, V42, P981, DOI 10.1128/JCM.42.3.981-986.2004; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472	8	70	73	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1311	1312		10.1016/j.jaci.2005.02.001	http://dx.doi.org/10.1016/j.jaci.2005.02.001			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940152	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000229815400032
J	Lombardi, C; Gani, F; Landi, M; Falagiani, P; Bruno, M; Canonica, GW; Passalacqua, G				Lombardi, C; Gani, F; Landi, M; Falagiani, P; Bruno, M; Canonica, GW; Passalacqua, G			Quantitative assessment of the adherence to sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									St Orsola Hosp, Dept Internal Med, Pneumoallergy Unit, Brescia, Italy; Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Lofarma SpA, Milan, Italy; Natl Pediat Healthcare, Turin, Italy; San Luigi Hosp, Allergy Unit, Turin, Italy	University of Genoa	Lombardi, C (corresponding author), St Orsola Hosp, Dept Internal Med, Pneumoallergy Unit, Brescia, Italy.		canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; Landi, Massimo/0000-0001-7587-4800				[Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; HAYNES RB, 1979, COMPLIANCE HEALTHCAR, P15; LOWER T, 1993, ANN ALLERGY, V70, P480; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200	9	70	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1219	1220		10.1016/j.jaci.2004.03.013	http://dx.doi.org/10.1016/j.jaci.2004.03.013			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15214362	Bronze			2022-12-18	WOS:000222091000033
J	Arbes, SJ; Sever, M; Mehta, J; Gore, JC; Schal, C; Vaughn, B; Mitchell, H; Zeldin, DC				Arbes, SJ; Sever, M; Mehta, J; Gore, JC; Schal, C; Vaughn, B; Mitchell, H; Zeldin, DC			Abatement of cockroach allergens (Bla g 1 and Bla g 2) in low-income, urban housing: Month 12 continuation results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroaches; cockroach allergen; Bla g 1; Bla g 2; indoor allergens; intervention trial	INNER-CITY CHILDREN; ASTHMA; EXPOSURE	Background: In the first 6 months of this previously published, randomized trial, the combined intervention of occupant education, insecticide bait application, and professional cleaning significantly reduced cockroach numbers and Bla g 1 allergen levels in inner-city homes. Objective: This continuation study investigated whether the cockroach allergen reductions achieved by month 6 could be maintained through month 12 with insecticide application alone. Methods: Because we had agreed to place insecticide bait in control homes at the conclusion of the first study, intervention and control homes were treated with insecticide bait at months 6 and 9. No other intervention was conducted in either arm. Vacuumed dust and swab samples were collected at month 12. Twenty-one of the 31 original homes completed the 12-month study. Results: Among the original intervention homes, Bla g I concentrations remained essentially unchanged from months 6 to 12. However, among the crossed-over control homes, the geometric mean Bla g I concentrations (Units per gram of dust) decreased from 287 to 14.4 for kitchen floors (95% reduction), from 28.8 to 5.6 for living room floors/sofas (81% reduction), from 26.7 to 4.7 for bedroom floors (82% reduction), and from 7.2 to 2.4 for beds (67% reduction). At month 12, Bla g I concentrations did not significantly differ between intervention and crossed-over control homes (P >.64 at each location). Similar results were seen for the allergen Bla g 2. Conclusions: Reductions in cockroach allergen concentrations achieved through the combined intervention of occupant education, insecticide application, and professional cleaning can be maintained with continued cockroach control. Surprisingly, and in contrast to other studies, insecticide application alone significantly lowered allergen concentrations in the crossed-over control homes. This unexpected result is being tested further in another randomized trial.	NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA; Rho Inc, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University; Rho	Zeldin, DC (corresponding author), NIEHS, Div Intramural Res, NIH, POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.		Schal, Coby/A-8717-2010; Zeldin, Darryl C/Y-7091-2018	Schal, Coby/0000-0001-7195-6358; Zeldin, Darryl C/0000-0002-2087-7307; Sever, Michelle/0000-0002-2435-1214	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025044, Z01ES025041, ZIAES025043, ZIAES025041, Z01ES025043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHAL C, 1990, ANNU REV ENTOMOL, V35, P521, DOI 10.1146/annurev.en.35.010190.002513; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5	8	70	72	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					109	114		10.1016/j.jaci.2003.10.042	http://dx.doi.org/10.1016/j.jaci.2003.10.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713915				2022-12-18	WOS:000187837900014
J	Gerhold, K; Bluemchen, K; Franke, A; Stock, P; Hamelmann, E				Gerhold, K; Bluemchen, K; Franke, A; Stock, P; Hamelmann, E			Exposure to endotoxin and allergen in early life and its effect on allergen sensitization in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cytokines; lipopolysaccharide; mice; ovalbumin	AIRWAY INFLAMMATION; BACTERIAL LIPOPOLYSACCHARIDE; INHALED ANTIGEN; IGE RESPONSES; TNF-ALPHA; T-CELLS; ASTHMA; HYPERREACTIVITY; EXPRESSION; TOLERANCE	Background: Exposure to endotoxins, allergens, or both in early life might regulate the development of tolerance to allergens later in life. Objective: We investigated whether continuous exposure of infant mice to aerosolized endotoxin, allergen, or both inhibits subsequent allergen-induced immune and inflammatory responses. Methods: Infant BALB/c mice were pre-exposed to aerosolized endotoxin, ovalbumin (OVA), or both (3 times a week for the first 4 weeks of life) before systemic sensitization (days 1-14) and repeated airway challenge (days 28-30) with OVA. Results: Compared with that seen in negative control animals, systemic sensitization and airway allergen challenges induced high serum levels of allergen-specific IgE (0.7 +/- 0.09 vs 0.02 +/- 0.01 OD units), predominant T(H)2-type cytokine production (IL-5 by splenic mononuclear cells in vitro, 1.2 +/- 0.2 vs 0.04 +/- 0.06 ng/mL), airway inflammation (bronchoalveolar lavage fluid leukocytes, 125 +/- 15 vs 64 +/- 7/muL; eosinophils, 28 +/- 5 vs 1 +/- 0/muL) and development of in vivo airway hyperreactivity (maximal enhanced pause, 11 +/- 1.9 vs 4 +/- 0.2). Pre-exposure with LPS before sensitization increased production of specific IgG2a (67 +/- 10 vs 32 +/- 5 U/mL) but failed to prevent T(H)2-mediated immune responses. Pre-exposure with OVA or with OVA plus LPS completely suppressed allergen sensitization, airway inflammation, and development of in vivo airway hyperreactivity; values were similar to those of negative control animals. Inhibition was due to allergen-specific T-cell anergy indicated by omitted allergen-specific T(H)2 and T(H)1 immune responses. In addition, combined exposure to endotoxin and allergen induced a general shift toward an unspecific T(H)1 immune response. Conclusion: Exposure with endotoxins before allergen sensitization is not able to induce unresponsiveness but might decrease the susceptibility for sensitization to a variety of common allergens.	Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hamelmann, E (corresponding author), Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.		Hamelmann, Eckard/AAJ-9124-2021					Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Crosby JR, 2002, AM J PHYSIOL-LUNG C, V282, pL99, DOI 10.1152/ajplung.2002.282.1.L99; Dankesreiter S, 2000, J IMMUNOL, V164, P4804, DOI 10.4049/jimmunol.164.9.4804; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Held HD, 2000, AM J RESP CRIT CARE, V162, P1547, DOI 10.1164/ajrccm.162.4.9912079; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Hoyne GF, 1997, INT IMMUNOL, V9, P1165, DOI 10.1093/intimm/9.8.1165; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kotanidou A, 2002, AM J RESP CRIT CARE, V165, P818, DOI 10.1164/ajrccm.165.6.2101049; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; LARSON KA, 1995, J IMMUNOL, V155, P3002; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowrey JA, 1998, INT ARCH ALLERGY IMM, V116, P93, DOI 10.1159/000023931; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sterk PJ, 1999, EUR RESPIR J, V14, P1435, DOI 10.1183/09031936.99.14614359; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 2000, ARCH DIS CHILD, V82, P2; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457, DOI 10.1165/ajrcmb.25.4.4505; 1998, AM J RESP CRIT CARE, V158, pS1	33	70	72	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					389	396		10.1067/mai.2003.1646	http://dx.doi.org/10.1067/mai.2003.1646			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897747				2022-12-18	WOS:000184650600025
J	Liu, X; Beaty, TH; Deindl, P; Huang, SK; Lau, S; Sommerfeld, C; Fallin, MD; Kao, WHL; Wahn, U; Nickel, R				Liu, X; Beaty, TH; Deindl, P; Huang, SK; Lau, S; Sommerfeld, C; Fallin, MD; Kao, WHL; Wahn, U; Nickel, R			Associations between total serum IgE levels and the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in German children: The German Multicenter Atopy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						total serum IgE levels; IL4; IL13; IL4RA; single nucleotide polymorphism; association	IL-4 RECEPTOR-ALPHA; HUMAN B-CELLS; INTERLEUKIN-4 RECEPTOR; PROMOTER POLYMORPHISM; JAPANESE FAMILIES; LINKAGE ANALYSIS; SUSCEPTIBILITY ALLELES; CHROMOSOME 5Q31-Q33; ALLERGIC-ASTHMA; TRANSGENIC MICE	Background: Increased total serum IgE levels are a common characteristic of atopic disorders. Six potentially functional variants, including C-590T in the IL4 gene, C-1055T and Arg130Gln in the IL13 gene, and Ile50Val, Ser478Pro, and Gln551Arg in the IL4RA gene, have been evaluated for their involvement in the control of total serum IgE levels and related atopic disorders, but the results of these studies have been inconsistent. Objective: We examined whether these 6 variants had genotypic effects on total serum IgE levels in 823 unrelated German children from a large infant cohort, the German Multicenter Atopy Study. Methods: Marginal effect models were used for the analyses of the repeated IgE measurements. Weighted linear regression and family-based tests of association were performed to minimize the possibility of spurious effects caused by selection bias or confounding on the basis of ethnic background. Results: There are significant associations between increased total serum IgE levels and 2 variants in the IL13 gene (P < .005 and .0002 for Arg130Gln and C-1055T, respectively). These genetic effects are unlikely to be due to solely linkage disequilibrium between 2 polymorphisms, population stratification, or nonrepresentative samples. In addition, exposure to maternal smoking appears to modify the above effects on total serum IgE levels. However, no statistical association was observed between this quantitative phenotype and the other 4 variants examined. Conclusion: These findings suggest that variants C-1055T and Arg130GIn of the IL13 gene might play an important role on total serum IgE production in this study population.	Humboldt Univ, Dept Pediat Pneumol & Immunol, Charite, D-13353 Berlin, Germany; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol, Baltimore, MD USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Nickel, R (corresponding author), Humboldt Univ, Dept Pediat Pneumol & Immunol, Charite, Augustenburger Pl 1, D-13353 Berlin, Germany.		Huang, Shau-Ku/F-5509-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-052468] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Atici Aytug, 1994, Acta Paediatrica Japonica, V36, P266; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; BURSTEIN HJ, 1991, J IMMUNOL, V147, P2950; Celedon JC, 2002, CLIN EXP ALLERGY, V32, P387, DOI 10.1046/j.1365-2222.2002.01348.x; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; HALL IP, 1996, GENETICS ASTHMA ATOP; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hijazi Z, 2000, INT ARCH ALLERGY IMM, V122, P190, DOI 10.1159/000024396; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Kauppi P, 2001, GENOMICS, V77, P35, DOI 10.1006/geno.2001.6613; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; KJELLMAN NI, 1981, LANCET, V1, P933; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Noguchi E, 1999, CLIN EXP ALLERGY, V29, P228; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Noguchi E, 2001, HUM IMMUNOL, V62, P1251, DOI 10.1016/S0198-8859(01)00338-X; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Ober C, 1999, CLIN EXP ALLERGY, V29, P11; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; Patuzzo C, 2000, J MED GENET, V37, P382, DOI 10.1136/jmg.37.5.382; PENE J, 1988, J IMMUNOL, V141, P1218; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; SCHABORT EJ, 1999, J SPORTS SCI, V17, P1; Schneider S., 2000, ARLEQUIN VER 2 0 SOF; Seymour Brian W P, 2002, Dev Immunol, V9, P47, DOI 10.1080/1044667021000003989; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Vinke JG, 1999, INT J PEDIATR OTORHI, V51, P73, DOI 10.1016/S0165-5876(99)00244-X; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; WJST M, 1994, ALLERGY, V49, P766, DOI 10.1111/j.1398-9995.1994.tb02100.x; XU J, 1995, AM J HUM GENET, V57, P425; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yokouchi Y, 2002, GENES IMMUN, V3, P9, DOI 10.1038/sj.gene.6363815; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086	60	70	79	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					382	388		10.1067/mai.2003.1635	http://dx.doi.org/10.1067/mai.2003.1635			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897746				2022-12-18	WOS:000184650600024
J	Chakir, J; Laviolette, M; Turcotte, H; Boutet, M; Boulet, LP				Chakir, J; Laviolette, M; Turcotte, H; Boutet, M; Boulet, LP			Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: Influence of natural allergen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; bronchial biopsy; IL-5; lymphocytes; immunohistochemistry; pollen season	NASAL-MUCOSA; MESSENGER-RNA; INFLAMMATION; EOSINOPHILS; INCREASE; ASTHMA; IL-4	Background: Natural exposure to pollen provokes an increase in airway responsiveness in nonasthmatic subjects with seasonal allergic rhinitis, This natural exposure map induce inflammatory cell recruitment and cytokine release, leading to lower airway inflammation. Objective: The aim of this study was to characterize loner airway inflammation in nonasthmatic pollen-sensitive subjects. Methods: We performed immunohistochemical tests on bronchial biopsy specimens from subjects with rhinitis who had no past or current history of asthma to evaluate cytokine expression and inflammatory cell numbers and activation both in and out of the pollen season. Results: The number of CD4(+), CD8(+), and CD45RO(+) lymphocyte subpopulations mere significantly higher during the pollen season compared with the out-of-season period (P <.14), Furthermore, EG1(+) cells tended to increase after natural pollen exposure (P =.06), The number of IL-5(+) cells increased significantly after natural exposure to pollen compared with out-of-season numbers (P <.01), This increase in IL-5 expression was correlated with the numbers of CD3(+), CD4(+), CD45RO(+), and EG1(+) cells. The numbers of tryptase-positive, IFN-gamma (+), and IL-4(+) cells did not change after natural exposure. Conclusion: This study showed that natural pollen exposure was associated with an increase in lymphocyte numbers, eosinophil recruitment, and IL-5 expression in the bronchial mucosa of nonasthmatic subjects with allergic rhinitis.	Univ Laval, Hop Laval, Ctr Rech, Unite Rech Pneumol,Inst Cardiol & Pneumol, Ste Foy, PQ G1V 4C5, Canada	Laval University	Chakir, J (corresponding author), Univ Laval, Hop Laval, Ctr Rech, Unite Rech Pneumol,Inst Cardiol & Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4C5, Canada.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BOULET LP, 1989, ANN ALLERGY, V63, P114; BOULET LP, 1995, EUR RESPIR J, V8, P913; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; Chakir J, 1996, LAB INVEST, V75, P735; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Djukanovic R, 1996, CLIN EXP ALLERGY, V26, P44, DOI 10.1111/j.1365-2222.1996.tb00659.x; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1998, CLIN EXP ALLERGY, V28, P11; Greiff L, 1999, THORAX, V54, P33, DOI 10.1136/thx.54.1.33; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Juniper EF, 1991, HISTAMINE METHACHOLI; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; MYGIND N, 1994, EUR RESPIR REV, V4, P247; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; Tilles SA, 1997, CLIN REV ALLERG IMMU, V15, P169, DOI 10.1007/BF02826585	25	70	74	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					904	910		10.1067/mai.2000.110100	http://dx.doi.org/10.1067/mai.2000.110100			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080713				2022-12-18	WOS:000167865200015
J	Sanchez-Monge, R; Blanco, C; Perales, AD; Collada, C; Carrillo, T; Aragoncillo, C; Salcedo, G				Sanchez-Monge, R; Blanco, C; Perales, AD; Collada, C; Carrillo, T; Aragoncillo, C; Salcedo, G			Class I chitinases, the panallergens responsible for the latex-fruit syndrome, are induced by ethylene treatment and inactivated by heating	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						class I chitinases; fruit panallergens; green bean; latex-fruit syndrome; ethylene induction; allergen heat inactivation	PHASEOLUS-VULGARIS; CROSS-REACTIVITY; ALLERGY; HEVEIN; IDENTIFICATION; AVOCADO; ENDOCHITINASE; EXPRESSION; PROTEINS; BINDING	Background: Class I chitinases have been identified as the major panallergens in fruits associated with the latex-fruit syndrome, such as avocado, banana, and chestnut. However, other plant foods containing these enzymes have not been related to this syndrome. Objective: We sought out class I chitinases in the green bean, a legume that is known to express chitinases but is not associated with latex allergy, and examined whether the content or allergenic activity of chitinases can be modified by physical or chemical treatments. Methods: IgE-binding proteins in untreated bean samples, as well as in ethylene- and heat-treated samples, were detected by using a pool of sera from patients with latex-fruit allergy. Putative allergens were purified by cation-exchange chromatography and characterized by N-terminal sequencing, enzymatic activity assays, immunodetection with sera and antichitinase antibodies, and immunoblot inhibition tests, Skin prick tests with untreated and heated purified allergens were also carried out. Results: An IgE-binding protein of 32 kd that was also recognized by antichitinase antibodies was detected in green bean extracts, This reactive component was strongly induced by ethylene treatment. The protein, designated PvChI, was identified as a class I chitinase closely related to the major avocado allergen Prs a 1. Immunoblot inhibition assays demonstrated crossreactivity between both allergens. Purified PvChI induced positive skin prick test responses in 7 of 8 patients with latex-fruit allergy. Heat treatment of both Prs a 1 and PvChI produced a full loss of their allergenic capacities both in vitro and in vivo. No IgE-binding component was detected in the white mature bean in which the main isolated 32-kd protein corresponded to a nonreactive phytohemagglutinin. Conclusions: Ethylene treatment induces the expression of plant class I chitinases. The allergenic activity of plant class I chitinases seems to be lost by heating. This fact could explain why plant foods containing these putative allergens that are consumed after cooking are not usually associated with the latex-fruit syndrome.	ETS Ingenieros Agron, Dept Biotechnol, Unidad Bioquim, Madrid, Spain; Hosp Gran Canaria Dr Negrin, Secc Alergia, Las Palmas Gran Canaria, Spain; ETS Ingenieros Agron, Dept Biotechnol, Unidad Quim & Bioquim, Madrid, Spain		Salcedo, G (corresponding author), ETS Ingenieros Agron, Dept Biotechnol, Unidad Bioquim, Ciudad Univ, Madrid, Spain.		Díaz-Perales, Araceli/D-8433-2016; Blanco, Carlos/B-3895-2012; Collada, Carmen/H-1529-2015	Díaz-Perales, Araceli/0000-0002-1093-3627; Blanco, Carlos/0000-0002-2893-6594; Collada, Carmen/0000-0003-0236-1312				Alenius H, 1996, J IMMUNOL, V156, P1618; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; BLANCO C, 1994, ANN ALLERGY, V73, P309; Blanco C, 1998, CLIN EXP ALLERGY, V28, P971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malling HJ., 2003, ALLERGY, V48, P55; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SLATER JE, 1997, ALLERGY ALLERGIC DIS, P981; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z	23	70	73	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				190	195		10.1067/mai.2000.107599	http://dx.doi.org/10.1067/mai.2000.107599			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887324				2022-12-18	WOS:000088393300026
J	Bellinghausen, I; Brand, U; Knop, J; Saloga, J				Bellinghausen, I; Brand, U; Knop, J; Saloga, J			Comparison of allergen-stimulated dendritic cells from atopic and nonatopic donors dissecting their effect on autologous naive and memory T helper cells of such donors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)2 cytokines atopy	EFFICIENT PRESENTATION; IN-VIVO; INTERLEUKIN-12; ANTIGEN; BLOOD; DIFFERENTIATION; LYMPHOCYTES; PROGENITORS; GENERATION; ACTIVATION	Background: Because of their production of IL-12, mature dendritic cells (DC) are potent inducers of T(H)1 responses, However recent reports have demonstrated that DCs can also induce T(H)2 differentiation. Objective: In the current study we investigated which immune response is induced by DCs in naive CD45RA(+) or memory CD45R0(+) CD4(+) T cells from atopic individuals (patients with grass pollen, birch pollen, or house dust mite allergy) compared with nonatopic control subjects. Methods: Immature DCs, generated from peripheral blood monocytes from atopic and nonatopic donors, were pulsed with the respective allergen and fully matured. Then the mature DCs were cocultured in vitro with autologous naive (CD45RA(+)) and memory (CD45R0(+)) CD4(+) T cells and cytokine and IgE production were measured by ELISA. Results: After the second restimulation with allergen-pulsed DCs, naive as well as memory autologous CD4(+) T cells from atopic but not from nonatopic donors showed an enhanced production of the T(H)2-type cytokines IL-4, IL-5, and IL-10, resulting in an increased IgE production, whereas IFN-gamma production and proliferation were not different. IL-12 production and surface marker expression of DCs derived from atopic and nonatopic donors did not differ and addition of neutralizing anti-IL-12 mAbs did not increase IL-4 but diminished IFN-gamma production. Conclusion: These data indicate that mature DCs are able to induce naive and activate allergen-specific T helper cells to produce T(H)2 cytokines if the T cells are derived from atopic donors. This phenomenon is not due to diminished IL-12 production by DCs of atopic donors.	Univ Mainz, Dept Dermatol, Mainz, Germany	Johannes Gutenberg University of Mainz	Bellinghausen, I (corresponding author), Univ Mainz, Hautklin, Langenbeckstr 1, D-55131 Mainz, Germany.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; COOKSON WOCM, 1992, LANCET, V340, P1110; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; de la Salle H, 1997, Int Rev Immunol, V16, P187, DOI 10.3109/08830189709045708; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; INABA K, 1990, J EXP MED, V172, P1275; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kalinski P, 1998, J IMMUNOL, V161, P2804; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; LEVIN D, 1993, J IMMUNOL, V151, P6742; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Roth R, 1996, SCAND J IMMUNOL, V43, P646, DOI 10.1046/j.1365-3083.1996.d01-270.x; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 1999, SCAND J IMMUNOL, V49, P96; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; van den Heuvel MM, 1998, J ALLERGY CLIN IMMUN, V101, P90, DOI 10.1016/S0091-6749(98)70198-8	29	70	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					988	996		10.1067/mai.2000.105526	http://dx.doi.org/10.1067/mai.2000.105526			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808181				2022-12-18	WOS:000087185000019
J	Saarinen, KM; Vaarala, O; Klemetti, P; Savilahti, E				Saarinen, KM; Vaarala, O; Klemetti, P; Savilahti, E			Transforming growth factor-beta 1 in mothers' colostrum and immune responses to cows' milk proteins in infants with cows' milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						colostrum; cytokines; transforming growth factor-beta 1; cows' milk allergy; alpha-casein; beta-lactoglobulin	NEWLY-DIAGNOSED IDDM; TGF-BETA; ANTIBODY-PRODUCTION; T-CELLS; LACTOGLOBULIN; ACTIVATION; MECHANISMS; SYSTEM	Background: Breast milk contains immune factors that compensate for the underdeveloped defenses of the gut of the newborn infant. Objective: Ne sought to study the importance of these factors in the immune responses of infants with cows' milk allergy (CMA) to the proteins in cows' milk (CM). Methods: We prospectively followed the development of CMA in 6209 healthy infants and collected samples of colostrum from mothers. Samples from mothers of infants with CMA and from control subjects were analyzed for immunoglobulins, CM-specific antibodies, and cytokines. In infants with CMA,: correlations between the concentration of transforming growth factor (TGF)-beta 1 in colostrum and the extent of the immune response to Chi proteins were studied. Results: The concentration of TGF-beta 1 in colostrum samples from mothers of infants with IgE-mediated CMA (n = 65) was lower (mean, 589 pg/mL; 95% confidence interval [CI], 413-840) than from mothers of infants with non-IgE-mediated CMA (n = 37; mean, 1162 pg/mL; 95% CI, 881-1531; t = 2.57, P = .012). In 126 control subjects the mean concentration was 807 pg/mL (95% CI, 677-963), In the infants with CMA (n = 96-100), the concentration of TGF-beta 1 in colostrum was positively correlated with IgA antibodies to beta-lactoglobulin and IgG antibodies to alpha-casein and whole formula and negatively with the diameter of a skin prick test response to CM and lymphocyte stimulation indices to alpha-casein and beta-lactoglobulin. Conclusions: In an infant prone to having CR-LA, the TGF-beta 1 content of mother's colostrum may promote IgG-IgA antibody production and inhibit IgE- and cell-mediated reactions to CM.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki HYKS, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Savilahti, E (corresponding author), Univ Helsinki, Hosp Children & Adolescents, Stenbackinkatu 11, FIN-00029 Helsinki HYKS, Finland.							AHUJA SS, 1993, J IMMUNOL, V150, P3109; [Anonymous], 1989, ALLERGY S10, V10, P1; BUESCHER ES, 1994, CLIN PERINATOL, V21, P247, DOI 10.1016/S0095-5108(18)30344-0; EGLINTON BA, 1994, IMMUNOL CELL BIOL, V72, P306, DOI 10.1038/icb.1994.46; EHRHARDT RO, 1992, J IMMUNOL, V148, P3830; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008; HOST A, 1995, EUR J CLIN NUTR, V49, pS13; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; ISHIZAKA S, 1994, CELL IMMUNOL, V159, P77, DOI 10.1006/cimm.1994.1296; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; ROSEN JP, 1994, J ALLERGY CLIN IMMUN, V93, P1068, DOI 10.1016/S0091-6749(94)70056-7; SAARINEN KM, 1999, IN PRESS J ALLERGY G; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; SAVILAHTI E, 1993, DIABETES CARE, V16, P984, DOI 10.2337/diacare.16.7.984; SAVILAHTI E, 1991, ACTA PAEDIATR SCAND, V80, P1207, DOI 10.1111/j.1651-2227.1991.tb11810.x; SKANSENSAPHIR U, 1993, PEDIATR RES, V34, P213, DOI 10.1203/00006450-199308000-00023; Srivastava MD, 1996, RES COMMUN MOL PATH, V93, P263; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Zeiger RS, 1997, J ROY SOC MED, V90, P21, DOI 10.1177/0141076897090030S05; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	27	70	72	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1093	1098		10.1016/S0091-6749(99)70094-1	http://dx.doi.org/10.1016/S0091-6749(99)70094-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550758				2022-12-18	WOS:000083778400037
J	Hemmann, S; Menz, G; Ismail, C; Blaser, K; Crameri, R				Hemmann, S; Menz, G; Ismail, C; Blaser, K; Crameri, R			Skin test reactivity to 2 recombinant Aspergillus fumigatus allergens in A fumigatus-sensitized asthmatic subjects allows diagnostic separation of allergic bronchopulmonary aspergillosis from fungal sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin test; Aspergillus fumigatus; IgE antibodies; allergy; allergic bronchopulmonary aspergillosis; recombinant allergens; Immuno-CAP	CYSTIC-FIBROSIS; MAJOR ALLERGEN; IGE; SYSTEM; BINDING; DISPLAY; CLONING; I/A	Background: Aspergillus fumigatus, an opportunistic pathogen, is associated with an impressive list of pulmonary complications. Among these, allergic bronchopulmonary aspergillosis (ABPA) represents a complex clinical syndrome that is difficult to diagnose. A clear distinction between allergic sensitization to A fumigatus and ABPA is essential for therapy to prevent deterioration of pulmonary function in subjects with ABPA, Objective: This study was carried out to determine the specificity and sensitivity of 2 A fumigatus allergens for the in vivo diagnosis of ABPA, Methods: Serologic investigations with recombinant A fumigatus allergens indicated the existence of disease-specific allergens that are useful for discrimination between ABPA and fungal sensitization. However, serologic studies fail to indicate the allergen-specific IgE levels required to elicit an allergic reaction in vivo. Results: We show that the recombinant A fumigatus allergens rAsp f 4, a protein with unknown biologic function, and rAsp f 6 (manganese superoxide dismutase) are able to provoke immediate skin reactions exclusively in patients with ABPA. The reactions, which are elicited by a few nonograms of the allergens, strictly depend on the presence of allergen-specific serum IgE. The IgE cut-off values for positive skin reactions to rAsp f 4 and rAsp f 6 of 0.9 and 1.2 kU(A)/L correspond to allergen-specific serum concentrations of 2 to 3 mu g/L and allow a sensitive, highly specific diagnosis of ABPA. Conclusions: In contrast to fungal extracts, rAsp f 4 and rAsp f 6 allow discrimination between ABPA and sensitization to A fumigatus. Moreover, the allergens are suitable for an automated serologic diagnosis of ABPA, facilitating their introduction in clinical practice.	Swiss Inst Allergy & Asthma Res, SIAF, CH-7270 Davos, Switzerland; Hochgebirgsklin Davos Wokfgang, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Crameri, R (corresponding author), Swiss Inst Allergy & Asthma Res, SIAF, Obere Str 22, CH-7270 Davos, Switzerland.							[Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; AXEN R, 1988, P CLIN WORKSH IGE AN; Banerjee B, 1997, J ALLERGY CLIN IMMUN, V99, P821, DOI 10.1016/S0091-6749(97)80017-6; BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; BORGA A, 1990, ALLERGENS ASPERGILLU; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41, DOI 10.1159/000237308; Crameri R, 1996, CLIN EXP ALLERGY, V26, P1411, DOI 10.1111/j.1365-2222.1996.tb00543.x; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V81, P646, DOI 10.1016/0091-6749(88)91034-2; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1155::AID-IMMU1155&gt;3.0.CO;2-6; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Hemmann S, 1998, CLIN EXP ALLERGY, V28, P860, DOI 10.1046/j.1365-2222.1998.00329.x; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; Mayer C, 1997, INT ARCH ALLERGY IMM, V113, P213, DOI 10.1159/000237550; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; Nikolaizik WH, 1996, INT ARCH ALLERGY IMM, V111, P403, DOI 10.1159/000237399; RIECHSON RB, 1988, POSTGRAD MED, V88, P217; Slavin RG, 1996, PEDIATR PULM, V21, P1, DOI 10.1002/1099-0496(199601)21:1<1::AID-PPUL1950210102>3.0.CO;2-K; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VIJAY HM, 1978, INT ARCH ALLER A IMM, V56, P517, DOI 10.1159/000232067	26	70	73	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				601	607		10.1016/S0091-6749(99)70330-1	http://dx.doi.org/10.1016/S0091-6749(99)70330-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482834				2022-12-18	WOS:000082870000022
J	Metz, DP; Bacon, AS; Holgate, S; Lightman, SL				Metz, DP; Bacon, AS; Holgate, S; Lightman, SL			Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; eye; conjunctiva; immunology; T cells; immunohistochemistry	GIANT PAPILLARY CONJUNCTIVITIS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; VERNAL CONJUNCTIVITIS; FUNCTIONAL SUBSETS; ATOPIC-DERMATITIS; LYMPHOCYTES-T; HUMAN CD4+; IL-4; EOSINOPHILS	Background: Chronic allergic conjunctivitis comprises a spectrum of diseases including atopic keratoconjunctivitis, atopic blepharoconjunctivitis. Each condition is characterized by a complex immunopathology with a mixed cellular infiltrate. Treatment with conventional mast cell stabilizers is often unsatisfactory, and therapy depends heavily on topical corticosteroids. Objective: Recent evidence suggests that T lymphocytes play an important role in mediating the immunopathology seen in the chronic allergic response in the skin and the lungs. Methods: We have therefore investigated the prevalence of T cells and their subsets in the different chronic allergic conditions by means of immunohistochemistry. Results: We found significantly increased numbers of CD4(+), CD45RO, and HLA-DR(+) T cells in the conjunctiva of patients with atopic and vernal keratoconjuctivitis and giant papillary conjunctivitis, with a corresponding upregulation of markers present on antigen presenting cells. Conclusions: These findings suggest that like allergic conditions in the skin and lungs, CD4(+) memory T cells are involved in the regulation of the immunopathology of chronic allergic eye responses. Further characterization of these T cells will provide the information necessary for future immunotherapeutic interventions.	MOORFIELDS EYE HOSP,LONDON EC1V 2EL,ENGLAND; YALE UNIV,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; INST OPHTHALMOL,LONDON,ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Yale University; University of Southampton; University of London; University College London								ABELSON MB, 1983, CORNEA, P307; ALLANSMITH MR, 1979, AM J OPHTHALMOL, V87, P544, DOI 10.1016/0002-9394(79)90247-2; BACON AS, 1993, EYE, V7, P21; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BUCKLEY RJ, 1987, CLIN THER, V9, P451; BUCKLEY RJ, 1987, INT OPHTHALMOLOGY CL, P303; CHAMBERS CA, 1992, CLIN EXP IMMUNOL, V88, P149; COILIN HB, 1977, INVEST OPHTH VIS SCI, V16, P858; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DART JKG, 1986, T OPHTHAL SOC UK, V105, P513; DURHAM SR, 1992, J IMMUNOL, V148, P2390; ELASRAR AMA, 1989, GRAEFES ARCH CLIN EX, V227, P374; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; JAY JL, 1981, BRIT J OPHTHALMOL, V65, P335, DOI 10.1136/bjo.65.5.335; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LUQMAN M, 1991, EUR J IMMUNOL, V21, P17, DOI 10.1002/eji.1830210104; MADDOX PH, 1987, J CLIN PATHOL, V40, P1256, DOI 10.1136/jcp.40.10.1256; MAGGI E, 1991, J IMMUNOL, V146, P1169; PALIARD X, 1988, J IMMUNOL, V141, P849; ROBINSON DS, 1993, CLIN EXP ALLERGY, V23, P1, DOI 10.1111/j.1365-2222.1993.tb02475.x; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SELBY WS, 1981, GUT, V22, P169, DOI 10.1136/gut.22.3.169; SMOLIN G, 1983, CORNEA, P99; TUFF SJ, 1991, OPHTHALMOLOGY, V98, P150; UDELL IJ, 1987, INT OPHTHALMOLOGY CL, P275; VOLLENWEIDER S, 1991, J ALLERGY CLIN IMMUN, V87, P1088, DOI 10.1016/0091-6749(91)92154-S; WALDORF HA, 1991, AM J PATHOL, V138, P477; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	36	70	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					686	696		10.1016/S0091-6749(96)70103-3	http://dx.doi.org/10.1016/S0091-6749(96)70103-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828547				2022-12-18	WOS:A1996VJ42800026
J	Kuna, P; Lazarovich, M; Kaplan, AP				Kuna, P; Lazarovich, M; Kaplan, AP			Chemokines in seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte chemotactic protein-1; IL-8; RANTES; rhinitis; histamine releasing factor; chemokines	HISTAMINE-RELEASING-FACTOR; ACTIVATING PEPTIDE-III; HUMAN BASOPHILS; CYTOKINE RANTES; MAST-CELLS; HUMAN EOSINOPHILS; MEDIATOR RELEASE; NASAL WASHINGS; MONOCYTE; CHALLENGE	Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1), RANTES, and macrophage inflammatory protein (MIP)-1 alpha are chemokines known to activate basophils (MCAF/RANTES) and eosinophils (RANTES/MIP-1 alpha). IL-8 inhibits MCAF-induced histamine release from basophils. We questioned whether a relationship exists between the levels of these chemokines and various inflammatory mediators released from mast cells, eosinophils, and basophils as assessed in nasal secretions obtained from patients during the allergy season and out of season. Samples were assessed Sor MCAF/MCP-1, RANTES, MIP-1 alpha, IL-8, histamine, tryptase and eosinophil cationic protein (ECP) in three subject groups: subjects with allergic rhinitis (n = 18), atopic subjects without rhinitis (n = 9), and healthy individuals (n = 6). Statistically significant differences were apparent only in the subjects with symptoms as follows. MCAF/MCP-1 increased during the season from 336 +/- 47 pg/ml to 829 +/- 137 pg/ml (p < 0.001), whereas IL-8 decreased from a baseline of 1932 +/- 335 pg/ml to 1070 +/- 202 pg/ml (p < 0.028). The ratio of IL-8 to MCAF/MCP-1 decreased during the symptomatic season from the baseline of 6.66 +/- 1.06 seen during winter to 1.3 +/- 0.22 during ragweed season (p < 0.001). Histamine increased from 6.3 +/- 1.5 to 89 +/- 15.5 ng/ml (p < 0.001), ECP increased from 20.6 +/- 6.4 to 237.1 +/- 50.2 ng/ml (p < 0.001), and tryptase increased from 2.34 +/- 0.6 to 9.7 +/- 2.3 U/ml (p < 0.001). Most samples did not have detectable quantities of MIP-1 alpha or RANTES. We also found a correlation between the level of MCAF/MCP-1 and IL-8 and the level of histamine or IL-8 and ECP. Our results suggest that the chemokines MCAF/MCP-1 and IL-8 may participate in the pathogenesis of allergic rhinitis, contributing to the attraction of the proinflammatory cells and mediator release, which might be very important during the late phase of the allergic reaction. Furthermore, the ratio of certain chemokines, such as MCAF/MCP-1 and IL-8 may reflect the magnitude of the reaction, as does the presence of histamine and ECP.	SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Lazarovich, Mark/0000-0002-9338-9355; Kuna, Piotr/0000-0003-2401-0070				ALAM R, 1994, J IMMUNOL, V153, P3155; ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALAM R, 1992, AM J RESP CELL MOL, V7, P427, DOI 10.1165/ajrcmb/7.4.427; ALAM R, 1993, J IMMUNOL, V150, P3442; ANTONY VB, 1993, J IMMUNOL, V151, P7216; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P87, DOI 10.1016/S0091-6749(05)80044-2; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAPLAN AP, 1994, ALLERGY, V49, P495, DOI 10.1111/j.1398-9995.1994.tb01119.x; KIMMITT P, 1995, J ALLERGY CLIN IMMUN, V95, P222; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; KUNA P, 1991, J IMMUNOL, V147, P1920; KUNA P, 1995, J ALLERGY CLIN IMMUN, V95, P574, DOI 10.1016/S0091-6749(95)70320-9; LEONARD EJ, 1991, ADV EXP MED BIOL, V305, P57; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LINDER A, 1988, ALLERGY, V43, P119, DOI 10.1111/j.1398-9995.1988.tb00405.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1990, J ALLERGY CLIN IMMUN, V86, P628, DOI 10.1016/S0091-6749(05)80227-1; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; REDDIGARI SR, 1992, J ALLERGY CLIN IMMUN, V89, P666, DOI 10.1016/0091-6749(92)90372-9; RESHEF A, 1989, J ALLERGY CLIN IMMUN, V84, P678, DOI 10.1016/0091-6749(89)90296-0; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; SIM TC, 1992, AM REV RESPIR DIS, V145, P1316, DOI 10.1164/ajrccm/145.6.1316; SIM TC, 1992, J ALLERGY CLIN IMMUN, V89, P1157, DOI 10.1016/0091-6749(92)90300-Q; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	42	70	71	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				104	112		10.1016/S0091-6749(96)70288-9	http://dx.doi.org/10.1016/S0091-6749(96)70288-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568122	Bronze			2022-12-18	WOS:A1996TR94700013
J	PETERSEN, LJ; POULSEN, LK; SONDERGAARD, J; SKOV, PS				PETERSEN, LJ; POULSEN, LK; SONDERGAARD, J; SKOV, PS			THE USE OF CUTANEOUS MICRODIALYSIS TO MEASURE SUBSTANCE-P-INDUCED HISTAMINE-RELEASE IN INTACT HUMAN SKIN IN-VIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SUBSTANCE P; HISTAMINE RELEASE; MICRODIALYSIS; SKIN; MAST CELL	INVIVO MEDIATOR RELEASE; MAST-CELLS; WATER SPACE; RESPONSES; INFLAMMATION; INVOLVEMENT; URTICARIA; FLARE	Background: The purpose of this study was to introduce a microdialysis technique: which makes it possible to measure the release of small inflammatory mediators into the extracellular water space in intact human skin in vivo. Using this technique, we have studied the histamine releasing properties of substance P, a putative skin mast cell releasing agent. Methods: Small hollow fibers were inserted into the upper dermis of nine healthy subjects. Each fiber was perfused with Kreb's Ringer bicarbonate buffer at a rate of 3.0 mu l/min. After establishment of a baseline, each fiber was challenged intracutaneously with substance P (0 to 4 mu mol/L). Samples were collected at 2-minute intervals for 18 minutes. Histamine was measured by a fluorometric method, which correlated with an enzyme immunoassay (r = 0.96). Results: Baseline dialysate histamine concentration was 1.7 +/- 0.3 ng/ml. Peak histamine release after injection of vehicle, 0.5, 1, 2 and 4 mu mol/L substance P was 0.0, 1.0, 6.0, 44.5, and 88.5 ng/ml, respectively (p = 0.00002). Statistically significant histamine release was demonstrated with 1.0 mu mol/L substance P and greater. Most peak values were seen 2 to 4 minutes after injection. The histamine elimination showed a monoexponential decline; dialysate histamine half-life was 3.81 +/- 0.28 minutes. Conclusions: This study showed chat substance P releases histamine in a dose-dependent manner from intact human skin in normal subjects. We suggest that microdialysis may be a promising technique for the evaluation of mediator levels in intact human skin after intradermal injection of an inflammatory or allergenic stimulus.	NATL UNIV HOSP,MED ALLERGOL LAB,COPENHAGEN,DENMARK; REFERENCE LAB,COPENHAGEN,DENMARK		PETERSEN, LJ (corresponding author), UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT DERMATOL,BISPEBJERG BAKKE 23,DK-2400 COPENHAGEN NV,DENMARK.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X				ANDERSON C, 1992, SKIN PHARMACOL, V5, P177, DOI 10.1159/000211035; ANDERSON C, 1991, ACTA DERM-VENEREOL, V71, P389; ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; [Anonymous], 1991, MICRODIALYSIS NEUROS; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BARNES PJ, 1986, BRIT J PHARMACOL, V88, P741, DOI 10.1111/j.1476-5381.1986.tb16246.x; BENNUN J, 1988, ARCH OPHTHALMOL-CHIC, V106, P254, DOI 10.1001/archopht.1988.01060130268041; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BENYON RC, 1987, J IMMUNOL, V138, P861; CAULFIELD JP, 1990, LAB INVEST, V63, P502; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; EBERTZ JM, 1987, J INVEST DERMATOL, V88, P682, DOI 10.1111/1523-1747.ep12470339; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092; HARTSCHUH W, 1983, BRIT J DERMATOL, V109, P14; HEAVEY DJ, 1984, BRIT J CLIN PHARMACO, V18, P915, DOI 10.1111/j.1365-2125.1984.tb02564.x; Juhlin L, 1990, Adv Dermatol, V5, P75; LEHMAN A, 1988, J NEUROCHEM, V51, P525; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228, DOI 10.1152/ajpendo.1987.253.2.E228; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; MCBRIDE P, 1989, J ALLERGY CLIN IMMUN, V83, P374, DOI 10.1016/0091-6749(89)90121-8; PETERSEN LJ, 1992, ALLERGY, V47, P635, DOI 10.1111/j.1398-9995.1992.tb02387.x; PETERSEN LJ, 1992, J INVEST DERMATOL, V99, P357, DOI 10.1111/1523-1747.ep12616676; SCOTT DO, 1990, J CHROMATOGR, V506, P461, DOI 10.1016/S0021-9673(01)91600-0; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; WALLENGREN J, 1987, EUR J PHARMACOL, V143, P267, DOI 10.1016/0014-2999(87)90542-5	31	70	70	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					773	783		10.1016/0091-6749(94)90186-4	http://dx.doi.org/10.1016/0091-6749(94)90186-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7523474				2022-12-18	WOS:A1994PM27300017
J	DYER, PD; VAUGHAN, TR; WEBER, RW				DYER, PD; VAUGHAN, TR; WEBER, RW			METHOTREXATE IN THE TREATMENT OF STEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						METHOTREXATE; CORTICOSTEROID; PREDNISONE; STEROID-DEPENDENT ASTHMA	LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; TRIAL	A double-blind, placebo-controlled, crossover study was designed to compare steroid requirements between placebo and methotrexate (MTX) treatment in subjects with corticosteroid-requiring asthma. Subjects began with a steroid taper and then were randomized to a 3-month trial of drug or placebo therapy. Subjects received 15 mg of MTX a week or identical placebo. A 1-month washout period was completed before the crossover trial. Symptom scores, peak flow rates, spirometry, and beta-agonist frequency were closely monitored. Ten subjects completed the study. The average dose of prednisone during the placebo-treatment period was 11.97 mg/day compared to 8.37 mg/day while subjects were taking MTX. This was a 30% reduction in daily steroid requirement (p < 0.01). Symptom scores and spirometry did not differ between the crossover trials, and overall clinical status was not altered. Complications from MTX were mild and included anorexia, alopecia, and stomatitis. All complications resolved with dose reduction or when MTX was stopped at the end of the study. No subjects withdrew from the study because of MTX complications. Low-dose MTX significantly reduced the steroid requirement in this group of subjects with steroid-dependent asthma. This reduction in steroid requirement was obtained without altering clinical status and without significant complication.	FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									COTT GR, 1988, NEW ENGL J MED, V318, P634, DOI 10.1056/NEJM198803103181010; HU SK, 1988, J RHEUMATOL, V15, P206; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; KORAREK RA, 1989, ANN INTERN MED, V110, P353; KREMER JM, 1988, ARTHRITIS RHEUM-US, V31, P577, DOI 10.1002/art.1780310501; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MULLARKEY MF, 1986, ANN ALLERGY, V56, P347; NOLTE H, 1988, AGENTS ACTIONS, V23, P173, DOI 10.1007/BF02142532; ROENIGK HH, 1982, J AM ACAD DERMATOL, V6, P145, DOI 10.1016/S0190-9622(82)80064-9; STCLAIR EW, 1985, ARCH INTERN MED, V145, P2035, DOI 10.1001/archinte.145.11.2035; SUAREZ CR, 1987, J RHEUMATOL, V14, P9; SUAREZALMAZOR ME, 1988, J RHEUMATOL, V15, P753; TERNOWITZ T, 1987, J INVEST DERMATOL, V89, P192, DOI 10.1111/1523-1747.ep12470559; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; VANDEKERKHOF PCM, 1985, BRIT J DERMATOL, V113, P251; WEINBLATT ME, 1988, ARTHRITIS RHEUM, V31, P167, DOI 10.1002/art.1780310203	16	70	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					208	212		10.1016/0091-6749(91)90330-Q	http://dx.doi.org/10.1016/0091-6749(91)90330-Q			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880321				2022-12-18	WOS:A1991GB22500009
J	JUNIPER, EF; GUYATT, GH; OBYRNE, PM; VIVEIROS, M				JUNIPER, EF; GUYATT, GH; OBYRNE, PM; VIVEIROS, M			AQUEOUS BECLOMETHASONE DIPROPRIONATE NASAL SPRAY - REGULAR VERSUS AS REQUIRED USE IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University	JUNIPER, EF (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.		Viveiros, Maria/P-4120-2015	O'Byrne, Paul/0000-0003-0979-281X				BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; DUNN AM, 1984, POSTGRAD MED J, V60, P404, DOI 10.1136/pgmj.60.704.404; GIRARD JP, 1978, ALLERGOL IMMUNOPATH, V6, P517; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; GUYATT GH, 1987, J CHRON DIS, V40, P1129, DOI 10.1016/0021-9681(87)90080-4; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HOLOPAINEN E, 1977, ACTA ALLERGOL, V32, P263, DOI 10.1111/j.1398-9995.1977.tb01358.x; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; JUNIPER EF, UNPUB CLIN ALLERGY; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; LEVINE MN, 1988, J CLIN ONCOL, V6, P1798, DOI 10.1200/JCO.1988.6.12.1798; NEUMAN I, 1978, ANN ALLERGY, V40, P346; VANZIELEGHEM MA, 1987, J ALLERGY CLIN IMMUN, V79, P887, DOI 10.1016/0091-6749(87)90237-5	19	70	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				380	386		10.1016/S0091-6749(05)80101-0	http://dx.doi.org/10.1016/S0091-6749(05)80101-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212409				2022-12-18	WOS:A1990EA85900012
J	SAMPSON, HA				SAMPSON, HA			PEANUT ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SAMPSON, HA (corresponding author), JOHNS HOPKINS UNIV HOSP,CMSC-1103,600 N WOLFE ST,BALTIMORE,MD 21205, USA.				NIAID NIH HHS [AI 244] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; Blackfan KD, 1920, AM J MED SCI, V160, P341; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, UNPUB J PEDIATR; BURKS AW, 1989, ALLERGY PROC, V10, P265, DOI 10.2500/108854189778960045; DUKE WW, 1925, ALLERGY ASTHMA HAY F, P187; FRIES JH, 1982, ANN ALLERGY, V48, P220; GERN J E, 1990, Journal of Allergy and Clinical Immunology, V85, P273; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; SAAVEDRADELGADO AM, 1989, ALLERGY PROC, V10, P291, DOI 10.2500/108854189778959957; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Walzer Matthew, 1942, JOUR ALLERGY, V13, P554, DOI 10.1016/S0021-8707(42)90068-6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	16	70	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					1	3		10.1016/S0091-6749(05)80115-0	http://dx.doi.org/10.1016/S0091-6749(05)80115-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2196300				2022-12-18	WOS:A1990DQ68800001
J	PHILLIPS, GD; FOORD, R; HOLGATE, ST				PHILLIPS, GD; FOORD, R; HOLGATE, ST			INHALED LYSINE-ASPIRIN AS A BRONCHOPROVOCATION PROCEDURE IN ASPIRIN-SENSITIVE ASTHMA - ITS REPEATABILITY, ABSENCE OF A LATE-PHASE REACTION, AND THE ROLE OF HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOUTHAMPTON GEN HOSP,DEPT IMMUNOPHARMACOL,LEVEL D,CTR BLOCK,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								ABRISHAMI MA, 1977, ANN ALLERGY, V39, P28; ALTMAN DG, 1986, LANCET, P307; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; BIANCO S, 1981, BRIT MED J, V282, P146, DOI 10.1136/bmj.282.6258.146-b; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1982, AM REV RESPIR DIS, V126, P849; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; DELANEY JC, 1976, CLIN ALLERGY, V6, P365, DOI 10.1111/j.1365-2222.1976.tb01917.x; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; DELANEY JC, 1983, CLIN ALLERGY, V13, P247, DOI 10.1111/j.1365-2222.1983.tb02595.x; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; GERSHWIN ME, 1985, J ALLERGY CLIN IMMUN, V75, P411, DOI 10.1016/0091-6749(85)90080-6; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; HOLLINGSWORTH HM, 1984, AM REV RESPIR DIS, V130, P373; HOVELL CJ, 1987, CLIN ALLERGY, V17, P469, DOI 10.1111/j.1365-2222.1987.tb02041.x; KOWALSKI ML, 1985, THORAX, V40, P598, DOI 10.1136/thx.40.8.598; LEWIS RA, 1984, DRUGS LUNG, P63; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MATHEWS KP, 1950, J LAB CLIN MED, V36, P416; OBRYNE PM, 1987, AM REV RESPIR DIS, V136, P740; PASARGIKLIAN M, 1977, RESPIRATION, V34, P79, DOI 10.1159/000193780; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHMITZSCHUMANN M, 1987, AGENTS ACTIONS, V21, P217; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SIMON R, 1983, J ALLERGY CLIN IMMUN, V71, P146, DOI 10.1016/0091-6749(83)90356-1; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; SZCZEKLIK A, 1983, DRUGS, V25, P533, DOI 10.2165/00003495-198325060-00001; TWENTYMAN O P, 1988, American Review of Respiratory Disease, V137, P135; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WASSERMAN SI, 1978, J ALLERGY CLIN IMMUN, V61, P139, DOI 10.1016/0091-6749(78)90276-2; WELTMAN JK, 1978, ALLERGY, V43, P273; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	46	70	74	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					232	241		10.1016/0091-6749(89)90330-8	http://dx.doi.org/10.1016/0091-6749(89)90330-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2503553				2022-12-18	WOS:A1989AL83600015
J	GEORGITIS, JW; REISMAN, RE				GEORGITIS, JW; REISMAN, RE			VENOM SKIN-TESTS IN INSECT-ALLERGIC AND INSECT-NONALLERGIC POPULATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14260; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PEDIAT,WINSTON SALEM,NC 27103	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wake Forest University; Wake Forest Baptist Medical Center					NIAID NIH HHS [2R01 AI 1450107] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARSELA S, 1983, J ALLERGY CLIN IMMUN, V72, P690, DOI 10.1016/0091-6749(83)90631-0; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; CLAYTON WF, 1983, J ALLERGY CLIN IMMUN, V71, P141, DOI 10.1016/0091-6749(83)90335-4; DIXON WJ, 1981, BMDP STATISTICAL SOF, P143; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1979, ANN ALLERGY, V43, P211; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; KING TP, 1978, BIOCHEMISTRY, V17, P5164; LANGLOIS C, 1965, J ALLERGY, V36, P12, DOI 10.1016/0021-8707(65)90028-6; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MERINEY D, 1980, INT ARCH ALLER A IMM, V62, P442, DOI 10.1159/000232547; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; RAMIREZ DA, 1981, ANN ALLERGY, V47, P303; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SCHULMAN S, 1964, J ALLERGY, V35, P446; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; Siegel S., 1956, NONPARAMETRIC STAT, P96; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V64, P1, DOI 10.1016/0091-6749(79)90073-3	24	70	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					803	807		10.1016/0091-6749(85)90752-3	http://dx.doi.org/10.1016/0091-6749(85)90752-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	3877747				2022-12-18	WOS:A1985AWX9300008
J	ROCKLIN, RE				ROCKLIN, RE			CLINICAL AND IMMUNOLOGICAL ASPECTS OF ALLERGEN-SPECIFIC IMMUNOTHERAPY IN PATIENTS WITH SEASONAL ALLERGIC RHINITIS AND OR ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ROCKLIN, RE (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, DEPT MED, DIV ALLERGY, BOSTON, MA 02111 USA.							AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; BROSTOFF J, 1969, LANCET, V2, P1269; CANONICA GW, 1979, J IMMUNOL, V123, P2669; CONNELL JT, 1970, J ALLERGY, V45, P115; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FORGACS P, 1968, BRIT MED J, V3, P774; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; FRANKLIN W, 1983, NEW ENGLAND REGIONAL; Freeman J, 1930, LANCET, V1, P744; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GECZY AF, 1978, J ALLERGY CLIN IMMUN, V62, P261, DOI 10.1016/0091-6749(78)90156-2; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLIECH GJ, 1975, CLIN ALLERGY, V1, P79; GREENBERGER P, 1978, ANN INTERN MED, V89, P234, DOI 10.7326/0003-4819-89-2-234; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; JOHANSSO.SG, 1974, CLIN ALLERGY, V4, P57, DOI 10.1111/j.1365-2222.1974.tb01363.x; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; KATZ DH, 1980, IMMUNOLOGY, V41, P1; KISHIMOTO T, 1976, J IMMUNOL, V117, P396; KOEHLER PB, 1968, J ALLERGY, V41, P237, DOI 10.1016/0021-8707(68)90049-X; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MATLOFF SM, 1983, J ALLERGY CLIN IMMUN, V72, P359, DOI 10.1016/0091-6749(83)90500-6; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MELAM HL, 1972, ALLERGIC DISEASES DI, P324; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; NEIBURGER RG, 1978, J ALLERGY CLIN IMMUN, V61, P88, DOI 10.1016/0091-6749(78)90230-0; NORMAN PS, 1979, J ALLERGY CLIN IMMUN, V63, P167; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V71, P91, DOI 10.1016/0091-6749(83)90134-3; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1973, J IMMUNOL, V110, P1412; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; REISMAN RE, 1965, INT ARCH ALLER A IMM, V28, P353, DOI 10.1159/000229681; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V67, P333, DOI 10.1016/0091-6749(81)90076-2; RICHTER M, 1968, J ALLERGY, V41, P140, DOI 10.1016/0021-8707(68)90054-3; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; ROMAGNANI S, 1975, CLIN EXP IMMUNOL, V19, P83; SAGAN N, 1969, NEW ENGL J MED, V280, P623; SEHON AH, 1979, J ALLERGY CLIN IMMUN, V64, P242, DOI 10.1016/0091-6749(79)90139-8; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SPIEGELMAN J, 1967, ANN ALLERGY, V25, P262; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; TAKATSU K, 1975, CELL IMMUNOL, V20, P276, DOI 10.1016/0008-8749(75)90105-7; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAKATSU K, 1975, J IMMUNOL, V115, P1469; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90381-0; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4; ZEISS CR, 1973, J IMMUNOL, V110, P414	70	70	70	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					323	334		10.1016/0091-6749(83)90492-X	http://dx.doi.org/10.1016/0091-6749(83)90492-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6194195	Bronze			2022-12-18	WOS:A1983RN33000001
J	SULLIVAN, TJ				SULLIVAN, TJ			PHARMACOLOGIC MODULATION OF THE WHEALING RESPONSE TO HISTAMINE IN HUMAN-SKIN - IDENTIFICATION OF DOXEPIN AS A POTENT INVIVO INHIBITOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas	SULLIVAN, TJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SECT,DALLAS,TX 75235, USA.				NIAID NIH HHS [K07-AI00414-04] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIN WA, 1949, P ROY SOC MED, V42, P615; BAIN WA, 1951, ANALYST, V76, P573, DOI 10.1039/an9517600573; BEAVEN MA, 1979, MONOGR ALLERGY, V13, P1; Bovet D, 1937, CR SOC BIOL, V124, P547; EPPINGER H, 1913, WIEN MED WCHNSCHR, V43, P1414; FAHEY JL, 1965, J IMMUNOL, V94, P84; FOWLE ASE, 1971, EUR J CLIN PHARMACOL, V3, P215, DOI 10.1007/BF00565009; FRIEDEL RO, 1975, SINEQUAN MONOGRAPH R, P51; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GREEN JP, 1977, NATURE, V269, P163, DOI 10.1038/269163a0; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; Kuhn R, 1970, DISCOVERIES BIOL PSY, P205; LEE RE, 1977, ANN ALLERGY, V38, P231; LEWIS T, 1927, BLOOD VESSELS HUMAN, P1; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; NORMAN PS, 1976, MANUAL CLIN IMMUNOLO, P585; OBRIEN PC, 1981, MAYO CLIN PROC, V56, P452; RICHELSON E, 1979, MAYO CLIN PROC, V54, P669; THOMAS L, 1924, HEART, V11, P109; TOZZI S, 1974, AGENTS ACTIONS, V4, P264, DOI 10.1007/BF01965229; UPRICHARD DC, 1978, SCIENCE, V199, P197, DOI 10.1126/science.202024; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924; ZAR JH, 1974, BIOSTAT ANAL, P230; ZIEGLER VE, 1977, ARCH GEN PSYCHIAT, V34, P607	27	70	70	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					260	267		10.1016/S0091-6749(82)80002-X	http://dx.doi.org/10.1016/S0091-6749(82)80002-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	6120966				2022-12-18	WOS:A1982NF69700002
J	COHEN, SH; KOETHE, SM; KOZIN, F; RODEY, G; ARKINS, JA; FINK, JN				COHEN, SH; KOETHE, SM; KOZIN, F; RODEY, G; ARKINS, JA; FINK, JN			ACQUIRED ANGIOEDEMA ASSOCIATED WITH RECTAL CARCINOMA AND ITS RESPONSE TO DANAZOL THERAPY - ACQUIRED ANGIOEDEMA TREATED WITH DANAZOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT MED,RHEUMATOL SECT,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53233	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	COHEN, SH (corresponding author), MILWAUKEE CTY MED COMPLEX,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							ALLISON AC, 1971, METHODS IMMUNOLOGY I, P217; BORSOS T, 1964, J IMMUNOL, V92, P108; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; COHEN SH, 1978, ANN INTERN MED, V88, P429, DOI 10.7326/0003-4819-88-3-429_1; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GIGLI I, 1968, J IMMUNOL, V100, P1154; HAUPTMANN G, 1977, ANN INTERN MED, V87, P577, DOI 10.7326/0003-4819-87-5-577; JORDON RE, 1974, CLIN EXP IMMUNOL, V18, P407; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, P149; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; Osler W, 1888, AM J MED SCI, V95, P362; PENCE HL, 1974, J ALLERGY CLIN IMMUN, V53, P298, DOI 10.1016/0091-6749(74)90109-2; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSSE WF, 1976, CLIN RES, V24, pA482; SCHREIBER AD, 1976, BLOOD, V48, P567; SCHULMAN NR, 1958, J EXP MED, V107, P665; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739	24	70	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					217	221		10.1016/0091-6749(78)90210-5	http://dx.doi.org/10.1016/0091-6749(78)90210-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701655				2022-12-18	WOS:A1978FS39200004
J	HOFFMAN, DR; SHIPMAN, WH				HOFFMAN, DR; SHIPMAN, WH			ALLERGENS IN BEE VENOM .1. SEPARATION AND IDENTIFICATION OF MAJOR ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,CTR UNDERSEA,SAN DIEGO,CA 92132; CREIGHTON UNIV,SCH MED,DEPT PATHOL,OMAHA,NB 68178	United States Department of Defense; United States Navy; Creighton University								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P529; BARR SE, 1974, JAMA-J AM MED ASSOC, V228, P718; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P73; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1974, PEDIATRICS, V54, P151; ILEA V, 1975, J ALLERGY CLIN IMMUN, V55, P74; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MAGEE WL, 1960, BIOCHEM J, V77, P526, DOI 10.1042/bj0770526; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MUELLER HL, 1975, PEDIATRICS, V55, P530; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V55, P79; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPMAN WH, 1969, ANAL BIOCHEM, V29, P490, DOI 10.1016/0003-2697(69)90333-9; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P103; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SOBOTKA AK, 1975, J ALLERGY CLIN IMMUN, V55, P73; TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74; TORSNEY PJ, 1973, J ALLERGY CLIN IMMUN, V52, P303, DOI 10.1016/0091-6749(73)90049-3; VICK JA, 1974, TOXICON, V12, P139, DOI 10.1016/0041-0101(74)90237-2	24	70	72	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					551	562		10.1016/0091-6749(76)90201-3	http://dx.doi.org/10.1016/0091-6749(76)90201-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	977862	Bronze			2022-12-18	WOS:A1976CL08800003
J	MAY, CD				MAY, CD			HIGH SPONTANEOUS RELEASE OF HISTAMINE INVITRO FROM LEUKOCYTES OF PERSONS HYPERSENSITIVE TO FOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80220	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAY C D, 1976, Journal of Allergy and Clinical Immunology, V57, P240; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, TO BE PUBLISHED; Schumacher M J, 1972, Clin Allergy, V2, P345, DOI 10.1111/j.1365-2222.1972.tb01299.x	6	70	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					432	437		10.1016/0091-6749(76)90124-X	http://dx.doi.org/10.1016/0091-6749(76)90124-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	61221				2022-12-18	WOS:A1976CD45400010
J	FALLIERS, CJ				FALLIERS, CJ			ASPIRIN AND SUBTYPES OF ASTHMA - RISK FACTOR-ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY & ASTHMA CLIN,155 COOK ST,DENVER,CO 80206									CAPLIN I, 1971, ANN ALLERGY, V29, P631; FALCONER DS, 1967, ANN HUM GENET, V31, P1; FALLIERS CJ, 1970, ANN ALLERGY, V28, P513; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; IISALO EI, 1969, ACTA MED SCAND, V185, P45; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; LOCKEY RF, 1971, J ALLERGY, V47, P115; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MOESTEL CG, 1972, N ENG J MED, V268, P813; PEARSON RS, 1963, SALICYLATES; PHILLS JA, 1972, J ALLERGY CLIN IMMUN, V49, P97; RACKEMANN FM, 1944, J ALLERGY, V15, P249; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; TAINTER ML, 1969, ASPIRIN MODERN TERAP; VANE J R, 1972, Hospital Practice, V7, P61; VATANASUK M, 1971, J ALLERGY, V47, P109; 1971, AMA COUNCIL DRUGS AM, P177	19	70	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	3					141	147		10.1016/0091-6749(73)90030-4	http://dx.doi.org/10.1016/0091-6749(73)90030-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q7045	4725111				2022-12-18	WOS:A1973Q704500002
J	Theiler, A; Barnthaler, T; Platzer, W; Richtig, G; Peinhaupt, M; Rittchen, S; Kargl, J; Ulven, T; Marsh, LM; Marsche, G; Schuligoi, R; Sturm, EM; Heinemann, A				Theiler, Anna; Baernthaler, Thomas; Platzer, Wolfgang; Richtig, Georg; Peinhaupt, Miriam; Rittchen, Sonja; Kargl, Julia; Ulven, Trond; Marsh, Leigh M.; Marsche, Gunther; Schuligoi, Rufina; Sturm, Eva M.; Heinemann, Akos			Butyrate ameliorates allergic airway inflammation by limiting eosinophil trafficking and survival	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Short-chain fatty acid; butyrate; eosinophils; asthma; allergic airway inflammation; histone deacetylase	CHAIN FATTY-ACIDS; COLONY-STIMULATING FACTOR; CANCER CELL-LINE; GUT MICROBIOTA; FAS LIGATION; TNF-ALPHA; RECEPTOR; APOPTOSIS; EXPRESSION; IDENTIFICATION	Background: Lung eosinophilia is a hallmark of asthma, and eosinophils are believed to play a crucial role in the pathogenesis of allergic inflammatory diseases. Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are produced in high amounts in the gastrointestinal tract by commensal bacteria and can be absorbed into the bloodstream. Although there is recent evidence that SCFAs are beneficial in allergic asthma models, the effect on eosinophils has remained elusive. Objective: The role of SCFAs was investigated in human eosinophil function and a mouse model of allergic asthma. Methods: Eosinophils were purified from self-reported allergic or healthy donors. Migration, adhesion to the endothelium, and eosinophil survival were studied in vitro. Ca2+ flux, apoptosis, mitochondrial membrane potential, and expression of surface markers were determined by using flow cytometry and in part by using real-time PCR. Allergic airway inflammation was assessed in vivo in an ovalbumin-induced asthma model by using invasive spirometry. Results: For the first time, we observed that SCFAs were able to attenuate human eosinophils at several functional levels, including (1) adhesion to the endothelium, (2) migration, and (3) survival. These effects were independent from GPR41 and GPR43 but were accompanied by histone acetylation and mimicked by trichostatin A, a pan-histone deacetylase inhibitor. In vivo butyrate ameliorated allergen-induced airway and lung eosinophilia, reduced type 2 cytokine levels in bronchial fluid, and improved airway hyperresponsiveness in mice. Conclusion: These in vitro and in vivo findings highlight the importance of SCFAs, especially butyrate as a promising therapeutic agent in allergic inflammatory diseases.	[Theiler, Anna; Baernthaler, Thomas; Platzer, Wolfgang; Richtig, Georg; Peinhaupt, Miriam; Rittchen, Sonja; Kargl, Julia; Marsche, Gunther; Schuligoi, Rufina; Sturm, Eva M.; Heinemann, Akos] Med Univ Graz, Div Pharmacol, Otto Loewi Res Ctr Vasc Biol Immunol & Inflammat, Univ Pl 4, A-8010 Graz, Austria; [Ulven, Trond] Univ Copenhagen, Dept Drug Design & Pharmacol, Copenhagen, Denmark; [Theiler, Anna; Marsh, Leigh M.] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria; [Marsche, Gunther; Heinemann, Akos] BioTechMed Graz, Graz, Austria	Medical University of Graz; University of Copenhagen; Ludwig Boltzmann Institute	Heinemann, A (corresponding author), Med Univ Graz, Div Pharmacol, Otto Loewi Res Ctr Vasc Biol Immunol & Inflammat, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemannn@medunigraz.at	Marsh, Leigh/AAB-5125-2021; Ulven, Trond/H-5500-2015	Marsh, Leigh/0000-0002-1754-9249; Ulven, Trond/0000-0002-8135-1755; Schuligoi, Rufina/0000-0002-9338-6904; Kargl, Julia/0000-0002-0870-0816; Sturm, Eva/0000-0003-4898-884X; Barnthaler, Thomas/0000-0002-4988-3700; Marsche, Gunther/0000-0002-2422-5381	Austrian science fund (FWF) [W1241]; FWF [P 26185-B19]; Start project of the Medical University of Graz; DOC Fellowship of the Austrian Academy of Sciences at the Otto Loewi Research Center for Vascular Biology, Immunology, and Inflammation, Division of Pharmacology, Medical University of Graz [24409, 24693]	Austrian science fund (FWF)(Austrian Science Fund (FWF)); FWF(Austrian Science Fund (FWF)); Start project of the Medical University of Graz; DOC Fellowship of the Austrian Academy of Sciences at the Otto Loewi Research Center for Vascular Biology, Immunology, and Inflammation, Division of Pharmacology, Medical University of Graz	A.T. and T.B. are recipients of a DOC Fellowship of the Austrian Academy of Sciences at the Otto Loewi Research Center for Vascular Biology, Immunology, and Inflammation, Division of Pharmacology, Medical University of Graz (24409 to A.T. and 24693 to T.B.). A.T., M. P., G.R., and S.R. were funded by the Austrian science fund (FWF) (W1241, DK-MOLIN). R.S. received FWF grant P 26185-B19. T.B. is a recipient of a Start project of the Medical University of Graz.	Aoyama M, 2010, NUTRITION, V26, P653, DOI 10.1016/j.nut.2009.07.006; Barnthaler T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08228-y; Barshishat M, 2002, BRIT J CANCER, V87, P1314, DOI 10.1038/sj.bjc.6600574; Beekman JM, 2009, BLOOD, V114, P3917, DOI 10.1182/blood-2009-03-208850; Bindels LB, 2013, TRENDS PHARMACOL SCI, V34, P226, DOI 10.1016/j.tips.2013.02.002; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; BRUNKHORST BA, 1992, INFECT IMMUN, V60, P2957, DOI 10.1128/IAI.60.7.2957-2968.1992; Cait A, 2018, MUCOSAL IMMUNOL, V11, P785, DOI 10.1038/mi.2017.75; Canella A, 2015, ONCOTARGET, V6, P31134, DOI 10.18632/oncotarget.5290; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Ebihara M, 1999, CURR EYE RES, V19, P20, DOI 10.1076/ceyr.19.1.20.5340; Egorin MJ, 1999, CANCER CHEMOTH PHARM, V43, P445, DOI 10.1007/s002800050922; Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451; Foster PS, 2008, CURR MOL MED, V8, P585, DOI 10.2174/156652408785748013; Frei RB, 2016, ALLERGY, V71, P944, DOI 10.1111/all.12858; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Giardina C, 1999, BBA-MOL CELL RES, V1448, P425, DOI 10.1016/S0167-4889(98)00156-6; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Hartnell A, 2004, J IMMUNOL, V173, P6448, DOI 10.4049/jimmunol.173.10.6448; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Hudson BD, 2014, MOL PHARMACOL, V86, P200, DOI 10.1124/mol.114.093294; Hudson BD, 2012, J BIOL CHEM, V287, P41195, DOI 10.1074/jbc.M112.396259; Kankaanranta H, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-9; Kim SJ, 2014, NANOSCALE RES LETT, V9, P1, DOI 10.1186/1556-276X-9-85; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; Kostylina G, 2008, CELL DEATH DIFFER, V15, P134, DOI 10.1038/sj.cdd.4402238; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lin KT, 2012, CLIN CANCER RES, V18, P4691, DOI 10.1158/1078-0432.CCR-12-0633; Luhrs H, 2002, ANTICANCER RES, V22, P1561; Mahlknecht U, 2008, HAEMATOLOGICA, V93, P443, DOI 10.3324/haematol.11796; Marchetti MC, 1997, NUTR CANCER, V28, P74, DOI 10.1080/01635589709514555; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Medina V, 1997, CANCER RES, V57, P3697; NAKAO S, 1992, INFECT IMMUN, V60, P5307, DOI 10.1128/IAI.60.12.5307-5311.1992; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P14, DOI 10.1016/S0091-6749(99)70107-7; Peinhaupt M, 2018, J LEUKOCYTE BIOL, V104, P159, DOI 10.1002/JLB.3MA1017-404R; Pizzonero M, 2014, J MED CHEM, V57, P10044, DOI 10.1021/jm5012885; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Roduit C, 2019, ALLERGY, V74, P799, DOI 10.1111/all.13660; Rossig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097; Ruemmele FM, 2003, GUT, V52, P94, DOI 10.1136/gut.52.1.94; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schwab M, 2006, APOPTOSIS, V11, P1801, DOI 10.1007/s10495-006-9788-2; Shinagawa K, 2003, INT ARCH ALLERGY IMM, V130, P150, DOI 10.1159/000069005; Sundh J, 2017, EUR CLIN RESPIR J, V4, P1, DOI 10.1080/20018525.2016.1270079; Theiler A, 2016, VASC PHARMACOL, V87, P180, DOI 10.1016/j.vph.2016.09.008; Thio CLP, 2018, J ALLERGY CLIN IMMUN, V142, P1867, DOI 10.1016/j.jaci.2018.02.032; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Vieira AT, 2016, J LEUKOC BIOL, V100; Walsh Garry M, 2013, J Cell Death, V6, P17, DOI 10.4137/JCD.S10818; WARRINGA RAJ, 1991, BLOOD, V77, P2694; Wilkerson EM, 2016, J PROTEOME RES, V15, P1524, DOI 10.1021/acs.jproteome.6b00006; Woerly G, 1999, INT ARCH ALLERGY IMM, V118, P95, DOI 10.1159/000024038; Zangrilli J, 2000, CLIN EXP IMMUNOL, V120, P12, DOI 10.1046/j.1365-2249.2000.01173.x	58	69	72	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					764	776		10.1016/j.jaci.2019.05.002	http://dx.doi.org/10.1016/j.jaci.2019.05.002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31082458	hybrid, Green Published			2022-12-18	WOS:000485222300021
J	Cai, T; Qiu, JX; Ji, Y; Li, WJ; Ding, ZY; Suo, CX; Chang, JL; Wang, JJ; He, R; Qian, YC; Guo, XH; Zhou, L; Sheng, HM; Shen, L; Qiu, J				Cai, Ting; Qiu, Jinxin; Ji, Yan; Li, Wenjing; Ding, Zhaoyun; Suo, Caixia; Chang, Jiali; Wang, Jingjing; He, Rui; Qian, Youcun; Guo, Xiaohuan; Zhou, Liang; Sheng, Huiming; Shen, Lei; Qiu, Ju			IL-17-producing ST2(+) group 2 innate lymphoid cells play a pathogenic role in lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; group 2 innate lymphoid cells; IL-17	ROR-GAMMA-T; NUCLEAR RECEPTOR; AIRWAY HYPERRESPONSIVENESS; TYPE-2; ASTHMA; CYTOKINE; LEUKOTRIENES; IL-33; IL-17; DIFFERENTIATION	Background: IL-17 plays a pathogenic role in asthma. ST2(-) inflammatory group 2 innate lymphoid cells (ILC2s) driven by IL-25 can produce IL-17, whereas ST2(+) natural ILC2s produce little IL-17. Objective: We characterized ST2(+) IL-17(+) ILC2s during lung inflammation and determined the pathogenesis and molecular regulation of ST2(+)IL-17(+) ILC2s. Methods: Lung inflammation was induced by papain or IL-33. IL-17 production by lung ILC2s from wild-type, Rag1(-/-), Rorc(gfp/gfp), and aryl hydrocarbon receptor (Ahr)(-/-) mice was examined by using flow cytometry. Bone marrow transfer experiments were performed to evaluate hematopoietic myeloid differentiation primary response gene-88 (MyD88) signaling in regulating IL-17 production by ILC2s. mRNA expression of IL-17 was analyzed in purified naive ILC2s treated with IL-33, leukotrienes, and inhibitors for nuclear factor of activated T cells, p38, c-Jun N-terminal kinase, or nuclear factor kappa light-chain enhancer of activated B cells. The pathogenesis of IL-17(+) ILC2s was determined by transferring wild-type or Il17(-/-) ILC2s to Rag2(-/-) Il2rg(-/-) mice, which further induced lung inflammation. Finally, expression of 106 ILC2 signature genes was compared between ST2(+)IL-17(+) ILC2s and ST2(+)IL-17(-) ILC2s. Results: Papain or IL-33 treatment boosted IL-17 production from ST2(+) ILC2s (referred to by us as ILC2(17)s) but not ST2(-) ILC2s. Ahr, but not retinoic acid receptor-related orphan receptor gamma t, facilitated the production of IL-17 by ILC2(17)s. The hematopoietic compartment of MyD88 signaling is essential for ILC2(17) induction. IL-33 works in synergy with leukotrienes, which signal through nuclear factor of activated T-cell activation to promote IL-17 in ILC2(17)s. Il17(-/-) ILC2s were less pathogenic in lung inflammation. ILC2(17)s concomitantly expressed IL-5 and IL-13 but expressed little GM-CSF. Conclusion: During lung inflammation, IL-33 and leukotrienes synergistically induce ILC2(17)s. ILC2(17)s are a highly pathogenic and unexpected source for IL-17 in lung inflammation.	[Cai, Ting; Qiu, Jinxin; Ji, Yan; Ding, Zhaoyun; Suo, Caixia; Chang, Jiali; Wang, Jingjing; Qian, Youcun; Qiu, Ju] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Univ Chinese Acad Sci,Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Li, Wenjing; He, Rui] Fudan Univ, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China; [Guo, Xiaohuan] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Guo, Xiaohuan] Tsinghua Univ, Dept Basic Med Sci, Sch Med, Beijing, Peoples R China; [Zhou, Liang] Univ Florida, Coll Vet Med, Dept Infect Dis & Immunol, Gainesville, FL USA; [Sheng, Huiming] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai 200336, Peoples R China; [Shen, Lei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai Inst Immunol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Tsinghua University; Tsinghua University; State University System of Florida; University of Florida; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Sheng, HM (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai 200336, Peoples R China.; Qiu, J (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, New Lifesci Bldg,Rm 1724,320 Yueyang Rd, Shanghai 20031, Peoples R China.; Shen, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, B5-1202,280 South Chongqing Rd, Shanghai 200025, Peoples R China.	polosheng@alumni.sjtu.edu.cn; lshen@shsmu.edu.cn; qiuju@sibs.ac.cn	sheng, huiming/T-8439-2019; Qiu, Ju/AAW-7301-2021; Guo, Xiaohuan/I-3710-2017; He, Rui/P-7302-2019; sheng, huiming/GQZ-8569-2022	Guo, Xiaohuan/0000-0001-5152-3010; He, Rui/0000-0001-5288-9786; sheng, huiming/0000-0001-9382-3687	Ministry of Science and Technology of China [2015CB943400, 2014CB943300]; Strategic priority Research Program of the Chinese Academy of Sciences [XDB19000000]; China's Youth 1000-Talent Program [91542102, 31570887]; Natural Science Foundation of Shanghai [16ZR1449900]; Youth Innovation Promotion Association of the Chinese Academy of Sciences [2017323]; National Institutes of Health [DK105562, R01AI132391]; Cancer Research Institute Investigator Award; Pew Charitable Trusts; Burroughs Wellcome Fund; National Natural Science Foundation of China [91542102, 31570887, 81571533]; China's Youth 1000-Talent Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI132391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK105562] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Strategic priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); China's Youth 1000-Talent Program; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Youth Innovation Promotion Association of the Chinese Academy of Sciences; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute Investigator Award; Pew Charitable Trusts; Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China's Youth 1000-Talent Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants 2015CB943400 and 2014CB943300 from the Ministry of Science and Technology of China, grant XDB19000000 from the Strategic priority Research Program of the Chinese Academy of Sciences, grants 91542102 and 31570887 from the National Natural Science Foundation of China and China's Youth 1000-Talent Program (to J.Q.) and grant 16ZR1449900 from the Natural Science Foundation of Shanghai and grant 2017323 from the Youth Innovation Promotion Association of the Chinese Academy of Sciences (to Y.J.). The work was also supported by the National Institutes of Health (DK105562 and R01AI132391 to L.Z.), and by a Cancer Research Institute Investigator Award (to L.Z.). L.Z. is a Pew Scholar in Biomedical Sciences supported by the Pew Charitable Trusts and an Investigator in the Pathogenesis of Infectious Disease supported by the Burroughs Wellcome Fund. The work was also supported by National Natural Science Foundation of China grant 81571533 (to L.S.) and China's Youth 1000-Talent Program (to L.S.).	Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Crabtree GR, 2009, CELL, V138, DOI 10.1016/j.cell.2009.06.026; Cui GL, 2011, J CLIN INVEST, V121, P658, DOI 10.1172/JCI42974; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Eberl G, 2017, MUCOSAL IMMUNOL, V10, P27, DOI 10.1038/mi.2016.86; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Huang YF, 2016, INT IMMUNOL, V28, P23, DOI 10.1093/intimm/dxv044; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kanai T, 2012, MUCOSAL IMMUNOL, V5, P240, DOI 10.1038/mi.2012.6; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim HY, 2013, J ALLERGY CLIN IMMUN, V132, P414, DOI 10.1016/j.jaci.2013.03.025; Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105; Kolls JK, 2003, AM J RESP CELL MOL, V28, P9, DOI 10.1165/rcmb.2002-0255PS; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Martin MU, 2013, SEMIN IMMUNOL, V25, P449, DOI 10.1016/j.smim.2013.10.006; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Menzies-Gow AN, 2007, CLIN EXP ALLERGY, V37, P1023, DOI 10.1111/j.1365-2222.2007.02735.x; Mizutani N, 2014, J IMMUNOL, V192, P1372, DOI 10.4049/jimmunol.1301538; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024, DOI 10.1016/S0091-6749(99)70084-9; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Peres CM, 2007, J IMMUNOL, V179, P5454, DOI 10.4049/jimmunol.179.8.5454; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Song XY, 2014, IMMUNITY, V40, P140, DOI 10.1016/j.immuni.2013.11.018; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Taylor S, 2017, J EXP MED, V214, P1663, DOI 10.1084/jem.20161653; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; Vonarbourg C, 2012, SEMIN IMMUNOL, V24, P165, DOI 10.1016/j.smim.2012.03.002; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421	60	69	73	1	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					229	+		10.1016/j.jaci.2018.03.007	http://dx.doi.org/10.1016/j.jaci.2018.03.007			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29625134	Bronze, Green Accepted			2022-12-18	WOS:000454918300028
J	Weinstein, SF; Katial, R; Jayawardena, S; Pirozzi, G; Staudinger, H; Eckert, L; Joish, VN; Amin, N; Maroni, J; Rowe, P; Graham, NMH; Teper, A				Weinstein, Steven F.; Katial, Rohit; Jayawardena, Shyamalie; Pirozzi, Gianluca; Staudinger, Heribert; Eckert, Laurent; Joish, Vijay N.; Amin, Nikhil; Maroni, Jaman; Rowe, Paul; Graham, Neil M. H.; Teper, Ariel			Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic rhinitis; perennial allergic rhinitis; comorbidity; dupilumab; nasal symptoms	IMPACT; EXACERBATIONS; RISK; INFLAMMATION; MANAGEMENT; DISEASE; PLACEBO; VISITS; BURDEN; ADULTS	Background: Dupilumab, an anti-IL-4 receptor alpha mAb, inhibits IL-4/IL-13 signaling, key drivers of type 2/T(H)2 immune diseases (eg, atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting beta 2-agonists. Objective: To examine dupilumab's effect on the 22-item Sino-Nasal Outcome Test (SNOT-22) total score and its allergic rhinitis (AR)-associated items in asthma patients with comorbid perennial allergic rhinitis (PAR). Methods: A post hoc analysis reporting data from the phase 2b study for the 200 and 300 mg every 2 week (q2w) doses under investigation in phase 3 (NCT02414854) was carried out. PAR was defined at study entry as a specific response to typical perennial antigens (IgE >= 0.35 Ku/L). Results: Overall, 241 (61%) patients had PAR. In asthma patients with PAR, dupilumab 300 mg q2w versus placebo significantly improved SNOT-22 total score (least squares mean difference, -5.98; 95% CI, -.45 to -1.51; P = .009) and all 4 AR-associated symptoms evaluated (nasal blockage, -0.60; 95% CI, -0.96 to -0.25; runny nose, -0.67; 95% CI, -1.04 to -0.31; sneezing, -0.55; 95% CI, -0.89 to -0.21; postnasal discharge, -0.49; 95% CI, -0.83 to -0.16; all P<.01). Dupilumab 200 mg q2w demonstrated numerical, but not statistically significant, decreases in SNOT-22 total score (-1.82; 95% CI, -6.46 to -.83; P=.443 vs placebo) and in each AR-associated symptom. In patients without PAR, no differences were observed for these measures versus placebo. Conclusions: Dupilumab 300 mg q2w significantly improved AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR.	[Weinstein, Steven F.] Allergy & Asthma Specialists Med Grp & Res Ctr, Huntington Beach, CA USA; [Katial, Rohit] Univ Colorado, Div Allergy & Immunol, Natl Jewish Hlth, Denver, CO 80202 USA; [Jayawardena, Shyamalie; Pirozzi, Gianluca; Staudinger, Heribert; Rowe, Paul; Teper, Ariel] Sanofi, Bridgewater, NJ USA; [Eckert, Laurent] Sanofi, Paris, France; [Joish, Vijay N.] Lexicon Pharmaceut Inc, Basking Ridge, NJ USA; [Amin, Nikhil; Maroni, Jaman; Graham, Neil M. H.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA	National Jewish Health; University of Colorado System; University of Colorado Denver; Sanofi-Aventis; Sanofi-Aventis; Sanofi France; Lexicon Pharmaceuticals; Regeneron	Weinstein, SF (corresponding author), 17742 Beach Blvd,Ste 310, Huntington Beach, CA 92647 USA.	sfw@ocallergy.com			Sanofi; Regeneron Pharmaceuticals, Inc.	Sanofi(Sanofi-Aventis); Regeneron Pharmaceuticals, Inc.(Regeneron)	This work was supported by Sanofi and Regeneron Pharmaceuticals, Inc.	Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bateman ED, 2015, J ALLERGY CLIN IMMUN, V135, P1457, DOI 10.1016/j.jaci.2014.08.015; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brandao HV, 2009, J BRAS PNEUMOL, V35, P1168, DOI 10.1590/S1806-37132009001200002; Clatworthy Jane, 2009, Prim Care Respir J, V18, P300, DOI 10.4104/pcrj.2009.00037; Forno E, 2012, CURR OPIN PULM MED, V18, P63, DOI 10.1097/MCP.0b013e32834db288; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Gaugris S, 2006, J ASTHMA, V43, P1, DOI 10.1080/02770900500446823; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Jeffery Peter K, 2006, BMC Pulm Med, V6 Suppl 1, pS5, DOI 10.1186/1471-2466-6-S1-S5; Ledford DK, 2013, CURR OPIN ALLERGY CL, V13, P78, DOI 10.1097/ACI.0b013e32835c16b6; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Magnan A, 2008, ALLERGY, V63, P292, DOI 10.1111/j.1398-9995.2007.01584.x; Passalacqua G, 2001, CURR OPIN ALLERGY CL, V1, P7; Pawankar R, 2011, ASIA PAC ALLERGY, V1, P157, DOI 10.5415/apallergy.2011.1.3.157; Peters SP, 2006, RESP MED, V100, P1139, DOI 10.1016/j.rmed.2006.03.031; Ponte EV, 2008, ALLERGY, V63, P564, DOI 10.1111/j.1398-9995.2007.01624.x; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Scadding GK, 2000, CLIN OTOLARYNGOL, V25, P551, DOI 10.1046/j.1365-2273.2000.00417.x; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Thomas Mike, 2006, BMC Pulm Med, V6 Suppl 1, pS4, DOI 10.1186/1471-2466-6-S1-S4; Valero A, 2009, J INVEST ALLERG CLIN, V19, P167; Valovirta Erkka, 2006, BMC Pulm Med, V6 Suppl 1, pS3, DOI 10.1186/1471-2466-6-S1-S3; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5	30	69	73	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					171	+		10.1016/j.jaci.2017.11.051	http://dx.doi.org/10.1016/j.jaci.2017.11.051			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29355679	hybrid			2022-12-18	WOS:000437837500021
J	Du Toit, G; Sampson, HA; Plaut, M; Burks, AW; Akdis, CA; Lack, G				Du Toit, George; Sampson, Hugh A.; Plaut, Marshall; Burks, A. Wesley; Akdis, Cezmi A.; Lack, Gideon			Food allergy: Update on prevention and tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; egg allergy; allergy prevention	HOUSEHOLD PEANUT CONSUMPTION; HIGH-RISK; INFANTS; SENSITIZATION; EXPOSURE; CHILDREN; ECZEMA	Of the many possible hypotheses that explain the recent increase in childhood food allergy (FA), the dual-allergen exposure hypothesis has been the most extensively investigated. This chapter serves as a review and update on the prevention of FA and focuses on recently published randomized controlled trials exploring the efficacy of oral tolerance induction in infancy for the prevention of FA. As a result of these RCTs, National Institutes of Health recommendations now actively encourage the early introduction of peanut for the prevention of peanut allergy, and other countries/settings recommend the inclusion of potential common food allergens, including peanut and egg, in complementary feeding regimens commencing at approximately 6 months but not before 4 months of age. Further studies that explore the efficacy of oral tolerance induction to other common food allergens and that focus on optimal timing, duration, and adherence are required.	[Du Toit, George; Lack, Gideon] Kings Coll London, Dept Paediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Kravis Childrens Hosp,Dept Pediat, New York, NY 10029 USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of North Carolina; University of North Carolina Chapel Hill; Swiss Institute of Allergy & Asthma Research; University of Zurich	Lack, G (corresponding author), Kings Coll London, Dept Paediat Allergy, MRC, 2nd Floor,South Wing, London SE1 7EH, England.; Lack, G (corresponding author), Kings Coll London, Asthma UK Ctr Allerg Mech, Childrens Allergies Dept, 2nd Floor,South Wing, London SE1 7EH, England.; Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, St Thomas Hosp, 2nd Floor,South Wing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021	National Institute of Allergy and Infectious Diseases (NIAID, NIH); Food Allergy & Research Education (FARE); MRC & Asthma UK Centre; UK Department of Health through NIHR; National Peanut Board (NPB); UK Food Standards Agency (FSA); National Institute of Allergy and Infectious Diseases [AI-44236]; NIH AITC Review Panel; Allertein; American Society for Microbiology; Elsevier; FARE; World Allergy Organization; Adept Field Solutions; Aimmune Therapeutics, Inc; Astellas Pharma Global Development, Inc; Biomerica, Inc; Evelo Biosciences, Inc/Epiva Biosciences, Inc; First Manhattan Co; Genentech; GLG Research, Inc; Insys Therapeutics; Intrommune Therapeutics; PPD Development, LP; Regeneron Pharmceuticals, Inc; Sanofi US Services; SRA International; Stallergenes; UKKO, Inc; Valeant Pharmaceuticals North America, LLC; Food Allergy Research and Education (FARE); National Institutes of Health; Wallace Research Foundation; Actellion; European Union project Medall; Allergopharma; Swiss National Science Foundation; Christine Kuhne Center for Allergy Research and Education; National Institutes of Allergy and Infectious Diseases [NO1-AI-15416, UM1AI109565]; UK Department of Health through the National Institute for Health Research; National Peanut Board; Osem; European Union project Predicta; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI109565] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy & Research Education (FARE); MRC & Asthma UK Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health through NIHR; National Peanut Board (NPB); UK Food Standards Agency (FSA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH AITC Review Panel(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Allertein; American Society for Microbiology; Elsevier; FARE; World Allergy Organization; Adept Field Solutions; Aimmune Therapeutics, Inc; Astellas Pharma Global Development, Inc; Biomerica, Inc; Evelo Biosciences, Inc/Epiva Biosciences, Inc; First Manhattan Co; Genentech(Roche HoldingGenentech); GLG Research, Inc; Insys Therapeutics; Intrommune Therapeutics; PPD Development, LP; Regeneron Pharmceuticals, Inc(Regeneron); Sanofi US Services; SRA International; Stallergenes; UKKO, Inc; Valeant Pharmaceuticals North America, LLC; Food Allergy Research and Education (FARE); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wallace Research Foundation; Actellion; European Union project Medall; Allergopharma; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education; National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); UK Department of Health through the National Institute for Health Research; National Peanut Board; Osem; European Union project Predicta; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	G. Du Toit reports income from grants from the National Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, UK Department of Health through NIHR, National Peanut Board (NPB), and grants from UK Food Standards Agency (FSA); these grants part funded salary over period of this submitted work. H. A. Sampson has received grants from the National Institute of Allergy and Infectious Diseases (AI-44236, CoFar, ITN); has consultant arrangements with Allertein Therapeutics, LLC, Hycor, and UCB; is Chief Scientific Officer of DBV Technologies; has received royalties from UpToDate; and has stock/stock options with DBV Technologies. A. W. Burks reports personal fees from NIH AITC Review Panel, Allertein, American Society for Microbiology, Elsevier, FARE, World Allergy Organization, Adept Field Solutions, Aimmune Therapeutics, Inc, Astellas Pharma Global Development, Inc, Biomerica, Inc, Evelo Biosciences, Inc/Epiva Biosciences, Inc, First Manhattan Co, Genentech, GLG Research, Inc, Insys Therapeutics, Intrommune Therapeutics, PPD Development, LP, Regeneron Pharmceuticals, Inc, Sanofi US Services, SRA International, Stallergenes, UKKO, Inc, and Valeant Pharmaceuticals North America, LLC and reports grants from Food Allergy Research and Education (FARE), National Institutes of Health, and Wallace Research Foundation. C. A. Akdis has received grants from Actellion, the European Union projects Medall and Predicta, Allergopharma, the Swiss National Science Foundation, and the Christine Kuhne Center for Allergy Research and Education. G. Lack has received grants from the National Institutes of Allergy and Infectious Diseases (NO1-AI-15416 [contract] and UM1AI109565 [grant]), Food Allergy Research and Education (FARE), MRC & Asthma UK Centre, UK Department of Health through the National Institute for Health Research, the National Peanut Board, and Osem; and has consultant arrangements and stock/stock options with DBV Technologies. M. Plaut declares no relevant conflicts of interest.	[Anonymous], 2017, JOINT SACN COT WORK; Bahnson HT, 2017, J ALLER CL IMM-PRACT, V5, P274, DOI 10.1016/j.jaip.2016.12.007; Bellach J, 2017, J ALLERGY CLIN IMMUN, V139, P1591, DOI 10.1016/j.jaci.2016.06.045; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; du Toit G, 2017, J ALLERGY CLIN IMMUN; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Koplin JJ, 2016, J ALLERGY CLIN IMMUN, V138, P1131, DOI 10.1016/j.jaci.2016.04.011; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Netting MJ, 2017, J ALLER CL IMM-PRACT, V5, P1617, DOI 10.1016/j.jaip.2017.03.013; Palmer DJ, 2017, J ALLERGY CLIN IMMUN, V139, P1600, DOI 10.1016/j.jaci.2016.06.052; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Tan JWL, 2017, J ALLERGY CLIN IMMUN, V139, P1621, DOI 10.1016/j.jaci.2016.08.035; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	25	69	70	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					30	40		10.1016/j.jaci.2017.11.010	http://dx.doi.org/10.1016/j.jaci.2017.11.010			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	29191680	Bronze, Green Published			2022-12-18	WOS:000419312200004
J	Akiyama, M; Takeichi, T; McGrath, JA; Sugiura, K				Akiyama, Masashi; Takeichi, Takuya; McGrath, John A.; Sugiura, Kazumitsu			Autoinflammatory keratinization diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Autoinflammation; CARD14; IL-36 receptor antagonist; keratinization; keratosis lichenoides chronica; NLRP1; pityriasis rubra pilaris; psoriasis; psoriatic arthritis; pustular psoriasis	GENERALIZED PUSTULAR PSORIASIS; MUTATIONS; CARD14; DEFICIENCY; VARIANTS; VULGARIS; IL36RN		[Akiyama, Masashi; Takeichi, Takuya] Nagoya Univ, Dept Dermatol, Grad Sch Med, Nagoya, Aichi, Japan; [McGrath, John A.] Kings Coll London, Guys Hosp, St Johns Inst Dermatol, London, England; [Sugiura, Kazumitsu] Fujita Hlth Univ, Sch Med, Dept Dermatol, Toyoake, Aichi, Japan	Nagoya University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Fujita Health University	Akiyama, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Dermatol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	makiyama@med.nagoya-u.ac.jp	McGrath, John/N-3529-2019; Akiyama, Masashi/I-1122-2012; McGrath, John/D-6824-2012	Akiyama, Masashi/0000-0001-5863-9315; McGrath, John/0000-0002-3708-9964				Hussain S, 2015, J ALLERGY CLIN IMMUN, V135, P1067, DOI 10.1016/j.jaci.2014.09.043; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Jordan CT, 2012, AM J HUM GENET, V90, P796, DOI 10.1016/j.ajhg.2012.03.013; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Mossner R, 2015, J INVEST DERMATOL, V135, P2538, DOI 10.1038/jid.2015.186; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Sugiura K, 2014, J INVEST DERMATOL, V134, P1755, DOI 10.1038/jid.2014.46; Sugiura K, 2013, J INVEST DERMATOL, V133, P2514, DOI 10.1038/jid.2013.230; Takeichi T, 2017, JAMA DERMATOL, V153, P66, DOI 10.1001/jamadermatol.2016.3601; Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001	10	69	71	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1545	1547		10.1016/j.jaci.2017.05.019	http://dx.doi.org/10.1016/j.jaci.2017.05.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28668225	Green Submitted, Bronze			2022-12-18	WOS:000417206000007
J	Berings, M; Karaaslan, C; Altunbulakli, C; Gevaert, P; Akdis, M; Bachert, C; Akdis, CA				Berings, Margot; Karaaslan, Cagatay; Altunbulakli, Can; Gevaert, Philippe; Akdis, Mubeccel; Bachert, Claus; Akdis, Cezmi A.			Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; asthma; allergen-specific immunotherapy; mechanisms; meta-analysis; clinical trials; immune tolerance; food allergy	REGULATORY T-CELLS; PEANUT ORAL IMMUNOTHERAPY; POLLEN-INDUCED RHINOCONJUNCTIVITIS; INNATE LYMPHOID-CELLS; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; B-CELLS; EPICUTANEOUS IMMUNOTHERAPY; ENVIRONMENTAL EXPOSURE; PRECISION MEDICINE	Allergen immunotherapy (AIT) is an effective treatment strategy for allergic diseases and has been used for more than 100 years. In recent years, however, the expectations on concepts, conduct, statistical evaluation, and reporting have developed significantly. Products have undergone dose-response and confirmative studies in adults and children to provide evidence for the optimal dosage, safety, and efficacy of AIT vaccines using subcutaneous and sublingual delivery pathways in large patient cohorts, ensuring solid conclusions to be drawn from them for the advantage of patients and societies alike. Those standards should be followed today, and products answering to them should be preferred over others lacking optimization and proof of efficacy and safety. Molecular and cellular mechanisms of AIT include early mast cell and basophil desensitization effects, regulation of T-and B-cell responses, regulation of IgE and IgG(4) production, and inhibition of responses from eosinophils, mast cells, and basophils in the affected tissues. There were many developments to improve vaccination strategies, demonstration of new molecules involved in molecular mechanisms, and demonstration of new biomarkers for AIT during the last few years. The combination of probiotics, vitamins, and biological agents with AIT is highlighting current advances. Development of allergoids and recombinant and hypoallergenic vaccines to skew the immune response from IgE to IgG(4) and regulation of dendritic cell, mast cell, basophil, innate lymphoid cell, T-cell, and B-cell responses to allergens are also discussed in detail.	[Berings, Margot; Gevaert, Philippe; Bachert, Claus] Ghent Univ Hosp, Upper Airways Res Lab, Ghent, Belgium; [Berings, Margot; Gevaert, Philippe; Bachert, Claus] Ghent Univ Hosp, ENT Dept, Ghent, Belgium; [Karaaslan, Cagatay; Altunbulakli, Can; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Karaaslan, Cagatay; Altunbulakli, Can; Akdis, Mubeccel; Akdis, Cezmi A.] CK CARE, Davos, Switzerland; [Karaaslan, Cagatay] Hacettepe Univ, Dept Mol Biol, Ankara, Turkey; [Bachert, Claus] Univ Stockholm, Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden; [Berings, Margot] VIB Inflammat Res Ctr, Lab Immunoregulat, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Swiss Institute of Allergy & Asthma Research; University of Zurich; Hacettepe University; Karolinska Institutet; Stockholm University; Flanders Institute for Biotechnology (VIB)	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Dept Immunol, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.; Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Univ Ghent, ENT Dept, De Pintelaan 185, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be; akdisac@siaf.uzh.ch	Gevaert, Philippe/AAP-1892-2020; Akdis, Cezmi/AAV-4844-2020; KARAASLAN, Cagatay/AAA-1621-2021; Gevaert, Philippe/ABA-4588-2021; Bachert, Claus/J-8825-2012	Gevaert, Philippe/0000-0002-1629-8468; Akdis, Cezmi/0000-0001-8020-019X; KARAASLAN, Cagatay/0000-0003-4857-0857; Altunbulakli, Can/0000-0003-2264-7377	Flemish Scientific Research Foundation (FWO)	Flemish Scientific Research Foundation (FWO)	M.B. received a PhD fellowship from the Flemish Scientific Research Foundation (FWO).	Akdis CA, 2016, J ALLERGY CLIN IMMUN, V137, P1359, DOI 10.1016/j.jaci.2016.03.020; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Bachert C, 2016, J ALLERGY CLIN IMMUN, V138, P1277, DOI 10.1016/j.jaci.2016.09.008; Bachert C, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0078-8; Bae JM, 2013, J ALLERGY CLIN IMMUN, V132, P110, DOI 10.1016/j.jaci.2013.02.044; Begin P, 2015, J ALLERGY CLIN IMMUN, V135, P1636, DOI 10.1016/j.jaci.2015.03.010; Berglund JP, 2017, J ALLER CL IMM-PRACT, V5, P1098, DOI 10.1016/j.jaip.2016.11.034; Boonpiyathad T, 2017, ALLERGY, V72, P407, DOI 10.1111/all.12966; Burk CM, 2016, CLIN EXP ALLERGY, V46, P347, DOI 10.1111/cea.12635; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2017, J ALLERGY CLIN IMMUN; Bush RK, 2016, J ALLERGY CLIN IMMUN, V138, P1284, DOI 10.1016/j.jaci.2016.09.007; Caillot N, 2017, J ALLERGY CLIN IMMUN, V140, P759, DOI 10.1016/j.jaci.2016.10.036; Calderon MA, 2017, ALLERGY, V72, P462, DOI 10.1111/all.13066; Calderon MA, 2017, J ALLERGY CLIN IMMUN, V140, P41, DOI 10.1016/j.jaci.2017.01.049; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Caminiti L, 2015, J ALLER CL IMM-PRACT, V3, P532, DOI 10.1016/j.jaip.2015.01.017; Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007; Chaker AM, 2016, J ALLERGY CLIN IMMUN, V137, P452, DOI 10.1016/j.jaci.2015.08.046; Clay CD, 2017, J ALLERGY CLIN IMMUN; Cox L, 2016, J ALLER CL IMM-PRACT, V4, P435, DOI 10.1016/j.jaip.2015.12.018; Cox LS, 2016, J ALLERGY CLIN IMMUN, V138, P314, DOI 10.1016/j.jaci.2016.01.039; Das M, 2017, J ALLERGY CLIN IMMUN, V139, P1403, DOI 10.1016/j.jaci.2016.09.062; Dawicki W, 2017, J ALLERGY CLIN IMMUN, V139, P1608, DOI 10.1016/j.jaci.2016.07.042; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Didier A, 2015, EXPERT OPIN DRUG SAF, V14, P777, DOI 10.1517/14740338.2015.1017468; Durham SR, 2016, J ALLERGY CLIN IMMUN, V137, P339, DOI 10.1016/j.jaci.2015.12.1298; Ellis A, 2015, J ALLERGY CLIN IMMUN, V135, pAB158, DOI 10.1016/j.jaci.2014.12.1457; Ellis AK, 2017, J ALLERGY CLIN IMMUN, V140, P486, DOI 10.1016/j.jaci.2016.11.043; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Freidl R, 2017, J ALLERGY CLIN IMMUN, V139, P1897, DOI 10.1016/j.jaci.2016.10.018; Frick M, 2016, J ALLERGY CLIN IMMUN, V138, P1663, DOI 10.1016/j.jaci.2016.04.024; Frischmeyer-Guerrerio PA, 2017, J ALLERGY CLIN IMMUN, V140, P1043, DOI 10.1016/j.jaci.2017.03.028; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Gepp B, 2016, J ALLERGY CLIN IMMUN, V137, P1600, DOI 10.1016/j.jaci.2015.10.022; Giavi S, 2016, ALLERGY, V71, P1575, DOI 10.1111/all.12905; Gueguen C, 2016, J ALLERGY CLIN IMMUN, V137, P545, DOI 10.1016/j.jaci.2015.09.015; Hafner R, 2014, J ALLERGY CLIN IMMUN, V133, pAB289, DOI 10.1016/j.jaci.2013.12.1023; Hamad A, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0700-7; Hansen CS, 2016, J ALLERGY CLIN IMMUN, V138, P1728, DOI 10.1016/j.jaci.2016.06.019; Hofer H, 2017, J ALLERGY CLIN IMMUN, V140, P525, DOI 10.1016/j.jaci.2016.09.055; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Hylander T, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0324-9; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kattan J, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0627-4; Kim AR, 2016, SCI REP-UK, V6, DOI 10.1038/srep19685; Klimek L, 2017, EXPERT REV CLIN IMMU, V13, P897, DOI 10.1080/1744666X.2017.1333423; Kowalski ML, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0122-3; Ledford D, 2017, J ALLERGY CLIN IMMUN, V140, P162, DOI 10.1016/j.jaci.2016.08.054; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; MacGlashan D, 2016, J ALLERGY CLIN IMMUN, V137, P1256, DOI 10.1016/j.jaci.2015.10.043; Madsen F, 2016, J ALLERGY CLIN IMMUN, V138, P1494, DOI 10.1016/j.jaci.2016.06.028; Majewska-Szczepanik M, 2016, J ALLERGY CLIN IMMUN, V138, P262, DOI 10.1016/j.jaci.2015.11.018; Mascarell L, 2017, MUCOSAL IMMUNOL, V10, P695, DOI 10.1038/mi.2016.87; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mondoulet L, 2015, J ALLERGY CLIN IMMUN, V135, P1546, DOI 10.1016/j.jaci.2014.11.028; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Nencini F, 2015, IMMUNOLOGY, V145, P570, DOI 10.1111/imm.12475; Niederberger V, 2015, J ALLERGY CLIN IMMUN, V136, P1101, DOI 10.1016/j.jaci.2015.03.034; Nolte H, 2016, J ALLERGY CLIN IMMUN, V138, P1631, DOI 10.1016/j.jaci.2016.06.044; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; O'Hehir RE, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0587-0; O'Mahony L, 2016, J ALLERGY CLIN IMMUN, V137, P559, DOI 10.1016/j.jaci.2015.10.047; Okamoto Y, 2017, ALLERGY, V72, P435, DOI 10.1111/all.12996; Okubo K, 2017, J ALLERGY CLIN IMMUN, V139, P1840, DOI 10.1016/j.jaci.2016.09.043; Orgel KA, 2017, J ALLERGY CLIN IMMUN, V139, P366, DOI 10.1016/j.jaci.2016.06.053; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Petrarca Claudia, 2016, Clin Mol Allergy, V14, P7, DOI 10.1186/s12948-016-0044-1; Pfaar O, 2016, ALLERGY, V71, P967, DOI 10.1111/all.12860; Ridolo E, 2017, CURR OPIN ALLERGY CL, V17, P12, DOI 10.1097/ACI.0000000000000330; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Ronka AL, 2015, J ALLERGY CLIN IMMUN, V136, P1047, DOI 10.1016/j.jaci.2015.02.025; Rotiroti G, 2012, J ALLERGY CLIN IMMUN, V130, P918, DOI 10.1016/j.jaci.2012.06.052; Roux M, 2016, J ALLERGY CLIN IMMUN, V138, P451, DOI 10.1016/j.jaci.2016.03.039; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Sampson HA, 2015, J ALLERGY CLIN IMMUN, V135, pAB390, DOI 10.1016/j.jaci.2014.12.1901; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Schmitt J, 2015, J ALLERGY CLIN IMMUN, V136, P1511, DOI 10.1016/j.jaci.2015.07.038; Schulke S, 2016, J ALLERGY CLIN IMMUN, V138, P568, DOI 10.1016/j.jaci.2016.06.006; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Selb R, 2017, J ALLERGY CLIN IMMUN, V139, P290, DOI 10.1016/j.jaci.2016.03.042; Senti G, 2015, ALLERGY, V70, P707, DOI 10.1111/all.12600; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Siroux V, 2017, J ALLERGY CLIN IMMUN, V139, P643, DOI 10.1016/j.jaci.2016.05.023; Sirvent S, 2016, J ALLERGY CLIN IMMUN, V138, P558, DOI 10.1016/j.jaci.2016.02.029; Slovick A, 2017, J ALLERGY CLIN IMMUN, V139, P1830, DOI 10.1016/j.jaci.2016.09.024; Spertini F, 2016, J ALLERGY CLIN IMMUN, V138, P162, DOI 10.1016/j.jaci.2016.02.044; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Subbarayal B, 2015, J ALLERGY CLIN IMMUN, V136, P1680, DOI 10.1016/j.jaci.2015.05.025; Tam HH, 2016, ALLERGY, V71, P1345, DOI 10.1111/all.12932; Tan JWL, 2017, J ALLERGY CLIN IMMUN, V139, P1621, DOI 10.1016/j.jaci.2016.08.035; Tanaka Y, 2017, MUCOSAL IMMUNOL, V10, P79, DOI 10.1038/mi.2016.46; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; Uotila R, 2017, J ALLERGY CLIN IMMUN, V139, P1393, DOI 10.1016/j.jaci.2016.09.054; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, pe1; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P1103, DOI 10.1016/j.jaci.2015.10.005; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895; Yamanaka K, 2017, J ALLERGY CLIN IMMUN, V139, P682, DOI 10.1016/j.jaci.2016.05.044; Yee CSK, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0602-0; Zieglmayer P, 2016, EBIOMEDICINE, V11, P43, DOI 10.1016/j.ebiom.2016.08.022; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045	123	69	75	0	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1250	1267		10.1016/j.jaci.2017.08.025	http://dx.doi.org/10.1016/j.jaci.2017.08.025			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28941667	Bronze			2022-12-18	WOS:000414304300005
J	Andersson, CK; Adams, A; Nagakumar, P; Bossley, C; Gupta, A; De Vries, D; Adnan, A; Bush, A; Saglani, S; Lloyd, CM				Andersson, Cecilia K.; Adams, Alexandra; Nagakumar, Prasad; Bossley, Cara; Gupta, Atul; De Vries, Daphne; Adnan, Afiqah; Bush, Andrew; Saglani, Sejal; Lloyd, Clare M.			Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; severe therapy-resistant asthma; IL-17A; IL-17A receptor; neutrophils	COLONY-STIMULATING FACTOR; AIRWAY INFLAMMATION; MESSENGER-RNA; T-CELLS; RECEPTOR; IL-17A; HYPERRESPONSIVENESS; INTERLEUKIN-17; REQUIREMENT; SPUTUM	Background: Neutrophils and IL-17A have been linked mechanistically in models of allergic airways disease and have been associated with asthma severity. However, their role in pediatric asthma is unknown. Objectives: We sought to investigate the role of neutrophils and the IL-17A pathway in mediating pediatric severe therapy-resistant asthma (STRA). Methods: Children with STRA (n = 51; age, 12.6 years; range, 6-16.3 years) and controls without asthma (n = 15; age, 4.75 years; range, 1.6-16 years) underwent clinically indicated fiberoptic bronchoscopy, bronchoalveolar lavage (BAL), endobronchial brushings, and biopsy. Neutrophils, IL-17A, and IL-17RA-expressing cells and levels of IL-17A and IL-22 were quantified in BAL and biopsies and related to clinical features. Primary bronchial epithelial cells were stimulated with IL-17A and/or IL-22, with and without budesonide. Results: Children with STRA had increased intraepithelial neutrophils, which positively correlated with FEV1 % predicted (r = 0.43; P = .008). Neutrophil(high) patients also had better symptom control, despite lower dose maintenance inhaled steroids. Submucosal neutrophils were not increased in children with STRA. Submucosal and epithelial IL-17A-positive cells and BAL IL-17A and IL-22 levels were similar in children with STRA and controls. However, there were significantly more IL-17RA-positive cells in the submucosa and epithelium in children with STRA compared with controls (P = .001). Stimulation of primary bronchial epithelial cells with IL-17A enhanced mRNA expression of IL-17RA and increased release of IL-8, even in the presence of budesonide. Conclusions: A proportion of children with STRA exhibit increased intraepithelial airway neutrophilia that correlated with better lung function. STRA was also characterized by increased airway IL-17RA expression. These data suggest a potential beneficial rather than adverse role for neutrophils in pediatric severe asthma pathophysiology.	[Andersson, Cecilia K.; Adams, Alexandra; Nagakumar, Prasad; De Vries, Daphne; Adnan, Afiqah; Saglani, Sejal; Lloyd, Clare M.] Imperial Coll, Natl Heart & Lung Inst, Inflammat Repair & Dev Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England; [Adams, Alexandra; Nagakumar, Prasad; Bossley, Cara; Gupta, Atul; Bush, Andrew; Saglani, Sejal] Royal Brompton & Harefield NHS Trust, Resp Paediat, Sydney Street, London, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Lloyd, CM (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Inflammat Repair & Dev Sect, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	s.saglani@imperial.ac.uk; c.lloyd@imperial.ac.uk	Andersson, Cecilia/ABC-1950-2021; Saglani, Sejal/AAE-5072-2019	Lloyd, Clare/0000-0001-8977-6726	Swedish Allergy and Asthma Foundation; Swedish Heart and Lung Foundation; Swedish Society for Medical Research; Asthma UK [11/050, AUK-IG-2016-339]; Wellcome Trust [107059/Z/15/Z]; National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0514-10053] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Swedish Allergy and Asthma Foundation; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Society for Medical Research; Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	This study was supported by the Swedish Allergy and Asthma Foundation, the Swedish Heart and Lung Foundation, the Swedish Society for Medical Research, Asthma UK grant ID 11/050 and AUK-IG-2016-339, and Wellcome Trust grant no. 107059/Z/15/Z. A.B. was supported by the National Institute for Health Research (NIHR) Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London. S.S. is an NIHR Career Development Fellow. C.M.L. is a Wellcome Senior Fellow in Basic Biomedical Sciences.	Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Bruijnzeel PLB, 2015, J LEUKOCYTE BIOL, V98, P549, DOI 10.1189/jlb.3VMR1214-600RR; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Cao J, 2011, CYTOKINE, V56, P823, DOI 10.1016/j.cyto.2011.09.016; Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chung KF, 2016, J INTERN MED, V279, P192, DOI 10.1111/joim.12382; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Colgan Sean P, 2002, ScientificWorldJournal, V2, P76; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Farfariello V, 2011, PEDIAT ALLERG IMM-UK, V22, P419, DOI 10.1111/j.1399-3038.2010.01116.x; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Hauber HP, 2005, J ALLERGY CLIN IMMUN, V115, P266, DOI 10.1016/j.jaci.2004.09.039; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Johnson JR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-118; Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005; Klesney-Tait J, 2013, J CLIN INVEST, V123, P138, DOI 10.1172/JCI64181; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Manni ML, 2014, MUCOSAL IMMUNOL, V7, P1186, DOI 10.1038/mi.2014.8; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2014, LANCET RESP MED, V2, P10, DOI 10.1016/S2213-2600(13)70288-1; Nagata T, 2008, J IMMUNOL, V181, P7473, DOI 10.4049/jimmunol.181.11.7473; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Pociask DA, 2013, AM J PATHOL, V182, P1286, DOI 10.1016/j.ajpath.2012.12.007; Prause O, 2003, EUR J PHARMACOL, V462, P193, DOI 10.1016/S0014-2999(03)01341-4; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; STALEY JT, 1985, ANNU REV MICROBIOL, V39, P321, DOI 10.1146/annurev.mi.39.100185.001541; Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Willis CR, 2015, AM J RESP CELL MOL, V53, P810, DOI 10.1165/rcmb.2015-0038OC; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76; Zijlstra GJ, 2012, EUR RESPIR J, V39, P439, DOI 10.1183/09031936.00017911	61	69	70	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1819	+		10.1016/j.jaci.2016.09.022	http://dx.doi.org/10.1016/j.jaci.2016.09.022			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27746241	Green Published, hybrid			2022-12-18	WOS:000402724600013
J	Hartley, RA; Barker, BL; Newby, C; Pakkal, M; Baldi, S; Kajekar, R; Kay, R; Laurencin, M; Marshall, RP; Sousa, AR; Parmar, H; Siddiqui, S; Gupta, S; Brightling, CE				Hartley, Ruth A.; Barker, Bethan L.; Newby, Chris; Pakkal, Mini; Baldi, Simonetta; Kajekar, Radhika; Kay, Richard; Laurencin, Marie; Marshall, Richard P.; Sousa, Ana R.; Parmar, Harsukh; Siddiqui, Salman; Gupta, Sumit; Brightling, Chris E.			Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; airway remodeling; quantitative computed tomography; asthma-COPD overlap syndrome; small airway disease; emphysema; gas trapping	WALL THICKNESS; COPD; CT; DIMENSIONS; COMPLEXITY; SCANS	Background: There is a paucity of studies comparing asthma and chronic obstructive pulmonary disease (COPD) based on thoracic quantitative computed tomographic (QCT) parameters. Objectives: We sought to compare QCT parameters of airway remodeling, air trapping, and emphysema between asthmatic patients and patients with COPD and explore their relationship with airflow limitation. Methods: Asthmatic patients (n = 171), patients with COPD (n = 81), and healthy subjects (n = 49) recruited from a single center underwent QCT and clinical characterization. Results: Proximal airway percentage wall area (%WA) was significantly increased in asthmatic patients (62.5% [SD, 2.2]) and patients with COPD (62.7% [SD, 2.3]) compared with that in healthy control subjects (60.3% [SD, 2.2], P < .001). Air trapping measured based on mean lung density expiratory/inspiratory ratio was significantly increased in patients with COPD (mean, 0.922 [SD, 0.037]) and asthmatic patients (mean, 0.852 [SD, 0.061]) compared with that in healthy subjects (mean, 0.816 [SD, 0.066], P < .001). Emphysema assessed based on lung density measured by using Hounsfield units below which 15% of the voxels lie (Perc15) was a feature of COPD only (patients with COPD: mean, -964 [SD, 19.62] vs asthmatic patients: mean, -937 [SD, 22.7] and healthy subjects: mean, -937 [SD, 17.1], P < .001). Multiple regression analyses showed that the strongest predictor of lung function impairment in asthmatic patients was %WA, whereas in the COPD and asthma subgrouped with postbronchodilator FEV1 percent predicted value of less than 80%, it was air trapping. Factor analysis of QCT parameters in asthmatic patients and patients with COPD combined determined 3 components, with %WA, air trapping, and Perc15 values being the highest loading factors. Cluster analysis identified 3 clusters with mild, moderate, or severe lung function impairment with corresponding decreased lung density (Perc15 values) and increased air trapping. Conclusions: In asthmatic patients and patients with COPD, lung function impairment is strongly associated with air trapping, with a contribution from proximal airway narrowing in asthmatic patients.	[Hartley, Ruth A.; Barker, Bethan L.; Newby, Chris; Pakkal, Mini; Baldi, Simonetta; Siddiqui, Salman; Gupta, Sumit; Brightling, Chris E.] Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun & Hlth Sci, Leicester LE3 9QP, Leics, England; [Gupta, Sumit] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Radiol, Leicester, Leics, England; [Kajekar, Radhika; Parmar, Harsukh] Hoffmann La Roche, Dept Expt Med, Nutley, NJ USA; [Kay, Richard; Laurencin, Marie] Novartis, Basel, Switzerland; [Marshall, Richard P.; Sousa, Ana R.] GlaxoSmithKline, Stevenage, Herts, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Roche Holding; GlaxoSmithKline	Brightling, CE (corresponding author), Univ Leicester, Glenfield Gen Hosp, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk		Siddiqui, Salman/0000-0003-3770-7870; Kay, Richard/0000-0002-8132-0721; brightling, chris/0000-0002-9345-4903	GlaxoSmithKline; Novartis; Roche; Wellcome Trust Senior Fellowship (CEB); Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (FP7 EU grant); Leicester National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit; MRC-ABPI COPD consortium(COPDMAP); National Institute for Health Research (NIHR); National Institute for Health Research [CL-2012-11-002] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Roche(Roche Holding); Wellcome Trust Senior Fellowship (CEB); Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (FP7 EU grant); Leicester National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit; MRC-ABPI COPD consortium(COPDMAP); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by GlaxoSmithKline, Novartis, Roche, a Wellcome Trust Senior Fellowship (CEB), the Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant), the Leicester National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, and the MRC-ABPI COPD consortium(COPDMAP). S.G. is a National Institute for Health Research (NIHR) Clinical Lecturer and is funded by a research and career development training scheme. This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	Achenbach T, 2008, EUR RADIOL, V18, P2731, DOI 10.1007/s00330-008-1089-4; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Choromanska A, 2012, POL J RADIOL, V77, P28, DOI 10.12659/PJR.882578; Diaz AA, 2013, RESP MED, V107, P570, DOI 10.1016/j.rmed.2012.12.011; Gorska K, 2009, EUR J MED RES, V14, P90; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hartley R, 2013, EUR RESPIR J, V42, P239; Hartley R, 2014, EUR RESPIR J, P4781; Hersh CP, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-42; Hong Ki Young, 2002, Korean J Intern Med, V17, P24; Johannessen A, 2013, AM J RESP CRIT CARE, V187, P602, DOI 10.1164/rccm.201209-1722OC; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kim V, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-52; Kosciuch J, 2013, RESP CARE, V58, P1335, DOI 10.4187/respcare.02175; McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955; Mishima M, 1999, P NATL ACAD SCI USA, V96, P8829, DOI 10.1073/pnas.96.16.8829; Mitsunobu F, 2003, AM J RESP CRIT CARE, V167, P411, DOI 10.1164/rccm.2112070; Montaudon M, 2009, RADIOLOGY, V253, P844, DOI 10.1148/radiol.2533090303; Moody A, 2004, THORAX, V59, P1; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120; Paganin F, 1997, EUR RESPIR J, V10, P2446, DOI 10.1183/09031936.97.10112446; Postma DS, 2014, CLIN CHEST MED, V35, P143, DOI 10.1016/j.ccm.2013.09.010; Schroeder JD, 2013, AM J ROENTGENOL, V201, pW460, DOI 10.2214/AJR.12.10102; Shimizu K, 2011, RESP MED, V105, P1275, DOI 10.1016/j.rmed.2011.04.007; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Xie XQ, 2012, EUR RADIOL, V22, P2085, DOI 10.1007/s00330-012-2480-8	35	69	73	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1413	+		10.1016/j.jaci.2016.02.001	http://dx.doi.org/10.1016/j.jaci.2016.02.001			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27006248	Green Published, Green Submitted, hybrid			2022-12-18	WOS:000376180200016
J	Goldberg, MR; Nachshon, L; Appel, MY; Elizur, A; Levy, MB; Eisenberg, E; Sampson, HA; Katz, Y				Goldberg, Michael R.; Nachshon, Liat; Appel, Michael Y.; Elizur, Arnon; Levy, Michael B.; Eisenberg, Eli; Sampson, Hugh A.; Katz, Yitzhak			Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; cow's milk allergy; baked milk	EGG ALLERGY; IGE ANTIBODIES; COWS; CHILDREN; TOLERANCE; EPITOPES; CHALLENGES; MANAGEMENT; RESOLUTION; OUTCOMES	Background: Patients with IgE-mediated cow's milk allergy who are nonreactive to baked milk (BM) can be desensitized with BM to promote tolerance to unheated milk (UM). Objective: We sought to test whether patients who are BM reactive can progress in BM oral immunotherapy (OIT) and become desensitized to UM as well. Methods: Fifteen patients (>4 years) who previously failed to complete our milk OIT program were enrolled into the BM OIT protocol. A dose of BM (180 degrees C for 30 minutes) which was less than the eliciting dose was increased 50% monthly while under medical supervision until the primary outcome dose of 1.3 g/d BM protein was achieved. Basophil reactivity and milk protein-specific IgE binding were analyzed at the first round of BM OIT therapy (T-0) and at 12 months of BM treatment. Results: In terms of the primary outcome, only 3 (21%) of 14 patients tolerated the 1.3 g/d BM dose. Although some patients initially progressed in BM OIT, 8 of 11 failed because of IgE-mediated reactions. Three did not complete the program because of non-IgE-mediated factors. An increase in challenge threshold to UM was noted in patients continuing until 12 months (P = .003), including those among whom reactions precluded continuation in the program. Patients (n = 3) who successfully reached maintenance had decreased milk-specific IgE reactivity. Furthermore, the mean difference at T-0 between induced HM and UM percentages of CD203c expression was significantly lower in patients who successfully completed BM OIT than in those who did not (211% vs 4.4%, P = .0002), which is consistent with their decreased clinical reactivity to BM. Conclusions: Although use of hypoallergenic BM in OIT is a promising therapy, care must be taken before its administration in BM-reactive patients because of the risk for anaphylaxis and only limited increase in challenge threshold attained.	[Goldberg, Michael R.; Nachshon, Liat; Appel, Michael Y.; Elizur, Arnon; Levy, Michael B.; Katz, Yitzhak] Assaf Harofeh Med Ctr, Allergy & Immunol Inst, IL-70300 Zerifin, Israel; [Elizur, Arnon; Katz, Yitzhak] Sackler Fac Med, Dept Pediat, New York, NY USA; [Eisenberg, Eli] Tel Aviv Univ, Raymond & Beverly Sackler Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY 10029 USA	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Icahn School of Medicine at Mount Sinai	Goldberg, MR (corresponding author), Assaf Harofeh Med Ctr, Inst Allergy Immunol & Pulmonol, IL-70300 Zerifin, Israel.	goldbergsm@yahoo.com	Eisenberg, Eli/D-2587-2009	Eisenberg, Eli/0000-0001-8681-3202; Appel, Michael/0000-0002-9089-9472; Elizur, Arnon/0000-0001-8157-8143	Ministry of Health, Israel; Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University; Ministry of Health (Chief Scientist Office) [3-00000-9115]; Allergists for Israel (AFI)	Ministry of Health, Israel; Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University; Ministry of Health (Chief Scientist Office); Allergists for Israel (AFI)	M.R.G. is supported by a Kamea grant from the Ministry of Health, Israel. Y.K. is supported by the Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University. Research was supported by the Ministry of Health (Chief Scientist Office no. 3-00000-9115) and the Allergists for Israel (AFI).	Bartnikas LM, 2012, ANN ALLERG ASTHMA IM, V109, P309, DOI 10.1016/j.anai.2012.07.026; Bloom KA, 2014, PEDIAT ALLERG IMM-UK, V25, P740, DOI 10.1111/pai.12283; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caubet JC, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Caubet JC, 2013, J ALLERGY CLIN IMMUN, V131, P222, DOI 10.1016/j.jaci.2012.06.049; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; GJESING B, 1986, ALLERGY, V41, P51, DOI 10.1111/j.1398-9995.1986.tb00275.x; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Konstantinou GN, 2012, IMMUNOL ALLERGY CLIN, V32, P151, DOI 10.1016/j.iac.2011.11.003; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2015, J ALLER CL IMM-PRACT, V3, P13, DOI 10.1016/j.jaip.2014.10.001; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Levy MB, 2014, ANN ALLERG ASTHMA IM, V112, P58, DOI 10.1016/j.anai.2013.10.001; Li XM, 2002, CURR OPIN ALLERGY CL, V2, P273, DOI 10.1097/00130832-200206000-00019; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Manohar Monali, 2014, Curr Treat Options Allergy, V1, P145; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pajno GB, 2010, ANN ALLERG ASTHMA IM, V105, P376, DOI 10.1016/j.anai.2010.03.015; Salmivesi S, 2013, ACTA PAEDIATR, V102, P172, DOI 10.1111/j.1651-2227.2012.02815.x; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Turner PJ, 2013, PEDIAT ALLERG IMM-UK, V24, P450, DOI 10.1111/pai.12093; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017	32	69	73	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1601	1606		10.1016/j.jaci.2015.05.040	http://dx.doi.org/10.1016/j.jaci.2015.05.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26194541				2022-12-18	WOS:000366044300022
J	Anderson, WC; Szefler, SJ				Anderson, William C., III; Szefler, Stanley J.			New and future strategies to improve asthma control in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; asthma exacerbations; dupilumab; biomarkers; inhaled corticosteroids; lebrikizumab; long-acting beta-adrenergic agonists; mepolizumab; omalizumab; reslizumab; severe asthma; therapeutics	FLUTICASONE/FORMOTEROL COMBINATION THERAPY; AUDIOVISUAL REMINDER FUNCTION; INNER-CITY CHILDREN; TO-MODERATE ASTHMA; STEP-UP THERAPY; ADD-ON THERAPY; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; PEDIATRIC ASTHMA	Symptomatic asthma in childhood has lifelong effects on lung function and disease severity, emphasizing the need for improved pediatric asthma control. Control of pediatric risk and impairment domains can be achieved through increased medication adherence or new therapeutic strategies. Developing electronic monitoring device technology with reminders might be a key noninvasive resource to address poor adherence in children and adolescents in a clinical setting. In patients who have persistently poor control despite optimal medication compliance, newly emerging pharmaceuticals, including inhaled therapies and biologics, might be key to their treatment. However, barriers exist to their development in the pediatric population, and insights must be drawn from adult studies, which has its own unique limitations. Biomarkers to direct the use of such potentially expensive therapies to those patients most likely to benefit are imperative. In this review the current literature regarding strategies to improve pediatric asthma control is addressed with the goal of exploring the potential and pitfalls of strategies that might be available in the near future.	[Anderson, William C., III] Childrens Hosp Colorado, Dept Pediat, Sect Allergy & Immunol, Aurora, CO 80045 USA; [Anderson, William C., III; Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Pediat Asthma Res Program, Sect Pediat Pulm Med, Breathing Inst,Dept Pediat, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Pediat Asthma Res Program, Breathing Inst, Sect Pulm Med, 13123 E 16th Ave,Box 395, Aurora, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	NCATS NIH HHS [UL1 TR000154] Funding Source: Medline; NCRR NIH HHS [UL1 RR025780] Funding Source: Medline; NHLBI NIH HHS [HL-98075] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098075] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson HM, 2014, J ALLERGY CLIN IMMUN, V133, pAB85, DOI 10.1016/j.jaci.2013.12.323; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; [Anonymous], BREO ELL FDA PRESCR; Arga M, 2014, J ASTHMA, V51, P299, DOI 10.3109/02770903.2013.867974; AstraZeneca, SYMB FDA PRESCR INF; Bauman LJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e6; Beasley R, 2014, J ALLERGY CLIN IMMUN, V133, P39, DOI 10.1016/j.jaci.2013.10.053; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bender BG, 2013, J ALLER CL IMM-PRACT, V1, P92, DOI 10.1016/j.jaip.2012.10.007; Bisgaard H, 2006, LANCET, V367, P286, DOI 10.1016/S0140-6736(06)68051-3; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Black P, 2008, AM J RESP CRIT CARE, V177, pA615; Bodzenta-Lukaszyk Anna, 2012, J Asthma, V49, P1060, DOI 10.3109/02770903.2012.719253; Bonini M, 2014, ANN ALLERG ASTHMA IM, V113, P513, DOI 10.1016/j.anai.2014.06.031; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bourgeois FT, 2012, PEDIATRICS, V130, P285, DOI 10.1542/peds.2012-0139; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Boyman O, 2015, ALLERGY, V70, P727, DOI 10.1111/all.12616; Brodlie M, 2012, ARCH DIS CHILD, V97, P604, DOI 10.1136/archdischild-2011-301570; Burgess SW, 2010, J ASTHMA, V47, P198, DOI 10.3109/02770900903483840; Busse W, 2013, J ALLERGY CLIN IMMUN, V132, P485, DOI 10.1016/j.jaci.2013.02.032; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cabana MD, 2014, J ALLERGY CLIN IMMUN, V133, P27, DOI 10.1016/j.jaci.2013.10.026; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chan AHY, 2015, LANCET RESP MED, V3, P210, DOI 10.1016/S2213-2600(15)00008-9; Chan AHY, 2015, J ALLER CL IMM-PRACT, V3, P335, DOI 10.1016/j.jaip.2015.01.024; Chan AHY, 2013, J ALLER CL IMM-PRACT, V1, P446, DOI 10.1016/j.jaip.2013.06.015; Chang TS, 2014, J ALLERGY CLIN IMMUN, V133, P363, DOI 10.1016/j.jaci.2013.09.002; Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Communication FDS, FDA REQ POSTM SAF TR; Corren J, 2013, RESP MED, V107, P180, DOI 10.1016/j.rmed.2012.10.025; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Darveaux J, 2015, J ALLER CL IMM-PRACT, V3, P152, DOI 10.1016/j.jaip.2014.09.014; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Eakin MN, 2012, ANN ALLERG ASTHMA IM, V109, P90, DOI 10.1016/j.anai.2012.06.009; Engelkes M, 2015, EUR RESPIR J, V45, P396, DOI 10.1183/09031936.00075614; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Foster JM, 2014, J ALLERGY CLIN IMMUN, V134, P1260, DOI 10.1016/j.jaci.2014.05.041; Genentech I, XOL FDA PRESCR INF; Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116; GlaxoSmithKline, ADV FDA PRESCR INF; Guest Julian F, 2005, Prim Care Respir J, V14, P88, DOI 10.1016/j.pcrj.2005.01.002; Guilbert TW, 2014, J ALLER CL IMM-PRACT, V2, P489, DOI 10.1016/j.jaip.2014.06.022; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P956, DOI 10.1016/j.jaci.2011.06.027; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamelmann E, 2014, EUR RESP J S58, V44, P1889; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; He XY, 2011, PAEDIATR RESPIR REV, V12, P165, DOI 10.1016/j.prrv.2011.04.007; Hendeles L, 2015, ANN ALLERG ASTHMA IM, V114, P58, DOI 10.1016/j.anai.2014.10.012; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Howrylak JA, 2014, J ALLERGY CLIN IMMUN, V133, P1289, DOI 10.1016/j.jaci.2014.02.006; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, P112, DOI 10.1016/j.jaci.2011.10.030; Kuhl K, 2012, CURR OPIN PULM MED, V18, P1, DOI 10.1097/MCP.0b013e32834deebb; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lodge CJ, 2014, AM J RESP CRIT CARE, V189, P1351, DOI 10.1164/rccm.201308-1487OC; Malka J, 2014, J ALLERGY CLIN IMMUN, V134, P483, DOI 10.1016/j.jaci.2014.03.039; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Merck, DUL FDA PRESCR INF; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan RA, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-67; Noonan M, 2013, J ALLERGY CLIN IMMUN, V132, P567, DOI 10.1016/j.jaci.2013.03.051; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Oliver A, 2014, CLIN THER, V36, P928, DOI 10.1016/j.clinthera.2014.03.014; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Patel M, 2013, J ALLER CL IMM-PRACT, V1, P83, DOI 10.1016/j.jaip.2012.08.004; Patel M, 2013, RESPIROLOGY, V18, P546, DOI 10.1111/resp.12059; Paton JY, 2007, PAEDIAT CHILD HLTH, V17, P180; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peters SP, 2013, J ALLERGY CLIN IMMUN, V132, P1068, DOI 10.1016/j.jaci.2013.08.003; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Rabinovitch N, 2014, J ALLERGY CLIN IMMUN, V133, P350, DOI 10.1016/j.jaci.2013.07.039; Radhakrishnan DK, 2014, J ALLERGY CLIN IMMUN, V134, P1057, DOI 10.1016/j.jaci.2014.05.012; Reddy MB, 2014, ALLERGY ASTHMA PROC, V35, P119, DOI 10.2500/aap.2014.35.3727; Robinson PD, 2013, PEDIATR DRUGS, V15, P291, DOI 10.1007/s40272-013-0020-x; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Sadatsafavi M, 2013, J ALLERGY CLIN IMMUN, V132, P63, DOI 10.1016/j.jaci.2013.02.007; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004; Silva D, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-4; Smyth AR, 2010, EUR RESPIR J, V35, P247, DOI 10.1183/09031936.00139508; Song JS, 2015, ALLERGY, V70, P674, DOI 10.1111/all.12599; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Sorkness CA, 2013, J ALLER CL IMM-PRACT, V1, P163, DOI 10.1016/j.jaip.2013.01.011; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Szefler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P644, DOI 10.1016/j.jaci.2014.12.1921; Szefler SJ, 2015, LANCET RESP MED, V3, P175, DOI 10.1016/S2213-2600(15)00009-0; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Szefler SJ, 2013, J ALLERGY CLIN IMMUN, V131, P36, DOI 10.1016/j.jaci.2012.11.009; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, P60, DOI 10.1016/j.jaci.2011.11.011; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Vogelberg C, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0175-9; Vogelberg C, 2014, RESP MED, V108, P1268, DOI 10.1016/j.rmed.2014.06.011; Weinstein AG, 2013, J ALLER CL IMM-PRACT, V1, P123, DOI 10.1016/j.jaip.2013.01.009; Wells KE, 2012, J ALLERGY CLIN IMMUN, V129, P1274, DOI 10.1016/j.jaci.2011.12.974; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Winzenburg G, 2014, INT J PHARMACEUT, V469, P260, DOI 10.1016/j.ijpharm.2014.03.058; Woodcock A, 2013, CHEST, V144, P1222, DOI 10.1378/chest.13-0178; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiang J, 2015, J ALLER CL IMM-PRACT, V3, P436, DOI 10.1016/j.jaip.2014.11.022; Zajicek A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00170; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647; Zeskind B, 2011, NEW ENGL J MED, V365, P2432, DOI 10.1056/NEJMc1112234; Zoratti E, 2014, ANN ALLERG ASTHMA IM, V113, P25, DOI 10.1016/j.anai.2014.04.013	132	69	70	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					848	859		10.1016/j.jaci.2015.07.007	http://dx.doi.org/10.1016/j.jaci.2015.07.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26318072	Bronze			2022-12-18	WOS:000362976300003
J	Fowler, SJ; Tavernier, G; Niven, R				Fowler, Stephen J.; Tavernier, Gael; Niven, Robert			High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONTROLLED TRIAL; MEPOLIZUMAB; EXACERBATIONS; INFLAMMATION		[Fowler, Stephen J.; Tavernier, Gael; Niven, Robert] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Fowler, Stephen J.; Tavernier, Gael; Niven, Robert] Univ S Manchester Hosp, NIHR Translat Res Facil Resp Med, Manchester M20 8LR, Lancs, England; [Fowler, Stephen J.] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Fowler, SJ (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.	stephen.fowler@manchester.ac.uk		Niven, Robert/0000-0003-2249-960X; Fowler, Stephen/0000-0002-4524-1663				Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Fulkerson PC, 2013, NAT REV DRUG DISCOV, V12, P117, DOI 10.1038/nrd3838; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST	9	69	73	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					822	824		10.1016/j.jaci.2014.09.034	http://dx.doi.org/10.1016/j.jaci.2014.09.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25445828				2022-12-18	WOS:000351065000034
J	Moreno-Macias, H; Romieu, I				Moreno-Macias, Hortensia; Romieu, Isabelle			Effects of antioxidant supplements and nutrients on patients with asthma and allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							VITAMIN-C INTAKE; OXIDATIVE STRESS; GENE POLYMORPHISMS; PULMONARY-FUNCTION; NATIONAL-HEALTH; OZONE EXPOSURE; AIR-POLLUTION; LUNG-FUNCTION; ASSOCIATION; CHILDHOOD		[Moreno-Macias, Hortensia] Univ Autonoma Metropolitana, Mexico City 09340, DF, Mexico; [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon, France	Universidad Autonoma Metropolitana - Mexico; World Health Organization; International Agency for Research on Cancer (IARC)	Moreno-Macias, H (corresponding author), Univ Autonoma Metropolitana, Unidad Iztapalapa, Ave San Rafael Atlixco 186,Edificio H-001, Mexico City 09340, DF, Mexico.	hmm@xanum.uam.mx						Allan K, 2010, CLIN EXP ALLERGY, V40, P370, DOI 10.1111/j.1365-2222.2009.03413.x; Allen S, 2009, THORAX, V64, P610, DOI 10.1136/thx.2008.101469; Bjelakovic G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074558; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Ciencewicki J, 2008, J ALLERGY CLIN IMMUN, V122, P456, DOI 10.1016/j.jaci.2008.08.004; Clark J, 2012, J ACAD NUTR DIET, V112, P297, DOI 10.1016/j.jada.2011.08.033; Comhair SAA, 2010, ANTIOXID REDOX SIGN, V12, P93, DOI 10.1089/ARS.2008.2425; Cook-Mills J. M., 2013, Journal of Clinical and Cellular Immunology, V4, P1000137; Cook-Mills JM, 2013, AM J RESP CRIT CARE, V188, P279, DOI 10.1164/rccm.201303-0503ED; Feary J, 2007, THORAX, V62, P466, DOI 10.1136/thx.2006.073866; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Guengerich FP, 2008, CHEM RES TOXICOL, V21, P70, DOI 10.1021/tx700079z; Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x; Halliwell B, 2011, TRENDS PHARMACOL SCI, V32, P125, DOI 10.1016/j.tips.2010.12.002; Hemila Harri, 2011, Clin Transl Allergy, V1, P9, DOI 10.1186/2045-7022-1-9; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975, DOI 10.1093/oxfordjournals.aje.a010141; Islam T, 2008, AM J RESP CRIT CARE, V177, P388, DOI 10.1164/rccm.200706-863OC; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; KELLY FJ, 1995, RESP MED, V89, P647, DOI 10.1016/0954-6111(95)90131-0; King MR, 2006, J IMMUNOL, V176, P2765, DOI 10.4049/jimmunol.176.5.2765; Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437; Kongerud J, 2003, INHAL TOXICOL, V15, P101, DOI [10.1080/08958370390168184, 10.1080/08958370304477]; Lazo-de-la-Vega-Monroy ML, OXIDATIVE STRESS DIA; Liang SQ, 2013, RESPIROLOGY, V18, P774, DOI 10.1111/resp.12097; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Minelli C, 2010, INT J EPIDEMIOL, V39, P539, DOI 10.1093/ije/dyp337; Moreno-Macias H, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-14; Murr C, 2005, MED HYPOTHESES, V64, P973, DOI 10.1016/j.mehy.2004.11.011; Neurauter G, 2004, PTERIDINES, V15, P1; Ngoc LP, 2005, CURR OPIN ALLERGY CL, V5, P161, DOI 10.1097/01.all.0000162309.97480.45; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Patel S, 2009, ALLERGY, V64, P1766, DOI 10.1111/j.1398-9995.2009.02099.x; Patelarou E, 2011, NUTR REV, V69, P627, DOI 10.1111/j.1753-4887.2011.00445.x; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Piacentini S, 2012, J INVEST ALLERG CLIN, V22, P252; Romieu I, 2006, THORAX, V61, P209, DOI 10.1136/thx.2004.039123; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; Rosenlund H, 2012, CLIN EXP ALLERGY, V42, P1491, DOI 10.1111/j.1365-2222.2012.04053.x; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Sackesen C, 2008, J ALLERGY CLIN IMMUN, V122, P78, DOI 10.1016/j.jaci.2008.03.035; Sahiner UM, 2011, WORLD ALLERGY ORGAN, V4, P151, DOI 10.1097/WOX.0b013e318232389e; Salam MT, 2012, EPIGENOMICS-UK, V4, P415, DOI [10.2217/EPI.12.32, 10.2217/epi.12.32]; Sausenthaler Stefanie, 2009, Central European Journal of Public Health, V17, P79; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; Shachar I, 2013, J LEUKOCYTE BIOL, V93, P51, DOI 10.1189/jlb.0612293; Soto-Ramirez N, 2013, J EPIDEMIOL, V23, P399, DOI 10.2188/jea.JE20120201; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tricon S., 2006, Clinical and Experimental Allergy Reviews, V6, P117, DOI 10.1111/j.1365-2222.2006.00114.x; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623; Yamamoto M, 2013, ENVIRON HEALTH PERSP, V121, P670, DOI 10.1289/ehp.1205963; Yang LL, 2011, INT ARCH ALLERGY IMM, V156, P373, DOI 10.1159/000324448	61	69	76	1	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1237	1245		10.1016/j.jaci.2014.03.020	http://dx.doi.org/10.1016/j.jaci.2014.03.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24766873				2022-12-18	WOS:000335450700001
J	Koplin, JJ; Tang, MLK; Martin, PE; Osborne, NJ; Lowe, AJ; Ponsonby, AL; Robinson, MN; Tey, D; Thiele, L; Hill, DJ; Gurrin, LC; Wake, M; Dharmage, SC; Allen, KJ				Koplin, Jennifer J.; Tang, Mimi L. K.; Martin, Pamela E.; Osborne, Nicholas J.; Lowe, Adrian J.; Ponsonby, Anne-Louise; Robinson, Marnie N.; Tey, Dean; Thiele, Leone; Hill, David J.; Gurrin, Lyle C.; Wake, Melissa; Dharmage, Shyamali C.; Allen, Katrina J.		HealthNuts Investigators	Predetermined challenge eligibility and cessation criteria for oral food challenges in the HealthNuts population-based study of infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Koplin, Jennifer J.; Tang, Mimi L. K.; Martin, Pamela E.; Lowe, Adrian J.; Ponsonby, Anne-Louise; Robinson, Marnie N.; Tey, Dean; Thiele, Leone; Hill, David J.; Gurrin, Lyle C.; Wake, Melissa; Dharmage, Shyamali C.; Allen, Katrina J.] Murdoch Childrens Res Inst, Murdoch, WA, Australia; [Koplin, Jennifer J.; Tang, Mimi L. K.; Martin, Pamela E.; Wake, Melissa; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Lowe, Adrian J.; Gurrin, Lyle C.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Tang, Mimi L. K.; Tey, Dean; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Osborne, Nicholas J.] Univ Exeter, Peninsula Coll Med & Dent, European Ctr Environm & Human Hlth, Truro, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Exeter; University of Plymouth	Koplin, JJ (corresponding author), Murdoch Childrens Res Inst, Murdoch, WA, Australia.	katie.allen@rch.org.au	Tey, Dean/U-4525-2019; Tang, Mimi/ABD-8350-2020; Wake, Melissa/J-1396-2012; Osborne, Nicholas/D-2086-2011; Ponsonby, Anne-Louise/AAE-4351-2019; Allen, Katrina/I-4361-2018; Matheson, Melanie C/O-4721-2015	Tang, Mimi/0000-0002-3839-5293; Wake, Melissa/0000-0001-7501-9257; Osborne, Nicholas/0000-0002-6700-2284; Allen, Katrina/0000-0002-1921-4493; Matheson, Melanie C/0000-0002-5822-3499; Gurrin, Lyle/0000-0001-7052-1969; Lowe, Adrian/0000-0002-4691-8162; Koplin, Jennifer/0000-0002-7576-5142; Zurzolo, Giovanni/0000-0003-0230-0691; Ponsonby, Anne-Louise/0000-0002-6581-3657				ASCIA, 2010, AN; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Lieberman JA, 2011, J ALLERGY CLIN IMMUN, V128, P1120, DOI 10.1016/j.jaci.2011.07.012; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044	7	69	70	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1145	1147		10.1016/j.jaci.2011.09.044	http://dx.doi.org/10.1016/j.jaci.2011.09.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22078469	Green Submitted			2022-12-18	WOS:000302144600032
J	Nakagawa, N; Imai, K; Kanegane, H; Sato, H; Yamada, M; Kondoh, K; Okada, S; Kobayashi, M; Agematsu, K; Takada, H; Mitsuiki, N; Oshima, K; Ohara, O; Suri, D; Rawat, A; Singh, S; Pan-Hammarstrom, Q; Hammarstrom, L; Reichenbach, J; Seger, R; Ariga, T; Hara, T; Miyawaki, T; Nonoyama, S				Nakagawa, Noriko; Imai, Kohsuke; Kanegane, Hirokazu; Sato, Hiroki; Yamada, Masafumi; Kondoh, Kensuke; Okada, Satoshi; Kobayashi, Masao; Agematsu, Kazunaga; Takada, Hidetoshi; Mitsuiki, Noriko; Oshima, Koichi; Ohara, Osamu; Suri, Deepti; Rawat, Amit; Singh, Surjit; Pan-Hammarstroem, Qiang; Hammarstroem, Lennart; Reichenbach, Janine; Seger, Reinhard; Ariga, Tadashi; Hara, Toshiro; Miyawaki, Toshio; Nonoyama, Shigeaki			Quantification of kappa-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES		[Nakagawa, Noriko; Imai, Kohsuke; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Imai, Kohsuke; Sato, Hiroki] Natl Def Med Coll Hosp, Dept Med Informat, Saitama, Japan; [Kanegane, Hirokazu; Miyawaki, Toshio] Toyama Univ, Dept Pediat, Toyama 930, Japan; [Yamada, Masafumi; Ariga, Tadashi] Hokkaido Univ, Dept Pediat, Sapporo, Hokkaido 060, Japan; [Kondoh, Kensuke] St Marianna Univ, Dept Pediat, Sch Med, Kanagawa, Japan; [Okada, Satoshi; Kobayashi, Masao] Hiroshima Univ, Dept Pediat, Hiroshima, Japan; [Agematsu, Kazunaga] Shinshu Univ, Dept Pediat, Nagano, Japan; [Takada, Hidetoshi; Hara, Toshiro] Kyushu Univ, Dept Pediat, Fukuoka 812, Japan; [Mitsuiki, Noriko] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Mitsuiki, Noriko; Oshima, Koichi; Ohara, Osamu] Kazusa DNA Res Inst, Dept Human Genome Technol, Chiba, Japan; [Oshima, Koichi] Kyoto Univ, Dept Clin Applicat, Ctr iPS Cell Res & Applicat, Kyoto, Japan; [Suri, Deepti; Rawat, Amit; Singh, Surjit] Post Grad Inst Med Educ & Res, Adv Pediat Ctr, Chandigarh, India; [Pan-Hammarstroem, Qiang; Hammarstroem, Lennart] Karolinska Inst, Huddinge Hosp, Div Clin Immunol, Dept Lab Med, S-10401 Stockholm, Sweden; [Reichenbach, Janine; Seger, Reinhard] Univ Childrens Hosp Zurich, Dept Immunol Hematol BMT, Zurich, Switzerland	National Defense Medical College - Japan; National Defense Medical College - Japan; University of Toyama; Hokkaido University; Saint Marianna University; Hiroshima University; Shinshu University; Kyushu University; Tokyo Medical & Dental University (TMDU); Kazusa DNA Research Institute; Kyoto University; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Karolinska Institutet; University Children's Hospital Zurich	Nakagawa, N (corresponding author), Natl Def Med Coll, Dept Pediat, Saitama, Japan.	kimai@ndmc.ac.jp	Rawat, Amit/A-3909-2014; Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015; Ariga, Tadashi/A-4252-2012; Reichenbach, Janine/U-2171-2018; Imai, Kohsuke/Q-2602-2015; hammarstrom, qiang pan/ABA-4589-2021; Oshima, Koichi/AAT-5670-2020; Okada, Satoshi/B-8901-2011	Rawat, Amit/0000-0002-5875-2892; Ohara, Osamu/0000-0002-3328-9571; Reichenbach, Janine/0000-0002-9008-1312; Imai, Kohsuke/0000-0003-2132-8403; Okada, Satoshi/0000-0002-4622-5657; Sato, Hiroki/0000-0002-6061-1511; pan-hammarstrom, qiang/0000-0003-1990-8804				ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Conley ME, 2005, IMMUNOL REV, V203, P216, DOI 10.1111/j.0105-2896.2005.00233.x; Eades-Perner AM, 2007, CLIN EXP IMMUNOL, V147, P306, DOI 10.1111/j.1365-2249.2006.03292.x; Kanegane H, 2001, J ALLERGY CLIN IMMUN, V108, P1012, DOI 10.1067/mai.2001.120133; Kaneko H, 2005, CLIN EXP IMMUNOL, V140, P520, DOI 10.1111/j.1365-2249.2005.02784.x; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Ozyurek E, 2006, CLIN LAB HAEMATOL, V28, P97, DOI 10.1111/j.1365-2257.2006.00767.x; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Prince AA, 2008, AM J RHINOL, V22, P239, DOI 10.2500/ajr.2008.22.3180; SIMINOVITCH KA, 1985, NATURE, V316, P260, DOI 10.1038/316260a0; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964	12	69	79	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					223	U352		10.1016/j.jaci.2011.01.052	http://dx.doi.org/10.1016/j.jaci.2011.01.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21397315				2022-12-18	WOS:000292245600034
J	Chang, Y; Al-Alwan, L; Risse, PA; Roussel, L; Rousseau, S; Halayko, AJ; Martin, JG; Hamid, Q; Eidelman, DH				Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Roussel, Lucie; Rousseau, Simon; Halayko, Andrew J.; Martin, James G.; Hamid, Qutayba; Eidelman, David H.			T(H)17 cytokines induce human airway smooth muscle cell migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; T(H)17; airway smooth muscle cells; migration	NF-KAPPA-B; P38 MAPK; ALLERGIC-ASTHMA; IN-VITRO; INTERLEUKIN-17; INFLAMMATION; RESPONSES; RECEPTOR; ROLES; RECRUITMENT	Background: Migration of airway smooth muscle cells (ASMCs) might contribute to increased airway smooth muscle mass in asthma. T(H)17 cells and T(H)17-associated cytokines are involved in the pathogenesis of asthma and might also contribute to airway remodeling. Objective: We sought to explore the possibility that migration of ASMCs might contribute to airway remodeling through the action of T(H)17-related cytokines. Methods: The effect of exogenous T(H)17 cytokines on ex vivo human ASMC migration was investigated by using a chemotaxis assay. The involvement of signaling pathways, including p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 MAPK, nuclear factor kappa B, and phosphoinositide 3-kinase, was also examined. Results: We demonstrated that IL-17A, IL-17F, and IL-22 promote migration in a dose-dependent manner. We further demonstrated that ASMCs express receptors for IL-17RA, IL-17RC, and IL-22R1. Using mAbs directed against these receptors, we confirmed that T(H)17-associated cytokine-induced migration was dependent on selective receptor activation. Moreover, IL-17A and IL-17F exert their effects through signaling pathways that are distinct from those used by IL-22. The p38 MAPK inhibitor BIRB0796 inhibited the migration induced by IL-17A and IL-17F. PS1145, an inhibitor of nuclear factor kB, abolished the IL-22-induced migration. Conclusion: These data raise the possibility that T(H)17-associated cytokines promote human ASMC migration in vivo and suggest an important new mechanism for the promotion of airway remodeling in asthma. (J Allergy Clin Immunol 2011;127:1046-53.)	[Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Roussel, Lucie; Rousseau, Simon; Martin, James G.; Hamid, Qutayba; Eidelman, David H.] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; [Chang, Ying; Al-Alwan, Laila; Risse, Paul-Andre; Roussel, Lucie; Rousseau, Simon; Martin, James G.; Hamid, Qutayba; Eidelman, David H.] McGill Univ, Div Resp, Dept Med, Montreal, PQ H2X 2P2, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Resp Hosp, Winnipeg, MB, Canada	McGill University; McGill University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 Rue St Urbain, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Chang, Ying/I-1362-2012	Rousseau, Simon/0000-0002-8773-575X; Halayko, Andrew/0000-0002-7865-4552; Martin, James/0000-0001-7574-5363	Canadian Institutes of Health Research; Costello Memorial Fund; McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec; GlaxoSmithKline; Merck Frosst Canada; Genentech; STRAUSS Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Costello Memorial Fund; McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec; GlaxoSmithKline(GlaxoSmithKline); Merck Frosst Canada; Genentech(Roche HoldingGenentech); STRAUSS Foundation	Supported by the Canadian Institutes of Health Research, the Costello Memorial Fund, and the McGill University Health Centre-Research Institute of les Fonds de la Recherche en Sante Quebec.; Disclosure of potential conflict of interest: A. J. Halayko has received research support from GlaxoSmithKline and Merck Frosst Canada. Q. Hamid has received research support from Genentech, the Canadian Institutes of Health Research, and the STRAUSS Foundation. The rest of the authors have declared that they have no conflict of interest.	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Carlin SM, 2003, AM J PHYSIOL-LUNG C, V284, pL1020, DOI 10.1152/ajplung.00092.2002; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gao C, 2009, CELL MOL NEUROBIOL, V29, P1161, DOI 10.1007/s10571-009-9409-z; Gerthoffer William T, 2008, Proc Am Thorac Soc, V5, P97, DOI 10.1513/pats.200704-051VS; Goncharova EA, 2006, NAT PROTOC, V1, P2933, DOI 10.1038/nprot.2006.434; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Joubert P, 2005, J ALLERGY CLIN IMMUN, V116, P713, DOI 10.1016/j.jaci.2005.05.042; Joubert P, 2005, J IMMUNOL, V175, P2702, DOI 10.4049/jimmunol.175.4.2702; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Kuestner RE, 2007, J IMMUNOL, V179, P5462, DOI 10.4049/jimmunol.179.8.5462; Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Linden A, 2006, PULM PHARMACOL THER, V19, P47, DOI 10.1016/j.pupt.2005.02.004; Linden A, 2001, INT ARCH ALLERGY IMM, V126, P179, DOI 10.1159/000049511; Madison JM, 2003, AM J RESP CELL MOL, V29, P8, DOI 10.1165/rcmb.F272; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Rahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clim.2005.01.014; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Shahrara S, 2009, J IMMUNOL, V182, P3884, DOI 10.4049/jimmunol.0802246; Sumi Yuki, 2007, Allergol Int, V56, P341, DOI 10.2332/allergolint.R-07-153; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wuyts WA, 2005, J HEART LUNG TRANSPL, V24, P875, DOI 10.1016/j.healun.2004.05.003; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zrioual S, 2008, J IMMUNOL, V180, P655, DOI 10.4049/jimmunol.180.1.655	38	69	77	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1046	U311		10.1016/j.jaci.2010.12.1117	http://dx.doi.org/10.1016/j.jaci.2010.12.1117			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21345484				2022-12-18	WOS:000289055800028
J	Cromwell, O; Hafner, D; Nandy, A				Cromwell, Oliver; Haefner, Dietrich; Nandy, Andreas			Recombinant allergens for specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recombinant allergen; allergen immunotherapy; allergen vaccines; personalized immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy; hypoallergenic variants	BIRCH POLLEN ALLERGEN; BET V 1; GRASS-POLLEN; SUBLINGUAL IMMUNOTHERAPY; HYPOALLERGENIC DERIVATIVES; RESPONSES; VACCINES; BET-V-1; DISEASE; RHINOCONJUNCTIVITIS	Recombinant DNA technology provides the means for producing allergens that are equivalent to their natural counterparts and also genetically engineered variants with reduced IgE-binding activity. The proteins are produced as chemically defined molecules with consistent structural and immunologic properties. Several hundred allergens have been cloned and expressed as recombinant proteins, and these provide the means for making a very detailed diagnosis of a patient's sensitization profile. Clinical development programs are now in progress to assess the suitability of recombinant allergens for both subcutaneous and sublingual immunotherapy. Recombinant hypoallergenic variants, which are developed with the aim of increasing the doses that can be administered while at the same time reducing the risks for therapy-associated side effects, are also in clinical trials for subcutaneous immunotherapy. Grass and birch pollen preparations have been shown to be clinically effective, and studies with various other allergens are in progress. Personalized or patient-tailored immunotherapy is still a very distant prospect, but the first recombinant products based on single allergens or defined mixtures could reach the market within the next 5 years. (J Allergy Clin Immunol 2011;127:865-72.)	[Cromwell, Oliver] Allergopharma Joachim Ganzer KG, Div Res & Dev, Res & Dev, D-21465 Reinbek, Germany	Allergopharma	Cromwell, O (corresponding author), Allergopharma Joachim Ganzer KG, Div Res & Dev, Res & Dev, Hermann Koerner Str 52, D-21465 Reinbek, Germany.	oliver.cromwell@allergopharma.de						Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Crameri R, 2007, ALLERGY, V62, P197, DOI 10.1111/j.1398-9995.2006.01292.x; Cromwell O, 2006, IMMUNOL ALLERGY CLIN, V26, P261, DOI 10.1016/j.iac.2006.02.001; Cromwell O, 2010, ALLERGY FRONT, V6, P31, DOI 10.1007/978-4-431-99365-0_3; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; *EMA, 2006, PUBL EMA; *EMA, 2008, PUBL EMA; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; HENAUT A, 1996, CELLULAR MOL BIOL, V2, P2047; Joetham A, 2009, J IMMUNOL, V183, P1821, DOI 10.4049/jimmunol.0900303; Johansen N, 2009, INT ARCH ALLERGY IMM, V150, P325, DOI 10.1159/000226233; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; KAHLERT H, 2003, CLIN IMMUNOL ALLERGY, P735; Kaul S, 2010, CURR OPIN ALLERGY CL, V10, P594, DOI 10.1097/ACI.0b013e32833fd5d2; Kettner J, 2007, ALLERGY, V62, P33; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2008, BIOL CHEM, V389, P925, DOI 10.1515/BC.2008.105; Mari A, 2008, CLIN EXP ALLERGY, V38, P1089, DOI 10.1111/j.1365-2222.2008.03011.x; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Moingeon P, 2006, ALLERGY, V61, P15, DOI 10.1111/j.1398-9995.2006.01157.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Narkus Annemie, 2009, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V96, P270; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Rak S, 2010, ALLERGY, V65, P4; Saarne T, 2005, CLIN EXP ALLERGY, V35, P657, DOI 10.1111/j.1365-2222.2005.02234.x; Saarne T, 2011, ALLERGY, V66, P255, DOI 10.1111/j.1398-9995.2010.02468.x; Schramm G, 1999, J IMMUNOL, V162, P2406; Senti G, 2009, ALLERGY, V64, P74; Suck R, 2000, CLIN EXP ALLERGY, V30, P324, DOI 10.1046/j.1365-2222.2000.00843.x; Suck R, 2006, BBA-PROTEINS PROTEOM, V1764, P1701, DOI 10.1016/j.bbapap.2006.09.015; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; Thalhamer T, 2010, J ALLERGY CLIN IMMUN, V125, P926, DOI 10.1016/j.jaci.2010.01.031; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wald M, 2007, CLIN EXP ALLERGY, V37, P441, DOI 10.1111/j.1365-2222.2007.02669.x; Wallner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008457; Westritschnig K, 2007, J IMMUNOL, V179, P7624, DOI 10.4049/jimmunol.179.11.7624; Winther L, 2009, J ALLERGY CLIN IMMUN, V123, pS215, DOI 10.1016/j.jaci.2008.12.822; FAST FOOD ALLERGY SP	55	69	78	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					865	872		10.1016/j.jaci.2011.01.047	http://dx.doi.org/10.1016/j.jaci.2011.01.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21377719				2022-12-18	WOS:000289055800006
J	Newcomb, DC; Boswell, MG; Zhou, WS; Huckabee, MM; Goleniewska, K; Sevin, CM; Hershey, GKK; Kolls, JK; Peebles, RS				Newcomb, Dawn C.; Boswell, Madison G.; Zhou, Weisong; Huckabee, Matthew M.; Goleniewska, Kasia; Sevin, Carla M.; Hershey, Gurjit K. Khurana; Kolls, Jay K.; Peebles, R. Stokes, Jr.			Human T(H)17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; IL-13 receptor; T(H)17; IL-17A; asthma	HELPER T-CELLS; ALLERGEN CHALLENGE; ALPHA-1 EXPRESSION; TH17 CELLS; INFLAMMATION; GENERATION; ASTHMA; PATHWAYS; DIFFERENTIATION; INTERLEUKIN-17	Background: IL-13 is a central mediator of airway responsiveness and mucus expression in patients with allergic airway inflammation, and IL-13 is currently a therapeutic target for asthma. However, little is known about how IL-13 regulates human CD4(+) T-cell lineages because IL-13 receptor (IL-13R) alpha 1, a subunit of IL-13R, has not previously been reported to exist on human T cells. Objective: We sought to determine whether human CD4(+) T(H)17 cells express IL-13R alpha 1 and whether IL-13 regulates T(H)17 cytokine production. Methods: Naive human CD4(+) cells were isolated from whole blood, activated with anti-CD3 and anti-CD28, and polarized to T(H)1, T(H)2, T(H)17, or induced regulatory T cells in the presence of IL-13 (0-10 ng/mL). Cell supernatants, total RNA, or total protein was examined 4 days after TH17 polarization. Results: T(H)17 cells, but not T(H)0, T(H)1, T(H)2, or induced regulatory T cells, expressed IL-13R alpha 1. IL-13 attenuated IL-17A production, as well as expression of retinoic acid-related orphan receptor, runt-related transcription factor-1, and interferon regulatory factor 4 in T(H)17-polarized cells. IL-13 neither inhibited IFN-gamma production from T(H)1 cells nor inhibited IL-4 production from T(H)2 cells. Furthermore, attenuation of IL-17A production only occurred when IL-13 was present within 24 hours of T-cell activation or at the time of restimulation. Conclusions: IL-13R alpha 1 is expressed on human CD4(+) T(H)17 cells, and IL-13 attenuates IL-17A production at polarization and restimulation. Although IL-13 is an attractive therapeutic target for decreasing symptoms associated with asthma, these results suggest that therapies inhibiting IL-13 production could have adverse side effects by increasing IL-17A production. (J Allergy Clin Immunol 2011;127:1006-13.)	[Newcomb, Dawn C.; Boswell, Madison G.; Zhou, Weisong; Huckabee, Matthew M.; Goleniewska, Kasia; Sevin, Carla M.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Kolls, Jay K.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA	Vanderbilt University; Cincinnati Children's Hospital Medical Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Newcomb, DC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 1161 21st Ave,T-1221 Med Ctr N, Nashville, TN 37232 USA.	dawn.newcomb@vanderbilt.edu	Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304; Khurana Hershey, Gurjit/0000-0001-6663-977X	National Institutes of Health [R01 HL 090664, R01 AI 070672, R01 AI 059108, GM015431, R21 HL106446, R56AI076411, F32 HL091653]; Department of Veteran Affairs [1I01BX000624]; Vanderbilt Institute for Clinical and Translational Research (VICTR) [UL1 RR024975]; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Veterans Administration; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL091653, R21HL106446, R01HL090664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI076411, R01AI070672, R01AI059108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veteran Affairs(US Department of Veterans Affairs); Vanderbilt Institute for Clinical and Translational Research (VICTR); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Administration(US Department of Veterans Affairs); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	Supported by the National Institutes of Health (R01 HL 090664, R01 AI 070672, R01 AI 059108, GM015431, R21 HL106446, R56AI076411 and F32 HL091653), the Department of Veteran Affairs (1I01BX000624), and Vanderbilt Institute for Clinical and Translational Research (VICTR) grant UL1 RR024975.; Disclosure of potential conflict of interest: G. K. Khurana Hershey and J. K. Kolls have received research support from the National Institutes of Health. R. S. Peebles, Jr, has received research support from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; and the Veterans Administration. The rest of the authors have declared that they have no conflict of interest.	Annunziato F, 2009, BLOOD, V114, P2213, DOI 10.1182/blood-2009-03-209189; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bree A, 2007, J ALLERGY CLIN IMMUN, V119, P1251, DOI 10.1016/j.jaci.2007.02.009; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; *CLIN TRIAL, 2010, IMA 026 CLIN TRIAL R; *CLIN TRIALS, 2010, CLIN TRIALS NEUTR IL; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; Hajoui O, 2007, J ALLERGY CLIN IMMUN, V120, P1425, DOI 10.1016/j.jaci.2007.07.011; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Peng J, 2010, CELL RES, V20, P62, DOI 10.1038/cr.2009.128; Romagnani S, 2009, MOL IMMUNOL, V47, P3, DOI 10.1016/j.molimm.2008.12.019; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhou L, 2009, CURR OPIN IMMUNOL, V21, P146, DOI 10.1016/j.coi.2009.03.001	35	69	73	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1006	U266		10.1016/j.jaci.2010.11.043	http://dx.doi.org/10.1016/j.jaci.2010.11.043			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21236478	Green Accepted			2022-12-18	WOS:000289055800023
J	Casale, TB; Stokes, JR				Casale, Thomas B.; Stokes, Jeffrey R.			Future forms of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Immunotherapy; allergy; asthma; omalizumab; allergens	ALLERGEN-SPECIFIC IMMUNOTHERAPY; T-CELL PEPTIDES; ORAL IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; IMMUNOSTIMULATORY DNA; TOLERANCE INDUCTION; CHILDREN; EFFICACY; CAT; VACCINATION	Allergic respiratory diseases affect approximately 15% of the US population. Allergen immunotherapy has been a treatment option for diseases such as allergic rhinitis, allergic asthma, and venom allergy for the last 100 years. During the first 75 years, conventional subcutaneous immunotherapy did not change much. However, the last 25 years has seen substantial growth in the development of alternatives to conventional subcutaneous immunotherapy. The addition of omalizumab, an anti-IgE mAb, to immunotherapy offers the potential for increased safety and efficacy. Activation of the innate immune system through Toll-like receptor agonists with and without specific allergens appears to improve the immunologic responses and clinical outcomes in patients with allergic diseases. The use of chemically altered allergens, allergoids, recombinant allergens, and relevant T-cell epitope peptides are all approaches that have yielded positive results. Finally, alternative modes of delivery hold promise, with sublingual immunotherapy rapidly approaching mainstream use in many countries. One thing is clear: the next century of immunotherapy will be vastly different from today's current standard of care. (J Allergy Clin Immunol 2011;127:8-15.)	[Casale, Thomas B.; Stokes, Jeffrey R.] Creighton Univ, Div Allergy Immunol, Omaha, NE 68131 USA	Creighton University	Casale, TB (corresponding author), Creighton Univ, Div Allergy Immunol, 601 N 30th St,Suite 3M-100, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Blaziene A, 2009, ANN ALLERG ASTHMA IM, V102, pS8; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Canonica GW, 2009, WORLD ALLERGY ORGAN, V2, P233, DOI 10.1097/WOX.0b013e3181c6c379; Canonica GW, 2011, J ALLERGY CLIN IMMUN, V127, P44, DOI 10.1016/j.jaci.2010.09.037; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Freeman J, 1911, LANCET, V2, P814; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Gawchik SM, 2009, EXPERT OPIN BIOL TH, V9, P377, DOI 10.1517/14712590802699596 ; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; Henmar H, 2008, CLIN EXP IMMUNOL, V153, P316, DOI 10.1111/j.1365-2249.2008.03710.x; Higgins D, 2006, J ALLERGY CLIN IMMUN, V118, P504, DOI 10.1016/j.jaci.2006.05.001; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P289, DOI 10.1016/j.jaci.2010.08.053; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.11.041; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; McCormack PL, 2006, DRUGS, V66, P931, DOI 10.2165/00003495-200666070-00004; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2007, J ALLERGY CLIN IMMUN, V119, P1013, DOI 10.1016/j.jaci.2006.12.661; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Pfaar O, 2010, ALLERGY; Pree I, 2007, J IMMUNOL, V179, P5309, DOI 10.4049/jimmunol.179.8.5309; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Rosewich M, 2010, PEDIAT ALLERG IMM-UK, V21, pE185, DOI 10.1111/j.1399-3038.2009.00953.x; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tulic Meri K., 2009, Allergology International, V58, P565, DOI 10.2332/allergolint.09-OA-0108; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Wasserman RL, 2011, J ALLERGY CLIN IMMUN, V127, P290, DOI 10.1016/j.jaci.2010.08.052; Williams A, 2007, Eur Ann Allergy Clin Immunol, V39, P123; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]; Zielen S, 2007, ALLERGOLOGIE, V30, pS1; Zielen S, 2010, J ALLERGY CLIN IMMUN	82	69	75	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					8	15		10.1016/j.jaci.2010.10.034	http://dx.doi.org/10.1016/j.jaci.2010.10.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094518	Bronze			2022-12-18	WOS:000285917300002
J	Busse, WW; Ring, J; Huss-Marp, J; Kahn, JE				Busse, William W.; Ring, Johannes; Huss-Marp, Johannes; Kahn, Jean-Emmanuel			A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anti-IL-5; hypereosinophilic syndrome; IL-5; mepolizumab	HUMANIZED MONOCLONAL-ANTIBODY; MESSENGER-RNA EXPRESSION; ANTI-INTERLEUKIN-5 ANTIBODY; HUMAN INTERLEUKIN-5; ATOPIC-DERMATITIS; T-CELLS; EOSINOPHILIC ESOPHAGITIS; HISTAMINE-RELEASE; IMATINIB THERAPY; DISEASE	The hypereosinophilic syndromes (HESs) are a heterogeneous group of diseases characterized by peripheral blood eosinophilia with end-organ damage and varying in severity from nonspecific symptoms to life-threatening. Treatment objectives are a safe reduction of blood and tissue eosinophil levels and prevention of eosinophil-mediated tissue damage. Current treatment of patients with HESs, who lack the FIP-1-like 1-platelet-derived growth factor receptor a (FIPILI-PDGFRA) fusion gene, is mainly systemic corticosteroid therapy. Eosinophil development from hematopoietic progenitor cells is regulated by IL-5, which influences maturation, differentiation, mobilization, activation, and survival. Consequently, inhibiting IL-5 is a logical therapeutic objective for patients with HESs or selected patients with asthma. Mepolizumab is a fully humanized anti IL-5 monoclonal IgG(I) antibody that binds to free IL-5 with high affinity and specificity to prevent IL-5 from associating with the IL-5 receptor complex a-chain on the surface of eosinophils. In clinical trials with patients with HESs, mepolizumab reduced blood eosinophil counts and the maintenance corticosteroid dose and had no major safety concerns. Mepolizumab reduced airway and blood eosinophils and prevented asthma exacerbations. Thus, mepolizumab may be effective for long-term treatment of patients with selected eosinophilic disorders. (J Allergy Clin Immunol 2010;125:803-13.)	[Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; [Ring, Johannes; Huss-Marp, Johannes] Tech Univ Munich, Div Environm Dermatol & Allergol, Helmholtz Zentrum, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Kahn, Jean-Emmanuel] Hop Foch, Serv Med Interne, Suresnes & French Eosinophil Network, Immunol Lab, Lille, France	University of Wisconsin System; University of Wisconsin Madison; Helmholtz Association; Technical University of Munich; Hospital Foch	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu	Ring, Johannes/GLN-4341-2022; KAHN, Jean-Emmanuel/S-8509-2018	Ring, Johannes/0000-0001-8236-3152; KAHN, Jean-Emmanuel/0000-0002-9565-6074	GlaxoSmithKline [MHE100185, MHE100901, SB-240563/001, SB-240563/006, SB-240563/036, SB-240563/046, GSK 110184]; Novartis; Schering-Plough; Fujisawa; GlaxoSmithKline; Bencard; Stallergenes; ALK-Abello; Allergopharma; Pharmacia; DPC Biermann; Aventis; Almirall; Leo; Galderma; Switch Biotech; National Institutes of Health National Institute of Allergy; Infections Diseases and National Heart, Lung, and Blood Institute	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Schering-Plough(Merck & CompanySchering Plough Corporation); Fujisawa; GlaxoSmithKline(GlaxoSmithKline); Bencard; Stallergenes; ALK-Abello; Allergopharma; Pharmacia; DPC Biermann; Aventis(Sanofi-Aventis); Almirall(Almirall); Leo(LEO Pharma); Galderma; Switch Biotech; National Institutes of Health National Institute of Allergy(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Infections Diseases and National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Editorial support in the form of initial literature search, writing assistance with outline and draft development, assembling tables and figures, collating author comments. grammatical editing, and referencing was provided by Dr Elaine F. Griffin at Evidence Scientific Solutions and was funded by GlaxoSmithKline. Study numbers MHE100185, MHE100901, SB-240563/001, SB-240563/006, SB-240563/036, SB-240563/046, and GSK 110184, which are discussed in this article, were funded by GlaxoSmithKline.; Disclosure of potential conflict of interest: J. Ring, has received research support front Novartis, Schering-Plough, Fujisawa, GlaxoSmithKline, Bencard, Stallergenes, ALK-Abello, Allergopharma, Pharmacia, DPC Biermann, Aventis, Almirall, Leo, Galderma, and Switch Biotech. J.-E. Kahn has received consulting fees from GlaxoSmithKline and received research support (through the French Eosinophil Network) front GlaxoSmithKline. W. W. Busse has served on advisory boards for Altair, Amgen, Abbott Laboratories, Asthmatx Inc, Bristol-Meyer Squibb, Centocor, Genentech, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, and Wyeth; has been a speaker for Merck; has consulted for Alexion, AstraZeneca, Boehringer Ingelheim, Dainippon Sumitomo, Funxional Therapeutics Ltd, Novartis, and TEVA; and has received research support from the National Institutes of Health National Institute of Allergy and Infections Diseases and National Heart, Lung, and Blood Institute, Novartis, Centocor, GlaxoSmithKline, MedImmune, and Ception. The other author has declared that he has no conflict of interest.	Adamko DJ, 2005, ALLERGY, V60, P13, DOI 10.1111/j.1398-9995.2005.00676.x; Baccarani M, 2007, HAEMATOLOGICA, V92, P1173, DOI 10.3324/haematol.11420; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braun-Falco M, 2004, BRIT J DERMATOL, V151, P1103, DOI 10.1111/j.1365-2133.2004.06239.x; Buchman AL, 2001, J CLIN GASTROENTEROL, V33, P289, DOI 10.1097/00004836-200110000-00006; Buitenhuis N, 2007, CANCER RES, V67, P3759, DOI 10.1158/0008-5472.CAN-06-4183; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Cook RM, 1998, AM J RESP CRIT CARE, V157, pA604; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fukushima K, 2009, J BIOL CHEM, V284, P7719, DOI 10.1074/jbc.M807489200; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gevaert P, 2008, J ALLERGY CLIN IMMUN, V121, P797, DOI 10.1016/j.jaci.2008.01.062; Gleich GJ, 2005, CURR OPIN IMMUNOL, V17, P679, DOI 10.1016/j.coi.2005.09.008; Delgado PG, 2008, J INVEST ALLERG CLIN, V18, P401; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Helbig G, 2006, EUR J HAEMATOL, V76, P535, DOI 10.1111/j.1600-0609.2006.00652.x; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Jain N, 2009, LEUKEMIA RES, V33, P837, DOI 10.1016/j.leukres.2008.10.004; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Kalac M, 2007, CANCER-AM CANCER SOC, V110, P955, DOI 10.1002/cncr.22920; Kariyawasam HH, 2006, SEMIN RESP CRIT CARE, V27, P117, DOI 10.1055/s-2006-939514; Kim SH, 2009, AM J RESP CRIT CARE, V179; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Klion AD, 2007, IMMUNOL ALLERGY CLIN, V27, P551, DOI 10.1016/j.iac.2007.07.006; Klion Amy D, 2005, Hematology Am Soc Hematol Educ Program, P209; Koury MJ, 2003, AM J MED, V115, P587, DOI 10.1016/S0002-9343(03)00475-3; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEFEBVRE C, 1989, ANN MED INTERNE, V140, P253; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Menzies-Gow A, 2002, CURR OPIN PULM MED, V8, P33, DOI 10.1097/00063198-200201000-00006; Miyazawa K, 2007, INT J HEMATOL, V85, P5, DOI 10.1532/IJH97.06047; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Oldhoff JM, 2006, INT ARCH ALLERGY IMM, V141, P290, DOI 10.1159/000095299; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Pardanani A, 2006, LEUKEMIA RES, V30, P965, DOI 10.1016/j.leukres.2005.11.011; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Roufosse F, 2006, SEMIN RESP CRIT CARE, V27, P158, DOI 10.1055/s-2006-939519; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Roufosse F, 2003, ANNU REV MED, V54, P169, DOI 10.1146/annurev.med.54.101601.152431; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Stanbury RM, 1998, BRIT J OPHTHALMOL, V82, P704, DOI 10.1136/bjo.82.6.704; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2008, J ALLERGY CLIN IMMUN, V121, pS44, DOI 10.1016/j.jaci.2007.12.179; Weller P.F., 2009, MIDDLETONS ALLERGY P, P859; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Yoshimura-Uchiyama C, 2003, BIOCHEM BIOPH RES CO, V302, P201, DOI 10.1016/S0006-291X(03)00153-0; Zhang J, 1999, INT IMMUNOL, V11, P1935, DOI 10.1093/intimm/11.12.1935; Zia-Amirhosseini P, 1999, J PHARMACOL EXP THER, V291, P1060	70	69	75	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					803	813		10.1016/j.jaci.2009.11.048	http://dx.doi.org/10.1016/j.jaci.2009.11.048			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371394				2022-12-18	WOS:000276787900004
J	Giwercman, C; Halkjaer, LB; Jensen, SM; Bonnelykke, K; Lauritzen, L; Bisgaard, H				Giwercman, Charlotte; Halkjaer, Liselotte B.; Jensen, Signe Marie; Bonnelykke, Klaus; Lauritzen, Lotte; Bisgaard, Hans			Increased risk of eczema but reduced risk of early wheezy disorder from exclusive breast-feeding in high-risk infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; eczema; wheezy disorder; infant	FATTY-ACID-COMPOSITION; 1ST 3 YEARS; ATOPIC-DERMATITIS; HUMAN-MILK; ASTHMA; CHILDHOOD; CHILDREN; BIRTH; ALLERGY; SYMPTOMS	Background: Breast-feeding is recommended for the prevention of eczema, asthma, and allergy, particularly in high-risk families, but recent studies have raised concern that this may not protect children and may even increase the risk. However, disease risk, disease manifestation, lifestyle, and the choice to breast-feed are interrelated, and therefore, analyzing true causal effects presents a number of methodologic challenges. Objective: First, to assess the effect from duration of exclusive breast-feeding on the development of eczema and wheezy disorders during the first 2 years of life in a high-risk clinical birth cohort. Second, to assess any influence from the fatty acid composition of mother's milk on the risk from breast-feeding. Methods: We studied disease development during the first two years of life of the 411 infants from the Copenhagen Study on Asthma in Childhood (COPSAC) birth cohort, born to mothers with a history of asthma. We analyzed the effect from duration of breast-feeding before disease onset on the disease risk, avoiding the effect from disease-related modification of exposure (inverse causation). Polyunsaturated fatty acids were measured in breast milk. Results: Breast-feeding significantly increased the risk of eczema adjusted for demographics, filaggrin variants, parents' eczema, and pets at home (N = 306; relative risk, 2.09; 95% CI 1.15-3.80; P=.016) but reduced the risk of wheezy episodes (relative risk, 0.67; 95% CI 0.48-0.96; P =.021) and of severe wheezy exacerbation (relative risk, 0.16; 95% CI 0.03-1.01; P=.051). There was no association between the fatty acid composition of mother's milk and the risk of eczema or wheeze. Conclusion: The risk of eczema was increased in infants with increasing duration of breast-feeding. In contrast, the risk of wheezy disorder and severe wheezy exacerbations was reduced. There were no significant effects from the fatty acid composition of the breast milk on risk of eczema or wheezy disorders. (J Allergy Clin Immunol 2010;125:866-71.)	[Giwercman, Charlotte; Halkjaer, Liselotte B.; Jensen, Signe Marie; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Study Asthma Childhood, DK-2820 Gentofte, Copenhagen, Denmark; [Lauritzen, Lotte] Univ Copenhagen, Ctr Adv Food Studies, Dept Human Nutr, Frederiksberg, Denmark	University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Study Asthma Childhood, Ledreborg Alle 34, DK-2820 Gentofte, Copenhagen, Denmark.	Bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Lauritzen, Lotte/F-2921-2013; Jensen, Signe/G-1026-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Lauritzen, Lotte/0000-0001-7184-5949; Jensen, Signe/0000-0002-7738-5231; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation; Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Center; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Center; Lundbeck Foundation(Lundbeckfonden)	COPSAC is funded by private and public research funds, all listed on www.copsac.com. The Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Center provide core support for COPSAC. The funding agencies did not have any role in study design, data collection and analysis, decision to publish. or preparation of the article.	Benn CS, 2004, AM J EPIDEMIOL, V160, P217, DOI 10.1093/aje/kwh208; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; BISGAARD H, 1987, ACTA PAEDIATR SCAND, V76, P719, DOI 10.1111/j.1651-2227.1987.tb10555.x; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Crane J, 2003, EUR RESPIR J, V21, P455, DOI 10.1183/09031936.03.00041403; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hoppu U, 2005, J PEDIATR GASTR NUTR, V41, P335, DOI 10.1097/01.mpg.0000168992.44428.fa; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lauritzen L, 2002, LIPIDS, V37, P237, DOI 10.1007/s11745-002-0886-2; Lauritzen L, 2006, AM J CLIN NUTR, V84, P190, DOI 10.1093/ajcn/84.1.190; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Mandhane PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1359, DOI 10.1016/j.jaci.2007.01.043; MANKU MS, 1984, BRIT J DERMATOL, V110, P643, DOI 10.1111/j.1365-2133.1984.tb04698.x; Martinussen T, 2006, STAT BIOL HEALTH; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Oddy WH, 2006, PEDIAT ALLERG IMM-UK, V17, P4, DOI 10.1111/j.1399-3038.2005.00340.x; Oddy WH, 2003, J ALLERGY CLIN IMMUN, V112, P723, DOI 10.1016/S0091-6749(03)01941-9; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Sala-Vila A, 2008, CLIN EXP ALLERGY, V38, P1432, DOI 10.1111/j.1365-2222.2008.03072.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Siltanen M, 2003, ALLERGY, V58, P524, DOI 10.1034/j.1398-9995.2003.00150.x; Snijders BEP, 2007, PEDIATRICS, V119, pE137, DOI 10.1542/peds.2006-0772; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; Van Sickle D, 2005, EUR RESPIR J, V26, P829, DOI 10.1183/09031936.05.00027205; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Wijga AH, 2006, J ALLERGY CLIN IMMUN, V117, P440, DOI 10.1016/j.jaci.2005.10.022; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	44	69	71	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					866	871		10.1016/j.jaci.2010.01.026	http://dx.doi.org/10.1016/j.jaci.2010.01.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20236698				2022-12-18	WOS:000276787900012
J	Neves, JS; Radke, AL; Weller, PF				Neves, Josiane S.; Radke, Amy L.; Weller, Peter F.			Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Granules; cysteinyl leukotriene; eosinophil allergy; asthma; montelukast	CYSLT(1) RECEPTOR; LIPID BODIES; MONTELUKAST; PROTEIN; ASTHMA; ESOPHAGITIS; ACTIVATION; MECHANISMS; RESPONSES; CHILDREN	Background: Cysteinyl leukotrienes (cysLTs) are recognized to act via receptors (cysLTRs) expressed on cell surface plasma membranes. Agents that block cysLT(1) receptor (cysLT(1)R) are therapeutics for allergic disorders. Eosinophils contain multiple preformed proteins stored within their intracellular granules. Cell-free eosinophil granules are present extracellularly as intact membrane-bound organelles in sites associated with eosinophil infiltration, including asthma, rhinitis, and urticaria, but have unknown functional capabilities. Objective: We evaluated the expression of cysLTRs oil eosinophil granule membranes and their functional roles in eliciting protein secretion from within eosinophil granules. Methods: We studied secretory responses of human eosinophil granules isolated by subcellular fractionation. Granules were stimulated with cysLTs, and eosinophil cationic protein and cytokines were measured in the supernatants. Receptor expression on granule membranes and eosinophils was evaluated by flow cytometry and Western blot. Results: We report that receptors for cysLTs, cysLT(1)R, cysLT(2) receptor, and the purinergic P2Y12 receptor, are expressed on eosinophil granule membranes. Leukotriene (LT) C(4) and extracellularly generated LTD(4) and LTE(4) stimulated isolated eosinophil granules to secrete eosinophil cationic protein. MRS 2395, a P2Y12 receptor antagonist, inhibited cysLT-induced eosinophil cationic protein release. Montelukast, likely not solely as an inhibitor of cysLT(1)R, inhibited eosinophil cationic protein release elicited by LTC(4) and LTD(4) as well as by LTE(4). Conclusion: These studies identify previously unrecognized sites of localization, the membranes of intracellular eosinophil granule organelles, and function for cysLT-responsive receptors that mediate cysteinyl leukotriene-stimulated secretion from within eosinophil granules, including those present extracellularly. (J Allergy Clin Immunol 2010;125:477-82.)	[Neves, Josiane S.; Radke, Amy L.; Weller, Peter F.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Allergy & Inflammat, Boston, MA 02215 USA; [Neves, Josiane S.] Univ Fed Rio de Janeiro, Inst Biomed Sci ICB, Rio De Janeiro, Brazil	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universidade Federal do Rio de Janeiro	Weller, PF (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Allergy & Inflammat, 330 Brookline Ave,CLS 943, Boston, MA 02215 USA.	pweller@bidmc.harvard.edu	Neves, Josiane S/C-3102-2009; Neves, Josiane Sabbadini/X-9801-2019	Neves, Josiane Sabbadini/0000-0002-6645-1715	National Institutes of Health [AI020241, AI022571, AI051645]; Merck; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051645, R01AI020241, R37AI020241, R01AI022571] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Merck(Merck & Company); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI020241, AI022571, and AI051645 and an investigator-initiated grant from Merck.	Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Austen KF, 2009, J ALLERGY CLIN IMMUN, V124, P406, DOI 10.1016/j.jaci.2009.05.046; Bandeira-Melo C, 2003, PROSTAG LEUKOTR ESS, V69, P135, DOI 10.1016/S0952-3278(03)00074-7; Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516; Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200; Blanchard C, 2009, ADV IMMUNOL, V101, P81, DOI 10.1016/S0065-2776(08)01003-1; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; Brock TG, 1999, J IMMUNOL, V162, P1669; Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074, DOI 10.1164/ajrccm.161.6.9906085; Ferrari D, 2006, J LEUKOCYTE BIOL, V79, P7, DOI 10.1189/jlb.0505286; Friesen CA, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-32; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gutierrez-Pena EJ, 1998, PARASITOL RES, V84, P607, DOI 10.1007/s004360050459; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kopriva F, 2006, CLIN DRUG INVEST, V26, P351; Langlois A, 2006, J ALLERGY CLIN IMMUN, V118, P113, DOI 10.1016/j.jaci.2006.03.010; Lee TH, 2009, J ALLERGY CLIN IMMUN, V124, P417, DOI 10.1016/j.jaci.2009.04.020; Lynch KR, 1999, NATURE, V399, P789; Mamedova L, 2005, BIOCHEM PHARMACOL, V71, P115, DOI 10.1016/j.bcp.2005.10.003; Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x; Neves JS, 2009, J IMMUNOL METHODS, V344, P64, DOI 10.1016/j.jim.2009.03.006; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; Nielsen CK, 2005, CANCER RES, V65, P732; Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rovati GE, 2007, THESCIENTIFICWORLDJO, V7, P1375, DOI 10.1100/tsw.2007.185; Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Storms W, 2007, EXPERT OPIN PHARMACO, V8, P2173, DOI 10.1517/14656566.8.13.2173; Toyoda M, 1996, AM J DERMATOPATH, V18, P49, DOI 10.1097/00000372-199602000-00008; Watanabe K, 2003, ANN OTO RHINOL LARYN, V112, P169, DOI 10.1177/000348940311200211	39	69	70	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					477	482		10.1016/j.jaci.2009.11.029	http://dx.doi.org/10.1016/j.jaci.2009.11.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159258	Green Accepted, Green Submitted			2022-12-18	WOS:000274764000028
J	Albrecht, M; Kuhne, Y; Ballmer-Weber, BK; Becker, WM; Holzhauser, T; Lauer, I; Reuter, A; Randow, S; Falk, S; Wangorsch, A; Lidholm, J; Reese, G; Vieths, S				Albrecht, Melanie; Kuehne, Yvonne; Ballmer-Weber, Barbara K.; Becker, Wolf-Meinhard; Holzhauser, Thomas; Lauer, Iris; Reuter, Andreas; Randow, Stefanie; Falk, Sabine; Wangorsch, Andrea; Lidholm, Jonas; Reese, Gerald; Vieths, Stefan			Relevance of IgE binding to short peptides for the allergenic activity of food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SPOT technique; B-cell epitopes; allergy; Pen a 1; Ara h 2; IgE binding	MAJOR PEANUT ALLERGEN; IN-VITRO; SHRIMP ALLERGEN; POLLEN ALLERGEN; BROWN SHRIMP; IDENTIFICATION; EPITOPES; PROTEIN; MILK; REACTIVITY	Background: Analysis of IgE antibody binding to epitopes provides information for food allergy diagnosis and management and construction of hypoallergenic candidate vaccines, but the contribution of sequential epitopes to functionally relevant IgE binding is not fully understood. Objectives: We sought to study the impact of IgE-binding peptides described as major sequence epitopes in the literature on IgE-binding capacity of 2 selected food allergens. Methods: IgE-binding peptides of the food allergens Ara h 2 (peanut) and Pen a 1 (shrimp) were identified. Synthetic soluble peptides representing the identified sequences were assessed for their capacity to inhibit IgE binding to the parent allergens by means of ELISA and in mediator release assay. The IgE-binding capacity of unfolded recombinant (r) Ara h 2 was analyzed. A hybrid tropomyosin carrying the IgE-binding regions of Pen a 1 grafted into the structural context of the nonallergenic mouse tropornyosin was applied in ELISA inhibition experiments and ImmunoCAP analysis. Results: Although IgE-binding peptides representing sections of the allergen sequences were detected, no relevant capacity to inhibit the IgE binding to the parent allergen in ELISA or basophil activation test was observed. Unfolded rAra h 2 showed reduced IgE-binding capacity compared with folded rAra h 2 and failed to elicit mediator release. Hybrid tropomyosin bound less IgE than rPen a 1 in ImmunoCAP analysis and revealed marginal inhibitory capacity. Conclusion: Peptides identified as major sequence epitopes on Pen a 1 and Ara h 2 show little contribution to the IgE binding of the allergens studied. (J Allergy Clin Immunol 2009;124: 328-36.)	[Albrecht, Melanie; Kuehne, Yvonne; Holzhauser, Thomas; Lauer, Iris; Reuter, Andreas; Randow, Stefanie; Falk, Sabine; Wangorsch, Andrea; Reese, Gerald; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-63225 Langen, Germany; [Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Becker, Wolf-Meinhard] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Borstel, Germany; [Lidholm, Jonas] Phadia AB, Uppsala, Sweden	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital; Forschungszentrum Borstel; Thermo Fisher Scientific; Phadia	Vieths, S (corresponding author), Paul Ehrlich Inst, Div Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	viest@pei.de	Holzhauser, Thomas/ABD-5038-2020	Holzhauser, Thomas/0000-0002-7818-7261; Reuter, Andreas/0000-0002-6082-9000; Lidholm, Jonas/0000-0002-7779-3411	Paul-Ehrlich-Institut, Langen, Germany	Paul-Ehrlich-Institut, Langen, Germany	Supported by Paul-Ehrlich-Institut, Langen, Germany.	Albrecht M, 2008, MOL NUTR FOOD RES, V52, pS186, DOI 10.1002/mnfr.200700424; Alcocer MJC, 2004, J MOL BIOL, V343, P759, DOI 10.1016/j.jmb.2004.08.065; AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; Ayuso R, 2002, INT ARCH ALLERGY IMM, V127, P27, DOI 10.1159/000048166; Bannon GA, 2004, CURR ALLERGY ASTHM R, V4, P43, DOI 10.1007/s11882-004-0042-0; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Bannon GA, 2006, MOL NUTR FOOD RES, V50, P638, DOI 10.1002/mnfr.200500276; Battais F, 2005, ALLERGY, V60, P815, DOI 10.1111/j.1398-9995.2005.00795.x; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; Buhot C, 2004, PROTEIN SCI, V13, P2970, DOI 10.1110/ps.04885404; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Chatel JM, 2003, INT ARCH ALLERGY IMM, V131, P14, DOI 10.1159/000070429; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DeWitt AM, 2004, MOL NUTR FOOD RES, V48, P370, DOI 10.1002/mnfr.200400015; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Gruber P, 2004, MOL NUTR FOOD RES, V48, P449, DOI 10.1002/mnfr.200400005; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Lehmann K, 2006, BIOCHEM J, V395, P463, DOI 10.1042/BJ20051728; Lehmann K, 2003, PROTEIN EXPRES PURIF, V31, P250, DOI 10.1016/S1046-5928(03)00190-6; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Reese G, 2006, CLIN EXP ALLERGY, V36, P517, DOI 10.1111/j.1365-2222.2006.02454.x; Reese G, 2005, J IMMUNOL, V175, P8354, DOI 10.4049/jimmunol.175.12.8354; Reese G, 2001, J CHROMATOGR B, V756, P157, DOI 10.1016/S0378-4347(01)00104-9; Reese G, 2007, J ALLERGY CLIN IMMUN, V119, P944, DOI 10.1016/j.jaci.2006.11.699; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Schramm G, 1999, J IMMUNOL, V162, P2406; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tanabe S, 2007, CURR PROTEIN PEPT SC, V8, P109, DOI 10.2174/138920307779941569; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2004, METHODS, V32, P313, DOI 10.1016/j.ymeth.2003.08.016	48	69	71	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					328	336		10.1016/j.jaci.2009.05.031	http://dx.doi.org/10.1016/j.jaci.2009.05.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19596143				2022-12-18	WOS:000268860400021
J	DeMore, JP; Weisshaar, EH; Vrtis, RF; Swenson, CA; Evans, MD; Morin, A; Hazel, E; Bork, JA; Kakumanu, S; Sorkness, R; Busse, WW; Gern, JE				DeMore, Jennifer P.; Weisshaar, Elizabeth H.; Vrtis, Rose F.; Swenson, Cheri A.; Evans, Michael D.; Morin, Allison; Hazel, Elizabeth; Bork, Jack A.; Kakumanu, Sujani; Sorkness, Ronald; Busse, William W.; Gern, James E.			Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral respiratory tract infections; virus-induced asthma; rhinovirus; eosinophil; CCL2; CXCL8; total serum IgE; allergy; common cold	RESPIRATORY VIRUSES; EPITHELIAL-CELLS; COMMON COLD; INFECTION; EXACERBATIONS; INFLAMMATION; ILLNESSES; CHILDREN; LAVAGE	Background: Rhinovirus infections are frequent causes of asthma exacerbations. Objective: This study was conducted to test whether subjects with and without allergic asthma have different responses to infection and to identify baseline patient risk factors that predict cold outcomes. Methods: Twenty subjects with mild persistent allergic asthma and 18 healthy subjects were experimentally inoculated with rhinovirus-16. Subjects were evaluated at baseline, during the acute infection, and during recovery for asthma and cold symptoms by using a validated questionnaire. Sputum and nasal lavage fluid were evaluated for viral shedding, cytokines, and cellular inflammation. Results: There were no group-specific significant differences in peak cold symptom scores (10.0 +/- 5.8 vs 11.1 +/- 6.2, asthmatic vs healthy subjects), peak nasal viral titers (log(10) 4.3 +/- 0.8 vs 3.7 +/- 1.4 50% tissue culture infective dose/mL, respectively), or changes in peak flow during the study (10% +/- 10% vs 8% +/- 6%, respectively). Rhinovirus-16 infection increased peak asthma index values in the asthmatic group (median, 6 -> 13; P = .003) but only marginally in the healthy group (median, 4 -> 7; P = .09). More asthmatic subjects had detectable eosinophils in nasal lavage and sputum samples at baseline and during infection, but otherwise, cellular and cytokine responses were similar. Baseline sputum eosinophilia and CXCL8 (IL-8) levels were positively associated with cold symptoms, whereas CCL2 (monocyte chemotactic protein 1) levels were inversely associated with nasal viral shedding. Conclusions: These findings suggest that subjects with mild allergic asthma and healthy subjects have similar cold symptoms and inflammatory and antiviral responses. In addition, eosinophilia and other selective baseline measures of airway inflammation in subjects with or without asthma might predict respiratory outcomes with rhinovirus infection. (J Allergy Clin Immunol 2009;124:245-52.)	[DeMore, Jennifer P.; Weisshaar, Elizabeth H.; Vrtis, Rose F.; Swenson, Cheri A.; Morin, Allison; Hazel, Elizabeth; Sorkness, Ronald; Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Bork, Jack A.; Sorkness, Ronald; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	DeMore, JP (corresponding author), K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.	jpd@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993; Hazel, Elizabeth A./0000-0002-9176-3278	National Institutes of Health; National Institute of Allergy and Infections Diseases [P01 AI50500, U19 AI070503-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050500, U19AI070503] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infections Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by funds from National Institutes of Health and National Institute of Allergy and Infections Diseases grants P01 AI50500 and U19 AI070503-01.	Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Chae P, 2002, INFECT IMMUN, V70, P3164, DOI 10.1128/IAI.70.6.3164-3169.2002; COME JM, 2002, LANCET, V359, P831; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Davoine F, 2008, J ALLERGY CLIN IMMUN, V122, P69, DOI 10.1016/j.jaci.2008.03.028; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Gern JE, 2002, AM J MED, V112, p19S; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Sorkness RL, 2008, J ALLERGY CLIN IMMUN, V122, P838, DOI 10.1016/j.jaci.2008.07.041; van Benten IJ, 2001, ALLERGY, V56, P949, DOI 10.1034/j.1398-9995.2001.00212.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	26	69	71	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					245	252		10.1016/j.jaci.2009.05.030	http://dx.doi.org/10.1016/j.jaci.2009.05.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19596142	Green Accepted			2022-12-18	WOS:000268860400010
J	Staden, U; Blumchen, K; Blankenstein, N; Dannenherg, N; Ulbricht, H; Dobberstein, K; Ziegert, M; Niggenzann, B; Wahn, U; Beyer, K				Staden, Ute; Blumchen, Katharina; Blankenstein, Nike; Dannenherg, Nicole; Ulbricht, Helen; Dobberstein, Kerstin; Ziegert, Mandy; Niggenzann, Bodo; Wahn, Ulrich; Beyer, Kirsten			Rush oral immunotherapy in children with persistent cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOLERANCE INDUCTION; FOOD ALLERGY; DESENSITIZATION		[Staden, Ute; Blumchen, Katharina; Blankenstein, Nike; Dannenherg, Nicole; Ulbricht, Helen; Dobberstein, Kerstin; Ziegert, Mandy; Niggenzann, Bodo; Wahn, Ulrich; Beyer, Kirsten] Campus Virchow Klinikum, Dept Pediat Pneumol & Immunol, Charite, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Staden, U (corresponding author), Campus Virchow Klinikum, Dept Pediat Pneumol & Immunol, Charite, Berlin, Germany.							Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	9	69	70	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					418	419		10.1016/j.jaci.2008.06.002	http://dx.doi.org/10.1016/j.jaci.2008.06.002			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18602681	Bronze			2022-12-18	WOS:000258426300034
J	Bree, A; Schlerman, FJ; Wadanoli, M; Tchistiakova, L; Marquette, K; Tan, XY; Jacobson, BA; Widom, A; Cook, TA; Wood, N; Vunnum, S; Krykbaev, R; Xu, X; Donaldson, DD; Goldman, SJ; Sypek, J; Kasaian, MT				Bree, Andrea; Schlerman, Franklin J.; Wadanoli, Michael; Tchistiakova, Lioudmila; Marquette, Kimberly; Tan, Xiang-Yang; Jacobson, Bruce A.; Widom, Angela; Cook, Timothy A.; Wood, Nancy; Vunnum, Suresh; Krykbaev, Rustem; Xu, Xin; Donaldson, Debra D.; Goldman, Samuel J.; Sypek, Joseph; Kasaian, Marion T.			IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; inflammation; cynomolgus monkey; asthma; Ascaris suum	SEGMENTAL ALLERGEN CHALLENGE; AIRWAY HYPERRESPONSIVENESS; CHRONIC ASTHMA; MOUSE MODEL; INTERLEUKIN-13; EXPRESSION; RELEASE; ANTIGEN; CELLS; ACCUMULATION	Background: Airway inflammation is a hallmark feature of asthma and a driver of airway hyperresponsiveness. IL-13 is a key inducer of airway inflammation in rodent models of respiratory disease, but a role for IL-13 has not been demonstrated in primates. Objective: We sought to test the efficacy of a neutralizing antibody to human IL-13 in a cynomolgus monkey model of lung inflammation. Methods: Using cynomolgus monkeys (Macaca fascicularis) that are sensitized to Ascaris suum through natural exposure, we developed a reproducible model of acute airway inflammation after segmental A suum antigen challenge. This model was used to test the in vivo efficacy of mAb13.2, a mouse mAb directed against human IL-13, and IMA-638, the humanized counterpart of mAb13.2. Bronchoalveolar lavage (BAL) cells and BAL fluid were collected before and after antigen challenge and assayed for cellular content by means of differential count. Results: Total BAL cell count, eosinophil number, and neutrophil number were all reduced in animals treated with mAb13.2 or IMA-638 compared with values in control animals that were untreated, given saline, or treated with human IgG of irrelevant specificity. In addition, levels of eotaxin and RANTES in BAL fluid were reduced in anti-IL-13-treated animals compared with levels seen in control animals. Conclusion: These findings support a role for IL-13 in maintaining lung inflammation in response to allergen challenge in nonhuman primates.	Wyeth Ayerst Res, Cambridge, MA 02140 USA	Pfizer	Kasaian, MT (corresponding author), Wyeth Ayerst Res, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	mkasaian@wyeth.com						Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Bost KL, 1997, AM J TROP MED HYG, V56, P351, DOI 10.4269/ajtmh.1997.56.351; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238, DOI 10.1164/ajrccm.157.6.mar6; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; Calhoun WJ, 2001, AM J RESP CRIT CARE, V163, P881, DOI 10.1164/ajrccm.163.4.2001060; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Coffman RL, 2005, J EXP MED, V201, P1875, DOI 10.1084/jem.20050901; de Swart RL, 2002, J VIROL, V76, P11561, DOI 10.1128/JVI.76.22.11561-11569.2002; Fahy JV, 2006, J ALLERGY CLIN IMMUN, V117, P1230, DOI 10.1016/j.jaci.2006.01.046; Ferreira MAR, 2003, MEDIAT INFLAMM, V12, P259, DOI 10.1080/09629350310001619717; GUNDEL RH, 1992, CLIN EXP ALLERGY, V22, P303, DOI 10.1111/j.1365-2222.1992.tb03087.x; GUNDEL RH, 1991, AM REV RESPIR DIS, V144, P76, DOI 10.1164/ajrccm/144.1.76; Hasday JD, 2000, AM J RESP CRIT CARE, V161, P1229, DOI 10.1164/ajrccm.161.4.9904026; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; HUANG SK, 1995, J IMMUNOL, V155, P2688; Kasaian MT, 2007, AM J RESP CELL MOL, V36, P368, DOI 10.1165/rcmb.2006-0244OC; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Li L, 1999, J IMMUNOL, V162, P2477; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Tamura K, 2003, INT ARCH ALLERGY IMM, V131, P33, DOI 10.1159/000070432; Tillie-Leblond I, 2005, ALLERGY, V60, P23, DOI 10.1111/j.1398-9995.2005.00632.x; Turner CR, 1996, INFLAMM RES, V45, P239, DOI 10.1007/BF02259610; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; WEGNER CD, 1991, J ALLERGY CLIN IMMUN, V87, P835, DOI 10.1016/0091-6749(91)90130-G; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Young SS, 1999, INT ARCH ALLERGY IMM, V120, P209, DOI 10.1159/000024269; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zou J, 2002, GENOME BIOL, V3	38	69	94	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1251	1257		10.1016/j.jaci.2007.02.009	http://dx.doi.org/10.1016/j.jaci.2007.02.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17379289				2022-12-18	WOS:000246427200029
J	Koya, T; Matsuda, H; Takeda, K; Matsubara, S; Miyahara, N; Balhorn, A; Dakhama, A; Gelfand, EW				Koya, Toshiyuki; Matsuda, Hiroyuki; Takeda, Katsuyuki; Matsubara, Shigeki; Miyahara, Nobuaki; Balhorn, Annette; Dakhama, Azzeddine; Gelfand, Erwin W.			IL-10-treated dendritic cells decrease airway hyperresponsiveness and airway inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10-treated dendritic cells; eosinophils; airway hyperresponsiveness; regulatory T cells	REGULATORY T-CELLS; CYTOKINE PRODUCTION; IMMUNE-RESPONSE; INHALED ANTIGEN; IN-VITRO; IL-10; INTERLEUKIN-10; CD4(+); EXPRESSION; INDUCTION	Background: IL-10 affects dendritic cell (DC) function, but the effects on airway hyperresponsiveness (AHR) and inflammation are not defined. Objective: We sought to determine the importance of IL-10 in regulating DC function in allergen-induced AHR and airway inflammation. Methods: DCs were generated from bone marrow in the presence or absence of IL-10. In vivo IL-10-treated DCs from IL-10(+/+) and IL-10(-/-) donors pulsed with ovalbumin (OVA) were transferred to naive or sensitized mice before challenge. In recipient mice AHR, cytokine levels, cell composition of bronchoalveolar lavage (BAL) fluid, and lung histology were monitored. Results: In vitro, IL-10-treated DCs expressed lower levels of CD11c, CD80, and CD86; expressed lower levels of IL-12; and suppressed T(H)2 cytokine production. In vivo, after transfer of OVA-pulsed IL-10-treated DCs, naive mice did not have AHR, airway eosinophilia, T(H)2 cytokine increase in BAL fluid, or goblet cell metaplasia when challenged, and in sensitized and challenged mice IL-10-treated I)Cs suppressed these responses. Levels of IL-10 in BAL fluid and numbers of lung CD4(+)IL-10(+) T cells were increased in mice that received OVA-pulsed IL-10-treated DCs. Transfer of IL-10-treated DCs from IL-10-deficient mice were ineffective in suppressing the responses in sensitized and challenged mice. Conclusions: These data demonstrate that IL-10-treated DCs are potent suppressors of the development of AHR, inflammation, and T(H)2 cytokine production; these regulatory functions are at least in part through the induction of endogenous (DQ production of IL-10. Clinical implications: Modification of DC function by IL-10 can attenuate lung allergic responses, including the development of AHR.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL036577, HL-61055, HL-36577, P01 HL036577-21A15977] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chan VWF, 1999, BLOOD, V93, P3610, DOI 10.1182/blood.V93.11.3610.411a48_3610_3616; Commeren DL, 2003, IMMUNOLOGY, V110, P188, DOI 10.1046/j.1365-2567.2003.01730.x; DEL PG, 1993, J IMMUNOL, V150, P353; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Haase C, 2002, IMMUNOLOGY, V107, P489, DOI 10.1046/j.1365-2567.2002.01529.x; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363, DOI 10.1152/ajplung.2001.280.2.L363; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Koya T, 2006, AM J RESP CRIT CARE, V173, P42, DOI 10.1164/rccm.200505-783OC; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liu LM, 1998, INT IMMUNOL, V10, P1017, DOI 10.1093/intimm/10.8.1017; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MALEFYT RD, 1991, J EXP MED, V174, P915; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nakagome K, 2005, J IMMUNOL, V174, P6955, DOI 10.4049/jimmunol.174.11.6955; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Steinbrink K, 1999, BLOOD, V93, P1634, DOI 10.1182/blood.V93.5.1634.405k11_1634_1642; Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4	47	69	74	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1241	1250		10.1016/j.jaci.2007.01.039	http://dx.doi.org/10.1016/j.jaci.2007.01.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17353041	Bronze			2022-12-18	WOS:000246427200028
J	Scirica, CV; Gold, DR; Ryan, L; Abulkerim, H; Celedon, JC; Platts-Mills, TAE; Naccara, LM; Weiss, ST; Litonjua, AA				Scirica, Christina V.; Gold, Diane R.; Ryan, Louise; Abulkerim, Hassen; Celedon, Juan C.; Platts-Mills, Thomas A. E.; Naccara, Lisa M.; Weiss, Scott T.; Litonjua, Augusto A.			Predictors of cord blood IgE levels in children at risk for asthma and a atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; cord blood; atopy; socioeconomic status; Hispanic ethnicity	CORONARY-ARTERY CALCIFICATION; QUALITY-OF-LIFE; SERUM IGE; CESAREAN-SECTION; IMMUNOGLOBULIN-E; FAMILY HISTORY; SOCIOECONOMIC-FACTORS; ALLERGIC DISORDERS; DELIVERY; DISEASE	Background: Increased cord blood IgE levels, in conjunction with a family history of atopy, are associated with the development of allergic diseases in children. However, little is known about predictors of cord blood IgE levels. Objective: Our objective was to identify predictors of cord blood IgE levels among infants at increased risk of atopy. Methods: Cord blood IgE levels were measured in 874 infants who were screened for participation in a birth cohort. Questionnaires were administered after birth of the infant, and maternal and cord blood was obtained for measurement of IgE levels. Logistic and tobit regression models were used to study the association between perinatal factors and cord blood IgE levels. Results: In multivariable models infant male sex, increased maternal total IgE level, maternal allergen sensitization, Hispanic ethnicity, and residence in low-income areas were associated with detectable or increased cord blood IgE levels, whereas increasing maternal age was associated with undetectable or lower cord blood IgE levels. Although maternal smoking during pregnancy was positively associated with cord blood IgE levels in univariable models, the effect did not persist after adjusting for potential confounders. Conclusion: Maternal allergen sensitization, markers of socioeconomic disadvantage and race/ethnicity, maternal age, and infant sex might influence fetal production of IgE. We found no association of maternal parity, mode of delivery, gestational age, or season of birth with cord blood IgE levels. Clinical implications: The identification of these definable familial and environmental factors that predict cord blood IgE levels might help in the early detection of infants at risk for atopic disorders.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02111 USA; Harvard Univ, Sch Publ Hlth, Dept Stat, Boston, MA 02111 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Virginia	Litonjua, AA (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 75 Francis St, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu	Ryan, Louise M/A-4562-2009	Ryan, Louise M/0000-0001-5957-2490; Platts-Mills, Thomas/0000-0002-1263-329X; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [5 T32 HL07427-23] Funding Source: Medline; NIAID NIH HHS [R01 AI20565, R01 AI35786-12] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R01AI035786] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Austin PC, 2002, VALUE HEALTH, V5, P329, DOI 10.1046/j.1524-4733.2002.54128.x; Austin PC, 2000, QUAL LIFE RES, V9, P901, DOI 10.1023/A:1008938326604; AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; BERGMANN RL, 1995, ALLERGY, V50, P65, DOI 10.1111/j.1398-9995.1995.tb02484.x; Bielak LF, 2004, J HYPERTENS, V22, P719, DOI 10.1097/00004872-200404000-00014; Bjerke T, 1994, Pediatr Allergy Immunol, V5, P88, DOI 10.1111/j.1399-3038.1994.tb00223.x; Caracta CF, 2003, MT SINAI J MED, V70, P215; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Fornage M, 2004, CIRCULATION, V109, P335, DOI 10.1161/01.CIR.0000109487.46725.02; Hahl J, 2002, QUAL LIFE RES, V11, P427, DOI 10.1023/A:1015684100227; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; Hansen L G, 1993, Pediatr Allergy Immunol, V4, P34, DOI 10.1111/j.1399-3038.1993.tb00063.x; HANSEN LG, 1992, ALLERGY, V47, P391, DOI 10.1111/j.1398-9995.1992.tb02078.x; HAUS M, 1988, J ALLERGY CLIN IMMUN, V82, P179, DOI 10.1016/0091-6749(88)90997-9; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Johnson CC, 1996, CLIN EXP ALLERGY, V26, P624, DOI 10.1111/j.1365-2222.1996.tb00588.x; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Karmaus W, 2004, CLIN EXP ALLERGY, V34, P853, DOI 10.1111/j.1365-2222.2004.01959.x; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Laubereau B, 2004, ARCH DIS CHILD, V89, P993, DOI 10.1136/adc.2003.043265; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Liu Chieh-An, 2003, Chang Gung Med J, V26, P561; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; Maitra A, 2004, CLIN EXP ALLERGY, V34, P1349, DOI 10.1111/j.1365-2222.2004.02048.x; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; Negele K, 2004, PEDIAT ALLERG IMM-UK, V15, P48, DOI 10.1046/j.0905-6157.2003.00101.x; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; ODELRAM H, 1995, ALLERGY, V50, P585, DOI 10.1111/j.1398-9995.1995.tb01204.x; Oryszczyn MP, 1999, CLIN EXP ALLERGY, V29, P334; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Reilly MP, 2004, ATHEROSCLEROSIS, V173, P69, DOI 10.1016/j.atherosclerosis.2003.10.010; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; RIVAS MA, 1994, ACTA PAEDIATR, V83, P1308, DOI 10.1111/j.1651-2227.1994.tb13023.x; SAS Institute Inc, 2006, SAS ONLINEDOC 9 1 3; Shirakawa T, 1997, EUR J EPIDEMIOL, V13, P395, DOI 10.1023/A:1007361013917; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	50	69	70	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					81	88		10.1016/j.jaci.2006.09.002	http://dx.doi.org/10.1016/j.jaci.2006.09.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208588				2022-12-18	WOS:000243622200013
J	Montuschi, P; Mondino, C; Koch, P; Barnes, PJ; Ciabattoni, G				Montuschi, Paolo; Mondino, Chiara; Koch, Pierluigi; Barnes, Peter J.; Ciabattoni, Giovanni			Effects of a leukotriene receptor antagonist on exhaled leukotriene E-4 and prostanoids in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotriene E-4; prostanoids; exhaled breath condensate; exhaled nitric oxide; childhood asthma; airway inflammation; noninvasive markers; leukotriene receptor antagonists	BREATH CONDENSATE; NITRIC-OXIDE; CYSTEINYL LEUKOTRIENES; AIRWAY INFLAMMATION; CHILDHOOD ASTHMA; MONTELUKAST; 8-ISOPROSTANE; MARKERS; BRONCHOCONSTRICTION; DISEASE	Background: Leukotriene (LT) E-4 and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma are unknown. Objective: (1) To study the effect of montelukast, a LTRA, on exhaled LTE4,8-isoprostane, and prostaglandin E-2 in children with asthma and atopic children; (2) to measure exhaled nitric oxide. Methods: An open-label study with oral montelukast (5 mg once daily for 4 weeks) was undertaken in 17 atopic children with asthma and 16 atopic children without asthma. Results: Pretreatment exhaled LTE4 (P < .0001) and 8-isoprostane (P < .0001) values were higher in atopic children with asthma than in atopic children without asthma. In atopic children with asthma, montelukast reduced exhaled LTE4 by 33% (P < .001), and this reduction was correlated with pretreatment LTE4 values (r = -0.90; P =.0001). Posttreatment exhaled LTE4 levels in children with asthma were higher than pretreatment LTE4 values in atopic children without asthma (P < .004). Montelukast had no effect on exhaled LTE4 in atopic children without asthma (P =.74), or on exhaled 8-isoprostane (atopic children with asthma, P =.94; atopic children without asthma, P =.55) and PGE(2) (atopic children with asthma, P =.56; atopic children without asthma, P =.93) in both groups. In atopic children with asthma, exhaled nitric oxide concentrations were reduced by 27% (P <.05) after montelukast. Conclusion: Leukotriene receptor antagonists decrease exhaled LTE4 in atopic children with asthma. This reduction is dependent on baseline exhaled LTE4 values. Clinical implications: Measurement of exhaled LTE4 might help identify children with asthma most likely to benefit from LTRAs.	Univ Cattolica Sacro Cuore, Fac Med, Dept Pharmacol, I-00168 Rome, Italy; IRCCS, Ist Dermopatico Immacolata, Dept Immunodermatol, Rome, Italy; Osped Pediat Bambino Gesu, Dept Pulmonol, Palidoro, Italy; Univ London Imperial Coll Sci & Technol, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England; Univ G DAnnunzio, Sch Pharm, Dept Drug Sci, Chieti, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Bambino Gesu; Imperial College London; G d'Annunzio University of Chieti-Pescara	Montuschi, P (corresponding author), Univ Cattolica Sacro Cuore, Fac Med, Dept Pharmacol, Largo F Vito,1, I-00168 Rome, Italy.	pmontuschi@rm.unicatt.it		Barnes, Peter/0000-0002-5122-4018; MONTUSCHI, Paolo/0000-0001-5589-1750				Baraldi E, 2003, THORAX, V58, P505, DOI 10.1136/thorax.58.6.505; BIEMACKI WA, 2005, CHEST, V128, P1958; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227, DOI 10.1164/ajrccm.160.4.9903004; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Cap P, 2004, THORAX, V59, P465, DOI 10.1136/thx.2003.011866; Carraro S, 2005, J ALLERGY CLIN IMMUN, V115, P764, DOI 10.1016/j.jaci.2004.10.043; CIABATTONI G, 1979, J ENDOCRINOL INVEST, V2, P173, DOI 10.1007/BF03349310; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Effros RM, 2002, AM J RESP CRIT CARE, V165, P663, DOI 10.1164/ajrccm.165.5.2101018; FLOREY CD, 1993, BRIT MED J, V306, P1181, DOI 10.1136/bmj.306.6886.1181; Frieri M, 2003, ALLERGY ASTHMA PROC, V24, P359; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Leff AR, 2001, ANNU REV MED, V52, P1; Leff AR, 2001, ANN ALLERG ASTHMA IM, V86, P1, DOI 10.1016/S1081-1206(10)62304-6; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Montuschi P, 2005, NEW PERSPECTIVES IN MONITORING LUNG INFLAMMATION: ANALYSIS OF EXHALED BREATH CONDENSATE, P11; Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev; Montuschi P, 2003, INFLAMM RES, V52, P502, DOI 10.1007/s00011-003-1212-6; Montuschi P, 2002, NAT REV DRUG DISCOV, V1, P238, DOI 10.1038/nrd751; Montuschi P, 2002, TRENDS PHARMACOL SCI, V23, P232, DOI 10.1016/S0165-6147(02)02020-5; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Murai A, 2005, J PHARMACOL EXP THER, V312, P432, DOI 10.1124/jpet.104.074922; *NAT ASTHM ED PREV, 2003, J ALLERGY CLIN IMMUN, V111, pS141; PAVORD I, 1995, LANCET, V336, P436; Ramires R, 2004, BIOCHEM BIOPH RES CO, V324, P815, DOI 10.1016/j.bbrc.2004.09.125; Straub DA, 2005, CHEST, V127, P509, DOI 10.1378/chest.127.2.509; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046; 1999, AM J RESP CRIT CARE, V160, P2104	35	69	74	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					347	353		10.1016/j.jaci.2006.04.010	http://dx.doi.org/10.1016/j.jaci.2006.04.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890757				2022-12-18	WOS:000239877700008
J	Lommatzsch, M; Julius, P; Kuepper, M; Garn, H; Bratke, K; Irmscher, S; Luttmann, W; Renz, H; Braun, A; Virchow, JC				Lommatzsch, Marek; Julius, Peter; Kuepper, Michael; Garn, Holger; Bratke, Kai; Irmscher, Sabrina; Luttmann, Werner; Renz, Harald; Braun, Armin; Virchow, J. Christian			The course of allergen-induced leukocyte infiltration in human and experimental asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen challenge; allergic airway inflammation; kinetics; leukocytes; eosinophils; bronchoalveolar lavage	AIRWAY HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; NEUROTROPHIC FACTOR; MURINE MODEL; EOSINOPHILS; INFLAMMATION; CHALLENGE; RECRUITMENT; LUNG; INTERLEUKIN-5	Background: Although the timing of allergen-induced bronchoconstriction is well defined, there is little information about the kinetics of allergen-induced leukocyte infiltration in asthma and its comparability between human and animal models of asthma. Objective: To investigate systematically allergen-induced leukocyte infiltration into the airway lumen in human and experimental asthma by using bronchoalveolar lavage. Methods: Patients with allergic asthma were lavaged at different time points as long as 1 week after segmental allergen challenge. Allergen-sensitized mice were lavaged as long as 3 weeks after allergen challenge. Differential cell counts, lymphocyte subsets, and cytokines were assessed in bronchoalveolar lavage fluid. Results: In both models, neutrophil infiltration was a relatively early event (maximum: 18 hours after challenge). In contrast, eosinophil infiltration peaked 42 hours (human model) to 4 days (mouse model) after allergen challenge, paralleled by an IL-5 peak in this period. There were elevated macrophage counts over a period of several days after allergen challenge in both models. Lymphocytes (predominantly CD4(+) T cells) peaked 18 hours after challenge in the human model, but not until 2 weeks after challenge in the murine model. Conclusion: Early neutrophil accumulation (within hours after challenge) and delayed eosinophil accumulation (within days after challenge) in the airway lumen are common features of allergen-induced airway inflammation, whereas lymphocyte kinetics are dependent on the asthma model. Clinical implications: Similarities in the infiltration kinetics of granulocytes after allergen challenge suggest a common role for these cells in asthma, whereas the presumed orchestration of allergic inflammation by lymphocytes appears to differ between the models.	Univ Rostock, Klin & Poliklin Innere Med, Abt Pneumol, Dept Pneumol, D-18057 Rostock, Germany; Univ Marburg, Inst Clin Chem & Mol Diagnost, D-35032 Marburg, Germany; Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany	University of Rostock; Philipps University Marburg; Fraunhofer Gesellschaft	Lommatzsch, M (corresponding author), Univ Rostock, Klin & Poliklin Innere Med, Abt Pneumol, Dept Pneumol, Ernst Heydemann Str 6, D-18057 Rostock, Germany.	marek.lommatzsch@med.uni-rostock.de	Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463; Garn, Holger/0000-0002-5178-4023				Bingham CO, 2000, J ALLERGY CLIN IMMUN, V105, pS527, DOI 10.1016/S0091-6749(00)90056-3; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Braun A, 2004, BRIT J PHARMACOL, V141, P431, DOI 10.1038/sj.bjp.0705638; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P565, DOI 10.1164/rccm.200307-1024OC; Erpenbeck VJ, 2004, AM J RESP CRIT CARE, V169, P578, DOI 10.1164/rccm.200301-104OC; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; FAIRBAIRN SM, 1993, CLIN EXP ALLERGY, V23, P821, DOI 10.1111/j.1365-2222.1993.tb00259.x; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Henderson AC, 2003, J APPL PHYSIOL, V95, P873, DOI 10.1152/japplphysiol.00075.2003; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Julius P, 1999, EUR RESPIR J, V13, P1253, DOI 10.1034/j.1399-3003.1999.13f07.x; Kay AB, 2003, AM J RESP CRIT CARE, V167, P1586, DOI 10.1164/rccm.2304001; Kobayashi T, 2003, J IMMUNOL, V170, P5756, DOI 10.4049/jimmunol.170.11.5756; Krug N, 1996, AM J RESP CRIT CARE, V153, P1391, DOI 10.1164/ajrccm.153.4.8616571; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemanske Robert F. Jr., 2003, Journal of Allergy and Clinical Immunology, V111, pS502; Liu LY, 2004, AM J RESP CRIT CARE, V169, P1118, DOI 10.1164/rccm.200312-1659OC; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510, DOI 10.1165/ajrcmb.16.5.9160833; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; Schneider T, 1997, AM J RESP CELL MOL, V17, P702, DOI 10.1165/ajrcmb.17.6.2849; Southam DS, 2005, J ALLERGY CLIN IMMUN, V115, P95, DOI 10.1016/j.jaci.2004.09.022; Teran LM, 1996, AM J RESP CRIT CARE, V154, P469, DOI 10.1164/ajrccm.154.2.8756824; Teran LM, 1999, CYTOKINE, V11, P518, DOI 10.1006/cyto.1998.0457; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326, DOI 10.1165/ajrcmb.20.6.3561; Williams TJ, 2004, J CLIN INVEST, V113, P507, DOI 10.1172/JCI200421073	36	69	73	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					91	97		10.1016/j.jaci.2006.02.034	http://dx.doi.org/10.1016/j.jaci.2006.02.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815143				2022-12-18	WOS:000239184800011
J	Knight, AK; Shreffler, WG; Sampson, HA; Sicherer, SH; Noone, S; Mofidi, S; Nowak-Wegrzyn, A				Knight, AK; Shreffler, WG; Sampson, HA; Sicherer, SH; Noone, S; Mofidi, S; Nowak-Wegrzyn, A			Skin prick test to egg white provides additional diagnostic utility to serum egg white-specific IgE antibody concentration in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg allergy; food allergy; oral food challenge; skin prick test	NATURAL-HISTORY; FOOD CHALLENGES; FOLLOW-UP; ATOPIC-DERMATITIS; PREDICTIVE-VALUE; ALLERGY; PEANUT; PREVALENCE; SENSITIZATION; RISK	Background: Levels of IgE antibody to egg white of greater than 7 kIU/L are highly predictive of clinical reactivity to egg, and lower levels often require evaluation with oral food challenge (OFC) to establish definitive diagnosis. OFCs have inherent risks, and diagnostic criteria indicating high likelihood of passing would be clinically useful. Objective: We sought to determine whether the size of the skin prick test (SPT) to egg white adds diagnostic utility for children with low egg white-specific IgE antibody levels. Methods: A retrospective analysis of clinical history, egg white-specific IgE antibody levels, SPT responses, and egg OFC outcomes was performed. Results: Children who passed (n = 29) egg OFCs and those who failed (n = 45) did not differ significantly in age, clinical characteristics, or egg white-specific IgE levels. There were, however, significant differences between both egg white SPT wheal response size and egg/histamine SPT wheal index. Children who failed egg OFCs had a median wheal of 5.0 mm; those who passed had a median wheal of 3.0 nim (P = .003). Children who failed egg OFCs had a median egg/histamine index of 1.00; those who passed had a median index of 0.71 (P = .001). For egg white-specific IgE levels of less than 2.5 kIU/L, an SPT wheal of 3 mm or an egg/histamine index of 0.65 was associated with a 50% chance of passing. Conclusion: In children with low egg white-specific IgE levels, those with smaller SPT wheal responses to egg were more likely to pass an egg OFC than those with larger wheal responses. The size of the egg white SPT response might provide additional information to determine the timing of egg OFC. Clinical implications: The size of the egg white SPT wheal response might provide the clinician with additional information to determine the timing of egg OFC in children with low egg white-specific IgE antibody levels.	CUNY Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Clin Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, Box 1198,1 Gustave Levy Pl, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	NCRR NIH HHS [M01-RR-00071] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Carr WW, 2005, J ALLERGY CLIN IMMUN, V116, P341, DOI 10.1016/j.jaci.2005.03.035; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; *FOOD ALL AN NETW, 2004, HLTH PROF GUID FOOD; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wolkerstorfer A, 2002, CLIN EXP ALLERGY, V32, P70, DOI 10.1046/j.0022-0477.2001.01265.x; Wood RA, 2003, PEDIATRICS, V111, P1631	27	69	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					842	847		10.1016/j.jaci.2005.12.1304	http://dx.doi.org/10.1016/j.jaci.2005.12.1304			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630943				2022-12-18	WOS:000236862800019
J	Schatz, M; Zeiger, RS; Mosen, D; Apter, AJ; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF				Schatz, M; Zeiger, RS; Mosen, D; Apter, AJ; Vollmer, WM; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF			Improved asthma outcomes from allergy specialist care: A population-based cross-sectional analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma outcomes; asthma specialist care; allergist care	INHALED CORTICOSTEROIDS; MANAGEMENT; SYMPTOMS; ADULTS; RISK	Background: Prior studies suggest that allergist care improves asthma outcomes, but many of these studies have methodological shortcomings. Objective: We sought to compare patient-based and medical utilization outcomes in randomly selected asthmatic patients cared for by allergists versus primary care providers. Methods: A random sample of 3568 patients enrolled in a staff model health maintenance organization who were given diagnoses of persistent asthma completed surveys. Of these participants, 1679 (47.1%) identified a primary care provider as their regular source of asthma care, 884 (24.8%) identified an allergist, 693 (19.4%) reported no regular source of asthma care, and 195 (5.5%) identified a pulmonologist. Validated quality of life, control, severity, patient satisfaction, and self-management knowledge tools and linked administrative data that captured medication use were compared between groups, adjusting for demographics and baseline hospital and corticosteroid use. Results: Compared with those followed by primary care providers, patients of allergists reported significantly higher (P < .001) generic physical and asthma-specific quality of life, less asthma control problems, less severe symptoms, higher satisfaction with care, and greater self-management knowledge. Patients of allergists were less likely than patients of primary care providers to require an asthma hospitalization (odds ratio, 0.45) or unscheduled visit (odds ratio, 0.71) and to overuse beta-agonists (odds ratio, 0.47) and were more likely to receive inhaled steroids (odds ratio, 1.81) during their past year. Conclusions: Allergist care is associated with a wide range of improved outcomes in asthmatic patients compared with care provided by primary care providers.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Dept Allergy, Sacramento, CA USA; Dept Allergy, Vacaville, CA USA; Ctr Hlth Res, Portland, OR USA; Care Management Inst, Oakland, CA USA; Univ Penn, Sch Med, Kaiser Permanente Med Care Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pulm & Crit Care Med, Div Allergy Immunol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Kaiser Permanente; Kaiser Permanente; University of Pennsylvania; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org	Leong, Albin/AAF-7215-2019	Zeiger, Robert/0000-0001-5788-5063				BAYLISS MS, 1999, ASTHMA OUTCOMES MONI; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Eisner MD, 1998, MED CARE, V36, P1567, DOI 10.1097/00005650-199811000-00006; *FDN ACC, 1999, FACCT QUAL MEAS MEAS; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Kanter LJ, 2002, ANN ALLERG ASTHMA IM, V89, P139, DOI 10.1016/S1081-1206(10)61929-1; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; MAHR TA, 1993, ANN ALLERGY, V71, P115; Moore CM, 1997, ANN ALLERG ASTHMA IM, V78, P373, DOI 10.1016/S1081-1206(10)63199-7; *NAT COMM QUAL ASS, 2001, HEDIS 2002, V2; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; SPERBER K, 1995, J ASTHMA, V32, P335, DOI 10.3109/02770909509082758; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Vilar MEB, 2000, ANN ALLERG ASTHMA IM, V84, P299, DOI 10.1016/S1081-1206(10)62777-9; Vollmer WM, 2002, CURR OPIN ALLERGY CL, V2, P189, DOI 10.1097/00130832-200206000-00006; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Westley CR, 1997, ALLERGY ASTHMA PROC, V18, P15, DOI 10.2500/108854197778612835; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	26	69	69	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1307	1313		10.1016/j.jaci.2005.09.027	http://dx.doi.org/10.1016/j.jaci.2005.09.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337464				2022-12-18	WOS:000235687000023
J	Hoetzenecker, W; Ecker, R; Kopp, T; Stuetz, A; Stingl, G; Elbe-Burger, A				Hoetzenecker, W; Ecker, R; Kopp, T; Stuetz, A; Stingl, G; Elbe-Burger, A			Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Langerhans cells; T cells; apoptosis; corticosteroids; pimecrolimus	SDZ ASM 981; DENDRITIC CELLS; IN-VITRO; TACROLIMUS OINTMENT; MURINE EPIDERMIS; SKIN DISEASES; GLUCOCORTICOSTEROIDS; FK506; EXPRESSION; CORTICOSTEROIDS	Background: Apart from the long-used corticosteroids, topical calcineurin inhibitors (tacrolimus, pimecrolimus) represent novel therapeutic options for the treatment of atopic dermatitis. Objective: This study was designed to investigate the pathophysiological target cells and mode of action of pimecrolimus in atopic skin. Methods: Twenty-two patients were randomly assigned to treatment with pimecrolimus cream 1%, matching vehicle cream, or beta-methasone-17-valerate (BMV) cream 0.1% in a randomized, double-blind, vehicle-controlled, parallel group clinical trial. Treatment was given twice daily for 3 weeks. Cryostat sections of skin biopsies were taken before as well as at selected time points after initiation of therapy. For certain experiments, healthy volunteers were topically treated with the creams described twice a day on 5 consecutive days. Epidermal sheets were prepared from suction blisters. For in vitro experiments, untreated, healthy human skin was obtained from patients undergoing plastic surgery. The effect of pimecrolimus and BMV on Langerhans cells (LCs), inflammatory dendritic epidermal cells, and T cells was investigated by using immunofluorescence and flow-cytometry techniques. Results: While topical BMV treatment depleted LCs in healthy and atopic skin, pimecrolimus did not affect their number. Correlating with the disappearance of inflammatory cells, we observed a depletion of inflammatory dendritic epidermal cells and T cells on pimecrolimus and BMV treatment. Furthermore, we show that pimecrolimus depletes T cells by the induction of apoptosis. Conclusion: In summary, our data show that pimecrolimus reduces pathological T cells in atopic dermatitis skin via apoptosis, whereas LCs remain unaffected.	Med Univ Vienna, Vienna Competence Ctr, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; Novartis Inst Biomed Res, Vienna, Austria	Medical University of Vienna; Novartis	Elbe-Burger, A (corresponding author), Med Univ Vienna, Vienna Competence Ctr, Dept Dermatol, Div Immunol Allergy & Infect Dis, Lazarettgasse 19, A-1090 Vienna, Austria.	adelheid.elbe-buerger@meduniwien.ac.at		Ecker, Rupert Christian/0000-0002-1095-8592				ABERER W, 1986, J IMMUNOL, V136, P1210; ABERER W, 1984, J IMMUNOL, V133, P792; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis M, 2001, ACTA ODONTOL SCAND, V59, P178, DOI 10.1080/000163501750266783; BELSITO DV, 1984, J INVEST DERMATOL, V83, P347, DOI 10.1111/1523-1747.ep12264457; BELSITO DV, 1984, J INVEST DERMATOL, V82, P136, DOI 10.1111/1523-1747.ep12259684; BELSITO DV, 1982, J EXP MED, V155, P291, DOI 10.1084/jem.155.1.291; BERMAN B, 1983, J INVEST DERMATOL, V80, P168, DOI 10.1111/1523-1747.ep12533397; BRAATHEN LR, 1979, BRIT J DERMATOL, V100, P511, DOI 10.1111/j.1365-2133.1979.tb05576.x; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; FURUE M, 1989, J INVEST DERMATOL, V92, P342, DOI 10.1111/1523-1747.ep12277165; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hashimoto Y, 2001, CLIN EXP IMMUNOL, V125, P19, DOI 10.1046/j.1365-2249.2001.01586.x; Hoetzenecker W, 2004, J INVEST DERMATOL, V122, P673, DOI 10.1111/j.0022-202X.2004.22324.x; Kalthoff ES, 2003, CLIN EXP IMMUNOL, V133, P350, DOI 10.1046/j.1365-2249.2003.02225.x; KIISTALA U, 1968, J INVEST DERMATOL, V50, P129, DOI 10.1038/jid.1968.15; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1998, J IMMUNOL, V161, P2731; Meingassner JG, 2003, BRIT J DERMATOL, V149, P853, DOI 10.1046/j.1365-2133.2003.05559.x; Nghiem P, 2002, J AM ACAD DERMATOL, V46, P228, DOI 10.1067/mjd.2002.120942; NORDLUND JJ, 1981, CELL IMMUNOL, V60, P50, DOI 10.1016/0008-8749(81)90247-1; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; O'Sullivan S, 2004, THORAX, V59, P657, DOI 10.1136/thx.2002.001586; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Salgado CG, 1999, J INVEST DERMATOL, V113, P1021, DOI 10.1046/j.1523-1747.1999.00785.x; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Steiner GE, 2000, J IMMUNOL METHODS, V237, P39, DOI 10.1016/S0022-1759(99)00240-9; STOPPOLONI G, 1983, AM J DIS CHILD, V137, P1130, DOI 10.1001/archpedi.1983.02140370086033; TOFTE S, 1998, J EUR ACAD DERMATO S, V11, P197; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; Vella AT, 1998, P NATL ACAD SCI USA, V95, P3810, DOI 10.1073/pnas.95.7.3810; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Yardin C, 1998, NEUROREPORT, V9, P2077, DOI 10.1097/00001756-199806220-00030	44	69	73	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1276	1283		10.1016/j.jaci.2005.02.011	http://dx.doi.org/10.1016/j.jaci.2005.02.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940147				2022-12-18	WOS:000229815400027
J	Kusunoki, T; Okafuji, I; Yoshioka, T; Saito, M; Nishikomori, R; Heike, T; Sugai, M; Shimizu, A; Nakahata, T				Kusunoki, T; Okafuji, I; Yoshioka, T; Saito, M; Nishikomori, R; Heike, T; Sugai, M; Shimizu, A; Nakahata, T			SPINK5 polymorphism is associated with disease severity and food allergy in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERINE-PROTEASE INHIBITOR; NETHERTON-SYNDROME; GENE; POPULATION; JAPANESE		Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto, Japan; Kyoto Univ Hosp, Translat Res Ctr, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Kusunoki, T (corresponding author), Kyoto Univ, Dept Pediat, Grad Sch Med, Sakyo Ku, 54 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.		Nishikomori, Ryuta/N-4039-2018; Kusunoki, Takashi/AAE-5512-2019; Nishikomori, Ryuta/AAM-5771-2020	Nishikomori, Ryuta/0000-0002-9407-6158; Nishikomori, Ryuta/0000-0002-9407-6158; Sugai, Manabu/0000-0003-1668-7647				Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728	9	69	72	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					636	638		10.1016/j.jaci.2004.12.1114	http://dx.doi.org/10.1016/j.jaci.2004.12.1114			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753919				2022-12-18	WOS:000227687000034
J	Simon, D; Vassina, E; Yousefi, S; Kozlowski, E; Braathen, LR; Simon, HU				Simon, D; Vassina, E; Yousefi, S; Kozlowski, E; Braathen, LR; Simon, HU			Reduced dermal infiltration of cytokineexpressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; cytokines; inflammation; tacrolimus; T cells	T-CELLS; KERATINOCYTE APOPTOSIS; INTERFERON-GAMMA; MAST-CELLS; HUMAN-SKIN; EXPRESSION; FK506; LYMPHOCYTES; ECZEMA; INTERLEUKIN-13	Background: In several clinical studies, topical calcineurin inhibitors have been shown to be effective in the treatment of atopic dermatitis (AD). They target signaling pathways that control gene expression, particularly the expression of cytokines. Objective: We examined the cellular infiltrate in skin lesions of 10 patients with AD and characterized the cytokine pattern expressed by the infiltrating cells before and after short-term topical therapy with tacrolimus 1% ointment. Methods: Skin biopsies were examined for histologic alterations (hematoxylin and eosin staining), composition of the cellular inflammatory infiltrate (immunofluorescence), and cytokine expression (ribonuclease protection assay, ELISA, immunofluorescence) before as well as 1 and 3 weeks after initiation of tacrolimus therapy. For comparison, biopsies from nonlesional AD and normal skin were analyzed. Systemic immunologic effects were assessed by analyzing peripheral blood leukocytes (immunofluorescence) as well as in vitro stimulated pan-T-cell cytokine production (ELISA). Results: All patients showed a significant improvement of their skin lesions associated with a marked regression of spongiosis, acanthosis, and density of the cellular infiltrate in the dermis. The last was a result of reduced infiltration of T cells, B cells, and eosinophils. In contrast, the numbers of mast cells did not change. Moreover, the expression of the T(H)2 cytokines IL-5, IL-10, and IL-13 in CD4(+) T cells was reduced after therapy. Interestingly, tacrolimus therapy was also associated with a reduction of CD8(+) T cells expressing the T(H)1 cytokine IFN-gamma. Furthermore, the numbers of epidermal CD1a(+) dendritic cells increased after treatment. In the peripheral blood, a decrease of granulocytes (eosinophils and neutrophils) but no changes in the distribution of lymphocyte subpopulations were noticed. Conclusion: Topical tacrolimus treatment has antiinflammatory effects on AD skin as indicated by reduced infiltration of cytokine expressing inflammatory cells. No evidence for drug-induced systemic immunosuppression was obtained.	Univ Bern, Dept Dermatol, Bern, Switzerland; Univ Bern, Dept Pharmacol, Bern, Switzerland	University of Bern; University of Bern	Simon, D (corresponding author), Univ Bern, Inselspital, Dept Dermatol, CH-3010 Bern, Switzerland.	dagmar.simon@insel.ch	Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020; Simon, Hans-Uwe/AAU-5079-2020; Vassina, Ekaterina/A-9218-2012; Yousefi, Shida/AAU-7986-2020	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305				Akbar AN, 1997, IMMUNOL TODAY, V18, P72, DOI 10.1016/S0167-5699(97)01003-7; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; BIEBER T, 1988, BRIT J DERMATOL, V118, P385, DOI 10.1111/j.1365-2133.1988.tb02432.x; BRAATHEN LR, 1979, BRIT J DERMATOL, V100, P511, DOI 10.1111/j.1365-2133.1979.tb05576.x; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kawashima M, 1996, LANCET, V348, P1240, DOI 10.1016/S0140-6736(05)65512-2; Kiehl P, 2001, BRIT J DERMATOL, V145, P720, DOI 10.1046/j.1365-2133.2001.04456.x; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MORIKAWA K, 1992, TRANSPLANTATION, V54, P1025, DOI 10.1097/00007890-199212000-00016; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Reynolds NJ, 2002, CLIN EXP DERMATOL, V27, P555, DOI 10.1046/j.1365-2230.2002.01148.x; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sengoku T, 2000, INT J IMMUNOPHARMACO, V22, P189, DOI 10.1016/S0192-0561(99)00076-4; Simon D, 2003, INT ARCH ALLERGY IMM, V132, P148, DOI 10.1159/000073716; Simon D, 2002, ALLERGY, V57, P431, DOI 10.1034/j.1398-9995.2002.13506.x; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; TOCCI MJ, 1989, J IMMUNOL, V143, P718; Tomi NS, 2003, CLIN DERMATOL, V21, P215, DOI 10.1016/S0738-081X(02)00367-X; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045	36	69	74	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					887	895		10.1016/j.jaci.2004.05.066	http://dx.doi.org/10.1016/j.jaci.2004.05.066			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480330				2022-12-18	WOS:000224439100024
J	Barderas, R; Villalba, M; Pascual, CY; Batanero, E; Rodriguez, R				Barderas, R; Villalba, M; Pascual, CY; Batanero, E; Rodriguez, R			Profilin (Che a 2) and polcalcin (Che a 3) are relevant allergens of Chenopodium album pollen: Isolation, amino acid sequences, and immunologic properties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chenopod allergy; pollinosis; profilin; polcalcin; 2 EF-hand calcium-binding allergen; cross-reactivity; amino acid sequence; panallergen; Chenopodium album; Chenopodiaceae	OLIVE-TREE POLLEN; BIRCH POLLEN; CROSS-REACTIVITY; MAJOR ALLERGEN; IGE; BINDING; PROTEINS; CLONING; FAMILY; IDENTIFICATION	Background: Little is known about the molecular properties of chenopod allergens. Recently, profilin and 2 EF-hand calcium-binding protein (polcalcin) have been shown to play a role in chenopod pollinosis. Objective: We sought to analyze these panallergens in chenopod pollen and to evaluate their involvement in the allergy to this biologic source. Methods: Profilin and polcalcin were purified to homogeneity and characterized by using spectrometric and chemical methods. Immunologic analyses were performed by means of immunoblotting, ELISA, and competitive inhibition assays with olive profilin- and polcalcin-specific rabbit polyclonal antibodies and sera from patients with chenopod allergy. cDNAs encoding these proteins were cloned by means of PCR and sequenced. Results: Purified Che a 2 (profilin) and Che a 3 (polcalcin) exhibited prevalences of 55% and 46%, respectively, in patients (n = 104) hypersensitive to chenopod pollen. Both purified allergens individually inhibited the IgE binding to the whole pollen extract and showed strong cross-reactivity with the corresponding olive pollen profilin (Ole e 2) and polcalcin (Ole e 3). Chenopod profilin consists of a 131-amino-acid chain that displays identities of approximately 75% and 82% with pollen and food profilins, respectively. Che a 3 (86 amino acids) displays similarity (65% to 82% identity) with polcalcins from pollens of olive, birch, alder, rapeseed, and timothy. Conclusion: Profilin and polcalcin are relevant panallergens in chenopod pollen and good candidates to be involved in IgE cross-reactivity with other pollen sources, thus explaining the highly frequent polysensitization of patients allergic to chenopod.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Hosp Infantil La Paz, Serv Alergia, Madrid, Spain	Complutense University of Madrid; Hospital Universitario La Paz	Rodriguez, R (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.		Villalba, María Teresa/AAW-1067-2020; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014; Barderas, Rodrigo/K-3560-2014	Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Barderas, Rodrigo/0000-0003-3539-7469				Anibarro B, 1997, J ALLERGY CLIN IMMUN, V100, P734, DOI 10.1016/S0091-6749(97)70266-5; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Barderas R, 2003, J ALLERGY CLIN IMMUN, V111, P1132, DOI 10.1067/mai.2003.1445; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; ELLULMICALLEF R, 1984, CLIN ALLERGY, V14, P509, DOI 10.1111/j.1365-2222.1984.tb02237.x; Ezeamuzie CI, 1997, ALLERGY, V52, P1194, DOI 10.1111/j.1398-9995.1997.tb02523.x; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Feo F, 1997, ALLERGY, V52, P633, DOI 10.1111/j.1398-9995.1997.tb01042.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Florido JF, 2000, ALLERGY S, V55, P158; GALAN C, 1989, ANN ALLERGY, V63, P435; Hayek B, 1998, J IMMUNOL, V161, P7031; HOMAN RB, 1963, ANN ALLERGY, V21, P647; KAY AB, 1997, ALLERGY ALLERGIC DIS, P852; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; Ledesma A, 2002, CLIN EXP ALLERGY, V32, P1476, DOI 10.1046/j.1365-2745.2002.01493.x; Ledesma A, 1998, EUR J BIOCHEM, V258, P454, DOI 10.1046/j.1432-1327.1998.2580454.x; LOMBARDERO M, 1985, ANN ALLERGY, V54, P430; Lombardero M., 1991, ALLERGENIC POLLEN PO, P128; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Quiralte J, 2002, ALLERGY, V57, P47, DOI 10.1034/j.1398-9995.2002.057s71047.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Vallverdu A, 1997, INT ARCH ALLERGY IMM, V112, P356, DOI 10.1159/000237480; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Verdino P, 2002, EMBO J, V21, P5007, DOI 10.1093/emboj/cdf526; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; Wopfner N, 2002, BIOL CHEM, V383, P1779, DOI 10.1515/BC.2002.199; WURTZEN PA, 1995, ALLERGY, V50, P489, DOI 10.1111/j.1398-9995.1995.tb01184.x	37	69	72	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1192	1198		10.1016/j.jaci.2003.12.587	http://dx.doi.org/10.1016/j.jaci.2003.12.587			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208604				2022-12-18	WOS:000222091000028
J	Choi, JH; Lee, KW; Oh, HB; Lee, KJ; Suh, YJ; Park, CS; Park, HS				Choi, JH; Lee, KW; Oh, HB; Lee, KJ; Suh, YJ; Park, CS; Park, HS			HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ajou Univ Hosp, Dept Allergy & Rheumatol, Suwon, South Korea; Soonchunhyang Univ Hosp, Div Allergy & Resp Med, Bucheon, South Korea; Dongguk Univ, Dept Stat, Seoul, South Korea; Univ Ulsan, Coll Med, Dept Lab Med, Ulsan 680749, South Korea; Hallym Univ, Hallym Inst Genome Applicat, Anyang, South Korea	Ajou University; Ajou University Hospital; Soonchunhyang University; Soonchunhyang University Hospital; Dongguk University; University of Ulsan; Hallym University	Choi, JH (corresponding author), Ajou Univ Hosp, Dept Allergy & Rheumatol, Suwon, South Korea.		Park, Hae-Sim/S-7974-2019	Park, Hae-Sim/0000-0003-2614-0303				ACTON RT, 2001, CLIN IMMUNOLOGY; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; LONG JC, 1995, AM J HUM GENET, V56, P799; LYMPANY PA, 1993, J ALLERGY CLIN IMMUN, V92, P114, DOI 10.1016/0091-6749(93)90045-H; PARK HS, 1995, CLIN EXP ALLERGY, V25, P38, DOI 10.1111/j.1365-2222.1995.tb01000.x; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; TILANUS MGJ, 2000, IHWG TECHNICAL MANUA; WA TCL, 1999, CLIN EXP ALLERGY, V29, P1024	9	69	74	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					562	564		10.1016/j.jaci.2003.12.012	http://dx.doi.org/10.1016/j.jaci.2003.12.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007363				2022-12-18	WOS:000220144200033
J	Altznauer, F; von Gunten, S; Spath, P; Simon, HU				Altznauer, F; von Gunten, S; Spath, P; Simon, HU			Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; autoantibodies; fas; IVIg; neutrophils	TOXIC EPIDERMAL NECROLYSIS; ANTI-FAS; KERATINOCYTE APOPTOSIS; NEUTROPHIL APOPTOSIS; IMMUNE GLOBULIN; IMMUNOGLOBULIN; EOSINOPHILS; EXPRESSION; RECEPTOR; INFLAMMATION	Background: Although there have been several reports suggesting the presence of physiologic anti-CD95 (Fas, APO-1) autoantibodies in human intravenous Ig (IVIg) preparations, it is still unclear whether and under which conditions these autoantibodies block or stimulate the CD95 receptor. Objective: We examined the effects of IVIg on CD95-mediated apoptosis in CD95-sensitive human blood neutrophils in vitro. Methods: The presence of anti-CD95 antibodies was determined by competition assays with flow cytometry. Cell death and apoptosis were assessed by ethidium bromide uptake test and annexin V staining, respectively. Results: Pretreatment of neutrophils with IVIg prevented binding of FITC-conjugated anti-CD95 mAb to the cell surface, suggesting that IVIg contains CD95 autoantibodies. By using low concentrations of IVIg (1 to 10 mg/mL), we observed a dose-dependent inhibition of anti-CD95 mAb (CH11)-mediated neutrophil apoptosis. Higher concentrations of IVIg (20 to 50 mg/mL), however, induced neutrophil death and apoptosis in a dose-dependent manner. This effect was partially blocked by soluble CD95 receptors (recombinant Fe-Fas) but not by an anti-CD95 blocking mAb, which was shown to recognize the CH11 epitope of CD95. Conclusion: Both agonistic and antagonistic anti-CD95 antibodies are present in IVIg, and the effect on CD95 is dose-dependent. Our findings have potential implications for IVIg treatment, which is intended to target the CD95 receptor.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; von Gunten, Stephan/0000-0002-2753-8738				Berkovitch M, 1999, INT J IMMUNOPHARMACO, V21, P411, DOI 10.1016/S0192-0561(99)00020-X; Binstadt BA, 2003, J ALLERGY CLIN IMMUN, V111, P697, DOI 10.1067/mai.2003.1380; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Fadeel B, 1997, INT IMMUNOL, V9, P201, DOI 10.1093/intimm/9.2.201; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P938, DOI 10.1067/mai.2002.129359; Hebestreit H, 1996, EUR J IMMUNOL, V26, P1775, DOI 10.1002/eji.1830260817; Heinisch IVWM, 2001, J ALLERGY CLIN IMMUN, V108, P21, DOI 10.1067/mai.2001.116864; IWAI K, 1994, BLOOD, V84, P1201; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Komada Y, 1999, HYBRIDOMA, V18, P391, DOI 10.1089/hyb.1999.18.391; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LASSITER HA, 1993, AM J PEDIAT HEMATOL, V15, P120; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Oomes PG, 1996, NEUROLOGY, V46, P96, DOI 10.1212/WNL.46.1.96; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Prins C, 2003, ARCH DERMATOL, V139, P26, DOI 10.1001/archderm.139.1.26; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Sooryanarayana, 1999, BIOCHEM BIOPH RES CO, V264, P896, DOI 10.1006/bbrc.1999.1592; Tam DA, 1996, J NEUROIMMUNOL, V64, P175, DOI 10.1016/0165-5728(95)00167-0; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407	26	69	71	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1185	1190		10.1016/j.jaci.2003.09.045	http://dx.doi.org/10.1016/j.jaci.2003.09.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657880				2022-12-18	WOS:000187154200023
J	Calhoun, WJ; Sutton, LB; Emmett, A; Dorinsky, PM				Calhoun, WJ; Sutton, LB; Emmett, A; Dorinsky, PM			Asthma variability in patients previously treated with beta(2)-agonists alone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	60th Annual Meeting of the American-College-of-Allergy-Asthma-and-Immunology	NOV 16-17, 2002	SAN ANTONIO, TX	Amer Coll Allergy Asthma & Immunol		asthma; asthma variability; lung function test; asthma severity; symptoms; albuterol use; clinical trial	SEVERITY; DEATHS	Background: According to national asthma guidelines, asthma severity can be classified as intermittent, mild, moderate, or severe on the basis of lung function, symptoms, nighttime awakenings, and exacerbations. Although it is widely believed that patients might not remain consistently in any given severity category over time, few studies have examined this directly. Objective: We sought to assess the variability in disease severity-control among patients with persistent asthma who have not yet received an asthma maintenance treatment. Methods: We performed an analysis of asthma severity-control over time in placebo-treated patients (n = 85) from 2 randomized, double-blind, 12-week clinical trials in patients with asthma previously receiving beta(2)-agonists alone. Asthma severity-control was assessed on the basis of morning percent predicted peak expiratory flow, albuterol use, and symptoms. Results: At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV1 of 64% of predicted value or albuterol use and symptoms on 4.7 and 6.0 days per week, respectively). The mean percentage of treatment weeks that patients met all criteria for intermittent, mild, moderate, and severe asthma were 9%, 14%, 71%, and 6%, respectively. On the basis of morning peak expiratory flow, patients were classified as having intermittent-mild, moderate, or severe disease on 52%, 41%, and 7% of days, respectively. With regard to days per week with albuterol use or asthma symptoms, patients spent 59% and 45% of weeks, respectively, in the intermittent and mild categories. Conclusion: Asthma control cannot be adequately assessed in many patients by using discrete point-in-time assessments of lung function, short-acting beta-agonist use, or asthma symptoms. This might lead to underestimation of disease severity and contribute to inadequate therapy and, ultimately, asthma morbidity.	Univ Pittsburgh, Allergy & Airway Res Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; GlaxoSmithKline	Calhoun, WJ (corresponding author), Univ Pittsburgh, Allergy & Airway Res Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.			Calhoun, William/0000-0001-7075-712X				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P77; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; Burr ML, 1999, THORAX, V54, P985, DOI 10.1136/thx.54.11.985; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; CRAPO R O, 1989, Respiratory Care, V34, P626; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; Meng YY, 1999, J EVAL CLIN PRACT, V5, P213, DOI 10.1046/j.1365-2753.1999.00177.x; *NIH NAT HEART LUN, 2002, NIH PUBL; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; POLGAR G, 1971, PULMONARY FUNCTION C; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; *SRBI, 1998, ASTHM AM SURV PROJ; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Weinstein SF, 2001, J ALLERGY CLIN IMMUN, V107, pS102; Wolfenden LL, 2003, ARCH INTERN MED, V163, P231, DOI 10.1001/archinte.163.2.231; *WORK PART EUR COM, 1983, CLIN RESP PHYSL S5, V19, P1; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	21	69	69	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1088	1094		10.1016/j.jaci.2003.09.044	http://dx.doi.org/10.1016/j.jaci.2003.09.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	752HC	14657863				2022-12-18	WOS:000187154200009
J	Rimaniol, AC; Till, SJ; Garcia, G; Capel, F; Godot, W; Balabanian, K; Durand-Gasselin, I; Varga, EM; Simonneau, G; Emilie, D; Durham, SR; Humbert, M				Rimaniol, AC; Till, SJ; Garcia, G; Capel, F; Godot, W; Balabanian, K; Durand-Gasselin, I; Varga, EM; Simonneau, G; Emilie, D; Durham, SR; Humbert, M			The CX3C chemokine fractalkine in allergic asthma and rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; allergy; asthma; chemokines; fractalkine; rhinitis; T lymphocytes	ACTIVATION-REGULATED CHEMOKINE; INTERFERON-GAMMA; RECEPTOR CX(3)CR1; T-CELLS; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES; MESSENGER-RNA; EXPRESSION; INTERLEUKIN-5; RECRUITMENT	Background: Unlike other chemokines, fractalkine is expressed as a membrane-bound form, mainly on endothelial and epithelial cells, and can be shed as a soluble chemotactic form. Fractalkine can capture leukocytes expressing its receptor (CX3CR1), including T lymphocytes, rapidly and firmly in an integrin-independent manner. Because of its dual activity, fractalkine plays a major role in the transendothelial and transepithelial migration of leukocytes during inflammation. Objective: We sought to study the fractalkine-CX3CR1 axis in patients with allergic airways diseases. Methods: Plasma fractalkine levels were measured by means of ELISA in 19 control subjects and 55 patients with symptomatic allergic rhinitis, asthma, or both, and CX3CR1 function was studied by using triple-color flow cytometry in circulating T-lymphocyte subpopulations. Segmental allergen challenge was performed in 16 allergic asthmatic patients to analyze fractalkine expression and inflammatory cell recruitment in bronchoalveolar lavage fluid and bronchial biopsy specimens. Results: Compared with control subjects, patients with symptomatic allergic rhinitis and asthmatic patients had increased circulating fractalkine levels, and CX3CR1 function was upregulated in circulating CD4(+) T lymphocytes. Twenty-four hours after segmental allergen challenge, bronchoalveolar lavage fluid soluble fractalkine concentrations increased and correlated with the total number of recruited cells. Bronchial epithelial and endothelial cells expressed high levels of the membrane-bound form of fractalkine before and after challenge. Conclusion: Allergic asthma and rhinitis are associated with systemic and bronchial upregulation of the chemotactic axis fractalkine-CX3CR1. This might contribute to the rapid recruitment of circulating CD4(+) T lymphocytes in the airways after allergen stimulation.	Univ Paris Sud, Serv Pneumol & Reanimat Resp, Hop Antoine Beclere, Inst Paris Sud Cytokines,UPRES EA2705, F-92140 Clamart, France; CEA, SNV, SPI BIO, Fontenay Aux Roses, France; Univ Paris Sud, Inst Paris Sud Cytokines, INSERM, U131, Clamart, France; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Humbert, M (corresponding author), Univ Paris Sud, Serv Pneumol & Reanimat Resp, Hop Antoine Beclere, Inst Paris Sud Cytokines,UPRES EA2705, 157 Rue Porte de Trivaux, F-92140 Clamart, France.		Balabanian, Karl/S-6250-2019; Balabanian, Karl/I-2990-2016; Simonneau, Gerald/ABE-6614-2020	Balabanian, Karl/0000-0002-0534-3198; Balabanian, Karl/0000-0002-0534-3198; Humbert, Marc/0000-0003-0703-2892; Till, Stephen/0000-0003-4518-3093				ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Balabanian K, 2002, AM J RESP CRIT CARE, V165, P1419, DOI 10.1164/rccm.2106007; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Foussat A, 2000, EUR J IMMUNOL, V30, P87, DOI 10.1002/1521-4141(200001)30:1<87::AID-IMMU87>3.3.CO;2-Z; Foussat A, 2001, BLOOD, V98, P1678, DOI 10.1182/blood.V98.6.1678; Fujimoto K, 2001, AM J RESP CELL MOL, V25, P233, DOI 10.1165/ajrcmb.25.2.4275; Furuichi K, 2001, NEPHRON, V87, P314, DOI 10.1159/000045936; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Greaves DR, 2001, ARTERIOSCL THROM VAS, V21, P923, DOI 10.1161/01.ATV.21.6.923; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Imaizumi T, 2000, TOHOKU J EXP MED, V192, P127, DOI 10.1620/tjem.192.127; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kon OM, 2001, EUR RESPIR J, V18, P45, DOI 10.1183/09031936.01.00064101; Lee YC, 2001, J ASTHMA, V38, P665, DOI 10.1081/JAS-100107544; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Lukacs NW, 1997, J IMMUNOL, V158, P4398; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; Raychaudhuri SP, 2001, BRIT J DERMATOL, V144, P1105, DOI 10.1046/j.1365-2133.2001.04219.x; Rimaniol AC, 2003, CLIN EXP IMMUNOL, V132, P76, DOI 10.1046/j.1365-2249.2003.02118.x; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Ruth JH, 2001, ARTHRITIS RHEUM, V44, P1568, DOI 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404, DOI 10.1164/ajrccm.158.2.9705007; Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Ying S, 1999, J IMMUNOL, V163, P6321; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Ying S, 1997, J IMMUNOL, V158, P3539; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	39	69	72	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1139	1146		10.1016/j.jaci.2003.09.041	http://dx.doi.org/10.1016/j.jaci.2003.09.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657873				2022-12-18	WOS:000187154200017
J	Qureshi, A; Ballard, RD				Qureshi, A; Ballard, RD			Obstructive sleep apnea	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						obstructive sleep apnea; continuous positive airway pressure; hypertension; cardiovascular disease; rhinitis; immune function	POSITIVE AIRWAY PRESSURE; GENIOGLOSSAL MUSCLE-ACTIVITY; NITRIC-OXIDE; RISK-FACTOR; PULMONARY-HYPERTENSION; CARDIAC-ARRHYTHMIAS; NEGATIVE-PRESSURE; HEART-FAILURE; ASSOCIATION; RESISTANCE	Obstructive sleep apnea is an increasingly well-recognized disease characterized by periodic collapse of the upper airway during sleep. This leads to either complete or partial obstruction of the airway, resulting in apneas, hypopneas, or both. This disorder causes daytime somnolence, neurocognitive defects, and depression. It affects almost every system in the body, resulting in an increased incidence of hypertension, cardiovascular disease, stroke, pulmonary hypertension, cardiac arrhythmias, and altered immune function. It also increases the risk of having an accident, presumably as a result of associated somnolence. The gold standard for the diagnosis of sleep apnea is an overnight polysomnogram. Split-night studies are becoming increasingly common and allow for quicker implementation of therapy at a reduced cost. Treatment options for sleep apnea include weight loss, positional therapy, oral devices, continuous positive airway pressure (CPAP), and upper airway surgery. CPAP is the most efficacious and widely used therapy. Its complications include nasal congestion or dryness, mask discomfort, and claustrophobia. Heated humidifiers, newer types of masks, and nasal steroids have improved tolerance of this therapy. Bilevel positive-pressure therapy can be considered for patients who find it difficult to exhale against the consistently increased pressure of CPAP The disease requires aggressive treatment to improve quality of life and prevent its complications.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med,Sleep Med Sect, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ballard, RD (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med,Sleep Med Sect, Room J-201,1400 Jackson St, Denver, CO 80206 USA.							ANCOLIISRAEL S, 1991, SLEEP, V14, P486, DOI 10.1093/sleep/14.6.486; Bradley TD, 2003, CLIN SCI, V104, P231, DOI 10.1042/CS20020157; BRADLEY TD, 1985, AM REV RESPIR DIS, V131, P835; Brander PE, 1999, RESPIRATION, V66, P128, DOI 10.1159/000029354; Brouillette RT, 2001, J PEDIATR-US, V138, P838, DOI 10.1067/mpd.2001.114474; Carpagnano GE, 2002, CHEST, V122, P1162, DOI 10.1378/chest.122.4.1162; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; CHAOUAT A, 1995, AM J RESP CRIT CARE, V151, P82, DOI 10.1164/ajrccm.151.1.7812577; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Dyugovskaya L, 2002, AM J RESP CRIT CARE, V165, P934, DOI 10.1164/ajrccm.165.7.2104126; Engleman HM, 2002, AM J RESP CRIT CARE, V166, P855, DOI 10.1164/rccm.2109023; Findley L, 2000, AM J RESP CRIT CARE, V161, P857, DOI 10.1164/ajrccm.161.3.9812154; FLEMONS WW, 1993, AM REV RESPIR DIS, V148, P618, DOI 10.1164/ajrccm/148.3.618; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; GUILLEMINAULT C, 1988, EUR RESPIR J, V1, P902; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; Hermann DM, 2003, CURR OPIN NEUROL, V16, P87, DOI 10.1097/00019052-200302000-00012; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; HOFFSTEIN V, 1994, CHEST, V106, P466, DOI 10.1378/chest.106.2.466; HOFFSTEIN V, 1993, SLEEP, V16, P118; HOFFSTEIN V, 1984, AM REV RESPIR DIS, V130, P175; HUDGEL DW, 1988, AM REV RESPIR DIS, V138, P1542, DOI 10.1164/ajrccm/138.6.1542; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P2166, DOI 10.1164/ajrccm.162.6.2002126; Isono S, 1997, J APPL PHYSIOL, V82, P1319, DOI 10.1152/jappl.1997.82.4.1319; ISSA FG, 1983, J APPL PHYSIOL, V55, P1113, DOI 10.1152/jappl.1983.55.4.1113; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; Kim HC, 1997, AM J RESP CRIT CARE, V156, P1813, DOI 10.1164/ajrccm.156.6.9610026; KOENIG JS, 1999, JA PPL PHYSL, V64, P2124; KOSKENVUO M, 1985, LANCET, V1, P893; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KROL RC, 1984, AM REV RESPIR DIS, V129, P247; Kuna S, 2000, PRINCIPLES PRACTICE, P840; Larsson LG, 2001, RESP MED, V95, P423, DOI 10.1053/rmed.2001.1054; Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; LEECH JA, 1987, CHEST, V92, P807, DOI 10.1378/chest.92.5.807; LEITER JC, 1985, AM REV RESPIR DIS, V132, P1242; LEITER JC, 1985, AM REV RESPIR DIS, V132, P216; Masa JF, 2000, AM J RESP CRIT CARE, V162, P1407, DOI 10.1164/ajrccm.162.4.9907019; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MAYER J, 1991, CARDIOLOGY, V79, P84, DOI 10.1159/000174864; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; MORIKAWA S, 1961, ANESTHESIOLOGY, V22, P265, DOI 10.1097/00000542-196103000-00016; MORRISON DL, 1993, AM REV RESPIR DIS, V148, P606, DOI 10.1164/ajrccm/148.3.606; Namen AM, 2002, CHEST, V121, P1741, DOI 10.1378/chest.121.6.1741; *NAT COMM SLEEP DI, 1995, WAK UP AM NAT SLEEP, V2; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; NISHINO T, 1984, ANESTHESIOLOGY, V60, P19, DOI 10.1097/00000542-198401000-00005; Ohga E, 2003, J APPL PHYSIOL, V94, P179, DOI 10.1152/japplphysiol.00177.2002; Olopade CO, 1997, CHEST, V111, P1500, DOI 10.1378/chest.111.6.1500; PALOMAKI H, 1991, STROKE, V22, P1021, DOI 10.1161/01.STR.22.8.1021; PARISH JM, 1990, CHEST, V97, P1220, DOI 10.1378/chest.97.5.1220; PARTINEN M, 1985, LANCET, V2, P1325; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; PEPIN JL, 1995, CHEST, V107, P375, DOI 10.1378/chest.107.2.375; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Rakotonanahary D, 2001, CHEST, V119, P460, DOI 10.1378/chest.119.2.460; Randerath WJ, 2002, CHEST, V122, P569, DOI 10.1378/chest.122.2.569; RILEY RW, 1993, OTOLARYNG HEAD NECK, V108, P117, DOI 10.1177/019459989310800203; SAJKOV D, 1994, AM J RESP CRIT CARE, V149, P416, DOI 10.1164/ajrccm.149.2.8306039; Sanders MH, 2003, AM J RESP CRIT CARE, V167, P7, DOI 10.1164/rccm.2203046; Schafer H, 1999, CARDIOLOGY, V92, P79, DOI 10.1159/000006952; Schulz R, 2000, THORAX, V55, P1046, DOI 10.1136/thorax.55.12.1046; Schulz R, 2000, AM J RESP CRIT CARE, V162, P566, DOI 10.1164/ajrccm.162.2.9908091; Smith R, 2002, CHEST, V121, P164, DOI 10.1378/chest.121.1.164; SPRIGGS DA, 1990, AGE AGEING, V19, P280, DOI 10.1093/ageing/19.5.280; Strollo PJ, 1996, SLEEP, V19, pS255, DOI 10.1093/sleep/19.suppl_10.S255; SULLIVAN CE, 1981, LANCET, V1, P862; TANGEL DJ, 1991, J APPL PHYSIOL, V70, P2574, DOI 10.1152/jappl.1991.70.6.2574; Tkacova R, 2000, J HYPERTENS, V18, P1257, DOI 10.1097/00004872-200018090-00012; WEINER D, 1982, J APPL PHYSIOL, V52, P530, DOI 10.1152/jappl.1982.52.3.530; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345; WHEATLEY JR, 1993, AM REV RESPIR DIS, V148, P597, DOI 10.1164/ajrccm/148.3.597; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	78	69	83	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					643	652		10.1016/j.jaci.2003.08.031	http://dx.doi.org/10.1016/j.jaci.2003.08.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564340				2022-12-18	WOS:000185831200001
J	Kowalski, ML; Ptasinska, A; Bienkiewicz, B; Pawliczak, R; DuBuske, L				Kowalski, ML; Ptasinska, A; Bienkiewicz, B; Pawliczak, R; DuBuske, L			Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin sensitivity; 15-hydroxyeicosatetraenoic acid; asthma; misoprostol; leukotrienes; prostaglandins; lipoxins	ARACHIDONIC-ACID; EPITHELIAL-CELLS; NASAL POLYPS; INDUCED BRONCHOCONSTRICTION; TOLERANT PATIENTS; BLOOD LEUKOCYTES; MAST-CELL; RELEASE; PATHOGENESIS; INTOLERANCE	Background: Although the mechanisms of aspirin-induced rhinosinusitis-asthma appear to be related to arachidonic acid abnormalities, only recently has a specific aspirin-triggered enhancement of 15-hydroxyeicosatetraenoic acid (15-HETE) generation in nasal polyp epithelial cells from aspirin-sensitive patients been demonstrated. Objective: The aim of this study was to assess generation of 15-HETE and other eicosanoids by peripheral blood leukocytes (PBLs) from aspirin-sensitive and aspirin-tolerant asthmatic patients and modulation of 15-HETE generation by a prostaglandin (PG) E-1 analogue (misoprostol). Methods: Twenty-four aspirin-sensitive patients with asthma-rhinosinusitis and 18 aspirin-tolerant asthmatic patients were studied, and eicosanoids released from PBLs were assessed by means of enzyme immunoassays. Results: Unstimulated PBLs from aspirin-sensitive and aspirin-tolerant patients generated similar amounts of PGE(2), leukutriene C-4, and 15-HETE, but lipoxin A(4) release was significantly less in aspirin-sensitive patients (300 +/- 70 pg/mL) in comparison with that seen in aspirin-tolerant patients (690 +/- 100 pg/mL, P < .05). Cell incubation with 2, 20, or 200 mumol/L aspirin resulted in a dose-dependent increase in 15-HETE generation (mean change of +85%, +189%, and +284% at each aspirin concentration, respectively) only in aspirin-sensitive asthmatic patients. Naproxen stimulated 15-HETE generation in aspirin-sensitive asthmatic patients, but indomethacin or specific COX-2 inhibitors (NS-398 and celecoxib) did not affect 15-HETE release. A synthetic PGE(1) analogue (misoprostol) inhibited aspirin-induced 15-HETE release but enhanced 15-HETE generation by aspirin in leukocytes from aspirin-tolerant patients. After preincubation with misoprostol, aspirin induced a dose-dependent production of lipoxin A(4) in both groups. Conclusion: PBLs from patients with aspirin-sensitive rhinosinusitis-asthma might be specifically triggered by aspirin to generate 15-HETE. Metabolism of 15-HETE is differentially regulated by misoprostol in aspirin-tolerant and aspirin-sensitive asthmatic patients.	Med Univ, Fac Med, Dept Allergy & Clin Immunol, PL-92213 Lodz, Poland; Immunol Res Inst New England, Boston, MA USA		Kowalski, ML (corresponding author), Med Univ, Fac Med, Dept Allergy & Clin Immunol, 251 Pomorska St, PL-92213 Lodz, Poland.		Pawliczak, Rafal Tomasz/S-9649-2016; Pawliczak, Rafa/S-2021-2019; DuBuske, Lawrence/AAV-3402-2020	Pawliczak, Rafa/0000-0001-6784-453X; 				Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Dahlen B, 1998, RESP MED, V92, P378, DOI 10.1016/S0954-6111(98)90279-7; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kowalski ML, 1996, CLIN EXP ALLERGY, V26, P807, DOI 10.1046/j.1365-2222.1996.d01-371.x; Kowalski ML, 2002, ALLERGY, V57, P493, DOI 10.1034/j.1398-9995.2002.13508.x; Kowalski ML, 2000, THORAX, V55, pS84, DOI 10.1136/thorax.55.suppl_2.S84; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; KUITERT LM, 1993, AM REV RESPIR DIS, V147, P82, DOI 10.1164/ajrccm/147.1.82; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; May A, 1999, CLIN EXP ALLERGY, V29, P1402; Melillo G, 2001, ALLERGY, V56, P899, DOI 10.1034/j.1398-9995.2001.00025.x; Mewes T, 1996, ALLERGY, V51, P506; Mita H, 2001, ALLERGY, V56, P1061; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; Pierzchalska M, 2000, CLIN EXP ALLERGY, V30, P1785, DOI 10.1046/j.1365-2222.2000.00953.x; Profita M, 2000, AM J PHYSIOL-CELL PH, V279, pC1249, DOI 10.1152/ajpcell.2000.279.4.C1249; Profita M, 2000, J ALLERGY CLIN IMMUN, V105, P711, DOI 10.1067/mai.2000.105122; SALARI H, 1991, PULM PHARMACOL, V4, P1, DOI 10.1016/0952-0600(91)90033-Y; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Schewe T, 1999, ADV EXP MED BIOL, V447, P95; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SHANNON VR, 1993, AM REV RESPIR DIS, V147, P1024, DOI 10.1164/ajrccm/147.4.1024; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Szmidt M, 1996, J INVEST ALLERG CLIN, V6, P121; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	36	69	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					505	512		10.1067/mai.2003.1678	http://dx.doi.org/10.1067/mai.2003.1678			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679808				2022-12-18	WOS:000185231200008
J	Almqvist, C; Egmar, AC; van Hage-Hamsten, M; Berglind, N; Pershagen, G; Nordvall, L; Svartengren, M; Hedlin, G; Wickman, M				Almqvist, C; Egmar, AC; van Hage-Hamsten, M; Berglind, N; Pershagen, G; Nordvall, L; Svartengren, M; Hedlin, G; Wickman, M			Heredity, pet ownership, and confounding control in a population-based birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cats; dogs; allergens; Fel d 1; Can f 1; heredity; primary prevention; confounding factors; prospective studies	HOUSE-DUST MITE; CAT ALLERGEN; RISK FACTOR; ATOPIC SENSITIZATION; SOCIOECONOMIC-STATUS; CHILDHOOD ASTHMA; EXPOSURE; CHILDREN; LIFE; DOG	Background: The association between pet ownership in childhood and subsequent allergic disease is controversial. Bias related to selection of pet exposure has been suggested as a reason for contradictory study results. Objective: The purpose of this investigation was to elucidate how pet exposure depends on family history of allergic disease, smoking, and socioeconomic factors in a prospective birth cohort. Methods: Parents of 4089 two-month-old children answered a questionnaire that included detailed questions about family history of asthma (maternal, paternal, and sibling), rhinoconjunctivitis, atopic eczema/dermatitis syndrome, pollen and pet allergy, smoking habits, parental occupation, and family pet ownership (cat and dog). Dust samples collected from the mothers' beds were analyzed for Fel d 1 and Can f 1 in a subgroup of the cohort. Results: Cats were less frequently kept in families with parental asthma, rhinoconjunctivitis, or pet or pollen allergy (3.5% to 5.8%) than in families without parental allergic disease (10.8% to 11.8%). Dogs were less common in families with (3.3%) than in families without (5.9%) parental atopic eczema/dermatitis syndrome. Families with smoking mothers and those with low socioeconomic index kept cats and dogs more frequently. Cat allergen levels were lower in homes with than in homes without maternal pet allergy, and this tended to hold true even for homes without a cat. Cat ownership decreased from birth to 2 years of age, especially in families with parental history of allergic diseases. Conclusion: There seems to be a selection of pet exposure based on parental history of allergy, maternal smoking, and socioeconomic factors. This has to be taken into consideration in evaluations of risk associations between pet exposure and allergic disease in childhood.	Karolinska Hosp, Dept Environm & Occupat Hlth, S-17176 Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Uppsala Univ, Inst Woman & Child Hlth, Uppsala, Sweden; Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; Sachs Childrens Hosp, Karolinska Inst, Inst Sodersjukuset, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska Institutet	Almqvist, C (corresponding author), Karolinska Hosp, Dept Environm & Occupat Hlth, Norrbacka,3rd Floor, S-17176 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017; Svartengren, Magnus/AAM-7777-2021	van Hage, Marianne/0000-0003-3091-1596; Svartengren, Magnus/0000-0002-8165-7236; Egmar, Ann-Charlotte/0000-0003-2504-343X; Pershagen, Goran/0000-0002-9701-1130				Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; Bjorksten B, 2001, CURR OPIN ALLERGY CL, V1, P545, DOI 10.1097/00130832-200112000-00009; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; Egmar AC, 1998, ALLERGY, V53, P957, DOI 10.1111/j.1398-9995.1998.tb03796.x; Halken S, 2000, ALLERGY, V55, P793, DOI 10.1034/j.1398-9995.2000.00117.x; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Kulig M, 2000, J ALLERGY CLIN IMMUN, V105, P274, DOI 10.1016/S0091-6749(00)90076-9; Lannero E, 2002, PEDIAT ALLERG IMM-UK, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; *SCB, 1989, OCC POP HOUS CENS 19; Sterk PJ, 1999, EUR RESPIR J, V14, P1435, DOI 10.1183/09031936.99.14614359; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x	32	69	71	2	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					800	806		10.1067/mai.2003.1334	http://dx.doi.org/10.1067/mai.2003.1334			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704361	Bronze			2022-12-18	WOS:000182258500021
J	Lemiere, C; Romeo, P; Chaboillez, S; Tremblay, C; Malo, JL				Lemiere, C; Romeo, P; Chaboillez, S; Tremblay, C; Malo, JL			Airway inflammation and functional changes after exposure to different concentrations of isocyanates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; specific inhalation challenges; airway inflammation; neutrophils	SPUTUM CELL COUNTS; OCCUPATIONAL AGENTS; ASTHMA; REPRODUCIBILITY; CHALLENGES; INDEXES	Background: Isocyanates are a common cause of occupational asthma (OA). Objectives: We sought (1) to examine whether asthmatic reactions to isocyanates could be induced at concentrations as low as 1 ppb in subjects with OA caused by isocyanates previously diagnosed in our center and (2) to compare the inflammatory and functional changes after exposure to I and 15 ppb of isocyanates with similar total doses (concentration of isocyanates x duration of exposure). Methods: Specific inhalation challenges were performed in 12 asthmatic subjects with previously confirmed OA caused by isocyanates. Eight subjects were exposed to 1 ppb at 10% of the dose of isocyanates that induced an asthmatic reaction at the time of the diagnosis. Seven subjects were exposed to the same total dose of isocyanates by using concentrations of 1 and 15 ppb 1 month apart. Results: Exposure to 1 ppb at 10% of the dose that had induced functional changes at the time of diagnosis induced an asthmatic reaction in 3 of 8 subjects. There was a significant correlation between the percentage of maximum decrease in FEV1 after exposure to 1 ppb and the increase in sputum neutrophils (rho = 0.8). By keeping the total dose (concentration of isocyanates x duration of exposure) of isocyanates similar, 4 of 7 subjects experienced an asthmatic reaction after exposure to 1 ppb, whereas only one subject experienced an 18.5% decrease in FEV1 after exposure to 15 ppb. Conclusion: Isocyanates can induce functional and inflammatory changes (mainly neutrophilic) at concentrations as low as 1 ppb. For the same total dose of exposure, low concentrations of isocyanates are as harmful as or even more harmful than higher concentrations for subjects with OA to isocyanates.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada	Universite de Montreal	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 W Gouin Blvd, Montreal, PQ H4J 1C5, Canada.							*AM C GOV IND HYG, 2001, THRESH LIM VAL CHEM; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Juniper E, 1994, HISTAMINE METHACHOLI; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329, DOI 10.1164/ajrccm.154.2.8756802; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; PAPI A, 2000, ASTHMA RHINITIS, P518; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227, DOI 10.5271/sjweh.203; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582, DOI 10.1164/ajrccm/145.3.582; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5	21	69	74	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					641	646		10.1067/mai.2002.128806	http://dx.doi.org/10.1067/mai.2002.128806			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373274				2022-12-18	WOS:000178501900016
J	Zuberbier, T; Pfrommer, C; Specht, K; Vieths, S; Bastl-Borrmann, R; Worm, M; Henz, BM				Zuberbier, T; Pfrommer, C; Specht, K; Vieths, S; Bastl-Borrmann, R; Worm, M; Henz, BM			Aromatic components of food as novel eliciting factors of pseudoallergic: reactions in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food intolerance; tomato; wine; herbs; histamine release; skin mast cells	SKIN MAST-CELLS; DIAMINE OXIDASE; IN-VITRO; RELEASE; ASTHMA; BASOPHILS; HISTAMINE; DRUGS	Background: Pseudoallergic reactions (PARs) against both additives and natural foods have been reported to elicit chronic urticaria, but in natural food the responsible ingredients are largely unknown. Objective: The study was aimed at identifying novel pseudoallergens in food and focused on evaluating tomatoes, white wine, and herbs as frequently reported food items eliciting wheal responses in urticaria. Methods: In 33 patients with chronic urticaria and PARs to food (proved by means of elimination diet and subsequent reexposure with provocation meals), oral provocation tests were performed with field-grown tomatoes, organically grown white wine (whole food, steam distillates, and residues), oily extracts from herbs, and food additives. In addition, skin biopsy specimens from patients were studied for in vitro mast-cell histamine release with tomato distillate alone or on subsequent stimulation with anti-IgE, substance P, and C5a. Results: Seventy-six percent of patients reacted to whole tomato (steam distillate, 45%; residue, 15%), 50% to food additives, 47% to herbs, and 44% to whole wine (extract,27%; residue, 0%). Histamine, protein, and high levels of salicylate were only found in residues. The tomato distillate was further analyzed by means of mass spectroscopy, identifying low-molecular-weight aldehydes, ketones, and alcohol as major ingredients. In vitro histamine release was not caused by tomato extract itself but was enhanced by means of subsequent stimulation with substance P and C5a but not by anti-IgE. Conclusion: Aromatic volatile ingredients in food are novel agents eliciting PARs in chronic urticaria. Histamine, salicylate, and a direct mast-cell histamine release are not involved in this reactivity to naturally occurring pseudoallergens.	Humboldt Univ, Dept Dermatol & Allergy, Charite, D-10117 Berlin, Germany; Tech Univ Berlin, Dept Food Sci, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Berlin	Zuberbier, T (corresponding author), Humboldt Univ, Dept Dermatol & Allergy, Charite, Charite Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.			Worm, Margitta/0000-0002-3449-1245				BLACK AK, 1991, BRIT J DERMATOL, V124, P100, DOI 10.1111/j.1365-2133.1991.tb03292.x; CZECH W, 1995, INFLAMM RES, V44, P291, DOI 10.1007/BF02032571; DIEMAIR W, 1961, Z ANAL CHEM, V178, P321; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; HARTMANN K, 1995, INT ARCH ALLERGY IMM, V108, P224, DOI 10.1159/000237157; HENZ BM, 1998, URTICARIA CLIN DIAGN, P1; Henz BM, 1998, URTICARIA CLIN DIAGN, P19; Kanny G, 2001, J ALLERGY CLIN IMMUN, V107, P375, DOI 10.1067/mai.2001.112122; LESSOF MH, 1990, CLIN EXP ALLERGY, V20, P373, DOI 10.1111/j.1365-2222.1990.tb02796.x; MACDONALD BR, 1990, CLIN EXP ALLERGY, V20, P341, DOI 10.1111/j.1365-2222.1990.tb02791.x; Mewes T, 1996, ALLERGY, V51, P506; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; Oosaki R, 1997, ALLERGY, V52, P470, DOI 10.1111/j.1398-9995.1997.tb01032.x; Pigatto PD, 2000, ALLERGY, V55, P306, DOI 10.1034/j.1398-9995.2000.00317.x; SCHLUMBERGER HD, 1983, ANN ALLERGY, V51, P317; SETTIPANE GA, 1987, NEW ENGL REG ALLERGY, V8, P39; Vally H, 2000, J ALLERGY CLIN IMMUN, V105, P462, DOI 10.1067/mai.2000.104548; Worm M, 2001, CLIN EXP ALLERGY, V31, P265, DOI 10.1046/j.1365-2222.2001.00979.x; Zuberbier T, 1995, ACTA DERM-VENEREOL, V75, P484; Zuberbier T, 1996, ALLERGY, V51, P24, DOI 10.1111/j.1398-9995.1996.tb04545.x; ZUBERBIER T, 1995, BBA-MOL CELL RES, V1269, P79, DOI 10.1016/0167-4889(95)00103-Y; ZUBERBIER T, 1998, URTICARIA CLIN DIAGN, P139	22	69	70	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					343	348		10.1067/mai.2002.121309	http://dx.doi.org/10.1067/mai.2002.121309			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842307				2022-12-18	WOS:000174232600022
J	Amin, K; Rinne, J; Haahtela, T; Simola, M; Peterson, CGB; Roomans, GM; Malmberg, H; Venge, P; Seveus, L				Amin, K; Rinne, J; Haahtela, T; Simola, M; Peterson, CGB; Roomans, GM; Malmberg, H; Venge, P; Seveus, L			Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						perennial allergic; rhinitis; eosinophils; neutrophils; mast cells; epithelium; nasal biopsy	NASAL-MUCOSA; BRONCHIAL REACTIVITY; DAMAGE; SECRETIONS; EOSINOPHIL; CHALLENGE; BIOPSIES; ASTHMA; LUNG	Background: Perennial rhinitis is an inflammatory condition of the mucosal lining of the nose that may be caused by allergic and nonallergic mechanisms. Objective: We sought to characterize the cellular pattern and structural changes in the nasal mucous membrane of patients with perennial rhinitis and compare them with those of control subjects. Methods: Biopsy specimens were obtained from 27 patients with perennial allergic rhinitis (PAR), from 12 patients with perennial nonallergic rhinitis (PNAR) with eosinophils present an the nasal smear, and from 6 control subjects without rhinitis. In 10 of 27 patients with PAR who were also allergic to pollen, biopsy specimens were taken within the respective season (PAR(season)). In the other 17 patients, the biopsy was taken outside the pollen season (PAR(outside season)). Inflammatory cells were identified by using mAbs to their unique granular proteins. Results: The characteristic feature of perennial rhinitis was the accumulation of activated (degranulated) mast cells and eosinophils in the nasal mucosa. The tissue cosinophil/meutrophil ratio was higher, and the loss of epithelial integrity was greater in all patient groups compared with the control subjects. The extent of epithelial damage was significantly larger in patients in the PAR(season) group compared with that in the PAR(outside season) and PNAR groups, which did not significantly differ from each other in this respect. The number of eosinophils and mast cells was higher in the PNAR group compared with the PAR groups. In all patient groups, the number of eosinophils correlated with the loss of epithelial integrity. The number of mast cells did not correlate with the extent of epithelial damage nor did the number of neutrophils, except in patients in the PAR(season) group. Conclusion: The accumulation of eosinophils and mast cells, as well as loss of epithelial integrity, was characteristic for perennial rhinitis. Loss of epithelial integrity in the nasal mucosa map be a consequence of the activity of accumulated eosinophils.	Uppsala Univ, Dept Med Cell Biol, Sect Human Anat, Uppsala, Sweden; Univ Helsinki, Cent Hosp, Dept Otolaryngol, Helsinki, Finland; Skin & Allergy Hosp, Helsinki, Finland; Pharmacia & Upjohn Diagnost, Uppsala, Sweden; Uppsala Univ, Dept Med Sci, Uppsala, Sweden	Uppsala University; University of Helsinki; Helsinki University Central Hospital; Pfizer; Pharmacia Corporation; Uppsala University	Amin, K (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbecks Lab, SE-75185 Uppsala, Sweden.							Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Berger G, 1997, AM J RHINOL, V11, P63, DOI 10.2500/105065897781446775; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; Holm AF, 1999, CLIN EXP ALLERGY, V29, P1356; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAWABORI S, 1987, Auris Nasus Larynx, V14, P77; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEE HS, 1993, LARYNGOSCOPE, V103, P533; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; LOZEWICZ S, 1990, RHINITIS ASTHMA SIMI; MCKENNA EL, 1974, LARYNGOSCOPE, V84, P112, DOI 10.1288/00005537-197401000-00010; MELZER EO, 1993, ALLERGIC NONALLERGIC, P66; RoweJones JM, 1997, ALLERGY, V52, P20, DOI 10.1111/j.1398-9995.1997.tb04818.x; Seveus L, 1997, HISTOCHEM CELL BIOL, V107, P423, DOI 10.1007/s004180050129; Slater A, 1996, J LARYNGOL OTOL, V110, P929, DOI 10.1017/S0022215100135388; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; Venge P, 1999, CLIN EXP ALLERGY, V29, P1172; VERMA K, 1987, INDIAN J MED RES, V86, P105; Wang DY, 1996, INT ARCH ALLERGY IMM, V110, P85, DOI 10.1159/000237316; Watanabe K, 1998, ANN OTO RHINOL LARYN, V107, P564, DOI 10.1177/000348949810700704; WEISELBERG L, 1990, LAB INVEST, V63, P405; [No title captured]	26	69	78	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					249	257		10.1067/mai.2001.112266	http://dx.doi.org/10.1067/mai.2001.112266			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174190	Bronze			2022-12-18	WOS:000167071400010
J	Fredberg, JJ				Fredberg, JJ			Frozen objects: Small airways, big breaths, and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						smooth muscle; myosin; inflammation; maturation; hyperresponsiveness; respiration	OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE CONTRACTION; DEEP INSPIRATION; LIGHT-CHAIN; INDUCED BRONCHOCONSTRICTION; LUNG-VOLUME; METHACHOLINE; INFLAMMATION; MYOSIN; RESPONSIVENESS	Airway hyperresponsiveness is one of the cardinal features of asthma but remains largely unexplained. The new concept of perturbed myosin binding within airway smooth muscle sheds light on the question of why airway narrowing is limited in the healthy lung and not in the asthmatic lung and points to unanticipated mechanisms through which lung development and allergic status may be major modulators of airway hyperresponsiveness.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Fredberg, JJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		fredberg, jeffrey j/A-7083-2009; Fredberg, Jeffrey/M-9877-2019					BENDIXEN HH, 1964, J APPL PHYSIOL, V19, P195, DOI 10.1152/jappl.1964.19.2.195; Black JL, 1996, AM J RESP CRIT CARE, V153, pS2, DOI 10.1164/ajrccm/153.6_Pt_2.S2; Boyer J, 1996, CHEST, V109, P1532, DOI 10.1378/chest.109.6.1532; Brown RH, 1998, J APPL PHYSIOL, V85, P2012, DOI 10.1152/jappl.1998.85.6.2012; Brusasco V, 1999, J APPL PHYSIOL, V87, P567, DOI 10.1152/jappl.1999.87.2.567; Butler TM, 1998, ACTA PHYSIOL SCAND, V164, P389; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chitano P, 2000, J APPL PHYSIOL, V88, P1338, DOI 10.1152/jappl.2000.88.4.1338; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; DING DJ, 1987, J APPL PHYSIOL, V62, P1324, DOI 10.1152/jappl.1987.62.3.1324; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; Eden E, 1997, AM J RESP CRIT CARE, V156, P68, DOI 10.1164/ajrccm.156.1.9508014; Fan T, 1997, AM J RESP CELL MOL, V17, P156, DOI 10.1165/ajrcmb.17.2.2628; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; Fredberg J.J., 1999, AM J RESP CRIT CARE, V159, P1; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016; Fredberg JJ, 1996, J APPL PHYSIOL, V81, P2703, DOI 10.1152/jappl.1996.81.6.2703; FROEB HF, 1968, J APPL PHYSIOL, V25, P244, DOI 10.1152/jappl.1968.25.3.244; Gennes P.G., 1979, SCALING CONCEPTS POL; GREEN M, 1974, J APPL PHYSIOL, V37, P793, DOI 10.1152/jappl.1974.37.6.793; GUNST SJ, 1990, J APPL PHYSIOL, V68, P2223, DOI 10.1152/jappl.1990.68.5.2223; GUNST SJ, 1988, J APPL PHYSIOL, V65, P2490, DOI 10.1152/jappl.1988.65.6.2490; GUNST SJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1267, DOI 10.1152/ajpcell.1995.268.5.C1267; HAEBERLE JR, 1994, CAN J PHYSIOL PHARM, V72, P1400, DOI 10.1139/y94-202; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; INGRAM RH, 1995, CHEST, V107, pS148, DOI 10.1378/chest.107.3_Supplement.148S; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; Jeffery PK, 1998, EUR RESPIR J, V11, P524; JIANG H, 1992, AM J RESP CELL MOL, V7, P567, DOI 10.1165/ajrcmb/7.6.567; JIANG H, 1995, AM J PHYSIOL-LUNG C, V268, pL739, DOI 10.1152/ajplung.1995.268.5.L739; Jones KA, 1999, AM J PHYSIOL-LUNG C, V277, pL334, DOI 10.1152/ajplung.1999.277.2.L334; KALLOK MJ, 1983, J APPL PHYSIOL, V54, P185, DOI 10.1152/jappl.1983.54.1.185; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; King GG, 1999, AM J RESP CRIT CARE, V160, P454, DOI 10.1164/ajrccm.160.2.9804012; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LAIFOOK SJ, 1981, ANN BIOMED ENG, V9, P451, DOI 10.1007/BF02364763; LAKSER O, 2000, AM J RESP CRIT CARE, V161, pA281; Lambert RK, 1997, J APPL PHYSIOL, V83, P140, DOI 10.1152/jappl.1997.83.1.140; LIM TK, 1987, AM REV RESPIR DIS, V135, P591; LIM TK, 1989, AM REV RESPIR DIS, V140, P340, DOI 10.1164/ajrccm/140.2.340; Low RB, 1999, AM J RESP CELL MOL, V20, P651, DOI 10.1165/ajrcmb.20.4.3050; MACKLEM PT, 1990, ANN ALLERGY, V64, P113; MACKLEM PT, 1986, AM REV RESPIR DIS, V134, P812; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; MARTIN RJ, 1993, J APPL PHYSIOL, V75, P1467, DOI 10.1152/jappl.1993.75.4.1467; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MIJAILOVICH M, IN PRESS BIOPHYS J; Moore BJ, 1997, AM J RESP CRIT CARE, V156, P1278, DOI 10.1164/ajrccm.156.4.96-11082; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORENO RH, 1993, J APPL PHYSIOL, V75, P738, DOI 10.1152/jappl.1993.75.2.738; MURPHY TM, 1991, AM J PHYSIOL, V260, pL471, DOI 10.1152/ajplung.1991.260.6.L471; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; NAGASE T, 1995, AM J RESP CRIT CARE, V152, P81, DOI 10.1164/ajrccm.152.1.7599867; Nicolis G., 1989, EXPLORING COMPLEXITY; OREHEK J, 1980, AM REV RESPIR DIS, V121, P297; Pare P D, 1997, Monaldi Arch Chest Dis, V52, P589; PARE PD, 1991, AM REV RESPIR DIS, V143, P1189, DOI 10.1164/ajrccm/143.5_Pt_1.1189; PRATUSEVICH VR, 1995, J GEN PHYSIOL, V105, P73, DOI 10.1085/jgp.105.1.73; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Shen X, 1997, J APPL PHYSIOL, V83, P1202, DOI 10.1152/jappl.1997.83.4.1202; Singas E, 1996, CHEST, V110, P911, DOI 10.1378/chest.110.4.911; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; SPARROW D, 1994, AM J RESP CRIT CARE, V149, P376, DOI 10.1164/ajrccm.149.2.8306033; STEPHENS NL, 1998, AM J RESP CRIT CARE, V157, pA746; TEPPER RS, 1995, J APPL PHYSIOL, V79, P1190, DOI 10.1152/jappl.1995.79.4.1190; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749, DOI 10.1164/ajrccm.154.3.8810615; WARNER DO, 1992, AM REV RESPIR DIS, V145, P553, DOI 10.1164/ajrccm/145.3.553; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; WHEATLEY JR, 1989, EUR RESPIR J, V2, P331; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	76	69	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					615	624		10.1067/mai.2000.109429	http://dx.doi.org/10.1067/mai.2000.109429			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031329				2022-12-18	WOS:000089980600002
J	Avila, PC; Abisheganaden, JA; Wong, H; Liu, J; Yagi, S; Schnurr, D; Kishiyama, JL; Boushey, HA				Avila, PC; Abisheganaden, JA; Wong, H; Liu, J; Yagi, S; Schnurr, D; Kishiyama, JL; Boushey, HA			Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinovirus; nasal allergen challenge; common colds; allergic rhinitis	LOWER AIRWAY RESPONSES; SUBJECTS IN-VIVO; UPPER RESPIRATORY-INFECTION; LATE ASTHMATIC REACTIONS; EXHALED NITRIC-OXIDE; NONALLERGIC SUBJECTS; COMMON COLD; ANTIGEN BRONCHOPROVOCATION; CYTOKINE PRODUCTION; VIRAL-INFECTIONS	Background: Despite the strong association of asthma exacerbations with rhinovirus (RV) infection, inoculation of asthmatic subjects with RV only causes small changes in loner airway function, suggesting that RV infection is not itself sufficient to provoke asthma exacerbations. Objective: Our purpose was to test whether allergic inflammation increases the airway response to RV infection. Methods: We compared the severity of RV type 16-induced colds in 2 groups of 10 subjects with allergic rhinitis. One group received 3 nasal challenges with allergen and the other received challenges with placebo over the week before nasal inoculation with RV type 16 (4000 tissue culture infective dose 50% per subject). Subjects kept symptom diaries and were assessed with spirometry, methacholine challenge, nasal lavage, and sputum induction on days 2, 4, 7, 10, 15, and 30 after inoculation. Results: The 2 groups developed equal rates of infection (90%), similar cold symptoms (Jackson score median [interquartile range], 11 [6-33] vs 20.5 [6-42] for allergen and placebo groups respectively, P = .54), and similar changes in cellular profile and in IL-6 and IL-8 concentrations in nasal lavage fluid and induced sputum after RV inoculation. The incubation period was significantly longer in the allergen group (2.5 [1-5.5] vs 1 [1-1] day, P = .03) and the duration of cold symptoms was shorter (5 [4.7] vs 8.5 [6-10] days, P = .008). We also found an inverse correlation between the percent of eosinophils in nasal lavage fluid before inoculation and the severity of cold symptoms (r = -0.58, P = .008). Conclusion: In subjects with allergic rhinitis, augmented nasal allergic inflammation before inoculation with RV type 16 does not worsen the severity of cold symptoms but delays their onset and shortens their duration.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Div Pulm Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Div Allergy & Immunol, San Francisco, CA 94143 USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Berkeley, CA 94704 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services	Boushey, HA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Div Pulm Med, 505 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.			Abisheganaden, John/0000-0002-3192-317X	NHLBI NIH HHS [HL 56385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056385, P50HL056385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alper CM, 1996, LARYNGOSCOPE, V106, P1298, DOI 10.1097/00005537-199610000-00025; ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; Angelini B, 1997, J ALLERGY CLIN IMMUN, V99, P618, DOI 10.1016/S0091-6749(97)70022-8; BARDIN PG, 1994, CLIN EXP ALLERGY, V24, P457, DOI 10.1111/j.1365-2222.1994.tb00934.x; Bianco A, 1998, Monaldi Arch Chest Dis, V53, P83; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Coyle AJ, 1996, ANN NY ACAD SCI, V796, P97, DOI 10.1111/j.1749-6632.1996.tb32571.x; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1994, AM J RESP CRIT CARE, V150, P1130, DOI 10.1164/ajrccm.150.4.7921447; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GARRELDS IM, 1995, THORAX, V50, P275, DOI 10.1136/thx.50.3.275; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1997, AM J RESP CRIT CARE, V155, P833; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; Harris JM, 1996, CLIN INFECT DIS, V23, P1287, DOI 10.1093/clinids/23.6.1287; Hendley JO, 1998, CLIN INFECT DIS, V26, P847, DOI 10.1086/513921; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;100::AID-JMV16&gt;3.0.CO;2-D; Robinson PJ, 1997, J ALLERGY CLIN IMMUN, V100, P492, DOI 10.1016/S0091-6749(97)70141-6; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Skoner DP, 1996, EUR RESPIR J, V9, P1402, DOI 10.1183/09031936.96.09071402; Skoner DP, 1996, AM J RESP CRIT CARE, V154, P661, DOI 10.1164/ajrccm.154.3.8810602; SUMMERS QA, 1992, EUR RESPIR J, V5, P313; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; Trigg CJ, 1996, CLIN EXP ALLERGY, V26, P665, DOI 10.1111/j.1365-2222.1996.tb00593.x; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	48	69	71	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					923	932		10.1067/mai.2000.106214	http://dx.doi.org/10.1067/mai.2000.106214			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808173				2022-12-18	WOS:000087185000011
J	Bingham, CO; Austen, KF				Bingham, CO; Austen, KF			Mast-cell responses in the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mast cell; asthma; asthma pathogenesis; Fc epsilon RI; inflammation; mediators	FC-EPSILON-RI; C-KIT LIGAND; CYTOSOLIC PHOSPHOLIPASE A(2); LEUKOTRIENE C-4 SYNTHASE; MULTIPLE BODY SITES; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; PLATELET-ACTIVATING-FACTOR; RECEPTOR TYROSINE KINASE; BLOOD MONONUCLEAR-CELLS; HIGH-AFFINITY RECEPTOR	Many cells participate in the pathogenesis of asthmatic inflammation. The mast cell is localized at the interface of the internal and external environment within the lung where it may respond to allergens and other exogenous stimuli. The activation of mast cells leads to the release of mediators that contribute to the early phase of asthmatic inflammation. Mast-cell-derived products may also contribute to the late-phase asthmatic response. This review summarizes the developmental biologic features of the mast cell, its receptor-mediated activation, and its range of preformed, newly synthesized, and induced mediators that contribute to asthmatic inflammation.	Harvard Univ, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Brigham & Womens Hosp, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bingham, CO (corresponding author), NYU, Hosp Joint Dis, Dept Rheumatol & Med, 301 E 17th St, New York, NY 10003 USA.							ARM JP, 1993, CLIN SCI, V84, P501, DOI 10.1042/cs0840501; Arm JP, 1997, J IMMUNOL, V159, P2342; AUSTEN KF, 1995, INT ARCH ALLERGY IMM, V107, P19; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; BINGHAM CO, 1999, SIGNAL TRANSDUCTION, P350; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1993, J IMMUNOL, V151, P3853; Bressler RB, 1997, J ALLERGY CLIN IMMUN, V99, P508, DOI 10.1016/S0091-6749(97)70078-2; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Cairns JA, 1996, J IMMUNOL, V156, P275; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; CHURCH MK, 1991, INT ARCH ALLER A IMM, V94, P310, DOI 10.1159/000235393; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; FALUS A, 1992, IMMUNOL TODAY, V13, P154; FERNANDEZ J, 1995, INT ARCH ALLERGY IMM, V107, P160, DOI 10.1159/000236964; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; FRUMAN DA, 1995, J IMMUNOL, V154, P1846; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GALLI SJ, 1993, AM J PATHOL, V142, P965; GALLUP G, 1991, GALLUP POLL NEWS SER, V55, P1; GOETZL EJ, 1981, MED CLIN N AM, V65, P809, DOI 10.1016/S0025-7125(16)31499-7; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; Gruber BL, 1997, J IMMUNOL, V158, P2310; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; HOZAWA S, 1995, AM J RESP CRIT CARE, V152, P1198, DOI 10.1164/ajrccm.152.4.7551370; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; IEMURA A, 1994, AM J PATHOL, V144, P321; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Katz HR, 1997, J IMMUNOL, V158, P5065; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KITAMURA Y, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P91; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 1997, J INVEST DERMATOL, V108, P792, DOI 10.1111/1523-1747.ep12292240; Longphre M, 1996, AM J RESP CELL MOL, V14, P461, DOI 10.1165/ajrcmb.14.5.8624251; Ludowyke RI, 1996, J IMMUNOL, V157, P5130; Lukacs NW, 1996, J IMMUNOL, V156, P3945; LuKuo JM, 1996, J BIOL CHEM, V271, P22169, DOI 10.1074/jbc.271.36.22169; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Meninger CJ, 1992, BLOOD, V4, P958; MOLLER A, 1993, J IMMUNOL, V151, P3261; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NILSSON G, 1995, SCAND J IMMUNOL, V42, P76, DOI 10.1111/j.1365-3083.1995.tb03628.x; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Ogasawara T, 1997, J IMMUNOL, V158, P393; Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PRIESCHL EE, 1995, J IMMUNOL, V155, P4963; QU ZH, 1995, AM J PATHOL, V147, P564; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; REYNOLDS DS, 1992, J CLIN INVEST, V89, P273, DOI 10.1172/JCI115571; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROTTEM M, 1994, BLOOD, V84, P2489; Saito H, 1996, J IMMUNOL, V157, P343; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P161; SHIMIZU Y, 1995, BLOOD, V86, P930; Smith TJ, 1996, IMMUNOL TODAY, V17, P60, DOI 10.1016/0167-5699(96)80580-9; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Tashiro M, 1997, J IMMUNOL, V158, P2382; Toru H, 1996, INT IMMUNOL, V8, P1367; TSUJIMURA T, 1994, BLOOD, V83, P2619; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; Wang LL, 1997, J IMMUNOL, V158, P13; WEIDNER N, 1990, LAB INVEST, V63, P63; WEIDNER N, 1991, J INVEST DERMATOL, V96, pS26, DOI 10.1111/1523-1747.ep12468966; WEIDNER N, 1993, PATHOL RES PRACT, V189, P156, DOI 10.1016/S0344-0338(11)80086-5; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	106	69	73	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S527	S534		10.1016/S0091-6749(00)90056-3	http://dx.doi.org/10.1016/S0091-6749(00)90056-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669537	Bronze			2022-12-18	WOS:000085439600014
J	Pastorello, EA; D'Ambrosio, FP; Pravettoni, V; Farioli, L; Giuffrida, G; Monza, M; Ansaloni, R; Fortunato, D; Scibola, E; Rivolta, F; Incorvaia, C; Bengtsson, A; Conti, A; Ortolani, C				Pastorello, EA; D'Ambrosio, FP; Pravettoni, V; Farioli, L; Giuffrida, G; Monza, M; Ansaloni, R; Fortunato, D; Scibola, E; Rivolta, F; Incorvaia, C; Bengtsson, A; Conti, A; Ortolani, C			Evidence for a lipid transfer protein as the major allergen of apricot	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apricot; oral allergy syndrome; immunoblotting; major allergen; lipid transfer protein	PLANTS; APPLE; PEACH	Background: Apricots are widely grown in Europe, and allergic reactions are becoming more common, especially oral allergy syndrome. Apricot belongs to the botanical subfamily of Prunoideae, which includes peach, the major allergen of which was identified as a 9-kd protein, a lipid transfer protein (LTP). Objective: The aim of the study was to evaluate the IgE reactivity pattern to an apricot extract in subjects with allergic reactions to apricot, as demonstrated by a positive oral challenge response. Methods: Thirty patients were investigated. All the patients displayed oral allergy syndrome (2 with systemic reactions) to apricot, with positive open food challenge responses, skin prick test responses, and serum-specific IgE antibodies to apricot. The IgE reactivity pattern to apricot extract was identified by using SDS-PAGE and immunoblotting. The major allergen, a 9-kd protein, was then purified by HPLC and characterized by periodic acid-Schiff stain, isoelectric point determination, and N-terminal amino acid sequencing. Results: The sera from all patients allergic to apricot recognized the 9-kd protein, whereas none of the other allergens, with molecular weights from 15 to 80 kd, acted as a major allergen. The 9-kd allergen has an isoelectric point of 8.7 and is not glycosylated. Determination of the N-terminal 34 amino acid sequence showed that it belongs to the LTP family, with a 94% homology with the LTP from peach. IgE blotting of the apricot extract was completely inhibited by the 9-kd purified LTP from peach. Conclusions: The major allergen of apricot is an LTP, which is highly cross-reactive with the LTP from peach.	Osped Maggiore, IRCCS, Div Gen Med 3, I-20122 Milan, Italy; Univ Messina, Sch Allergy & Clin Immunol, Messina, Italy; Unita Operat Osped Med Lavoro, Milan, Italy; Niguarda Ca Granda Hosp, Bizzozzero Div, Milan, Italy; Natl Res Council, Turin, Italy; Pharmacia & Upjohn Diagnost AB, Uppsala, Sweden	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Messina; IRCCS Ca Granda Ospedale Maggiore Policlinico; Pfizer; Pharmacia Corporation	Pastorello, EA (corresponding author), Osped Maggiore, IRCCS, Div Gen Med 3, Via Francesco Sforza 35, I-20122 Milan, Italy.		Giuffrida, Maria Gabriella/AAY-6314-2020; PASTORELLO, ELIDE ANNA/E-3897-2017	Giuffrida, Maria Gabriella/0000-0002-1297-2558; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Colombo P, 1998, J IMMUNOL, V160, P2780; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; FIDEGHELLI C, 1998, ITALIAN HORTICULTURE; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PRAVETTONI V, 1998, P 7 INT S IMM CHEM C, P11; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; TCHANG F, 1988, J BIOL CHEM, V263, P16849; TORRESSCHUMANN S, 1992, PLANT MOL BIOL, V18, P749, DOI 10.1007/BF00020016; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Yman L, 1975, Dev Biol Stand, V29, P151	18	69	70	0	13	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				371	377		10.1016/S0091-6749(00)90090-3	http://dx.doi.org/10.1016/S0091-6749(00)90090-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669861				2022-12-18	WOS:000085402200025
J	Lumry, WR				Lumry, WR			A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						intranasal steroids; allergic rhinitis; perennial rhinitis	AQUEOUS NASAL SPRAY; DAILY BECLOMETHASONE DIPROPIONATE; MOMETASONE FUROATE; FLUTICASONE PROPIONATE; PHARMACOLOGICAL PROPERTIES; INHALED CORTICOSTEROIDS; TRIAMCINOLONE ACETONIDE; THERAPEUTIC EFFICACY; MESSENGER-RNA; INFLAMMATION	The anti-inflammatory activity of corticosteroids has prompted the exploration of their use in the treatment of allergic rhinitis, The development of intranasal steroids has resulted in several agents with quick actions, localized effects, and great efficacy in the treatment of seasonal allergic rhinitis and the prophylactic management of perennial rhinitis, This article presents a concise review of the preclinical and clinical evidence with these new agents and provides data-based guidance for the selection of optimal agents. The survey reveals that mometasone furoate, a new inhaled steroid with topical activity, has the greatest binding affinity for the glucocorticoid receptor, followed by fluticasone propionate, budesonide, triamcinolone acetonide, and dexamethasone. Mometasone furoate also has strong anti-inflammatory activity, with IL-4 and IL-5 inhibition activities equivalent to those of fluticasone propionate. Clinically, both mometasone furoate and fluticasone propionate appear to be well tolerated, to have quick onsets of action, and to be equivalent in efficacy in the treatment of seasonal allergic and perennial rhinitis, Of the intranasal steroids currently available. mometasone furoate has been shown to have the least systemic availability and, consequently, is expected to have the fewest systemic side effects. Some suppression of overnight cortisol levels has been reported with fluticasone propionate (indicative of hypothalamic-pituitary-adrenal axis suppression).	Univ Texas, SW Med Sch, Allergy & Asthma Res Assoc, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lumry, WR (corresponding author), Amer Board Allergy & Immunol, 9900 N Cent,Suite 525, Dallas, TX 75231 USA.							Allen DB, 1998, ACTA PAEDIATR, V87, P123, DOI 10.1080/08035259850157516; BARTON BE, 1991, IMMUNOPHARM IMMUNOT, V13, P251, DOI 10.3109/08923979109019704; Berg OH, 1997, ALLERGY, V52, P627, DOI 10.1111/j.1398-9995.1997.tb01041.x; Berkowitz R. B., 1997, Journal of Allergy and Clinical Immunology, V99, pS441; Berkowitz RB, 1998, J ALLERGY CLIN IMMUN, V101, pS244; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62; Brannan MD, 1997, ANN ALLERG ASTHMA IM, V78, P154; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; Chervinsky P, 1996, CLIN THER, V18, P790, DOI 10.1016/S0149-2918(96)80039-7; Davies RJ, 1997, CLIN THER, V19, P27; Day J., 1997, Journal of Allergy and Clinical Immunology, V99, pS441; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Fokkens WJ, 1998, AM J RHINOL, V12, P21, DOI 10.2500/105065898782102990; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hebert JR, 1996, ALLERGY, V51, P569; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; LAFORCE CF, 1994, J FAM PRACTICE, V38, P145; Levenson T, 1996, ALLERGY ASTHMA PROC, V17, P157, DOI 10.2500/108854196779165021; LUZZANI F, 1982, METHOD FIND EXP CLIN, V4, P237; Marazzi P., 1997, Journal of Allergy and Clinical Immunology, V99, pS440; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; MOLLER C, 1994, ALLERGY CLIN IMMU S2, V6, P427; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1988, CLIN ALLERGY, V18, P253, DOI 10.1111/j.1365-2222.1988.tb02867.x; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; SCHENKEL EJ, 1999, EUR J ALLEGY CLI S52, V54, P74; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; THERATTIL J, 1997, ANN ALLERG ASTHMA IM, V78, P129; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x; 1998, PHYSICIANS DESK REF	44	69	72	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				S150	S158		10.1016/S0091-6749(99)70311-8	http://dx.doi.org/10.1016/S0091-6749(99)70311-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518812				2022-12-18	WOS:000083281200032
J	Borish, L; Schmaling, K; DiClementi, JD; Streib, J; Negri, J; Jones, JF				Borish, L; Schmaling, K; DiClementi, JD; Streib, J; Negri, J; Jones, JF			Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic fatigue syndrome; cytokines; allergic; tumor necrosis factor; IL-10; psychologic morbidity	INHIBITS CYTOKINE PRODUCTION; T-CELL CLONES; SERUM LEVELS; IL-10; INTERLEUKIN-10; MONOCYTES; RELEASE; SUBSETS	Background: We investigated a role for allergic inflammation and psychologic parameters in the development of chronic fatigue syndrome (CFS), Methods: The design was a comparison between subjects with CFS and age- and sex-matched control cohorts. Studies were performed on CFS subjects (n =18) and control cohorts consisting of normal subjects (n = 11), allergic subjects (n = 14), and individuals with primary depression (n = 12), We quantified cytokines at baseline as cell-associated immunoreactive peptides and as transcripts evaluated by means of semiquantitative RNA-based polymerase chain reactions. Psychologic evaluations included administration of the Diagnostic Interview Schedule, the Structured Clinical Interview, and the Symptom Checklist 90-Revised. Results: Increases in tumor necrosis factor (TNF)-alpha were identified in individual subjects with CFS (50.1 +/- 14.4 pg TNF-alpha per 10(7) peripheral blood mononuclear cells [PBMCs]; mean +/- SEM) and allergic subjects (41.6 +/- 7.6) in comparison with normal subjects (13.1 +/- 8.8) (P <.01 and P <.05, respectively), Similar trends were observed for interferon (IFN)-alpha in allergic subjects (3.0 +/- 1.7 pg/10(7) PBMCs) and subjects with CFS (6.4 +/- 3.4) compared with normal subjects (1.9 +/- 1.4), A significant increase (P <.05) in TNF-alpha transcripts was demonstrated between subjects with CFS and depressed subjects. In contrast to these proinflammatory cytokines, both subjects with CFS (2.6 +/- 1.8 pg/10(7) PBMCs) and allergic subjects (3.4 +/- 2.8) mere associated with a statistically significant (P <.01) decrease in IL-10 concentrations compared with normal subjects (60.2 +/- 18.2). As shown in other studies, most of our subjects with CFS were allergic (15 of 18) and therefore presumably demonstrated cytokine gene activation on that basis. The seasonal exacerbation of allergy was associated with a further increase in cellular IFN-alpha (from 2.1 +/- 1.2 to 14.2 +/- 4.5 pg/10(7) PBMCs; P <.05) but no further modulation of TNF-alpha or IL-10. Similarly, self-reported exacerbations of CFS were associated with a further increase in IFN-alpha (from 2.5 +/- 1.0 to 21.9 +/- 7.8; P <.05) and occurred at times of seasonal exposures to allergens. This Linkage does not permit making any definitive conclusions regarding a causative influence of either seasonal allergies or the increase in cellular IFN-alpha with the increase in CFS symptoms. The close association between atopy and CFS led us to speculate that CFS may arise from an abnormal psychologic response to the disordered expression of these proinflammatory and antiinflammatory cytokines. Psychologic variables were predictive of immune status within the CFS sample (65.9% of the variance in immune status; F (3,10) = 6.44, P <.05), Specifically, the absence of a personality disorder but greater endorsement of global psychiatric symptoms was predictive of immune activation. Conclusions: Most of our subjects with CFS were allergic, and the CFS and allergy cohorts were similar in terms of their immune status. However, the CFS subjects could be discriminated by the distinct psychologic profiles among subjects with and without immune activation. We propose that in at lease a large subgroup of subjects with CFS who had allergies, the concomitant influences of immune activation brought on by allergic inflammation in an individual with the appropriate psychologic profile may interact to produce the symptoms of CFS, In a psychologically predisposed individual, symptoms associated with allergic inflammation are recognized as illness.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle	Jones, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.		Schmaling, Karen B/F-5217-2011	Schmaling, Karen B/0000-0003-2085-134X	NCRR NIH HHS [MO1 RR00051] Funding Source: Medline; NIAID NIH HHS [AI32244] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032244] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; CANNON JG, 1993, J APPL PHYSIOL, V75, P1897, DOI 10.1152/jappl.1993.75.4.1897; CHAO CC, 1991, CYTOKINE, V3, P292, DOI 10.1016/1043-4666(91)90497-2; CHAO CC, 1990, J INFECT DIS, V162, P1412, DOI 10.1093/infdis/162.6.1412-a; CHENEY PR, 1989, ANN INTERN MED, V110, P321, DOI 10.7326/0003-4819-110-4-321_1; CLEVELAND CH, 1992, ALLERGY PROC, V13, P263, DOI 10.2500/108854192778817077; Conti F, 1996, ALLERGY, V51, P124; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DEROGATIS LR, 1975, SCL 90R ADM SCORING; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; First M.B., 1989, STRUCTURED CLIN INTE; FONTAINE S, 1989, LYMPHOKINE RES, V8, P129; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOYEN DO, 1988, LANCET, V1, P125; LINDE A, 1992, J INFECT DIS, V165, P994, DOI 10.1093/infdis/165.6.994; LLOYD AR, 1994, CLIN INFECT DIS, V18, pS134, DOI 10.1093/clinids/18.Supplement_1.S134; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MARSHALL PS, 1993, PSYCHOL BULL, V113, P23, DOI 10.1037/0033-2909.113.1.23; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; OLSON GB, 1986, J ALLERGY CLIN IMMUN, V78, P308, DOI 10.1016/S0091-6749(86)80081-1; PATARCA R, 1994, CLIN INFECT DIS, V18, pS147, DOI 10.1093/clinids/18.Supplement_1.S147; RALPH P, 1992, J IMMUNOL, V148, P808; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; Steinberg P, 1996, J ALLERGY CLIN IMMUN, V97, P119, DOI 10.1016/S0091-6749(96)70290-7; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; STRAUS SE, 1989, J INFECT DIS, V160, P1085, DOI 10.1093/infdis/160.6.1085; YSSEL H, 1992, J IMMUNOL, V149, P2378	32	69	69	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					222	230		10.1016/S0091-6749(98)70090-9	http://dx.doi.org/10.1016/S0091-6749(98)70090-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723665	Bronze			2022-12-18	WOS:000075537100013
J	Eberlein-Konig, B; Przybilla, B; Kuhnl, P; Pechak, J; Gebefugi, I; Kleinschmidt, J; Ring, J				Eberlein-Konig, B; Przybilla, B; Kuhnl, P; Pechak, J; Gebefugi, I; Kleinschmidt, J; Ring, J			Influence of airborne nitrogen dioxide or formaldehyde on parameters of skin function and cellular activation in patients with atopic eczema and control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMATIC-PATIENTS; ALLERGEN		Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, D-80802 Munich, Germany; Univ Munich, Dermatol Klin & Poliklin, D-8000 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Okol Chem Oberschleissheim, Munich, Germany; Univ Munich, Inst Med Balneol & Klimatol, Munich, Germany	Technical University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Eberlein-Konig, B (corresponding author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; EberleinKonig B, 1996, ACTA DERM-VENEREOL, V76, P447; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	5	69	71	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				141	143		10.1016/S0091-6749(98)70212-X	http://dx.doi.org/10.1016/S0091-6749(98)70212-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449520				2022-12-18	WOS:000071539800028
J	Klimek, L; Eggers, G				Klimek, L; Eggers, G			Olfactory dysfunction in allergic rhinitis is related to nasal eosinophilic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; olfaction; eosinophil cationic protein; rhinomanometry	CATIONIC PROTEIN; AIR-FLOW; RADIOIMMUNOASSAY; EXPOSURE	Background: Olfactory dysfunction is a common finding in patients suffering from allergic rhinitis. However, little is known about the pathophysiology underlying this phenomenon and about the time course of hyposmia in seasonal allergy. Methods: A prospective controlled study was performed on 17 patients with allergic rhinitis to grass pollen in order to evaluate olfactory function in correlation to the duration of allergen exposition, symptoms, eosinophil cationic protein (ECP) in nasal secretions, and nasal volume flow (NVF), Olfactory function was evaluated preseasonally and on days 3, 7, 14, and 21 of the season using a modified Connecticut Chemosensory Clinical Research Center testing procedure for threshold, identification, and discrimination. Twelve volunteers without allergy served as controls. Results: Preseasonally, patients and controls performed equally in discrimination and identification testing, but not in threshold testing. No changes were found in the controls, but a significant decrease in threshold and identification from the 7th day of the season in patients with allergy was noted that was better correlated to ECP than to NVF. NVF was already maximally decreased from the 3rd intraseasonal day with no further changes, ECP increase became significant at day 14. Conclusion: Patients with grass pollen allergy develop olfactory dysfunction during natural allergen exposure that might be related to allergic inflammatory mechanisms.			Klimek, L (corresponding author), MAINZ UNIV HOSP,DEPT OTORHINOLARYNGOL,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.							ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BROWN HM, 1977, BR J CLIN PHARM, V4, P283; BUTTKUS R, 1988, MED OLFAKTOLOGIE GUS, P201; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; COHEN AB, 1970, CLIN EXP IMMUNOL, V6, P753; COWART BJ, 1993, J ALLERGY CLIN IMMUN, V91, P747, DOI 10.1016/0091-6749(93)90194-K; Debain J J, 1970, Rev Laryngol Otol Rhinol (Bord), V91, P204; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; FEIN BT, 1966, ANN ALLERGY, V24, P278; Filou M, 1969, Ann Otolaryngol Chir Cervicofac, V86, P578; JAFEK BW, 1987, ARCH OTOLARYNGOL, V113, P547; JOHANSSON SGO, 1976, INT ARCH ALLER A IMM, V52, P364, DOI 10.1159/000231703; KEITH PK, 1994, J ALLERGY CLIN IMMUN, V93, P567, DOI 10.1016/S0091-6749(94)70068-0; KLIMEK L, 1996, ALLERGOLOGIE, V19, P23; Kobal G., 1992, Chemical Senses, V17, P850; Mann W, 1989, Arch Otorhinolaryngol Suppl, V1, P71; MESSERKLINGER W, 1972, HNO-WEGW FACHARZT PR, V20, P133; Perrin C, 1970, Rev Fr Allergol, V10, P273, DOI 10.1016/S0035-2845(70)80052-X; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RIECHELMANN H, 1995, ALLERGOLOGIE, V18, P126; SCHERER PW, 1989, OTOLARYNG CLIN N AM, V22, P265; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x	31	69	70	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					158	164		10.1016/S0091-6749(97)70218-5	http://dx.doi.org/10.1016/S0091-6749(97)70218-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275134				2022-12-18	WOS:A1997XR35100003
J	Hamilton, RG; Adkinson, NF				Hamilton, RG; Adkinson, NF			Natural rubber latex skin testing reagents: Safety and diagnostic accuracy of nonammoniated latex, ammoniated latex, and latex rubber glove extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber later; diagnosis; skin testing; glove provocation	SYSTEMIC REACTIONS; ALLERGY; ANAPHYLAXIS; AVOCADO; BANANA	Background: Nonammoniated latex, ammoniated latex, and rubber glove extracts are the only sources of natural rubber (Hevea brasiliensis) latex that have potential for use as skin testing reagents in the diagnosis of latex allergy. Their diagnostic sensitivity and specificity as skin test reagents are unknown. Objective: We conducted a phase 1/2 clinical study to examine the safety and diagnostic accuracy (sensitivity and specificity) of nonammoniated latex, ammoniated latex, and rubber glove extracts as skin test extracts to identify the most efficacious source material for future skin test reagent development. Methods: Twenty-four adults not allergic of latex, 19 adults with hand dermatitis or pruritus, and 59 adults with a latex allergy were identified by clinical history. All provided blood and then received puncture skin tests and intradermal skin tests with nonammoniated latex, ammoniated latex, and rubber glove extracts from Malaysian H. brasiliensis latex by use of sequential titration. A glove provocation test and IgE anti-latex RAST were used to clarify positive history-negative skin test response and negative history-positive skin test response mismatches. Results: All three extracts were biologically safe and sterile. After normalization to 1 mg/ml of total protein, all three extracts produced equivalent diagnostic sensitivity and specificity in puncture skin tests and intradermal skin tests at various extract concentrations. Optimal diagnostic accuracy was safely achieved at 100 mu g/ml for puncture skin tests and 1 mu g/ml for intradermal skin tests (e.g., nonammoniated latex: puncture skin test sensitivity 96%, specificity 100%; intradermal ski test sensitivity 93%, specificity 96%). The presence of IgE antibody in skin was highly correlated with IgE anti-latex in serum (nonammoniated latex: r = 0.98, p < 0.001; ammoniated latex: r = 0.94, p < 0.001; rubber glove extract: r = 0.96, p < 0.001). All five available subjects with a positive history, negative skin test response, and absence of IgE antibody in serum had a negative glove provocation test response, indicating no clinical evidence of latex allergy. No systemic or large local allergic reactions were observed with puncture skin tests or intradermal skin tests. Conclusions: Equivalent diagnostic sensitivity and specificity were observed with the nonammoniated latex, ammoniated latex, and rubber glove extract skin test reagents after normalization for total protein; nonammoniated latex may be considered the reagent of choice on the basis of practical quality control and reproducibility considerations.			Hamilton, RG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL & ALLERGY,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031867] Funding Source: NIH RePORTER; NIAID NIH HHS [U19-AI-31867] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BRONZERT CT, 1994, J ALLERGY CLIN IMMUN, V93, P306; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; Butler JE, 1991, IMMUNOCHEMISTRY SOLI, P173; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; Hamilton R. G., 1996, Journal of Allergy and Clinical Immunology, V97, P429, DOI 10.1016/S0091-6749(96)81204-8; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8; Turijamaa K, 1987, CONTACT DERMATITIS, V17, P270; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; ZELDIN RK, 1995, ANN ALLERG ASTHMA IM, V74, P56; ZWSEG MH, 1995, GP10A NAT COMM CLIN, P1	28	69	70	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				872	883		10.1016/S0091-6749(96)80003-0	http://dx.doi.org/10.1016/S0091-6749(96)80003-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939150	hybrid			2022-12-18	WOS:A1996VU76400003
J	SMITH, CH; KEPLEY, C; SCHWARTZ, LB; LEE, TH				SMITH, CH; KEPLEY, C; SCHWARTZ, LB; LEE, TH			MAST-CELL NUMBER AND PHENOTYPE IN CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						URTICARIA; MAST CELLS; MC(TC); MC(T); IMMUNOHISTOCHEMISTRY	HISTAMINE-RELEASE; TRYPTASE; AUTOANTIBODIES; VASCULITIS; CHYMASE; IGE	Background: Increased levels of histamine have been previously demonstrated in patients with chronic idiopathic urticaria. Objective: The purpose of the study was to determine whether increased numbers of mast cells are present in lesional skin from such patients. Methods: Mast cells have been quantified in lesional (n = 11) and nonlesional (n = 9) skirt from patients with chronic idiopathic urticaria and compared with site-matched skin from healthy control subjects (n = 10). Mast cells were identified by using a sensitive, double-labeling immunohistochemical technique with specific monoclonal antibodies to mast cell tryptase and chymase and quantified under light microscopy. Results: No significant differences in mast cell numbers from lesional, nonlesional, or control skin were observed (p > 0.1, Student's t test). In both patients with urticaria and control subjects, more than 99% of cutaneous mast cells contained tryptase and chymase. Conclusions: These date: indicate that increased skin histamine in chronic idiopathic urticaria is not caused by increased mast cells and may alternatively reflect an increase in histamine content per mast cell, enhanced mast cell activation, or recruitment of basophils into skin in patients with chronic idiopathic urticaria.	UNITED MED & DENT SCH,GUYS HOSP,DEPT ALLERGY & RESP MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020; Smith, Catherine H./G-5268-2012	Lee, Tak/0000-0002-7554-4059; Smith, Catherine H./0000-0001-9918-1144				ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENYON RC, 1987, J IMMUNOL, V138, P861; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CHARLESWORTH EN, 1988, J CLIN INVEST, V83, P1519; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; CHURCH MK, 1992, J IMMUNOL, V129, P2116; CLAVEAU J, 1993, J ALLERGY CLIN IMMUN, V92, P132, DOI 10.1016/0091-6749(93)90047-J; DAVIES MG, 1980, BRIT J CLIN PHARMACO, V9, P461; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; IRANI AA, 1990, CLIN EXP ALLERGY, V20, P53, DOI 10.1111/j.1365-2222.1990.tb02775.x; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; JACQUES P, 1992, J ALLERGY CLIN IMMUN, V89, P1139, DOI 10.1016/0091-6749(92)90297-F; JUHLIN L, 1979, MAST CELL ITS ROLE H, P613; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; MONROE EW, 1981, J INVEST DERMATOL, V76, P103, DOI 10.1111/1523-1747.ep12525403; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SMITH CH, 1992, J ALLERGY CLIN IMMUN, V89, P944, DOI 10.1016/0091-6749(92)90216-O; WONG E, 1982, ACTA DERM-VENEREOL, V62, P431	26	69	72	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					360	364		10.1016/S0091-6749(95)70055-2	http://dx.doi.org/10.1016/S0091-6749(95)70055-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560638				2022-12-18	WOS:A1995RU66000008
J	MELTZER, EO				MELTZER, EO			AN OVERVIEW OF CURRENT PHARMACOTHERAPY IN PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						RHINITIS; PHARMACOTHERAPY; ANTIHISTAMINES; DECONGESTANT ANTICHOLINERGIC; CROMOLYN SODIUM; INTRANASAL CORTICOSTEROID; COMPLIANCE; COST	SEASONAL ALLERGIC RHINITIS; AQUEOUS NASAL SPRAY; QUALITY-OF-LIFE; DOUBLE-BLIND; IPRATROPIUM BROMIDE; CROMOLYN-SODIUM; ANTIHISTAMINE-DECONGESTANT; PHARMACOKINETIC PROPERTIES; FLUTICASONE PROPIONATE; CORTICOSTEROID-THERAPY	Background: Individuals with rhinitis experience significant morbidity due to their disease. Research and clinical care to reduce this suffering are important. Objective: To review the pharmacological agents that have been developed for the treatment of perennial rhinitis. Method: Literature review of human studies. Results: Medication classes include antihistamines, decongestants anticholinergics, cromolyn sodium, and corticosteroids. These vary in regard to their pharmacology, efficacy, and adverse Conclusion: Carefully chosen pharmacotherapy based on an understanding of the pathophysiology of the disease, knowledge of the potential of medications, and commitment to an ongoing patient/physician education and monitoring prog am can lead to improved well-being for individuals with perennial rhinitis.			MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR, APC, 9610 GRANITE RIDGE DR, SUITE B, SAN DIEGO, CA 92123 USA.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; AFFRIME MB, 1993, J ALLERGY CLIN IMMUN, V91, P259; ALFORD C, 1992, HUM PSYCHOPHARM CLIN, V7, P25, DOI 10.1002/hup.470070104; ALPERT JJ, 1964, PEDIATRICS, V34, P127; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V90, P373, DOI 10.1016/S0091-6749(05)80017-X; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BRADLEY CM, 1987, EUR J CLIN PHARMACOL, V32, P419, DOI 10.1007/BF00543979; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BROGDEN RN, 1974, DRUGS, V7, P164, DOI 10.2165/00003495-197407030-00002; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; COLCHER IS, 1972, J AMER MED ASSOC, V222, P657, DOI 10.1001/jama.222.6.657; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DAY JH, 1990, ANN ALLERGY, V64, P445; DECHANT KL, 1991, DRUGS, V41, P202, DOI 10.2165/00003495-199141020-00006; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; DRUCE HM, 1992, ANN ALLERGY, V69, P53; ESTELLE F, 1994, DRUG SAFETY, V10, P350, DOI 10.2165/00002018-199410050-00002; FALLIERS CJ, 1980, ANN ALLERGY, V45, P75; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; FRIEDMAN HM, 1986, AM J RHINOL, V1, P95; GOETZ DW, 1991, ANN ALLERGY, V67, P448; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GRANT SM, 1990, DRUGS, V40, P412, DOI 10.2165/00003495-199040030-00006; HENDELES L, 1993, PHARMACOTHERAPY, V13, pS129; HOLMBERG K, 1986, EUR J CLIN PHARMACOL, V30, P625, DOI 10.1007/BF00542425; HOWARTH P, 1993, ALLERGIC NONALLERGIC, P101; JACKSON RT, 1991, OTOLARYNG HEAD NECK, V104, P433, DOI 10.1177/019459989110400403; JACKSON RT, 1981, ARCH OTOLARYNGOL, V107, P288; JACOBS RL, 1987, IMMUNOL ALLERGY CLIN, V7, P93; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; JONES AS, 1988, BIOMED PHARMACOTHER, V42, P499; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KEMP JP, 1985, ANN ALLERGY, V54, P502; KNIGHT A, 1986, ANN ALLERGY, V57, P348; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; LEESON GA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1173; Ley P, 1974, Br J Orthod, V1, P173; LUND V, 1994, ALLERGY S19, V49, P5; MABRY RL, 1981, EAR NOSE THROAT J, V60, P506; MALM L, 1983, ACTA OTO-LARYNGOL, V96, P149, DOI 10.3109/00016488309132885; Malm L, 1993, ALLERGIC NONALLERGIC, P95; MCCLEVE D, 1978, OTOLARYNG HEAD NECK, V86, P851, DOI 10.1177/019459987808600603; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; MELTZER EO, 1991, ANN ALLERGY, V67, P625; MELTZER EO, 1994, ANN ALLERGY, V72, P354; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; MELTZER EO, 1990, ANN ALLERGY, V64, P536; MILFORD CA, 1990, J LARYNGOL OTOL, V104, P123, DOI 10.1017/S0022215100112022; MURAD F, 1985, PHARMACOL BASIS THER, P1459; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; Naclerio RM, 1993, ALLERGIC NONALLERGIC, P114; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; NELSON C, 1985, PHS881754 US DEP HLT; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; ORGEL HA, 1991, ANN ALLERGY, V66, P237; ORIE NGM, 1970, DISODIUM CROMOGLYCAT, P33; Passalacqua G, 1993, Allergol Immunopathol (Madr), V21, P79; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Rice D.P., 1966, HLTH EC SERIES, V6; SACKETT DL, 1979, COMPLIANCE HLTH CARE; SALE ME, 1993, J ALLERGY CLIN IMMUN, V91, P258; SBARBARO JA, 1990, ANN ALLERGY, V64, P325; SELNER J, 1994, J ALLERGY CLIN IMMUN, V93, P165; SHARPE TR, 1974, AM J HOSP PHARM, V31, P479, DOI 10.1093/ajhp/31.5.479; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V81, P975, DOI 10.1016/0091-6749(88)90164-9; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SMITH JM, 1983, ALLERGY PRINCIPLES P, P771; SODERBERGWARNER ML, 1984, J PEDIATR-US, V105, P840, DOI 10.1016/S0022-3476(84)80320-0; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; SPECTOR SL, 1989, CLIN ADV TREATME DEC, P5; STORMS WW, 1989, J ALLERGY CLIN IMMUN, V83, P1083, DOI 10.1016/0091-6749(89)90450-8; TIMMERMAN H, 1992, THERAPEUTIC INDEX AN, P19; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WEISS K, 1994, ALLERGY PROC, V15, P189, DOI 10.2500/108854194778702757; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; YOUNG P, NIH80388 US DEP HLTH; 1993, IMS DRUGSTORE HOSPIT; 1994, MED LETT, V36, P63; 1994, MED LETT, V36, P77; 1994, PHYSICIAN DRUG DIAGN	105	69	70	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1097	1110		10.1016/S0091-6749(95)70213-X	http://dx.doi.org/10.1016/S0091-6749(95)70213-X			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7538519				2022-12-18	WOS:A1995QY91800005
J	KANNY, G; MONERETVAUTRIN, DA				KANNY, G; MONERETVAUTRIN, DA			ALPHA-AMYLASE CONTAINED IN BREAD CAN INDUCE FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							OCCUPATIONAL ASTHMA				KANNY, G (corresponding author), CHU NANCY,HOP BRABOIS HOP ADULTES,SERV MED D,RUE MORVAN,F-54511 VANDOEUVRE NANCY,FRANCE.		Kanny, Gisèle/AHA-8910-2022					BAUR X, 1986, LANCET, V1, P43; CARMONA JGB, 1991, ALLERGY, V46, P274, DOI 10.1111/j.1398-9995.1991.tb00585.x; LOSADA E, 1992, J ALLERGY CLIN IMMUN, V89, P118, DOI 10.1016/S0091-6749(05)80048-X; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; 1993, COMPENDIUM FOOD ADDI	5	69	69	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				132	133		10.1016/S0091-6749(95)70161-3	http://dx.doi.org/10.1016/S0091-6749(95)70161-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822654				2022-12-18	WOS:A1995QC31200017
J	MALO, JL; BOULET, LP; DEWITTE, JD; CARTIER, A; LARCHEVEQUE, J; COTE, J; BEDARD, G; BOUCHER, S; CHAMPAGNE, F; TESSIER, G; CONTANDRIOPOULOS, AP; JUNIPER, EF; GUYATT, GH				MALO, JL; BOULET, LP; DEWITTE, JD; CARTIER, A; LARCHEVEQUE, J; COTE, J; BEDARD, G; BOUCHER, S; CHAMPAGNE, F; TESSIER, G; CONTANDRIOPOULOS, AP; JUNIPER, EF; GUYATT, GH			QUALITY-OF-LIFE OF SUBJECTS WITH OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC LUNG-DISEASE; CEDAR THUJA-PLICATA; FOLLOW-UP; OF-LIFE; VOLUME; SCALE	Background: The aim of the study was to assess the quality of life in subjects with occupational asthma after removal from exposure to the offending agent by comparison with a group of subjects paired for clinical and functional indices in order to show the separation between the two groups of subjects with a hypothesized different quality of life and relate the impairment in quality of life to anthropometric, clinical, and functional variables. Methods: A previously described asthma quality of life questionnaire (Juniper EF, et al. Thorax 1992;47:76-83) was administered to two groups of subjects in a prospective manner. Information on the clinical and functional severity of asthma was obtained from each subject. Two groups of subjects were assessed: group 1, 134 subjects with occupational asthma who were seen more than 2 years after the diagnosis was confirmed, and group 2, 91 subjects who were seen in specialized asthma clinics of tertiary care hospitals for treatment of nonoccupational asthma and matched with 91 of the 134 subjects with occupational asthma from group 1 according to need for medication and (when available), baseline forced expiratory volume in 1 second (FEV1) and level of bronchial responsiveness. Results: A statistically significant difference was seen in the four domains (asthma symptoms, limitation of activities, emotional dysfunction, environmental stimuli) and in the total score of the quality of life questionnaire between the two groups of matched subjects; the mean difference in the total score was 0.6 on a scale of 1 (no limitation or none of the time) to 7 (severe limitation or all the time). A weak but statistically significant correlation between the total score and several indices (FEV1, bronchial responsiveness and asthma severity) was generally obtained Conclusion: The quality of life of subjects with occupational asthma is slightly less satisfactory than that of subjects paired for clinical and functional indices, although the magnitude of the difference is small, and quality of life is weakly correlated with clinical and functional indices.	HOP LAVAL, QUEBE CITY, PQ, CANADA; HOP ST SACREMENT, QUEBEC CITY G1S 4L8, QUEBEC, CANADA; UNIV MONTREAL, RECH INTERDISCIPLINAIRE SANTE, MONTREAL H3C 3J7, QUEBEC, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA	Laval University; Laval University; Universite de Montreal; McMaster University	MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BURGE PS, 1982, EUR J RESPIR DIS, V63, P91; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHANYEUNG M, IN PRESS AM REV RESP; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; GUYATT GH, 1989, RESP MED, V83, P293, DOI 10.1016/S0954-6111(89)80199-4; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; HYLAND ME, 1991, BRIT J GEN PRACT, V41, P214; HYLAND ME, 1991, J PSYCHOSOM RES, V35, P99, DOI 10.1016/0022-3999(91)90011-C; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1990, CHEST, V98, pS236; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MALO JL, IN PRESS QUEBEC SYST; QUIRK FH, 1990, CLIN SCI, V79, P17, DOI 10.1042/cs0790017; Spilker B., 1990, QUALITY LIFE ASSESSM; [No title captured]	21	69	69	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1121	1127		10.1016/0091-6749(93)90313-5	http://dx.doi.org/10.1016/0091-6749(93)90313-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509574				2022-12-18	WOS:A1993LG74000002
J	VARSANO, I; VOLOVITZ, B; MALIK, H; AMIR, Y				VARSANO, I; VOLOVITZ, B; MALIK, H; AMIR, Y			SAFETY OF 1 YEAR OF TREATMENT WITH BUDESONIDE IN YOUNG-CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VARSANO, I (corresponding author), TEL AVIV UNIV, HASHARON HOSP, SACKLER SCH MED, DEPT PEDIAT, IL-49372 PETAH TIQWA, ISRAEL.		Malik, Hrudananda/AAU-1515-2020	Malik, Hrudananda/0000-0003-1213-4455				BHAN GL, 1980, LANCET, V1, P96; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V81, P1088, DOI 10.1016/0091-6749(88)90874-3; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; FIELD HV, 1982, ARCH DIS CHILD, V57, P864, DOI 10.1136/adc.57.11.864; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; GREULICH WW, 1983, RADIOGRAPHIC ATLAS S; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; LAW CM, 1986, LANCET, V1, P942; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; RIBEIRO LB, 1987, GLUCOCORTICOSTEROIDS, P95; SCHULLER CF, 1986, EUR J RESPIR DIS, V69, pA152; SPRINGER C, 1987, ARCH DIS CHILD, V62, P815, DOI 10.1136/adc.62.8.815; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	21	69	70	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					914	920		10.1016/0091-6749(90)90077-H	http://dx.doi.org/10.1016/0091-6749(90)90077-H			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332566				2022-12-18	WOS:A1990DD95900015
J	STEVENSON, DD; LEWIS, RA				STEVENSON, DD; LEWIS, RA			PROPOSED MECHANISMS OF ASPIRIN SENSITIVITY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									SYNTEX RES,PALO ALTO,CA 94305	Syntex Corporation	STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037, USA.							CHOUAIB S, 1985, J IMMUNOL, V135, P1172; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; DESSEIN AJ, 1986, J IMMUNOL, V136, P3829; FITZHARRIS P, 1986, CLIN EXP IMMUNOL, V66, P673; GERBER JG, 1979, J ALLERGY CLIN IMMUN, V63, P289, DOI 10.1016/0091-6749(79)90115-5; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHLUMBERGER HD, 1974, ACTA MED SCAND, V196, P451; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1986, J ALLERGY CLIN IMMUN, V78, P182, DOI 10.1016/0091-6749(86)90011-4; STEVENSON DD, 1987, INTERNAL MED, V8, P60; SZCZEKLIK A, 1987, J ALLERGY CLIN IMMUN, V80, P839, DOI 10.1016/S0091-6749(87)80274-9; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TOOGOOD JH, 1977, CHEST, V72, P35; VANARSDEL PP, 1984, J ALLERGY CLIN IMMUN, V73, P431, DOI 10.1016/0091-6749(84)90351-8; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WOLF M, 1982, CELL IMMUNOL, V72, P286, DOI 10.1016/0008-8749(82)90476-2	25	69	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					788	790		10.1016/S0091-6749(87)80266-X	http://dx.doi.org/10.1016/S0091-6749(87)80266-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3320159	Bronze			2022-12-18	WOS:A1987L502000003
J	LEHRER, SB; MCCANTS, ML				LEHRER, SB; MCCANTS, ML			REACTIVITY OF IGE ANTIBODIES WITH CRUSTACEA AND OYSTER ALLERGENS - EVIDENCE FOR COMMON ANTIGENIC STRUCTURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEHRER, SB (corresponding author), TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				NIAID NIH HHS [AI-19266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DAUL CB, UNPUB CRUSTACEA ALLE; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HALMEPURO L, IN PRESS INT ARCH AL; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; LEHRER S B, 1984, Journal of Allergy and Clinical Immunology, V73, P114; LEHRER SB, 1985, J ALLERGY CLIN IMMUN, V75, P147, DOI 10.1016/0091-6749(85)90307-0; LEHRER SB, 1986, ANN ALLERGY, V57, P267; MAY CD, 1978, ALLERGY PRINCIPLES P, P1159; NAKASHIMA T, 1969, HIROSHIMA J MED SCI, V18, P141; WADA S, 1967, HIROSHIMA J MED SCI, V16, P255; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9	12	69	73	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					133	139		10.1016/0091-6749(87)90121-7	http://dx.doi.org/10.1016/0091-6749(87)90121-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	2440933				2022-12-18	WOS:A1987J657500003
J	KAUFFMAN, HF; VANDERBELT, B; DEMONCHY, JGR; BOELENS, H; KOETER, GH; DEVRIES, K				KAUFFMAN, HF; VANDERBELT, B; DEMONCHY, JGR; BOELENS, H; KOETER, GH; DEVRIES, K			LEUKOTRIENE-C4 PRODUCTION BY NORMAL-DENSITY AND LOW-DENSITY EOSINOPHILS OF ATOPIC INDIVIDUALS AND OTHER PATIENTS WITH EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							BOOYNOORD H, 1972, CLIN ALLERGY, V2, P63; BRUYNZEEL PLB, 1985, PROSTA LEUKOTR MED, V20, P11, DOI 10.1016/0262-1746(85)90090-3; BRUYNZEEL PLB, 1985, FEBS LETT, V189, P350, DOI 10.1016/0014-5793(85)81054-1; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P738; CAPRON M, 1984, J IMMUNOL, V132, P462; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAUFFMAN HF, 1983, J IMMUNOL METHODS, V57, P1, DOI 10.1016/0022-1759(83)90058-3; KAY AB, 1976, BRIT J HAEMATOL, V33, P313, DOI 10.1111/j.1365-2141.1976.tb03546.x; LAM S, 1985, AM REV RESPIR DIS, V129, pA42; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; TAI PC, 1985, CLIN EXP IMMUNOL, V60, P427; VADAS MA, 1979, J IMMUNOL, V122, P1228; VERHAGEN J, 1984, FEBS LETT, V168, P23, DOI 10.1016/0014-5793(84)80199-4; WASSERMAN SI, 1976, J CLIN INVEST, V57, P738, DOI 10.1172/JCI108332; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	31	69	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					611	619		10.1016/S0091-6749(87)80157-4	http://dx.doi.org/10.1016/S0091-6749(87)80157-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3558998	Bronze			2022-12-18	WOS:A1987G972000010
J	TAMIR, R; CASTRACANE, JM; ROCKLIN, RE				TAMIR, R; CASTRACANE, JM; ROCKLIN, RE			GENERATION OF SUPPRESSOR CELLS IN ATOPIC PATIENTS DURING IMMUNOTHERAPY THAT MODULATE IGE SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NEW ENGLAND MED CTR,DEPT MED,DIV ALLERGY,171 HARRISON AVE,BOSTON,MA 02111	Tufts Medical Center					NIAID NIH HHS [AI-15912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITSTEAD JG, 1983, J CLIN LAB IMMUNOL, V12, P179; BUTLER M, 1982, CLIN EXP IMMUNOL, V50, P92; CHANDRA RK, 1983, LANCET, V2, P1393; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DOMINGUEZ MA, 1983, ALLERGOL IMMUNOPATH, V11, P415; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GEHA RS, 1984, J ALLERGY CLIN IMMUN, V74, P109, DOI 10.1016/0091-6749(84)90270-7; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GUPTA S, 1980, INT ARCH ALLER A IMM, V61, P293, DOI 10.1159/000232448; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; HEMADY Z, 1985, CLIN IMMUNOL IMMUNOP, V35, P156, DOI 10.1016/0090-1229(85)90062-5; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; LEE WY, 1976, INT ARCH ALLERGY APP, V56, P103; LEUNG D Y M, 1984, Clinical Immunology Reviews, V3, P1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; MARTINEZ JD, 1979, J ALLERGY CLIN IMMUN, V64, P485, DOI 10.1016/0091-6749(79)90057-5; NAGAYA H, 1980, ANN ALLERGY, V44, P193; NAGOYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388; ROCKLIN RE, 1980, N ENGL J MED, V302, P213; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P167; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARAYAN JA, 1983, J CLIN INVEST, V71, P556; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SAXON A, 1979, CLIN IMMUNOL IMMUNOP, V14, P474, DOI 10.1016/0090-1229(79)90100-4; SCHUSTER DL, 1980, J IMMUNOL, V124, P1662; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TJIO AH, 1979, J IMMUNOL, V122, P2131; ZACHARY CB, 1983, BRIT J DERMATOL, V108, P411, DOI 10.1111/j.1365-2133.1983.tb04593.x	30	69	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					591	598		10.1016/S0091-6749(87)80154-9	http://dx.doi.org/10.1016/S0091-6749(87)80154-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	2951427				2022-12-18	WOS:A1987G972000007
J	CRIMI, E; BRUSASCO, V; LOSURDO, E; CRIMI, P				CRIMI, E; BRUSASCO, V; LOSURDO, E; CRIMI, P			PREDICTIVE ACCURACY OF LATE ASTHMATIC REACTION TO DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRIMI, E (corresponding author), UNIV GENOA,OSPED S MARTINO,IST MED & CHIRURG BRONCOPOLMONARE,I-16132 GENOA,ITALY.							ANDERSON MC, 1983, RASTINHIBITION PROCE; BLACKLEY C, 1959, EXPT RES CAUSES NATU, P77; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CRIMI E, 1986, ANN ALLERGY, V56, P183; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HOWARTH PH, 1983, THORAX, V38, P705; KAY AB, 1984, ASTHMA PHYSL IMMUNOP, P211; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MACINTYRE D, 1984, CLIN ALLERGY, V14, P311, DOI 10.1111/j.1365-2222.1984.tb02211.x; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NATHAN RA, 1979, J ALLERGY CLIN IMMUN, V64, P491, DOI 10.1016/0091-6749(79)90058-7; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; PRICE JF, 1983, CLIN ALLERGY, V13, P419, DOI 10.1111/j.1365-2222.1983.tb02617.x; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOKAL RR, 1969, BIOMETRY PRINCIPLES, P486; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	26	69	69	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				908	913		10.1016/0091-6749(86)90239-3	http://dx.doi.org/10.1016/0091-6749(86)90239-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3537082				2022-12-18	WOS:A1986E971300014
J	SCHUMACHER, MJ; COTA, KA; TAUSSIG, LM				SCHUMACHER, MJ; COTA, KA; TAUSSIG, LM			PULMONARY RESPONSE TO NASAL-CHALLENGE TESTING OF ATOPIC SUBJECTS WITH STABLE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA,ARIZONA HLTH SCI CTR,DIV RESP SCI,WESTEND LABS,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724, USA.							AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; Berger D, 1979, Rhinology, V17, P193; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; COLE P, 1982, NOSE UPPER AIRWAY PH, P163; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; Hilding A, 1932, ARCHIV OTOLARYNGOL, V15, P92; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; MEAD J, 1960, J APPL PHYSIOL, V15, P736, DOI 10.1152/jappl.1960.15.4.736; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; Sato T, 1980, Auris Nasus Larynx, V7, P39; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SCHUMACHER MJ, 1985, COMPUT BIOL MED, V15, P187, DOI 10.1016/0010-4825(85)90060-5; SPECTOR S, 1979, J ALLERGY CLIN IMMUN, V64, P580, DOI 10.1016/0091-6749(79)90016-2; STEIN JF, 1975, RESP PHYSIOL, V25, P363, DOI 10.1016/0034-5687(75)90010-9; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TAUSSIG LM, 1977, AM REV RESPIR DIS, V116, P1031; WIDDICOMBE JG, 1966, ADV RESPIRATORY PHYS, P48; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; YAN K, 1983, EUR J RESPIR DIS, V64, P105	27	69	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				30	35		10.1016/0091-6749(86)90111-9	http://dx.doi.org/10.1016/0091-6749(86)90111-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722633				2022-12-18	WOS:A1986D299600006
J	ARLIAN, LG; GEIS, DP; VYSZENSKIMOHER, DL; BERNSTEIN, IL; GALLAGHER, JS				ARLIAN, LG; GEIS, DP; VYSZENSKIMOHER, DL; BERNSTEIN, IL; GALLAGHER, JS			ANTIGENIC AND ALLERGENIC PROPERTIES OF THE STORAGE MITE TYROPHAGUS-PUTRESCENTIAE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT PHYSIOL,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DAYTON,OH 45435; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; University System of Ohio; University of Cincinnati	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT BIOL SCI,DAYTON,OH 45435, USA.				PHS HHS [R01 A1 13702] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MC, 1981, J IMMUNOL, V127, P972; ARLIAN LG, 1979, J MED ENTOMOL, V16, P128, DOI 10.1093/jmedent/16.2.128; ARLIAN LG, 1982, UNPUB; BRADY J, 1970, J APPL ECOL, V7, P331, DOI 10.2307/2401384; CARTER HF, 1946, T ROY SOC TROP MED H, V39, P373, DOI 10.1016/0035-9203(46)90016-8; CUNNINGTON AM, 1967, ACTA ALLERGOL, V22, P415; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; CUTHBERT OD, 1980, CLIN ALLERGY, V10, P601, DOI 10.1111/j.1365-2222.1980.tb02142.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DESCHIENS R, 1951, ANN I PASTEUR PARIS, V80, P107; GREEN WF, 1978, CLIN ALLERGY, V8, P135, DOI 10.1111/j.1365-2222.1978.tb00458.x; GRIFFITHS DA, 1976, ANN APPL BIOL, V82, P180; HUGHES AM, 1976, MIN AGR FISH FOOD TE, V9; INGRAM CG, 1979, LANCET, V2, P1330; JEFFREY IG, 1976, J STORED PROD RES, V12, P149, DOI 10.1016/0022-474X(76)90003-5; KRANTZ G. W., 1961, ANN ENT SOC AMER, V54, P169, DOI 10.1093/aesa/54.2.169; Krantz GW, 1978, MANUAL ACAROLOGY, V2nd; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; MAUNSELL K, 1968, LANCET, V1, P1267; MUMCUOGLU Y, 1977, ACTA ALLERGOL, V32, P333; SINHA R. N., 1964, PROC ENTOMOL SOC MANITOBA, V20, P19; SINHA RN, 1968, ANN ENTOMOL SOC AM, V61, P938, DOI 10.1093/aesa/61.4.938; SINHA RN, 1963, ADV ACAROLOGY, V1, P480; SOLOMON ME, 1961, SANIT            MAR; Soysa E, 1945, Br Med J, V1, P1; Spieksma F. Th. M., 1967, Acarologia, V9, P226; SPIEKSMA FT, 1969, ACTA ALLERGOL, V24, P124, DOI 10.1111/j.1398-9995.1969.tb03762.x; TABOADA MD, 1954, BMJ-BRIT MED J, V1, P437, DOI 10.1136/bmj.1.4859.437; TERHO EO, 1982, ALLERGY, V37, P15, DOI 10.1111/j.1398-9995.1982.tb04112.x; VANLEEUWEN WS, 1924, Z IMMUNITATSFORSCH, V40, P552; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WARREN P, 1974, J ALLERGY CLIN IMMUN, V33, P139; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WOODCOCK AA, 1980, CLIN ALLERGY, V10, P609, DOI 10.1111/j.1365-2222.1980.tb02143.x; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	36	69	75	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					166	171		10.1016/0091-6749(84)90281-1	http://dx.doi.org/10.1016/0091-6749(84)90281-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747137	Bronze			2022-12-18	WOS:A1984TE22600009
J	LOPEZ, LR; DAVIS, KC; KOHLER, PF; SCHOCKET, AL				LOPEZ, LR; DAVIS, KC; KOHLER, PF; SCHOCKET, AL			THE HYPOCOMPLEMENTEMIC URTICARIAL-VASCULITIS SYNDROME - THERAPEUTIC RESPONSE TO HYDROXYCHLOROQUINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO, HLTH SCI CTR, DIV CLIN IMMUNOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCRR NIH HHS [RR-00051] Funding Source: Medline; NIAID NIH HHS [AI-12028, AI-07166] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGNELLO V, 1970, IMMUNOLOGY, V19, P909; DUBOIS EL, 1966, LUPUS ERYTHEMATOSUS, P344; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1978, ANN INTERN MED, V89, P674; FAUCI AS, 1980, CLIN IMMUNOLOGY, P473; Mainland D., 1962, B RHEUM DIS, V13, P287; MARDER RJ, 1978, J IMMUNOL, V121, P613; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MAYER MM, 1971, EXPT IMMUNOCHEMISTRY, P133; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443; SOTER NA, 1976, J INVEST DERMATOL, V66, P344, DOI 10.1111/1523-1747.ep12482901; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; ZEISS CR, 1980, AM J MED, V68, P867, DOI 10.1016/0002-9343(80)90216-8; ZUBLER RH, 1976, J IMMUNOL, V116, P232	15	69	72	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					600	603		10.1016/0091-6749(84)90518-9	http://dx.doi.org/10.1016/0091-6749(84)90518-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6371104				2022-12-18	WOS:A1984SS04500011
J	SOLOMON, WR				SOLOMON, WR			AEROBIOLOGY OF POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, DIV ALLERGY, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan					NIAID NIH HHS [AI 10181] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL M K, 1984, Journal of Allergy and Clinical Immunology, V73, P157; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; BALYEAT RAY M., 1932, JOUR ALLERGY, V3, P7; BASSETT IJ, 1978, ATLAS AIRBORNE POLLE, P307; BIANCHI D. E., 1959, BOT GAZ, V120, P235, DOI 10.1086/336030; Blackley C, 1873, EXPT RES CAUSES NATU, P202; BOLD HC, 1977, PLANT KINGDOM; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CHANG WWY, 1972, ALLERGIC DISEASES DI, P148; CHARPIN J, 1974, ATLAS EUROPEAN ALLER, P229; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRYST S, 1955, J LAB CLIN MED, V46, P471; D'AMATO G, 1981, Zeitschrift fuer Erkrankungen der Atmungsorgane, V157, P281; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; DAVIES RR, 1974, CLIN ALLERGY, V4, P95, DOI 10.1111/j.1365-2222.1974.tb01367.x; DAVIS GL, 1967, AUSTR J SCI, V30, P235; DURHAM OC, 1946, J ALLERGY, V17, P79, DOI 10.1016/0021-8707(46)90025-1; ECHLIN P, 1968, SCI AM, V218, P81; Echlin P., 1971, SPOROPOLLENIN, P220; GOODWIN JE, 1957, FED PROC, V16, P628; GREGORY PH, 1973, MICROBIOLOGY ATMOSPH, P377; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HARRINGTON JB, 1959, J ALLERGY, V30, P357, DOI 10.1016/0021-8707(59)90044-9; HATCH TF, 1974, PULMONARY DEPOSITION, P192; HAYES JV, 1969, ANN ALLERGY, V27, P575; HEISE HA, 1948, J ALLERGY, V19, P403, DOI 10.1016/0021-8707(48)90037-9; HIRST JM, 1963, J GEN MICROBIOL, V33, P335, DOI 10.1099/00221287-33-2-335; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; HUBSCHER T, 1972, INT ARCH ALLER A IMM, V42, P466, DOI 10.1159/000230626; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; Hyde H. A., 1958, ATLAS AIRBORNE POLLE, P112; KAILIN E W, 1964, Med Ann Dist Columbia, V33, P1; KAPYLA M, 1981, Grana, V20, P131; KNOX RB, 1973, J CELL SCI, V12, P421; KNOX RB, 1970, NATURE, V225, P1066, DOI 10.1038/2251066a0; KNOX RB, 1972, NATURE, V237, P381, DOI 10.1038/237381a0; KOOLSTRA JB, 1978, J ALLERGY CLIN IMMUN, V61, P315; LEUSCHNER RM, 1979, CLIN ALLERGY, V9, P175, DOI 10.1111/j.1365-2222.1979.tb01539.x; Lewis W.H., 1983, AIRBORNE ALLERGENIC, P254; LEWIS WH, 1979, ANN ALLERGY, V42, P309; MAYRON LW, 1972, CLIN SCI, V42, P25, DOI 10.1042/cs0420025; MCDONALD JE, 1962, SCIENCE, V135, P435, DOI 10.1126/science.135.3502.435; MCDONALD JL, 1975, J ALLERGY CLIN IMMUN, V55, P89; MICHEL FB, 1976, CLIN ALLERGY, V6, P383, DOI 10.1111/j.1365-2222.1976.tb01920.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NEUBERGER H., 1967, BIOMETEOROLOGY, V2, P693; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; Ogden EU, 1974, MANUAL SAMPLING AIRB, P182; PETERSON JE, 1979, ASHRAE J, V21, P60; RAYNOR GS, 1973, J ALLERGY CLIN IMMUN, V51, P199, DOI 10.1016/0091-6749(73)90139-5; RAYNOR GS, 1969, ARCH ENVIRON HEALTH, V19, P92, DOI 10.1080/00039896.1969.10666809; RAYNOR GS, 1974, AGR METEOROL, V13, P181, DOI 10.1016/0002-1571(74)90045-4; REISS NM, 1976, J ALLERGY CLIN IMMUN, V57, P609, DOI 10.1016/0091-6749(76)90013-0; ROTH A, 1978, ALLERGY WORLD GUIDE, P171; SCHLICHTING HE, 1974, J ALLERGY CLIN IMMUN, V53, P185, DOI 10.1016/0091-6749(74)90006-2; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; SHELDON JM, 1960, 4 U MICH OFF RES ADM; SKELLENGER WS, 1981, J ALLERGY CLIN IMMUN, V67, P56; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P467, DOI 10.1016/0091-6749(80)90241-9; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SOLOMON WR, 1980, INT J BIOMETEOROL, V24, P107, DOI 10.1007/BF02253798; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P318, DOI 10.1016/0091-6749(76)90088-9; SOLOMON WR, 1969, J ALLERGY, V43, P181; SPIEGELMAN J, 1968, J ALLERGY, V42, P193, DOI 10.1016/S0021-8707(68)90116-0; TUCHIN DA, 1976, ANN ALLERGY, V37, P26; VILLAVECES JW, 1973, J ASTHMA RES, V11, P47, DOI 10.3109/02770907309100278; WATSON H H, 1954, Am Ind Hyg Assoc Q, V15, P21; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	73	69	73	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					449	461		10.1016/0091-6749(84)90376-2	http://dx.doi.org/10.1016/0091-6749(84)90376-2			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491091	Bronze			2022-12-18	WOS:A1984TN62000001
J	BAUR, X				BAUR, X			IMMUNOLOGICAL CROSS-REACTIVITY BETWEEN DIFFERENT ALBUMIN-BOUND ISOCYANATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BAUR, X (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED CLIN 1,PULM SECT,D-8000 MUNICH 70,FED REP GER.							BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; Baur X, 1981, Chest, V80, P73; BAUR X, UNPUB DETECTION IMMU; BAYER O, 1947, ANGEW CHEM, V9, P257; BUTCHER B T, 1982, Journal of Allergy and Clinical Immunology, V69, P123; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DEWAIR MA, 1982, J CLIN CHEM CLIN BIO, V20, P337; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; KAROL MH, 1980, TOXICOL APPL PHARM, V53, P260, DOI 10.1016/0041-008X(80)90425-1; KAROL MH, 1980, AM REV RESPIR DIS, V122, P965; KAROL MH, 1981, TOXICOL APPL PHARM, V58, P221, DOI 10.1016/0041-008X(81)90426-9; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; Weill H, 1975, Environ Health Perspect, V11, P101; WURTZ A, 1849, LIEBIGS ANN CHEM, V71, P326; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	18	69	69	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					197	205		10.1016/0091-6749(83)90100-8	http://dx.doi.org/10.1016/0091-6749(83)90100-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6296214				2022-12-18	WOS:A1983QC18800005
J	LUMRY, WR; CURD, JG; ZEIGER, RS; PLESKOW, WW; STEVENSON, DD				LUMRY, WR; CURD, JG; ZEIGER, RS; PLESKOW, WW; STEVENSON, DD			ASPIRIN-SENSITIVE RHINOSINUSITIS - THE CLINICAL SYNDROME AND EFFECTS OF ASPIRIN ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DEPT BASIC & CLIN RES,10666 N TORREY PINES RD,LA JOLLA,CA 92037; KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,SAN DIEGO,CA; SCRIPPS CLIN & RES FDN,DEPT MOLEC IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute; Kaiser Permanente; Scripps Research Institute				Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; HARNETT JC, 1978, ALLERGY PRINCIPLES P, P1002; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; PLESKOW WW, 1981, J ALLERGY CLIN IMM S, V67, P285; PRICKMAN LE, 1947, MED CLIN NO AM, V31, P954; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1978, IMMUNOLOGICAL DIS, V2, P900; SCHATZ M, 1980, CONSULTANT       MAY, P61; SEEBOHM PM, 1978, ALLERGY PRINCIPLES P, P868; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1982, PSEUDOALLERGIC REACT, V3, P133; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2; 1978, PHADEBAS IGE PRIST R	24	69	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					580	587		10.1016/0091-6749(83)90440-2	http://dx.doi.org/10.1016/0091-6749(83)90440-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853927				2022-12-18	WOS:A1983QV13900010
J	MURRAY, AB; FERGUSON, AC; MORRISON, BJ				MURRAY, AB; FERGUSON, AC; MORRISON, BJ			THE FREQUENCY AND SEVERITY OF CAT ALLERGY VS DOG ALLERGY IN ATOPIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DIV ALLERGY,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PAEDIAT & HLTH CARE,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				BAKER E, 1979, ANN ALLERGY, V43, P214; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; Corson S A, 1975, Curr Psychiatr Ther, V15, P277; GUERIN B, 1981, ANN ALLERGY, V46, P127; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HERRING S, 1981, ANN ALLERGY, V46, P24; KING N, 1982, ROY SOC HEALTH J, V102, P99, DOI 10.1177/146642408210200303; LEVINSON BM, 1968, MENT HYG, V52, P411; OHMAN J L JR, 1982, Journal of Allergy and Clinical Immunology, V69, P127; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x	14	69	69	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					145	149		10.1016/0091-6749(83)90522-5	http://dx.doi.org/10.1016/0091-6749(83)90522-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	RD959	6886252				2022-12-18	WOS:A1983RD95900007
J	VERVLOET, D; NIZANKOWSKA, E; ARNAUD, A; SENFT, M; ALAZIA, M; CHARPIN, J				VERVLOET, D; NIZANKOWSKA, E; ARNAUD, A; SENFT, M; ALAZIA, M; CHARPIN, J			ADVERSE REACTIONS TO SUXAMETHONIUM AND OTHER MUSCLE-RELAXANTS UNDER GENERAL-ANESTHESIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INSERM,U174,F-13009 MARSEILLE,FRANCE; CHU TIMONE,DEPT ANESTHESIA & INTENS CARE,F-13385 MARSEILLE 4,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT CHEST DIS,F-13277 MARSEILLE 9,FRANCE.							ASSEM ESK, 1981, ANAESTHESIA, V36, P405, DOI 10.1111/j.1365-2044.1981.tb10248.x; CLARKE RSJ, 1977, P ROY SOC MED, V70, P782, DOI 10.1177/003591577707001109; CLARKE RSJ, 1975, BRIT J ANAESTH, V47, P575, DOI 10.1093/bja/47.5.575; DUNDEE J, 1976, BR J ANAESTH, V48, P51; Fisher M M, 1975, Anaesth Intensive Care, V3, P180; FISHER MM, 1980, ANAESTH INTENS CARE, V8, P211, DOI 10.1177/0310057X8000800222; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1978, ANAESTH INTENS CARE, V6, P62, DOI 10.1177/0310057X7800600110; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; FISHER MMC, 1980, ANESTHESIOLOGY, V52, P15; FISHER MMD, 1978, ANAESTH INTENS CARE, V6, P125, DOI 10.1177/0310057X7800600204; FOREMAN JC, 1980, BIOCHIM BIOPHYS ACTA, V629, P587, DOI 10.1016/0304-4165(80)90164-6; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GRANT JA, 1976, J IMMUNOL, V117, P450; JERUMS G, 1967, BRIT J ANAESTH, V39, P73, DOI 10.1093/bja/39.1.73; LAFOREST M, 1980, ANAESTH INTENS CARE, V8, P454, DOI 10.1177/0310057X8000800412; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1962; LORENZ W, 1978, MT SINAI J MED, V45, P357; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MONERETVAUTRIN DA, 1981, CLIN ALLERGY, V11, P175, DOI 10.1111/j.1365-2222.1981.tb01582.x; PARISH W E, 1973, P71; ROYSTON D, 1978, BRIT J ANAESTH, V50, P611, DOI 10.1093/bja/50.6.611; SCAVIN RG, 1974, MED CLIN N AM, V58, P65; SEBAHOUN G, 1978, J CLIN PATHOL, V31, P749, DOI 10.1136/jcp.31.8.749; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; SOBOTKA AK, 1978, IMMUNOL REV, V41, P171, DOI 10.1111/j.1600-065X.1978.tb01464.x; STOVNER J, 1970, BRIT J ANAESTH, V42, P235, DOI 10.1093/bja/42.3.235; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P348, DOI 10.1016/0091-6749(79)90130-1	32	69	70	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					552	559		10.1016/0091-6749(83)90436-0	http://dx.doi.org/10.1016/0091-6749(83)90436-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6189877	Bronze			2022-12-18	WOS:A1983QV13900006
J	NELSON, HS				NELSON, HS			EFFECT OF PRESERVATIVES AND CONDITIONS OF STORAGE ON THE POTENCY OF ALLERGY EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NELSON, HS (corresponding author), FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SECT,AURORA,CO 80045, USA.							ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; AUGUSTIN R, 1962, IMMUNOLOGY, V5, P424; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; CENTER JG, 1974, J ALLERGY CLIN IMMUN, V54, P305, DOI 10.1016/0091-6749(74)90016-5; CLOCK RO, 1917, J INFECT DIS, V21, P387; DERRICK E, 1964, ACTA ALLERGOL, V19, P121, DOI 10.1111/j.1398-9995.1964.tb03234.x; DOCKHORN RJ, 1977, ANN ALLERGY, V38, P129; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HAMPTON SF, 1949, J ALLERGY, V20, P19, DOI 10.1016/0021-8707(49)90080-5; HJORTH NIELS, 1958, ACTA ALLERGOL, V12, P316, DOI 10.1111/j.1398-9995.1958.tb03088.x; JOHNSON MC, 1955, J ALLERGY, V26, P429, DOI 10.1016/0021-8707(55)90034-4; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; NELSON HS, 1979, J ALLERGY CLIN IMMUN, V63, P417, DOI 10.1016/0091-6749(79)90216-1; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1	18	69	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					64	69		10.1016/0091-6749(81)90047-6	http://dx.doi.org/10.1016/0091-6749(81)90047-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451773				2022-12-18	WOS:A1981KZ17300012
J	RICHERSON, HB; RAJTORA, DW; PENICK, GD; DICK, FR; YOO, TJ; KAMMERMEYER, JK; ANURAS, JS				RICHERSON, HB; RAJTORA, DW; PENICK, GD; DICK, FR; YOO, TJ; KAMMERMEYER, JK; ANURAS, JS			CUTANEOUS AND NASAL ALLERGIC RESPONSES IN RAGWEED HAY-FEVER - LACK OF CLINICAL AND HISTOPATHOLOGIC CORRELATIONS WITH LATE PHASE REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242	University of Iowa	RICHERSON, HB (corresponding author), UNIV IOWA,HOSP & CLIN,DEPT INTERNAL MED,ALLERGY IMMUNOL SECT,IOWA CITY,IA 52242, USA.							ANURAS JS, 1979, J ALLERGY CLIN IMMUN, V63, P122, DOI 10.1016/0091-6749(79)90202-1; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; ASKENASE PW, 1973, J EXP MED, V138, P1144, DOI 10.1084/jem.138.5.1144; ASKENASE PW, 1976, J CLIN INVEST, V58, P1145, DOI 10.1172/JCI108567; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BROSTOFF J, 1969, LANCET, V2, P1269; COLVIN RB, 1974, LANCET, V1, P212, DOI 10.1016/S0140-6736(74)92512-4; CONNELL JT, 1969, J ALLERGY, V43, P182; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; DVORAK HF, 1976, J INVEST DERMATOL, V67, P391, DOI 10.1111/1523-1747.ep12514713; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; GELL PGA, 1975, CLIN ASPECTS IMMUNOL, P764; GILBERT HS, 1975, BLOOD, V46, P279; GREEN GR, 1967, J ALLERGY, V40, P244; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HIRSCH SR, 1976, J ALLERGY CLIN IMMUN, V58, P676, DOI 10.1016/0091-6749(76)90179-2; HUTCHINSON GW, 1972, J ALLERGY CLIN IMMUN, V49, P316, DOI 10.1016/0091-6749(72)90100-5; Jones TD, 1934, NEW ENGL J MED, V210, P120, DOI 10.1056/NEJM193401182100302; KAMMERMEYER JK, 1977, J ALLERGY CLIN IMMUN, V59, P287, DOI 10.1016/0091-6749(77)90049-5; KATZ SI, 1974, NATURE, V251, P550, DOI 10.1038/251550a0; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; KOEPKE JA, 1977, AM J CLIN PATHOL, V68, P202; LETTBROWN MA, 1976, J IMMUNOL, V117, P346; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; OWNBY DR, 1979, J ALLERGY CLIN IMMUN, V63, P65, DOI 10.1016/0091-6749(79)90164-7; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; RAFFEL S, 1958, J EXP MED, V108, P823, DOI 10.1084/jem.108.6.823; RICHERSO.HB, 1969, FED PROC, V28, P563; RICHERSON HB, 1969, J IMMUNOL, V103, P1431; RICHERSON HB, 1971, J EXP MED, V134, P630, DOI 10.1084/jem.134.3.630; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SALVIN SB, 1958, J EXP MED, V107, P109, DOI 10.1084/jem.107.1.109; SLAVIN RG, 1964, J ALLERGY, V35, P499, DOI 10.1016/0021-8707(64)90081-4; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STADECKE.MJ, 1974, J IMMUNOL, V113, P496; STADECKER M, 1976, J EXP MED, V143, P206, DOI 10.1084/jem.143.1.206; STADECKER MJ, 1976, J IMMUNOL, V116, P1646; STADECKER MJ, 1973, P SOC EXP BIOL MED, V142, P150; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; UHR JW, 1957, J EXP MED, V105, P11, DOI 10.1084/jem.105.1.11; WARD PA, 1975, J IMMUNOL, V114, P1523; YOO TJ, 1978, INT ARCH ALLER A IMM, V56, P106, DOI 10.1159/000232012	50	69	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					67	77		10.1016/0091-6749(79)90085-X	http://dx.doi.org/10.1016/0091-6749(79)90085-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447953				2022-12-18	WOS:A1979HC42400013
J	DAVIES, RJ; BUTCHER, BT; ONEIL, CE; SALVAGGIO, JE				DAVIES, RJ; BUTCHER, BT; ONEIL, CE; SALVAGGIO, JE			INVITRO EFFECT OF TOLUENE DIISOCYANATE ON LYMPHOCYTE CYCLIC ADENOSINE-MONOPHOSPHATE PRODUCTION BY ISOPROTERENOL, PROSTAGLANDIN, AND HISTAMINE - POSSIBLE MODE OF ACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70112	Tulane University								ALLEGRA J, 1976, J ALLERGY CLIN IMMUN, V58, P546, DOI 10.1016/0091-6749(76)90200-1; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; ARIENS EJ, 1964, MOL PHARMACOL, V1, P169; AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BOURNE HR, 1971, J PHARMACOL EXP THER, V198, P1; Boyum A, 1968, SCAND J CLIN LAB S97, V21, P7; BURNET FM, 1965, J PATHOL BACTERIOL, V89, P271, DOI 10.1002/path.1700890128; BURNET FM, 1975, MED HYPOTHESES, V1, P3; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CONOLLY ME, 1977, BRIT J PHARMACOL, V59, P17, DOI 10.1111/j.1476-5381.1977.tb06971.x; FUCHS S, 1951, Arch Mal Prof, V12, P191; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; HARRIS S, 1954, J IMMUNOL, V72, P148; HENSCHLER D., 1962, ARCH TOXIKOLOGIE, V19, P364; KALINER M, 1974, J IMMUNOL, V112, P664; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOWE A, 1970, P ROY SOC MED, V63, P367, DOI 10.1177/003591577006300415; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MCNEILL RS, 1964, LANCET, V2, P1101; ORANGE RP, 1971, J EXP MED       S136, V134; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; PARKER CW, 1973, ANN INTERN MED, V78, P963, DOI 10.7326/0003-4819-78-6-963; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PETERS JM, 1975, P S ISOCYANATES IND, P5; SCHWARZ, 1974, PROCEDURES RADIOIMMU; TAYLOR G, 1970, P ROY SOC MED, V63, P379, DOI 10.1177/003591577006300421; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; VANERT M, 1975, ANN ALLERGY, V35, P142; 1973, OCCUPATIONAL EXPOSUR, P18	34	69	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					223	229		10.1016/0091-6749(77)90134-8	http://dx.doi.org/10.1016/0091-6749(77)90134-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	198451				2022-12-18	WOS:A1977DX45800004
J	BRUCE, CA; ROSENTHAL, RR; LICHTENSTEIN, LM; NORMAN, PS				BRUCE, CA; ROSENTHAL, RR; LICHTENSTEIN, LM; NORMAN, PS			DIAGNOSTIC TESTS IN RAGWEED-ALLERGIC ASTHMA - COMPARISON OF DIRECT SKIN-TESTS, LEUKOCYTE HISTAMINE-RELEASE, AND QUANTITATIVE BRONCHIAL CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,SCH MED,CLIN IMMUNOL DIV, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA	Johns Hopkins University								AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ARNER B, 1950, Acta Med Scand Suppl, V239, P327; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERNSTEIN IL, 1964, ANN ALLERGY, V22, P49; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; BRUCE RA, 1963, INT ARCH ALLER A IMM, V22, P294, DOI 10.1159/000229372; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; CITRON KM, 1967, ACTA ALLERGOL, VS 22, P17; COLLDAHL H, 1964, ACTA ALLERGOL, V19, P325, DOI 10.1111/j.1398-9995.1964.tb03254.x; COLLDAHL H, 1967, ACTA ALLERGOL, VS 22, P7; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P143, DOI 10.1111/j.1398-9995.1952.tb03445.x; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P133, DOI 10.1111/j.1398-9995.1952.tb03444.x; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; ENGSTROM I, 1958, Acta Paediatr, V47, P441, DOI 10.1111/j.1651-2227.1958.tb07656.x; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; FAGERBERG ERIK, 1960, ACTA ALLERGOL, V15, P449, DOI 10.1111/j.1398-9995.1960.tb02873.x; GAYRARD P, 1972, ACTA ALLERGOL, V27, P87, DOI 10.1111/j.1398-9995.1972.tb01407.x; HARRIS LEONARD H., 1941, JOUR ALLERGY, V12, P279, DOI 10.1016/S0021-8707(41)80011-2; HOLMAN JG, 1972, ANN ALLERGY, V30, P250; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; ITKIN IH, 1963, J ALLERGY, V34, P97, DOI 10.1016/0021-8707(63)90062-5; JUHLIN-DANNFELT C, 1950, Acta Med Scand Suppl, V239, P320; KAUDE J, 1960, HELV PAEDIATR ACTA, V6, P580; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1969, J IMMUNOL, V103, P866; LOWELL FC, 1948, J ALLERGY, V19, P172, DOI 10.1016/0021-8707(48)90050-1; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MCALLEN MK, 1967, BMJ-BRIT MED J, V1, P22, DOI 10.1136/bmj.1.5531.22; MCALLEN MK, 1967, ACTA ALLERGOL, VS 22, P43; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; MELON J, 1964, INT ARCH ALLER A IMM, V25, P271, DOI 10.1159/000229528; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OLIVE JT, 1972, AM REV RESPIR DIS, V106, P366, DOI 10.1164/arrd.1972.106.3.366; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; PATTERSON R, 1970, AM REV RESPIR DIS, V102, P412; PEGELOW KO, 1967, ACTA ALLERGOL, VS 22, P47; POPA V, 1968, J ALLERGY, V42, P130, DOI 10.1016/0021-8707(68)90086-5; RADERMECKER M, 1972, Clinical Allergy, V2, P247, DOI 10.1111/j.1365-2222.1972.tb01289.x; ROSENTHAL RR, 1973, J ALLERGY CLIN IMMUN, V51, P95, DOI 10.1016/S0091-6749(73)80038-7; SCHILLER IW, 1952, J ALLERGY, V23, P234, DOI 10.1016/0021-8707(52)90022-1; SPECTOR SL, 1973, J ALLERGY CLIN IMMUN, V51, P87, DOI 10.1016/S0091-6749(73)80021-1; STENIUS B, 1969, LANCET, V2, P455; STEVENS FRANKLIN A., 1934, JOUR ALLERGY, V5, P285, DOI 10.1016/S0021-8707(34)90226-4; TSE KS, 1972, J ALLERGY CLIN IMMUN, V49, P130; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3	48	69	69	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					230	239		10.1016/0091-6749(74)90085-2	http://dx.doi.org/10.1016/0091-6749(74)90085-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4134207	Bronze			2022-12-18	WOS:A1974S673200006
J	EGGLESTON, PA; VANARSDE.PP; STAMM, SJ; BIERMAN, CW; PIERSON, WE				EGGLESTON, PA; VANARSDE.PP; STAMM, SJ; BIERMAN, CW; PIERSON, WE			DOUBLE-BLIND TRIAL OF EFFECT OF CROMOLYN SODIUM ON EXERCISE-INDUCED BRONCHOSPASM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; BLACKHALL MI, 1970, DISODIUM CROMOGLYCAT, P63; COX JSG, 1970, DISODIUM CROMOGLYCAT, P13; DAVIES SE, 1970, DISODIUM CROMOGLYCAT, P55; JONES RS, 1970, ARCH DIS CHILD, V45, P49, DOI 10.1136/adc.45.239.49; KOOPMAN WJ, 1970, J IMMUNOL, V105, P1096; MCNEILL RS, 1966, Q J MED, V35, P55; MUITTARI A, 1969, BRIT MED J, V4, P170, DOI 10.1136/bmj.4.5676.170-a; ORANGE RP, 1970, J IMMUNOL, V105, P1087; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; RUSNAKOVA A, 1969, SCHWEIZ MED WSCHR, V99, P1217; SLY RM, 7 INT C ALL FLO	12	69	70	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	1					57	+		10.1016/0091-6749(72)90079-6	http://dx.doi.org/10.1016/0091-6749(72)90079-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M9284	4624443	Bronze			2022-12-18	WOS:A1972M928400006
J	Nunes-Santos, CJ; Uzel, G; Rosenzweig, SD				Nunes-Santos, Cristiane J.; Uzel, Gulbu; Rosenzweig, Sergio D.			PI3K pathway defects leading to immunodeficiency and immune dysregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phosphatidylinositol 3-kinase delta; p110 delta; p85 alpha; PIK3CD; PIK3R1; phosphatase and tensin homolog; activated phosphoinositide 3-kinase delta syndrome; mechanistic target of rapamycin pathway	PHOSPHOINOSITIDE 3-KINASE DELTA; HAMARTOMA TUMOR SYNDROME; HYPER IGM SYNDROME; GAIN-OF-FUNCTION; PI3K-DELTA INHIBITOR; GENETIC-DEFECTS; B-CELLS; MUTATIONS; PIK3R1; PATIENT	The phosphatidylinositol 3-kinase (PI3K) signaling pathway is involved in a broad range of cellular processes, including growth, metabolism, differentiation, proliferation, motility, and survival. The PI3K delta enzyme complex is primarily present in the immune system and comprises a catalytic (p110 delta) and regulatory (p85 alpha) subunit. Dynamic regulation of PI3K delta activity is required to ensure normal function and differentiation of immune cells. In the last decade, discovery of germline mutations in genes involved in the PI3K delta pathway (PIK3CD, PIK3R1, or phosphatase and tensin homolog [PTEN]) proved that both overactivation and underactivation (gain of function and loss of function, respectively) of PI3K delta lead to impaired and dysregulated immunity. Although a small group of patients reported to underactivate PI3K delta show predominantly humoral defects and autoimmune features, more than 200 patients have been described with overactivation of PI3K delta, presenting with a much more complex phenotype of combined immunodeficiency and immune dysregulation. The clinical and immunologic characterization, as well as current pathophysiologic understanding and specific therapies for PI3K pathway defects leading to immunodeficiency and immune dysregulation, are reviewed here.	[Nunes-Santos, Cristiane J.; Rosenzweig, Sergio D.] NIH, Serv Immunol, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Nunes-Santos, Cristiane J.] Univ Sao Paulo, Inst Crianca, Fac Med, Sao Paulo, Brazil; [Uzel, Gulbu] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rosenzweig, SD (corresponding author), Immunol Serv, 10 Ctr Dr,Bldg 10,Rm 2C410F, Bethesda, MD 20892 USA.	srosenzweig@cc.nih.gov		Nunes-Santos, Cristiane/0000-0002-2727-1877	Intramural Research Program, National Institutes of Health Clinical Center; National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001122] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	Intramural Research Program, National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Intramural Research Program, National Institutes of Health Clinical Center and National Institute of Allergy and Infectious Diseases. The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Asano T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00568; Avery DT, 2018, J EXP MED, V215, P2073, DOI 10.1084/jem.20180010; Baleydier F, 2018, J PEDIATR HEMATOL ON; Ben-Yakov G, 2018, J ALLER CL IMM-PRACT, V6, P1763, DOI 10.1016/j.jaip.2018.01.005; Browning MJ, 2015, J MED GENET, V52, P856, DOI 10.1136/jmedgenet-2015-103266; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Cahn A, 2017, PULM PHARMACOL THER, V46, P69, DOI 10.1016/j.pupt.2017.08.008; Cannons JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01758; Carpier JM, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02005; Chellappa S, 2019, J IMMUNOL, V202, P1397, DOI 10.4049/jimmunol.1701703; Chen HH, 2017, J ALLERGY CLIN IMMUN, V139, P607, DOI 10.1016/j.jaci.2016.03.059; Chiriaco M, 2017, CLIN IMMUNOL, V178, P20, DOI 10.1016/j.clim.2015.12.008; Cohen JI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00237; Cohen SB, 2019, J ALLERGY CLIN IMMUN, V143, P797, DOI 10.1016/j.jaci.2018.10.005; Compagno M, 2017, NATURE, V542, P489, DOI 10.1038/nature21406; Condliffe AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00338; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Conley ME, 2000, CLIN REV ALLERG IMMU, V19, P183, DOI 10.1385/CRIAI:19:2:183; Coulter TI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02043; Coulter TI, 2017, J ALLERGY CLIN IMMUN, V139, P597, DOI 10.1016/j.jaci.2016.06.021; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Di Fonte R, 2016, CLIN IMMUNOL, V164, P43, DOI 10.1016/j.clim.2016.01.016; Dornan GL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00575; Dornan GL, 2017, P NATL ACAD SCI USA, V114, P1982, DOI 10.1073/pnas.1617244114; Down K, 2015, J MED CHEM, V58, P7381, DOI 10.1021/acs.jmedchem.5b00767; Driessen GJ, 2016, J ALLERGY CLIN IMMUN, V138, P1744, DOI 10.1016/j.jaci.2016.07.010; Dyment DA, 2013, AM J HUM GENET, V93, P158, DOI 10.1016/j.ajhg.2013.06.005; Edwards ESJ, 2019, J ALLERGY CLIN IMMUN, V143, P276, DOI 10.1016/j.jaci.2018.04.030; Eissing M, 2019, TRANSL ONCOL, V12, P361, DOI 10.1016/j.tranon.2018.11.003; Elgizouli M, 2016, CLIN EXP IMMUNOL, V183, P221, DOI 10.1111/cei.12706; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Farachi S, 2018, J CROHNS COLITIS, V12, pS36; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Fruman DA, 2014, NEW ENGL J MED, V370, P1061, DOI 10.1056/NEJMe1400055; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Goto F, 2017, J CLIN IMMUNOL, V37, P347, DOI 10.1007/s10875-017-0393-7; Hansen-Kiss E, 2017, J MED GENET, V54, P471, DOI 10.1136/jmedgenet-2016-104484; Hartman HN, 2015, J CLIN IMMUNOL, V35, P11, DOI 10.1007/s10875-014-0109-1; Hauck F, 2017, KLIN PADIATR, V229, P113, DOI 10.1055/s-0043-104218; Heindl M, 2012, GASTROENTEROLOGY, V142, P1093, DOI 10.1053/j.gastro.2012.01.011; Hernandez-Trujillo VP, 2014, J CLIN IMMUNOL, V34, P627, DOI 10.1007/s10875-014-0056-x; Hoegenauer K, 2017, ACS MED CHEM LETT, V8, P975, DOI 10.1021/acsmedchemlett.7b00293; Ino H, 2019, CLIN PHARM DRUG DEV, V8, P78, DOI 10.1002/cpdd.614; Jhamnani RD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02172; Jung S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00966; Khindri S, 2018, J PHARMACOL EXP THER, V367, P405, DOI 10.1124/jpet.118.249516; Kuhlen M, 2016, CLIN IMMUNOL, V162, P27, DOI 10.1016/j.clim.2015.10.008; Lampson BL, 2016, BLOOD, V128, P195, DOI 10.1182/blood-2016-03-707133; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; Lucas CL, 2016, NAT REV IMMUNOL, V16, P702, DOI 10.1038/nri.2016.93; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Maccari ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00543; Nademi Z, 2017, J ALLERGY CLIN IMMUN, V139, P1046, DOI 10.1016/j.jaci.2016.09.040; Notarangelo LD, 2019, J ALLERGY CLIN IMMUN, V143, P91, DOI 10.1016/j.jaci.2018.08.039; Okano T, 2019, J ALLERGY CLIN IMMUN, V143, P266, DOI 10.1016/j.jaci.2018.04.032; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2013, ANNU REV IMMUNOL, V31, P675, DOI 10.1146/annurev-immunol-032712-095946; Olbrich P, 2016, PEDIAT ALLERG IMM-UK, V27, P640, DOI 10.1111/pai.12585; Petrovski S, 2016, J CLIN IMMUNOL, V36, P462, DOI 10.1007/s10875-016-0281-6; Preite S, 2018, NAT IMMUNOL, V19, P986, DOI 10.1038/s41590-018-0182-3; Rao N, 2015, HUM PATHOL, V46, P1306, DOI 10.1016/j.humpath.2015.05.011; Schroeder C, 2014, CLIN GENET, V86, P292, DOI 10.1111/cge.12263; Sharfe N, 2018, J ALLERGY CLIN IMMUN, V142, P618, DOI 10.1016/j.jaci.2017.10.033; Sharma MR, 2007, ARCH OTOLARYNGOL, V133, P1157, DOI 10.1001/archotol.133.11.1157; Sogkas G, 2018, J ALLERGY CLIN IMMUN, V142, P1650, DOI 10.1016/j.jaci.2018.06.039; Stark AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05674-8; Takeda AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1152, DOI 10.1016/j.jaci.2017.03.026; Tang P, 2018, J CLIN IMMUNOL, V38, P88, DOI 10.1007/s10875-017-0462-y; Martinez-Saavedra MT, 2016, CLIN IMMUNOL, V173, P117, DOI 10.1016/j.clim.2016.09.011; Thauvin-Robinet C, 2013, AM J HUM GENET, V93, P141, DOI 10.1016/j.ajhg.2013.05.019; Tsujita Y, 2016, J ALLERGY CLIN IMMUN, V138, P1672, DOI 10.1016/j.jaci.2016.03.055; Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109-015-1352-5; Wentink M, 2017, CLIN IMMUNOL, V176, P77, DOI 10.1016/j.clim.2017.01.004; Wilson R, 2018, CLIN THER, V40, P1410, DOI 10.1016/j.clinthera.2018.06.011; Wray-Dutra MN, 2018, J EXP MED, V215, P2485, DOI 10.1084/jem.20180617; Yeung KS, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0182-4; Zhang KJ, 2013, J CLIN IMMUNOL, V33, P673; 2013, AM J HUM GENET, V93, P150; 2017, J ALLERGY CLIN IMMUN, V139, P1032; 2017, BLOOD, V130, P2307; 2018, J ALLERGY CLIN IMMUN, V142, P605; 2002, IMMUNOBIOLOGY, V206, P502; 2017, CLIN IMMUNOL, V179, P77	86	68	69	5	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1676	1687		10.1016/j.jaci.2019.03.017	http://dx.doi.org/10.1016/j.jaci.2019.03.017			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	31060715	Bronze			2022-12-18	WOS:000466784600002
J	McFarlane, AJ; McSorley, HJ; Davidson, DJ; Fitch, PM; Errington, C; Mackenzie, KJ; Gollwitzer, ES; Johnston, CJC; MacDonald, AS; Edwards, MR; Harris, NL; Marsland, BJ; Maizels, RM; Schwarze, J				McFarlane, Amanda J.; McSorley, Henry J.; Davidson, Donald J.; Fitch, Paul M.; Errington, Claire; Mackenzie, Karen J.; Gollwitzer, Eva S.; Johnston, Chris J. C.; MacDonald, Andrew S.; Edwards, Michael R.; Harris, Nicola L.; Marsland, Benjamin J.; Maizels, Rick M.; Schwarze, Jurgen			Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory syncytial virus; helminths; Heligmosomoides polygyrus; type I interferon; microbiome	RESPIRATORY SYNCYTIAL VIRUS; ALLERGIC AIRWAY INFLAMMATION; PLASMACYTOID DENDRITIC CELLS; RSV BRONCHIOLITIS; RESPONSES; IMMUNITY; INNATE; MICE; ACTIVATION; MECHANISMS	Background: Helminth parasites have been reported to have beneficial immunomodulatory effects in patients with allergic and autoimmune conditions and detrimental consequences in patients with tuberculosis and some viral infections. Their role in coinfection with respiratory viruses is not clear. Objective: Here we investigated the effects of strictly enteric helminth infection with Heligmosomoides polygyrus on respiratory syncytial virus (RSV) infection in a mouse model. Methods: A murine helminth/RSV coinfection model was developed. Mice were infected by means of oral gavage with 200 stage 3 H polygyrus larvae. Ten days later, mice were infected intranasallywith either RSV or UV-inactivated RSV. Results: H polygyrus-infected mice showed significantly less disease and pulmonary inflammation after RSV infection associated with reduced viral load. Adaptive immune responses,including T(H)2 responses, were not essential because protection against RSV was maintained in Rag1(-/-) and Il4r alpha(-/-) mice. Importantly, H polygyrus infection upregulated expression of type I interferons and interferon-stimulated genes in both the duodenum and lung, and its protective effects were lost in both Ifnar1(-/-) and germ-free mice, revealing essential roles for type I interferon signaling and microbiota in H polygyrus-induced protection against RSV. Conclusion: These data demonstrate that a strictly enteric helminth infection can have remote protective antiviral effects in the lung through induction of a microbiota-dependent type I interferon response.	[McFarlane, Amanda J.; McSorley, Henry J.; Davidson, Donald J.; Fitch, Paul M.; Mackenzie, Karen J.; Schwarze, Jurgen] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [McFarlane, Amanda J.; McSorley, Henry J.; Fitch, Paul M.; Schwarze, Jurgen] Univ Edinburgh, Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Johnston, Chris J. C.; Maizels, Rick M.] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland; [Errington, Claire] Natl Hlth Serv Lothian, Simpson Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland; [Gollwitzer, Eva S.; Marsland, Benjamin J.] Univ Lausanne, Serv Pneumol, CHUV, Fac Biol & Med, Lausanne, Switzerland; [MacDonald, Andrew S.] Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester, Lancs, England; [Edwards, Michael R.] Imperial Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Airway Dis Infect Sect, London, England; [Edwards, Michael R.] Imperial Coll London, Ctr Resp Infect, Natl Heart & Lung Inst, London, England; [Harris, Nicola L.] Ecole Polytech Fed Lausanne, Global Hlth Inst, Lausanne, Switzerland	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Manchester; Imperial College London; University of London; King's College London; Imperial College London; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Schwarze, J (corresponding author), Univ Edinburgh, Queens Med Res Inst, Sch Clin Sci, UoE MRC Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	Jurgen.Schwarze@ed.ac.uk	Schwarze, Jürgen/F-7396-2011; harris, nicola/E-5342-2019; Johnston, Chris/ABC-5875-2020	harris, nicola/0000-0003-2922-0210; Johnston, Chris/0000-0001-9935-7365; McSorley, Henry/0000-0003-1300-7407; FITCH, PAUL/0000-0001-5294-3340; Mackenzie, Karen/0000-0002-5441-1476	MRC DTA [G09000184-2/1, G1000388-1/1]; MRC [MR/L008394/1]; Medical Research Council [G1002046]; Medical Research Council [G1000758B, G0701437, MR/L008394/1, G0901697, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, SPD-2012-172, MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [G0901697, G1002046, G0701437] Funding Source: UKRI	MRC DTA(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants MRC DTA 2009-2013 G09000184-2/1, MRC DTA 2010-2014 G1000388-1/1, and MRC MR/L008394/1. D.J.D. was supported by a Medical Research Council Senior Non-clinical Fellowship (G1002046).	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; ASANO M, 1990, VIROLOGY, V176, P30, DOI 10.1016/0042-6822(90)90227-I; Babu S, 2009, J INFECT DIS, V200, P288, DOI 10.1086/599797; Beaumont PE, 2013, ANTIMICROBIAL PEPTID, P97; Behera AK, 2002, J BIOL CHEM, V277, P25601, DOI 10.1074/jbc.M200211200; Carroll KN, 2008, IMMUNOL ALLERGY CLIN, V28, P539, DOI 10.1016/j.iac.2008.03.001; Chamilos G, 2012, BLOOD, V120, P3699, DOI 10.1182/blood-2012-01-401364; Chavez-Bueno S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-46; Chi H, 2011, J FORMOS MED ASSOC, V110, P388, DOI 10.1016/S0929-6646(11)60057-0; Chiba E, 2013, INT IMMUNOPHARMACOL, V17, P373, DOI 10.1016/j.intimp.2013.06.024; CHIPPS BE, 1993, PEDIATR INFECT DIS J, V12, P653, DOI 10.1097/00006454-199308000-00006; CHOWANIEC W, 1972, EXP PARASITOL, V32, P33, DOI 10.1016/0014-4894(72)90007-0; Cormier SA, 2014, J VIROL, V88, P9350, DOI 10.1128/JVI.00818-14; Currie SM, 2016, J IMMUNOL, V196, P2699, DOI 10.4049/jimmunol.1502478; Currie SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073659; Elliott DE, 2007, INT J PARASITOL, V37, P457, DOI 10.1016/j.ijpara.2006.12.009; Elliott DE, 2009, ADV EXP MED BIOL, V666, P157; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Filbey KJ, 2014, IMMUNOL CELL BIOL, V92, P436, DOI 10.1038/icb.2013.109; Fjaerli Hans-Olav, 2005, BMC Pediatr, V5, P31, DOI 10.1186/1471-2431-5-31; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flohr C, 2010, CLIN EXP ALLERGY, V40, P131, DOI 10.1111/j.1365-2222.2009.03346.x; Foronjy RF, 2015, MUCOSAL IMMUNOL, V8, P161, DOI 10.1038/mi.2014.54; Furze RC, 2006, INFECT IMMUN, V74, P1924, DOI 10.1128/IAI.74.3.1924-1932.2006; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; George PJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001830; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Goritzka M, 2015, J EXP MED, V212, P699, DOI 10.1084/jem.20140825; Grencis RK, 2014, IMMUNOL REV, V260, P183, DOI 10.1111/imr.12188; Guerrero-Plata A, 2005, J VIROL, V79, P10190, DOI 10.1128/JVI.79.16.10190-10199.2005; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hayes KS, 2010, SCIENCE, V328, P1391, DOI 10.1126/science.1187703; Helmby H, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0074-3; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; HIGGINS PG, 1990, ANTIVIR RES, V14, P3, DOI 10.1016/0166-3542(90)90061-B; Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jewell NA, 2007, J VIROL, V81, P9790, DOI 10.1128/JVI.00530-07; Johnston CJC, 2015, JOVE-J VIS EXP, DOI 10.3791/52412; Jumat MR, 2015, ANTIVIR RES, V114, P11, DOI 10.1016/j.antiviral.2014.11.007; Kawashima T, 2013, IMMUNITY, V38, P1187, DOI 10.1016/j.immuni.2013.02.024; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Knudson CJ, 2015, VET PATHOL, V52, P97, DOI 10.1177/0300985814520639; Lai Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026632; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Lee SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002880; LeMessurier KS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003727; Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926; Maizels RM, 2012, CURR OPIN IMMUNOL, V24, P459, DOI 10.1016/j.coi.2012.06.003; McGillivary G, 2013, J INNATE IMMUN, V5, P60, DOI 10.1159/000342473; McSorley HJ, 2013, INT J PARASITOL, V43, P301, DOI 10.1016/j.ijpara.2012.11.011; McSorley HJ, 2012, EUR J IMMUNOL, V42, P2667, DOI 10.1002/eji.201142161; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; NAVAS L, 1992, J PEDIATR-US, V121, P348, DOI 10.1016/S0022-3476(05)90000-0; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Osborne LC, 2014, SCIENCE, V345, P578, DOI 10.1126/science.1256942; OSUNDWA VM, 1993, EUR J PEDIATR, V152, P1001, DOI 10.1007/BF01957225; PLEASS RJ, 1995, INT J PARASITOL, V25, P1099, DOI 10.1016/0020-7519(95)00010-Y; Pletneva LM, 2008, J GEN VIROL, V89, P261, DOI 10.1099/vir.0.83294-0; Pribul PK, 2008, J VIROL, V82, P4441, DOI 10.1128/JVI.02541-07; Reese TA, 2014, SCIENCE, V345, P573, DOI 10.1126/science.1254517; Reynolds LA, 2014, GUT MICROBES, V5, P522, DOI 10.4161/gmic.32155; Reynolds LA, 2014, J IMMUNOL, V193, P2984, DOI 10.4049/jimmunol.1401056; Salgame P, 2013, NAT IMMUNOL, V14, P1118, DOI 10.1038/ni.2736; Scheer S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112469; Secor WE, 2007, CURR OPIN INFECT DIS, V20, P519, DOI 10.1097/QCO.0b013e3282e9ac03; Singleton RJ, 2003, PEDIATRICS, V112, P285, DOI 10.1542/peds.112.2.285; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; SUNG RYT, 1993, ARCH DIS CHILD, V69, P440, DOI 10.1136/adc.69.4.440; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Walson JL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006419.pub3; Wammes LJ, 2014, LANCET INFECT DIS, V14, P1150, DOI 10.1016/S1473-3099(14)70771-6; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Zaiss MM, 2015, IMMUNITY, V43, P998, DOI 10.1016/j.immuni.2015.09.012	85	68	69	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1068	+		10.1016/j.jaci.2017.01.016	http://dx.doi.org/10.1016/j.jaci.2017.01.016			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28196762	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000412172900018
J	Pothoven, KL; Norton, JE; Suh, LA; Carter, RG; Harris, KE; Biyasheva, A; Welch, K; Shintani-Smith, S; Conley, DB; Liu, MC; Kato, A; Avila, PC; Hamid, Q; Grammer, LC; Peters, AT; Kern, RC; Tan, BK; Schleimer, RP				Pothoven, Kathryn L.; Norton, James E.; Suh, Lydia A.; Carter, Roderick G.; Harris, Kathleen E.; Biyasheva, Assel; Welch, Kevin; Shintani-Smith, Stephanie; Conley, David B.; Liu, Mark C.; Kato, Atsushi; Avila, Pedro C.; Hamid, Qutayba; Grammer, Leslie C., III; Peters, Anju T.; Kern, Robert C.; Tan, Bruce K.; Schleimer, Robert P.			Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oncostatin M; epithelial barrier; neutrophils; chronic rhinosinusitis; atopic asthma; granulocyte-monocyte colony-stimulating factor	COLONY-STIMULATING FACTOR; CHRONIC RHINOSINUSITIS; NASAL POLYPS; RHEUMATOID-ARTHRITIS; PERSISTENT ASTHMA; TUMOR PROGRESSION; HUMAN MACROPHAGES; AP-1 ACTIVATION; M EXPRESSION; INFLAMMATION	Background: We have previously shown that oncostatin M (OSM) levels are increased in nasal polyps (NPs) of patients with chronic rhinosinusitis (CRS), as well as in bronchoalveolar lavage fluid, after segmental allergen challenge in allergic asthmatic patients. We also showed in vitro that physiologic levels of OSM impair barrier function in differentiated airway epithelium. Objective: We sought to determine which hematopoietic or resident cell type or types were the source of the OSM expressed in patients with mucosal airways disease. Methods: Paraffin-embedded NP sections were stained with fluorescence-labeled specific antibodies against OSM, GM-CSF, and hematopoietic cell-specific markers. Live cells were isolated from NPs and matched blood samples for flow cytometric analysis. Neutrophils were isolated from whole blood and cultured with the known OSM inducers GM-CSF and follistatin-like 1, and OSM levels were measured in the supernatants. Bronchial biopsy sections from control subjects, patients with moderate asthma, and patients with severe asthma were stained for OSM and neutrophil elastase. Results: OSM staining was observed in NPs, showed colocalization with neutrophil elastase (n = 10), and did not colocalize with markers for eosinophils, macrophages, T cells, or B cells (n = 3-5). Flow cytometric analysis of NPs (n = 9) showed that 5.1% +/- 2% of CD45(+) cells were OSM+, and of the OSM+ cells, 56% +/- 7% were CD16(+)Siglec-8(-), indicating neutrophil lineage. Only 0.6 +/- 0.4% of CD45(+) events from matched blood samples (n = 5) were OSM+, suggesting that increased OSM levels in patients with CRS was locally stimulated and produced. A majority of OSM+ neutrophils expressed arginase 1 (72.5% +/- 12%), suggesting an N2 phenotype. GM-CSF levels were increased in NPs compared with those in control tissue and were sufficient to induce OSM production (P < .001) in peripheral blood neutrophils in vitro. OSM+ neutrophils were also observed at increased levels in biopsy specimens from patients with severe asthma. Additionally, OSM protein levels were increased in induced sputum from asthmatic patients compared with that from control subjects (P < .05). Conclusions: Neutrophils are a major source of OSM-producing cells in patients with CRS and severe asthma.	[Pothoven, Kathryn L.; Norton, James E.; Suh, Lydia A.; Carter, Roderick G.; Harris, Kathleen E.; Biyasheva, Assel; Kato, Atsushi; Avila, Pedro C.; Grammer, Leslie C., III; Peters, Anju T.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Welch, Kevin; Shintani-Smith, Stephanie; Conley, David B.; Tan, Bruce K.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Pulm Med, Baltimore, MD USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Crit Care Med, Baltimore, MD USA; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Hamid, Qutayba] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; McGill University; McGill University	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, MED Allergy Immunol, McGaw Rm M-318,240 E Huron St, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R37HL068546, R01HL078860, U19AI106683, T32AI007476-16]; Ernest S. Bazley Foundation;  [NCI CCSG P30 CA060553]; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007476, U19AI106683] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants R37HL068546 (NHLBI), R01HL078860 (NHLBI), U19AI106683 (NIAID), and T32AI007476-16 (NIAID) from the National Institutes of Health and by the Ernest S. Bazley Foundation. Imaging work was performed at the Northwestern University Center for Advanced Microscopy generously supported by grant NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center.	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Beigel F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093498; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Cross A, 2004, ARTHRITIS RHEUM-US, V50, P1430, DOI 10.1002/art.20166; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Durand Y, 2001, J IMMUNOL, V167, P3996, DOI 10.4049/jimmunol.167.7.3996; Elbjeirami WM, 2011, AM J PHYSIOL-CELL PH, V301, pC947, DOI 10.1152/ajpcell.00205.2011; Engelhardt E, 1998, AM J PATHOL, V153, P1849, DOI 10.1016/S0002-9440(10)65699-4; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Goren I, 2006, J INVEST DERMATOL, V126, P628, DOI 10.1038/sj.jid.5700136; Grenier A, 2001, LAB INVEST, V81, P133, DOI 10.1038/labinvest.3780220; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; Homma T, 2015, AM J RESP CELL MOL, V52, P471, DOI 10.1165/rcmb.2014-0240OC; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jankowski R, 2002, RHINOLOGY, V40, P173; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kastl SP, 2008, ARTERIOSCL THROM VAS, V28, P498, DOI 10.1161/ATVBAHA.107.160580; Kastl SP, 2009, BLOOD, V114, P2812, DOI 10.1182/blood-2009-01-200915; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kato A, 2009, J ALLERGY CLIN IMMUN, V123, P369, DOI 10.1016/j.jaci.2008.11.022; KATO M, 1992, LYMPHOKINE CYTOK RES, V11, P287; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Ma YG, 2016, CARDIOVASC RES, V110, P51, DOI 10.1093/cvr/cvw024; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Miller M, 2016, J ALLERGY CLIN IMMUN, V138, P596, DOI 10.1016/j.jaci.2016.01.019; Miller M, 2015, J IMMUNOL, V195, P3546, DOI 10.4049/jimmunol.1501105; Mishalian I, 2013, CANCER IMMUNOL IMMUN, V62, P1745, DOI 10.1007/s00262-013-1476-9; Molfino NA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-007709; Nightingale J, 2004, J AM SOC NEPHROL, V15, P21, DOI 10.1097/01.ASN.0000102479.92582.43; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Repovic P, 2002, J NEUROSCI, V22, P5334; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Schleimer RP, 2016, ANN REV PATHOL; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Simpson JL, 2009, EXP LUNG RES, V35, P781, DOI 10.3109/01902140902906412; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Su CM, 2015, J IMMUNOL, V195, P3355, DOI 10.4049/jimmunol.1403191; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zhang N, 2016, ALLERGY, V71, P295, DOI 10.1111/all.12809	59	68	72	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1966	+		10.1016/j.jaci.2016.10.039	http://dx.doi.org/10.1016/j.jaci.2016.10.039			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27993536	Green Accepted			2022-12-18	WOS:000402724600027
J	Gensollen, T; Blumberg, RS				Gensollen, Thomas; Blumberg, Richard S.			Correlation between early-life regulation of the immune system by microbiota and allergy development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; microbiota; early-life; window of opportunity; neonate	HUMAN GUT MICROBIOME; INTESTINAL MICROBIOTA; FECAL MICROBIOTA; EOSINOPHILIC ESOPHAGITIS; BACTERIAL-COLONIZATION; OXAZOLONE COLITIS; NKT CELLS; EXPOSURE; SHAPES; ASTHMA	Early postnatal life is a key time for development of the immune system and colonization of the host by microbiota. Recent studies have shown that specific limbs of the immune system can be regulated by microbiota in a time-restricted period during early life. Studies in mouse models have shown that perturbations of the microbiota during early life can cause immune effects that can persist into adulthood and create increased host susceptibility to certain diseases. Here we discuss the role of early-life regulation of the immune system by the microbiota and how it can be related to allergy development.	[Gensollen, Thomas; Blumberg, Richard S.] Harvard Med Sch, Div Gastroenterol Hepatol & Endoscopy, Dept Med, Brigham & Womens Hosp, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 75 Francis St,Thorn Biomed Res Bldg,Room 1419, Boston, MA 02115 USA.	rblumberg@bwh.harvard.edu		/0000-0002-9834-5490	National Institutes of Health [RO1 DK44319]; Harvard Digestive Diseases Center; Crohn's and Colitis Foundation of America [418509]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319, R37DK044319, P30DK034854] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Digestive Diseases Center; Crohn's and Colitis Foundation of America; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grant RO1 DK44319 and the Harvard Digestive Diseases Center (to R.S.B.) and Crohn's and Colitis Foundation of America grant no. 418509 (to T.G.).	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; An DD, 2014, CELL, V156, P123, DOI 10.1016/j.cell.2013.11.042; Arrieta MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00427; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Baptista AP, 2013, MUCOSAL IMMUNOL, V6, P511, DOI 10.1038/mi.2012.90; Bergstrom A, 2014, APPL ENVIRON MICROB, V80, P2889, DOI 10.1128/AEM.00342-14; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Cheng J, 2016, ISME J, V10, P1002, DOI 10.1038/ismej.2015.177; Claesson MJ, 2011, P NATL ACAD SCI USA, V108, P4586, DOI 10.1073/pnas.1000097107; CRABBE PA, 1970, LAB INVEST, V22, P448; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Dicksved J, 2007, APPL ENVIRON MICROB, V73, P2284, DOI 10.1128/AEM.02223-06; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Donia MS, 2015, SCIENCE, V349, DOI 10.1126/science.1254766; El Aidy S, 2013, GUT MICROBES, V4, P118, DOI 10.4161/gmic.23362; Fallani M, 2011, MICROBIOL-SGM, V157, P1385, DOI 10.1099/mic.0.042143-0; Flint HJ, 2012, GUT MICROBES, V3, P289, DOI 10.4161/gmic.19897; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hold GL, 2014, WORLD J GASTROENTERO, V20, P1192, DOI 10.3748/wjg.v20.i5.1192; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Jimenez E, 2005, CURR MICROBIOL, V51, P270, DOI 10.1007/s00284-005-0020-3; Jimenez E, 2008, RES MICROBIOL, V159, P187, DOI 10.1016/j.resmic.2007.12.007; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Klonowski KD, 2004, IMMUNITY, V20, P551, DOI 10.1016/S1074-7613(04)00103-7; Koch MA, 2016, CELL, V165, P827, DOI 10.1016/j.cell.2016.04.055; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Lexmond WS, 2014, AM J GASTROENTEROL, V109, P646, DOI 10.1038/ajg.2014.12; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Mardinoglu A, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20156487; Metsala J, 2015, CLIN EXP ALLERGY, V45, P137, DOI 10.1111/cea.12356; Moles L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066986; Mosconi I, 2013, MUCOSAL IMMUNOL, V6, P1157, DOI 10.1038/mi.2013.12; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Nieuwenhuis EES, 2009, J CLIN INVEST, V119, P1241, DOI 10.1172/JCI36509; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; Olivares M, 2015, GUT, V64, P406, DOI 10.1136/gutjnl-2014-306931; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Pfefferle PI, 2014, ALLERGOL INT, V63, P3, DOI 10.2332/allergolint.13-RAI-0671; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Rajavelu P, 2012, AM J PHYSIOL-GASTR L, V302, pG645, DOI 10.1152/ajpgi.00223.2011; Reinhardt C, 2009, J PEDIATR GASTR NUTR, V48, P249, DOI 10.1097/MPG.0b013e318183187c; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Shi YN, 2012, J DIGEST DIS, V13, P304, DOI 10.1111/j.1751-2980.2012.00593.x; Spergel JM, 2011, J PEDIATR GASTR NUTR, V52, P300, DOI 10.1097/MPG.0b013e3181eb5a9f; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; UMESAKI Y, 1993, IMMUNOLOGY, V79, P32; van Dieren JM, 2007, INFLAMM BOWEL DIS, V13, P1146, DOI 10.1002/ibd.20164; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zeng MY, 2017, MUCOSAL IMMUNOL, V10, P18, DOI 10.1038/mi.2016.75	77	68	71	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1084	1091		10.1016/j.jaci.2017.02.011	http://dx.doi.org/10.1016/j.jaci.2017.02.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	28390575	Green Accepted, Bronze			2022-12-18	WOS:000398771800002
J	Mansbach, JM; Hasegawa, K; Henke, DM; Ajami, NJ; Petrosino, JF; Shaw, CA; Piedra, PA; Sullivan, AF; Espinola, JA; Camargo, CA				Mansbach, Jonathan M.; Hasegawa, Kohei; Henke, David M.; Ajami, Nadim J.; Petrosino, Joseph F.; Shaw, Chad A.; Piedra, Pedro A.; Sullivan, Ashley F.; Espinola, Janice A.; Camargo, Carlos A., Jr.			Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; INFECTIONS; SYMPTOMS		[Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Hasegawa, Kohei; Sullivan, Ashley F.; Espinola, Janice A.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Henke, David M.; Shaw, Chad A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Ajami, Nadim J.; Petrosino, Joseph F.; Piedra, Pedro A.] Baylor Coll Med, Alkek Ctr Metagen & Microbiome Res, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol & Pediat, Houston, TX 77030 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Massachusetts General Hospital	Mansbach, JM (corresponding author), Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA.	jonathan.mansbach@childrens.harvard.edu	Petrosino, Joseph F./AAF-1621-2019; Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL129909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI108588, U01AI067693, U01AI087881] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL129909] Funding Source: Medline; NIAID NIH HHS [U01 AI067693, U01 AI087881, R01 AI108588] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bosch AATM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003057; Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548; Gulraiz F, 2015, FASEB J, V29, P849, DOI 10.1096/fj.14-254359; Hasegawa K, 2014, EXPERT REV ANTI-INFE, V12, P817, DOI 10.1586/14787210.2014.906901; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Vissers M, 2014, MUCOSAL IMMUNOL, V7, P227, DOI 10.1038/mi.2013.93	9	68	73	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1909	1913		10.1016/j.jaci.2016.01.036	http://dx.doi.org/10.1016/j.jaci.2016.01.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27061249	Bronze, Green Accepted			2022-12-18	WOS:000377527200041
J	Her, M; Kavanaugh, A				Her, Minyoung; Kavanaugh, Arthur			Alterations in immune function with biologic therapies for autoimmune disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biologic agents; adverse effect; infection; autoimmunity; paradoxical inflammation	TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; INDUCED LUPUS-ERYTHEMATOSUS; ANTAGONIST-INDUCED LUPUS; FACTOR-ALPHA THERAPY; LONG-TERM SAFETY; RHEUMATOID-ARTHRITIS; MYCOBACTERIUM-TUBERCULOSIS; SERIOUS INFECTIONS	Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and others, are characterized by dysregulation of various aspects of normal immunity and inflammation. Biologic agents targeting key components of the dysregulated immune response have dramatically improved patient outcomes and transformed treatment paradigms for a number of systemic inflammatory autoimmune diseases. Despite their excellent efficacy, because they do affect normal immune responsiveness, biologic agents can potentially be associated with a variety of adverse effects. Important potential adverse effects related to the use of biologic agents include immunosuppression, which might result in outcomes such as infection, and autoimmunity, that could result in paradoxical inflammation or even autoimmune disease. In this article the current clinical evidence and immunologic mechanisms of the adverse effects related to biologic agents are discussed.	[Her, Minyoung] Inje Univ, Busan Paik Hosp, Div Rheumatol, Busan, South Korea; [Kavanaugh, Arthur] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92037 USA	Inje University; University of California System; University of California San Diego	Kavanaugh, A (corresponding author), Univ Calif San Diego, Ctr Innovat Therapy, Div Rheumatol Allergy & Immunol, 9500 Gilman Dr,Mail Code 0943, La Jolla, CA 92037 USA.	akavanaugh@ucsd.edu	Her, minyoung/AAH-9901-2019	her, minyoung/0000-0002-2733-9501				Aeberli D, 2005, RHEUMATOLOGY, V44, P172, DOI 10.1093/rheumatology/keh437; Albanesi C, 2010, AUTOIMMUNITY, V43, P215, DOI 10.3109/08916930903510906; Atzeni F, 2012, AUTOIMMUN REV, V12, P225, DOI 10.1016/j.autrev.2012.06.008; Aubin F, 2013, J CROHNS COLITIS, V7, P257, DOI 10.1016/j.crohns.2012.06.024; Beigel F, 2011, INFLAMM BOWEL DIS, V17, P91, DOI 10.1002/ibd.21362; Bekker LG, 2001, J IMMUNOL, V166, P6728, DOI 10.4049/jimmunol.166.11.6728; Bosch X, 2011, NAT REV NEUROL, V7, P165, DOI 10.1038/nrneurol.2011.1; Boyman O, 2014, NAT REV RHEUMATOL, V10, P612, DOI 10.1038/nrrheum.2014.123; Bruns H, 2009, J CLIN INVEST, V119, P1167, DOI 10.1172/JCI38482; Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168; Burmester GR, 2013, ANN RHEUM DIS, V72, P517, DOI 10.1136/annrheumdis-2011-201244; Cantini F, 2014, J RHEUMATOL, V41, P56, DOI 10.3899/jrheum.140103; Chakravarty SD, 2008, INFECT IMMUN, V76, P916, DOI 10.1128/IAI.01011-07; Chang C, 2011, DRUG SAFETY, V34, P357, DOI 10.2165/11588500-000000000-00000; Chang C, 2010, J AUTOIMMUN, V34, pJ266, DOI 10.1016/j.jaut.2009.11.012; Che H, 2014, JOINT BONE SPINE, V81, P215, DOI 10.1016/j.jbspin.2013.07.009; Choi HK, 2014, NAT REV RHEUMATOL, V10, P403, DOI 10.1038/nrrheum.2014.36; Cleynen I, 2012, NAT REV GASTRO HEPAT, V9, P496, DOI 10.1038/nrgastro.2012.125; Cullen G, 2011, ALIMENT PHARM THER, V34, P1318, DOI 10.1111/j.1365-2036.2011.04866.x; Curtis JR, 2014, ARTHRIT CARE RES, V66, P990, DOI 10.1002/acr.22281; D'Auria F, 2004, J INTERN MED, V255, P409, DOI 10.1111/j.1365-2796.2003.01298.x; De Bandt M, 2005, ARTHRITIS RES THER, V7, pR545, DOI 10.1186/ar1715; de Gannes GC, 2007, ARCH DERMATOL, V143, P223, DOI 10.1001/archderm.143.2.223; Denadai R, 2013, J CROHNS COLITIS, V7, P517, DOI 10.1016/j.crohns.2012.08.007; Dixon WG, 2010, ANN RHEUM DIS, V69, P522, DOI 10.1136/ard.2009.118935; Fallahi-Sichani M, 2012, J IMMUNOL, V188, P3169, DOI 10.4049/jimmunol.1103298; Filler SG, 2005, CLIN INFECT DIS, V41, pS208, DOI 10.1086/430000; Fiorino G, 2014, AUTOIMMUN REV, V13, P15, DOI 10.1016/j.autrev.2013.06.005; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138; Freling E, 2015, AM J GASTROENTEROL, V110, P1186, DOI 10.1038/ajg.2015.205; Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242; Genovese MC, 2013, J RHEUMATOL, V40, P768, DOI 10.3899/jrheum.120687; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Grijalva CG, 2011, JAMA-J AM MED ASSOC, V306, P2331, DOI 10.1001/jama.2011.1692; Guerra I, 2013, EXPERT REV GASTROENT, V7, P41, DOI [10.1586/EGH.12.64, 10.1586/egh.12.64]; Hadjinicolaou AV, 2012, RHEUMATOLOGY, V51, P653, DOI 10.1093/rheumatology/ker290; Hudson M, 2010, ARTHRIT CARE RES, V62, P805, DOI 10.1002/acr.20124; Kary S, 2006, ANN RHEUM DIS, V65, P405, DOI 10.1136/ard.2005.037424; Khader SA, 2011, J IMMUNOL, V187, P5402, DOI 10.4049/jimmunol.1101377; Kourbeti IS, 2014, CLIN INFECT DIS, V58, P1649, DOI 10.1093/cid/ciu185; Ladel CH, 1997, INFECT IMMUN, V65, P4843, DOI 10.1128/IAI.65.11.4843-4849.1997; Laga AC, 2010, AM J DERMATOPATH, V32, P568, DOI 10.1097/DAD.0b013e3181cb3ff7; Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028; Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025; Lin PL, 2010, ARTHRITIS RHEUM-US, V62, P340, DOI 10.1002/art.27271; Ma HL, 2010, ARTHRITIS RHEUM-US, V62, P430, DOI 10.1002/art.27203; Matucci A, 2014, J RHEUMATOL, V41, P17, DOI 10.3899/jrheum.140098; Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189; McDonald JR, 2009, CLIN INFECT DIS, V48, P1364, DOI 10.1086/598331; Michaud TL, 2014, AM J MED, V127, P1208, DOI 10.1016/j.amjmed.2014.06.012; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nunes-Alves C, 2014, NAT REV MICROBIOL, V12, P289, DOI 10.1038/nrmicro3230; Palucka AK, 2005, P NATL ACAD SCI USA, V102, P3372, DOI 10.1073/pnas.0408506102; Perez-Alvarez R, 2013, CURR OPIN RHEUMATOL, V25, P56, DOI 10.1097/BOR.0b013e32835b1366; Perez-Alvarez R, 2011, SEMIN ARTHRITIS RHEU, V41, P256, DOI 10.1016/j.semarthrit.2010.11.002; Pichler WJ, 2006, ALLERGY, V61, P912, DOI 10.1111/j.1398-9995.2006.01058.x; Rahier JF, 2010, CLIN GASTROENTEROL H, V8, P1048, DOI 10.1016/j.cgh.2010.07.022; Ramos-Casals M, 2010, AUTOIMMUN REV, V9, P188, DOI 10.1016/j.autrev.2009.10.003; Ramos-Casals M, 2008, BEST PRACT RES CL RH, V22, P847, DOI 10.1016/j.berh.2008.09.008; Raychaudhuri SK, 2014, AUTOIMMUN REV, V13, P490, DOI 10.1016/j.autrev.2014.01.008; Rosman Z, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-88; Roubille C, 2014, SEMIN ARTHRITIS RHEU, V43, P613, DOI 10.1016/j.semarthrit.2013.09.005; Salliot C, 2009, ANN RHEUM DIS, V68, P25, DOI 10.1136/ard.2007.083188; Saunders BM, 2004, CLIN EXP IMMUNOL, V137, P279, DOI 10.1111/j.1365-2249.2004.02518.x; Seneschal J, 2009, BRIT J DERMATOL, V161, P1081, DOI 10.1111/j.1365-2133.2009.09329.x; Shmidt E, 2012, J AM ACAD DERMATOL, V67, pE179, DOI 10.1016/j.jaad.2011.05.038; Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9; Smolen JS, 2013, ANN RHEUM DIS, V72, P482, DOI 10.1136/annrheumdis-2012-202469; Sokumbi O, 2012, MAYO CLIN PROC, V87, P739, DOI 10.1016/j.mayocp.2012.04.011; Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043; Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146; Thomas L, 2012, J RHEUMATOL, V39, P893, DOI 10.3899/jrheum.111347; Thompson AE, 2011, ARTHRITIS RHEUM-US, V63, P1479, DOI 10.1002/art.30310; Tillack C, 2014, GUT, V63, P567, DOI 10.1136/gutjnl-2012-302853; Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004; Toussirot E, 2012, JOINT BONE SPINE, V79, P457, DOI 10.1016/j.jbspin.2011.10.001; Tsai TF, 2013, BRIT J DERMATOL, V168, P444, DOI 10.1111/j.1365-2133.2012.11162.x; Tsai TF, 2012, BRIT J DERMATOL, V167, P1145, DOI 10.1111/j.1365-2133.2012.11142.x; Tubach F, 2009, ARTHRITIS RHEUM-US, V60, P1884, DOI 10.1002/art.24632; van Dartel SAA, 2013, ANN RHEUM DIS, V72, P895, DOI 10.1136/annrheumdis-2012-201338; Vedove CD, 2012, J DTSCH DERMATOL GES, V10, P889, DOI 10.1111/j.1610-0387.2012.08000.x; Wada Takuma, 2012, Nihon Rinsho Meneki Gakkai Kaishi, V35, P433; Wahren-Herlenius M, 2013, LANCET, V382, P819, DOI 10.1016/S0140-6736(13)60954-X; Wallis RS, 2011, INFECT DIS CLIN N AM, V25, P895, DOI 10.1016/j.idc.2011.08.002; Weinblatt M, 2007, ANN RHEUM DIS, V66, P228, DOI 10.1136/ard.2006.055111; Weissert R, 2011, J NEUROIMMUNOL, V231, P73, DOI 10.1016/j.jneuroim.2010.09.021; Wendling D, 2014, EXPERT REV CLIN IMMU, V10, P159, DOI 10.1586/1744666X.2014.866038; Wendling D, 2011, SEMIN ARTHRITIS RHEU, V41, P503, DOI 10.1016/j.semarthrit.2011.05.005; Williams VL, 2011, INT J DERMATOL, V50, P619, DOI 10.1111/j.1365-4632.2011.04871.x; Winthrop KL, 2013, ANN RHEUM DIS, V72, P37, DOI 10.1136/annrheumdis-2011-200690; Winthrop KL, 2014, ARTHRITIS RHEUMATOL, V66, P2675, DOI 10.1002/art.38745; Winthrop KL, 2013, JAMA-J AM MED ASSOC, V309, P887, DOI 10.1001/jama.2013.1099; Xu Y, 2015, ARTHRITIS RHEUMATOL, V67, P225, DOI 10.1002/art.38882; Yamamoto K, 2015, J RHEUMATOL, V42, P1368, DOI 10.3899/jrheum.141210; Yoo JW, 2014, EUR RESPIR J, V44, P1289, DOI 10.1183/09031936.00063514	97	68	71	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					19	27		10.1016/j.jaci.2015.10.023	http://dx.doi.org/10.1016/j.jaci.2015.10.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26768759	Bronze			2022-12-18	WOS:000367724300010
J	Hanna, S; Etzioni, A				Hanna, Suheir; Etzioni, Amos			MHC class I and II deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MHC class I and II; immunodeficiency; regulatory factor X; class II transactivator; transporter associated with antigen processing I and II; tapasin	BARE-LYMPHOCYTE-SYNDROME; IMMUNODEFICIENCY; MECHANISMS; MUTATION; DISEASE	Deficiencies of MHC complex class I or II are rare primary immunodeficiencies, both of which are inherited in an autosomal recessive pattern. MHC class II deficiency is a prototype of a disease of gene regulation. Defects in transacting regulatory factors required for expression of MHC class II genes, rather than the genes themselves, are responsible for the disease phenotype. The affected genes are known to encode 4 distinct regulatory factors controlling transcription of MHC class II genes. These transacting factors are the class II transactivator and 3 subunits of regulatory factor X (RFX): RFX containing ankyrin repeats (RFXANK), the fifth member of the RFX family (RFX5), and RFX-associated protein (RFXAP). Mutations in one of each define 4 distinct complementation groups termed A, B, C, and D, respectively. MHC class I deficiency is extremely rare and has been reported in less than 30 patients worldwide. Here we review the clinical, genetic, and molecular features that characterize these primary immunodeficiencies and discuss therapy options. Beyond the description of MHC class I and II deficiencies, their discovery has fascinated scientists and clinicians because of their ability to reveal the molecular basis of MCH regulation.	Rambam Med Ctr, Dept Pediat, Haifa, Israel; Rambam Med Ctr, Pediat Immunol Unit, Haifa, Israel; Technion Israel Inst Technol, B Rappaport Fac Med, IL-32000 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Etzioni, A (corresponding author), Ruth Children Hosp, Rambam Med Campus, IL-31096 Haifa, Israel.	Etzioni@rambam.Health.gov.il						Al-Herz W, 2013, J CLIN IMMUNOL, V33, P513, DOI 10.1007/s10875-012-9831-8; Al-Mousa H, 2010, BIOL BLOOD MARROW TR, V16, P818, DOI 10.1016/j.bbmt.2010.01.002; Ballachanda ND, 2013, FRONT IMMUNOL, V4; Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454; Ben-Mustapha I, 2013, J CLIN IMMUNOL, V33, P865, DOI 10.1007/s10875-013-9863-8; De la Salle H, 2002, CLIN EXP IMMUNOL, V128, P525, DOI 10.1046/j.1365-2249.2002.01862.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; de la Salle H, 2014, PRIMARY IMMUNODEFICI, P258; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; Elhasid R, 1996, BLOOD REV, V10, P242, DOI 10.1016/S0268-960X(96)90008-9; Gadola SD, 2000, CLIN EXP IMMUNOL, V121, P173, DOI 10.1046/j.1365-2249.2000.01264.x; Kuo CY, 2013, J ALLERGY CLIN IMMUN, V131, P1693, DOI 10.1016/j.jaci.2013.01.019; Lev A, 2013, J ALLERGY CLIN IMMUN, V131, P831, DOI 10.1016/j.jaci.2012.10.040; Markel G, 2004, BLOOD, V103, P1770, DOI 10.1182/blood-2003-06-2114; Matamoros N, 2001, CLIN EXP IMMUNOL, V125, P274, DOI 10.1046/j.1365-2249.2001.01595.x; Matheux F, 2004, NEWS PHYSIOL SCI, V19, P154, DOI 10.1152/nips.01462.2003; Nekrep N, 2003, IMMUNITY, V18, P453, DOI 10.1016/S1074-7613(03)00086-4; Nekrep N, 2002, NAT IMMUNOL, V3, P1075, DOI 10.1038/ni840; Ouederni M, 2011, BLOOD, V118, P5108, DOI 10.1182/blood-2011-05-352716; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Piertney SB, 2006, HEREDITY, V96, P7, DOI 10.1038/sj.hdy.6800724; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Reith W., 2014, PRIMARY IMMUNODEFICI, P241; Renella R, 2006, BRIT J HAEMATOL, V134, P510, DOI 10.1111/j.1365-2141.2006.06213.x; Rozmus J, 2013, J CLIN IMMUNOL, V33, P1310, DOI 10.1007/s10875-013-9952-8; Siepermann M, 2011, PEDIATR TRANSPLANT, V15, pE80, DOI 10.1111/j.1399-3046.2010.01292.x; Small TN, 2013, BONE MARROW TRANSPL, V48, P226, DOI 10.1038/bmt.2012.140; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; Villard J, 1997, NEW ENGL J MED, V337, P748, DOI 10.1056/NEJM199709113371104; Waldburger JM, 2000, IMMUNOL REV, V178, P148, DOI 10.1034/j.1600-065X.2000.17813.x; Yabe T, 2002, BLOOD, V100, P1496, DOI 10.1182/blood-2001-12-0252	32	68	80	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					269	275		10.1016/j.jaci.2014.06.001	http://dx.doi.org/10.1016/j.jaci.2014.06.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	25001848				2022-12-18	WOS:000341370800004
J	Rondon, C; Campo, P; Zambonino, MA; Blanca-Lopez, N; Torres, MJ; Melendez, L; Herrera, R; Gueant-Rodriguez, RM; Gueant, JL; Canto, G; Blanca, M				Rondon, Carmen; Campo, Paloma; Zambonino, Maria Angeles; Blanca-Lopez, Natalia; Torres, Maria J.; Melendez, Lidia; Herrera, Rocio; Gueant-Rodriguez, Rosa-Maria; Gueant, Jean-Louis; Canto, Gabriela; Blanca, Miguel			Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; local allergic rhinitis; natural history; nasal allergen provocation test; systemic atopy	CHRONIC RHINOSINUSITIS; IDIOPATHIC RHINITIS; ABSENCE; IGE; PATHOPHYSIOLOGY; DISEASE; IMPACT; AREAS	Background: Local allergic rhinitis (LAR) is a common disease that affects 25.7% of the rhinitis population and more than 47% of patients previously diagnosed with nonallergic rhinitis. Whether LAR is the first step in the natural history of allergic rhinitis (AR) with systemic atopy or a consistent entity is unknown. Objective: The aim was to evaluate the natural history of a population with LAR of recent onset and the development of AR and asthma. Methods: A prospective 10-year follow-up study with initial cohorts of 194 patients with LAR of recent onset and 130 healthy controls is being undertaken. A clinical-demographic questionnaire, spirometry, skin prick test, and specific IgE to aeroallergens were done yearly. Nasal allergen provocation tests with Dermatophagoides pteronyssinus, Alternaria alternata, Olea europea, and a mix of grass pollen were performed at baseline and after 5 years. Results: At disease onset, most of the patients with LAR had moderate-to-severe persistent-perennial rhinitis; conjunctivitis and asthma were the main comorbidities (51.1% and 18.8%, respectively), and D pteronyssinus was the most relevant aeroallergen (51.1%). After 5 years of follow-up, a worsening of rhinitis was detected in 26.2%, with an increase in symptom persistence and severity, and new associations with conjunctivitis and asthma. Atopy was detected by skin prick test and/or serum specific-IgE in patients with LAR (6.81%) and in controls (4.5%). Conclusions: This study shows a similar rate of development of systemic atopy in LAR and controls, which suggests that LAR is an entity well differentiated from AR. To determine the natural course of LAR more precisely, this study is in progress to complete 10 years of follow-up.	[Rondon, Carmen; Campo, Paloma; Zambonino, Maria Angeles; Torres, Maria J.; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Blanca-Lopez, Natalia; Canto, Gabriela] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain; [Melendez, Lidia; Herrera, Rocio] Carlos Haya Hosp, Res Lab, Fdn IMABIS, Malaga, Spain; [Gueant-Rodriguez, Rosa-Maria; Gueant, Jean-Louis] Fac Med Vandoeuvre Nancy, INSERM, U 954, Nutr Genet Exposit Risques Environm, Vandoeuvre Les Nancy, France	Hospital Carlos Haya; Hospital Universitario Infanta Leonor; FIMABIS; Hospital Carlos Haya; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Rondon, C (corresponding author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com	Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017	Torres, María José/0000-0001-5228-471X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402	FIS network RIRAAF [RD07/0064]; National Health Ministry [FIS PI11/02619, FIS PI12/00900]	FIS network RIRAAF; National Health Ministry	Supported by grants from FIS network RIRAAF (RD07/0064), National Health Ministry FIS PI11/02619 and FIS PI12/00900.	Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Niesvaara DC, 2012, J ALLERGY CLIN IMMUN, V129, pAB111; de la Roca F, 2012, J ALLERGY CLIN IMMUN, V129, pAB111, DOI 10.1016/j.jaci.2011.12.546; Demoly P., 2003, MIDDLETONS ALLERGY P, P631; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Hilberg O, 2001, RHINOLOGY, V39, P119; Kormelink TG, 2012, ALLERGY, V67, P1165, DOI 10.1111/j.1398-9995.2012.02866.x; Lopez S, 2010, CLIN EXP ALLERGY, V40, P1007, DOI 10.1111/j.1365-2222.2010.03492.x; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, P139, DOI 10.1016/j.jaci.2009.07.025; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2012, ALLERGY, V67, P1282, DOI 10.1111/all.12002; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2012, J ALLERGY CLIN IMMUN, V129, P1460, DOI 10.1016/j.jaci.2012.02.032; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006; Wedback A, 2005, RHINOLOGY, V43, P86	22	68	71	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1026	1031		10.1016/j.jaci.2013.10.034	http://dx.doi.org/10.1016/j.jaci.2013.10.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24332860				2022-12-18	WOS:000333531700012
J	Pelucchi, C; Galeone, C; Bach, JF; La Vecchia, C; Chatenoud, L				Pelucchi, Claudio; Galeone, Carlotta; Bach, Jean-Francois; La Vecchia, Carlo; Chatenoud, Liliane			Pet exposure and risk of atopic dermatitis at the pediatric age: A meta-analysis of birth cohort studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; child; epidemiology; hygiene hypothesis; pets	1ST YEAR; DOG OWNERSHIP; HAY-FEVER; ALLERGIC DISEASES; EARLY-CHILDHOOD; FURRY PETS; ENVIRONMENTAL-FACTORS; ENDOTOXIN EXPOSURE; IMMUNE DEVELOPMENT; ASTHMA	Background: Findings on pet exposure and the risk of atopic dermatitis (AD) in children are inconsistent. Objective: With the aim to summarize the results of exposure to different pets on AD, we undertook a meta-analysis of epidemiologic studies on this issue. Methods: In August 2012, we conducted a systematic literature search in Medline and Embase. We included analytic studies considering exposure to dogs, cats, other pets, or pets overall during pregnancy, infancy, and/or childhood, with AD assessment performed during infancy or childhood. We calculated summary relative risks and 95% CIs using both fixed-and random-effects models. We computed summary estimates across selected subgroups. Results: Twenty-six publications from 21 birth cohort studies were used in the meta-analyses. The pooled relative risks of AD for exposure versus no exposure were 0.72 (95% CI, 0.61-0.85; I-2 = 46%; results based on 15 studies) for exposure to dogs, 0.94 (95% CI, 0.76-1.16; I-2 = 54%; results based on 13 studies) for exposure to cats, and 0.75 (95% CI, 0.67-0.85; I-2 = 54%; results based on 11 studies) for exposure to pets overall. No heterogeneity emerged across the subgroups examined, except for geographic area. Conclusion: This meta-analysis reported a favorable effect of exposure to dogs and pets on the risk of AD in infants or children, whereas no association emerged with exposure to cats.	[Pelucchi, Claudio; Galeone, Carlotta; La Vecchia, Carlo; Chatenoud, Liliane] IRCCS Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy; [Galeone, Carlotta; La Vecchia, Carlo] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy; [Bach, Jean-Francois] Univ Paris 05, INSERM, Paris, France; [Bach, Jean-Francois] INSERM, Unite 1013, Paris, France	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pelucchi, C (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	claudio.pelucchi@marionegri.it	Chatenoud, Liliane/AAA-6377-2020	Chatenoud, Liliane/0000-0001-9599-8229; La Vecchia, Carlo/0000-0003-1441-897X; Pelucchi, Claudio/0000-0003-1425-8945; Galeone, Carlotta/0000-0003-1934-5167	European Research Council [250290]; European Research Council	European Research Council(European Research Council (ERC)European Commission); European Research Council(European Research Council (ERC)European Commission)	Supported by the European Research Council, grant agreement no. 250290.; The authors have been supported by one or more grants from the European Research Council.	Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Almqvist C, 2010, PAEDIATR PERINAT EP, V24, P171, DOI 10.1111/j.1365-3016.2010.01095.x; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bradburn MJ, 1998, STATA TECH B, V44, P4; Brunekreef B, 2012, EPIDEMIOLOGY, V23, P742, DOI 10.1097/EDE.0b013e318261f040; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Chen CM, 2009, ALLERGY, V64, P494, DOI 10.1111/j.1398-9995.2008.01930.x; Chen CM, 2008, EUR RESPIR J, V31, P963, DOI 10.1183/09031936.00092807; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dom S, 2010, CLIN EXP ALLERGY, V40, P1378, DOI 10.1111/j.1365-2222.2010.03538.x; Dunlop AL, 2006, PEDIAT ALLERG IMM-UK, V17, P103, DOI 10.1111/j.1399-3038.2005.00372.x; Eder W, 2004, CURR OPIN ALLERGY CL, V4, P113, DOI 10.1097/01.all.0000123970.96233.fc; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eller E, 2008, ALLERGY, V63, P1491, DOI 10.1111/j.1398-9995.2008.01790.x; Epstein TG, 2011, J PEDIATR-US, V158, P265, DOI 10.1016/j.jpeds.2010.07.026; Flohr C, 2011, CURR PROBL DERMATOL, V41, P1, DOI 10.1159/000323290; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Handl S, 2011, FEMS MICROBIOL ECOL, V76, P301, DOI 10.1111/j.1574-6941.2011.01058.x; Harris RJ, 2009, METAANALYSIS STATA U, P29; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Langan SM, 2007, ARCH DERMATOL, V143, P1570, DOI 10.1001/archderm.143.12.1570; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Lodge CJ, 2012, CLIN EXP ALLERGY, V42, P1377, DOI 10.1111/j.1365-2222.2012.04032.x; Ludvigsson JF, 2005, PEDIAT ALLERG IMM-UK, V16, P201, DOI 10.1111/j.1399-3038.2005.00257.x; Miyake Y, 2007, PEDIATR ALLERGY IMMU, V18, P425, DOI 10.1111/j.1399-3038.2007.00545.x; Myers JMB, 2010, J INVEST DERMATOL, V130, P430, DOI 10.1038/jid.2009.300; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Oberle D, 2003, ALLERGY, V58, P1033, DOI 10.1034/j.1398-9995.2003.00285.x; Pelucchi C., 2012, CRD REGISTER; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sandini U, 2011, INT ARCH ALLERGY IMM, V156, P339, DOI 10.1159/000323907; Sariachvili M, 2007, PEDIATR ALLERGY IMMU, V18, P410, DOI 10.1111/j.1399-3038.2007.00543.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Takkouche B, 2008, ALLERGY, V63, P857, DOI 10.1111/j.1398-9995.2008.01732.x; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Zirngibl A, 2002, PEDIAT ALLERG IMM-UK, V13, P394, DOI 10.1034/j.1399-3038.2002.01110.x	67	68	70	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					616	+		10.1016/j.jaci.2013.04.009	http://dx.doi.org/10.1016/j.jaci.2013.04.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23711545	Green Submitted			2022-12-18	WOS:000323612000013
J	Lee, S; Hess, EP; Nestler, DM; Athmaram, VRB; Bellolio, MF; Decker, WW; Li, JTC; Hagan, JB; Manivannan, V; Vukov, SC; Campbell, RL				Lee, Sangil; Hess, Erik P.; Nestler, David M.; Athmaram, Venkatesh R. Bellamkonda; Bellolio, M. Fernanda; Decker, Wyatt W.; Li, James T. C.; Hagan, John B.; Manivannan, Veena; Vukov, Samuel C.; Campbell, Ronna L.			Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; antihypertensive medications; angiotensin-converting enzyme inhibitor; beta-blocker; risk factors; emergency department	BETA-ADRENERGIC-BLOCKADE; RISK; EPINEPHRINE; MANAGEMENT; BLOCKERS; ALLERGY	Background: Risk factors for increased anaphylaxis severity are poorly understood. Angiotensin-converting enzyme (ACE) inhibitors have been associated with severe anaphylactic reactions in patients with hymenoptera venom allergy. Studies evaluating the association between beta-blockers and severe anaphylaxis have been conflicting. Objective: To evaluate the association between antihypertensive medication use and increased anaphylaxis severity. Methods: We included emergency department anaphylaxis patients aged 18 years and older. Markers of severe anaphylaxis were defined as (1) syncope, hypotension, or hypoxia; (2) signs and symptoms involving 3 or more organ systems; and (3) hospitalization. Antihypertensive medications evaluated included beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics. Simple and multiple logistic regression analyses were conducted to estimate the association between antihypertensive medication use and markers of increased anaphylaxis severity. Results: Among 302 patients with anaphylaxis, 55 (18%) had syncope, hypoxia, or hypotension, 57 (19%) required hospitalization, and 139 (46%) had 3 or more organ system involvement. After adjusting for age, gender, suspected trigger, and preexisting lung disease, beta-blocker, ACE-inhibitor, diuretic, or antihypertensive medication use in aggregate remained associated with both 3 or more organ system involvement and need for hospital admission. The adjusted associations between antihypertensive medication use in aggregate and 3 or more organ system involvement yielded an odds ratio of 2.8 (95% CI, 1.5-5.2; P =.0008) and with hospitalization an odds ratio of 4.0 (95% CI, 1.9-8.4; P =.0001). Conclusions: In emergency department anaphylaxis patients, antihypertensive medication use is associated with increased organ system involvement and increased odds of hospital admission, independent of age, gender, suspected trigger, or preexisting lung disease. (J Allergy Clin Immunol 2013; 131:1103-8.)	[Lee, Sangil; Hess, Erik P.; Nestler, David M.; Athmaram, Venkatesh R. Bellamkonda; Bellolio, M. Fernanda; Decker, Wyatt W.; Manivannan, Veena; Vukov, Samuel C.; Campbell, Ronna L.] Mayo Clin, Dept Emergency Med, Rochester, MN 55905 USA; [Li, James T. C.; Hagan, John B.] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Campbell, RL (corresponding author), Mayo Clin, Dept Emergency Med, 200 1st St SW, Rochester, MN 55905 USA.	campbell.ronna@mayo.edu		Lee, Sangil/0000-0001-8529-4500; Campbell, Ronna/0000-0001-6305-6990; Bellolio, Fernanda/0000-0002-1632-4750	National Institutes of Health/NCRR/NCATS CTSA [UL1 RR024150]; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; MedImmune; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER	National Institutes of Health/NCRR/NCATS CTSA; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This publication was supported by National Institutes of Health/NCRR/NCATS CTSA grant no. UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.; Disclosure of potential conflict of interest: S. Lee, E. P. Hess, D. M. Nestler, V. R. Bellamkonda Athmaram, M. F. Bellolio, W. W. Decker, V. Manivannan, S. C. Vukov, and R. L. Campbell have received research support from the National Institutes of Health (NIH). J. T. C. Li has received research support from the NIH and has stock options in Novartis, Abbott, and Johnson& Johnson. J. B. Hagan has received research support from the NIH, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, and MedImmune; was chairman of the Dyax Adjudication panel of KALBITOR; and has held stock in Johnson & Johnson and TEVA in the last 3 years.	AWAI LE, 1984, ANN ALLERGY, V53, P48; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Campbell RL, 2011, ANN ALLERG ASTHMA IM, V106, P401, DOI 10.1016/j.anai.2011.01.011; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Gates PE, 2009, EXP PHYSIOL, V94, P311, DOI 10.1113/expphysiol.2008.043349; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Overlack A, 1996, DRUG SAFETY, V15, P72, DOI 10.2165/00002018-199615010-00006; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Smith CJ, 2011, HYPERTENSION, V58, P935, DOI 10.1161/HYPERTENSIONAHA.111.178129; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929	19	68	68	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1103	1108		10.1016/j.jaci.2013.01.011	http://dx.doi.org/10.1016/j.jaci.2013.01.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23453138				2022-12-18	WOS:000317187200020
J	Patelis, A; Gunnbjornsdottir, M; Malinovschi, A; Matsson, P; Onell, A; Hogman, M; Alving, K; Janson, C				Patelis, Antonios; Gunnbjornsdottir, Maria; Malinovschi, Andrei; Matsson, Per; Onell, Annica; Hogman, Marieann; Alving, Kjell; Janson, Christer			Population-based study of multiplexed IgE sensitization in relation to asthma, exhaled nitric oxide, and bronchial responsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; FENO; airway inflammation; methacholine test; bronchial responsiveness; ISAC; food allergy; multisensitization	HOUSE-DUST MITE; ALLERGENS; HEALTH; ATOPY; MICROARRAY; REACTIVITY; RELEVANCE; ADULTS; RISK	Background: IgE sensitization is an important risk factor for the development of asthma. Objective: The aim of this study was to investigate the IgE antibody profile for a broad spectrum of allergen molecules in asthmatic patients. Methods: Participants from the European Community Respiratory Health Survey II (n = 467) were tested with ImmunoCAP ISAC against 103 allergen molecules. The presence of bronchial hyperresponsiveness was measured with a methacholine challenge test and bronchial inflammation with fraction of exhaled nitric oxide (FENO). Results: A total of 38% of the controls and 72% of the asthmatic patients were sensitized against at least 1 of the allergen components (P < .0001). Asthma was independently related to having IgE antibodies against pollen (odds ratio = 2.2) and perennial airway allergens (odds ratio = 5.6), increased FENO was independently related to having IgE antibodies against food allergens and perennial allergens, while bronchial responsiveness was independently associated with having IgE antibodies against only perennial allergens. Sensitization to food allergens was related to asthma and increased FENO if IgE antibody against pollen allergens was present. Simultaneous sensitization to perennial, pollen, and food allergens involves the highest risk of asthma (odds ratio = 18.3), bronchial inflammation, and responsiveness. Conclusions: FENO, bronchial responsiveness, and the risk of asthma increase with multiple sensitizations to different allergen groups. We show for the first time that the presence of IgE antibodies against food allergens is independently associated with increased FENO and increases the risk of asthma in subjects with simultaneous sensitization to pollen allergens. (J Allergy Clin Immunol 2012;130:397-402.)	[Patelis, Antonios; Gunnbjornsdottir, Maria; Malinovschi, Andrei; Hogman, Marieann; Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, S-75185 Uppsala, Sweden; [Malinovschi, Andrei] Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden; [Matsson, Per; Hogman, Marieann] Thermo Fisher Sci, Uppsala, Sweden; [Hogman, Marieann] Uppsala Univ, Cty Council Gavleborg, Ctr Res & Dev, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Thermo Fisher Scientific; Uppsala University	Patelis, A (corresponding author), Uppsala Univ, Dept Med Sci Resp Med & Allergol, Akad Sjukhuset, Ing 40,2 Tr, S-75185 Uppsala, Sweden.	antonios.patelis@medsci.uu.se	; Alving, Kjell/M-4579-2014	Patelis, Antonios/0000-0001-7837-1862; Alving, Kjell/0000-0003-0784-0443	Swedish Agency for Innovation Systems; Swedish Heart and Lung Foundation; Vardal Foundation for Health Care Science and Allergy Research; Swedish Association Against Asthma and Allergy; Agnes and Mac Rudberg's Foundation; Bror Hjerpstedt Foundation; Phadia (Sweden)	Swedish Agency for Innovation Systems(Vinnova); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Vardal Foundation for Health Care Science and Allergy Research; Swedish Association Against Asthma and Allergy; Agnes and Mac Rudberg's Foundation; Bror Hjerpstedt Foundation; Phadia (Sweden)	This study was supported financially by the Swedish Agency for Innovation Systems, the Swedish Heart and Lung Foundation, the Vardal Foundation for Health Care Science and Allergy Research, the Swedish Association Against Asthma and Allergy, Phadia (Sweden), Agnes and Mac Rudberg's Foundation, and the Bror Hjerpstedt Foundation.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 2007, AM J RESP CRIT CARE, V176, P20, DOI 10.1164/rccm.200612-1840OC; Chong HJ, 2009, ALLERGOL IMMUNOPATH, V37, P31, DOI 10.1016/S0301-0546(09)70249-6; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Harwanegg C, 2005, CLIN CHEM LAB MED, V43, P1321, DOI 10.1515/CCLM.2005.226; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Janson C, 2008, CLIN RESPIR J, V2, P88, DOI 10.1111/j.1752-699X.2008.00090.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Kerkhof M, 2003, ALLERGY, V58, P1261, DOI 10.1046/j.1398-9995.2003.00020.x; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Malinovschi A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-92; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Nopp A, 2006, ALLERGY, V61, P1366, DOI 10.1111/j.1398-9995.2006.01211.x; Olafsdottir IS, 2005, THORAX, V60, P451, DOI 10.1136/thx.2004.035774; Pallasaho P, 2006, CLIN EXP ALLERGY, V36, P503, DOI 10.1111/j.1365-2222.2006.02460.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Scala E, 2013, PLOS ONE, V6; Schroeder A, 2009, CLIN EXP ALLERGY, V39, P261, DOI 10.1111/j.1365-2222.2008.03160.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Syk J, 2009, CLIN RESPIR J, V3, P143, DOI 10.1111/j.1752-699X.2008.00124.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Wickman M, 2005, ALLERGY, V60, P14, DOI 10.1111/j.1398-9995.2005.00852.x; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	36	68	69	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					397	+		10.1016/j.jaci.2012.03.046	http://dx.doi.org/10.1016/j.jaci.2012.03.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22633327				2022-12-18	WOS:000307002200019
J	Farah, CS; King, GG; Brown, NJ; Peters, MJ; Berend, N; Salome, CM				Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Peters, Matthew J.; Berend, Norbert; Salome, Cheryl M.			Ventilation heterogeneity predicts asthma control in adults following inhaled corticosteroid dose titration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ventilation heterogeneity; small airways; asthma control; symptoms; inflammation; asthma; multiple breath nitrogen washout; forced oscillation technique	EXHALED NITRIC-OXIDE; DISTAL AIRWAY FUNCTION; NITROGEN WASHOUT; LUNG-FUNCTION; HYPERRESPONSIVENESS; INFLAMMATION; METHACHOLINE; MARKERS; STANDARDIZATION; OBSTRUCTION	Background: Asthma guidelines recommend inhaled corticosteroid (ICS) dose titration for patients on the basis of an assessment of current asthma control. However, the physiological determinants of asthma symptom control are poorly understood and spirometry is a poor predictor of symptomatic response. Objective: To determine the role of small airway measurements in predicting the symptom response following ICS dose titration. Methods: Adult asthmatic patients had the Asthma Control Questionnaire (ACQ) scores and lung function measured at baseline and after 8 weeks. Tests included spirometry, plethysmography, sputum cell count, exhaled nitric oxide, airway hyperresponsiveness to mannitol, respiratory system mechanics using the forced oscillation technique, and ventilation heterogeneity using the multiple breath nitrogen washout. The parameters ventilation heterogeneity in convection-dependent airways and ventilation heterogeneity in diffusion-dependent airways were derived as measures of ventilation heterogeneity in the small airways. The dose of ICS was doubled if the ACQ score was greater than or equal to 1.5 (uptitration) and quartered if the ACQ score was less than 1.5 (downtitration). The relationships between baseline physiological parameters and the change in the symptom-only 5-item ACQ (deltaACQ-5) were examined by using Spearman correlations, forward stepwise linear regressions, and receiver operator curve analyses. Results: ICS dose uptitration (n = 20) improved ACQ-5 scores (1.76 to 1.16; P = .04). Baseline fraction of exhaled nitric oxide (r = -0.55; P = .01) and ventilation heterogeneity in convection-dependent airways (r = -0.64; P = .002) correlated with deltaACQ-5, but ventilation heterogeneity in convection-dependent airways was the only independent predictor (r(2) = 0.34; P = 0.007). ICS dose downtitration (n = 41) worsened ACQ-5 scores (0.46 to 0.80; P < .001), with 29% of the patients having a deltaACQ-5 of greater than 0.5. Only baseline ventilation heterogeneity in diffusion-dependent airways correlated with deltaACQ-5 (r = 0.40; P = .009) and identified subjects with deltaACQ-5 of greater than 0.5 (receiver operator curve area under the curve = 0.78; P = .0003). Conclusions: Ventilation heterogeneity predicts symptomatic responses to ICS dose titration. Worse small airways function predicts symptomatic improvement to ICS dose uptitration and loss of symptom control during downtitration. (J Allergy Clin Immunol 2012;130:61-8.)	[Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Berend, Norbert; Salome, Cheryl M.] Woolcock Inst Med Res, Airway Physiol Grp, Glebe, NSW 2050, Australia; [Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Peters, Matthew J.; Berend, Norbert; Salome, Cheryl M.] Univ Sydney, Sydney, NSW 2006, Australia; [Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Berend, Norbert; Salome, Cheryl M.] Cooperat Res Ctr Asthma & Airways, Glebe, NSW, Australia; [King, Gregory G.] Royal N Shore Hosp, Dept Resp Med, St Leonards, NSW 2065, Australia; [Peters, Matthew J.] Concord Hosp, Dept Resp Med, Concord, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Royal North Shore Hospital; Concord Repatriation General Hospital	Farah, CS (corresponding author), Woolcock Inst Med Res, Airway Physiol Grp, POB M77,Missenden Rd, Glebe, NSW 2050, Australia.	cfarah@med.usyd.edu.au	Brown, Nathan J/H-8347-2019; Brown, Nathan/H-4317-2011; Farah, Claude S/G-6217-2012	Brown, Nathan J/0000-0001-7149-8895; Brown, Nathan/0000-0001-7149-8895; Farah, Claude S/0000-0003-2489-227X; Peters, Matthew/0000-0002-9649-8741	Cooperative Research Centre for Asthma and Airways; National Health and Medical Research Council; GlaxoSmithKline; National Health and Medical Research Council of Australia	Cooperative Research Centre for Asthma and Airways(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); GlaxoSmithKline(GlaxoSmithKline); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a research grant from the Cooperative Research Centre for Asthma and Airways. Pharmaxis Ltd provided the mannitol kits for the bronchial challenge.; C. S. Farah has received honoraria from AstraZeneca, GlaxoSmithKline, Novartis, and Pfizer. G. G. King has received research support from the Cooperative Research Centre for Asthma and Airways, National Health and Medical Research Council, and GlaxoSmithKline and has provided legal consultation/expert witness testimony for GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. C. M. Salome has received research support from the Cooperative Research Centre for Asthma and Airways, National Health and Medical Research Council of Australia, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; Australian Institute of Health and Welfare, ASTHM AUSTR 2008; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; Brannan JD, 2002, RESPIROLOGY, V7, P37, DOI 10.1046/j.1440-1843.2002.00357.x; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; CLEMENT J, 1983, CHEST, V83, P215, DOI 10.1378/chest.83.2.215; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CUIJPERS CEJ, 1994, J ASTHMA, V31, P301, DOI 10.3109/02770909409089477; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; FERRER A, 1993, AM REV RESPIR DIS, V147, P579, DOI 10.1164/ajrccm/147.3.579; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; Global Initiative for Asthma, 2009, GLOB IN ASTHM GINA R; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hanxiang N, 2008, INT J CLIN PRACT, V62, P599, DOI 10.1111/j.1742-1241.2007.01373.x; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kaminsky DA, 2004, J APPL PHYSIOL, V97, P1849, DOI 10.1152/japplphysiol.00300.2004; King GG, 2005, RESP PHYSIOL NEUROBI, V148, P165, DOI 10.1016/j.resp.2005.05.001; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Kostikas K, 2011, RESP MED, V105, P526, DOI 10.1016/j.rmed.2010.10.015; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Leuppi JD, 2001, EUR RESPIR J, V18, P444, DOI 10.1183/09031936.01.00058601; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Oppenheimer BW, 2007, CHEST, V132, P1275, DOI 10.1378/chest.07-0913; Oppenheimer BW, 2009, COPD, V6, P162, DOI 10.1080/15412550902918410; Papaioannou AI, 2009, EUR RESPIR J, V34, P1006, DOI 10.1183/09031936.00065209; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; Porsbjerg C, 2008, CLIN EXP ALLERGY, V38, P43, DOI 10.1111/j.1365-2222.2007.02878.x; Puckett JL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-47; Reddel Helen K, 2008, Prim Care Respir J, V17, P39, DOI 10.3132/pcrj.2008.00014; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Robinson PD, 2011, RESP PHYSIOL NEUROBI, V177, P199, DOI 10.1016/j.resp.2011.02.004; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; Segal LN, 2011, COPD, V8, P145, DOI 10.3109/15412555.2011.560127; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Tonelli M, 2006, RESP MED, V100, P622, DOI 10.1016/j.rmed.2005.08.010; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 1998, AM J RESP CRIT CARE, V157, P1573, DOI 10.1164/ajrccm.157.5.9710042; Verbanck S, 1997, J APPL PHYSIOL, V83, P1907, DOI 10.1152/jappl.1997.83.6.1907; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Verbanck S, 2010, J ALLERGY CLIN IMMUN, V125, P611, DOI 10.1016/j.jaci.2009.10.053; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; WANNER A, 1974, J CLIN INVEST, V54, P1200, DOI 10.1172/JCI107863	54	68	69	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					61	68		10.1016/j.jaci.2012.02.015	http://dx.doi.org/10.1016/j.jaci.2012.02.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22460065				2022-12-18	WOS:000306644800008
J	Tabar, AI; Arroabarren, E; Echechipia, S; Garcia, BE; Martin, S; Alvarez-Puebla, MJ				Tabar, Ana I.; Arroabarren, Esozia; Echechipia, Susana; Garcia, Blanca E.; Martin, Santiago; Alvarez-Puebla, Maria J.			Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Specific immunotherapy; duration; quality of life; asthma; rhinitis; house dust mite; clinical efficacy; compliance; children; immunotherapy relapses	DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; TERM CLINICAL-EFFICACY; QUALITY-OF-LIFE; FOLLOW-UP; POLLEN IMMUNOTHERAPY; BRONCHIAL-ASTHMA; DOUBLE-BLIND; CHILDREN; RHINITIS; RHINOCONJUNCTIVITIS	Background: Specific immunotherapy (SIT) duration for respiratory allergy is currently based on individual decisions. Objective: To evaluate the differences in clinical efficacy of SIT as a result of the duration between the current recommended limits (3-5 years). Methods: A 5-year prospective, controlled clinical trial of SIT blind until the first year and randomization to a 3-year (IT3) or 5-year (IT5) course was conducted. Of the 239 patients with respiratory allergy caused by D pteronyssinus initially included, 142 completed 3 years of SIT with good compliance. Twenty-seven controls were included at the third year. Efficacy of SIT after 3 (T3) and 5 (T5) years was assessed by using clinical scores, visual analog scales (VASs), rhinitis (RQLQ) and asthma (AQLQ) quality of life questionnaires, skin tests, and serum immunoglobulins. Results: At T3, significant reductions were observed in rhinitis (44% in IT3 and 50% in IT5; P < .001), asthma (80.9% in IT3 and 70.9% in IT5; P < .001) scores, VAS (P < .001 in both), RQLQ (P <. 001 in both) and AQLQ (P <. 001 in both). At T5, the clinical benefit was maintained in both groups, and IT5 patients presented additional decreases (19%; P = .019) in rhinitis scores. At Tf, specific IgG(4) measurements were lower in IT3 (P = 5.03) without detecting differences in IT5. An increase in asthma score of 133% was the only difference observed in controls. Conclusion: Clinical improvement is obtained with 3 years of D pteronyssinus SIT. Two additional years of SIT add clinical benefit in rhinitis only. (J Allergy Clin Immunol 2011;127:57-63.)	[Tabar, Ana I.] Hosp Virgen Camino, CS Conde Oliveto, Dept Allergy, Pamplona 31002, Spain; [Arroabarren, Esozia] Hosp Univ Donostia, Dept Pediat, San Sebastian, Spain; [Martin, Santiago] ALK Abello, Dept Clin Res, Madrid, Spain	Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; ALK-Abello AS	Tabar, AI (corresponding author), Hosp Virgen Camino, CS Conde Oliveto, Dept Allergy, Plaza Paz S-N, Pamplona 31002, Spain.	ana.tabar.purroy@cfnavarra.es	Arroabarren, Esozia/AAR-8187-2021	Arroabarren, Esozia/0000-0001-7191-3390	Regional Government of Navarra	Regional Government of Navarra	Supported by a research grant from the Regional Government of Navarra.	AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Ali I, 2008, ADV THER, V25, P29, DOI 10.1007/s12325-008-0004-3; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Bruggenjurgen B, 2008, ANN ALLERG ASTHMA IM, V101, P316, DOI 10.1016/S1081-1206(10)60498-X; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Chanez P, 1996, ALLERGY, V51, P850; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Cox L, 2007, ANN ALLERG ASTHMA IM, V98, P416, DOI 10.1016/S1081-1206(10)60755-7; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; Malling HJ, 1998, ALLERGY, V53, P461; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mullol J, 2008, J INVEST ALLERG CLIN, V18, P327; National Institutes of Health 1995 epidemiology, 1995, NIH PUBL, P3659; Noon L, 1911, LANCET; Olaguibel JM, 1999, J INVEST ALLERG CLIN, V9, P110; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Pajno GB, 2005, J ALLERGY CLIN IMMUN, V116, P1380, DOI 10.1016/j.jaci.2005.07.034; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pocock SJ, 1983, CLIN TRIALS PRACTICA; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 2008, PEDIAT ALLERG IMM-UK, V19, P67, DOI 10.1111/j.1399-3038.2007.00589.x; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	40	68	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					57	U526		10.1016/j.jaci.2010.10.025	http://dx.doi.org/10.1016/j.jaci.2010.10.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211641				2022-12-18	WOS:000285917300009
J	Yang, AC; Arruda, LK; Santos, ABR; Barbosa, MCR; Chapman, MD; Galvao, CES; Kalil, J; Morato-Castro, FF				Yang, Ariana C.; Arruda, L. Karla; Santos, Ana Beatriz R.; Barbosa, Michelle C. R.; Chapman, Martin D.; Galvao, Clovis E. S.; Kalil, Jorge; Morato-Castro, Fabio F.			Measurement of IgE antibodies to shrimp tropomyosin is superior to skin prick testing with commercial extract and measurement of IgE to shrimp for predicting clinically relevant allergic reactions after shrimp ingestion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; shrimp; tropomyosin; food challenge; skin prick test; specific IgE	COMPONENT-RESOLVED DIAGNOSIS; ORAL FOOD CHALLENGES; RECOMBINANT ALLERGENS; CROSS-REACTIVITY; PENAEUS-MONODON; SEAFOOD ALLERGY; MAJOR ALLERGEN; APPLE ALLERGY; MITE; CHILDREN	Background: Shrimp is a frequent cause of food allergy. Tropomyosin is the major allergen in shrimp, and it shares homology to tropomyosins from other crustaceans, dust mites, cockroach, and parasites. Objective: The aim of this study was to determine the value of detection of IgE to shrimp tropomyosin in the diagnosis of shrimp allergy. Methods: We have studied 35 patients with asthma, rhinitis, or both who were sensitized to Dermatophagoides pteronyssinus. All subjects underwent skin prick testing in addition to double-blind, placebo-controlled food challenges (DBPCFC); oral open challenges; or both with shrimp. Measurements of IgE to shrimp and shrimp tropomyosin were carried out by means of CAP and chimeric ELISA, respectively. Results: Oral challenges confirmed the diagnosis of shrimp allergy in 7 patients. IgE measurement to shrimp tropomyosin was positive in 71.4% of the patients with shrimp allergy. Of the 28 patients without shrimp allergy, only 7.1% (2/28) had IgE to shrimp tropomyosin compared with 25% (7/28) who had IgE to shrimp and 35.7% (10/28) who had positive skin prick test responses to shrimp. Sensitivity was similar for all 3 methods (71.4%); in contrast, specificity of IgE to shrimp tropomyosin (92.8%) was greater than that of IgE to shrimp (75%) and skin prick testing (64.2%). With regard to diagnostic efficiency, measurement of IgE to shrimp tropomyosin was superior to measurement of IgE to shrimp and skin prick testing (88.5%, 74.2%, and 65.7%, respectively). Conclusion: Use of measurements of IgE to shrimp tropomyosin provided added value to the diagnosis of shrimp allergy. (J Allergy Clin Immunol 2010;125:872-8.)	[Arruda, L. Karla] Univ Sao Paulo, Dept Med, Sch Med Ribeirao Preto, Div Clin Immunol, BR-14110000 Ribeirao Preto, SP, Brazil; [Yang, Ariana C.; Galvao, Clovis E. S.; Kalil, Jorge; Morato-Castro, Fabio F.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil; [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA	Universidade de Sao Paulo; Universidade de Sao Paulo; INDOOR Biotechnologies	Arruda, LK (corresponding author), Univ Sao Paulo, Dept Med, Sch Med Ribeirao Preto, Div Clin Immunol, Av Bandeirantes 3900, BR-14110000 Ribeirao Preto, SP, Brazil.	karla@fmrp.usp.br	Arruda, L. Karla/D-5845-2013; KALIL, JORGE/C-8029-2012	Arruda, L. Karla/0000-0002-7505-210X; KALIL, JORGE/0000-0001-8415-4274; Chapman, Martin/0000-0002-0845-3632	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Institute of Investigative Immunology; National Institute of Science and Technology; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Institute of Investigative Immunology; National Institute of Science and Technology; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Supported by grants front Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and by the Institute of Investigative Immunology, iii, a National Institute of Science and Technology, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.; Disclosure of potential conflict of interest: L. K. Arruda has received research support from FAPESP and CNPq, and received honoraria from Novartis and Mantecorp. A. B. R. Santos and M. C. R. Barbosa have received research support from FAPESP. M. D. Chapman is a co-owner of Indoor Biotechnologies, Inc, and has received support front the National Institute of Environmental Health Sciences. J. Kalil is a member of the Council for EMS. F. F. Morato-Castro has received research support front Novartis, AstraZeneca, MSD, Sanofi-Aventis, Boeringher, and Ache and has consulted for Sanofi-Aventis. Schering-Plough, and Phadia Brazil. The rest of the authors have declared that they have no conflict of interest.	Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Anibarro B, 2007, J INVEST ALLERG CLIN, V17, P168; Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Audicana MT, 2008, CLIN MICROBIOL REV, V21, P360, DOI 10.1128/CMR.00012-07; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bohle B, 2004, METHODS, V32, P292, DOI 10.1016/j.ymeth.2003.08.008; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; CHEGINI S, 2003, FOOD ALLERGY ADVERSE, P487; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; Jirapongsananuruk O, 2008, CLIN EXP ALLERGY, V38, P1038, DOI 10.1111/j.1365-2222.2008.02979.x; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Lopata AL, 2009, CURR OPIN ALLERGY CL, V9, P270, DOI 10.1097/ACI.0b013e32832b3e6f; Ma Y, 2006, CLIN EXP ALLERGY, V36, P1087, DOI 10.1111/j.1365-2222.2006.02541.x; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; Niggemann B, 2007, J PEDIATR GASTR NUTR, V45, P399, DOI 10.1097/MPG.0b013e318054b0c3; Niggemenn B, 2007, ALLERGY, V62, P729, DOI 10.1111/j.1398-9995.2007.01396.x; Ott H, 2008, ALLERGY, V63, P1521, DOI 10.1111/j.1398-9995.2008.01748.x; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Purohit A, 2007, Eur Ann Allergy Clin Immunol, V39, P85; Reese G, 2006, CLIN EXP ALLERGY, V36, P517, DOI 10.1111/j.1365-2222.2006.02454.x; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Shiomi K, 2008, INT ARCH ALLERGY IMM, V146, P91, DOI 10.1159/000113512; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x; vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Wild LG, 2005, CURR ALLERGY ASTHM R, V5, P74, DOI 10.1007/s11882-005-0059-z; Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445	43	68	73	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					872	878		10.1016/j.jaci.2009.11.043	http://dx.doi.org/10.1016/j.jaci.2009.11.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20226506				2022-12-18	WOS:000276787900013
J	Bruzzese, JM; Evans, D; Kattan, M				Bruzzese, Jean-Marie; Evans, David; Kattan, Meyer			School-based asthma programs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inner-city asthma; school-based programs; asthma education	NEW-YORK-CITY; RANDOMIZED CONTROLLED-TRIAL; MANAGEMENT PROGRAM; HEALTH CENTERS; CHILDHOOD ASTHMA; UNDIAGNOSED ASTHMA; EDUCATION-PROGRAM; PUBLIC-SCHOOLS; OPEN AIRWAYS; ACTION PLANS	Asthma is prevalent in school-age children and contributes to school absenteeism and limitation of activity. There is a sizable literature on school-based interventions for asthma that attempt to identify children with asthma and improve outcomes. The purpose of this review is to describe and discuss limitations of screening tools and school-based asthma interventions. Identification of children with asthma may be appropriate in schools located in districts with a high prevalence of children experiencing significant morbidity and a high prevalence of undiagnosed asthma, provided there is access to high-quality asthma care. We review strategies for improving access to care, for teaching self-management skills in schools, and for improving school personnel management skills. Although studies indicate that school-based programs have the potential to improve outcomes, competing priorities in the educational system present challenges to their implementation and emphasize the need for practical, targeted, and cost-effective strategies. (J Allergy Clin Immunol 2009;124:195-200.)	[Kattan, Meyer] Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Bruzzese, Jean-Marie] NYU, Sch Med, New York Univ Child Study Ctr, New York, NY 10003 USA	Columbia University; New York University	Kattan, M (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pediat, 3959 Broad Way,CHC 7-701, New York, NY 10032 USA.	mk2833@columbia.edu	Bruzzese, Jean-Marie/AAN-1061-2021	Bruzzese, Jean-Marie/0000-0002-1866-488X	National Institutes of Health; National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; Merck Childhood Asthma Network	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Merck Childhood Asthma Network	Disclosure of potential conflict of interest: M. Kattan has received research support from the National Institutes of Health. D. Evans has received research support from the National Institute of Environmental Health Sciences, the National Heart, Lung, and Blood Institute, and the Merck Childhood Asthma Network. J.-M. Bruzzese has declared that she has no conflict of interest.	Akinbami, 2006, STATE CHILDHOOD ASTH, V381; BALAJI AB, 2006, SCH HLTH PROFILES CH; Barbot O, 2006, J SCHOOL HEALTH, V76, P329, DOI 10.1111/j.1746-1561.2006.00122.x; Bartholomew LK, 2006, J SCHOOL HEALTH, V76, P283; Bonner S, 2006, J SCHOOL HEALTH, V76, P471, DOI 10.1111/j.1746-1561.2006.00144.x; Boss LP, 2003, J ASTHMA, V40, P335, DOI 10.1081/JAS-120018627; Brener ND, 2007, J SCHOOL HEALTH, V77, P464, DOI 10.1111/j.1746-1561.2007.00230.x; Bruzzese JM, 2008, FAM PROCESS, V47, P95, DOI 10.1111/j.1545-5300.2008.00241.x; Bruzzese JM, 2006, J SCHOOL HEALTH, V76, P307, DOI 10.1111/j.1746-1561.2006.00118.x; Bruzzese JM, 2004, PATIENT EDUC COUNS, V55, P396, DOI 10.1016/j.pec.2003.04.009; Bruzzese JM, 2001, J ASTHMA, V38, P337, DOI 10.1081/JAS-100000261; Calabrese BJ, 1999, J SCHOOL HEALTH, V69, P233, DOI 10.1111/j.1746-1561.1999.tb06395.x; Clark NM, 2004, CHEST, V125, P1674, DOI 10.1378/chest.125.5.1674; Clark NM, 2002, J CLIN EPIDEMIOL, V55, P870, DOI 10.1016/S0895-4356(02)00451-1; Clark NM, 2009, PEDIATRICS, V123, pS185, DOI 10.1542/peds.2008-2233I; Evans D, 2001, HEALTH EDUC BEHAV, V28, P500, DOI 10.1177/109019810102800409; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FOWLER MG, 1992, PEDIATRICS, V90, P939; Frankowski BL, 2006, J SCHOOL HEALTH, V76, P303, DOI 10.1111/j.1746-1561.2006.00117.x; Galant SP, 2004, PEDIATRICS, V114, pE307, DOI 10.1542/peds.2003-0575-F; Gerald LB, 2004, PEDIATRICS, V114, pE459, DOI 10.1542/peds.2004-0455; Gerald Lynn B, 2007, Proc Am Thorac Soc, V4, P133, DOI 10.1513/pats.200604-103ST; Gerald LB, 2006, J SCHOOL HEALTH, V76, P291, DOI 10.1111/j.1746-1561.2006.00114.x; Gerald LB, 2009, PEDIATRICS, V123, P466, DOI 10.1542/peds.2008-0499; Goei R, 2006, J SCHOOL HEALTH, V76, P259, DOI 10.1111/j.1746-1561.2006.00108.x; Greiling AK, 2005, J SCHOOL HEALTH, V75, P286, DOI 10.1111/j.1746-1561.2005.00039.x; Guo JJ, 2005, J ADOLESCENT HEALTH, V37, P266, DOI 10.1016/j.jadohealth.2004.09.006; HALFON N, 1993, PEDIATRICS, V91, P56; Halterman JS, 2004, ARCH PEDIAT ADOL MED, V158, P460, DOI 10.1001/archpedi.158.5.460; Joseph CLM, 2007, AM J RESP CRIT CARE, V175, P888, DOI 10.1164/rccm.200608-1244OC; Joseph CLM, 2005, J PEDIATR-US, V146, P96, DOI 10.1016/j.jpeds.2004.09.001; Kann L, 2007, J SCHOOL HEALTH, V77, P385, DOI 10.1111/j.1746-1561.2007.00226.x; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Keysser J, 2006, J SCHOOL HEALTH, V76, P264, DOI 10.1111/j.1746-1561.2006.00109.x; Levy M, 2006, J SCHOOL HEALTH, V76, P320, DOI 10.1111/j.1746-1561.2006.00120.x; Lewis TC, 2004, J URBAN HEALTH, V81, P472, DOI 10.1093/jurban/jth131; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; Lwebuga-Mukasa J, 2002, J SCHOOL HEALTH, V72, P27, DOI 10.1111/j.1746-1561.2002.tb06508.x; McEwen M, 1998, J SCHOOL HEALTH, V68, P196, DOI 10.1111/j.1746-1561.1998.tb01300.x; McLaughlin T, 2006, J SCHOOL HEALTH, V76, P325, DOI 10.1111/j.1746-1561.2006.00121.x; Millard MW, 2003, J ASTHMA, V40, P769, DOI 10.1081/JAS-120023504; *N H L B I EXP PAN, 2007, 3 N H L B I EXP PAN; Neuharth-Pritchett S, 2001, J Sch Nurs, V17, P323; Oruwariye T, 2003, J SCHOOL HEALTH, V73, P186, DOI 10.1111/j.1746-1561.2003.tb03601.x; Patel B, 2007, J ASTHMA, V44, P113, DOI 10.1080/02770900601182343; Purmort J, 2008, J HEALTH CARE POOR U, V19, P1241, DOI 10.1353/hpu.0.0082; Quinn K, 2006, AM J PUBLIC HEALTH, V96, P1599, DOI 10.2105/AJPH.2005.071514; Redline S, 2004, ANN ALLERG ASTHMA IM, V93, P36, DOI 10.1016/S1081-1206(10)61445-7; Richmond CM, 2006, J SCHOOL HEALTH, V76, P333, DOI 10.1111/j.1746-1561.2006.00123.x; Rodehorst T Kim, 2003, Pediatr Nurs, V29, P184; Sapien RE, 2000, J ASTHMA, V37, P719, DOI 10.3109/02770900009087311; Shah S, 2001, BRIT MED J, V322, P583, DOI 10.1136/bmj.322.7286.583; Shah S, 2008, AUST FAM PHYSICIAN, V37, P952; Shohat T, 2005, J ADOLESCENT HEALTH, V37, P275, DOI 10.1016/j.jadohealth.2004.12.013; Snow RE, 2005, J ASTHMA, V42, P51, DOI 10.1081/JAS-200044776; Spencer GA, 2000, FAM COMMUNITY HEALTH, V23, P20, DOI 10.1097/00003727-200007000-00005; Splett PL, 2006, J SCHOOL HEALTH, V76, P276, DOI 10.1111/j.1746-1561.2006.00112.x; Taras HL, 2001, PEDIATRICS, V108, P1231; Webber MP, 2005, PEDIATR PULM, V40, P487, DOI 10.1002/ppul.20307; Webber MP, 2003, ARCH PEDIAT ADOL MED, V157, P125, DOI 10.1001/archpedi.157.2.125; Yawn BP, 2006, CURR OPIN PULM MED, V12, P23, DOI 10.1097/01.mcp.0000198063.19963.24; Yawn BP, 2000, J SCHOOL HEALTH, V70, P153, DOI 10.1111/j.1746-1561.2000.tb06462.x; Yawn BP, 2003, ANN ALLERG ASTHMA IM, V90, P508, DOI 10.1016/S1081-1206(10)61844-3; Yeatts K, 2003, PEDIATRICS, V111, P1046, DOI 10.1542/peds.111.5.1046	64	68	71	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					195	200		10.1016/j.jaci.2009.05.040	http://dx.doi.org/10.1016/j.jaci.2009.05.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	482CD	19615728				2022-12-18	WOS:000268860400003
J	Simons, FER; Sampson, HA				Simons, F. Estelle R.; Sampson, Hugh A.			Anaphylaxis epidemic: Fact or fiction?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Anaphylaxis	EMERGENCY-DEPARTMENT VISITS; POSTMORTEM FINDINGS; ALLERGIC REACTIONS; FOOD; POPULATION; HOSPITALIZATIONS; MULTICENTER; MANAGEMENT		[Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol,Dept Pediat & Child Hlth, CIHR Natl Training Program Allergy & Asthma, Winnipeg, MB R3T 2N2, Canada; [Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, New York, NY USA	University of Manitoba; Icahn School of Medicine at Mount Sinai	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Buckley MG, 2006, J ALLERGY CLIN IMMUN, V117, pS69, DOI 10.1016/j.jaci.2005.12.278; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Nishio H, 2005, INT J LEGAL MED, V119, P331, DOI 10.1007/s00414-005-0524-1; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	29	68	77	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1166	1168		10.1016/j.jaci.2008.10.019	http://dx.doi.org/10.1016/j.jaci.2008.10.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	19084110				2022-12-18	WOS:000261711800015
J	Lee, JH; Kim, JW; Ko, NY; Mun, SH; Her, E; Kim, BK; Han, JW; Lee, HY; Beaven, MA; Kim, YM; Choi, WS				Lee, Jun Ho; Kim, Jie Wan; Ko, Na Young; Mun, Se Hwan; Her, Erk; Kim, Bo Kyung; Han, Jeung Whan; Lee, Hoi Young; Beaven, Michael A.; Kim, Young Mi; Choi, Wahn Soo			Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						curry spice; curcumin; allergy; passive cutaneous anaphylaxis; inast cells; IgE; Syk kinase	KINASE INHIBITOR; RECEPTOR; IMMUNOLOGY; SYMPTOMS; DISEASES; IL-4; R112	Background Activation of mast cells through the high-affinity receptor for IgE (Fc epsilon RI) underlies atopic allergic reactions. Curcumin can block this activation, but the mechanism and the effects of curcumin on IgE-mediated allergic reactions are unknown. Objectives: We sought to determine the antiallergic activity of curcumin in vivo and its mechanism of action in mast cells. Methods: The antiallergic activity of curcumin was evaluated in mast cell cultures and the passive cutaneous anaphylaxis model. The effects of curcumin on mast cell signaling events were examined by using immunoblotting, immunoprecipitation, RT-PCR, and other molecular biologic approaches. Results: Curcumin inhibited antigen-mediated activation of mast cells and passive cutaneous anaphylaxis in mice. Suppression of degranulation and secretion of TNF-alpha and IL-4 was apparent at concentrations as low as 3 mu mol/L curcumin in activated mast cells. Similar concentrations of curcumin suppressed Syk-dependent phosphorylations of the adaptor proteins linker of activated T cells and Grb2-associated binder 2, which are critical for mast cell activation. Although curcumin did not inhibit the phosphorylation of Syk itself, it directly inhibited Syk kinase activity in vitro. Further downstream, activating phosphorylations of Akt and the mitogen-activated protein kinases p38, p44/42 (extracellular signal-regulated kinase 1/2), and c-Jun N-terminal kinase, which are critical for the production of inflammatory cytokines, were also inhibited. Conclusions: Curcumin inhibits Syk kinase-dependent signaling events in mast cells and might thus contribute to its antiallergic activity. Therefore curcumin might be useful for the treatment of mast cell-related immediate and delayed allergic diseases.	[Lee, Jun Ho; Kim, Jie Wan; Ko, Na Young; Mun, Se Hwan; Her, Erk; Kim, Bo Kyung; Choi, Wahn Soo] Konkuk Univ, Coll Med, Dept Immunol & Physiol, Chungju, South Korea; [Han, Jeung Whan] Sungkyunkwan Univ, Suwon, South Korea; [Lee, Hoi Young] Konyang Univ, Coll Med, Nonsan, South Korea; [Beaven, Michael A.] Lung & Blood Inst, Immunol Lab, Natl Inst Hlth, Bethesda, MD USA; [Kim, Young Mi] Duksung Womens Univ, Coll Pharm, Seoul, South Korea	Konkuk University; Konkuk University Medical Center; Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; National Institutes of Health (NIH) - USA; Duksung Women's University	Choi, WS (corresponding author), Konkuk Univ, Coll Med, Dept Immunol, Chungju 380701, South Korea.	wahnchoi@kku.ac.kr			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000990, ZIAHL000990] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade MVM, 2004, J IMMUNOL, V172, P7254, DOI 10.4049/jimmunol.172.12.7254; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Frossi B, 2007, J IMMUNOL, V178, P2549, DOI 10.4049/jimmunol.178.4.2549; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gregory Gregory D, 2006, Methods Mol Biol, V315, P35; Guyer BJ, 2006, ALLERGY ASTHMA PROC, V27, P208, DOI 10.2500/aap.2006.27.2861; Hsu CH, 2007, ADV EXP MED BIOL, V595, P471; Jurrmann N, 2005, J NUTR, V135, P1859, DOI 10.1093/jn/135.8.1859; Kabu K, 2006, J IMMUNOL, V177, P1296, DOI 10.4049/jimmunol.177.2.1296; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kurup Viswanath P, 2007, Clin Mol Allergy, V5, P1, DOI 10.1186/1476-7961-5-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law CL, 1996, MOL CELL BIOL, V16, P1305; Liddle M, 2006, DERMATITIS, V17, P196, DOI 10.2310/6620.2006.06004; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; Luskova P, 2004, CURR PHARM DESIGN, V10, P1727, DOI 10.2174/1381612043384538; Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007; MASUDA ES, 2007, PULM PHARM THER; Matsubara S, 2006, AM J RESP CRIT CARE, V173, P56, DOI 10.1164/rccm.200503-361OC; Matsuda H, 2004, BIOORGAN MED CHEM, V12, P5891, DOI 10.1016/j.bmc.2004.08.027; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Moos PJ, 2004, CARCINOGENESIS, V25, P1611, DOI 10.1093/carcin/bgh163; Nadler M J, 2000, Adv Immunol, V76, P325; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Ram A, 2003, BIOL PHARM BULL, V26, P1021, DOI 10.1248/bpb.26.1021; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Sandur SK, 2007, FREE RADICAL BIO MED, V43, P568, DOI 10.1016/j.freeradbiomed.2007.05.009; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Suzuki M, 2005, BIOL PHARM BULL, V28, P1438, DOI 10.1248/bpb.28.1438; Theoharides TC, 2006, ANN NY ACAD SCI, V1088, P78, DOI 10.1196/annals.1366.025; Thompson DA, 2006, CONTACT DERMATITIS, V55, P254, DOI 10.1111/j.1600-0536.2006.00857.x; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316; Zhang C, 1996, CHINESE CHEM LETT, V7, P1	44	68	69	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1225	1231		10.1016/j.jaci.2007.12.1160	http://dx.doi.org/10.1016/j.jaci.2007.12.1160			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18394691	Bronze			2022-12-18	WOS:000255961700023
J	Li, XM				Li, Xiu-Min			Traditional Chinese herbal remedies for asthma and food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; TCM; food allergy-induced anaphylaxis; herbal remedies; CAM; clinical trials; animal study	PEANUT-INDUCED ANAPHYLAXIS; MURINE MODEL; ALTERNATIVE MEDICINE; AIRWAY INFLAMMATION; FORMULA; COMPLEMENTARY; THERAPIES; EFFICACY; HYPERREACTIVITY; RESPONSES	The increasing prevalence of allergic diseases in Westernized countries is a significant health problem. Curative therapies for these diseases are not available. There are also significant concerns regarding the potential side effects from the chronic use of conventional drugs such as corticosteroids, especially in children. Many patients with chronic allergic conditions seek complementary and alternative medicine therapies including traditional Chinese medicines. This trend has begun to attract interest from mainstream health care providers and scientific investigators and has stimulated government agencies in the United States to provide support and guidance for the scientific investigation of complementary and alternative medicine. This effort may lead to improved therapies and better health care/patient outcomes. This review presents an update on the most promising Chinese herbal remedies for asthma and food allergy.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl,Pediat Box 1198, New York, NY 10029 USA.	xiu-min.li@mssm.edu	li, xiu/GXV-1745-2022		NCCIH NIH HHS [R01 AT001495, P01 AT002647-030001, 1 P01 AT002644725-01, R01 AT00114, R01 AT001495-03, P01 AT002647] Funding Source: Medline; NCRR NIH HHS [RR00071, M01 RR000071] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002647, R01AT000114, R01AT001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bensky D, 1990, CHINESE HERBAL MED F; Bensky D, 2004, CHINESE HERBAL MED M, V3rd; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Bielory L, 2004, ALLERGY ASTHMA PROC, V25, P283; Bolleddula J, 2007, J ALLERGY CLIN IMMUN, V119, pS172, DOI 10.1016/j.jaci.2006.12.035; Busse P. J., 2004, Journal of Allergy and Clinical Immunology, V113, pS220, DOI 10.1016/j.jaci.2004.01.243; Chan CK, 2006, PEDIAT ALLERG IMM-UK, V17, P316, DOI 10.1111/j.1399-3038.2006.00406.x; Chang TT, 2006, IMMUNOPHARM IMMUNOT, V28, P683, DOI 10.1080/08923970601067409; Chang TT, 2006, PHYTOTHER RES, V20, P342, DOI 10.1002/ptr.1843; Cohen MH, 2005, ALTERN THER HEALTH M, V11, P36; Engler RJM, 2000, J ALLERGY CLIN IMMUN, V106, P627, DOI 10.1067/mai.2000.110504; Fang SP, 2005, BIOL PHARM BULL, V28, P829, DOI 10.1248/bpb.28.829; Hassed Craig, 2005, Aust Fam Physician, V34, P573; Hoang BX, 2007, PHYTOTHER RES, V21, P554, DOI 10.1002/ptr.2107; Hope B E, 1993, Hawaii Med J, V52, P160; Hsu CH, 2005, PEDIATR ALLERGY IMMU, V16, P76, DOI 10.1111/j.1399-3038.2005.00230.x; Kattan JD, 2006, J ALLERGY CLIN IMMUN, V117, pS34, DOI 10.1016/j.jaci.2005.12.138; Kim JY, 2006, MOL CELLS, V22, P104; Ko J, 2005, J ALLERGY CLIN IMMUN, V115, pS34; Ko J, 2006, ANN ALLERG ASTHMA IM, V97, P365, DOI 10.1016/S1081-1206(10)60802-2; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2005, CURR OPIN ALLERGY CL, V5, P287, DOI 10.1097/01.all.0000168796.20324.bd; Li XM, 2004, ANN ALLERG ASTHMA IM, V93, pS35, DOI 10.1016/S1081-1206(10)61485-8; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Massey D G, 1994, Hawaii Med J, V53, P350; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; SNYDERMAN R, 2005, INTEGRATIVE MED FDN; Srivastava KD, 2006, J ALLERGY CLIN IMMUN, V117, pS328, DOI 10.1016/j.jaci.2005.12.1292; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; The State Pharmacopoeia Commission of P.R. China, 2005, PHARM PEOPL REP CHIN; *US FDA CTR DRUG E, 2000, GUID IND BOT DRUG PR; Wang YM, 1998, UTILIZATION CLASSICA; Wen M., 2003, Journal of Allergy and Clinical Immunology, V111, pS320, DOI 10.1016/S0091-6749(03)81164-8; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; WEN MC, 2004, J ALLERGY CLIN IMMUN, V113, P218	38	68	70	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					25	31		10.1016/j.jaci.2007.04.030	http://dx.doi.org/10.1016/j.jaci.2007.04.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17560638	Green Accepted			2022-12-18	WOS:000248066400003
J	Tunon-de-Lara, JM; Laurent, F; Giraud, V; Perez, T; Aguilaniu, B; Meziane, H; Basset-Merle, A; Chanez, P				Tunon-de-Lara, Jose-Manuel; Laurent, Francois; Giraud, Violaine; Perez, Thierry; Aguilaniu, Bernard; Meziane, Houari; Basset-Merle, Armelle; Chanez, Pascal			Air trapping in mild and moderate asthma: Effect of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung attenuation; small airways; hyperresponsiveness; inflammation; asthma	THIN-SECTION CT; SPIROMETRICALLY CONTROLLED CT; POORLY CONTROLLED ASTHMA; SMALL AIRWAYS; COMPUTED-TOMOGRAPHY; EXERCISE CHALLENGE; EXPIRATORY CT; LUNGS; OBSTRUCTION; INFLAMMATION	Background: Air trapping reflects small airway obstruction in asthma and can be assessed quantitatively by high-resolution computed tomography (HRCT). Hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) is deposited across all sizes of airways, including the small ones. However, its long-term effect on air trapping remains unknown in uncontrolled asthma. Objectives: To compare the effect of inhaled corticosteroids of different particle size-HFA-BDP and fluticasone propionate (FP)-on lung attenuation in mild-to-moderate uncontrolled asthma. Methods: A randomized study was performed to analyze the effect of HFA-BDP (400 mu g/d) or FP (500 mu g/d) given over a period of 3 months to patients with uncontrolled mild-tomoderate asthma. HRCT was performed with spirometric gating, and lung attenuation was measured at residual volume and at pulmonary total capacity. The difference between inspiratory and expiratory attenuation was calculated as an air trapping index. Results: Twenty-five out of 58 patients had abnormal air trapping and could be included in the study. Lung attenuation significantly diminished in the posterior zones of the lung after a 3-month treatment with UFA-BDP or FP, but the difference between the groups was not significant. Adjusted mean variations of the air trapping index from baseline to treatment completion were 34.3 (11.2, 57.3) and 27.3 (6.4, 48.2) for the HFA-BDP and FP groups, respectively. However, the reduction of air trapping area was more pronounced in the group treated with HFA-BDP. Conclusion: Inhaled corticosteroids decrease air trapping in uncontrolled asthma regardless of their particle size.	Univ Bordeaux 2, F-33076 Bordeaux, France; INSERM, U885, F-33076 Bordeaux, France; CHU Bordeaux, F-33076 Bordeaux, France; Serv Malad Resp, Bordeaux, France; Lab Ivax, Neuilly Sur Seine, France; Hop Calmette, Serv Explorat Fonctionnelles Resp, Lille, France; Clin Mail, Lab Physiol Clin, Grenoble, France; CHU Montpellier, Clin Malad Resp, Montpellier, France; INSERM, U454, F-75654 Paris 13, France; Synarc, Sevres, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux; Universite de Lille - ISITE; CHU Lille; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Synarc	Tunon-de-Lara, JM (corresponding author), CHU Bordeaux, Hop Haut Leveque, Serv Malad Resp, F-33604 Pessac, France.	manuel.tunondelara@u-bordeaux2.fr	Thierry, PEREZ/AAB-4853-2020	chanez, pascal/0000-0003-4059-0917				Austin JHM, 1996, RADIOLOGY, V200, P327, DOI 10.1148/radiology.200.2.8685321; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102; Berger P, 2003, RADIOLOGY, V228, P85, DOI 10.1148/radiol.2281020187; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; de Jong PA, 2006, AM J RESP CRIT CARE, V173, P199, DOI 10.1164/rccm.200505-810OC; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; Grenier P, 1996, EUR RADIOL, V6, P199; Guckel C, 1999, J APPL PHYSIOL, V86, P701, DOI 10.1152/jappl.1999.86.2.701; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hansell DM, 1997, RADIOLOGY, V203, P721, DOI 10.1148/radiology.203.3.9169694; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; KALENDER WA, 1990, RADIOLOGY, V175, P265, DOI 10.1148/radiology.175.1.2315492; KOHZ P, 1995, RADIOLOGY, V197, P539, DOI 10.1148/radiology.197.2.7480708; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Lamers RJS, 1998, EUR RESPIR J, V11, P942, DOI 10.1183/09031936.98.11040942; Laurent F, 2000, EUR RADIOL, V10, P1404, DOI 10.1007/s003300000504; Lee KW, 2000, RADIOLOGY, V214, P831, DOI 10.1148/radiology.214.3.r00mr05831; Lemanske RF, 1998, J ALLERGY CLIN IMMUN, V101, pS392, DOI 10.1016/S0091-6749(98)70228-3; LYNCH DA, 1993, RADIOLOGY, V188, P829, DOI 10.1148/radiology.188.3.8351357; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; PAGANIN F, 1995, CHEST, V107, pS145, DOI 10.1378/chest.107.3_Supplement.145S; Park CS, 1997, RADIOLOGY, V203, P361, DOI 10.1148/radiology.203.2.9114089; Pellegrino R, 2001, J APPL PHYSIOL, V91, P2190, DOI 10.1152/jappl.2001.91.5.2190; Popa V, 2001, AM J RESP CRIT CARE, V163, P292, DOI 10.1164/ajrccm.163.1.16310b; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Small JH, 1996, CLIN RADIOL, V51, P684, DOI 10.1016/S0009-9260(96)80238-8; STERN EJ, 1994, AM J ROENTGENOL, V163, P37, DOI 10.2214/ajr.163.1.8010242; Stocks J, 2001, EUR RESPIR J, V17, P302, DOI 10.1183/09031936.01.17203020; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Thongngarm T, 2005, J ASTHMA, V42, P257, DOI 10.1081/JAS-200057888; Verschakelen JA, 1998, EUR RADIOL, V8, P1391, DOI 10.1007/s003300050558; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605	41	68	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					583	590		10.1016/j.jaci.2006.11.005	http://dx.doi.org/10.1016/j.jaci.2006.11.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17204317	Bronze			2022-12-18	WOS:000244925000009
J	Nikasinovic, L; Just, J; Sahraoui, F; Seta, N; Grimfeld, A; Momas, I				Nikasinovic, Lydia; Just, Jocelyne; Sahraoui, Fatiha; Seta, Nathalie; Grimfeld, Alain; Momas, Isabelle			Nasal inflammation and personal exposure to fine particles PM2.5 in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal lavage fluid; inflammation; allergy; asthma; eosinophil; children; personal exposure; fine particle; PM2.5	UPPER-AIRWAY INFLAMMATION; DIESEL EXHAUST PARTICLES; TOBACCO-SMOKE; AMBIENT OZONE; IGE ANTIBODY; IN-VIVO; POLLUTION; INDOOR; CHALLENGE; SENSITIZATION	Background: Outdoor and indoor air pollutants are suspected to induce harmful effects on respiratory health, raising the question of their involvement in allergic asthma and rhinitis. Objective: The potential effect of short-term personal exposure to particulate matter with a diameter of less than 2.5 mu m (PM2.5) on nasal inflammation was examined in children living in the Paris area. Methods: Forty-one children with allergic asthma and 44 healthy children participated in this study. They were monitored during 48 hours for their personal exposure to PM2.5. At the end of the measurement period, children underwent one nasal lavage. Nasal lavage fluid was investigated for cellular (neutrophils and eosinophils) and soluble (albumin, urea, elastase, oil-antitrypsin, IL-6, and IL-8) mediators. Results: Pollutant concentrations did not differ between the 2 groups. In asthmatic subjects, but not in healthy children, personal PM2.5 levels were correlated to nasal percentage of eosinophils and to albumin, urea, and oil-antitrypsin concentrations after adjustment for confounders (age, sex, house dust mites, pollens, cat, environmental tobacco smoke through urinary cotinine, barometric pressure, and respiratory infection). Conclusion: The association observed with the percentage of eosinophils supports recent speculations on fine particle involvement in allergic phenotype overexpression. Clinical implications: This study highlights the link between personal fine particle exposures and nasal inflammation in asthmatic allergic children living in urban areas. Because the view of united airways is still not completely understood, the question of pulmonary inflammation in such a situation deserves further investigation.	Univ Paris 05, Serv Sante Publ Environm, Fac Pharm, F-75270 Paris 06, France; Hop Enfants Armand Trousseau, Assistance Publ Hop, Serv Pneumol & Allergol Pediat, Paris, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Nikasinovic, L (corresponding author), Univ Paris 05, Serv Sante Publ Environm, Fac Pharm, 4,Ave Observ, F-75270 Paris 06, France.	lydia.nikasinovic@univ-paris5.fr	Seta, Nathalie S/F-1824-2018	Seta, Nathalie S/0000-0002-9240-8630; momas, isabelle/0000-0003-4344-3787				*APPA, 1998, POLL ATM SOURC EFF P; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Callais F, 2003, PREV MED, V36, P108, DOI 10.1006/pmed.2002.1132; *CCFA, 1996, AUT MOND 1994 95; CRESTANI B, 1994, J CLIN INVEST, V94, P731, DOI 10.1172/JCI117392; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473, DOI 10.1289/ehp.99107s3473; FRISCHER TM, 1993, AM REV RESPIR DIS, V148, P961, DOI 10.1164/ajrccm/148.4_Pt_1.961; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; Hiltermann TJN, 1997, AM J RESP CRIT CARE, V156, P1765, DOI 10.1164/ajrccm.156.6.9704127; Janssen NAH, 1999, ARCH ENVIRON HEALTH, V54, P95, DOI 10.1080/00039899909602242; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Jurvelin J, 2001, J ENVIRON MONITOR, V3, P159, DOI 10.1039/b007600g; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Kopp MV, 1999, EUR RESPIR J, V14, P854, DOI 10.1034/j.1399-3003.1999.14d22.x; KOREN HS, 1990, TOXICOLOGY, V60, P15, DOI 10.1016/0300-483X(90)90159-E; Miadonna A, 1999, CLIN EXP ALLERGY, V29, P941; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Murphy SA, 1998, LIFE SCI, V62, P1789, DOI 10.1016/S0024-3205(98)00141-6; NACLERIO RM, 1986, CLIN ALLERGY, V16, P101, DOI 10.1111/j.1365-2222.1986.tb00753.x; *NHLBI WHO WORKSH, 2002, GLOB STRAT ASTHM MAN; Nikasinovic L, 2004, J TOXICOL ENV HEAL B, V7, P81, DOI 10.1080/10937400490241952; Nikasinovic L, 2003, J TOXICOL ENV HEAL B, V6, P521, DOI 10.1080/10937400306477; Nikasinovic-Fournier L, 2002, J LAB CLIN MED, V139, P173, DOI 10.1067/mlc.2002.121661; Ormstad H, 1998, TOXICOLOGY, V129, P227, DOI 10.1016/S0300-483X(98)00079-1; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peters A, 1996, AM J EPIDEMIOL, V144, P570, DOI 10.1093/oxfordjournals.aje.a008967; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; PlattsMills TAE, 1996, J ALLERGY CLIN IMMUN, V98, pS297, DOI 10.1016/S0091-6749(96)80115-1; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Roche D, 2001, CLIN CHEM, V47, P950; Rojas-Bracho L, 2000, J EXPO ANAL ENV EPID, V10, P294, DOI 10.1038/sj.jea.7500092; RUDELL B, 1990, J AEROSOL SCI, V21, pS411; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; SAMAT JA, 2000, J AIR WASTE MANAGE, V50, P1184; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167, DOI 10.1080/00039890109604069; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1, DOI 10.1159/000234990; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Vedal S, 2002, CLIN CHEST MED, V23, P763, DOI 10.1016/S0272-5231(02)00028-X; Vinke JG, 1999, EUR RESPIR J, V13, P797, DOI 10.1034/j.1399-3003.1999.13d17.x; Wallace L, 2005, ENVIRON SCI TECHNOL, V39, P1707, DOI 10.1021/es049547u; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98, DOI 10.1080/10473289.1996.10467451; *WHO, 2004, HLTH IMP TRANSP REL; Witschi H, 1997, ANNU REV PHARMACOL, V37, P29, DOI 10.1146/annurev.pharmtox.37.1.29; World Health Organization, AIR QUAL GUID EUR; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	49	68	73	2	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1382	1388		10.1016/j.jaci.2006.03.023	http://dx.doi.org/10.1016/j.jaci.2006.03.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751001				2022-12-18	WOS:000238332300027
J	Liu, AH; Leung, DYM				Liu, Andrew H.; Leung, Donald Y. M.			Renaissance of the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						hygiene; endotoxin; toll-like receptor; asthma; allergy; atopic dermatitis; allergic rhinitis; atopy; microbes; injection	TOLL-LIKE RECEPTOR-2; ENDOTOXIN EXPOSURE; MICROBIAL EXPOSURE; DENDRITIC CELLS; HAY-FEVER; ASTHMA; HOUSE; DUST; EXPRESSION; RESPONSES		Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pediat, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St K1023, Denver, CO 80206 USA.	liua@njc.org						Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chang YS, 2005, J ALLERGY CLIN IMMUN, V116, P1388, DOI 10.1016/j.jaci.2005.09.022; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Chu HW, 2003, CHEST, V123, p390S, DOI 10.1378/chest.123.3_suppl.390S; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; FRANKLAND AW, 1955, BMJ-BRIT MED J, V4945, P941; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Horner AA, 2006, J ALLERGY CLIN IMMUN, V117, P1133, DOI 10.1016/j.jaci.2006.02.035; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kraft M, 2006, J ALLERGY CLIN IMMUN, V117, P1197, DOI 10.1016/j.jaci.2006.03.001; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360; MARTINEZ FD, 1999, LANCET S2, V354, pS1112; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Roponen M, 2005, J ALLERGY CLIN IMMUN, V116, P1048, DOI 10.1016/j.jaci.2005.08.039; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Taylor RC, 2006, J ALLERGY CLIN IMMUN, V117, P1148, DOI 10.1016/j.jaci.2006.02.014; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P334, DOI 10.1016/j.jaci.2005.11.013	38	68	71	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1063	1066		10.1016/j.jaci.2006.03.027	http://dx.doi.org/10.1016/j.jaci.2006.03.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675333				2022-12-18	WOS:000237436300013
J	Scibilia, J; Pastorello, EA; Zisa, G; Ottolenghi, A; Bindslev-Jensen, C; Pravettoni, V; Scovena, E; Robino, A; Ortolani, C				Scibilia, J; Pastorello, EA; Zisa, G; Ottolenghi, A; Bindslev-Jensen, C; Pravettoni, V; Scovena, E; Robino, A; Ortolani, C			Wheat allergy: A double-blind, placebo-controlled study in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; wheat allergy; hypersensitivity anaphy-laxis; symptoms; double-blind; placebo-controlled food challenge.; provocation dose; peformance characteristics; exercise-induced	CONTROLLED FOOD CHALLENGE; ATOPIC-DERMATITIS; ADVERSE REACTIONS; HYPERSENSITIVITY REACTIONS; IGE CONCENTRATIONS; CLINICAL-TRIALS; CHILDREN; GLIADIN; RISK	Background: Wheat is believed to be an uncommon cause of food allergy in adults; the number of studies that address IgE mediated wheat allergy in adults is all too few. Objective: Determine how many subjects with a history of wheat allergy have real allergy by double-blind, placebo-controlled food challenge; identify the symptoms manifested during the challenge; determine the lowest provocation dose; determine the performance characteristics of wheat skin prick test and specific IgE; identify subjects with real wheat allergy for potential immunoblotting studies. Methods: Patients underwent skin test with commercial wheat extract; specific wheat IgE was determined. Subjects were challenged with 25 g wheat. Subjects who were positive to raw wheat challenge underwent cooked wheat challenge. Results: Thirty-seven double-blind placebo-controlled wheat challenges were performed on 27 patients. A total of 13 of 27 (48%) patients had a positive result. Eleven subjects with positive raw wheat challenge underwent cooked wheat challenge: 10 were positive. The provocation dose range was 0.1 to 25 g. Twenty-seven percent of the subjects allergic to wheat had a provocation dose that was <= 1.6 g. Conclusion: Wheat causes real food allergy in adults. More than a quarter of the patients allergic to wheat reacted to less than 1.6 g wheat. Specific IgE was more sensitive than skin test for wheat; however, specificity and predictive values were low for both tests. Thus, these tests should not be used to validate diagnosis of wheat allergy.	Azienda Osped Niguarda Hosp, Unit Allergol & Clin Immunol, Milan, Italy; Odense Univ Hosp, Dept Dermatol, Allergy Ctr, DK-5000 Odense, Denmark; Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn Ist Ric & Cura Carattera Sci Nat Publ, Milan, Italy	Ospedale Niguarda Ca' Granda; University of Southern Denmark; Odense University Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico	Pastorello, EA (corresponding author), AO Niguarda Ca Granda Hosp, SC Allergol & Immunol Clin, Piazza Osped Maggiore 3, I-20162 Milan, Italy.	allergologia@ospedaleniguarda.it	Bindslev-Jensen, Carsten/H-1877-2011; SCIBILIA, GIUSEPPE/AAC-9673-2022; PASTORELLO, ELIDE ANNA/E-3897-2017	Bindslev-Jensen, Carsten/0000-0002-8940-038X; SCIBILIA, GIUSEPPE/0000-0002-5452-4024; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				Armentia A, 2002, CLIN EXP ALLERGY, V32, P1216, DOI 10.1046/j.1365-2745.2002.01456.x; ATKINS FM, 1986, J ALLERGY CLIN IMMUN, V78, P174, DOI 10.1016/0091-6749(86)90010-2; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Ellman LK, 2002, PEDIATR ALLERGY IMMU, V13, P295, DOI 10.1034/j.1399-3038.2002.01061.x; FAO, 1995, FAO TECHN CONS FOOD; Goldman L, 1998, HARRISONS PRINCIPLES, P9; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;529::AID-AJIM1&gt;3.0.CO;2-I; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; MEILGAARD M, 1991, SENSORY EVALUATION T, P60; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; SAMPSON HA, 1986, ANN ALLERGY, V57, P209; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SICHERER SH, 2000, J ALLERGY CLIN IMMUN, V105, P282; Simonato B, 2001, CLIN EXP ALLERGY, V31, P1771, DOI 10.1046/j.1365-2222.2001.01200.x; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Varjonen E, 2000, ALLERGY, V55, P386, DOI 10.1034/j.1398-9995.2000.00451.x	26	68	73	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					433	439		10.1016/J.JACI.2005.10.014	http://dx.doi.org/10.1016/J.JACI.2005.10.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461145				2022-12-18	WOS:000235687300026
J	Chan, IHS; Leung, TF; Tang, NLS; Li, CY; Sung, YM; Wong, GWK; Wong, CK; Lam, CWK				Chan, IHS; Leung, TF; Tang, NLS; Li, CY; Sung, YM; Wong, GWK; Wong, CK; Lam, CWK			Gene-gene interactions for asthma and plasma total 19E concentration in Chinese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; candidate gene; gene-gene interactions; IgE; polymorphism	MULTIFACTOR-DIMENSIONALITY REDUCTION; ACTIVATION-REGULATED CHEMOKINE; SERUM IGE LEVELS; RECEPTOR-ALPHA; POLYMORPHISM; ATOPY; ASSOCIATION; PROMOTER; THYMUS; POPULATIONS	Background: Asthma is a complex disease resulting from interactions between multiple genes and environmental factors. Study of gene-gene interactions could provide insight into asthma pathophysiology. Objective: We investigated the interaction among 12 different loci in 8 candidate genes and asthma and increased plasma total IgE concentrations in 240 Chinese asthmatic subjects and 140 control subjects. Methods: Genotyping was performed by means of RFLP analysis. Multifactor dimensionality reduction and logistic regression were used to analyze gene-gene interactions. Results: A significant interaction was found between R130Q in the IL-13 gene (IL13) and 150V in the IL-4 receptor alpha gene (IL4RA) on the risk of asthma, with a cross-validation consistency of 10 of 10 and a prediction error of 33.7% (P = .014). The odds ratio of the high-risk to low-risk group was 2.6 (95% CI, 1.4-5.0; P = .004). For increased plasma total IgE concentration, the best 2-locus model consisted of R130Q in IL13 and C-431T in the thymus and activation-regulated chemokine gene (TARC). This model showed a maximum cross-validation consistency of 10 and a minimum prediction error of 36.1% (P = .022). The odds ratio of the high-risk to low-risk group was 3.9 (95% CI, 2.0-7.7; P = .0001). Logistic regression revealed significant interactions between IL13 and IL4RA for asthma (P = .042) and IL13 and TARC for increased total IgE concentration (P = .012). Conclusions: Our data suggest significant interactions between IL13 and IL4RA for asthma and IL13 and TARC for increased plasma total IgE concentrations in Chinese children.	Chinese Univ Hong Kong, Dept Chem Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Paediat, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Lam, CWK (corresponding author), Chinese Univ Hong Kong, Dept Chem Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	waikeilam@cuhk.edu.hk	Tang, Nelson L/P-5018-2017; Wong, CK/H-3256-2016; Wong, Gary WK/AAY-9207-2020; LEUNG, Ting Fan/E-7728-2013	Tang, Nelson L/0000-0002-3607-5819; Wong, CK/0000-0002-5637-8331; Wong, Gary WK/0000-0001-5939-812X; LEUNG, Ting Fan/0000-0002-6469-1926				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Borish L, 1999, ANN ALLERG ASTHMA IM, V82, P413, DOI 10.1016/S1081-1206(10)62715-9; Cho YM, 2004, DIABETOLOGIA, V47, P549, DOI 10.1007/s00125-003-1321-3; Coffey CS, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-49; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Leung TF, 2004, J ALLERGY CLIN IMMUN, V114, P199, DOI 10.1016/j.jaci.2004.03.048; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; Leung TF, 2003, EUR RESPIR J, V21, P616, DOI 10.1183/09031936.03.00083303; Leung TF, 2002, PEDIATR PULM, V34, P419, DOI 10.1002/ppul.10210; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Liggett SB, 1997, AM J RESP CRIT CARE, V156, pS156, DOI 10.1164/ajrccm.156.4.12tac-15; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Madsen HO, 1998, J IMMUNOL, V161, P3169; Marsh DG, 1997, NAT GENET, V15, P389; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sekiya T, 2003, IMMUNOGENETICS, V54, P742, DOI 10.1007/s00251-002-0520-2; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26; Tsunemi Y, 2004, EXP DERMATOL, V13, P715, DOI 10.1111/j.0906-6705.2004.00225.x; Vercelli D, 2005, J ALLERGY CLIN IMMUN, V116, P60, DOI 10.1016/j.jaci.2005.04.031; Wiesch DG, 1999, J ALLERGY CLIN IMMUN, V104, P895, DOI 10.1016/S0091-6749(99)70065-5; Williams SM, 2004, HUM HERED, V57, P28, DOI 10.1159/000077387; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; XU J, 1995, AM J HUM GENET, V57, P425; Yang KD, 2004, CLIN EXP ALLERGY, V34, P32, DOI 10.1111/j.1365-2222.2004.01776.x	43	68	75	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					127	133		10.1016/j.jaci.2005.09.031	http://dx.doi.org/10.1016/j.jaci.2005.09.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387595				2022-12-18	WOS:000235687100020
J	Sutherland, ER				Sutherland, ER			Nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						inflammation; chronobiology; chronotherapy; melatonin; cortisol	EXHALED NITRIC-OXIDE; CONTROLLED CROSS-OVER; GASTROESOPHAGEAL-REFLUX; STEROID RESPONSIVENESS; RELEASE THEOPHYLLINE; CIRCADIAN VARIATION; INHALED STEROIDS; ALVEOLAR TISSUE; DRUG EFFICACY; DOUBLE-BLIND	Nocturnal symptoms and overnight decrements in lung function are a common part of the asthma clinical syndrome. As many as 75% of asthmatic subjects are awakened by asthma symptoms at least once per week, with approximately 40% experiencing nocturnal symptoms on a nightly basis. An extensive body of research has demonstrated that nocturnal symptoms of cough and dyspnea are accompanied by circadian variations in airway inflammation and physiologic variables, including airflow limitation and airways hyperresponsiveness. Alterations in beta(2)-adrenergic and glucocorticoid receptors and hypothalamic-pituitary-adrenal axis function might play a role in modulating the nocturnal asthma phenotype, and recent studies have suggested that melatonin, a neurohormonal controller of circadian rhythms, might be important as well. Treatment strategies in nocturnal asthma are similar to those used in persistent asthma, although dosing of medications to target optimum effect during periods of nocturnal worsening is beneficial.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,Room J-217, Denver, CO 80206 USA.	sutherlande@njc.org						BALLARD RD, 1990, J APPL PHYSIOL, V68, P2034, DOI 10.1152/jappl.1990.68.5.2034; BARNES PJ, 1982, LANCET, V1, P299; BEAM WR, 1992, AM REV RESPIR DIS, V146, P1524, DOI 10.1164/ajrccm/146.6.1524; Boeree MJ, 1998, EUR RESPIR J, V11, P1070, DOI 10.1183/09031936.98.11051070; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; Calhoun WJ, 2003, CHEST, V123, p399S, DOI 10.1378/chest.123.3_suppl.399S; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; COE CI, 1986, CHEST, V90, P485, DOI 10.1378/chest.90.4.485; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; DETHLEFSEN U, 1985, MED KLIN, V80, P44; EKSTROM T, 1989, THORAX, V44, P19, DOI 10.1136/thx.44.1.19; ELIASJONES AC, 1984, ARCH DIS CHILD, V59, P1159, DOI 10.1136/adc.59.12.1159; FORD GA, 1994, POSTGRAD MED J, V70, P350, DOI 10.1136/pgmj.70.823.350; Georges G, 1999, J ASTHMA, V36, P467, DOI 10.3109/02770909909087289; GIBSON PG, 2005, GASTRO OESOPHAGEAL R, V3; Gislason T, 2002, CHEST, V121, P158, DOI 10.1378/chest.121.1.158; GOLDENHEIM PD, 1987, CHRONOBIOL INT, V4, P397, DOI 10.3109/07420528709083529; GOODALL RJR, 1981, THORAX, V36, P116, DOI 10.1136/thx.36.2.116; GUSTAFSSON PM, 1992, EUR RESPIR J, V5, P201; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hendeles L, 2004, J ALLERGY CLIN IMMUN, V113, P1058, DOI 10.1016/j.jaci.2004.03.046; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Kelly EAB, 2004, CLIN EXP ALLERGY, V34, P227, DOI 10.1111/j.1365-2222.2004.01866.x; Kiljander TO, 1999, CHEST, V116, P1257, DOI 10.1378/chest.116.5.1257; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1999, AM J RESP CRIT CARE, V159, pA632; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Landstra AM, 2003, EUR RESPIR J, V21, P627, DOI 10.1183/09031936.03.00085802; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; Lockey RF, 1999, CHEST, V115, P666, DOI 10.1378/chest.115.3.666; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MARTIN RJ, 1989, AM REV RESPIR DIS, V139, P475, DOI 10.1164/ajrccm/139.2.475; Martin RJ, 1996, CLIN IMMUNOTHER, V6, P443, DOI 10.1007/BF03259366; MARTIN RJ, 1991, CHEST, V100, P1024, DOI 10.1378/chest.100.4.1024; Martin RJ, 1999, CHRONOBIOL INT, V16, P623, DOI 10.3109/07420529908998731; Pincus DJ, 1997, J ALLERGY CLIN IMMUN, V100, P771, DOI 10.1016/S0091-6749(97)70272-0; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P513, DOI 10.1067/mai.2003.1679; Sutherland ER, 2002, AM J RESP CRIT CARE, V166, P1055, DOI 10.1164/rccm.200204-356OC; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P52, DOI 10.1067/mai.2003.1608; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; TAN WC, 1990, AM REV RESPIR DIS, V141, P1394, DOI 10.1164/ajrccm/141.6.1394; ten Hacken NHT, 1998, AM J RESP CRIT CARE, V158, P902, DOI 10.1164/ajrccm.158.3.9712021; TUMERWARWICK M, 1988, AM J MED, V85, P6; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; VanKeimpema ARJ, 1997, RESPIRATION, V64, P29	51	68	74	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1179	1186		10.1016/j.jaci.2005.09.028	http://dx.doi.org/10.1016/j.jaci.2005.09.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337443				2022-12-18	WOS:000235687000001
J	Eldeirawi, K; McConnell, R; Freels, S; Persky, VW				Eldeirawi, K; McConnell, R; Freels, S; Persky, VW			Associations of place of birth with asthma and wheezing in Mexican American children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; children and adolescents; immigrants; Mexican American; Mexico; place of birth; prevalence; respiratory symptoms; skin test reactivity; wheezing	HAY-FEVER; PREVALENCE; SYMPTOMS; POPULATION; MIGRATION; ENDOTOXIN; EXPOSURE; GERMANY; ATOPY; FARM	Background: There are wide global variations in the prevalence of asthma and wheezing. Objectives: We examined the associations of place of birth with doctor-diagnosed asthma, wheezing in the past 12 months, and other allergic conditions in Mexican American children. Methods: The study used data on 4121 Mexican American children age 2 months to 16 years who participated in the Third National Health and Nutrition Examination Survey. Results: The risk of asthma was associated with being born in the United States after adjusting for sex, age, history of ear infection, and having a regular place for health care (odds ratio, 2.19; 95% CI, 1.09-4.40). Among children with no previous history of ear infection, US-born children were more likely to report wheezing in the past 12 months than their peers born in Mexico after controlling for confounding variables (odds ratio, 2.05; 95% CI, 1.09-3.87). Mexican American children born in the United States were more likely to have positive skin reaction to cat, house mite, Alternaria alternata, peanut, Bermuda grass, and short ragweed but were less likely to have a positive skin test to German cockroaches after adjusting for sex, age, ear infection, having a regular place for health care, and area of residence. Conclusion: Our study indicated significant associations of place of birth with respiratory symptoms and allergic conditions in Mexican American children. These findings highlight the need for further studies to examine environmental factors that change by migration and explain the observed differential in the risk of asthma or wheezing.	Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Southern California	Eldeirawi, K (corresponding author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, MC 923,1603 W Taylor St,Room 912, Chicago, IL 60612 USA.	Keldeil@uic.edu						[Anonymous], 1994, VITAL HLTH STAT, V32, P1, DOI DOI 10.1136/BMJ.L42; Asher MI, 1998, EUR RESPIR J, V12, P315; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Collins James W. Jr., 2001, Ethnicity and Disease, V11, P606; Crump C, 1999, Ethn Health, V4, P29; Durand J, 2001, LAT AM RES REV, V36, P107; Fussell E, 2004, SOC FORCES, V82, P937, DOI 10.1353/sof.2004.0039; Gibson PG, 2003, PEDIATR PULM, V36, P209, DOI 10.1002/ppul.10323; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; *ISAAC, 1998, LANCET, V3515, P1225; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ormerod LP, 1999, RESP MED, V93, P16, DOI 10.1016/S0954-6111(99)90071-9; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Powell CVE, 1999, ARCH DIS CHILD, V81, P159, DOI 10.1136/adc.81.2.159; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Tatto-Cano MI, 1997, SALUD PUBLICA MEXICO, V39, P497; Tobias A, 2001, EUR RESPIR J, V18, P459, DOI 10.1183/09031936.01.00026501; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x	28	68	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					42	48		10.1016/j.jaci.2005.03.041	http://dx.doi.org/10.1016/j.jaci.2005.03.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990771				2022-12-18	WOS:000235686300006
J	Bousquet, PJ; Co-Minh, HB; Arnoux, B; Daures, JP; Demoly, P				Bousquet, PJ; Co-Minh, HB; Arnoux, B; Daures, JP; Demoly, P			Importance of mixture of minor determinants and benzylpenicilloyl poly-L-lysine skin testing in the diagnosis of beta-lactam allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DRUG HYPERSENSITIVITY; HISTORY		CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, U454,IFR3, F-34295 Montpellier, France; IURC, Lab Biostat Epidemiol, Rech Clin, F-34395 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Bousquet, PJ (corresponding author), CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, U454,IFR3, F-34295 Montpellier, France.		Bousquet, Philippe Jean/AAW-8608-2021; Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; Demoly, Pascal/0000-0001-7827-7964; 				Brockow K, 2002, ALLERGY, V57, P45; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; Gruchalla RS, 2000, LANCET, V356, P1505, DOI 10.1016/S0140-6736(00)02885-3; Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x	8	68	73	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1314	1316		10.1016/j.jaci.2005.02.026	http://dx.doi.org/10.1016/j.jaci.2005.02.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940154				2022-12-18	WOS:000229815400034
J	Takai, T; Kato, T; Yasueda, H; Okumura, K; Ogawa, H				Takai, T; Kato, T; Yasueda, H; Okumura, K; Ogawa, H			Analysis of the structure and allergenicity of recombinant pro- and mature Der p 1 and Der f 1: Major conformational IgE epitopes blocked by prodomains	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite; Der p 1; Der f 1; recombinant allergen; conformational IgE epitopes; prodomain; proform; mature form; cysteine protease; molecular modeling	HOUSE-DUST MITE; DER-P-I; DERMATOPHAGOIDES-FARINAE; CYSTEINE PROTEASE; F-I; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; GROUP-1 ALLERGEN; PICHIA-PASTORIS; DER-P-1	Background: The major house dust mite group 1 allergens Der p 1 and Der f 1, which belong to the papain-like cysteine protease family, are the most potent of indoor allergens. However, little information is available on the location of IgE epitopes. Objective: We investigated the allergenicities of recombinant proforms and mature forms of Der p 1 and Der f 1 to compare them with natural Der p 1 and Der f 1 and to obtain information on the conformational IgE-binding epitopes. Methods: Secreted pro-Der p 1 and pro-Der f 1 and their mutants without hyperglycosylation expressed in yeast were converted to mature forms. We purified the proforms and mature forms and analyzed their apparent molecular sizes and secondary structures by means of get-filtration and circular dichroism analysis and their allergenicities by means of assays for IgE binding, IgE-binding inhibition, and basophil histamine release. The tertiary structure of pro-Der f 1 was predicted by molecular modeling. Results: The recombinant mature forms exhibited similar molecular sizes, secondary structures, and allergenicities as their natural types. On the other hand, their proforms exhibited different secondary structures and less allergenicities than the mature forms in all sera and volunteers tested. Molecular modeling revealed that the prosegment is anchored at the prosegment-binding loop and the substrate-binding cleft on the surface of the mature portion. Conclusions: Our studies indicate that the prodomains of Der p 1 and Der f 1 reduce allergenicity and that the major conformational IgE epitopes commonly found in a broad population of patients exist within the 2 regions blocked by the prosegments. Recombinant Der p 1 and Der f 1 and the findings in the present study will be the basis for allergen standardization and the design of safer and more effective allergen vaccines.	Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan; Natl Sagamihara Hosp, Clin Res Ctr, Kanagawa, Japan	Juntendo University; Juntendo University; Juntendo University	Takai, T (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-takai@med.juntendo.ac.jp	Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355				Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Best EA, 2000, PROTEIN EXPRES PURIF, V20, P462, DOI 10.1006/prep.2000.1327; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Collins SP, 1996, CLIN EXP ALLERGY, V26, P36, DOI 10.1111/j.1365-2222.1996.tb00054.x; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; Furmonaviciene R, 1999, CLIN EXP ALLERGY, V29, P1563, DOI 10.1046/j.1365-2222.1999.00686.x; GREENE WK, 1991, J IMMUNOL, V147, P3768; GREENE WK, 1992, MOL IMMUNOL, V29, P257, DOI 10.1016/0161-5890(92)90107-9; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; Jacquet A, 2002, CLIN EXP ALLERGY, V32, P1048, DOI 10.1046/j.1365-2222.2002.01437.x; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; LIND P, 1988, J IMMUNOL, V140, P4256; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; Nishi K, 2000, J IMMUNOL METHODS, V240, P39; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwardt O, 2003, CURR TOP MED CHEM, V3, P1, DOI 10.2174/1568026033392642; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Takahashi K, 2000, INT ARCH ALLERGY IMM, V122, P108, DOI 10.1159/000024366; Takai T, 2000, EUR J BIOCHEM, V267, P6650, DOI 10.1046/j.1432-1327.2000.01760.x; Takai T, 1999, MOL IMMUNOL, V36, P1055, DOI 10.1016/S0161-5890(99)00098-X; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724; Yasuhara T, 2001, BIOSCI BIOTECH BIOCH, V65, P563, DOI 10.1271/bbb.65.563; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x	38	68	74	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					555	563		10.1016/j.jaci.2004.11.024	http://dx.doi.org/10.1016/j.jaci.2004.11.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753904				2022-12-18	WOS:000227687000019
J	Aalberse, RC; Platts-Mills, TAE				Aalberse, RC; Platts-Mills, TAE			How do we avoid developing allergy: Modifications of the T(H)2 response from a B-cell perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE regulation; IgG4; T(H)2; germinal center; class switch; hygiene hypothesis; atopy	ANTIBODY-RESPONSES; ANTIGEN RECEPTOR; PLASMA-CELLS; BONE-MARROW; IGE; LONG; DISEASES; SWITCH	The synthesis of IgE by B cells occurs at a low rate compared with that of other antibodies, even in allergic subjects. One rate-limiting step is the class switch, by which B lymphocytes switch to produce immunoglobulin epsilon heavy chains rather than mu or gamma heavy chains. We propose an additional rate-limiting step: survival of the B lymphocyte after the switch to IgE. The hypothesis we present here is that the survival of the IgE-switched B cell is compromised, particularly in an active germinal center. Antigenic stimulation in the absence of a danger signal fails to induce a mature germinal center, which allows IgE-switched B cells to escape and mature into plasma cells. Antigenic stimulation in the presence of a danger signal (or under nonhygienic conditions) induces germinal centers, which eliminate IgE-switched B cells. Thus the essence of an allergen is antigenic stimulation in the absence of conditions that generate mature germinal centers. Because germinal centers are important for the generation of B-cell memory, the IgE immune response is characteristically poor in memory (but might be long lasting because of the generation of long-lived plasma cells). In addition to this direct route to IgE, typical for atopic sensitization, another type of T(H)2 response exists. On chronic allergen exposure with the concomitant induction of germinal centers, IgG4-switched B memory cells are induced that are slow to differentiate into plasma cells. These IgG4-switched B memory cells might occasionally undergo a secondary switch to IgE.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands	University of Virginia; University of Amsterdam; Academic Medical Center Amsterdam	Aalberse, RC (corresponding author), Sanquin Res CLB, NL-1006 AD Amsterdam, Netherlands.			Platts-Mills, Thomas/0000-0002-1263-329X				Achatz G, 2001, INT ARCH ALLERGY IMM, V124, P31, DOI 10.1159/000053661; Anand S, 1997, MOL IMMUNOL, V34, P175, DOI 10.1016/S0161-5890(96)00110-1; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; BENNER R, 1981, CLIN EXP IMMUNOL, V46, P1; BRINKMANN V, 1993, CELL IMMUNOL, V152, P323, DOI 10.1006/cimm.1993.1294; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; HOLT PG, 1984, CELL IMMUNOL, V89, P281, DOI 10.1016/0008-8749(84)90330-7; Karnowski A, 2000, Immunobiology, V203, P268; Karnowski A, 2000, AM J RESP CRIT CARE, V162, pS71, DOI 10.1164/ajrccm.162.supplement_2.ras-3; Manz RA, 2002, CURR OPIN IMMUNOL, V14, P517, DOI 10.1016/S0952-7915(02)00356-4; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Payet-Jamroz M, 2001, J IMMUNOL, V166, P4863, DOI 10.4049/jimmunol.166.8.4863; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rabah D, 2002, IMMUNOLOGY, V106, P503, DOI 10.1046/j.1365-2567.2002.01435.x; Sandel PC, 2001, J IMMUNOL, V166, P5935, DOI 10.4049/jimmunol.166.10.5935; SAXON A, 1992, T ASSOC AM PHYSICIAN, V105, P93; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Sudowe S, 1997, IMMUNOLOGY, V91, P464, DOI 10.1046/j.1365-2567.1997.00268.x; van der Kleij D, 2003, EUR J IMMUNOL, V33, P2953, DOI 10.1002/eji.200324340; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANTHOF W, 1993, INT ARCH ALLERGY IMM, V101, P437, DOI 10.1159/000236488; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P147, DOI 10.1097/00130832-200204000-00011; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161	25	68	74	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					983	986		10.1016/j.jaci.2004.02.046	http://dx.doi.org/10.1016/j.jaci.2004.02.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131584				2022-12-18	WOS:000221269000024
J	Wen, L; Atkinson, JP; Giclas, PC				Wen, L; Atkinson, JP; Giclas, PC			Clinical and laboratory evaluation of complement deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						systemic lupus erythematosus classical pathway; alternative pathway lectin pathway	HEMOLYTIC-UREMIC SYNDROME; MANNOSE-BINDING LECTIN; 1ST COMPONENT; HEREDITARY ANGIOEDEMA; MOLECULAR-BASIS; C1 INHIBITOR; ANTIBODY; DISEASE; PATHOGENESIS; IMMUNOLOGY	The complement system provides innate defense against microbial pathogens and is a "complement" to Immoral (antibody-mediated) immunity. Consisting of plasma and membrane proteins, this proinflammatory system works in part by a cascade involving limited proteolysis whereby one component activates the next, resulting in a dramatic amplification. The overall goal is deposition of complement fragments on pathologic targets for the purposes of opsonization, lysis, and liberation of peptides that promote the inflammatory response. Deficiencies of complement components predispose to infections and autoimmune syndromes. Even though total deficiency of a complement component is rare, patients presenting with certain bacterial infections and autoimmune syndromes, especially SLE, have a much greater incidence of deficiency. This review will summarize the clinical manifestations and pathophysiology of congenital and acquired complement deficiency diseases. We will also present an algorithm for laboratory diagnosis of complement deficiency and discuss current and future therapeutic options.	Natl Jewish Med & Res Ctr, Diagnost Complement Lab, Denver, CO 80206 USA; Washington Univ, Sch Med, St Louis, MO USA	National Jewish Health; Washington University (WUSTL)	Giclas, PC (corresponding author), Natl Jewish Med & Res Ctr, Diagnost Complement Lab, 1400 Jackson St, Denver, CO 80206 USA.			Wen, Leana/0000-0003-0259-0537; Atkinson, John/0000-0002-2514-3441				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ATKINSON JP, 1989, CLIN EXP RHEUMATOL, V7, pS95; Atkinson JP, 1999, SYSTEMIC LUPUS ERYTH, P91; Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069; Badesch DB, 1998, J HEART LUNG TRANSPL, V17, P415; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Bork K, 2000, LANCET, V356, P1440, DOI 10.1016/S0140-6736(05)74079-4; Botto M, 2002, IMMUNOBIOLOGY, V205, P395, DOI 10.1078/0171-2985-00141; Bowen B, 2001, CLIN IMMUNOL, V98, P157, DOI 10.1006/clim.2000.4947; Cacoub P, 2002, CURR OPIN RHEUMATOL, V14, P29, DOI 10.1097/00002281-200201000-00006; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; COLTEN HR, 1992, ANNU REV IMMUNOL, V10, P809, DOI 10.1146/annurev.iy.10.040192.004113; COOPER NR, 1978, J IMMUNOL, V120, P1862; Davis A., 1998, HUMAN COMPLEMENT SYS, P229; De Vries B, 2003, TRANSPLANTATION, V75, P375, DOI 10.1097/01.TP.0000044455.05584.2A; DONALDSON VH, 1992, J LAB CLIN MED, V119, P330; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1993, COMPLEMENT HLTH DIS; Fremeaux-Bacchi V, 2002, AM J MED, V113, P194, DOI 10.1016/S0002-9343(02)01124-5; Fukumori Y, 1989, INT IMMUNOL, V1, P85, DOI 10.1093/intimm/1.1.85; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Garred P, 2000, J RHEUMATOL, V27, P26; GICLAS PC, 1979, J IMMUNOL, V122, P146; Giclas PC, 2002, MANUAL CLIN LAB IMMU, V6th, P111; Giclas PC, 1997, MANUAL CLIN LAB IMMU, V5, P181; GICLAS PC, 1991, DIAGN IMMUNOL, P99; Giclas PC, 1997, MANUAL CLIN LAB IMMU, P960; Heymann WR, 1997, J AM ACAD DERMATOL, V36, P611, DOI 10.1016/S0190-9622(97)70250-0; HUGLI T E, 1986, Complement, V3, P111; Huong DLT, 1999, MEDICINE, V78, P148; INAI S, 1989, INT ARCH ALLER A IMM, V90, P274, DOI 10.1159/000235037; JOHNSON CA, 1992, NEW ENGL J MED, V326, P871, DOI 10.1056/NEJM199203263261306; KILPATRICK DC, 2002, BIOCHIM BIOPHYS ACTA, V1577, P401; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; LACHMANN PJ, 1970, J EXP MED, V131, P643, DOI 10.1084/jem.131.4.643; LACHMANN PJ, 1973, LANCET, V1, P465; Levy Y, 1998, IMMUNOL RES, V18, P55, DOI 10.1007/BF02786513; Liszewski M K, 1998, Expert Opin Investig Drugs, V7, P323, DOI 10.1517/13543784.7.3.323; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; LISZEWSKI MK, 1993, FUNDAMENTAL IMMUNOLO; MA CG, 1995, J NEUROIMMUNOL, V58, P51, DOI 10.1016/0165-5728(94)00187-S; Markovic SN, 2000, ANN INTERN MED, V133, P839, DOI [10.7326/0003-4819-133-10-200011210-00025, 10.7326/0003-4819-132-2-200001180-00009]; Matsushita M, 1996, MICROBIOL IMMUNOL, V40, P887, DOI 10.1111/j.1348-0421.1996.tb01156.x; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; Morley B.J., 2000, COMPLEMENT FACTS BOO; Ninomiya H, 2000, BRIT J HAEMATOL, V109, P875, DOI 10.1046/j.1365-2141.2000.02125.x; Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; OLTVAI ZN, 1991, LAB INVEST, V65, P381; Perry GJ, 1998, J AM COLL CARDIOL, V31, p411A, DOI 10.1016/S0735-1097(97)85487-3; Petersen SV, 2001, J IMMUNOL METHODS, V257, P107, DOI 10.1016/S0022-1759(01)00453-7; Petry F, 1998, IMMUNOBIOLOGY, V199, P286, DOI 10.1016/S0171-2985(98)80033-8; Pickering M C, 2000, Adv Immunol, V76, P227; Pickering MC, 2000, RHEUMATOLOGY, V39, P133, DOI 10.1093/rheumatology/39.2.133; PLATTSMILLS TAE, 1974, J IMMUNOL, V113, P358; Podack E.R., 1986, IMMUNOBIOLOGY COMPLE, P115; Quigg RJ, 2000, CONT IMMUN, V9, P155; Quigg RJ, 2002, TRENDS MOL MED, V8, P430, DOI 10.1016/S1471-4914(02)02386-9; RABSON AR, 1997, MANUAL CLIN LAB IMMU, P187; Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100; Richards A, 2002, CURR OPIN NEPHROL HY, V11, P431, DOI 10.1097/00041552-200207000-00010; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; ROSSE WF, 1998, HUMAN COMPLEMENT SYS, P481; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; SANCHEZCRESPO M, 1982, CLIN EXP IMMUNOL, V49, P631; SCHIFFERLI JA, 1989, KIDNEY INT, V35, P993, DOI 10.1038/ki.1989.83; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; SUBRAMANIAN VB, 2000, TXB AUTOIMMUNE DIS; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; THOMPSON C, 1995, SCIENCE, V269, P301, DOI 10.1126/science.7618098; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Walport MJ, 1998, IMMUNOBIOLOGY, V199, P265, DOI 10.1016/S0171-2985(98)80032-6; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WENER MH, 1989, ARTHRITIS RHEUM, V32, P544, DOI 10.1002/anr.1780320506; WEST CD, 1995, PEDIATR NEPHROL, V13, P786; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003; Yu CY, 2002, MANUAL CLIN LAB IMMU, V6th, P117; ZICCARDI RJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P465, DOI 10.1016/0090-1229(80)90058-6; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	89	68	80	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					585	593		10.1016/j.jaci.2004.02.003	http://dx.doi.org/10.1016/j.jaci.2004.02.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100659				2022-12-18	WOS:000220956600001
J	Leynadier, F; Doudou, O; Gaouar, H; Le Gros, V; Bourdeix, I; Guyomarch-Cocco, L; Trunet, P				Leynadier, F; Doudou, O; Gaouar, H; Le Gros, V; Bourdeix, I; Guyomarch-Cocco, L; Trunet, P			Effect of omalizumab in health care workers with occupational latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Hop Tenon, Serv Med Interne & Allergol, APHP, F-75970 Paris, France; Novartis Pharma SAS, F-92500 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Leynadier, F (corresponding author), Hop Tenon, Serv Med Interne & Allergol, APHP, F-75970 Paris, France.							ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Agarwal S, 2002, EUR J DERMATOL, V12, P311; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101	5	68	70	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					360	361		10.1016/j.jaci.2003.11.020	http://dx.doi.org/10.1016/j.jaci.2003.11.020			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767458	Bronze			2022-12-18	WOS:000188885700031
J	Morkjaroenpong, V; Rand, CS; Butz, AM; Huss, K; Eggleston, P; Malveaux, FJ; Bartlett, SJ				Morkjaroenpong, V; Rand, CS; Butz, AM; Huss, K; Eggleston, P; Malveaux, FJ; Bartlett, SJ			Environmental tobacco smoke exposure and nocturnal symptoms among inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ETS; asthma; inner city; children; asthma symptoms	PARENTAL SMOKING; PASSIVE SMOKING; PULMONARY-FUNCTION; RESPIRATORY ILLNESS; CIGARETTE-SMOKING; RISK-FACTORS; RESPONSIVENESS; EMERGENCY; HEALTH; PREVALENCE	Background: Environmental tobacco smoke (ETS) is a frequent exposure and is linked to asthma among inner-city children. Objective: We sought to examine the relationship among ETS exposure, select asthma symptoms, and consequences among inner-city children with asthma. Methods: Data from interviews with primary caregivers of inner-city elementary school children with asthma were evaluated (n = 590). Caregiver reports of child asthma symptoms, exercise limitations, asthma management, health care use, and ETS exposure were examined. Results: Smoking in the home was reported by 29.4% of primary caregivers. ETS exposure (yes/no) was not related to frequency of child nocturnal symptoms or other select asthma morbidity markers. However, among children exposed to ETS, the frequency and severity of child nocturnal symptoms were highest among children exposed to moderate-to-heavy levels of ETS. After controlling for child age, anti-inflammatory medication use, asthma primary care, and caregiver's education, exposure to higher levels of ETS was associated with nearly a 3-fold increase in nocturnal symptoms in children (odds ratio, 2.83; 95% CI, 1.22-6.55). Conclusion: Among elementary school inner-city children with asthma, exposure to higher levels of ETS was associated with increased frequency of nocturnal symptoms. Reducing the exposure of children with asthma to ETS should be a clear priority in developing effective asthma management plans for inner-city families.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Pediat Allergy & Immunol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA; Johns Hopkins Sch Nursing, Baltimore, MD USA; Howard Univ, Coll Med, Washington, DC USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Howard University	Bartlett, SJ (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Bartlett, Susan Joan/AAD-4103-2020; Bartlett, Susan J./J-9864-2012	Bartlett, Susan Joan/0000-0001-9755-2490; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052833, R01HL052013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 5201304, HL 5283303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1988, POSTGRAD MED J, V64, P68; BARNES PJ, 1984, BRIT MED J, V288, P1397, DOI 10.1136/bmj.288.6428.1397; Bartlett SJ, 2001, ARCH PEDIAT ADOL MED, V155, P347, DOI 10.1001/archpedi.155.3.347; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P350; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365, DOI 10.1164/ajrccm.149.2.8306031; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; GREENBERG RA, 1991, AM J PUBLIC HEALTH, V81, P850, DOI 10.2105/AJPH.81.7.850; Halfon N, 1996, PEDIATRICS, V98, P28; HALKEN S, 1995, ALLERGY, V50, P97; Hopper JA, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.4.e47; Jackson C, 1997, AM J PUBLIC HEALTH, V87, P359, DOI 10.2105/AJPH.87.3.359; MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751; MALVEAUX FJ, 1995, ENVIRON HEALTH PERSP, V103, P59, DOI 10.2307/3432347; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Meijer GG, 1996, AM J RESP CRIT CARE, V153, P237, DOI 10.1164/ajrccm.153.1.8542122; *NAT HEART LUNG BL, 1997, PUBL; Nowak D, 1997, INT ARCH OCC ENV HEA, V69, P125; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Samet J.M., 2001, WOMEN TOBACCO EPIDEM, P17; Seery JP, 1998, ANN ALLERG ASTHMA IM, V80, P329, DOI 10.1016/S1081-1206(10)62978-X; Starr GJ, 1999, AUST NZ J PUBL HEAL, V23, P528, DOI 10.1111/j.1467-842X.1999.tb01311.x; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96, DOI 10.1093/oxfordjournals.aje.a117418; Strachan DP, 1997, THORAX, V52, P905, DOI 10.1136/thx.52.10.905; TAGER IB, 1985, AM REV RESPIR DIS, V131, P752; TAGER IB, 1979, AM J EPIDEMIOL, V110, P15, DOI 10.1093/oxfordjournals.aje.a112783; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; *US EPA, 1992, PUBL; Weaver VM, 1996, CANCER EPIDEM BIOMAR, V5, P135; Willers S, 2000, J CLIN EPIDEMIOL, V53, P715, DOI 10.1016/S0895-4356(99)00212-7; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	33	68	72	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					147	153		10.1067/mai.2002.125832	http://dx.doi.org/10.1067/mai.2002.125832			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110834				2022-12-18	WOS:000176870300026
J	Basomba, A; Tabar, AI; de Rojas, DHF; Garcia, BE; Alamar, R; Olaguibel, JM; del Prado, JM; Martin, S; Rico, P				Basomba, A; Tabar, AI; de Rojas, DHF; Garcia, BE; Alamar, R; Olaguibel, JM; del Prado, JM; Martin, S; Rico, P			Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; allergens; liposomes; Dermatophagoides pteronyssinus; randomized controlled trial	HOUSE-DUST-MITE; CLINICAL-EFFICACY; IMMUNOTHERAPY; SAFETY; CLUSTER	Background: Liposomes are potent immunologic adjuvants and have been proposed as allergen carriers in allergy vaccination. Objective: We sought to investigate the efficacy and safety of vaccination with Dermatophagoides pteronyssinus encapsulated in liposomes. Methods: We conducted a double-blind, placebo-controlled study. Fifty-five asthmatic patients sensitized to mites were randomly assigned vaccination with D pteronyssinus extract encapsulated in liposomes or empty liposomes for a period of 12 months. The principal parameters were symptom and medication-consumption scores. The percentage of healthy days (ie, days without medication and with absent or mild symptoms) was calculated. Immediate and late skin test results, allergen bronchial challenge test results, and allergen-specific serum immunoglobulin levels were evaluated be ore and after treatment. Results: All clinical Scores were markedly lower in the active group than in the placebo group after vaccination. Nearly half (45.8%) of the patients actively treated reduced their symptom and medication scores by at least 60% versus only 12% of patients receiving placebo treatment (P = .0388). The percentage of healthy days in the active group rose from 10.5% before treatment to 64.5% afterward (P = .0008). Reduction in organ sensitivity was demonstrated by skin prick test responses (P < .01), late-phase response after intradermal testing (P = .009), and bronchial challenge test results (P = .026) in the active group. Serum levels of specific IgG increased throughout the treatment, whereas specific IgE levels showed only an initial transient increase. No change in these parameters was observed in the placebo group. Vaccination was well tolerated, and no subcutaneous nodules appeared. Conclusion: Vaccination with D pteronyssinus encapsulated in liposomes is an effective and safe treatment for allergy-induced asthma.	ALK ABELLO SA, Madrid 28037, Spain; Univ Valencia, Hosp La Fe, Valencia, Spain; Hosp Virgen del Camino, Pamplona, Spain	ALK-Abello AS; Hospital Universitari i Politecnic La Fe; University of Valencia; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea	Rico, P (corresponding author), ALK ABELLO SA, Miguel Fleta 19, Madrid 28037, Spain.		RIVERA, JOSE MARIA OLAGUIBEL/AAK-3845-2020; rico, pilar/AAG-6038-2020	RIVERA, JOSE MARIA OLAGUIBEL/0000-0002-9126-4559; rico, pilar/0000-0002-2269-2568				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Anderson PM, 1997, BIODRUGS, V7, P51, DOI 10.2165/00063030-199707010-00007; ARORA N, 1991, ALLERGY, V46, P386, DOI 10.1111/j.1398-9995.1991.tb00603.x; AUDERA C, 1991, CLIN EXP ALLERGY, V21, P139, DOI 10.1111/j.1365-2222.1991.tb00816.x; Bangham A., 1974, METHODS MEMBRANE BIO, P1, DOI DOI 10.1007/978-1-4615-7422-4_1; Barber D, 1990, REV ESP ALERGOL IMMU, V5, P125; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DELPRADO JM, 2000, ALLERGY S, V55, P176; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; Gudex C, 1996, QUAL LIFE RES, V5, P521, DOI 10.1007/BF00439226; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; Jimeno Nogales L, 1990, Int Arch Allergy Appl Immunol, V92, P175; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 1998, ALLERGY, V53, P461; Martin S, 1997, ALLERGY, V52, P97, DOI 10.1111/j.1398-9995.1997.tb02552.x; Muro MD, 1999, J INVEST ALLERG CLIN, V9, P146; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323, DOI 10.1164/ajrccm/143.2.323; RAMIREZ J, 1990, Clinical and Experimental Allergy, V20, P12; RICO P, 1998, REV ESP ALERGOL IMMU, V13, P280; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; Tabar AI, 1999, J INVEST ALLERG CLIN, V9, P155; TRAN XT, 1994, ARB PEI GSH, V87, P203; VENTAS P, 1990, REV ESP ALERGOL IMMU, V5, P71; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x	30	68	79	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					943	948		10.1067/mai.2002.124465	http://dx.doi.org/10.1067/mai.2002.124465			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063522	Bronze			2022-12-18	WOS:000176442700008
J	Nel, AE; Slaughter, N				Nel, AE; Slaughter, N			T-cell activation through the antigen receptor. Part 2: Role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						T-cell activation; TCR; T(H)1/T(H)2 differentiation; anergy; therapy; senescence	ALTERED PEPTIDE LIGANDS; KAPPA-B CASCADE; KINASE C-THETA; PROTEIN-KINASE; CLONAL ANERGY; IL-2 GENE; TRANSCRIPTIONAL REGULATION; MOLECULAR MECHANISMS; CYCLOSPORINE-A; TH1 CELLS	Part 2 of this review on cellular activation by the T-cell antigen receptor (TCR) will highlight how TCR signaling pathways are adapted to achieve specific biologic outcomes, including different states of T-cell differentiation and the induction of T-cell tolerance. We will also explore how, treatment with altered peptide ligands affects TCR signaling to change T-cell differentiation or to induce an anergy state. These changes are accomplished through alteration of protein tyrosine kinase activity, the stoichiometry of phosphorylation of immunoreceptor tyrosine-based activation motifs, intracellular free ionized calcium flux, mitogen-activated protein kinase activity, and transcriptional activation of key cytokine promoters. The CTLA-4 plays an important role in the induction and maintenance of anergy. The second theme will highlight how altered TCR signal transduction, including changes in the compartmentalization of signaling components at the TCR synapse, contributes to decreased T-cell activation during immune senescence. Finally, we will illustrate how the molecular details of TCR activation can be used to modify the function of the immune system. This includes a description of the mechanism of action of altered peptide ligands, CTLA-4Ig, and pharmacologic inhibitors of mitogen-activated protein kinases, nuclear factor kappaB, and protein kinase C cascades.	Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nel, AE (corresponding author), Univ Calif Los Angeles, Sch Med, Div Clin Immunol Allergy, Dept Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nel, Andre E/J-2808-2012		NIAID NIH HHS [P0-1 AI50495] Funding Source: Medline; NIA NIH HHS [R0-1 AG14992] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014992] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P2375, DOI 10.1073/pnas.92.6.2375; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blair PJ, 1998, J IMMUNOL, V160, P12; Boucher N, 1998, EXP GERONTOL, V33, P267, DOI 10.1016/S0531-5565(97)00132-0; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Boutin Y, 1997, J IMMUNOL, V159, P5802; Brockdorff J, 2000, EUR CYTOKINE NETW, V11, P225; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; CHO EA, 1993, J IMMUNOL, V151, P20; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Crowe PD, 2000, ANN NEUROL, V48, P758, DOI 10.1002/1531-8249(200011)48:5<758::AID-ANA9>3.3.CO;2-U; Daikh DI, 2001, J IMMUNOL, V166, P2913, DOI 10.4049/jimmunol.166.5.2913; Danovitch GM, 2001, KIDNEY INT, V59, P388, DOI 10.1046/j.1523-1755.2001.00501.x; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; De Palma R, 2000, ALLERGY, V55, P56; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Eisenbraun MD, 2000, J IMMUNOL, V164, P6105, DOI 10.4049/jimmunol.164.12.6105; ENGWERDA CR, 1994, J IMMUNOL, V152, P3740; Fazekas de St Groth B, 2001, SEMIN IMMUNOL, V13, P311, DOI 10.1006/smim.2001.0327; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fijen JW, 2001, CLIN EXP IMMUNOL, V124, P16, DOI 10.1046/j.1365-2249.2001.01485.x; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia GG, 2001, J IMMUNOL, V166, P3151, DOI 10.4049/jimmunol.166.5.3151; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Griffiths B, 2001, LUPUS, V10, P165, DOI 10.1191/096120301672970034; HODES RJ, 1995, J EXP MED, V182, P1, DOI 10.1084/jem.182.1.1; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Kempiak SJ, 1999, J IMMUNOL, V162, P3176; Kenyon NS, 1999, DIABETES, V48, P1473, DOI 10.2337/diabetes.48.7.1473; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106; Krauss S, 2001, IMMUNITY, V15, P497, DOI 10.1016/S1074-7613(01)00205-9; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Leitenberg D, 1998, J IMMUNOL, V161, P1194; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Mason U, 2002, J RHEUMATOL, V29, P220; Masteller EL, 2000, J IMMUNOL, V164, P5319, DOI 10.4049/jimmunol.164.10.5319; MATOUR D, 1989, CLIN IMMUNOL IMMUNOP, V50, P82, DOI 10.1016/0090-1229(89)90224-9; Miller RA, 2000, VACCINE, V18, P1654, DOI 10.1016/S0264-410X(99)00502-2; Mondino A, 1996, J IMMUNOL, V157, P2048; Mori A, 1999, J IMMUNOL, V163, P4763; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Papadopoulos NG, 2002, J RHEUMATOL, V29, P261; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Powell JD, 1999, J IMMUNOL, V162, P2775; Powell JD, 1999, J IMMUNOL, V163, P6631; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Reitamo S, 2001, J ALLERGY CLIN IMMUN, V107, P445, DOI 10.1067/mai.2001.113521; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Rincon Mercedes, 1997, Genes and Function, V1, P51; RIVNAY B, 1980, MECH AGEING DEV, V12, P119, DOI 10.1016/0047-6374(80)90088-3; Rogers PR, 1998, J IMMUNOL, V161, P3844; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; SAUNDERS RN, 2001, KIDNEY INT, P59; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schweitzer AN, 1998, J IMMUNOL, V161, P2762; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Solomou EE, 2001, J IMMUNOL, V166, P5665, DOI 10.4049/jimmunol.166.9.5665; STULNIG TM, 1995, J GERONTOL A-BIOL, V50, pB383, DOI 10.1093/gerona/50A.6.B383; Tamir A, 2000, J IMMUNOL, V165, P1243, DOI 10.4049/jimmunol.165.3.1243; Tamura T, 2000, INT IMMUNOL, V12, P1205, DOI 10.1093/intimm/12.8.1205; Tao X, 1997, J IMMUNOL, V158, P4237; THOMAN ML, 1989, ADV IMMUNOL, V46, P221, DOI 10.1016/S0065-2776(08)60655-0; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; Vincenti MP, 2001, J CLIN INVEST, V108, P181; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wells AD, 2001, J CLIN INVEST, V108, P895, DOI 10.1172/JCI200113220; Whisler RL, 1996, CELL IMMUNOL, V168, P201, DOI 10.1006/cimm.1996.0067; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yasui DH, 1998, J IMMUNOL, V160, P4433; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P9273, DOI 10.1073/pnas.94.17.9273; Ziemssen T, 2001, DRUG SAFETY, V24, P979, DOI 10.2165/00002018-200124130-00005	125	68	74	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					901	915		10.1067/mai.2002.124965	http://dx.doi.org/10.1067/mai.2002.124965			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063516	Bronze			2022-12-18	WOS:000176442700002
J	McKeever, TM; Lewis, SA; Smith, C; Hubbard, R				McKeever, TM; Lewis, SA; Smith, C; Hubbard, R			Mode of delivery and risk of developing allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mode of delivery; asthma; eczema; hay fever; birth cohort	ASTHMA; COMPLICATIONS; CHILDHOOD	The aim of this study was to quantify the relationship between mode of delivery and subsequent incidence of allergic disease. The analysis is based on data derived from a birth cohort of 24,690 children who contributed data to the West Midlands General Practice Research Database. We found no convincing evidence to suggest that babies born by caesarean, forceps, or breech delivery had an increased risk of developing allergic disease.	Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England	University of Nottingham	McKeever, TM (corresponding author), City Hosp Nottingham, Div Resp Med, Clin Sci Bldg, Hucknall Rd, Nottingham NG5 1PB, England.		svirko, yuri/R-6980-2016	svirko, yuri/0000-0002-2927-6233; McKeever, Tricia/0000-0003-0914-0416				Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814	8	68	71	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					800	802		10.1067/mai.2002.124046	http://dx.doi.org/10.1067/mai.2002.124046			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994703				2022-12-18	WOS:000175687800009
J	Szefler, SJ				Szefler, SJ			Pharmacokinetics of intranasal corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beclomethasone dipropionate; budesonide; flunisolide; fluticasone propionate; corticosteroids; half-life; hypothalamic-pituitary-adrenal axis; intranasal corticosteroids; mometasone furoate; triamcinolone acetonide	SEASONAL ALLERGIC RHINITIS; AQUEOUS NASAL SPRAY; MOMETASONE FUROATE NASONEX; INHALED CORTICOSTEROIDS; TRIAMCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; PHARMACOLOGICAL PROPERTIES; GLUCOCORTICOID BUDESONIDE; PERENNIAL RHINITIS; ADRENAL-FUNCTION	Topical administration of corticosteroids can reduce the total dose of corticosteroid required to treat the patient and minimize side effects. This logic has led to the development of intranasal corticosteroids (INCS) for allergic and perennial rhinitis. The second generation of these compounds includes beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate, and triamcinolone acetonide. There is evidence that the INCS are effective in rhinitis; however, there is concern about the potential for these compounds to cause growth suppression. In one study, beclomethasone dipropionate significantly reduced growth in children; however, treatment of children with mometasone furoate nasal spray for 1 year showed no signs of growth th suppression. It is evident that the differences among INCS lie in their pharmacokinetics. Structural differences among the various INCS influence their metabolism. The goal of INCS therapy is to have a high ratio of topical to systemic activity. The drug delivery device, absorption of the drug, and drug distribution all contribute to effective topical activity of an INCS. In addition, individual drug metabolism and elimination (half-life and drug clearance) also contribute to the therapeutic index of a drug. Overall, the second-generation INCS cause minimal systemic effects at recommended doses.	Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Natl Jewish Ctr, Med & Res Ctr, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Szefler, SJ (corresponding author), 1400 Jackson St,Annex Bldg,Room J 209, Denver, CO 80206 USA.							Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; Allen DB, 1998, ACTA PAEDIATR, V87, P123, DOI 10.1080/08035259850157516; ARGENTI D, 1994, J CLIN PHARMACOL, V34, P854, DOI 10.1002/j.1552-4604.1994.tb02051.x; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Benninger MS, 1997, OTOLARYNG HEAD NECK, V117, pS41, DOI 10.1016/S0194-5998(97)70006-8; Berridge MS, 1998, J NUCL MED, V39, P1972; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHAPLIN MD, 1980, J ALLERGY CLIN IMMUN, V65, P445, DOI 10.1016/0091-6749(80)90238-9; Davies RJ, 1997, CLIN THER, V19, P27; Derendorf H, 1998, J ALLERGY CLIN IMMUN, V101, pS440, DOI 10.1016/S0091-6749(98)70156-3; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; HALLWORTH GW, 1986, J ALLERGY CLIN IMMUN, V77, P348, DOI 10.1016/S0091-6749(86)80116-6; Hebert JR, 1996, ALLERGY, V51, P569; IRANDER K, 1984, CLIN OTOLARYNGOL, V9, P235, DOI 10.1111/j.1365-2273.1984.tb01503.x; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; Kelly HW, 1998, J ALLERGY CLIN IMMUN, V102, pS36, DOI 10.1016/S0091-6749(98)70004-1; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; Lipworth BJ, 1997, THORAX, V52, P476, DOI 10.1136/thx.52.5.476; Lund VJ, 1996, ALLERGY, V51, P5, DOI 10.1111/j.1398-9995.1996.tb04772.x; Malo JL, 1999, EUR RESPIR J, V13, P993, DOI 10.1183/09031936.99.13599399; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P370, DOI 10.1016/S1081-1206(10)63030-X; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; McDowall JE, 1997, CLIN DRUG INVEST, V14, P44, DOI 10.2165/00044011-199714010-00006; MCDOWALL JE, 1995, J ALLERGY CLIN IMMUN, V95, P194; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; Meltzer EO, 1998, CLIN EXP ALLERGY, V28, P27; MOLLER C, 1990, Clinical and Experimental Allergy, V20, P101; MOLLMANN H, 1985, EUR J CLIN PHARMACOL, V29, P85, DOI 10.1007/BF00547374; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; Mygind N, 1996, CLIN IMMUNOTHER, V5, P122, DOI 10.1007/BF03259319; MYGIND N, 1978, Rhinology (Utrecht), V16, P79; MYGIND N, 1999, RHINITIS MECH MANAGE, P221; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157, DOI 10.1016/S0091-6749(98)70379-3; NEWMAN SP, 1987, J LARYNGOL OTOL, V101, P127, DOI 10.1017/S0022215100101380; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Passali D, 1999, ALLERGY, V54, P5, DOI 10.1111/j.1398-9995.1999.tb04420.x; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Prakash A, 1998, DRUGS, V55, P145, DOI 10.2165/00003495-199855010-00009; RYRFELDT A, 1984, CLIN PHARMACOL THER, V35, P525, DOI 10.1038/clpt.1984.71; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Smith Carolyn L., 1998, Arzneimittel-Forschung, V48, P956; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; Wolthers OD, 1998, CLIN EXP ALLERGY, V28, P545	54	68	76	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S26	S31		10.1067/mai.2001.115563	http://dx.doi.org/10.1067/mai.2001.115563			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449203				2022-12-18	WOS:000170230600005
J	Archambault, S; Malo, JL; Infante-Rivard, C; Ghezzo, H; Gautrin, D				Archambault, S; Malo, JL; Infante-Rivard, C; Ghezzo, H; Gautrin, D			Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; occupational asthma; immunological sensitization	DETERMINANTS; PREVALENCE; PERSONNEL	Latex is a well-known sensitizer. Prospective studies in apprentices beginning to be exposed to latex have not been carried out. We wanted to determine the incidence of skin reactivity, cutaneous symptoms, rhinoconjunctivitis (RC) symptoms, respiratory symptoms, probable occupational RC, and asthma in apprentices in dental hygiene. A total of 122 students starting a program in dental hygiene technology were recruited between 1993 and 1995, A questionnaire, skin-prick tests with common aeroallergens and latex, and assessment of spirometry and responsiveness to methacholine were carried out on entry and at follow-up visits at 20 and 32 months after the start of exposure. Of the 110 subjects who participated for at least 1 follow-up visit, skin reactivity to latex developed in 7, Cutaneous symptoms developed in 6 of the 7, RC symptoms developed in 2, and respiratory symptoms developed in 1, Five of the 7 subjects had significant changes in methacholine responsiveness and fulfilled the definition of probable occupational asthma, Sensitized subjects were more likely to be atopic and to have a previous history of asthma and respiratory symptoms on exercise than were nonsensitized subjects. Three subjects at the 20-month assessment and 4 subjects at the 32-month visit showed skin reactivity. The cumulative incidences for skin sensitization, probable occupational RC, and occupational asthma to latex were 6.4%, 1.8%, and 4.5%, respectively.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; McGill Univ, Joint Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Joint Dept Occupat Hlth, Montreal, PQ, Canada	Universite de Montreal; McGill University; McGill University	Gautrin, D (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.							COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; DUFRESNE A, 1997, ANN OCCUP HYG, V41, P621; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; GAUTRIN D, IN PRESS AM J RESP C; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LEVI DA, 1999, JAMA-J AM MED ASSOC, V281, P988; MALO JL, 1990, AM REV RESPIR DIS, V142, P1359, DOI 10.1164/ajrccm/142.6_Pt_1.1359; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1999, ASTHMA WORKPLACE, P425	13	68	70	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					921	923						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344363				2022-12-18	WOS:000168812300024
J	Tankersley, MS; Butler, KK; Butler, WK; Goetz, DW				Tankersley, MS; Butler, KK; Butler, WK; Goetz, DW			Local reactions during allergen immunotherapy do not require dose adjustment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen vaccine; immunotherapy; anaphylaxis		Background: The recent World Health Organization position paper on allergen immunotherapy states that local reactions to immunotherapy are not predictive of subsequent systemic reactions. Nevertheless, in clinical practice dose adjustment after local reactions continues to be recommended, presumably in an effort to prevent future systemic reactions. Objective: We sought to determine whether dose adjustment versus no adjustment for local reactions during allergen immunotherapy influences the occurrence of subsequent systemic reactions. Methods: In a single-site allergy clinic before October 1, 1997, local reactions after allergen vaccine injection resulted in adjustment of the subsequent dose. After October 1, 1997, no dose adjustments were made for immediate and late local reactions, For the same 9-month period before and after the change in local reaction dose-adjustment policy, systemic reaction rates were compared retrospectively. For individuals experiencing a systemic reaction, local reaction rates and local reactions immediately preceding a systemic reaction were also compared before and after the policy change. Results: Comparing the 9-month period (October 1996-June 1997) preceding the policy change and the 9 months (October 1997-June 1998) after the change in policy, the systemic reaction rates (0.80% and 1.01%, respectively) were not statistically different (P =.24). Among those experiencing a systemic reaction, the rate of local reactions was unchanged (7.3 % and 4.7%, respectively; P =.07), and the rate of local reactions immediately preceding a systemic reaction did not increase (18.8% and 10.5%, respectively; P =.37), The sensitivity of a local reaction predicting a systemic reaction at the next immunotherapy dose was 15%. Conclusions: A local reaction is a very insensitive predictor for a subsequent systemic reaction at the next allergen vaccine dose. Dose adjustment for most local reactions is unnecessary and may delay therapy, increase costs, and put the patient at increased risk of dose administration errors.	Wilford Hall USAF Med Ctr, Allergy & Immunol Dept, Lackland AFB, TX 78236 USA	United States Department of Defense; United States Air Force	Tankersley, MS (corresponding author), 3MDG-GOMA,5955 Zeamer Ave, Elmendorf AFB, AK 99506 USA.							Bousquet J., 1998, Allergy (Copenhagen), V53, P1; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; NELSON BL, 1986, ANN ALLERGY, V56, P331; NELSON HS, 1998, ALLERGY PRINCIPLES P, P1050; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; PRIGAL SJ, 1972, ANN ALLERGY, V30, P529; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435	7	68	74	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					840	843		10.1067/mai.2000.110468	http://dx.doi.org/10.1067/mai.2000.110468			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080704				2022-12-18	WOS:000167865200006
J	Kemp, JP; Berkowitz, RB; Miller, SD; Murray, JJ; Nolop, K; Harrison, JE				Kemp, JP; Berkowitz, RB; Miller, SD; Murray, JJ; Nolop, K; Harrison, JE			Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; mometasone furoate; inhaled corticosteroids; once daily dosing	INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; GLUCOCORTICOIDS; GUIDELINES; EFFICACY; MANAGEMENT; SAFETY; CARE	Background: Despite current recommendations, many patients with persistent asthma are still treated with bronchodilators alone. Objective: The safety and efficacy of two once daily dosing regimens (200 mu g and 400 mu g) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 mu g administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists. Methods: All patients (306 patients; age range, 12-70 years) were given a diagnosis of asthma for at least 6 months before enrollment in this 12-week, placebo-controlled, double-blind, randomized study. The primary efficacy variable was change in FEV1 from baseline to endpoint (last evaluable visit). Results: At endpoint, FEV1 was significantly improved (P less than or equal to .02) after MF-DPI 400 mu g once daily morning treatment and MF-DPI 200 mu g twice daily treatment (16.0% and 16.1%, respectively) compared with placebo (5.5%). The improvement seen with MF-DPI 200 mu g once daily morning treatment (10.4%) was not significantly different from that with placebo. Secondary efficacy variables also showed significant improvement for the MF-DPI 400 mu g once daily morning treatment group and the MF-DPI 200 mu g twice daily treatment group compared with the placebo group. All doses of MF administered by means of a DPI were well tolerated. Conclusion: This is the first study to demonstrate that a total daily dose of 400 mu g of MF administered by means of a DPI is an effective treatment for patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists. This treatment was equally effective when administered either as a once daily or twice daily regimen.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA 92123 USA; Atlanta Allergy & Immunol Res Fdn, Marietta, GA USA; New England Clin Studies, N Dartmouth, MA USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Vanderbilt University; Merck & Company; Schering Plough Corporation	Kemp, JP (corresponding author), Allergy & Asthma Med Grp & Res Ctr, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.							AFFRIME MB, IN PRESS CHEST; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; BARTON BE, 1991, IMMUNOPHARM IMMUNOT, V13, P251, DOI 10.3109/08923979109019704; BEAM WR, 1992, AM REV RESPIR DIS, V145, P1082, DOI 10.1164/ajrccm/145.5.1082; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Bernstein DI, 1999, RESP MED, V93, P603, DOI 10.1016/S0954-6111(99)90099-9; Campbell LM, 1991, BR J CLIN RES, V2, P111; Chambers CV, 1999, RESP MED, V93, P88, DOI 10.1016/S0954-6111(99)90296-2; Cochrane GM, 1999, RESP MED, V93, P763, DOI 10.1016/S0954-6111(99)90260-3; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Creer TL, 1999, J ASTHMA, V36, P391, DOI 10.3109/02770909909087282; Crocker IC, 1998, ANN ALLERG ASTHMA IM, V80, P509, DOI 10.1016/S1081-1206(10)63075-X; Crocker IC, 1997, ANN ALLERG ASTHMA IM, V78, P497, DOI 10.1016/S1081-1206(10)63238-3; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; FARMER KC, 1994, CLIN THER, V16, P316; GAGNON M, 1994, CHEST, V105, P1732, DOI 10.1378/chest.105.6.1732; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; Johnson FN, 1998, REV CONTEMP PHARMACO, V9, P551; KENYON D, 1999, EUR RESPIR J, V14, pS291; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; McFadden ER, 1999, J ALLERGY CLIN IMMUN, V104, P46, DOI 10.1016/S0091-6749(99)70112-0; *NAT HEART LUNG BL, 1997, 2 NAT HEART LUNG BLO, P1; Nayak AS, 2000, ANN ALLERG ASTHMA IM, V84, P417, DOI 10.1016/S1081-1206(10)62275-2; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Petrovsky N, 1998, CYTOKINE, V10, P307, DOI 10.1006/cyto.1997.0289; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; Venables T., 1996, BRIT J CLIN PHARMACO, V7, P15; Wilson AM, 1997, EUR J CLIN PHARMACOL, V53, P33, DOI 10.1007/s002280050333; YANT TT, 1999, EUR RESPIR J, V14, pS62	34	68	70	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					485	492		10.1067/mai.2000.109431	http://dx.doi.org/10.1067/mai.2000.109431			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984368				2022-12-18	WOS:000089471900011
J	Bukstein, DA; McGrath, MM; Buchner, DA; Landgraf, J; Goss, TF				Bukstein, DA; McGrath, MM; Buchner, DA; Landgraf, J; Goss, TF			Evaluation of a short form for measuring health-related quality of life among pediatric asthma patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						health-related quality of life; pediatrics; asthma; psychometrics; parent report	OF-LIFE; CHILDHOOD ASTHMA; UNITED-STATES; CHILDREN; CARE; ADULTS	Background: This study was undertaken to derive and validate a short form parent-completed questionnaire to measure health-related quality of life (HRQL) in pediatric asthma patients. Objective: The objectives of this study were to (1) use stepwise analysis to derive a shorter questionnaire from the original long-form questionnaire and (2) determine the tradeoff in precision between the long- and short-form surveys. Methods: One hundred eighty-one pediatric asthma patients were enrolled from 4 sites, A parent of each patient completed a general and an asthma-specific questionnaire during routine office visits from June 1995 to January 1997, The questionnaire included the Child Health Questionnaire Parent Form 50, a general HRQL survey, and a 17-item asthma-specific battery assessing daytime symptoms, nighttime symptoms, and functional limitations, All scales were scored from 0 to 100, with higher scores indicating better HRQL, Analysis of variance models were used to derive short-form scales from the 17-item long-form scales, and the final asthma-specific short-form scale structure was confirmed with use of stepwise regression. Scale reliability was assessed with Cronbach's alpha. Validity of the short-form questionnaire was assessed by comparing mean scale scores according to the level of asthma severity defined by several clinical criteria. Asthma severity was assessed with use of percent predicted FEV1, frequency and type of symptoms, parent rating of disease severity, physician rating of disease severity, and resource use (emergency department use and hospitalizations). The relative validity of each of the short-form scales was measured by comparing the proportion of variance explained by each of the short-form scales compared with the respective long-form scales. Results: The 17-item asthma-specific battery was reduced to 8 items, the Integrated Therapeutics Group Child Asthma Short Form. The daytime and nighttime symptom scales for each contain 2 items and the functional limitations scale 4 items. Reliability was greater than 0.70 for each of the short-form scales, The absence of ceiling and floor effects indicates each scale's ability to detect changes at both low and high levels of functioning. Lower (poorer) mean HRQL scores for severe cases compared with mild cases, for all disease severity indicators, demonstrated clinical validity, Relative validity estimates, comparing the proportion of explained variance of the short-form scales with that of the long-form scales, ranged from 0.85 to 1.20, indicating a similar ability to measure change. Conclusions: This study documents the development of a brief, multidimensional, 8-item questionnaire for measuring HRQL in pediatric asthma patients. The brevity of the questionnaire makes it practical for use in practice settings and to monitor patients.	Covance Hlth Econ & Outcomes Serv Inc, Washington, DC 20005 USA; Dean Fdn, Madison, WI USA; Integrated Therapeut Grp Inc, Kenilworth, NJ USA; HealthAct, Boston, MA USA	Covance	McGrath, MM (corresponding author), Covance Hlth Econ & Outcomes Serv Inc, Suite 200 E,1100 New York Ave NW, Washington, DC 20005 USA.							BUKSTEIN D, 1995, J CLIN OUTCOMES MANA, V2, P45; Bukstein DA, 1996, IMMUNOL ALLERGY CLIN, V16, P859, DOI 10.1016/S0889-8561(05)70276-9; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; CLARK NM, 1993, J ASTHMA, V30, P241, DOI 10.3109/02770909309054524; CREER T, 1976, REHABIL LIT, V39, P226; DEYO RA, 1989, MED CARE, V27, pS254, DOI 10.1097/00005650-198903001-00020; ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7; FOWLER MG, 1992, PEDIATRICS, V90, P939; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HALFON N, 1993, PEDIATRICS, V91, P56; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; KAPLAN SH, 1989, PROVIDING QUALITY CA, P25; Landgraf JM, 1996, CHQ USERS MANUAL; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; MCGRATH MM, 1995, AMBULATORY CHILD HLT, V5, P249; MCGRATH MM, 1998, P ANN M AM COLL ALL; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MEYER KB, 1994, AM J KIDNEY DIS, V24, P267, DOI 10.1016/S0272-6386(12)80192-2; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Nunnally J., 1994, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; SHEET DF, 1992, ASTHMA STAT; Starfield B, 1998, JAMA-J AM MED ASSOC, V280, P1006, DOI 10.1001/jama.280.11.1006; TAYLOR WR, 1992, PEDIATRICS, V90, P657; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; Ware J.E, 1994, PHYS MENTAL HLTH SUM; Ware JE, 1998, QUAL LIFE RES, V7, P235, DOI 10.1023/A:1024946316424; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WASSON J, 1992, MED CARE, V30, pMS42, DOI 10.1097/00005650-199205001-00004; WU AW, 1996, QUALITY LIFE PHARMAC, P517; 1996, PHARM APPROVALS MONT, V1, P4	34	68	73	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				245	251		10.1016/S0091-6749(00)90072-1	http://dx.doi.org/10.1016/S0091-6749(00)90072-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	285RQ	10669843				2022-12-18	WOS:000085402200007
J	Kodama, T; Matsuyama, T; Kuribayashi, K; Nishioka, Y; Sugita, M; Akira, S; Nakanishi, K; Okamura, H				Kodama, T; Matsuyama, T; Kuribayashi, K; Nishioka, Y; Sugita, M; Akira, S; Nakanishi, K; Okamura, H			IL-18 deficiency selectively enhances allergen-induced eosinophilia in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-18; eosinophil; bronchial asthma; apoptosis; Fas ligand	INDUCED AIRWAY HYPERRESPONSIVENESS; T-CELL ACTIVATION; HUMAN NK CELLS; IFN-GAMMA; INTERFERON-GAMMA; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; TRANSGENIC MICE; MURINE MODEL; MOUSE MODEL	Background: T-H2 cytokines are associated with airway inflammation and hyperreactivity in bronchial asthma, and restoration of the T-H1/T-H2 imbalance is a potential avenue for novel therapies. IL-18 is a cytokine secreted by activated macrophages, and it shares some of its biologic activities with IL-12, a typical T-H1-type cytokine. Although IL-18 and IL-12 act on T cells synergistically to induce IFN-gamma production, the contribution of IL-18 T-H1/T-H2 imbalance and to subsequent asthmatic response has not been elucidated in vivo. Objective: We studied a model of allergic asthma in IL-18-deficient mice to investigate the modulatory role of IL-18 on induction and maintenance of T-H2 mucosal immunity. We also have investigated the ability of intraperitoneal instilled IL-18 to reduce T-H2 mucosal immunity in IL-18-deficient mice. Methods: IL-18-deficient mice immunized to ovalbumin by means of intraperitoneal injection were challenged 3 times with an aerosol of ovalbumin every second day for 8 days. Recombinant (r)IL-18 was intraperitoneally administered in mice before every first challenge. Mice were analyzed for effects on lung eosinophilia, cytokines, and serum IgE levels. Results: In IL-18-deficient mice, Levels of eosinophilia and lung damage were significantly higher than in wild-type C57/BL6 litter mates. Intraperitoneal administration of rIL-18 in deficient mice reduced these antigen-induced changes to levels seen in wild-type mice in association with a decrease in IL-4 in bronchoalveolar lavage fluid and lung tissue. However, administration of rIL-18 did not affect the IFN-gamma level and somewhat enhanced the production of IL-5, Notably, reconstitution with rIL-18 increased the numbers of cells staining for Fas ligand, as well as apoptotic cells stained by nick end-labeling in bronchial submucosa infiltrates. Conclusion: These findings indicate that in vivo IL-18 not only inhibited antigen-specific T-H2 development but also affected apoptosis through Fas-Fas ligand interactions. These data support a role for IL-18 in the complex pathogenesis of allergic inflammation in which IL-18 limited the development of the local inflammatory response to antigen.	Hyogo Coll Med, Dept Internal Med 5, Nishinomiya, Hyogo 6638501, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Osaka, Japan; Hyogo Coll Med, Dept Immunol & Med Zool, Nishinomiya, Hyogo, Japan; Hyogo Coll Med, Inst Adv Med Sci, Host Def Lab, Nishinomiya, Hyogo, Japan	Hyogo College of Medicine; Osaka University; Hyogo College of Medicine; Hyogo College of Medicine	Matsuyama, T (corresponding author), Hyogo Coll Med, Dept Internal Med 5, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Akira, Shizuo/C-3134-2009					Ahn HJ, 1997, J IMMUNOL, V159, P2125; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Dao T, 1996, CELL IMMUNOL, V173, P230, DOI 10.1006/cimm.1996.0272; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hyodo Y, 1999, J IMMUNOL, V162, P1662; IWAMOTO T, 1995, INT ARCH ALLERGY IMM, V108, P28, DOI 10.1159/000237196; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Kodama T, 1998, CLIN EXP ALLERGY, V28, P1435; Lack G, 1996, J IMMUNOL, V157, P1432; Lefort J, 1996, J ALLERGY CLIN IMMUN, V97, P788, DOI 10.1016/S0091-6749(96)80157-6; Li XM, 1996, J IMMUNOL, V157, P3216; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sagara H, 1997, INT ARCH ALLERGY IMM, V112, P287, DOI 10.1159/000237468; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Takeuchi M, 1997, CELL TISSUE RES, V289, P499, DOI 10.1007/s004410050895; Tsutsui H, 1996, J IMMUNOL, V157, P3967; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Ushio S, 1996, J IMMUNOL, V156, P4274; Walker C, 1998, J IMMUNOL, V161, P1962; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Warren HS, 1996, J IMMUNOL, V156, P3254; WARREN HS, 1995, J IMMUNOL, V154, P5144; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	43	68	73	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				45	53		10.1016/S0091-6749(00)90176-3	http://dx.doi.org/10.1016/S0091-6749(00)90176-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629451				2022-12-18	WOS:000084992100006
J	Teuber, SS; Peterson, WR				Teuber, SS; Peterson, WR			Systemic allergic reaction to coconut (Cocos nucifera) in 2 subjects with hypersensitivity to tree nut and demonstration of cross-reactivity to legumin-like seed storage proteins: New coconut and walnut food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						coconut allergy; glycinin; legumin; tree nut allergy; food allergy	JUGLANS-REGIA; GLOBULIN; ENDOSPERM; CLONING	Background: Two patients with tree nut allergy manifested by life-threatening systemic reactions reported the subsequent onset of systemic reactions after the consumption of coconut. Objective: Herein, the IgE-binding proteins from coconut are described, and in vitro cross-reactivity with other nuts is investigated. Methods: The IgE-binding profile of coconut endosperm tissue extract was analyzed by SDS-PAGE followed by immunoblotting. Immunoblot inhibition studies with walnut, almond, peanut, and coconut were performed. Results: Sera IgE from both patients recognized reduced coconut allergens with molecular weights of 35 and 36.5 kd, IgE from 1 patient also bound a 55-kd antigen, Preabsorption of sera with nut extracts suppressed IgE binding to coconut proteins. Preabsorption of sera with coconut caused the disappearance of IgE binding to protein bands at 35 and 36 kd on a reduced immunoblot of walnut protein extract in 1 patient and suppression of IgE binding to a protein at 36 kd in the other patient. Conclusion: The reduced coconut protein at 35 kd was previously shown to be immunologically similar to soy glycinin (legumin group of seed storage proteins). The clinical reactivity in these 2 patients is likely due to cross-reacting IgE antibodies primarily directed against walnut, the original clinical allergy reported, and most likely to a walnut legumin-like protein. Coconut allergy in patients with tree nut allergy is rare; these are the first 2 patients ever reported, and therefore there is no general indication to advise patients with tree nut allergy to avoid coconut.	Dept Vet Affairs No Calif Healthcare Syst, Pleasant Hill, CA 94523 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA	University of California System; University of California Davis	Teuber, SS (corresponding author), Dept Vet Affairs No Calif Healthcare Syst, Pleasant Hill, CA 94523 USA.				NIDDK NIH HHS [DK 3547] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGOS P, 1985, EMBO J, V4, P1111, DOI 10.1002/j.1460-2075.1985.tb03747.x; BALACHANDRAN C, 1992, J FOOD SCI TECH MYS, V29, P91; BORROTO K, 1987, PLANT MOL BIOL, V8, P113, DOI 10.1007/BF00025323; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; CARR HJ, 1990, FOOD CHEM, V38, P11, DOI 10.1016/0308-8146(90)90202-F; Couturier P, 1994, Allerg Immunol (Paris), V26, P386; Dandekar A. M., 1993, WALNUT RES REPORTS; DEMASON DA, 1990, BOT GAZ, V151, P302, DOI 10.1086/337830; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; Rabjohn P, 1998, J ALLERGY CLIN IMMUN, V101, pS240; RASYID F, 1992, FOOD HYDROCOLLOID, V6, P301, DOI 10.1016/S0268-005X(09)80097-0; Sjogren B, 1930, J AM CHEM SOC, V52, P4400, DOI 10.1021/ja01374a031; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; TEUBER SS, 1995, J ALLERGY CLIN IMMUN, V95, P332; VOIGT J, 1994, FOOD CHEM, V51, P197, DOI 10.1016/0308-8146(94)90257-7; WALLACE RW, 1976, ANAL BIOCHEM, V75, P498, DOI 10.1016/0003-2697(76)90105-6	16	68	71	2	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1180	1185		10.1016/S0091-6749(99)70196-X	http://dx.doi.org/10.1016/S0091-6749(99)70196-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359903				2022-12-18	WOS:000080929500030
J	Puhakka, T; Makela, MJ; Malstrom, K; Uhari, M; Savolainen, J; Terho, EO; Pulkkinen, M; Ruuskanen, O				Puhakka, T; Makela, MJ; Malstrom, K; Uhari, M; Savolainen, J; Terho, EO; Pulkkinen, M; Ruuskanen, O			The common cold: Effects of intranasal fluticasone propionate treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						common cold; cold; fluticasone propionate; rhinovirus; viral respiratory infection	CLINICAL SPECIMENS; RHINOVIRUS COLDS; GLUCOCORTICOSTEROIDS; PICORNAVIRUSES; ENTEROVIRUSES; INFECTIONS; SEQUENCE; BACTERIA; THERAPY; PCR	Objective: A double-blind, randomized, placebo-controlled trial was conducted to study the effect of the intranasal corticosteroid, fluticasone propionate (FP), in the naturally occur ring common cold. Methods: One hundred ninety-nine young adults received high-dose FP (200 mu g four times daily) or placebo beginning 23 to 48 hours after onset of the common cold for 6 days. All symptoms were recorded on diary cards on days 1 to 20, and clinical examinations were carried out on days 1, 7, and 21, Nasopharyngeal aspirates were collected on days 1 and 7 for detection of rhinoviruses (found in 105 subjects) and Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis (found in 52 subjects) in the nasopharynx. Results: In general, FP treatment had no clinically recognizable effects on the symptoms of the common cold, although it significantly reduced nasal congestion and cough on some study days. After treatment, rhinoviruses were cultured more often in the FP treatment group (37% vs 14%, p < 0.001), but this had no Effect on the symptoms of common cold. FP treatment produced no changes in the colonization of pathogenic bacteria in the nasopharynx. Some symptoms of common cold were significantly more severe during days 1 to 10 (p < 0.05) in subjects found to have positive cultures for S. pneumoniae, H. influenzae, or M. catarrhalis in the nasopharynx on day 1 (n = 33). Conclusion: FP treatment does not have any marked effects on the symptoms of the common cold. FP treatment induced prolonged shedding of viable rhinoviruses. Some symptoms of the common cold were significantly more severe in subjects with pathogenic bacteria in the nasopharynx.	Univ Turku, Dept Pediat, Res Unit, SF-20500 Turku, Finland; Univ Turku, Dept Pulm Dis, SF-20500 Turku, Finland; Univ Turku, Dept Clin Allergol, SF-20500 Turku, Finland; Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland	University of Turku; University of Turku; University of Turku; University of Oulu	Puhakka, T (corresponding author), Univ Turku, Dept Pediat, Res Unit, Vaha Hameenkatu 1 A 3, SF-20500 Turku, Finland.		Savolainen, Johannes/D-2241-2011					Arola A, 1996, J CLIN MICROBIOL, V34, P313, DOI 10.1128/JCM.34.2.313-318.1996; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; CLEMENTSEN P, 1990, ALLERGY, V45, P464, DOI 10.1111/j.1398-9995.1990.tb01098.x; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995; HAYDEN FG, 1995, ANTIMICROB AGENTS CH, V39, P290, DOI 10.1128/AAC.39.2.290; HUGHES PJ, 1988, J GEN VIROL, V69, P49, DOI 10.1099/0022-1317-69-1-49; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; Klassen TP, 1997, PEDIATR CLIN N AM, V44, P249, DOI 10.1016/S0031-3955(05)70472-7; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; OLIVE DM, 1990, J GEN VIROL, V71, P2141, DOI 10.1099/0022-1317-71-9-2141; SPERBER SJ, 1988, ANTIMICROB AGENTS CH, V32, P409, DOI 10.1128/AAC.32.4.409; TASHIRO M, 1987, VIROLOGY, V157, P421, DOI 10.1016/0042-6822(87)90284-4; Turner RB, 1997, ANN ALLERG ASTHMA IM, V78, P531, DOI 10.1016/S1081-1206(10)63213-9	18	68	73	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				726	731		10.1016/S0091-6749(98)70301-X	http://dx.doi.org/10.1016/S0091-6749(98)70301-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648698				2022-12-18	WOS:000074414200003
J	Peden, DB; Boehlecke, B; Horstman, D; Devlin, R				Peden, DB; Boehlecke, B; Horstman, D; Devlin, R			Prolonged acute exposure to 0.16 ppm ozone induces eosinophilic airway inflammation in asthmatic subjects with allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ozone; asthma; eosinophils; air pollution	BRONCHOALVEOLAR LAVAGE; EPITHELIAL-CELLS; RESPONSES; POLLUTION; RESPONSIVENESS; CHALLENGE; CYTOKINES; ANTIGEN; RELEASE	Background: Increased ambient ozone levels have been associated with increased asthma morbidity in epidemiologic studies. Given that asthma is characterized by airway inflammation and increased sensitivity to airway irritants, it has been suggested that asthmatic subjects may be particularly sensitive to the effect of ozone. Objective: The objective of this study was to determine whether exposure to 0.16 ppm ozone induces eosinophilic inflammation in the lower airways of asthmatic subjects. Methods: Eight asthmatic subjects sensitive to mites were exposed to 0.16 ppm ozone and clean air on separate occasions no less than 4 weeks apart in a double-blind, randomized fashion followed by bronchoscopy 18 hours later. Bronchoalveolar lavage fluid and bronchial lavage fluid were examined for eosinophils. Results: Ozone induced significant increases in airway eosinophils, especially in bronchial lavage fluid. Conclusions: Ozone exposure results in increased eosinophilic inflammation in the lower airways of asthmatic subjects with allergies.	Univ N Carolina, Ctr Environm Med & Lung Biol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Div Pulm Med & Allergy, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Div Pulm & Crit Care Med, Chapel Hill, NC 27599 USA; US EPA, Human Studies Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; United States Environmental Protection Agency	Peden, DB (corresponding author), Univ N Carolina, Ctr Environm Med & Lung Biol, Sch Med, CB 7310,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627	NCRR NIH HHS [RR00046] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BALMES JR, 1993, ENVIRON HEALTH PERSP, V101, P219, DOI 10.2307/3431683; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P243, DOI 10.2307/3432380; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; BECK NB, 1994, INHAL TOXICOL, V6, P345, DOI 10.3109/08958379409003032; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; Devlin RB, 1996, TOXICOL APPL PHARM, V138, P176, DOI 10.1006/taap.1996.0111; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; FOLINSBEE LJ, 1993, ENVIRON HEALTH PERSP, V100, P45, DOI 10.2307/3431520; Horstman DH, 1995, TOXICOL IND HEALTH, V11, P369, DOI 10.1177/074823379501100401; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; KLEEBERGER SR, 1993, AM REV RESPIR DIS, V148, P1284, DOI 10.1164/ajrccm/148.5.1284; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; MCBRIDE DE, 1994, AM J RESP CRIT CARE, V149, P1192, DOI 10.1164/ajrccm.149.5.8173759; MCKINNON K, 1992, CHEST, V101, pS22, DOI 10.1378/chest.101.3_Supplement.22S; MCKINNON KP, 1993, TOXICOL APPL PHARM, V118, P215, DOI 10.1006/taap.1993.1027; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; RENNARD SI, 1990, AM REV RESPIR DIS, V141, P208, DOI 10.1164/ajrccm/141.1.208; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021	25	68	70	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				802	808		10.1016/S0091-6749(97)70277-X	http://dx.doi.org/10.1016/S0091-6749(97)70277-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438490				2022-12-18	WOS:000071353600014
J	Calderon, MA; Devalia, JL; Prior, AJ; Sapsford, RJ; Davies, RJ				Calderon, MA; Devalia, JL; Prior, AJ; Sapsford, RJ; Davies, RJ			A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergic rhinitis; nasal epithelial cells; cytokines; eosinophils	COLONY-STIMULATING FACTOR; SEASONAL ALLERGIC RHINITIS; INFLAMMATORY CYTOKINES; HUMAN EOSINOPHILS; MUCOUS-MEMBRANE; MAST-CELLS; IN-VITRO; RANTES; INTERLEUKIN-8; INFILTRATION	Background: Recent studies have suggested that airway epithelial cells of atopic and nonatopic individuals may differ in their ability to produce proinflammatory cytokines. Methods: We have cultured human nasal epithelial cells (NECs) as confluent explant cultures from nasal biopsy specimens of well-characterized nonatopic normal volunteers without rhinitis (n = 8), atopic volunteers without rhinitis (n = 9), and atopic patient volunteers with rhinitis (n = 10) and measured the amounts of IL-1 beta, IL-8, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and RANTES released spontaneously into the culture medium by these cells in vitro. NECs from patients with allergic rhinitis were cultured from biopsy specimens obtained on two different occasions, during and after the pollen season. Results: In general, NECs from atopic individuals released significantly greater amounts of IL-1 beta, IL-8, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and RANTES than NECs from nonatopic individuals. IL-8 was released iir greatest quantity and IL-1 beta in lowest quantity, regardless of whether the NECs were derived from atopic or nonatopic volunteers. Of the atopic individuals, NECs of atopic patients with rhinitis naturally exposed to pollen released greater quantities of all these cytokines, compared with NECs of atopic patients with rhinitis and atopic patients without rhinitis who were not exposed To allergen. Conclusions: These results suggest that NECs of atopic individuals, who are genetically predisposed to upper airway disease, release increased amounts of proinflammatory cytokines and that natural exposure to allergen enhances the release of these cytokines, exacerbating the symptoms of allergic disease.	ST BARTHOLOMEWS HOSP, DEPT RESP MED & ALLERGY, LONDON, ENGLAND; ST BARTHOLOMEWS HOSP, DEPT OTOLARYNGOL, LONDON, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								ABDELAZIZ MM, 1995, AM J RESP CELL MOL, V13, P728, DOI 10.1165/ajrcmb.13.6.7576711; ALAM R, 1993, J IMMUNOL, V150, P3442; BACHERT C, 1995, EUR ARCH OTO-RHINO-L, V252, pS44, DOI 10.1007/BF02484434; BAROODY FM, 1995, EUR ARCH OTO-RHINO-L, V252, pS50, DOI 10.1007/BF02484435; BECK LA, 1994, J ALLERGY CLIN IMMUN, V93, P234; Bjerke T, 1994, Pediatr Allergy Immunol, V5, P88, DOI 10.1111/j.1399-3038.1994.tb00223.x; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P406, DOI 10.1111/j.1365-2222.1995.tb01071.x; BYRON KA, 1994, CLIN EXP IMMUNOL, V95, P333, DOI 10.1111/j.1365-2249.1994.tb06533.x; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; CANONICA GW, 1995, P 16 EUR C ALL CLIN, P137; DAVIES RJ, 1992, ASTHMA BASIC MECHANI, P143; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, RESP MED, V87, P405, DOI 10.1016/0954-6111(93)90064-7; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DEVALIA JL, 1992, CLIN EXP ALLERY, V22, P120; DUFF AL, 1993, PEDIATRICS, V92, P535; Durham S R, 1993, Pediatr Allergy Immunol, V4, P7; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; LOZEWICZ S, 1991, INT ARCH ALLER A IMM, V95, P273, DOI 10.1159/000235441; LOZEWICZ S, 1991, RESP MED, V85, P259, DOI 10.1016/S0954-6111(06)80093-4; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; MULLOL J, 1995, CLIN EXP ALLERGY, V25, P607, DOI 10.1111/j.1365-2222.1995.tb01108.x; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; OHTOSHI T, 1991, INT ARCH ALLER A IMM, V95, P376, DOI 10.1159/000235476; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PRIOR AJ, 1995, RESP MED, V89, P161, DOI 10.1016/0954-6111(95)90242-2; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; SCHWEIZER RC, 1994, BLOOD, V83, P3697; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; SHUTE J, 1994, CLIN EXP ALLERGY, V24, P203, DOI 10.1111/j.1365-2222.1994.tb00220.x; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; VANOVERVELD FJ, 1991, CLIN EXP ALLERGY, V21, P711; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x; ZHANG L, 1994, CLIN EXP ALLERGY, V24, P899, DOI 10.1111/j.1365-2222.1994.tb02720.x	43	68	72	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				65	76		10.1016/S0091-6749(97)70302-6	http://dx.doi.org/10.1016/S0091-6749(97)70302-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003213				2022-12-18	WOS:A1997WD06100010
J	Kraft, M; Torvik, JA; Trudeau, JB; Wenzel, SE; Martin, RJ				Kraft, M; Torvik, JA; Trudeau, JB; Wenzel, SE; Martin, RJ			Theophylline: Potential antiinflammatory effects in nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						theophylline; asthma; nocturnal; inflammation; lung function		Background: Recent information suggests that one of the therapeutic properties of theophylline is an antiinflammatory effect. Objective: We evaluated this potential effect of theophylline in eight patients with nocturnal asthma. Methods: The study design was a randomized, a double-blind, placebo-controlled crossover of 2-week treatment periods, separated by a 1-week washout period. Spirometry and bronchoscopy were performed. Results: Theophylline, compared with placebo, significantly improved the overnight decrement in lung function. The higher the nocturnal theophylline level, the greater the improvement in lung function. Theophylline also significantly decreased the percentage of neutrophils in the 4:00 AM bronchoalveolar lavage fluid and stimulated leukotriene B-4 levels from macrophages obtained at 4:00 AM. The greater change in neutrophils correlated with increasing serum theophylline concentration. Also, the change in leukotriene B-4 production was significantly correlated with the theophylline-induced decrement in lavage granulocytes (neutrophils and eosinophils). Conclusion: This study suggests that one action of theophylline is to alter inflammatory cell number and function in nocturnal asthma and that it may do this through an leukotriene B-4-mediated mechanism.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DIV PULM SCI & CRIT CARE MED,DENVER,CO 80202	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P577, DOI 10.1164/ajrccm/145.3.577; COHEN J, 1989, STAT POWER ANAL BEHA, P19; DALONZO GE, 1990, AM REV RESPIR DIS, V142, P84, DOI 10.1164/ajrccm/142.1.84; DENT G, 1994, AM J RESP CELL MOL, V10, P565, DOI 10.1165/ajrcmb.10.5.8179921; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; JONES B, 1989, DESIGN ANAL CROSSOVE; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; PAUWELS RA, 1989, J ALLERGY CLIN IMMUN, V83, P548, DOI 10.1016/0091-6749(89)90036-5; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; WENZEL SE, 1994, J ALLERGY CLIN IMMUN, V94, P870, DOI 10.1016/0091-6749(94)90155-4; WILLCOX M, 1988, AM REV RESPIR DIS, V138, P74, DOI 10.1164/ajrccm/138.1.74	13	68	69	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1242	1246		10.1016/S0091-6749(96)70191-4	http://dx.doi.org/10.1016/S0091-6749(96)70191-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648019				2022-12-18	WOS:A1996VD60700011
J	ASANO, K; LILLY, CM; ODONNELL, WJ; ISRAEL, E; FISCHER, A; RANSIL, BJ; DRAZEN, JM				ASANO, K; LILLY, CM; ODONNELL, WJ; ISRAEL, E; FISCHER, A; RANSIL, BJ; DRAZEN, JM			DIURNAL-VARIATION OF URINARY LEUKOTRIENE E(4) AND HISTAMINE EXCRETION RATES IN NORMAL SUBJECTS AND PATIENTS WITH MILD-TO-MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MEDIATORS; LEUKOTRIENES; EXCRETION RATE; URINE; HISTAMINE; ASTHMA	RESPIRATORY-DISTRESS SYNDROME; CYSTEINYL LEUKOTRIENES; ANTIGEN CHALLENGE; BRONCHIAL-ASTHMA; NOCTURNAL ASTHMA; ALLERGEN; METABOLISM; RELEASE; HUMANS; ACID	Background: Leukotriene E(4) (LTE(4)) and histamine excreted into the urine reflect the in vivo synthesis and release of cysteinyl leukotrienes and histamine, respectively. We examined the diurnal variation of the excretion rate of these mediators over 4 consecutive days in normal subjects (n = 5) and patients with stable mild-to-moderate asthma (n = 8). Methods: Sixteen consecutive 6-hour urine samples were collected over 4 days. Urinary LTE(4) concentrations were determined by reverse-phase high-pressure liquid chromatography, followed by ELISA. Urinary histamine concentrations were measured by ELISA. The excretion rates of these compounds were normalized relative to urinary creatinine content. Results: The mean urinary LTE(4) excretion rate was 83.8 +/- 38.2 pg/mg creatinine (mean +/- SD) in normal subjects; in patients with asthma, the urinary LTE(4) excretion, rate (110.0 +/- 59.2 pg/mg creatinine) was significantly higher than that in normal subjects (p < 0.05). The urinary histamine excretion rate was not different between normal subjects (24.0 +/- 12.5 ng/mg creatinine) and patients with asthma (31.5 +/- 25.8 ng/mg creatinine). A robust and systematic within-day variation (p < 0.01), but no day-to-clay variation was observed in histamine excretion rate. Although the magnitude of variation in LTE(4) excretion within a day was significantly greater in patients with asthma than in normal subjects (p < 0.05), we could not identify any specific diurnal variation pattern in either the normal or the asthma group. No significant correlation was observed between urinary LTE(4) and histamine excretion rate within airy subject. Conclusions: Patients with asthma excrete LTE(4) in the urine at a greater rate than normal subjects. Although no systematic variation in urinary LTE(4) excretion rates over the course of a day was observed in either normal subjects or patients with stable asthma, the presence of a systematic diurnal variation of urinary histamine excretion exists in both groups.	BRIGHAM & WOMENS HOSP,COMBINED PROGRAM PULM & CRIT CARE MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BETH ISRAEL HOSP,DEPT MED,CHARLES A DANA RES INST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BETH ISRAEL HOSP,DEPT MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Brigham & Women's Hospital; Harvard University								BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263; CARRY M, 1992, CIRCULATION, V85, P230, DOI 10.1161/01.CIR.85.1.230; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; DENZLINGER C, 1993, BLOOD, V81, P2007; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; DUNER H, 1960, ACTA MED SCAND, V168, P307; FAULER J, 1992, J INVEST DERMATOL, V99, P8, DOI 10.1111/1523-1747.ep12611380; FAULER J, 1991, CLIN SCI, V80, P497, DOI 10.1042/cs0800497; GRANERUS G, 1980, ALLERGY, V35, P31, DOI 10.1111/j.1398-9995.1980.tb01714.x; HAKANSON R, 1991, SCAND J GASTROENTERO, V26, P88, DOI 10.3109/00365529109093183; HUBER M, 1989, EUR J CLIN INVEST, V19, P53, DOI 10.1111/j.1365-2362.1989.tb00195.x; IMAMURA I, 1984, J BIOCHEM-TOKYO, V96, P1931, DOI 10.1093/oxfordjournals.jbchem.a135028; KEYZER JJ, 1984, AGENTS ACTIONS, V15, P189, DOI 10.1007/BF01972348; KIKKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MANSO G, 1992, EUR RESPIR J, V5, P712; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; SCHULZE S, 1992, ALLERGY, V47, P644, DOI 10.1111/j.1398-9995.1992.tb02389.x; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; SMITH CM, 1992, EUR RESPIR J, V5, P693; SOUTAR CA, 1977, THORAX, V32, P677, DOI 10.1136/thx.32.6.677; TAGARI P, 1989, CLIN CHEM, V35, P388; TAYLOR GW, 1989, LANCET, V1, P584; VANAALDEREN WMC, 1991, THORAX, V46, P366, DOI 10.1136/thx.46.5.366; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322; 1987, AM REV RESPIR DIS, V136, P225	34	68	70	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				643	651		10.1016/S0091-6749(95)70263-6	http://dx.doi.org/10.1016/S0091-6749(95)70263-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499681				2022-12-18	WOS:A1995TG52800010
J	MULLER, UR; DUDLER, T; SCHNEIDER, T; CRAMERI, R; FISCHER, H; SKRBIC, D; MAIBACH, R; BLASER, K; SUTER, M				MULLER, UR; DUDLER, T; SCHNEIDER, T; CRAMERI, R; FISCHER, H; SKRBIC, D; MAIBACH, R; BLASER, K; SUTER, M			TYPE-I SKIN REACTIVITY TO NATIVE AND RECOMBINANT PHOSPHOLIPASE A(2) FROM HONEYBEE VENOM IS SIMILAR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SKIN REACTIVITY; PHOSPHOLIPASE A(2); HONEYBEE VENOM; RECOMBINANT DNA TECHNOLOGY	AMINO-ACID-SEQUENCE; BEE-VENOM; CDNA CLONING; MAJOR ALLERGEN; EXPRESSION; ANTIBODIES; DIAGNOSIS; EPITOPE	Phospholipase A(2) is the major allergen in honeybee venom. Recombinant phospholipase A(2) was produced in prokaryotes and tested for its biologic activity by intracutaneous skin testing with serial 10-fold dilutions in comparison with native and deglycosylated phospholipase A2( )in patients allergic to bee venom. Lineal regressions of the log of the wheal area versus the log of the allergen concentration were calculated for all allergens in each patient. The relative allergenic potency of the various preparations was analyzed by comparing the linear regressions. Native phospholipase A(2) was about 10 times more potent than whole bee venom. None of 58 patients allergic to bee venom was missed by testing with native phospholipase A(2) alone. This allergen and deglycosylated native phospholipase A(2) resulted in similar skin reactions, indicating that the sugar residues were of little relevance for IgE-binding in the patients tested. Native phospholipase A(2) also had relative potency similar to that of recombinant refolded phospholipase A(2) whereas recombinant nonrefolded phospholipase A(2) had almost no biologic activity in skin testing. These results demonstrate in vivo activity of the recombinant bee venom allergen phospholipase A(2). Although correct refolding is a prerequisite for type I skin reactivity, glycosylation seems to be less important.	SWISS INST ALLERGY & ASTHMA RES,CH-7270 DAVOS,SWITZERLAND	Swiss Institute of Allergy & Asthma Research	MULLER, UR (corresponding author), ZIEGLERSPITAL BERN,DIV MED,CH-3007 BERN,SWITZERLAND.							AUKRUST L, 1982, ALLERGY, V37, P265, DOI 10.1111/j.1398-9995.1982.tb01909.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; CHUA KY, 1988, J EXP MED, V167, P275; Dreborg S., 1989, ALLERGY S10, V44; DUDLER T, 1994, J IMMUNOL, V152, P5514; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FORSTER E, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P307; HELD W, 1989, SCAND J IMMUNOL, V29, P203, DOI 10.1111/j.1365-3083.1989.tb01117.x; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LOWENSTEIN H, 1991, CLIN EXP ALLERGY S1, V21, P227; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MOSER M, 1992, J IMMUNOL, V149, P454; Muller UR., 1990, INSECT STING ALLERGY; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V260, P1229; SACHS L, 1978, ANGEWANDTE STATISTIK; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; SCHNEIDER T, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P303; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; STUBER D, 1990, IMMUNOLOGICAL METHOD, P121; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	35	68	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					395	402		10.1016/S0091-6749(95)70059-5	http://dx.doi.org/10.1016/S0091-6749(95)70059-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560642				2022-12-18	WOS:A1995RU66000012
J	INMAN, MD; WATSON, R; COCKCROFT, DW; WONG, BJO; HARGREAVE, FE; OBYRNE, PM				INMAN, MD; WATSON, R; COCKCROFT, DW; WONG, BJO; HARGREAVE, FE; OBYRNE, PM			REPRODUCIBILITY OF ALLERGEN-INDUCED EARLY AND LATE ASTHMATIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGEN INHALATION CHALLENGE; EARLY ASTHMATIC RESPONSE; LATE ASTHMATIC RESPONSE; REPRODUCIBILITY; SAMPLE SIZE	INDUCED BRONCHOCONSTRICTION; AIRWAY RESPONSIVENESS; BRONCHIAL RESPONSIVENESS; INHALED SALBUTAMOL; HISTAMINE; INCREASE; THEOPHYLLINE; SALMETEROL; ANTAGONIST; REACTIVITY	Background: Constant-dose allergen inhalation challenges are frequently used to examine the effect of antiasthma drugs on the allergen-induced early and late asthmatic responses. The end-point measurements in such studies ave the maximal early and late percent decreases in the forced expiratory volume in I second (FEV(1)). Objective: Our purpose was to observe the reproducibility and to determine the sample sizes required for such studies. Methods: Twenty-eight subjects with allergen-induced early and late responses were studied with two constant-dose allergen challenges separated by 2 to 12 weeks. The early response was measured as the maximum percent decrease in FEY(1) during the first 2 hours and the late response as the maximum percent decrease in FEV(1) between 3 to 7 hours. Results: The mean +/- SEM early responses were 23.1% +/- 1.0% and 24.7% +/- 2.0%, whereas the mean late responses were 23.3% +/- 2.0% and 24.5% +/- 2.2%. Reproducibility of measurements were such that fewer than eight subjects are required, to show 50% attenuation of either the early or late response (with 90% power). Conclusions: The method of constant-dose allergen challenge is a sensitive tool for detecting changes in early and late asthmatic responses after the use of antiasthma medication.	MCMASTER UNIV,HLTH SCI CTR,DEPT MED,ASTHMA RES GRP,HAMILTON,ON L8N 3Z5,CANADA; UNIV SASKATCHEWAN HOSP,RESP MED SECT,SASKATOON,SK S7N 0W8,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Saskatchewan				O'Byrne, Paul/0000-0003-0979-281X				CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; FREITAG A, 1993, THORAX, V48, P594, DOI 10.1136/thx.48.6.594; KEPPEL G, 1982, DESIGN ANAL RES HDB, P70; MANNING PJ, 1991, EUR RESPIR J, V4, P667; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1431, DOI 10.1164/ajrccm/147.6_Pt_1.1431; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PELIKAN Z, 1993, J ALLERGY CLIN IMMUN, V92, P19, DOI 10.1016/0091-6749(93)90032-B; PEPYS J, 1968, LANCET, V2, P134; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; STEINER DL, 1989, HLTH MEASUREMENT SCA, P79; TAYLOR IK, 1992, J ALLERGY CLIN IMMUN, V89, P575, DOI 10.1016/0091-6749(92)90325-V; TWENTYMAN OP, 1993, AM REV RESPIR DIS, V147, P1425, DOI 10.1164/ajrccm/147.6_Pt_1.1425; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; TWENTYMAN OP, 1991, AM REV RESPIR DIS, V144, P782, DOI 10.1164/ajrccm/144.4.782; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518	25	68	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1191	1195		10.1016/S0091-6749(95)70075-7	http://dx.doi.org/10.1016/S0091-6749(95)70075-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797787				2022-12-18	WOS:A1995RD30900006
J	MELISKA, CJ; STUNKARD, ME; GILBERT, DG; JENSEN, RA; MARTINKO, JM				MELISKA, CJ; STUNKARD, ME; GILBERT, DG; JENSEN, RA; MARTINKO, JM			IMMUNE FUNCTION IN CIGARETTE SMOKERS WHO QUIT SMOKING FOR 31 DAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SMOKING; IMMUNITY; NATURAL KILLER CELL; CON A; PHA; CORTISOL; NICOTINE; COTININE; ALCOHOL	KILLER-CELL-ACTIVITY; MAJOR DEPRESSIVE DISORDER; NATURAL-KILLER; HUMAN-LYMPHOCYTES; NICOTINE; ALCOHOL; SUPPRESSION; CORTISOL; SYSTEM; MECHANISMS	A group of 28 healthy, white, male, light-to-moderate smokers, 21 to 35 years of age, were offered a financial inducement to abstain from smoking for 31 days. A matched control group of 11 smokers were paid to continue smoking during the same period. Nonspecific parameters of immune system function were monitored before and at various times after smoking abstinence. Abstinence increased natural killer cell cytotoxic activity but did nor alter mitogen-induced T-lymphocyte proliferation as measured by responses to concanavalin A or phytohemagglutinin. Serum cortisol concentrations also decreased after smoking cessation; however, changes in immune function were not correlated with serum cortisol change, nor with indices of smoking such as plasma nicotine and cotinine levels. Responses to concanavalin A and phytohemmaglutinin were positively correlated with change in self-reported alcohol ingestion during smoking abstinence. Results indicate that elevation in natural kill cell cytotoxic activity is detectable within 1 month of smoking cessation, even in light-to-moderate smokers. However, elevation in natural killer cell cytotoxic activity appears nor to be directly related to cessation-induced reductions in plasma nicotine, cotinine, or circulating cortisol levels.	SO ILLINOIS UNIV,DEPT MICROBIOL,CARBONDALE,IL 62901; SO ILLINOIS UNIV,DEPT PSYCHOL,CARBONDALE,IL 62901	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University	MELISKA, CJ (corresponding author), SO ILLINOIS UNIV,SCH MED,DEPT PHYSIOL,CARBONDALE,IL 62901, USA.							ALDOBENSON M, 1989, ALCOHOL CLIN EXP RES, V13, P469, DOI 10.1111/j.1530-0277.1989.tb00358.x; BAHNA SL, 1980, J ALLERGY CLIN IMMUN, V65, P231; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; BENSCHOP RJ, 1993, LIFE SCI, V52, P1825, DOI 10.1016/0024-3205(93)90002-K; BRODIE C, 1994, CLIN IMMUNOL IMMUNOP, V70, P129, DOI 10.1006/clin.1994.1020; CAGGIULA AR, 1992, DRUG DEVELOP RES, V26, P473, DOI 10.1002/ddr.430260411; FERSON M, 1979, INT J CANCER, V23, P603, DOI 10.1002/ijc.2910230504; FUXE K, 1989, PSYCHONEUROENDOCRINO, V14, P19, DOI 10.1016/0306-4530(89)90054-1; GATTI G, 1987, J STEROID BIOCHEM, V26, P49, DOI 10.1016/0022-4731(87)90030-6; GEISER DS, 1989, CLIN PSYCHOL REV, V9, P689, DOI 10.1016/0272-7358(89)90018-4; GLASSMAN AB, 1985, ARCH PATHOL LAB MED, V109, P540; HADDEN JW, 1976, P NATL ACAD SCI USA, V73, P29; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; HERSEY P, 1983, MED J AUSTRALIA, V2, P425, DOI 10.5694/j.1326-5377.1983.tb122565.x; IRWIN M, 1988, BIOL PSYCHIAT, V24, P173, DOI 10.1016/0006-3223(88)90272-7; JACOB P, 1991, BIOL MASS SPECTROM, V20, P247, DOI 10.1002/bms.1200200503; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; JAFFE JH, 1992, NICOTINE PSYCHOPHARM, P1; KIECOLTGLASER JK, 1986, PSYCHOSOMATICS, V27, P621, DOI 10.1016/S0033-3182(86)72630-3; KRONFOL Z, 1984, LANCET, V1, P1026; KUSAKA Y, 1992, PREV MED, V21, P602, DOI 10.1016/0091-7435(92)90068-S; LINDEMANN RA, 1989, ARCH ORAL BIOL, V34, P283, DOI 10.1016/0003-9969(89)90069-1; MELISKA CJ, 1991, PHARMACOL BIOCHEM BE, V40, P229, DOI 10.1016/0091-3057(91)90544-C; MILI F, 1991, CLIN IMMUNOL IMMUNOP, V59, P187, DOI 10.1016/0090-1229(91)90017-5; MILLER LG, 1982, CHEST, V82, P526, DOI 10.1378/chest.82.5.526; MUFTI SI, 1989, CRIT REV ONCOL HEMAT, V9, P243, DOI 10.1016/S1040-8428(89)80003-4; MUFTI SI, 1988, IMMUNOPHARMACOLOGY, V15, P85, DOI 10.1016/0162-3109(88)90055-0; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NAIR MPN, 1984, J IMMUNOL, V132, P2876; NAIR MPN, 1990, CLIN IMMUNOL IMMUNOP, V54, P395, DOI 10.1016/0090-1229(90)90053-S; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; NEROZZI D, 1989, PSYCHONEUROENDOCRINO, V14, P295, DOI 10.1016/0306-4530(89)90031-0; NEWMAN LS, 1991, CLIN IMMUNOL IMMUNOP, V60, P399, DOI 10.1016/0090-1229(91)90096-S; ONSRUD M, 1981, SCAND J IMMUNOL, V13, P573, DOI 10.1111/j.1365-3083.1981.tb00171.x; PETERSEN BH, 1983, CLIN IMMUNOL IMMUNOP, V27, P135, DOI 10.1016/0090-1229(83)90062-4; PHILLIPS B, 1985, CANCER, V56, P2789, DOI 10.1002/1097-0142(19851215)56:12<2789::AID-CNCR2820561213>3.0.CO;2-2; POMERLEAU OF, 1983, PSYCHOPHARMACOLOGY, V81, P61, DOI 10.1007/BF00439275; RICE C, 1983, IMMUNOPHARMACOLOGY, V6, P303, DOI 10.1016/0162-3109(83)90036-X; SANTELLA RM, 1992, CARCINOGENESIS, V13, P2041, DOI 10.1093/carcin/13.11.2041; SCHLEIFER SJ, 1989, ARCH GEN PSYCHIAT, V46, P81; SCHLEIFER SJ, 1984, ARCH GEN PSYCHIAT, V41, P484; STITZER ML, 1988, NICOTINE REPLACEMENT, P163; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P612, DOI 10.1164/ajrccm/144.3_Pt_1.612; WATSON RR, 1993, ADV NEUROIMMUNOL, V3, P151, DOI 10.1016/S0960-5428(06)80045-8; WHITESIDE TL, 1990, J CLIN LAB ANAL, V4, P102, DOI 10.1002/jcla.1860040207; WILKINS JN, 1982, PSYCHOPHARMACOLOGY, V78, P305, DOI 10.1007/BF00433730	46	68	69	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					901	910		10.1016/S0091-6749(95)70135-4	http://dx.doi.org/10.1016/S0091-6749(95)70135-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722172	Bronze			2022-12-18	WOS:A1995QT46800017
J	CORBO, GM; FORASTIERE, F; DELLORCO, V; PISTELLI, R; AGABITI, N; DESTEFANIS, B; CIAPPI, G; PERUCCI, CA				CORBO, GM; FORASTIERE, F; DELLORCO, V; PISTELLI, R; AGABITI, N; DESTEFANIS, B; CIAPPI, G; PERUCCI, CA			EFFECTS OF ENVIRONMENT ON ATOPIC STATUS AND RESPIRATORY DISORDERS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ATOPY; ENVIRONMENTAL AIR POLLUTION; EPIDEMIOLOGY; SYNERGISM; RESPIRATORY HEALTH; CHILDREN	LEVEL AIR-POLLUTION; SULFUR-DIOXIDE; BRONCHIAL RESPONSIVENESS; ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE; SYMPTOMS; PREVALENCE; OZONE; IGE	Background: We investigated whether living in areas with higher air pollution levels increases the prevalence of positive skin reactivity in children and the possible synergic effect of air pollution exposure and atopy on respiratory disorders. Methods: This cross-sectional study was conducted in an urban area, in an industrialized area, and in a rural control area in the Latium region of Italy. A total of 2226 subjects, aged 7 to 11 years, were studied Results: The prevalence of children with positive skin test results did not vary significantly over the areas (urban area = 21.0%, industrialized area = 22.0%, rural area = 20.2%). Children living in polluted areas experienced significantly more cough and phlegm (odds ratio [OR] = 1.5), rhinitis (OR = 1.7), pneumonia (OR = 1.7), and early respiratory infections (OR = 1.4) than control subjects. The pattern of the odds ratios for atopy and air pollution suggested that the two factors were probably additive in affecting asthma and early respiratory infections (synergy index [SI] = 1.04 and 1.27, respectively), whereas they seemed to act synergically in regard to cough and phlegm (SI = 1.59), rhinitis (SI = 3.01), and pneumonia (SI = 2.75). Conclusion: Environmental air pollution seems not to increase the prevalence of atopic status; it seems, however, to enhance the development of clinical symptoms among already sensitized subjects.	UNIV CATTOLICA SACRO CUORE, DEPT RESP PHYSIOL, I-00168 ROME, ITALY; LATIUM REG HLTH AUTHOR, EPIDEMIOL UNIT, ROME, ITALY; LOCAL HLTH UNIT RM21, CIVITAVECCHIA, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			CORBO, Giuseppe Maria/AAB-9964-2019; Agabiti, Nera/K-1053-2016; Forastiere, Francesco/J-9067-2016	CORBO, Giuseppe Maria/0000-0002-8104-4659; Agabiti, Nera/0000-0003-3385-1197; Forastiere, Francesco/0000-0002-9162-5684				ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BERCIANO FA, 1989, ANN ALLERGY, V62, P135; BERCIANO FA, 1987, ALLERGY, V42, P276, DOI 10.1111/j.1398-9995.1987.tb02210.x; BJORKSTEN B, 1990, CLIN EXP ALLERGY, V20, P3, DOI 10.1111/j.1365-2222.1990.tb02463.x; COOKSON WOCM, 1988, LANCET, V1, P86; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P36; FORASTIERE F, 1992, INT J EPIDEMIOL, V21, P66, DOI 10.1093/ije/21.1.66; FORASTIERE F, 1991, CHEST, V100, P927, DOI 10.1378/chest.100.4.927; FRICK OL, 1986, J ALLERGY CLIN IMMUN, V78, P1013, DOI 10.1016/0091-6749(86)90295-2; GEHA RS, 1986, J ALLERGY CLIN IMMUN, V78, P995, DOI 10.1016/0091-6749(86)90291-5; Greenland S, 1983, Stat Med, V2, P243, DOI 10.1002/sim.4780020219; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; HOLT PG, 1988, INT ARCH ALLER A IMM, V86, P121, DOI 10.1159/000234617; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JAAKKOLA JJK, 1991, AM J PUBLIC HEALTH, V81, P1060, DOI 10.2105/AJPH.81.8.1060; JAKAB GJ, 1987, ENVIRON RES, V42, P215, DOI 10.1016/S0013-9351(87)80023-3; KAGAMIMORI S, 1986, CLIN ALLERGY, V16, P299, DOI 10.1111/j.1365-2222.1986.tb01961.x; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; LAWTHER P J, 1969, British Journal of Diseases of the Chest, V63, P45, DOI 10.1016/S0007-0971(69)80043-4; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; NELSON HS, 1985, ANN ALLERGY, V55, P441; NELSON HS, 1983, ANN ALLERGY, V51, P411; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262, DOI 10.1080/00039896.1991.9934386; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SPEKTOR DM, 1989, ENVIRON HEALTH PERSP, V79, P167, DOI 10.2307/3430545; STEBBINGS JH, 1979, AM J EPIDEMIOL, V110, P27, DOI 10.1093/oxfordjournals.aje.a112784; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TSENG RYM, 1990, ANN ALLERGY, V65, P379; VIEGI G, 1991, ENVIRON HEALTH PERSP, V94, P95, DOI 10.2307/3431299; WANNER A, 1983, J ALLERGY CLIN IMMUN, V72, P347, DOI 10.1016/0091-6749(83)90498-0; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; ZHONG NS, 1990, THORAX, V45, P860, DOI 10.1136/thx.45.11.860; ZWICK H, 1991, AM REV RESPIR DIS, V144, P1075, DOI 10.1164/ajrccm/144.5.1075	41	68	69	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					616	623		10.1016/0091-6749(93)90086-U	http://dx.doi.org/10.1016/0091-6749(93)90086-U			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8409121				2022-12-18	WOS:A1993MC59000014
J	VANAS, A; BRONSKY, EA; DOCKHORN, RJ; GROSSMAN, J; LUMRY, W; MELTZER, EO; SELTZER, JM; ROGENES, PR				VANAS, A; BRONSKY, EA; DOCKHORN, RJ; GROSSMAN, J; LUMRY, W; MELTZER, EO; SELTZER, JM; ROGENES, PR			ONCE-DAILY FLUTICASONE PROPIONATE IS AS EFFECTIVE FOR PERENNIAL ALLERGIC RHINITIS AS TWICE-DAILY BECLOMETHASONE DIPROPRIONATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; INTRANASAL CORTICOSTEROIDS; PERENNIAL ALLERGIC RHINITIS	AQUEOUS NASAL SPRAY; CATARACT FORMATION; STEROID AEROSOLS; CORTICOSTEROIDS; DIPROPIONATE; TRIAL	Background: Fluticasone propionate aqueous nasal spray, a new potent corticosteroid, is effective when given once or twice daily for seasonal allergic rhinitis. Methods: Fluticasone propionate was compared with beclomethasone dipropionate in a multicenter double-blind, randomized, placebo-controlled, parallel-group study in 466 patients with perennial allergic rhinitis. Adults and adolescents (aged 12 to 71 years) with moderate to severe symptoms, nasal eosinophilia, and a positive skin test reaction (greater-than-or-equal-to 2+) to a perennial allergen received fluticasone propionate aqueous nasal spray 100 mug twice daily or 200 mug Once daily, or beclomethasone dipropionate aqueous nasal spray 168 mug twice daily, Or Placebo for 6 months. Results: Clinician- and patient-rated scores for nasal obstruction (including obstruction on awakening), rhinorrhea, sneezing, and nasal itching were reduced by the first visit at 7 days after initiation of active treatment and remained lower than those of patients receiving placebo throughout the 6-month treatment period. Nasal eosinophilia was reduced in significantly more patients receiving active treatment. The incidence of adverse events was similar in all four treatment groups except for blood in nasal mucus, which was reported by significantly more patients in the two twice-daily active treatment groups compared with the placebo group. There was no evidence of systemic effects of fluticasone propionate, There were no significant differences between fluticasone propionate given once or twice daily or beclomethasone dipropionate given twice daily for any efficacy or safety evaluation. Conclusions: Fluticasone propionate aqueous nasal spray given once daily in the morning is safe and effective therapy for perennial allergic rhinitis and is as effective as twice daily dosing with fluticasone propionate or beclomethasone dipropionate.	ASTHMA & ALLERGY RES CTR INC, ALBUQUERQUE, NM USA; IMMUNO ALLERGY TECH CONSULTANTS INC, PRAIRIE VILLAGE, KS USA; DALLAS ALLERGY CLIN, DALLAS, TX USA; CLIN RES INST INC, SAN DIEGO, CA USA; INTERMT ALLERGY & ASTHMA, SALT LAKE CITY, UT USA; ADV ALLERGY & ASTHMA PC, ALBANY, WY USA; ALLERGY & ASTHMA MED GRP & RES CTR, SAN DIEGO, CA USA; GLAXO INC, RES INST, RES TRIANGLE PK, NC USA	GlaxoSmithKline								ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; ENBERG RN, 1989, ANN ALLERGY, V63, P513; ESTELLE F, 1989, DRUGS, V38, P313, DOI 10.2165/00003495-198938020-00010; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; JACOBS RL, 1987, IMMUNOL ALLERGY CLIN, V7, P93; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; NATHAN RA, 1991, ANN ALLERGY, V67, P332; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; ROBINSON AC, 1989, CLIN EXP ALLERGY, V19, P569, DOI 10.1111/j.1365-2222.1989.tb02437.x; TURNERWARWICK M, 1980, CLIN ALLERGY, V10, P239; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; VANAS A, 1991, ANN ALLERGY, V67, P156; ZEIGER RS, 1989, AM J RHINOL, V3, P21	21	68	70	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1146	1154		10.1016/0091-6749(93)90317-9	http://dx.doi.org/10.1016/0091-6749(93)90317-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509578				2022-12-18	WOS:A1993LG74000006
J	GOLDEN, DBK; LAWRENCE, ID; HAMILTON, RH; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; LAWRENCE, ID; HAMILTON, RH; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			CLINICAL CORRELATION OF THE VENOM-SPECIFIC IGG ANTIBODY LEVEL DURING MAINTENANCE VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INSECT-STING ALLERGY; VENOM; ANAPHYLAXIS; IMMUNOTHERAPY; IGG ANTIBODIES; HYMENOPTERA	IMMUNOGLOBULIN-G ANTIBODIES; DIAGNOSTIC METHODS; STING CHALLENGE; INSECT ALLERGY; HYMENOPTERA; HYPERSENSITIVITY; BEE; VIT	Allergen immunotherapy is associated with a significant increase of specific IgG antibodies that have been suggested as a mechanism of action and as a marker of efficacy for immunotherapy. The value of venom-specific IgG antibody determinations as a measure of clinical protection against sting anaphylaxis has been difficult to prove in individual patients. We performed 211 insect sting challenges in 109 patients over a 4-year period to determine the significance of venom IgG levels 3 mug/ml or lower. Systemic symptoms occurred in only 1.6% of those with venom IgG more than 3 mug/ml, but in 16% of those with less than 3 mug/ml IgG, and notably in 26% of patients with low venom IgG who had received less than 4 years of treatment. The venom IgG level had no predictive value in patients who had received more than 4 years of therapy. Honeybee sting data were inconclusive because of the small number of subjects. We conclude that low venom-specific IgG levels are associated with an elevated risk of treatment failure during the first 4 years of immunotherapy with yellow jacket or mixed vespid venoms.			GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270, T32AI007056] Funding Source: NIH RePORTER; NIAID NIH HHS [P2-T32-AI07056, AI08270, AI07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BOUSQUET J, 1988, ANN ALLERGY, V61, P63; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DVORIN D, 1984, Journal of Allergy and Clinical Immunology, V73, P188; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GENTLESK MJ, 1983, INT ARCH ALLER A IMM, V71, P233, DOI 10.1159/000233396; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1987, J ALLERGY CLIN IMMUN, V79, P126; GOLDEN DBK, 1985, J ALLERGY CLIN IMMUN, V75, P208, DOI 10.1016/0091-6749(85)90550-0; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; GOLDEN DBK, 1988, IMMUNOLOGIC DISEASES, P1173; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HOFFMAN DR, 1981, ANN ALLERGY, V46, P1723; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAGEYSOBOTKA A, 1976, J IMMUNOL, V117, P84; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; Loveless MH, 1943, J IMMUNOL, V47, P165; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; URBANEK R, 1983, CLIN ALLERGY, V13, P229, DOI 10.1111/j.1365-2222.1983.tb02592.x; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V64, P1, DOI 10.1016/0091-6749(79)90073-3	38	68	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				386	393		10.1016/S0091-6749(05)80019-3	http://dx.doi.org/10.1016/S0091-6749(05)80019-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527321				2022-12-18	WOS:A1992JP52000017
J	CROSS, D; NELSON, HS				CROSS, D; NELSON, HS			THE ROLE OF THE PEAK FLOW METER IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACUTE BRONCHIAL-ASTHMA; EXPIRATORY FLOW; AIR-FLOW; OCCUPATIONAL ASTHMA; LUNG-FUNCTION; DIURNAL-VARIATION; NOCTURNAL ASTHMA; TRACHEAL SIZE; MINI-WRIGHT; OBSTRUCTION		NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206	National Jewish Health								ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; AYRES JG, 1989, RESP MED, V83, P503, DOI 10.1016/S0954-6111(89)80135-0; BAGG LR, 1980, EUR J RESPIR DIS, V61, P298; BALLARD RD, 1987, SEMIN RESPIR MED, V8, P302, DOI 10.1055/s-2007-1012668; BANNER AS, 1976, JAMA-J AM MED ASSOC, V235, P1337, DOI 10.1001/jama.235.13.1337; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BELLIA V, 1985, CHEST, V88, P89, DOI 10.1378/chest.88.1.89; BELLIA V, 1988, CHEST, V94, P108, DOI 10.1378/chest.94.1.108; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BROWN LA, 1980, ANN ALLERGY, V45, P72; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BUIST AS, 1989, J ALLERGY CLIN IMMUN, V84, P275, DOI 10.1016/0091-6749(89)90408-9; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURGE PS, 1989, CLIN EXP ALLERGY, V19, P649, DOI 10.1111/j.1365-2222.1989.tb02762.x; BURNS KL, 1979, ANN ALLERGY, V43, P246; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; CONNOLLY CK, 1987, RESPIRATION, V52, P22, DOI 10.1159/000195300; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; DAMAN HR, 1980, NEW YORK STATE J MED, V80, P1125; DEHAMEL FA, 1982, NEW ZEAL MED J, V95, P666; DOLYNIUK MV, 1986, J APPL PHYSIOL, V60, P501, DOI 10.1152/jappl.1986.60.2.501; EICHENHORN MS, 1982, CHEST, V82, P306, DOI 10.1378/chest.82.3.306; FUBINFELD AR, 1977, THORAX, V32, P177; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARM DL, 1985, J ALLERGY CLIN IMMUN, V76, P688, DOI 10.1016/0091-6749(85)90672-4; HAYDU SP, 1976, LANCET, V2, P1225; HEALY F, 1984, CHEST, V85, P476, DOI 10.1378/chest.85.4.476; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HETZEL MR, 1979, LANCET, V1, P597; HIGGS CMB, 1986, THORAX, V41, P671, DOI 10.1136/thx.41.9.671; IMBRUCE RP, 1986, DETERMINATION ACCURA; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; KELSEN SG, 1978, AM J MED, V64, P622, DOI 10.1016/0002-9343(78)90582-X; LEBOWITZ MD, 1982, CHEST, V81, P566, DOI 10.1378/chest.81.5.566; LOREN ML, 1978, CHEST, V74, P1269; MARTIN TG, 1982, ANN EMERG MED, V11, P70, DOI 10.1016/S0196-0644(82)80299-0; MATTILA MJ, 1973, CURR THER RES CLIN E, V15, P273; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MENDOZA GR, 1989, UNDERSTANDING ASTHMA, P155; MORRILL CG, 1981, ANN ALLERGY, V46, P70; NICKLAUS TM, 1969, AM REV RESPIR DIS, V100, P153; NOWAK RM, 1982, ANN EMERG MED, V11, P64, DOI 10.1016/S0196-0644(82)80298-9; OLDHAM HG, 1979, THORAX, V34, P807, DOI 10.1136/thx.34.6.807; OSMANLIEV D, 1982, AM REV RESPIR DIS, V126, P179; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; ROBIN ED, 1988, CHEST, V93, P614, DOI 10.1378/chest.93.3.614; ROBINSON DR, 1984, ARCH INTERN MED, V144, P1457, DOI 10.1001/archinte.144.7.1457; RUBINFELD AR, 1976, LANCET, V1, P882; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SILVERMAN B, 1990, ANN ALLERGY, V64, P373; SILVERMAN BA, 1987, ANN ALLERGY, V59, P350; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; STEIN LM, 1990, ANN INTERN MED, V112, P822, DOI 10.7326/0003-4819-112-11-822; TSANAKAS J, 1986, AM J DIS CHILD, V140, P738, DOI 10.1001/archpedi.1986.02140220020007; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; VAUGHAN TR, 1989, CHEST, V95, P558, DOI 10.1378/chest.95.3.558; WEBB J, 1981, THORAX, V36, P18, DOI 10.1136/thx.36.1.18; WILLIAMS MH, 1982, HOSP PRACT, V17, P95; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; WRIGHT BM, 1978, BRIT MED J, V2, P1627, DOI 10.1136/bmj.2.6152.1627; 1962, AM REV RESPIR DIS, V85, P762	70	68	70	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				120	128		10.1016/0091-6749(91)90223-B	http://dx.doi.org/10.1016/0091-6749(91)90223-B			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1825099				2022-12-18	WOS:A1991EX98500018
J	RUHNO, J; ANDERSSON, B; DENBURG, J; ANDERSON, M; HITCH, D; LAPP, P; VANZIELEGHEM, M; DOLOVICH, J				RUHNO, J; ANDERSSON, B; DENBURG, J; ANDERSON, M; HITCH, D; LAPP, P; VANZIELEGHEM, M; DOLOVICH, J			A DOUBLE-BLIND COMPARISON OF INTRANASAL BUDESONIDE WITH PLACEBO FOR NASAL POLYPOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROGENITORS; CELLS	Intranasal budesonide, 400-mu-g two times a day, was evaluated in 36 patients referred for treatment of nasal polyposis. The age range was 20 to 68 years. Polypectomy was done 5.6 (mean) times previously. After a 5-week, treatment-free, baseline period, patients were treated in a double-blind fashion with either budesonide or placebo during 4 weeks. After this treatment period, placebo-treated patients started receiving budesonide in an open trial for an additional 4 weeks. The patients rated their nasal symptoms daily. Nasal examinations and nasal inspiratory flow rate (IFR) measurements were done at clinic visits. After 3 and 4 weeks of treatment, the response to budesonide was significantly greater than response to placebo. The greater reduction in nasal blockage caused by polyps, observed on physical examination, p = 0.005, was mirrored by an increase in nasal IFR (p = 0.0001). Patient rating of the severity and frequency of nasal blockage were reduced more by budesonide than by placebo (p less-than-or-equal-to 0.0005). Switching placebo-treated patients to budesonide treatment resulted in a reduction of nasal blockage (p < 0.001) and an increase in nasal IFR (p < 0.001). The results demonstrate that topical nasal budesonide, 400-mu-g two times a day, is an effective treatment of nasal polyps.	MCMASTER UNIV, FAC HLTH SCI, DEPT PEDIAT, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT SURG, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DOLOVICH J, 1990, RHINITIS ASTHMA SIMI, P233; DRETTNER B, 1982, Rhinology (Utrecht), V20, P149; ELLULMICALLEF R, 1988, ASTHMA BASIC MECHANI, P653; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; GORDON ACH, 1987, EUR J RESPIR DIS, V71, P10; HARTWIG S, 1988, J LARYNGOL OTOL, V102, P148, DOI 10.1017/S0022215100104372; KARLSSON G, 1982, Rhinology (Utrecht), V20, P144; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; MYGIND N, 1979, NASAL ALLERGY, P233; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; Pipkorn U, 1985, ALLERGIC VASOMOTOR R, P165; RUHNO J, 1990, ALLERGY, V45, P370, DOI 10.1111/j.1398-9995.1990.tb00513.x; SLOVICK FT, 1985, BLOOD, V66, P1072; SMALL P, 1985, ANN ALLERGY, V55, P736; STIKSA G, 1985, RESPIRATION, V48, P91, DOI 10.1159/000194805; TAKASAKA T, 1986, ACTA OTO-LARYNGOL, P39; VANCHERI C, 1989, AM J RESP CELL MOL, V1, P289, DOI 10.1165/ajrcmb/1.4.289	20	68	68	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				946	953		10.1016/S0091-6749(05)80158-7	http://dx.doi.org/10.1016/S0091-6749(05)80158-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262649				2022-12-18	WOS:A1990EQ04500016
J	RODRIGO, MJ; MORELL, F; HELM, RM; SWANSON, M; GREIFE, A; ANTO, JM; SUNYER, J; REED, CE				RODRIGO, MJ; MORELL, F; HELM, RM; SWANSON, M; GREIFE, A; ANTO, JM; SUNYER, J; REED, CE			IDENTIFICATION AND PARTIAL CHARACTERIZATION OF THE SOYBEAN-DUST ALLERGENS INVOLVED IN THE BARCELONA ASTHMA EPIDEMIC	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP GEN VALLE HEBRON,SERV PNEUMOL,E-08035 BARCELONA,SPAIN; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; NATL INST ENVIRONM SCI,CINCINNATI,OH; INST MUNICIPAL INVEST MED,BARCELONA,SPAIN	Hospital Universitari Vall d'Hebron; Mayo Clinic	RODRIGO, MJ (corresponding author), HOSP GEN VALLE HEBRON,SERV BIQUIM,UNIDAD IMMUNOL,E-08035 BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; Morell Brotad, Ferran/0000-0002-7206-4543	NIAID NIH HHS [AI-21255] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021255] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; ANTO JM, 1989, NEW ENGL J MED, V320, P1997; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BUSCH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251; HERIAN AM, 1988, J ALLERGY CLIN IMMUN, V81, P264, DOI 10.1016/0091-6749(88)90619-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; REINHART MP, 1982, ANAL BIOCHEM, V123, P229, DOI 10.1016/0003-2697(82)90439-0; SUNYER J, 1989, LANCET, V1, P179; SWANSON MC, 1987, J INFECT DIS, V155, P909, DOI 10.1093/infdis/155.5.909; TAYLOR SL, 1988, J ALLERGY CLIN IMMUN, V81, P264, DOI 10.1016/0091-6749(88)90618-5; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	13	68	69	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					778	784		10.1016/0091-6749(90)90198-D	http://dx.doi.org/10.1016/0091-6749(90)90198-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324415				2022-12-18	WOS:A1990DA43700015
J	FULLER, RW; BLACK, PN; DOLLERY, CT				FULLER, RW; BLACK, PN; DOLLERY, CT			EFFECT OF THE ORAL LEUKOTRIENE D4 ANTAGONIST LY171883 ON INHALED AND INTRADERMAL CHALLENGE WITH ANTIGEN AND LEUKOTRIENE D4 IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FULLER, RW (corresponding author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DUCANE RD,LONDON W12 0HS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM WM, 1986, PROSTAGLANDINS, V31, P457, DOI 10.1016/0090-6980(86)90108-5; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BLACK PN, 1988, AM REV RESPIR DIS, V137, pA427; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P677, DOI 10.1111/j.1365-2125.1987.tb03101.x; ISRAEL E, 1988, AM REV RESPIR DIS, V137, pA27; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MANN JS, 1986, THORAX, V41, P746, DOI 10.1136/thx.41.10.746; MCFARLANE CS, 1987, AGENTS ACTIONS, V22, P63, DOI 10.1007/BF01968818; PHILLIPS GD, 1988, J PHARMACOL EXP THER, V246, P732; SHAKER G, 1988, J ALLERGY CLIN IMMUN, V81, P315, DOI 10.1016/0091-6749(88)90823-8; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TURNER N C, 1987, American Review of Respiratory Disease, V135, pA223	16	68	68	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					939	944		10.1016/0091-6749(89)90109-7	http://dx.doi.org/10.1016/0091-6749(89)90109-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2715552				2022-12-18	WOS:A1989U716100015
J	LAN, JL; LEE, DT; WU, CH; CHANG, CP; YEH, CL				LAN, JL; LEE, DT; WU, CH; CHANG, CP; YEH, CL			COCKROACH HYPERSENSITIVITY - PRELIMINARY-STUDY OF ALLERGIC COCKROACH ASTHMA IN TAIWAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET GEN HOSP,DEPT INTERNAL MED,DIV ALLERGY IMMUNOL & RHEUMATOL,VACRS,TAICHUNG 40705,TAIWAN									ASA K, 1971, J ALLERGY CLIN IMMUN, V48, P134; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1970, ANN ALLERGY, V28, P420; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY CLIN IMMUN, P35506; CAPRIO RE, 1983, IMMUNOL ALLERGY PRAC, V5, P13; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; HAMBURGER RN, 1981, IMMUNOL ALLERGY PRAC, V3, P10; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P365; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MCNICHOL RN, 1973, MED J AUST, V1, P1293; MENDOZA J, 1970, ANN ALLERGY, V28, P159; NELSON HS, 1983, ANN ALLERGY, V51, P411; SELTZER JM, 1985, ANN ALLERGY, V54, P25; SHULANER FA, 1970, PEDIATRICS, V45, P465; STENIUS B, 1969, LANCET, V2, P455; TSAY YG, IGE FLUOROALLERGOSOR; WIDE L, 1967, LANCET, V2, P1105	21	68	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				736	740		10.1016/0091-6749(88)90072-3	http://dx.doi.org/10.1016/0091-6749(88)90072-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3057039				2022-12-18	WOS:A1988R170800004
J	SIEGEL, SC				SIEGEL, SC			TOPICAL INTRANASAL CORTICOSTEROID-THERAPY IN RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AARON TH, 1964, ANN ALLERGY, V22, P155; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BJERRUM P, 1985, ALLERGY, V40, P65, DOI 10.1111/j.1398-9995.1985.tb04156.x; BLACKHOUSE CI, 1986, J INT MED RES, V14, P35; BRODER I, 1987, CAN MED ASSOC J, V136, P129; BRONSKY EA, 1987, IMMUNOL ALLERGY PRAC, V9, P165; CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; CHAMPION PK, 1974, ARCH INTERN MED, V4, P134; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; CREPEA SB, 1963, J ALLERGY, V34, P119, DOI 10.1016/0021-8707(63)90065-0; DECHATEAU GSM, 1986, ALLERGY, V41, P260; DICKSON DJ, 1984, BRIT J CLIN PRACT, V38, P416; DOBLE N, 1985, BRIT MED J, V290, P518; DRETTNER B, 1982, Rhinology (Utrecht), V20, P149; HARTLEY TF, 1985, J ALLERGY CLIN IMMUN, V75, P501, DOI 10.1016/S0091-6749(85)80024-5; HOLMBERG K, 1986, EUR J CLIN PHARMACOL, V30, P625, DOI 10.1007/BF00542425; KALINER M, 1985, J ALLERGY CLIN IMMUN, V76, P321, DOI 10.1016/0091-6749(85)90648-7; KARLSSON G, 1982, Rhinology (Utrecht), V20, P144; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; LANGRICK AF, 1984, CURR MED RES OPIN, V9, P290, DOI 10.1185/03007998409109594; MALM L, 1981, ALLERGY, V36, P209, DOI 10.1111/j.1398-9995.1981.tb01836.x; MARTIN LE, 1975, POSTGRAD MED J S, V4, P11; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P608, DOI 10.1001/archderm.1962.01590110044005; MEDING B, 1986, CONTACT DERMATITIS, V14, P253, DOI 10.1111/j.1600-0536.1986.tb01241.x; MELTZER EO, 1985, ANN ALLERGY, V55, P802; MICKELS MI, 1967, ANN ALLERGY, V25, P569; MORRIS HG, 1985, CHEST, V88, P1335; MORROWBROWN H, 1984, ALLERGOL IMMUNOPATH, V12, P355; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; PELIKAN Z, 1984, ANN ALLERGY, V52, P111; PIPKORN U, 1982, EUR J RESPIR DIS, V63, P211; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN V, 1986, TOPICAL STEROIDS, P165; PIPKORN V, 1983, RHINOLOGY, V21, P335; PIPKORN V, 1984, ALLERGOL IMMUNOPATHO, V12, P355; PLACE VA, 1970, ARCH DERMATOL, V101, P531, DOI 10.1001/archderm.101.5.531; RYRFELDT A, 1982, EUR J CLIN PHARM, V22, P86; SAMUELSSON A, 1983, FOLIA ALLERGOLOGI S4, V30, P102; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SCHOELZEL EP, 1985, JAMA-J AM MED ASSOC, V253, P2046, DOI 10.1001/jama.1985.03350380062017; SIBBALD B, 1986, CLIN ALLERGY, V16, P203, DOI 10.1111/j.1365-2222.1986.tb00767.x; SIDWELL S, 1983, CURR MED RES OPIN, V8, P659, DOI 10.1185/03007998309109815; SIEGEL SC, 1964, PEDIATRICS, V33, P245; SIEGEL SC, 1982, J ALLERGY CLIN IMMUN, V69, P345, DOI 10.1016/0091-6749(82)90144-0; SIPILA P, 1983, ALLERGY, V38, P303, DOI 10.1111/j.1398-9995.1983.tb04123.x; SODERBERGWARNER ML, 1984, J PEDIATR-US, V105, P840, DOI 10.1016/S0022-3476(84)80320-0; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; SORKIN S, 1986, J FAM PRACTICE, V22, P449; SPECTOR SL, 1987, JAN AM COLL ALL M LA; STEPHENS AL, 1968, ANN ALLERGY, V26, P612; TOWNLEY RG, 1987, ANN ALLERGY, V58, P1; VANZIELEGHEM MA, 1987, J ALLERGY CLIN IMMUN, V79, P887, DOI 10.1016/0091-6749(87)90237-5; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WIHL JA, 1982, EUR J RESPIR DIS, V63, P205; WIHL JA, 1982, EUR J RESPIR DIS S, V63, P122; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x	63	68	68	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			984	991		10.1016/0091-6749(88)90166-2	http://dx.doi.org/10.1016/0091-6749(88)90166-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	2897390				2022-12-18	WOS:A1988N703700011
J	ALAM, R; KUNA, P; ROZNIECKI, J; KUZMINSKA, B				ALAM, R; KUNA, P; ROZNIECKI, J; KUZMINSKA, B			THE MAGNITUDE OF THE SPONTANEOUS PRODUCTION OF HISTAMINE-RELEASING FACTOR (HRF) BY LYMPHOCYTES INVITRO CORRELATES WITH THE STATE OF BRONCHIAL HYPERREACTIVITY IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED ACAD LODZ,DEPT PNEUMONOL & ALLERGOL,LODZ,POLAND; MED ACAD LODZ,INST INTERNAL MED,LODZ,POLAND					Kuna, Piotr/0000-0003-2401-0070				ALAM R, 1985, ANN ALLERGY, V55, P825; ALAM R, 1986, CLIN EXP IMMUNOL, V63, P241; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1985, IMMUNOL LETT, V11, P111, DOI 10.1016/0165-2478(85)90152-X; ALAM R, 1984, ANN ALLERGY, V53, P66; ARVILOMMI H, 1975, NATURE, V257, P144, DOI 10.1038/257144a0; BERGENDORFF A, 1972, ACTA PHYSIOL SCAND, V84, P320, DOI 10.1111/j.1748-1716.1972.tb05183.x; BOYUM A, 1976, SCAND J IMMUNOL   S5, V5, P9; BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CREESE BR, 1983, PROSTA LEUKOTR MED, V11, P161, DOI 10.1016/0262-1746(83)90016-1; DORSCH W, 1984, N-S ARCH PHARMACOL, V327, P148, DOI 10.1007/BF00500910; EZEAMUZIE IC, 1983, AGENTS ACTIONS, V13, P222, DOI 10.1007/BF01967337; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAZIMIERCZAK W, 1984, AM REV RESPIR DIS, V129, P592; KUS J, 1985, CLIN ALLERGY, V15, P523, DOI 10.1111/j.1365-2222.1985.tb02305.x; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P434, DOI 10.1016/0008-8749(84)90012-1; MORLEY J, 1985, INT ARCH ALLER A IMM, V77, P73, DOI 10.1159/000233756; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; PARISH WE, 1982, CLIN ALLERGY, V12, P47; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P339; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; TUNG R, 1982, J IMMUNOL, V128, P2067; WARDLEY RC, 1976, IMMUNOL COMMUN, V5, P637, DOI 10.3109/08820137609033872	32	68	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					103	108		10.1016/S0091-6749(87)80023-4	http://dx.doi.org/10.1016/S0091-6749(87)80023-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805541				2022-12-18	WOS:A1987F881000019
J	ORGEL, HA; MELTZER, EO; KEMP, JP; WELCH, MJ				ORGEL, HA; MELTZER, EO; KEMP, JP; WELCH, MJ			CLINICAL, RHINOMANOMETRIC, AND CYTOLOGIC EVALUATION OF SEASONAL ALLERGIC RHINITIS TREATED WITH BECLOMETHASONE DIPROPIONATE AS AQUEOUS NASAL SPRAY OR PRESSURIZED AEROSOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ORGEL, HA (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,SUITE 100,7920 FROST ST,SAN DIEGO,CA 92123, USA.							BROWN HM, 1977, BRIT J CLIN PHARMACO, V4, pS283, DOI 10.1111/j.1365-2125.1977.tb04522.x; CONNELL JT, 1982, ANN ALLERGY, V49, P179; INCAUDO G, 1980, J ALLERGY CLIN IMMUN, V65, P41, DOI 10.1016/0091-6749(80)90175-X; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P243; KAPP JF, 1984, RHINITIS; LAFORCE C, 1985, J ALLERGY CLIN IMMUN, V75, P186, DOI 10.1016/0091-6749(85)90461-0; MICHELS MI, 1967, ANN ALLERGY, V25, P569; MILLER FF, 1975, ANN ALLERGY, V34, P107; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MUNCH E, 1981, CLIN ALLERGY, V11, P303, DOI 10.1111/j.1365-2222.1981.tb01598.x; MYGIND N, 1982, CLIN OTOLARYNGOL, V7, P343, DOI 10.1111/j.1365-2273.1982.tb01918.x; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; PRAHL P, 1975, ARCH DIS CHILD, V50, P875, DOI 10.1136/adc.50.11.875; SIEGEL SC, 1982, J ALLERGY CLIN IMMUN, V69, P345, DOI 10.1016/0091-6749(82)90144-0; SMALL P, 1982, J ALLERGY CLIN IMMUN, V70, P178, DOI 10.1016/0091-6749(82)90039-2; SODERBERGWARNER ML, 1984, J PEDIATR-US, V105, P840, DOI 10.1016/S0022-3476(84)80320-0; TARLO SM, 1977, J ALLERGY CLIN IMMUN, V59, P232, DOI 10.1016/0091-6749(77)90155-5; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; WELCH MJ, 1985, ANN ALLERGY, V55, P577	21	68	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					858	864		10.1016/0091-6749(86)90384-2	http://dx.doi.org/10.1016/0091-6749(86)90384-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711553				2022-12-18	WOS:A1986C869400011
J	MELAMED, J; ALPER, CA; CICARDI, M; ROSEN, FS				MELAMED, J; ALPER, CA; CICARDI, M; ROSEN, FS			THE METABOLISM OF C1-INHIBITOR AND C1Q IN PATIENTS WITH ACQUIRED C1-INHIBITOR DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT MED,CTR BLOOD RES,BOSTON,MA 02115; UNIV MILAN,OSPED SAN PAOLO,DEPT MED,I-20122 MILAN,ITALY	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); San Paolo-Polo Universitaria Hospital; University of Milan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 02172] Funding Source: Medline; NIADDK NIH HHS [AM 05577] Funding Source: Medline; NIAID NIH HHS [AI 21163] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; HARRISON RA, 1983, BIOCHEMISTRY-US, V22, P5001, DOI 10.1021/bi00290a019; KOHLER PF, 1972, J CLIN INVEST, V51, P868, DOI 10.1172/JCI106881; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MELAMED J, 1982, J IMMUNOL, V128, P2313; NOSSLIN B, 1973, CIBA F S PROTEIN TUR, V9, P113; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; TENNER AJ, 1980, J IMMUNOL, V125, P1658; YONEMASU K, 1971, J IMMUNOL, V106, P304	16	68	68	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					322	326						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3484761				2022-12-18	WOS:A1986A089900009
J	BAUR, X; DEWAIR, M; FRUHMANN, G				BAUR, X; DEWAIR, M; FRUHMANN, G			DETECTION OF IMMUNOLOGICALLY SENSITIZED ISOCYANATE WORKERS BY RAST AND INTRACUTANEOUS SKIN-TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MUNICH,INST ARBEITSMED,D-8000 MUNICH 2,FED REP GER; UNIV MUNICH,ARBEITSMED POLIKLIN,D-8000 MUNICH 2,FED REP GER	University of Munich; University of Munich	BAUR, X (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 1,PULMONOL ABT,D-8000 MUNICH 70,FED REP GER.							BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; Baur X, 1981, Chest, V80, P73; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BROWN WE, 1982, TOXICOL APPL PHARM, V63, P45, DOI 10.1016/0041-008X(82)90025-4; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; DEWAIR M, 1983, J OCCUP ENVIRON MED, V25, P279; DEWAIR M, 1983, INT ARCH OCC ENV HEA, V52, P257, DOI 10.1007/BF00526524; DEWAIR MA, 1982, J CLIN CHEM CLIN BIO, V20, P337; GUTMANN HR, 1952, CANCER RES, V12, P350; KAROL MH, 1981, J OCCUP ENVIRON MED, V23, P741, DOI 10.1097/00043764-198111000-00007; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; MARCALI K, 1957, ANAL CHEM, V29, P552, DOI 10.1021/ac50162a039; McKay R T, 1981, Chest, V80, P61; OBRIEN M, 1976, CLIN ALLERGY, V9, P1; PETERS JM, 1975, P S ISOCYANATES IND, P5; TAYLOR G, 1970, P ROY SOC MED, V63, P379, DOI 10.1177/003591577006300421; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; VANERT M, 1975, ANN ALLERGY, V35, P142; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; 1975, BERUFSGENOSSENSCHAFT, P27	23	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					610	618		10.1016/0091-6749(84)90520-7	http://dx.doi.org/10.1016/0091-6749(84)90520-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6609183				2022-12-18	WOS:A1984SS04500013
J	DESHAZO, RD; GRIFFING, C; KWAN, TH; BANKS, WA; DVORAK, HF				DESHAZO, RD; GRIFFING, C; KWAN, TH; BANKS, WA; DVORAK, HF			DERMAL HYPERSENSITIVITY REACTIONS TO IMPORTED FIRE ANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,CHARLES A DANA LAB,BOSTON,MA 02215; USDA ARS,INSECT RES LAB,GAINESVILLE,FL 32604	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; United States Department of Agriculture (USDA)	DESHAZO, RD (corresponding author), TULANE UNIV,SCH MED,CLIN IMMUNOL SECT,HERBERT H HARVEY LAB,NEW ORLEANS,LA 70112, USA.							ADAMS CT, 1982, J MED ENTOMOL, V19, P366, DOI 10.1093/jmedent/19.4.366; BUREN WF, 1982, FLA ENTOMOL, V65, P188, DOI 10.2307/3494163; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; CLEMMER DI, 1975, SOUTHERN MED J, V68, P1133, DOI 10.1097/00007611-197509000-00017; DANIEL WW, 1978, BIOSTATISTICS F ANAL, P254; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P229, DOI 10.1016/0091-6749(82)90104-X; DESHAZO RD, 1983, ANN ALLERGY, V51, P166; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; LOFGREN CS, 1982, BIOL SOCIAL INSECTS, P420; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; RHODES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STROM GB, 1980, J ALLERGY CLIN IMMUN, V65, P202; Yeager W, 1978, J Med Assoc Ga, V67, P101; [No title captured]	19	68	70	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					841	847		10.1016/0091-6749(84)90188-X	http://dx.doi.org/10.1016/0091-6749(84)90188-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6501749	Bronze			2022-12-18	WOS:A1984TW41800013
J	LEWIS, J; LIEBERMAN, P; TREADWELL, G; ERFFMEYER, J				LEWIS, J; LIEBERMAN, P; TREADWELL, G; ERFFMEYER, J			EXERCISE-INDUCED URTICARIA, ANGIOEDEMA, AND ANAPHYLACTOID EPISODES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,DIV ALLERGY IMMUNOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BLUMBERG MZ, 1978, ANN ALLERGY, V41, P99; DAVIS NC, 1976, MANUAL CLINICAL IMMU, P5; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; GRANT RT, 1935, CLIN SCI, V2, P266; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KAPLAN AP, 1978, ALLERGY PRINCIPLES P, P1080; KAPLAN AP, 1981, 37TH P ANN M AM AC A; MATHEWS K P, 1970, Algerie Medicale, V72, P241; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; TSE KS, 1980, J ALLERGY CLIN IMMUN, V65, P227	15	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					432	437		10.1016/0091-6749(81)90197-4	http://dx.doi.org/10.1016/0091-6749(81)90197-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	7310010				2022-12-18	WOS:A1981MU79000005
J	NICKELSEN, JA; GOLDSTEIN, S; MUELLER, U; WYPYCH, J; REISMAN, RE; ARBESMAN, CE				NICKELSEN, JA; GOLDSTEIN, S; MUELLER, U; WYPYCH, J; REISMAN, RE; ARBESMAN, CE			LOCAL INTRANASAL IMMUNOTHERAPY FOR RAGWEED ALLERGIC RHINITIS .1. CLINICAL-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP, ALLERGY RES LAB, BUFFALO, NY 14203 USA; SUNY BUFFALO, SCH MED, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BUFFALO, NY 14214 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI 01303] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; BACON JR, 1980, J ALLERGY CLIN IMMUN, V65, P191; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; COOK N, 1974, Journal of Laryngology and Otology, V88, P1169, DOI 10.1017/S0022215100079901; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P40, DOI 10.1159/000227899; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P447, DOI 10.1159/000232376; KRAYANEK D, 1971, J ALLERGY, V47, P114; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V65, P191; MCLEAN JA, 1978, J ALLERGY CLIN IMMUN, V61, P191, DOI 10.1016/0091-6749(78)90450-5; MEHTA S B, 1975, Clinical Allergy, V5, P279; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1979, J ALLERGY CLIN IMMUN, V63, P166; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1978, ALLERGY, V33, P62; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; OGRA PL, 1973, AAAS S COMP IMMUNOLO, P38; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; VIANDER M, 1978, CLIN ALLERGY, V8, P387, DOI 10.1111/j.1365-2222.1978.tb00474.x; WELSH W, 1980, J ALLERGY CLIN IMMUN, V65, P191	26	68	70	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					33	40		10.1016/0091-6749(81)90120-2	http://dx.doi.org/10.1016/0091-6749(81)90120-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240598				2022-12-18	WOS:A1981LY10100006
J	KELLY, JF; PATTERSON, R; LIEBERMAN, P; MATHISON, DA; STEVENSON, DD				KELLY, JF; PATTERSON, R; LIEBERMAN, P; MATHISON, DA; STEVENSON, DD			RADIOGRAPHIC CONTRAST-MEDIA STUDIES IN HIGH-RISK PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; UNIV TENNESSEE,MEMPHIS,TN 38103; SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Northwestern University; University of Tennessee System; University of Tennessee Health Science Center; Scripps Research Institute								COLEMAN WF, COMMUNICATION; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; PATTERSON R, 1975, ANN INTERN MED, V83, P277, DOI 10.7326/0003-4819-83-2-277; PATTERSON R, 1975, J ALLERGY CLIN IMMUN, V56, P328, DOI 10.1016/0091-6749(75)90108-6; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; YOCUM MW, 1977, P AM C ALLERGY NEW Y; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	12	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					181	184		10.1016/0091-6749(78)90104-5	http://dx.doi.org/10.1016/0091-6749(78)90104-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	681630				2022-12-18	WOS:A1978FP55400009
J	LIEBERMAN, P; SIEGLE, RL; TAYLOR, WW				LIEBERMAN, P; SIEGLE, RL; TAYLOR, WW			ANAPHYLACTOID REACTIONS TO IODINATED CONTRAST MATERIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT DIAGNOST RADIOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center	LIEBERMAN, P (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,DIV ALLERGY IMMUNOL,MEMPHIS,TN 38163, USA.							ALYEA EP, 1947, JAMA-J AM MED ASSOC, V135, P25, DOI 10.1001/jama.1947.02890010027008; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; Ansell G, 1968, Clin Radiol, V19, P175, DOI 10.1016/S0009-9260(68)80059-5; Archer VW, 1942, AM J ROENTGENOL RADI, V48, P763; ARROYAVE CM, 1977, CLIN EXP IMMUNOL, V29, P89; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; BENTLEY PE, 1968, THESIS U LOUISVILLE; Bernstein E F, 1966, Invest Radiol, V1, P162, DOI 10.1097/00004424-196603000-00030; BERNSTEIN EF, 1960, JAMA-J AM MED ASSOC, V174, P1417, DOI 10.1001/jama.1960.63030110005012; BERNSTEIN EFR, 1964, ACTA RADIOL, V2, P101; BHAT KN, 1976, ANN ALLERGY, V37, P169; BRASCH RC, 1976, INVEST RADIOL, V11, P1, DOI 10.1097/00004424-197601000-00001; BRASCH RC, 1976, INVEST RADIOL, V11, P347, DOI 10.1097/00004424-197609000-00002; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; COGEN FC, 1978, FEB AM AC ALL PHOEN; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DOLAN LP, 1940, JAMA-J AM MED ASSOC, V114, P138; DUNN CR, 1975, INVEST RADIOL, V10, P317, DOI 10.1097/00004424-197507000-00006; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; FREEDMAN S, 1976, CLIN IMMUNOLOGY; GATES DF, 1972, J UROLOGY, V108, P627, DOI 10.1016/S0022-5347(17)60821-8; HALPERN B, 1967, J ALLERGY, V40, P168, DOI 10.1016/0021-8707(67)90006-8; HILDRETH EA, 1960, RADIOLOGY, V74, P246, DOI 10.1148/74.2.246; KELLY JF, 1977, FEB AM AC ALL PHOEN; KLEINKNECHT D, 1974, CLIN NEPHROL, V2, P116; Lang J H, 1967, Invest Radiol, V2, P396, DOI 10.1097/00004424-196711000-00017; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1966, RADIOL CLIN N AM, V4, P511; LASSER EC, 1977, RADIOLOGY, V125, P1; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; LASSER EC, 1970, INVEST RADIOL, V5, P446; LASSER EC, 1971, AMER J ROENTGENOL RA, V113, P415; LASSER EC, 1976, RADIOLOGY, V119, P91, DOI 10.1148/119.1.91; LIEBERMAN P, 1976, JAMA-J AM MED ASSOC, V236, P1495; LIEBERMAN P, 1978, FEB AM AC ALL PHOEN; LITTNER MR, 1977, RADIOLOGY, V124, P17, DOI 10.1148/124.1.17; MANN MR, 1961, P ROY SOC MED, V54, P473; MCCLENNAN BL, 1976, INVEST RADIOL    MAY, P240; MESCHAN I, 1965, RADIOL CLIN N AM, V3, P13; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; Naterman HL, 1942, J AMER MED ASSOC, V119, P491, DOI 10.1001/jama.1942.02830230025008; OCHSNER SF, 1971, SOUTHERN MED J, V64, P907, DOI 10.1097/00007611-197108000-00002; PATTERSON R, 1975, J ALLERGY CLIN IMMUN, V56, P328, DOI 10.1016/0091-6749(75)90108-6; Pendergrass EP, 1942, AM J ROENTGENOL RADI, V48, P741; PENDERGRASS HP, 1958, RADIOLOGY, V71, P1; PETERS GA, 1966, J ALLERGY, V38, P74, DOI 10.1016/0021-8707(66)90046-3; READ RC, 1959, J THORAC CARDIOV SUR, V38, P685, DOI 10.1016/S0022-5223(19)32431-6; RING J, 1978, FEB AM AC ALL PHOEN; ROCKOFF SD, 1971, INVEST RADIOL, V6, P110, DOI 10.1097/00004424-197103000-00004; ROCKOFF SD, 1970, INVEST RADIOL, V5, P503, DOI 10.1097/00004424-197011000-00016; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; SANGER MAURY D., 1959, ANN ALLERGY, V17, P762; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SEIDEL G, 1974, AGENTS ACTIONS, V4, P143, DOI 10.1007/BF01970254; SHAPIRO GA, 1977, RADIOLOGY, V124, P641, DOI 10.1148/124.3.641; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHEHADI WH, 1969, AMER J ROENTGENOL RA, V107, P207, DOI 10.2214/ajr.107.1.207; SHEHADI WH, 1966, AMER J ROENTGENOL RA, V97, P762, DOI 10.2214/ajr.97.3.762; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIEGLE RL, 1977, 63RD SCI ASS ANN M R; SIMON RA, 1978, FEB AM AC ALL PHOEN; THOMPSON WL, 1964, J PHARMACOL EXP THER, V143, P131; TILL G, 1977, P FED AM SOC EXP BIO, V36, P1264; WAKKERSGARRITSEN BG, 1976, ANN ALLERGY, V36, P122; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; YOCUM MW, 1977, AM C ALLERGY IMMUNOL; ZEMAN RK, 1977, INVEST RADIOL, V12, P203, DOI 10.1097/00004424-197703000-00022; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	70	68	68	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					174	180		10.1016/0091-6749(78)90103-3	http://dx.doi.org/10.1016/0091-6749(78)90103-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	79585				2022-12-18	WOS:A1978FP55400008
J	REDDY, PM; NAGAYA, H; PASCUAL, HC; LEE, SK; GUPTA, S; LAURIDSEN, JI; JEROME, DC				REDDY, PM; NAGAYA, H; PASCUAL, HC; LEE, SK; GUPTA, S; LAURIDSEN, JI; JEROME, DC			REAPPRAISAL OF INTRACUTANEOUS TESTS IN DIAGNOSIS OF REAGINIC ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,ALLERGY & IMMUNOL SECT,LONG BEACH,CA 90822; UNIV CALIF IRVINE,COLL MED,DEPT MED,IRVINE,CA 92664	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BERRENS L, 1974, ANN NY ACAD SCI, V221, P183, DOI 10.1111/j.1749-6632.1974.tb28216.x; BLACKLEY GH, 1873, EXPT RESEARCHES CAUS; BOOTH BH, 1972, ALLERGIC DIS DIAGNOS, P74; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; HUGGINS KG, 1975, LANCET, V2, P148; INDRAJANA T, 1971, ANN ALLERGY, V29, P639; KOBAYASHI Y, 1972, ANAL BIOCHEM, V46, P85, DOI 10.1016/0003-2697(72)90397-1; LEWIS THOMAS, 1926, HEART, V13, P219; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; MILLER RL, 1970, J PHARMACOL EXP THER, V175, P228; PASCUAL H, 1977, MAR AM C ALL IMM NEW; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; Pepys J., 1975, BR J HOSP MED, V14, P412; PERERA MG, 1975, AM REV RESPIR DIS, V111, P605; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; STENIUS B, 1973, ACTA ALLERGOL, V26, P81; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55	22	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					36	41		10.1016/0091-6749(78)90471-2	http://dx.doi.org/10.1016/0091-6749(78)90471-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618945	Bronze			2022-12-18	WOS:A1978EH11200006
J	WOENNE, R; KATTAN, M; ORANGE, RP; LEVISON, H				WOENNE, R; KATTAN, M; ORANGE, RP; LEVISON, H			BRONCHIAL HYPER-REACTIVITY TO HISTAMINE AND METHACHOLINE IN ASTHMATIC-CHILDREN AFTER INHALATION OF SCH-1000 AND CHLORPHENIRAMINE MALEATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DOLOVICH MB, 1976, J APPL PHYSIOL, V40, P468, DOI 10.1152/jappl.1976.40.3.468; DOUGLAS W, 1975, PHARM BASIS THERAPEU, P594; DOUGLAS WW, 1975, PHARMACOL BASIS THER, P608; ENGELHARDT A, 1975, POSTGRAD MED J, V51, P82; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; MACKLEM PT, 1969, J APPL PHYSIOL, V26, P798, DOI 10.1152/jappl.1969.26.6.798; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; MITCHELL C, 1976, YALE J BIOL MED, V49, P317; MITCHELL IV, UNPUBLISHED; NAIR N S, 1977, American Review of Respiratory Disease, V115, P68; OROHEK J, 1977, AM REV RESPIR DIS, V115, P937; ORR T S C, 1970, Clinical and Experimental Immunology, V7, P745; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; POPA VT, 1975, J ALLERGY CLIN IMMUN, V56, P323; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; STORMS WW, 1975, AM REV RESPIR DIS, V111, P419; TOZZI S, 1974, AGENTS ACTIONS, V4, P264, DOI 10.1007/BF01965229; VIDRUK E, 1975, PHYSIOLOGIST, V18, P432; WENG TR, 1969, AM REV RESPIR DIS, V99, P879; WIDDICOMBE J, 1961, CLIN SCI, V21, P163; WIDDICOMBE JG, 1963, PHYSIOL REV, V43, P1, DOI 10.1152/physrev.1963.43.1.1; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	31	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					119	124		10.1016/0091-6749(78)90089-1	http://dx.doi.org/10.1016/0091-6749(78)90089-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	149804				2022-12-18	WOS:A1978FL83500009
J	BUSSE, WW; LEE, TP				BUSSE, WW; LEE, TP			DECREASED ADRENERGIC RESPONSES IN LYMPHOCYTES AND GRANULOCYTES IN ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BLACK W, 1958, ARCH KLIN EXP DERMAT, V203, P63; Boyum A., 1967, SCAND J CLIN LAB INV, V97, P77; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUSSE WW, 1975, CLIN RES, V23, P502; CARR RH, 1973, J ALLERGY CLIN IMMUN, V51, P255, DOI 10.1016/0091-6749(73)90127-9; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; COBAUD P, 1958, AM J CLIN PATHOL, V30, P234; FISHER LB, 1971, ARCH DERMATOL, V103, P39, DOI 10.1001/archderm.103.1.39; FISHMAN WH, 1967, CLIN CHIM ACTA, V15, P435, DOI 10.1016/0009-8981(67)90008-3; HEMELS HGW, 1970, BRIT J DERMATOL, V83, P313; HILL HR, 1974, LANCET, V1, P183; HOLLA SWJ, 1972, BRIT J DERMATOL, V86, P147, DOI 10.1111/j.1365-2133.1972.tb16077.x; JENNE JW, 1975, J ALLERGY CLIN IMMUN, V55, P96; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; JOHNSON LA, 1965, ARCH DERMATOL, V92, P621, DOI 10.1001/archderm.92.6.621; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; JUHLIN L, 1961, J INVEST DERMATOL, V37, P201, DOI 10.1038/jid.1961.107; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; LEE TP, 1974, J ALLERGY CLIN IMMUN, V53, P283, DOI 10.1016/0091-6749(74)90107-9; LEE TP, 1975, CLIN RES, V23, P502; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MCGREADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393; MICHAELSSON G, 1973, ACTA DERM-VENEREOL, V53, P279; MIER PD, 1970, BRIT J DERMATOL, V83, P364, DOI 10.1111/j.1365-2133.1970.tb15717.x; MIER PD, 1972, BRIT J DERMATOL, V87, P577, DOI 10.1111/j.1365-2133.1972.tb07448.x; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NELSON HS, 1973, J ALLERGY CLIN IMMUN, V51, P191, DOI 10.1016/0091-6749(73)90138-3; PARKER C W, 1972, Clinical Research, V20, P418; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; POWELL JA, 1971, ARCH DERMATOL, V104, P359, DOI 10.1001/archderm.104.4.359; REED CE, 1972, J ALLERGY CLIN IMMUN, V49, P174, DOI 10.1016/0091-6749(72)90111-X; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; Sulzberger MB, 1936, J AMER MED ASSOC, V106, P1000; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TADA T, 1973, MECHANISMS ALLERGY, P43; VOORHEES JJ, 1972, ARCH DERMATOL, V105, P384, DOI 10.1001/archderm.105.3.384; WARNDORF.JA, 1970, BRIT J DERMATOL, V83, P306, DOI 10.1111/j.1365-2133.1970.tb15705.x; WEDNER H, 1972, Clinical Research, V20, P798; Whitfield A, 1938, BRIT J DERMATOL SYPH, V50, P71, DOI 10.1111/j.1365-2133.1938.tb10475.x; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550; ZURIER RB, 1973, P NATL ACAD SCI USA, V70, P844, DOI 10.1073/pnas.70.3.844	44	68	68	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					586	596		10.1016/0091-6749(76)90205-0	http://dx.doi.org/10.1016/0091-6749(76)90205-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	185243				2022-12-18	WOS:A1976CL08800007
J	POOTHULLIL, J; UMEMOTO, L; DOLOVICH, J; HARGREAVE, FE; DAY, RP				POOTHULLIL, J; UMEMOTO, L; DOLOVICH, J; HARGREAVE, FE; DAY, RP			INHIBITION BY PREDNISONE OF LATE CUTANEOUS ALLERGIC RESPONSES INDUCED BY ANTISERUM TO HUMAN IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									ST JOSEPHS HOSP,DEPT MED,HAMILTON,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,1200 MAIN ST,HAMILTON L8S 4J9,ONTARIO,CANADA; ST JOSEPHS HOSP,DEPT PEDIAT,HAMILTON,ONTARIO,CANADA	McGill University; McMaster University; McMaster University; McGill University; McMaster University								BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; Coombs RRA., 1968, CLIN ASPECTS IMMUNOL, V2, P575; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0	10	68	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					164	167		10.1016/0091-6749(76)90035-X	http://dx.doi.org/10.1016/0091-6749(76)90035-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	1249350				2022-12-18	WOS:A1976BE95200008
J	BRUCE, CA; ROSENTHAL, RR; LICHTENSTEIN, LM; NORMAN, PS				BRUCE, CA; ROSENTHAL, RR; LICHTENSTEIN, LM; NORMAN, PS			QUANTITATIVE INHALATION BRONCHIAL CHALLENGE IN RAGWEED HAY-FEVER PATIENTS - COMPARISON WITH RAGWEED-ALLERGIC ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,CLIN IMMUNOL DIV,5601LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University								BROWN EA, 1946, DIS CHEST, V12, P205, DOI 10.1378/chest.12.3.205; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARSH DG, 1973, MECHANISMS ALLERGY R, P113; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; ROSENTHAL RR, 1973, J ALLERGY CLIN IMMUN, V51, P95, DOI 10.1016/S0091-6749(73)80038-7; SWINEFORD O, 1955, J ALLERGY, V26, P305, DOI 10.1016/0021-8707(55)90060-5; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9	12	68	68	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					331	337		10.1016/0091-6749(75)90126-8	http://dx.doi.org/10.1016/0091-6749(75)90126-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	52665				2022-12-18	WOS:A1975AW33000002
J	JOHANSEN, KS; JOHANSEN, TS; TALMAGE, DW				JOHANSEN, KS; JOHANSEN, TS; TALMAGE, DW			T-CELL ROSETTE FORMATION IN PRIMATES, PIGS, AND GUINEA-PIGS - INFLUENCE OF IMMUNOSUPPRESSIVE AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,WEBB WARING LUNG INST,DENVER,CO; UNIV COLORADO,MED CTR,DEPT MICROBIOL,4200 E NINTH AVE,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BRAIN P, 1970, CLIN EXP IMMUNOL, V6, P681; CAWEIN MJ, 1973, PERSONAL COMMUNICATI; CHAPEL HM, 1973, TRANSPLANTATION, V15, P320, DOI 10.1097/00007890-197303000-00009; COOMBS R R A, 1970, International Archives of Allergy and Applied Immunology, V39, P658; HARRIS R, 1969, LANCET, V2, P327; HUSBERG BS, 1973, THESIS U LUND; LAY WH, 1971, NATURE, V230, P531, DOI 10.1038/230531a0; LOPEZ LR, 1974, J ALLERGY CLIN IMMUN, V53, P336, DOI 10.1016/0091-6749(74)90117-1; MINOWADA J, 1972, J NATL CANCER I, V49, P891; RABELLINO E, 1971, J EXP MED, V133, P156, DOI 10.1084/jem.133.1.156; SILVEIRA NP, 1972, J IMMUNOL, V108, P1456; STARZL TE, 1971, SURG GYNECOL OBSTETR, V133, P981; TURK JL, 1972, CLIN EXP IMMUNOL, V10, P285; WILLIAMS RC, 1973, J CLIN INVEST, V52, P283, DOI 10.1172/JCI107184; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069	16	68	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	2					86	93		10.1016/0091-6749(74)90036-0	http://dx.doi.org/10.1016/0091-6749(74)90036-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T7816	4546937				2022-12-18	WOS:A1974T781600003
J	SLOTT, RI; ZWEIMAN, B				SLOTT, RI; ZWEIMAN, B			CONTROLLED-STUDY OF EFFECT OF CORTICOSTEROIDS ON IMMEDIATE SKIN-TEST REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,3400 SPRUCE ST,PHILADELPHIA,PA 19104	University of Pennsylvania								CAREY RA, 1950, 87 JOHNS HOPK HOSP B, P387; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; FEINBERG SM, 1951, J ALLERGY, V22, P195, DOI 10.1016/0021-8707(51)90015-9; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; HAGUE HE, 1965, ACTA ALLERGOL, V20, P496; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NYFORS A, 1968, ACTA ALLERGOL, V23, P130, DOI 10.1111/j.1398-9995.1968.tb03712.x; PATTERSON R, 1972, ALLERGIC DISEASES DI, P80; THON IL, 1967, ACTA PHYSIOL SCAND, V71, P303, DOI 10.1111/j.1748-1716.1967.tb03737.x; VOORHORST R, 1973, ANN ALLERGY, V31, P137	10	68	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	4					229	234		10.1016/0091-6749(74)90065-7	http://dx.doi.org/10.1016/0091-6749(74)90065-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3236	4153255				2022-12-18	WOS:A1974U323600005
J	McCauley, K; Durack, J; Valladares, R; Fadrosh, DW; Lin, DL; Calatroni, A; LeBeau, PK; Tran, HT; Fujimura, KE; LaMere, B; Merana, G; Lynch, K; Cohen, RT; Pongracic, J; Hershey, GKK; Kercsmar, CM; Gill, M; Liu, AH; Kim, H; Kattan, M; Teach, SJ; Togias, A; Boushey, HA; Gern, JE; Jackson, DJ; Lynch, SV				McCauley, Kathryn; Durack, Juliana; Valladares, Ricardo; Fadrosh, Douglas W.; Lin, Din L.; Calatroni, Agustin; LeBeau, Petra K.; Tran, Hoang T.; Fujimura, Kei E.; LaMere, Brandon; Merana, Geil; Lynch, Kole; Cohen, Robyn T.; Pongracic, Jacqueline; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Gill, Michelle; Liu, Andrew H.; Kim, Haejin; Kattan, Meyer; Teach, Stephen J.; Togias, Alkis; Boushey, Homer A.; Gern, James E.; Jackson, Daniel J.; Lynch, Susan V.		Natl Inst Allergy Infect Dis; Sponsored Inner-City Asthma Conso	Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiota; Moraxella species; Staphylococcus species; 16S rRNA; airway; asthma; exacerbation; rhinovirus	OMALIZUMAB; PATHOGENESIS; INFECTIONS	Background: In infants, distinct nasopharyngeal bacterial microbiotas differentially associate with the incidence and severity of acute respiratory tract infection and childhood asthma development. Objective: We hypothesized that distinct nasal airway microbiota structures also exist in children with asthma and relate to clinical outcomes. Methods: Nasal secretion samples (n = 3122) collected after randomization during the fall season from children with asthma (6-17 years, n = 413) enrolled in a trial of omalizumab (anti-IgE) underwent 16S rRNA profiling. Statistical analyses with exacerbation as the primary outcome and rhinovirus infection and respiratory illnesses as secondary outcomes were performed. Using A549 epithelial cells, we assessed nasal isolates of Moraxella, Staphylococcus, and Corynebacterium species for their capacity to induce epithelial damage and inflammatory responses. Results: Six nasal airway microbiota assemblages, each dominated by Moraxella, Staphylococcus, Corynebacterium, Streptococcus, Alloiococcus, or Haemophilus species, were observed. Moraxella and Staphylococcus species-dominated microbiotas were most frequently detected and exhibited temporal stability. Nasal microbiotas dominated by Moraxella species were associated with increased exacerbation risk and eosinophil activation. Staphylococcus or Corynebacterium species-dominated microbiotas were associated with reduced respiratory illness and exacerbation events, whereas Streptococcus species-dominated assemblages increased the risk of rhinovirus infection. Nasal microbiota composition remained relatively stable despite viral infection or exacerbation; only a few taxa belonging to the dominant genera exhibited relative abundance fluctuations during these events. In vitro, Moraxella catarrhalis induced significantly greater epithelial damage and inflammatory cytokine expression (IL-33 and IL-8) compared with other dominant nasal bacterial isolates tested. Conclusion: Distinct nasal airway microbiotas of children with asthma relate to the likelihood of exacerbation, rhinovirus infection, and respiratory illnesses during the fall season.	[McCauley, Kathryn; Durack, Juliana; Valladares, Ricardo; Fadrosh, Douglas W.; Lin, Din L.; Fujimura, Kei E.; LaMere, Brandon; Merana, Geil; Lynch, Kole; Boushey, Homer A.; Lynch, Susan V.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Calatroni, Agustin; LeBeau, Petra K.; Tran, Hoang T.] Rho Fed Syst Div, Chapel Hill, NC USA; [Cohen, Robyn T.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Pongracic, Jacqueline] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA; [Gill, Michelle] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Gill, Michelle] Univ Texas Southwestern Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA; [Liu, Andrew H.] Natl Jewish Hlth, Dept Pedatr & Pulmonol Med, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Kim, Haejin] Henry Ford Hlth Syst, Div Allergy & Immunol, Dept Internal Med, Detroit, MI USA; [Kattan, Meyer] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gern, James E.; Jackson, Daniel J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Valladares, Ricardo] Siolta Therapeut, San Francisco, CA USA	University of California System; University of California San Francisco; Boston University; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Henry Ford Health System; Henry Ford Hospital; Columbia University; Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison	Lynch, SV (corresponding author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, 513 Parnassus Ave,S357D, San Francisco, CA 94143 USA.; Jackson, DJ (corresponding author), Univ Wisconsin, Dept Pediat, Div Allergy Immunol & Rheumatol, 600 Highland Ave,K4-936 CSC, Madison, WI 53792 USA.	djj@medicine.wisc.edu; susan.lynch@ucsf.edu	McCauley, Kathryn/GMW-8630-2022	Tran, Hoang/0000-0003-1529-5692	federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources, NIH [NIH/NIAID 5R01AI098077]; National Center for Advancing Translational Sciences, NIH [NIH/NIAID 5R01AI098077]; National Center for Advancing Translational Sciences (NCATS)/NIH [UL1TR000150]; National Center for Research Resources (NCRR)/NCATS/NIH [UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154, UL1TR001082]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001105, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870, UM1AI114271, UM1AI109565] Funding Source: NIH RePORTER	federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences, NIH; National Center for Advancing Translational Sciences (NCATS)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Research Resources (NCRR)/NCATS/NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under contract and grant numbers HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, under grants NIH/NIAID 5R01AI098077; National Center for Advancing Translational Sciences (NCATS)/NIH UL1TR000150; and National Center for Research Resources (NCRR)/NCATS/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154 and UL1TR001082. The following were donated: omalizumab and matching placebo by Novartis and fluticasone and matching placebo by GlaxoSmithKline under a clinical trial agreement with the University of Wisconsin-Madison; EpiPens by Mylan; and Ayr nasal rinse by B.F. Ascher & Company. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Durack J, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0487-3; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Fazlollahi M, 2018, J ALLERGY CLIN IMMUN, V142, P834, DOI 10.1016/j.jaci.2018.02.020; Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Johnston Sebastian L, 2007, Proc Am Thorac Soc, V4, P267, DOI 10.1513/pats.200701-030AW; Kim BS, 2018, ALLERGY, V73, P644, DOI 10.1111/all.13331; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kozik AJ, 2019, ANN ALLERG ASTHMA IM, V122, P270, DOI 10.1016/j.anai.2018.12.005; Lan F, 2018, AM J RESP CRIT CARE, V198, P452, DOI 10.1164/rccm.201710-2112OC; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Marsh RL, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0182-1; Oksanen J., **DATA OBJECT**; Park HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109479; R Core Team, 2018, R LANG ENV STAT COMP; Robinson CM, 2014, CELL HOST MICROBE, V15, P36, DOI 10.1016/j.chom.2013.12.004; Rofael SAD, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01225-2018; Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-4; Santee CA, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0179-9; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Vidakovics MLP, 2009, CURR OPIN INFECT DIS, V22, P279, DOI 10.1097/QCO.0b013e3283298e4e; Vrtis R, 2018, J ALLERGY CLIN IMMUN, V141, P822, DOI 10.1016/j.jaci.2017.09.027	30	67	69	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1187	1197		10.1016/j.jaci.2019.05.035	http://dx.doi.org/10.1016/j.jaci.2019.05.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31201890	Green Accepted, Bronze			2022-12-18	WOS:000495004700012
J	Tliba, O; Jr, RA				Tliba, Omar; Panettieri, Reynold A., Jr.			Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Irreversible airway obstruction; airway remodeling; structural cells; airway smooth muscle; steroid insensitivity; asthma phenotypes; asthma endotypes; precision medicine; biomarkers	TO-MODERATE ASTHMA; SPUTUM EOSINOPHILS; SMOOTH-MUSCLE; HYPERRESPONSIVENESS; PHENOTYPES; MANAGEMENT; SUBTYPES; RESPONSIVENESS; NEUTROPHILS; INHIBITION	Among patients with asthma, heterogeneity exists regarding the pattern of airway inflammation and response to treatment, prompting the necessity of recognizing specific phenotypes. Based on the analysis of inflammatory cell counts in induced sputum, asthmatic patients can be classified into 4 unique phenotypes: eosinophilic asthma, neutrophilic asthma, mixed granulocytic asthma, and paucigranulocytic asthma (PGA). PGA is an asthma phenotype with no evidence of increased numbers of eosinophils or neutrophils in sputum or blood and in which anti-inflammatory therapies are ineffective at controlling symptoms. Although underinvestigated, PGA is the most common asthma phenotype in patients with stable asthma. However, PGA is sometimes underestimated because of the exclusive reliance on induced sputum cell counts, which are variable among cohorts of studies, prompting the necessity of developing improved biomarkers. Importantly, investigators have reported that inhaled corticosteroids had a limited effect on airway inflammatory markers in patients with PGA and therefore defining PGA as a potentially "steroid-insensitive'' phenotype that requires exploration of alternative therapies. PGA manifests as an uncoupling of airway obstruction from airway inflammation that can be driven by structural changes within the airways, such as airway smooth muscle tissue hypertrophy. Animal models provide evidence that processes evoking airway hyperresponsiveness and airway smooth muscle thickening occur independent from inflammation and might be a consequence of a loss of negative homeostatic processes. Collectively, further understanding of PGA with a focus on the characterization, prevalence, clinical significance, and pathobiology derived from animal studies will likely provide precision therapies that will improve PGA clinical outcomes.	[Tliba, Omar; Panettieri, Reynold A., Jr.] Rutgers State Univ, Robert Wood Johnson Sch Med, Rutgers Inst Translat Med & Sci, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jr, RA (corresponding author), Rutgers State Univ, Rutgers Inst Translat Med & Sci, 89 French St,Suite 4210, New Brunswick, NJ 08901 USA.	rp856@rbhs.rutgers.edu	panettieri, reynold/AAG-9485-2019		National Institutes of Health [HL 2P01HL114471-06, 7R01HL111541-06]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL114471, R01HL111541, P01HL067663] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants HL 2P01HL114471-06 and 7R01HL111541-06.	Aleman F, 2016, IMMUNOL ALLERGY CLIN, V36, P559, DOI 10.1016/j.iac.2016.03.006; Amrani Y, 2004, CURR OPIN PHARMACOL, V4, P230, DOI 10.1016/j.coph.2004.02.004; Arron JR, 2014, EUR RESPIR J, V43, P627, DOI 10.1183/09031936.00117013; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Balenga NA, 2014, J ALLERGY CLIN IMMUN, V134, P451, DOI 10.1016/j.jaci.2014.01.019; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berair R, 2014, DRUGS, V74, P1345, DOI 10.1007/s40265-014-0250-4; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Braun A, 2001, INT ARCH ALLERGY IMM, V124, P205, DOI 10.1159/000053711; Brooks CR, 2016, RESPIROLOGY, V21, P460, DOI 10.1111/resp.12701; Carey MA, 2007, AM J RESP CRIT CARE, V175, P126, DOI 10.1164/rccm.200509-1493OC; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chaudhuri R, 2014, PULM PHARMACOL THER, V27, P62, DOI 10.1016/j.pupt.2013.11.007; Chen J, 2018, J ALLERGY CLIN IMMUN, V142, P207, DOI 10.1016/j.jaci.2017.08.015; Chung KF, 2014, DRUGS, V74, P719, DOI 10.1007/s40265-014-0213-9; Cooper PR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010235; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; Cox C, 2015, CAN RESPIR J, V22, P221, DOI 10.1155/2015/459187; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Das S, 2016, P NATL ACAD SCI USA, V113, P13132, DOI 10.1073/pnas.1610433113; Demarche S, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0208-2; Duncan CJA, 2003, EUR RESPIR J, V22, P484, DOI 10.1183/09031936.03.00109803a; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; Fahy JV, 1998, EUR RESPIR J, V11, P1240, DOI 10.1183/09031936.98.11061240; Gabehart KE, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-110; Gao P, 2015, RESP RES, V16, DOI 10.1186/s12931-014-0163-5; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Hall C, 2017, J ALLER CL IMM-PRACT, V5, P928, DOI 10.1016/j.jaip.2017.04.030; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hirota JA, 2009, PULM PHARMACOL THER, V22, P370, DOI 10.1016/j.pupt.2008.12.004; Koziol-White CJ, 2016, BRIT J PHARMACOL, V173, P2726, DOI 10.1111/bph.13542; Kramer EL, 2009, AM J RESP CELL MOL, V41, P415, DOI 10.1165/rcmb.2008-0470OC; Kuipers I, 2013, EUR RESPIR J, V41, P469, DOI 10.1183/09031936.00115212; Lambert RK, 1985, J APPL PHYSIOL, V1993, P2771; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2015, CURR OPIN PULM MED, V21, P33, DOI 10.1097/MCP.0000000000000120; Ntontsi P, 2017, ALLERGY, V72, P1761, DOI 10.1111/all.13184; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Porsbjerg C, 2009, J ASTHMA, V46, P606, DOI 10.1080/02770900903015654; Reynaert NL, 2011, BBA-GEN SUBJECTS, V1810, P1045, DOI 10.1016/j.bbagen.2011.01.010; Sandstrom T, 2010, CLIN RESPIR J, V4, P41, DOI 10.1111/j.1752-699X.2010.00196.x; Schleich F, 2016, CURR TOP MED CHEM, V16, P1561, DOI 10.2174/1568026616666151015093406; Schleich FN, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-11; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Simpson JL, 2010, RESPIRATION, V79, P147, DOI 10.1159/000245899; Slats AM, 2007, AM J RESP CRIT CARE, V176, P121, DOI 10.1164/rccm.200612-1814OC; Svenningsen S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00158; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; Thomson NC, 2016, THER ADV RESPIR DIS, V10, P211, DOI 10.1177/1753465816632638; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634; Wang F, 2011, EUR RESPIR J, V38, P567, DOI 10.1183/09031936.00170110; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Woodruff PG, 2002, SEM RESP CRIT CARE M, V23, P361, DOI 10.1055/s-2002-34331; Xiong Y, 2011, ANTIOXID REDOX SIGN, V15, P233, DOI 10.1089/ars.2010.3540; Zhang JY, 2007, IMMUNOL ALLERGY CLIN, V27, P623, DOI 10.1016/j.iac.2007.09.003; Zhang XY, 2014, CLIN EXP ALLERGY, V44, P1137, DOI 10.1111/cea.12345	66	67	67	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1287	1294		10.1016/j.jaci.2018.06.008	http://dx.doi.org/10.1016/j.jaci.2018.06.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	29928921	Green Accepted, hybrid			2022-12-18	WOS:000463348900002
J	Mayorga, C; Ebo, DG; Lang, DM; Pichler, WJ; Sabato, V; Park, MA; Makowska, J; Atanaskovic-Markovic, M; Bonadonna, P; Jares, E				Mayorga, Cristobalina; Ebo, Didier G.; Lang, David M.; Pichler, Werner J.; Sabato, Vito; Park, Miguel A.; Makowska, Joanna; Atanaskovic-Markovic, Marina; Bonadonna, Patrizia; Jares, Edgardo			Controversies in drug allergy: In vitro testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Drug hypersensitivity; in vitro tests; diagnostic; IgE; T-cells; p-i concept; anaphylaxis; severe cutaneous reactions; proliferation; cytokine	BASOPHIL ACTIVATION TEST; STEVENS-JOHNSON-SYNDROME; LYMPHOCYTE-TRANSFORMATION TEST; IMMEDIATE HYPERSENSITIVITY REACTIONS; CUTANEOUS ADVERSE-REACTIONS; TOXIC EPIDERMAL NECROLYSIS; IGE-MEDIATED ALLERGY; HLA-B-ASTERISK-1502 ALLELE; T-CELLS; MOXIFLOXACIN HYPERSENSITIVITY	Despite their low frequency, drug hypersensitivity reactions (DHRs) can be serious and result in lifelong sequelae. The diagnosis is critical to avert future reactions and should identify the culprit drug or drugs and safe alternatives. However, making the diagnosis can be complex and challenging. Reliable in vitro tests can offer the potential to improve a diagnosis of DHR and influence medical decision making. Importantly, in vitro testing is frequently not performed as a test in isolation but rather as a component of a diagnostic algorithm along with additional tests. There are several in vitro approaches for the different endotypes of DHRs. However, only few are available for routine diagnosis, and many are restricted to research laboratories. In vitro tests exhibit varying sensitivity and specificity depending on the drug involved and the clinical phenotype. In vitro tests can complement skin tests, especially in patients with negative or equivocal skin test responses inconsistent with the clinical presentation and in severe reactions in which drug provocation tests are contraindicated. The main unmet need for many in vitro tests for the diagnosis of DHRs is validation in larger studies with standardized controls that could harmonize diagnostic management between the United States, European Union, and other regions of the world.	[Mayorga, Cristobalina] UMA, Reg Univ Hosp Malaga, IBIMA, Res Lab, Malaga, Spain; [Mayorga, Cristobalina] UMA, Reg Univ Hosp Malaga, IBIMA, Allergy Unit, Malaga, Spain; [Ebo, Didier G.; Sabato, Vito] Univ Antwerp, Immunol Allergol Rheumatol, Antwerp, Belgium; [Ebo, Didier G.; Sabato, Vito] Antwerp Univ Hosp, Antwerp, Belgium; [Lang, David M.] Cleveland Clin, Dept Allergy, Cleveland, OH 44106 USA; [Lang, David M.] Cleveland Clin, Clin Immunol Resp Inst, Cleveland, OH 44106 USA; [Pichler, Werner J.] ADR AC GmbH, Bern, Switzerland; [Park, Miguel A.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Makowska, Joanna] Med Univ Lodz, Dept Rheumatol, Lodz, Poland; [Atanaskovic-Markovic, Marina] Univ Belgrade, Univ Childrens Hosp, Fac Med, Belgrade, Serbia; [Bonadonna, Patrizia] Azienda Osped Univ Integrata, Allergy Unit, Verona, Italy; [Jares, Edgardo] LIBRA Fdn, Buenos Aires, DF, Argentina	Universidad de Malaga; Universidad de Malaga; University of Antwerp; University of Antwerp; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Mayo Clinic; Medical University Lodz; University of Belgrade; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Mayorga, C (corresponding author), Hosp Reg Univ Malaga, Allergy Unit, Res Lab, Pavil 5,Plaza Hosp Civil, Malaga 29009, Spain.	lina.mayorga@ibima.eu	Mayorga, Lina/FBO-7730-2022; Sabato, Vito/B-6479-2017; Mayorga, Cristobalina/D-7167-2018	Sabato, Vito/0000-0002-1321-314X; Mayorga, Cristobalina/0000-0001-8852-8077; Makowska, Joanna/0000-0003-2036-375X; Jares, Edgardo/0000-0001-9411-0582				Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; Abuaf N, 2012, J Allergy (Cairo), V2012, P580873, DOI 10.1155/2012/580873; Abuaf N, 1999, J ALLERGY CLIN IMMUN, V104, P411, DOI 10.1016/S0091-6749(99)70386-6; [Anonymous], 2018, INTERN MED J, V48, P363, DOI 10.1111/imj.13730; Antunez C, 2011, CLIN EXP ALLERGY, V41, P657, DOI 10.1111/j.1365-2222.2010.03693.x; Aranda A, 2011, ALLERGY, V66, P247, DOI 10.1111/j.1398-9995.2010.02460.x; Ariza A, 2016, SCI REP-UK, V6, DOI 10.1038/srep35113; Ariza A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23845; Ariza A, 2014, CYTOM PART A, V85, P400, DOI 10.1002/cyto.a.22443; Baretto RL, 2017, ALLERGY, V72, P2031, DOI 10.1111/all.13226; Bavbek S, 2009, INT ARCH ALLERGY IMM, V150, P261, DOI 10.1159/000222678; Bavbek S, 2009, INT ARCH ALLERGY IMM, V149, P58, DOI 10.1159/000176307; Berroa F, 2014, CLIN EXP ALLERGY, V44, P270, DOI 10.1111/cea.12237; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; Blanca M, 2001, ALLERGY, V56, P862, DOI 10.1034/j.1398-9995.2001.00995.x; Bochenek G, 2018, J ALLER CL IMM-PRACT, V6, P528, DOI 10.1016/j.jaip.2017.07.001; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Brozek JL, 2009, ALLERGY, V64, P1109, DOI 10.1111/j.1398-9995.2009.02083.x; Caiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002; Celik GE, 2009, CLIN EXP ALLERGY, V39, P1522, DOI 10.1111/j.1365-2222.2009.03277.x; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Colombo S, 2008, J INFECT DIS, V198, P864, DOI 10.1086/591184; De Weck AL, 2009, J INVEST ALLERG CLIN, V19, P91; Decuyper II, 2017, DRUGS R&D, V17, P265, DOI 10.1007/s40268-017-0176-x; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Dybendal T, 2003, ACTA ANAESTH SCAND, V47, P1211, DOI 10.1046/j.1399-6576.2003.00237.x; Eberlein B, 2010, CLIN EXP ALLERGY, V40, P411, DOI 10.1111/j.1365-2222.2009.03426.x; Ebo DG, 2006, ALLERGY, V61, P935, DOI 10.1111/j.1398-9995.2006.01094.x; Ebo DG, 2011, ALLERGY, V66, P1275, DOI 10.1111/j.1398-9995.2011.02661.x; Ebo DG, 2007, ANESTHESIOLOGY, V107, P253, DOI 10.1097/01.anes.0000270735.40872.f2; Ebo DG, 2018, J ALLER CL IMM-PRACT, V6, P1176, DOI 10.1016/j.jaip.2018.01.004; Elsheikh A, 2011, J ALLERGY CLIN IMMUN, V127, P1543, DOI 10.1016/j.jaci.2010.12.1119; Fernandez TD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003679; Fontaine C, 2007, ALLERGY, V62, P47, DOI 10.1111/j.1398-9995.2006.01268.x; Gamboa PM, 2003, ALLERGY, V58, P312, DOI 10.1034/j.1398-9995.2003.00096.x; Garvey LH, 2007, J ALLERGY CLIN IMMUN, V120, P409, DOI 10.1016/j.jaci.2007.04.029; Genin E, 2014, PHARMACOGENOMICS J, V14, P281, DOI 10.1038/tpj.2013.40; Giavina-Bianchi P, 2017, J ALLER CL IMM-PRACT, V5, P728, DOI 10.1016/j.jaip.2016.11.006; Gomez E, 2009, CLIN EXP ALLERGY, V39, P1217, DOI 10.1111/j.1365-2222.2009.03237.x; Hagau N, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-42; Hagau N, 2013, ALLERGY ASTHMA IMMUN, V5, P383, DOI 10.4168/aair.2013.5.6.383; Hanafusa T, 2012, J DERMATOL SCI, V65, P213, DOI 10.1016/j.jdermsci.2011.12.002; Harboe T, 2005, ANESTHESIOLOGY, V102, P897, DOI 10.1097/00000542-200505000-00006; Hirata S, 2009, CLIN CHIM ACTA, V407, P25, DOI 10.1016/j.cca.2009.06.024; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; HOUWERZIJL J, 1977, CLIN EXP IMMUNOL, V29, P272; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Iwamoto T, 2012, BIOL PHARM BULL, V35, P1487, DOI 10.1248/bpb.b12-00150; Johansson SGO, 2013, J ALLERGY CLIN IMMUN, V132, P235, DOI 10.1016/j.jaci.2012.11.017; JOHNSTON C, 1988, CLIN EXP RHEUMATOL, V6, P391; Joint Task Force on Practice Parameters, 2000, Ann Allergy Asthma Immunol, V85, P521; Torres MJ, 2010, J ALLERGY CLIN IMMUN, V125, P502, DOI 10.1016/j.jaci.2009.11.032; Kano Y, 2007, ALLERGY, V62, P1439, DOI 10.1111/j.1398-9995.2007.01553.x; Karami Z, 2016, INT ARCH ALLERGY IMM, V170, P158, DOI 10.1159/000448284; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KNOL EF, 1992, J ALLERGY CLIN IMMUN, V90, P92, DOI 10.1016/S0091-6749(06)80015-1; Komericki P, 2006, INT ARCH ALLERGY IMM, V140, P164, DOI 10.1159/000092556; Korosec P, 2011, RESP MED, V105, pS81, DOI 10.1016/S0954-6111(11)70017-8; Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260; Kvedariene V, 2006, ALLERGY, V61, P311, DOI 10.1111/j.1398-9995.2006.00978.x; Laguna JJ, 2018, J ALLER CL IMM-PRACT, V6, P1628, DOI 10.1016/j.jaip.2017.12.001; Laroche D, 2011, ANESTHESIOLOGY, V114, P91, DOI 10.1097/ALN.0b013e31820164d2; Lee MH, 2012, INTERN MED J, V42, P411, DOI 10.1111/j.1445-5994.2011.02567.x; Leysen J, 2014, CLIN EXP ALLERGY, V44, P1069, DOI 10.1111/cea.12344; Leysen J, 2013, CYTOM PART B-CLIN CY, V84B, P65, DOI 10.1002/cyto.b.21074; Leysen J, 2011, ALLERGY, V66, P1014, DOI 10.1111/j.1398-9995.2011.02569.x; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lochmatter P, 2009, ALLERGY, V64, P1269, DOI 10.1111/j.1398-9995.2009.01985.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Lopez S, 2009, BRIT J DERMATOL, V160, P259, DOI 10.1111/j.1365-2133.2008.08875.x; Luque I, 2001, ALLERGY, V56, P611, DOI 10.1034/j.1398-9995.2001.000115.x; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Macy E, 2010, ANN ALLERG ASTHMA IM, V105, P136, DOI 10.1016/j.anai.2010.06.014; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Manfredi M, 2004, J ALLERGY CLIN IMMUN, V113, P155, DOI 10.1016/j.jaci.2003.09.035; MATA E, 1992, ALLERGY, V47, P471, DOI 10.1111/j.1398-9995.1992.tb00667.x; Matucci A, 2013, CLIN EXP ALLERGY, V43, P659, DOI 10.1111/cea.12098; Mayorga C, 2016, ALLERGY, V71, P1103, DOI 10.1111/all.12886; Mayorga C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061222; Mayorga C, 2013, INT ARCH ALLERGY IMM, V160, P377, DOI 10.1159/000343023; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Monneret G, 2002, CLIN IMMUNOL, V102, P192, DOI 10.1006/clim.2001.5156; Opstrup MS, 2014, ALLERGY, V69, P1390, DOI 10.1111/all.12466; Orasch CE, 1999, CLIN EXP ALLERGY, V29, P1549; Phillips EJ, 2011, J ALLERGY CLIN IMMUN, V127, pS60, DOI 10.1016/j.jaci.2010.11.046; Pichler WJ, 2016, INT ARCH ALLERGY IMM, V171, P166, DOI 10.1159/000453265; Pichler WJ, 2015, INT ARCH ALLERGY IMM, V168, P13, DOI 10.1159/000441280; Pinnobphun P, 2011, ANN ALLERG ASTHMA IM, V106, P387, DOI 10.1016/j.anai.2010.12.020; Pirmohamed M, 2015, J ALLERGY CLIN IMMUN, V136, P236, DOI 10.1016/j.jaci.2015.06.022; Polak ME, 2013, BRIT J DERMATOL, V168, P539, DOI 10.1111/bjd.12109; Porebski G, 2013, CLIN EXP ALLERGY, V43, P1027, DOI 10.1111/cea.12145; Porebski G, 2011, CLIN EXP ALLERGY, V41, P461, DOI 10.1111/j.1365-2222.2011.03701.x; Porebski G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081737; Rodriguez-Pena R, 2006, J ALLERGY CLIN IMMUN, V118, P949, DOI 10.1016/j.jaci.2006.07.013; Rodriguez-Trabado A, 2008, ALLERGY ASTHMA PROC, V29, P241, DOI 10.2500/aap.2008.29.3114; ROUJEAU JC, 1985, INT ARCH ALLER A IMM, V78, P22, DOI 10.1159/000233856; Rouzaire P, 2012, ACTA ANAESTH SCAND, V56, P263, DOI 10.1111/j.1399-6576.2011.02540.x; Rouzaire P, 2012, INT ARCH ALLERGY IMM, V157, P299, DOI 10.1159/000328211; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x; Sachs B, 2002, CLIN EXP ALLERGY, V32, P736, DOI 10.1046/j.1365-2222.2002.01382.x; Sala-Cunill A, 2013, INT ARCH ALLERGY IMM, V160, P192, DOI 10.1159/000339749; Salas M, 2013, ALLERGY, V68, P1203, DOI 10.1111/all.12214; Salas M, 2018, J ALLER CL IMM-PRACT, V6, P1010, DOI 10.1016/j.jaip.2017.08.009; Salas M, 2017, J ALLER CL IMM-PRACT, V5, P694, DOI 10.1016/j.jaip.2017.02.007; Sanchez-Morillas L, 2010, J ALLERGY CLIN IMMUN, V126, P177, DOI 10.1016/j.jaci.2010.03.012; Sanchez-Quintero MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074198; Sanz ML, 2010, CHEM IMMUNOL ALLERGY, V95, P125, DOI 10.1159/000315947; Sanz ML, 2005, INT ARCH ALLERGY IMM, V136, P58, DOI 10.1159/000082586; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Schrijvers R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0073-8; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Spoerl D, 2016, INT ARCH ALLERGY IMM, V169, P256, DOI 10.1159/000446182; Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Tangamornsuksan W, 2018, JAMA DERMATOL, V154, P441, DOI 10.1001/jamadermatol.2017.6484; Tangamornsuksan W, 2013, JAMA DERMATOL, V149, P1025, DOI 10.1001/jamadermatol.2013.4114; Torres MJ, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0144-0; Torres MJ, 2004, CLIN EXP ALLERGY, V34, P1768, DOI 10.1111/j.1365-2222.2004.02110.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x; Uyttebroek AP, 2014, ALLERGY, V69, P1324, DOI 10.1111/all.12468; Uyttebroek AP, 2015, J ALLER CL IMM-PRACT, V3, P443, DOI 10.1016/j.jaip.2014.12.012; Uyttebroek AP, 2014, IMMUNOL ALLERGY CLIN, V34, P681, DOI 10.1016/j.iac.2014.04.007; Van Gasse AL, 2017, ALLERGY, V72, P2039, DOI 10.1111/all.13236; Vultaggio A, 2010, ALLERGY, V65, P657, DOI 10.1111/j.1398-9995.2009.02280.x; Vultaggio A, 2009, CLIN EXP ALLERGY, V39, P838, DOI 10.1111/j.1365-2222.2009.03219.x; Vultaggio A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121857; Zawodniak A, 2010, ALLERGY, V65, P376, DOI 10.1111/j.1398-9995.2009.02180.x; Zhang FR, 2013, NEW ENGL J MED, V369, P1620, DOI 10.1056/NEJMoa1213096	133	67	68	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					56	65		10.1016/j.jaci.2018.09.022	http://dx.doi.org/10.1016/j.jaci.2018.09.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30573343	Green Accepted, Bronze			2022-12-18	WOS:000454918300006
J	DeVries, A; Wlasiuk, G; Miller, SJ; Bosco, A; Stern, DA; Lohman, IC; Rothers, J; Jones, AC; Nicodemus-Johnson, J; Vasquez, MM; Curtin, JA; Simpson, A; Custovic, A; Jackson, DJ; Gern, JE; Lemanske, RF; Guerra, S; Wright, AL; Ober, C; Halonen, M; Vercelli, D				DeVries, Avery; Wlasiuk, Gabriela; Miller, Susan J.; Bosco, Anthony; Stern, Debra A.; Carla Lohman, I.; Rothers, Janet; Jones, Anya C.; Nicodemus-Johnson, Jessie; Vasquez, Monica M.; Curtin, John A.; Simpson, Angela; Custovic, Adnan; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.; Guerra, Stefano; Wright, Anne L.; Ober, Carole; Halonen, Marilyn; Vercelli, Donata			Epigenome-wide analysis links SMAD3 methylation at birth to asthma in children of asthmatic mothers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetics; DNA methylation; childhood asthma; SMAD3	DNA METHYLATION; CHILDHOOD; LIFE; ASSOCIATION; RISK; AGE; EXACERBATIONS; EPIGENETICS; PREDICTORS; ACTIVATION	Background: The timing and mechanisms of asthma inception remain imprecisely defined. Although epigenetic mechanisms likely contribute to asthma pathogenesis, little is known about their role in asthma inception. Objective: We sought to assess whether the trajectory to asthma begins already at birth and whether epigenetic mechanisms, specifically DNA methylation, contribute to asthma inception. Methods: We used the Methylated CpG Island Recovery Assay chip to survey DNA methylation in cord blood mononuclear cells from 36 children (18 nonasthmatic and 18 asthmatic subjects by age 9 years) from the Infant Immune Study (IIS), an unselected birth cohort closely monitored for asthma for a decade. SMAD3 methylation in IIS (n = 60) and in 2 replication cohorts (the Manchester Asthma and Allergy Study [n = 30] and the Childhood Origins of Asthma Study [n = 28]) was analyzed by using bisulfite sequencing or Illumina 450K arrays. Cord blood mononuclear cell-derived IL-1b levels were measured by means of ELISA. Results: Neonatal immune cells harbored 589 differentially methylated regions that distinguished IIS children who did and did not have asthma by age 9 years. In all 3 cohorts methylation in SMAD3, the most connected node within the network of asthma-associated, differentially methylated regions, was selectively increased in asthmatic children of asthmatic mothers and was associated with childhood asthma risk. Moreover, SMAD3 methylation in IIS neonates with maternal asthma was strongly and positively associated with neonatal production of IL-1b, an innate inflammatory mediator. Conclusions: The trajectory to childhood asthma begins at birth and involves epigenetic modifications in immunoregulatory and proinflammatory pathways. Maternal asthma influences epigenetic mechanisms that contribute to the inception of this trajectory.	[DeVries, Avery; Wlasiuk, Gabriela; Stern, Debra A.; Carla Lohman, I.; Vasquez, Monica M.; Guerra, Stefano; Wright, Anne L.; Halonen, Marilyn; Vercelli, Donata] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA; [DeVries, Avery; Vercelli, Donata] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ USA; [Miller, Susan J.] Univ Arizona, Arizona Res Labs, Tucson, AZ USA; [Rothers, Janet] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA; [Wright, Anne L.] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA; [Halonen, Marilyn] Univ Arizona, Dept Pharmacol, Tucson, AZ USA; [Halonen, Marilyn; Vercelli, Donata] Univ Arizona, Arizona Ctr Biol Complex Dis, Tucson, AZ USA; [Halonen, Marilyn; Vercelli, Donata] Univ Arizona, Inst Bio5, Tucson, AZ USA; [Bosco, Anthony; Jones, Anya C.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Nicodemus-Johnson, Jessie; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Curtin, John A.; Simpson, Angela; Custovic, Adnan] Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Curtin, John A.; Simpson, Angela; Custovic, Adnan] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Guerra, Stefano] Univ Pompeu Fabra, CREAL, Barcelona, Spain	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; Telethon Kids Institute; University of Western Australia; University of Chicago; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Wisconsin System; University of Wisconsin Madison; Pompeu Fabra University	Vercelli, D (corresponding author), BIO5 Inst, Rm 339,1657 E Helen St, Tucson, AZ 85721 USA.	donata@email.arizona.edu	Bosco, Anthony/AAC-6900-2022; DeVries, Avery/AAQ-9183-2020; Jones, Anya/AAE-8029-2021; Custovic, Adnan/A-2435-2012	Jones, Anya/0000-0002-6649-4977; Custovic, Adnan/0000-0001-5218-7071; Bosco, Anthony/0000-0002-4335-615X; Simpson, Angela/0000-0003-2733-6666; Ober, Carole/0000-0003-4626-9809; Miller, Susan J/0000-0002-3759-7547; Halonen, Marilyn/0000-0001-9606-935X	BrightSpark Foundation McCusker Fellowship; National Institute for Health Research Respiratory and Allergy Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Asthma UK [301, 362, 01/012, 04/014]; BMA James Trust; Moulton Charitable Foundation; Medical Research Council (MRC) [G0601361]; North West Lung Centre Charity;  [RC1HL100800];  [ES006694];  [R01AI042268];  [P01HL070831]; Medical Research Council [G1000758, MR/K002449/2, MR/K002449/1, G1000758B, G0601361] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish; MRC [MR/K002449/1, G0601361, MR/K002449/2] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, RC1HL100800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	BrightSpark Foundation McCusker Fellowship; National Institute for Health Research Respiratory and Allergy Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Asthma UK; BMA James Trust; Moulton Charitable Foundation; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Lung Centre Charity; ; ; ; ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by RC1HL100800 and ES006694 (to D.V.), R01AI042268 (to A.L.W.), and P01HL070831 (to R.F.L.). A.B. is supported by a BrightSpark Foundation McCusker Fellowship. This report includes independent research supported by National Institute for Health Research Respiratory and Allergy Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. MAAS was supported by Asthma UK grants no. 301 (1995-1998), 362 (1998-2001), 01/012 (2001-2004), and 04/014 (2004-2007); the BMA James Trust; the Moulton Charitable Foundation (2004-current); and Medical Research Council (MRC) grant G0601361. We thank the North West Lung Centre Charity for supporting this project.	Anthoni M, 2008, BRIT J DERMATOL, V159, P546, DOI 10.1111/j.1365-2133.2008.08696.x; Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875; Barua S, 2015, EPIGENOMICS-UK, V7, P85, DOI [10.2217/EPI.14.71, 10.2217/epi.14.71]; Basu R, 2015, NAT IMMUNOL, V16, P286, DOI 10.1038/ni.3099; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Curtin JA, 2013, CLIN EXP ALLERGY, V43, P304, DOI 10.1111/cea.12046; Damrauer SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017715; Deliu M, 2014, ALLERGY, V69, P1515, DOI 10.1111/all.12467; DeVries A, 2015, CURR OPIN PEDIATR, V27, P719, DOI 10.1097/MOP.0000000000000285; DeVries A, 2015, CURR OPIN ALLERGY CL, V15, P435, DOI 10.1097/ACI.0000000000000201; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Halonen M, 2013, AM J RESP CRIT CARE, V188, P35, DOI 10.1164/rccm.201207-1265OC; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P864, DOI 10.1016/j.jaci.2013.09.030; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; McDade TW, 2012, P NATL ACAD SCI USA, V109, P17281, DOI 10.1073/pnas.1202244109; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2014, LANCET RESP MED, V2, P10, DOI 10.1016/S2213-2600(13)70288-1; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Oddy WH, 2003, J ALLERGY CLIN IMMUN, V112, P723, DOI 10.1016/S0091-6749(03)01941-9; Paaso EMS, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0152-8; Pendergrass SA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003087; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P397, DOI 10.1016/j.jaci.2011.04.044; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; van Breda SGJ, 2015, ARCH TOXICOL, V89, P1959, DOI 10.1007/s00204-014-1351-2; Wang GY, 2013, J ADOLESCENT HEALTH, V52, pS14, DOI 10.1016/j.jadohealth.2012.04.019; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yegnasubramanian S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj022	39	67	69	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					534	542		10.1016/j.jaci.2016.10.041	http://dx.doi.org/10.1016/j.jaci.2016.10.041			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28011059	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000406855500025
J	Rabito, FA; Carlson, JC; He, H; Werthmann, D; Schal, C				Rabito, Felicia A.; Carlson, John C.; He, Hua; Werthmann, Derek; Schal, Coby			A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cockroach; integrated pest management; indoor allergens; intervention studies; FEV1; FENO	INTEGRATED PEST-MANAGEMENT; INNER-CITY ASTHMA; ALLERGEN EXPOSURE; LOW-INCOME; ENVIRONMENTAL INTERVENTION; MITE; RISK; COMMUNITY; ABATEMENT; SENSITIZATION	Background: Exposure to cockroaches is an important asthma trigger, particularly for children with asthma living in inner cities. Integrated pest management is the recommended approach to cockroach abatement; however, it is costly and difficult to implement. The impact of reducing cockroach exposure on asthma outcomes is not known. Objective: We sought to test the use of a single intervention, insecticidal bait, to reduce cockroach exposure in the home of children with asthma in New Orleans and to examine the impact of cockroach reduction on asthma outcomes. Methods: One hundred two children aged 5 to 17 years with moderate to severe asthma were enrolled in a 12-month randomized controlled trial testing the use of insecticidal bait on cockroach counts and asthma morbidity. Homes were visited 6 times and asthma symptoms were assessed every 2 months. Results: After adjustment, intervention homes had significantly fewer cockroaches than did control homes (mean change in cockroaches trapped, 13.14; 95% CI, 6.88-19.39; P < .01). Children in control homes had more asthma symptoms and unscheduled health care utilization in the previous 2 weeks (1.82, 95% CI, 0.14-3.50, P = .03; 1.17, 95% CI, 0.11-2.24, P = .03, respectively) and a higher proportion of children with FEV1 of less than 80% predicted (odds ratio, 5.74; 95% CI, 1.60-20.57; P = .01) compared with children living in intervention homes. Conclusions: Previous research has demonstrated improvement in asthma health outcomes using multifaceted interventions. The strategic placement of insecticidal bait, which is inexpensive, has low toxicity, and is widely available, resulted in sustained cockroach elimination over 12 months and was associated with improved asthma outcomes. This single intervention may be an alternative to multifaceted interventions currently recommended to improve asthma morbidity.	[Rabito, Felicia A.; He, Hua; Werthmann, Derek] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Ste 2016, New Orleans, LA 70112 USA; [Carlson, John C.] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; [Schal, Coby] North Carolina State Univ, Dept Entomol, Raleigh, NC USA	Tulane University; Tulane University; University of North Carolina; North Carolina State University	Rabito, FA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Ste 2016, New Orleans, LA 70112 USA.	rabito@tulane.edu	Schal, Coby/A-8717-2010	Schal, Coby/0000-0001-7195-6358	Department of Housing and Urban Development, Healthy Homes Technical Studies [LALHH0228-10]	Department of Housing and Urban Development, Healthy Homes Technical Studies	This study was funded by the Department of Housing and Urban Development, Healthy Homes Technical Studies (grant no. LALHH0228-10).	Akinbami LJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2354; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arroyave WD, 2014, ANN ALLERG ASTHMA IM, V112, P237, DOI 10.1016/j.anai.2014.01.006; Arruda LK, 2005, CURR ALLERGY ASTHM R, V5, P411, DOI 10.1007/s11882-005-0015-y; Brenner BL, 2003, ENVIRON HEALTH PERSP, V111, P1649, DOI 10.1289/ehp.6069; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Crocker DD, 2011, AM J PREV MED, V41, pS5, DOI [10.1016/j.amepre.2011.04.011, 10.1016/j.amepre.2011.05.012]; Do DC, 2016, ALLERGY, V71, P463, DOI 10.1111/all.12827; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Eggleston PA, 2001, ANN ALLERG ASTHMA IM, V87, P44, DOI 10.1016/S1081-1206(10)62340-X; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Forno E, 2012, AM J RESP CRIT CARE, V185, P1033, DOI 10.1164/rccm.201202-0350ED; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Kass D, 2009, ENVIRON HEALTH PERSP, V117, P1219, DOI 10.1289/ehp.0800149; Krieger J, 2010, J PUBLIC HEALTH MAN, V16, pS11, DOI 10.1097/PHH.0b013e3181ddcbd9; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nurmatov U, 2012, ALLERGY, V67, P158, DOI 10.1111/j.1398-9995.2011.02752.x; Page K, 2012, CURR ALLERGY ASTHM R, V12, P448, DOI 10.1007/s11882-012-0276-1; Peters JL, 2007, J ASTHMA, V44, P455, DOI 10.1080/02770900701421971; Rabito FA, 2007, J URBAN HEALTH, V84, P782, DOI 10.1007/s11524-007-9216-0; Rabito FA, 2011, ANN ALLERG ASTHMA IM, V106, P103, DOI 10.1016/j.anai.2010.10.013; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sever ML, 2007, J ALLERGY CLIN IMMUN, V120, P849, DOI 10.1016/j.jaci.2007.07.003; Sheehan WJ, 2010, J ALLERGY CLIN IMMUN, V125, P575, DOI 10.1016/j.jaci.2010.01.023; Silva JM, 2005, PEDIAT ALLERG IMM-UK, V16, P393, DOI 10.1111/j.1399-3038.2005.00308.x; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Wang CL, 2009, J ECON ENTOMOL, V102, P1614, DOI 10.1603/029.102.0428; Wright LS, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0419-7	43	67	67	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					565	570		10.1016/j.jaci.2016.10.019	http://dx.doi.org/10.1016/j.jaci.2016.10.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28108117	Bronze			2022-12-18	WOS:000406855500028
J	Wright, BL; Kulis, M; Guo, RS; Orgel, KA; Wolf, WA; Burks, AW; Vickery, BP; Dellon, ES				Wright, Benjamin L.; Kulis, Mike; Guo, Rishu; Orgel, Kelly A.; Wolf, W. Asher; Burks, A. Wesley; Vickery, Brian P.; Dellon, Evan S.			Food-specific igG(4) is associated with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL IMMUNOTHERAPY; ALLERGY; ADULTS; PEANUT		[Wright, Benjamin L.; Kulis, Mike; Guo, Rishu; Orgel, Kelly A.; Wolf, W. Asher; Burks, A. Wesley; Vickery, Brian P.; Dellon, Evan S.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Wright, Benjamin L.] Duke Univ, Med Ctr, Durham, NC 27708 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Wright, BL (corresponding author), Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA.; Wright, BL (corresponding author), Duke Univ, Med Ctr, Durham, NC 27708 USA.	wright.benjamin@mayo.edu		Burks, Wesley/0000-0003-1873-5702; Vickery, Brian/0000-0002-7243-5543; Guo, Rishu/0000-0002-6442-8482	NCATS NIH HHS [UL1 TR001111] Funding Source: Medline; NIAID NIH HHS [T32 AI007062] Funding Source: Medline; NIDDK NIH HHS [K23 DK090073, T32 DK007634] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007634, K23DK090073] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Dellon ES, 2015, AM J GASTROENTEROL, V110, P821, DOI 10.1038/ajg.2015.57; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Zukerberg L, 2015, HISTOPATHOLOGY	9	67	70	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1190	1192		10.1016/j.jaci.2016.02.024	http://dx.doi.org/10.1016/j.jaci.2016.02.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27130859	Green Accepted, Bronze			2022-12-18	WOS:000385499400025
J	Chang, HY; Suh, DI; Yang, SI; Kang, MJ; Lee, SY; Lee, E; Choi, IA; Lee, KS; Shin, YJ; Shin, YH; Kim, YH; Kim, KW; Ahn, K; Won, HS; Choi, SJ; Oh, SY; Kwon, JY; Kim, YH; Park, HJ; Lee, KJ; Jun, JK; Yu, HS; Lee, SH; Jung, BK; Kwon, JW; Choi, YK; Do, N; Bae, YJ; Kim, H; Chang, WS; Kim, EJ; Lee, JK; Hong, SJ				Chang, Hyoung Yoon; Suh, Dong In; Yang, Song-I.; Kang, Mi-Jin; Lee, So-Yeon; Lee, Eun; Choi, In Ae; Lee, Kyung-Sook; Shin, Yee-Jin; Shin, Youn Ho; Kim, Yoon Hee; Kim, Kyung Won; Ahn, Kangmo; Won, Hye-Sung; Choi, Suk-Joo; Oh, Soo-Young; Kwon, Ja-Young; Kim, Young Han; Park, Hee Jin; Lee, Kyung-Ju; Jun, Jong Kwan; Yu, Ho-Sung; Lee, Seung-Hwa; Jung, Bok Kyoung; Kwon, Ji-Won; Choi, Yoon Kyung; Do, Namhee; Bae, Yun Jin; Kim, Ho; Chang, Woo-Sung; Kim, Eun-Jin; Lee, Jeom Kyu; Hong, Soo-Jong			Prenatal maternal distress affects atopic dermatitis in offspring mediated by oxidative stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anxiety; depression; atopic dermatitis; prenatal; psychological stress; cohort; reactive oxygen species	ALLERGIC DISEASES; ASTHMA; CHILDREN; RISK; CHILDHOOD; IMPACT; BIRTH; DEPRESSION; ILLNESS	Objective: We investigated whether prenatal maternal distress is associated with AD risk in offspring and whether the mechanism is mediated by reactive oxygen species. Methods: Two general population-based birth cohorts formed the study. One cohort (Cohort for Childhood Origin of Asthma and Allergic Diseases [COCOA]) consisted of 973 mother-baby dyads, and the other (Panel Study on Korean Children [PSKC]) consisted of 1531 mother-baby dyads. The association between prenatal distress and AD was assessed by using Cox proportional hazards and logistic regression models. In COCOA placental 11 beta-hydroxysteroid dehydrogenase type 2 and glutathione levels and serum IgE levels in 1-year-old children were measured. Results: In COCOA and PSKC AD occurred in 30.6% (lifetime prevalence) and 11.6% (1 year prevalence) of offspring, respectively. Prenatal maternal distress increased the risk of AD in offspring, both in COCOA (hazard ratio for depression, 1.31 [95% CI, 1.02-1.69]; hazard ratio for anxiety, 1.41 [95% CI, 1.06-1.89]) and PSKC (odds ratio for distress, 1.85 [95% CI, 1.06-3.25]). In COCOA both prenatal maternal depression and anxiety scores were positively related to the predicted probability of AD (P < .001 in both). Prenatal distress decreased placental glutathione to glutathione disulfide ratios (P = .037) and, especially in those who later had AD, decreased placental 11b-hydroxysteroid dehydrogenase type 2 levels (P = .010) and increased IgE levels at 1 year of age (P = .005). Conclusion: Prenatal maternal depression and anxiety promote risk of AD in offspring. Maternal distress increases the predicted probability of AD. The mechanism might involve chronic stress, abnormal steroid levels, and reactive oxygen species.	[Chang, Hyoung Yoon] Ajou Univ, Sch Med, Dept Psychiat, Suwon, South Korea; [Chang, Hyoung Yoon] Sunflower Ctr So Gyeonggi forWomen & Children Vic, Suwon, South Korea; [Chang, Hyoung Yoon] Ajou Univ, Med Ctr, Ctr Traumat Stress, Suwon, South Korea; [Suh, Dong In] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Jun, Jong Kwan] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Yang, Song-I.; Lee, So-Yeon] Hallym Univ, Hallym Sacred Heart Hosp, Coll Med, Dept Pediat, Anyang, South Korea; [Kang, Mi-Jin; Yu, Ho-Sung; Lee, Seung-Hwa; Jung, Bok Kyoung; Hong, Soo-Jong] Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul, South Korea; [Lee, Eun; Hong, Soo-Jong] Univ Ulsan, Coll Med, Ctr Environm Hlth,Dept Pediat, Res Ctr Standardizat Allerg Dis,Childhood Asthma, Seoul, South Korea; [Won, Hye-Sung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; Sewon Infant Child Dev Ctr, Seoul, South Korea; [Lee, Kyung-Sook] Hanshin Univ, Dept Rehabil, Osan, South Korea; [Shin, Yee-Jin] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Psychiat, Seoul, South Korea; [Kim, Yoon Hee; Kim, Kyung Won] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Kwon, Ja-Young; Kim, Young Han] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Shin, Youn Ho] CHA Univ, Sch Med, CHA Gangnam Med Ctr, Dept Pediat, Seoul, South Korea; [Kim, Kyung Won] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; [Choi, Suk-Joo; Oh, Soo-Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Park, Hee Jin; Lee, Kyung-Ju] CHA Univ, Sch Med, CHA Gangnam Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Kwon, Ji-Won] Seoul Natl Univ, Bundang Hosp, Dept Pediat, Songnam, South Korea; [Choi, Yoon Kyung; Do, Namhee; Bae, Yun Jin] Korea Inst Child Care & Educ, Seoul, South Korea; [Kim, Ho] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul, South Korea; [Chang, Woo-Sung; Kim, Eun-Jin; Lee, Jeom Kyu] Korea Natl Inst Hlth, Ctr Biomed Sci, Div Allergy & Chron Resp Dis, Cheongju, South Korea	Ajou University; Ajou University; Seoul National University (SNU); Seoul National University (SNU); Hallym University; University of Ulsan; University of Ulsan; University of Ulsan; Asan Medical Center; Hanshin University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Pochon Cha University; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Pochon Cha University; Seoul National University (SNU); Seoul National University (SNU); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science	Hong, SJ (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr,Childhood Asthama Atopy Ctr,Dept Ped, Ctr Environm Hlth,Res Ctr Standardizat Allerg Dis, 88 Olympic Ro 43 Gil, Seoul 05505, South Korea.	sjhong@amc.seoul.kr	Kim, Ho/AAS-2402-2021; Hong, Soo-Jong/AAR-1788-2020	Kim, Ho/0000-0001-7472-3752; Hong, Soo-Jong/0000-0003-1409-2113; Kwon, Ja-Young/0000-0003-3009-6325; Kim, Kyung Won/0000-0003-4529-6135; Chang, Hyoung Yoon/0000-0002-5248-3433; Kim, Young-Han/0000-0003-0645-6028; Kim, Yoon Hee/0000-0002-2149-8501; Shin, Yee Jin/0000-0001-8573-4342	Research of Korea Centers for Disease Control and Prevention [2008-E33030-00, 2009-E33033-00, 2011-E33021-00, 2012-E33012-00, 2013-E51003-00, 2014-E51004-00]; Panel Study of Korean Children (PSKC) of the Korea Institute of Child Care and Education (KICCE)	Research of Korea Centers for Disease Control and Prevention; Panel Study of Korean Children (PSKC) of the Korea Institute of Child Care and Education (KICCE)	Supported by a fund (2008-E33030-00, 2009-E33033-00, 2011-E33021-00, 2012-E33012-00, 2013-E51003-00, and 2014-E51004-00) from the Research of Korea Centers for Disease Control and Prevention. This study was also funded by the Panel Study of Korean Children (PSKC) of the Korea Institute of Child Care and Education (KICCE) and developed based on the PSKC data set of 2008-2013.	Addolorato G, 1999, J PSYCHOSOM RES, V46, P283, DOI 10.1016/S0022-3999(98)00109-3; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bito T, 2012, J DERMATOL SCI, V68, P3, DOI 10.1016/j.jdermsci.2012.06.006; Bradley Kristina L, 2010, Issues Ment Health Nurs, V31, P408, DOI 10.3109/01612840903484105; Braido F, 2014, RHINOLOGY, V52, P66, DOI [10.4193/Rhin13.040, 10.4193/Rhino13.040]; Chang HY, 2014, EARLY HUM DEV, V90, P15, DOI 10.1016/j.earlhumdev.2013.11.006; Clark NM, 2012, J ASTHMA, V49, P1037, DOI 10.3109/02770903.2012.739239; de Marco R, 2012, PEDIAT ALLERG IMM-UK, V23, P724, DOI 10.1111/j.1399-3038.2012.01346.x; Guxens M, 2014, J ALLERGY CLIN IMMUN, V133, P59, DOI 10.1016/j.jaci.2013.04.044; Hahn DW., 1996, KOREAN J HLTH PSYCHO, V1, P1, DOI DOI 10.4069/kjwhn.2011.17.5.439; Hartwig IRV, 2014, J ALLERGY CLIN IMMUN, V134, P160, DOI 10.1016/j.jaci.2014.01.033; Hong SJ, 2004, CLIN EXP ALLERGY, V34, P1556, DOI 10.1111/j.1365-2222.2004.02084.x; Hyde MJ, 2012, EARLY HUM DEV, V88, P943, DOI 10.1016/j.earlhumdev.2012.09.006; Kessler RC, 2006, B WORLD HEALTH ORGAN, V84, P930, DOI 10.2471/BLT.06.033019; Kim KH, 2013, ASIA PAC ALLERGY, V3, P79, DOI 10.5415/apallergy.2013.3.2.79; Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166; Lee SI, 2001, J KOREAN MED SCI, V16, P155, DOI 10.3346/jkms.2001.16.2.155; Myllynen P, 2007, EXPERT OPIN DRUG MET, V3, P331, DOI 10.1517/17425255.3.3.331; Nam S, 2014, CHILD YOUTH SERV REV, V36, P81, DOI 10.1016/j.childyouth.2013.11.008; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; Patelarou E, 2011, NUTR REV, V69, P627, DOI 10.1111/j.1753-4887.2011.00445.x; Sanna L, 2014, J AFFECT DISORDERS, V155, P261, DOI 10.1016/j.jad.2013.11.009; Schiavone S, 2013, ANTIOXID REDOX SIGN, V18, P1475, DOI 10.1089/ars.2012.4720; Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wen HJ, 2011, PEDIAT ALLERG IMM-UK, V22, P695, DOI 10.1111/j.1399-3038.2011.01177.x; Wendland JR, 2006, MOL PSYCHIATR, V11, P224, DOI 10.1038/sj.mp.4001789; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Yamamoto N, 2015, BIOPSYCHOSOC MED, V9, DOI 10.1186/s13030-015-0034-4; Yang HJ, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-109	30	67	67	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					468	+		10.1016/j.jaci.2016.01.020	http://dx.doi.org/10.1016/j.jaci.2016.01.020			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27016803				2022-12-18	WOS:000380835800017
J	Jones, SM; Agbotounou, WK; Fleischer, DM; Burks, AW; Pesek, RD; Harris, MW; Martin, L; Thebault, C; Ruban, C; Benhamou, PH				Jones, Stacie M.; Agbotounou, Wence K.; Fleischer, David M.; Burks, A. Wesley; Pesek, Robert D.; Harris, Michael W.; Martin, Laurent; Thebault, Claude; Ruban, Charles; Benhamou, Pierre-Henri			Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-GAMMA RECEPTORS; HUMAN BASOPHILS; DELIVERY-SYSTEM; IGG; ANTIBODIES; INHIBITION; ACTIVATION; VARIANTS; REGION; CELLS		[Jones, Stacie M.; Pesek, Robert D.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.; Pesek, Robert D.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Agbotounou, Wence K.; Martin, Laurent; Thebault, Claude; Ruban, Charles; Benhamou, Pierre-Henri] DBV Technol, Bagneux, France; [Fleischer, David M.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA; [Fleischer, David M.] Childrens Hosp Colorado, Aurora, CO USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Harris, Michael W.] Aspen Clin Res, Orem, UT USA	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of North Carolina; University of North Carolina Chapel Hill	Jones, SM (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.; Jones, SM (corresponding author), Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA.	JonesStacieM@uams.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068074] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI068074] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1980, MEASUREMENT TOTAL SE; Agbotounou W, 2012, J ALLERGY CLIN IMM S, V131, pAB91; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chu SY, 2008, MOL IMMUNOL, V45, P3926, DOI 10.1016/j.molimm.2008.06.027; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; HAMILTON RG, 1987, CLIN CHEM, V33, P1707; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Kyogoku C, 2002, ARTHRITIS RHEUM, V46, P1242, DOI 10.1002/art.10257; Li XL, 2003, ARTHRITIS RHEUM, V48, P3242, DOI 10.1002/art.11313; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MacGlashan D, 2014, CLIN EXP ALLERGY, V44, P713, DOI 10.1111/cea.12155; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Ramirez J, 2012, J RHEUMATOL, V39, P1035, DOI 10.3899/jrheum.110980; Sakai E, 2012, PEDIATR INT, V54, P758, DOI 10.1111/j.1442-200X.2012.03691.x; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WARNER JA, 1987, J IMMUNOL, V139, P161; WEINBERGER JZ, 1979, J EXP MED, V149, P1336, DOI 10.1084/jem.149.6.1336	33	67	67	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1258	+		10.1016/j.jaci.2016.01.008	http://dx.doi.org/10.1016/j.jaci.2016.01.008			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26920463	Bronze			2022-12-18	WOS:000373351200038
J	Jartti, T; Nieminen, R; Vuorinen, T; Lehtinen, P; Vahlberg, T; Gern, J; Camargo, CA; Ruuskanen, O				Jartti, Tuomas; Nieminen, Riitta; Vuorinen, Tytti; Lehtinen, Pasi; Vahlberg, Tero; Gern, James; Camargo, Carlos A., Jr.; Ruuskanen, Olli			Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchiolitis; child; corticosteroid; glucocorticoid; treatment; prednisolone; rhinovirus; virus; wheeze; wheezing	RESPIRATORY SYNCYTIAL VIRUS; VIRAL-ETIOLOGY; ALLERGIC SENSITIZATION; BRONCHIAL EPITHELIUM; ORAL PREDNISOLONE; CHILDREN; BRONCHIOLITIS; RISK; DEXAMETHASONE; INFECTIONS	Background: Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease. Objective: We sought to study the short-and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children. Methods: After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load. Results: Seventy-four patients completed the study (mean age, 13 months; 28% atopic). Long-term outcomes did not differ between groups (all P >= .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P <.05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P <.05). Conclusions: Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.	[Jartti, Tuomas; Nieminen, Riitta; Lehtinen, Pasi; Ruuskanen, Olli] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; [Nieminen, Riitta; Vuorinen, Tytti] Univ Turku, Dept Virol, SF-20500 Turku, Finland; [Vahlberg, Tero] Univ Turku, Dept Biostat, SF-20500 Turku, Finland; [Gern, James] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Gern, James] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA	University of Turku; University of Turku; University of Turku; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jartti, T (corresponding author), Turku Univ Hosp, Dept Pediat, POB 52, FIN-20520 Turku, Finland.	tuomas.jartti@utu.fi	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	Suomen Akatemia Helsinki, Finland [132595, 114034]; Finnish Medical Foundation, Helsinki, Finland; Sigrid Juselius Foundation, Helsinki, Finland; Foundation for Pediatric Research, Helsinki, Finland; Suomen Kulttuurirahasto, Turku and Helsinki, Finland; Turku University Foundation, Turku, Finland; Paulo Foundation, Helsinki, Finland; Allergy Research Foundation, Helsinki, Finland	Suomen Akatemia Helsinki, Finland; Finnish Medical Foundation, Helsinki, Finland; Sigrid Juselius Foundation, Helsinki, Finland(Sigrid Juselius Foundation); Foundation for Pediatric Research, Helsinki, Finland; Suomen Kulttuurirahasto, Turku and Helsinki, Finland; Turku University Foundation, Turku, Finland; Paulo Foundation, Helsinki, Finland; Allergy Research Foundation, Helsinki, Finland	Supported by the Suomen Akatemia (grant nos. 132595 and 114034), Helsinki, Finland; the Finnish Medical Foundation, Helsinki, Finland; the Sigrid Juselius Foundation, Helsinki, Finland; the Foundation for Pediatric Research, Helsinki, Finland; the Suomen Kulttuurirahasto, Turku and Helsinki, Finland; the Turku University Foundation, Turku, Finland; the Paulo Foundation, Helsinki, Finland; and the Allergy Research Foundation, Helsinki, Finland.	Alansari K, 2013, PEDIATRICS, V132, pE810, DOI 10.1542/peds.2012-3746; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carroll KN, 2012, J ALLERGY CLIN IMMUN, V129, P1236, DOI 10.1016/j.jaci.2012.01.045; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; De Boeck K, 1997, J PEDIATR-US, V131, P919, DOI 10.1016/S0022-3476(97)70044-1; Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2002, PEDIATR INFECT DIS J, V21, P873, DOI 10.1097/00006454-200209000-00019; Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c; Jartti T, 2013, PAEDIATR RESPIR REV, V14, P38, DOI 10.1016/j.prrv.2012.04.002; Jartti T, 2010, J ALLERGY CLIN IMMUN, V126, P1074, DOI 10.1016/j.jaci.2010.09.004; Jartti T, 2009, PEDIATR INFECT DIS J, V28, P311, DOI 10.1097/INF.0b013e31818ee0c1; Kotaniemi-Syrjanen A, 2008, PEDIATR INT, V50, P506, DOI 10.1111/j.1442-200X.2008.02620.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Lukkarinen M, 2013, PEDIAT ALLERG IMM-UK, V24, P237, DOI 10.1111/pai.12046; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Midulla F, 2012, EUR RESPIR J, V39, P396, DOI 10.1183/09031936.00188210; Moher David, 2010, J Clin Epidemiol, V63, pe1, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Osterback R, 2013, J CLIN MICROBIOL, V51, P3960, DOI 10.1128/JCM.01646-13; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542; Plint AC, 2009, NEW ENGL J MED, V360, P2079, DOI 10.1056/NEJMoa0900544; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Roosevelt G, 1996, LANCET, V348, P292, DOI 10.1016/S0140-6736(96)02285-4; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Taylor CE, 2011, NUTR REV, V69, P259, DOI 10.1111/j.1753-4887.2011.00386.x; Utokaparch S, 2011, PEDIATR INFECT DIS J, V30, pE18, DOI 10.1097/INF.0b013e3181ff2fac	42	67	69	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					691	U178		10.1016/j.jaci.2014.07.001	http://dx.doi.org/10.1016/j.jaci.2014.07.001			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25129681	Bronze, Green Published			2022-12-18	WOS:000351065000014
J	Creticos, PS; Esch, RE; Couroux, P; Gentile, D; D'Angelo, P; Whitlow, B; Alexander, M; Coyne, TC				Creticos, Peter S.; Esch, Robert E.; Couroux, Peter; Gentile, Deborah; D'Angelo, Pina; Whitlow, Brad; Alexander, Michael; Coyne, Terrance C.			Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific IgE; allergen-specific IgG(4); allergy immunotherapy; combined score; ragweed; specific immunotherapy; sublingual immunotherapy	GRASS-POLLEN EXTRACT; NORTH-AMERICAN; IMMUNOGLOBULIN-E; DOSE-RESPONSE; EFFICACY; SAFETY; TABLET; ORGANIZATION; CHILDREN; RHINITIS	Background: Sublingual immunotherapy with liquid extracts provides an appealing alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis (ARC), but a lack of robust evidence has deterred its use in North America. Objective: To determine the efficacy and tolerability of standardized glycerinated short ragweed sublingual allergen immunotherapy liquid (RW-SAIL) extract in subjects with ragweed-related ARC. Methods: This phase 3, randomized, placebo-controlled trial was conducted in North America. Subjects (age range, 18-55 years) with or without asthma were selected based on ARC symptom severity and erythema skin prick reaction to short ragweed. Subjects self-administered the maximum tolerated dose of RW-SAIL (n 5 218) or placebo (n 5 211) daily beginning approximately 8 to 16 weeks before and through the end of the ragweed pollen season. The primary end point was subject-assessed total combined daily rhinoconjunctivitis symptom and medication scores (TCS). Results: During the entire season, there was a 43% decrease in TCS in subjects treated with RW-SAIL compared with placebo. Similar decreases were observed in TCS between the 2 groups during peak season (42%) and in daily symptom scores during the entire (42%) and peak (41%) seasons. The occurrence of adverse events was similar between the treatment groups; most were mild in severity. Treatment-related oromucosal local application site reactions occurred early and were transient and self-limited. No anaphylaxis occurred. Conclusions: This is the first successful North American confirmatory phase 3 clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract for the treatment of ARC.	[Creticos, Peter S.] Creticos Res Grp, Crownsville, MD 21032 USA; [Creticos, Peter S.] Allergy & Asthma Specialists Greater Washington, Warrenton, VA USA; [Esch, Robert E.; Whitlow, Brad; Coyne, Terrance C.] Greer Labs, Lenoir, NC USA; [Couroux, Peter] Topstone Res, Toronto, ON, Canada; [Gentile, Deborah] Allegheny Gen Hosp, Dept Med, Div Allergy Asthma & Immunol, Pittsburgh, PA 15212 USA; [D'Angelo, Pina] Novum Pharmaceut Res Serv, Pittsburgh, PA USA; [Alexander, Michael] Niagara Clin Res, Niagara Falls, ON, Canada	Allegheny General Hospital	Creticos, PS (corresponding author), Creticos Res Grp, 1300 St Pauls Way, Crownsville, MD 21032 USA.	psocrates@comcast.net			Greer Laboratories	Greer Laboratories	Supported by Greer Laboratories.	Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bahceciler NN, 2012, CURR OPIN ALLERGY CL, V12, P640, DOI 10.1097/ACI.0b013e328358d5f2; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P974, DOI 10.1016/j.jaci.2010.11.045; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox LS, 2012, J ALLERGY CLIN IMMUN, V130, P1327, DOI 10.1016/j.jaci.2012.08.032; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 2013, ORAL SUBLINGUAL IMMU; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Hsu NM, 2012, INT FORUM ALLERGY RH, V2, P280, DOI 10.1002/alr.21037; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Mohapatra SS, 2010, CURR OPIN PHARMACOL, V10, P276, DOI 10.1016/j.coph.2010.05.012; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256, DOI 10.1016/S1081-1206(10)60451-6; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Wahn U, 2012, J ALLERGY CLIN IMMUN, V130, P886, DOI 10.1016/j.jaci.2012.06.047	35	67	69	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					751	758		10.1016/j.jaci.2013.10.041	http://dx.doi.org/10.1016/j.jaci.2013.10.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24332263				2022-12-18	WOS:000332397600017
J	Hankin, CS; Cox, L; Bronstone, A; Wang, ZH				Hankin, Cheryl S.; Cox, Linda; Bronstone, Amy; Wang, Zhaohui			Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergy immunotherapy; allergy immunotherapy; costs; health care use; Medicaid; matched cohort; retrospective; administrative claims	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST MITE; FOLLOW-UP; SUBLINGUAL IMMUNOTHERAPY; DERMATOPHAGOIDES-PTERONYSSINUS; SPECIALIST CARE; ASTHMA; PREVENTION; SENSITIZATIONS; OUTCOMES	Background: Research demonstrates significant health care cost savings conferred by allergen-specific immunotherapy (AIT) to US children with allergic rhinitis (AR). Objective: We sought to examine whether AIT-related cost benefits conferred to US children with AR similarly extend to adults. Methods: A retrospective (1997-2009) Florida Medicaid claims analysis compared mean 18-month health care costs of patients with newly diagnosed AR who received de novo AIT and were continuously enrolled for 18 months or more versus matched control subjects not receiving AIT. Analyses were conducted for the total sample and separately for adults (age >= 18 years) and children (age < 18 years). Results: Matched were 4,967 patients receiving AIT (1,319 adults and 3,648 children) and 19,278 control subjects (4,815 adults and 14,463 children). AIT-treated enrollees incurred 38% ($6,637 vs $10,644, P <.0001) lower mean 18-month total health care costs than matched control subjects, with significant savings observed within 3 months of AIT initiation. Compared with control subjects, significantly lower 18-month mean health care costs were demonstrated overall (38%; $6,637 for patients receiving AIT vs $10,644 for control subjects, P <.0001), and for both AIT-treated adults (30%; $10,457 AIT vs $14,854 controls, P <.0001) and children (42%; $5,253 AIT vs $9,118 controls, P <.0001). The magnitude of 18-month health care cost savings realized by AIT-treated adults and children did not significantly differ ($4,397 vs $3,965, P = .435). Conclusions: Patients with newly diagnosed AR initiating AIT incurred significantly lower health care costs than matched control subjects beginning 3 months after AIT initiation and continuing throughout the 18-month follow-up period. The significant cost benefits achieved by children with AR diagnoses who initiated AIT were also observed for adults with AR diagnoses who initiated AIT. (J Allergy Clin Immunol 2013; 131:1084-91.)	[Hankin, Cheryl S.; Bronstone, Amy; Wang, Zhaohui] BioMedEcon LLC, Moss Beach, CA 94038 USA; [Cox, Linda] Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA	Nova Southeastern University	Hankin, CS (corresponding author), BioMedEcon LLC, POB 129, Moss Beach, CA 94038 USA.	chankin@biomedecon.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870	American Academy of Allergy, Asthma Immunology; American College of Allergy, Asthma Immunology	American Academy of Allergy, Asthma Immunology; American College of Allergy, Asthma Immunology	Support for this research was provided by the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology.; Disclosure of potential conflict of interest: C. S. Hankin, A. Bronstone, and Z. Wang have been supported by one or more grants from the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology and have consultancy arrangements with Teva Pharmaceuticals and ALK-Abello. L. Cox has consultancy arrangements with Teva Pharmaceuticals, Genentech, Stallergenes, Baxter Pharmaceuticals, and Ista and has received one or more grants from or has one or more grants pending with Stallergenes.	AAAAI, 2000, ALL REP; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Backer V, 2006, ANN ALLERG ASTHMA IM, V97, P490, DOI 10.1016/S1081-1206(10)60940-4; Baptist AP, 2004, ANN ALLERG ASTHMA IM, V93, P227, DOI 10.1016/S1081-1206(10)61492-5; Blaiss MS, 2010, ALLERGY ASTHMA PROC, V31, P375, DOI 10.2500/aap.2010.31.3329; Can D, 2007, PEDIATR INT, V49, P64, DOI 10.1111/j.1442-200X.2007.02307.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; Corso P, 2009, 13 PARTN AM EC SUCC; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Diette GB, 2001, PEDIATRICS, V108, P432, DOI 10.1542/peds.108.2.432; Dominick KL, 2005, ARTHRIT RHEUM-ARTHR, V53, P666, DOI 10.1002/art.21440; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339, DOI 10.1016/S1081-1206(10)63282-6; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Hankin CS, 2011, J ALLERGY CLIN IMMUN, V127, P46, DOI 10.1016/j.jaci.2010.10.014; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; Harmsen L, 2010, INT ARCH ALLERGY IMM, V152, P288, DOI 10.1159/000283041; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; Huntley AL, 2012, ANN FAM MED, V10, P134, DOI 10.1370/afm.1363; Inal A, 2007, J INVEST ALLERG CLIN, V17, P85; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Kleinman NL, 2009, ANN ALLERG ASTHMA IM, V103, P114, DOI 10.1016/S1081-1206(10)60163-9; Laforest L, 2006, EUR RESPIR J, V27, P42, DOI 10.1183/09031936.06.00035805; Lamb CE, 2006, CURR MED RES OPIN, V22, P1203, DOI 10.1185/030079906X112552; Lockey RF, 2011, J ALLERGY CLIN IMMUN, V127, P39, DOI 10.1016/j.jaci.2010.09.033; Long AA, 2007, CLIN THER, V29, P342, DOI 10.1016/j.clinthera.2007.02.007; LOWER T, 1993, ANN ALLERGY, V70, P480; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Marple BF, 2007, OTOLARYNG HEAD NECK, V136, pS107, DOI 10.1016/j.otohns.2007.02.031; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Noon L, 1911, LANCET, V1, P1572; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Perkins AJ, 2004, J CLIN EPIDEMIOL, V57, P1040, DOI 10.1016/j.jclinepi.2004.03.002; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Poowuttikul P, 2011, ALLERGY ASTHMA PROC, V32, P307, DOI 10.2500/aap.2011.32.3445; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Reha CM, 2007, ALLERGOL IMMUNOPATH, V35, P44, DOI 10.1157/13101337; Schatz M, 2005, J ALLERGY CLIN IMMUN, V116, P1307, DOI 10.1016/j.jaci.2005.09.027; Szeinbach SL, 2005, ANN ALLERG ASTHMA IM, V95, P167, DOI 10.1016/S1081-1206(10)61207-0; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Wu AW, 2001, ARCH INTERN MED, V161, P2554, DOI 10.1001/archinte.161.21.2554; Zhang L, 2009, INT ARCH ALLERGY IMM, V148, P161, DOI 10.1159/000155747; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	57	67	71	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1084	1091		10.1016/j.jaci.2012.12.662	http://dx.doi.org/10.1016/j.jaci.2012.12.662			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23375206				2022-12-18	WOS:000317187200017
J	Gao, ZS; Yang, ZW; Wu, SD; Wang, HY; Liu, ML; Mao, WL; Wang, J; Gadermaier, G; Ferreira, F; Zheng, M; van Ree, R				Gao, Zhong-Shan; Yang, Zhao-Wei; Wu, Shan-Dong; Wang, Hui-Ying; Liu, Mei-Ling; Mao, Wei-Lin; Wang, Jian; Gadermaier, Gabriele; Ferreira, Fatima; Zheng, Min; van Ree, Ronald			Peach allergy in China: A dominant role for mugwort pollen lipid transfer protein as a primary sensitizer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLANT FOODS; PREVALENCE; REACTIVITY; RHINITIS; PROFILES; ASTHMA		[Gao, Zhong-Shan; Wu, Shan-Dong; Wang, Hui-Ying; Zheng, Min] Zhejiang Univ, Allergy Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China; [Gao, Zhong-Shan; Yang, Zhao-Wei] Zhejiang Univ, State Agr Minist, Lab Hort Plant Growth Dev & Qual Improvement, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Hui-Ying] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Allergy, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, Mei-Ling] Shanxi Datong Univ, Affiliated Hosp, Dept Allergy, Datong, Shanxi, Peoples R China; [Mao, Wei-Lin] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Wang, Jian] Commerce Workers Hosp Shanxi Prov, Taiyuan, Peoples R China; [Gadermaier, Gabriele; Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, A-5020 Salzburg, Austria; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands	Zhejiang University; Zhejiang University; Zhejiang University; Shanxi Datong University; Zhejiang University; Salzburg University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Gao, ZS (corresponding author), Zhejiang Univ, Allergy Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China.	gaozhongshan@zju.edu.cn	Ferreira, Fatima/AAB-4321-2019; Gadermaier, Gabriele/L-5997-2015; wang, hui/GRS-4730-2022; Gao, zhongshan/C-2582-2008; Ferreira, Fatima/E-4889-2011; wang, huimin/HDM-8421-2022	Ferreira, Fatima/0000-0003-0989-2335; Gadermaier, Gabriele/0000-0002-4886-417X; Ferreira, Fatima/0000-0003-0989-2335; Gao, zhongshan/0000-0001-6944-9955; Yang, Zhaowei/0000-0002-1805-4360				Egger M, 2010, CURR ALLERGY ASTHM R, V10, P326, DOI 10.1007/s11882-010-0128-9; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Gamboa PM, 2007, ALLERGY, V62, P408, DOI 10.1111/j.1398-9995.2006.01284.x; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; Hai-Juan HE., 2008, CHIN J ALLERGY CLIN, V2, P179, DOI [10.3969/j.issn.1673-8705.2008.03.003, DOI 10.3969/J.ISSN.1673-8705.2008.03.003]; Li J, 2009, ALLERGY, V64, P1083, DOI 10.1111/j.1398-9995.2009.01967.x; Li J, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-95; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	9	67	68	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					224	226		10.1016/j.jaci.2012.07.015	http://dx.doi.org/10.1016/j.jaci.2012.07.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22939759				2022-12-18	WOS:000312961200029
J	Le, TM; Bublin, M; Breiteneder, H; Fernandez-Rivas, M; Asero, R; Ballmer-Weber, B; Barreales, L; Bures, P; Belohlavkova, S; de Blay, F; Clausen, M; Dubakiene, R; Gislason, D; van Hoffen, E; Jedrzejczak-Czechowicz, M; Kowalski, ML; Kralimarkova, T; Lidholm, J; DeWitt, AM; Mills, CEN; Papadopoulos, NG; Popov, T; Purohit, A; van Ree, R; Seneviratne, S; Sinaniotis, A; Summers, C; Vazquez-Cortes, S; Vieths, S; Vogel, L; Hoffmann-Sommergruber, K; Knulst, AC				Le, Thuy-My; Bublin, Merima; Breiteneder, Heimo; Fernandez-Rivas, Montserrat; Asero, Riccardo; Ballmer-Weber, Barbara; Barreales, Laura; Bures, Peter; Belohlavkova, Simona; de Blay, Frederic; Clausen, Michael; Dubakiene, Ruta; Gislason, David; van Hoffen, Els; Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L.; Kralimarkova, Tanya; Lidholm, Jonas; DeWitt, Asa Marknell; Mills, Clare E. N.; Papadopoulos, Nikolaos G.; Popov, Todor; Purohit, Ashok; van Ree, Ronald; Seneviratne, Suranjith; Sinaniotis, Athanasios; Summers, Colin; Vazquez-Cortes, Sonia; Vieths, Stefan; Vogel, Lothar; Hoffmann-Sommergruber, Karin; Knulst, Andre C.			Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Actinidin; allergens; component resolved diagnosis; diagnosis; food allergy; ImmunoCAP; kiwifruit; skin prick test	LIPID TRANSFER PROTEIN; KIWI FRUIT ALLERGY; SKIN-PRICK-TEST; FOOD ALLERGY; SENSITIZATION PROFILES; CROSS-REACTIVITY; PREVALENCE; ACTINIDIN; HYPERSENSITIVITY; IDENTIFICATION	Background: Kiwifruit is a common cause of food allergy. Symptoms range from mild to anaphylactic reactions. Objective: We sought to elucidate geographic differences across Europe regarding clinical patterns and sensitization to kiwifruit allergens. Factors associated with the severity of kiwifruit allergy were identified, and the diagnostic performance of specific kiwifruit allergens was investigated. Methods: This study was part of EuroPrevall, a multicenter European study investigating several aspects of food allergy. Three hundred eleven patients with kiwifruit allergy from 12 countries representing 4 climatic regions were included. Specific IgE to 6 allergens (Act d 1, Act d 2, Act d 5, Act d 8, Act d 9, and Act d 10) and kiwifruit extract were tested by using ImmunoCAP. Results: Patients from Iceland were mainly sensitized to Act d 1 (32%), those from western/central and eastern Europe were mainly sensitized to Act d 8 (pathogenesis-related class 10 protein, 58% and 44%, respectively), and those from southern Europe were mainly sensitized to Act d 9 (profilin, 31%) and Act d 10 (nonspecific lipid transfer protein, 22%). Sensitization to Act d 1 and living in Iceland were independently and significantly associated with severe kiwifruit allergy (odds ratio, 3.98 [P = 5.003] and 5.60 [P < .001], respectively). Using a panel of 6 kiwifruit allergens in ImmunoCAP increased the diagnostic sensitivity to 65% compared with 20% for skin prick tests and 46% ImmunoCAP using kiwi extract. Conclusion: Kiwifruit allergen sensitization patterns differ across Europe. The use of specific kiwifruit allergens improved the diagnostic performance compared with kiwifruit extract. Sensitization to Act d 1 and living in Iceland are strong risk factors for severe kiwifruit allergy. (J Allergy Clin Immunol 2013;131:164-71.)	[Le, Thuy-My; van Hoffen, Els; Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; [Bublin, Merima; Breiteneder, Heimo; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Fernandez-Rivas, Montserrat; Barreales, Laura; Vazquez-Cortes, Sonia] IdISSC, Hosp Clin San Carlos, Dept Allergy, Madrid, Spain; [Asero, Riccardo] Clin San Carlo, Paderno Dugnano, Italy; [Ballmer-Weber, Barbara; Bures, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Belohlavkova, Simona] Fac Hosp Bulovka, Dept Pediat, Prague, Czech Republic; [de Blay, Frederic; Purohit, Ashok] Univ Hosp Strasbourg, Chest Dis Dept, Div Allergy, Strasbourg, France; [Dubakiene, Ruta] Vilnius State Univ, Fac Med, Vilnius, Lithuania; [Clausen, Michael; Gislason, David] Landspitali Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; [Clausen, Michael; Gislason, David] Univ Iceland, Fac Med, Reykjavik, Iceland; [Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L.] Med Univ Lodz, Fac Med, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Kralimarkova, Tanya; Popov, Todor] Med Univ Sofia, Clin Allergy & Asthma, Sofia, Bulgaria; [Lidholm, Jonas; DeWitt, Asa Marknell] Phadia AB, Uppsala, Sweden; [Mills, Clare E. N.] Univ Manchester, Sch Translat Med, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Mills, Clare E. N.] Univ Manchester, Manchester Inst Biotechnol, Manchester M13 9PL, Lancs, England; [Papadopoulos, Nikolaos G.; Sinaniotis, Athanasios] Univ Athens, Dept Allergy, Pediat Clin 2, GR-10679 Athens, Greece; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1012 WX Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands; [Seneviratne, Suranjith] St Marys Hosp, Dept Clin Immunol, London, England; [Summers, Colin] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; [Vieths, Stefan; Vogel, Lothar] Fed Inst Vaccines & Biomed, Paul Ehrlich Inst, Div Allergol, Langen, Germany	Utrecht University; Utrecht University Medical Center; Medical University of Vienna; Hospital Clinico San Carlos; University of Zurich; University Zurich Hospital; Bulovka University Hospital; CHU Strasbourg; Vilnius University; Landspitali National University Hospital; University of Iceland; Medical University Lodz; Medical University Sofia; Thermo Fisher Scientific; Phadia; University of Manchester; University of Manchester; National & Kapodistrian University of Athens; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; University of Manchester; Paul Ehrlich Institute	Le, TM (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol G02 124, POB 85500, NL-3508 GA Utrecht, Netherlands.	t.t.m.le-2@umcutrecht.nl	Popov, Todor/Q-9928-2016; Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013	Popov, Todor/0000-0001-5052-5866; Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Bublin, Merima/0000-0002-7191-9431; Jedrzejczak-Czechowicz, Monika/0000-0003-2292-2770; Lidholm, Jonas/0000-0002-7779-3411; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Knulst, Andre/0000-0002-1056-3179; Papadopoulos, Nikolaos/0000-0002-2508-3872	European Union through EuroPrevall [FP6-FOOD-CT-2005-514000]; European Commission; ALK-Abello; GlaxoSmithKline; Thermo Fisher; SERMAS; Faculty Hospital Bulovka; Stallergenes; Chiesi; Mundipharma; Novartis; HAL Allergy BV; NCN; Nycomed; UK Biological and Biotechnological Sciences Research Council; DBV Technologies; BBSRC Institute of Food Research; Food Allergy Research and Resource Programme; UK Technology Strategy Board; Exponent; Nestle; EuroPrevall; Contrato Post-Formacion Sanitaria Instituto De Salud Carlos III Madrid; US Food Allergy Resource and Research Program; German Institute for Product Quality; Fresenius Academy (Germany); Deutsche Dermatologische Gesellschaft; Spanish Society of Allergy and Clinical Immunology; Westdeutsche Arbeitsgemeinschaft fur padiatrische Pneumologie und Allergologie e.V.; Gesellschaft fur padiatrische Allergologie und Umweltmedizin; American Academy of Allergy, Asthma Immunology; Biotechnology and Biological Sciences Research Council [BBS/E/F/00041800] Funding Source: researchfish	European Union through EuroPrevall; European Commission(European CommissionEuropean Commission Joint Research Centre); ALK-Abello; GlaxoSmithKline(GlaxoSmithKline); Thermo Fisher; SERMAS; Faculty Hospital Bulovka; Stallergenes; Chiesi(Chiesi Pharmaceuticals Inc); Mundipharma; Novartis(Novartis); HAL Allergy BV(HAL Allergy Group); NCN; Nycomed; UK Biological and Biotechnological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); DBV Technologies; BBSRC Institute of Food Research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Food Allergy Research and Resource Programme; UK Technology Strategy Board; Exponent; Nestle(Nestle SA); EuroPrevall; Contrato Post-Formacion Sanitaria Instituto De Salud Carlos III Madrid; US Food Allergy Resource and Research Program; German Institute for Product Quality; Fresenius Academy (Germany); Deutsche Dermatologische Gesellschaft; Spanish Society of Allergy and Clinical Immunology; Westdeutsche Arbeitsgemeinschaft fur padiatrische Pneumologie und Allergologie e.V.; Gesellschaft fur padiatrische Allergologie und Umweltmedizin; American Academy of Allergy, Asthma Immunology; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Supported by the European Union through EuroPrevall (FP6-FOOD-CT-2005-514000).; Disclosure of potential conflict of interest: M. Bublin, H. Breiteneder, K. Hoffmann-Sommergruber, and A. C. Knulst have received research support from the European Commission. M. Fernandez-Rivas has received research and travel support from the European Commission and has received lecture fees from ALK-Abello and GlaxoSmithKline. B. Ballmer-Weber has received research support from the European Union and has received consultancy and lecture fees from Thermo Fisher. L. Barreales has received research support from SERMAS. S. Belohlavkova has received research and travel support from the Faculty Hospital Bulovka. F. de Blay has received research support from Stallergenes and Chiesi; has received consulting fees from Stallergenes, ALK-Abello, Mundipharma, and Novartis; has received fees for review activities from Stallergenes and ALK-Abello ; and is on the advisory board for and received consulting fees from Stallergenes, ALK-Abello, Mundipharma, and Novartis. D. Gislason has received research and travel support from the European Union. E. van Hoffen has received research support from HAL Allergy BV. M. Jedrzejczak-Czechowicz is employed by the Medical University of Lodz. M. L. Kowalski is on the Uriach advisory board, is employed by the Medical University of Lodz, has received research support from the EC and NCN, has received lecture fees from Nycomed, and has received travel expenses from Adamed. T. Kralimarkova and T. Popov have received research support from the EC and are employed by Medical University Sofia. J. Lidholm and A. Marknell DeWitt have received research and travel support from the European Commission and are employed by Phadia AB. C. E. N. Mills has received research support from the UK Biological and Biotechnological Sciences Research Council, the European Union, Novartis, DBV Technologies, the BBSRC Institute of Food Research, the Food Allergy Research and Resource Programme, and the UK Technology Strategy Board; is on the Pepsico advisory board; has received consultancy fees from Exponent; is employed by the UK Food Standards Agency, the UK Biological Sciences Research Council, and the University of Manchester; has received travel support from the European Academy of Allergy and Clinical Immunology and ILSI; and has received one or more honoraria as an external examiner from the University of Birmingham. N. G. Papadopoulos has received research support from Nestle. R. van Ree has received research and travel support from the European Union. S. Seneviratne has received research support from EuroPrevall and is employed by the Royal Free Hospital. S. Vazquez-Cortes has received research support from Contrato Post-Formacion Sanitaria Instituto De Salud Carlos III Madrid and is employed by Hospital Del Henares. S. Vieths has received consultancy fees from the US Food Allergy Resource and Research Program, the German Institute for Product Quality, and the Fresenius Academy (Germany); is employed by Johann Wolfgang Goethe-Universitat Frankfurt/Main; has received an honorarium from the Medical University of Vienna for the evaluation of a PhD thesis; has received research support from Monsanto Company and Pioneer Hi-Bred International; has received lecture fees from Deutsche Dermatologische Gesellschaft, the Spanish Society of Allergy and Clinical Immunology, Westdeutsche Arbeitsgemeinschaft fur padiatrische Pneumologie und Allergologie e.V.; , Gesellschaft fur padiatrische Allergologie und Umweltmedizin, and the American Academy of Allergy, Asthma & Immunology; receives royalties from Schattauer Allergologie Handbuch and Elsevier Nahrungsmittelaller-gien und Intoleranzen; and has received travel support from the German Research Foundation, the Federal Institute for Risk Assessment, the Austrian Society for Allergology and Immunology, the French Society of Allergology, the European Directorate for the Quality of Medicines and Health Care, the European Academy of Allergy and Clinical Immunology, the World Allergy Organization, Technical University of Munich, Deutscher Allergie und Asthmabund, Association Monegasque pour le Perfectionnement des Connaissances des Medicins, and the Federal Office of Consumer Protection and Food Safety. L. Vogel has received research support from the European Union. The rest of the authors declare that they have no relevant conflicts of interest.	Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Asero R, 2008, CLIN EXP ALLERGY, V38, P1033, DOI 10.1111/j.1365-2222.2008.02980.x; Asero R, 2001, INT ARCH ALLERGY IMM, V124, P67, DOI 10.1159/000053671; Asero R, 2007, MOL NUTR FOOD RES, V51, P135, DOI 10.1002/mnfr.200600132; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; BROCKLEHURST K, 1981, BIOCHEM J, V197, P739, DOI 10.1042/bj1970739; Brovkin V, 2002, J PHYS IV, V12, P57, DOI 10.1051/jp4:20020452; Bublin M, 2004, J ALLERGY CLIN IMMUN, V114, P1169, DOI 10.1016/j.jaci.2004.07.016; Bublin M, 2011, CLIN EXP ALLERGY, V41, P129, DOI 10.1111/j.1365-2222.2010.03619.x; Bublin M, 2008, MOL NUTR FOOD RES, V52, P1130, DOI 10.1002/mnfr.200700167; Bublin M, 2010, J ALLERGY CLIN IMMUN, V125, P687, DOI 10.1016/j.jaci.2009.10.017; Cuesta-Herranz J, 2010, INT ARCH ALLERGY IMM, V153, P182, DOI 10.1159/000312636; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Avino R, 2011, ALLERGY, V66, P870, DOI 10.1111/j.1398-9995.2011.02555.x; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; FALLIERS CJ, 1983, J ASTHMA, V20, P193, DOI 10.3109/02770908309114944; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; Gadermaier G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024150; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; GARCIA BE, 1989, ALLERGOL IMMUNOPATH, V17, P217; Gislason D, 1999, ALLERGY, V54, P1160, DOI 10.1034/j.1398-9995.1999.00093.x; Goldman L, 1987, QUANTITATIVE ASPECTS; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; Le TM, 2011, J ALLERGY CLIN IMMUN, V127, P677, DOI 10.1016/j.jaci.2010.10.003; Lucas JSA, 2005, PEDIAT ALLERG IMM-UK, V16, P647, DOI 10.1111/j.1399-3038.2005.00330.x; Lucas JSA, 2004, CLIN EXP ALLERGY, V34, P1115, DOI 10.1111/j.1365-2222.2004.01982.x; Lucas JSA, 2003, PEDIAT ALLERG IMM-UK, V14, P420, DOI 10.1046/j.0905-6157.2003.00095.x; Mancuso G, 2001, CONTACT DERMATITIS, V45, P41, DOI 10.1034/j.1600-0536.2001.045001041.x; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x; Mills ENC, 2007, ALLERGY, V62, P717, DOI 10.1111/j.1398-9995.2007.01425.x; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; NOVEMBRE E, 1995, ALLERGY, V50, P511, DOI 10.1111/j.1398-9995.1995.tb01187.x; Oberhuber C, 2008, MOL NUTR FOOD RES, V52, pS230, DOI 10.1002/mnfr.200800146; Palacin A, 2008, CLIN EXP ALLERGY, V38, P1220, DOI 10.1111/j.1365-2222.2007.02927.x; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; Villalta D, 2010, J ALLERGY CLIN IMMUN, V125, P1158, DOI 10.1016/j.jaci.2010.01.043; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	45	67	69	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					164	171		10.1016/j.jaci.2012.09.009	http://dx.doi.org/10.1016/j.jaci.2012.09.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23141741				2022-12-18	WOS:000312961200021
J	van der Velde, JL; Flokstra-de Blok, BMJ; de Groot, H; Oude-Elberink, JNG; Kerkhof, M; Duiverman, EJ; Dubois, AEJ				van der Velde, Jantina L.; Flokstra-de Blok, Bertine M. J.; de Groot, Hans; Oude-Elberink, Joanne N. G.; Kerkhof, Marjan; Duiverman, Eric J.; Dubois, Anthony E. J.			Food allergy-related quality of life after double-blind, placebo-controlled food challenges in adults, adolescents, and children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Double-blind; placebo-controlled food challenge; food allergy; health-related quality of life; longitudinal validation; responsiveness	IMPORTANT DIFFERENCE; STANDARD ERROR; QUESTIONNAIRE; VALIDATION; RESPONSIVENESS; RELIABILITY; VALIDITY; OUTCOMES; RECIPES; PEANUT	Background: Currently, the longitudinal validity (validity over time) and responsiveness (ability to measure change over time) of the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF), the Food Allergy Quality of Life Questionnaire-Teenager Form (FAQLQ-TF), and the Food Allergy Quality of Life Questionnaire-Child Form (FAQLQ-CF) are unknown. Additionally, the self-reported impact of a double-blind, placebo-controlled food challenge (DBPCFC) on health-related quality of life (HRQL) in adults (>= 18 years of age), adolescents (13-17 years of age), and children (8-12 years of age) is unknown. Objective: The aims of this study were to assess the longitudinal validity and responsiveness of the FAQLQ-AF, FAQLQ-TF, and FAQLQ-CF and to assess the impact of a DBPCFC on HRQL. Methods: Two hundred twenty-one participants suspected of food allergy were included from Dutch allergy centers. Participants undergoing a DBPCFC (experimental group) completed the FAQLQ and Food Allergy Independent Measure (FAIM) 1 month before (baseline) and 6 months after (follow-up) a DBPCFC. Participants not undergoing a DBPCFC(control group) completed the questionnaire package twice with a 7-month interval. Results: HRQL scores improved after a DBPCFC, with greater improvements in HRQL scores after a negative outcome (food allergy ruled out) than a positive outcome (food allergy confirmed), demonstrating responsiveness of the FAQLQs. Significant correlations were shown between the change (follow-up minus baseline) in FAQLQ and FAIM scores supporting longitudinal validity of these questionnaires: FAQLQ-AF (Pearson correlation coefficient = 0.71, P < .001), FAQLQ-TF (Pearson correlation coefficient = 0.35, P = .018), and FAQLQ-CF (Pearson correlation coefficient = 0.51, P < .001). Conclusions: Our findings demonstrate the longitudinal validity and responsiveness of the FAQLQs. Greater improvements in HRQL scores were shown after a negative outcome than after a positive outcome. (J Allergy Clin Immunol 2012;130: 1136-43.)	[van der Velde, Jantina L.; Duiverman, Eric J.; Dubois, Anthony E. J.] Univ Groningen, Div Pediat Pulmonol & Pediat Allergy, Dept Pediat, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [van der Velde, Jantina L.; Flokstra-de Blok, Bertine M. J.; Oude-Elberink, Joanne N. G.; Kerkhof, Marjan; Duiverman, Eric J.; Dubois, Anthony E. J.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [Flokstra-de Blok, Bertine M. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, NL-9700 RB Groningen, Netherlands; [Oude-Elberink, Joanne N. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Allergy, NL-9700 RB Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [de Groot, Hans] Reinier Graaf Grp, Dept Pediat Allergol, Delft, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Reinier de Graaf Hospital	van der Velde, JL (corresponding author), Univ Groningen, Div Pediat Pulmonol & Pediat Allergy, Dept Pediat, Univ Med Ctr Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.l.van.der.velde@umcg.nl			European Union [FOOD-CT-2005514000]; Nutricia Research Foundation; Stichting Astma Bestrijding	European Union(European Commission); Nutricia Research Foundation(Danone Nutricia); Stichting Astma Bestrijding	Supported by the European Union through the EuroPrevall Project (FOOD-CT-2005514000), by the Nutricia Research Foundation, and by the Stichting Astma Bestrijding.	Blok BMJF, 2008, J ALLERGY CLIN IMMUN, V122, P139, DOI 10.1016/j.jaci.2008.05.008; BULLINGER M, 1993, QUAL LIFE RES, V2, P451, DOI 10.1007/BF00422219; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; DEYO RA, 1991, CONTROL CLIN TRIALS, V12, pS142, DOI 10.1016/S0197-2456(05)80019-4; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; DunnGalvin A, 2009, ADV FOOD NUTR RES, V56, P65, DOI 10.1016/S1043-4526(08)00603-7; DunnGalvin A, 2010, CLIN EXP ALLERGY, V40, P476, DOI 10.1111/j.1365-2222.2010.03454.x; DunnGalvin A, 2009, ALLERGY, V64, P560, DOI 10.1111/j.1398-9995.2008.01862.x; DunnGalvin A, 2008, J ALLERGY CLIN IMMUN, V122, pe1; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Flokstra-de Blok BMJ, 2010, ALLERGY, V65, P238, DOI 10.1111/j.1398-9995.2009.02121.x; Flokstra-de Blok BMJ, 2009, CLIN EXP ALLERGY, V39, P127, DOI [10.1111/j.1365-2222.2008.03120.x, 10.1111/j.1365-2222.2009.03376.x]; Flokstra-de Blok BMJ, 2009, ALLERGY, V64, P1209, DOI 10.1111/j.1398-9995.2009.01968.x; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kemp AS, 2009, PEDIAT ALLERG IMM-UK, V20, P648, DOI 10.1111/j.1399-3038.2009.00859.x; Kocks JWH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-62; Nguyen M, 2010, PEDIAT ALLERG IMM-UK, V21, P1119, DOI 10.1111/j.1399-3038.2010.01043.x; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Elberink JNG, 2006, CURR OPIN ALLERGY CL, V6, P298, DOI 10.1097/01.all.0000235906.95300.3e; Rejas J, 2008, J CLIN EPIDEMIOL, V61, P350, DOI 10.1016/j.jclinepi.2007.05.011; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Schunemann HJ, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-62; Strinnholm A, 2010, J CHILD HEALTH CARE, V14, P179, DOI 10.1177/1367493509359227; Turner D, 2010, J CLIN EPIDEMIOL, V63, P28, DOI 10.1016/j.jclinepi.2009.01.024; van der Velde JL, 2011, ALLERGY, V66, P1580, DOI 10.1111/j.1398-9995.2011.02726.x; van der Velde JL, 2011, CLIN EXP ALLERGY, V41, P1431, DOI 10.1111/j.1365-2222.2011.03753.x; van der Velde JL, 2010, ALLERGY, V65, P630, DOI 10.1111/j.1398-9995.2009.02216.x; van der Velde JL, 2009, QUAL LIFE RES, V18, P245, DOI 10.1007/s11136-008-9434-2; Vlieg-Boerstra B, 2005, ALLERGY, V60, P1212, DOI 10.1111/j.1398-9995.2005.00935.x; Vlieg-Boerstra BJ, 2011, ALLERGY, V66, P948, DOI 10.1111/j.1398-9995.2010.02539.x; Wyrwich KW, 2002, QUAL LIFE RES, V11, P1, DOI 10.1023/A:1014485627744; Zijlstra WT, 2010, PEDIAT ALLERG IMM-UK, V21, pE439, DOI 10.1111/j.1399-3038.2009.00929.x	35	67	67	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1136	+		10.1016/j.jaci.2012.05.037	http://dx.doi.org/10.1016/j.jaci.2012.05.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	030LE	22835403				2022-12-18	WOS:000310571400015
J	James, LK; Bowen, H; Calvert, RA; Dodev, TS; Shamji, MH; Beavil, AJ; McDonnell, JM; Durham, SR; Gould, HJ				James, Louisa K.; Bowen, Holly; Calvert, Rosaleen A.; Dodev, Tihomir S.; Shamji, Mohamed H.; Beavil, Andrew J.; McDonnell, James M.; Durham, Stephen R.; Gould, Hannah J.			Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; IgG(4); Phl p 7; blocking antibody	HUMAN MONOCLONAL-ANTIBODIES; 3-DIMENSIONAL STRUCTURE; PERIPHERAL-BLOOD; IGE ANTIBODIES; ANTIGEN; BINDING; GENERATION; IGG4; TRANSCRIPTS; RECOGNITION	Background: Serum IgG(4) responses to allergen immunotherapy are well documented as blocking allergen binding to receptor-bound IgE on antigen-presenting cells and effector cells, but the molecular characteristics of treatment-induced IgG(4), particularly in relation to expressed antibody, are poorly defined. Objectives: We aimed to clone and express recombinant IgG(4) from patients receiving grass pollen immunotherapy using single B cells to obtain matched heavy-and light-chain pairs. Methods: IgG(4)(+) B cells were enriched from blood samples taken from 5 patients receiving grass pollen immunotherapy. Matched heavy-and light-chain variable-region sequences were amplified from single IgG(4)(+) B cells. Variable regions were cloned and expressed as recombinant IgG(4). Binding analysis of grass pollen-specific IgG(4) was performed by using surface plasmon resonance. Functional assays were used to determine IgE blocking activity. In a separate experiment grass pollen-specific antibodies were depleted from serum samples to determine the proportion of grass pollen-specific IgG(4) within total IgG(4). Results: Depletion of grass pollen-specific antibodies from serum led to a modest reduction in total IgG(4) levels. Matched heavy-and light-chain sequences were cloned from single IgG(4)(+) B cells and expressed as recombinant IgG(4). We identified an IgG(4) that binds with extremely high affinity to the grass pollen allergen Phl p 7. Furthermore, we found that a single specific mAb can block IgE-mediated facilitated allergen presentation, as well as IgE-mediated basophil activation. Conclusion: Although increases in IgG(4) levels cannot be wholly accounted for within the allergen-specific fraction, allergen immunotherapy might result in the production of high-affinity allergen-specific blocking IgG(4). (J Allergy Clin Immunol 2012;130:663-70.)	[James, Louisa K.; Bowen, Holly; Calvert, Rosaleen A.; Dodev, Tihomir S.; Beavil, Andrew J.; McDonnell, James M.; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Shamji, Mohamed H.; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, London, England	University of London; King's College London; Imperial College London	James, LK (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, New Hunts House, London SE1 1UL, England.	louisa.james@kcl.ac.uk	Shamji, Mohamed/AAD-1788-2019; Beavil, Andrew/B-5624-2009; James, Louisa/C-9831-2010; Shamji, Mohamed/AAU-8811-2020	Beavil, Andrew/0000-0002-0768-122X; James, Louisa/0000-0002-2252-4636; Shamji, Mohamed/0000-0003-3425-3463; McDonnell, James/0000-0001-9037-2980; Gould, Hannah/0000-0003-0411-688X	Asthma UK; London Law Trust; Department of Health through a National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre; Medical Research Council UK; ALK-Abello; Merck; Circassia; Novartis; Medical Research Council [G1100090, G0200485, G0601303, MR/J006742/1, G0400106, G1000758B, G1000758] Funding Source: researchfish; MRC [G0400106, G0200485, G0601303, G1100090] Funding Source: UKRI	Asthma UK; London Law Trust; Department of Health through a National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ALK-Abello; Merck(Merck & Company); Circassia; Novartis(Novartis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a grant from Asthma UK (S. R. D. and H.J.G.) and a fellowship from the London Law Trust (L.K.J.). The authors acknowledge financial support from the Department of Health through a National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.; A. J. Beavil has received research support from Asthma UK and the Medical Research Council UK. S. R. Durham has received lecture fees from ALK-Abello and Merck, has received consultancy fees from Circassia, has received research support from Novartis and ALK-Abello, has provided legal consultation/expert witness testimony for Merck, and is on the Immune Tolerance Network National Institute of Allergy and Infectious Diseases Steering Committee. The rest of the authors declare that they have no relevant conflicts of interest.	Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Corti D, 2011, CURR OPIN IMMUNOL, V23, P430, DOI 10.1016/j.coi.2011.04.006; De Boer BA, 1998, CLIN EXP IMMUNOL, V114, P252; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Glanville J, 2009, P NATL ACAD SCI USA, V106, P20216, DOI 10.1073/pnas.0909775106; HAMILTON RG, 1987, CLIN CHEM, V33, P1707; Hershberg U, 2008, INT IMMUNOL, V20, P683, DOI 10.1093/intimm/dxn026; Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; Hunt J, 2009, US patent, Patent No. [61/060,239, 61060239]; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jeannin P, 1998, J IMMUNOL, V160, P3555; KING CL, 1991, J IMMUNOL, V146, P1478; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; Leyendeckers H, 1999, EUR J IMMUNOL, V29, P1406, DOI 10.1002/(SICI)1521-4141(199904)29:04<1406::AID-IMMU1406>3.0.CO;2-P; MacDonald CM, 2010, LUPUS, V19, P1161, DOI 10.1177/0961203310367657; Madritsch C, 2011, CLIN EXP ALLERGY, V41, P270, DOI 10.1111/j.1365-2222.2010.03666.x; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3; SNOW RE, 1995, J IMMUNOL, V154, P5576; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Twardosz-Kropfmuller A, 2010, ALLERGY, V65, P296, DOI 10.1111/j.1398-9995.2009.02202.x; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; Verdino P, 2003, INT ARCH ALLERGY IMM, V130, P10, DOI 10.1159/000068378; Verdino P, 2002, EMBO J, V21, P5007, DOI 10.1093/emboj/cdf526; Visco V, 1996, J IMMUNOL, V157, P956; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Wilcock LK, 2006, IMMUNOL ALLERGY CLIN, V26, P333, DOI 10.1016/j.iac.2006.02.004; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352	41	67	67	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					663	+		10.1016/j.jaci.2012.04.006	http://dx.doi.org/10.1016/j.jaci.2012.04.006			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22583928				2022-12-18	WOS:000308463500015
J	Morizane, S; Yamasaki, K; Kajita, A; Ikeda, K; Zhan, MS; Aoyama, Y; Gallo, RL; Iwatsuki, K				Morizane, Shin; Yamasaki, Kenshi; Kajita, Ai; Ikeda, Kazuko; Zhan, Maosheng; Aoyama, Yumi; Gallo, Richard L.; Iwatsuki, Keiji			T(H)2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Morizane, Shin; Kajita, Ai; Ikeda, Kazuko; Zhan, Maosheng; Aoyama, Yumi; Iwatsuki, Keiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dermatol, Okayama 7008530, Japan; [Yamasaki, Kenshi] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan; [Gallo, Richard L.] Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA; [Gallo, Richard L.] VA San Diego Healthcare Syst, San Diego, CA USA	Okayama University; Tohoku University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Morizane, S (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dermatol, Okayama 7008530, Japan.	zanemori@cc.okayama-u.ac.jp	Gallo, Richard L/A-8931-2009; Yamasaki, Kenshi/C-8905-2018	Gallo, Richard L/0000-0002-1401-7861; Yamasaki, Kenshi/0000-0002-5495-4956	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI083358] Funding Source: Medline; NIAMS NIH HHS [R01 AR052728-02, R01 AR052728-07, R01 AR052728-03, R01 AR052728-06, R01 AR052728-01A1, R01 AR052728-04, R01 AR052728, R01 AR052728-05, R01 AR052728-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Brandt Eric B, 2011, J Clin Cell Immunol, V2; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Ogg G, 2009, CLIN EXP ALLERGY, V39, P310, DOI 10.1111/j.1365-2222.2008.03146.x; Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001; Schauber J, 2009, J ALLERGY CLIN IMMUN, V124, pR13, DOI 10.1016/j.jaci.2009.07.014; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com	9	67	74	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					259	261		10.1016/j.jaci.2012.03.006	http://dx.doi.org/10.1016/j.jaci.2012.03.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22521249	Green Accepted, Bronze			2022-12-18	WOS:000306644800036
J	Patil, SU; Long, ADA; Ling, M; Wilson, MT; Hesterberg, P; Wong, JT; Banerji, A				Patil, Sarita U.; Long, Aidan A.; Ling, Morris; Wilson, Michael T.; Hesterberg, Paul; Wong, Johnson T.; Banerji, Aleena			A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Carboplatin; hypersensitivity; skin testing; drug allergy; desensitization	RAPID DESENSITIZATION; SKIN-TEST; CHEMOTHERAPY; ANAPHYLAXIS; EXPERIENCE; PREDICT	Background: Management of patients with carboplatin-induced hypersensitivity reactions (HSR) has been complicated by high false-negative rates of carboplatin skin test (ST) results. These patients might be at risk for future carboplatin-induced HSRs. In this article we identify a strategy to improve risk stratification of patients with a history of carboplatin-induced HSRs by using a protocol that includes repeat skin testing and drug desensitization. Objective: We sought to identify a management strategy for patients with a history of carboplatin-induced HSRs with negative carboplatin ST results. Methods: From 2008-2010, patients with carboplatin-induced HSR underwent risk stratification per a protocol using 3 repeat STs with intervening drug desensitizations. Results: Of the 44 patients with carboplatin-induced HSRs, 39 completed the protocol. Patients were classified as having positive ST results (n = 16), having negative ST results (n = 11), or ST converters when the ST result converted to positive after an initial negative result (n = 12). ST converters are more likely to have HSRs during subsequent desensitizations than patients with negative ST results (56.1% vs 4.5%, P < .001). ST converters had a significantly longer time interval between their initial HSR and initial ST evaluation compared with either patients with true-negative ST results (22.1 vs 6.0 months, P = .03) or patients with positive ST results (22.1 vs 1.8 months, P = .001). Conclusion: Our experience suggests that repeat STs are necessary for risk stratification in patients with a remote clinical history of HSR and an initial negative ST result because there is a significant rate of conversion to a positive ST result. ST converters have an increased risk of HSRs during subsequent carboplatin treatment. (J Allergy Clin Immunol 2012;129:443-7.)	[Patil, Sarita U.; Long, Aidan A.; Ling, Morris; Wilson, Michael T.; Hesterberg, Paul; Wong, Johnson T.; Banerji, Aleena] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Patil, SU (corresponding author), 55 Fruit St,Cox 201, Boston, MA 02441 USA.	spatil35@partners.org	Banerji, Aleena/ABG-1245-2021	Ling, Morris/0000-0002-9657-8960	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI121491] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Breslow RG, 2009, ANN ALLERG ASTHMA IM, V102, P155, DOI 10.1016/S1081-1206(10)60247-5; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Gomez R, 2009, INT J GYNECOL CANCER, V19, P1284, DOI 10.1111/IGC.0b013e3181a418ff; Hesterberg PE, 2009, J ALLERGY CLIN IMMUN, V123, P1262, DOI 10.1016/j.jaci.2009.02.042; Lee CW, 2004, GYNECOL ONCOL, V95, P370, DOI 10.1016/j.ygyno.2004.08.002; Leguy-Seguin V, 2007, J ALLERGY CLIN IMMUN, V119, P726, DOI 10.1016/j.jaci.2006.11.640; Markman M, 1999, J CLIN ONCOL, V17, P1141, DOI 10.1200/JCO.1999.17.4.1141; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; Polyzos A, 2001, ONCOLOGY-BASEL, V61, P129, DOI 10.1159/000055363; Robinson JB, 2001, GYNECOL ONCOL, V82, P550, DOI 10.1006/gyno.2001.6331; Rose PG, 2003, GYNECOL ONCOL, V89, P429, DOI 10.1016/S0090-8258(03)00178-1; SOOD AK, 1995, GYNECOL ONCOL, V57, P131, DOI 10.1006/gyno.1995.1111; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V90, P681, DOI 10.1016/0091-6749(92)90142-O; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126, DOI 10.1200/JCO.2001.19.12.3126	14	67	70	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					443	447		10.1016/j.jaci.2011.10.010	http://dx.doi.org/10.1016/j.jaci.2011.10.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22099941				2022-12-18	WOS:000299951700023
J	Ji, H; Hershey, GKK				Ji, Hong; Hershey, Gurjit K. Khurana			Genetic and epigenetic influence on the response to environmental particulate matter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; particulate matter; genetics; epigenetics; allergy; asthma	DIESEL EXHAUST PARTICLES; NASAL EPITHELIAL-CELLS; S-TRANSFERASE P1; AIR-POLLUTION; OXIDATIVE STRESS; DNA METHYLATION; INFLAMMATORY RESPONSES; AROMATIC-HYDROCARBONS; ALLERGIC RESPONSES; PERIPHERAL-BLOOD	Ambient air pollution, including particulate matter ( PM) and gaseous pollutants, represents important environmental exposures that adversely affect human health. Because of their heritable and reversible nature, epigenetic modifications provide a plausible link between the environment and alterations in gene expression that might lead to disease. Epidemiologic evidence supports that environmental exposures in childhood affect susceptibility to disease later in life, supporting the belief that epigenetic changes can affect ongoing development and promote disease long after the environmental exposure has ceased. Indeed, allergic disorders often have their roots in early childhood, and early exposure to PM has been strongly associated with the subsequent development of asthma. The purpose of this review is to summarize recent findings on the genetic and epigenetic regulation of responses to ambient air pollutants, specifically respirable PM, and their association with the development of allergic disorders. Understanding these epigenetic biomarkers and how they integrate with genetic influences to translate the biologic effect of particulate exposure is critical to developing novel preventative and therapeutic strategies for allergic disorders. (J Allergy Clin Immunol 2012; 129: 33-41.)	[Ji, Hong; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Div Asthma Res, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Asthma Res, Dept Pediat, Cincinnati, OH USA.	Gurjit.Khurana.Hershey@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X; Ji, Hong/0000-0002-9558-0620	National Institutes of Health [U19A170235, R01HL098134]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants U19A170235 and R01HL098134 (to G.K.K.H.).	Ahsan MK, 2005, FREE RADICAL BIO MED, V39, P1549, DOI 10.1016/j.freeradbiomed.2005.07.016; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767; Bollati V, 2010, ENVIRON HEALTH PERSP, V118, P763, DOI 10.1289/ehp.0901300; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Chia N, 2011, EPIGENETICS-US, V6, P853, DOI 10.4161/epi.6.7.16461; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3; El-Maarri O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016252; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Grigg Jonathan, 2009, Proc Am Thorac Soc, V6, P564, DOI 10.1513/pats.200905-026RM; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Ichinose T, 2002, TOXICOLOGY, V180, P293, DOI 10.1016/S0300-483X(02)00420-1; Inoue K, 2009, EXP BIOL MED, V234, P200, DOI 10.3181/0809-RM-285; Iqbal K, 2011, P NATL ACAD SCI USA, V108, P3642, DOI 10.1073/pnas.1014033108; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Jardim MJ, 2011, MUTAT RES-FUND MOL M, V717, P38, DOI 10.1016/j.mrfmmm.2011.03.014; Jardim MJ, 2009, ENVIRON HEALTH PERSP, V117, P1745, DOI 10.1289/ehp.0900756; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; Kerkhof M, 2010, THORAX, V65, P690, DOI 10.1136/thx.2009.119636; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kuroda A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006953; Lee DH, 2009, ENVIRON HEALTH PERSP, V117, P1799, DOI 10.1289/ehp.0900741; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Madrigano J, 2011, ENVIRON HEALTH PERSP, V119, P977, DOI 10.1289/ehp.1002773; Maier KL, 2008, INHAL TOXICOL, V20, P319, DOI [10.1080/08958370701866313, 10.1080/08958370701866313 ]; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Michel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013894; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nemmar A, 2004, TOXICOL LETT, V149, P243, DOI 10.1016/j.toxlet.2003.12.061; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009; Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565, DOI 10.1289/ehp.110-1241207; Pelucchi C, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-453; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Porter M, 2007, AM J RESP CELL MOL, V37, P706, DOI 10.1165/rcmb.2007-0199OC; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Romieu Isabelle, 2010, Proc Am Thorac Soc, V7, P116, DOI 10.1513/pats.200909-097RM; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Saito Y, 2002, EXP LUNG RES, V28, P201, DOI 10.1080/019021402753570509; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550, DOI 10.1164/ajrccm.161.2.9905052; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Stevens T, 2009, TOXICOL SCI, V107, P522, DOI 10.1093/toxsci/kfn248; Suter M, 2010, METABOLISM, V59, P1481, DOI 10.1016/j.metabol.2010.01.013; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Tal TL, 2010, TOXICOL APPL PHARM, V243, P46, DOI 10.1016/j.taap.2009.11.011; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167, DOI 10.1159/000237663; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tzivian L, 2011, J ASTHMA, V48, P470, DOI 10.3109/02770903.2011.570407; Wang MY, 2005, ELECTROPHORESIS, V26, P2092, DOI 10.1002/elps.200410428; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yauk C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/pnas.0705896105; Zanobetti A, 2011, PROG CARDIOVASC DIS, V53, P344, DOI 10.1016/j.pcad.2011.01.001; Zanobetti A, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-48; Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366	95	67	74	0	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					33	41		10.1016/j.jaci.2011.11.008	http://dx.doi.org/10.1016/j.jaci.2011.11.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22196522	Bronze, Green Accepted			2022-12-18	WOS:000298634000005
J	Jyonouchi, S; Abraham, V; Orange, JS; Spergel, JM; Gober, L; Dudek, E; Saltzman, R; Nichols, KE; Cianferoni, A				Jyonouchi, Soma; Abraham, Valsamma; Orange, Jordan S.; Spergel, Jonathan M.; Gober, Laura; Dudek, Emily; Saltzman, Rushani; Nichols, Kim E.; Cianferoni, Antonella			Invariant natural killer T cells from children with versus without food allergy exhibit differential responsiveness to milk-derived sphingomyelin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; invariant natural killer T cells; sphingolipids	V-ALPHA-14 NKT CELLS; GENE-EXPRESSION; HUMAN CD1D; SPHINGOLIPIDS; MICE; INTERLEUKIN-4; LYMPHOCYTES; ACTIVATION; SUBSETS; ANTIGEN	Background: A key immunologic feature of food allergy (FA) is the presence of a T(H)2-type cytokine bias. Ligation of the invariant natural killer T cell (iNKT) T-cell receptor (TCR) by sphingolipids presented via the CD1d molecule leads to copious secretion of T(H)2-type cytokines. Major food allergens (eg, milk, egg) are the richest dietary source of sphingolipids (food-derived sphingolipids [food-SLs]). Nonetheless, the role of iNKTs in FA is unknown. Objective: To investigate the role of iNKTs in FA and to assess whether food-SL-CD1d complexes can engage the iNKT-TCR and induce iNKT functions. Methods: PBMCs from 15 children with cow's milk allergy (MA), 12 children tolerant to cow's milk but with allergy to egg, and 13 healthy controls were incubated with alpha-galactosylceramide (alpha Gal), cow's milk-sphingomyelin, or hen's egg-ceramide. iNKTs were quantified, and their cytokine production and proliferation were assessed. Human CD1d tetramers loaded with milk-sphingomyelin or egg-ceramide were used to determine food-SL binding to the iNKT-TCR. Results: Milk-sphingomyelin, but not egg-ceramide, can engage the iNKT-TCR and induce iNKT proliferation and T(H)2-type cytokine secretion. Children with FA, especially those with MA, had significantly fewer peripheral blood iNKTs and their iNKTs exhibited a greater T(H)2 response to alpha Gal and milk-sphingomyelin than iNKTs of healthy controls. Conclusion: iNKTs from children with FA, especially those with MA, are reduced in number and exhibit a T(H)2 bias in response to alpha Gal and milk-sphingomyelin. These data suggest a potential role for iNKTs in FA. (J Allergy Clin Immunol 2011; 128: 102-9.)	[Jyonouchi, Soma; Abraham, Valsamma; Orange, Jordan S.; Spergel, Jonathan M.; Gober, Laura; Dudek, Emily; Saltzman, Rushani; Cianferoni, Antonella] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Jyonouchi, Soma; Abraham, Valsamma; Orange, Jordan S.; Spergel, Jonathan M.; Gober, Laura; Dudek, Emily; Saltzman, Rushani; Nichols, Kim E.; Cianferoni, Antonella] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Nichols, Kim E.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cianferoni, A (corresponding author), Childrens Hosp Philadelphia, Div Allergy & Immunol, ARC 1216H,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	nicholsk@email.chop.edu; cianferonia@email.chop.edu	Nichols, Kim/AAP-8592-2020; Nichols, Kim/E-9353-2016	Nichols, Kim/0000-0002-5581-6555; Nichols, Kim/0000-0002-5581-6555; orange, jordan/0000-0001-7117-7725; Spergel, Jonathan/0000-0002-4658-5353	NIH [K12HD043245-06]; CTRC; National Center for Research Resources [UL1-RR-024134]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043245] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024134] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTRC; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by NIH K12HD043245-06, CTRC Junior Investigator Pilot Grant Program, and grant no. UL1-RR-024134 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Araki M, 2003, INT IMMUNOL, V15, P279, DOI 10.1093/intimm/dxg029; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Berra B, 2002, EUR J CANCER PREV, V11, P193, DOI 10.1097/00008469-200204000-00013; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P13741, DOI 10.1073/pnas.162491699; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Cianferoni A, 2005, J ALLERGY CLIN IMMUN, V116, P1364, DOI 10.1016/j.jaci.2005.09.006; Cohen NR, 2009, ADV IMMUNOL, V102, P1, DOI 10.1016/S0065-2776(09)01201-2; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Fox LM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000228; Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616; Gausling R, 2001, CLIN IMMUNOL, V98, P11, DOI 10.1006/clim.2000.4942; Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786; Gupta S, 2009, J VIROL, V83, P5442, DOI 10.1128/JVI.00106-09; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Lee PT, 2002, J CLIN INVEST, V110, P793, DOI 10.1172/JCI200215832; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Marsh RA, 2009, CLIN IMMUNOL, V132, P116, DOI 10.1016/j.clim.2009.03.517; McCarthy C, 2007, J EXP MED, V204, P1131, DOI 10.1084/jem.20062342; Oki S, 2005, INT IMMUNOL, V17, P1619, DOI 10.1093/intimm/dxh342; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Russano AM, 2007, J IMMUNOL, V178, P3620, DOI 10.4049/jimmunol.178.6.3620; Sakuishi K, 2007, J IMMUNOL, V179, P3452, DOI 10.4049/jimmunol.179.6.3452; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sriram V, 2005, EUR J IMMUNOL, V35, P1692, DOI 10.1002/eji.200526157; Symolon H, 2004, J NUTR, V134, P1157, DOI 10.1093/jn/134.5.1157; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Tupin E, 2004, J EXP MED, V199, P417, DOI 10.1084/jem.20030997; Vazquez E, 2001, BIOFACTORS, V15, P1, DOI 10.1002/biof.5520150101; Vazquez E, 2000, CYTOKINE, V12, P1267, DOI 10.1006/cyto.2000.0706; Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239; Wu DY, 2003, J EXP MED, V198, P173, DOI 10.1084/jem.20030446	41	67	69	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					102	U176		10.1016/j.jaci.2011.02.026	http://dx.doi.org/10.1016/j.jaci.2011.02.026			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21458849	Green Accepted			2022-12-18	WOS:000292245600013
J	Duan, W; Mehta, AK; Magalhaes, JG; Ziegler, SF; Dong, C; Philpott, DJ; Croft, M				Duan, Wei; Mehta, Amit K.; Magalhaes, Joao G.; Ziegler, Steven F.; Dong, Chen; Philpott, Dana J.; Croft, Michael			Innate signals from Nod2 block respiratory tolerance and program T(H)2-driven allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mouse; Nod2; asthma; TSLP; OX40L; IL-25; regulatory T cell	THYMIC STROMAL LYMPHOPOIETIN; DENDRITIC CELLS INDUCE; REGULATORY T-CELLS; AIRWAY INFLAMMATION; IMMUNE-RESPONSES; EPITHELIAL-CELLS; CUTTING EDGE; OX40 LIGAND; IN-VIVO; ADAPTIVE IMMUNITY	Background: Airway tolerance is critical for protecting the lung from inflammatory disease driven by allergens. However, factors that disrupt tolerance processes and then lead to susceptibility to developing allergic asthma remain elusive. Objective: To investigate whether recognition of bacterial microbial-associated molecular patterns in the lung may result in susceptibility to developing allergic reactions, and to understand the molecular mechanisms by which such triggers block natural tolerance. Methods: Ligands of intracellular microbial-associated molecular pattern recognition receptors-the nucleotide-binding oligomerization domain (Nod)-like receptors, Nod1 and Nod2-were given intranasally with antigen, and their ability to modulate airway tolerance was analyzed. Results: Intranasal Nod2 ligand rapidly induced lung expression of the innate cytokines thymic stromal lymphopoietin and IL-25, and thymic stromal lymphopoietin promoted expression of OX40 ligand, a T-cell-costimulatory ligand, on lung CD11c(+) CD11b(+) cells and B220(+) cells. Together these 3 molecules blocked the generation of antigen-specific CD4(+) forkhead box protein 3(+) adaptive regulatory T cells and concomitantly drove IL-4-producing CD4 T cells. By altering the regulatory T/T(H)2-cell balance, tolerance was blocked, and sensing of Nod2 ligand resulted in subsequent susceptibility to developing eosinophil-dominated airway inflammation. Conclusion: We show that a Nod-like receptor is a novel, previously unrecognized, pathway that adversely links innate and adaptive immunity and leads to allergic disease and asthmatic lung inflammation. (J Allergy Clin Immunol 2010;126:1284-93.)	[Duan, Wei; Mehta, Amit K.; Croft, Michael] La Jolla Inst Allergy & Immunol, Div Mol Immunol, La Jolla, CA 92037 USA; [Magalhaes, Joao G.; Philpott, Dana J.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Ziegler, Steven F.] Benaroya Res Inst, Seattle, WA USA; [Dong, Chen] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	La Jolla Institute for Immunology; University of Toronto; Benaroya Research Institute; University of Texas System; UTMD Anderson Cancer Center	Croft, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.	mick@liai.org	Mehta, Amit Kumar/D-7585-2016; dong, chen/B-3181-2009; Magalhaes, Joao/AAK-2686-2020	dong, chen/0000-0002-0084-9130; 	NIH [AI070535, CA91837, AI071130]; NATIONAL CANCER INSTITUTE [R01CA091837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, U19AI071130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056113] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by NIH grants AI070535 and CA91837 to M. C. and AI071130 to C.D.	Akiba H, 1999, J IMMUNOL, V162, P7058; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Buckland KF, 2008, INFLAMM RES, V57, P379, DOI 10.1007/s00011-008-8004-y; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; DAMAYANTI T, AM J RESP CRIT CARE, V181, P688; Dong C, 2008, IMMUNOL REV, V226, P80, DOI 10.1111/j.1600-065X.2008.00709.x; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Franchi L, 2009, IMMUNOL REV, V227, P106, DOI 10.1111/j.1600-065X.2008.00734.x; Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hollingsworth JW, 2006, J IMMUNOL, V176, P5856, DOI 10.4049/jimmunol.176.10.5856; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Iwasaki A, 1999, AM J PHYSIOL-GASTR L, V276, pG1074, DOI 10.1152/ajpgi.1999.276.5.G1074; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kuipers H, 2003, J IMMUNOL, V171, P3645, DOI 10.4049/jimmunol.171.7.3645; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Magalhaes JG, 2008, J IMMUNOL, V181, P7925, DOI 10.4049/jimmunol.181.11.7925; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Prioult G, 2005, IMMUNOL REV, V206, P204, DOI 10.1111/j.0105-2896.2005.00277.x; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Revets H, 2005, J IMMUNOL, V174, P1097, DOI 10.4049/jimmunol.174.2.1097; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Sabbah A, 2009, NAT IMMUNOL, V10, P1073, DOI 10.1038/ni.1782; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; So T, 2006, P NATL ACAD SCI USA, V103, P3740, DOI 10.1073/pnas.0600205103; So T, 2007, J IMMUNOL, V179, P1427, DOI 10.4049/jimmunol.179.3.1427; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STROBEL S, 1986, GUT, V27, P829, DOI 10.1136/gut.27.7.829; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wenink MH, 2009, J IMMUNOL, V183, P6960, DOI 10.4049/jimmunol.0900713; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	54	67	70	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1284	U334		10.1016/j.jaci.2010.09.021	http://dx.doi.org/10.1016/j.jaci.2010.09.021			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21051079	Green Accepted, Bronze			2022-12-18	WOS:000284947800029
J	Higashi, N; Mita, H; Ono, E; Fukutomi, Y; Yamaguchi, H; Kajiwara, K; Tanimoto, H; Sekiya, K; Akiyama, K; Taniguchi, M				Higashi, Noritaka; Mita, Haruhisa; Ono, Emiko; Fukutomi, Yuma; Yamaguchi, Hiromichi; Kajiwara, Keiichi; Tanimoto, Hidenori; Sekiya, Kiyoshi; Akiyama, Kazuo; Taniguchi, Masami			Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin; asthma; anaphylaxis; cysteinyl-leukotriene; 2,3-dinor-9 alpha,11 beta-PGF(2); ent-PGF(2)alpha; urine	MAST-CELL ACTIVATION; PROSTAGLANDIN D-2 METABOLITE; CYSTEINYL-LEUKOTRIENES; ISOPROSTANE PATHWAY; URINARY METABOLITE; NASAL POLYPS; PLASMA; CYCLOOXYGENASE; EXCRETION; RHINOSINUSITIS	Background: It has recently demonstrated that a free radical mediated pathway generates prostaglandins (PGs) and the corresponding prostaglandin enantiomers (ent-PGs). Aspirin-intolerant asthma and anaphylaxis accompany PGD(2) overproduction, possibly associated with mast cell activation via the COX pathway. However, free radical-mediated PG generation in the pathophysiology of these diseases, which can be demonstrated by measuring urinary ent-PGF(2)alpha, has not been reported. Objectives: To evaluate the characteristic profile of eicosanoid generation via the COX and/or free radical mediated pathway underlying aspirin-intolerant asthma and anaphylaxis. Methods: A comparative group analysis consisted of asthma (n = 17) and anaphylaxis (n = 8, none with aspirin-induced anaphylaxis) cases. Urinary eicosanoid concentrations were quantified as follows: 2,3-dinor-9 alpha,11 beta-PGF(2) by gas chromatography-mass spectrometry; leukotriene E-4, 9 alpha,11 beta-PGF(2), and PGs by enzyme immunoassay. Results: 2,3-Dinor-9 alpha,11 beta-PGF(2) is a more predominant PGD(2) metabolite in urine than 9 alpha,11 beta-PGF(2). At baseline, the aspirin-intolerant asthma group (n = 10) had significantly higher leukotriene E-4 and lower PGE(2) concentrations in urine than the aspirin-tolerant asthma group. During the reaction, the urinary concentrations of leukotriene E-4 and PGD(2) metabolites correlatively increased, but with markedly different patterns of the mediator release, in the aspirin-intolerant asthma group and the anaphylaxis group, respectively. The urinary PGD(2) metabolites and primary PGs were significantly decreased in the aspirin-tolerant asthma group. Urinary ent-PGF(2)alpha concentrations were significantly increased in the anaphylaxis group but not the aspirin-intolerant asthma group. Conclusions: When assessed by urinary 2,3-dinor-9 alpha,11 beta-PGF(2), PGD(2) overproduction during aspirin-intolerant bronchoconstriction was clearly identified, regardless of COX inhibition. It is evident that free radical mediated PG generation is involved in the pathophysiology of anaphylaxis. (J Allergy Clin Immunol 2010;125:1084-91.)	[Higashi, Noritaka; Mita, Haruhisa; Ono, Emiko; Fukutomi, Yuma; Yamaguchi, Hiromichi; Kajiwara, Keiichi; Tanimoto, Hidenori; Sekiya, Kiyoshi; Akiyama, Kazuo; Taniguchi, Masami] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Kanagawa 2288522, Japan		Higashi, N (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, 18-1 Sakuradai, Kanagawa 2288522, Japan.	n-higashi@sagamihara-hosp.gr.jp	Fukutomi, Yuma/AFQ-4306-2022	Fukutomi, Yuma/0000-0001-9913-4524	Ministry of Health, Labor and Welfare (Japan)	Ministry of Health, Labor and Welfare (Japan)(Ministry of Health, Labour and Welfare, Japan)	Supported by the Ministry of Health, Labor and Welfare (Japan).	[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bochenek G, 2004, THORAX, V59, P459, DOI 10.1136/thx.2003.013573; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Boyce JA, 2005, CHEM IMMUNOL ALLERGY, V87, P59, DOI 10.1159/000087571; Butterfield JH, 2009, PROSTAG OTH LIPID M, V88, P122, DOI 10.1016/j.prostaglandins.2009.01.001; DAHLEN B, 1994, ALLERGY, V49, P43, DOI 10.1111/j.1398-9995.1994.tb00772.x; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; Dworski R, 1998, CLIN EXP ALLERGY, V28, P1309; Farooque S, 2008, THORAX, V63, P2, DOI 10.1136/thx.2007.084475; FROLICH JC, 1975, J CLIN INVEST, V55, P763, DOI 10.1172/JCI107987; Gaber F, 2008, THORAX, V63, P1076, DOI 10.1136/thx.2008.101196; Gao L, 2003, J BIOL CHEM, V278, P28479, DOI 10.1074/jbc.M303984200; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Kumlin M, 1997, ALLERGY, V52, P124, DOI 10.1111/j.1398-9995.1997.tb00966.x; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, P483, DOI DOI 10.1016/j.jaci.2005.01.010; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; Mita H, 2004, CLIN EXP ALLERGY, V34, P1262, DOI 10.1111/j.1365-2222.2004.02034.x; Mita H, 2004, CLIN EXP ALLERGY, V34, P931, DOI 10.1111/j.1365-2222.2004.01968.x; Mita H, 2001, ALLERGY, V56, P1061; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1995, J INVEST DERMATOL, V104, P937, DOI 10.1111/1523-1747.ep12606209; Mortaz E, 2006, EUR J PHARMACOL, V543, P190, DOI 10.1016/j.ejphar.2006.05.044; *NIH, 2008, NHBLI WHO WORKSH REP; O'Sullivan S, 1999, PROSTAG OTH LIPID M, V57, P149, DOI 10.1016/S0090-6980(98)00076-8; O'Sullivan S, 1999, ACTA PHYSIOL SCAND, V166, P1; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; PICKETT WC, 1981, ANAL BIOCHEM, V111, P115, DOI 10.1016/0003-2697(81)90237-2; Pujols L, 2004, J ALLERGY CLIN IMMUN, V114, P814, DOI 10.1016/j.jaci.2004.07.050; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Song WL, 2008, J BIOL CHEM, V283, P1179, DOI 10.1074/jbc.M706839200; Stafforini DM, 2006, J BIOL CHEM, V281, P4616, DOI 10.1074/jbc.M507340200; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; Swindle EJ, 2004, J BIOL CHEM, V279, P48751, DOI 10.1074/jbc.M409738200; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Treudler R, 2008, J INVEST ALLERG CLIN, V18, P52; WESTCOTT JY, 1985, BIOMED ENVIRON MASS, V12, P714, DOI 10.1002/bms.1200121208; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; Yin HY, 2007, J BIOL CHEM, V282, P329, DOI 10.1074/jbc.M608975200	53	67	71	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1084	1091		10.1016/j.jaci.2009.12.977	http://dx.doi.org/10.1016/j.jaci.2009.12.977			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20304469				2022-12-18	WOS:000277686700018
J	Togias, A; Fenton, MJ; Gergen, PJ; Rotrosen, D; Fauci, AS				Togias, Alkis; Fenton, Matthew J.; Gergen, Peter J.; Rotrosen, Daniel; Fauci, Anthony S.			Asthma in the inner city: The perspective of the National Institute of Allergy and Infectious Diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inner-city asthma; asthma research funding; cockroach allergy	ENVIRONMENTAL INTERVENTION; CHILDREN; IMMUNOTHERAPY; MORBIDITY; RHINITIS; TRIAL; CARE	Since 1991, the National Institute of Allergy and Infectious Diseases (NIAID) has funded four consecutive research initiatives to investigate the problem of high asthma prevalence, morbidity and mortality in poor urban communities. The multi-site studies conducted under these initiatives have identified key risk factors for asthma morbidity and novel interventions to improve asthma control. NIAID focuses its asthma and allergy programs on understanding the interaction of the immune system with allergens and infectious agents and identifying genetic and epigenetic elements that influence the immune system. A key goal in this field is to define mechanisms of immune system deviation and immune tolerance and apply this knowledge to generate improvements in asthma care and allergen immunotherapy. A related goal is to further understand the environmental, social, and immunological elements that impact on the development of inner-city asthma through in-depth characterization and longitudinal follow-up of inner-city children from the time of birth. In the past 5 years, NIH budgetary constraints have imposed many challenges for the academic research community. Despite these constraints, NIAID has maintained its support of a highly productive asthma and allergy research program. (J Allergy Clin Immunol 2010;125:540-4.)	[Togias, Alkis] NIAID, AAIB, DAIT, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Togias, A (corresponding author), NIAID, AAIB, DAIT, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	togiasa@niaid.nih.gov						Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Crocker D, 2009, CHEST, V136, P1063, DOI 10.1378/chest.09-0013; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; EVANS R, 1987, CHEST S, V91, P65; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Hackett CJ, 2007, NAT IMMUNOL, V8, P114, DOI 10.1038/ni0207-114; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; NIH, 2009, NIH PUBL; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 2009, BIOMEDICAL RES DEV P	25	67	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					540	544		10.1016/j.jaci.2010.01.040	http://dx.doi.org/10.1016/j.jaci.2010.01.040			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226290				2022-12-18	WOS:000275883200005
J	Castro, C; Gourley, M				Castro, Christine; Gourley, Mark			Diagnostic testing and interpretation of tests for autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune; disease; laboratory; inflammatory markers; evaluation; rheumatic; serologies; flow cytometry; HLA; organ specific	ANTIPHOSPHOLIPID SYNDROME; HEMOLYTIC-ANEMIA	Laboratory testing is of great value when evaluating a patient with a suspected autoimmune disease. The results can confirm a diagnosis, estimate disease severity, aid in assessing prognosis and are useful for following disease activity. Components of the laboratory examination include a complete blood count with differential, a comprehensive metabolic panel, measurement of inflammatory markers and autoantibodies, and flow cytometry. This chapter discusses these components and includes a discussion about organ-specific immunologic diseases for which immunologic laboratory testing is used. Comprehensive laboratory evaluation of a suspected autoimmune illness in conjunction with a thorough clinical evaluation provides a better understanding of a patient's immunologic disease. (J Allergy Clin Immunol 2010;125:S238-47.)	[Castro, Christine; Gourley, Mark] NIAMSD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Castro, C (corresponding author), NIAMSD, NIH, Bldg 10,CRC,Room 5,SEN 5-3481, Bethesda, MD 20892 USA.	castroc2@mail.nih.gov			Intramural NIH HHS [Z01 AR041176-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIDAR041180, Z01AR041176, ZIEAR041176] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Batal I, 2009, HUM PATHOL, V40, P332, DOI 10.1016/j.humpath.2008.08.001; BREDA L, 2009, SEMIN ARTHRITIS RHEU; Colglazier CL, 2005, SOUTH MED J, V98, P185, DOI 10.1097/01.SMJ.0000153572.22346.E9; Dalakas MC, 2002, RHEUM DIS CLIN N AM, V28, P779, DOI 10.1016/S0889-857X(02)00030-3; Das SS, 2009, ANN HEMATOL, V88, P727, DOI 10.1007/s00277-008-0674-6; Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023; Favaloro EJ, 2008, SEMIN THROMB HEMOST, V34, P389, DOI 10.1055/s-0028-1085482; FLEISHER TA, 2005, BETHESDA HDB CLIN HE, P415; FLEISHER TA, CLIN IMMUNOLOGY PRIN, P1435; Harndahl M, 2009, J BIOMOL SCREEN, V14, P173, DOI 10.1177/1087057108329453; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; HOMBURGER HA, CLIN IMMUNOLOGY PRIN, P1419; Katz JD, 2009, ANN NY ACAD SCI, V1154, P3, DOI 10.1111/j.1749-6632.2009.04380.x; KERSTIN M, 2008, PRIMER RHEUMATIC DIS, P15; Koulaouzidis A, 2009, EUR J INTERN MED, V20, P168, DOI 10.1016/j.ejim.2007.09.024; Lin JS, 2009, TRANSFUSION, V49, P1335, DOI 10.1111/j.1537-2995.2009.02130.x; McPherson RA, 2007, HENRYS CLIN DIAGNOSI, P40; MILLER FW, 2005, INFLAMMATORY MYOPATH, P1593; Milos M, 2009, INT J LAB HEMATOL, V31, P26, DOI 10.1111/j.1751-553X.2007.00999.x; Packman CH, 2008, BLOOD REV, V22, P17, DOI 10.1016/j.blre.2007.08.001; Petz LD, 2008, BLOOD REV, V22, P1, DOI 10.1016/j.blre.2007.08.002; Reymond JL, 2009, CHEM COMMUN, P34, DOI 10.1039/b813732c; Rostaing L, 1999, CYTOMETRY, V35, P318, DOI 10.1002/(SICI)1097-0320(19990401)35:4<318::AID-CYTO4>3.0.CO;2-4; Seshan SV, 2009, ARCH PATHOL LAB MED, V133, P233, DOI 10.1043/1543-2165-133.2.233; Shtalrid M, 2006, ISR MED ASSOC J, V8, P672; Tebo AE, 2008, CLIN EXP IMMUNOL, V154, P332, DOI 10.1111/j.1365-2249.2008.03774.x; Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651; Tripodi A, 2009, LUPUS, V18, P291, DOI 10.1177/0961203308101436; WENER MH, 2007, ED REV MANUAL RHEUMA, P1	29	67	73	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S238	S247		10.1016/j.jaci.2009.09.041	http://dx.doi.org/10.1016/j.jaci.2009.09.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20061009	Bronze, Green Accepted			2022-12-18	WOS:000280170600021
J	Novak, N; Koch, S; Allam, JP; Bieber, T				Novak, Natalija; Koch, Susanne; Allam, Jean-Pierre; Bieber, Thomas			Dendritic cells: Bridging innate and adaptive immunity in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Dendritic cells; innate immunity; adaptive immunity; Toll-like receptors	TOLL-LIKE RECEPTORS; FC-EPSILON-RI; ANTIGEN-PRESENTING CELLS; EPIDERMAL LANGERHANS CELLS; MONOPHOSPHORYL-LIPID-A; CD4(+) T-CELLS; CPG OLIGODEOXYNUCLEOTIDES; DIFFERENTIAL EXPRESSION; CYTOKINE PRODUCTION; RESPONSE MODIFIER	Much knowledge has been gained about the multifaceted functions of dendritic cells (DCs). The central role of various DC subtypes as bridges between innate and adaptive immunity has become more and more evident. However, a high number of differences exist in the expression of pattern-recognition receptors, the first sensors of the innate immune system, in particular Toll-like receptors (TLRs) by distinct DC subtypes (including myeloid and plasmacytoid DO), their maturation stage, and tissue distribution, as well as state of health or disease. Furthermore, a plethora of variations in human and murine model systems have to be considered. This review sheds some light on this complex and rapidly growing field. It summarizes the most recent findings and deals with the role of TLR-expressing DCs as promoters of chronic inflammatory immune responses in patients with atopic dermatitis, as well as tolerogenic pathways. Therefore TLR-bearing DCs represent promising targets, which might help to improve tolerance induction during immunotherapeutic approaches in the future. (J Allergy Clin Immunol 2010;125:50-9.)	[Novak, Natalija; Koch, Susanne; Allam, Jean-Pierre; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany	University of Bonn	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Thomas.Bieber@ukb.uni-bonn.de			Deutsche Forschungsgemeinschaft [SFB704 TPA4, SFB704 TPA15, FOR208 TPA1, DFG NO454/5-2]; University of Bonn	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Bonn	Supported by grants from the Deutsche Forschungsgemeinschaft (SFB704 TPA4 and TPA15 and FOR208 TPA1) and a BONFOR grant of the University of Bonn. N.N. is supported by a Heisenberg-Professorship of the DFG NO454/5-2.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Angel CE, 2007, INT IMMUNOL, V19, P1271, DOI 10.1093/intimm/dxm096; Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Beygo J, 2009, MOL CELL PROBE, V23, P16, DOI 10.1016/j.mcp.2008.10.002; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Broad A, 2006, CURR MED CHEM, V13, P2487, DOI 10.2174/092986706778201675; Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804; Bussmann Caroline, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000756; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dalpke AH, 2004, INT J MED MICROBIOL, V294, P345, DOI 10.1016/j.ijmm.2004.07.005; Dearman RJ, 2009, IMMUNOLOGY, V126, P475, DOI 10.1111/j.1365-2567.2008.02922.x; DePaolo RW, 2008, CELL HOST MICROBE, V4, P350, DOI 10.1016/j.chom.2008.09.004; Diebold Sandra S, 2009, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-540-71029-5_1; Doxsee CL, 2003, J IMMUNOL, V171, P1156, DOI 10.4049/jimmunol.171.3.1156; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Esnault S, 2008, INT J CLIN EXP PATHO, V1, P325; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Flacher V, 2006, J IMMUNOL, V177, P7959, DOI 10.4049/jimmunol.177.11.7959; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Fukui R, 2009, J EXP MED, V206, P1339, DOI 10.1084/jem.20082316; Funderburg N, 2007, P NATL ACAD SCI USA, V104, P18631, DOI 10.1073/PNAS.0702130104; Gaudreault E, 2007, J VIROL, V81, P8016, DOI 10.1128/JVI.00403-07; Geisel J, 2007, J IMMUNOL, V179, P5811, DOI 10.4049/jimmunol.179.9.5811; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; Hasannejad H, 2007, J ALLERGY CLIN IMMUN, V120, P69, DOI 10.1016/j.jaci.2007.04.010; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Hirata N, 2009, CELL IMMUNOL, V258, P9, DOI 10.1016/j.cellimm.2009.03.006; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ito T, 2002, J EXP MED, V195, P1507, DOI 10.1084/jem.20020207; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jin MS, 2008, IMMUNITY, V29, P182, DOI 10.1016/j.immuni.2008.07.007; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawasaki N, 2009, DIGEST ENDOSC, V21, P37, DOI 10.1111/j.1443-1661.2008.00816.x; Kelsall BL, 2008, J PATHOL, V214, P242, DOI 10.1002/path.2286; Khatri I, 2009, IMMUNOL LETT, V124, P44, DOI 10.1016/j.imlet.2009.04.002; Kline JN, 2008, DRUG NEWS PERSPECT, V21, P434, DOI 10.1358/dnp.2008.21.8.1272133; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Lombardi V, 2009, J IMMUNOL, V182, P3372, DOI 10.4049/jimmunol.0801969; Mandron M, 2008, J INVEST DERMATOL, V128, P882, DOI 10.1038/sj.jid.5701112; Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Matsui K, 2009, INT ARCH ALLERGY IMM, V149, P167, DOI 10.1159/000189201; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mitsui H, 2004, J INVEST DERMATOL, V122, P95, DOI 10.1046/j.0022-202X.2003.22116.x; Monteleone I, 2008, EUR J IMMUNOL, V38, P1533, DOI 10.1002/eji.200737909; Morrison LA, 2004, TRENDS MICROBIOL, V12, P353, DOI 10.1016/j.tim.2004.06.001; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Niebuhr M, 2008, ALLERGY, V63, P728, DOI 10.1111/j.1398-9995.2008.01721.x; Niebuhr M, 2009, ALLERGY, V64, P1580, DOI 10.1111/j.1398-9995.2009.02050.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2007, ALLERGY, V62, P766, DOI 10.1111/j.1398-9995.2007.01358.x; Novak N, 1999, ALLERGY, V54, P792, DOI 10.1034/j.1398-9995.1999.00101.x; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2009, ALLERGY, V64, P265, DOI 10.1111/j.1398-9995.2008.01922.x; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Qian C, 2007, BLOOD, V109, P3308, DOI 10.1182/blood-2006-08-040337; Razafindratsita A, 2007, J ALLERGY CLIN IMMUN, V120, P278, DOI 10.1016/j.jaci.2007.04.009; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Renn CN, 2006, J IMMUNOL, V177, P298, DOI 10.4049/jimmunol.177.1.298; Reske A, 2008, J IMMUNOL, V180, P7525, DOI 10.4049/jimmunol.180.11.7525; Sakurai D, 2004, J IMMUNOL, V172, P2374, DOI 10.4049/jimmunol.172.4.2374; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Schimming TT, 2007, BMC DERMATOL, V7, DOI 10.1186/1471-5945-7-3; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Schroder NWJ, 2007, ALLERGY, V62, P579, DOI 10.1111/j.1398-9995.2007.01386.x; Selander C, 2009, J IMMUNOL, V182, P4208, DOI 10.4049/jimmunol.0800885; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Sumegi A, 2007, INT ARCH ALLERGY IMM, V143, P177, DOI 10.1159/000099309; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Terhorst D, 2007, CLIN EXP ALLERGY, V37, P381, DOI 10.1111/j.1365-2222.2006.02639.x; Torii Y, 2008, J IMMUNOL, V181, P5340, DOI 10.4049/jimmunol.181.8.5340; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; van der Aar AMG, 2007, J IMMUNOL, V178, P1986, DOI 10.4049/jimmunol.178.4.1986; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P277, DOI 10.1016/j.jaci.2006.04.034; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Wittebole X, 2005, CLIN EXP IMMUNOL, V141, P99, DOI 10.1111/j.1365-2249.2005.02831.x; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Xu YK, 2007, J IMMUNOL, V179, P7577, DOI 10.4049/jimmunol.179.11.7577; Yanagawa Y, 2007, J IMMUNOL, V178, P6173, DOI 10.4049/jimmunol.178.10.6173; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893	108	67	69	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					50	59		10.1016/j.jaci.2009.11.019	http://dx.doi.org/10.1016/j.jaci.2009.11.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109736				2022-12-18	WOS:000273660500005
J	Powe, DG; Kormelink, TG; Sisson, M; Blokhuis, BJ; Kramer, MF; Jones, NS; Redegeld, FA				Powe, Desmond G.; Kormelink, Tom Groot; Sisson, Melanie; Blokhuis, Bart J.; Kramer, Matthias F.; Jones, Nicholas S.; Redegeld, Frank A.			Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; allergy; nonallergic; immunoglobulin; free light chains	NASAL-MUCOSA; MULTIPLE-SCLEROSIS; LOCAL PRODUCTION; MAST-CELLS; IDIOPATHIC RHINITIS; IGE ANTIBODIES; HAY-FEVER; ASTHMA; INFLAMMATION; DISEASES	Background: Allergic rhinitis is characterized by mast cell degranulation induced by antigen cross-linking of IgE. It has been proposed that some patients with rhinitis show nasal allergy in the absence of systemic markers of atopy, termed entopy. Recent murine studies suggest the existence of an IgE-independent hypersensitivity response involving antigen-induced mast cell activation, mediated by immunoglobulin free light chains (FLCs). Objectives: To determine whether FLC is associated with mast cell-mediated nasal hypersensitivity and its relationship with eosinophilic activity in allergic and nonatopic rhinitis. Methods: Patients with allergy and nonallergic rhinitis with eosinophilia syndrome (NARES) had levels of soluble FLC measured in nasal secretions and serum. In addition, levels of the nasal inflammatory mediators mast cell tryptase and eosinophil cationic protein were quantified. Cellular expression Of K and X FLC was characterized in the nasal mucosa of allergic and nonatopic idiopathic rhinitis and control subjects by using immunohistochemistry. Immunopositive cells were phenotyped by using laser microdissection and PCR. Results: Free light chain was significantly increased in nasal secretions of subjects with allergy and NARES, and in serum of patients with NARES. Nonatopic patients with allergy showed significantly increased nasal mast cell tryptase and eosinophil cationic protein. FLC-positive cells were significantly, increased in allergic and nonatopic mucosa, and were shown to be mast cells and plasma cells. Conclusion: Nasal FLC is significantly. increased in allergic and nonatopic rhinitis nasal mucosa, suggesting a role in nasal hypersensitivity. Further studies are needed to identify which allergens trigger FLC-mediated responses in nonatopic rhinitis. (J Allergy Clin Immunol 2010;125:139-45.)	[Powe, Desmond G.] Nottingham Univ Hosp Trust, Div Pathol, Sch Mol Med Sci, Queens Med Ctr,Dept Histopathol Surg & Med Sci, Nottingham NG7 2UH, England; [Kormelink, Tom Groot; Blokhuis, Bart J.; Redegeld, Frank A.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol & Pathophysiol, NL-3508 TC Utrecht, Netherlands; [Kramer, Matthias F.] Univ Munich, Dept Otorhinolaryngol Head & Neck Surg, Munich, Germany	Nottingham University Hospital NHS Trust; University of Nottingham; Utrecht University; University of Munich	Powe, DG (corresponding author), Nottingham Univ Hosp Trust, Div Pathol, Sch Mol Med Sci, Queens Med Ctr,Dept Histopathol Surg & Med Sci, Nottingham NG7 2UH, England.	des.powe@nottingham.ac.uk	Redegeld, Frank A/O-6534-2016; Kramer, Matthias F./AAK-9279-2021	Redegeld, Frank A/0000-0001-8830-7960; Kramer, Matthias F./0000-0002-3740-4733				Abe M, 1998, CLIN EXP IMMUNOL, V111, P457; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; Berger G, 1997, AM J RHINOL, V11, P63, DOI 10.2500/105065897781446775; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Cameron L, 1998, J ALLERGY CLIN IMMUN, V101, pS162; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; COFFMAN RL, 1987, J IMMUNOL, V139, P3685; COOPER A, 1968, ANN RHEUM DIS, V27, P537, DOI 10.1136/ard.27.6.537; Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x; Davern S, 2008, AM J CLIN PATHOL, V130, P702, DOI 10.1309/AJCPNS6K1CYJPDBA; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Goffette S, 2004, J NEUROL NEUROSUR PS, V75, P308, DOI 10.1136/jnnp.2003.010710; Groot Kormelink T, 2009, CLIN EXP ALLERGY, V39, P33, DOI 10.1111/j.1365-2222.2008.03135.x; HOPPER JE, 1989, J CLIN IMMUNOL, V9, P338, DOI 10.1007/BF00918666; HUGGINS KG, 1975, LANCET, V2, P148; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; Jenkins MA, 2001, ANN CLIN BIOCHEM, V38, P235, DOI 10.1258/0004563011900669; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAY AB, 1991, INT ARCH ALLER A IMM, V94, P189, DOI 10.1159/000235360; Kim HJ, 1999, J IMMUNOL, V162, P3053; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; Kramer MF, 2004, CLIN EXP ALLERGY, V34, P1086, DOI 10.1111/j.1365-2222.2004.01989.x; Kraneveld AD, 2005, P NATL ACAD SCI USA, V102, P1578, DOI 10.1073/pnas.0406808102; MEHTA PD, 1991, NEUROLOGY, V41, P540, DOI 10.1212/WNL.41.4.540; Pawankar R, 2001, INT ARCH ALLERGY IMM, V124, P166, DOI 10.1159/000053700; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Redegeld FA, 2003, TRENDS IMMUNOL, V24, P181, DOI 10.1016/S1471-4906(03)00059-0; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; van Houwelingen AH, 2007, CLIN EXP ALLERGY, V37, P270, DOI 10.1111/j.1365-2222.2007.02655.x; Wedback A, 2005, RHINOLOGY, V43, P86; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22, DOI 10.1164/ajrccm.165.1.2010112; Yoshida T, 2005, MICROBIOL IMMUNOL, V49, P529, DOI 10.1111/j.1348-0421.2005.tb03758.x	43	67	75	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					139	145		10.1016/j.jaci.2009.07.025	http://dx.doi.org/10.1016/j.jaci.2009.07.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19818484				2022-12-18	WOS:000273660500016
J	Blais, L; Beauchesne, MF; Lemiere, C; Elftouh, N				Blais, Lucie; Beauchesne, Marie-France; Lemiere, Catherine; Elftouh, Naoual			High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pregnancy; inhaled corticosteroids; congenital malformations; cohort study	ASTHMA MEDICATION USE; PERINATAL OUTCOMES; INDUCED HYPERTENSION; DRUG-USE; WOMEN; RISK; THERAPY; BUDESONIDE; DATABASE; EXACERBATIONS	Background: Although reassuring data exist on the use of low-to-moderate doses of inhaled corticosteroids (ICSs) during pregnancy, there are inadequate data for women receiving high doses. Objective: To investigate the association between doses of ICS during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Methods: We conducted a cohort study of 13,280 pregnancies of women with asthma (1990-2002) by linking 3 administrative databases from Quebec (Canada). By using generalized estimation equation models, we compared women taking >0 to 1000 mu g/d ICS (beclomethasone dipropionate-chlorofluorocarbone equivalent) with women taking >1000 mu g/d and those not taking ICSs. The main outcome measures were all and major congenital malformations. Results: We identified 1257 infants with a congenital malformation (9.5%) and 782 infants with a major malformation (5.9%). We found that women who used >1000 mu g/d ICS (n = 154) were significantly more likely (63%) to have a baby with a malformation than the 4392 women who used >0 to 1000 mu g/d (adjusted risk ratio, 1.63; 95% CI, 1.02-2.60). On the other hand, women who used >0 to 1000 mu g/d were not found to be more at risk than women who did not use ICSs during the first trimester (n = 8734). Nonsignificant trends of similar magnitude were found for major malformations. Conclusions: Our study adds evidence on the safety of low-to-moderate doses of ICS taken during the first trimester but raises concerns about high doses. However, we cannot rule out the possibility of residual confounding by severity in this association. (J Allergy Clin Immunol 2009;124:1229-34.)	[Blais, Lucie; Beauchesne, Marie-France] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Lemiere, Catherine] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Blais, Lucie; Beauchesne, Marie-France; Lemiere, Catherine; Elftouh, Naoual] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Blais, Lucie; Beauchesne, Marie-France] Endowment Pharmaceut Chair AstraZeneca Resp Hlth, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; AstraZeneca	Blais, L (corresponding author), Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca			Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34; Bakhireva LN, 2005, J ALLERGY CLIN IMMUN, V116, P503, DOI 10.1016/j.jaci.2005.05.027; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Blais L, 2006, PHARMACOEPIDEM DR S, V15, P245, DOI 10.1002/pds.1202; Blais L, 2004, THORAX, V59, P943, DOI 10.1136/thx.2004.022475; Blais L, 2008, J ALLERGY CLIN IMMUN, V121, P1379, DOI 10.1016/j.jaci.2008.02.038; Blais L, 2007, THORAX, V62, P320, DOI 10.1136/thx.2006.062950; Braems G, 2003, EUR J OBSTET GYN R B, V110, pS63, DOI 10.1016/S0301-2115(03)00174-X; Breton MC, 2008, RESP MED, V102, P862, DOI 10.1016/j.rmed.2008.01.008; Carmichael SL, 1999, AM J MED GENET, V86, P242, DOI 10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U; Cousins L, 1999, J ALLERGY CLIN IMMUN, V103, pS343, DOI 10.1016/S0091-6749(99)70260-5; Danielsson BR, 2003, TOXICOL APPL PHARM, V193, P168, DOI 10.1016/j.taap.2003.07.002; Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; ERICSON A, 1999, USE DRUGS PREGNANCY, P1; Firoozi F, 2007, THORAX, V62, P581, DOI 10.1136/thx.2006.061572; Guy ES, 2004, CRIT CARE CLIN, V20, P731, DOI 10.1016/j.ccc.2004.05.013; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; Kallen BAJ, 2003, REPROD TOXICOL, V17, P255, DOI 10.1016/S0890-6238(03)00012-1; Kallen B, 2007, EUR J CLIN PHARMACOL, V63, P383, DOI 10.1007/s00228-006-0259-z; Koren G, 1998, NEW ENGL J MED, V338, P1128, DOI 10.1056/NEJM199804163381607; Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Martel MJ, 2007, J ALLERGY CLIN IMMUN, V119, P576, DOI 10.1016/j.jaci.2006.10.034; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; Namazy J, 2004, J ALLERGY CLIN IMMUN, V113, P427, DOI 10.1016/j.jaci.2003.11.046; National Institutes of Health, 2007, NIH PUBL, V02-3659; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Olesen C, 2001, RESPIRATION, V68, P256, DOI 10.1159/000050507; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; *REG ASS MAL QUEB, 2006, STAT ANN; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Silverman M, 2005, ANN ALLERG ASTHMA IM, V95, P566, DOI 10.1016/S1081-1206(10)61020-4; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Vilain A, 2008, PHARMACOEPIDEM DR S, V17, P345, DOI 10.1002/pds.1558; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	43	67	68	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1229	1234		10.1016/j.jaci.2009.09.025	http://dx.doi.org/10.1016/j.jaci.2009.09.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910032				2022-12-18	WOS:000273071500014
J	Raymond, M; Rubio, M; Fortin, G; Shalaby, KH; Hammad, H; Lambrecht, BN; Sarfati, M				Raymond, Marianne; Rubio, Manuel; Fortin, Genevieve; Shalaby, Karim Hamdy; Hammad, Hamida; Lambrecht, Bart N.; Sarfati, Marika			Selective control of SIRP-alpha-positive airway dendritic cell trafficking through CD47 is critical for the development of T(H)2-mediated allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; migration; CD103; allergic inflammation; T(H)2; CD47; SIRP-alpha	RECEPTOR AGONIST FTY720; BRONCHIAL LYMPH-NODE; IMMUNE-RESPONSE; T-CELLS; ADAPTIVE IMMUNITY; INHALED ANTIGEN; IN-VIVO; LUNG; ASTHMA; MIGRATION	Background: Dendritic cells (DCs) are essential for the initiation and maintenance of T(H)2 responses to inhaled antigen that lead to the establishment of allergic diseases. Two subpopulations of nonplasmacytoid DCs (ie, CD11b(low)CD103(+) and CD11b(high)CD103(-)) are found in lung/airway tissues. Yet the identification and migratory properties of the DC subset that contributes to T(H)2-mediated responses remain to be clarified. CD47, a signal regulatory protein (SIRP)-alpha partner, reportedly governed skin DC migration. Objective: We here thought to investigate the role of CD47/SIRP-alpha interactions in airway DC trafficking and the development of allergic airway inflammation. Methods: We characterized the DC influx into lungs and mediastinal lymph nodes in CD47(-/-) and CD47(+/+) BALB/c mice by using experimental models of allergic asthma. Mice were systemically (intraperitoneal ovalbumin/alum) or locally (intratracheal ovalbumin-loaded bone marrow-derived DCs) immunized and challenged by ovalbumin aerosol. We also evaluated the consequences of SIRP-alpha-Fc fusion molecule administration on the induction of airway disease in BALB/c mice. Results: SIRP-alpha selectively identified the CD11b(high)CD103(-) DC subset that predominantly accumulated in mediastinal lymph nodes during airway inflammation. However, CD103(-)SIRP-alpha(+) DC trafficking, T(H)2 responses, and airway disease were impaired in CD47(-/-) mice. Importantly, the adoptive transfer of CD103(-) SIRP-alpha(+)CD47(+/+) but not CD47(-/-) DCs elicited a strong T(H)2 response in CD47(-/-) mice. Finally, the administration of SIRP-alpha-Fc molecule protected BALB/c mice from allergic airway inflammation. Conclusion: Lung CD11b(high)CD103(-)SIRP-alpha(+) DC migration is governed by self-CD47 expression, and manipulation of the CD47/SIRP-alpha pathway suppresses CD103(-)SIRP-alpha(+) DC-driven pathogenic T(H)2 responses and airway inflammation. (I Allergy Clin Immunol 2009;124:1333-42.)	[Raymond, Marianne; Rubio, Manuel; Fortin, Genevieve; Sarfati, Marika] Hop Notre Dame de Bon Secours, CHU Montreal, Immunoregulat Lab, Res Ctr, Montreal, PQ H2L 4M1, Canada; [Shalaby, Karim Hamdy] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, Immunoregulat Lab, Ghent, Belgium	Universite de Montreal; McGill University; Ghent University	Sarfati, M (corresponding author), Hop Notre Dame de Bon Secours, CHU Montreal, Immunoregulat Lab, Res Ctr, Pavillon Mailloux,M4211K,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	m.sarfati@umontreal.ca	Hammad, Hamida/J-9391-2015; Lambrecht, Bart N/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart N/0000-0003-4376-6834	Canadian Institute for Health and Research (CIHR) [MOP-53152]	Canadian Institute for Health and Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institute for Health and Research (CIHR Grant, MOP-53152).	Beaty SR, 2007, J IMMUNOL, V178, P1882, DOI 10.4049/jimmunol.178.3.1882; Bouguermouh S, 2008, J IMMUNOL, V180, P8073, DOI 10.4049/jimmunol.180.12.8073; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cook Donald N, 2007, Proc Am Thorac Soc, V4, P234, DOI 10.1513/pats.200701-026AW; Czeloth N, 2005, J IMMUNOL, V175, P2960, DOI 10.4049/jimmunol.175.5.2960; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2008, J IMMUNOL, V181, P6178, DOI 10.4049/jimmunol.181.9.6178; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Florian S, 2005, J LEUKOCYTE BIOL, V77, P984, DOI 10.1189/jlb.0604349; Fukunaga A, 2004, J IMMUNOL, V172, P4091, DOI 10.4049/jimmunol.172.7.4091; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Grinnan D, 2006, J ALLERGY CLIN IMMUN, V118, P1234, DOI 10.1016/j.jaci.2006.07.036; Hagnerud S, 2006, J IMMUNOL, V176, P5772, DOI 10.4049/jimmunol.176.10.5772; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hintzen G, 2006, J IMMUNOL, V177, P7346, DOI 10.4049/jimmunol.177.10.7346; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jakubzick C, 2008, J IMMUNOL, V180, P3019, DOI 10.4049/jimmunol.180.5.3019; Jakubzick C, 2006, J IMMUNOL, V176, P3578, DOI 10.4049/jimmunol.176.6.3578; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2007, CURR OPIN IMMUNOL, V19, P701, DOI 10.1016/j.coi.2007.09.003; Lahoud MH, 2006, J IMMUNOL, V177, P372, DOI 10.4049/jimmunol.177.1.372; Lan YY, 2005, AM J TRANSPLANT, V5, P2649, DOI 10.1111/j.1600-6143.2005.01085.x; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Sarfati M, 2008, CURR DRUG TARGETS, V9, P842, DOI 10.2174/138945008785909310; Sawicka E, 2003, J IMMUNOL, V171, P6206, DOI 10.4049/jimmunol.171.11.6206; Shao ZF, 2009, J ALLERGY CLIN IMMUN, V123, P917, DOI 10.1016/j.jaci.2009.01.052; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Van VQ, 2006, EMBO J, V25, P5560, DOI 10.1038/sj.emboj.7601415; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	43	67	69	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1333	1342		10.1016/j.jaci.2009.07.021	http://dx.doi.org/10.1016/j.jaci.2009.07.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19748659				2022-12-18	WOS:000273071500028
J	Casale, TB; Canonica, GW; Bousquet, J; Cox, L; Lockey, R; Nelson, HS; Passalacqua, G				Casale, Thomas B.; Canonica, G. Walter; Bousquet, Jean; Cox, Linda; Lockey, Richard; Nelson, Harold S.; Passalacqua, Giovanni			Recommendations for appropriate sublingual immunotherapy clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; sublingual immunotherapy; subcutaneous immunotherapy; allergic rhinitis; allergic conjunctivitis; allergic asthma	ALLERGIC RHINITIS; RESPIRATORY ALLERGY; SAFETY; EFFICACY; ANAPHYLAXIS; ORGANIZATION; UPDATE; TABLET; AGE	Sublingual immunotherapy is gaining widespread attention as a viable alternative to subcutaneous immunotherapy for the treatment of allergic rhinoconjunctivitis. In addition, sublingual immunotherapy has been studied in other allergic disorders including asthma. However, a review of published studies indicates that there are deficiencies and considerable heterogeneity in both design and data interpretation of sublingual immunotherapy studies. These deficiencies have made it somewhat difficult to assess the appropriate place of sublingual immunotherapy in guidelines for the therapy of allergic diseases. Moreover, several unpublished oral and sublingual immunotherapy studies in the United States failed to meet primary endpoints. This article reviews data from sublingual immunotherapy trials and makes recommendations about appropriate designs of future sublingual immunotherapy studies. It is hoped that these recommendations will result in more adequately designed sublingual immunotherapy trials to facilitate the appropriate placement of this therapy to treat patients with allergic rhinoconjunctivitis and other allergic diseases. (J Allergy Clin Immunol 2009;124:665-70.)	[Casale, Thomas B.] Creighton Univ, Omaha, NE 68131 USA; [Bousquet, Jean] Hop Arnaud Villeneuve, Montpellier, France; [Canonica, G. Walter; Passalacqua, Giovanni] Univ Genoa, I-16126 Genoa, Italy; [Bousquet, Jean] Inst Natl Santi & Rech Midicale, U780, Montpellier, France; [Cox, Linda] Nova SE Univ, Sch Osteopath Med, Davie, FL USA; [Lockey, Richard] Univ S Florida, Tampa, FL USA; [Nelson, Harold S.] Natl Jewish Hlth, Denver, CO USA	Creighton University; Universite de Montpellier; CHU de Montpellier; University of Genoa; Nova Southeastern University; State University System of Florida; University of South Florida; National Jewish Health	Casale, TB (corresponding author), Creighton Univ, 601 N 30 St,Suite 5850, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Cox, Linda/AAP-1697-2021; canonica, giorgio walter/ABF-2037-2020; Casale, Thomas B/K-4334-2013; Bousquet, Jean/O-4221-2019	Cox, Linda/0000-0002-5258-6870; canonica, giorgio walter/0000-0001-8467-2557; Casale, Thomas B/0000-0002-3149-7377; 	Stallergenes; Hollister-Steir; ALK-Abello; Lofarma; Anallergo; Schering-Plough; Novartis; Genentech; Ception; AstraZeneca	Stallergenes; Hollister-Steir; ALK-Abello; Lofarma; Anallergo; Schering-Plough(Merck & CompanySchering Plough Corporation); Novartis(Novartis); Genentech(Roche HoldingGenentech); Ception; AstraZeneca(AstraZeneca)	T. B. Casale has received research support from Stallergenes. J. Bousquet is an advisor and board member for Stallergenes and has received honoraria front ALK-Abello. L. Cox is a consultant for Stallergenes and Hollister-Steir, is on the speakers' bureau for Genentech/Novartis and Sanoti-Aventis, hits received research support front Hollister-Steir, and is a member of the Food and Drug Administration Allergic Products Advisory Committee. G. W. Canonica has received research support from ALK-Abello, Stallergenes, Lofarma. and Anallergo. H. S. Nelson is it consultant for Genentech/Novartis, Abbott Laboratories, Medici-Nova. AstraZeneca, Amgen, GlaxoSmithKline, Schering-Plough, Dyson, Sepracor. and NyCoMed: hits received research support from Schering-Plough. Novartis. Genentech, Ception. and AstraZeneca and is on the speakers' bureau for GlaxoSmilhKline. G. Passalacqua and R. F. Lockey have declared that they have no conflict of interest.	Agostinis F, 2008, ALLERGY, V63, P1637, DOI 10.1111/j.1398-9995.2008.01742.x; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA), 2008, CHMPEWP185042006; Compalati E, 2009, ANN ALLERG ASTHMA IM, V102, P22, DOI 10.1016/S1081-1206(10)60103-2; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Didier A, 2009, ALLERGY, V64, P166, DOI 10.1111/j.1398-9995.2008.01767.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Guerra Laura, 2006, Allergol Immunopathol (Madr), V34, P82, DOI 10.1016/S0301-0546(06)73518-2; Lombardi C, 2008, ALLERGY, V63, P375, DOI 10.1111/j.1398-9995.2007.01608.x; Lombardi C, 2009, ALLERGY, V64, P849, DOI 10.1111/j.1398-9995.2009.02063.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Rodriguez F, 2006, INT ARCH ALLERGY IMM, V140, P321, DOI 10.1159/000093710; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Windom HH, 2008, CURR OPIN ALLERGY CL, V8, P571, DOI 10.1097/ACI.0b013e32831845fb	26	67	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					665	670		10.1016/j.jaci.2009.07.054	http://dx.doi.org/10.1016/j.jaci.2009.07.054			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19766297	Bronze			2022-12-18	WOS:000270802800006
J	Naimi, DR; Freedman, TG; Ginsburg, KR; Bogen, D; Rand, CS; Apter, AJ				Naimi, David R.; Freedman, Tovia G.; Ginsburg, Kenneth R.; Bogen, Daniel; Rand, Cynthia S.; Apter, Andrea J.			Adolescents and asthma: Why bother with our meds?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adolescent; adherence; inhaled corticosteroid	QUALITATIVE RESEARCH; MEDICAL ADHERENCE; PEDIATRIC ASTHMA; INHALED STEROIDS; CHRONIC ILLNESS; LUNG-FUNCTION; HEALTH-CARE; CHILDREN; MANAGEMENT; ADULTS	Background: Adherence to inhaled steroid regimens for asthma is poor in adults and children. Although it is assumed that nonadherence contributes to morbidity in older adolescents, investigation is limited. Objective: We sought to describe adherence to preventive asthma medications and explore relevant beliefs and attitudes in older urban adolescents, including their ideas for improving adherence. Methods: Quantitative and qualitative methods were used to collect data from a convenience sample of adolescents with asthma previously prescribed fluticasone/salmeterol (F/S). Two semistructured face-to-face interviews were conducted 1 month apart and analyzed for themes. F/S use was electronically monitored between visits and calculated as the number of actuations divided by the number of inhalations prescribed. Results: Forty participants, (15-18 years of age, 19 female subjects, 30 black/African American subjects, 11 Medicaid-insured subjects, and 24 previously hospitalized for asthma) with a median FEV1 of 98% of predicted value (range, 67% to 127%) had median adherence of 43% (range, 4% to 89%). Adherence was not associated with FEV1 or emergency department visits. Themes emerged from interviews as follows. Teens (1) take F/S inconsistently; (2) believe F/S is "supposed to help me breathe"; (3) dislike its taste; (4) are "too busy" and "forget"; and (5) recommend "reminder" solutions to poor adherence. Twenty percent believed that taking F/S was unnecessary, and another 18% expressed ambivalence about its benefits. Conclusion: Adherence was poor. Examining and acknowledging health beliefs of older teens in the context of their complicated lives might facilitate discussions about self-management. (J Allergy Clin Immunol 2009;123:1335-41.)	[Naimi, David R.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Ginsburg, Kenneth R.] Childrens Hosp Philadelphia, Div Adolescent Med, Philadelphia, PA 19104 USA; [Freedman, Tovia G.] Clin & Res Consultant, Philadelphia, PA USA; [Bogen, Daniel] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Apter, Andrea J.] Univ Penn, Div Pulm Allergy & Crit Care Med, Sect Allergy & Immunol, Philadelphia, PA 19104 USA; [Rand, Cynthia S.] Johns Hopkins Sch Med, Baltimore, MD USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			American Academy of Allergy, Asthma & Immunology Sepracor Research Excellence Research;  [HL070392];  [HL088469]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073932, K02HL088469] Funding Source: NIH RePORTER	American Academy of Allergy, Asthma & Immunology Sepracor Research Excellence Research; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	D. R. Naimi is supported by the American Academy of Allergy, Asthma & Immunology Sepracor Research Excellence Award and A. J. Apter is supported by grants HL070392 and HL088469.	Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; Akinbami LJ., 2006, STATE CHILDHOOD ASTH; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2007, 3 US DEP HLTH HUM SE; APLER AJ, 2002, J ALLERGY CLIN IMM S, V109, pS184; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; Bogen D, 2004, J ALLERGY CLIN IMMUN, V114, P863, DOI 10.1016/j.jaci.2004.07.017; Bruzzese JM, 2004, PATIENT EDUC COUNS, V55, P396, DOI 10.1016/j.pec.2003.04.009; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Byrne M, 2001, AORN J, V73, P1155, DOI 10.1016/S0001-2092(06)61841-3; EISEN M, 1992, HEALTH EDUC QUART, V19, P249, DOI 10.1177/109019819201900208; Ellis DA, 2007, J PEDIATR PSYCHOL, V32, P907, DOI 10.1093/jpepsy/jsm009; Fiese BH, 2006, CURR OPIN PEDIATR, V18, P551, DOI 10.1097/01.mop.0000245357.68207.9b; Fiese BH, 2003, J PEDIATR-US, V143, P457, DOI 10.1067/S0022-3476(03)00448-7; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; George M, 2004, CURR OPIN ALLERGY CL, V4, P185, DOI 10.1097/01.all.0000129448.73727.86; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; Gillibrand R, 2006, BRIT J HEALTH PSYCH, V11, P155, DOI 10.1348/135910705X39485; Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024; Glanz K., 2015, HLTH BEHAV HLTH ED T; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Haynes RB., 1979, COMPLIANCE HLTH CARE; Horak E, 2003, PEDIATR PULM, V35, P23, DOI 10.1002/ppul.10218; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jonasson G, 1999, EUR RESPIR J, V14, P150, DOI 10.1034/j.1399-3003.1999.14a25.x; Krueger R.A., 2015, FOCUS GROUPS PRACTIC; Kyngas H A, 1999, Nurs Health Sci, V1, P195, DOI 10.1046/j.1442-2018.1999.00025.x; Le TT, 2008, J ASTHMA, V45, P33, DOI 10.1080/02770900701815552; Logan D, 2003, J PEDIATR PSYCHOL, V28, P383, DOI 10.1093/jpepsy/jsg028; McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; *NIH PUBL HLTH SER, 1997, PUBL NIH; Onyirimba F, 2003, ANN ALLERG ASTHMA IM, V90, P411, DOI 10.1016/S1081-1206(10)61825-X; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Penza-Clyve SM, 2004, J ASTHMA, V41, P189, DOI 10.1081/JAS-120026076; Power R, 2002, SEX TRANSM INFECT, V78, P87, DOI 10.1136/sti.78.2.87; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; RAND CS, 1993, AM J CARDIOL, V72, pD68, DOI 10.1016/0002-9149(93)90014-4; RAND CS, 1998, EUR RESPIR REV, V8, P270; Rand CS, 2008, J ALLERGY CLIN IMMUN, V122, P319, DOI 10.1016/j.jaci.2008.07.004; RUBINFELD AR, 1976, LANCET, V1, P882; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; U.S. Census Bureau, 2000, AM FACTFINDER; van Es SM, 2001, PATIENT EDUC COUNS, V44, P193, DOI 10.1016/S0738-3991(00)00195-6; van Es SM, 2002, PATIENT EDUC COUNS, V47, P165, DOI 10.1016/S0738-3991(01)00195-1; van Es SM, 1998, J ASTHMA, V35, P637, DOI 10.3109/02770909809048966	54	67	68	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1335	1341		10.1016/j.jaci.2009.02.022	http://dx.doi.org/10.1016/j.jaci.2009.02.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	455WO	19395075	Green Accepted			2022-12-18	WOS:000266799100026
J	Reijmerink, NE; Postma, DS; Bruinenberg, M; Nolte, IM; Meyers, DA; Bleecker, ER; Koppelman, GH				Reijmerink, Naomi E.; Postma, Dirkje S.; Bruinenberg, Marcel; Nolte, Ilja M.; Meyers, Deborah A.; Bleecker, Eugene R.; Koppelman, Gerard H.			Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-1 RECEPTOR; ST2; INFLAMMATION; CYTOKINE; T1/ST2		[Reijmerink, Naomi E.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Reijmerink, Naomi E.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Bruinenberg, Marcel] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Nolte, Ilja M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Univ, Sch Med, Dept Pediat Med & Publ Hlth Sci, Ctr Human Genom, Winston Salem, NC 27109 USA	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Wake Forest University	Reijmerink, NE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands.	g.h.koppelman@bkk.umcg.nl	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252				Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Dale M, 1999, GENOMICS, V57, P177, DOI 10.1006/geno.1999.5767; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Mangan NE, 2007, EUR J IMMUNOL, V37, P1302, DOI 10.1002/eji.200636520; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; ZHU G, 2008, EUR J HUM GENET 0402	13	67	70	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					651	654		10.1016/j.jaci.2008.06.030	http://dx.doi.org/10.1016/j.jaci.2008.06.030			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774397				2022-12-18	WOS:000259234000033
J	Sediva, A; Kayserova, J; Vernerova, E; Polouckova, A; Capkova, S; Spisek, R; Bartunkova, J				Sediva, Anna; Kayserova, Jana; Vernerova, Eva; Polouckova, Andrea; Capkova, Stepanka; Spisek, Radek; Bartunkova, Jirina			Anti-CD20 (rituximab) treatment for atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHEUMATOID-ARTHRITIS; THERAPY		[Sediva, Anna; Kayserova, Jana; Vernerova, Eva; Polouckova, Andrea; Spisek, Radek; Bartunkova, Jirina] Second Med Fac, Dept Immunol, Prague, Czech Republic; [Sediva, Anna; Kayserova, Jana; Vernerova, Eva; Polouckova, Andrea; Spisek, Radek; Bartunkova, Jirina] Second Med Fac, Dept Dermatovenerol, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic	Charles University Prague; Charles University Prague; Motol University Hospital	Sediva, A (corresponding author), Second Med Fac, Dept Immunol, Prague, Czech Republic.	anna.sediva@lfmotolcuni.cz	Sediva, Anna/AAE-2774-2019; Spisek, Radek/E-6724-2011; Sediva, Anna/J-5904-2017	Sediva, Anna/0000-0001-7730-2304; 				Admyre C, 2007, J ALLERGY CLIN IMMUN, V120, P1418, DOI 10.1016/j.jaci.2007.06.040; De Vita S, 2006, AUTOIMMUN REV, V5, P443, DOI 10.1016/j.autrev.2006.02.007; Morrison LH, 2004, J AM ACAD DERMATOL, V51, P817, DOI 10.1016/j.jaad.2004.06.007; Silverman GJ, 2003, ARTHRITIS RES THER, V5, pS1, DOI 10.1186/ar1010; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Vallerskog T, 2007, CLIN IMMUNOL, V122, P62, DOI 10.1016/j.clim.2006.08.016; Vigna-Perez M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1954	7	67	70	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1515	1516		10.1016/j.jaci.2008.03.007	http://dx.doi.org/10.1016/j.jaci.2008.03.007			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410962				2022-12-18	WOS:000256771700035
J	Yoshioka, M; Fukuishi, N; Iriguchi, S; Ohsaki, K; Yamanobe, H; Inukai, A; Kurihara, D; Imajo, N; Yasui, Y; Matsui, N; Tsujita, T; Ishii, A; Seya, T; Takahama, M; Akagi, M				Yoshioka, Mino; Fukuishi, Nobuyuki; Iriguchi, Sayuri; Ohsaki, Kanae; Yamanobe, Hiroyuki; Inukai, Asumi; Kurihara, Daisuke; Imajo, Naoki; Yasui, Yumiko; Matsui, Nobuaki; Tsujita, Tadayuki; Ishii, Akihiro; Seya, Tsukasa; Takahama, Makoto; Akagi, Masaaki			Lipoteichoic acid downregulates FC epsilon RI expression on human mast cells through Toll-like receptor 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; basophils; Fc receptors; allergy	GAMMA RECEPTORS; INNATE IMMUNITY; CUTTING EDGE; ACTIVATION; PEPTIDOGLYCAN; CYTOKINES; FLAGELLIN; ALPHA; TLR4	Background: Fc is an element of RI on the surface of mast cells (MCs) plays a central role in allergic responses. Recent evidence shows that exposure to microbial components corresponds with a significant reduction in the risk for allergic diseases. Although many reports suggest that this is due to changes in T-cell functions, how MC functions are altered by bacterial infection remains unknown. Objective: We sought to elucidate the effect of bacterial infection on MC function and expression of Fe receptors, such as Fc is an element of RI. Methods: Isolated human pulmonary MCs and a human MC line (LAD2) were stimulated with bacterial components, and the function and surface expression of Fc receptors were measured. Results: Lipoteichoic acid (LTA) and peptidoglycan, but not LPS, flagellin, or 3CpG-oligodeoxynucleotide, reduced the expression of Fc is an element of RI on LAD2 cells. An antibody to Toll-like receptor (TLR) 2 partially blocked the effect of LTA but not peptidoglycan. Both LTA and peptirloglycan reduced MC degrarnalation caused by an antigen-specific IgE. Furthermore, exposure of pulmonary MCs to LTA reduced both Fc is an element of RI expression and IgE-induced degranulation. None of the bacterial components affected the expression of other Fc receptors, such as Fc gamma receptors or Fc alpha receptor I. Conclusions: Our results indicate that LTA reduces the surface expression of Fc is an element of RI through TLR2 and suggests that TLR2 ligands could be used as a novel therapy for controlling allergic disorders. Clinical implications: By knowing how bacterial components modulate MC function, we can expand our possibilities for therapeutic interventions of allergic diseases.	Tokushima Bunri Univ, Dept Pharmacol, Fac Pharmaceut Sci, Tokushima 7708514, Japan; Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Sapporo, Hokkaido 060, Japan; Nara Med Univ, Dept Thorac & Cardiovasc Surg, Sch Med, Nara, Japan	Tokushima Bunri University; Hokkaido University; Nara Medical University	Fukuishi, N (corresponding author), Tokushima Bunri Univ, Dept Pharmacol, Fac Pharmaceut Sci, Nishihama Bouji 180, Tokushima 7708514, Japan.	nobuf@ph.bunri-u.ac.jp	Seya, Tsukasa/A-4336-2012; Tsujita, Tadayuki/AAH-2347-2019	Tsujita, Tadayuki/0000-0002-7189-0376				Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; Fureder W, 1997, J LEUKOCYTE BIOL, V61, P592; Gillespie SR, 2004, J IMMUNOL, V172, P3181, DOI 10.4049/jimmunol.172.5.3181; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Gomez G, 2005, J IMMUNOL, V174, P5987, DOI 10.4049/jimmunol.174.10.5987; Hasegawa M, 2003, J IMMUNOL, V170, P3732, DOI 10.4049/jimmunol.170.7.3732; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kulka A, 2006, MOL IMMUNOL, V43, P1579, DOI 10.1016/j.molimm.2005.09.019; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kulka M, 2006, J LEUKOCYTE BIOL, V79, P339, DOI 10.1189/jlb.1004600; Matsushima H, 2004, J IMMUNOL, V173, P531, DOI 10.4049/jimmunol.173.1.531; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; OKAYAMA Y, 1994, J IMMUNOL METHODS, V169, P153, DOI 10.1016/0022-1759(94)90259-3; Poncet P, 1999, J LEUKOCYTE BIOL, V66, P105, DOI 10.1002/jlb.66.1.105; Qiao HH, 2006, BLOOD, V107, P610, DOI 10.1182/blood-2005-06-2271; Sakurai D, 2004, J IMMUNOL, V172, P2374, DOI 10.4049/jimmunol.172.4.2374; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; Tsujita T, 2006, VACCINE, V24, P2193, DOI 10.1016/j.vaccine.2005.11.003; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Watanabe N, 1999, BLOOD, V94, P3855; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhu FG, 2001, J LEUKOCYTE BIOL, V69, P253	36	67	69	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					452	461		10.1016/j.jaci.2007.03.027	http://dx.doi.org/10.1016/j.jaci.2007.03.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17481719				2022-12-18	WOS:000248654900035
J	Erwin, EA; Ronmark, E; Wickens, K; Perzanowski, MS; Barry, D; Lundback, B; Crane, J; Platts-Mills, TAE				Erwin, Elizabeth A.; Ronmark, Eva; Wickens, Kristin; Perzanowski, Matthew S.; Barry, David; Lundback, Bo; Crane, Julian; Platts-Mills, Thomas A. E.			Contribution of dust mite and cat specific IgE to total IgE: Relevance to asthma prevalence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidemiology; asthma; aeroallergens	SERUM IMMUNOGLOBULIN-E; MODIFIED TH2 RESPONSE; RISK-FACTORS; HOSPITAL ADMISSION; NORTHERN SWEDEN; HIGH EXPOSURE; ALLERGENS; CHILDREN; SENSITIZATION; CHILDHOOD	Background: The prevalence of asthma is strikingly different in some Westernized countries: similar to 20% in New Zealand and -8% in northern Sweden. Objective: We investigated differences in total IgE and in the prevalence of wheezing related to the observation that high exposure to dust mite allergens induces high titers of IgE antibodies. Methods: Two age-matched, population-based cohorts-1155 children in New Zealand (224 sera) and 3431 children (797 sera) in the Norrbotten area of Sweden-were studied. Sera were assayed for total IgE and specific IgE antibodies to relevant allergens. Results: The mean total IgE among wheezing children was higher in New Zealand than Sweden (218 IU/mL vs 65.2 IU/mL; P < .001). In addition, the prevalence of high titer specific IgE antibody (>= 50 IU/mL) was greater among the wheezing children in New Zealand compared with Sweden (35.7% vs 13.0%; P < .001). Specific IgE antibody to mite in New Zealand was significantly related to high total IgE (>= 200 IU/mL; r = 0.47; P < .001), whereas the IgE antibody response to cat allergens did not make a significant contribution to high total IgE in either country. Conclusion: The quantity of IgE antibody produced to dust mite provides a possible explanation for the higher total IgE levels found in children in New Zealand and may help to explain the differences in prevalence and severity of asthma between these 2 countries. Clinical implications: Specific IgE antibody responses to dust mite and cat allergens may contribute differently to total serum IgE and to the prevalence of allergic disease.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Sunderby Cent Hosp Norrbotten, Obstruct Lung Dis Norbotten Studies, Lulea, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Wellington Sch Med & Hlth Sci, Wellington Asthma Res Grp, Wellington, New Zealand; Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA; Healthcare Hawkes Bay, Hastings, New Zealand	University of Virginia; Karolinska Institutet; University of Otago; Columbia University	Platts-Mills, TAE (corresponding author), POB 801355, Charlottesville, VA 22908 USA.	eae9m@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-20565, AI/EHS-P01-AI-50989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, P01AI050989, R01AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Burney P, 1996, EUR RESPIR J, V9, P687; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Crater SE, 1999, AM J ROENTGENOL, V173, P127, DOI 10.2214/ajr.173.1.10397112; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackola DR, 2004, HUM IMMUNOL, V65, P20, DOI 10.1016/j.humimm.2003.10.012; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; JOHANSSO.SG, 1967, LANCET, V2, P951; KLINK M, 1990, J ALLERGY CLIN IMMUN, V85, P440, DOI 10.1016/0091-6749(90)90153-U; Lewis G, 2004, IMMUNOGENETICS, V56, P564, DOI 10.1007/s00251-004-0728-4; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; Okano M, 1999, J IMMUNOL, V163, P6712; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SHAW RA, 1991, NEW ZEAL MED J, V104, P40; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	48	67	71	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					359	365		10.1016/j.jaci.2006.12.648	http://dx.doi.org/10.1016/j.jaci.2006.12.648			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291853				2022-12-18	WOS:000244327900013
J	McCoy, K; Shade, DM; Irvin, CG; Mastronarde, JG; Hanania, NA; Castro, M; Anthonisen, NR				McCoy, Karen; Shade, David M.; Irvin, Charles G.; Mastronarde, John G.; Hanania, Nicola A.; Castro, Mario; Anthonisen, N. R.		Amer Lung Assoc Asthma Clin Res Ct	Predicting episodes of poor asthma control in treated patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma exacerbations; asthma symptom questionnaires; asthma control	CIGARETTE-SMOKING; MILD ASTHMA; CHILDREN; ADULTS; RISK; HOSPITALIZATION; CORTICOSTEROIDS; EXACERBATIONS; SALMETEROL; SEVERITY	Background: Asthma exacerbations are dangerous, expensive, and difficult to anticipate. Objective: To characterize patients with asthma who had asthma episodes and exacerbations during 4 weeks of observation. Methods: A total of 2032 volunteers with asthma (age, 3-64 years; 62% female subjects) were studied over two 2-week intervals after flu vaccine and placebo. Baseline data, including several asthma questionnaires, were analyzed for prediction of subsequent asthma events as recorded on diaries detailing peak flow, medication use, and health care use. Results: During 28 days of diary collection, 43.2% of participants had at least 1 episode of poor asthma control. Most episodes were characterized by increased use of rescue medications or reductions in peak flow, but nearly 15% of participants had exacerbations characterized by use of systemic corticosteroids, unscheduled health care visits, or both. Episode frequency was highest in children < 10 years of age. Additional risk factors were smoking, African American ethnicity, low lung function, and past history of severe asthma. The best predictors were symptom questionnaires, and a simple questionnaire concerning the preceding 2 weeks worked as well as more complex questionnaires or those reflecting longer periods. In regression analyses, questionnaire results, smoking, lung function, ethnicity, and asthma history all were associated with asthma episodes in people older than 10 years, whereas only asthma history was predictive in those < 10 years. Conclusion: Symptom questionnaires are predictive of subsequent asthma episodes in people older than age 10 years, but not in younger people. Clinical implications: Simple assessments may be helpful in identifying patients most at risk for future asthma episodes.	Ohio State Univ, Columbus, OH 43210 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; Univ Vermont, Burlington, VT 05405 USA; Baylor Coll Med, Houston, TX 77030 USA; Washington Univ, Sch Med, St Louis, MO 63130 USA; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada	University System of Ohio; Ohio State University; Johns Hopkins University; University of Vermont; Baylor College of Medicine; Washington University (WUSTL); University of Manitoba	Shade, DM (corresponding author), Johns Hopkins Sch Publ Hlth, Ctr Clin Trials, 615 N Wolfe St,Room 5025-D, Baltimore, MD 21205 USA.	dshade@jhsph.edu	Hanania, Nicola A/C-5875-2016	Hanania, Nicola A/0000-0003-3087-9530				Annett RD, 2003, J ASTHMA, V40, P577, DOI 10.1081/JAS-120019030; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; *NAT CTR HLTH STAT, 2002, ASTHM PREV HLTH CAR; *NAT HEART LUNG BL, 1997, NAT ASTHM ED PROGR E; *NAT HEART LUNG BL, 1995, 953659 NHLBIVVHO; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	25	67	70	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1226	1233		10.1016/j.jaci.2006.09.006	http://dx.doi.org/10.1016/j.jaci.2006.09.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157651	Bronze			2022-12-18	WOS:000242880300004
J	Verbanck, S; Schuermans, D; Paiva, M; Vincken, W				Verbanck, Sylvia; Schuermans, Daniel; Paiva, Manuel; Vincken, Walter			The functional benefit of anti-inflammatory aerosols in the lung periphery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; small airways; inhaled corticosteroids; ultrafine aerosols	BECLOMETHASONE DIPROPIONATE; HYDROFLUOROALKANE-134A BECLOMETHASONE; EXTRAFINE AEROSOL; CHLOROFLUOROCARBON BECLOMETHASONE; APPROXIMATELY HALF; ASTHMA CONTROL; SMALL AIRWAYS; DISTAL LUNG; FLUTICASONE; DEPOSITION	Background: The target of anti-inflammatory therapy in asthma is thought to be situated, at least partly, in the lung periphery, and inhaled steroid aerosols are being engineered to reach it. However, the potential effect of such aerosols cannot be fully evaluated by conventional lung function tests because these are insensitive to peripheral lung structure. Objective: A prospective cohort study was conducted to investigate whether ultrafine steroid aerosols can elicit a response in the lung periphery, using a validated multibreath washout technique that can distinguish acinar from conductive lung zone function. Methods: In 30 stable patients with asthma with a wide range of disease severity (FEV, 27 % to 108 % predicted), we assessed conductive and acinar airway function abnormality at baseline, with patients on a standard dry powder steroid aerosol and after switching them to an ultrafine steroid aerosol. Results: Only in those patients with abnormal acinar airway function at baseline (n = 16) did acinar heterogeneity show a consistent improvement after switching to an ultrafine steroid aerosol; the improvement was also correlated with baseline acinar heterogeneity (r = -0.67; P =.007). Although all patients with asthma also presented conductive airway abnormality at baseline, no changes were observed in this lung zone with the switch to the ultrafine aerosol (P > .1). Conclusion: Among stable patients with asthma, those with acinar lung zone abnormality at baseline have the potential to receive functional benefit from an ultrafine steroid aerosol. Clinical studies comparing the efficacy of steroid aerosols targeted to the deep lung should at least include a measurement of peripheral lung zone function. Clinical implications: A new noninvasive measure of small airways function reveals why, and for which particular patients with asthma, small steroid aerosol particles can be of therapeutic use.	Vrije Univ Brussels, Acad Hosp, Div Resp, B-1090 Brussels, Belgium; Univ Libre Bruxelles, Biomed Phys Lab, Brussels, Belgium	Vrije Universiteit Brussel; Universite Libre de Bruxelles	Verbanck, S (corresponding author), Vrije Univ Brussels, Acad Hosp, Div Resp, Laarbeeklaan 101, B-1090 Brussels, Belgium.	sylvia.verbanck@az.vub.ac.be	Verbanck, Sylvia/L-7849-2016	Verbanck, Sylvia/0000-0003-0231-2756				BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Davies RJ, 1998, RESP MED, V92, P23, DOI 10.1016/S0954-6111(98)90214-1; Ederle K, 2003, Eur Rev Med Pharmacol Sci, V7, P45; Fireman P, 2001, ANN ALLERG ASTHMA IM, V86, P557, DOI 10.1016/S1081-1206(10)62905-5; Fowler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P929, DOI 10.1067/mai.2002.123869; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Hampel F, 2000, J ASTHMA, V37, P389, DOI 10.3109/02770900009055464; Juniper EF, 2002, CHEST, V121, P1824, DOI 10.1378/chest.121.6.1824; Leach C, 1999, J ALLERGY CLIN IMMUN, V104, pS250, DOI 10.1016/S0091-6749(99)70041-2; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Lipworth BJ, 2000, RESP MED, V94, pS21, DOI 10.1016/S0954-6111(00)80137-7; Marshall BG, 2000, EUR RESPIR J, V15, P764, DOI 10.1034/j.1399-3003.2000.15d22.x; Molimard M, 2005, RESP MED, V99, P770, DOI 10.1016/j.rmed.2004.10.024; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; Reichel W, 2001, INT J CLIN PRACT, V55, P100; Ross DL, 1996, J AEROSOL MED, V9, P215, DOI 10.1089/jam.1996.9.215; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Thongngarm T, 2005, J ASTHMA, V42, P257, DOI 10.1081/JAS-200057888; Tulic MK, 2002, SEMIN RESP CRIT CARE, V23, P347, DOI 10.1055/s-2002-34330; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; Verbanck S, 1997, J APPL PHYSIOL, V83, P1907, DOI 10.1152/jappl.1997.83.6.1907; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Worth H, 2001, RESPIRATION, V68, P517, DOI 10.1159/000050561	26	67	70	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					340	346		10.1016/j.jaci.2006.04.056	http://dx.doi.org/10.1016/j.jaci.2006.04.056			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890756				2022-12-18	WOS:000239877700007
J	Subbarao, P; Duong, M; Adelroth, E; Otis, J; Obminski, G; Inman, M; Pedersen, S; O'Byrne, PM				Subbarao, Padmaja; Duong, Mylinh; Adelroth, Ellinor; Otis, Joceline; Obminski, George; Inman, Mark; Pedersen, Soren; O'Byrne, Paul M.			Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise induced; inhaled corticosteroids; randomized controlled trial; dose response	BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; INHALED BUDESONIDE; CHILDREN	Background: Inhaled corticosteroid therapy improves exercise symptoms in asthmatic subjects. Objective: We sought to evaluate exercise-induced broncho-constriction (EIB) as a method of determining the dose and time responses of inhaled corticosteroid therapy. Methods: In this double-blind, randomized, cross-over study with 2 parallel arms, 4 doses of inhaled ciclesonide (40 mu g and 160 mu g or 80 mu g and 320 mu g) were compared over 3 weeks of treatment. Twenty-six asthmatic subjects (age range, 14-27 years) with baseline FEV1 values of greater than 70% of predicted value were enrolled. The primary outcome was the maximum percentage decrease in FEV1 after standardized exercise challenge. Results: After 1 week of therapy, the mean +/- SEM reduction in maximum decrease in FEV1 in the ciclesonide 40-mu g/80-mu g dose group was 9% 2.6% (95% CI, 3.9% to 14%), with no additional reduction thereafter. In the ciclesonide 160-mu g/320-mu g dose group, there was an 8.7% +/- 2.5% (95% CI, 3.7% to 13.7%) reduction in maximum decrease in FEV1 after week 1, which continued in a linear fashion during subsequent weeks of treatment. No difference was found between the 2 treatment arms in the temporal response of EIB to ciclesonide treatment. The maximum percentage attenuation in EIB achieved was 51.1% +/- 7.9%, which was achieved by using the 320-mu g dose after 3 weeks of treatment. Conclusions: A significant improvement in EIB was demonstrated for all doses of ciclesonide. Use of 160 mu g/320 mu g of ciclesonide resulted in a continuing improvement in FEV1 with time, and no plateau was seen in protective effect during 3 weeks of treatment. Clinical implications: Attenuation in exercise-induced decrease can be seen as early as after 1 week of therapy with inhaled ciclesonide at doses greater than 40 mu g. However, maximal attenuation in exercise response continues to increase at doses greater than or equal to 200 mu g, even after 3 weeks of therapy.	Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; St Josephs Hosp, Firestone Inst Resp Hlth, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Umea Univ, Umea, Sweden; Univ So Denmark, Kolding, Denmark	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McMaster University; McMaster University; Umea University; University of Southern Denmark	Subbarao, P (corresponding author), Univ Toronto, Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	padmaja.subbarao@sickkids.ca		Subbarao, Padmaja/0000-0003-0394-1933; O'Byrne, Paul/0000-0003-0979-281X				ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Belvisi MG, 2003, PULM PHARMACOL THER, V16, P321, DOI 10.1016/S1094-5539(03)00105-6; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; Carlsen Kai-Hakon, 2002, Paediatr Respir Rev, V3, P154, DOI 10.1016/S1526-0550(02)00009-4; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HENRIKSEN JM, 1985, BRIT MED J, V291, P248, DOI 10.1136/bmj.291.6490.248-a; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; Kanniess F, 2001, PULM PHARMACOL THER, V14, P141, DOI 10.1006/pupt.2001.0288; Kelly H W, 1999, Respir Care Clin N Am, V5, P537; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; MACKENZIE CA, 1993, EUR J PEDIATR, V152, P856, DOI 10.1007/BF02073387; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Petersen R, 2004, EUR RESPIR J, V24, P932, DOI 10.1183/09031936.04.00141303; Stoeck M, 2004, J PHARMACOL EXP THER, V309, P249, DOI 10.1124/jpet.103.059592; Thio BJ, 2001, PEDIATR PULM, V32, P115; Vidal C, 2001, ANN ALLERG ASTHMA IM, V86, P655, DOI 10.1016/S1081-1206(10)62294-6	21	67	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1008	1013		10.1016/j.jaci.2005.11.048	http://dx.doi.org/10.1016/j.jaci.2005.11.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675326	Bronze			2022-12-18	WOS:000237436300006
J	Wang, SW; Oh, CK; Cho, SH; Hu, GH; Martin, R; Demissie-Sanders, S; Li, K; Moyle, M; Yao, ZB				Wang, SW; Oh, CK; Cho, SH; Hu, GH; Martin, R; Demissie-Sanders, S; Li, K; Moyle, M; Yao, ZB			Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; amphiregulin; IgE cross-linking	INDUCED PULMONARY FIBROSIS; AIRWAY SMOOTH-MUSCLE; GROWTH-FACTOR; HEPARIN-BINDING; GENE-EXPRESSION; FACTOR-ALPHA; ACTIVIN-A; ASTHMA; PROLIFERATION; DISORDERS	Background: Amphiregulin is a member of the epidermal growth factor family and has been shown to stimulate the proliferation of human keratinocytes in an autocrine manner. Objective: The aim of the present study was to examine the expression change of growth factors, especially amphiregulin, in human mast cells induced by IgE cross-linking. Methods: Microarray analysis and RT-PCR were used to analyze the gene expression profile of human cord blood-derived mast cells (CBMCs) stimulated with IgE cross-linking. Protein secretion in the supernatants of CBMCs was measured by means of ELISA. Double-immunofluorescence staining was used to analyze the expression in the lung mast cells. Results: Of the 64 different growth factor genes analyzed, 5 were found to be substantially upregulated. Among them, amphiregulin mRNA was induced by 44-fold in CBMCs on activation through IgE cross-linking. Secretion of amphiregulin protein was evident in CBMCs 8 hours after stimulation. Amphiregulin was also expressed in human lung mast cells from patients with asthma, as demonstrated by means of double-immunofluorescence staining. Amphiregulin promoted the proliferation of the primary human lung fibroblasts, and amphiregulin-treated primary human lung fibroblasts showed a marked increase in the expression of c-fos, a proto-oncogene that facilitates or is required for the proliferation of a wide variety of cells. Conclusion: Human CBMCs secreted amphiregulin on IgE cross-linking, and the amphiregulin induced proliferation of primary human lung fibroblasts. These data suggest that local release of amphiregulin by human mast cells could play an important role in lung fibrosis by promoting the proliferation of primary human lung fibroblasts.	Tanox Biosyst Inc, Houston, TX 77025 USA; Univ Calif Los Angeles, Harbor UCLA Med Ctr, Sch Med, Div Allergy & Immunol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yao, ZB (corresponding author), Tanox Biosyst Inc, 10555 Stella Link, Houston, TX 77025 USA.	byao@tanox.com	Cho, Seong/I-7102-2015					Artuc M, 2002, J INVEST DERMATOL, V118, P391, DOI 10.1046/j.0022-202x.2001.01705.x; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROIDE DH, 1990, J IMMUNOL, V145, P1838; CASTELLS M, MAST CELLS MOL CELL; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Cho SH, 2000, J IMMUNOL, V165, P3154, DOI 10.4049/jimmunol.165.6.3154; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; DAY R, 1987, AM REV RESPIR DIS, V136, P908, DOI 10.1164/ajrccm/136.4.908; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GOTO T, 1984, AM REV RESPIR DIS, V130, P797; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; HAWKINS RA, 1985, ANN INTERN MED, V102, P182, DOI 10.7326/0003-4819-102-2-182; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Kanbe N, 2000, J ALLERGY CLIN IMMUN, V106, pS85, DOI 10.1067/mai.2000.106777; KAWANAMI O, 1979, LAB INVEST, V40, P717; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; PESCI A, 1993, CHEST, V103, P989, DOI 10.1378/chest.103.4.989; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WATANABE S, 1974, LAB INVEST, V31, P555; Yang JH, 2003, J BIOL CHEM, V278, P16797, DOI 10.1074/jbc.M211060200; Zhang LM, 2001, AM J RESP CELL MOL, V24, P123, DOI 10.1165/ajrcmb.24.2.4096	30	67	77	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					287	294		10.1016/j.jaci.2004.11.037	http://dx.doi.org/10.1016/j.jaci.2004.11.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696083				2022-12-18	WOS:000227043600012
J	de Marco, R; Pattaro, C; Locatelli, F; Svanes, C				de Marco, R; Pattaro, C; Locatelli, F; Svanes, C		ECRHS Study Group	Influence of early life exposures on incidence and remission of asthma throughout life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; incidence; remission; hygiene hypothesis; natural history; early infections; congenital factors; ECRHS	RESPIRATORY-HEALTH-SURVEY; CHILDHOOD ASTHMA; SYNCYTIAL VIRUS; HAY-FEVER; GAMMA PRODUCTION; ADULT ASTHMA; CAT ALLERGEN; CHILDREN; AGE; HISTORY	Background: Knowledge of the effects of early environmental and congenital factors on the natural history of asthma may provide important clues to the pathogenesis of asthma. Objective: We assessed associations between potential, early determinants and the incidence and remission of asthma throughout life, and tested whether the strength and direction of these associations varied in childhood, adolescence, and adulthood. Methods: The data pertaining to the individual asthma history of 18,156 subjects, age 0 to 44 years, who attended the clinical stage of the European Community Respiratory Health Survey were analyzed retrospectively by life-event methods. Onset of asthma was defined as age at the first attack, and asthmatic patients were considered to be in remission if they had not been under treatment or had an attack of asthma in the past 24 months. Onset and remission were evaluated in 3 time windows: < 10, 10 to 20, and greater than or equal to20 years of age. The associations of asthma with early determinants were estimated by hazard ratios (HRs). Results: A family history of asthma or allergy was associated with a higher risk of developing asthma (HR, 1.89; 95% CI, 1.67-2.13) and a lower chance of remission (HR, 0.79; 95% CI, 0.64-0.99) throughout life. No matter what one's genetic predisposition was, early, acute respiratory infections were associated with an increased lifelong risk of asthma onset (pooled HR, 3.19; 95% CI, 2.75-3.69), whereas early contact with older children, which is a marker of prolonged, intermittent exposure to infectious agents, conferred permanent protection against asthma (HR, 0.84; 95% CI, 0.74-0.96) and increased the chance of remission in childhood asthma (HR, 1.50; 95% CI, 1.10-2.04). Pet ownership had a protective effect only in childhood (HR, 0.78; 95% CI, 0.74-0.96), whereas maternal smoking did not show a significant association with asthma. Female sex was negatively associated with the onset of asthma in childhood (HR, 0.62; 95% CI, 0.52-0.75) and positively in adulthood (HR, 2.01; 95% CI, 1.61-2.51). The pattern of associations was similar in sensitized (positive assay to specific IgE) and nonsensitized asthmatic patients. Conclusion: Genetic predisposition and exposure to infectious agents are major early determinants that influence a subsequent history of asthma. The length and type of exposure to infectious agents seem able either to promote or to suppress an antiinflammatory process, unrelated to IgE, which can partially interfere with an acquired predisposition for asthma.	Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Ist Biol 2, I-37134 Verona, Italy; Univ Bergen, Inst Med, Sect Resp Med, Bergen, Norway; Haraldsplass Hosp, Dept Med, Bergen, Norway	University of Verona; University of Bergen	de Marco, R (corresponding author), Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Ist Biol 2, Strada Le Grazie 8, I-37134 Verona, Italy.	roberto.demarco@univr.it	de Marco, Roberto/A-5470-2008; Svanes, Cecilie/N-7556-2017; SESM, SESM/C-1440-2008	Svanes, Cecilie/0000-0001-8512-5192; LOCATELLI, Francesca/0000-0001-9190-7190				Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Bauer PJ, 1996, AM PSYCHOL, V51, P29, DOI 10.1037/0003-066X.51.1.29; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; de Marco R, 1998, EUR RESPIR J, V11, P599; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; DEMARCO R, 2002, P 16 WORLD C EP INT, P71; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; EVERARD ML, 1992, EUR J PEDIATR, V151, P638, DOI 10.1007/BF01957564; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; Marubini E, 1995, ANAL SURVIVAL DATA C; MASTERS S, 1985, EPIDEMIOL REV, V7, P49, DOI 10.1093/oxfordjournals.epirev.a036285; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; ORNSTEIN PA, 1995, J TRAUMA STRESS, V8, P581, DOI 10.1002/jts.2490080405; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Svanes C, 2002, THORAX, V57, P945, DOI 10.1136/thorax.57.11.945; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	40	67	69	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					845	852		10.1016/j.jaci.2004.01.780	http://dx.doi.org/10.1016/j.jaci.2004.01.780			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131565	Bronze			2022-12-18	WOS:000221269000005
J	Teraki, Y; Shiohara, T				Teraki, Y; Shiohara, T			IFN-gamma-producing effector CD8(+)T cells and IL-10-producing regulatory CD4(+)T cells in fixed drug eruption	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fixed drug eruption; intraepidermal T cell; effector-memory T cell; regulatory T cell; IFN-gamma; IL-10; homing receptor; chemokine receptor; skin inflammation	MEMORY T-CELLS; GROWTH-FACTOR; CD8+T CELLS; BETA-CHAIN; RECEPTOR; LYMPHOCYTES; EXPRESSION; DIFFERENTIATION; INTEGRIN; HOMEOSTASIS	Background: Although effector and regulatory T cells play roles in the progression and resolution of inflammatory diseases, respectively, little in vivo data exist regarding the T-cell dynamics in the pathogenesis of inflammatory skin diseases in humans. Objective: Our aim is to phenotypically and functionally characterize the T cells responsible for initiation and regulation of inflammatory events in fixed drug eruption (FDE) as a disease model to study the role of cytokines produced within the epidermis in the pathogenesis of inflammatory skin disease. Methods: By use of flow cytometry, we phenotypically and functionally characterized the intraepidermal T cells that persist as a stable population in resting (pigmented) FDE lesions and that are present in active FIDE lesions. Results: In resting FDE lesions, most of the intraepidermal T cells were of the CD8 phenotype, most of which expressed cutaneous lymphocyte-associated antigen, alpha4beta1, CD11a, alphaEbeta7, and CD45RA but not CD27, CD62L, CCR4, or CCR7. This population selectively expressed CD122 but not CD25. Intracellular staining demonstrated that most intraepidermal CD8(+) T cells were capable of producing IFN-gamma and TNF-alpha but produced little IL-2 and IL-4. On the other hand, in the FIDE lesions that arose after challenge, a significant number of CD4(+) T cells capable of producing IL-10 migrated into the lesional epidermis. Moreover, nearly 70% of the CD4(+) T cells migrating into the lesional epidermis expressed CD25. Conclusions: Effector IFN-gamma-producing CD8(+) T cells and regulatory IL-10-producing CD4(+) T cells might be responsible for the progression and resolution of FDE, respectively.	Kyorin Univ, Dept Dermatol, Sch Med, Mitake, Tokyo 1818611, Japan	Kyorin University	Teraki, Y (corresponding author), Kyorin Univ, Dept Dermatol, Sch Med, 6-20-2 Shinkawa, Mitake, Tokyo 1818611, Japan.							Baars PA, 2000, J IMMUNOL, V165, P1910, DOI 10.4049/jimmunol.165.4.1910; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Faint JM, 2001, J IMMUNOL, V167, P212, DOI 10.4049/jimmunol.167.1.212; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HINDSEN M, 1987, BRIT J DERMATOL, V116, P351, DOI 10.1111/j.1365-2133.1987.tb05849.x; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Komatsu T, 1996, CLIN EXP IMMUNOL, V104, P343, DOI 10.1046/j.1365-2249.1996.30738.x; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Lai YG, 1999, J IMMUNOL, V163, P5843; MOHAMADZADEH M, 1995, J IMMUNOL, V155, P4492; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murakami M, 2002, P NATL ACAD SCI USA, V99, P8832, DOI 10.1073/pnas.132254399; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shiohara T, 1997, J INVEST DERMATOL, V109, P271, DOI 10.1111/1523-1747.ep12335465; Teraki Y, 2002, BRIT J DERMATOL, V147, P1118, DOI 10.1046/j.1365-2133.2002.05005.x; Teraki Y, 1997, J IMMUNOL, V159, P6018; TERAKI Y, 1994, AM J PATHOL, V145, P550; Tomiyama H, 2002, J IMMUNOL, V168, P5538, DOI 10.4049/jimmunol.168.11.5538; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001	36	67	69	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					609	615		10.1037/mai.2003.1653	http://dx.doi.org/10.1037/mai.2003.1653			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679823				2022-12-18	WOS:000185231200023
J	Schatz, M; Cook, EF; Nakahiro, R; Petitti, D				Schatz, M; Cook, EF; Nakahiro, R; Petitti, D			Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled corticosteroids; allergist; hospitalization; specialist; emergency care	COMPUTER-BASED MODELS; MEDICAID POPULATION; RISK; ADHERENCE; CHILDREN; OUTCOMES; THERAPY; IMPACT; COST; INTERVENTION	Background: The interrelationships between optimal inhaled corticosteroid (IC) therapy, allergy specialist care, and reduced emergency hospital care for asthma have not been well defined. Objective: We sought to evaluate the independent effectiveness of various levels of IC dispensing and allergy specialist care in reducing subsequent emergency asthma hospital use. Methods: Asthmatic patients (n = 9608) aged 3 to 64 years were identified from an electronic database of a large health maintenance organization. The outcome was any year 2000 asthma hospitalization or emergency department visit. The main predictors were at least one allergy department visit and the number of IC canisters dispensed in 1999. Analyses were adjusted for age, sex, insurance type, and asthma severity (1999 emergency asthma hospital use, P-agonist use, and oral corticosteroid use). Results: Dispensing of 7 or more canisters of ICs (odds ratio [OR], 0.64; 95% CI, 0.43-0.94) and allergy care (OR, 0.73; 95% CI, 0.55-0.97) were associated with reduced subsequent emergency asthma hospital use. More patients with allergy specialist care than those without such care received 7 or more dispensations of ICs (24.7% vs 8.3%, P <.001). When 7 or more dispensations of ICs and allergy specialist care were simultaneously included in an adjusted model, both ICs (OR, 0.68; 95% CI, 0.46-1.00) and allergy care (OR, 0.77; 95% CI, 0.58-1.02) were independently associated with a lower risk of year 2000 emergency asthma hospital care, although significance was borderline. Conclusion: Allergy care reduces emergency hospital use for asthma by increasing use of ICs but probably also has an independent effect. (J Allergy Clin Immunol 2003; 111: 503-8.).	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Kaiser Permanente Med Ctr, Pharm Analyt Serv, San Diego, CA 92111 USA; Kaiser Permanente Med Ctr, Dept Res & Evaluat, San Diego, CA 92111 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.							Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; ADELROTH E, 1988, LANCET, V1, P476; Balkrishnan R, 1998, CLIN THER, V20, P567, DOI 10.1016/S0149-2918(98)80066-0; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; FREUND DA, 1989, J ALLERGY CLIN IMMUN, V84, P401, DOI 10.1016/0091-6749(89)90428-4; GEORGE M, 2001, CLIN PULM MED, V8, P257; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; Laumann JM, 1998, ANN PHARMACOTHER, V32, P1290, DOI 10.1345/aph.18147; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; Lieu TA, 1999, J ASTHMA, V36, P359, DOI 10.3109/02770909909068229; MAHR TA, 1993, ANN ALLERGY, V71, P115; Milgrom H, 2002, ANN ALLERG ASTHMA IM, V88, P429, DOI 10.1016/S1081-1206(10)62377-0; Nyman JA, 1997, ANN ALLERG ASTHMA IM, V79, P496, DOI 10.1016/S1081-1206(10)63055-4; Piecoro LT, 2001, HEALTH SERV RES, V36, P357; Sherman J, 2000, J PEDIATR-US, V136, P532, DOI 10.1016/S0022-3476(00)90019-2; Sin DD, 2001, EUR RESPIR J, V17, P380, DOI 10.1183/09031936.01.17303800; Stempel DA, 1997, ANN ALLERG ASTHMA IM, V79, P517, DOI 10.1016/S1081-1206(10)63059-1; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Westley CR, 1997, ALLERGY ASTHMA PROC, V18, P15, DOI 10.2500/108854197778612835; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; Zeiger RS, 2000, J ALLERGY CLIN IMMUN, V106, P995, DOI 10.1067/mai.2000.110921; 2002, ASTHMA AM LANDMARK S	30	67	67	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					503	508		10.1067/mai.2003.178	http://dx.doi.org/10.1067/mai.2003.178			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642829				2022-12-18	WOS:000181639500010
J	Vierk, K; Falci, K; Wolyniak, C; Klontz, KC				Vierk, K; Falci, K; Wolyniak, C; Klontz, KC			Recalls of foods containing undeclared allergens reported to the US Food and Drug Administration, fiscal year 1999	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; egg; peanut; dairy; recalls	PEANUT	Background: Food recalls can play a role in preventing or reducing the number of allergic reactions that may occur after a product containing an undeclared allergen has been introduced into commerce. Objective: We sought to summarize the US Food and Drug Administration's records of recalls classified for fiscal year 1999 involving foods containing undeclared allergens. Methods: Food and Drug Administration food recall records were reviewed for fiscal year 1999 to identify recalls that occurred because of the undeclared presence of one or more of the following allergens: milk, eggs, fish, wheat, crustacean shellfish, tree nuts, peanuts, and soy. Each record was reviewed to determine the recalled product, the undeclared allergen present, the reason for recall, and reported adverse events. Results: Of 659 total food products classified for recall during fiscal year 1999, 236 (36%) products were recalled because they contained one or more undeclared allergens. Consumers were the party most often responsible for identifying that an undeclared allergen was present in a product (56% of recalled products). A total of 34 consumers reported allergic reactions after consumption of the recalled products. Three principal factors contributed to the presence of undeclared allergens in the recalled products: ingredient-statement omissions and errors (51% of all recalled products); manufacturing equipment cross-contact (40%); and errors by ingredient suppliers or manufacturing firm employees (5%). Conclusion: The presence of undeclared allergens in food products represents one of the more common reasons for food-product recall in the United States. A number of well-recognized allergens may be introduced into foods as a result of several different factors.	US FDA, Ctr Food Safety & Appl Nutr, Epidemiol Team, College Pk, MD 20740 USA	US Food & Drug Administration (FDA)	Vierk, K (corresponding author), US FDA, Ctr Food Safety & Appl Nutr, Epidemiol Team, HFS-728,5100 Paint Branch Pkwy,Room 2C-077, College Pk, MD 20740 USA.							Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Kemp SF, 1996, JAMA-J AM MED ASSOC, V275, P1636, DOI 10.1001/jama.275.21.1636; McKenna C, 1997, ANN ALLERG ASTHMA IM, V79, P234, DOI 10.1016/S1081-1206(10)63008-6; Pumphrey RSH, 2000, LANCET, V355, P1099, DOI 10.1016/S0140-6736(05)72220-0; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	9	67	75	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1022	1026		10.1067/mai.2002.124500	http://dx.doi.org/10.1067/mai.2002.124500			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063535				2022-12-18	WOS:000176442700021
J	Chen, CY; Bonham, AC; Schelegle, ES; Gershwin, LJ; Plopper, CG; Joad, JP				Chen, CY; Bonham, AC; Schelegle, ES; Gershwin, LJ; Plopper, CG; Joad, JP			Extended allergen exposure in asthmatic monkeys induces neuroplasticity in nucleus tractus solitarius	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; vagus nerve; solitary nucleus	AFFERENT NEURONS; EXPRESSION; PLASTICITY; AIRWAYS; LUNGS; PAIN; RAT	Background: Extended exposure to allergen exacerbates asthma symptoms, in part via complex interactions between inflammatory cells and mediators. One consequence of these interactions is the triggering of local and central nervous system (CNS) neuronal activity that might further exacerbate the asthmalike symptoms by causing bronchoconstriction, mucous secretion, increased microvascular leak, and cough. One CNS region that might be particularly important is the caudomedial nucleus tractus solitarius (NTS). NTS neurons not only integrate primary afferent inputs from lung sensory nerve fibers but also have direct exposure to inhaled allergens and allergen-induced Wood-borne inflammatory mediators via a deficient blood-brain barrier. Given the capacity of CNS neurons to undergo plasticity, allergen-induced changes in NTS neuronal properties could contribute to the exaggerated respiratory responses to extended allergen exposure. Objective: In a recently developed rhesus monkey model of allergic asthma, we tested the hypothesis that extended exposure to allergen increases the intrinsic excitability of NTS neurons. Methods: Three adult monkeys were sensitized and then repeatedly exposed to aerosols of house dust mite allergen; 4 monkeys served as controls. Whole-cell current-clamp recordings were made to measure 3 indices of excitability: resting membrane potential, input resistance, and number of action potentials evoked by current injections. Results: Extended allergen exposure depolarized the resting membrane potential by 14% and increased the number of action potentials evoked by current injections (5-fold). Conclusion: The finding that NTS neurons in a primate model of allergic asthma undergo intrinsic increases in excitability suggests that CNS mechanisms might contribute to the exaggerated symptoms in asthmatic individuals exposed to allergen.	Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Anat Physiol & Cell Biol, Davis, CA 95616 USA; Univ Calif Davis, Calif Reg Primate Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Joad, JP (corresponding author), Univ Calif Davis, Sch Med, Dept Pediat, 256 Stockton Blvd, Sacramento, CA 95817 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000628] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES00628] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arshad SH, 1998, AM J RESP CRIT CARE, V157, P1900, DOI 10.1164/ajrccm.157.6.9603034; Aylwin ML, 1998, AM J PHYSIOL-HEART C, V275, pH1236, DOI 10.1152/ajpheart.1998.275.4.H1236; BERGREN DR, 1985, ARCH INT PHARMACOD T, V273, P88; BONHAM AC, 1991, J PHYSIOL-LONDON, V441, P95, DOI 10.1113/jphysiol.1991.sp018740; BONHAM AC, 1993, AM J PHYSIOL, V264, pH1674, DOI 10.1152/ajpheart.1993.264.5.H1674; BOWER A J, 1990, British Journal of Neurosurgery, V4, P253, DOI 10.3109/02688699008992734; Chan RKW, 2000, J COMP NEUROL, V422, P338; Chen CY, 1999, AM J PHYSIOL-HEART C, V277, pH1350, DOI 10.1152/ajpheart.1999.277.4.H1350; Chen CY, 1998, AM J PHYSIOL-HEART C, V275, pH1695, DOI 10.1152/ajpheart.1998.275.5.H1695; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; Dantzer R, 2000, AUTON NEUROSCI-BASIC, V85, P60, DOI 10.1016/S1566-0702(00)00220-4; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Goehler LE, 2000, AUTON NEUROSCI-BASIC, V85, P49, DOI 10.1016/S1566-0702(00)00219-8; Gordon FJ, 2000, AUTON NEUROSCI-BASIC, V85, P102, DOI 10.1016/S1566-0702(00)00228-9; GROSS PM, 1990, AM J PHYSIOL, V259, pR1131, DOI 10.1152/ajpregu.1990.259.6.R1131; Lemanske RF, 2000, J ALLERGY CLIN IMMUN, V105, pS633; Loewy AD., 1990, CENTRAL REGULATION A, P88; Marshall PS, 2000, ANN ALLERG ASTHMA IM, V84, P403, DOI 10.1016/S1081-1206(10)62273-9; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OU L, 1977, INTRO STAT METHODS D; Paulsen O, 2000, CURR OPIN NEUROBIOL, V10, P172, DOI 10.1016/S0959-4388(00)00076-3; Riccio MM, 1996, J PHYSIOL-LONDON, V491, P499, DOI 10.1113/jphysiol.1996.sp021234; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; THAKUR IS, 1988, BIOCHEM INT, V16, P235; Undem BJ, 1999, INT ARCH ALLERGY IMM, V118, P150, DOI 10.1159/000024053; UNDEM BJ, 1998, J AUTONOM NERV SYST, V44, P7; Undem Bradley J., 2000, Journal of Allergy and Clinical Immunology, V106, pS213; VANDERKOOY D, 1983, J COMP NEUROL, V219, P328, DOI 10.1002/cne.902190307; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1	33	67	71	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					557	562						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590381				2022-12-18	WOS:000171760300014
J	Tsitoura, DC; Blumenthal, RL; Berry, G; DeKruyff, RH; Umetsu, DT				Tsitoura, DC; Blumenthal, RL; Berry, G; DeKruyff, RH; Umetsu, DT			Mechanisms preventing allergen-induced airways hyperreactivity: Role of tolerance and immune deviation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; airway hyperreactivity; T lymphocytes; tolerance; immune deviation	CD4(+) T-CELLS; MURINE MODEL; IMMUNOGLOBULIN (IG)-E; PASSIVE TRANSFER; ORAL TOLERANCE; TH2 CELLS; RESPONSES; IMMUNOTHERAPY; ANTIGEN; ASTHMA	Background: Aeroallergens continuously enter the respiratory tract of atopic individuals and provoke the development of asthma characterized by airway hyperreactivity; (AHR) and inflammation, By contrast, nonatopic individuals are exposed to the same aeroallergens, but airway inflammation does not develop, However, the mechanisms that prevent allergen-induced respiratory diseases in nonatopic subjects are poorly characterized. Objective: In this study we compared the role of allergen-specific T-cell tolerance and immune deviation in conferring protection against the development of allergen-induced AHR, Methods: We exposed mice to intranasal ovalbumin (OVA) to induce T-cell tolerance and examined its effects on the subsequent development of AHR and inflammation. Results: We demonstrated that exposure of mice to intranasal OVA resulted in peripheral CD4(+) T-cell unresponsiveness that very efficiently prevented not only the development of AHR but also greatly inhibited airway inflammation and OVA-specific IgE production. The induction of peripheral T-cell tolerance and protection against AHR were not dependent on the presence of IFN-gamma or IL-4, The development of AHR was also prevented by an OVA-specific T(H)1-biased immune response induced by inhalation of OVA in the presence of IL-12, However, the OVA-specific T(H)1 response was associated with a significant degree of pulmonary inflammation. Conclusion: These results indicate that both allergen-specific T-cell tolerance and T(H)1-biased immune deviation prevent the development of AHR, but T(H)1 responses are associated with significantly greater inflammation in the lung than is associated with T-cell unresponsiveness. Therefore CD4(+) T-cell unresponsiveness critically regulates immune responses to aeroallergens and protects against the development of allergic disease and asthma.	Stanford Univ, Med Ctr, Dept Pediat, Div Clin Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Med Ctr, Dept Pediat, Div Clin Immunol & Allergy, Rm G309, Stanford, CA 94305 USA.			Berry, Gerald/0000-0002-6176-2629	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322, R01AI024571] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL62348] Funding Source: Medline; NIAID NIH HHS [R01AI26322, R01AI24571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Haneda K, 1997, J IMMUNOL, V159, P4484; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Hogan SP, 1998, J IMMUNOL, V161, P1501; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; Kim TS, 1997, J IMMUNOL, V158, P4137; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Li L, 1998, J IMMUNOL, V161, P3128; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Yeung VP, 1998, J IMMUNOL, V161, P4146	38	67	72	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					239	246						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932065				2022-12-18	WOS:000088708100004
